10087562	0	(S1 (NP (NP (NNP Torsade) (FW de) (NNP pointes) (NNP Doc_10087562_19_42_Disease)) (PP (IN during) (NP (NP (JJ low) (NN dose) (JJ intermittent) (JJ Doc_10087562_72_82_Chemical) (NN treatment)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (JJ dilated) (NNP Doc_10087562_119_133_Disease) (CC and) (NNP Doc_10087562_138_162_Disease))))))) (. .)))
10087562	1	(S1 (S (NP (DT The) (NNS authors)) (VP (VBP describe) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 56-year-old) (NN woman)) (PP (IN with) (NP (JJ chronic) (, ,) (JJ severe) (ADJP (NNP Doc_10087562_238_251_Disease) (JJ secondary) (PP (TO to) (NP (NP (JJ dilated) (NN Doc_10087562_273_287_Disease) (CC and) (NN absence)) (PP (IN of) (NP (JJ significant) (NNP Doc_10087562_315_338_Disease))) (SBAR (WHNP (WP who)) (S (VP (VP (VBD developed) (NP (NNP Doc_10087562_353_368_Disease))) (CC and) (VP (VBD torsade) (PP (IN de) (NP (NNP pointes) (NNP Doc_10087562_392_415_Disease))) (PP (IN during) (NP (NP (CD one) (NN cycle)) (PP (IN of) (NP (JJ intermittent) (JJ low) (NN dose)))))))))))) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 2.5) (CD mcg/kg))) (PP (IN per) (NP (NN min)))) (-RRB- -RRB-)) (NNP Doc_10087562_479_489_Chemical))))))) (. .)))
10087562	2	(S1 (S (NP (NP (DT This) (NN report)) (PP (IN of) (NP (NNP torsade) (FW de) (NNP pointes) (NNP Doc_10087562_525_548_Disease))) (PP (IN during) (NP (JJ intermittent) (NNP Doc_10087562_569_579_Chemical)))) (VP (VBZ supports) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (ADJP (JJ unpredictable) (JJ fatal)) (NNP Doc_10087562_629_640_Disease)) (VP (MD may) (VP (VB occur) (PP (RB even) (PP (IN with) (NP (JJ low) (NNS doses))) (CC and) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT no) (NN history)) (PP (IN of) (NP (JJ significant) (NN Doc_10087562_718_737_Disease)))))))))))))) (. .)))
10087562	3	(S1 (S (NP (NP (DT The) (NNS mechanisms)) (PP (IN of) (NP (NP (JJ proarrhythmic) (NNS effects)) (PP (IN of) (NP (NNP Doc_10087562_782_792_Chemical)))))) (VP (AUX are) (VP (VBN discussed))) (. .)))
10219427	0	(S1 (NP (NP (JJ Positive) (NN skin) (NNS tests)) (PP (IN in) (NP (NP (JJ late) (NNS reactions)) (PP (TO to) (NP (JJ radiographic) (NN contrast) (NNS media))))) (. .)))
10219427	1	(S1 (S (PP (IN In) (NP (DT the) (JJ last) (JJ few) (NNS years))) (NP (JJ delayed) (NNS reactions)) (PP (NP (JJ several) (NNS hours)) (IN after) (NP (NP (DT the) (NN injection)) (PP (IN of) (NP (NP (NN radiographic)) (CC and) (NP (NP (NN contrast) (NNS materials)) (PRN (-LRB- -LRB-) (NP (NNP PRC)) (-RRB- -RRB-))))))) (VP (AUX have) (VP (AUX been) (VP (VBN described) (PP (IN with) (NP (JJ increasing) (NN frequency)))))) (. .)))
10219427	2	(S1 (S (NP (DT The) (NNS authors)) (VP (VBP report) (NP (CD two) (NNS observations)) (PP (IN on) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ delayed) (NNS reactions)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NP (NP (NP (NNS intradermoreactions)) (PRN (-LRB- -LRB-) (NP (NNP IDR)) (-RRB- -RRB-))) (CC and) (NP (NN patch) (NNS tests))) (PP (TO to) (NP (NP (DT a) (NN series)) (PP (IN of) (NP (ADJP (JJ ionic) (CC and) (JJ non)) (JJ ionic) (NNS PRC)))))) (VP (AUX were) (VP (VBN studied)))))))))) (. .)))
10219427	3	(S1 (S (SBAR (IN After) (S (NP (NP (NN angiography)) (PP (IN by) (NP (NP (DT the) (JJ venous) (NN route)) (PP (IN in) (NP (NP (NP (NP (JJ patient) (NNP n) (NN degree) (CD 1)) (NP (DT a) (JJ biphasic) (NN reaction))) (PP (IN with) (NP (NP (DT an) (JJ immediate) (NN reaction)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10219427_518_525_Disease)) (, ,) (NP (NNP Doc_10219427_527_548_Disease)) (-RRB- -RRB-))))) (CC and) (NP (JJ delayed) (JJ macro-papular) (NN Doc_10219427_576_580_Disease))))))) (VP (VBD appeared)))) (, ,) (NP (JJ whilst) (NN patient) (NNP n) (NN degree) (CD 2)) (VP (VBD developed) (NP (NP (NP (DT a) (JJ generalised) (NN sensation)) (PP (IN of) (NP (NN heat)))) (, ,) (NP (NP (JJ persistent) (NN Doc_10219427_671_675_Disease)) (PP (IN at) (NP (NP (DT the) (NN site)) (PP (IN of) (NP (NN injection))) (ADVP (RB immediately))))) (CC and) (NP (DT a) (JJ generalised) (JJ macro-papular) (NN reaction))) (PP (IN after) (NP (CD 24) (NNS hours)))) (. .)))
10219427	4	(S1 (S (NP (DT The) (NN skin) (NNS tests)) (VP (VBD revealed) (NP (NP (NP (JJ positive) (JJ delayed) (NNS reactions)) (PP (IN of) (NP (NP (CD 24) (NNS hours)) (CC and) (NP (NP (CD 48) (NNS hours)) (PP (IN by) (NP (NNP IDR))))))) (CC and) (NP (NP (NN patch) (NNS tests)) (PP (TO to) (NP (NP (RB only) (DT some) (NN PRC)) (PP (IN with) (NP (NP (JJ common) (NNS chains)) (PP (IN in) (NP (PRP$ their) (NNS structures)))))))))) (. .)))
10219427	5	(S1 (S (NP (DT The) (JJ positive) (NN skin) (NNS tests)) (VP (VP (AUX are) (PP (IN in) (NP (NP (NN favour)) (PP (IN of) (NP (JJ immunological) (NNS reactions)))))) (CC and) (VP (MD may) (VP (VB help) (PP (IN in) (NP (NP (NN diagnosis)) (PP (IN of) (NP (NNP Doc_10219427_1020_1027_Disease))))) (PP (IN in) (NP (DT the) (NNS patients)))))) (. .)))
10327032	0	(S1 (NP (NP (NN Risk)) (PP (IN of) (NP (JJ transient) (JJ hyperammonemic) (NNP Doc_10327032_33_47_Disease))) (PP (IN in) (NP (NP (JJ Doc_10327032_51_57_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (JJ continuous) (NN infusion)) (PP (IN of) (NP (NNP Doc_10327032_103_117_Chemical)))) (PP (IN with) (NP (NP (DT the) (NN complication)) (PP (IN of) (NP (NP (NNP Doc_10327032_143_154_Disease)) (CC and) (NP (NNP Doc_10327032_159_168_Disease))))))))))) (. .)))
10327032	1	(S1 (S (PP (IN From) (NP (CD 1986) (TO to) (CD 1998))) (, ,) (NP (NP (CD 29) (JJ Doc_10327032_192_198_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (CD 32) (NNS episodes)) (PP (IN of) (NP (JJ transient) (JJ hyperammonemic) (NN Doc_10327032_256_270_Disease))) (VP (VBN related) (PP (TO to) (NP (NP (JJ continuous) (NN infusion)) (PP (IN of) (NP (NP (NNP Doc_10327032_305_319_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10327032_321_325_Chemical)) (-RRB- -RRB-)))))))))))) (VP (AUX were) (VP (VBN identified))) (. .)))
10327032	2	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX had) (VP (VBN decompensated) (NP (NNP Doc_10327032_383_396_Disease)))) (. .)))
10327032	3	(S1 (S (NP (NP (NN Onset)) (PP (IN of) (NP (JJ hyperammonemic) (NNP Doc_10327032_422_436_Disease)))) (VP (VBN varied) (PP (IN from) (NP (NP (QP (CD 0.5) (TO to) (CD 5)) (NNS days)) (PRN (-LRB- -LRB-) (NP (NP (NN mean)) (: :) (NP (QP (CD 2.6) (CD +/-) (CD 1.3)) (NNS days))) (-RRB- -RRB-)))) (PP (IN after) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NN chemotherapy)))))) (. .)))
10327032	4	(S1 (S (NP (NN Plasma) (JJ Doc_10327032_533_541_Chemical) (NN level)) (VP (VBD ranged) (PP (IN from) (NP (NP (QP (CD 248) (TO to) (CD 2387) (NN microg)) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NN mean)) (: :) (NP (CD 626) (NN +/-) (CD 431) (NN microg) (NN %))) (-RRB- -RRB-))))) (. .)))
10327032	5	(S1 (S (PP (IN Among) (NP (DT the) (CD 32) (NNS episodes))) (, ,) (NP (NP (CD 26)) (PRN (-LRB- -LRB-) (NP (CD 81) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NP (JJ various) (NNS degrees)) (PP (IN of) (NP (NP (NNP Doc_10327032_664_672_Disease)) (, ,) (NP (NP (NP (CD 18)) (PRN (-LRB- -LRB-) (NP (CD 56) (NN %)) (-RRB- -RRB-)) (VP (VBD occurred) (PP (IN during) (NP (NNP Doc_10327032_699_719_Disease))))) (CC and) (NP (NP (CD 14)) (PRN (-LRB- -LRB-) (NP (CD 44) (NN %)) (-RRB- -RRB-))))))) (SBAR (IN without) (S (NP (NNP Doc_10327032_741_750_Disease)) (VP (VBD occurred) (PP (IN during) (NP (NP (NNS periods)) (PP (IN of) (NP (NNP Doc_10327032_778_789_Disease))))))))) (. .)))
10327032	6	(S1 (S (NP (NP (JJR Higher) (NN plasma) (NN Doc_10327032_805_813_Chemical) (NNS levels)) (CC and) (NP (NP (JJR more) (JJ rapid) (NN onset)) (PP (IN of) (NP (NNP Doc_10327032_845_859_Disease))))) (VP (AUX were) (VP (VBN seen) (PP (PP (IN in) (NP (NP (CD 18) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_10327032_890_910_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD p=0.003)) (CC and) (NP (CD 0.0006))) (, ,) (NP (RB respectively))) (-RRB- -RRB-)))))) (CC and) (PP (IN in) (NP (NP (CD nine) (NNS patients)) (VP (VBG receiving) (NP (NP (JJ high) (JJ daily) (NNS doses)) (PRN (-LRB- -LRB-) (NP (QP (CD 2600) (CC or) (CD 1800)) (NNS mg/m2)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NNP Doc_10327032_1018_1022_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD p=0.0001)) (CC and) (NP (QP (CD <) (CD 0.0001)))) (, ,) (NP (RB respectively))) (-RRB- -RRB-))))))))))) (. .)))
10327032	7	(S1 (S (PP (IN In) (NP (NP (CD 25) (NN out)) (PP (IN of) (NP (NP (CD 32) (NNS episodes)) (PRN (-LRB- -LRB-) (NP (CD 78) (NN %)) (-RRB- -RRB-)))))) (, ,) (NP (NP (NN plasma) (NN Doc_10327032_1101_1109_Chemical) (NNS levels)) (CC and) (NP (JJ mental) (NN status))) (VP (VBD returned) (PP (TO to) (NP (JJ normal))) (PP (IN within) (NP (CD 2) (NNS days))) (PP (IN after) (NP (JJ adequate) (NN management)))) (. .)))
10327032	8	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (JJ hyperammonemic) (NN Doc_10327032_1225_1239_Disease)) (VP (MD can) (VP (VB occur) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ continuous) (NN infusion)) (PP (IN of) (NP (NNP Doc_10327032_1295_1299_Chemical))))))))) (. .)))
10327032	9	(S1 (S (NP (NP (NN Doc_10327032_1301_1309_Disease)) (, ,) (NP (NN body) (NN fluid) (NN insufficiency)) (CC and) (NP (NNP Doc_10327032_1340_1360_Disease))) (VP (AUX were) (ADVP (RB frequently)) (VP (VBN found) (PP (IN in) (NP (DT these) (NNS patients))))) (. .)))
10327032	10	(S1 (S (NP (PRP It)) (VP (AUX is) (ADVP (RB therefore)) (ADJP (JJ important)) (S (VP (TO to) (VP (VB recognize) (NP (DT this) (NN condition)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ continuous) (NN infusion)) (PP (IN of) (NP (NNP Doc_10327032_1501_1505_Chemical))))))))))) (. .)))
10390729	0	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_10390729_15_22_Chemical)) (CC and) (NP (NNP Doc_10390729_27_42_Chemical)))) (PP (IN on) (NP (NP (VBN conditioned) (NN place) (NN preference)) (CC and) (NP (NP (NNS changes)) (PP (IN in) (NP (NN motor) (NN activity))))))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_10390729_116_124_Chemical))) (PP (IN in) (NP (NN rats.) (CD 1)))) (. .)))
10390729	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (CD two) (JJ unselective) (NNP Doc_10390729_168_177_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_10390729_179_183_Chemical-)) (-RRB- -RRB-)) (NN channel) (NNS blockers)) (, ,) (NP (NP (NP (NNP Doc_10390729_204_211_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 12.5) (, ,) (CD 25) (CC and) (CD 50) (NNS mg/kg)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_10390729_240_255_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CC and) (CD 2) (CD mg/kg))) (-RRB- -RRB-)))) (, ,))) (PP (IN on) (NP (NP (VBN conditioned) (NN place) (NN preference)) (CC and) (NP (NP (JJ biphasic) (NNS changes)) (PP (IN in) (NP (NP (NN motor) (NN activity)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_10390729_355_363_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10) (NNS mg/kg)) (-RRB- -RRB-))))))))))) (VP (AUX were) (VP (VBN tested) (PP (IN in) (NP (NNP Wistar) (NNS rats))))) (. .)))
10390729	2	(S1 (S (NP (NN Doc_10390729_403_410_Chemical)) (VP (AUX is) (VP (VBN known) (S (VP (TO to) (VP (VB block) (NP (JJ voltage-) (, ,) (JJ Doc_10390729_439_446_Chemical-) (CC and) (JJ Doc_10390729_452_455_Chemical-sensitive) (NNS Doc_10390729_466_470_Chemical-channels)) (SBAR (IN while) (S (NP (NNP Doc_10390729_486_501_Chemical)) (VP (AUX is) (VP (VBN known) (S (VP (TO to) (VP (VB block) (NP (JJ voltage-sensitive) (NNP Doc_10390729_538_542_Chemical-channels.) (CD 2)))))))))))))) (. .)))
10390729	3	(S1 (S (PP (IN In) (NP (DT the) (VBN counterbalanced) (NN method))) (, ,) (NP (NNP Doc_10390729_587_594_Chemical)) (VP (VBD attenuated) (NP (JJ Doc_10390729_606_614_Chemical-induced) (NN place) (NN preference)) (, ,) (SBAR (IN whereas) (S (NP (NNP Doc_10390729_649_664_Chemical)) (VP (AUX was) (ADJP (JJ ineffective)))))) (. .)))
10390729	4	(S1 (S (S (PP (IN In) (NP (NP (DT the) (NN motor) (NN activity) (NN test)) (VP (VBN measured) (PP (IN with) (NP (DT an) (JJ Animex-activity) (NN meter)))))) (NP (NP (DT neither)) (PP (IN of) (NP (DT the) (JJ Doc_10390729_763_767_Chemical-channel) (NNS blockers)))) (VP (VBD affected) (NP (JJ Doc_10390729_794_802_Chemical-induced) (NNP Doc_10390729_811_823_Disease)))) (, ,) (CC but) (S (NP (DT both) (JJ Doc_10390729_834_838_Chemical-channel) (NNS blockers)) (VP (VBD prevented) (ADJP (JJ Doc_10390729_866_874_Chemical-induced)) (NP (JJ secondary) (NNP Doc_10390729_893_906_Disease.) (CD 3)))) (. .)))
10390729	5	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (ADJP (ADJP (JJ Doc_10390729_952_959_Chemical-sensitive)) (CC but) (ADJP (RB not) (JJ Doc_10390729_978_993_Chemical-sensitive))) (NNS Doc_10390729_1004_1008_Chemical-channels))) (PP (IN in) (NP (JJ Doc_10390729_1021_1029_Chemical) (NN reward))))) (. .)))
10390729	6	(S1 (S (NP (PRP It)) (VP (AUX is) (ADVP (RB also)) (VP (VBN suggested) (SBAR (IN that) (S (NP (NP (DT the) (NN blockade)) (PP (IN of) (NP (NP (NNS Doc_10390729_1080_1084_Chemical-channels)) (ADJP (JJ sensitive) (PP (TO to) (NP (DT these) (NNS blockers))))))) (VP (AUX is) (RB not) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB prevent) (NP (JJ Doc_10390729_1151_1159_Chemical-induced) (NN Doc_10390729_1168_1180_Disease)) (SBAR (IN whereas) (S (NP (NNP Doc_10390729_1189_1197_Chemical-induced) (NNP Doc_10390729_1206_1219_Disease)) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (VP (VBN connected) (PP (TO to) (NP (DT both) (JJ Doc_10390729_1250_1257_Chemical-) (CC and) (JJ Doc_10390729_1263_1278_Chemical-sensitive) (NNS Doc_10390729_1289_1293_Chemical-channels))))))))))))))))))) (. .)))
10401555	0	(S1 (NP (NP (NP (NP (NNP Doc_10401555_0_10_Chemical/orphanin) (NNP FQ) (CC and) (NNP Doc_10401555_27_37_Chemical)) (PP (IN on) (NP (NN learning)))) (CC and) (NP (NNP Doc_10401555_54_71_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_10401555_83_94_Chemical))) (PP (IN in) (NP (NNP mice.) (CD 1)))) (. .)))
10401555	1	(S1 (S (NP (NP (NNP Doc_10401555_107_117_Chemical)) (, ,) (VP (ADVP (RB also)) (VBN known) (PP (IN as) (NP (JJ orphanin) (NNS FQ)))) (, ,)) (VP (VP (AUX is) (NP (NP (DT an) (JJ endogenous) (NN ligand)) (PP (IN for) (NP (DT the) (JJ orphan) (JJ opioid) (JJ receptor-like) (NN receptor)))) (NP (NP (CD 1)) (PRN (-LRB- -LRB-) (NP (NNP ORL1)) (-RRB- -RRB-)))) (CC and) (VP (VBZ involves) (PP (IN in) (NP (NP (JJ various) (NNS functions)) (PP (IN in) (NP (NP (DT the) (JJ central) (JJ nervous) (NN system)) (PRN (-LRB- -LRB-) (NP (NNP CNS)) (-RRB- -RRB-)))))))) (. .)))
10401555	2	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NNP Doc_10401555_314_324_Chemical)) (VP (AUX is) (ADVP (RB recently)) (VP (VBN isolated) (PP (IN from) (NP (DT the) (JJ same) (NN precursor))) (PP (IN as) (NP (NP (NNP Doc_10401555_373_383_Chemical)) (CC and) (NP (NNS blocks) (NNP Doc_10401555_395_405_Chemical-induced) (NNP Doc_10401555_414_423_Disease) (CC and) (NNP Doc_10401555_428_440_Disease.) (CD 2)))))) (. .)))
10401555	3	(S1 (S (SBAR (IN Although) (S (NP (NP (JJ ORL1) (NNS receptors)) (SBAR (WHNP (WDT which)) (S (VP (VBP display) (NP (NP (DT a) (JJ high) (NN degree)) (PP (IN of) (NP (NP (NN sequence) (NN homology)) (PP (IN with) (NP (JJ classical) (JJ opioid) (NNS receptors)))))))))) (VP (AUX are) (ADJP (JJ abundant)) (PP (IN in) (NP (DT the) (NN hippocampus)))))) (, ,) (NP (RB little)) (VP (AUX is) (VP (VBN known) (S (VP (VBG regarding) (NP (NP (PRP$ their) (NN role)) (PP (IN in) (S (VP (VBG learning) (CC and) (VBG memory.) (NP (CD 3)))))))))) (. .)))
10401555	4	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB investigate) (SBAR (IN whether) (S (NP (NNP Doc_10401555_701_711_Chemical/orphanin) (NNP FQ) (CC and) (NNP Doc_10401555_728_738_Chemical)) (VP (MD could) (VP (VBP modulate) (S (NP (NNP Doc_10401555_754_787_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_10401555_799_810_Chemical)) (, ,) (NP (DT a) (JJ muscarinic) (JJ cholinergic) (NN receptor) (NN antagonist)))) (, ,) (S (VP (VBG using) (NP (NP (JJ spontaneous) (NN alternation)) (PP (IN of) (NP (NP (ADJP (JJ Y-maze) (CC and) (JJ step-down)) (NN type) (NN passive) (NN avoidance) (NNS tasks)) (PP (IN in) (NP (NNP mice.) (CD 4))))))))))))))))))) (. .)))
10401555	5	(S1 (S (SBAR (IN While) (S (NP (NP (NNP Doc_10401555_959_969_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.5-5.0) (NN nmol) (NN mouse-1)) (, ,) (NP (CD i.c.v.)) (-RRB- -RRB-)) (VP (VBN administered) (PP (NP (CD 30) (NN min)) (IN before) (NP (NP (JJ spontaneous) (JJ alternation) (NN performance)) (CC or) (NP (NP (DT the) (NN training) (NN session)) (PP (IN of) (NP (DT the) (JJ passive) (NN avoidance) (NN task))))))) (, ,)) (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (JJ spontaneous) (NN alternation)) (CC or) (NP (JJ passive) (NN avoidance) (NNS behaviours)))))))) (, ,) (NP (NP (DT a) (ADJP (ADJP (JJR lower) (PP (IN per) (NP (NN cent) (NN alternation)))) (CC and) (ADJP (JJR shorter))) (JJ median) (JJ step-down) (NN latency)) (PP (IN in) (NP (DT the) (NN retention) (NN test)))) (VP (AUX were) (VP (VBN obtained) (PP (IN in) (NP (NP (NNP Doc_10401555_1298_1308_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1.5) (NN and/or) (CD 5.0) (NN nmol) (NN mouse-1)) (, ,) (NP (NNP i.c.v.)) (-RRB- -RRB-)))) (NP (JJ -treated) (JJ normal) (FW mice.) (CD 5)))) (. .)))
10401555	6	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (NNP Doc_10401555_1389_1399_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1.5) (NN and/or) (CD 5.0) (NN nmol) (NN mouse-1)) (, ,) (NP (CD i.c.v.)) (-RRB- -RRB-)) (NP (NP (CD 30) (NN min)) (PP (IN before) (NP (NP (JJ spontaneous) (JJ alternation) (NN performance)) (CC or) (NP (NP (DT the) (NN training) (NN session)) (PP (IN of) (NP (DT the) (JJ passive) (NN avoidance) (NN task))))))) (, ,)))) (VP (VBD attenuated) (NP (DT the) (JJ Doc_10401555_1558_1569_Chemical-induced) (NNP Doc_10401555_1578_1648_Disease.) (CD 6))) (. .)))
10401555	7	(S1 (S (NP (DT These) (NNS results)) (VP (VP (VBD indicated) (SBAR (IN that) (S (NP (NP (NNP Doc_10401555_1682_1692_Chemical)) (, ,) (NP (DT a) (JJ new) (ADJP (RB biologically) (JJ active)) (NN peptide)) (, ,) (NP (NP (NNP Doc_10401555_1729_1752_Disease)) (PP (IN of) (NP (JJ spontaneous) (NN alternation) (CC and) (NN passive) (NN avoidance))))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_10401555_1813_1824_Chemical))))))) (, ,) (CC and) (VP (VBD suggested) (SBAR (IN that) (S (NP (DT these) (NNS peptides)) (VP (VB play) (NP (JJ opposite) (NNS roles)) (PP (IN in) (NP (NP (NN learning)) (CC and) (NP (NN memory))))))))) (. .)))
10427794	0	(S1 (FRAG (NP (JJ Doc_10427794_0_9_Chemical-induced) (NN liver) (NN Doc_10427794_24_32_Disease)) (. .)))
10427794	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ female) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_10427794_78_98_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_10427794_113_138_Disease)) (PP (JJ due) (TO to) (NP (NNP Doc_10427794_146_155_Chemical)))))))))))) (. .)))
10427794	2	(S1 (S (S (ADVP (RB Recently)) (VP (VBN introduced) (PP (IN in) (NP (NNP Belgium))))) (, ,) (NP (NNP Doc_10427794_189_198_Chemical)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN nonsteroidal) (NN antiinflammatory) (NN drug)) (PP (IN with) (NP (NP (JJ selective) (NN action)) (PP (IN on) (NP (NP (DT the) (JJ inducible) (NN form)) (PP (IN of) (NP (NN cyclooxygenase) (CD 2))))))))) (. .)))
10427794	3	(S1 (S (NP (DT The) (NN Doc_10427794_316_341_Disease)) (VP (VP (VBD occurred) (ADVP (RB rapidly)) (PP (IN after) (NP (NNP Doc_10427794_365_374_Chemical) (NN administration)))) (CC and) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (JJ antinuclear) (NNS antibodies)) (VP (VBG suggesting) (NP (DT a) (JJ Doc_10427794_469_485_Disease) (NN mechanism)))))))))) (. .)))
10427794	4	(S1 (S (NP (NP (DT This) (JJ first) (NN case)) (PP (IN of) (NP (JJ Doc_10427794_516_525_Chemical) (JJ related) (NN liver) (NN Doc_10427794_540_548_Disease)))) (VP (VBZ demonstrates) (NP (NP (DT the) (NN potential)) (PP (IN of) (NP (DT this) (NN drug))) (S (VP (TO to) (VP (VB induce) (NP (NN Doc_10427794_599_613_Disease))))))) (. .)))
10462057	0	(S1 (NP (NP (NP (NN Induction)) (PP (IN of) (NP (NN apoptosis))) (PP (IN by) (NP (NP (NP (NNP Doc_10462057_26_37_Chemical) (NNS metabolites)) (PP (IN in) (NP (CD HL60)))) (CC and) (NP (JJ CD34+/CD19-) (JJ human) (NN bone) (NN marrow) (NN progenitor) (NNS cells))))) (: :) (NP (NP (JJ potential) (NN relevance)) (PP (TO to) (NP (NNP Doc_10462057_133_144_Chemical-induced) (NNP Doc_10462057_153_168_Disease)))) (. .)))
10462057	1	(S1 (S (NP (DT The) (JJ antipsychotic) (NN agent) (, ,) (JJ Doc_10462057_195_206_Chemical) (JJ -LSB-Doc_10462057_208_282_Chemical) (NN -RSB-)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (VBN acquired) (NN Doc_10462057_318_333_Disease)))))) (. .)))
10462057	2	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN examined) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NP (NNP Doc_10462057_367_378_Chemical)) (, ,) (NP (CD three) (JJ Doc_10462057_386_397_Chemical) (NN ring) (NNS metabolites)) (CC and) (NP (NP (CD five) (JJ aromatic) (NN ring) (NNS metabolites)) (PP (IN of) (NP (DT the) (NN parent) (NN compound)))))) (S (VP (TO to) (VP (VB induce) (NP (NN apoptosis)) (PP (IN in) (NP (NP (CD HL60) (NNS cells)) (CC and) (NP (JJ human) (NN bone) (NN marrow) (NN progenitor) (-LRB- -LRB-) (NN HBMP) (-RRB- -RRB-) (NNS cells)))))))))) (. .)))
10462057	3	(S1 (S (NP (NNS Cells)) (VP (AUX were) (VP (VBN treated) (PP (IN for) (S (VP (VBG 0-24) (NP (NNP h)) (PP (IN with) (NP (NP (DT each) (JJ compound)) (PRN (-LRB- -LRB-) (NP (CD 0-200) (NN microM)) (-RRB- -RRB-))))))))) (. .)))
10462057	4	(S1 (S (NP (NN Apoptosis)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (NP (NP (NN fluorescence) (NN microscopy)) (PP (IN in) (NP (NP (NNP Doc_10462057_672_686_Chemical)) (CC and) (NP (JJ Doc_10462057_691_707_Chemical) (JJ stained) (NN cell) (NNS samples)))))))) (. .)))
10462057	5	(S1 (S (NP (NNS Results)) (VP (AUX were) (VP (VBN confirmed) (PP (IN by) (NP (NP (NN determination)) (PP (IN of) (NP (NP (JJ internucleosomal) (NN DNA) (NN fragmentation)) (VP (VBG using) (NP (JJ gel) (NNS electrophoresis)) (PP (IN for) (NP (NP (CD HL60) (NN cell) (NNS samples) (CC and) (NN terminal) (NN deoxynucleotidyl) (NN transferase) (NN assay)) (PP (IN in) (NP (JJ HBMP) (NNS cells)))))))))))) (. .)))
10462057	6	(S1 (S (NP (NP (DT The) (NNP Doc_10462057_923_931_Chemical) (CC and) (NNP Doc_10462057_936_948_Chemical) (NNS metabolites)) (, ,) (NP (NP (NNP Doc_10462057_962_968_Chemical)) (CC and) (NP (NNP Doc_10462057_973_979_Chemical))) (, ,)) (VP (VBN induced) (NP (NP (NP (NNS apoptosis)) (PP (IN in) (NP (CD HL60)))) (CC and) (NP (NN HBMP) (NNS cells))) (PP (IN in) (NP (DT a) (NN time-) (CC and) (NN concentration) (JJ dependent) (NN manner))) (, ,) (SBAR (IN while) (S (NP (NP (DT the) (NAC (NNP Doc_10462057_1079_1086_Chemical) (, ,) (NNP Doc_10462057_1088_1094_Chemical) (, ,)) (NNP Doc_10462057_1096_1102_Chemical)) (, ,) (CC and) (NP (NNP Doc_10462057_1108_1114_Chemical)) (, ,) (CC and) (NP (NP (DT the) (NNS derivatives)) (VP (VBN formed) (PP (IN by) (NP (NP (NN oxidation)) (PP (IN of) (NP (DT the) (JJ Doc_10462057_1163_1174_Chemical) (NN ring))))))) (, ,) (NP (NNP Doc_10462057_1181_1187_Chemical)) (, ,) (NP (CD NCM001)) (, ,) (CC and) (NP (CD NCL118)) (, ,)) (VP (AUX had) (NP (DT no) (NN effect)))))) (. .)))
10462057	7	(S1 (S (S (NP (DT No) (NN Doc_10462057_1227_1235_Disease)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NNS cells))) (PP (VBN treated) (PP (IN with) (NP (NNP Doc_10462057_1271_1277_Chemical))))))) (CC but) (S (NP (NNP Doc_10462057_1282_1288_Chemical)) (VP (AUX had) (NP (DT a) (JJ biphasic) (NN effect)) (PP (IN in) (NP (DT both) (NN cell) (NNS types))) (, ,) (S (VP (VBG inducing) (NP (NP (NP (NN apoptosis)) (PP (IN at) (NP (JJR lower) (NNS concentrations)))) (CC and) (NP (NP (NN Doc_10462057_1378_1386_Disease)) (PP (IN at) (NP (JJR higher) (NNS concentrations))))))))) (. .)))
10462057	8	(S1 (S (NP (DT These) (NNS data)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (NNP Doc_10462057_1438_1446_Chemical) (CC and) (NNP Doc_10462057_1451_1463_Chemical) (NNS metabolites)) (PP (IN of) (NP (NNP Doc_10462057_1479_1490_Chemical)))) (VP (AUX have) (NP (JJ direct) (JJ toxic) (NNS effects)) (PP (IN in) (NP (CD HL60) (CC and) (JJ HBMP) (NNS cells))) (, ,) (PP (VBG leading) (PP (TO to) (NP (NN apoptosis)))) (, ,) (SBAR (IN while) (S (NP (DT the) (JJ Doc_10462057_1573_1579_Chemical) (NNS metabolites)) (VP (AUX were) (ADJP (JJ inactive))))))))) (. .)))
10462057	9	(S1 (S (ADVP (RB Similarly)) (, ,) (NP (NP (NNP Doc_10462057_1618_1625_Chemical-derived) (NNP Doc_10462057_1634_1642_Chemical) (CC and) (NNP Doc_10462057_1647_1659_Chemical)) (, ,) (CONJP (CC but) (RB not)) (NP (NNP Doc_10462057_1669_1675_Chemical)) (, ,)) (VP (VB induce) (NP (NN apoptosis)) (PP (IN in) (NP (NP (NP (JJ HBMP) (NNS cells)) (ADJP (JJ -LSB-Moran) (CC et) (JJ al.))) (, ,) (NP (NNP Mol))))) (. .)))
10462057	10	(S1 (NP (NP (NNP Pharmacol.)) (, ,) (NP (CD 50) (-LRB- -LRB-) (CD 1996) (-RRB- -RRB-) (NN 610-615) (NN -RSB-)) (. .)))
10462057	11	(S1 (S (NP (PRP We)) (VP (VB propose) (SBAR (SBAR (IN that) (S (NP (NNP Doc_10462057_1776_1787_Chemical) (CC and) (NNP Doc_10462057_1792_1799_Chemical)) (VP (MD may) (VP (VB induce) (NP (NNP Doc_10462057_1811_1826_Disease)) (PP (IN via) (NP (NP (NN production)) (PP (IN of) (NP (JJ similar) (JJ reactive) (NNS metabolites))))))))) (CC and) (SBAR (IN that) (S (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NNP Doc_10462057_1898_1904_Chemical) (CC and) (NNP Doc_10462057_1909_1915_Chemical))) (S (VP (TO to) (VP (VB induce) (NP (NN apoptosis)) (PP (IN in) (NP (JJ HBMP) (NNS cells))))))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (NN mechanism)) (VP (VBG underlying) (NP (NP (VBN acquired) (NN Doc_10462057_2002_2017_Disease)) (SBAR (WHNP (WDT that)) (S (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_10462057_2048_2059_Chemical)))))))))))))))))) (. .)))
10510854	0	(S1 (NP (NP (NP (NN Synthesis)) (CC and) (NP (JJ preliminary) (NN pharmacological) (NNS investigations))) (PP (IN of) (NP (NP (JJ Doc_10510854_60_103_Chemical) (NNS derivatives)) (PP (IN as) (NP (NP (JJ potential) (JJ atypical) (NN antipsychotic) (NNS agents)) (PP (IN in) (NP (NNS mice))))))) (. .)))
10510854	1	(S1 (S (PP (IN In) (NP (NP (NN research)) (PP (IN towards) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ new) (JJ atypical) (NN antipsychotic) (NNS agents))))))) (, ,) (NP (CD one) (NN strategy)) (VP (AUX is) (SBAR (IN that) (S (NP (DT the) (JJ dopaminergic) (NN system)) (VP (MD can) (VP (AUX be) (VP (VBN modulated) (PP (IN through) (NP (NP (NN manipulation)) (PP (IN of) (NP (DT the) (JJ serotonergic) (NN system))))))))))) (. .)))
10510854	2	(S1 (S (NP (NP (NP (DT The) (NN synthesis)) (CC and) (NP (JJ preliminary) (JJ pharmacological) (NN evaluation))) (PP (IN of) (NP (NP (DT a) (NN series)) (PP (IN of) (NP (JJ potential) (JJ atypical) (JJ antipsychotic) (NNS agents))) (VP (VBN based) (PP (IN on) (NP (NP (DT the) (NN structure)) (PP (IN of) (NP (NNP Doc_10510854_491_534_Chemical))))))))) (PRN (-LRB- -LRB-) (NP (CD 7)) (-RRB- -RRB-)) (VP (AUX is) (VP (VBN described))) (. .)))
10510854	3	(S1 (S (NP (NP (NP (NN Compound) (NN 7e)) (, ,) (NP (NNP Doc_10510854_566_652_Chemical)) (, ,)) (PP (IN from) (NP (DT this) (NN series)))) (VP (VBD showed) (NP (NP (NP (JJ significant) (NNS affinities)) (PP (IN at) (NP (DT the) (JJ 5-HT1A) (CC and) (JJ 5-HT2A) (NNS receptors)))) (CC and) (NP (NP (JJ moderate) (NN affinity)) (PP (IN at) (NP (DT the) (NNP D2) (NN receptor.) (NN 7e) (NNS exhibits))))) (NP (NP (DT a) (JJ high) (NN reversal)) (PP (IN of) (NP (NP (NNP Doc_10510854_809_818_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_10510854_830_841_Chemical))))))) (S (VP (VBG indicating) (NP (PRP$ its) (JJ atypical) (JJ antipsychotic) (NN nature))))) (. .)))
10672628	0	(S1 (S (NP (NP (JJ Sub-chronic) (NN inhibition)) (PP (IN of) (NP (JJ Doc_10672628_26_38_Chemical) (NN synthesis)))) (VP (VBZ modifies) (NP (NP (JJ Doc_10672628_58_69_Chemical-induced) (NN Doc_10672628_78_87_Disease)) (CC and) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (JJ Doc_10672628_106_111_Chemical-diaphorase) (NNS neurons))) (PP (IN in) (NP (NNS mice)))))) (. .)))
10672628	1	(S1 (S (NP (NP (NP (NNP Doc_10672628_151_170_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10672628_172_179_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NP (JJ Doc_10672628_198_210_Chemical) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NNP NOS)) (-RRB- -RRB-))))) (, ,)) (VP (VBZ induces) (NP (NNP Doc_10672628_235_244_Disease)) (PP (IN in) (NP (NNS mice)))) (. .)))
10672628	2	(S1 (S (NP (DT This) (NN effect)) (VP (VBZ undergoes) (NP (JJ rapid) (NN tolerance)) (, ,) (S (VP (VBG showing) (NP (DT a) (JJ significant) (NN decrease)) (PP (IN after) (NP (NP (CD 2) (NNS days)) (PP (IN of) (NP (JJ sub-chronic) (JJ Doc_10672628_352_359_Chemical) (NN treatment)))))))) (. .)))
10672628	3	(S1 (S (NP (NP (NN Doc_10672628_371_383_Chemical)) (PRN (-LRB- -LRB-) (NP (DT NO)) (-RRB- -RRB-))) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VB influence) (NP (JJ dopaminergic) (NN neurotransmission)) (PP (IN in) (NP (DT the) (NN striatum))))))))) (. .)))
10672628	4	(S1 (S (NP (NP (JJ Neuroleptic) (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_10672628_491_502_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP block) (NP (JJ Doc_10672628_516_524_Chemical) (NNS receptors))))) (, ,)))) (ADVP (RB also)) (VP (VBP cause) (NP (NP (NN Doc_10672628_547_556_Disease)) (PP (IN in) (NP (NNS rodents))))) (. .)))
10672628	5	(S1 (S (S (VP (TO To) (VP (VB investigate) (NP (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ subchronic) (JJ Doc_10672628_622_629_Chemical) (NN treatment)) (PP (IN in) (NP (NNP Doc_10672628_643_654_Chemical-induced) (NNP Doc_10672628_663_672_Disease)))))) (CC and) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NNS NOS)))))))) (VP (VBZ neurons) (PP (IN in) (NP (NP (NNS areas)) (VP (VBN related) (PP (TO to) (NP (NN motor) (NN control))))))) (. .)))
10672628	6	(S1 (S (NP (JJ Male) (JJ albino) (JJ Swiss) (NNS mice)) (VP (AUX were) (VP (VBN treated) (ADVP (RB sub-chronically)) (PRN (-LRB- -LRB-) (ADVP (RB twice)) (NP (NP (DT a) (NN day)) (PP (IN for) (NP (CD 4) (NNS days)))) (-RRB- -RRB-)) (PP (IN with) (NP (NP (NP (NNP Doc_10672628_829_836_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 40) (CD mg/kg)) (NN i.p.)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_10672628_856_867_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CD mg/kg)) (NN i.p.)) (-RRB- -RRB-))))))) (. .)))
10672628	7	(S1 (S (NP (NN Doc_10672628_884_893_Disease)) (VP (AUX was) (VP (VBN evaluated) (PP (IN at) (NP (NP (NP (DT the) (NN beginning)) (CC and) (NP (DT the) (NN end))) (PP (IN of) (NP (DT the) (NNS treatments))))))) (. .)))
10672628	8	(S1 (S (NP (NP (JJ Reduced) (NNP Doc_10672628_964_1007_Chemical-diaphorase)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10672628_1020_1025_Chemical-d)) (-RRB- -RRB-))) (ADVP (RB histochemistry)) (VP (AUX was) (ADVP (RB also)) (VP (VBN employed) (S (VP (TO to) (VP (VB visualize) (NP (NNS NOS)) (PP (IN as) (NP (NP (DT an) (NN index)) (PP (IN of) (NP (NP (JJ enzyme) (NN expression)) (PP (IN in) (NP (NP (NNS mice) (NN brain) (NNS regions)) (VP (VBN related) (PP (TO to) (NP (NN motor) (NN control))))))))))))))) (. .)))
10672628	9	(S1 (S (NP (JJ Doc_10672628_1169_1176_Chemical) (JJ sub-chronic) (NN administration)) (VP (VBD produced) (NP (NP (NN tolerance)) (PP (PP (IN of) (NP (NNP Doc_10672628_1226_1233_Chemical))) (CC and) (PP (IN of) (NP (NNP Doc_10672628_1241_1252_Chemical-induced) (NNP Doc_10672628_1261_1270_Disease)))))) (. .)))
10672628	10	(S1 (S (NP (PRP It)) (ADVP (RB also)) (VP (VP (VBN induced) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (JJ Doc_10672628_1317_1322_Chemical-d-positive) (NNS cells)))))) (PP (IN in) (NP (NP (DT the) (JJ dorsal) (NN part)) (PP (IN of) (NP (DT the) (NN caudate)))))) (CC and) (VP (VBZ accumbens) (NP (NP (NNS nuclei)) (PP (VBN compared) (PP (IN with) (NP (NNP Doc_10672628_1409_1420_Chemical))) (CC and) (PP (IN in) (NP (DT the) (JJ pedunculopontine) (JJ tegmental) (NN nucleus))))) (PP (VBN compared) (PP (IN with) (NP (NN saline)))))) (. .)))
10672628	11	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (JJ Doc_10672628_1526_1531_Chemical-d) (NN neuron) (NN number))) (PP (IN in) (NP (DT the) (NN substantia) (NN nigra)))) (, ,) (NP (NP (NNS pars) (NN compacta)) (PP (IN in) (NP (DT both) (JJ Doc_10672628_1595_1606_Chemical-treated) (CC and) (JJ Doc_10672628_1619_1626_Chemical-treated) (NNS animals)))))) (. .)))
10672628	12	(S1 (S (NP (DT The) (NNS results)) (VP (VP (VBP give) (NP (JJ further) (NN support)) (PP (TO to) (NP (NP (DT the) (NNS hypothesis)) (SBAR (WHNP (WDT that)) (S (ADVP (RB NO)) (VP (VBZ plays) (NP (NP (DT a) (NN role)) (PP (IN in) (NP (NN motor) (NN behavior) (NN control)))))))))) (CC and) (VP (VBP suggest) (SBAR (IN that) (S (NP (PRP it)) (VP (MD may) (VP (VB take) (NP (NN part)) (PP (IN in) (NP (NP (DT the) (JJ synaptic) (NNS changes)) (VP (VBN produced) (PP (IN by) (NP (JJ antipsychotic) (NN treatment)))))))))))) (. .)))
10677406	0	(S1 (S (NP (NN Doc_10677406_0_38_Disease)) (VP (VBZ occurs) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10677406_63_86_Disease))))) (PP (IN after) (NP (NP (DT both) (NNP Doc_10677406_98_108_Chemical)) (CC and) (NP (NP (NN exercise)) (VP (VBN induced) (NP (NNP Doc_10677406_130_150_Disease))))))) (. .)))
10677406	1	(S1 (FRAG (S (VP (TO To) (VP (VB determine) (SBAR (IN whether) (S (NP (JJ pharmacological) (NN stress)) (VP (VBZ leads) (PP (TO to) (NP (NP (ADJP (JJ prolonged) (CC but) (JJ reversible)) (NN Doc_10677406_241_269_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10677406_287_310_Disease))))) (, ,) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (VP (VBN seen) (PP (IN after) (NP (NN exercise))))))))))))))) (. .)))
10677406	2	(S1 (S (NP (NP (DT A) (JJ randomised) (NN crossover) (NN study)) (PP (IN of) (NP (NP (NN recovery) (NN time)) (PP (IN of) (NP (NN systolic) (CC and) (NN diastolic)))))) (VP (VBD left) (NP (NN ventricular) (NN function)) (PP (IN after) (NP (NP (NN exercise)) (CC and) (NP (JJ Doc_10677406_474_484_Chemical) (VBN induced) (NN ischaemia))))) (. .)))
10677406	3	(S1 (S (NP (NP (CD 10) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_10677406_531_544_Disease)) (, ,) (NP (ADJP (RB angiographically) (VBN proven)) (NNP Doc_10677406_570_593_Disease)) (, ,) (CC and) (NP (JJ normal) (NN left) (NN ventricular))))) (VP (VBP function)) (. .)))
10677406	4	(S1 (S (NP (NP (JJ Treadmill) (NN exercise)) (CC and) (NP (JJ Doc_10677406_671_681_Chemical) (NN stress))) (VP (AUX were) (VP (VBN performed) (PP (IN on) (NP (JJ different) (NNS days))))) (. .)))
10677406	5	(S1 (S (NP (NP (NP (JJ Quantitative) (NN assessment)) (PP (IN of) (NP (NN systolic)))) (CC and) (NP (JJ diastolic) (JJ left) (NN ventricular) (NN function))) (VP (AUX was) (VP (VBN performed) (S (VP (VBG using) (NP (JJ transthoracic) (NN echocardiography)) (PP (PP (IN at) (NP (NN baseline))) (CC and) (PP (IN at) (NP (JJ regular) (NNS intervals)))) (PP (IN after) (NP (DT each) (NN test))))))) (. .)))
10677406	6	(S1 (S (NP (NP (DT Both) (NNS forms)) (PP (IN of) (NP (NN stress)))) (VP (VBD led) (PP (TO to) (NP (ADJP (JJ prolonged) (CC but) (JJ reversible)) (NNP Doc_10677406_966_1000_Disease)))) (. .)))
10677406	7	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN difference)) (PP (IN in) (NP (NP (NP (DT the) (JJ maximum) (JJ double) (NN product)) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (SYM =) (NP (CD 0.53)))) (-RRB- -RRB-))) (CC or) (NP (NP (NNP ST) (NNP Doc_10677406_1073_1083_Disease)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.63)) (-RRB- -RRB-))))) (PP (IN with) (NP (NP (DT either) (NN form)) (PP (IN of) (NP (NN stress))))))) (. .)))
10677406	8	(S1 (S (PP (IN After) (NP (NN exercise))) (, ,) (NP (NN ejection) (NN fraction)) (VP (AUX was) (VP (VBN reduced) (PP (PP (IN at) (NP (NP (QP (CD 15) (CC and) (CD 30)) (NNS minutes)) (PP (VBN compared) (PP (IN with) (NP (NP (NN baseline)) (PRN (-LRB- -LRB-) (S (VP (VB mean) (NP (NP (NP (NP (NP (NP (NP (-LRB- -LRB-) (NNP SEM) (-RRB- -RRB-)) (, ,) (NP (CD -5.6)) (PRN (-LRB- -LRB-) (NP (CD 1.5)) (-RRB- -RRB-))) (NN %)) (, ,) (VP (VBD p) (NP (QP (CD <) (CD 0.05))))) (: ;) (CC and) (NP (NP (CD -6.1)) (PRN (-LRB- -LRB-) (NP (CD 2.2)) (-RRB- -RRB-)))) (NN %)) (, ,) (NP (NP (CD p) (NN <)) (NP (CD 0.) (NNS 01)))))) (-RRB- -RRB-))))))) (, ,) (CC and) (PP (IN at) (NP (NP (CD 30) (CC and) (CD 45) (NNS minutes)) (PP (IN after) (NP (NP (NNP Doc_10677406_1309_1319_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD -10.8) (-LRB- -LRB-) (CD 1.8) (-RRB- -RRB-) (NN %)) (CC and) (NP (QP (CD -5.) (CD 5)) (PRN (-LRB- -LRB-) (NP (CD 1.8)) (-RRB- -RRB-)) (NN %))) (, ,) (NP (DT both) (NNP p) (NNP <) (CD 0.01)) (-RRB- -RRB-))))))))) (. .)))
10677406	9	(S1 (S (NP (JJ Regional) (NN analysis)) (VP (VBD showed) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (DT the) (JJS worst) (JJ affected) (NN segment)))) (NP (NP (NP (QP (CD 15) (CC and) (CD 30)) (NNS minutes)) (PP (IN after) (NP (NP (NN exercise)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD -27.9) (-LRB- -LRB-) (CD 7.2) (-RRB- -RRB-) (NN %)) (CC and) (NP (NP (CD -28.6)) (PRN (-LRB- -LRB-) (NP (CD 5.7)) (-RRB- -RRB-)))) (NN %)) (, ,) (NP (DT both) (NNP p) (NNP <) (CD 0.01))) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (QP (IN at) (CD 30)) (NNS minutes)) (PP (IN after) (NP (NP (NNP Doc_10677406_1540_1550_Chemical)) (PRN (-LRB- -LRB-) (NP (CD -32) (-LRB- -LRB-) (CD 5.3) (-RRB- -RRB-) (NN %)) (, ,) (NP (NNP p) (NNP <) (CD 0.01)) (-RRB- -RRB-))))))) (. .)))
10677406	10	(S1 (S (NP (DT The) (JJ isovolumic) (NN relaxation) (NN period)) (VP (AUX was) (VP (VBN prolonged) (NP (CD 45) (NNS minutes)) (PP (IN after) (NP (NP (DT each) (NN form)) (PP (IN of) (NP (NN stress))))) (PRN (-LRB- -LRB-) (S (NP (NNP p)) (VP (VBD <) (NP (CD 0.05)))) (-RRB- -RRB-)))) (. .)))
10677406	11	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10677406_1701_1724_Disease))))) (, ,) (NP (NNP Doc_10677406_1726_1736_Chemical)) (VP (VBN induced) (NP (NN ischaemia) (NNS results)) (PP (IN in) (NP (NP (VBN prolonged) (JJ reversible) (NN Doc_10677406_1787_1815_Disease)) (, ,) (VP (VBN presumed) (S (VP (TO to) (VP (AUX be) (ADJP (JJ Doc_10677406_1832_1851_Disease)))))) (, ,) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (VP (VBN seen) (PP (IN after) (NP (NN exercise)))))))))) (. .)))
10677406	12	(S1 (S (NP (JJ Doc_10677406_1890_1900_Chemical) (VBN induced) (NNS ischaemia)) (VP (MD could) (ADVP (RB therefore)) (VP (AUX be) (VP (VBN used) (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (DT this) (NN phenomenon)))) (ADVP (RB further)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10677406_2016_2039_Disease))))))))))) (. .)))
10713017	0	(S1 (NP (NP (NP (NP (NNP Anorexigens)) (CC and) (NP (NNP Doc_10713017_16_38_Disease))) (PP (IN in) (NP (DT the) (NNP United) (NNPS States)))) (: :) (NP (NP (NNS results)) (PP (IN from) (NP (NP (DT the) (NN surveillance)) (PP (IN of) (NP (NNP North) (NNP Doc_10713017_100_131_Disease)))))) (. .)))
10713017	1	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NNP Doc_10713017_156_177_Chemical))) (PP (IN in) (NP (NNP Europe)))) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NNP Doc_10713017_232_262_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10713017_264_267_Chemical)) (-RRB- -RRB-))))))))) (. .)))
10713017	2	(S1 (S (ADVP (RB Recently)) (, ,) (NP (NNP Doc_10713017_280_301_Chemical) (NNS suppressants)) (VP (VP (VBD became) (ADJP (RB widely) (JJ used) (PP (IN in) (NP (DT the) (NNP United) (NNPS States))))) (CC but) (VP (AUX were) (VP (VBN withdrawn) (PP (IN in) (NP (NNP September) (CD 1997))) (PP (IN because) (IN of) (NP (NP (NNS concerns)) (PP (IN over) (NP (JJ adverse) (NNS effects)))))))) (. .)))
10713017	3	(S1 (FRAG (NP (NNS MATERIALS) (CC AND) (NNS METHODS)) (: :) (S (NP (PRP We)) (VP (VBD conducted) (NP (DT a) (JJ prospective) (NN surveillance) (NN study)) (PP (IN on) (NP (NP (NNS patients)) (VP (VBN diagnosed) (PP (IN with) (NP (NNP Doc_10713017_530_552_Disease))) (PP (IN at) (NP (NP (CD 12) (JJ large) (NN referral) (NNS centers)) (PP (IN in) (NP (NNP North) (NNP America)))))))))) (. .)))
10713017	4	(S1 (S (NP (NP (NNS Data)) (VP (VBN collected) (PP (IN on) (NP (NP (NNS patients)) (VP (VBN seen) (PP (IN from) (NP (NNP September) (CD 1) (, ,) (CD 1996) (, ,))) (PP (TO to) (NP (NNP December) (CD 31) (, ,) (CD 1997) (, ,)))))))) (VP (VBD included) (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (NP (DT the) (NNP Doc_10713017_704_726_Disease)) (CC and) (NP (PRP$ its) (NN severity)))))) (. .)))
10713017	5	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (DT no) (JJ identifiable) (NN cause)) (PP (IN of) (NP (NNP Doc_10713017_784_806_Disease)))))) (VP (AUX were) (VP (VBN classed) (PP (IN as) (NP (NNP Doc_10713017_823_826_Chemical))))) (. .)))
10713017	6	(S1 (S (NP (NP (DT A) (NN history)) (PP (IN of) (NP (NN drug) (NN exposure)))) (ADVP (RB also)) (VP (AUX was) (VP (VBN taken) (PP (IN with) (NP (JJ special) (NN attention))) (PP (IN on) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NNS antidepressants)) (, ,) (NP (NNS anorexigens)) (, ,) (CC and) (NP (NNP Doc_10713017_941_953_Chemical)))))))) (. .)))
10713017	7	(S1 (S (NP (QP (CD Five) (CD hundred)) (JJ seventy-nine) (NNS patients)) (VP (AUX were) (VP (VBN studied) (, ,) (NP (NP (NP (NP (CD 205)) (PP (IN with) (NP (NNP Doc_10713017_1022_1025_Chemical)))) (CC and) (NP (NP (CD 374)) (PP (IN with) (NP (NNP Doc_10713017_1039_1061_Disease))))) (PP (IN from) (NP (NP (JJ other) (NNS causes)) (PRN (-LRB- -LRB-) (NP (JJ Doc_10713017_1081_1113_Disease) (JJ -LSB-Doc_10713017_1115_1118_Disease) (NNS -RSB-)) (-RRB- -RRB-))))))) (. .)))
10713017	8	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NNS anorexigens)))) (VP (AUX was) (ADJP (JJ common)) (PP (IN in) (NP (DT both) (NNS groups)))) (. .)))
10713017	9	(S1 (S (ADVP (RB However)) (, ,) (PP (IN of) (NP (NP (DT the) (NNS medications)) (VP (VBN surveyed)))) (, ,) (NP (RB only) (DT the) (NNP Doc_10713017_1219_1232_Chemical)) (VP (AUX had) (NP (NP (DT a) (JJ significant) (JJ preferential) (NN association)) (PP (IN with) (NP (NNP Doc_10713017_1281_1284_Chemical)))) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NP (NNP Doc_10713017_1302_1305_Disease)) (PRN (-LRB- -LRB-) (NP (NP (JJ adjusted) (NNS odds) (NN ratio)) (PP (IN for) (NP (NP (NP (NN use) (CD >)) (NP (CD 6) (NNS months))) (, ,) (NP (NP (CD 7.5)) (: ;) (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval)))))) (, ,) (NP (QP (CD 1.7) (TO to) (CD 32.4))) (-RRB- -RRB-)))))))) (. .)))
10713017	10	(S1 (S (NP (DT The) (NN association)) (VP (VP (AUX was) (ADJP (JJR stronger)) (PP (IN with) (NP (NP (JJR longer) (NN duration)) (PP (IN of) (NP (NN use))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NP (JJR shorter) (NN duration)) (PP (IN of) (NP (NN use))))))))) (CC and) (VP (AUX was) (ADJP (ADJP (RBR more) (JJ pronounced)) (PP (IN in) (NP (JJ recent) (NNS users))) (PP (IN than) (PP (IN in) (NP (JJ remote) (NNS users))))))) (. .)))
10713017	11	(S1 (S (NP (NP (DT An) (ADJP (ADJP (RB unexpectedly) (JJ high)) (PRN (-LRB- -LRB-) (NP (CD 11.4) (NN %)) (-RRB- -RRB-))) (NN number)) (PP (IN of) (NP (NNS patients))) (PP (IN with) (NP (NNP Doc_10713017_1604_1607_Disease)))) (VP (AUX had) (VP (VBN used) (NP (NNS anorexigens)))) (. .)))
10713017	12	(S1 (S (NP (NP (DT The) (NN magnitude)) (PP (IN of) (NP (NP (NP (DT the) (NN association)) (PP (IN with) (NP (NP (NNP Doc_10713017_1680_1683_Chemical)) (, ,) (NP (NP (DT the) (NN increase)) (PP (IN of) (NP (NN association))) (PP (IN with) (NP (NP (VBG increasing) (NN duration)) (PP (IN of) (NP (NN use)))))) (, ,)))) (CC and) (NP (NP (DT the) (NN specificity)) (PP (IN for) (NP (NNP Doc_10713017_1770_1783_Chemical))))))) (VP (AUX are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (JJ previous) (NNS studies)) (VP (VBG indicating) (SBAR (IN that) (S (NP (NNP Doc_10713017_1837_1850_Chemical)) (VP (AUX are) (ADVP (RB causally)) (VP (VBN related) (PP (TO to) (NP (NNP Doc_10713017_1875_1878_Chemical)))))))))))) (. .)))
10713017	13	(S1 (S (NP (NP (DT The) (JJ high) (NN prevalence)) (PP (IN of) (NP (JJ anorexigen) (NN use))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_10713017_1935_1938_Disease)))))) (ADVP (RB also)) (VP (VBZ raises) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP (DT these) (NNS drugs)) (VP (VBP precipitate) (NP (NNP Doc_10713017_1996_2018_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ underlying) (NNS conditions)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_10713017_2074_2077_Disease))))))))))))) (. .)))
10726030	0	(S1 (NP (NP (NP (NP (JJ Clinical) (NNS aspects)) (PP (IN of) (NP (NNP Doc_10726030_20_27_Chemical-induced) (NNP Doc_10726030_36_52_Disease) (CC and) (NNP Doc_10726030_57_67_Disease)))) (CC and) (NP (NP (JJ other) (JJ side) (NNS effects)) (PP (IN of) (NP (JJ Doc_10726030_94_101_Chemical) (NN therapy))))) (. .)))
10726030	1	(S1 (S (NP (NP (NNP Doc_10726030_111_118_Chemical)) (, ,) (VP (ADVP (RB first)) (VBN used) (S (VP (TO to) (VP (VB prevent) (NP (NP (DT the) (NN clotting)) (PP (IN of) (NP (NN blood))) (PP (IN in) (NP (NN vitro)))))))) (, ,)) (VP (AUX has) (VP (AUX been) (ADVP (RB clinically)) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NN Doc_10726030_208_218_Disease)) (PP (IN for) (NP (QP (JJR more) (IN than) (CD 50)) (NNS years))))))))) (. .)))
10726030	2	(S1 (S (SBAR (IN Although) (S (NP (JJ several) (JJ new) (NN anticoagulant) (NNS drugs)) (VP (AUX are) (PP (IN in) (NP (NN development)))))) (, ,) (NP (NNP Doc_10726030_304_311_Chemical)) (VP (VBZ remains) (NP (NP (DT the) (NN anticoagulant)) (PP (IN of) (NP (NN choice))) (S (VP (TO to) (VP (VB treat) (NP (JJ acute) (JJ Doc_10726030_363_373_Disease) (NNS episodes))))))) (. .)))
10726030	3	(S1 (S (S (NP (NP (DT The) (JJ clinical) (NNS effects)) (PP (IN of) (NP (NNP Doc_10726030_408_415_Chemical)))) (VP (AUX are) (ADJP (JJ meritorious)))) (, ,) (CC but) (S (NP (NN side) (NNS effects)) (VP (AUX do) (VP (VB exist)))) (. .)))
10726030	4	(S1 (S (NP (NN Doc_10726030_460_468_Disease)) (VP (AUX is) (NP (NP (DT the) (JJ primary) (JJ untoward) (NN effect)) (PP (IN of) (NP (NNP Doc_10726030_503_510_Chemical))))) (. .)))
10726030	5	(S1 (S (NP (NN Doc_10726030_512_526_Disease)) (VP (AUX is) (PP (IN of) (NP (NP (JJ primary) (NN concern)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ Doc_10726030_571_578_Chemical) (NN therapy)))))))) (. .)))
10726030	6	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (JJ additional) (JJ important) (JJ untoward) (NNS effects)) (PP (IN of) (NP (JJ Doc_10726030_638_645_Chemical) (NN therapy)))) (VP (VBP include) (NP (NP (JJ Doc_10726030_662_669_Chemical-induced) (NNP Doc_10726030_678_694_Disease)) (, ,) (NP (JJ Doc_10726030_696_703_Chemical-associated) (NNP Doc_10726030_715_727_Disease)) (, ,) (NP (NNP Doc_10726030_729_741_Disease)) (, ,) (NP (NN skin) (NNS reactions)) (, ,) (NP (NP (NNP Doc_10726030_759_777_Disease)) (ADJP (JJ other) (PP (IN than) (NP (NAC (NNP Doc_10726030_789_805_Disease) (, ,) (NNP Doc_10726030_807_815_Disease) (, ,)) (NN transaminasemia))))) (, ,) (NP (NNP Doc_10726030_834_846_Disease)) (, ,) (NP (NNP Doc_10726030_848_865_Disease)) (, ,) (CC and) (NP (NNP Doc_10726030_871_879_Disease)))) (. .)))
10726030	7	(S1 (S (S (NP (DT These) (JJ side) (NNS effects)) (VP (AUX are) (ADJP (RB relatively) (JJ rare) (PP (IN in) (NP (DT a) (VBN given) (NN individual)))))) (, ,) (CC but) (S (PP (VBN given) (NP (NP (DT the) (ADJP (RB extremely) (JJ widespread)) (NN use)) (PP (IN of) (NP (NNP Doc_10726030_985_992_Chemical))))) (, ,) (NP (DT some)) (VP (AUX are) (ADJP (ADJP (RB quite) (JJ common)) (, ,) (RB particularly) (NP (NP (NNP HITT)) (CC and) (NP (NNP Doc_10726030_1039_1051_Disease)))))) (. .)))
10726030	8	(S1 (S (SBAR (IN Although) (S (NP (NP (JJ reasonable) (NNS incidences)) (PP (IN of) (NP (NP (DT many)) (PP (IN of) (NP (DT these) (NN side) (NNS effects)))))) (VP (MD can) (VP (AUX be) (`` ``) (ADVP (RB softly)) ('' '') (VP (VBN deduced) (PP (IN from) (NP (NP (JJ current) (NNS reports)) (VP (VBG dealing) (PP (IN with) (NP (JJ unfractionated) (NNP Doc_10726030_1187_1194_Chemical))))))))))) (, ,) (PP (IN at) (NP (NN present))) (NP (NP (DT the) (NNS incidences)) (PP (IN of) (NP (NP (DT these) (JJ side) (NNS effects)) (PP (IN with) (NP (JJR newer) (NN Doc_10726030_1255_1284_Disease)))))) (VP (VBP appear) (S (VP (TO to) (VP (AUX be) (ADJP (ADVP (RB much) (RBR less)) (JJ common)))))) (. .)))
10726030	9	(S1 (S (ADVP (RB However)) (, ,) (NP (RB only) (JJR longer) (NN experience)) (VP (MD will) (ADVP (RBR more) (RB clearly)) (VP (VB define) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (DT each) (NN side) (NN effect))) (PP (IN with) (NP (JJ low) (JJ molecular) (NN weight) (NNS preparations)))))) (. .)))
10764869	0	(S1 (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NNP Doc_10764869_10_36_Disease))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN on) (NP (NP (NNP Doc_10764869_53_63_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_10764869_65_70_Chemical)) (-RRB- -RRB-)) (NN therapy)) (PP (IN after) (NP (NN liver) (NN transplantation))))))) (. .)))
10764869	1	(S1 (FRAG (S (VP (TO To) (VP (VB report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_10764869_138_164_Disease)))) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBG receiving) (NP (NP (NNP Doc_10764869_188_198_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10764869_200_206_Chemical)) (, ,) (NP (NP (NNP Prograf)) (: ;) (NP (NP (NNP Fujisawa) (NNP USA)) (, ,) (NP (NNP Inc)) (, ,) (NP (NNP Deerfield)) (, ,) (NP (NNP Illinois)))) (-RRB- -RRB-))) (PP (IN for) (NP (NN immunosuppression)))))) (PP (IN after) (NP (JJ orthotropic) (NN liver) (NN transplantation)))))) (. .)))
10764869	2	(S1 (S (NP (NN Case)) (VP (VBP report)) (. .)))
10764869	3	(S1 (S (PP (IN In) (NP (NP (DT a) (JJ 58-year-old) (NN man)) (VP (VBG receiving) (NP (NNP Doc_10764869_372_382_Chemical)) (PP (IN after) (NP (JJ orthotropic) (NN liver) (NN transplantation)))))) (, ,) (NP (NP (JJ serial) (JJ neuro-ophthalmologic) (NNS examinations)) (CC and) (NP (NN laboratory) (NNS studies))) (VP (AUX were) (VP (VBN performed))) (. .)))
10764869	4	(S1 (S (NP (DT The) (NN patient)) (VP (AUX had) (NP (JJ episodic) (NN Doc_10764869_538_561_Disease)) (PP (IN in) (NP (DT both) (NNS eyes))) (, ,) (PP (IN with) (NP (NP (JJ clinical) (NNS features)) (VP (VBG resembling) (NP (NNP Doc_10764869_610_637_Disease)))))) (. .)))
10764869	5	(S1 (S (NP (NN Doc_10764869_639_662_Disease)) (VP (VBD occurred) (PP (IN despite) (NP (NP (NN discontinuation)) (PP (IN of) (NP (DT the) (NNP Doc_10764869_703_713_Chemical)))))) (. .)))
10764869	6	(S1 (S (NP (NP (NN Doc_10764869_727_737_Chemical)) (CC and) (NP (JJ other) (NN immunosuppressive) (NNS agents))) (VP (MD may) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (JJ optic) (NN nerve) (NN Doc_10764869_808_816_Disease)))))) (. .)))
10770468	0	(S1 (NP (NP (NN Doc_10770468_0_13_Disease)) (, ,) (NP (NN Doc_10770468_15_25_Disease)) (, ,) (CC and) (NP (NN mood) (NNS stabilizers)) (. .)))
10770468	1	(S1 (S (NP (NP (JJ Recent) (NNS findings)) (PP (IN in) (NP (NP (NP (DT a) (NNP Doc_10770468_70_77_Disease) (NN patient) (NN receiving) (NN maintenance) (JJ Doc_10770468_108_115_Chemical) (NN therapy)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_10770468_138_151_Disease)))))) (CC and) (NP (JJ severe) (NN Doc_10770468_163_178_Disease))))) (VP (VBD prompted) (S (NP (DT the) (NNS authors)) (VP (TO to) (VP (VB conduct) (NP (NP (DT a) (JJ retrospective) (NN study)) (PP (IN of) (NP (NNP Doc_10770468_236_243_Disease) (NNS patients)))) (PP (IN with) (NP (JJ Doc_10770468_258_265_Chemical-associated) (NNP Doc_10770468_277_290_Disease))))))) (. .)))
10770468	2	(S1 (S (NP (NP (DT A) (NN printout)) (PP (IN of) (NP (NP (DT all) (NNS cases)) (PP (IN of) (NP (NNP Doc_10770468_319_332_Disease))))) (SBAR (WHNP (WDT that)) (S (VP (VBD presented) (PP (IN during) (NP (DT a) (JJ 1-year) (NN period))))))) (VP (AUX was) (VP (VBN generated))) (. .)))
10770468	3	(S1 (S (PP (IN After) (S (VP (VBG eliminating) (NP (NP (JJ spurious) (NN Doc_10770468_413_427_Disease)) (CC or) (NP (NP (DT those)) (VP (VBN associated) (PP (IN with) (NP (JJ intravenous) (NNS fluids))))))))) (, ,) (NP (DT the) (NNS authors)) (VP (VBD identified) (NP (NP (NP (NP (NP (CD 18) (JJ non-Doc_10770468_503_510_Chemical-treated) (NNS patients)) (PP (IN with) (NP (NNP Doc_10770468_533_547_Disease))) (VP (VBN related) (PP (TO to) (NP (NNP Doc_10770468_559_571_Disease))))) (CC and) (NP (JJ other) (JJ medical) (NNS conditions))) (PRN (-LRB- -LRB-) (NP (NN group)) (NP (DT A)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (CD 12) (NNS patients)) (PP (IN with) (NP (NNP Doc_10770468_632_639_Chemical-associated) (NNP Doc_10770468_651_664_Disease)))) (PRN (-LRB- -LRB-) (NP (NN group) (NN B)) (-RRB- -RRB-))))) (. .)))
10770468	4	(S1 (S (NP (NP (NNS Patients)) (PP (IN in) (NP (NN group) (NN B)))) (VP (AUX were) (ADJP (RB not) (JJ comparable) (PP (TO to) (NP (NP (DT those)) (PP (IN in) (NP (NN group) (DT A)))))) (, ,) (SBAR (IN as) (S (NP (DT the) (JJ latter)) (VP (VP (AUX were) (ADVP (RB medically)) (VP (VBN compromised))) (CC and) (VP (AUX were) (VP (VBG receiving) (NP (JJ multiple) (NNS pharmacotherapies)))))))) (. .)))
10770468	5	(S1 (S (ADVP (RB Thus)) (, ,) (NP (CD two) (NN control) (NNS groups)) (VP (AUX were) (VP (VBN generated) (: :) (NP (NP (NP (NNP group) (NNP C1)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD included) (NP (ADJP (JJ age-) (CC and) (JJ sex-comparable)) (JJ Doc_10770468_915_922_Chemical-treated) (NNP Doc_10770468_931_952_Disease) (NNS patients)))))) (, ,) (CC and) (NP (NP (NNP group) (NNP C2)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD included) (NP (NP (JJ Doc_10770468_992_1013_Disease) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (JJ anticonvulsant) (NN mood) (NNS stabilizers)))))))))))) (. .)))
10770468	6	(S1 (S (NP (NP (DT The) (JJ electrocardiographic) (PRN (-LRB- -LRB-) (NP (NNP ECG)) (-RRB- -RRB-)) (NNS findings)) (PP (IN for) (NP (NNS patients))) (PP (IN in) (NP (NN group) (NN B)))) (VP (AUX were) (PP (VBN compared) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (NNS groups) (NNP C1) (CC and) (NNP C2))))))))) (. .)))
10770468	7	(S1 (S (S (NP (PRP It)) (VP (AUX was) (VP (VBN found) (SBAR (IN that) (S (NP (DT these) (NNS groups)) (VP (AUX did) (RB not) (VP (VB differ) (PP (IN in) (NP (NP (PRP$ their) (JJ overall) (NN frequency)) (PP (IN of) (NP (JJ ECG) (NNS abnormalities)))))))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (EX there)) (VP (AUX were) (NP (NP (JJ significant) (NNS differences)) (PP (IN in) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NNP Doc_10770468_1350_1368_Disease)))))))) (. .)))
10770468	8	(S1 (S (NP (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (NNP Doc_10770468_1384_1397_Disease)) (VP (VBG resulting) (PP (IN from) (NP (JJ medical) (NNS diseases))))))) (CC and) (NP (NP (JJ Doc_10770468_1434_1441_Disease) (NNS patients)) (PP (IN with) (NP (NNP Doc_10770468_1456_1463_Chemical-associated) (NNP Doc_10770468_1475_1488_Disease))))) (VP (AUX had) (NP (NP (ADJP (RB significantly) (JJR higher)) (NNS frequencies)) (PP (IN of) (NP (NNP Doc_10770468_1529_1547_Disease))))) (. .)))
10770468	9	(S1 (S (NP (NP (NNS Patients)) (PP (IN in) (NP (NN group)))) (DT A) (VP (AUX had) (NP (JJ significant) (NN mortality)) (PP (IN at) (NP (NP (JJ 2-year) (NN follow-up)) (PRN (-LRB- -LRB-) (NP (CD 28) (NN %)) (-RRB- -RRB-)))) (, ,) (PP (IN in) (NP (NP (NN contrast)) (PP (TO to) (NP (NP (CD zero) (NN mortality)) (PP (IN in) (NP (DT the) (JJ other) (CD three) (NNS groups)))))))) (. .)))
10770468	10	(S1 (S (NP (NP (DT The) (JJ clinical) (NNS implications)) (PP (IN of) (NP (DT these) (NNS findings)))) (VP (AUX are) (VP (VBN discussed))) (. .)))
10933650	0	(S1 (S (NP (NP (NN Attenuation)) (PP (IN of) (NP (NN nephrotoxicity))) (PP (IN by) (NP (NP (DT a) (JJ novel) (NN lipid) (NN nanosphere)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10933650_59_65_Chemical)) (-RRB- -RRB-))))) (VP (VBG incorporating) (NP (NNP Doc_10933650_81_95_Chemical))) (. .)))
10933650	1	(S1 (S (NP (NP (NNP Doc_10933650_97_103_Chemical)) (, ,) (NP (NP (DT a) (NN lipid) (NN nanosphere)) (VP (VBG incorporating) (NP (NNP Doc_10933650_138_152_Chemical)))) (, ,)) (VP (VP (AUX is) (ADJP (JJ effective)) (PP (IN against) (NP (JJ pathogenic) (NNS fungi)))) (CC and) (VP (AUX has) (NP (JJ low) (NN Doc_10933650_204_212_Disease)))) (. .)))
10933650	2	(S1 (S (NP (PRP We)) (VP (VBD compared) (NP (NP (DT the) (NN Doc_10933650_230_238_Disease)) (PP (IN of) (NP (NNP Doc_10933650_242_248_Chemical)))) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (NP (NNP Doc_10933650_262_271_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_10933650_273_287_Chemical-Doc_10933650_288_307_Chemical)) (: ;) (NP (NNP Doc_10933650_309_314_Chemical))) (-RRB- -RRB-)))))) (PP (IN in) (S (S (NP (NN vitro)) (VP (VBG using) (NP (JJ renal) (NN cell) (NNS cultures)))) (CC and) (S (PP (IN in) (NP (NP (NN vivo)) (PP (IN by) (NP (JJ biochemical) (NN analysis))))) (, ,) (NP (NP (JJ histopathological) (NN study)) (PP (IN of) (NP (NP (DT the) (NN kidney) (CC and) (NN pharmacokinetic) (NN study)) (PP (IN of) (NP (NNP Doc_10933650_455_469_Chemical)))))) (VP (VBG following) (NP (NP (JJ intravenous) (NN infusion)) (PP (IN of) (NP (NP (DT the) (NN formulation)) (PP (IN in) (NP (NNS rats))))))))))) (. .)))
10933650	3	(S1 (S (NP (NP (NN Incubation)) (PP (IN with) (NP (NNP Doc_10933650_545_551_Chemical)))) (VP (VBD resulted) (PP (IN in) (NP (NP (ADJP (RB significantly) (JJR less)) (NN damage)) (PP (IN of) (NP (JJ cultured) (JJ human) (JJ renal) (NN proximal) (JJ tubular) (NN epithelial) (NNS cells))))) (PP (VBN compared) (PP (IN with) (NP (NNP Doc_10933650_662_667_Chemical))))) (. .)))
10933650	4	(S1 (S (NP (NN Serum) (NN blood) (NNP Doc_10933650_681_685_Chemical) (CC and) (NNP Doc_10933650_690_700_Chemical) (NNS concentrations)) (VP (VBD increased) (ADVP (RB significantly)) (PP (IN in) (NP (NP (NNS rats)) (VP (VP (VBN given) (NP (NP (DT an) (NNP iv) (NN infusion)) (PP (IN of) (NP (NNP Doc_10933650_772_777_Chemical) (CD 3)))) (ADVP (RB mg/kg))) (CC but) (VP (ADVP (RB not)) (PP (IN in) (NP (NP (DT those)) (PP (VBN given) (NP (NP (DT the) (JJ same) (NN dose)) (PP (IN of) (NP (NNP Doc_10933650_826_832_Chemical)))))))))))) (. .)))
10933650	5	(S1 (S (NP (NP (JJ Histopathological) (NN examination)) (PP (IN of) (NP (DT the) (NN kidney)))) (VP (VBD showed) (NP (NP (NP (NN Doc_10933650_885_901_Disease)) (PP (IN in) (NP (JJ Doc_10933650_905_910_Chemical-treated) (NNS rats)))) (CC but) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (JJ Doc_10933650_941_947_Chemical-treated) (NNS rats)))))) (. .)))
10933650	6	(S1 (S (NP (NP (JJ Doc_10933650_962_976_Chemical) (NNS concentrations)) (PP (IN in) (NP (NP (DT the) (NN kidney)) (PP (IN in) (NP (JJ Doc_10933650_1009_1015_Chemical-treated) (NNS rats)))))) (VP (AUX were) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (NP (DT those)) (PP (IN in) (NP (JJ Doc_10933650_1055_1060_Chemical-treated) (NNS rats))))))) (. .)))
10933650	7	(S1 (S (NP (PRP$ Our) (UCP (PP (IN in) (NP (NN vitro))) (CC and) (PP (IN in) (NP (NN vivo)))) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN incorporation)) (PP (IN of) (NP (NNP Doc_10933650_1138_1152_Chemical))) (PP (IN into) (NP (NP (NN lipid) (NNS nanospheres)) (PP (IN of) (NP (NNP Doc_10933650_1179_1185_Chemical)))))) (VP (VBZ attenuates) (NP (NP (DT the) (NN nephrotoxicity)) (PP (IN of) (NP (NNP Doc_10933650_1219_1233_Chemical)))))))) (. .)))
10939760	0	(S1 (NP (NP (NP (NNS Patterns)) (PP (IN of) (NP (JJ Doc_10939760_12_24_Chemical) (JJ acute) (NN nephrotoxicity)))) (. .)))
10939760	1	(S1 (S (NP (JJ Doc_10939760_47_59_Chemical) (JJ acute) (NN nephrotoxicity)) (VP (AUX is) (VP (VBG reviving) (ADVP (RB specially)) (PP (IN because) (IN of) (NP (NP (PRP$ its) (NN use)) (PP (IN in) (NP (NP (NNS toxoplasmosis)) (PP (IN in) (NP (JJ HIV-positive) (NNS patients))))))))) (. .)))
10939760	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (CD 4) (NNS cases)) (, ,) (NP (NP (CD one)) (PP (IN of) (NP (PRP them))))) (PP (IN in) (NP (DT a) (ADJP (RB previously) (JJ healthy)) (NN person)))) (. .)))
10939760	3	(S1 (S (PP (IN Under) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_10939760_249_261_Chemical))))) (NP (PRP they)) (VP (VP (VBD developed) (NP (NNP Doc_10939760_277_285_Disease) (, ,) (NNP Doc_10939760_287_301_Disease) (, ,) (NNP Doc_10939760_303_316_Disease))) (CC and) (VP (VBD showed) (NP (NP (JJ multiple) (NN radiolucent) (NN Doc_10939760_349_362_Disease)) (PP (IN in) (NP (NN echography)))))) (. .)))
10939760	4	(S1 (S (NP (DT All) (NNS patients)) (VP (VBD recovered) (NP (PRP$ their) (JJ previous) (JJ normal) (JJ renal) (NN function)) (PP (IN after) (NP (NP (JJ adequate) (NN hydration)) (CC and) (NP (NN alcalinization))))) (. .)))
10939760	5	(S1 (S (NP (DT A) (JJ nephrostomy) (NN tube)) (VP (AUX had) (S (VP (TO to) (VP (AUX be) (VP (VBN placed) (PP (IN in) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (NNS patients)) (PP (IN for) (NP (NNP Doc_10939760_546_564_Disease))) (PP (IN in) (NP (DT a) (JJ single) (JJ functional) (NN kidney)))))))))))) (. .)))
10939760	6	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (PRP them)))) (VP (VBD needed) (NP (NP (NN dialysis)) (CC or) (NP (DT a) (JJ renal) (NN biopsy))) (PP (IN because) (IN of) (NP (DT a) (JJ typical) (JJ benign) (NN course)))) (. .)))
10939760	7	(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NNP Doc_10939760_694_706_Chemical)))) (VP (VBZ requires) (NP (NP (NP (JJ exquisite) (NN control)) (PP (IN of) (NP (JJ renal) (NN function)))) (, ,) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN water) (NN ingestion)))) (CC and) (NP (NP (ADVP (RB possibly)) (DT the) (NN alcalinization)) (PP (IN of) (NP (DT the) (NN urine)))))) (. .)))
10939760	8	(S1 (S (NP (PRP We)) (VP (VB communicate) (NP (DT a) (NN case)) (PP (IN in) (NP (DT a) (ADJP (RB previously) (JJ healthy)) (NN person))) (, ,) (NP (NP (DT a) (NN fact)) (VP (RB not) (VBN found) (PP (IN in) (NP (DT the) (JJ recent) (NN literature)))))) (. .)))
10939760	9	(S1 (S (NP (QP (RB Probably) (JJ many) (JJR more)) (NNS cases)) (VP (AUX are) (RB not) (VP (VBN detected))) (. .)))
10939760	10	(S1 (S (NP (PRP We)) (VP (VBP think) (SBAR (IN that) (S (NP (DT a) (JJ prospective) (NN study)) (VP (MD would) (VP (AUX be) (ADJP (JJ useful))))))) (. .)))
10960401	0	(S1 (S (NP (NN Downbeat) (NN Doc_10960401_9_18_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ intravenous) (JJ patient-controlled) (NN administration)) (PP (IN of) (NP (NNP Doc_10960401_84_92_Chemical)))))) (. .)))
10960401	1	(S1 (S (NP (DT This) (NN case)) (VP (VBZ documents) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_10960401_152_161_Disease)) (PP (IN with) (S (VP (VBG downbeating) (NP (NNP Doc_10960401_179_188_Disease)) (SBAR (IN while) (S (VP (VBG receiving) (NP (NP (DT a) (ADJP (RB relatively) (JJ large)) (NN dose)) (PP (IN of) (NP (NNP IV) (JJ patient-controlled) (NN analgesia) (NN Doc_10960401_264_272_Chemical))))))))))))))) (. .)))
10960401	2	(S1 (S (SBAR (IN Although) (S (NP (EX there)) (VP (AUX have) (VP (AUX been) (NP (NP (NN case) (NNS reports)) (PP (IN of) (NP (JJ epidural) (NNP Doc_10960401_324_332_Chemical)))) (PP (IN with) (NP (DT these) (NNS symptoms) (CC and) (NNS signs))))))) (, ,) (NP (DT this)) (VP (AUX has) (RB not) (VP (AUX been) (ADVP (RB previously)) (VP (VBN documented) (PP (IN with) (NP (NP (NNP IV)) (CC or) (NP (JJ patient-controlled) (NN analgesia) (NNP Doc_10960401_444_452_Chemical))))))) (. .)))
10975596	0	(S1 (NP (NP (NP (NN Hemodynamic)) (CC and) (NP (JJ antiadrenergic) (NNS effects))) (PP (IN of) (NP (NNP Doc_10975596_42_53_Chemical) (CC and) (NNP Doc_10975596_58_68_Chemical))) (PP (IN in) (NP (NP (NNS animals)) (PP (IN with) (NP (DT a) (VBN healed) (NN Doc_10975596_94_115_Disease))))) (. .)))
10975596	1	(S1 (S (NP (NP (DT The) (JJ hemodynamic) (CC and) (JJ antiadrenergic) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_10975596_163_174_Chemical)) (, ,) (NP (NP (DT a) (JJ noniodinated) (NN compound)) (VP (ADVP (RB structurally)) (VBN related) (PP (TO to) (NP (NNP Doc_10975596_224_234_Chemical))))) (, ,)))) (VP (AUX were) (VP (VBN compared) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (NNP Doc_10975596_264_274_Chemical))))) (PP (IN after) (NP (VBN prolonged) (JJ oral) (NN administration))) (, ,) (PP (DT both) (PP (IN at) (NP (NN rest))) (CC and) (PP (IN during) (NP (NP (JJ sympathetic) (NN stimulation)) (PP (IN in) (NP (NP (JJ conscious) (NNS dogs)) (PP (IN with) (NP (DT a) (VBN healed) (NN Doc_10975596_392_413_Disease)))))))))) (. .)))
10975596	2	(S1 (S (NP (DT All) (NNS dogs)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 6)) (-RRB- -RRB-)) (ADVP (RB randomly)) (VP (VBD received) (NP (RB orally) (JJ Doc_10975596_457_468_Chemical) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CC and) (CD 30)) (NNS mg/kg)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_10975596_488_498_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CC and) (CD 30)) (NNS mg/kg)) (-RRB- -RRB-)) (, ,) (CC and) (NP (NN placebo))) (ADVP (RB twice) (RB daily)) (PP (IN for) (NP (CD 7) (NNS days))) (, ,) (PP (IN with) (NP (NP (DT a) (JJ 3-week) (NN washout)) (PP (IN between) (NP (JJ consecutive) (NNS treatments)))))) (. .)))
10975596	3	(S1 (S (NP (NP (NN Heart) (NN rate)) (PRN (-LRB- -LRB-) (NP (NNP HR)) (-RRB- -RRB-))) (PRN (, ,) (S (VP (VB mean) (NP (NP (NP (JJ arterial) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NNP MBP)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ positive) (NN rate)) (PP (IN of) (NP (NP (NN increase)) (PP (IN of) (NP (JJ left) (JJ ventricular) (NN pressure))) (PRN (-LRB- -LRB-) (NP (NNP +LVdP/dt)) (-RRB- -RRB-)))))))) (, ,)) (ADVP (RB echocardiographically)) (VP (VBD assessed) (SBAR (S (NP (NP (VBN left) (JJ ventricular) (NN ejection) (NN fraction)) (PRN (-LRB- -LRB-) (NP (NN LVEF)) (-RRB- -RRB-)) (, ,) (CC and) (NP (NP (JJ fractional) (NN shortening)) (PRN (-LRB- -LRB-) (NP (NNP FS)) (-RRB- -RRB-))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ chronotropic) (NN response)) (PP (TO to) (NP (NNP Doc_10975596_864_877_Chemical)))) (CC and) (NP (JJ exercise-induced) (JJ sympathetic) (NN stimulation))) (VP (AUX were) (VP (VBN evaluated) (PP (IN under) (NP (NN baseline) (CC and) (NN posttreatment) (NNS conditions)))))))) (. .)))
10975596	4	(S1 (S (NP (NP (JJ Resting) (NNS values)) (PP (IN of) (NP (NN LVEF) (, ,) (NN FS) (, ,) (NN +LVdP/dt) (, ,) (CC and) (NN MBP)))) (VP (VBD remained) (ADJP (JJ unchanged)) (SBAR (WHNP (WDT whatever)) (S (NP (NP (DT the) (NN drug)) (CC and) (NP (DT the) (JJ dosing) (NN regimen))))) (, ,) (SBAR (IN whereas) (S (NP (JJ resting) (NN HR)) (VP (AUX was) (ADVP (RB significantly) (CC and) (RB dose-dependently)) (VP (VBN lowered) (PP (PP (IN after) (NP (NNP Doc_10975596_1162_1173_Chemical))) (CC and) (PP (TO to) (NP (DT a) (JJR lesser) (NN extent)))) (PP (IN after) (NP (NNP Doc_10975596_1203_1213_Chemical)))))))) (. .)))
10975596	5	(S1 (S (NP (DT Both) (NNP Doc_10975596_1220_1231_Chemical) (CC and) (NNP Doc_10975596_1236_1246_Chemical)) (VP (VP (ADVP (RB significantly)) (VBD reduced) (NP (DT the) (JJ exercise-induced) (NN Doc_10975596_1290_1301_Disease))) (CC and) (VP (, ,) (PP (IN at) (NP (DT the) (JJS highest) (NN dose))) (, ,) (VBD decreased) (NP (DT the) (JJ Doc_10975596_1342_1355_Chemical-induced) (NN Doc_10975596_1364_1375_Disease)))) (. .)))
10975596	6	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (NNP Doc_10975596_1383_1394_Chemical)) (CC and) (NP (NNP Doc_10975596_1399_1409_Chemical))) (VP (VP (VBD displayed) (NP (NP (DT a) (JJ similar) (NN level)) (PP (IN of) (NP (JJ antiadrenergic) (NN effect))))) (CC and) (VP (AUX did) (RB not) (VP (VB impair) (NP (DT the) (JJ resting) (NN left) (NN ventricular) (NN function))))) (. .)))
10975596	7	(S1 (S (ADVP (RB Consequently)) (, ,) (NP (NNP Doc_10975596_1533_1544_Chemical)) (VP (MD might) (VP (AUX be) (ADJP (RB particularly) (JJ suitable) (PP (IN for) (NP (NP (DT the) (NN treatment) (CC and) (NN prevention)) (PP (IN of) (NP (JJ various) (JJ clinical) (NN Doc_10975596_1629_1640_Disease)))))) (, ,) (PP (IN without) (S (VP (VBG compromising) (NP (DT the) (JJ left) (NN ventricular) (NN function))))))) (. .)))
10985896	0	(S1 (NP (NP (NN Phase) (CD 2) (NN trial)) (PP (IN of) (NP (NP (JJ liposomal) (NNP Doc_10985896_27_38_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 40) (NN mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (JJ Doc_10985896_55_63_Chemical/Doc_10985896_64_74_Chemical-refractory) (NN ovarian) (CC and) (JJ fallopian) (NNP Doc_10985896_108_120_Disease) (CC and) (NNP Doc_10985896_125_142_Disease)) (PP (IN of) (NP (DT the) (NN peritoneum))))) (. .)))
10985896	1	(S1 (S (NP (JJ Several) (NNS studies)) (VP (AUX have) (VP (VBN demonstrated) (NP (NP (JJ liposomal) (NNP Doc_10985896_218_229_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10985896_231_236_Chemical)) (-RRB- -RRB-))) (S (VP (TO to) (VP (AUX be) (NP (NP (DT an) (JJ active) (JJ antineoplastic) (NN agent)) (PP (IN in) (NP (NNP Doc_10985896_278_286_Chemical-resistant) (NNP Doc_10985896_297_311_Disease))) (, ,) (PP (IN with) (NP (NP (NN dose)) (VP (VBG limiting) (NP (NP (NP (NNP Doc_10985896_332_340_Disease)) (PP (IN of) (S (NP (NP (DT the) (JJ standard) (NN dosing) (NN regimen)) (PRN (-LRB- -LRB-) (NP (QP (CD 50) (CD mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NNP q)) (NP (CD 4) (NNS weeks)) (-RRB- -RRB-))) (VP (AUXG being) (NP (JJ severe) (NN erythrodysesthesia))))) (PRN (-LRB- -LRB-) (NP (`` ``) (NP (NNP Doc_10985896_429_447_Disease)) ('' '')) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_10985896_454_464_Disease)))))))))))) (. .)))
10985896	2	(S1 (S (NP (PRP We)) (VP (VBD wished) (S (VP (TO to) (VP (VP (VB develop) (NP (DT a) (ADJP (RBR more) (JJ tolerable)) (NN liposomal) (NN Doc_10985896_514_525_Chemical) (NN treatment) (NN regimen))) (CC and) (VP (VB document) (NP (NP (PRP$ its) (NN level)) (PP (IN of) (NP (NP (NN activity)) (PP (IN in) (NP (NP (DT a) (JJ well-defined) (JJ patient) (NN population)) (PP (IN with) (NP (JJ Doc_10985896_621_629_Chemical/Doc_10985896_630_640_Chemical-refractory) (NN disease))))))))))))) (. .)))
10985896	3	(S1 (FRAG (NP (NNS METHODS) (CC AND) (NNS MATERIALS)) (: :) (S (NP (NP (NNPS Patients)) (PP (IN with) (NP (NP (NNP Doc_10985896_698_731_Disease)) (CC or) (NP (NP (JJ primary) (JJ peritoneal) (NNP Doc_10985896_754_763_Disease)) (PP (IN with) (NP (JJ Doc_10985896_769_777_Chemical/Doc_10985896_778_788_Chemical-refractory) (NN disease))) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NP (JJ stable) (CC or) (JJ progressive) (NN disease)) (VP (VBG following) (NP (NN treatment)) (PP (IN with) (NP (DT these) (NNS agents))))) (CC or) (NP (JJ previous) (JJ objective) (NN response))) (NP (CD <3) (NNS months))) (PP (IN in) (NP (NN duration)))) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (JJ liposomal) (NAC (NNP Doc_10985896_959_970_Chemical) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NP (CD 40) (NNS mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))))))) (NNP q) (CD 4) (NNS weeks)))))) (. .)))
10985896	4	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (CD 49) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (JJ median) (NN age)) (: :) (NP (CD 60)) (: ;) (NP (NN range) (CD 41-81))) (-RRB- -RRB-))))) (VP (VBD entered) (NP (DT this) (NN phase) (CD 2) (NN trial))) (. .)))
10985896	5	(S1 (S (NP (NP (DT The) (JJ median) (NN number)) (PP (IN of) (NP (JJ prior) (NNS regimens)))) (VP (AUX was) (NP (NP (CD 2)) (PRN (-LRB- -LRB-) (NP (NP (NN range)) (: :) (NP (NN 1-6))) (-RRB- -RRB-)))) (. .)))
10985896	6	(S1 (S (NP (NP (NP (NP (CD Six)) (PRN (-LRB- -LRB-) (NP (CD 12) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 4)) (PRN (-LRB- -LRB-) (NP (CD 8) (NN %)) (-RRB- -RRB-)))) (NNS patients)) (VP (VBD experienced) (NP (NN grade)) (NP (CD 2) (NNP Doc_10985896_1202_1220_Disease) (CC and) (NNP Doc_10985896_1225_1235_Disease)) (, ,) (ADVP (RB respectively)) (PRN (-LRB- -LRB-) (NP (NP (DT no) (NNS episodes)) (PP (IN of) (NP (NN grade) (CD 3)))) (-RRB- -RRB-))) (. .)))
10985896	7	(S1 (S (NP (CD One) (NN patient)) (VP (VBD developed) (NP (NP (NN grade) (CD 3) (NN diarrhea)) (VP (VBG requiring) (NP (NN hospitalization)) (PP (IN for) (NP (NN hydration)))))) (. .)))
10985896	8	(S1 (S (NP (CD Six) (PRN (-LRB- -LRB-) (NP (CD 12) (NN %)) (-RRB- -RRB-)) (NNS individuals)) (VP (VBD required) (NP (NN dose) (NNS reductions))) (. .)))
10985896	9	(S1 (S (NP (NP (DT The) (JJ median) (NN number)) (PP (IN of) (NP (NP (NNS courses)) (PP (IN of) (NP (JJ liposomal) (NNP Doc_10985896_1446_1457_Chemical))))) (VP (VBN administered) (PP (IN on) (NP (DT this) (NN protocol))))) (VP (AUX was) (NP (NP (CD 2)) (PRN (-LRB- -LRB-) (NP (NP (NN range)) (: :) (NP (CD 1-12))) (-RRB- -RRB-)))) (. .)))
10985896	10	(S1 (S (NP (NP (QP (CD Four) (IN of) (CD 44)) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 9) (NN %)) (-RRB- -RRB-))) (VP (VBP evaluable) (PP (IN for) (NP (NP (NN response) (JJ exhibited) (NN objective)) (CC and) (NP (NP (JJ subjective) (NN evidence)) (PP (IN of) (NP (NP (DT an) (JJ antineoplastic) (NN effect)) (PP (IN of) (NP (NN therapy))))))))) (. .)))
10985896	11	(S1 (S (NP (DT This) (VBN modified) (JJ liposomal) (JJ Doc_10985896_1677_1688_Chemical) (NN regimen)) (VP (VBZ results) (PP (IN in) (NP (NP (NP (RBR less)) (NP (NP (NNP Doc_10985896_1713_1721_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_10985896_1723_1733_Disease)) (, ,) (NP (NNP Doc_10985896_1735_1753_Disease)) (-RRB- -RRB-)))) (PP (IN than) (NP (DT the) (JJ standard) (JJ FDA-approved) (NN dose) (NN schedule)))))) (. .)))
10985896	12	(S1 (S (NP (NN Doc_10985896_1801_1809_Chemical)) (, ,) (SBAR (IN although) (FRAG (ADJP (JJ limited)))) (, ,) (NP (NN antineoplastic) (NN activity)) (VP (AUX is) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ well-defined) (NNP Doc_10985896_1895_1903_Chemical-)) (CC and) (NP (NNP Doc_10985896_1909_1919_Chemical-refractory) (NNP Doc_10985896_1931_1945_Disease)))))))) (. .)))
10986547	0	(S1 (NP (NP (NP (NN Efficacy)) (PP (IN of) (NP (NNP Doc_10986547_12_22_Chemical))) (PP (IN in) (NP (JJ acute) (NNP Doc_10986547_32_45_Disease)))) (: :) (NP (DT a) (JJ double-blind) (, ,) (JJ placebo-controlled) (NN study)) (. .)))
10986547	1	(S1 (NP (DT The) (NNP Doc_10986547_93_103_Chemical) (NNP HGGW) (NNP Study) (NNP Group) (. .)))
10986547	2	(S1 (S (NP (PRP We)) (VP (VBD compared) (NP (NP (DT the) (NN efficacy) (CC and) (NN safety)) (PP (IN of) (NP (NNP Doc_10986547_173_183_Chemical) (NNP vs) (NN placebo))) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ acute) (NNP Doc_10986547_222_235_Disease))))))) (. .)))
10986547	3	(S1 (UCP (ADJP (JJ Four-week)) (, ,) (ADJP (JJ randomized)) (, ,) (ADJP (JJ double-blind)) (, ,) (NP (JJ parallel) (NN study)) (. .)))
10986547	4	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (CD 115) (NNS patients)) (PP (IN with) (NP (NP (DT a) (JJ DSM-IV) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_10986547_350_366_Disease))) (, ,) (ADJP (JJ Doc_10986547_368_373_Disease) (CC or) (JJ mixed)) (, ,)))))) (VP (AUX were) (VP (VBN randomized) (PP (TO to) (NP (NP (NNP Doc_10986547_403_413_Chemical)) (, ,) (NP (NP (QP (CD 5) (TO to) (CD 20)) (NNS mg/d)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 55)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 60)) (-RRB- -RRB-))))))) (. .)))
10986547	5	(S1 (S (NP (DT The) (JJ primary) (NN efficacy) (NN measure)) (VP (AUX was) (NP (DT the) (NNP Young-Doc_10986547_502_507_Disease) (NNP Rating) (NNP Scale) (PRN (-LRB- -LRB-) (NP (NNP Y-MRS)) (-RRB- -RRB-)) (NN total) (NN score))) (. .)))
10986547	6	(S1 (S (NP (NN Response) (CC and) (NNS euthymia)) (VP (AUX were) (VP (VBN defined) (, ,) (NP (DT a) (FW priori)) (, ,) (PP (PP (IN as) (NP (NP (ADVP (IN at) (JJS least)) (DT a) (ADJP (CD 50) (NN %)) (NN improvement)) (PP (IN from) (NP (NN baseline))) (PP (TO to) (NP (NN end) (NN point))))) (CC and) (PP (IN as) (NP (NP (DT a) (NN score)) (PP (IN of) (NP (NP (QP (DT no) (JJR less) (IN than) (CD 12))) (PP (IN at) (NP (NP (JJ end) (NN point)) (PP (IN in) (NP (DT the) (JJ Y-MRS) (JJ total) (NN score))))))) (, ,) (ADVP (RB respectively))))))) (. .)))
10986547	7	(S1 (S (NP (NN Safety)) (VP (AUX was) (VP (VBN assessed) (S (VP (VBG using) (NP (NP (JJ adverse) (NNS events)) (, ,) (NP (JJ Extrapyramidal) (NN Symptom) (PRN (-LRB- -LRB-) (NP (NNP EPS)) (-RRB- -RRB-)) (NN rating) (NNS scales)) (, ,) (NP (NN laboratory) (NNS values)) (, ,) (NP (NNS electrocardiograms)) (, ,) (NP (JJ vital) (NNS signs)) (, ,) (CC and) (NP (NN weight) (NN change))))))) (. .)))
10986547	8	(S1 (S (NP (JJ Doc_10986547_898_908_Chemical-treated) (NNS patients)) (VP (VP (VBD demonstrated) (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (JJR greater) (JJ mean) (-LRB- -LRB-) (JJ +/-) (NN SD) (-RRB- -RRB-) (NN improvement)) (PP (IN in) (NP (JJ Y-MRS) (JJ total) (NN score))) (PP (IN than) (NP (NP (JJ placebo-treated) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD -14.8) (NNS +/-)) (NP (NP (CD 12.5) (CC and) (CD -8.1) (NN +/-) (CD 12.7)) (, ,) (ADVP (RB respectively)))) (: ;) (NP (CD P<.001)) (-RRB- -RRB-)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (ADJP (JJ evident)) (PP (IN at) (NP (NP (DT the) (JJ first) (NN postbaseline) (NN observation)) (NP (CD 1) (NN week)))))))) (PP (IN after) (NP (NN randomization)))) (CC and) (VP (AUX was) (VP (VBN maintained) (PP (IN throughout) (NP (NP (DT the) (NN study)) (PRN (-LRB- -LRB-) (S (NP (JJ last) (NN observation)) (VP (VBN carried) (ADVP (RB forward)))) (-RRB- -RRB-))))))) (. .)))
10986547	9	(S1 (S (NP (JJ Doc_10986547_1269_1279_Chemical-treated) (NNS patients)) (VP (VBD demonstrated) (NP (NP (DT a) (JJR higher) (NN rate)) (PP (IN of) (NP (NP (NP (NN response)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD 65) (NN %)) (NNP vs) (CD 43) (NN %)) (, ,) (ADVP (RB respectively))) (: ;) (NP (NNP P) (CD =.02))) (-RRB- -RRB-))) (CC and) (NP (NP (NN euthymia)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD 61) (NN %)) (NNP vs) (CD 36) (NN %)) (, ,) (ADVP (RB respectively))) (: ;) (NP (QP (CD P) (CD =.)) (NNS 01))) (-RRB- -RRB-))))) (PP (IN than) (NP (JJ placebo-treated) (NNS patients))))) (. .)))
10986547	10	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (ADJP (RB statistically) (JJ significant)) (NNS differences)) (PP (IN in) (NP (NN EPSs))) (PP (IN between) (NP (NNS groups))))) (. .)))
10986547	11	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ Doc_10986547_1536_1546_Chemical-treated) (NNS patients)) (VP (VP (AUX had) (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (JJR greater) (JJ mean) (-LRB- -LRB-) (JJ +/-) (NN SD) (-RRB- -RRB-) (NN weight) (NN gain)) (PP (IN than) (NP (NP (JJ placebo-treated) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 2.1) (JJ +/-) (CD 2.8) (NNP vs) (CD 0.45) (NN +/-) (CD 2.3) (NN kg)) (, ,) (NP (RB respectively)) (-RRB- -RRB-)))))) (CC and) (ADVP (RB also)) (VP (VBD experienced) (ADJP (ADJP (RBR more) (JJ Doc_10986547_1733_1762_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 21) (NNS patients)) (NP (NP (CD -LSB-38.2) (NN %)) (JJ -RSB-) (NNP vs) (CD 5) (ADJP (CD -LSB-8.3) (NN %)) (NN -RSB-))) (, ,) (ADVP (RB respectively)) (-RRB- -RRB-))))) (. .)))
10986547	12	(S1 (S (NP (NN Doc_10986547_1825_1835_Chemical)) (VP (VP (VBD demonstrated) (NP (NP (JJR greater) (NN efficacy)) (PP (IN than) (NP (NN placebo)))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ acute) (NNP Doc_10986547_1905_1918_Disease)))))) (CC and) (VP (AUX was) (ADVP (RB generally)) (ADVP (RB well)) (VP (VBN tolerated)))) (. .)))
11026989	0	(S1 (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_11026989_14_28_Disease))) (PP (IN with) (NP (NNP Doc_11026989_34_45_Chemical))) (PP (IN on) (NP (NP (NN vision)) (CC and) (NP (NN driving) (NN simulator) (NN performance)))) (. .)))
11026989	1	(S1 (FRAG (S (VP (TO To) (VP (VB assess) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_11026989_124_138_Disease))) (PP (IN on) (NP (NP (NN vision)) (CC and) (NP (NN driving) (NN ability)))))))) (. .)))
11026989	2	(S1 (S (NP (NP (DT A) (NN series)) (PP (IN of) (NP (NP (NNS tests)) (PP (IN on) (NP (NP (JJ various) (NNS parameters)) (PP (IN of) (NP (NP (JJ visual) (NN function)) (CC and) (NP (JJ driving) (NN simulator) (NN performance))))))))) (VP (VP (AUX were) (VP (VBN performed) (PP (IN on) (NP (CD 12) (JJ healthy) (NNS drivers))) (, ,) (ADVP (RB before)))) (CC and) (VP (PP (IN after) (S (NP (NNP Doc_11026989_327_341_Disease)) (VP (VBG using) (NP (NNS guttae))))) (VBD tropicamide) (NP (CD 1) (NN %)))) (. .)))
11026989	3	(S1 (S (NP (NP (DT A) (VBG driving) (NN simulator)) (PRN (-LRB- -LRB-) (NP (NNP Transport) (NNP Research) (NNP Laboratory)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB measure) (NP (NP (NP (NNP Doc_11026989_443_456_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11026989_458_460_Disease)) (-RRB- -RRB-))) (, ,) (NP (NN speed) (NN maintenance)) (CC and) (NP (NN steering) (NN accuracy)))))))) (. .)))
11026989	4	(S1 (S (NP (NP (NNS Tests)) (PP (IN of) (NP (JJ basic) (JJ visual) (NN function)))) (VP (VBD included) (NP (NP (NN high-)) (CC and) (NP (NP (NP (NNP Doc_11026989_554_580_Disease)) (PRN (-LRB- -LRB-) (NP (NNP HCVA) (CC and) (NNP LCVA)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (JJ Pelli-Robson) (NN contrast) (NN threshold)) (PRN (-LRB- -LRB-) (NP (NN CT)) (-RRB- -RRB-))) (CC and) (NP (NNP Goldmann) (NN perimetry))) (PRN (-LRB- -LRB-) (NP (NNP FIELDS)) (-RRB- -RRB-))))) (. .)))
11026989	5	(S1 (S (NP (NP (NP (JJ Useful) (NN Field)) (PP (IN of) (NP (NN View)))) (PRN (-LRB- -LRB-) (NP (NP (JJ UFOV--a) (NN test)) (PP (IN of) (NP (JJ visual) (NN attention)))) (-RRB- -RRB-))) (VP (AUX was) (ADVP (RB also)) (VP (VBN undertaken))) (. .)))
11026989	6	(S1 (S (NP (NP (DT The) (JJ mean) (NNS differences)) (PP (IN in) (NP (DT the) (NN pre-) (CC and) (NN post-dilatation) (NNS measurements)))) (VP (AUX were) (VP (VBN tested) (PP (IN for) (NP (JJ statistical) (NN significance))) (PP (IN at) (NP (NP (DT the) (ADJP (CD 95) (NN %)) (NN level)) (VP (VBG using) (NP (JJ one-tail) (VBN paired) (NNS t-tests))))))) (. .)))
11026989	7	(S1 (S (NP (NN Doc_11026989_909_927_Disease)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN deterioration)) (PP (IN in) (NP (NP (NNP CT)) (CC and) (NP (NNP HCVA)) (ADVP (RB only))))))) (. .)))
11026989	8	(S1 (S (NP (NP (CD Five)) (PP (IN of) (NP (CD 12) (NNS drivers)))) (ADVP (RB also)) (VP (VBD exhibited) (NP (NN deterioration)) (PP (IN in) (NP (NP (NNP LCVA)) (, ,) (NP (NNP CT)) (CC and) (NP (NNP Doc_11026989_1067_1069_Disease))))) (. .)))
11026989	9	(S1 (S (NP (JJ Little) (NN evidence)) (VP (VBD emerged) (PP (IN for) (NP (NN deterioration))) (PP (IN in) (NP (NP (NNS FIELDS)) (CC and) (NP (NNS UFOV))))) (. .)))
11026989	10	(S1 (S (ADVP (RB Also)) (, ,) (NP (QP (CD 7) (IN of) (CD 12)) (NNS drivers)) (VP (VBD appeared) (S (VP (TO to) (VP (VB adjust) (NP (PRP$ their) (VBG driving) (NN behaviour)) (PP (IN by) (S (VP (VBG reducing) (NP (PRP$ their) (NN speed)) (PP (IN on) (NP (DT the) (JJ driving) (NN simulator))))))))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (VBN improved) (NN steering) (NN accuracy)))))) (. .)))
11026989	11	(S1 (S (NP (NN Doc_11026989_1300_1318_Disease)) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NN vision)))) (CC and) (NP (NP (NN daylight) (VBG driving) (NN performance)) (PP (IN in) (NP (JJ young) (NNS people)))))))) (. .)))
11026989	12	(S1 (S (NP (NP (DT A) (JJR larger) (NN study)) (, ,) (PP (VBG including) (NP (NP (DT a) (JJR broader) (NN spectrum)) (PP (IN of) (NP (NNS subjects))))) (, ,)) (VP (AUX is) (VP (VBN warranted) (SBAR (IN before) (S (NP (NNS guidelines)) (VP (MD can) (VP (AUX be) (VP (VBN recommended)))))))) (. .)))
11105626	0	(S1 (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NP (JJ Doc_11105626_10_22_Chemical) (NN embryopathy)) (PP (IN with) (NP (NP (NNP Doc_11105626_40_56_Disease)) (CC and) (NP (NNP Taussig-Doc_11105626_69_86_Disease)))))) (. .)))
11105626	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (JJ newborn) (NN infant)) (PP (IN with) (NP (NNP Doc_11105626_120_149_Disease))) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_11105626_151_157_Disease)) (CC and) (NP (NNP Taussig-Doc_11105626_170_187_Disease))) (-RRB- -RRB-)) (ADJP (JJ due) (PP (TO to) (NP (NP (NN exposure)) (PP (TO to) (NP (NNP Doc_11105626_208_220_Chemical))) (PP (IN within) (NP (DT the) (JJ first) (NN trimester)))))))) (. .)))
11105626	2	(S1 (S (PP (IN In) (NP (DT this) (NN paper))) (NP (PRP we)) (VP (VBP aim) (S (VP (TO to) (VP (VB draw) (PP (TO to) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (NN caution)) (VP (AUX is) (VP (VBN needed) (SBAR (WHADVP (WRB when)) (S (VP (VBG prescribing) (NP (JJ Doc_11105626_330_339_Chemical-containing) (NNS drugs)) (PP (TO to) (NP (NP (NNS women)) (PP (IN of) (NP (VBG childbearing) (NNS years)))))))))))))))))) (. .)))
11135381	0	(S1 (NP (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_11135381_10_21_Chemical))) (PP (IN on) (NP (NP (JJ maximum) (JJ urethral) (NN pressure)) (PP (IN in) (NP (NP (NNS women)) (PP (IN with) (NP (NNP Doc_11135381_65_92_Disease)))))))) (: :) (NP (DT a) (JJ placebo-controlled) (, ,) (JJ double-blind) (NN crossover) (NN study)) (. .)))
11135381	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ potential) (NN role)) (PP (IN for) (NP (DT a) (JJ selective) (NN alpha1-adrenoceptor) (NN agonist))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_11135381_266_293_Disease)))))))))) (. .)))
11135381	2	(S1 (S (NP (DT A) (JJ randomised) (, ,) (JJ double-blind) (, ,) (JJ placebo-controlled) (, ,) (JJ crossover) (NN study) (NN design)) (VP (AUX was) (VP (VBN employed))) (. .)))
11135381	3	(S1 (S (NP (NP (DT Half) (NN log) (JJ incremental) (NNS doses)) (PP (IN of) (NP (NP (JJ intravenous) (NNP Doc_11135381_422_433_Chemical)) (CC or) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NN saline)) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN administered) (PP (TO to) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NP (NNS women)) (PP (IN with) (NP (NNP Doc_11135381_497_524_Disease))))))) (SBAR (IN while) (S (VP (VBG measuring) (NP (NP (NP (JJ maximum) (JJ urethral) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN MUP)) (-RRB- -RRB-))) (, ,) (NP (NN blood) (NN pressure)) (, ,) (NP (NN heart) (NN rate)) (, ,) (CC and) (NP (JJ symptomatic) (NN side) (NNS effects)))))))) (. .)))
11135381	4	(S1 (S (NP (NNP Doc_11135381_632_643_Chemical)) (VP (VP (VBD evoked) (NP (JJ non-significant) (NNP Doc_11135381_667_712_Disease))) (CC but) (VP (VBD caused) (NP (NP (DT a) (JJ significant) (NN Doc_11135381_738_769_Disease)) (CC and) (NP (JJ significant) (NN fall))) (PP (IN in) (NP (NP (NN heart) (NN rate)) (PP (IN at) (NP (NN maximum) (NN dosage))))))) (. .)))
11135381	5	(S1 (S (NP (NP (JJ Systemic) (JJ side) (NNS effects)) (PP (VBG including) (NP (NP (NN piloerection)) (, ,) (NP (NN Doc_11135381_870_878_Disease)) (, ,) (CC and) (NP (JJ cold) (NNS extremities))))) (VP (AUX were) (VP (VBN experienced) (PP (IN in) (NP (DT all) (NNS subjects))))) (. .)))
11135381	6	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (JJ clinical) (NN usefulness)) (PP (IN of) (NP (NP (JJ direct) (, ,) (ADJP (RB peripherally) (JJ acting)) (JJ sub-type-selective) (JJ alpha1-adrenoceptor) (NNS agonists)) (PP (IN in) (NP (NP (DT the) (JJ medical) (NN treatment)) (PP (IN of) (NP (NNP Doc_11135381_1092_1111_Disease)))))))) (VP (MD may) (VP (AUX be) (VP (VBN limited) (PP (IN by) (NP (NP (JJ associated) (NN piloerection)) (CC and) (NP (JJ cardiovascular) (NN side) (NNS effects)))))))))) (. .)))
1117341	0	(S1 (S (NP (NP (JJ Doc_1117341_0_13_Disease) (NN effect)) (PP (IN of) (NP (JJ Doc_1117341_24_29_Chemical) (NNS compounds)))) (ADVP (RB structurally)) (VP (VBD related) (PP (TO to) (NP (NP (NNP Doc_1117341_64_72_Chemical)) (PP (IN in) (NP (NNS rats)))))) (. .)))
1117341	1	(S1 (S (NP (NP (DT The) (JJ chronic) (NN feeding)) (PP (IN of) (NP (NP (NP (JJ small) (NNS amounts)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.3-3) (NN %)) (PP (IN of) (NP (NN diet) (NN weight)))) (-RRB- -RRB-))) (PP (IN of) (NP (NP (JJ certain) (JJ Doc_1117341_154_159_Chemical) (NNS derivatives)) (PP (IN of) (NP (NNP Doc_1117341_175_183_Chemical)))))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NNP Doc_1117341_196_209_Disease)) (, ,) (NP (DT an) (JJ elevated) (NNP Doc_1117341_223_230_Chemical) (NN tolerance) (NN curve)) (CC and) (, ,) (ADVP (RB occasionally)) (, ,) (NP (NNP Doc_1117341_266_276_Disease))))) (. .)))
1117341	2	(S1 (S (NP (JJ Effective) (NNS compounds)) (VP (VBD included) (NP (NNP Doc_1117341_307_317_Chemical) (, ,) (NNP Doc_1117341_319_328_Chemical) (, ,) (NNP Doc_1117341_330_339_Chemical) (, ,) (NNP Doc_1117341_341_362_Chemical) (, ,) (NNP Doc_1117341_364_374_Chemical) (, ,) (CC and) (NNP Doc_1117341_380_387_Chemical))) (. .)))
11176729	0	(S1 (NP (NP (NP (NN Toleration)) (PP (IN of) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (JJ Doc_11176729_28_39_Chemical-converting) (JJ enzyme) (NNS inhibitors))))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_11176729_86_107_Disease)))))) (: :) (NP (NP (NNS results)) (PP (IN from) (NP (DT the) (NNP ATLAS) (NN trial)))) (. .)))
11176729	1	(S1 (NP (NP (DT The) (NNP Assessment)) (PP (IN of) (NP (NN Treatment))) (PP (IN with) (NP (NP (NN Doc_11176729_172_182_Chemical)) (CC and) (NP (NN Survival)))) (. .)))
11176729	2	(S1 (S (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NNP Doc_11176729_224_270_Chemical)))) (VP (VBZ reduces) (NP (NP (NN mortality)) (CC and) (NP (NN morbidity))) (PP (IN in) (NP (NNS patients))) (PP (IN with) (NP (NP (NNP Doc_11176729_320_341_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11176729_343_346_Disease)) (-RRB- -RRB-)))))) (, ,) (CC but) (S (NP (JJS most) (JJ affected) (NNS patients)) (VP (VP (AUX are) (RB not) (VP (VBG receiving) (NP (DT these) (NNS agents)))) (CC or) (VP (AUX are) (VP (AUXG being) (VP (VBN treated) (PP (IN with) (NP (NP (NNS doses)) (ADJP (ADJP (JJR lower)) (PP (IN than) (NP (NP (DT those)) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADJP (JJ efficacious)) (PP (IN in) (NP (NNS trials))) (, ,) (PP (ADVP (RB primarily)) (IN because) (IN of) (NP (NP (NNS concerns)) (PP (IN about) (NP (NP (DT the) (NN safety) (CC and) (NN tolerability)) (PP (IN of) (NP (DT these) (NNS agents))))))) (, ,) (PP (ADVP (RB especially)) (IN at) (NP (DT the) (VBN recommended) (NNS doses))))))))))))))))) (. .)))
11176729	3	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ examines) (NP (NP (DT the) (NN safety) (CC and) (NN tolerability)) (PP (IN of) (NP (NN high-)))) (PP (VBN compared) (PP (IN with) (NP (NP (JJ low-dose) (NNP Doc_11176729_696_706_Chemical)) (PP (IN in) (NP (NNP Doc_11176729_710_713_Disease))))))) (. .)))
11176729	4	(S1 (S (NP (NP (DT The) (NN Assessment)) (PP (IN of) (NP (NP (NNP Doc_11176729_742_752_Chemical)) (CC and) (NP (NN Survival) (NN study))))) (VP (AUX was) (NP (NP (DT a) (JJ multicenter) (, ,) (JJ randomized) (, ,) (JJ double-blind) (NN trial)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (NNS patients)) (PP (IN with) (CC or) (IN without) (NP (JJ previous) (NN ACE) (NN inhibitor) (NN treatment)))) (VP (VP (AUX were) (VP (VBN stabilized) (S (VP (VBG receiving) (NP (JJ medium-dose) (NNP Doc_11176729_927_937_Chemical) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 12.5) (CC or) (CD 15.0)) (NNS mg)) (PP (IN once) (NP (JJ daily) (JJ -LSB-OD) (NN -RSB-)))) (-RRB- -RRB-))) (PP (IN for) (NP (QP (CD 2) (TO to) (CD 4)) (NNS weeks))))))) (CC and) (VP (ADVP (RB then)) (VBD randomized) (PP (TO to) (NP (NP (NP (NN high-)) (PRN (-LRB- -LRB-) (NP (QP (CD 35.0) (CC or) (CD 32.5) (CD mg)) (NNS OD)) (-RRB- -RRB-))) (CC or) (NP (JJ low-dose) (PRN (-LRB- -LRB-) (NP (QP (CD 5.0) (CC or) (CD 2.5) (CD mg)) (NNS OD)) (-RRB- -RRB-)) (NNS groups)))))))))) (. .)))
11176729	5	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NNP New) (NNP York) (NNP Heart) (NNP Association)))) (VP (VP (NNS classes) (NP (NNP II)) (PP (TO to) (NP (NNP IV) (NNP Doc_11176729_1136_1139_Disease)))) (CC and) (VP (VBD left) (SBAR (S (NP (NP (JJ ventricular) (NN ejection) (NNS fractions)) (PP (IN of) (NP (NP (QP (DT no) (JJR greater) (IN than) (CD 0.30))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 3164)) (-RRB- -RRB-))))) (VP (VP (AUX were) (VP (VBN randomized))) (CC and) (VP (VBD followed) (PRT (RP up)) (PP (IN for) (NP (NP (DT a) (NN median)) (PP (IN of) (NP (CD 46) (NNS months))))))))))) (. .)))
11176729	6	(S1 (S (NP (PRP We)) (VP (VBD examined) (NP (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (JJ adverse) (NNS events)))) (CC and) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (NN discontinuation)) (CC and) (NP (NN dose) (NN reduction)))))) (PP (IN during) (NP (NN treatment))) (, ,) (PP (IN with) (NP (NP (DT a) (NN focus)) (PP (IN on) (NP (NP (NNP Doc_11176729_1405_1416_Disease)) (CC and) (NP (NNP Doc_11176729_1421_1438_Disease))))))) (. .)))
11176729	7	(S1 (S (PP (IN Of) (NP (NP (CD 405) (NNS patients)) (VP (ADVP (RB not) (RB previously)) (VBG receiving) (NP (DT an) (NN ACE) (NN inhibitor))))) (, ,) (NP (NP (NNS doses)) (PP (IN in) (NP (QP (RB only) (CD 4.2)) (NN %)))) (VP (MD could) (RB not) (VP (AUX be) (VP (VBN titrated) (PP (TO to) (NP (NP (DT the) (JJ medium) (NNS doses)) (VP (VBN required) (PP (IN for) (NP (NN randomization))) (PP (PP (IN because) (IN of) (NP (NP (NNS symptoms)) (VP (ADVP (RB possibly)) (VBN related) (PP (TO to) (NP (NP (NNP Doc_11176729_1636_1647_Disease)) (PRN (-LRB- -LRB-) (NP (CD 2.0) (NN %)) (-RRB- -RRB-))))))) (CC or) (PP (IN because) (IN of) (NP (NP (NNP Doc_11176729_1669_1686_Disease) (CC or) (NNP Doc_11176729_1690_1702_Disease)) (PRN (-LRB- -LRB-) (NP (CD 2.3) (NN %)) (-RRB- -RRB-))))))))))) (. .)))
11176729	8	(S1 (S (S (NP (NP (NNS Doses)) (PP (IN in) (NP (NP (NP (QP (JJR more) (IN than) (CD 90)) (NN %)) (PP (IN of) (NP (NP (JJ randomized) (NNS patients)) (PP (IN in) (NP (DT the) (NN high-)))))) (CC and) (NP (JJ low-dose) (NNS groups))))) (VP (AUX were) (VP (VBN titrated) (PP (TO to) (NP (PRP$ their) (VBN assigned) (NN target)))))) (, ,) (CC and) (S (NP (NP (DT the) (JJ mean) (NNS doses)) (PP (IN of) (NP (JJ blinded) (NN medication))) (PP (IN in) (NP (DT both) (NNS groups)))) (VP (VBD remained) (ADJP (JJ similar)) (PP (IN throughout) (NP (DT the) (NN study))))) (. .)))
11176729	9	(S1 (S (NP (NNS Withdrawals)) (VP (VBD occurred) (PP (IN in) (NP (NP (NP (CD 27.1) (NN %)) (PP (IN of) (NP (DT the) (NN high-)))) (CC and) (NP (NP (CD 30.7) (NN %)) (PP (IN of) (NP (DT the) (JJ low-dose) (NNS groups))))))) (. .)))
11176729	10	(S1 (S (NP (NP (NNS Subgroups)) (VP (VBN presumed) (S (VP (TO to) (VP (AUX be) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN for) (NP (NP (NN ACE) (NN inhibitor) (NN intolerance)) (PRN (-LRB- -LRB-) (NP (NN blood) (NN pressure)) (, ,) (NP (NP (CD <120) (NNS mm)) (NP (NP (NNP Hg)) (: ;) (NP (NP (NNP Doc_11176729_2101_2111_Chemical)) (, ,) (NP (QP (CD >) (CC or) (CD =132.6) (CD micromol/L) (NN -LSB->) (CC or) (CD =1.5) (CD mg/dL)) (NN -RSB-))) (: ;) (NP (NP (NN age)) (, ,) (NP (QP (CD >) (CC or) (CD =70)) (NNS years))) (: ;) (CC and) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_11176729_2194_2202_Disease)))))) (-RRB- -RRB-))))))))))) (ADVP (RB generally)) (VP (VBD tolerated) (NP (DT the) (JJ high-dose) (NN strategy))) (. .)))
11176729	11	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP demonstrate) (SBAR (SBAR (IN that) (S (NP (NP (NN ACE) (NN inhibitor) (NN therapy)) (PP (IN in) (NP (JJS most) (NNS patients))) (PP (IN with) (NP (NNP Doc_11176729_2337_2340_Disease)))) (VP (MD can) (VP (AUX be) (VP (VP (ADVP (RB successfully)) (VBN titrated) (PP (TO to))) (CC and) (VP (VBN maintained) (PP (IN at) (NP (JJ high) (NNS doses))))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NP (ADJP (RBR more) (JJ aggressive)) (NN use)) (PP (IN of) (NP (DT these) (NNS agents)))) (VP (AUX is) (VP (VBN warranted))))))) (. .)))
11229942	0	(S1 (NP (NP (NNP Doc_11229942_0_7_Chemical)) (, ,) (NP (NNP Doc_11229942_9_16_Chemical)) (, ,) (CC and) (NP (NP (NNP Doc_11229942_22_34_Chemical) (NNP Doc_11229942_35_47_Disease)) (PP (IN in) (NP (NP (DT an) (NN animal) (NN model)) (PP (IN of) (NP (NNP Doc_11229942_70_77_Chemical) (CC and) (NNP Doc_11229942_82_89_Chemical) (NN abuse)))))) (. .)))
11229942	1	(S1 (S (NP (NP (JJ Simultaneous) (NN abuse)) (PP (IN of) (NP (NP (NNP Doc_11229942_131_138_Chemical)) (CC and) (NP (NNP Doc_11229942_143_150_Chemical))))) (VP (VBZ affects) (NP (QP (CD 12) (CD million)) (NNPS Americans)) (ADVP (RB annually))) (. .)))
11229942	2	(S1 (S (PP (IN In) (NP (NN combination))) (, ,) (NP (DT these) (NNS substances)) (VP (AUX are) (ADJP (ADVP (RB substantially) (RBR more)) (JJ toxic) (PP (IN than) (NP (NP (DT either) (NN drug)) (ADVP (RB alone)))))) (. .)))
11229942	3	(S1 (S (S (NP (PRP$ Their) (JJ combined) (NN Doc_11229942_291_307_Disease)) (VP (MD may) (VP (AUX be) (ADVP (RB due) (PP (TO to) (NP (NP (JJ independent) (NNS effects)) (PP (IN of) (NP (DT each) (NN drug))))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (PRP they)) (VP (MD may) (ADVP (RB also)) (VP (AUX be) (ADJP (JJ due) (PP (TO to) (NP (NP (NP (NNP Doc_11229942_389_401_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP CE)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (JJ Doc_11229942_410_417_Chemical) (NN metabolite)) (VP (VBN formed) (PP (ADVP (RB only)) (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_11229942_460_467_Chemical))))))))))))) (. .)))
11229942	4	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB delineate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN CE))) (PP (IN in) (NP (NP (DT the) (VBN combined) (NNP Doc_11229942_543_557_Disease)) (PP (IN of) (NP (NNP Doc_11229942_561_568_Chemical) (CC and) (NNP Doc_11229942_573_580_Chemical))) (PP (IN in) (NP (NP (DT a) (NN model)) (VP (VBG simulating) (NP (PRP$ their) (NN abuse)))))))))))) (. .)))
11229942	5	(S1 (S (NP (JJ Twenty-three) (NNS dogs)) (VP (AUX were) (VP (VBN randomized) (S (VP (TO to) (VP (VB receive) (ADVP (RB either)) (S (LST (LS 1)) (-RRB- -RRB-) (S (NP (NP (CD three) (JJ intravenous) (PRN (-LRB- -LRB-) (NP (NNP IV)) (-RRB- -RRB-)) (NNS boluses)) (PP (IN of) (NP (NNP Doc_11229942_714_721_Chemical) (CD 7.5)))) (VP (VBN mg/kg) (PP (IN with) (NP (NP (NNP Doc_11229942_737_744_Chemical) (PRN (-LRB- -LRB-) (NP (CD 1) (NN g/kg)) (-RRB- -RRB-) (PP (IN as) (NP (NP (DT an) (NNP IV) (NN infusion)) (PRN (-LRB- -LRB-) (NP (NNP C+E) (, ,) (NNP n) (SYM =) (CD 8)) (-RRB- -RRB-)) (, ,) (CD 2))) (-RRB- -RRB-) (NP (NP (NP (CD three) (JJ Doc_11229942_795_802_Chemical) (NNS boluses) (RB only)) (PRN (-LRB- -LRB-) (NP (NP (NNP C)) (, ,) (NP (NNP n) (SYM =) (CD 6))) (-RRB- -RRB-))) (, ,) (NP (CD 3))) (-RRB- -RRB-)) (NNP Doc_11229942_831_838_Chemical) (NN infusion) (RB only)) (PRN (-LRB- -LRB-) (NP (NNP E)) (, ,) (NP (NNP n) (SYM =) (CD 5)) (-RRB- -RRB-)))))) (, ,) (CC or) (S (LST (LS 4)) (-RRB- -RRB-) (NP (NP (NN placebo) (NNS boluses)) (CC and) (NP (NP (NN infusion)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 4)) (-RRB- -RRB-))))))))))) (. .)))
11229942	6	(S1 (S (NP (NP (JJ Hemodynamic) (NNS measurements)) (, ,) (NP (NNS electrocardiograms)) (, ,) (CC and) (NP (NN serum) (NN drug) (NNS concentrations))) (VP (VP (AUX were) (VP (VBN obtained) (PP (IN at) (NP (NN baseline))))) (, ,) (CC and) (VP (ADVP (RB then)) (PP (IN at) (NP (VBN fixed) (NN time) (NNS intervals))) (SBAR (IN after) (S (NP (DT each) (NN drug)) (VP (AUX was) (VP (VBN administered))))))) (. .)))
11229942	7	(S1 (NP (NP (CD Two)) (PP (IN of) (NP (CD eight) (NNS dogs))) (PP (IN in) (NP (NP (DT the) (NNP C+E) (NN group)) (VP (VBN experienced) (NP (NNP Doc_11229942_1135_1158_Disease))))) (. .)))
11229942	8	(S1 (S (S (NP (DT The) (JJS most) (JJ dramatic) (JJ hemodynamic) (NNS changes)) (VP (VBD occurred) (PP (IN after) (NP (NP (DT each) (JJ Doc_11229942_1218_1225_Chemical) (NN bolus)) (PP (IN in) (NP (NP (DT the) (NNP C+E)) (CC and) (NP (NNP C) (JJ only) (NNS groups)))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (JJ persistent) (NN hemodynamic) (NNS changes)) (VP (VBD occurred) (PP (IN in) (NP (DT the) (NNP C+E) (NN group))))) (. .)))
11229942	9	(S1 (S (NP (NN Peak) (NN CE) (NNS levels)) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT a) (ADJP (ADJP (CD 45) (NN %)) (PRN (-LRB- -LRB-) (NP (CD SD) (NN +/-)) (ADJP (CD 22) (NN %)) (, ,) (NP (NP (CD 95) (NN %)) (NP (QP (CD CI) (SYM =) (CD 22) (NN %) (TO to) (CD 69) (NN %)))) (-RRB- -RRB-))) (NN decrease)) (PP (IN in) (NP (JJ cardiac) (NN output)))) (PRN (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.05)) (-RRB- -RRB-)) (, ,) (NP (NP (NP (DT a) (ADJP (ADJP (CD 56) (NN %)) (PRN (-LRB- -LRB-) (NP (CD SD) (NN +/-)) (ADJP (CD 23) (NN %)) (, ,) (NP (NP (CD 95) (NN %)) (NN CI)) (ADJP (QP (SYM =) (CD 32) (NN %) (TO to) (CD 80) (NN %))) (-RRB- -RRB-))) (NN decrease)) (PP (IN in) (NP (NP (CD dP/dt)) (-LRB- -LRB-) (NP (NNP max)) (-RRB- -RRB-)))) (-LRB- -LRB-) (NP (NNP p) (CD <.006)) (-RRB- -RRB-)) (, ,) (CC and) (NP (NP (NP (NP (DT a) (ADJP (ADJP (CD 23) (NN %)) (PRN (-LRB- -LRB-) (NP (CD SD) (NN +/-)) (ADJP (CD 15) (NN %)) (, ,) (NP (NP (CD 95) (NN %)) (NN CI)) (ADJP (QP (SYM =) (CD 7) (NN %) (TO to) (CD 49) (NN %))) (-RRB- -RRB-))) (NN decrease)) (PP (IN in) (NP (NNP SVO)))) (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.025)) (-RRB- -RRB-)))))) (. .)))
11229942	10	(S1 (S (NP (NN Doc_11229942_1593_1616_Disease)) (VP (AUX were) (ADVP (RB primarily)) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NNP C+E) (NN group)) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (CD four)) (PP (IN of) (NP (CD eight) (NNS dogs)))) (VP (VBD experienced) (NP (NN Doc_11229942_1699_1722_Disease))))))))) (. .)))
11229942	11	(S1 (S (NP (NP (NP (NNP Doc_11229942_1737_1744_Chemical)) (CC and) (NP (NNP Doc_11229942_1749_1756_Chemical))) (PP (IN in) (NP (NN combination)))) (VP (AUX were) (ADJP (ADJP (RBR more) (JJ toxic)) (PP (IN than) (NP (NP (DT either) (NN substance)) (ADVP (RB alone)))))) (. .)))
11229942	12	(S1 (S (NP (NN Co-administration)) (VP (VP (VBD resulted) (PP (IN in) (NP (JJ prolonged) (NNP Doc_11229942_1857_1873_Disease)))) (CC and) (VP (AUX was) (ADVP (RB dysrhythmogenic)))) (. .)))
11229942	13	(S1 (S (NP (JJ Peak) (NN serum) (NN Doc_11229942_1910_1922_Chemical) (NNS concentrations)) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_11229942_1959_1990_Disease))))) (. .)))
11299446	0	(S1 (FRAG (S (VP (VBG Worsening) (PP (IN of) (NP (NNP Doc_11299446_13_25_Disease))) (PP (IN after) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_11299446_43_54_Chemical))) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (NN menopause))))))))) (: :) (NP (NN case) (NN report)) (. .)))
11299446	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (JJ female) (NN patient)) (PP (IN with) (NP (JJ stable) (NNP Doc_11299446_137_156_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX has) (VP (VBN shown) (NP (NP (NP (DT a) (VBN marked) (VBG worsening)) (PP (IN of) (NP (NP (PRP$ her) (NN motor) (NNS functions)) (VP (VBG following) (NP (NP (NN therapy)) (PP (IN of) (NP (JJ menopause) (JJ related) (NNS symptoms))) (PP (IN with) (NP (NNP Doc_11299446_266_277_Chemical)))))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NN improvement)) (PP (IN of) (NP (PRP$ her) (NNS symptoms))))) (ADVP (RB back) (PP (TO to) (NP (NN baseline)))) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (DT the) (NN drug))))))))))) (. .)))
11299446	2	(S1 (S (NP (PRP We)) (VP (VB emphasize) (NP (NP (DT the) (JJ anti-dopaminergic) (NN effect)) (PP (IN of) (NP (NNP Doc_11299446_419_430_Chemical))))) (. .)))
11366874	0	(S1 (NP (NN Viracept) (CC and) (NN irregular) (NN heartbeat) (NN warning) (. .)))
11366874	1	(S1 (S (NP (NP (DT A) (NN group)) (PP (IN of) (NP (NNS doctors))) (PP (IN in) (NP (NNP Boston)))) (VP (VBP warn) (SBAR (IN that) (S (NP (DT the) (JJ protease) (NN inhibitor) (NN Viracept)) (VP (MD may) (VP (VB cause) (NP (NP (DT an) (JJ irregular) (NN heart) (NN beat)) (, ,) (VP (VBN known) (PP (IN as) (NP (NNP Doc_11366874_157_168_Disease)))) (, ,)) (PP (IN in) (NP (NP (NNS people)) (PP (IN with) (NP (NNP HIV)))))))))) (. .)))
11366874	2	(S1 (S (NP (NN Doc_11366874_190_201_Disease)) (VP (VBD occurred) (PP (IN in) (NP (NP (DT a) (JJ 45-year-old) (NN male) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBN Viracept) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (JJ anti-HIV) (NNS drugs)))))))))))) (. .)))
11366874	3	(S1 (S (NP (DT The) (NNS symptoms)) (VP (VBD ceased) (PP (IN after) (S (VP (VBG switching) (PP (TO to) (NP (DT another) (NN drug) (NN combination))))))) (. .)))
11380496	0	(S1 (S (NP (NP (NN Frequency)) (PP (IN of) (NP (NP (NN appearance)) (PP (IN of) (NP (NP (JJ myeloperoxidase-antineutrophil) (JJ cytoplasmic) (NN antibody)) (PRN (-LRB- -LRB-) (NP (NNP MPO-ANCA)) (-RRB- -RRB-)))) (PP (IN in) (NP (NNP Doc_11380496_93_108_Disease) (NNS patients)))))) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_11380496_131_147_Chemical)) (CC and) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NN MPO-ANCA)) (CC and) (NP (JJ clinical) (NNS manifestations)))))))) (. .)))
11380496	1	(S1 (S (NP (NP (JJ Myeloperoxidase) (JJ antineutrophil) (NN cytoplasmic) (NN antibody)) (PRN (-LRB- -LRB-) (NP (NNP MPO-ANCA)) (-RRB- -RRB-)) (NP (JJ -positive) (NNP Doc_11380496_298_308_Disease))) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_11380496_344_359_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_11380496_382_398_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11380496_400_403_Chemical)) (-RRB- -RRB-))))))))))))) (. .)))
11380496	2	(S1 (S (NP (NP (DT The) (NN appearance)) (PP (IN of) (NP (NN MPO-ANCA))) (PP (IN in) (NP (DT these) (NNS cases)))) (VP (AUX was) (VP (VBN suspected) (PP (IN of) (S (VP (AUXG being) (VP (VBN related) (PP (TO to) (NP (NNP Doc_11380496_482_485_Chemical))) (SBAR (IN because) (S (NP (NP (DT the) (NNS titres)) (PP (IN of) (NP (NNP MPO-ANCA)))) (VP (VBD decreased) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_11380496_532_535_Chemical)) (VP (AUX was) (VP (VBN stopped)))))))))))))) (. .)))
11380496	3	(S1 (S (ADVP (RB Nevertheless)) (, ,) (NP (EX there)) (VP (AUX have) (VP (AUX been) (NP (NP (DT no) (NNS studies)) (PP (PP (IN on) (NP (NP (DT the) (JJ temporal) (NN relationship)) (PP (IN between) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (NP (NNP MPO-ANCA)) (CC and) (NP (NNP Doc_11380496_658_668_Disease)))) (PP (IN during) (NP (JJ Doc_11380496_676_679_Chemical) (NN therapy))))))) (, ,) (CC or) (PP (IN on) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP MPO-ANCA))) (PP (IN in) (NP (JJ untreated) (NNP Doc_11380496_734_749_Disease) (NNS patients))))))))) (. .)))
11380496	4	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (PRP we)) (VP (VBD sought) (S (VP (TO to) (VP (VB address) (NP (DT these) (NNS parameters)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN Doc_11380496_826_841_Disease))))))))) (. .)))
11380496	5	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (CD 102) (JJ untreated) (NNS patients)) (PP (IN with) (NP (NNP Doc_11380496_897_912_Disease)))) (PP (JJ due) (TO to) (NP (NNP Doc_11380496_920_935_Disease))) (PP (PP (IN for) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP MPO-ANCA))))) (, ,) (CC and) (PP (IN for) (NP (NP (DT the) (NN development) (NN Doc_11380496_990_1000_Disease)) (PP (IN after) (S (VP (VBG starting) (NP (JJ Doc_11380496_1016_1019_Chemical) (NN therapy))))))))) (. .)))
11380496	6	(S1 (S (NP (NP (NN Twenty-nine)) (PP (IN of) (NP (PRP them)))) (VP (AUX were) (ADVP (RB later)) (VP (VBN excluded) (UCP (PP (IN because) (IN of) (NP (NP (JJ adverse) (NNS effects)) (PP (IN of) (NP (NNP Doc_11380496_1099_1102_Chemical))))) (CC or) (SBAR (IN because) (S (NP (DT the) (JJ observation) (NN period)) (VP (AUX was) (NP (QP (JJR less) (IN than) (CD 3)) (NNS months)))))))) (. .)))
11380496	7	(S1 (S (NP (NP (NP (DT The) (JJ remaining) (CD 73) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD 55) (NNS women)) (CC and) (NP (CD 18) (NNS men))) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (DT all) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (AUX were) (VP (VBN examined) (PP (IN for) (NP (QP (JJR more) (IN than) (CD 3)) (NNS months))))))) (, ,)) (VP (AUX were) (VP (VBN adopted) (PP (IN as) (NP (NP (DT the) (NNS subjects)) (PP (IN of) (NP (DT the) (NN investigation))))))) (. .)))
11380496	8	(S1 (S (NP (DT The) (JJ median) (NN observation) (NN period)) (VP (AUX was) (NP (NP (CD 23.6) (NNS months)) (PRN (-LRB- -LRB-) (NP (NP (NN range)) (: :) (NP (CD 3-37) (NNS months))) (-RRB- -RRB-)))) (. .)))
11380496	9	(S1 (S (NP (NN MPO-ANCA)) (VP (AUX was) (VP (VBN measured) (PP (IN at) (NP (NP (NNS intervals)) (PP (IN of) (NP (JJ 2-6) (NNS months))))))) (. .)))
11380496	10	(S1 (S (PP (IN Before) (NP (NN treatment))) (, ,) (NP (NP (DT the) (JJ MPO-ANCA) (NNS titres)) (PP (IN of) (NP (DT all) (CD 102) (JJ untreated) (NN Doc_11380496_1511_1526_Disease) (NNS patients)))) (VP (AUX were) (PP (IN within) (NP (NP (DT the) (NN reference) (NN range)) (PRN (-LRB- -LRB-) (NP (QP (IN below) (CD 10)) (NNP U/ml)) (-RRB- -RRB-))))) (. .)))
11380496	11	(S1 (S (NP (NP (NP (CD Three)) (PRN (-LRB- -LRB-) (NP (CD 4.1) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (CD 73) (NNS patients)))) (VP (AUX were) (ADJP (JJ positive)) (PP (IN for) (NP (NN MPO-ANCA))) (PP (IN at) (NP (CD 13) (, ,) (CD 16) (CC and) (CD 17) (NNS months))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN after) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (JJ Doc_11380496_1702_1705_Chemical) (NN therapy)))))) (. .)))
11380496	12	(S1 (S (PP (IN In) (NP (NP (CD two)) (PP (IN of) (NP (PRP them))))) (, ,) (S (NP (DT the) (NNP MPO-ANCA) (NNS titres)) (ADVP (RB transiently)) (VP (VBD increased) (PP (TO to) (NP (CD 12.8) (CC and) (CD 15.0))) (NP (NNP U/ml)) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN despite) (NP (JJ continued) (JJ Doc_11380496_1828_1831_Chemical) (NN therapy))))) (, ,) (CC but) (S (NP (DT no) (NN Doc_11380496_1848_1868_Disease)) (VP (VBD developed))) (. .)))
11380496	13	(S1 (S (PP (IN In) (NP (DT the) (JJ third) (NN patient))) (, ,) (S (NP (DT the) (NNP MPO-ANCA) (NN titre)) (VP (VBD increased) (PP (TO to) (NP (CD 204))) (NP (NNP U/ml)))) (CC and) (S (NP (PRP she)) (VP (VBD developed) (NP (NP (DT a) (JJR higher) (NN Doc_11380496_1970_1988_Disease)) (CC and) (NP (NNP Doc_11380496_1993_2007_Disease))))) (, ,) (CC but) (S (NP (DT the) (NNS symptoms)) (VP (VBD resolved) (NP (CD 2) (NNS weeks)) (PP (IN after) (S (VP (VBG stopping) (NP (JJ Doc_11380496_2058_2061_Chemical) (NN therapy))))))) (, ,) (CC and) (S (NP (DT the) (NNP MPO-ANCA) (NN titre)) (VP (VBD decreased) (PP (TO to) (NP (CD 20.7) (NN U/ml))) (PP (IN by) (NP (CD 4) (NNS months))) (PP (IN after) (S (VP (VBG discontinuing) (NP (NNP Doc_11380496_2149_2152_Chemical))))))) (. .)))
11380496	14	(S1 (S (S (NP (JJ Doc_11380496_2167_2170_Chemical) (NN therapy)) (VP (MD may) (VP (AUX be) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (NNP MPO-ANCA))))))))) (, ,) (CC but) (S (NP (NNP MPO-ANCA)) (VP (AUX does) (RB not) (VP (VB appear) (S (VP (TO to) (VP (AUX be) (ADJP (RB closely) (JJ related) (PP (TO to) (NP (NNP Doc_11380496_2279_2289_Disease)))))))))) (. .)))
11385188	0	(S1 (NP (NP (NN Prevalence)) (PP (IN of) (NP (NNP Doc_11385188_14_27_Disease))) (PP (IN in) (NP (JJ asymptomatic) (NN chronic) (NN Doc_11385188_52_59_Chemical) (NNS users))) (. .)))
11385188	1	(S1 (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NNP Doc_11385188_98_111_Disease)))) (PP (IN in) (NP (NN outpatient) (JJ young) (JJ asymptomatic) (NN chronic)))))) (NP (NP (JJ Doc_11385188_153_160_Chemical) (NNS users)) (, ,) (NP (CD 35) (JJ Doc_11385188_171_178_Chemical) (NNS users)) (CC and) (NP (CD 32) (JJ age-matched) (NNS controls))) (VP (VBD underwent) (NP (NP (NP (NP (NN resting)) (CC and) (NP (NN exercise) (NN electrocardiography))) (PRN (-LRB- -LRB-) (NP (NNP ECG)) (-RRB- -RRB-))) (CC and) (NP (NNP Doppler) (NN echocardiography)))) (. .)))
11385188	2	(S1 (S (S (NP (NP (NNS Findings)) (ADJP (JJ consistent) (PP (IN with) (NP (NNP Doc_11385188_325_348_Disease))))) (VP (AUX were) (VP (VBN detected) (PP (IN in) (NP (NP (CD 12) (PRN (-LRB- -LRB-) (NP (CD 34) (NN %)) (-RRB- -RRB-)) (NNS patients)) (CC and) (NP (CD 3) (PRN (-LRB- -LRB-) (NP (CD 9) (NN %)) (-RRB- -RRB-)) (NNS controls))))))) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.01)) (-RRB- -RRB-)) (. .)))
11385188	3	(S1 (S (NP (NN Doc_11385188_416_460_Disease)) (VP (AUX was) (VP (VBN demonstrated) (PP (PP (IN in) (NP (CD 5) (PRN (-LRB- -LRB-) (NP (CD 14) (NN %)) (-RRB- -RRB-)) (NNS patients))) (, ,) (CC but) (PP (IN in) (NP (NP (NN none)) (PP (IN of) (NP (NP (DT the) (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.055)) (-RRB- -RRB-))))))))) (. .)))
11385188	4	(S1 (S (ADVP (RB Finally)) (, ,) (NP (NP (NN resting)) (CC and) (NP (NP (JJ peak) (NN exercise) (JJ abnormal) (NN left) (NN ventricular)) (VP (VBG filling)))) (VP (AUX was) (VP (VBN detected) (PP (IN in) (NP (NP (CD 38)) (CC and) (NP (NP (CD 35) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN as) (PP (VBN compared) (PP (TO to) (NP (NP (QP (CD 19) (CC and) (CD 9)) (NN %)) (PP (IN of) (NP (NP (NNS controls)) (, ,) (ADVP (RB respectively)))) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (SYM =) (NP (CD 0.11) (CC and) (CD 0.02)) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))))))))))))) (. .)))
11385188	5	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (JJ coronary) (NN artery)) (CC or) (NP (NNP Doc_11385188_770_788_Disease))) (VP (AUX is) (ADJP (JJ common)) (PRN (-LRB- -LRB-) (NP (CD 38) (NN %)) (-RRB- -RRB-)) (PP (IN in) (NP (JJ young) (JJ asymptomatic) (NN chronic) (NN Doc_11385188_835_842_Chemical) (NNS users))))))) (. .)))
11385188	6	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN screening) (NN ECG)) (CC and) (NP (NN echocardiography))) (VP (MD may) (VP (AUX be) (VP (VBN warranted) (PP (IN in) (NP (DT these) (NNS patients)))))) (. .)))
11395263	0	(S1 (S (NP (NP (JJ Cardioprotective) (NNS effects)) (PP (IN of) (NP (NNP Picrorrhiza)))) (VP (VBP kurroa) (PP (IN against) (NP (NP (NNP Doc_11395263_55_68_Chemical-induced) (NNP Doc_11395263_77_94_Disease)) (PP (IN in) (NP (NNS rats)))))) (. .)))
11395263	1	(S1 (S (NP (NP (DT The) (JJ cardioprotective) (NN effect)) (PP (IN of) (NP (DT the) (NNP Doc_11395263_139_146_Chemical)))) (VP (VB extract) (PP (IN of) (NP (NP (NNP Picrorrhiza) (NN kurroa) (NNS rhizomes)) (CC and) (NP (NP (NNS roots)) (PRN (-LRB- -LRB-) (NP (NNP PK)) (-RRB- -RRB-))))) (PP (IN on) (NP (NP (JJ Doc_11395263_204_217_Chemical-induced) (NN Doc_11395263_226_247_Disease)) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (NN lipid) (NN metabolism)) (PP (IN in) (NP (NP (NN serum) (CC and) (NN heart) (NN tissue)) (SBAR (S (VP (AUX has) (VP (AUX been) (VP (VBN investigated))))))))))))))))) (. .)))
11395263	2	(S1 (S (NP (NP (JJ Oral) (NN pre-treatment)) (PP (IN with) (NP (NP (NNS PK)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (QP (CD 80) (CD mg)) (NNS kg)) (NP (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (NN day))) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-))) (PP (IN for) (NP (CD 15) (NNS days)))) (-RRB- -RRB-))))) (VP (VP (ADVP (RB significantly)) (VBD prevented) (NP (DT the) (JJ Doc_11395263_428_441_Chemical-induced) (NNP Doc_11395263_450_471_Disease))) (CC and) (VP (VBD maintained) (NP (DT the) (NNS rats)) (PP (IN at) (NP (JJ near) (JJ normal) (NN status))))) (. .)))
11401944	0	(S1 (NP (NP (NP (NN Phase) (CD 2) (JJ early) (NN afterdepolarization)) (PP (IN as) (NP (NP (DT a) (NN trigger)) (PP (IN of) (NP (NP (JJ polymorphic) (NNP Doc_11401944_62_85_Disease)) (PP (IN in) (NP (VBN acquired) (NNP Doc_11401944_98_114_Disease)))))))) (: :) (NP (NP (JJ direct) (NN evidence)) (PP (IN from) (NP (NP (JJ intracellular) (NNS recordings)) (PP (IN in) (NP (DT the) (JJ intact) (JJ left) (NN ventricular) (NN wall)))))) (. .)))
11401944	1	(S1 (S (NP (DT This) (NN study)) (VP (VBD examined) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (NN phase) (CD 2) (JJ early) (NN afterdepolarization)) (PRN (-LRB- -LRB-) (INTJ (UH EAD)) (-RRB- -RRB-)))) (PP (IN in) (S (VP (VBG producing) (NP (NP (DT a) (NN trigger)) (SBAR (S (VP (TO to) (VP (VB initiate) (NP (NP (NNP Doc_11401944_319_337_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11401944_339_342_Disease)) (-RRB- -RRB-))) (SBAR (IN with) (S (NP (NNP Doc_11401944_349_364_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_11401944_376_386_Chemical) (CC and) (NNP Doc_11401944_391_400_Chemical)))))))))))))))) (. .)))
11401944	2	(S1 (S (NP (NP (DT The) (NN contribution)) (PP (IN of) (NP (NP (JJ transmural) (NN dispersion)) (PP (IN of) (NP (NP (NN repolarization)) (PRN (-LRB- -LRB-) (NP (NNP TDR)) (-RRB- -RRB-)))))) (PP (TO to) (NP (NP (NP (JJ transmural) (NN propagation)) (PP (IN of) (NP (NN EAD)))) (CC and) (NP (NP (DT the) (NN maintenance)) (PP (IN of) (NP (NNP Doc_11401944_524_527_Disease))))))) (VP (AUX was) (ADVP (RB also)) (VP (VBN evaluated))) (. .)))
11401944	3	(S1 (S (S (NP (NP (NNS METHODS) (CC AND) (NNS RESULTS)) (: :) (NP (NP (NNP Transmembrane) (NN action) (NNS potentials)) (PP (IN from) (NP (NP (NN epicardium)) (, ,) (NP (NNP Doc_11401944_618_631_Chemical))))) (, ,) (CC and) (NP (NN endocardium))) (VP (AUX were) (VP (VBN recorded) (ADVP (RB simultaneously)) (, ,) (ADVP (RB together) (PP (IN with) (NP (DT a) (JJ transmural) (NN ECG)))) (, ,) (PP (IN in) (NP (ADJP (RB arterially) (VBN perfused)) (NN canine)))))) (CC and) (S (NP (NN rabbit)) (VP (VBD left) (NP (NP (JJ ventricular) (JJ preparations.) (JJ Doc_11401944_783_793_Chemical) (ADJP (RB preferentially) (VBN prolonged)) (NN action) (JJ potential) (NN duration)) (PRN (-LRB- -LRB-) (NP (NNP APD)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NNP M) (NNS cells)) (ADJP (ADJP (JJ dose-dependently)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (TO to) (CD 100)) (NNS micromol/L)) (-RRB- -RRB-))) (, ,) (VP (VBG leading) (PP (TO to) (NP (NP (NNP Doc_11401944_913_928_Disease)) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NNP TDR))))))))))) (. .)))
11401944	4	(S1 (S (NP (NN Doc_11401944_953_962_Chemical)) (, ,) (ADVP (RB however)) (, ,) (VP (VP (ADVP (RB significantly)) (VBN prolonged) (NP (NNP APD) (CC and) (NNP QT) (NN interval)) (PP (IN at) (NP (NP (NNS concentrations)) (PP (IN from) (NP (QP (CD 0.1) (TO to) (CD 10)) (NN micromol/L)))))) (CC but) (VP (VBN shortened) (NP (PRP them)) (PP (IN at) (NP (CD 30) (NNS micromol/L))))) (. .)))
11401944	5	(S1 (S (PP (IN Unlike) (NP (NNP Doc_11401944_1105_1115_Chemical))) (, ,) (NP (NP (NNP Doc_11401944_1117_1126_Chemical)) (PRN (-LRB- -LRB-) (NP (CD >3) (NN micromol/L)) (-RRB- -RRB-))) (VP (VBD increased) (NP (JJ epicardial) (NN APD)) (ADVP (RB markedly)) (, ,) (S (VP (VBG causing) (NP (DT a) (JJ diminished) (NN TDR))))) (. .)))
11401944	6	(S1 (S (SBAR (IN Although) (S (NP (DT both) (NNP Doc_11401944_1218_1228_Chemical) (CC and) (NNP Doc_11401944_1233_1242_Chemical)) (ADVP (RB rarely)) (VP (VBN induced) (ADVP (RB EADs)) (PP (IN in) (NP (JJ canine) (NN left) (NNS ventricles)))))) (, ,) (NP (PRP they)) (VP (VBD produced) (NP (NP (JJ frequent) (NNS EADs)) (PP (IN in) (NP (NP (NNS rabbits)) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (JJR more) (JJ pronounced) (NN Doc_11401944_1355_1370_Disease)) (VP (AUX was) (VP (VBN seen))))))))) (. .)))
11401944	7	(S1 (S (NP (NP (DT An) (NN increase)) (PP (IN in) (NP (NNP TDR))) (PP (IN by) (NP (NNP Doc_11401944_1403_1413_Chemical)))) (VP (VBD facilitated) (NP (NP (JJ transmural) (NN propagation)) (PP (IN of) (NP (NP (NNS EADs)) (SBAR (WHNP (WDT that)) (S (VP (VBD initiated) (NP (NP (JJ multiple) (NNS episodes)) (PP (IN of) (NP (JJ spontaneous) (NNP Doc_11401944_1505_1508_Disease)))) (PP (IN in) (NP (QP (CD 3) (IN of) (CD 6)) (NN rabbit) (NN left) (NNS ventricles)))))))))) (. .)))
11401944	8	(S1 (S (PP (IN Of) (NP (NN note))) (, ,) (SBAR (IN although) (S (NP (NP (NNP Doc_11401944_1561_1570_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 3) (TO to) (CD 10)) (NN micromol/L)) (-RRB- -RRB-))) (VP (VBD increased) (NP (NN APD)) (ADVP (RBR more) (PP (IN than) (NP (NNP Doc_11401944_1616_1626_Chemical))))))) (, ,) (NP (PRP$ its) (NNS EADs)) (ADVP (RB often)) (VP (VBD failed) (S (VP (TO to) (VP (VB propagate) (ADVP (RB transmurally))))) (, ,) (PP (ADVP (RB probably)) (IN because) (IN of) (NP (DT a) (JJ diminished) (NN TDR)))) (. .)))
11401944	9	(S1 (S (NP (DT This) (NN study)) (VP (VP (VBZ provides) (NP (NP (DT the) (JJ first) (JJ direct) (NN evidence)) (PP (IN from) (NP (JJ intracellular) (NN action)))) (NP (JJ potential) (NNS recordings)) (SBAR (IN that) (S (NP (NN phase) (CD 2) (NN EAD)) (VP (MD can) (VP (AUX be) (VP (VBN generated) (PP (IN from) (NP (JJ intact) (JJ ventricular) (NN wall))))))))) (CC and) (VP (VBP produce) (NP (DT a) (NN trigger) (S (VP (TO to) (VP (VB initiate) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNP Doc_11401944_1931_1956_Disease)))))))))) (. .)))
11423811	0	(S1 (S (NP (DT A) (NN pilot) (NN study)) (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN safety)) (PP (IN of) (NP (JJ Doc_11423811_38_48_Chemical) (NN stress) (NN echocardiography))) (PP (IN in) (NP (NP (DT the) (NN emergency) (NN department) (NN evaluation)) (PP (IN of) (NP (NNP Doc_11423811_115_122_Chemical-associated) (NNP Doc_11423811_134_144_Disease)))))))) (. .)))
11423811	1	(S1 (S (S (VP (VB STUDY) (NP (NN OBJECTIVE)))) (: :) (S (NP (NP (NN Doc_11423811_163_173_Disease)) (PP (IN in) (NP (NP (DT the) (NN setting)) (PP (IN of) (NP (JJ Doc_11423811_192_199_Chemical) (NN use)))))) (VP (VBZ poses) (NP (DT a) (JJ diagnostic) (NN dilemma)))) (. .)))
11423811	2	(S1 (S (NP (NP (JJ Doc_11423811_232_242_Chemical) (NN stress) (NN echocardiography)) (PRN (-LRB- -LRB-) (NP (NN DSE)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (ADJP (ADJP (RB widely) (JJ available)) (CC and) (ADJP (JJ sensitive))) (NN test)) (PP (IN for) (S (VP (VBG evaluating) (NP (NN Doc_11423811_329_345_Disease))))))) (. .)))
11423811	3	(S1 (S (PP (IN Because) (IN of) (NP (NP (DT the) (JJ theoretical) (NN concern)) (VP (VBG regarding) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_11423811_410_420_Chemical)))) (PP (IN in) (NP (NP (DT the) (NN setting)) (PP (IN of) (NP (JJ Doc_11423811_439_446_Chemical) (NN use)))))))) (, ,) (NP (PRP we)) (VP (VBD conducted) (NP (NP (DT a) (NN pilot) (NN study)) (SBAR (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN safety)) (PP (IN of) (NP (NN DSE)))) (PP (IN in) (NP (NP (NN emergency) (NN department) (NNS patients)) (PP (IN with) (NP (JJ Doc_11423811_545_552_Chemical-associated) (NNP Doc_11423811_564_574_Disease))))))))))) (. .)))
11423811	4	(S1 (S (NP (DT A) (JJ prospective) (NN case) (NN series)) (VP (AUX was) (VP (VBN conducted) (PP (IN in) (NP (NP (DT the) (JJ intensive) (JJ diagnostic) (CC and) (NN treatment) (NN unit)) (PP (IN in) (NP (NP (DT the) (NNP ED)) (PP (IN of) (NP (DT an) (JJ urban) (JJ tertiary-care) (NN teaching) (NN hospital))))))))) (. .)))
11423811	5	(S1 (S (NP (NNS Patients)) (VP (AUX were) (ADJP (JJ eligible) (PP (IN for) (NP (NN DSE)))) (SBAR (IN if) (S (NP (PRP they)) (VP (VP (AUX had) (VP (VBN used) (NP (NNP Doc_11423811_775_782_Chemical)) (PP (IN within) (NP (NP (CD 24) (NNS hours)) (VP (VBG preceding) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNP Doc_11423811_822_832_Disease))))))))) (CC and) (VP (AUX had) (NP (NP (DT a) (JJ normal) (NN ECG)) (CC and) (NP (JJ Doc_11423811_858_868_Chemical) (NN level)))))))) (. .)))
11423811	6	(S1 (S (NP (NP (NNS Patients)) (VP (VBG exhibiting) (NP (NP (NNS signs)) (PP (IN of) (NP (VBG continuing) (NNP Doc_11423811_916_923_Chemical) (NN toxicity)))))) (VP (AUX were) (VP (VBN excluded) (PP (IN from) (NP (DT the) (NN study))))) (. .)))
11423811	7	(S1 (S (NP (DT All) (NNS patients)) (VP (AUX were) (VP (VBN admitted) (PP (TO to) (NP (DT the) (NN hospital))) (PP (IN for) (NP (JJ serial) (NN testing))) (PP (IN after) (NP (NP (DT the) (JJ DSE) (NN testing)) (PP (IN in) (NP (DT the) (JJ intensive) (JJ diagnostic) (CC and) (NN treatment) (NN unit))))))) (. .)))
11423811	8	(S1 (S (NP (JJ Twenty-four) (NNS patients)) (VP (AUX were) (VP (VBD enrolled))) (. .)))
11423811	9	(S1 (S (S (NP (CD Two) (NNS patients)) (VP (AUX had) (NP (JJ inadequate) (NN resting) (NNS images)))) (, ,) (S (NP (CD one) (NN DSE)) (VP (AUX was) (VP (VBN terminated) (PP (IN because) (IN of) (NP (JJ inferior) (NNS hypokinesis)))))) (, ,) (S (NP (DT another) (NN DSE)) (VP (AUX was) (VP (VBN terminated) (PP (IN because) (IN of) (NP (DT a) (JJ rate-related) (JJ atrial) (NN conduction) (NN deficit)))))) (, ,) (CC and) (S (NP (CD 1) (NN patient)) (VP (AUX did) (RB not) (VP (VB reach) (NP (DT the) (NN target) (NN heart) (NN rate))))) (. .)))
11423811	10	(S1 (S (ADVP (RB Thus)) (, ,) (NP (CD 19) (NNS patients)) (VP (VP (VBD completed) (NP (DT a) (NN DSE))) (CC and) (VP (VBD reached) (NP (PRP$ their) (NN target) (NN heart) (NNS rates)))) (. .)))
11423811	11	(S1 (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VBD experienced) (NP (NP (NNS signs)) (PP (IN of) (NP (NP (JJ exaggerated) (JJ adrenergic) (NN response)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN defined) (PP (IN as) (NP (NP (NP (DT a) (JJ systolic) (NN blood) (NN pressure)) (PP (IN of) (NP (QP (JJR greater) (IN than) (CD 200)) (JJ mm) (NNP Hg)))) (CC or) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NP (NNS tachydysrhythmias)) (PRN (-LRB- -LRB-) (PP (VBG excluding) (NP (NNP Doc_11423811_1641_1658_Disease))) (-RRB- -RRB-))))))))))))))) (. .)))
11423811	12	(S1 (S (NP (NP (JJ Further) (VBG suggesting) (NN lack)) (PP (IN of) (NP (NP (JJ exaggerated) (JJ adrenergic) (NN response)) (, ,) (NP (CD 13)))) (PRN (-LRB- -LRB-) (NP (CD 65) (NN %)) (-RRB- -RRB-)) (PP (IN of) (NP (CD 20) (NNS patients)))) (VP (VBD required) (NP (JJ supplemental) (NNP Doc_11423811_1767_1775_Chemical)) (S (VP (TO to) (VP (VB reach) (NP (PRP$ their) (NN target) (NN heart) (NNS rates)))))) (. .)))
11423811	13	(S1 (S (NP (DT No) (JJ exaggerated) (JJ adrenergic) (NN response)) (VP (AUX was) (VP (VBN detected) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_11423811_1876_1886_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ Doc_11423811_1921_1928_Chemical-related) (NN Doc_11423811_1937_1947_Disease))))))))))) (. .)))
11425091	0	(S1 (NP (NP (NP (JJ Prenatal) (JJ Doc_11425091_9_16_Chemical) (NN exposure)) (CC and) (NP (JJ cranial) (JJ sonographic) (NNS findings))) (PP (IN in) (NP (JJ preterm) (NNS infants))) (. .)))
11425091	1	(S1 (S (NP (JJ Prenatal) (NN Doc_11425091_97_104_Chemical) (NN exposure)) (VP (AUX has) (VP (AUX been) (VP (VBN linked) (PP (IN with) (NP (NP (NN Doc_11425091_135_158_Disease)) (CC and) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NP (NNS cysts)) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (ADJP (JJ detectable)) (PP (IN on) (NP (NP (JJ cranial) (NN sonography)) (PP (IN in) (NP (NP (NNS neonates)) (VP (VBN born) (PP (IN at) (NP (NN term))))))))))))))))))) (. .)))
11425091	2	(S1 (S (NP (PRP We)) (VP (VBD sought) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (JJ prenatal) (JJ Doc_11425091_289_296_Chemical) (NN exposure)) (VP (VBZ increases) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_11425091_333_351_Disease))) (PP (IN in) (NP (JJ preterm) (NNS infants))))))))))) (. .)))
11425091	3	(S1 (S (NP (PRP We)) (ADVP (RB retrospectively)) (VP (VBN reviewed) (NP (NP (DT the) (JJ medical) (NNS records)) (CC and) (NP (NP (JJ cranial) (NNS sonograms)) (VP (VBN obtained) (PP (IN during) (NP (NP (DT a) (JJ 1-year) (NN period)) (PP (IN on) (NP (CD 122) (JJ premature) (PRN (-LRB- -LRB-) (NP (NP (QP (CD <) (CD 36)) (NNS weeks)) (PP (IN of) (NP (NN gestation)))) (-RRB- -RRB-)) (NNS infants))))))))) (. .)))
11425091	4	(S1 (S (NP (NNS Infants)) (VP (AUX were) (VP (VBN categorized) (PP (IN into) (NP (NP (QP (CD 1) (IN of) (CD 2)) (NNS groups)) (: :) (NP (NP (NP (DT those)) (VP (VBN exposed) (PP (TO to) (NP (NNP Doc_11425091_597_604_Chemical))))) (CC and) (NP (NP (DT those)) (VP (RB not) (VBN exposed) (PP (TO to) (NP (NN Doc_11425091_630_637_Chemical)))))))))) (. .)))
11425091	5	(S1 (S (NP (NNS Infants)) (VP (AUX were) (VP (VBN assigned) (PP (TO to) (NP (DT the) (JJ Doc_11425091_668_675_Chemical-exposed) (NN group))) (SBAR (SBAR (IN if) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ maternal) (NN history)) (PP (IN of) (NP (JJ Doc_11425091_725_732_Chemical) (NN abuse)))) (PP (IN during) (NP (NN pregnancy)))))) (CC or) (SBAR (IN if) (S (NP (ADJP (JJ maternal) (CC or) (JJ neonatal)) (NN urine) (NN toxicology) (NNS results)) (VP (AUX were) (ADJP (JJ positive)) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN delivery))))))))))) (. .)))
11425091	6	(S1 (S (NP (NP (CD Five)) (PP (IN of) (NP (DT the) (CD 122) (NNS infants)))) (VP (AUX were) (VP (VBN excluded) (PP (IN from) (NP (DT the) (NN study))) (PP (IN because) (IN of) (NP (JJ insufficient) (UCP (JJ medical) (CC and) (NN drug)) (NNS histories))))) (. .)))
11425091	7	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_11425091_978_996_Disease))) (PP (IN in) (NP (DT the) (CD 117) (JJ remaining) (NNS infants)))) (VP (AUX was) (NP (NP (CD 14) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 16)) (PP (IN of) (NP (CD 117)))) (-RRB- -RRB-)))) (. .)))
11425091	8	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_11425091_1064_1082_Disease))) (PP (IN in) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NNP Doc_11425091_1105_1112_Chemical))))))) (ADVP (RB prenatally)) (VP (AUX was) (NP (NP (CD 44) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 8)) (PP (IN of) (NP (CD 18)))) (-RRB- -RRB-))) (PP (VBN compared) (PP (IN with) (NP (CD 8) (NN %)))) (PRN (-LRB- -LRB-) (NP (NP (CD 8)) (PP (IN of) (NP (CD 99)))) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (JJ unexposed) (NN group))) (PRN (-LRB- -LRB-) (NP (QP (CD p) (CD <)) (CD 0.01)) (-RRB- -RRB-))) (. .)))
11425091	9	(S1 (S (NP (PRP We)) (VP (VBD found) (NP (NP (DT an) (VBN increased) (NN incidence)) (PP (IN of) (NP (NN Doc_11425091_1252_1269_Disease) (NN formation))) (PP (IN in) (NP (NP (JJ preterm) (NNS infants)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN exposed) (PP (TO to) (NP (NNP Doc_11425091_1319_1326_Chemical))) (ADVP (RB prenatally)))))))))) (. .)))
11425091	10	(S1 (S (NP (DT This) (NN result)) (VP (AUX is) (ADJP (JJ consistent) (PP (IN with) (NP (NP (NNS results)) (PP (IN of) (NP (NP (JJ similar) (NNS studies)) (PP (IN in) (NP (NN term) (NNS infants))))))))) (. .)))
11439380	0	(S1 (NP (NP (NNP Doc_11439380_0_11_Chemical) (NNP Doc_11439380_12_22_Disease)) (PP (IN in) (NP (NNS patients))) (VP (VBN treated) (PP (IN for) (NP (JJ metastatic) (NN Doc_11439380_58_73_Disease)))) (. .)))
11439380	1	(S1 (S (NP (PRP We)) (ADVP (RB prospectively)) (VP (VBN evaluated) (NP (JJ Doc_11439380_102_113_Chemical-induced) (NNP Doc_11439380_122_132_Disease)) (S (VP (VBG using) (NP (JJ electrodiagnostic) (NNS studies))))) (. .)))
11439380	2	(S1 (S (NP (NP (JJ Sixty-seven) (NNS men)) (PP (IN with) (NP (NP (JJ metastatic) (JJ androgen-independent) (NNP Doc_11439380_219_234_Disease)) (PP (IN in) (NP (NP (DT an) (JJ open-label) (NN trial)) (PP (IN of) (NP (JJ oral) (NNP Doc_11439380_266_277_Chemical)))))))) (VP (VBD underwent) (NP (NP (NP (JJ neurologic) (NNS examinations)) (CC and) (NP (NN nerve) (NN conduction) (NNS studies))) (PRN (-LRB- -LRB-) (NP (NNP NCS)) (-RRB- -RRB-))) (PP (RB prior) (TO to) (CC and) (PP (IN at) (NP (JJ 3-month) (NNS intervals)))) (PP (IN during) (NP (NN treatment)))) (. .)))
11439380	3	(S1 (S (NP (NNS NCS)) (VP (VBD included) (NP (NP (NN recording)) (PP (IN of) (NP (NP (JJ sensory) (NN nerve) (NN action) (NNS potentials)) (PRN (-LRB- -LRB-) (VP (VBZ SNAPs)) (-RRB- -RRB-)))) (PP (IN from) (NP (NP (NN median)) (, ,) (NP (NN radial)) (, ,) (NP (NN ulnar)) (, ,) (CC and) (NP (JJ sural) (NNS nerves)))))) (. .)))
11439380	4	(S1 (S (S (NP (NP (JJ SNAP) (NNS amplitudes)) (PP (IN for) (NP (DT each) (NN nerve)))) (VP (AUX were) (VP (VBN expressed) (PP (IN as) (NP (NP (DT the) (NN percentage)) (PP (IN of) (NP (PRP$ its) (NN baseline)))))))) (, ,) (CC and) (S (NP (NP (DT the) (NN mean)) (PP (IN of) (NP (DT the) (CD four)))) (VP (AUX was) (VP (VBN termed) (S (NP (DT the) (JJ SNAP) (NN index)))))) (. .)))
11439380	5	(S1 (S (NP (NP (DT A) (ADJP (CD 40) (NN %)) (NN decline)) (PP (IN in) (NP (DT the) (JJ SNAP) (NN index)))) (VP (AUX was) (VP (VBN considered) (S (ADJP (RB clinically) (JJ significant))))) (. .)))
11439380	6	(S1 (S (NP (NN Doc_11439380_715_726_Chemical)) (VP (AUX was) (VP (VBN discontinued) (PP (IN in) (NP (CD 55) (NNS patients))) (PP (IN for) (NP (NP (NN lack)) (PP (IN of) (NP (JJ therapeutic) (NN response))))))) (. .)))
11439380	7	(S1 (S (S (NP (QP (IN Of) (CD 67)) (NNS patients)) (ADVP (RB initially)) (VP (VBD enrolled))) (, ,) (S (NP (CD 24)) (VP (VBD remained) (PP (IN on) (NP (NNP Doc_11439380_843_854_Chemical))) (PP (IN for) (NP (CD 3) (NNS months))))) (, ,) (S (NP (CD 8)) (VP (VBD remained) (PP (IN at) (NP (CD 6) (NNS months))))) (, ,) (CC and) (S (NP (CD 3)) (VP (VBD remained) (PP (IN at) (NP (CD 9) (NNS months))))) (. .)))
11439380	8	(S1 (S (NP (CD Six) (NNS patients)) (VP (VBD developed) (NP (NN Doc_11439380_944_954_Disease))) (. .)))
11439380	9	(S1 (S (NP (NP (JJ Clinical) (NNS symptoms)) (CC and) (NP (NP (DT a) (NN decline)) (PP (IN in) (NP (DT the) (JJ SNAP) (NN index))))) (VP (VBD occurred) (ADVP (RB concurrently))) (. .)))
11439380	10	(S1 (S (NP (NP (JJR Older) (NN age)) (CC and) (NP (JJ cumulative) (NN dose))) (VP (AUX were) (NP (JJ possible) (JJ contributing) (NNS factors))) (. .)))
11439380	11	(S1 (S (NP (NN Doc_11439380_1095_1105_Disease)) (VP (MD may) (ADVP (RB thus)) (VP (AUX be) (NP (NP (DT a) (JJ common) (NN complication)) (PP (IN of) (NP (NNP Doc_11439380_1143_1154_Chemical))) (PP (IN in) (NP (JJR older) (NNS patients)))))) (. .)))
11439380	12	(S1 (S (NP (DT The) (JJ SNAP) (NN index)) (VP (MD can) (VP (AUX be) (VP (VBN used) (S (VP (TO to) (VP (VB monitor) (NP (NN Doc_11439380_1212_1233_Disease))))) (, ,) (FRAG (CC but) (RB not) (PP (IN for) (NP (JJ early) (NN detection))))))) (. .)))
11474137	0	(S1 (S (NP (NP (NN Overexpression)) (PP (IN of) (NP (JJ Doc_11474137_18_24_Chemical/Doc_11474137_25_29_Chemical-Doc_11474137_30_40_Chemical) (NN dismutase)))) (VP (VBZ protects) (PP (IN from) (NP (NNP Doc_11474137_65_74_Chemical-induced) (NNP Doc_11474137_83_95_Disease)))) (. .)))
11474137	1	(S1 (S (NP (NP (DT The) (NN participation)) (PP (IN of) (NP (JJ reactive) (JJ Doc_11474137_127_133_Chemical) (NNS species))) (PP (IN in) (NP (JJ Doc_11474137_145_159_Chemical-induced) (NNP Doc_11474137_168_179_Disease)))) (VP (AUX has) (VP (AUX been) (VP (VBN deduced) (PP (IN from) (NP (NP (NNS observations)) (SBAR (SBAR (IN that) (S (NP (JJ Doc_11474137_220_234_Chemical-Doc_11474137_235_239_Chemical) (NNS complexes)) (VP (VBP catalyze) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (JJ Doc_11474137_276_286_Chemical) (NNS radicals))) (PP (IN in) (NP (NN vitro))))))) (CC and) (SBAR (IN that) (S (NP (NNS antioxidants)) (VP (VBP attenuate) (NP (NNP Doc_11474137_337_348_Disease)) (PP (IN in) (NP (NN vivo)))))))))))) (. .)))
11474137	2	(S1 (S (NP (PRP We)) (ADVP (RB therefore)) (VP (VBN hypothesized) (SBAR (IN that) (S (NP (NP (NN overexpression)) (PP (IN of) (NP (NP (JJ Doc_11474137_407_409_Chemical/Doc_11474137_410_412_Chemical-Doc_11474137_413_423_Chemical) (NN dismutase)) (PRN (-LRB- -LRB-) (NP (NN h-SOD1)) (-RRB- -RRB-))))) (VP (MD should) (VP (VB protect) (NP (NNP transgenic) (NNS mice)) (PP (IN from) (NP (NNP Doc_11474137_479_490_Disease)))))))) (. .)))
11474137	3	(S1 (S (NP (NN Immunocytochemistry)) (VP (VBD confirmed) (NP (NP (NN expression)) (PP (IN of) (NP (NN h-SOD1))) (PP (IN in) (NP (NP (JJ inner) (NN ear) (NNS tissues)) (PP (IN of) (NP (NNP transgenic) (NNP C57BL/6-TgN-LSB-SOD1) (JJ -RSB-) (NN 3Cje) (NNS mice))))))) (. .)))
11474137	4	(S1 (S (NP (NP (NNP Transgenic)) (CC and) (NP (JJ nontransgenic) (NNS littermates))) (VP (VBD received) (NP (NP (NNP Doc_11474137_656_665_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 400) (CD mg/kg)) (NN body) (NN weight/day)) (-RRB- -RRB-))) (PP (IN for) (NP (NP (CD 10) (NNS days)) (VP (VBG beginning) (PP (IN on) (NP (NN day) (CD 10))) (PP (IN after) (NP (NN birth))))))) (. .)))
11474137	5	(S1 (S (NP (NN Auditory) (NNS thresholds)) (VP (AUX were) (VP (VBN tested) (PP (IN by) (NP (JJ evoked) (NN auditory) (NN brain) (NN stem) (NNS responses))) (PP (IN at) (NP (NP (CD 1) (NN month)) (PP (IN after) (NP (NN birth))))))) (. .)))
11474137	6	(S1 (S (PP (IN In) (NP (JJ nontransgenic) (NNS animals))) (, ,) (NP (NP (DT the) (NN threshold)) (PP (IN in) (NP (DT the) (JJ Doc_11474137_882_891_Chemical-treated) (NN group)))) (VP (AUX was) (ADJP (ADJP (NP (CD 45-50) (NN dB)) (JJR higher)) (PP (IN than) (PP (IN in) (NP (JJ saline-injected) (NNS controls)))))) (. .)))
11474137	7	(S1 (S (PP (IN In) (NP (DT the) (NNP transgenic) (NN group))) (, ,) (NP (NNP Doc_11474137_985_994_Chemical)) (VP (VBD increased) (NP (DT the) (NN threshold)) (PP (IN by) (NP (QP (RB only) (CD 15)) (NN dB))) (PP (IN over) (NP (DT the) (JJ respective) (NNS controls)))) (. .)))
11474137	8	(S1 (S (NP (DT The) (NNS effects)) (VP (AUX were) (ADJP (JJ similar)) (PP (IN at) (NP (QP (CD 12) (CC and) (CD 24) (CD kHz))))) (. .)))
11474137	9	(S1 (S (NP (NP (DT The) (NN protection)) (PP (IN by) (NP (NP (NN overexpression)) (PP (IN of) (NP (JJ Doc_11474137_1142_1152_Chemical) (NN dismutase)))))) (VP (VBZ supports) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (JJ oxidant) (NN stress)) (VP (VBZ plays) (NP (DT a) (JJ significant) (NN role)) (PP (IN in) (NP (NNP Doc_11474137_1235_1249_Chemical-induced) (NNP Doc_11474137_1258_1269_Disease)))))))) (. .)))
11474137	10	(S1 (S (NP (DT The) (NNS results)) (ADVP (RB also)) (VP (VBP suggest) (NP (NP (NNP transgenic) (NNS animals)) (PP (IN as) (NP (NP (NP (JJ suitable) (NNS models)) (SBAR (S (VP (TO to) (VP (VB investigate) (NP (DT the) (VBG underlying) (NNS mechanisms))))))) (CC and) (NP (NP (JJ possible) (NNS strategies)) (PP (IN for) (NP (NN prevention)))))))) (. .)))
1158089	0	(S1 (S (NP (NN Doc_1158089_0_11_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_1158089_23_35_Chemical))) (PP (IN in) (NP (DT the) (NN rat)))) (. .)))
1158089	1	(S1 (NP (NP (NP (JJ Dose-response) (NNS relationships)) (CC and) (NP (NP (NN effect)) (PP (IN of) (NP (NN sex))))) (. .)))
1158089	2	(S1 (S (NP (NP (NP (JJ Dose-response) (NNS relationships)) (, ,) (NP (JJ biochemical) (NNS mechanisms)) (, ,) (CC and) (NP (NN sex) (NNS differences))) (PP (IN in) (NP (NP (DT the) (JJ experimental) (NN Doc_1158089_188_199_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_1158089_211_223_Chemical))))))) (VP (AUX were) (VP (VBN studied) (PP (PP (IN in) (NP (DT the) (JJ intact) (NN rat))) (CC and) (PP (IN with) (NP (NP (DT the) (VBN isolated) (JJ perfused) (NN rat) (NN liver)) (PP (IN in) (NP (NN vitro)))))))) (. .)))
1158089	3	(S1 (S (PP (IN In) (NP (DT the) (JJ intact) (NN male) (CC and) (NN female) (NN rat))) (, ,) (NP (DT no) (JJ direct) (NN relationship)) (VP (AUX was) (VP (VBN observed) (PP (IN between) (NP (NP (NP (NN dose)) (PP (IN of) (NP (NNP Doc_1158089_393_405_Chemical)))) (CC and) (NP (NP (JJ hepatic) (NN accumulation)) (PP (IN of) (NP (NNP Doc_1158089_434_446_Chemical)))))))) (. .)))
1158089	4	(S1 (S (PP (IN With) (NP (NP (NN provision)) (PP (IN of) (NP (JJ adequate) (NNP Doc_1158089_475_485_Chemical))) (PP (IN as) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (DT the) (VBN isolated) (JJ perfused) (NN liver))))))) (, ,) (NP (DT a) (JJ direct) (NN relationship)) (VP (AUX was) (VP (VBN observed) (PP (IN between) (NP (NP (NP (NN dose)) (PP (IN of) (NP (NNP Doc_1158089_585_597_Chemical)))) (CC and) (NP (NP (DT both) (NN accumulation)) (PP (IN of) (NP (NP (NP (NNP Doc_1158089_623_635_Chemical)) (PP (IN in) (NP (DT the) (NN liver)))) (CC and) (NP (NP (NNP Doc_1158089_653_663_Disease)) (PP (IN of) (NP (NP (NN output)) (PP (IN of) (NP (NNP Doc_1158089_677_689_Chemical))))))))))) (PP (IN by) (NP (NP (NNS livers)) (PP (IN from) (NP (ADJP (JJ male) (CC and) (JJ female)) (NNS rats))))))) (. .)))
1158089	5	(S1 (S (NP (JJ Marked) (NNS differences)) (VP (AUX were) (VP (VBN observed) (PP (IN between) (NP (NP (JJ female) (CC and) (JJ male) (NNS rats)) (PP (IN with) (NP (NP (NP (NN regard)) (PP (TO to) (NP (NP (NN base) (NN line) (-LRB- -LRB-) (NN control) (-RRB- -RRB-) (JJ hepatic) (NN concentration)) (PP (IN of) (NP (NNP Doc_1158089_849_861_Chemical)))))) (CC and) (NP (NP (NN output)) (PP (IN of) (NP (NNP Doc_1158089_876_888_Chemical)))))))))) (. .)))
1158089	6	(S1 (S (NP (NP (NN Accumulation)) (PP (IN of) (NP (JJ hepatic) (NNP Doc_1158089_914_926_Chemical)))) (, ,) (PP (IN as) (NP (NP (DT a) (FW per) (NN cent)) (PP (IN of) (NP (NN control) (NNS values))))) (, ,) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (JJ graded) (NNS doses)) (PP (IN of) (NP (NNP Doc_1158089_992_1004_Chemical))))))) (, ,) (VP (AUX did) (RB not) (VP (VB differ) (ADVP (RB significantly)) (PP (IN between) (NP (ADJP (NN male) (, ,) (JJ female) (CC and) (JJ pregnant)) (NN rat) (NNS livers))))) (. .)))
1158089	7	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NP (NNS livers)) (PP (IN from) (NP (NN female)))) (, ,) (CC and) (ADVP (RB especially)) (NP (JJ pregnant) (NN female) (NNS rats)) (, ,)) (VP (AUX were) (ADJP (RB strikingly) (JJ resistant) (PP (TO to) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_1158089_1191_1203_Chemical))) (PP (IN on) (NP (NP (NNP Doc_1158089_1207_1217_Disease)) (PP (IN of) (NP (NP (NN output)) (PP (IN of) (NP (NNP Doc_1158089_1231_1243_Chemical)))))))))) (PP (IN under) (NP (DT these) (JJ experimental) (NNS conditions)))) (. .)))
1158089	8	(S1 (S (NP (NP (DT These) (NNS differences)) (PP (IN between) (NP (DT the) (NNS sexes)))) (VP (MD could) (RB not) (VP (AUX be) (ADJP (JJ related) (PP (TO to) (NP (NP (NP (VBN altered) (NN disposition)) (PP (IN of) (NP (NNP Doc_1158089_1364_1376_Chemical)))) (CC or) (NP (NP (VBN altered) (NN uptake)) (PP (IN of) (NP (NNP Doc_1158089_1398_1408_Chemical))))))))) (. .)))
1158089	9	(S1 (S (NP (NP (JJ Depressed) (JJ hepatic) (NN secretion)) (PP (IN of) (NP (NNP Doc_1158089_1441_1453_Chemical)))) (VP (VBD accounted) (ADVP (RB only)) (PP (IN for) (NP (NP (QP (CD 30) (TO to) (CD 50)) (NN %)) (PP (IN of) (NP (VBN accumulated) (JJ hepatic) (NNP Doc_1158089_1506_1518_Chemical))))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (JJ additional) (NNS mechanisms)) (VP (MD must) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NP (DT the) (NNP Doc_1158089_1600_1612_Chemical-rich) (NNP Doc_1158089_1618_1629_Disease)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NNP Doc_1158089_1645_1657_Chemical))))))))))))))))) (. .)))
11708428	0	(S1 (S (NP (NN Doc_11708428_0_10_Chemical)) (VP (VBZ induces) (NP (NP (NN Doc_11708428_19_26_Disease)) (CC and) (NP (NP (JJ glial) (JJ cerebral) (NNS changes)) (PP (IN in) (NP (NNS rats)))))) (. .)))
11708428	1	(S1 (S (VP (TO To) (VP (VB assess) (SBAR (IN whether) (S (NP (NP (NNP Doc_11708428_92_102_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11708428_104_107_Chemical)) (-RRB- -RRB-))) (VP (VBZ produces) (NP (NP (NNP Doc_11708428_118_125_Disease) (NN and/or) (NN cerebral) (JJ glial) (NNS changes)) (PP (IN in) (NP (NNS rats))))))))) (. .)))
11708428	2	(S1 (S (S (NP (JJ Male) (JJ Wistar) (NNS rats)) (VP (AUX were) (VP (VBN studied)))) (CC and) (S (NP (CD 3) (NNS groups)) (VP (AUX were) (VP (VBN formed) (PRN (-LRB- -LRB-) (NP (NP (CD 8) (NNS rats)) (PP (IN per) (NP (NN group)))) (-RRB- -RRB-))))) (. .)))
11708428	3	(S1 (S (NP (DT The) (JJ moderate-dose) (NN group)) (VP (VBD received) (NP (NP (CD 5) (JJ mg/kg/day) (NN Doc_11708428_294_297_Chemical)) (VP (VBN released) (PP (IN from) (NP (DT a) (JJ subcutaneous) (NN implant)))))) (. .)))
11708428	4	(S1 (S (PP (IN In) (NP (DT the) (JJ high-dose) (NN group))) (, ,) (NP (NP (NNS implants)) (VP (VBG containing) (NP (JJ Doc_11708428_380_383_Chemical) (NN equivalent)) (PP (TO to) (NP (CD 60) (NN mg/kg/day))))) (VP (AUX were) (VP (VBN applied))) (. .)))
11708428	5	(S1 (S (PP (IN In) (NP (DT the) (NN control) (NN group))) (NP (NNS implants)) (VP (VBD contained) (NP (DT no) (NN Doc_11708428_468_471_Chemical))) (. .)))
11708428	6	(S1 (S (NP (NN Doc_11708428_473_480_Disease)) (VP (AUX was) (VP (VBN assessed) (S (VP (VBG using) (NP (NP (DT an) (JJ open) (NN field)) (CC and) (NP (JJ elevated) (JJ plus-maze) (NNS devices))))))) (. .)))
11708428	7	(S1 (S (NP (NP (NP (DT The) (NN number)) (PP (IN of) (NP (NNS cells)))) (CC and) (NP (NP (JJ cytoplasmic) (NN transformation)) (PP (IN of) (NP (NP (NNS astrocytes)) (CC and) (NP (NN microglia) (NNS cells)))))) (VP (AUX were) (VP (VBN assessed) (PP (IN by) (NP (JJ immunohistochemical) (NNS analyses))))) (. .)))
11708428	8	(S1 (S (NP (NN Doc_11708428_687_694_Disease)) (VP (AUX was) (VP (VBN documented) (PP (IN in) (NP (NP (DT both) (NNS groups)) (PP (IN of) (NP (JJ Doc_11708428_728_731_Chemical) (VBN treated) (NNS rats))))) (PP (VBN compared) (PP (IN with) (NP (NNS controls)))))) (. .)))
11708428	9	(S1 (S (NP (NP (DT The) (NN magnitude)) (PP (IN of) (NP (NP (NN transformation)) (PP (IN of) (NP (NP (DT the) (NN microglia)) (VP (VBN assessed) (PP (IN by) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NNS intersections))))))))))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR higher) (PP (IN in) (NP (DT the) (JJ Doc_11708428_890_893_Chemical) (NNS groups)))) (PP (IN than) (PP (IN in) (NP (NP (NNS controls)) (PP (IN in) (NP (NP (NP (DT the) (JJ prefrontal) (NN cortex)) (PRN (-LRB- -LRB-) (NP (NN moderate-dose)) (, ,) (NP (NP (CD 24.1)) (: ;) (NP (NP (NN high-dose)) (, ,) (NP (CD 23.6))) (: ;) (NP (NP (NNS controls)) (NP (CD 18.7))) (: ;) (NP (NNP p) (NNP <) (CD 0.01))) (-RRB- -RRB-))) (CC and) (NP (NP (NN striatum)) (PRN (-LRB- -LRB-) (NP (NP (NN moderate-dose) (CD 25.6)) (: ;) (NP (NN high-dose) (CD 26.3)) (: ;) (NP (NP (NNS controls)) (NP (CD 18.9))) (: ;) (NP (NNP p) (NNP <) (CD 0.01))) (-RRB- -RRB-))))))) (, ,) (CONJP (CC but) (RB not)) (PP (IN in) (NP (NN hippocampus)))))) (. .)))
11708428	10	(S1 (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (JJ stained) (NN microglia) (NNS cells)))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR higher) (PP (IN in) (NP (NP (DT the) (JJ Doc_11708428_1177_1180_Chemical) (VBN treated) (NNS groups)) (PP (IN in) (NP (DT the) (JJ prefrontal) (NN cortex)))))) (PP (IN than) (PP (IN in) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NP (NN moderate-dose)) (, ,) (NP (CD 29.1)) (: ;) (NP (NP (NN high-dose)) (, ,) (NP (CD 28.4))) (: ;) (NP (NP (NP (NN control)) (, ,) (NP (CD 17.7) (NNS cells))) (PP (IN per) (NP (NN field)))) (: ;) (NP (NNP p) (NNP <) (CD 0.01))) (-RRB- -RRB-))))))) (. .)))
11708428	11	(S1 (S (NP (JJ Stained) (NN microglia) (NNS cells)) (VP (AUX were) (NP (NP (ADJP (RB significantly) (JJR more)) (JJ numerous) (NN striatum)) (CC and) (NP (NP (NNS hippocampus)) (PP (IN in) (NP (DT the) (JJ high-dose) (NN group))))) (PP (VBN compared) (PP (TO to) (NP (NNS controls))))) (. .)))
11708428	12	(S1 (S (NP (NP (JJ Subacute) (NN exposure)) (PP (TO to) (NP (NNP Doc_11708428_1479_1482_Chemical)))) (VP (VBN induced) (NP (NP (NN Doc_11708428_1491_1498_Disease) (CC and) (NN reactivity)) (PP (IN of) (NP (NN microglia))))) (. .)))
11708428	13	(S1 (S (NP (NP (DT The) (NN relevance)) (PP (IN of) (NP (NP (DT these) (NNS features)) (PP (IN for) (NP (NP (NNS patients)) (VP (VBG using) (NP (NNP Doc_11708428_1579_1582_Chemical)))))))) (VP (VBZ remains) (S (VP (TO to) (VP (AUX be) (VP (VBN elucidated)))))) (. .)))
11745287	0	(S1 (S (VP (VP (VB Phase) (NP (NP (NNP II) (NN study)) (PP (IN of) (NP (NNP Doc_11745287_18_29_Chemical))))) (CC and) (VP (VB liposomal) (NP (NP (NNP Doc_11745287_44_55_Chemical)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ recurrent) (NNP Doc_11745287_83_120_Disease)))))))) (. .)))
11745287	1	(S1 (S (NP (NP (DT The) (NN activity)) (PP (IN of) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_11745287_169_180_Chemical)) (CC and) (NP (JJ liposomal) (NNP Doc_11745287_195_206_Chemical))))))) (VP (AUX was) (VP (VBN tested) (PP (IN in) (NP (NP (DT a) (NN Phase) (NNP II) (NN study)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ recurrent) (JJ cervical) (NN Doc_11745287_274_283_Disease))))))))) (. .)))
11745287	2	(S1 (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (NP (NP (NNP Doc_11745287_313_324_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NN area)) (PP (IN under) (NP (NP (DT the) (NN concentration) (NN curve)) (ADJP (JJ -LSB-AUC) (JJ -RSB-))))) (, ,) (NP (CD 5)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ liposomal) (NNP Doc_11745287_385_396_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11745287_398_403_Chemical)) (: ;) (NP (NP (JJ starting) (NN dose)) (, ,) (NP (CD 40) (NN mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (-RRB- -RRB-)))))) (VP (AUX was) (VP (VBN administered) (ADVP (RB intravenously) (NP (QP (DT every) (CD 28)) (NNS days)) (PP (TO to) (NP (CD 37) (NNS patients)))) (PP (IN with) (NP (JJ recurrent) (NNP Doc_11745287_507_539_Disease))) (S (VP (TO to) (VP (VB determine) (NP (NP (JJ antitumor) (NN activity)) (CC and) (NP (JJ Doc_11745287_576_584_Disease) (NN profile)))))))) (. .)))
11745287	3	(S1 (S (S (NP (NN Twenty-nine) (NNS patients)) (VP (AUX were) (ADJP (JJ assessable)) (PP (IN for) (NP (NN response))))) (, ,) (CC and) (S (NP (CD 35) (NNS patients)) (VP (AUX were) (ADJP (JJ assessable) (PP (IN for) (NP (NNP Doc_11745287_690_698_Disease)))))) (. .)))
11745287	4	(S1 (S (S (NP (DT The) (JJ overall) (NN response) (NN rate)) (VP (AUX was) (NP (CD 38) (NN %)))) (, ,) (S (NP (NP (DT the) (JJ median) (NN time)) (PP (TO to) (NP (NN response)))) (VP (AUX was) (NP (CD 10) (NNS weeks)))) (, ,) (S (NP (NP (DT the) (JJ median) (NN duration)) (PP (IN of) (NP (NN response)))) (VP (AUX was) (NP (CD 26) (NNS weeks)))) (, ,) (CC and) (S (NP (DT the) (JJ median) (NN survival)) (VP (AUX was) (NP (CD 37) (NNS weeks)))) (. .)))
11745287	5	(S1 (S (NP (DT The) (JJ main) (NN toxic) (NN effect)) (VP (AUX was) (NP (NN myelosuppression)) (, ,) (PP (IN with) (NP (NP (NNP Grade) (NNP 3)) (CC and) (NP (NP (CD 4) (NNP Doc_11745287_924_935_Disease)) (PP (IN in) (NP (CD 16) (NNS patients)))))) (, ,) (NP (NP (NP (NNP Doc_11745287_952_958_Disease)) (PP (IN in) (NP (CD 12) (NNS patients)))) (, ,) (NP (NP (NNP Doc_11745287_975_991_Disease)) (PP (IN in) (NP (CD 11) (NNS patients)))) (, ,) (CC and) (NP (NP (NNP Doc_11745287_1012_1029_Disease)) (PP (IN in) (NP (CD 3) (NNS patients)))))) (. .)))
11745287	6	(S1 (S (NP (CD Four) (NNS patients)) (VP (AUX had) (NP (CD five) (JJ infusion-related) (NNS reactions)) (PP (IN during) (NP (NP (DT the) (NN infusion)) (PP (IN of) (NP (JJ liposomal) (NNP Doc_11745287_1128_1139_Chemical))))) (, ,) (PP (VBG leading) (PP (TO to) (NP (NP (NN treatment) (NN discontinuation)) (PP (IN in) (NP (CD three) (NNS patients))))))) (. .)))
11745287	7	(S1 (S (NP (NNP Grade) (NNP >) (CC or) (SYM =)) (NP (CD 2) (JJ nonhematologic) (NN Doc_11745287_1227_1235_Disease)) (VP (VBD included) (NP (NP (NP (NNP Doc_11745287_1245_1251_Disease)) (PP (IN in) (NP (CD 17) (NNS patients)))) (, ,) (NP (NP (NN emesis)) (PP (IN in) (NP (CD 14) (NNS patients)))) (, ,) (NP (NP (NN fatigue)) (PP (IN in) (NP (CD 9) (NNS patients)))) (, ,) (NP (NP (NNP Doc_11745287_1314_1323_Disease) (NN and/or) (NNP Doc_11745287_1331_1341_Disease)) (PP (IN in) (NP (CD 8) (NNS patients)))) (, ,) (NP (NP (NNP Doc_11745287_1357_1369_Disease)) (PP (IN in) (NP (CD 6) (NNS patients)))) (, ,) (NP (NP (NNP Doc_11745287_1385_1396_Disease)) (PP (IN in) (NP (CD 5) (NNS patients)))) (, ,) (NP (NP (NNP Doc_11745287_1412_1430_Disease)) (PP (IN in) (NP (CD 2) (NNS patients)))) (, ,) (CC and) (NP (NN skin) (NNS reactions))) (PP (IN in) (NP (CD 3) (NNS patients)))) (. .)))
11745287	8	(S1 (S (NP (NP (DT The) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_11745287_1512_1523_Chemical)) (CC and) (NP (JJ liposomal) (NNP Doc_11745287_1538_1549_Chemical))))) (VP (AUX has) (NP (NP (JJ modest) (NN activity)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ recurrent) (JJ cervical) (NN Doc_11745287_1606_1615_Disease))))))) (. .)))
11799346	0	(S1 (NP (NP (NP (JJ Antimicrobial-induced) (NNP Doc_11799346_22_27_Disease)) (PRN (-LRB- -LRB-) (NP (NN antibiomania)) (-RRB- -RRB-))) (: :) (NP (NP (DT a) (NN review)) (PP (IN of) (NP (JJ spontaneous) (NNS reports)))) (. .)))
11799346	1	(S1 (S (NP (NP (DT The) (NNS authors)) (VP (VBN reviewed))) (VP (VBD reported) (NP (NP (NNS cases)) (PP (IN of) (NP (JJ antibiotic-induced) (JJ Doc_11799346_135_140_Disease) (NNS episodes))) (PP (IN by) (NP (NP (NNS means)) (PP (IN of) (NP (NP (DT a) (ADJP (JJ MEDLINE) (CC and) (JJ PsychLit)) (NN search)) (PP (IN for) (NP (NP (NNS reports)) (PP (IN of) (NP (JJ antibiotic-induced) (NNP Doc_11799346_226_231_Disease))))))))))) (. .)))
11799346	2	(S1 (S (NP (JJ Unpublished) (NNS reports)) (VP (AUX were) (VP (VBN requested) (PP (IN from) (NP (NP (NP (DT the) (NNP World) (NNP Health) (NNP Organization)) (PRN (-LRB- -LRB-) (NP (WP WHO)) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (NNP Food) (CC and) (NNP Drug) (NNP Administration)) (PRN (-LRB- -LRB-) (NP (NNP FDA)) (-RRB- -RRB-))))))) (. .)))
11799346	3	(S1 (S (NP (NP (CD Twenty-one) (NNS reports)) (PP (IN of) (NP (JJ antimicrobial-induced) (NNP Doc_11799346_397_402_Disease)))) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (DT the) (NN literature))))) (. .)))
11799346	4	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (CD 6) (NNS cases)) (VP (VBG implicating) (NP (NP (NP (NNP Doc_11799346_464_478_Chemical)) (, ,) (NP (CD 13) (NN implicating) (NNP Doc_11799346_495_504_Chemical)) (, ,)) (CC and) (NP (NP (CD 1) (NN case)) (NP (NP (DT each)) (VP (VBG implicating) (NP (NP (NNP Doc_11799346_534_546_Chemical)) (CC and) (NP (NNP Doc_11799346_551_562_Chemical)))))))))) (. .)))
11799346	5	(S1 (S (NP (DT The) (WP WHO)) (VP (VBD reported) (NP (CD 82) (NNS cases))) (. .)))
11799346	6	(S1 (S (PP (IN Of) (NP (DT these))) (, ,) (NP (NNP Doc_11799346_601_615_Chemical)) (VP (AUX was) (VP (VBN implicated) (PP (IN in) (NP (NP (CD 23) (ADJP (-LRB- -LRB-) (NP (CD 27.6) (NN %)) (-RRB- -RRB-)) (NNS cases)) (, ,) (NP (NP (NP (NNP Doc_11799346_652_665_Chemical)) (PP (IN in) (NP (CD 12) (PRN (-LRB- -LRB-) (NP (CD 14.4) (NN %)) (-RRB- -RRB-)) (NNS cases)))) (, ,) (CC and) (NP (NP (NNP Doc_11799346_691_700_Chemical)) (PP (IN in) (NP (CD 10) (PRN (-LRB- -LRB-) (NP (CD 12) (NN %)) (-RRB- -RRB-)) (NNS cases))))))))) (. .)))
11799346	7	(S1 (S (NP (NP (NNP Doc_11799346_720_733_Chemical)) (, ,) (NP (NNP Doc_11799346_735_748_Chemical)) (, ,) (CC and) (NP (NNP Doc_11799346_754_766_Chemical))) (VP (AUX were) (VP (VBN involved) (PP (IN in) (NP (CD 15) (JJ reported) (NN Doc_11799346_796_801_Disease) (NNS episodes))))) (. .)))
11799346	8	(S1 (S (NP (NP (NNS Cases)) (VP (VBN reported) (PP (IN by) (NP (DT the) (NNP FDA))))) (VP (VBD showed) (NP (NP (NNP Doc_11799346_845_859_Chemical)) (CC and) (NP (NNP Doc_11799346_864_877_Chemical))) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (JJS most)) (VP (ADVP (RB frequently)) (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_11799346_939_944_Disease))))))))))) (. .)))
11799346	9	(S1 (S (NP (NP (JJ Statistical) (NN analysis)) (PP (IN of) (NP (DT the) (NNS data)))) (VP (MD would) (RB not) (VP (AUX have) (VP (VP (VBD demonstrated) (NP (DT a) (JJ significant) (JJ statistical) (NN correlative) (NN risk))) (CC and) (VP (AUX was) (ADVP (RB therefore)) (RB not) (VP (VBN undertaken)))))) (. .)))
11799346	10	(S1 (S (NP (NNS Patients)) (VP (AUX have) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (VBG developing) (NNP Doc_11799346_1130_1135_Disease)))) (SBAR (IN while) (S (VP (AUXG being) (VP (VBN treated) (PP (IN with) (NP (NNS antimicrobials)))))))) (. .)))
11799346	11	(S1 (S (SBAR (IN Although) (S (NP (DT this)) (VP (AUX is) (RB not) (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN risk))))) (, ,) (NP (NNS physicians)) (VP (MD must) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT the) (NN effect) (CC and) (NN reversibility)))))) (. .)))
11799346	12	(S1 (S (NP (JJ Further) (NN research)) (ADVP (RB clearly)) (VP (AUX is) (VP (VBN required) (S (VP (TO to) (VP (VB determine) (NP (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ antimicrobial-induced) (NNP Doc_11799346_1379_1384_Disease)))) (, ,) (NP (NP (DT the) (JJ relative) (NN risk) (NNS factors)) (PP (IN of) (S (VP (VBG developing) (NP (NP (DT an) (JJ antimicrobial-induced) (NN Doc_11799346_1451_1464_Disease)) (PP (IN among) (NP (JJ various) (JJ demographic) (NNS populations)))))))) (, ,) (CC and) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP continue) (S (VP (TO to) (VP (AUX have) (NP (JJ persistent) (NN Doc_11799346_1566_1585_Disease)) (SBAR (IN once) (S (NP (NP (DT the) (JJ initial) (NN episode)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ occurs) (SBAR (IN while) (S (NP (DT the) (NN patient)) (VP (AUX is) (VP (VBG taking) (NP (NNS antibiotics))))))))) (, ,)) (NP (NNS subsides))))))))))))))))))) (. .)))
11799346	13	(S1 (S (NP (DT The) (NNS authors)) (VP (VBD elected) (S (VP (TO to) (VP (VB name) (NP (DT this) (NN syndrome)) (`` ``) (NP (NN antibiomania)))))) (. .) ('' '')))
11835460	0	(S1 (NP (NP (JJ Doc_11835460_0_8_Chemical-induced) (NNP Doc_11835460_17_35_Disease)) (PP (IN in) (NP (NNP Doc_11835460_39_58_Disease))) (. .)))
11835460	1	(S1 (S (NP (JJ Doc_11835460_60_68_Chemical-induced) (NN Doc_11835460_77_95_Disease)) (VP (AUX are) (ADJP (RB very) (JJ uncommon))) (. .)))
11835460	2	(S1 (S (ADVP (RB Usually)) (NP (PRP they)) (VP (VBP occur) (ADVP (RB simultaneously)) (PP (IN with) (NP (NN limb) (JJ peak-dose) (JJ choreatic) (NN Doc_11835460_179_190_Disease)))) (. .)))
11835460	3	(S1 (S (NP (PRP We)) (VP (VBP report) (PP (IN on) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (ADJP (JJ leftward) (CC and) (JJ upward)) (NNS deviations)) (SBAR (WHNP (IN of)) (S (VP (VP (VBP gaze) (PP (IN during) (NP (NP (DT the) (JJ peak) (NN effect)) (PP (IN of) (NP (NNP Doc_11835460_285_293_Chemical)))))) (, ,) (CC and) (VP (VBP hypothesize) (SBAR (IN that) (S (NP (NP (DT a) (JJ severe) (JJ dopaminergic) (NN denervation)) (PP (IN in) (NP (DT the) (JJ caudate) (NN nucleus)))) (VP (AUX is) (VP (VBN needed) (PP (IN for) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (DT these) (NNP Doc_11835460_411_419_Chemical-induce) (NNP Doc_11835460_427_445_Disease)))))))))))))))))) (. .)))
11915580	0	(S1 (NP (NP (NP (DT A) (NN comparison)) (PP (IN of) (NP (NNP Doc_11915580_16_35_Chemical))) (PP (IN with) (NP (NNP Doc_11915580_41_51_Chemical))) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_11915580_73_93_Disease)))))) (: :) (NP (DT an) (JJ open) (, ,) (JJ randomized) (, ,) (JJ cross-over) (NN trial)) (. .)))
11915580	1	(S1 (S (S (NP (JJ Primary) (NN Doc_11915580_142_154_Disease)) (VP (AUX is) (NP (NP (DT a) (NN syndrome)) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ painful) (NN uterine) (NN contractility)) (VP (VBN caused) (PP (IN by) (NP (NP (DT a) (NN hypersecretion)) (PP (IN of) (NP (JJ endometrial) (NN Doc_11915580_258_272_Chemical)))))))))))) (: ;) (S (NP (JJ non-steroidal) (JJ anti-inflammatory) (NNS drugs)) (VP (AUX are) (NP (NP (DT the) (JJ first) (NN choice)) (PP (IN for) (NP (PRP$ its) (NN treatment)))))) (. .)))
11915580	2	(S1 (S (ADVP (RB However)) (, ,) (PP (PP (IN in) (NP (NN vivo))) (CC and) (PP (IN in) (NP (NN vitro) (NNS studies)))) (VP (AUX have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (JJ myometrial) (NNS cells)) (VP (AUX are) (ADVP (RB also)) (NP (NP (NNS targets)) (PP (IN of) (NP (NP (DT the) (JJ relaxant) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_11915580_474_486_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP NO)) (-RRB- -RRB-)))))))))))) (. .)))
11915580	3	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NP (NP (NNP Doc_11915580_555_574_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11915580_576_579_Chemical)) (-RRB- -RRB-))) (, ,) (NP (DT an) (NNP NO) (NN donor)) (, ,))) (PP (IN in) (NP (NP (DT the) (NN resolution)) (PP (IN of) (NP (NP (NNP Doc_11915580_616_636_Disease)) (PP (IN in) (NP (NP (NN comparison)) (PP (IN with) (NP (NP (NNP Doc_11915580_656_666_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11915580_668_671_Chemical)) (-RRB- -RRB-))))))))))))))) (. .)))
11915580	4	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 24) (NNS patients))) (PP (IN with) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (JJ severe) (NN Doc_11915580_726_746_Disease)))))) (VP (AUX were) (VP (VBN studied) (PP (IN during) (NP (CD two) (JJ consecutive) (JJ menstrual) (NNS cycles))))) (. .)))
11915580	5	(S1 (S (PP (IN In) (NP (DT an) (JJ open) (, ,) (JJ cross-over) (, ,) (JJ controlled) (NN design))) (, ,) (NP (NNS patients)) (VP (AUX were) (VP (VBN randomized) (S (VP (TO to) (VP (VB receive) (NP (NP (DT either) (NN Doc_11915580_887_890_Chemical)) (PP (IN per) (NP (NP (NN os)) (CC or) (NP (JJ Doc_11915580_901_904_Chemical) (NNS patches))))) (NP (NP (DT the) (JJ first) (NNS days)) (PP (IN of) (NP (NNS menses))) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (JJ menstrual) (NNS cramps)) (VP (VBD became) (ADJP (JJ unendurable))))))))))) (. .)))
11915580	6	(S1 (S (PP (IN In) (NP (DT the) (JJ subsequent) (NN cycle))) (NP (DT the) (JJ other) (NN treatment)) (VP (AUX was) (VP (VBN used))) (. .)))
11915580	7	(S1 (S (NP (NNS Patients)) (VP (VBD received) (NP (NP (QP (IN up) (TO to) (CD 3)) (NN doses/day)) (PP (IN of) (NP (QP (CD 50) (CD mg) (NN Doc_11915580_1080_1083_Chemical) (CC or) (CD 2.5) (CD mg/24)) (NNP h) (JJ transdermal) (NN Doc_11915580_1111_1114_Chemical)))) (PP (IN for) (NP (NP (DT the) (JJ first) (CD 3) (NNS days)) (PP (IN of) (NP (DT the) (NN cycle))))) (, ,) (PP (VBG according) (PP (TO to) (NP (PRP$ their) (NNS needs))))) (. .)))
11915580	8	(S1 (S (NP (DT The) (NNS participants)) (VP (VBD recorded) (NP (NP (JJ menstrual) (NNS symptoms)) (CC and) (NP (JJ possible) (NNS side-effects))) (PP (IN at) (NP (NP (JJ different) (NNS times)) (PRN (-LRB- -LRB-) (NP (CD 0) (, ,) (CD 30) (, ,) (CD 60) (, ,) (CD 120) (NNS minutes)) (-RRB- -RRB-)))) (PP (IN after) (NP (NP (DT the) (JJ first) (NN dose)) (PP (IN of) (NP (NN medication))) (PP (IN on) (NP (NP (DT the) (JJ first) (NN day)) (PP (IN of) (NP (DT the) (NN cycle))))))) (, ,) (PP (IN with) (NP (DT both) (NNS drugs)))) (. .)))
11915580	9	(S1 (S (NP (NP (DT The) (NN difference)) (PP (IN in) (NP (NP (JJ Doc_11915580_1392_1396_Disease) (NN intensity) (NN score)) (PRN (-LRB- -LRB-) (NP (NNP DPI)) (-RRB- -RRB-))))) (VP (AUX was) (NP (DT the) (JJ main) (NN outcome) (NN variable))) (. .)))
11915580	10	(S1 (S (NP (DT Both) (NNS treatments)) (VP (ADVP (RB significantly)) (VBN reduced) (NP (NNP DPI)) (PP (IN by) (NP (NP (DT the) (JJ 30th) (NN minute)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11915580_1512_1515_Chemical)) (, ,) (NP (NP (QP (CD -12.8) (JJR +/-) (CD 17.9))) (: ;) (NP (NNP Doc_11915580_1533_1536_Chemical))) (, ,) (NP (QP (CD -18.9) (CD +/-)) (CD 16.6)) (-RRB- -RRB-))))) (. .)))
11915580	11	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_11915580_1564_1567_Chemical)) (VP (VBD continued) (S (VP (TO to) (VP (AUX be) (ADJP (ADJP (JJ effective) (PP (IN in) (S (VP (VBG reducing) (NP (NNP Doc_11915580_1606_1617_Disease)) (PP (IN for) (NP (CD two) (NNS hours))) (, ,) (SBAR (IN whereas) (S (NP (NNP Doc_11915580_1641_1644_Chemical) (NNS scores)) (VP (VBD remained) (ADJP (JJR more) (CC or) (JJR less) (JJ stable)) (PP (IN after) (NP (CD 30) (NN min)))))))))) (CC and) (ADJP (RB significantly) (JJR higher) (PP (IN than) (NP (NP (DT those)) (PP (IN for) (NP (NP (NP (NNP DFC)) (PRN (-LRB- -LRB-) (PP (IN after) (NP (CD one) (NN hour)))) (: :) (NP (NP (NNP Doc_11915580_1755_1758_Chemical)) (, ,) (NP (NP (CD -12.8) (NN +/-)) (NP (CD 17.9)))) (: ;) (NP (NP (NNP DFC)) (, ,) (NP (NP (NP (CD -18.9) (NN +/-)) (NP (CD 16.6))) (CC and) (NP (IN after) (CD two) (NNS hours)))) (: :) (NP (NNP Doc_11915580_1817_1820_Chemical))) (, ,) (NP (QP (CD -23.7) (CD +/-)) (CD 20.5)))))))) (PRN (: ;) (FRAG (NP (NNP DFC)) (, ,) (NP (NP (CD -59.7) (NNS +/-)) (NP (CD 17.9))) (, ,) (NP (NNP p)) (X (SYM =)) (NP (CD 0.0001))) (-RRB- -RRB-)))))) (. .)))
11915580	12	(S1 (S (NP (NN Doc_11915580_1872_1885_Disease)) (VP (AUX was) (ADVP (RB also)) (VP (VBN relieved) (PP (IN by) (NP (DT both) (NNS drugs))))) (. .)))
11915580	13	(S1 (S (NP (NN Headache)) (VP (AUX was) (UCP (VP (ADVP (RB significantly)) (VBN increased) (PP (IN by) (NP (NNP Doc_11915580_1959_1962_Chemical)))) (CC but) (RB not) (PP (IN by) (NP (NNP Doc_11915580_1974_1977_Chemical))))) (. .)))
11915580	14	(S1 (S (NP (CD Eight) (NNS patients)) (VP (VBD stopped) (S (VP (VBG using) (NP (NNP Doc_11915580_2008_2011_Chemical)))) (PP (IN because) (NP (JJ Doc_11915580_2020_2028_Disease--attributed))) (PP (TO to) (NP (PRP$ its) (JJ use--became) (JJ intolerable)))) (. .)))
11915580	15	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_11915580_2102_2105_Chemical)) (VP (AUX has) (NP (NP (DT a) (JJ reduced) (NN efficacy)) (CC and) (NP (NN tolerability))) (PP (IN by) (NP (NP (NN comparison)) (PP (IN with) (NP (NNP Doc_11915580_2165_2168_Chemical))))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_11915580_2189_2209_Disease))))))))) (. .)))
11936424	0	(S1 (S (NP (NP (NNP Doc_11936424_0_10_Chemical)) (, ,) (NP (NP (DT a) (JJ long-acting) (JJ non-SH) (NN group) (NN angiotensin)) (VP (VBG converting) (NP (NN enzyme) (NN inhibitor)))) (, ,)) (VP (VBZ modulates) (NP (NNP Doc_11936424_90_107_Disease)) (PP (IN in) (NP (JJ chronic) (NNP Doc_11936424_119_144_Chemical) (NNP Doc_11936424_145_154_Disease)))) (. .)))
11936424	1	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (PP (IN whether) (NP (NP (NN chronic) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_11936424_240_250_Chemical)) (, ,) (NP (NP (DT a) (JJ long-acting) (JJ non-SH) (NN group) (NN angiotensin)) (VP (VBG converting) (SBAR (S (NP (NP (JJ enzyme) (PRN (-LRB- -LRB-) (NP (NNP ACE)) (-RRB- -RRB-)) (NN inhibitor)) (, ,) (NP (JJ reduced) (NNP Doc_11936424_334_345_Disease)) (, ,)) (VP (VP (VBD inhibited) (NP (NNP Doc_11936424_357_379_Disease))) (CC and) (VP (VBD prevented) (NP (NNP Doc_11936424_394_412_Disease)) (PP (IN in) (NP (NP (JJ chronic) (NNP Doc_11936424_424_449_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_11936424_451_454_Chemical)) (-RRB- -RRB-)))) (: -) (NP (VBN induced) (NNP Doc_11936424_466_475_Disease) (NNS rats)))))))))))))))) (. .)))
11936424	2	(S1 (S (NP (NN Doc_11936424_482_491_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NP (NN injection)) (PP (IN of) (NP (NP (NNP Doc_11936424_520_523_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ 15mg/100g) (NN body) (NN weight)) (-RRB- -RRB-)))))) (PP (IN in) (NP (JJ male) (NNP Sprague-Dawley) (PRN (-LRB- -LRB-) (NP (NNP SD)) (-RRB- -RRB-)) (NNS rats))))) (. .)))
11936424	3	(S1 (S (NP (CD Four) (NNS groups)) (VP (AUX were) (VP (VBN used) (PRN (, ,) (NP (PRP i)) (-RRB- -RRB-)) (S (NP (NP (DT the) (JJ Doc_11936424_612_615_Chemical) (NN group)) (PRN (-LRB- -LRB-) (CD 14) (-RRB- -RRB-) (, ,) (NP (NP (NP (NNP ii) (-RRB- -RRB-) (NNP Doc_11936424_632_635_Chemical/Doc_11936424_636_646_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 13)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP iii) (-RRB- -RRB-) (NNP Doc_11936424_658_668_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 14)) (-RRB- -RRB-))) (CC and) (NP (NNP iv))) (-RRB- -RRB-))) (NP (NP (JJ untreated) (NNS controls)) (PRN (-LRB- -LRB-) (NP (CD 15)) (-RRB- -RRB-)))))) (. .)))
11936424	4	(S1 (S (NP (NP (NN Doc_11936424_707_717_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 8) (NN mg/kg/day)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN administered) (PP (TO to) (NP (NP (DT the) (NNS rats)) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VBN killed) (PP (IN at) (NP (NP (NNS weeks)) (CD 4) (, ,) (CD 14) (CC or) (CD 20))))))))))) (. .)))
11936424	5	(S1 (S (PP (IN At) (NP (DT each) (NN time) (NN point))) (, ,) (S (NP (NP (JJ systolic) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NNP BP)) (-RRB- -RRB-)) (, ,) (NP (NN urinary) (NN protein) (NN excretion)) (CC and) (NP (JJ renal) (JJ histopathological) (NNS findings))) (VP (AUX were) (VP (VBN evaluated)))) (, ,) (CC and) (S (NP (JJ morphometric) (NN image) (NN analysis)) (VP (AUX was) (VP (AUX done)))) (. .)))
11936424	6	(S1 (S (NP (NP (NNP Systolic) (NNP BP)) (PP (IN in) (NP (DT the) (NNP Doc_11936424_991_994_Chemical) (NN group)))) (VP (VP (AUX was) (ADJP (RB significantly) (JJ high)) (PP (IN at) (NP (CD 4) (, ,) (CD 14) (CC and) (CD 20) (NNS weeks)))) (, ,) (CC but) (VP (AUX was) (ADJP (JJ normal)) (PP (IN in) (NP (DT the) (NNP Doc_11936424_1069_1072_Chemical/Doc_11936424_1073_1083_Chemical) (NN group))))) (. .)))
11936424	7	(S1 (S (S (NP (NP (JJ Urinary) (NN protein) (NN excretion)) (PP (IN in) (NP (DT the) (NNP Doc_11936424_1124_1127_Chemical) (NN group)))) (VP (VBD increased) (ADVP (RB significantly)) (, ,) (S (VP (VBG peaking) (PP (IN at) (NP (CD 8) (NNS days))))))) (, ,) (ADVP (RB then)) (VP (VP (VBD decreased) (PP (IN at) (NP (CD 4) (NNS weeks)))) (, ,) (CC but) (VP (VBD rose) (ADVP (RB again)) (ADVP (RB significantly) (NP (QP (IN at) (CD 14) (CC and) (CD 20)) (NNS weeks))))) (. .)))
11936424	8	(S1 (S (S (NP (NN Doc_11936424_1254_1264_Chemical)) (VP (AUX did) (RB not) (VP (VB attenuate) (NP (NNP Doc_11936424_1283_1294_Disease)) (PP (IN at) (NP (CD 8) (NN days)))))) (, ,) (CC but) (S (NP (PRP it)) (VP (AUX did) (RB markedly) (VP (VB lower) (NP (PRP it)) (PP (IN from) (NP (NNS weeks))) (ADVP (CD 4) (TO to) (CD 20))))) (. .)))
11936424	9	(S1 (S (NP (NP (DT The) (NNP Doc_11936424_1359_1377_Disease) (NN index)) (PRN (-LRB- -LRB-) (NP (NNP GSI)) (-RRB- -RRB-))) (VP (AUX was) (NP (NP (NP (CD 6.21) (NN %)) (PP (IN at) (NP (CD 4) (NNS weeks)))) (CC and) (NP (NP (NP (ADVP (RB respectively)) (QP (CD 25.35) (NN %) (CC and) (CD 30.49) (NN %))) (NP (QP (IN at) (CD 14) (CC and) (CD 20)) (NNS weeks))) (PP (IN in) (NP (DT the) (NNP Doc_11936424_1475_1478_Chemical) (NN group)))))) (. .)))
11936424	10	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (NN correlation)) (PP (IN between) (NP (NP (JJ urinary) (NN protein) (NN excretion)) (CC and) (NP (NP (NNS GSI)) (PRN (-LRB- -LRB-) (NP (SYM r) (X (SYM =)) (CD 0.808)) (, ,) (NP (QP ($ p) (CD <) (CD 0.0001))) (-RRB- -RRB-))))))) (. .)))
11936424	11	(S1 (S (S (NP (NP (DT The) (NN ratio)) (PP (IN of) (NP (JJ glomerular) (NN tuft) (NN area))) (PP (TO to) (NP (NP (DT the) (NN area)) (PP (IN of) (NP (NP (NP (NNP Bowman) (POS 's)) (NNS capsules)) (PRN (-LRB- -LRB-) (NP (NNP GT/BC)) (-RRB- -RRB-)))) (PP (IN in) (NP (DT the) (NNP Doc_11936424_1671_1674_Chemical) (NN group)))))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN increased)))) (, ,) (CC but) (S (NP (PRP it)) (VP (AUX was) (ADJP (RB significantly) (JJR lower)) (PP (IN in) (NP (DT the) (NNP Doc_11936424_1748_1751_Chemical/Doc_11936424_1752_1762_Chemical) (NN group))))) (. .)))
11936424	12	(S1 (S (NP (PRP It)) (VP (VBZ appears) (SBAR (IN that) (S (NP (NNP Doc_11936424_1786_1796_Chemical)) (VP (VP (AUX was) (ADJP (JJ effective)) (PP (IN in) (NP (NNP Doc_11936424_1814_1841_Disease)))) (CC and) (VP (VBD protected) (NP (JJ renal) (NN function)) (PP (IN in) (NP (JJ Doc_11936424_1874_1877_Chemical) (JJ neprotic) (NNS rats)))))))) (. .)))
11988250	0	(S1 (NP (NP (NN Doc_11988250_0_22_Disease)) (PP (IN after) (NP (NP (JJ Doc_11988250_29_38_Chemical) (NNS prophylaxis)) (PP (IN in) (NP (ADJP (RB very) (JJ preterm)) (NNS infants))))) (. .)))
11988250	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (CD three) (NNS cases)) (PP (IN of) (NP (JJ severe) (NNS hypoxaemia))) (PP (IN after) (NP (NNP Doc_11988250_125_134_Chemical) (NN administration)))) (PP (IN during) (NP (NP (DT a) (JJ randomised) (JJ controlled) (NN trial)) (PP (IN of) (NP (NP (JJ prophylactic) (NN treatment)) (PP (IN of) (NP (NNP Doc_11988250_216_240_Disease))))) (PP (IN with) (NP (NNP Doc_11988250_246_255_Chemical))) (PP (IN in) (NP (NP (JJ premature) (NNS infants)) (VP (VBN born) (PP (IN at) (NP (NP (QP (JJR less) (IN than) (CD 28)) (NNS weeks)) (PP (IN of) (NP (NN gestation))))))))))) (. .)))
11988250	2	(S1 (S (NP (NN Echocardiography)) (VP (VBD showed) (NP (ADJP (RB severely) (VBN decreased)) (NN pulmonary) (NN blood) (NN flow))) (. .)))
11988250	3	(S1 (S (NP (NN Hypoxaemia)) (VP (VBD resolved) (ADVP (RB quickly)) (PP (IN on) (NP (JJ inhaled) (JJ Doc_11988250_422_434_Chemical) (NN therapy)))) (. .)))
11988250	4	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNS investigators)) (VP (VBN involved) (PP (IN in) (NP (JJ similar) (NNS trials))))) (VP (VBP pay) (NP (JJ close) (NN attention)) (S (VP (TO to) (VP (VB pulmonary) (NP (NN pressure)) (SBAR (IN if) (S (NP (NN hypoxaemia)) (VP (VBZ occurs) (PP (IN after) (NP (NP (JJ prophylactic) (NN administration)) (PP (IN of) (NP (NN Doc_11988250_601_610_Chemical))))))))))))))) (. .)))
12051122	0	(S1 (NP (NP (NP (NP (NN Doc_12051122_0_12_Disease)) (CC and) (NP (NN syndrome))) (PP (IN of) (NP (JJ inappropriate) (JJ anti-diuretic) (NN hormone))) (VP (VBN reported) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_12051122_90_101_Chemical))))))) (: :) (NP (NP (DT an) (NN over-representation)) (PP (IN of) (NP (NNPS Asians)))) (. ?)))
12051122	1	(S1 (S (NP (DT This) (NN retrospective) (NN study)) (VP (VBD used) (NP (NP (DT a) (JJ pharmaceutical) (NN company) (POS 's)) (JJ global) (NN safety) (NN database)) (S (VP (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN reporting) (NN rate)) (PP (IN of) (NP (NP (JJ Doc_12051122_261_273_Disease) (NN and/or) (NN syndrome)) (PP (IN of) (NP (NP (JJ inappropriate) (NNP Doc_12051122_307_341_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12051122_343_348_Disease)) (-RRB- -RRB-)))))) (PP (IN among) (NP (JJ Doc_12051122_356_367_Chemical-treated) (NNS patients)))))) (CC and) (VP (TO to) (VP (VB explore) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (JJ at-risk) (NN population) (NNS subgroups))))))))) (. .)))
12051122	2	(S1 (S (NP (PRP We)) (VP (VBD searched) (NP (NP (DT the) (NNP Eli) (NNP Lilly)) (CC and) (NP (NP (NN Company) (POS 's)) (JJ computerized) (JJ adverse) (NN event) (NN database))) (PP (IN for) (NP (NP (DT all) (VBN reported) (NNS cases)) (PP (IN of) (NP (NP (NNP Doc_12051122_559_571_Disease) (FW and/or) (NNP Doc_12051122_579_584_Disease)) (CONJP (RB as) (IN of)) (NP (CD 1) (NNP November) (CD 1999)))) (SBAR (WHNP (WDT that)) (S (VP (AUX had) (VP (AUX been) (VP (VBN reported) (PP (IN during) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_12051122_648_659_Chemical))))))))))))) (. .)))
12051122	3	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (CD 76) (NNS cases)) (PP (IN of) (NP (NNP Doc_12051122_693_705_Disease) (FW and/or) (NNP Doc_12051122_713_718_Disease))))) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_12051122_735_746_Chemical) (NN use))))) (VP (AUX were) (VP (VBN identified))) (. .)))
12051122	4	(S1 (S (NP (DT The) (JJ overall) (NN reporting) (NN rate)) (VP (AUX was) (VP (VBN estimated) (S (VP (TO to) (VP (AUX be) (NP (CD 1.3/100,000) (VBN treated) (NNS patients))))))) (. .)))
12051122	5	(S1 (S (S (NP (NP (DT The) (JJ average) (NN age)) (PP (IN of) (NP (NNS patients)))) (VP (AUX was) (NP (CD 35.6) (JJ +/-) (CD 28.3) (NNS years)))) (, ,) (CC and) (S (NP (CD 62) (NN %)) (VP (AUX were) (NP (NNS males)))) (. .)))
12051122	6	(S1 (S (NP (NP (QP (RB Approximately) (CD 75)) (NN %)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX were) (S (VP (VBG receiving) (NP (NN treatment)) (PP (IN for) (NP (NP (NNP Doc_12051122_981_989_Disease)) (CC or) (NP (NNP Doc_12051122_993_1001_Disease))))))) (. .)))
12051122	7	(S1 (S (PP (IN Among) (NP (NP (DT the) (CD 39) (NNS reports)) (SBAR (WHNP (WDT that)) (S (VP (VBD included) (NP (NP (NN information)) (PP (IN on) (NP (NN race))))))))) (, ,) (NP (DT the) (JJ racial) (NN distribution)) (VP (AUX was) (: :) (NP (NP (CD 1) (NNP Black)) (, ,) (NP (CD 3) (NNP Caucasian)) (, ,) (CC and) (NP (CD 35) (NNP Asian)))) (. .)))
12051122	8	(S1 (S (NP (PRP$ Our) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ Asian) (NNS patients)) (VP (MD may) (VP (AUX be) (PP (IN at) (NP (NP (VBN increased) (NN risk)) (PP (IN of) (NP (NNP Doc_12051122_1201_1213_Disease) (FW and/or) (NNP Doc_12051122_1221_1226_Disease))) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_12051122_1243_1254_Chemical) (NN use))))))))))) (. .)))
12051122	9	(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (JJ overall) (JJ reported) (NN rate)) (PP (IN of) (NP (NNP Doc_12051122_1298_1303_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_12051122_1320_1331_Chemical))))) (VP (AUX is) (ADJP (RB very) (JJ low))))) (, ,) (NP (NP (NNS physicians)) (VP (VBG caring) (PP (IN for) (NP (JJ Asian) (NN oncology) (NNS patients))))) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT this) (JJ potential) (ADJP (JJ serious) (CC but) (JJ reversible)) (JJ adverse) (NN event)))))) (. .)))
12059909	0	(S1 (S (VP (VBN Delayed) (NP (NP (NN Doc_12059909_8_16_Disease)) (PP (IN of) (NP (NNP Doc_12059909_20_36_Chemical)))) (PP (IN on) (NP (NP (DT the) (NN bladder)) (PP (IN of) (NP (NNP DBA/2) (CC and) (NNP C57BL/6) (NN female) (NN mouse)))))) (. .)))
12059909	1	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VP (VBZ describes) (NP (NP (DT the) (VBN delayed) (NN development)) (PP (IN of) (NP (DT a) (JJ severe) (NN bladder) (NN pathology))) (PP (PP (IN in) (NP (NP (DT a) (JJ susceptible) (NN strain)) (PP (IN of) (NP (NP (NNS mice)) (PRN (-LRB- -LRB-) (NP (NNP DBA/2)) (-RRB- -RRB-)))))) (CC but) (PP (RB not) (IN in) (NP (NP (DT a) (JJ resistant) (NN strain)) (PRN (-LRB- -LRB-) (NP (NNP C57BL/6)) (-RRB- -RRB-)))))) (ADVP (WRB when))) (CC both) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (DT a) (JJ single) (CD 300) (JJ mg/kg) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_12059909_304_320_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP CY)) (-RRB- -RRB-))))))))) (. .)))
12059909	2	(S1 (S (S (NP (JJ Inbred) (NNP DBA/2) (CC and) (NNP C57BL/6) (NN female) (NNS mice)) (VP (AUX were) (VP (VBN injected) (PP (IN with) (NP (NNP CY)))))) (, ,) (CC and) (S (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (DT the) (NN drug))) (PP (IN on) (NP (DT the) (NN bladder)))) (VP (AUX was) (VP (VBN assessed) (PP (IN during) (NP (CD 100) (NNS days))) (PP (PP (IN by) (NP (NP (JJ light) (NNS microscopy)) (VP (VBG using) (NP (JJ different) (NN staining) (NNS procedures))))) (, ,) (CC and) (PP (IN after) (NP (CD 30) (NNS days))) (PP (IN by) (NP (JJ conventional) (NNP electron) (NN microscopy))))))) (. .)))
12059909	3	(S1 (S (NP (JJ Early) (NNP CY) (NNP Doc_12059909_579_587_Disease)) (VP (VBD caused) (NP (NP (DT a) (JJ typical) (NN Doc_12059909_605_626_Disease)) (PP (IN in) (NP (DT both) (NNS strains))) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (ADVP (RB completely)) (VP (VBN repaired) (PP (IN in) (NP (QP (RB about) (CD 7-10)) (NNS days))))))))) (. .)))
12059909	4	(S1 (S (PP (IN After) (NP (NP (CD 30) (NNS days)) (PP (IN of) (NP (NNP CY) (NN injection))))) (NP (NP (JJ ulcerous) (CC and) (JJ non-ulcerous) (NNS forms)) (PP (IN of) (NP (JJ chronic) (NNP Doc_12059909_765_773_Disease)))) (VP (VBD appeared) (PP (IN in) (NP (NP (NP (CD 86) (NN %)) (PP (IN of) (NP (NNP DBA/2) (NNS mice)))) (CC but) (NP (NP (QP (RB only) (IN in) (CD 4)) (NN %)) (PP (IN of) (NP (JJ C57BL/6) (NNS mice))))))) (. .)))
12059909	5	(S1 (S (NP (JJ Delayed) (NNP Doc_12059909_844_852_Disease)) (VP (AUX was) (VP (VBN characterized) (PP (IN by) (NP (NP (NN infiltration)) (CC and) (NP (JJ transepithelial) (NN passage)))) (PP (PP (IN into) (NP (NP (DT the) (NNS lumen)) (PP (IN of) (NP (JJ inflammatory) (NNS cells))))) (CC and) (PP (IN by) (NP (NP (JJ frequent) (NN exfoliation)) (PP (IN of) (NP (DT the) (NN urothelium)))))))) (. .)))
12059909	6	(S1 (S (NP (NN Mast) (NNS cells)) (VP (VBD appeared) (PP (IN in) (NP (NP (DT the) (JJ connective) (CC and) (JJ muscular) (NNS layers)) (PP (IN of) (NP (DT the) (NN bladder))))) (PP (IN at) (NP (NP (DT a) (ADJP (RB much) (JJR higher)) (NN number)) (PP (IN in) (NP (NP (NNP DBA/2) (NNS mice)) (PP (IN than) (PP (IN in) (NP (NP (JJ C57BL/6) (NNS mice)) (CC or) (NP (JJ untreated) (NNS controls)))))))))) (. .)))
12059909	7	(S1 (S (NP (NNP Electron) (NN microscopy)) (VP (VBD disclosed) (SBAR (S (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (DT the) (JJ typical) (JJ discoidal) (NNS vesicles)))) (ADVP (RB normally)) (VP (VBP present) (PP (IN in) (NP (NP (DT the) (NN cytoplasm)) (PP (IN of) (NP (NN surface) (NNS cells))))))))) (. .)))
12059909	8	(S1 (S (ADVP (RB Instead)) (, ,) (NP (NP (JJ numerous) (JJ abnormal) (NNS vesicles)) (VP (VBG containing) (NP (NP (NN one)) (CC or) (NP (JJ several) (JJ dark) (NNS granules))))) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NN cytoplasm)) (PP (IN of) (NP (NP (NNS cells)) (PP (IN from) (NP (PDT all) (DT the) (JJ epithelial) (NNS layers))))))))) (. .)))
12059909	9	(S1 (S (NP (JJ Delayed) (NN Doc_12059909_1438_1446_Disease)) (ADVP (RB still)) (VP (VBD persisted) (PP (IN in) (NP (JJ DBA/2) (NNS mice))) (PP (NP (CD 100) (NNS days)) (IN after) (NP (NN treatment)))) (. .)))
12059909	10	(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ delayed) (NN Doc_12059909_1539_1547_Disease)) (PP (IN of) (NP (NNP CY))) (PP (IN in) (NP (JJ female) (NN DBA/2) (NNS mice)))) (VP (VBZ causes) (NP (NP (DT a) (NN bladder) (NN pathology)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (RB not) (VP (VBN observed) (PP (IN in) (NP (JJ C57BL/6) (NNS mice)))))))))))) (. .)))
12059909	11	(S1 (S (NP (DT This) (NN pathology)) (VP (VP (VBZ resembles) (NP (NP (NNP Doc_12059909_1665_1686_Disease)) (PP (IN in) (NP (NNS humans))))) (CC and) (VP (MD could) (ADVP (RB perhaps)) (VP (AUX be) (VP (VBN used) (PP (IN as) (NP (NP (DT an) (NN animal) (NN model)) (PP (IN for) (NP (NP (NNS studies)) (PP (IN on) (NP (DT the) (NN disease))))))))))) (. .)))
12119460	0	(S1 (S (NP (NNP High-dose) (NNP Doc_12119460_10_24_Chemical)) (VP (VBD /) (NP (NNP Doc_12119460_27_39_Chemical)) (PP (IN in) (NP (NN combination))) (PP (IN with) (NP (NP (JJ three-weekly) (NN Doc_12119460_73_84_Chemical)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ advanced) (NNP Doc_12119460_114_128_Disease)))))))) (. .)))
12119460	1	(S1 (NP (NP (DT A) (NN phase) (NNP II) (NN study)) (. .)))
12119460	2	(S1 (S (NP (NP (DT The) (JJ 24-hour) (JJ continuous) (NN infusion)) (PP (IN of) (NP (NP (NP (NNP Doc_12119460_195_209_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12119460_211_215_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_12119460_221_233_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP FA)) (-RRB- -RRB-))))) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (NP (JJ several) (JJ new) (JJ multidrug) (JJ chemotherapy) (NNS regimens)) (PP (IN in) (NP (NP (JJ advanced) (NNP Doc_12119460_306_320_Disease)) (PRN (-LRB- -LRB-) (NP (NNP AGC)) (-RRB- -RRB-))))))))) (VP (AUX has) (VP (VBN shown) (S (VP (TO to) (VP (AUX be) (ADJP (JJ effective))))) (, ,) (PP (IN with) (NP (JJ low) (NNP Doc_12119460_363_371_Disease))))) (. .)))
12119460	3	(S1 (S (PP (IN In) (NP (NP (DT a) (JJ previous) (NN phase) (NNP II) (NN study)) (PP (IN with) (NP (NP (JJ 3-weekly) (JJ bolus) (NNP Doc_12119460_422_426_Chemical) (, ,) (NNP FA) (CC and) (NNP Doc_12119460_435_446_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12119460_448_451_Chemical)) (-RRB- -RRB-)))))) (NP (PRP we)) (VP (VBD found) (NP (NP (DT a) (JJ low) (NNP Doc_12119460_468_476_Disease) (NN rate) (CC and) (NN response) (NNS rates)) (ADJP (JJ comparable) (PP (TO to) (NP (NP (DT those)) (PP (IN of) (NP (NP (NNS regimens)) (PP (JJ such) (IN as) (NP (NP (NNP ELF) (, ,) (NNP FAM) (CC or) (NNP FAMTX)) (, ,) (CC and) (NP (DT a) (JJ promising) (JJ median) (JJ overall) (NN survival))))))))))) (. .)))
12119460	4	(S1 (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB improve) (NP (DT this) (JJ Doc_12119460_626_629_Chemical-dependent) (NN schedule)))))) (NP (PRP we)) (VP (VBD initiated) (NP (NP (DT a) (NN phase) (NNP II) (NN study)) (PP (IN with) (NP (NP (JJ high-dose) (NN Doc_12119460_694_698_Chemical/FA)) (CC and) (NP (JJ 3-weekly) (JJ bolus) (NN Doc_12119460_721_724_Chemical)))))) (. .)))
12119460	5	(S1 (NP (NP (NP (NNS PATIENTS) (CC AND) (NNS METHODS) (: :)) (PP (IN From) (NP (NNP February)))) (, ,) (NP (NP (CD 1998)) (PP (TO to) (NP (NNP September)))) (, ,) (NP (NP (CD 2000)) (SBAR (S (NP (PRP we)) (VP (VBD recruited) (NP (CD 33) (NNS patients)) (PP (IN with) (S (VP (VBG AGC) (S (VP (TO to) (VP (VB receive) (NP (NP (JJ weekly) (JJ 24-hour) (NNP Doc_12119460_847_851_Chemical) (CD 2,600) (NN mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (VP (VBN preceded) (PP (IN by) (NP (NP (JJ 2-hour) (CD FA) (CD 500) (NNS mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (PP (IN for) (NP (CD 6) (NNS weeks))) (, ,) (VP (VBN followed) (PP (IN by) (NP (DT a) (JJ 2-week) (NN rest) (NN period)))))))))))))))))) (. .)))
12119460	6	(S1 (S (NP (NP (JJ Bolus) (NNP Doc_12119460_953_956_Chemical) (CD 10) (NN mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN added) (PP (IN in) (NP (JJ 3-weekly) (NNS intervals))))) (. .)))
12119460	7	(S1 (S (NP (NP (NN Treatment)) (VP (VBN given) (PP (IN on) (NP (DT an) (NN outpatient) (NN basis))))) (, ,) (S (VP (VBG using) (NP (JJ portable) (NN pump) (NNS systems)))) (, ,) (VP (AUX was) (VP (VBN repeated) (PP (IN on) (NP (NN day) (CD 57))))) (. .)))
12119460	8	(S1 (S (S (NP (NP (NNS Patients) (POS ')) (NNS characteristics)) (VP (AUX were) (: :) (NP (NP (NP (JJ male/female) (NN ratio) (NN 20/13)) (: ;) (NP (NP (JJ median) (NN age)) (NP (CD 57) (-LRB- -LRB-) (CD 27-75) (-RRB- -RRB-) (NNS years))) (: ;) (NP (NN median))) (SBAR (WHNP (WP WHO)) (S (NP (NP (NN status) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN 0-2)) (-RRB- -RRB-)) (. .) (NP (CD 18) (NNS patients))) (VP (AUX had) (NP (DT a) (JJ primary) (NN AGC)))))))) (, ,) (CC and) (S (NP (CD 15)) (VP (VBD showed) (NP (DT a) (JJ relapsed) (NN AGC)))) (. .)))
12119460	9	(S1 (S (NP (JJ Median) (NN follow-up)) (VP (AUX was) (NP (NP (CD 11.8) (NNS months)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN range)) (PP (IN of) (NP (NP (DT those)) (VP (VBG surviving))))) (: :) (NP (CD 2.7-11.8) (NNS months))) (-RRB- -RRB-)))) (. .)))
12119460	10	(S1 (S (NP (CD 32) (NNS patients)) (VP (AUX were) (ADJP (JJ evaluable) (PP (IN for) (NP (NN response)))) (: -) (NP (NP (NP (JJ complete) (NN remission)) (ADJP (CD 9.1) (NN %))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 3)) (-RRB- -RRB-)) (, ,) (NP (NP (JJ partial) (NN remission)) (NP (CD 45.5) (NN %))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 15)) (-RRB- -RRB-)) (, ,) (NP (NP (DT no) (NN change)) (ADJP (CD 27.3) (NN %))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 9)) (-RRB- -RRB-)) (, ,) (NP (NP (JJ progressive) (NN disease)) (ADJP (CD 15.1) (NN %))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 5)) (-RRB- -RRB-)))) (. .)))
12119460	11	(S1 (S (S (NP (JJ Median) (JJ overall) (NN survival) (NN time)) (VP (AUX was) (NP (NP (NP (NP (CD 10.2) (NNS months)) (NP (CD -LSB-95) (NN %)) (NN confidence) (NN interval)) (PRN (-LRB- -LRB-) (NP (NNP CI)) (-RRB- -RRB-))) (: :) (NP (CD 8.7-11.6) (NN -RSB-))))) (, ,) (CC and) (S (NP (JJ median) (JJ progression-free) (NN survival) (NN time)) (VP (AUX was) (NP (NP (CD 7.6) (NNS months)) (PRN (-LRB- -LRB-) (NP (NP (CD 95) (NN %) (NN CI)) (: :) (NP (CD 4.4-10.9))) (-RRB- -RRB-))))) (. .)))
12119460	12	(S1 (S (S (NP (NP (DT The) (JJS worst) (NN Doc_12119460_1698_1708_Disease)) (PRN (-LRB- -LRB-) (NN %) (-RRB- -RRB-))) (VP (VBD observed) (SBAR (S (VP (AUX were) (PRN (-LRB- -LRB-) (NP (NNP CTC-NCI) (CD 1/2/3)) (-RRB- -RRB-))))))) (: :) (S (NP (NP (NNP Doc_12119460_1744_1754_Disease) (CD 45.5/18.2/6.1)) (, ,) (NP (NNP Doc_12119460_1770_1786_Disease) (CD 33.3/9.1/6.1)) (, ,) (NP (JJ vomitus) (NNS 24.2/9.1/0)) (, ,) (NP (NN diarrhea) (CD 36.4/6.1/3.0)) (, ,) (NP (NNP Doc_12119460_1844_1854_Disease) (CD 18.2/9.1/0)) (, ,) (NP (NNP Doc_12119460_1867_1885_Disease))) (VP (VBD 12.1/0/0))) (. .)))
12119460	13	(S1 (S (NP (CD Two) (NNS patients)) (VP (VBD developed) (NP (NP (NNP Doc_12119460_1919_1944_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12119460_1946_1949_Disease)) (-RRB- -RRB-)))) (. .)))
12119460	14	(S1 (S (NP (NNP High-dose) (NNP Doc_12119460_1975_1979_Chemical/FA/Doc_12119460_1983_1986_Chemical)) (VP (AUX is) (NP (NP (DT an) (ADJP (ADJP (JJ effective)) (CC and) (ADJP (JJ well-tolerated))) (NN outpatient) (NN regimen)) (PP (IN for) (NP (NP (NNS AGC)) (PRN (-LRB- -LRB-) (NP (NP (JJ objective) (NN response) (NN rate)) (NP (CD 54.6) (NN %))) (-RRB- -RRB-)))))) (. .)))
12119460	15	(S1 (S (S (NP (PRP It)) (VP (MD may) (VP (VB serve) (PP (IN as) (NP (NP (DT an) (NN alternative)) (PP (TO to) (NP (JJ Doc_12119460_2116_2125_Chemical-containing) (NNS regimens)))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (PRP it)) (VP (AUX has) (S (VP (TO to) (VP (AUX be) (VP (VBN considered) (SBAR (IN that) (S (ADVP (RB possibly)) (NP (NNP Doc_12119460_2194_2197_Disease)) (VP (MD may) (VP (VB occur))))))))))) (. .)))
12165618	0	(S1 (S (NP (JJ Persistent) (JJ sterile) (NN leukocyturia)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_12165618_51_74_Disease)) (PP (IN in) (NP (NP (JJ human) (NNP Doc_12165618_84_100_Disease) (NN virus) (NN type) (JJ 1-infected) (NNS children)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_12165618_145_154_Chemical)))))))))) (. .)))
12165618	1	(S1 (S (NP (NP (JJ Prolonged) (NN administration)) (PP (IN of) (NP (NNP Doc_12165618_196_205_Chemical)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (NNP Doc_12165618_256_275_Disease)) (PP (IN in) (NP (NNS adults))))))))))) (. .)))
12165618	2	(S1 (S (NP (DT These) (JJ well-documented) (NN side) (NNS effects)) (VP (AUX have) (VP (VBN restricted) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT this) (JJ potent) (NN protease) (NN inhibitor))) (PP (IN in) (NP (NNS children)))))) (. .)))
12165618	3	(S1 (S (NP (NP (DT A) (JJ prospective) (NN study)) (SBAR (S (VP (TO to) (VP (VB monitor) (NP (JJ Doc_12165618_432_441_Chemical-related) (NN nephrotoxicity)) (PP (IN in) (NP (NP (DT a) (NN cohort)) (PP (IN of) (NP (CD 30) (JJ human) (NNP Doc_12165618_489_505_Disease) (NN virus) (NN type) (JJ 1-infected) (NNS children)))))))))) (VP (VBD treated) (PP (IN with) (NP (NNP Doc_12165618_550_559_Chemical)))) (. .)))
12165618	4	(S1 (S (NP (NP (NN Urinary) (NNS pH)) (, ,) (NP (NN albumin)) (, ,) (NP (NP (NNP Doc_12165618_591_601_Chemical)) (, ,) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNS erythrocytes) (, ,) (NNS leukocytes) (, ,) (NNS bacteria) (CC and) (NNS crystals))))) (, ,) (CC and) (NP (NN culture))) (VP (AUX were) (VP (VBN analyzed) (NP (NP (DT every) (CD 3) (NNS months)) (PP (IN for) (NP (CD 96) (NNS weeks)))))) (. .)))
12165618	5	(S1 (S (NP (NNP Serum) (NNP Doc_12165618_729_739_Chemical) (NNS levels)) (VP (AUX were) (ADVP (RB routinely)) (VP (VBN determined) (PP (IN at) (NP (DT the) (JJ same) (NN time) (NNS points))))) (. .)))
12165618	6	(S1 (S (NP (NP (JJ Steady-state) (NNS pharmacokinetics)) (PP (IN of) (NP (NNP Doc_12165618_831_840_Chemical)))) (VP (AUX were) (ADVP (RB done)) (PP (IN at) (NP (NN week) (CD 4))) (PP (IN after) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NNP Doc_12165618_885_894_Chemical)))))) (. .)))
12165618	7	(S1 (S (NP (NP (DT The) (JJ cumulative) (NN incidence)) (PP (IN of) (NP (NP (JJ persistent) (JJ sterile) (NN leukocyturia)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD >) (CC or) (CD =75)) (JJ cells/) (JJ micro) (NN L)) (PP (IN in) (NP (QP (IN at) (JJS least) (CD 2)) (JJ consecutive) (NNS visits)))) (-RRB- -RRB-)))) (PP (IN after) (NP (CD 96) (NNS weeks)))) (VP (AUX was) (NP (CD 53) (NN %))) (. .)))
12165618	8	(S1 (S (NP (JJ Persistent) (JJ sterile) (NN leukocyturia)) (VP (AUX was) (ADVP (RB frequently)) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJ mild) (NN increase)) (PP (PP (IN in) (NP (DT the) (NN urine) (NN albumin/Doc_12165618_1148_1158_Chemical) (NN ratio))) (CC and) (PP (IN by) (NP (JJ microscopic) (NNP Doc_12165618_1184_1193_Disease)))))))) (. .)))
12165618	9	(S1 (S (NP (NP (DT The) (JJ cumulative) (NN incidence)) (PP (IN of) (NP (JJ serum) (JJ Doc_12165618_1229_1239_Chemical) (NNS levels))) (PP (NP (CD >50) (NN %)) (IN above) (NP (JJ normal)))) (VP (AUX was) (NP (CD 33) (NN %)) (PP (IN after) (NP (CD 96) (NNS weeks)))) (. .)))
12165618	10	(S1 (S (NP (NP (NNS Children)) (PP (IN with) (NP (JJ persistent) (JJ sterile) (NNS leukocyturia)))) (ADVP (RBR more) (RB frequently)) (VP (AUX had) (NP (NP (JJ serum) (JJ Doc_12165618_1361_1371_Chemical) (NNS levels)) (PP (IN of) (NP (CD 50) (NN %))) (PP (IN above) (ADJP (JJ normal) (PP (IN than) (NP (NP (DT those) (NNS children)) (PP (IN without) (NP (JJ persistent) (JJ sterile) (NNS leukocyturia))))))))) (. .)))
12165618	11	(S1 (S (PP (IN In) (NP (NP (NNS children)) (ADJP (ADJP (JJR younger)) (PP (IN than) (NP (CD 5.6) (NNS years)))))) (, ,) (NP (JJ persistent) (JJ sterile) (NN leukocyturia)) (VP (AUX was) (ADJP (ADVP (RB significantly) (RBR more)) (JJ frequent) (PP (IN than) (PP (IN in) (NP (JJR older) (NNS children)))))) (. .)))
12165618	12	(S1 (S (NP (NP (DT A) (JJR higher) (JJ cumulative) (NN incidence)) (PP (IN of) (NP (JJ persistent) (NNS leukocyturia)))) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NP (DT an) (NN area)) (PP (IN under) (NP (DT the) (NN curve) (CD >19))) (PP (VBG mg/L) (NP (NP (NNP x) (NNP h)) (CC or) (NP (NP (DT a) (JJ peak) (NN serum) (NN level)) (PP (IN of) (NP (NNP Doc_12165618_1730_1739_Chemical) (CD >12) (NNS mg/L)))))))))))) (. .)))
12165618	13	(S1 (S (PP (IN In) (NP (CD 4) (NNS children))) (, ,) (NP (NNP Doc_12165618_1765_1774_Chemical)) (VP (AUX was) (VP (VBN discontinued) (PP (IN because) (IN of) (NP (NN nephrotoxicity))))) (. .)))
12165618	14	(S1 (S (ADVP (RB Subsequently)) (, ,) (S (NP (DT the) (NN serum) (NN Doc_12165618_1843_1853_Chemical) (NNS levels)) (VP (VBD decreased))) (, ,) (S (NP (DT the) (NN urine) (NN albumin/Doc_12165618_1890_1900_Chemical) (NNS ratios)) (VP (VBD returned) (PP (TO to) (NP (CD zero))))) (, ,) (CC and) (S (NP (DT the) (NN leukocyturia)) (VP (VBD disappeared) (PP (IN within) (NP (CD 3) (NNS months))))) (. .)))
12165618	15	(S1 (S (NP (NP (NNS Children)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_12165618_2011_2020_Chemical))))) (VP (AUX have) (NP (NP (DT a) (JJ high) (JJ cumulative) (NN incidence)) (PP (IN of) (NP (JJ persistent) (JJ sterile) (NN leukocyturia))))) (. .)))
12165618	16	(S1 (S (NP (NP (NNS Children)) (PP (IN with) (NP (JJ persistent) (JJ sterile) (NNS leukocyturia)))) (ADVP (RBR more) (RB frequently)) (VP (AUX had) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ serum) (JJ Doc_12165618_2177_2187_Chemical) (NNS levels)) (PP (IN of) (NP (CD >50) (NN %))) (PP (IN above) (NP (JJ normal))))))) (. .)))
12165618	17	(S1 (S (NP (JJR Younger) (NNS children)) (VP (AUX have) (NP (NP (DT an) (JJ additional) (NN risk)) (PP (IN for) (NP (NNP Doc_12165618_2262_2281_Disease))))) (. .)))
12165618	18	(S1 (S (NP (NP (DT The) (NN impairment)) (PP (IN of) (NP (DT the) (JJ renal) (NN function))) (PP (IN in) (NP (DT these) (NNS children)))) (VP (VBD occurred) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (JJ clinical) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_12165618_2386_2401_Disease)))))))) (. .)))
12165618	19	(S1 (S (NP (JJ Doc_12165618_2403_2412_Chemical-associated) (NN nephrotoxicity)) (VP (MD must) (VP (AUX be) (VP (VBN monitored) (ADVP (RB closely)) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NP (NN risk) (NNS factors)) (PP (JJ such) (IN as) (NP (NP (JJ persistent) (JJ sterile) (NN leukocyturia)) (, ,) (NP (NP (NN age)) (NP (CD <5.6) (NNS years))) (, ,) (NP (NP (DT an) (NN area)) (PP (IN under) (NP (NP (DT the) (NN curve)) (PP (IN of) (NP (NNP Doc_12165618_2591_2600_Chemical) (CD >19))) (VP (VBN mg/L) (NP (NNP x) (NNP h)))))) (, ,) (CC and) (NP (DT a) (NNP C) (PRN (-LRB- -LRB-) (NNP max) (-RRB- -RRB-)) (NN >12) (NN mg/L))))))))))) (. .)))
12359538	0	(S1 (NP (NP (NN Utility)) (PP (IN of) (S (VP (VBG troponin) (NP (PRP I)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_12359538_39_46_Chemical-associated) (NNP Doc_12359538_58_68_Disease)))))))) (. .)))
12359538	1	(S1 (S (NP (NP (NP (JJ Baseline) (NN electrocardiogram) (NNS abnormalities)) (CC and) (NP (NN market) (NNS elevations))) (VP (ADVP (RB not)) (VBN associated) (PP (IN with) (NP (NNP Doc_12359538_153_172_Disease))))) (VP (VBP make) (NP (NP (JJ accurate) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_12359538_200_221_Disease))) (PRN (-LRB- -LRB-) (NP (NNP Doc_12359538_223_225_Disease)) (-RRB- -RRB-)) (ADJP (JJ difficult) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ Doc_12359538_254_261_Chemical-associated) (NNP Doc_12359538_273_283_Disease)))))))) (. .)))
12359538	2	(S1 (S (NP (JJ Troponin) (NN sampling)) (VP (MD may) (VP (VB offer) (NP (JJR greater) (JJ diagnostic) (NN utility)) (PP (IN in) (NP (DT these) (NNS patients))))) (. .)))
12359538	3	(S1 (S (VP (TO To) (VP (VB assess) (NP (NP (NNS outcomes)) (VP (VBN based) (PP (IN on) (NP (NP (JJ troponin) (NN positivity)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_12359538_435_442_Chemical) (NNP Doc_12359538_443_453_Disease)) (VP (VBN admitted) (PP (IN for) (NP (NP (NN exclusion)) (PP (IN of) (NP (NNP Doc_12359538_480_482_Disease)))))))))))))))) (. .)))
12359538	4	(S1 (S (NP (NNS Outcomes)) (VP (AUX were) (VP (VBN examined) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN admitted) (PP (IN for) (NP (JJ possible) (NN Doc_12359538_550_552_Disease))) (PP (IN after) (NP (JJ Doc_12359538_559_566_Chemical) (NN use)))))))) (. .)))
12359538	5	(S1 (S (NP (DT All) (NNS patients)) (VP (VBD underwent) (NP (NP (NP (DT a) (JJ rapid) (NN rule-in) (NN protocol)) (SBAR (WHNP (WDT that)) (S (VP (VBD included) (NP (NP (JJ serial) (NN sampling)) (PP (IN of) (NP (JJ Doc_12359538_653_661_Chemical) (NN kinase)))))))) (PRN (-LRB- -LRB-) (NP (NNP CK)) (-RRB- -RRB-)) (, ,) (NP (NN CK-MB)) (, ,) (CC and) (NP (NP (JJ cardiac) (NN troponin) (NN I)) (PRN (-LRB- -LRB-) (NP (NN cTnI)) (-RRB- -RRB-)))) (PP (IN over) (NP (CD eight) (NNS hours)))) (. .)))
12359538	6	(S1 (S (NP (NNS Outcomes)) (VP (VBD included) (NP (NP (NNP Doc_12359538_748_756_Disease) (-LRB- -LRB-) (NN CK-MB)) (VP (VBG >or=) (NP (CD 8) (NN ng/mL)) (PP (IN with) (NP (NP (DT a) (JJ relative) (NN index) (NN -LSB-) (PRN (-LRB- -LRB-) (NP (NNP CK-MB) (NNP x) (CD 100)) (-RRB- -RRB-)) (NN /total)) (VP (VBG CK) (NP (NP (JJ -RSB-) (NN >or=) (CD 4)) (, ,) (NP (NNP Doc_12359538_832_845_Disease)) (, ,) (CC and) (NP (NP (JJ significant) (NN Doc_12359538_863_879_Disease)) (PRN (-LRB- -LRB-) (NP (CD >or=50) (NN %)) (-RRB- -RRB-)))))))))) (. .)))
12359538	7	(S1 (S (PP (IN Of) (NP (DT the) (CD 246) (VBN admitted) (NNS patients))) (, ,) (NP (NP (CD 34)) (PRN (-LRB- -LRB-) (NP (CD 14) (NN %)) (-RRB- -RRB-))) (VP (VBD met) (SBAR (S (NP (NP (JJ CK-MB) (NNS criteria)) (PP (IN for) (NP (NP (NNP Doc_12359538_962_964_Disease)) (CC and) (NP (NP (CD 38)) (PRN (-LRB- -LRB-) (NP (CD 16) (NN %)) (-RRB- -RRB-)))))) (VP (AUX had) (NP (JJ cTnI) (NNS elevations)))))) (. .)))
12359538	8	(S1 (S (NP (NN Angiography)) (VP (AUX was) (VP (VBN performed) (PP (IN in) (NP (NP (QP (CD 29) (IN of) (CD 38)) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (ADJP (JJ cTnI-positive))))))) (, ,) (PP (IN with) (NP (NP (JJ significant) (NN disease) (NN present)) (PP (IN in) (NP (NP (CD 25)) (PRN (-LRB- -LRB-) (NP (CD 86) (NN %)) (-RRB- -RRB-)))))))) (. .)))
12359538	9	(S1 (S (S (NP (NP (CD Three)) (PP (IN of) (NP (NP (DT the) (CD four) (NNS patients)) (PP (IN without) (NP (JJ significant) (NN disease))) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (JJ cTnI) (NNS elevations)))))))) (VP (VBD met) (NP (NP (JJ CK-MB) (NNS criteria)) (PP (IN for) (NP (NNP Doc_12359538_1218_1220_Disease)))))) (, ,) (CC and) (S (NP (DT the) (JJ other)) (VP (AUX had) (NP (NP (DT a) (JJ peak) (NN CK-MB) (NN level)) (PP (IN of) (NP (CD 13) (NN ng/mL)))))) (. .)))
12359538	10	(S1 (S (NP (NP (NNS Sensitivities)) (, ,) (NP (NNS specificities)) (, ,) (CC and) (NP (NP (ADJP (JJ positive) (CC and) (JJ negative)) (NN likelihood) (NNS ratios)) (PP (IN for) (S (VP (VBG predicting) (NP (NNP Doc_12359538_1361_1374_Disease) (CC or) (JJ significant) (NN disease))))))) (VP (VP (AUX were) (ADJP (ADJP (JJ high) (PP (IN for) (NP (DT both) (NNP Doc_12359538_1417_1425_Disease)))) (CC and) (ADJP (JJ cTnI)))) (CC and) (VP (AUX were) (RB not) (ADJP (RB significantly) (JJ different)))) (. .)))
12359538	11	(S1 (S (NP (NP (JJS Most) (NNS patients)) (PP (IN with) (NP (JJ cTnI) (NNS elevations)))) (VP (VP (VBP meet) (NP (NP (JJ CK-MB) (NNS criteria)) (PP (IN for) (NP (NNP Doc_12359538_1545_1547_Disease))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (VP (AUX have) (NP (NP (DT a) (JJ high) (NN incidence)) (PP (IN of) (NP (JJ underlying) (JJ significant) (NN disease)))))) (. .)))
12359538	12	(S1 (S (NP (NNP Troponin)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX have) (NP (NP (DT an) (JJ equivalent) (JJ diagnostic) (NN accuracy)) (PP (VBN compared) (PP (IN with) (NP (NN CK-MB))))) (PP (IN for) (S (VP (VBG diagnosing) (NP (NNP Doc_12359538_1711_1719_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ Doc_12359538_1737_1744_Chemical-associated) (NNP Doc_12359538_1756_1766_Disease)) (CC and) (NP (JJ suspected) (NNP Doc_12359538_1781_1783_Disease))))))))))))) (. .)))
12372954	0	(S1 (NP (NP (JJ Acute) (NN Doc_12372954_6_28_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NP (NNP Doc_12372954_36_47_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Sermion)) (-RRB- -RRB-))))) (. .)))
12372954	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (NNP Doc_12372954_79_107_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12372954_109_112_Disease)) (-RRB- -RRB-))))) (PP (RB due) (TO to) (NP (NP (NNP Doc_12372954_121_132_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Sermion)) (-RRB- -RRB-))))) (. .)))
12372954	2	(S1 (S (NP (DT A) (JJ 50-year-old) (NN patient)) (VP (VBD admitted) (PP (TO to) (NP (PRP$ our) (NN hospital))) (PP (IN for) (NP (NP (NNP Doc_12372954_195_200_Disease)) (CC and) (NP (NNP Doc_12372954_205_224_Disease))))) (. .)))
12372954	3	(S1 (S (PP (IN Before) (NP (NN admission))) (, ,) (NP (PRP he)) (VP (AUX had) (VP (AUX been) (VP (VBG taking) (NP (NNP Doc_12372954_263_274_Chemical) (CC and) (NNP bendazac) (NNP Doc_12372954_288_294_Chemical) (NN due)) (S (VP (TO to) (VP (VB Doc_12372954_302_324_Disease) (PP (IN at) (NP (JJ ophthalmologic) (NN department))))))))) (. .)))
12372954	4	(S1 (S (ADVP (RB Thereafter)) (, ,) (NP (PRP he)) (VP (VBD experienced) (NP (NP (JJ intermittent) (NN Doc_12372954_395_400_Disease)) (CC and) (NP (NN Doc_12372954_405_414_Disease)))) (. .)))
12372954	5	(S1 (S (PP (IN On) (NP (NN admission))) (, ,) (NP (NP (NP (JJ clinical) (NNS symptoms)) (PRN (-LRB- -LRB-) (PP (FW i.e.) (NP (NNP Doc_12372954_454_464_Disease) (CC and) (NNP Doc_12372954_469_474_Disease))) (-RRB- -RRB-))) (CC and) (NP (NP (NN laboratory) (NNS findings)) (PRN (-LRB- -LRB-) (PP (FW i.e.) (NP (NNP Doc_12372954_506_518_Disease) (CC and) (NNP Doc_12372954_523_536_Disease))) (-RRB- -RRB-)))) (VP (VBD suggested) (NP (NP (NNP Doc_12372954_548_551_Disease)) (, ,) (CC and) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN confirmed) (PP (IN by) (NP (NP (JJ pathologic) (NNS findings)) (PP (IN on) (NP (JJ renal) (NN biopsy))))))))))) (. .)))
12372954	6	(S1 (S (NP (DT A) (NN lymphocyte) (NN transformation) (NN test)) (VP (VBD demonstrated) (NP (NP (DT a) (JJ positive) (NN result)) (PP (IN against) (NP (NNP Doc_12372954_689_700_Chemical))))) (. .)))
12372954	7	(S1 (S (S (NP (NN Treatment)) (VP (AUX was) (VP (VBN consisted) (PP (IN of) (NP (NP (NN withdrawal)) (PP (IN of) (NP (NP (NNP Doc_12372954_743_754_Chemical)) (CC and) (NP (JJ intravenous) (NNP Doc_12372954_771_789_Chemical))))))))) (, ,) (CC and) (S (NP (PRP$ his) (JJ renal) (NN function)) (VP (AUX was) (ADVP (RB completely)) (VP (VBN recovered)))) (. .)))
12372954	8	(S1 (S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (, ,) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN report)) (PP (IN of) (NP (JJ Doc_12372954_886_897_Chemical-associated) (NN Doc_12372954_909_912_Disease))))) (. .)))
12452552	0	(S1 (S (NP (NN Doc_12452552_0_30_Disease)) (VP (VBN complicated) (PP (IN by) (NP (JJ massive) (NN Doc_12452552_54_73_Disease))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_12452552_92_113_Disease)))))) (. .)))
12452552	1	(S1 (S (NP (NP (DT A) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_12452552_130_151_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12452552_153_156_Disease)) (-RRB- -RRB-))))) (VP (VBD developed) (NP (NP (NNP Doc_12452552_168_198_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12452552_200_203_Disease)) (-RRB- -RRB-))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NNP Doc_12452552_229_240_Chemical)) (CC and) (NP (NNP Doc_12452552_245_260_Chemical))))))) (. .)))
12452552	2	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (NP (DT the) (JJ typical) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_12452552_301_304_Disease))))))) (, ,) (NP (JJ massive) (NN Doc_12452552_314_333_Disease)) (VP (AUX was) (VP (VBN observed) (PP (IN during) (NP (DT the) (NN episode))))) (. .)))
12452552	3	(S1 (S (NP (DT This) (NN report)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (NN Doc_12452552_393_396_Disease)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_12452552_415_418_Disease)))))) (VP (VP (MD may) (VP (AUX be) (VP (VBN complicated) (PP (IN by) (NP (NNP Doc_12452552_441_460_Disease)))))) (CC and) (VP (VBZ needs) (NP (JJ special) (NN caution)) (PP (IN for) (NP (DT this) (NN complication)))))))) (. .)))
12487093	0	(S1 (NP (NP (NN Blood) (NN brain) (NN barrier)) (PP (IN in) (NP (NP (ADJP (JJ right-) (CC and) (JJ left-pawed)) (JJ female) (NNS rats)) (VP (VBN assessed) (PP (IN by) (NP (DT a) (JJ new) (NN staining) (NN method)))))) (. .)))
12487093	1	(S1 (S (NP (NP (NP (DT The) (JJ asymmetrical) (NN breakdown)) (PP (IN of) (NP (DT the) (JJ blood-brain) (NN barrier)))) (PRN (-LRB- -LRB-) (NP (NNP BBB)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (JJ female) (NNS rats))))) (. .)))
12487093	2	(S1 (S (NP (JJ Paw) (NN preference)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (NP (DT a) (NN food) (VBG reaching) (NN test))))) (. .)))
12487093	3	(S1 (S (NP (JJ Doc_12487093_233_243_Chemical-induced) (NNP Doc_12487093_252_264_Disease)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB destroy) (NP (NP (DT the) (NNP BBB)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN evaluated) (S (VP (VBG using) (NP (NP (NNP Doc_12487093_320_340_Chemical) (PRN (-LRB- -LRB-) (NP (NNP TTC)) (-RRB- -RRB-)) (NN staining)) (PP (IN of) (NP (DT the) (NN brain) (NNS slices)))) (PP (ADVP (RB just)) (IN after) (S (VP (VBG giving) (NP (NP (NN Doc_12487093_394_404_Chemical)) (PP (IN for) (NP (CD 30)))) (NP (PRP s))))))))))))))))) (. .)))
12487093	4	(S1 (S (PP (IN In) (NP (JJ normal) (NNS rats))) (, ,) (NP (DT the) (JJ whole) (NN brain) (NNS sections)) (VP (VBD exhibited) (NP (JJ complete) (NN staining)) (PP (IN with) (NP (NN TTC)))) (. .)))
12487093	5	(S1 (S (PP (IN After) (S (NP (NP (JJ Doc_12487093_500_510_Chemical) (NN infusion)) (PP (IN for) (NP (CD 30)))) (VP (VBZ s)))) (, ,) (NP (EX there)) (VP (AUX were) (UCP (NP (NP (JJ large) (JJ unstained) (NNS areas)) (PP (IN in) (NP (NP (DT the) (JJ left) (NN brain)) (PP (IN in) (NP (JJ right-pawed) (NNS animals)))))) (, ,) (CC and) (ADVP (RB vice) (RB versa)) (PP (IN in) (NP (JJ left-pawed) (NNS animals))))) (. .)))
12487093	6	(S1 (S (NP (JJ Similar) (NNS results)) (VP (AUX were) (VP (VBN obtained) (PP (IN in) (NP (NP (JJ Doc_12487093_676_683_Disease-induced) (NN breakdown)) (PP (IN of) (NP (NNP BBB))))))) (. .)))
12487093	7	(S1 (S (NP (DT These) (NNS results)) (VP (AUX were) (VP (VBN explained) (PP (IN by) (NP (NP (DT an) (JJ asymmetric) (JJ cerebral) (NN blood) (NN flow)) (VP (VBG depending) (PP (IN upon) (NP (NP (DT the) (NN paw) (NN preference)) (PP (IN in) (NP (NNS rats)))))))))) (. .)))
12487093	8	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN suggested) (SBAR (IN that) (S (NP (NP (DT this) (JJ new) (NN method)) (CC and) (NP (DT the) (NNS results))) (VP (AUX are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (JJ contralateral) (NN motor) (NN control)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (AUX be) (ADJP (JJ important) (PP (IN in) (S (VP (VBG determining) (NP (NP (DT the) (JJ dominant) (JJ cerebral) (NN hemisphere)) (PP (IN in) (NP (NNS animals)))))))))))))))))))) (. .)))
12498738	0	(S1 (S (NP (NN Doc_12498738_0_10_Chemical)) (VP (VBZ protects) (PP (IN against) (NP (NNP Doc_12498738_28_39_Chemical-induced) (NNP Doc_12498738_48_76_Disease)))) (. .)))
12498738	1	(S1 (S (NP (JJ Several) (JJ cytopathic) (NNS mechanisms)) (VP (AUX have) (VP (AUX been) (VP (VBN suggested) (S (VP (TO to) (VP (VB mediate) (NP (NP (DT the) (JJ dose-limiting) (ADJP (JJ cumulative) (CC and) (JJ irreversible)) (NN Doc_12498738_185_199_Disease)) (VP (VBN caused) (PP (IN by) (NP (NN Doc_12498738_210_221_Chemical))))))))))) (. .)))
12498738	2	(S1 (S (NP (JJ Recent) (NN evidence)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NP (JJ oxidative) (NN stress)) (CC and) (NP (NNP Doc_12498738_275_300_Disease))) (VP (AUX are) (NP (NP (JJ key) (NNS factors)) (PP (IN in) (NP (DT the) (JJ pathogenic) (NN process)))))))) (. .)))
12498738	3	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN investigation)))) (VP (AUX was) (S (VP (TO to) (VP (VB test) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NP (NNP Doc_12498738_412_422_Chemical)) (, ,) (NP (NP (DT a) (JJ nonselective) (JJ beta-adrenergic) (NN receptor) (NN antagonist)) (PP (IN with) (NP (JJ potent) (NN antioxidant) (NNS properties)))) (, ,)) (VP (VBZ protects) (PP (IN against) (NP (NP (DT the) (NNP Doc_12498738_532_590_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ subchronic) (NNP Doc_12498738_618_629_Chemical) (NNP Doc_12498738_630_638_Disease)))))))))))))) (. .)))
12498738	4	(S1 (S (NP (NNP Heart) (CC and) (NNP Doc_12498738_650_668_Disease)) (VP (AUX were) (VP (VBN isolated) (PP (IN from) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN for) (NP (CD 7) (NNS weeks))) (PP (IN with) (NP (NP (NP (NNP Doc_12498738_718_729_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2) (CD mg/kg)) (NN sc/week)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_12498738_749_759_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CD mg/kg)) (NN ip/week)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (DT the) (CD two) (NNS drugs))))))))))) (. .)))
12498738	5	(S1 (S (NP (NP (NN Heart) (NNS mitochondria)) (VP (VBN isolated) (PP (IN from) (NP (JJ Doc_12498738_849_860_Chemical-treated) (NNS rats))))) (VP (VBD exhibited) (NP (NP (NP (NP (NP (JJ depressed) (NNS rates)) (PP (IN for) (NP (NP (NN state) (CD 3) (NN respiration)) (PRN (-LRB- -LRB-) (NP (NP (CD 336) (NN +/-)) (NP (QP (CD 26) (CC versus) (CD 425)) (JJ +/-) (CD 53) (JJ natom) (NNP O/min/mg) (NN protein))) (-RRB- -RRB-))))) (CC and) (NP (DT a) (JJR lower) (NN respiratory) (NN control) (NN ratio))) (PRN (-LRB- -LRB-) (NP (NNP RCR)) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NP (CD 4.3) (NN +/-)) (NP (CD 0.6) (CC versus) (CD 5.8) (NN +/-) (CD 0.4))) (-RRB- -RRB-)) (PP (VBN compared) (PP (IN with) (NP (NP (JJ cardiac) (NNS mitochondria)) (VP (VBN isolated) (PP (IN from) (NP (JJ saline-treated) (NNS rats)))))))) (. .)))
12498738	6	(S1 (S (NP (NP (JJ Mitochondrial) (JJ Doc_12498738_1139_1146_Chemical-loading) (NN capacity)) (CC and) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NNP Doc_12498738_1184_1188_Chemical-dehydrogenase))))) (VP (AUX were) (ADVP (RB also)) (VP (VBN suppressed) (PP (IN in) (NP (NP (JJ cardiac) (NNS mitochondria)) (PP (IN from) (NP (JJ Doc_12498738_1253_1264_Chemical-treated) (NNS rats))))))) (. .)))
12498738	7	(S1 (S (NP (JJ Doc_12498738_1279_1290_Chemical) (NN treatment)) (ADVP (RB also)) (VP (VBD caused) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NNP RCR))) (PP (IN for) (NP (NP (NP (NNP Doc_12498738_1335_1353_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 3.9) (NN +/-)) (NP (CD 0.9) (CC versus) (CD 5.6) (NN +/-) (CD 0.7))) (PP (IN for) (NP (NN control) (NNS rats)))) (-RRB- -RRB-))) (CC and) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ hepatic) (JJ cytochrome) (NN oxidase) (NN activity)))))))) (. .)))
12498738	8	(S1 (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NNP Doc_12498738_1479_1489_Chemical)))) (VP (VP (VBD decreased) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (JJ cellular) (NN vacuolization))) (PP (IN in) (NP (JJ cardiac) (NNS myocytes))))) (CC and) (VP (VBD prevented) (NP (NP (DT the) (JJ inhibitory) (NN effect)) (PP (IN of) (NP (NNP Doc_12498738_1596_1607_Chemical))) (PP (IN on) (NP (NP (JJ mitochondrial) (NN respiration)) (PP (IN in) (NP (DT both) (NN heart) (CC and) (NN liver)))))))) (. .)))
12498738	9	(S1 (S (NP (NN Doc_12498738_1662_1672_Chemical)) (ADVP (RB also)) (VP (VBD prevented) (NP (NP (NP (DT the) (NN decrease)) (PP (IN in) (NP (JJ mitochondrial) (JJ Doc_12498738_1718_1724_Chemical) (NN loading) (NN capacity)))) (CC and) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NP (DT the) (JJ respiratory) (NNS complexes)) (PP (IN of) (NP (NNP Doc_12498738_1793_1811_Disease))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_12498738_1822_1833_Chemical))))))))) (. .)))
12498738	10	(S1 (S (NP (NP (NN Doc_12498738_1835_1845_Chemical)) (PP (IN by) (NP (PRP itself)))) (VP (AUX did) (RB not) (VP (VB affect) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (NNS parameters)) (VP (VBN measured) (PP (IN for) (NP (NP (NN heart)) (CC or) (NP (NN Doc_12498738_1915_1933_Disease)))))))))) (. .)))
12498738	11	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NP (DT this) (NN protection)) (PP (IN by) (NP (NNP Doc_12498738_1975_1985_Chemical))) (PP (IN against) (NP (CC both) (DT the) (JJ structural) (CC and) (JJ functional) (JJ cardiac) (NN tissue) (NN damage)))) (VP (MD may) (VP (VB afford) (NP (JJ significant) (JJ clinical) (NN advantage)) (PP (IN in) (S (VP (VBG minimizing) (NP (NP (DT the) (JJ dose-limiting) (NNP Doc_12498738_2125_2150_Disease) (CC and) (NNP Doc_12498738_2155_2169_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBZ accompanies) (NP (NP (JJ long-term) (JJ Doc_12498738_2197_2208_Chemical) (NN therapy)) (PP (IN in) (NP (NNP Doc_12498738_2220_2226_Disease) (NNS patients))))))))))))))))) (. .)))
12523489	0	(S1 (S (NP (JJ Doc_12523489_0_7_Chemical-induced) (NNP Doc_12523489_16_29_Disease)) (VP (AUX is) (ADVP (RBR more)) (VP (VBN influenced) (PP (IN by) (NP (NP (JJ Doc_12523489_52_61_Chemical) (NN receptor) (NNS agonists)) (PP (IN than) (NP (JJ Doc_12523489_85_96_Chemical-induced) (NNP Doc_12523489_105_118_Disease))))))) (. .)))
12523489	1	(S1 (S (NP (NP (DT The) (NN influence)) (PP (IN of) (NP (NP (JJ Doc_12523489_137_146_Chemical) (NN receptor) (NNS agonists)) (CC and) (NP (NNS antagonists)))) (PP (IN on) (NP (NNP Doc_12523489_184_191_Chemical-and) (NNP Doc_12523489_196_207_Chemical-induced) (NNP Doc_12523489_216_229_Disease)))) (VP (AUX was) (VP (VBN examined) (PP (IN in) (NP (NNS mice))))) (. .)))
12523489	2	(S1 (S (S (NP (DT All) (JJ Doc_12523489_256_265_Chemical) (NN receptor) (NNS agonists)) (VP (ADVP (RB significantly)) (VBN decreased) (NP (NP (DT the) (JJ locomotor) (NN activity)) (PP (IN in) (NP (NNS mice)))))) (, ,) (CC and) (S (NP (DT the) (NNS effects)) (VP (AUX were) (ADJP (JJ dose-dependent)))) (. .)))
12523489	3	(S1 (S (NP (PRP It)) (VP (VBZ seems) (SBAR (IN that) (S (NP (NNP Doc_12523489_391_400_Chemical) (NNP A1) (CC and) (NNP A2) (NNS receptors)) (VP (MD might) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (DT this) (NN reaction))))))))) (. .)))
12523489	4	(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (DT all) (NNP Doc_12523489_471_480_Chemical) (NN receptor)) (VP (VBZ agonists))) (: :) (S (NP (NP (NP (NNP Doc_12523489_500_565_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12523489_567_576_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NNP A2A) (NN receptor) (NN agonist)) (, ,) (NP (NP (NP (NNP Doc_12523489_601_624_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12523489_626_629_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NNP A1) (NN receptor) (NN agonist)) (, ,) (CC and) (NP (NP (NNP Doc_12523489_657_687_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12523489_689_693_Chemical)) (-RRB- -RRB-)))) (, ,)) (NP (NNP A2/A1) (NN receptor) (NN agonist)) (VP (ADVP (RB significantly) (CC and) (RB dose-dependently)) (VBD decreased) (NP (JJ Doc_12523489_764_771_Chemical-induced) (JJ locomotor) (NN activity)))) (. .)))
12523489	5	(S1 (S (NP (NN Doc_12523489_800_803_Chemical)) (VP (VBD reduced) (NP (JJ Doc_12523489_812_819_Chemical) (NN action)) (PP (IN at) (NP (NP (DT the) (NNS doses)) (SBAR (WHNP (WDT which)) (S (, ,) (S (VP (VBN given) (ADVP (RB alone)))) (, ,) (VP (AUX did) (RB not) (VP (VB influence) (NP (NN motility)) (, ,) (SBAR (IN while) (S (NP (NNP Doc_12523489_894_903_Chemical) (CC and) (NNP Doc_12523489_908_912_Chemical)) (VP (VBD decreased) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NNP Doc_12523489_937_944_Chemical)))) (PP (IN at) (NP (NP (DT the) (NNS doses)) (SBAR (WHNP (WDT which)) (S (PRN (, ,) (S (VP (VBN given) (ADVP (RB alone)))) (, ,)) (VP (VBD decreased) (NP (NP (NN locomotor) (NN activity)) (PP (IN in) (NP (NNS animals))))))))))))))))))) (. .)))
12523489	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (DT both) (JJ Doc_12523489_1065_1074_Chemical) (NNS receptors))) (PP (IN in) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NNP Doc_12523489_1102_1109_Chemical)))))) (SBAR (IN although) (S (NP (NP (NNS agonists)) (PP (IN of) (NP (NNP A1) (NNS receptors)))) (VP (VBP seem) (S (VP (TO to) (VP (AUX have) (NP (JJR stronger) (NN influence)) (PP (IN on) (NP (PRP it)))))))))) (. .)))
12523489	7	(S1 (S (NP (NP (DT The) (JJ selective) (NN blockade)) (PP (IN of) (NP (NNP A2) (NNP Doc_12523489_1212_1221_Chemical) (NN receptor))) (PP (IN by) (NP (NP (NNP Doc_12523489_1234_1238_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12523489_1240_1272_Chemical)) (-RRB- -RRB-))))) (ADVP (RB significantly)) (VP (VBD enhanced) (NP (NP (JJ Doc_12523489_1297_1304_Chemical-induced) (NN locomotor) (NN activity)) (PP (IN of) (NP (NNS animals))))) (. .)))
12523489	8	(S1 (S (S (NP (NN Doc_12523489_1344_1352_Chemical)) (VP (AUX had) (NP (JJ similar) (NN action)))) (CC but) (S (NP (DT the) (NN effect)) (VP (AUX was) (RB not) (ADJP (JJ significant)))) (. .)))
12523489	9	(S1 (S (NP (JJ Doc_12523489_1408_1411_Chemical) (PRN (-LRB- -LRB-) (NP (NN 8-cyclopentyltheophylline)) (-RRB- -RRB-)) (JJ --A1) (NN receptor) (NN antagonist)) (, ,) (VP (AUX did) (RB not) (VP (VB show) (NP (DT any) (NN influence)) (PP (IN in) (NP (DT this) (NN test))))) (. .)))
12523489	10	(S1 (S (ADVP (RB Similarly)) (, ,) (NP (DT all) (JJ Doc_12523489_1521_1530_Chemical) (NN receptor) (NNS agonists)) (VP (VBD decreased) (NP (JJ Doc_12523489_1559_1570_Chemical-induced) (NNP Doc_12523489_1579_1592_Disease)) (, ,) (FRAG (CC but) (PP (IN at) (NP (NP (DT the) (JJR higher) (NNS doses)) (PP (IN than) (NP (NP (DT those)) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (ADJP (JJ active)) (PP (IN in) (NP (NNP Doc_12523489_1650_1657_Chemical-induced) (NNP Doc_12523489_1666_1679_Disease)))))))))))) (. .)))
12523489	11	(S1 (S (NP (NP (NP (DT The) (JJ selective) (NN blockade)) (PP (IN of) (NP (NP (NNP A2) (NNP Doc_12523489_1710_1719_Chemical) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12523489_1731_1735_Chemical)) (-RRB- -RRB-))))) (CC and) (NP (NP (JJ non-selective) (NN blockade)) (PP (IN of) (NP (NP (JJ Doc_12523489_1767_1776_Chemical) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12523489_1788_1796_Chemical)) (-RRB- -RRB-)))))) (VP (ADVP (RB significantly)) (VBD increased) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NNP Doc_12523489_1836_1847_Chemical)))) (PP (IN in) (NP (DT the) (NN locomotor) (NN activity) (NN test)))) (. .)))
12523489	12	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (AUX have) (VP (VBN shown) (S (PP (IN that) (NP (NP (DT all) (JJ Doc_12523489_1912_1921_Chemical) (NN receptor) (NNS agonists)) (PRN (-LRB- -LRB-) (NP (NNP A1) (CC and) (NNP A2)) (-RRB- -RRB-)) (SBAR (S (VP (VP (VBP reduce) (NP (ADJP (JJ Doc_12523489_1959_1966_Chemical-) (CC and) (JJ Doc_12523489_1972_1983_Chemical-induced)) (JJ locomotor) (NN activity))) (CC and) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_12523489_2029_2036_Chemical-induced) (NNP Doc_12523489_2045_2058_Disease)) (VP (AUX is) (ADJP (ADJP (RBR more) (VBN influenced)) (PP (IN by) (NP (NP (JJ Doc_12523489_2081_2090_Chemical) (NN receptor) (NNS agonists)) (PRN (-LRB- -LRB-) (ADVP (RB particularly)) (NP (NNP A1) (NNS receptors)) (-RRB- -RRB-)))) (PP (IN than) (NP (JJ Doc_12523489_2142_2153_Chemical-induced) (NN Doc_12523489_2162_2175_Disease)))))))))))))))) (. .)))
12535818	0	(S1 (S (NP (NP (NN Doc_12535818_0_10_Chemical)) (CC and) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_12535818_27_42_Disease))))) (VP (VBG requiring) (NP (JJ permanent) (NN pacemaker)) (PP (IN in) (NP (NP (JJ elderly) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_12535818_98_117_Disease)) (CC and) (NP (JJ prior) (NNP Doc_12535818_128_149_Disease))))))) (. .)))
12535818	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_12535818_221_231_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_12535818_249_268_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12535818_270_272_Disease)) (-RRB- -RRB-))))))) (VP (VBZ increases) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_12535818_296_311_Disease)))) (S (VP (VBG requiring) (NP (DT a) (JJ permanent) (NN pacemaker))))))))))) (. .)))
12535818	2	(S1 (S (NP (NP (NNS Reports)) (PP (IN of) (NP (JJ severe) (NN Doc_12535818_375_390_Disease))) (PP (IN during) (NP (JJ Doc_12535818_398_408_Chemical) (NN therapy)))) (VP (AUX are) (ADJP (ADJP (JJ infrequent)) (CC and) (ADJP (JJ limited) (PP (TO to) (NP (NP (NNS studies)) (VP (VBG assessing) (NP (NP (NP (DT the) (NN therapy) (POS 's)) (NN use)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_12535818_518_541_Disease)))))))))))))) (. .)))
12535818	3	(S1 (S (NP (NP (DT A) (NN study) (NN cohort)) (PP (IN of) (NP (NP (NP (CD 8,770) (NNS patients)) (NP (NN age) (NN >))) (CC or) (NP (CD =65) (NNS years)))) (PP (IN with) (NP (NP (DT a) (JJ new) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_12535818_628_630_Disease)))))) (VP (AUX was) (VP (VBN identified) (PP (IN from) (NP (NP (DT a) (JJ provincewide) (NN database)) (PP (IN of) (NP (NP (NNP Quebec) (NNS residents)) (PP (IN with) (NP (NP (DT a) (NNP Doc_12535818_702_723_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12535818_725_727_Disease)) (-RRB- -RRB-)))))))) (PP (IN between) (NP (NP (CD 1991)) (CC and) (NP (CD 1999)))))) (. .)))
12535818	4	(S1 (S (S (VP (VBG Using) (NP (DT a) (JJ nested) (JJ case-control) (NN design)))) (, ,) (NP (NP (CD 477) (NNS cases)) (PP (IN of) (NP (NNP Doc_12535818_801_816_Disease))) (VP (VBG requiring) (NP (DT a) (JJ permanent) (NN pacemaker)))) (VP (AUX were) (VP (VBN matched) (PRN (-LRB- -LRB-) (NP (NN 1:4)) (-RRB- -RRB-)) (PP (TO to) (NP (CD 1,908) (NNS controls))))) (. .)))
12535818	5	(S1 (S (NP (JJ Multivariable) (JJ logistic) (NN regression)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB estimate) (NP (NP (DT the) (NNS odds) (NN ratio)) (PRN (-LRB- -LRB-) (CC OR) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NN pacemaker) (NN insertion)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_12535818_1001_1011_Chemical) (NN use)))))) (, ,) (VP (VBG controlling) (PP (IN for) (NP (NP (NN baseline) (NN risk) (NNS factors)) (CC and) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (NNP Doc_12535818_1071_1078_Chemical)) (, ,) (NP (NNP Class)))) (SBAR (S (NP (PRP I)) (VP (VBP antiarrhythmic) (NP (NP (NNS agents)) (, ,) (NP (NNS beta-blockers)) (, ,) (NP (JJ Doc_12535818_1126_1133_Chemical) (NN channel) (NNS blockers)) (, ,) (CC and) (NP (NNP Doc_12535818_1156_1163_Chemical)))))))))))))))) (. .)))
12535818	6	(S1 (S (NP (JJ Doc_12535818_1174_1184_Chemical) (NN use)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NN pacemaker) (NN insertion))) (PRN (-LRB- -LRB-) (CC OR) (: :) (NP (NP (CD 2.14)) (, ,) (NP (NP (CD 95) (NN %)) (NP (NN confidence) (NN interval) (JJ -LSB-CI) (NNS -RSB-))) (: :) (NP (QP (CD 1.30) (TO to) (CD 3.54)))) (-RRB- -RRB-)))))) (. .)))
12535818	7	(S1 (S (NP (DT This) (NN effect)) (VP (AUX was) (VP (VBN modified) (PP (IN by) (NP (NN gender))) (, ,) (PP (IN with) (NP (NP (DT a) (JJR greater) (NN risk)) (PP (IN in) (NP (NP (NNS women) (CC versus) (NNS men)) (PRN (-LRB- -LRB-) (CC OR) (: :) (NP (NP (CD 3.86)) (, ,) (NP (NP (ADJP (CD 95) (NN %)) (NNS CI)) (: :) (NP (NP (NP (CD 1.70)) (PP (TO to) (NP (CD 8.75) (NN vs.)))) (CC OR) (NP (: :) (NP (NP (CD 1.52)) (, ,) (ADVP (NP (CD 95) (NN %)) (RB CI))) (: :) (NP (QP (CD 0.80) (TO to) (CD 2.89))))))) (-RRB- -RRB-)))))))) (. .)))
12535818	8	(S1 (S (NP (NN Doc_12535818_1451_1458_Chemical)) (VP (AUX was) (NP (NP (DT the) (RB only) (JJ other) (NN medication)) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NN pacemaker) (NN insertion))) (PRN (-LRB- -LRB-) (CC OR) (: :) (NP (NP (NP (CD 1.78)) (, ,) (ADVP (NP (CD 95) (NN %)) (RB CI))) (: :) (NP (QP (CD 1.37) (TO to) (CD 2.31)))) (-RRB- -RRB-))))))) (. .)))
12535818	9	(S1 (S (NP (DT This) (NN study)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_12535818_1629_1639_Chemical))) (PP (IN in) (NP (NP (JJ elderly) (NNS patients)) (PP (IN with) (NP (NNP Doc_12535818_1665_1667_Disease)))))) (CC and) (NP (DT a) (JJ previous) (NN Doc_12535818_1683_1685_Disease))) (VP (VBZ increases) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_12535818_1708_1723_Disease)))) (S (VP (VBG requiring) (NP (DT a) (JJ permanent) (NN pacemaker)))))))) (. .)))
12535818	10	(S1 (S (NP (NP (DT The) (NN finding)) (PP (IN of) (NP (NP (DT an) (JJ augmented) (NN risk)) (PP (IN of) (NP (NN pacemaker) (NN insertion))))) (PP (IN in) (NP (NP (JJ elderly) (NNS women)) (VP (VBG receiving) (NP (NNP Doc_12535818_1840_1850_Chemical)))))) (VP (VBZ requires) (NP (JJ further) (NN investigation))) (. .)))
12559315	0	(S1 (NP (NP (JJ Doc_12559315_0_12_Chemical-induced) (JJ morphologic) (NNS changes)) (PP (IN in) (NP (DT the) (NN rat) (NN urinary) (NN bladder) (NN epithelium))) (. .)))
12559315	1	(S1 (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (JJ morphologic) (NNS changes)) (PP (IN in) (NP (NP (NN rat) (NN urothelium)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_12559315_157_169_Chemical))))))))) (. .)))
12559315	2	(S1 (S (NP (JJ Nonsteroidal) (JJ anti-inflammatory) (JJ drug-induced) (NN Doc_12559315_215_223_Disease)) (VP (AUX is) (NP (DT a) (ADJP (ADJP (RB poorly) (VBN recognized)) (CC and) (ADJP (JJ under-reported))) (NN condition))) (. .)))
12559315	3	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (NNP Doc_12559315_292_308_Chemical))))) (, ,) (NP (NNP Doc_12559315_310_322_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (S (VP (TO to) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (DT this) (NN condition)))))))))) (. .)))
12559315	4	(S1 (S (S (NP (CD Three) (NNS groups)) (VP (AUX were) (VP (VBN established)))) (: :) (S (NP (NP (NP (DT a) (NN control) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 10)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (DT a) (JJ high-dose) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 10)) (-RRB- -RRB-))) (, ,) (VP (VBN treated) (PP (IN with) (NP (NP (CD one) (JJ intraperitoneal) (NN injection)) (PP (IN of) (NP (NNP Doc_12559315_519_531_Chemical) (CD 20) (NNS mg/kg)))))) (, ,)) (CC and) (NP (NP (NP (DT a) (JJ therapeutic) (NN dose) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 10)) (-RRB- -RRB-))) (PP (IN in) (NP (WDT which) (JJ oral) (NN Doc_12559315_594_606_Chemical))))) (VP (AUX was) (VP (VBN administered) (NP (CD 3.25) (JJ mg/kg) (NN body) (NN weight)) (ADVP (RB daily)) (PP (IN for) (NP (CD 3) (NNS weeks)))))) (. .)))
12559315	5	(S1 (S (S (NP (DT The) (NNS animals)) (VP (AUX were) (ADVP (RB then)) (VP (VBN killed)))) (CC and) (S (NP (DT the) (NNS bladders)) (VP (VBN removed) (PP (IN for) (NP (NP (NN light)) (CC and) (NP (NNP electron) (JJ microscopic) (NNS studies)))))) (. .)))
12559315	6	(S1 (S (NP (DT The) (JJ light) (JJ microscopic) (NNS findings)) (VP (VBD showed) (NP (NP (DT some) (JJ focal) (NN epithelial) (NN degeneration)) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (ADJP (RBR more) (JJ prominent)) (PP (IN in) (NP (DT the) (JJ high-dose) (NN group)))))))) (. .)))
12559315	7	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN compared) (PP (IN with) (NP (DT the) (NN control) (NN group)))))) (, ,) (NP (DT both) (JJ Doc_12559315_937_949_Chemical) (NNS groups)) (VP (VBD revealed) (NP (NP (NP (RB statistically) (VBN increased) (NNS numbers)) (PP (IN of) (NP (NP (JJ mast) (NNS cells)) (PP (IN in) (NP (NP (DT the) (NNP mucosa)) (PRN (-LRB- -LRB-) (NP (NNP P) (CD <0.0001)) (-RRB- -RRB-))))))) (CC and) (NP (NP (NN penetration)) (PP (IN of) (NP (NNP Doc_12559315_1057_1074_Chemical))))) (PP (IN through) (NP (NP (JJ intercellular) (NNS areas)) (PP (IN of) (NP (DT the) (NN epithelium)))))) (. .)))
12559315	8	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (DT the) (NN difference)) (PP (IN in) (NP (NN mast) (NN cell) (NNS counts))) (PP (IN between) (NP (DT the) (JJ high) (CC and) (JJ therapeutic) (NN dose) (NNS groups)))) (VP (AUX was) (ADVP (RB also)) (ADJP (RB statistically) (JJ significant) (PRN (-LRB- -LRB-) (NP (QP (CD P) (CD <0.0001))) (-RRB- -RRB-)))) (. .)))
12559315	9	(S1 (S (NP (NN Doc_12559315_1276_1288_Chemical)) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ histopathologic) (NNS findings)) (ADJP (JJ typical) (PP (IN of) (NP (NNP Doc_12559315_1337_1358_Disease)))) (, ,) (PP (JJ such) (IN as) (NP (NP (JJ leaky) (NN bladder) (NN epithelium)) (CC and) (NP (NNP Doc_12559315_1397_1417_Disease))))))) (. .)))
12559315	10	(S1 (S (NP (NP (DT The) (JJ true) (NN incidence)) (PP (IN of) (NP (NP (JJ nonsteroidal) (JJ anti-inflammatory) (JJ drug-induced) (NN Doc_12559315_1485_1493_Disease)) (PP (IN in) (NP (NNS humans)))))) (VP (MD must) (VP (AUX be) (VP (VBN clarified) (PP (IN by) (NP (JJ prospective) (JJ clinical) (NNS trials)))))) (. .)))
12644816	0	(S1 (NP (NP (DT An) (JJ open-label) (NN phase) (NNP II) (NN study)) (PP (IN of) (NP (NP (JJ low-dose) (NNP Doc_12644816_41_52_Chemical)) (PP (IN in) (NP (NNP Doc_12644816_56_64_Chemical-independent) (NNP Doc_12644816_77_92_Disease))))) (. .)))
12644816	1	(S1 (S (NP (NP (DT The) (JJ antiangiogenic) (NNS effects)) (PP (IN of) (NP (NNP Doc_12644816_124_135_Chemical)))) (VP (AUX have) (VP (AUX been) (VP (VBN assessed) (PP (IN in) (NP (NP (JJ clinical) (NNS trials)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ various) (JJ solid) (CC and) (JJ haematological) (NN Doc_12644816_224_236_Disease)))))))))) (. .)))
12644816	2	(S1 (NP (NP (JJ Doc_12644816_238_249_Chemical) (NNS blocks)) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (JJ angiogenic) (NNS agents)) (PP (VBG including) (NP (NP (CD bFGF)) (, ,) (NP (CD VEGF)) (CC and) (NP (CD IL-6))))))) (. .)))
12644816	3	(S1 (S (NP (PRP We)) (VP (VBD undertook) (NP (NP (DT an) (JJ open-label) (NN study)) (VP (VBG using) (NP (NNP Doc_12644816_361_372_Chemical) (CD 100) (NNS mg)))) (ADVP (RB once) (RB daily)) (PP (IN for) (NP (QP (IN up) (TO to) (CD 6)) (NNS months))) (PP (IN in) (NP (NP (CD 20) (NNS men)) (PP (IN with) (NP (JJ androgen-independent) (NNP Doc_12644816_446_461_Disease)))))) (. .)))
12644816	4	(S1 (S (NP (NP (DT The) (JJ mean) (NN time)) (PP (IN of) (NP (NN study)))) (VP (AUX was) (NP (NP (CD 109) (NNS days)) (PRN (-LRB- -LRB-) (NP (NP (NN median) (CD 107)) (, ,) (NP (NP (NN range)) (NP (CD 4-184) (NNS days)))) (-RRB- -RRB-)))) (. .)))
12644816	5	(S1 (S (NP (NNS Patients)) (VP (VBD underwent) (NP (NP (JJ regular) (NN measurement)) (PP (IN of) (NP (NP (JJ prostate-specific) (NN antigen)) (PRN (-LRB- -LRB-) (NP (NNP PSA)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_12644816_606_610_Chemical) (CC and) (NNS electrolytes)) (, ,) (NP (NN serum) (NN bFGF)) (CC and) (NP (NN VEGF)))))) (. .)))
12644816	6	(S1 (S (NP (NP (CD Three) (NNS men)) (PRN (-LRB- -LRB-) (NP (CD 15) (NN %)) (-RRB- -RRB-))) (VP (VBD showed) (NP (NP (DT a) (NN decline)) (PP (IN in) (NP (NP (JJ serum) (NNP PSA)) (PP (IN of) (NP (QP (IN at) (JJS least) (CD 50)) (NN %))))) (, ,) (VP (VBN sustained) (PP (IN throughout) (NP (NN treatment)))))) (. .)))
12644816	7	(S1 (S (PP (IN Of) (NP (NP (CD 16) (NNS men)) (VP (VBN treated) (PP (IN for) (NP (QP (IN at) (JJS least) (CD 2)) (NNS months)))))) (, ,) (NP (NP (CD six)) (PRN (-LRB- -LRB-) (NP (CD 37.5) (NN %)) (-RRB- -RRB-))) (VP (VBD showed) (NP (DT a) (NN fall)) (PP (IN in) (NP (JJ absolute) (NNP PSA))) (PP (IN by) (NP (NP (DT a) (NN median)) (PP (IN of) (NP (CD 48) (NN %)))))) (. .)))
12644816	8	(S1 (S (S (NP (NP (VBG Increasing) (NNS levels)) (PP (IN of) (NP (NP (NN serum) (NNS bFGF)) (CC and) (NP (NNS VEGF))))) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (JJ progressive) (NN disease)))))) (: ;) (S (S (NP (NP (QP (CD five) (IN of) (CD six)) (NNS men)) (SBAR (WHNP (WP who)) (S (VP (VBD demonstrated) (NP (DT a) (NN fall)) (PP (IN in) (NP (NNP PSA))))))) (ADVP (RB also)) (VP (VBD showed) (NP (NP (DT a) (NN decline)) (PP (IN in) (NP (ADJP (JJ bFGF) (CC and) (JJ VEGF)) (NNS levels)))))) (, ,) (CC and) (S (NP (NP (CD three)) (PP (IN of) (NP (NP (CD four) (NNS men)) (PP (IN with) (NP (DT a) (VBG rising) (NNP PSA)))))) (VP (VBD showed) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (DT both) (NN growth) (NNS factors))))))) (. .)))
12644816	9	(S1 (S (NP (JJ Adverse) (NNS effects)) (VP (VP (VBD included) (NP (NP (NNP Doc_12644816_1133_1145_Disease)) (, ,) (NP (NN morning) (NN drowsiness)) (, ,) (NP (NNP Doc_12644816_1167_1176_Disease)) (CC and) (NP (NNP Doc_12644816_1181_1185_Disease)))) (, ,) (CC and) (VP (VBD resulted) (PP (IN in) (NP (NP (NN withdrawal)) (PP (IN from) (NP (DT the) (NN study))) (PP (IN by) (NP (CD three) (NNS men))))))) (. .)))
12644816	10	(S1 (S (NP (NP (NN Evidence)) (PP (IN of) (NP (NNP Doc_12644816_1255_1284_Disease)))) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NP (CD nine)) (PP (IN of) (NP (NP (CD 13) (NNS men)) (PP (IN before) (NP (NN treatment))))))))) (. .)))
12644816	11	(S1 (S (PP (IN In) (NP (NP (DT the) (CD seven) (NNS men)) (SBAR (WHNP (WP who)) (S (VP (VBD completed) (NP (CD six) (NNS months)) (PP (IN on) (NP (NNP Doc_12644816_1376_1387_Chemical)))))))) (, ,) (NP (NP (JJ subclinical) (NN evidence)) (PP (IN of) (NP (NNP Doc_12644816_1413_1434_Disease)))) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (CD four))) (PP (PP (IN before) (NP (NN treatment))) (, ,) (CC but) (PP (IN in) (NP (DT all) (CD seven))) (PP (IN at) (NP (NN repeat) (NN testing)))))) (. .)))
12644816	12	(S1 (S (NP (DT The) (NNS findings)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_12644816_1534_1545_Chemical)) (VP (MD may) (VP (AUX be) (NP (NP (DT an) (NN option)) (PP (IN for) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (VBN failed) (NP (NP (JJ other) (NNS forms)) (PP (IN of) (NP (NN therapy))))))))))) (, ,) (PP (VBN provided) (SBAR (S (NP (JJ close) (NN follow-up)) (VP (AUX is) (VP (VBN maintained) (PP (IN for) (NP (NP (NN development)) (PP (IN of) (NP (NN Doc_12644816_1674_1695_Disease))))))))))))))) (. .)))
12677626	0	(S1 (NP (NP (NP (NN Doc_12677626_0_31_Disease)) (VP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_12677626_64_79_Chemical))) (PP (IN for) (NP (JJ lumbar) (JJ plexus) (NN block)))))) (: :) (NP (NP (DT A) (NN report)) (PP (IN of) (NP (CD two) (NNS cases)))) (. .)))
12677626	1	(S1 (NP (NP (NP (NN BACKGROUND)) (CC AND) (NP (NNS OBJECTIVES))) (: :) (S (NP (NP (NP (JJ Central) (JJ nervous) (NN system)) (CC and) (NP (NNP Doc_12677626_182_198_Disease))) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (JJ local) (NNS anesthetics)))))) (VP (AUX is) (NP (NP (DT a) (VBN recognized) (NN complication)) (PP (IN of) (NP (JJ regional) (NNS anesthesia)))))) (. .)))
12677626	2	(S1 (S (NP (NP (NNP Doc_12677626_302_317_Chemical)) (, ,) (NP (DT the) (JJ pure) (NNP S) (-LRB- -LRB-) (LST (: -) (-RRB- -RRB-)) (NP (NN enantiomer)) (PP (IN of) (NP (NNP Doc_12677626_347_358_Chemical)))) (, ,)) (VP (AUX was) (VP (VBN developed) (S (VP (TO to) (VP (VB improve) (NP (NP (DT the) (JJ cardiac) (NN safety) (NN profile)) (PP (IN of) (NP (NNP Doc_12677626_415_426_Chemical))))))))) (. .)))
12677626	3	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (CD 2) (NNS cases)) (PP (IN of) (NP (JJ grand) (JJ mal) (NN Doc_12677626_461_469_Disease)))) (PP (VBG following) (NP (NP (JJ accidental) (NN intravascular) (NN injection)) (PP (IN of) (NP (NNP Doc_12677626_518_533_Chemical)))))) (. .)))
12677626	4	(S1 (NP (NN CASE) (NN REPORT) (: :) (S (NP (NP (CD Two) (NNS patients)) (VP (VBG presenting) (PP (IN for) (NP (NP (JJ elective) (JJ orthopedic) (NN surgery)) (PP (IN of) (NP (DT the) (JJR lower) (NN limb))))))) (VP (VBD underwent) (NP (NP (NN blockade)) (PP (IN of) (NP (DT the) (JJ lumbar) (NNS plexus)))) (PP (IN via) (NP (DT the) (JJ posterior) (NN approach))))) (. .)))
12677626	5	(S1 (S (PP (ADVP (RB Immediately)) (IN after) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_12677626_730_745_Chemical) (CD 0.5) (NN %))) (PP (IN with) (NP (NNP Doc_12677626_756_767_Chemical) (CD 2.5) (NN microgram/mL))))) (, ,) (NP (DT the) (NNS patients)) (VP (VBD developed) (NP (JJ grand) (JJ mal) (NN Doc_12677626_819_827_Disease)) (, ,) (PP (IN despite) (NP (NP (NP (JJ negative) (NN aspiration)) (PP (IN for) (NP (NN blood)))) (CC and) (NP (NP (DT no) (JJ clinical) (NNS signs)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_12677626_904_915_Chemical) (NN administration))))))) (. .)))
12677626	6	(S1 (S (NP (DT The) (NNP Doc_12677626_936_944_Disease)) (VP (AUX were) (ADVP (RB successfully)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_12677626_976_993_Chemical))) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (NP (NNP Doc_12677626_1009_1024_Chemical)) (PP (IN in) (NP (CD 1) (NN patient))))))))) (. .)))
12677626	7	(S1 (S (NP (DT Neither) (NN patient)) (VP (VBD developed) (NP (NP (NNS signs)) (PP (IN of) (NP (NNP Doc_12677626_1074_1097_Disease))))) (. .)))
12677626	8	(S1 (S (NP (DT Both) (NNS patients)) (VP (AUX were) (VP (VBN treated) (ADVP (RB preoperatively)) (PP (IN with) (NP (NP (JJ beta-adrenergic) (NN antagonist) (NNS medications)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (AUX have) (VP (VBN masked) (NP (NP (DT the) (JJ cardiovascular) (NNS signs)) (PP (IN of) (NP (NP (DT the) (JJ unintentional) (NN intravascular) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_12677626_1286_1301_Chemical)) (PP (IN with) (NP (NNP Doc_12677626_1307_1318_Chemical))))))))))))))))) (. .)))
12677626	9	(S1 (S (SBAR (IN Although) (S (NP (NNP Doc_12677626_1342_1357_Chemical)) (VP (MD may) (VP (AUX have) (NP (NP (DT a) (JJR safer) (NN Doc_12677626_1375_1391_Disease) (NN profile)) (PP (IN than) (NP (JJ racemic) (NN Doc_12677626_1413_1424_Chemical)))))))) (, ,) (SBAR (IN if) (S (NP (NP (JJ adequate) (NNS amounts)) (PP (IN of) (NP (NNP Doc_12677626_1449_1464_Chemical)))) (VP (VBP reach) (NP (DT the) (NN circulation))))) (, ,) (NP (PRP it)) (VP (MD will) (VP (VB result) (PP (IN in) (NP (NNP Doc_12677626_1506_1517_Disease))))) (. .)))
12677626	10	(S1 (S (NP (NP (NN Plasma) (NNS concentrations)) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB result) (PP (IN in) (NP (NNP Doc_12677626_1565_1596_Disease)))))))) (VP (AUX did) (RB not) (VP (VB produce) (NP (NP (NNS manifestations)) (PP (IN of) (NP (NNP Doc_12677626_1631_1647_Disease)))) (PP (IN in) (NP (DT these) (CD 2) (NNS patients))))) (. .)))
12678199	0	(S1 (NP (NP (NP (JJ Doc_12678199_0_10_Chemical-induced) (NN Doc_12678199_19_37_Disease)) (PP (IN during) (NP (NN bladder) (NN irrigation)))) (: :) (NP (DT an) (JJ unusual) (JJ presentation--a) (NN case) (NN report)) (. .)))
12678199	1	(S1 (S (NP (DT The) (NNS authors)) (VP (VBP present) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ early) (PRN (-LRB- -LRB-) (PP (IN within) (NP (CD 4) (NNS days))) (-RRB- -RRB-)) (NN development)) (PP (IN of) (NP (NP (NNP Doc_12678199_172_190_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_12678199_192_195_Disease)) (-RRB- -RRB-)))) (VP (VBN associated) (PP (IN with) (NP (JJ oral) (JJ Doc_12678199_218_228_Chemical) (NN therapy)))))))) (. .)))
12678199	2	(S1 (S (NP (NP (ADJP (JJ Consistent) (PP (IN with) (NP (JJ other) (NNS reports)))) (DT this) (NN case)) (PP (IN of) (NP (NNP Doc_12678199_281_284_Disease)))) (VP (VBD occurred) (PP (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (NP (JJ multiple) (VBG exacerbating) (NNS factors)) (PP (VBG including) (NP (NP (NN Doc_12678199_352_363_Disease)) (CC and) (NP (JJ Doc_12678199_368_375_Chemical) (NN excess))))))))) (. .)))
12678199	3	(S1 (S (NP (NP (JJ Transient) (NN prolongation)) (PP (IN of) (NP (DT the) (NN QT))) (PP (IN during) (NP (NN bladder) (NN irrigation)))) (VP (VBD prompted) (NP (NP (DT the) (NN episode)) (PP (IN of) (NP (NNP Doc_12678199_467_470_Disease))))) (. .)))
12678199	4	(S1 (S (NP (PRP It)) (VP (AUX is) (ADVP (RB well)) (VP (VBN known) (SBAR (IN that) (S (NP (NNP Doc_12678199_494_505_Disease)) (VP (VBZ exacerbates) (NP (VBN acquired) (NN Doc_12678199_527_530_Disease))))))) (. .)))
12678199	5	(S1 (S (NP (DT The) (NNS authors)) (VP (VBP speculate) (SBAR (IN that) (S (NP (NP (DT the) (VBN increased) (JJ vagal) (NN tone)) (PP (IN during) (NP (NP (NN bladder) (NN irrigation)) (, ,) (NP (NP (DT a) (JJ vagal) (NN maneuver)) (, ,) (PP (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (JJ Doc_12678199_647_657_Chemical) (NN therapy))))))))) (VP (VBD resulted) (PP (IN in) (NP (JJ Doc_12678199_678_688_Chemical-induced) (NN proarrhythmia))))))) (. .)))
12678199	6	(S1 (S (PP (IN In) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ Doc_12678199_730_740_Chemical) (NN therapy))))) (, ,) (NP (DT a) (JJ second) (NN bladder) (NN irrigation)) (VP (AUX did) (RB not) (VP (VB induce) (NP (NN Doc_12678199_793_796_Disease)) (PP (IN despite) (NP (NP (NNP Doc_12678199_805_816_Disease)) (CC and) (NP (NNP Doc_12678199_821_835_Disease)))))) (. .)))
12699527	0	(S1 (NP (NP (NP (JJ Anaesthetic) (NNS complications)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_12699527_42_50_Disease) (NNS congenita))))) (: :) (NP (NP (NN case) (NN study)) (CC and) (NP (NP (NN comparison)) (PP (IN with) (NP (JJ other) (NNP Doc_12699527_99_117_Disease))))) (. .)))
12699527	1	(S1 (S (NP (NP (JJ Doc_12699527_119_127_Disease) (NN congenita)) (PRN (-LRB- -LRB-) (NP (NNP MC)) (-RRB- -RRB-))) (VP (AUX is) (VP (VBN caused) (PP (IN by) (NP (NP (DT a) (NN defect)) (PP (IN in) (NP (DT the) (JJ skeletal) (NN muscle) (JJ Doc_12699527_188_196_Chemical) (NN channel) (NN function))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB cause) (NP (JJ sustained) (JJ membrane) (NN depolarisation)))))))))) (. .)))
12699527	2	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (ADJP (RB previously) (JJ healthy)) (JJ 32-year-old) (NN woman)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (DT a) (JJ life-threatening) (NN muscle) (NN Doc_12699527_357_362_Disease)) (CC and) (NP (JJ secondary) (NN ventilation) (NNS difficulties))) (PP (VBG following) (NP (NP (DT a) (JJ preoperative) (NN injection)) (PP (IN of) (NP (NNP Doc_12699527_440_453_Chemical)))))))))) (. .)))
12699527	3	(S1 (S (S (NP (DT The) (NN muscle) (NN Doc_12699527_466_472_Disease)) (VP (VBD disappeared) (ADVP (RB spontaneously)))) (CC and) (S (NP (DT the) (NN surgery)) (VP (VBD proceeded) (PP (IN without) (NP (JJ further) (NNS problems))))) (. .)))
12699527	4	(S1 (S (SBAR (WHADVP (WRB When)) (S (ADVP (RB subsequently)) (VP (VBD questioned)))) (, ,) (NP (PRP she)) (VP (VBD reported) (NP (NP (JJ minor) (NNS symptoms)) (VP (VBG suggesting) (NP (DT a) (JJ Doc_12699527_622_630_Disease) (NN condition))))) (. .)))
12699527	5	(S1 (S (NP (NN Doc_12699527_642_650_Disease)) (VP (AUX was) (VP (VBN found) (PP (IN on) (NP (NP (JJ clinical) (NN examination)) (CC and) (NP (NN EMG)))))) (. .)))
12699527	6	(S1 (S (NP (DT The) (NN diagnosis) (NNP MC)) (VP (AUX was) (VP (VBN confirmed) (ADVP (RB genetically)))) (. .)))
12699527	7	(S1 (S (NP (CC Neither) (NP (DT the) (NN patient)) (CC nor) (NP (DT the) (NN anaesthetist))) (VP (AUX were) (ADJP (JJ aware) (PP (IN of) (NP (DT the) (NN diagnosis)))) (SBAR (IN before) (S (NP (DT this) (ADJP (RB potentially) (JJ lethal)) (NN complication)) (VP (VBD occurred))))) (. .)))
12699527	8	(S1 (S (NP (PRP We)) (VP (VBP give) (NP (NP (DT a) (JJ brief) (NN overview)) (PP (IN of) (NP (NP (NN ion) (NN channel) (NNS disorders)) (PP (VBG including) (NP (NP (NNP Doc_12699527_921_943_Disease)) (CC and) (NP (PRP$ their) (JJ anaesthetic) (NNS considerations)))))))) (. .)))
12752472	0	(S1 (NP (NP (NN Respiratory) (NN pattern)) (PP (IN in) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NNP Doc_12752472_38_46_Disease))))) (. .)))
12752472	1	(S1 (S (S (NP (NN Doc_12752472_57_62_Disease)) (VP (AUX is) (VP (VBN known) (S (VP (TO to) (VP (VB occur) (PP (IN during) (NP (NN Doc_12752472_88_96_Disease))))))))) (, ,) (CC but) (S (NP (NP (JJ systematic) (NNS studies)) (PP (IN of) (NP (NP (JJ ictal) (JJ respiratory) (NNS changes)) (PP (IN in) (NP (NNS adults)))))) (VP (AUX are) (NP (JJ few)))) (. .)))
12752472	2	(S1 (S (NP (NP (NNS Data)) (VP (VBG regarding) (NP (NN respiratory) (NN pattern) (NNS defects)) (PP (IN during) (NP (JJ interictal) (NNS periods))))) (ADVP (RB also)) (VP (AUX are) (ADJP (JJ scarce))) (. .)))
12752472	3	(S1 (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBD sought) (S (VP (TO to) (VP (VB generate) (NP (NN information)) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (NP (DT the) (JJ interictal) (NN period)) (PP (IN in) (NP (NP (NNS animals)) (PP (IN with) (NP (JJ Doc_12752472_347_358_Chemical-induced) (NN Doc_12752472_367_375_Disease))))))))))))) (. .)))
12752472	4	(S1 (S (NP (NP (CD Twelve) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NP (CD six) (RB chronically) (JJ Doc_12752472_415_424_Disease) (NNS animals)) (CC and) (NP (CD six) (NNS controls))) (-RRB- -RRB-))) (VP (AUX were) (ADJP (JJ anesthetized)) (, ,) (S (VP (VP (VBN given) (NP (NNS tracheotomies))) (, ,) (CC and) (VP (VBN subjected) (PP (TO to) (NP (NP (NN hyperventilation)) (CC or) (NP (JJ Doc_12752472_528_543_Disease) (NNS conditions)))))))) (. .)))
12752472	5	(S1 (S (NP (NN Doc_12752472_556_575_Disease)) (VP (VBD caused) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (JJ thoracic) (NN volume)) (CC and) (NP (JJ forced) (NN air))))) (S (VP (TO to) (VP (VB flow) (ADVP (RB tidally)) (PP (IN through) (NP (DT a) (NN pneumotachograph))))))) (. .)))
12752472	6	(S1 (S (NP (DT This) (NN flow)) (VP (AUX was) (VP (VBN measured) (PP (IN by) (S (VP (VP (VBG using) (NP (NP (DT a) (NN differential) (NN pressure) (NN transducer)) (, ,) (VP (VBN passed) (PP (IN through) (NP (DT a) (NN polygraph)))) (, ,) (PP (CC and) (PP (IN from) (NP (NP (NP (NP (NP (DT this)) (PP (TO to) (NP (DT a) (NN computer))) (PP (IN with) (NP (NP (NN custom) (NN software)) (PP (IN that) (NP (VBN derived) (NN ventilation)))))) (PRN (-LRB- -LRB-) (NP (NNP VE)) (-RRB- -RRB-)) (, ,) (NP (NP (JJ tidal) (NN volume)) (PRN (-LRB- -LRB-) (NP (NNP VT)) (-RRB- -RRB-))) (, ,)) (JJ inspiratory) (NN time)) (PRN (-LRB- -LRB-) (NP (NNP TI)) (-RRB- -RRB-)) (, ,) (NP (JJ expiratory) (NN time)))) (PRN (-LRB- -LRB-) (NP (NNP TE)) (-RRB- -RRB-))))) (, ,) (VP (VBG breathing) (NP (NP (NN frequency)) (PRN (-LRB- -LRB-) (NNP f) (-RRB- -RRB-)))) (, ,) (CC and) (VP (VBP mean) (NP (NP (NN inspiratory) (NN flow)) (PRN (-LRB- -LRB-) (NP (NNP VT/TI)) (-RRB- -RRB-))) (PP (IN on) (NP (DT a) (JJ breath-by-breath) (NN basis))))))))) (. .)))
12752472	7	(S1 (S (NP (DT The) (JJ hyperventilation) (NN maneuver)) (VP (VBD caused) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (JJ spontaneous) (NN ventilation)) (PP (IN in) (NP (UCP (JJ Doc_12752472_1084_1095_Chemical-treated) (CC and) (NN control)) (NNS rats))))))) (. .)))
12752472	8	(S1 (S (SBAR (IN Although) (S (NP (NNP VE)) (VP (AUX had) (NP (DT a) (JJ similar) (NN decrease)) (PP (IN in) (NP (DT both) (NNS groups))) (, ,) (PP (IN in) (NP (DT the) (NNP Doc_12752472_1180_1189_Disease) (NN group)))))) (, ,) (NP (NP (DT the) (NN decrease)) (PP (IN in) (NP (NNP VE)))) (VP (AUX was) (ADJP (JJ due) (PP (TO to) (NP (NP (DT a) (JJ significant) (PRN (-LRB- -LRB-) (NP (QP (CD p) (CD <)) (CD 0.05)) (-RRB- -RRB-)) (NN increase)) (PP (IN in) (NP (NP (CD TE) (NN peak)) (PP (IN in) (NP (NP (NN relation)) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (NN control) (NNS animals))))))))))))) (. .)))
12752472	9	(S1 (S (NP (DT The) (NNP Doc_12752472_1320_1335_Disease) (NN maneuver)) (VP (VBD led) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (JJ arterial) (NNP Paco2)) (, ,) (VP (VBN followed) (PP (IN by) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (CD VE))))))))))) (. .)))
12752472	10	(S1 (S (PP (IN In) (NP (DT the) (NNP Doc_12752472_1425_1434_Disease) (NN group))) (, ,) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NNP VE)))) (VP (AUX was) (VP (VBN mediated) (PP (IN by) (NP (NP (DT a) (JJ significant) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.05))) (-RRB- -RRB-)) (NN decrease)) (PP (IN in) (S (VP (VBG TE) (NP (NN peak)) (PP (VBN compared) (PP (IN with) (NP (DT the) (NN control) (NN group))))))))))) (. .)))
12752472	11	(S1 (S (NP (NP (JJ Systemic) (NN application)) (PP (IN of) (NP (NN KCN))) (, ,) (SBAR (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ peripheral) (NN chemoreception) (NN activation))) (PP (IN on) (NP (NN ventilation)))))))) (, ,)) (VP (VBD led) (PP (TO to) (NP (NP (DT a) (JJ similar) (NN increase)) (PP (IN in) (NP (NNP VE))) (PP (IN for) (NP (DT both) (NNS groups)))))) (. .)))
12752472	12	(S1 (S (NP (DT The) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ Doc_12752472_1749_1760_Chemical-treated) (NNS animals)) (VP (AUX have) (NP (DT an) (JJ altered) (NN ability) (S (VP (TO to) (VP (VP (VB react) (S (VP (TO to) (-LRB- -LRB-) (CC or) (VP (VB compensate) (PP (IN for) (NP (-RRB- -RRB-) (NN blood) (NN gas) (NNS changes))) (PP (IN with) (NP (NP (NNS changes)) (PP (IN in) (NP (NN ventilation))))))))) (CC and) (VP (VB suggest) (SBAR (IN that) (S (NP (PRP it)) (VP (AUX is) (ADJP (RB centrally) (VBN determined)))))))))))))) (. .)))
12752472	13	(S1 (S (NP (PRP We)) (VP (VBP speculate) (PP (IN on) (NP (NP (DT the) (JJ possible) (NN relation)) (PP (IN of) (NP (DT the) (JJ current) (NNS findings))))) (PP (IN on) (S (VP (VBG treating) (NP (JJ different) (JJ Doc_12752472_2008_2016_Disease-associated) (NNS conditions)))))) (. .)))
1280054	0	(S1 (S (NP (JJ Fatal) (NN myeloencephalopathy)) (ADJP (JJ due) (PP (TO to) (NP (JJ intrathecal) (NNP Doc_1280054_45_56_Chemical) (NN administration)))) (. .)))
1280054	1	(S1 (S (NP (NNP Doc_1280054_73_84_Chemical)) (VP (AUX was) (ADVP (RB accidentally)) (VP (VBN given) (ADVP (RB intrathecally)) (PP (TO to) (NP (NP (DT a) (NN child)) (PP (IN with) (NP (NNP Doc_1280054_138_147_Disease))))) (, ,) (S (VP (VBG producing) (NP (NP (NN Doc_1280054_159_188_Disease)) (VP (VBN followed) (PP (IN by) (NP (NP (NNP Doc_1280054_201_215_Disease)) (CC and) (NP (NNP Doc_1280054_220_225_Disease)))))))))) (. .)))
1280054	2	(S1 (S (NP (NP (JJ Separate) (NNS times)) (PP (IN for) (NP (NP (JJ administering) (NN Doc_1280054_260_271_Chemical)) (CC and) (NP (JJ intrathecal) (NN therapy))))) (VP (AUX is) (ADJP (JJ recommended))) (. .)))
1280707	0	(S1 (NP (NP (JJ Doc_1280707_0_12_Chemical) (NN potentiation)) (PP (IN of) (NP (JJ Doc_1280707_29_40_Chemical) (NN arrhythmogenicity))) (PP (IN in) (NP (NP (JJ Doc_1280707_62_75_Chemical-anesthetized) (NNS rats)) (CC and) (NP (VBG beating) (NN rat) (NN heart) (NN cell) (NNS cultures)))) (. .)))
1280707	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (JJ Doc_1280707_146_158_Chemical) (NN treatment))) (PP (PP (IN on) (NP (NP (JJ Doc_1280707_172_183_Chemical) (NN arrhythmogenicity)) (PP (IN in) (S (VP (VBG beating) (NP (NN rat) (NN heart) (NN myocyte) (NNS cultures))))))) (CC and) (PP (IN on) (NP (JJ anesthetized) (NNS rats))))) (VP (AUX were) (VP (VBN determined))) (. .)))
1280707	2	(S1 (S (PP (IN After) (S (VP (VBG determining) (NP (NP (DT the) (NNP Doc_1280707_304_315_Chemical) (CD AD50)) (PRN (-LRB- -LRB-) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NNP Doc_1280707_343_354_Chemical))) (SBAR (WHNP (WDT that)) (S (VP (VBD caused) (NP (NP (CD 50) (NN %)) (PP (IN of) (NP (DT all) (VBG beating) (NN rat) (NN heart) (NN myocyte) (NNS cultures)))) (S (VP (TO to) (VP (VB become) (ADJP (JJ arrhythmic))))))))) (-RRB- -RRB-)))))) (, ,) (NP (PRP we)) (VP (VBD determined) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ 1-hour) (JJ Doc_1280707_471_487_Chemical) (NN exposure))) (PP (IN on) (NP (JJ myocyte) (JJ contractile) (NN rhythm))))) (. .)))
1280707	3	(S1 (S (NP (NP (DT Each) (NN concentration)) (PP (IN of) (NP (NP (NNP Doc_1280707_550_562_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 6.25)) (, ,) (NP (CD 12.5)) (, ,) (NP (CD 25)) (, ,) (CC and) (NP (CD 50) (NN micrograms/ml))) (-RRB- -RRB-))))) (VP (VBD caused) (NP (NP (DT a) (ADJP (JJ significant) (CC and) (JJ concentration-dependent)) (NN reduction)) (PP (IN in) (NP (NP (DT the) (CD AD50)) (PP (IN for) (NP (NNP Doc_1280707_677_688_Chemical))))))) (. .)))
1280707	4	(S1 (S (NP (JJ Doc_1280707_690_699_Chemical) (NN treatment)) (ADVP (RB also)) (VP (VP (VBD increased) (NP (NP (DT the) (NN arrhythmogenicity)) (PP (IN of) (NP (NNP Doc_1280707_750_761_Chemical))) (PP (IN in) (NP (JJ myocyte) (NNS cultures))))) (, ,) (CC but) (VP (AUX was) (NP (NP (RB only) (CD one)) (ADJP (ADJP (RB fourth) (RB as) (JJ potent)) (PP (IN as) (NP (NNP Doc_1280707_820_832_Chemical))))))) (. .)))
1280707	5	(S1 (S (NP (CC Neither) (NP (NNP Doc_1280707_842_854_Chemical)) (CC nor) (NP (NP (JJ Doc_1280707_859_868_Chemical) (NNS effects)) (PP (IN on) (NP (JJ Doc_1280707_880_891_Chemical) (NN arrhythmogenicity))))) (VP (AUX were) (VP (VBN potentiated) (PP (IN by) (NP (NNP Doc_1280707_930_941_Chemical))))) (. .)))
1280707	6	(S1 (S (NP (NP (JJ Chronic) (JJ Doc_1280707_951_963_Chemical) (NN pretreatment)) (PRN (-LRB- -LRB-) (NP (NP (CD 5) (NN mg/kg/day)) (PP (IN for) (NP (CD 21) (NNS days)))) (-RRB- -RRB-))) (VP (VBD caused) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NNP Doc_1280707_1036_1047_Chemical) (CD arrhythmogenicity))) (PP (IN in) (NP (JJ intact) (JJ Doc_1280707_1076_1089_Chemical-anesthetized) (NNS rats))))) (. .)))
1280707	7	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (DT the) (NN time))) (PP (TO to) (NP (NP (NN onset)) (PP (IN of) (NP (NNP Doc_1280707_1166_1176_Disease)))))) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NP (JJ control) (JJ Doc_1280707_1202_1217_Chemical-treated) (NNS rats)) (PRN (-LRB- -LRB-) (NP (CD 6.2) (ADJP (JJ +/-) (NP (CD 1.3) (CC vs.) (CD 30.8))) (JJ +/-) (CD 2.5) (NN min)) (, ,) (NP (JJ mean) (FW +/-) (FW SE)) (-RRB- -RRB-)))))))) (. .)))
1280707	8	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_1280707_1320_1332_Chemical)) (VP (MD can) (VP (VB potentiate) (NP (JJ Doc_1280707_1348_1359_Chemical) (NN arrhythmogenicity)) (PP (CC both) (PP (IN in) (NP (NN vivo))) (CC and) (PP (IN in) (NP (NN vitro))))))))) (. .)))
1280707	9	(S1 (S (NP (NP (NN Potentiation)) (PP (IN of) (NP (NNP Doc_1280707_1421_1432_Chemical) (NNP Doc_1280707_1433_1443_Disease))) (PP (IN in) (NP (JJ myocyte) (NNS cultures)))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (DT this) (NN effect)) (VP (AUX is) (ADVP (ADVP (IN at) (JJS least)) (RB partly)) (VP (VBN mediated) (PP (IN at) (NP (DT the) (JJ myocyte) (NN level)))))))) (. .)))
12828076	0	(S1 (S (VP (VBN Increased) (NP (JJ serum) (JJ soluble) (NNS Fas)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_12828076_45_64_Disease))))) (PP (JJ due) (TO to) (NP (NNP Doc_12828076_72_83_Chemical) (NNP Doc_12828076_84_92_Disease)))) (. .)))
12828076	1	(S1 (NP (NP (NNS BACKGROUND/AIMS)) (: :) (S (NP (JJ Experimental) (NNS studies)) (VP (AUX have) (VP (VBN suggested) (SBAR (IN that) (S (NP (NP (NNS apoptosis)) (PP (IN via) (NP (DT the) (NNP Fas/Fas) (NNP Ligand) (VBG signaling) (NN system)))) (VP (MD may) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_12828076_251_270_Disease)))))))))))) (. .)))
12828076	2	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (JJ soluble) (NN form)) (PP (IN of) (NP (NNP Fas))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_12828076_353_372_Disease)))))))))) (. .)))
12828076	3	(S1 (S (NP (NP (NN Serum) (NNS levels)) (PP (IN of) (NP (NP (NNS sFas)) (PRN (-LRB- -LRB-) (NP (JJ soluble) (NNS Fas)) (-RRB- -RRB-))))) (VP (AUX were) (VP (VBN measured) (PP (IN by) (NP (NNP ELISA))) (PP (IN in) (NP (NP (NP (CD 24) (NNS patients)) (PP (IN with) (NP (NNP Doc_12828076_465_484_Disease)))) (CC and) (NP (CD 10) (JJ normal) (NN control) (NNS subjects)))))) (. .)))
12828076	4	(S1 (S (NP (NP (NN Serum) (NNS levels)) (PP (IN of) (NP (NP (JJ Doc_12828076_533_538_Disease) (JJ Doc_12828076_539_547_Disease) (NN factor-alpha)) (CC and) (NP (NN interferon-gamma))))) (VP (AUX were) (ADVP (RB also)) (VP (VBN determined) (PP (IN by) (NP (NNP ELISA))))) (. .)))
12828076	5	(S1 (S (NP (NN Serum) (NNS sFas)) (VP (AUX was) (ADVP (RB significantly)) (VP (VBN increased) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_12828076_678_697_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN median)) (, ,) (NP (CD 26.8) (NNP U/mL))) (: ;) (NP (NP (NN range)) (, ,) (NP (CD 6.9-52.7) (NNP U/mL))) (-RRB- -RRB-)))))) (PP (VBN compared) (PP (TO to) (NP (NP (DT the) (JJ normal) (NNS controls)) (PRN (-LRB- -LRB-) (NP (NP (NN median)) (, ,) (NP (CD 8.6) (NNP U/mL))) (: ;) (NP (NP (NN range)) (, ,) (NP (JJ 6.5-12.0) (NNP U/mL)) (, ,) (NP (NNP P) (NNP <) (CD 0.0001))) (-RRB- -RRB-))))))) (. .)))
12828076	6	(S1 (S (NP (NNS Levels)) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR greater) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_12828076_877_896_Disease))) (ADJP (JJ due) (PP (TO to) (NP (NP (NNP Doc_12828076_904_915_Chemical) (NNP Doc_12828076_916_924_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN median)) (, ,) (NP (CD 28.7) (NNP U/mL))) (: ;) (NP (NP (NP (NN range)) (, ,) (NP (CD 12.8-52.7) (NNP U/mL))) (, ,) (NP (NNP n) (SYM =) (CD 17))) (-RRB- -RRB-)))))))) (PP (IN than) (NP (NP (DT those)) (ADJP (JJ due) (PP (TO to) (NP (NN non-A))) (PP (TO to) (NP (NP (NNP E) (NNP Doc_12828076_1005_1014_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN median)) (, ,) (NP (CD 12.5) (NNP U/mL))) (: ;) (NP (NP (NN range)) (, ,) (NP (JJ 6.9-46.0) (NNP U/mL)) (, ,) (NP (NNP n) (SYM =) (CD 7)) (, ,) (NP (NNP P) (NNP <) (CD 0.01))) (-RRB- -RRB-))))))))) (. .)))
12828076	7	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN relationship)) (PP (IN of) (NP (NNS sFas))) (PP (TO to) (NP (NP (JJ eventual) (NN outcome)) (PP (IN in) (NP (DT the) (NNS patients))))))) (. .)))
12828076	8	(S1 (S (NP (DT A) (JJ significant) (NN correlation)) (VP (AUX was) (VP (VBN observed) (PP (IN between) (NP (NP (NN serum) (NN sFas) (NNS levels)) (CC and) (NP (NP (JJ Doc_12828076_1215_1224_Chemical) (NN aminotransferase)) (PRN (-LRB- -LRB-) (NP (SYM r) (X (SYM =)) (CD 0.613)) (, ,) (NP (QP ($ P) (CD <) (CD 0.01))) (-RRB- -RRB-))))))) (. .)))
12828076	9	(S1 (S (S (NP (NP (DT The) (VBN increased) (NN concentration)) (PP (IN of) (NP (NNS sFas))) (PP (IN in) (NP (NP (NN serum)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_12828076_1340_1359_Disease)))))))) (VP (MD may) (VP (VB reflect) (NP (NP (NN activation)) (PP (IN of) (NP (NP (JJ Fas-mediated) (NNS apoptosis)) (PP (IN in) (NP (DT the) (NN liver))))))))) (CC and) (S (NP (DT this)) (ADVP (RB together) (PP (IN with) (NP (VBN increased) (NNP Doc_12828076_1455_1460_Disease) (NNP Doc_12828076_1461_1469_Disease) (NN factor-alpha)))) (VP (MD may) (VP (AUX be) (NP (NP (DT an) (JJ important) (NN factor)) (PP (IN in) (NP (NN liver) (NN cell) (NN loss))))))) (. .)))
12865514	0	(S1 (NP (NP (JJ Bilateral) (JJ subthalamic) (NN nucleus) (NN stimulation)) (PP (IN for) (NP (NNP Doc_12865514_46_65_Disease))) (. .)))
12865514	1	(S1 (S (NP (NP (JJ High) (NN frequency) (NN stimulation)) (PP (IN of) (NP (DT the) (JJ subthalamic) (NN nucleus))) (PRN (-LRB- -LRB-) (NP (NNP STN)) (-RRB- -RRB-))) (VP (AUX is) (VP (VBN known) (S (VP (TO to) (VP (VB ameliorate) (NP (NP (DT the) (NNS signs) (CC and) (NNS symptoms)) (PP (IN of) (NP (JJ advanced) (NN Doc_12865514_185_204_Disease))))))))) (. .)))
12865514	2	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ high) (NN frequency) (NN STN) (NN stimulation))) (PP (IN in) (NP (CD 23) (NNS patients))))) (. .)))
12865514	3	(S1 (S (NP (NP (JJ Twenty-three) (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (NP (NP (JJ severe) (NNP Doc_12865514_335_354_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NNS Stages) (NN III-V)) (PP (IN on) (NP (NNP Hoehn) (CC and) (NNP Yahr) (NN scale)))) (-RRB- -RRB-))) (CC and) (, ,) (ADVP (RB particularly)) (NP (NNP Doc_12865514_412_424_Disease)) (, ,) (NP (NNP Doc_12865514_426_434_Disease)) (, ,) (CC and) (NP (NNP Doc_12865514_440_448_Chemical-induced) (NNP Doc_12865514_457_468_Disease)))))) (VP (VBD underwent) (NP (NP (JJ bilateral) (NN implantation)) (PP (IN of) (NP (NNS electrodes)))) (PP (IN in) (NP (DT the) (NN STN)))) (. .)))
12865514	4	(S1 (S (NP (NP (NN Preoperative)) (CC and) (NP (NP (JJ postoperative) (NNS assessments)) (PP (IN of) (NP (DT these) (NNS patients))) (PP (IN at) (NP (CD 1) (, ,) (CD 3) (, ,) (CD 6) (CC and) (CD 12) (NNS months) (NN follow-up))))) (, ,) (PP (IN in) (`` ``) (PP (IN on) (NP ('' '') (CC and) (`` ``) (ADJP (RB off)) ('' '') (NN drug) (NNS conditions)))) (, ,) (VP (AUX was) (VP (VBN carried) (PRT (RP out)) (S (VP (VBG using) (NP (NP (JJ Unified) (NNP Doc_12865514_690_709_Disease) (NNP Rating) (NNP Scale) (, ,) (NNP Hoehn) (CC and) (NNP Yahr) (NN staging)) (, ,) (NP (NP (NNP England) (NNS activities)) (PP (IN of) (NP (JJ daily) (NN living) (NN score)))) (CC and) (NP (JJ video) (NNS recordings))))))) (. .)))
12865514	5	(S1 (S (PP (IN After) (NP (NP (CD one) (NN year)) (PP (IN of) (NP (NP (JJ electrical) (NN stimulation)) (PP (IN of) (NP (DT the) (NN STN))))))) (, ,) (NP (NP (NP (DT the) (NNS patients) (POS ')) (NNS scores)) (PP (IN for) (NP (NP (NNS activities)) (PP (IN of) (NP (NP (JJ daily) (NN living)) (CC and) (NP (NP (NN motor) (NN examination) (NNS scores)) (PRN (-LRB- -LRB-) (NP (JJ Unified) (NNP Doc_12865514_963_982_Disease) (NNP Rating) (NNP Scale) (NNS parts) (NNP II) (CC and) (NNP III)) (-RRB- -RRB-))))) (PP (IN off) (NP (NN medication)))))) (VP (VBN improved) (PP (IN by) (NP (NP (CD 62) (NN %)) (CC and) (NP (NP (CD 61) (NN %)) (ADVP (RB respectively) (PRN (-LRB- -LRB-) (NP (CD p<0.0005)) (-RRB- -RRB-))))))) (. .)))
12865514	6	(S1 (S (S (NP (NP (DT The) (NNS subscores)) (PP (IN for) (NP (NP (DT the) (NNP Doc_12865514_1100_1108_Disease)) (, ,) (NP (NNP Doc_12865514_1110_1118_Disease)) (, ,) (NP (NNP Doc_12865514_1120_1126_Disease)) (CC and) (NP (NN gait))))) (ADVP (RB also)) (VP (VBD improved)) (. .)) (PRN (-LRB- -LRB-) (NP (CD p<0.0005)) (-RRB- -RRB-)) (. .)))
12865514	7	(S1 (S (NP (DT The) (JJ average) (JJ Doc_12865514_1175_1183_Chemical) (NN dose)) (VP (VBD decreased) (PP (IN from) (NP (CD 813) (NN mg))) (PP (TO to) (NP (QP (CD 359) (CD mg))))) (. .)))
12865514	8	(S1 (S (NP (DT The) (JJ cognitive) (NNS functions)) (VP (VBD remained) (ADJP (JJ unchanged))) (. .)))
12865514	9	(S1 (S (NP (CD Two) (NNS patients)) (VP (VBD developed) (NP (NP (JJ device-related) (NNS complications)) (CC and) (NP (NP (CD two) (NNS patients)) (VP (VBN experienced) (NP (JJ abnormal) (NNP Doc_12865514_1356_1367_Disease)))))) (. .)))
12865514	10	(S1 (S (NP (JJ Bilateral) (JJ subthalamic) (NN nucleus) (NN stimulation)) (VP (AUX is) (NP (NP (DT an) (JJ effective) (NN treatment)) (PP (IN for) (NP (JJ advanced) (NN Doc_12865514_1462_1481_Disease))))) (. .)))
12865514	11	(S1 (S (NP (PRP It)) (VP (VP (VBZ reduces) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (`` ``) (JJ off) ('' '') (NN phase) (NNS symptoms))))) (, ,) (VP (VBZ improves) (NP (DT the) (JJ axial) (NNS symptoms))) (CC and) (VP (VBZ reduces) (NP (JJ Doc_12865514_1572_1580_Chemical) (NNS requirements)))) (. .)))
12865514	12	(S1 (S (NP (NP (DT The) (NN reduction)) (PP (IN in) (NP (DT the) (JJ Doc_12865514_1616_1624_Chemical) (NN dose)))) (VP (AUX is) (ADJP (JJ useful) (PP (IN in) (S (VP (VBG controlling) (NP (JJ drug-induced) (NNP Doc_12865514_1668_1679_Disease))))))) (. .)))
1289188	0	(S1 (NP (NP (NP (NN Doc_1289188_0_19_Disease)) (VP (VBG occurring) (PP (IN during) (NP (JJ intravenous) (JJ Doc_1289188_49_64_Chemical) (NN therapy))))) (: :) (NP (NP (NN recovery)) (PP (IN after) (NP (NN haemodialysis)))) (. .)))
1289188	1	(S1 (S (NP (NP (DT A) (NN patient)) (PP (IN with) (NP (JJ transfusion-dependent) (NNP Doc_1289188_141_152_Disease)))) (VP (AUX was) (VP (VBG undergoing) (NP (NP (NN home) (JJ intravenous) (NNP Doc_1289188_185_200_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_1289188_202_205_Chemical)) (-RRB- -RRB-)) (NN treatment)) (PP (IN by) (NP (NP (NNS means)) (PP (IN of) (NP (DT a) (ADJP (RB totally) (VBN implanted)) (NN system)))))) (PP (IN because) (IN of) (NP (NP (PRP$ his) (JJ poor) (NN compliance)) (PP (IN with) (NP (DT the) (JJ nightly) (JJ subcutaneous) (NN therapy))))))) (. .)))
1289188	2	(S1 (S (PP (JJ Due) (TO to) (NP (NP (DT an) (JJ accidental) (NN malfunctioning)) (PP (IN of) (NP (DT the) (NN infusion) (NN pump))))) (, ,) (NP (DT the) (NN patient)) (VP (AUX was) (ADVP (RB inadvertently)) (VP (VBN administered) (NP (NP (DT a) (JJ toxic) (NN dosage)) (PP (IN of) (NP (NP (DT the) (NN drug)) (SBAR (WHNP (WDT which)) (S (VP (VBD caused) (NP (NN Doc_1289188_467_486_Disease)))))))))) (. .)))
1289188	3	(S1 (S (PP (VBN Given) (NP (NP (DT the) (JJ progressive) (NN deterioration)) (PP (PP (IN of) (NP (DT the) (NNS symptoms))) (CC and) (PP (IN of) (NP (DT the) (NN laboratory) (NNS values)))))) (, ,) (PP (IN despite) (NP (JJ adequate) (JJ medical) (NN treatment))) (, ,) (NP (DT a) (NN decision)) (VP (AUX was) (VP (VBN made) (S (VP (TO to) (VP (VB introduce) (NP (JJ haemodialytical) (NN therapy)) (PP (IN in) (NP (NN order))) (S (VP (TO to) (VP (VP (VB remove) (NP (DT the) (NN drug))) (CC and) (VP (NN therapy) (VB reduce) (NP (DT the) (NN nephrotoxicity))))))))))) (. .)))
1289188	4	(S1 (S (PP (IN From) (NP (NP (DT the) (NNS results)) (VP (VBN obtained)))) (, ,) (NP (NN haemodialysis)) (VP (MD can) (ADVP (RB therefore)) (VP (AUX be) (VP (VBN suggested) (PP (IN as) (NP (NP (DT a) (JJ useful) (NN therapy)) (PP (IN in) (NP (NP (JJ rare) (NNS cases)) (PP (IN of) (NP (NP (JJ progressive) (NN Doc_1289188_847_866_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_1289188_877_892_Chemical))))))))))))) (. .)))
12912689	0	(S1 (NP (NP (JJ Ocular) (JJ motility) (NNS changes)) (PP (IN after) (NP (NP (JJ subtenon) (JJ Doc_12912689_39_50_Chemical) (NN chemotherapy)) (PP (IN for) (NP (NNP Doc_12912689_68_82_Disease))))) (. .)))
12912689	1	(S1 (S (NP (JJ Focal) (NN subtenon) (NN Doc_12912689_111_122_Chemical) (NNS injections)) (VP (AUX have) (ADVP (RB recently)) (VP (AUX been) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (ADJP (RB presumably) (JJ Doc_12912689_174_182_Disease-free)) (NN adjunct)) (PP (TO to) (NP (JJ systemic) (NN chemotherapy))) (PP (IN for) (NP (NNP Doc_12912689_225_251_Disease)))))))) (. .)))
12912689	2	(S1 (FRAG (S (VP (TO To) (VP (VB report) (NP (NP (PRP$ our) (JJ clinical) (NN experience)) (PP (IN with) (NP (NNP Doc_12912689_303_327_Disease))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (JJ Doc_12912689_353_373_Chemical) (NN chemotherapy)))))))))) (. .)))
12912689	3	(S1 (S (NP (PRP We)) (VP (VBD noted) (NP (NNP Doc_12912689_406_430_Disease)) (PP (IN in) (NP (NP (CD 10) (JJ consecutive) (NNS patients)) (PP (IN with) (NP (NNP Doc_12912689_463_477_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN received) (NP (NN subtenon) (NN Doc_12912689_504_515_Chemical))))))))) (. .)))
12912689	4	(S1 (S (PP (IN During) (NP (NP (JJ ocular) (NN manipulation)) (PP (IN under) (NP (JJ general) (NNS anesthesia))))) (, ,) (NP (PRP we)) (VP (VBD assessed) (NP (PRP$ their) (NNS eyes)) (PP (IN by) (NP (JJ forced) (NN duction) (NN testing))) (, ,) (S (VP (VBG comparing) (NP (JJ ocular) (NN motility)) (PP (IN after) (NP (NP (JJ Doc_12912689_652_657_Disease) (NN control)) (PP (IN with) (NP (NP (JJ ocular) (NN motility)) (PP (IN at) (NP (NN diagnosis)))))))))) (. .)))
12912689	5	(S1 (S (NP (NP (NNS Eyes)) (VP (ADVP (RB subsequently)) (VBN enucleated) (PP (IN because) (IN of) (NP (NN treatment) (NN failure))))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 4)) (-RRB- -RRB-)) (VP (AUX were) (VP (VBN examined) (ADVP (RB histologically)))) (. .)))
12912689	6	(S1 (S (NP (NP (NN Limitation)) (PP (IN of) (NP (JJ ocular) (NN motility)))) (VP (AUX was) (VP (VBN detected) (PP (IN in) (NP (NP (DT all) (CD 12) (NNS eyes)) (PP (IN of) (NP (NP (CD 10) (NNS patients)) (VP (VBN treated) (PP (IN for) (NP (NNP Doc_12912689_891_917_Disease))) (PP (IN with) (NP (NP (QP (CD 1) (TO to) (CD 6)) (NNS injections)) (PP (IN of) (NP (NN subtenon) (NN Doc_12912689_953_964_Chemical))))) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (JJ multimodality) (NN therapy)))))))))))) (. .)))
12912689	7	(S1 (S (NP (JJ Histopathological) (NN examination)) (VP (VBD revealed) (NP (JJ many) (NNS lipophages)) (PP (IN in) (NP (NP (DT the) (JJ periorbital) (NN fat)) (VP (VBG surrounding) (NP (NP (DT the) (JJ optic) (NN nerve)) (PP (IN in) (NP (CD 1) (NN eye))))))) (, ,) (UCP (ADJP (JJ indicative) (PP (IN of) (NP (NP (NN phagocytosis)) (PP (IN of) (NP (ADJP (RB previously) (VBG existing)) (JJ fat) (NNS cells)))))) (CC and) (VP (VBG suggesting) (NP (JJ prior) (JJ fat) (NN Doc_12912689_1200_1208_Disease))))) (. .)))
12912689	8	(S1 (S (NP (DT The) (NNS enucleations)) (VP (AUX were) (ADJP (RB technically) (JJ difficult) (CC and) (JJ hazardous)) (PP (IN for) (NP (NNP Doc_12912689_1272_1285_Disease))) (PP (IN because) (IN of) (NP (JJ extensive) (JJ orbital) (JJ soft) (NN tissue) (NNS adhesions)))) (. .)))
12912689	9	(S1 (S (NP (NNP Subtenon) (NNP Doc_12912689_1360_1371_Chemical) (NN chemotherapy)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ significant) (NN Doc_12912689_1416_1424_Disease)) (PP (IN of) (NP (JJ orbital) (JJ soft) (NNS tissues))))) (, ,) (S (VP (VP (VBG leading) (PP (TO to) (NP (NP (JJ mechanical) (NN restriction)) (PP (IN of) (NP (NN eye) (NNS movements)))))) (CC and) (VP (VBG making) (S (NP (JJ subsequent) (NN enucleation)) (ADJP (JJ difficult)))))))) (. .)))
12912689	10	(S1 (S (S (NP (NNP Subtenon) (NNP Doc_12912689_1555_1566_Chemical)) (VP (AUX is) (RB not) (ADJP (JJ free) (PP (IN of) (NP (NNP Doc_12912689_1582_1590_Disease)))))) (, ,) (CC and) (S (NP (PRP$ its) (NN use)) (VP (AUX is) (ADVP (RB best)) (VP (VBN restricted) (PP (TO to) (NP (JJ specific) (NNS indications)))))) (. .)))
12948256	0	(S1 (NP (NNP Doc_12948256_0_10_Chemical) (CC and) (NNP Doc_12948256_15_31_Disease) (. .)))
12948256	1	(S1 (S (S (VP (TO To) (VP (VB demonstrate) (NP (NP (DT the) (NN association)) (PP (IN between) (NP (NP (NNP Doc_12948256_81_91_Chemical)) (CC and) (NP (NNP Doc_12948256_96_112_Disease)))))))) (. .)))
12948256	2	(S1 (S (NP (NP (JJ Thirteen) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_12948256_154_170_Disease)) (PP (IN after) (S (VP (AUXG being) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_12948256_196_206_Chemical))) (PP (IN for) (NP (NP (NNP Doc_12948256_211_223_Disease)) (PP (IN of) (NP (NP (DT the) (NN lung) (CC or) (NN lymph) (NN node)) (PP (IN at) (NP (NNP Siriraj) (NNP Hospital))) (PP (IN between) (NP (NP (CD 1997)) (CC and) (NP (CD 2001)))))))))))))))) (VP (AUX were) (ADVP (RB retrospectively)) (VP (VBN reviewed))) (. .)))
12948256	3	(S1 (S (NP (NP (DT The) (JJ clinical) (NNS characteristics)) (CC and) (NP (NNP Doc_12948256_356_387_Disease))) (VP (AUX were) (VP (VBN analyzed) (S (VP (TO to) (VP (VB determine) (NP (JJ visual) (NN outcome))))))) (. .)))
12948256	4	(S1 (S (NP (DT All) (NNS patients)) (VP (AUX had) (NP (NP (NN Doc_12948256_457_473_Disease)) (PP (IN between) (NP (NP (QP (CD 1) (TO to) (CD 6)) (NNS months)) (PRN (-LRB- -LRB-) (S (NP (NN mean)) (VP (SYM =) (NP (CD 2.9) (NNS months)))) (-RRB- -RRB-))))) (PP (IN after) (S (VP (VBG starting) (NP (JJ Doc_12948256_531_541_Chemical) (NN therapy)) (PP (IN at) (NP (NP (DT a) (NN dosage)) (VP (VBG ranging) (PP (IN from) (NP (NP (QP (CD 13) (TO to) (CD 20)) (NN mg/kg/day)) (PRN (-LRB- -LRB-) (S (NP (NN mean)) (VP (SYM =) (NP (CD 17) (NN mg/kg/day)))) (-RRB- -RRB-))))))))))) (. .)))
12948256	5	(S1 (S (NP (NP (NP (CD Seven)) (PRN (-LRB- -LRB-) (NP (CD 54) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (CD 13) (NNS patients)))) (VP (VBD experienced) (NP (JJ visual) (NN recovery)) (PP (IN after) (S (VP (VBG stopping) (NP (DT the) (NN drug)))))) (. .)))
12948256	6	(S1 (S (PP (IN Of) (NP (NP (CD 6) (NNS patients)) (PP (IN with) (NP (JJ irreversible) (NNP Doc_12948256_733_750_Disease))))) (, ,) (NP (CD 4) (NNS patients)) (VP (AUX had) (NP (NP (NN Doc_12948256_767_784_Disease)) (, ,) (NP (NN Doc_12948256_786_794_Disease)) (CC and) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (JJ heavy) (NN smoking)))))) (. .)))
12948256	7	(S1 (S (NP (NP (JJ Early) (NN recognition)) (PP (IN of) (NP (NNP Doc_12948256_860_876_Disease)))) (VP (MD should) (VP (AUX be) (VP (VBN considered) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ Doc_12948256_915_925_Chemical) (NN therapy)))))))) (. .)))
12948256	8	(S1 (S (NP (NP (NP (DT A) (JJ low) (NN dose)) (CC and) (NP (JJ prompt) (NN discontinuation))) (PP (IN of) (NP (DT the) (NN drug)))) (VP (AUX is) (VP (VBN recommended) (ADVP (RB particularly)) (UCP (PP (IN in) (NP (NP (NNS individuals)) (PP (IN with) (NP (NP (NNP Doc_12948256_1033_1050_Disease)) (, ,) (NP (NNP Doc_12948256_1052_1060_Disease)))))) (CC or) (SBAR (WHNP (WP who)) (S (VP (AUX are) (NP (JJ heavy) (NNS smokers)))))))) (. .)))
12950111	0	(S1 (NP (NP (NN Treatment)) (PP (IN of) (NP (NP (JJ compensatory) (NN Doc_12950111_26_49_Disease)) (PP (IN with) (NP (JJ topical) (NNP Doc_12950111_63_77_Chemical))))) (. .)))
12950111	1	(S1 (S (NP (NN Doc_12950111_79_102_Disease)) (VP (AUX is) (NP (NP (JJ facial) (NN sweating)) (VP (ADVP (RB usually)) (VBN associated) (PP (IN with) (S (NP (NP (DT the) (NN eating)) (PP (IN of) (NP (JJ hot) (NN spicy) (NN food)))) (ADVP (CC or) (RB even)) (VP (VBG smelling) (NP (DT this) (NN food)))))))) (. .)))
12950111	2	(S1 (S (NP (NP (JJ Current) (NNS options)) (PP (IN of) (NP (NN treatment)))) (VP (VBP include) (NP (NP (JJ oral) (JJ anticholinergic) (NNS drugs)) (, ,) (NP (NP (DT the) (JJ topical) (NN application)) (PP (IN of) (NP (NP (NNS anticholinergics)) (CC or) (NP (NNP Doc_12950111_315_332_Chemical))))) (, ,) (CC and) (NP (NP (DT the) (NN injection)) (PP (IN of) (NP (NN botulinum) (NN toxin)))))) (. .)))
12950111	3	(S1 (S (NP (JJ Thirteen) (NNS patients)) (VP (AUX have) (VP (AUX been) (VP (VBN treated) (PP (TO to) (NP (NN date))) (PP (IN with) (NP (NP (CD 1.5) (NN %)) (CC or) (NP (ADJP (CD 2) (NN %)) (JJ topical) (NN Doc_12950111_440_454_Chemical))))))) (. .)))
12950111	4	(S1 (S (NP (DT All) (NNS patients)) (VP (AUX had) (NP (NN Doc_12950111_473_496_Disease)) (, ,) (SBAR (SBAR (WHNP (WDT which)) (S (VP (VBD interfered) (PP (IN with) (NP (PRP$ their) (JJ social) (NNS activities))) (, ,) (PP (IN after) (NP (JJ transthroacic) (JJ endoscopic) (NN sympathectomy)))))) (, ,) (CC and) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (JJ compensatory) (JJ focal) (NN Doc_12950111_640_653_Disease))))))))) (. .)))
12950111	5	(S1 (S (SBAR (IN After) (S (VP (VBG applying) (NP (JJ topical) (NNP Doc_12950111_678_692_Chemical))))) (, ,) (NP (DT the) (JJ subjective) (NN effect)) (VP (AUX was) (ADJP (ADJP (ADJP (JJ excellent)) (PRN (-LRB- -LRB-) (NP (NP (DT no) (NN sweating)) (PP (IN after) (NP (VBG eating) (JJ hot) (NN spicy) (NN food)))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (CD 10) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 77) (NN %)) (-RRB- -RRB-)))) (, ,) (CC and) (ADJP (JJ fair))) (PRN (-LRB- -LRB-) (NP (RB clearly) (VBN reduced) (NN sweating)) (-RRB- -RRB-)) (PP (IN in) (NP (CD 3) (NNS patients))) (PRN (-LRB- -LRB-) (NP (CD 23) (NN %)) (-RRB- -RRB-))) (. .)))
12950111	6	(S1 (S (NP (DT All)) (VP (AUX had) (VP (VBN reported) (NP (NNS incidents)) (PP (IN of) (S (VP (AUXG being) (ADJP (RB very) (JJ embarrassed)) (PP (JJ whilst) (S (VP (VBG eating) (NP (JJ hot) (NN spicy) (NNS foods)))))))))) (. .)))
12950111	7	(S1 (S (NP (JJ Adverse) (NNS effects)) (VP (VBD included) (NP (NP (NP (DT a) (ADJP (RB mildly) (JJ Doc_12950111_969_978_Disease))) (CC and) (NP (DT a) (JJ sore) (NN throat))) (PP (IN in) (NP (CD 2) (NNS patients))) (PRN (-LRB- -LRB-) (NP (NP (CD 2) (NN %)) (NP (NNP Doc_12950111_1015_1029_Chemical))) (-RRB- -RRB-)) (, ,) (NP (NP (DT a) (JJ light) (NN Doc_12950111_1040_1048_Disease)) (PP (IN in) (NP (CD 1) (NN patient)))) (PRN (-LRB- -LRB-) (NP (NP (CD 1.5) (NN %)) (NP (NNP Doc_12950111_1068_1082_Chemical))) (-RRB- -RRB-)))) (. .)))
12950111	8	(S1 (S (NP (NP (DT The) (JJ topical) (NN application)) (PP (IN of) (NP (DT a) (JJ Doc_12950111_1114_1128_Chemical) (NN pad)))) (VP (VBD appeared) (S (VP (TO to) (VP (AUX be) (UCP (ADJP (JJ safe)) (, ,) (ADJP (JJ efficacious)) (, ,) (ADJP (RB well) (VBN tolerated)) (, ,) (CC and) (NP (NP (DT a) (JJ convenient) (NN method)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN for) (NP (ADJP (JJ moderate) (PP (TO to) (NP (NP (JJ severe) (NNS symptoms)) (PP (IN of) (NP (NP (NNP Doc_12950111_1255_1278_Disease)) (PP (IN in) (NP (NN post)))))))) (JJ transthoracic) (JJ endoscopic) (NN sympathectomy) (CC or) (NN sympathicotomy) (NNS patients)))))))))) (, ,) (PP (IN with) (NP (JJ few) (NN side) (NNS effects)))) (. .)))
1359137	0	(S1 (NP (JJ Neuroleptic-associated) (NN Doc_1359137_23_41_Disease) (. .)))
1359137	1	(S1 (SQ (MD Can) (NP (PRP it)) (VP (AUX be) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_1359137_66_79_Chemical))))) (. ?)))
1359137	2	(S1 (S (NP (NP (CD Six) (JJ stable) (NNP Doc_1359137_92_103_Disease) (NNS outpatients)) (PP (IN with) (NP (NP (NNP Doc_1359137_121_139_Disease)) (CC and) (NP (NNP Doc_1359137_144_154_Disease/Doc_1359137_155_169_Disease)))) (VP (VBN associated) (PP (IN with) (NP (PRP$ their) (JJ neuroleptic) (NNS medications))))) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_1359137_234_247_Chemical))))) (. .)))
1359137	3	(S1 (S (NP (NP (JJ Daily) (NNS dosages)) (PP (IN of) (NP (JJ 5-10) (NNS mg)))) (VP (VP (VBD corrected) (NP (DT the) (NNP Doc_1359137_288_306_Disease))) (CC and) (VP (VBD restored) (NP (NN menstruation)) (PP (IN in) (NP (NP (CD four)) (PP (IN of) (NP (DT the) (CD six) (NNS patients))))))) (. .)))
1359137	4	(S1 (S (S (NP (NP (CD One) (NN woman)) (PRN (, ,) (ADVP (RB however)) (, ,))) (VP (VBD developed) (NP (VBN worsened) (NNP Doc_1359137_401_412_Disease) (NNS symptoms)) (PP (IN while) (S (VP (VBG taking) (NP (NNP Doc_1359137_435_448_Chemical))))))) (, ,) (CC and) (S (NP (PRP it)) (VP (AUX was) (VP (VBN discontinued)))) (. .)))
1359137	5	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (CD three)) (PP (IN of) (NP (CD six) (NNS patients)))) (VP (AUX had) (NP (NP (PRP$ their) (JJ menstrual) (NN irregularity)) (VP (ADVP (RB successfully)) (VBN corrected) (PP (IN with) (NP (NNP Doc_1359137_564_577_Chemical)))))) (. .)))
1359137	6	(S1 (S (NP (DT This)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP Doc_1359137_598_611_Chemical)) (VP (MD should) (VP (AUX be) (ADVP (RB further)) (VP (VBN evaluated) (PP (IN as) (NP (NP (JJ potential) (NN therapy)) (PP (IN for) (NP (JJ neuroleptic-associated) (NNP Doc_1359137_688_706_Disease) (CC and) (NNP Doc_1359137_711_721_Disease/Doc_1359137_722_734_Disease))))))))))) (. .)))
1360900	0	(S1 (NP (NP (NP (JJ Doc_1360900_0_15_Chemical-induced) (NN Doc_1360900_24_35_Disease)) (CC and) (NP (NN brain) (NNS neurotransmitters))) (PP (IN in) (NP (NNS mice))) (. .)))
1360900	1	(S1 (S (NP (NP (JJ Intracerebroventricular) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_1360900_110_125_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 50) (NN %)) (JJ convulsive) (NN dose)) (: ;) (NP (CD 50) (NN micrograms/mouse))) (-RRB- -RRB-))))) (VP (VP (VBD accelerated) (NP (NP (DT the) (NN synthesis/turnover)) (PP (IN of) (NP (NP (NNP Doc_1360900_207_226_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1360900_228_232_Chemical)) (-RRB- -RRB-)))))) (CC but) (VP (VBD suppressed) (NP (NP (DT the) (NN synthesis)) (PP (IN of) (NP (NP (NNP Doc_1360900_266_289_Chemical) (CC and) (NNP Doc_1360900_294_307_Chemical)) (PP (IN in) (NP (NN mouse) (NN brain)))))))) (. .)))
1360900	2	(S1 (S (NP (DT These) (NNS effects)) (VP (AUX were) (VP (ADVP (RB completely)) (VBN antagonized) (PP (IN by) (NP (NN pretreatment))) (PP (IN with) (NP (NP (DT a) (JJ Doc_1360900_389_398_Chemical/Doc_1360900_399_419_Chemical) (NN antagonist)) (, ,) (NP (NNP Doc_1360900_432_458_Chemical)))))) (. .)))
1360900	3	(S1 (S (PP (IN In) (NP (JJ Doc_1360900_463_478_Chemical-induced) (NNP Doc_1360900_487_498_Disease))) (, ,) (NP (DT these) (NN neurotransmitter) (NNS systems)) (VP (MD may) (VP (AUX be) (ADVP (RB differentially)) (VP (VBN modulated) (, ,) (PP (ADVP (RB probably)) (IN through) (NP (NP (NN activation)) (PP (IN of) (NP (JJ glutaminergic) (NNS neurons))) (PP (IN in) (NP (DT the) (NN brain)))))))) (. .)))
1361574	0	(S1 (NP (NP (NN Pharmacology)) (PP (IN of) (NP (JJ Doc_1361574_16_40_Chemical) (NN receptor) (NN complex))) (PP (IN after) (NP (NP (DT the)) (PP (IN in) (NP (NP (NN vivo) (NN administration)) (PP (IN of) (NP (DT the) (ADJP (JJ anxioselective) (CC and) (JJ anticonvulsant)) (NNP Doc_1361574_132_146_Chemical) (NN derivative) (NN Doc_1361574_158_167_Chemical))))))) (. .)))
1361574	1	(S1 (S (PP (IN In) (NP (NNS rodents))) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NP (DT the) (JJ Doc_1361574_199_213_Chemical) (JJ derivative) (NNP Doc_1361574_225_292_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1361574_294_304_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (JJ new) (NN ligand)) (PP (IN for) (NP (NP (JJ Doc_1361574_324_338_Chemical) (NNS receptors)) (VP (VBG possessing) (NP (NN anxiolytic) (CC and) (NN anticonvulsant) (NNS properties)))))) (, ,)))) (VP (AUX was) (VP (VBN evaluated) (PP (IN on) (NP (NP (DT the) (NN function)) (PP (IN of) (NP (NP (JJ central) (NNP Doc_1361574_443_466_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1361574_468_472_Chemical)) (-RRB- -RRB-)))))) (NP (DT A) (NN receptor) (NN complex)) (, ,) (PP (DT both) (PP (IN in) (NP (NN vitro))) (CC and) (PP (IN in) (NP (NN vivo)))))) (. .)))
1361574	2	(S1 (S (S (VP (VBN Added) (SBAR (IN in) (NN vitro) (S (VP (TO to) (VP (VB rat) (NP (JJ cortical) (JJ membrane) (NN preparation)))))))) (, ,) (NP (NNP Doc_1361574_573_582_Chemical)) (VP (VP (VBD increased) (NP (ADJP (JJ -LSB-3H) (JJ -RSB-)) (JJ Doc_1361574_597_601_Chemical) (JJ binding) (, ,) (JJ enhanced) (JJ Doc_1361574_620_645_Chemical) (NN uptake))) (CC and) (VP (VBD reduced) (NP (NP (DT the) (JJ binding)) (PP (IN of) (NP (NP (NNP Doc_1361574_680_716_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1361574_718_727_Chemical)) (-RRB- -RRB-))))))) (. .)))
1361574	3	(S1 (S (NP (DT These) (NNS effects)) (VP (AUX were) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_1361574_777_785_Chemical))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (JJ partial) (NN agonist) (NN Doc_1361574_815_825_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1361574_827_947_Chemical)) (-RRB- -RRB-))) (VP (VBD showed) (NP (ADJP (RB very) (JJ weak)) (NN efficacy)) (PP (IN in) (NP (DT these) (JJ biochemical) (NNS tests))))))) (. .)))
1361574	4	(S1 (S (PP (IN After) (NP (NP (JJ i.p.) (NN injection)) (PP (TO to) (NP (NNS rats))))) (, ,) (NP (NNP Doc_1361574_1033_1042_Chemical) (CC and) (NNP Doc_1361574_1047_1055_Chemical)) (VP (VBD decreased) (PP (IN in) (NP (NP (DT a) (ADJP (JJ time-dependent) (CC and) (JJ dose-related)) (PRN (-LRB- -LRB-) (NP (QP (CD 0.25-20) (CD mg/kg)) (NN i.p.)) (-RRB- -RRB-)) (NN manner) (JJ Doc_1361574_1131_1140_Chemical) (VBG binding)) (VP (VBN measured) (ADVP (FW ex) (FW vivo)) (PP (IN in) (NP (DT the) (JJ cerebral) (NN cortex))))))) (. .)))
1361574	5	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT both) (NNS drugs)) (PP (IN at) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (CD 0.5) (NN mg/kg)))))) (VP (VBD antagonized) (ADVP (RB completely)) (S (NP (NP (DT the) (JJ convulsant) (NN activity)) (CC and) (NP (NP (DT the) (NN increase)) (PP (IN of) (NP (JJ -LSB-35S) (JJ -RSB-) (NNS TBPS))))) (VP (VBG binding) (S (VP (VBN induced) (PP (IN by) (NP (NP (NP (NNP Doc_1361574_1332_1342_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 350) (CD mg/kg)) (NNP s.c.)) (-RRB- -RRB-))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NN increase)) (PP (IN of) (NP (NP (NNP Doc_1361574_1387_1396_Chemical) (VBG binding)) (VP (VBN induced) (PP (IN by) (NP (JJ foot-shock) (NN stress)))))))))))))) (. .)))
1361574	6	(S1 (S (S (VP (TO To) (ADVP (RB better)) (VP (VB correlate) (NP (NP (DT the) (NN biochemical)) (CC and) (NP (DT the) (JJ pharmacological) (NNS effects)))))) (, ,) (NP (PRP we)) (VP (VBD studied) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NNP Doc_1361574_1529_1538_Chemical))) (PP (PP (IN on) (NP (ADJP (NNP Doc_1361574_1542_1551_Chemical) (JJ binding)) (, ,) (JJ exploratory) (NN motility))) (CC and) (PP (IN on) (NP (NP (JJ Doc_1361574_1589_1598_Chemical-induced) (NN biochemical)) (CC and) (NP (NP (JJ pharmacological) (NNS effects)) (PP (IN in) (NP (NNS mice))))))))) (. .)))
1361574	7	(S1 (S (PP (IN In) (NP (DT these) (NNS animals))) (, ,) (NP (NNP Doc_1361574_1674_1683_Chemical)) (VP (VBD produced) (NP (NP (NP (DT a) (JJ paralleled) (NN dose-dependent) (PRN (-LRB- -LRB-) (JJ 0.05-1) (NN mg/kg) (NN i.p.) (-RRB- -RRB-)) (NN reduction)) (PP (IN of) (NP (DT both) (NN motor) (NN behavior)))) (CC and) (NP (JJ cortical) (JJ -LSB-35S) (JJ -RSB-) (NNS TBPS) (JJ binding)))) (. .)))
1361574	8	(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (NP (CD 0.05) (NN mg/kg)) (PP (IN of) (NP (DT this) (NNP Doc_1361574_1835_1849_Chemical)))) (VP (VBD reduced) (NP (NP (RB markedly) (DT the) (NN increase)) (PP (IN of) (NP (NP (NNP Doc_1361574_1883_1892_Chemical) (VBG binding)) (CC and) (NP (NP (NP (DT the) (NNP Doc_1361574_1909_1920_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_1361574_1932_1941_Chemical))))) (PRN (-LRB- -LRB-) (NP (NP (CD 200) (NNS mg/kg)) (NP (NNP s.c.))) (-RRB- -RRB-))))))) (. .)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-))))
1395192	0	(S1 (NP (NP (NNP Recurrent) (NNP Doc_1395192_10_31_Disease)) (PP (IN in) (NP (DT a) (JJ postpartum) (NN patient))) (VP (VBG receiving) (NP (NNP Doc_1395192_66_79_Chemical))) (. .)))
1395192	1	(S1 (S (NP (NP (NN Doc_1395192_81_102_Disease)) (PP (IN in) (NP (NN puerperium)))) (VP (AUX is) (ADVP (RB infrequently)) (VP (VBN reported))) (. .)))
1395192	2	(S1 (S (NP (NP (NN Spasm)) (, ,) (NP (JJ coronary) (NN dissection)) (, ,) (CC or) (NP (JJ Doc_1395192_174_186_Disease) (NN etiology))) (VP (AUX has) (VP (AUX been) (VP (VBN described)))) (. .)))
1395192	3	(S1 (S (NP (NN Doc_1395192_216_229_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN implicated) (PP (IN in) (NP (NP (JJ several) (JJ previous) (NN case) (NNS reports)) (PP (IN of) (NP (NP (NNP Doc_1395192_286_307_Disease)) (PP (IN in) (NP (DT the) (NN puerperium)))))))))) (. .)))
1395192	4	(S1 (S (NP (NP (PRP$ Our) (NN case)) (PRN (-LRB- -LRB-) (S (VP (VBG including) (NP (DT an) (JJ inadvertent) (NN rechallenge)))) (-RRB- -RRB-))) (VP (VBZ suggests) (NP (PDT such) (DT a) (NN relationship))) (. .)))
1395192	5	(S1 (S (SBAR (IN Although) (S (ADVP (RB generally)) (VP (VBN regarded) (PP (IN as) (`` ``) (ADJP (JJ safe)))))) (, ,) ('' '') (NP (NP (JJ possible) (JJ serious) (JJ cardiac) (NNS effects)) (PP (IN of) (NP (NNP Doc_1395192_480_493_Chemical)))) (VP (MD should) (VP (AUX be) (VP (VBN acknowledged)))) (. .)))
1420650	0	(S1 (S (NP (NN Asterixis)) (VP (VBN induced) (PP (IN by) (NP (JJ Doc_1420650_21_34_Chemical) (NN therapy)))) (. .)))
1420650	1	(S1 (S (NP (EX There)) (VP (AUX are) (NP (NP (ADJP (RB very) (JJ few)) (NNS reports)) (PP (IN about) (NP (NNP Doc_1420650_77_86_Disease)))) (PP (IN as) (NP (NP (DT a) (NN side) (NN effect)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (JJ psychopharmacologic) (NNS agents)))))) (. .)))
1420650	2	(S1 (S (PP (IN In) (NP (DT this) (NN report))) (NP (PRP we)) (VP (VBP present) (NP (NP (CD four) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (JJ different) (JJ psychotropic) (NNS drugs))) (, ,) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NNP Doc_1420650_258_267_Disease)) (VP (AUX was) (VP (VBN triggered) (ADVP (RB either)) (PP (PP (IN by) (S (VP (VBG adding) (NP (NP (NNP Doc_1420650_299_312_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1420650_314_317_Chemical)) (-RRB- -RRB-))) (PP (TO to) (NP (DT a) (NN treatment) (NN regimen)))))) (, ,) (CC or) (PP (IN by) (S (VP (VBG increasing) (NP (PRP$ its) (NN dosage))))))))))))))) (. .)))
1420650	3	(S1 (S (NP (CC Neither) (NP (NN dosage)) (CC nor) (NP (NP (NN serum) (NNS levels)) (PP (IN of) (NP (NNP Doc_1420650_407_410_Chemical))))) (VP (AUX were) (PP (IN in) (NP (DT a) (JJR higher) (NN range)))) (. .)))
1420650	4	(S1 (S (NP (PRP We)) (VP (VBP consider) (S (NP (NNP Doc_1420650_447_456_Disease)) (VP (TO to) (VP (AUX be) (NP (NP (DT an) (ADJP (RB easily) (VBN overlooked)) (NN sign)) (PP (IN of) (NP (NP (NNP Doc_1420650_492_505_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB occur) (ADVP (RB even)) (PP (IN at) (NP (JJ low) (CC or) (JJ moderate) (NN dosage) (NNS levels)))))))))) (, ,) (SBAR (IN if) (S (NP (NP (JJ certain) (NNS drugs)) (PP (IN as) (NP (NP (NNP Doc_1420650_582_589_Chemical)) (CC or) (NP (NNP Doc_1420650_593_602_Chemical))))) (VP (AUX are) (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_1420650_632_635_Chemical))))))))))))) (. .)))
1423336	0	(S1 (NP (NP (NNS Pharmacodynamics)) (PP (IN of) (NP (NP (DT the) (JJ Doc_1423336_24_35_Disease) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_1423336_46_54_Chemical)) (PP (IN in) (NP (NNP Doc_1423336_58_70_Disease) (NNS patients))))))) (. .)))
1423336	1	(S1 (S (NP (NP (NN Blood) (NN pressure) (NNS effects)) (PP (IN of) (NP (NNP i.v.) (NNP Doc_1423336_112_120_Chemical)))) (VP (AUX were) (VP (VBN examined) (PP (IN in) (NP (NP (JJ Doc_1423336_138_150_Disease) (NNS patients)) (PP (IN with) (NP (NP (JJ stable) (CC and) (JJ fluctuating) (NNS responses)) (PP (TO to) (NP (NNP Doc_1423336_201_209_Chemical))))))))) (. .)))
1423336	2	(S1 (S (NP (NP (DT The) (NN magnitude)) (PP (IN of) (NP (NP (DT the) (JJ Doc_1423336_232_243_Disease) (NN effect)) (PP (IN of) (NP (NNP Doc_1423336_254_262_Chemical)))))) (VP (VP (AUX was) (ADJP (NN concentration) (JJ dependent))) (CC and) (VP (AUX was) (ADJP (JJ fit) (PP (TO to) (NP (NP (DT an) (JJ Emax) (NN model)) (PP (IN in) (NP (JJ fluctuating) (NNS responders)))))))) (. .)))
1423336	3	(S1 (S (NP (JJ Stable) (NNS responders)) (VP (VBD demonstrated) (NP (DT a) (JJ small) (NN Doc_1423336_386_397_Disease) (NN response))) (. .)))
1423336	4	(S1 (S (S (NP (JJ Baseline) (NN blood) (NNS pressures)) (VP (AUX were) (ADJP (JJR higher)) (PP (IN in) (NP (JJ fluctuating) (NNS patients))))) (: ;) (S (NP (DT a) (JJR higher) (NN baseline) (NN blood) (NN pressure)) (VP (VBD correlated) (PP (IN with) (NP (JJR greater) (NNP Doc_1423336_527_538_Disease) (NNS effects))))) (. .)))
1423336	5	(S1 (S (NP (NP (JJ Antiparkinsonian) (NNS effects)) (PP (IN of) (NP (NNP Doc_1423336_576_584_Chemical)))) (ADVP (RB temporally)) (VP (VBD correlated) (PP (IN with) (NP (NN blood) (NN pressure) (NNS changes)))) (. .)))
1423336	6	(S1 (S (NP (NP (NNP Doc_1423336_636_649_Chemical)) (, ,) (NP (DT a) (JJ large) (JJ neutral) (NN Doc_1423336_667_677_Chemical) (PRN (-LRB- -LRB-) (NNP Doc_1423336_679_683_Chemical) (-RRB- -RRB-)) (S (VP (VBG competing) (PP (IN with) (NP (NNP Doc_1423336_700_708_Chemical))) (PP (IN for) (NP (NN transport))) (PP (IN across) (NP (DT the) (JJ blood-brain) (NN barrier)))))) (, ,)) (VP (VBD reduced) (NP (NP (DT the) (JJ Doc_1423336_767_778_Disease) (CC and) (JJ antiparkinsonian) (NNS effects)) (PP (IN of) (NP (NNP Doc_1423336_811_819_Chemical))))) (. .)))
1423336	7	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NNP Doc_1423336_838_846_Chemical)) (VP (AUX has) (NP (NP (DT a) (JJ central) (NN Doc_1423336_861_872_Disease) (NN action)) (SBAR (WHNP (WDT that)) (S (VP (VBZ parallels) (NP (NP (DT the) (NN motor) (NNS effects)) (PP (IN in) (NP (VBG fluctuating) (NNS patients)))))))))))) (. .)))
1423336	8	(S1 (S (NP (DT The) (NNP Doc_1423336_942_953_Disease) (NN effect)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (JJR higher) (NN baseline) (NN blood) (NN pressure)) (SBAR (S (NP (PRP we)) (VP (VBD observed) (PP (IN in) (NP (NP (JJ fluctuating) (NNS patients)) (ADJP (JJ relative) (PP (TO to) (NP (JJ stable) (NNS patients)))))))))))))))) (. .)))
1424076	0	(S1 (NP (NP (NN Doc_1424076_0_59_Disease)) (PP (IN after) (NP (JJ infusional) (NNP Doc_1424076_77_88_Chemical))) (. .)))
1424076	1	(S1 (S (NP (NP (DT A) (JJ 77-year-old) (NN woman)) (PP (IN with) (NP (JJ refractory) (JJ multiple) (NN Doc_1424076_135_142_Disease)))) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NP (DT a) (JJ 4-day) (JJ continuous) (JJ intravenous) (NN infusion)) (PP (IN of) (NP (NP (NNP Doc_1424076_203_214_Chemical)) (CC and) (NP (NNP Doc_1424076_219_230_Chemical))))) (CC and) (NP (NP (CD 4) (NNS days)) (PP (IN of) (NP (JJ oral) (NNP Doc_1424076_250_263_Chemical)))))))) (. .)))
1424076	2	(S1 (S (PP (NP (CD Nine) (NNS days)) (IN after) (NP (PRP$ her) (JJ second) (NN cycle))) (NP (PRP she)) (VP (VBD presented) (PP (IN with) (NP (NP (NP (NN lethargy)) (CC and) (NP (NN Doc_1424076_330_338_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_1424076_355_367_Disease))))))) (. .)))
1424076	3	(S1 (S (NP (NN Evaluation)) (VP (VBD revealed) (NP (NP (DT the) (NNP Doc_1424076_393_452_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN attributed) (PP (TO to) (NP (DT the) (JJ Doc_1424076_482_493_Chemical) (NN infusion))))))))) (. .)))
1424076	4	(S1 (S (SBAR (IN After) (S (NP (JJ normal) (NN serum) (NN Doc_1424076_523_529_Chemical) (NNS levels)) (VP (VBD returned)))) (, ,) (ADVP (RB further)) (NP (NP (NNP Doc_1424076_555_566_Chemical) (CC and) (NNP Doc_1424076_571_584_Chemical) (NN chemotherapy)) (PP (IN without) (NP (NNP Doc_1424076_606_617_Chemical)))) (VP (AUX did) (RB not) (VP (VB produce) (NP (DT this) (NN complication)))) (. .)))
1449452	0	(S1 (FRAG (NP (NN Doc_1449452_0_13_Disease)) (: :) (S (VP (TO to) (VP (VP (VB digitalise)) (CC or) (RB not)))) (. ?)))
1449452	1	(S1 (FRAG (NP (DT The) (NN view)) (ADVP (IN against)) (. .)))
1449452	2	(S1 (S (PP (IN Despite) (NP (JJ extensive) (JJ clinical) (NN experience))) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNP Doc_1449452_105_112_Chemical)))) (VP (AUX is) (ADVP (RB still)) (RB not) (VP (ADVP (RB well)) (VBN defined))) (. .)))
1449452	3	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_1449452_157_176_Disease))))) (NP (NNP Doc_1449452_177_184_Chemical)) (VP (AUX is) (ADJP (JJ beneficial) (PP (IN for) (NP (JJ ventricular) (NN rate) (NN control))))) (. .)))
1449452	4	(S1 (S (PP (IN For) (NP (NP (NNS patients)) (PP (IN in) (NP (NP (JJ sinus) (NN rhythm)) (CC and) (NP (NNP Doc_1449452_262_275_Disease)))))) (NP (DT the) (NN situation)) (VP (AUX is) (ADJP (RBR less) (JJ clear))) (. .)))
1449452	5	(S1 (S (S (NP (NN Doc_1449452_305_312_Chemical)) (VP (AUX has) (NP (DT a) (JJ narrow) (JJ therapeutic)))) (: :) (S (NP (NP (JJ toxic) (NN ratio)) (CC and) (NP (NNS concentrations))) (VP (AUX are) (VP (VBN affected) (PP (IN by) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NNS drugs)))))))) (. .)))
1449452	6	(S1 (S (ADVP (RB Also)) (, ,) (NP (NNP Doc_1449452_410_417_Chemical)) (VP (AUX has) (NP (NP (JJ undesirable) (NNS effects)) (PP (JJ such) (IN as) (S (VP (VP (VBG increasing) (NP (NP (JJ peripheral) (NN resistance)) (CC and) (NP (JJ myocardial) (NNS demands)))) (, ,) (CC and) (VP (VBG causing) (NP (NN Doc_1449452_519_530_Disease)))))))) (. .)))
1449452	7	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NP (DT a) (NN paucity)) (PP (IN of) (NP (NP (NNS data)) (PP (IN from) (NP (JJ well-designed) (NNS trials))))))) (. .)))
1449452	8	(S1 (S (S (NP (NP (DT The) (NNS trials)) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (ADJP (JJ available)))))) (VP (AUX are) (ADJP (RB generally) (JJ small) (PP (IN with) (NP (NP (NNS limitations)) (PP (IN in) (NP (NN design)))))))) (CC and) (S (NP (DT these)) (VP (VBP show) (NP (NN variation)) (PP (IN in) (NP (JJ patient) (NN benefit))))) (. .)))
1449452	9	(S1 (S (NP (ADJP (RBR More) (JJ convincing)) (NN evidence)) (VP (AUX is) (VP (VBN required) (S (VP (VBG showing) (SBAR (IN that) (S (NP (NNP Doc_1449452_758_765_Chemical)) (VP (VBZ improves) (NP (NP (NNS symptoms)) (CC or) (NP (NN exercise) (NN capacity)))))))))) (. .)))
1449452	10	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (DT no) (NN trial)) (VP (AUX has) (VP (AUX had) (NP (JJ sufficient) (NN power)) (S (VP (TO to) (VP (VB evaluate) (NP (NN mortality))))))) (. .)))
1449452	11	(S1 (S (S (NP (NP (VBN Pooled) (NN analysis)) (PP (IN of) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ other) (JJ inotropic) (NNS drugs)))))) (VP (VBZ shows) (NP (DT an) (JJ excess) (NN mortality)))) (CC and) (S (NP (EX there)) (VP (AUX is) (NP (NP (DT a) (NN possibility)) (SBAR (WHNP (IN that)) (S (NP (NNP Doc_1449452_990_997_Chemical)) (VP (MD may) (VP (VB increase) (NP (NN mortality)) (PP (IN after) (NP (NP (NNP Doc_1449452_1027_1048_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1449452_1050_1052_Disease)) (-RRB- -RRB-))))))))))) (. .)))
1449452	12	(S1 (S (NP (NN Doc_1449452_1055_1101_Chemical)) (VP (MD should) (VP (AUX be) (VP (VBN used) (ADVP (RB first)) (SBAR (IN as) (S (NP (PRP they)) (VP (VP (AUX are) (ADJP (JJR safer))) (, ,) (VP (AUX do) (RB not) (VP (VP (VB require) (NP (NN blood) (NN level) (NN monitoring))) (, ,) (VP (VB modify) (NP (NP (NN progression)) (PP (IN of) (NP (NN disease))))) (, ,) (VP (VB relieve) (NP (NNS symptoms))) (, ,) (VP (VB improve) (NP (NN exercise) (NN tolerance))) (CC and) (VP (VB reduce) (NP (NN mortality))))))))))) (. .)))
1449452	13	(S1 (S (NP (NN Caution)) (VP (MD should) (VP (AUX be) (VP (VBN exercised) (PP (IN in) (S (VP (VBG using) (NP (NNP Doc_1449452_1316_1323_Chemical)) (SBAR (IN until) (S (NP (JJ large) (NN mortality) (NNS trials)) (VP (AUX are) (VP (VBN completed) (S (VP (VBG showing) (NP (DT either) (NN benefit) (CC or) (NN harm)))))))))))))) (. .)))
1449452	14	(S1 (S (PP (IN Until) (NP (RB then))) (NP (NNP Doc_1449452_1410_1417_Chemical)) (VP (MD should) (VP (AUX be) (VP (VBN considered) (S (NP (DT a) (JJ third-line) (NN therapy)))))) (. .)))
1451544	0	(S1 (NP (NP (JJ Doc_1451544_0_10_Chemical) (NN treatment)) (PP (IN for) (NP (NNP Doc_1451544_25_37_Disease))) (PP (IN in) (NP (NP (JJ general) (NN practice)) (PP (IN in) (NP (NNP Hong) (NNP Kong))))) (. .)))
1451544	1	(S1 (S (NP (NP (DT A) (JJ 6-week) (JJ open) (NN study)) (PP (IN of) (NP (NP (DT the) (NN introduction)) (PP (IN of) (NP (JJ Doc_1451544_115_125_Chemical) (NN treatment)))))) (VP (AUX was) (VP (VBN conducted) (PP (IN in) (NP (NP (JJ general) (NN practice)) (PP (IN in) (NP (NNP Hong) (NNP Kong.))))) (NP (CD 303) (JJ Chinese) (NNS patients)) (SBAR (IN with) (S (NP (ADJP (JJ mild) (TO to) (JJ moderate)) (NNP Doc_1451544_227_239_Disease)) (VP (VBD entered) (NP (DT the) (NN study))))))) (. .)))
1451544	2	(S1 (S (NP (NN Side) (NNS effects)) (VP (VP (AUX were) (VP (VBN reported) (PP (IN in) (NP (NP (CD 21) (NN %)) (PP (IN of) (NP (NNS patients))))))) (CC and) (VP (VBD caused) (NP (NP (NN withdrawal)) (PP (IN from) (NP (DT the) (NN study)))) (PP (IN in) (NP (CD 3) (NNS patients))))) (. .)))
1451544	3	(S1 (S (S (NP (DT The) (JJ main) (NNS side-effects)) (VP (AUX were) (ADJP (NNP Doc_1451544_384_392_Disease) (, ,) (NNP Doc_1451544_394_403_Disease) (, ,) (JJ palpitation) (CC and) (JJ flushing)))) (CC and) (S (NP (DT these)) (VP (AUX were) (RB not) (ADJP (ADJP (RBR more) (JJ frequent)) (SBAR (IN than) (S (VP (VBN reported) (PP (IN in) (NP (NP (JJ other) (NNS studies)) (PP (PP (IN with) (NP (NNP Doc_1451544_499_509_Chemical))) (CC or) (PP (IN with) (NP (NN placebo)))))))))))) (. .)))
1451544	4	(S1 (S (NP (JJ Supine) (NN blood) (NN pressure)) (VP (AUX was) (VP (VBN reduced) (PP (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-)) (IN from) (NP (CD 170) (JJ +/-) (CD 20/102) (NNS +/-))) (NP (NP (QP (CD 6) (NN mmHg) (TO to) (CD 153) (CD +/-) (NN 19/92) (CD +/-) (CD 8))) (, ,) (NP (NP (CD 147) (NN +/-)) (ADVP (NP (CD 18/88) (ADJP (JJ +/-) (NP (CD 7) (CC and) (CD 144))) (JJ +/-) (JJ 14/87) (JJ +/-) (ADJP (CD 6) (NN mmHg) (PP (IN at) (NP (CD 2) (, ,) (CD 4) (CC and) (CD 6)))) (NNS weeks)) (RB respectively)) (PP (IN in) (NP (JJ evaluable) (NNS patients))))))) (. .)))
1451544	5	(S1 (S (S (NP (NN Doc_1451544_740_758_Disease)) (VP (VBD occurred) (PP (IN in) (S (VP (VBG standing) (NP (NN blood) (NN pressure))))))) (CC and) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NNP Doc_1451544_824_844_Disease)))))) (. .)))
1451544	6	(S1 (S (NP (NP (NN Normalization) (CC and) (NN responder) (NNS rates)) (PP (IN at) (NP (CD 6) (NNS weeks)))) (VP (AUX were) (NP (NP (CD 86) (NN %)) (CC and) (NP (CD 69) (NN %))) (ADVP (RB respectively))) (. .)))
1451544	7	(S1 (S (S (NP (NN Dosage)) (VP (AUX was) (VP (VBN increased) (PP (IN from) (NP (NP (QP (CD 2.5) (CD mg) (NN b.d.) (TO to) (CD 5) (NN mg))) (VP (VBN b.d.) (PP (IN at) (NP (CD 4) (NNS weeks))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ diastolic) (NN blood) (NN pressure)) (NP (QP (JJR greater) (IN than) (CD 90)) (NN mmHg)))))))))))) (CC and) (S (NP (PRP$ their) (JJ further) (NN response)) (VP (AUX was) (ADJP (ADJP (JJR greater)) (PP (IN than) (NP (NP (DT those)) (VP (VBG remaining) (PP (IN on) (NP (QP (CD 2.5) (CD mg)) (NNS b.d.)))))))))))
14616590	0	(S1 (NP (NP (NP (JJ Pharmacological) (NNS characteristics)) (CC and) (NP (JJ side) (NNS effects))) (PP (IN of) (NP (NP (DT a) (JJ new) (JJ Doc_14616590_58_65_Disease) (NN formulation)) (PP (IN of) (NP (NNP Doc_14616590_81_89_Chemical))) (PP (IN without) (NP (JJ soyabean) (NN oil))))) (. .)))
14616590	1	(S1 (S (NP (PRP We)) (VP (VBD compared) (NP (NP (DT the) (NNS pharmacokinetics) (, ,) (NNS pharmacodynamics) (CC and) (NN safety) (NN profile)) (PP (IN of) (NP (NP (DT a) (JJ new) (NN Doc_14616590_191_198_Disease) (NN formulation)) (PP (IN of) (NP (NP (NNP Doc_14616590_214_222_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD AM149) (CD 1)) (NN %)) (-RRB- -RRB-)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX does) (RB not) (VP (VB contain) (NP (JJ soyabean) (NN oil)))))) (, ,)))))) (PP (IN with) (NP (NP (DT a) (JJ standard) (NN formulation)) (PP (IN of) (NP (NP (NNP Doc_14616590_303_311_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Disoprivan) (CD 1) (NN %)) (-RRB- -RRB-))))))) (. .)))
14616590	2	(S1 (S (PP (IN In) (NP (DT a) (JJ randomised) (, ,) (JJ double-blind) (, ,) (JJ cross-over) (NN study))) (, ,) (NP (CD 30) (JJ healthy) (NNS volunteers)) (VP (VBD received) (NP (NP (DT a) (JJ single) (JJ intravenous) (NN bolus) (NN injection)) (PP (IN of) (NP (CD 2.5) (JJ mg.kg-1) (NN Doc_14616590_461_469_Chemical))))) (. .)))
14616590	3	(S1 (S (NP (NN Plasma) (NN Doc_14616590_478_486_Chemical) (NNS levels)) (VP (AUX were) (VP (VP (VBN measured) (PP (IN for) (NP (CD 48) (NNP h) (JJ following) (NN drug) (NN administration)))) (CC and) (VP (VBN evaluated) (PP (VBG according) (PP (TO to) (NP (DT a) (JJ three-compartment) (NN model))))))) (. .)))
14616590	4	(S1 (S (NP (NP (DT The) (JJ pharmacodynamic) (NNS parameters)) (VP (VBN assessed))) (VP (VBD included) (NP (NP (NP (NN induction)) (CC and) (NP (NN emergence) (NNS times))) (, ,) (NP (NN respiratory) (CC and) (JJ cardiovascular) (NNS effects)) (, ,) (CC and) (NP (NNP Doc_14616590_725_729_Disease))) (PP (IN on) (NP (NN injection)))) (. .)))
14616590	5	(S1 (S (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN monitored) (PP (IN for) (NP (NP (JJ side) (NNS effects)) (PP (IN over) (NP (CD 48) (NNP h.) (NNP Owing))))) (PP (TO to) (NP (NP (DT a) (JJ high) (NN incidence)) (PP (IN of) (NP (NNP Doc_14616590_825_841_Disease)))))))) (, ,) (S (NP (DT the) (NN study)) (VP (AUX was) (VP (VBN terminated) (ADVP (RB prematurely))))) (CC and) (S (NP (NP (RB only) (DT the) (NN data)) (PP (IN of) (NP (NP (DT the) (CD two) (JJ parallel) (NN treatment) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NP (CD 15) (NNS patients)) (PP (IN in) (NP (DT each) (NN group)))) (-RRB- -RRB-))))) (VP (AUX were) (VP (VBN analysed)))) (. .)))
14616590	6	(S1 (S (NP (NN Plasma) (NNS concentrations)) (VP (AUX did) (RB not) (VP (VB differ) (ADVP (RB significantly)) (PP (IN between) (NP (DT the) (CD two) (NNS formulations))))) (. .)))
14616590	7	(S1 (S (NP (NP (NP (NN Anaesthesia) (NN induction)) (CC and) (NP (NN emergence) (NNS times))) (, ,) (NP (NN respiratory)) (CC and) (NP (JJ cardiovascular) (NNS variables))) (VP (VBD showed) (NP (NP (DT no) (JJ significant) (NNS differences)) (PP (IN between) (NP (DT the) (CD two) (NN treatment) (NNS groups))))) (. .)))
14616590	8	(S1 (S (NP (NP (NN Doc_14616590_1211_1215_Disease)) (PP (IN on) (NP (NP (NP (NN injection)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 80) (CC vs.) (CD 20) (NN %))) (, ,) (NP (NNP p) (NNP <) (CD 0.01))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_14616590_1256_1272_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 93.3)) (CC vs.) (NP (CD 6.6) (NN %))) (, ,) (NP (NNP p) (QP (CD <) (CD 0.001))) (-RRB- -RRB-)))))) (VP (VBD occurred) (ADVP (RBR more) (RB frequently)) (PP (IN with) (NP (NNP Doc_14616590_1330_1335_Chemical))) (PP (IN than) (PP (IN with) (NP (NNP Doc_14616590_1346_1356_Chemical))))) (. .)))
14616590	9	(S1 (S (SBAR (IN Although) (S (NP (DT both) (NNS formulations)) (VP (AUX had) (NP (JJ similar) (JJ pharmacokinetic) (CC and) (JJ pharmacodynamic) (NNS profiles)) (NP (DT the) (JJ new) (NN formulation))))) (VP (AUX is) (RB not) (ADJP (JJ suitable) (PP (IN for) (NP (NP (JJ clinical) (NN use)) (ADJP (JJ due) (PP (TO to) (NP (NP (DT the) (JJ high) (NN incidence)) (PP (IN of) (NP (NNP Doc_14616590_1524_1540_Disease))) (VP (VBN produced))))))))) (. .)))
146391	0	(S1 (FRAG (NP (NP (JJ Pure) (NNP Doc_146391_5_21_Disease)) (, ,) (NP (JJ toxic) (NNP Doc_146391_29_39_Disease)) (CC and) (NP (NNP Doc_146391_44_59_Disease))) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBG taking) (NP (NNP Doc_146391_80_97_Chemical))))) (. .)))
146391	1	(S1 (S (NP (NP (DT A) (NN patient)) (VP (VBG taking) (NP (NNP Doc_146391_116_133_Chemical)) (PP (IN for) (NP (CD 3) (NNS weeks))))) (VP (VBD developed) (NP (NP (DT a) (JJ generalized) (NN Doc_146391_170_179_Disease)) (, ,) (NP (NNP Doc_146391_181_196_Disease)) (CC and) (NP (JJ pure) (NN Doc_146391_206_222_Disease)))) (. .)))
146391	2	(S1 (S (PP (IN After) (NP (NP (NN withdrawal)) (PP (IN of) (NP (DT the) (NN pharmacon))))) (NP (DT all) (NNS symptoms)) (VP (VBD disappeared) (ADVP (RB spontaneously))) (. .)))
146391	3	(S1 (S (NP (NN Doc_146391_298_307_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ well-known) (NN complication)) (PP (IN of) (NP (JJ Doc_146391_340_357_Chemical) (NN treatment)))) (SBAR (IN as) (SINV (VP (AUX is) (ADJP (ADJP (JJ benign)) (CC and) (ADJP (JJ malignant)))) (NP (NNP Doc_146391_395_410_Disease))))) (. .)))
146391	4	(S1 (S (NP (NP (JJ Pure) (NNP Doc_146391_417_433_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_146391_450_467_Chemical) (NN medication))))) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (CD 3) (NNS patients)))))) (. .)))
146391	5	(S1 (S (NP (NP (DT The) (JJ exact) (NN mechanism)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NNP Doc_146391_541_558_Chemical)) (VP (VBZ exerts) (NP (PRP$ its) (JJ toxic) (NNS effects)))))) (VP (AUX is) (RB not) (VP (VBN known))) (. .)))
146391	6	(S1 (S (PP (IN In) (NP (DT this) (NN patient))) (NP (NP (DT the) (NN time) (NN relation)) (PP (IN between) (NP (NP (NP (DT the) (NN ingestion)) (PP (IN of) (NP (NNP Doc_146391_657_674_Chemical)))) (CC and) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (DT the) (NNP Doc_146391_701_710_Disease))))))) (, ,) (NP (NP (NNP Doc_146391_712_727_Disease)) (CC and) (NP (JJ pure) (NNP Doc_146391_737_753_Disease))) (VP (AUX is) (ADJP (RB very) (JJ suggestive) (PP (IN of) (NP (DT a) (JJ direct) (NN connection))))) (. .)))
14748761	0	(S1 (NP (NP (JJ Doc_14748761_0_11_Chemical-related) (NN Doc_14748761_20_34_Disease)) (: :) (NP (NP (DT a) (NN meta-analysis)) (PP (IN of) (NP (JJ randomized) (JJ clinical) (NNS trials)))) (. .)))
14748761	1	(S1 (S (NP (NP (JJ Several) (NNS cases)) (PP (IN of) (NP (NP (JJ cardiac) (JJ adverse) (NNS reactions)) (VP (VBN related) (PP (TO to) (NP (NP (NNP Doc_14748761_137_148_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP VNR)) (-RRB- -RRB-)))))))) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (DT the) (NN literature)))))) (. .)))
14748761	2	(S1 (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB quantify) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (DT these) (NNP Doc_14748761_237_251_Disease)))))))) (, ,) (NP (PRP we)) (VP (VBD performed) (NP (NP (DT a) (NN meta-analysis)) (PP (IN of) (NP (JJ clinical) (NNS trials)))) (S (VP (VBG comparing) (NP (NN VNR)) (PP (IN with) (NP (NP (JJ other) (JJ chemotherapeutic) (NNS agents)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_14748761_370_390_Disease)))))))))) (. .)))
14748761	3	(S1 (S (NP (NP (JJ Randomized) (JJ clinical) (NNS trials)) (VP (VBG comparing) (NP (NNS VNR)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_14748761_470_476_Disease))))))))) (VP (AUX were) (VP (VBD searched) (PP (IN in) (NP (NP (NNP Medline)) (, ,) (NP (NNP Embase)) (, ,) (NP (JJ Evidence-based) (NNP Medicine) (NNS Reviews) (NNS databases)) (CC and) (NP (DT the) (NNP Cochrane) (NN library)))) (PP (IN from) (NP (NP (CD 1987)) (PP (TO to) (NP (CD 2002))))))) (. .)))
14748761	4	(S1 (S (NP (NP (NNS Outcomes)) (PP (IN of) (NP (NN interest)))) (VP (AUX were) (NP (NP (NP (JJ severe) (NN Doc_14748761_630_644_Disease)) (, ,) (NP (JJ toxic) (NN Doc_14748761_652_658_Disease)) (CC and) (NP (JJ cardiac) (JJ event-related) (NN Doc_14748761_685_691_Disease))) (VP (VBN reported) (PP (IN in) (NP (DT each) (NN publication)))))) (. .)))
14748761	5	(S1 (S (NP (PRP We)) (VP (VBD found) (NP (CD 19) (NNS trials)) (, ,) (PP (VBG involving) (NP (NP (NP (CD 2441) (NNS patients)) (VP (VBN treated) (PP (IN by) (NP (NN VNR))))) (CC and) (NP (CD 2050) (NN control) (NNS patients))))) (. .)))
14748761	6	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_14748761_825_839_Disease))) (PP (IN with) (NP (NNP VNR)))) (VP (AUX was) (NP (NP (NP (NP (CD 1.19) (NN %)) (ADJP (CD -LSB-95) (NN %)) (NN confidence) (NN interval)) (PRN (-LRB- -LRB-) (NP (NNP CI)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD 0.75)) (: ;) (NP (CD 1.67)) (-RRB- -RRB-)) (NP (NN -RSB-)))) (. .)))
14748761	7	(S1 (S (NP (EX There)) (VP (VP (AUX was) (NP (NP (DT no) (NN difference)) (PP (IN in) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_14748761_943_957_Disease))))) (PP (IN between) (NP (NP (NNP VNR)) (CC and) (NP (JJ other) (NNS drugs))))) (NP (JJ -LSB-odds) (NN ratio))) (: :) (NP (NP (CD 0.92)) (, ,) (NP (ADJP (CD 95) (NN %)) (NN CI) (PRN (-LRB- -LRB-) (NP (NP (CD 0.54)) (: ;) (NP (CD 1.55))) (-RRB- -RRB-)) (NNS -RSB-)))) (. .)))
14748761	8	(S1 (S (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (NNP VNR) (NNP Doc_14748761_1043_1057_Disease)))) (VP (AUX was) (ADJP (JJ similar) (PP (TO to) (NP (NP (NP (NNP Doc_14748761_1073_1082_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP VDS)) (-RRB- -RRB-))) (CC and) (NP (JJ other) (JJ Doc_14748761_1099_1110_Disease) (NNS drugs) (JJ -LSB-Doc_14748761_1118_1130_Chemical))))))) (, ,) (NP (NP (NNP Doc_14748761_1132_1146_Chemical) (, ,) (NNP Doc_14748761_1148_1159_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_14748761_1161_1164_Chemical)) (-RRB- -RRB-))) (VP (VBZ em) (NP (NN leader) (NNS -RSB-))) (. .)))
14748761	9	(S1 (S (SBAR (RB Even) (IN if) (S (NP (PRP it)) (VP (AUX did) (RB not) (VP (VB reach) (NP (JJ statistical) (NN significance)) (PP (IN because) (IN of) (NP (NP (DT a) (JJ few) (NN number)) (PP (IN of) (NP (NNS cases))))))))) (, ,) (NP (DT the) (NN risk)) (VP (VP (AUX was) (ADJP (JJR lower)) (PP (IN in) (NP (NP (NNS trials)) (PP (VBG excluding) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ cardiac) (NN history)))))))) (, ,) (CC and) (VP (VBD seemed) (S (VP (TO to) (VP (AUX be) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS trials)) (PP (VBG including) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ pre-existing) (NNP Doc_14748761_1404_1420_Disease)))))))))))) (. .)))
14748761	10	(S1 (NP (NP (JJ Doc_14748761_1422_1433_Chemical-related) (JJ Doc_14748761_1442_1456_Disease) (NN concern)) (PP (IN about) (NP (NP (CD 1) (NN %)) (PP (IN of) (NP (NP (VBN treated) (NNS patients)) (PP (IN in) (NP (JJ clinical) (NNS trials))))))) (. .)))
14748761	11	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN risk)) (VP (VBN associated) (PP (IN with) (NP (NN VNR))))) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NP (JJ other) (JJ chemotherapeutic) (NNS agents)) (PP (IN in) (NP (DT the) (JJ same) (NNS indications)))))))))))) (. .)))
15018178	0	(S1 (S (NP (NP (NNP MRI) (NNS findings)) (PP (IN of) (NP (NN hypoxic)))) (VP (VBP Doc_15018178_24_49_Disease) (PP (IN in) (NP (NP (DT a) (NN child)) (PP (IN with) (NP (NNP Doc_15018178_66_82_Disease) (NN crisis)))))) (. .)))
15018178	1	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (JJ magnetic) (NN resonance) (NN imaging) (NNS findings)) (PP (IN of) (NP (NP (DT a) (JJ 5-year-old) (NN girl)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (DT a) (ADJP (RB rapidly) (VBG installing)) (NN Doc_15018178_188_204_Disease) (NN crisis)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_15018178_223_235_Chemical-Doc_15018178_236_252_Chemical))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (NNP Doc_15018178_267_282_Disease)) (VP (VBG leading) (PP (TO to) (NP (JJ permanent) (NN damage))))))))))))))) (. .)))
15018178	2	(S1 (S (NP (JJ Magnetic) (NN Resonance) (NN imaging)) (VP (VBD revealed) (NP (NNP Doc_15018178_348_373_Disease)) (PP (IN in) (NP (NNP Doc_15018178_377_398_Disease))) (PP (IN in) (NP (DT both) (JJ cerebral) (NNS hemispheres))) (, ,) (NP (NP (JJ ischemic) (NNS changes)) (PP (PP (IN in) (NP (NP (JJ subcortical) (JJ white) (NN matter)) (PP (IN of) (NP (JJ left) (JJ cerebral) (NN hemisphere))))) (, ,) (CC and) (PP (IN in) (NP (DT the) (JJ left) (NN putamen)))))) (. .)))
15018178	3	(S1 (S (SBAR (IN Although) (S (NP (NNP Doc_15018178_537_562_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ classic) (NN entity)) (PP (IN in) (NP (NN adulthood))) (ADJP (JJ related) (PP (TO to) (NP (NP (NNS conditions)) (PP (IN of) (NP (NN energy) (NNS depletions)))))))))) (, ,) (NP (EX there)) (VP (AUX are) (NP (NP (JJ few) (NNS reports)) (ADJP (JJ available) (PP (IN in) (NP (NNS children)))))) (. .)))
15018178	4	(S1 (S (NP (NP (DT A) (JJ wide) (NN review)) (PP (IN of) (NP (DT the) (NN literature)))) (VP (AUX is) (ADVP (RB also)) (VP (VBN presented))) (. .)))
15094729	0	(S1 (S (NP (NP (DT The) (JJ natural) (NN history)) (PP (IN of) (NP (NP (NNP Doc_15094729_23_33_Chemical) (NNP associated) (NNP Doc_15094729_45_65_Disease)) (PP (IN in) (NP (NNS patients)))))) (VP (VBD electing) (S (VP (TO to) (VP (VB continue) (NP (PRP$ their) (NN medication)))))) (. .)))
15094729	1	(S1 (FRAG (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (JJ natural) (NN history)) (PP (IN of) (NP (NNP Doc_15094729_162_182_Disease)))) (PP (IN in) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NNS patients))) (VP (VBN known) (S (VP (TO to) (VP (AUX have) (NP (NP (JJ Doc_15094729_220_230_Chemical-associated) (NNS changes)) (SBAR (WHNP (WP who)) (S (VP (VBD elected) (S (VP (TO to) (VP (VB continue) (NP (DT the) (NN medication)) (PP (IN because) (IN of) (NP (JJ good) (NN Doc_15094729_305_312_Disease) (NN control))))))))))))))))))) (. .)))
15094729	2	(S1 (S (NP (NP (DT All) (NNS patients)) (VP (VBG taking) (NP (NP (NNP Doc_15094729_351_361_Chemical)) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (JJ other) (JJ antiepileptic) (NNS drugs)) (PP (IN for) (NP (NP (QP (IN at) (JJS least) (CD 5)) (NNS years)) (PRN (-LRB- -LRB-) (S (VP (VB range) (NP (CD 5-12) (NNS years)))) (-RRB- -RRB-)))))))))))) (VP (AUX were) (VP (VBN entered) (PP (IN into) (NP (DT a) (JJ visual) (NN surveillance) (NN programme))))) (. .)))
15094729	3	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN followed) (PRT (RP up)) (PP (IN at) (NP (NP (JJ 6-monthly) (NNS intervals)) (PP (IN for) (NP (NP (QP (RB not) (JJR less) (IN than) (CD 18)) (NNS months)) (PRN (-LRB- -LRB-) (NP (NP (NN range)) (NP (CD 18-43) (NNS months))) (-RRB- -RRB-)))))))) (. .)))
15094729	4	(S1 (S (PP (IN In) (NP (DT all))) (, ,) (NP (NP (CD 16) (NNS patients)) (PP (IN with) (NP (JJ unequivocal) (NNS defects)))) (VP (VBD continued) (NP (DT the) (NN medication))) (. .)))
15094729	5	(S1 (S (S (VP (VBG Following) (NP (NP (ADJP (RB already) (VBN published)) (NN methodology)) (PRN (-LRB- -LRB-) (NP (NP (NNP Eye) (CD 2002)) (: ;) (NP (CD 16)) (: ;) (NP (CD 567-571))) (-RRB- -RRB-)) (NP (NP (JJ monocular) (NNP Doc_15094729_751_770_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15094729_772_776_Disease)) (-RRB- -RRB-)))) (PP (TO to) (NP (DT the) (NNP I/4e) (NN isopter))) (PP (IN on) (NP (NNP Goldmann) (NN perimetry))))) (VP (AUX was) (VP (VBN calculated) (PP (IN for) (NP (DT the) (JJ right) (NN eye))) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NP (NN discovery)) (PP (IN of) (NP (NP (DT a) (NN Doc_15094729_883_902_Disease)) (CC and) (ADVP (RB again) (PP (IN after) (NP (QP (RB not) (JJR less) (IN than) (CD 18)) (NNS months)))) (NP (NN follow-up)))))))))) (. .)))
15094729	6	(S1 (S (S (NP (NP (JJ Mean) (JJ right) (NN eye) (NN Doc_15094729_978_981_Disease)) (PP (IN at) (NP (NN presentation)))) (VP (AUX was) (NP (NP (CD 36.98) (NNS degrees)) (PRN (-LRB- -LRB-) (NP (NN range) (CD 22.25-51.0)) (-RRB- -RRB-))) (, ,) (PP (VBN compared) (PP (TO to) (NP (NP (CD 38.40) (NNS degrees)) (PRN (-LRB- -LRB-) (NP (NN range) (CD 22.5-49.75)) (-RRB- -RRB-))))) (PP (IN after) (NP (NN follow-up))))) (: ;) (S (NP (NNP P=0.338)) (VP (VBD unpaired) (NP (NN t-test)))) (. .)))
15094729	7	(S1 (S (NP (QP (RB Only) (CD one)) (NN patient)) (VP (VBD demonstrated) (NP (DT a) (NN deterioration)) (PP (IN in) (NP (JJ visual) (NN field))) (PP (IN during) (NP (NP (DT the) (NN study) (NN period)) (CC and) (NP (JJ discontinued) (NN treatment))))) (. .)))
15094729	8	(S1 (S (NP (NP (JJ Established) (NNP Doc_15094729_1261_1281_Disease)) (VP (VBN presumed) (S (VP (TO to) (VP (AUX be) (ADVP (RB due) (PP (TO to) (NP (JJ Doc_15094729_1304_1314_Chemical) (NN therapy))))))))) (VP (AUX did) (RB not) (ADVP (RB usually)) (VP (VB progress) (PP (IN in) (NP (NP (NN spite)) (PP (IN of) (NP (NP (JJ continuing) (NN use)) (PP (IN of) (NP (DT the) (NN medication))))))))) (. .)))
15094729	9	(S1 (S (NP (DT These) (NNS data)) (VP (VBP give) (NP (NN support)) (PP (TO to) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NNP Doc_15094729_1461_1471_Chemical-associated) (NNP Doc_15094729_1483_1503_Disease)))) (VP (MD may) (VP (AUX be) (NP (NP (DT an) (JJ idiosyncratic) (JJ adverse) (NN drug) (NN reaction)) (CONJP (RB rather) (IN than)) (NP (JJ dose-dependent) (NN Doc_15094729_1577_1585_Disease)))))))))) (. .)))
15096374	0	(S1 (S (NP (NP (NN Induction)) (PP (IN of) (NP (NN rosaceiform)))) (VP (VBP Doc_15096374_25_35_Disease) (PP (IN during) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (JJ facial) (JJ inflammatory) (NNS dermatoses)) (PP (IN with) (NP (JJ Doc_15096374_92_102_Chemical) (NN ointment)))))))) (. .)))
15096374	1	(S1 (S (S (NP (JJ Doc_15096374_125_135_Chemical) (NN ointment)) (VP (AUX is) (ADVP (RB increasingly)) (VP (VBN used) (PP (IN for) (NP (NP (JJ anti-inflammatory) (NN treatment)) (PP (IN of) (NP (NP (JJ sensitive) (NNS areas)) (PP (JJ such) (IN as) (NP (DT the) (NN face)))))))))) (, ,) (CC and) (S (NP (JJ recent) (NNS observations)) (VP (VBP indicate) (SBAR (IN that) (S (NP (DT the) (NN treatment)) (VP (AUX is) (ADJP (JJ effective)) (PP (IN in) (NP (NP (JJ Doc_15096374_303_310_Chemical-aggravated) (NN Doc_15096374_322_329_Disease)) (CC and) (NP (JJ perioral) (NN Doc_15096374_343_353_Disease))))))))) (. .)))
15096374	2	(S1 (S (NP (PRP We)) (VP (VBP report) (PP (IN on) (NP (JJ rosaceiform) (NN Doc_15096374_380_390_Disease))) (PP (IN as) (NP (NP (DT a) (NN complication)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (JJ Doc_15096374_427_437_Chemical) (NN ointment)))))) (. .)))
15096374	3	(S1 (S (NP (NP (CD Six) (JJ adult) (NNS patients)) (PP (IN with) (NP (JJ inflammatory) (NNP Doc_15096374_499_516_Disease)))) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (JJ Doc_15096374_535_545_Chemical) (NN ointment))) (PP (IN because) (IN of) (NP (NP (DT the) (NN ineffectiveness)) (PP (IN of) (NP (JJ standard) (NNS treatments))))))) (. .)))
15096374	4	(S1 (S (PP (IN Within) (NP (NP (QP (CD 2) (TO to) (CD 3)) (NNS weeks)) (PP (IN of) (NP (ADJP (ADJP (RB initially) (JJ effective)) (CC and) (ADJP (JJ well-tolerated))) (NN treatment))))) (, ,) (NP (NP (NP (CD 3) (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_15096374_712_719_Disease)))))) (CC and) (NP (NP (CD 1)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NN acne))))))) (VP (VBD experienced) (NP (NP (JJ sudden) (VBG worsening)) (PP (IN with) (NP (NNP Doc_15096374_783_811_Disease))))) (. .)))
15096374	5	(S1 (S (NP (NN Biopsy)) (VP (VBD revealed) (NP (NP (DT an) (NN abundance)) (PP (IN of) (NP (NNP Demodex) (NNS mites))) (PP (IN in) (NP (NP (CD 2)) (PP (IN of) (NP (DT these) (NNS patients))))))) (. .)))
15096374	6	(S1 (S (PP (IN In) (NP (NP (CD 1) (NN patient)) (PP (IN with) (NP (NNP Doc_15096374_901_914_Disease))))) (, ,) (NP (JJ rosaceiform) (NN periocular) (NN Doc_15096374_939_949_Disease)) (ADVP (RB gradually)) (VP (VBD appeared) (PP (IN after) (NP (NP (CD 3) (NNS weeks)) (PP (IN of) (NP (NN treatment)))))) (. .)))
15096374	7	(S1 (S (PP (IN In) (NP (NP (CD 1) (NN patient)) (PP (IN with) (NP (NNP Doc_15096374_1015_1032_Disease))))) (, ,) (NP (NP (NNP Doc_15096374_1034_1048_Disease)) (CC and) (NP (NN papular) (NN Doc_15096374_1061_1068_Disease))) (ADVP (RB insidiously)) (VP (VBD appeared) (PP (IN after) (NP (NP (CD 5) (NNS months)) (PP (IN of) (NP (NN treatment)))))) (. .)))
15096374	8	(S1 (S (NP (PRP$ Our) (NNS observations)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN spectrum)) (PP (IN of) (NP (JJ rosaceiform) (NN Doc_15096374_1190_1200_Disease))) (PP (IN as) (NP (NP (DT a) (NN complication)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (JJ Doc_15096374_1237_1247_Chemical) (NN ointment)))))) (VP (AUX is) (ADJP (JJ heterogeneous)))))) (. .)))
15096374	9	(S1 (S (NP (NP (DT A) (NN variety)) (PP (IN of) (NP (NP (NNS factors)) (, ,) (PP (JJ such) (IN as) (NP (NP (NP (JJ vasoactive) (NNS properties)) (PP (IN of) (NP (NP (NNP Doc_15096374_1330_1340_Chemical)) (, ,) (NP (NP (NN proliferation)) (PP (IN of) (NP (NNP Demodex))) (PP (JJ due) (TO to) (NP (JJ local) (NN immunosuppression)))) (, ,)))) (CC and) (NP (NP (DT the) (JJ occlusive) (NNS properties)) (PP (IN of) (NP (DT the) (NN ointment)))))) (, ,)))) (VP (MD may) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (DT the) (JJ observed) (NNS phenomena)))))) (. .)))
15096374	10	(S1 (S (NP (JJ Future) (NNS studies)) (VP (AUX are) (VP (VBN needed) (S (VP (TO to) (VP (VB identify) (NP (JJ individual) (NN risk) (NNS factors))))))) (. .)))
1522360	0	(S1 (S (NP (NP (NN Doc_1522360_0_23_Disease)) (CC and) (NP (NN Doc_1522360_28_47_Disease))) (VP (VBG following) (NP (JJ intermittent) (JJ Doc_1522360_71_79_Chemical) (NN therapy))) (. .)))
1522360	1	(S1 (S (NP (NN Doc_1522360_89_102_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ rare) (NN complication)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_1522360_153_161_Chemical)))))))) (. .)))
1522360	2	(S1 (S (NP (NP (NN Doc_1522360_163_186_Disease)) (VP (VBG leading) (PP (TO to) (NP (NNP Doc_1522360_198_217_Disease))) (PP (VBG following) (NP (JJ Doc_1522360_228_236_Chemical) (NN therapy))))) (VP (AUX is) (ADJP (RB extremely) (JJ rare))) (. .)))
1522360	3	(S1 (S (NP (NP (CD Two) (NNS patients)) (PP (IN with) (NP (NNP Doc_1522360_282_289_Disease))) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (NNP Doc_1522360_304_313_Disease)) (CC and) (NP (NNP Doc_1522360_318_337_Disease))) (PP (VBG following) (NP (NNP Doc_1522360_348_356_Chemical))))))) (VP (AUX are) (VP (VBN reported))) (. .)))
15229250	0	(S1 (NP (NP (NN Doc_15229250_0_24_Disease)) (PP (IN in) (NP (NP (DT the) (NNS brains)) (PP (IN of) (NP (NP (JJ human) (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (VBP use) (NP (NNP Doc_15229250_65_80_Chemical))))))))) (. .)))
15229250	1	(S1 (S (NP (PRP We)) (VP (VB visualize) (, ,) (PP (IN for) (NP (DT the) (JJ first) (NN time))) (, ,) (NP (NP (DT the) (NN profile)) (PP (IN of) (NP (JJ structural) (NNS deficits))) (PP (IN in) (NP (NP (DT the) (JJ human) (NN brain)) (VP (VBN associated) (PP (IN with) (NP (JJ chronic) (NNP Doc_15229250_194_209_Chemical) (PRN (-LRB- -LRB-) (NP (NNP MA)) (-RRB- -RRB-)) (NN abuse)))))))) (. .)))
15229250	2	(S1 (S (NP (NP (NNS Studies)) (PP (IN of) (NP (JJ human) (NNS subjects))) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (VBN used) (NP (NNP MA))))))) (ADVP (RB chronically)) (VP (AUX have) (VP (VBN revealed) (NP (NNP Doc_15229250_291_377_Disease)))) (. .)))
15229250	3	(S1 (S (S (VP (VBG Using) (NP (NP (NP (JJ magnetic) (NN resonance) (NN imaging)) (PRN (-LRB- -LRB-) (NP (NNP MRI)) (-RRB- -RRB-))) (CC and) (NP (JJ new) (JJ computational) (NN brain-mapping) (NNS techniques))))) (, ,) (NP (PRP we)) (VP (VP (VBD determined) (NP (NP (DT the) (NN pattern)) (PP (IN of) (NP (NP (JJ structural) (NN brain) (NNS alterations)) (VP (VBN associated) (PP (IN with) (NP (JJ chronic) (NNP Doc_15229250_548_556_Disease)))))) (PP (IN in) (NP (JJ human) (NNS subjects))))) (CC and) (VP (VBD related) (NP (DT these) (NNP Doc_15229250_593_625_Disease)))) (. .)))
15229250	4	(S1 (S (NP (PRP We)) (VP (VBD used) (NP (NP (NP (JJ high-resolution) (UCP (NNP MRI) (CC and) (JJ surface-based)) (JJ computational) (NN image) (NNS analyses)) (SBAR (S (VP (TO to) (VP (NN map) (NP (JJ regional) (NNS abnormalities)) (PP (IN in) (NP (DT the) (JJ cortex) (, ,) (JJ hippocampus) (, ,) (JJ white) (NN matter)))))))) (, ,) (CC and) (NP (NNS ventricles))) (PP (IN in) (NP (NP (NP (CD 22) (JJ human) (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (VBD used) (NP (NNP MA)))))) (CC and) (NP (CD 21) (JJ age-matched) (, ,) (JJ healthy) (NNS controls))))) (. .)))
15229250	5	(S1 (S (NP (JJ Cortical) (NNS maps)) (VP (VBD revealed) (NP (NP (JJ severe) (NN Doc_15229250_890_910_Disease)) (PP (IN in) (NP (NP (DT the) (ADJP (JJ cingulate) (, ,) (JJ limbic) (, ,) (CC and) (JJ paralimbic)) (NNS cortices)) (PP (IN of) (NP (NNP MA) (NNS abusers))))) (PRN (-LRB- -LRB-) (VP (VBG averaging) (NP (CD 11.3) (NN %)) (PP (IN below) (NP (NN control))) (: ;) (NP (QP (CD p) (CD <)) (CD 0.05))) (-RRB- -RRB-)))) (. .)))
15229250	6	(S1 (S (S (PP (IN On) (NP (NN average))) (, ,) (NP (NNP MA) (NNS abusers)) (VP (AUX had) (NP (NP (ADJP (NP (CD 7.8) (NN %)) (JJR smaller)) (JJ hippocampal) (NNS volumes)) (PP (IN than) (NP (NN control) (NNS subjects)))) (PRN (-LRB- -LRB-) (PP (FW p) (NP (NNP <) (CD 0.01))) (: ;)) (S (VP (VBN left))))) (, ,) (NP (NN p)) (VP (SYM =) (NP (NP (NP (CD 0.01)) (PRN (: ;) (ADVP (RB right)) (, ,) (NP (NNP p) (NNP <) (CD 0.05)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ significant) (NN white-matter) (NN Doc_15229250_1173_1184_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 7.0) (NN %)) (: ;) (NP (NNP p) (NNP <) (CD 0.01))) (-RRB- -RRB-))))) (. .)))
15229250	7	(S1 (S (NP (NN Doc_15229250_1203_1223_Disease)) (VP (AUX were) (VP (VBN mapped) (CC and) (VBN correlated) (PP (IN with) (NP (NN memory) (NN performance))) (PP (IN on) (NP (NP (DT a) (JJ word-recall) (NN test)) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.05))) (-RRB- -RRB-)))))) (. .)))
15229250	8	(S1 (S (NP (JJ MRI-based) (NNS maps)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ chronic) (JJ Doc_15229250_1345_1360_Chemical) (NN abuse)) (VP (VBZ causes) (NP (NP (DT a) (JJ selective) (NN pattern)) (PP (IN of) (NP (JJ cerebral) (NN deterioration))) (SBAR (WHNP (WDT that)) (S (VP (VBZ contributes) (PP (TO to) (NP (VBN impaired) (NN memory) (NN performance))))))))))) (. .)))
15229250	9	(S1 (S (NP (NNP MA)) (VP (MD may) (ADVP (RB selectively)) (VP (VB damage) (NP (NP (DT the) (JJ medial) (JJ temporal) (NN lobe)) (CC and) (, ,) (ADJP (JJ consistent) (PP (IN with) (NP (JJ metabolic) (NNS studies)))) (, ,)) (NP (DT the) (JJ cingulate-limbic) (NN cortex)) (, ,) (S (VP (VBG inducing) (NP (NP (NN neuroadaptation)) (, ,) (NP (NN Doc_15229250_1615_1633_Disease)) (, ,) (CC or) (NP (NN cell) (NN death))))))) (. .)))
15229250	10	(S1 (S (NP (JJ Prominent) (NN white-matter) (NN Doc_15229250_1673_1684_Disease)) (VP (MD may) (VP (VB result) (PP (IN from) (NP (NP (JJ altered) (NN myelination)) (CC and) (NP (NP (JJ adaptive) (JJ glial) (NNS changes)) (, ,) (PP (VBG including) (NP (NP (NNP Doc_15229250_1759_1766_Disease)) (ADVP (JJ secondary) (PP (TO to) (NP (NNP Doc_15229250_1780_1795_Disease))))))))))) (. .)))
15229250	11	(S1 (S (NP (DT These) (NN brain) (NNS substrates)) (VP (MD may) (VP (VB help) (S (VP (VBP account) (PP (IN for) (NP (NP (DT the) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_15229250_1857_1865_Disease))))) (, ,) (S (VP (VBG providing) (NP (NP (JJ therapeutic) (NNS targets)) (PP (IN for) (NP (JJ drug-induced) (NN Doc_15229250_1914_1926_Disease)))))))))) (. .)))
15265979	0	(S1 (S (NP (NP (NN Disruption)) (PP (IN of) (NP (JJ hepatic) (NN lipid) (NNS homeostasis))) (PP (IN in) (NP (NNS mice))) (PP (IN after) (NP (JJ Doc_15265979_54_64_Chemical) (NN treatment)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (JJ peroxisome) (JJ proliferator-activated) (NN receptor-alpha) (NN target) (NN gene) (NN activation))))) (. .)))
15265979	1	(S1 (S (NP (NP (NNP Doc_15265979_167_177_Chemical)) (, ,) (NP (NP (DT an) (NN efficacious)) (CC and) (NP (ADJP (RB widely) (VBN used)) (JJ antiarrhythmic) (NN agent))) (, ,)) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (S (VP (TO to) (VP (VB cause) (NP (NN hepatotoxicity)) (PP (IN in) (NP (DT some) (NNS patients))))))))) (. .)))
15265979	2	(S1 (S (S (VP (TO To) (VP (VB gain) (NP (NNP insight)) (PP (IN into) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (DT this) (JJ unwanted) (NN effect)))))))) (, ,) (NP (NNS mice)) (VP (AUX were) (VP (VP (VBN administered) (NP (NP (JJ various) (NNS doses)) (PP (IN of) (NP (NNP Doc_15265979_392_402_Chemical))))) (CC and) (VP (VBN examined) (PP (IN for) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NN hepatic) (NN histology)) (CC and) (NP (NN gene) (NN regulation))))))))) (. .)))
15265979	3	(S1 (S (NP (NN Doc_15265979_470_480_Chemical)) (VP (VBN induced) (NP (NP (NP (NNP Doc_15265979_489_501_Disease)) (, ,) (NP (JJ hepatocyte) (JJ microvesicular) (NN lipid) (NN accumulation)) (, ,)) (CC and) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NN serum) (NNP Doc_15265979_585_598_Chemical) (CC and) (NNP Doc_15265979_603_610_Chemical)))))) (. .)))
15265979	4	(S1 (S (NP (NP (NNP Northern) (NNP blot) (NN analysis)) (PP (IN of) (NP (JJ hepatic) (NNP RNA)))) (VP (VBD revealed) (NP (NP (DT a) (JJ dose-dependent) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NP (NNS genes)) (ADJP (JJ critical) (PP (IN for) (NP (NP (NN Doc_15265979_737_747_Chemical) (NN oxidation)) (, ,) (NP (NN lipoprotein) (NN assembly)) (, ,) (CC and) (NP (NN lipid) (NN transport))))))))))))) (. .)))
15265979	5	(S1 (S (NP (NP (JJ Many)) (PP (IN of) (NP (DT these) (NNS genes)))) (VP (AUX are) (VP (VBN regulated) (PP (IN by) (NP (NP (NP (DT the) (JJ peroxisome) (JJ proliferator-activated) (NN receptor-alpha)) (PRN (-LRB- -LRB-) (NP (NN PPARalpha)) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ ligand-activated) (JJ nuclear) (NN hormone) (NN receptor) (NN transcription) (NN factor)))))) (. .)))
15265979	6	(S1 (S (NP (NP (DT The) (NN absence)) (PP (IN of) (NP (NP (NP (NN induction)) (PP (IN of) (NP (DT these) (NNS genes)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NN Doc_15265979_1022_1034_Disease)) (PP (IN in) (NP (NNP PPARalpha) (NN knockout) (NN -LSB-PPARalpha-/-) (JJ -RSB-) (NNS mice))))))) (VP (VBD indicated) (SBAR (IN that) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_15265979_1107_1117_Chemical)))) (VP (AUX were) (ADJP (JJ dependent) (PP (IN upon) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT a) (JJ functional) (NN PPARalpha) (NN gene)))))))))) (. .)))
15265979	7	(S1 (S (PP (VBN Compared) (PP (TO to) (NP (JJ wild-type) (NNS mice)))) (, ,) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (JJ PPARalpha-/-) (NNS mice)) (PP (IN with) (NP (NNP Doc_15265979_1247_1257_Chemical)))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (VBN increased) (NN rate)) (CC and) (NP (NP (NN extent)) (PP (IN of) (NP (JJ total) (NN body) (NN Doc_15265979_1313_1324_Disease))))))) (. .)))
15265979	8	(S1 (S (NP (NP (DT The) (NN inability)) (PP (IN of) (NP (NNP Doc_15265979_1343_1353_Chemical))) (S (VP (TO to) (VP (ADVP (RB directly)) (VBP activate) (NP (NP (DT either) (NN human) (CC or) (NN mouse) (NN PPARalpha)) (VP (ADVP (RB transiently)) (VBN expressed) (PP (IN in) (NP (JJ human) (NNP HepG2) (NNP Doc_15265979_1444_1452_Disease) (NNS cells))))))))) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_15265979_1489_1499_Chemical))) (PP (IN on) (NP (NP (DT the) (NN function)) (PP (IN of) (NP (DT this) (NN receptor)))))) (VP (AUX were) (ADJP (JJ indirect)))))) (. .)))
15265979	9	(S1 (S (PP (VBN Based) (PP (IN upon) (NP (DT these) (NNS results)))) (, ,) (NP (PRP we)) (VP (VBP conclude) (SBAR (SBAR (IN that) (S (NP (NNP Doc_15265979_1591_1601_Chemical)) (VP (VBZ disrupts) (NP (JJ hepatic) (NN lipid) (NN homeostasis))))) (CC and) (SBAR (IN that) (S (NP (NP (DT the) (VBN increased) (NN expression)) (PP (IN of) (NP (NN PPARalpha) (NN target) (NNS genes)))) (VP (AUX is) (ADJP (JJ secondary) (PP (TO to) (NP (DT this) (JJ toxic) (NN effect))))))))) (. .)))
15265979	10	(S1 (S (NP (DT These) (NNS results)) (VP (VP (VBP provide) (NP (NP (JJ important) (JJ new) (JJ mechanistic) (NN information)) (PP (VBG regarding) (NP (NP (DT the) (JJ hepatotoxic) (NNS effects)) (PP (IN of) (NP (NNP Doc_15265979_1829_1839_Chemical))))))) (CC and) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN PPARalpha)) (VP (VBZ protects) (PP (IN against) (NP (JJ Doc_15265979_1885_1895_Chemical-induced) (NN hepatotoxicity)))))))) (. .)))
15276093	0	(S1 (NP (NP (NP (NN Safety)) (CC and) (NP (NP (NN compliance)) (PP (IN with) (NP (NP (JJ once-daily) (NNP Doc_15276093_38_44_Chemical)) (PP (JJ extended-release/Doc_15276093_62_72_Chemical) (IN as) (NP (JJ initial) (NN therapy))))))) (PP (IN in) (NP (NP (DT the) (NN Impact)) (PP (IN of) (NP (NNP Medical) (NNP Subspecialty))) (PP (IN on) (NP (JJ Patient) (NN Compliance))))) (PP (TO to) (NP (NNP Treatment) (PRN (-LRB- -LRB-) (NP (NN IMPACT)) (-RRB- -RRB-)) (NN study))) (. .)))
15276093	1	(S1 (S (NP (JJ Doc_15276093_181_187_Chemical) (NN extended-release/Doc_15276093_205_215_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ new) (NN combination) (NN product)) (VP (VBN approved) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (JJ primary) (NNP Doc_15276093_279_299_Disease)) (CC and) (NP (JJ mixed) (NNP Doc_15276093_310_322_Disease))))))))) (. .)))
15276093	2	(S1 (S (NP (DT This) (JJ open-labeled) (, ,) (JJ multicenter) (NN study)) (VP (VBN evaluated) (NP (NP (DT the) (NN safety)) (PP (IN of) (NP (JJ bedtime) (JJ Doc_15276093_393_399_Chemical) (NN extended-release/Doc_15276093_417_427_Chemical)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN dosed) (PP (IN as) (NP (NP (JJ initial) (NN therapy) (CC and) (NN patient) (NN compliance)) (PP (TO to) (NP (NN treatment))) (PP (IN in) (NP (JJ various) (JJ clinical) (NN practice) (NNS settings))))))))) (. .)))
15276093	3	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (JJ 4,499) (NNS patients)) (PP (IN with) (NP (NNP Doc_15276093_564_576_Disease))))) (VP (VBG requiring) (NP (NN drug) (NN intervention)))) (VP (AUX was) (VP (VBD enrolled) (PP (IN at) (NP (CD 1,081) (NNS sites))))) (. .)))
15276093	4	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (CD 1) (NN tablet)) (PRN (-LRB- -LRB-) (NP (NP (CD 500) (NN mg)) (PP (IN of) (NP (NP (NNP Doc_15276093_681_687_Chemical) (CD extended-release/20) (NNS mg)) (PP (IN of) (NP (NNP Doc_15276093_714_724_Chemical)))))) (-RRB- -RRB-)))) (ADVP (RB once) (RB nightly)) (PP (IN for) (NP (NP (CD 4) (NNS weeks)) (CC and) (NP (QP (RB then) (CD 2)) (NNS tablets)))) (PP (IN for) (NP (CD 8) (NNS weeks))))) (. .)))
15276093	5	(S1 (S (NP (NNS Patients)) (ADVP (RB also)) (VP (VBD received) (NP (NP (JJ dietary) (NN counseling)) (, ,) (NP (JJ educational) (NNS materials)) (, ,) (CC and) (NP (NNS reminders))) (S (VP (TO to) (VP (VB call) (NP (NP (DT a) (JJ toll-free) (NN number)) (SBAR (WHNP (WDT that)) (S (VP (VBD provided) (NP (JJ further) (NN education)) (PP (IN about) (NP (NNP Doc_15276093_928_940_Disease) (CC and) (NNP Doc_15276093_945_951_Chemical) (NN extended-release/Doc_15276093_969_979_Chemical))))))))))) (. .)))
15276093	6	(S1 (S (NP (JJ Primary) (NN end) (NNS points)) (VP (AUX were) (NP (NP (NN study) (NN compliance)) (, ,) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NN liver) (NNS transaminases)) (PP (TO to) (NP (NN >3)))))) (CC times) (NP (NP (DT the) (JJ upper) (NN limit)) (PP (IN of) (NP (NP (JJ normal)) (, ,) (CC and) (NP (JJ clinical) (NNP Doc_15276093_1108_1116_Disease))))))) (. .)))
15276093	7	(S1 (S (NP (JJ Final) (NN study) (NN status)) (VP (AUX was) (ADJP (JJ available) (PP (IN for) (NP (NP (CD 4,217) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 94) (NN %)) (-RRB- -RRB-)))))) (. .)))
15276093	8	(S1 (S (NP (NP (NN Compliance)) (PP (TO to) (NP (JJ Doc_15276093_1191_1197_Chemical) (NN extended-release/Doc_15276093_1215_1225_Chemical)))) (VP (AUX was) (NP (CD 77) (NN %)) (, ,) (PP (IN with) (NP (NP (JJ 3,245) (NNS patients)) (VP (VBG completing) (NP (DT the) (NN study)))))) (. .)))
15276093	9	(S1 (S (NP (NP (NP (NNS Patients)) (PP (IN in) (NP (DT the) (NN southeast)))) (CC and) (NP (NP (DT those)) (VP (VBD enrolled) (PP (IN by) (NP (NNS endocrinologists)))))) (VP (AUX had) (NP (NP (DT the) (JJS lowest) (NN compliance)) (CC and) (NP (JJS highest) (JJ adverse) (NN event) (NNS rates)))) (. .)))
15276093	10	(S1 (S (NP (NN Flushing)) (VP (AUX was) (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (JJ adverse) (NN event)) (, ,) (VP (VP (VBN reported) (PP (IN by) (NP (NP (CD 18) (NN %)) (PP (IN of) (NP (NNS patients)))))) (CC and) (VP (VBG leading) (PP (TO to) (NP (NN discontinuation))) (PP (IN by) (NP (CD 6) (NN %))))))) (. .)))
15276093	11	(S1 (S (NP (NP (NN Incidence)) (PP (IN of) (NP (VBN increased) (JJ Doc_15276093_1534_1543_Chemical) (NN aminotransferase) (NN and/or) (NNP Doc_15276093_1568_1575_Chemical) (NN aminotransferase) (NN >3) (NNS times)))) (NP (NP (DT the) (JJ upper) (NN limit)) (PP (IN of) (NP (JJ normal)))) (VP (AUX was) (NP (CD <0.3) (NN %))) (. .)))
15276093	12	(S1 (S (S (NP (NP (DT An) (NN increase)) (PP (IN of) (NP (JJ Doc_15276093_1654_1662_Chemical) (NN phosphokinase))) (PP (TO to) (NP (NP (QP (CD >5) (NNS times)) (DT the) (JJ upper) (NN limit)) (PP (IN of) (NP (JJ normal)))))) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 0.24) (NN %)) (PP (IN of) (NP (NNS patients))))))) (, ,) (CC and) (S (NP (NP (DT no) (NNS cases)) (PP (IN of) (NP (NNP Doc_15276093_1762_1783_Disease)))) (VP (AUX were) (VP (VBN observed)))) (. .)))
15276093	13	(S1 (S (NP (NP (JJ Doc_15276093_1799_1805_Chemical) (JJ extended-release/Doc_15276093_1823_1833_Chemical) (JJ 1,000/40) (NN mg)) (, ,) (VP (VBN dosed) (PP (IN as) (NP (JJ initial) (NN therapy)))) (, ,)) (VP (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ good) (NN compliance)) (CC and) (NP (NN safety)))))) (CC and) (VP (AUX had) (NP (NP (ADJP (RB very) (JJ low)) (NNS incidences)) (PP (IN of) (NP (VBN increased) (NN liver) (CC and) (NN muscle) (NNS enzymes)))))) (. .)))
15282950	0	(S1 (NP (NP (JJ Protective) (NN effect)) (PP (IN of) (NP (NNP Terminalia) (NN chebula))) (PP (IN against) (NP (NP (JJ experimental) (NN Doc_15282950_61_78_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_15282950_90_103_Chemical)))))) (. .)))
15282950	1	(S1 (S (NP (NP (JJ Cardioprotective) (NN effect)) (PP (IN of) (NP (NP (JJ ethanolic) (VB extract)) (PP (IN of) (NP (NP (NNP Terminalia) (NN chebula) (NNS fruits)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN mg/kg) (NN body) (NNS wt)) (-RRB- -RRB-))))))) (VP (AUX was) (VP (VBN examined) (PP (IN in) (NP (NP (NNP Doc_15282950_215_228_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 200) (CD mg/kg)) (NN body) (NN wt)) (-RRB- -RRB-)) (VP (VBN induced) (NP (NNP Doc_15282950_257_274_Disease)) (PP (IN in) (NP (NNS rats)))))))) (. .)))
15282950	2	(S1 (S (PP (IN In) (NP (JJ Doc_15282950_287_300_Chemical) (VBN administered) (NNS rats))) (, ,) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN lipid) (NN Doc_15282950_339_348_Chemical)))) (VP (VBD increased) (ADVP (RB significantly)) (PP (IN in) (NP (DT the) (NN serum) (CC and) (NN heart)))) (. .)))
15282950	3	(S1 (S (NP (DT A) (JJ significant) (NN decrease)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT the) (JJ myocardial) (NN marker) (NNS enzymes))))) (PP (IN with) (NP (NP (DT a) (JJ concomitant) (NN increase)) (PP (IN in) (NP (NP (PRP$ their) (NN activity)) (PP (IN in) (NP (NN serum))))))))) (. .)))
15282950	4	(S1 (S (NP (JJ Histopathological) (NN examination)) (VP (AUX was) (VP (VBN carried) (PRT (RP out)) (S (VP (TO to) (VP (VB confirm) (NP (DT the) (NNP Doc_15282950_599_618_Disease))))))) (. .)))
15282950	5	(S1 (S (NP (NNP T.) (NN chebula)) (VP (VB extract) (SBAR (S (NP (NN pretreatment)) (VP (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (VB ameliorate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_15282950_690_703_Chemical))) (PP (IN on) (NP (NN lipid) (JJ Doc_15282950_713_721_Chemical) (NN formation))))))))) (CC and) (VP (VBD retained) (NP (NP (DT the) (NNS activities)) (PP (IN of) (NP (DT the) (JJ diagnostic) (NN marker) (NNS enzymes))))))))) (. .)))
15321332	0	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (ADJP (NNP Doc_15321332_10_31_Disease) (JJ due) (PP (TO to) (NP (JJ low) (NN dose)))) (NNP Doc_15321332_48_58_Chemical)))) (VP (VBD used) (PP (IN with) (NP (JJ patient-controlled) (NNS analgesia)))) (. .)))
15321332	1	(S1 (S (NP (NP (DT A) (JJ multiparous) (NN woman)) (PP (IN in) (NP (JJ good) (NN Doc_15321332_127_147_Disease)))) (VP (VBD underwent) (NP (JJ urgent) (JJ caesarean) (NN section)) (PP (IN in) (NP (NN labour)))) (. .)))
15321332	2	(S1 (S (ADVP (RB Postoperatively)) (, ,) (NP (PRP she)) (VP (AUX was) (VP (VBN given) (NP (NP (DT a) (JJ patient-controlled) (NN analgesia) (NN device)) (VP (VBG delivering) (NP (NP (NNS boluses)) (PP (IN of) (NP (NP (NNP Doc_15321332_285_296_Chemical) (CD 0.5) (NN mg)) (CC and) (NP (NNP Doc_15321332_308_318_Chemical) (CD 0.025) (NN mg))))))))) (. .)))
15321332	3	(S1 (S (S (NP (NN Whilst)) (VP (VBG using) (NP (DT the) (NN device)))) (S (NP (PRP she)) (ADVP (RB gradually)) (VP (VBD became) (ADJP (JJ anxious)))) (, ,) (S (NP (DT the) (NN feeling)) (VP (VBG worsening) (PP (IN after) (NP (DT each) (JJ bolus))))) (. .)))
15321332	4	(S1 (S (NP (NP (DT The) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_15321332_440_450_Chemical-induced) (NNP Doc_15321332_459_484_Disease)))) (VP (AUX was) (RB not) (VP (VBN made) (ADVP (RB straight) (RB away)) (SBAR (IN although) (S (PP (IN on) (NP (JJ subsequent) (NN close) (VBG questioning))) (NP (DT the) (NN patient)) (VP (VBD gave) (NP (DT a) (ADJP (RB very) (JJ clear)) (NN history))))))) (. .)))
15321332	5	(S1 (S (SBAR (IN After) (S (NP (PRP she)) (VP (AUX had) (VP (VBN received) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (QP (RB only) (CD 0.9) (CD mg)) (NN Doc_15321332_638_648_Chemical)))))))) (, ,) (S (NP (NP (DT a) (NN syringe)) (VP (VBG containing) (NP (NNP Doc_15321332_671_682_Chemical) (RB only)))) (VP (AUX was) (VP (VBN substituted)))) (CC and) (S (NP (PRP$ her) (NN unease)) (VP (VBN resolved) (ADVP (RB completely)))) (. .)))
15321332	6	(S1 (S (NP (PRP We)) (VP (VBP feel) (SBAR (IN that) (S (, ,) (SBAR (IN although) (S (NP (NP (DT the) (JJ dramatic) (JJ extrapyramidal) (NN side) (NNS effects)) (PP (IN of) (NP (JJ dopaminergic) (NNS antiemetics)))) (VP (AUX are) (VP (ADVP (RB well)) (VBN known))))) (, ,) (NP (ADJP (RBR more) (JJ subtle)) (NNS manifestations)) (VP (MD may) (ADVP (RB easily)) (VP (AUX be) (VP (VBN overlooked))))))) (. .)))
15366550	0	(S1 (S (NP (JJ Accurate) (NN patient) (NN history)) (VP (VBZ contributes) (PP (TO to) (S (VP (VBG differentiating) (NP (NNP Doc_15366550_56_74_Disease))))) (: :) (NP (DT a) (NN case) (NN study))) (. .)))
15366550	1	(S1 (S (NP (DT This) (NN case) (NN study)) (VP (VBZ highlights) (NP (NP (DT the) (JJ important) (NN contribution)) (PP (IN of) (NP (NN nursing))) (PP (IN in) (S (VP (VBG obtaining) (NP (DT an) (JJ accurate) (NN health) (NN history))))))) (. .)))
15366550	2	(S1 (S (NP (DT The) (NN case)) (VP (VBD discussed) (SBAR (S (NP (NN herein)) (ADVP (RB initially)) (VP (VBD appeared) (S (VP (TO to) (VP (AUX be) (NP (NP (NNP Doc_15366550_247_276_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15366550_278_280_Disease)) (-RRB- -RRB-))) (ADVP (JJ secondary) (PP (TO to) (NP (DT a) (JJ traumatic) (NN Doc_15366550_307_319_Disease))))))))))) (. .)))
15366550	3	(S1 (S (NP (DT The) (NN nursing) (NN staff)) (, ,) (PP (IN by) (S (VP (VBG reviewing) (NP (NP (DT the) (NN patient) (POS 's)) (NN health) (NN history)) (PP (IN with) (NP (PRP$ his) (NN family)))))) (, ,) (VP (VBD discovered) (NP (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_15366550_423_433_Disease)))) (CC and) (NP (JJ long-standing) (JJ Doc_15366550_452_459_Chemical) (NN use)))) (. .)))
15366550	4	(S1 (S (S (NP (NN Doc_15366550_465_472_Chemical)) (VP (AUX is) (VP (VBN implicated) (PP (IN in) (NP (JJ drug-induced) (NN Doc_15366550_503_517_Disease)))))) (, ,) (CC and) (S (SBAR (IN because) (S (NP (DT the) (NN patient)) (VP (AUX had) (RB not) (VP (VBN received) (NP (NNP Doc_15366550_560_567_Chemical)) (PP (IN since) (S (VP (AUXG being) (VP (VBN admitted) (PP (TO to) (NP (DT the) (NN hospital))))))))))) (, ,) (NP (PRP$ his) (NN treatment)) (VP (VBN changed) (S (VP (TO to) (VP (VB focus) (PP (IN on) (NP (NNP Doc_15366550_640_654_Disease)))))))) (. .)))
15366550	5	(S1 (S (PP (IN By) (S (VP (VBG combining) (NP (NN information)) (PP (IN from) (NP (NP (DT the) (JJ patient) (NN history)) (, ,) (NP (DT the) (JJ physical) (NN examination)) (, ,) (CC and) (NP (NN radiologic) (CC and) (NN laboratory) (NNS studies))))))) (, ,) (NP (DT the) (JJ critical) (NN care) (NN team)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (DT the) (NN patient)) (VP (VP (AUX had) (VP (AUX been) (VP (VBG self-treating) (NP (PRP$ his) (JJ Doc_15366550_852_859_Chemical-induced) (NN Doc_15366550_868_882_Disease))))) (CC and) (VP (VBD developed) (NP (JJ neurogenic) (NNP Doc_15366550_908_910_Disease)) (PP (JJ secondary) (TO to) (NP (NNP Doc_15366550_924_936_Disease)))))))) (. .)))
15366550	6	(S1 (S (NP (RB Thus) (JJ successful) (NN treatment)) (VP (VBD required) (SBAR (IN that) (S (NP (NNP Doc_15366550_978_1007_Disease)) (VP (AUX be) (VP (VBN treated) (ADVP (RB concomitantly))))))) (. .)))
15482540	0	(S1 (S (NP (NNS Factors)) (VP (VBG contributing) (PP (TO to) (NP (NNP Doc_15482540_24_33_Chemical-induced) (NNP Doc_15482540_42_48_Disease)))) (. .)))
15482540	1	(S1 (NP (NP (NP (NN BACKGROUND)) (CC AND) (NP (NN AIM))) (: :) (NP (NP (NNP Interferon) (CC and) (NNP Doc_15482540_85_94_Chemical) (NN combination) (NN therapy)) (PP (IN for) (NP (NNP Doc_15482540_119_138_Disease))) (SBAR (S (VP (VBZ produces) (NP (NNP Doc_15482540_148_164_Disease)))))) (. .)))
15482540	2	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN conducted) (S (VP (TO to) (VP (VB identify) (NP (NP (DT the) (NNS factors)) (VP (VBG contributing) (PP (TO to) (NP (JJ Doc_15482540_231_240_Chemical-induced) (NN Doc_15482540_249_255_Disease)))))))))) (. .)))
15482540	3	(S1 (S (NP (NP (JJ Eighty-eight) (NNS patients)) (PP (IN with) (NP (NNP Doc_15482540_293_312_Disease))) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NN interferon-alpha-2b)) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 6) (NN MU))) (VP (VBN administered) (ADVP (RB intramuscularly)) (PP (IN for) (NP (CD 24) (NNS weeks))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_15482540_426_435_Chemical))) (VP (VBN administered) (ADVP (RB orally)) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (QP (CD 600) (CD mg) (CC or) (CD 800)) (NNS mg))))))))))))))) (VP (VBD participated) (PP (IN in) (NP (DT the) (NN study)))) (. .)))
15482540	4	(S1 (S (NP (NP (DT A) (NN hemoglobin) (NN concentration)) (PP (IN of) (NP (JJ <10) (NNS g/dL)))) (VP (AUX was) (VP (VBN defined) (PP (IN as) (NP (JJ Doc_15482540_567_576_Chemical-induced) (NN Doc_15482540_585_591_Disease))))) (. .)))
15482540	5	(S1 (S (NP (JJ Doc_15482540_602_611_Chemical-induced) (NN Doc_15482540_620_626_Disease)) (VP (VBD occurred) (PP (IN in) (NP (CD 18) (PRN (-LRB- -LRB-) (NP (CD 20.5) (NN %)) (-RRB- -RRB-)) (NNS patients))) (PP (IN during) (NP (NN treatment)))) (. .)))
15482540	6	(S1 (S (NP (NP (DT A) (ADJP (CD 2) (NN g/dL)) (NN decrease)) (PP (IN in) (NP (NP (NN hemoglobin) (NNS concentrations)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_15482540_741_747_Disease)))))))) (VP (AUX was) (VP (VBN observed) (PP (IN at) (NP (NN week) (CD 2))) (PP (IN after) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (NN treatment))))))) (. .)))
15482540	7	(S1 (S (NP (NP (DT The) (NN hemoglobin) (NN concentration)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN >)) (CC or) (NP (NP (QP (CD =2) (CD g/dL)) (NN decrease)) (PP (IN at) (NP (NN week) (CD 2))))))))) (VP (AUX was) (VP (VBN observed) (S (VP (TO to) (VP (AUX be) (ADJP (RB significantly) (JJR lower)) (PP (ADVP (RB even)) (IN after) (NP (NN week) (CD 2))) (PP (IN than) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (S (VP (VBG <2) (NP (NP (CD g/dL) (NN decrease)) (PRN (-LRB- -LRB-) (NP (NNP P) (NNP <) (CD 0.01)) (-RRB- -RRB-)))))))))))))) (. .)))
15482540	8	(S1 (S (NP (DT A) (JJ significant) (NN relationship)) (VP (AUX was) (VP (VBN observed) (PP (IN between) (NP (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NP (NN reduction)) (PP (IN of) (NP (NP (NN hemoglobin) (NNS concentrations)) (PP (IN at) (NP (NN week) (CD 2)))))))) (CC and) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NP (NNP Doc_15482540_1116_1122_Disease)) (PRN (-LRB- -LRB-) (NP (NNP P) (NNP <) (CD 0.01)) (-RRB- -RRB-))))))))) (. .)))
15482540	9	(S1 (S (NP (NP (JJ Such) (NNS factors)) (PP (IN as) (NP (NP (NP (NN sex)) (PRN (-LRB- -LRB-) (NP (NN female)) (-RRB- -RRB-))) (, ,) (NP (NP (NN age)) (PRN (-LRB- -LRB-) (ADJP (QP (CD >) (CC or) (CD =60)) (NNS years) (JJ old)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (DT the) (JJ Doc_15482540_1199_1208_Chemical) (NN dose)) (PP (IN by) (NP (NN body) (NN weight))) (PRN (-LRB- -LRB-) (NP (QP (CD 12) (CD mg/kg) (CC or) (JJR more))) (-RRB- -RRB-)))))) (VP (AUX were) (ADJP (JJ significant) (PP (IN by) (NP (NN univariate) (NN analysis))))) (. .)))
15482540	10	(S1 (S (NP (JJ Careful) (NN administration)) (VP (AUX is) (ADJP (JJ necessary)) (PP (PP (IN in) (NP (NP (NNS patients)) (ADJP (NP (QP (CD >) (CC or) (CD =60)) (NNS years)) (JJ old)) (, ,) (PP (IN in) (NP (JJ female) (NNS patients))) (, ,))) (CC and) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (DT a) (JJ Doc_15482540_1418_1427_Chemical) (NN dose)) (PP (IN of) (NP (QP (CD 12) (CD mg/kg) (CC or) (JJR more)))))))))) (. .)))
15482540	11	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBP experience) (NP (NP (DT a) (NN fall)) (PP (IN in) (NP (NP (NN hemoglobin) (NNS concentrations)) (PP (IN of) (NP (QP (CD 2) (CD g/dL) (CC or) (JJR more)))) (PP (IN at) (NP (NN week) (CD 2)))))) (PP (IN after) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (NN treatment))))))))) (VP (MD should) (VP (AUX be) (VP (VBN monitored) (PP (IN with) (NP (JJ particular) (NN care)))))) (. .)))
1556529	0	(S1 (NP (JJ Doc_1556529_0_10_Chemical-induced) (NN Doc_1556529_19_28_Disease) (. .)))
1556529	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (JJ acute) (NNP Doc_1556529_46_55_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_1556529_67_77_Chemical))) (PP (IN in) (NP (NP (DT a) (JJ 38-year-old) (NN patient)) (PP (IN with) (NP (NNP Doc_1556529_108_112_Disease))))))) (VP (AUX is) (VP (VBN presented))) (. .)))
1556529	2	(S1 (S (NP (NP (DT The) (NN mechanism)) (SBAR (WHADVP (WRB whereby)) (S (NP (DT the) (NNP Doc_1556529_153_162_Disease)) (VP (AUX was) (VP (VBN induced)))))) (VP (AUX is) (RB not) (VP (VBN known))) (. .)))
1556529	3	(S1 (S (ADVP (RB However)) (, ,) (NP (DT the) (NN patient)) (VP (VBD tolerated) (ADVP (RB well)) (NP (NP (DT an) (JJ alternative) (JJ reverse) (NN transcriptase) (NN inhibitor)) (, ,) (NP (NNP Doc_1556529_273_292_Chemical)))) (. .)))
1556529	4	(S1 (S (NP (NP (NNS Physicians)) (VP (VBG caring) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_1556529_330_334_Disease))))))) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (NP (DT this) (NN hitherto)) (VP (ADVP (RB rarely)) (VBN reported) (NP (NN complication)))))))) (. .)))
15605432	0	(S1 (S (NP (JJ Oxidative) (NN damage) (NNS precedes)) (VP (VBP nitrative) (NP (NN damage)) (PP (IN in) (NP (NNP Doc_15605432_46_56_Chemical-induced) (NNP Doc_15605432_65_93_Disease)))) (. .)))
15605432	1	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (S (PP (IN if) (NP (NP (NP (JJ elevated) (JJ reactive) (NNP Doc_15605432_166_172_Chemical) (PRN (-LRB- -LRB-) (NP (NNP ROS)) (-RRB- -RRB-)) (JJ /Doc_15605432_179_187_Chemical) (NNS species)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15605432_197_200_Disease)) (-RRB- -RRB-))) (VP (VBN reported) (S (VP (TO to) (VP (AUX be) (ADJP (JJ present) (PP (IN in) (NP (NP (NNP Doc_15605432_228_238_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15605432_240_243_Chemical)) (-RRB- -RRB-)) (SBAR (S (NP (JJ -induced) (NNP Doc_15605432_253_267_Disease)) (ADVP (RB actually)) (VP (VP (VBD resulted) (PP (IN in) (NP (JJ cardiomyocyte) (JJ oxidative/nitrative) (NN damage)))) (, ,) (CC and) (VP (TO to) (ADVP (RB quantitatively)) (VP (VB determine) (NP (NP (DT the) (NN time) (NN course)) (CC and) (NP (NP (JJ subcellular) (NN localization)) (PP (IN of) (NP (NP (DT these) (JJ postulated) (NN damage) (NNS products)) (VP (VBG using) (NP (NP (DT an)) (PP (IN in) (NP (NN vivo) (NN approach)))))))))))))))))))))))))))) (. .)))
15605432	2	(S1 (S (NP (NN B6C3) (NNS mice)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (CD 20) (NN mg/kg) (NNP Doc_15605432_525_528_Chemical))))))) (. .)))
15605432	3	(S1 (S (NP (NP (NN Doc_15605432_530_552_Disease) (CC and) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_15605432_567_586_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_15605432_588_592_Chemical)) (-RRB- -RRB-)) (NN -protein) (NNS adducts)) (CC and) (NP (NP (NNP Doc_15605432_614_629_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15605432_631_634_Chemical)) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN analyzed))) (. .)))
15605432	4	(S1 (S (NP (NP (JJ Quantitative) (JJ ultrastructural) (NN damage)) (VP (VBG using) (NP (JJ computerized) (NN image) (NNS techniques)))) (VP (VBD showed) (NP (JJ cardiomyocyte) (NN injury)) (ADVP (ADVP (RB as) (RB early)) (PP (IN as) (NP (CD 3) (NNS hours)))) (, ,) (PP (IN with) (S (NP (NN mitochondria)) (VP (AUXG being) (NP (DT the) (ADJP (ADVP (RBS most) (RB extensively) (CC and) (RB progressively)) (VBN injured)) (NN subcellular) (NN organelle)))))) (. .)))
15605432	5	(S1 (S (NP (NP (NN Analysis)) (PP (IN of) (NP (JJ 4HNE) (NN protein)))) (VP (VBZ adducts) (PP (IN by) (NP (JJ immunogold) (NNP electron))) (SBAR (S (NP (NN microscopy)) (VP (VBD showed) (NP (NP (NN appearance)) (PP (IN of) (NP (JJ 4HNE) (NN protein) (NNS adducts)))) (PP (IN in) (NP (NN mitochondria))) (SBAR (IN as) (S (ADVP (RB early) (PP (IN as) (NP (CD 3) (NNS hours)))) (, ,) (PP (IN with) (NP (NP (NP (DT a) (NN peak)) (PP (IN at) (NP (CD 6) (NNS hours)))) (CC and) (NP (NP (JJ subsequent) (NN decline)) (PP (IN at) (NP (CD 24) (JJ hours.) (NN 3NT) (NNS levels)))))) (VP (AUX were) (VP (VP (ADVP (RB significantly)) (VBN increased) (PP (IN in) (NP (DT all) (JJ subcellular) (NNS compartments))) (PP (IN at) (NP (CD 6) (NNS hours)))) (CC and) (VP (ADVP (RB subsequently)) (VBN declined) (PP (IN at) (NP (CD 24) (NNS hours)))))))))))) (. .)))
15605432	6	(S1 (S (NP (PRP$ Our) (NNS data)) (VP (VBD showed) (NP (NP (JJ Doc_15605432_1209_1212_Chemical) (VBN induced) (NN 4HNE-protein) (NNS adducts)) (PP (IN in) (NP (NN mitochondria)))) (PP (IN at) (NP (DT the) (JJ same) (NN time) (NN point))) (SBAR (IN as) (WHADVP (WRB when)) (S (NP (NNP Doc_15605432_1289_1309_Disease)) (ADVP (RB initially)) (VP (VBD appeared))))) (. .)))
15605432	7	(S1 (S (NP (DT These) (NNS results)) (VP (VB document) (PP (IN for) (NP (NP (DT the) (JJ first) (NN time)) (PP (IN in) (NP (NN vivo))))) (SBAR (IN that) (S (NP (JJ mitochondrial) (NN oxidative) (NN damage)) (VP (VBZ precedes) (NP (JJ nitrative) (NN damage)))))) (. .)))
15605432	8	(S1 (S (NP (NP (DT The) (JJ progressive) (NN nature)) (PP (IN of) (NP (NNP Doc_15605432_1469_1489_Disease)))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NN mitochondria)) (, ,) (NP (RB not) (JJ other) (NN subcellular) (NNS organelles)) (, ,) (VP (AUX are) (NP (NP (DT the) (JJ major) (NN site)) (PP (IN of) (NP (JJ intracellular) (NN injury)))))))) (. .)))
15609701	0	(S1 (S (NP (NP (JJ Doc_15609701_0_7_Chemical-induced) (NN Doc_15609701_16_30_Disease)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_15609701_49_71_Disease)))))) (VP (VBN associated) (PP (IN with) (NP (JJ sustained) (NN Doc_15609701_98_121_Disease)))) (. .)))
15609701	1	(S1 (SINV (S (NP (NP (DT A) (JJ 54-year-old) (NN man)) (PP (IN with) (NP (NP (JJ severe) (NN left) (NN Doc_15609701_158_181_Disease)) (PP (JJ due) (TO to) (NP (NNP Doc_15609701_189_211_Disease)))))) (VP (AUX was) (VP (VBN referred) (PP (TO to) (NP (PRP$ our) (NN hospital))) (PP (IN for) (NP (JJ symptomatic) (NN incessant)))))) (VP (VBD sustained)) (NP (NP (NNP Doc_15609701_277_300_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15609701_302_304_Disease)) (-RRB- -RRB-))) (. .)))
15609701	2	(S1 (S (PP (IN After) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (JJ nifekalant) (NNP Doc_15609701_346_359_Chemical))))) (, ,) (NP (JJ sustained) (NN Doc_15609701_371_373_Disease)) (VP (AUX was) (VP (VBN terminated))) (. .)))
15609701	3	(S1 (S (NP (NP (DT An) (JJ alternate) (NN class) (NNP III) (NN agent)) (, ,) (NP (NNP Doc_15609701_420_427_Chemical)) (, ,)) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ effective)) (PP (IN for) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NNP Doc_15609701_470_472_Disease)))))) (. .)))
15609701	4	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (CD one) (NN month)) (PP (IN after) (S (VP (VBG switching) (PP (IN over) (NP (NN nifekalant))) (PP (TO to) (NP (NP (NNP Doc_15609701_528_535_Chemical)) (, ,) (NP (NP (DT a) (JJ short) (NN duration)) (PP (IN of) (NP (NNP ST) (NN elevation)))))))))) (VP (AUX was) (VP (VBN documented) (PP (IN in) (S (VP (VBG ECG) (NP (NN monitoring)) (PP (IN at) (NP (NP (RB almost) (DT the) (JJ same) (NN time)) (PP (IN for) (NP (CD three) (JJ consecutive) (NNS days)))))))))) (. .)))
15609701	5	(S1 (S (NP (NP (NNP ST) (NN elevation)) (PP (IN with) (NP (NN chest) (NN discomfort)))) (VP (VBD disappeared) (SBAR (IN since) (S (NP (PRP he)) (VP (VBD began) (S (VP (VBG taking) (NP (JJ long-acting) (NN Doc_15609701_736_745_Chemical)))))))) (. .)))
15609701	6	(S1 (S (NP (NN Doc_15609701_747_765_Disease)) (VP (MD may) (VP (AUX be) (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (JJ non-selective) (JJ beta-blocking) (NNS properties)) (PP (IN of) (NP (NNP Doc_15609701_830_837_Chemical)))))))) (. .)))
15614572	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NP (DT the) (JJ antidepressant) (NNP Doc_15614572_30_39_Chemical)) (, ,) (NP (DT a) (JJ 5-HT) (NN 2A/2C) (NN receptor) (NN antagonist)) (, ,))) (PP (IN on) (NP (NP (JJ Doc_15614572_78_86_Chemical-dependent) (NNS behaviors)) (PP (IN in) (NP (NNS rats))))) (. .)))
15614572	1	(S1 (S (NP (NP (NNP Doc_15614572_127_146_Chemical)) (, ,) (PP (IN via) (NP (NP (NN stimulation)) (PP (IN of) (NP (JJ 5-HT) (NN 2C) (NNS receptors))))) (, ,)) (VP (VBZ exerts) (NP (NP (DT a) (NN tonic) (NN inhibitory) (NN influence)) (PP (IN on) (NP (JJ dopaminergic) (NN neurotransmission)))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN activation)) (PP (IN of) (NP (JJ 5-HT) (NN 2A) (NNS receptors)))) (VP (VBZ enhances) (NP (VBN stimulated) (JJ DAergic) (NN neurotransmission)))))) (. .)))
15614572	2	(S1 (S (NP (DT The) (JJ antidepressant) (NN Doc_15614572_363_372_Chemical)) (VP (AUX is) (NP (DT a) (JJ 5-HT) (NN 2A/2C) (NN receptor) (NN antagonist))) (. .)))
15614572	3	(S1 (FRAG (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ Doc_15614572_448_457_Chemical) (NN treatment))) (PP (IN on) (NP (NP (NNS behaviors)) (ADJP (JJ dependent) (PP (IN on) (NP (NP (DT the) (JJ functional) (NN status)) (PP (IN of) (NP (DT the) (JJ nigrostriatal) (JJ DAergic) (NN system)))))))))))) (. .)))
15614572	4	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NNP Doc_15614572_594_603_Chemical))))) (PP (IN on) (NP (NP (ADJP (JJ Doc_15614572_607_621_Chemical-) (CC and) (JJ Doc_15614572_627_638_Chemical-induced)) (JJ oral) (NNS stereotypies)) (, ,) (PP (IN on) (NP (NP (NNP Doc_15614572_669_678_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_15614572_690_701_Chemical) (CC and) (NNP Doc_15614572_706_717_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.05) (NN mg/kg)) (, ,) (NP (NNP i.p.)) (-RRB- -RRB-))))))) (, ,))) (PP (IN on) (NP (NP (JJ Doc_15614572_741_752_Chemical-induced) (JJ wet) (NN dog) (NN shake) (PRN (-LRB- -LRB-) (NP (NNP WDS)) (-RRB- -RRB-)) (NN behavior)) (CC and) (NP (JJ Doc_15614572_794_804_Chemical-induced) (JJ penile) (NNS erections))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NNS rats))))) (. .)))
15614572	5	(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NNP Doc_15614572_880_889_Chemical)) (VP (VBZ induces) (NP (NNP Doc_15614572_898_907_Disease)) (PP (IN in) (NP (NNS rats))))))) (. .)))
15614572	6	(S1 (S (NP (NP (NN Doc_15614572_926_935_Chemical)) (PP (IN at) (NP (QP (CD 2.5-20) (CD mg/kg)) (NNS i.p.)))) (VP (VP (AUX did) (RB not) (VP (VB induce) (NP (NNP Doc_15614572_972_981_Disease)))) (, ,) (CC and) (VP (AUX did) (RB not) (VP (VB antagonize) (NP (NP (NNP Doc_15614572_1006_1017_Chemical) (PRN (-LRB- -LRB-) (NP (QP (CD 1.5) (CC and) (CD 3)) (NN mg/kg)) (-RRB- -RRB-)) (NN stereotypy)) (CC and) (NP (JJ Doc_15614572_1051_1062_Chemical) (PRN (-LRB- -LRB-) (NP (CD 0.05) (NN mg/kg)) (-RRB- -RRB-)) (JJ -induced) (NN Doc_15614572_1084_1093_Disease)))))) (. .)))
15614572	7	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN pretreatment)) (PP (IN with) (NP (CD 5) (, ,) (CD 10) (CC and) (CD 20) (NN mg/kg) (NNP i.p.) (NNP Doc_15614572_1146_1155_Chemical)))) (VP (VP (VBD enhanced) (NP (NNP Doc_15614572_1165_1179_Chemical) (CD stereotypy))) (, ,) (CC and) (VP (VBD antagonized) (NP (NP (NNP Doc_15614572_1208_1219_Chemical) (NNP Doc_15614572_1220_1229_Disease)) (, ,) (NP (JJ Doc_15614572_1231_1242_Chemical-induced) (NNS WDS) (NN behavior)) (CC and) (NP (JJ Doc_15614572_1268_1278_Chemical-induced) (JJ penile) (NNS erections))))) (. .)))
15614572	8	(S1 (S (NP (NP (NN Doc_15614572_1305_1314_Chemical)) (PP (IN at) (NP (CD 30) (, ,) (CD 40) (CC and) (CD 50) (JJ mg/kg) (NNS i.p.)))) (VP (VP (VBN induced) (NP (NNP Doc_15614572_1351_1360_Disease))) (CC and) (VP (VBN antagonized) (NP (NNP Doc_15614572_1377_1388_Chemical) (CC and) (NNP Doc_15614572_1393_1407_Chemical) (NNS stereotypies)))) (. .)))
15614572	9	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_15614572_1461_1470_Chemical)) (PP (IN at) (NP (CD 2.5-20) (CD mg/kg))) (VP (AUX does) (RB not) (VP (VB block) (NP (ADJP (JJ pre-) (CC and) (JJ postsynaptic)) (JJ striatal) (NNP D2) (NNP DA) (NNS receptors)))))) (, ,) (SBAR (IN while) (S (PP (IN at) (NP (CD 30) (, ,) (CD 40) (CC and) (CD 50) (NNS mg/kg))) (NP (PRP it)) (VP (NNS blocks) (NP (JJ postsynaptic) (JJ striatal) (JJ D2) (NN DA) (NNS receptors)))))) (. .)))
15614572	10	(S1 (S (ADVP (RB Furthermore)) (, ,) (PP (IN at) (NP (CD 5) (, ,) (CD 10) (CC and) (CD 20) (NN mg/kg))) (, ,) (NP (NNP Doc_15614572_1664_1673_Chemical) (NNS blocks)) (VP (VBP 5-HT) (NP (NP (NNS 2A)) (CC and) (NP (JJ 5-HT) (NN 2C) (NNS receptors)))) (. .)))
15614572	11	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNP Doc_15614572_1728_1737_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5) (, ,) (CD 10) (CC and) (CD 20) (NN mg/kg)) (-RRB- -RRB-))) (, ,) (PP (IN by) (S (VP (VBG blocking) (NP (DT the) (JJ 5-HT) (NN 2C) (NNS receptors))))) (, ,) (VP (VP (VBZ releases) (NP (NP (DT the) (JJ nigrostriatal) (JJ DAergic) (NNS neurons)) (PP (IN from) (NP (NP (NN tonic) (NN inhibition)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_15614572_1870_1874_Chemical)))))))) (, ,) (CC and) (ADVP (RB thereby)) (VP (VBZ potentiates) (NP (JJ Doc_15614572_1900_1914_Chemical) (NN stereotypy))) (CC and) (VP (VBZ antagonizes) (NP (NNP Doc_15614572_1942_1953_Chemical) (NNP Doc_15614572_1954_1963_Disease))))))) (. .)))
15625689	0	(S1 (NP (NP (NP (NN Doc_15625689_0_24_Disease)) (CC and) (NP (NN Doc_15625689_29_39_Disease))) (PP (IN in) (NP (NNP Doc_15625689_43_62_Disease))) (. .)))
15625689	1	(S1 (S (S (NP (NP (NN Doc_15625689_64_94_Disease)) (PP (IN in) (NP (NP (NNP Doc_15625689_98_117_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15625689_119_121_Disease)) (-RRB- -RRB-))))) (VP (AUX have) (VP (AUX been) (VP (VBN known) (PP (IN for) (NP (QP (RB almost) (CD two)) (NNS centuries))))))) (, ,) (CC but) (S (NP (NP (JJ many) (NNS aspects)) (VP (VBG concerning) (NP (PRP$ their) (NNS pathophysiology)))) (VP (AUX have) (RB not) (VP (AUX been) (VP (ADVP (RB completely)) (VBN clarified))))) (. .)))
15625689	2	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB characterize) (NP (NP (DT the) (JJ oropharyngeal) (NNS dynamics)) (PP (IN in) (NP (NNP Doc_15625689_323_325_Disease) (NNS patients)))) (PP (PP (IN with)) (CC and) (PP (IN without) (NP (JJ Doc_15625689_352_360_Chemical-induced) (NN Doc_15625689_369_379_Disease)))))))) (. .)))
15625689	3	(S1 (S (NP (NP (NNP Fifteen) (NNP Doc_15625689_389_399_Disease)) (, ,) (NP (CD 12) (JJ nondyskinetic) (NNS patients)) (, ,) (CC and) (NP (DT a) (NN control) (NN group))) (VP (AUX were) (VP (VBN included))) (. .)))
15625689	4	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VP (VBN asked) (PP (IN about) (NP (NNP Doc_15625689_489_498_Disease)))) (CC and) (VP (VBN evaluated) (PP (IN with) (NP (DT the) (JJ Unified) (NNP Doc_15625689_530_549_Disease) (NNP Rating) (NNP Scale) (NNP Parts) (NNP II) (CC and) (NNP III) (CC and) (DT the) (NNP Hoehn) (CC and) (NNP Yahr) (NN scale)))))) (. .)))
15625689	5	(S1 (S (NP (NN Deglutition)) (VP (AUX was) (VP (VBN assessed) (S (VP (VBG using) (NP (VBN modified) (NN barium) (VB swallow)) (PP (IN with) (NP (NN videofluoroscopy))))))) (. .)))
15625689	6	(S1 (S (NP (NP (JJ Nondyskinetic) (NNS patients)) (, ,) (CONJP (CC but) (RB not)) (NP (DT the) (JJ Doc_15625689_724_734_Disease) (NNS ones)) (, ,)) (VP (VBD showed) (NP (NP (JJR less) (NX (NX (NN oropharyngeal) (VBG swallowing) (NN efficiency)) (PRN (-LRB- -LRB-) (NP (NNP OPSE)) (-RRB- -RRB-)))) (PP (IN for) (NP (JJ liquid) (NN food))) (PP (IN than) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP Dunnett)) (, ,) (NP (NP (NNS P)) (VP (SYM =) (NP (CD 0.02)))) (-RRB- -RRB-)))))) (. .)))
15625689	7	(S1 (S (NP (NN Doc_15625689_847_857_Disease) (NNS patients)) (VP (VBD tended) (S (VP (TO to) (VP (AUX have) (NP (DT a) (JJR greater) (NN OPSE)) (PP (IN than) (NP (NP (JJ nondyskinetic)) (PRN (-LRB- -LRB-) (NP (NP (NNP Dunnett)) (, ,) (NP (NNP P) (SYM =) (CD 0.06))) (-RRB- -RRB-)))))))) (. .)))
15625689	8	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBG using) (NP (NP (DT a) (JJR higher) (NN dose)) (PP (IN of) (NP (NNP Doc_15625689_978_986_Chemical))))))))) (VP (AUX had) (NP (NP (DT a) (JJR greater) (NN OPSE)) (CC and) (NP (NP (DT a) (NN trend)) (PP (IN toward) (NP (NP (DT a) (JJR smaller) (JJ oral) (NN transit) (NN time)) (PRN (-LRB- -LRB-) (NP (NP (NP (NNP Pearson) (POS 's)) (NN correlation)) (, ,) (NP (NNP P) (SYM =) (CD 0.01)) (CC and) (NP (NP (CD 0.08)) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))))))) (. .)))
15625689	9	(S1 (S (NP (CC Neither) (NP (NP (DT the) (NN report)) (PP (IN of) (NP (NNP Doc_15625689_1133_1142_Disease)))) (CC nor) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (JJ Doc_15625689_1158_1160_Disease) (NN severity) (NNS parameters))))) (VP (VBD correlated) (PP (TO to) (NP (DT the) (JJ videofluoroscopic) (NNS variables)))) (. .)))
15625689	10	(S1 (S (PP (IN In) (NP (DT the) (JJ current) (NN study))) (, ,) (NP (NNP Doc_15625689_1250_1260_Disease) (NNS patients)) (VP (VBD performed) (ADVP (RB better)) (PP (IN in) (S (VP (VBG swallowing) (NP (NP (NN function)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (AUX be) (VP (VBN explained) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (DT a) (JJR greater) (JJ Doc_15625689_1362_1370_Chemical) (NN dose))))))))))))))) (. .)))
15625689	11	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VP (VBP suggest) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NNP Doc_15625689_1408_1416_Chemical)))) (PP (IN in) (NP (NP (DT the) (JJ oral) (NN phase)) (PP (IN of) (NP (NN deglutition)))))) (CC and) (VP (VBP confirm) (SBAR (IN that) (S (NP (NNP Doc_15625689_1467_1476_Disease)) (VP (AUX is) (RB not) (NP (NP (DT a) (JJ good) (NN predictor)) (PP (IN of) (NP (NP (JJ deglutition) (NNS alterations)) (PP (IN in) (NP (NNP Doc_15625689_1531_1533_Disease))))))))))) (. .)))
15627798	0	(S1 (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (JJ nuclear) (NN factor-kappaB) (NN activation)))) (VP (VBZ attenuates) (NP (NP (NNP Doc_15627798_58_86_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_15627798_98_108_Chemical)))))) (. .)))
15627798	1	(S1 (S (NP (NP (NNS Animals)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_15627798_143_153_Chemical))))) (VP (MD can) (VP (VB show) (NP (NP (JJ residual) (NNS areas)) (PP (IN of) (NP (JJ interstitial) (NNP Doc_15627798_194_202_Disease)))) (PP (IN in) (NP (DT the) (JJ renal) (NN cortex))))) (. .)))
15627798	2	(S1 (S (NP (DT This) (NN study)) (VP (VBD investigated) (SBAR (S (NP (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ nuclear) (NN factor-kappaB)))) (PRN (-LRB- -LRB-) (JJ NF-kappaB) (-RRB- -RRB-)) (, ,) (NP (JJ mitogen-activated) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN MAP)) (-RRB- -RRB-))) (VP (VBZ kinases) (CC and) (VBZ macrophages) (PP (IN in) (NP (NP (NP (DT the) (JJ renal) (NN cortex)) (CC and) (NP (ADJP (JJ structural) (CC and) (JJ functional)) (JJ renal) (NNS changes))) (PP (IN of) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NNP Doc_15627798_442_452_Chemical) (CC or) (NNP Doc_15627798_456_466_Chemical) (NNP +) (NNP Doc_15627798_469_496_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15627798_498_502_Chemical)) (-RRB- -RRB-))) (, ,) (NP (DT an) (JJ NF-kappaB) (NN inhibitor))))))))))))) (. .)))
15627798	3	(S1 (S (NP (CD 38) (JJ female) (NNP Wistar) (NNS rats)) (VP (AUX were) (VP (VBN injected) (PP (IN with) (NP (NP (NNP Doc_15627798_579_589_Chemical)) (, ,) (NP (NP (QP (CD 40) (CD mg/kg))) (, ,) (NP (NP (RB twice) (DT a) (NN day)) (PP (IN for) (NP (CD 9) (NNS days)))) (, ,) (NP (NP (CD 38)) (PP (IN with) (NP (NNP Doc_15627798_633_643_Chemical) (NNP +) (NNP Doc_15627798_646_650_Chemical)))) (, ,) (CC and) (NP (NP (CD 28)) (PP (IN with) (NP (CD 0.15) (NNP M) (NNP Doc_15627798_671_675_Chemical) (NN solution))))))))) (. .)))
15627798	4	(S1 (S (NP (DT The) (NNS animals)) (VP (AUX were) (VP (VBN killed) (SBAR (NP (QP (CD 5) (CC and) (CD 30)) (NNS days)) (IN after) (S (NP (NP (DT these) (NNS injections)) (CC and) (NP (DT the) (NNS kidneys))) (VP (AUX were) (VP (VBN removed) (PP (IN for) (NP (NP (NN histological)) (CC and) (NP (JJ immunohistochemical) (NNS studies)))))))))) (. .)))
15627798	5	(S1 (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (DT the) (JJ immunohistochemical) (NNS studies)))) (VP (AUX were) (VP (VBN scored) (PP (VBG according) (PP (TO to) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NN staining)))))))) (. .)))
15627798	6	(S1 (S (NP (DT The) (JJ fractional) (NN interstitial) (NN area)) (VP (AUX was) (VP (VBN determined) (PP (IN by) (NP (NN morphometry))))) (. .)))
15627798	7	(S1 (S (NP (JJ Doc_15627798_995_1005_Chemical-treated) (NNS rats)) (VP (VBD presented) (NP (NP (DT a) (JJ transitory) (NN increase)) (PP (IN in) (NP (NN plasma) (JJ Doc_15627798_1061_1071_Chemical) (NNS levels))))) (. .)))
15627798	8	(S1 (S (NP (NP (JJ Increased) (NN ED-1)) (, ,) (NP (NN MAP) (NNS kinases)) (CC and) (NP (JJ NF-kappaB) (NN staining))) (VP (AUX were) (ADVP (RB also)) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (JJ renal) (NN cortex)) (PP (IN from) (NP (DT all) (JJ Doc_15627798_1179_1189_Chemical-treated) (NNS rats))))) (PP (VBN compared) (PP (TO to) (NP (NP (NN control)) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.05))) (-RRB- -RRB-))))))) (. .)))
15627798	9	(S1 (S (NP (NP (DT The) (NNS animals)) (VP (VBN killed) (PP (IN on) (NP (NN day) (CD 30))))) (ADVP (RB also)) (VP (VBD presented) (NP (NN Doc_15627798_1279_1287_Disease)) (PP (IN in) (NP (DT the) (JJ renal) (NN cortex))) (PP (IN despite) (NP (NP (DT the) (NN recovery)) (PP (IN of) (NP (JJ renal) (NN function)))))) (. .)))
15627798	10	(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NNP Doc_15627798_1363_1367_Chemical)))) (VP (VBD reduced) (NP (NP (DT the) (ADJP (ADJP (JJ functional)) (CC and) (ADJP (JJ structural))) (NNS changes)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_15627798_1425_1435_Chemical)))))) (. .)))
15627798	11	(S1 (S (NP (DT These) (NNS data)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NN inhibition)) (PP (IN of) (NP (NN NF-kappaB) (NN activation) (NNS attenuates)))) (ADVP (NNP Doc_15627798_1517_1545_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_15627798_1557_1567_Chemical))))))) (. .)))
15630069	0	(S1 (NP (NP (NP (JJ Doc_15630069_0_7_Chemical) (NN metabolism)) (PP (IN in) (NP (NNS patients))) (PP (IN with) (NP (NP (NNP Doc_15630069_36_49_Disease)) (VP (VBN treated) (PP (IN with) (NP (JJ atypical) (JJ antipsychotic) (NNS agents))))))) (: :) (NP (NP (DT a) (ADJP (RB frequently) (VBN sampled)) (JJ intravenous) (JJ Doc_15630069_127_134_Chemical) (NN tolerance) (NN test)) (CC and) (NP (JJ minimal) (NN model) (NN analysis))) (. .)))
15630069	1	(S1 (S (SBAR (IN While) (S (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_15630069_213_240_Disease)))) (VP (MD may) (VP (AUX be) (S (VP (VBG increasing) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_15630069_276_289_Disease))) (VP (VBN treated) (PP (IN with) (NP (JJ certain) (JJ atypical) (JJ antipsychotic) (NNS agents)))))))))))) (, ,) (NP (PRP it)) (VP (VBZ remains) (ADJP (JJ unclear)) (SBAR (IN whether) (S (NP (JJ atypical) (NNS agents)) (VP (AUX are) (VP (VP (ADVP (RB directly)) (VBG affecting) (NP (JJ Doc_15630069_408_415_Chemical) (NN metabolism))) (CC or) (VP (ADVP (RB simply)) (VBG increasing) (NP (NP (VBN known) (NN risk) (NNS factors)) (PP (IN for) (NP (NNP Doc_15630069_471_479_Disease)))))))))) (. .)))
15630069	2	(S1 (S (S (VP (TO To) (VP (VB study) (NP (NP (DT the) (CD 2) (NNS drugs)) (VP (ADVP (RBS most) (RB clearly)) (VBN implicated)))))) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_15630069_538_547_Chemical)) (CC and) (NP (NNP Doc_15630069_552_562_Chemical))) (-RRB- -RRB-)) (CC and) (S (NP (NNP Doc_15630069_568_579_Chemical)) (VP (VBG using) (NP (DT a) (ADJP (RB frequently) (VBN sampled)) (JJ intravenous) (JJ Doc_15630069_619_626_Chemical) (NN tolerance) (NN test)))) (. .)))
15630069	3	(S1 (S (NP (NP (DT A) (JJ cross-sectional) (NN design)) (PP (IN in) (NP (NN stable)))) (, ,) (NP (NP (VBN treated) (NNS patients)) (PP (IN with) (NP (NNP Doc_15630069_709_722_Disease)))) (VP (VBN evaluated) (S (VP (VBG using) (NP (NP (DT a) (ADJP (RB frequently) (VBN sampled)) (JJ intravenous) (JJ Doc_15630069_772_779_Chemical) (NN tolerance) (NN test)) (CC and) (NP (DT the) (NNP Bergman) (JJ minimal) (NN model) (NN analysis)))))) (. .)))
15630069	4	(S1 (S (NP (NNS Subjects)) (VP (VP (AUX were) (VP (VBN recruited) (PP (IN from) (NP (DT an) (JJ urban) (NN community) (JJ mental) (NN health) (NN clinic))))) (CC and) (VP (AUX were) (VP (VBN studied) (PP (IN at) (NP (DT a) (JJ general) (JJ clinical) (NN research) (NN center)))))) (. .)))
15630069	5	(S1 (S (NP (NP (NNS Patients)) (SBAR (S (NP (NNP Fifty) (NNS subjects)) (VP (VBD signed) (NP (NP (VBN informed) (NN consent)) (CC and) (NP (CD 41))))))) (VP (VBD underwent) (NP (DT the) (ADJP (RB frequently) (VBN sampled)) (JJ intravenous) (JJ Doc_15630069_1069_1076_Chemical) (NN tolerance) (NN test))) (. .)))
15630069	6	(S1 (S (NP (NP (JJ Thirty-six) (JJ nonobese) (NNS subjects)) (PP (IN with) (NP (NP (NNP Doc_15630069_1127_1140_Disease)) (CC or) (NP (NNP Doc_15630069_1144_1168_Disease)))) (, ,) (VP (VP (VBN matched) (PP (IN by) (NP (NN body) (NN mass) (NN index)))) (CC and) (VP (VBN treated) (PP (IN with) (NP (NP (DT either) (NNP Doc_15630069_1221_1230_Chemical)) (, ,) (NP (NNP Doc_15630069_1232_1242_Chemical)) (, ,) (CC or) (NP (NNP Doc_15630069_1247_1258_Chemical)))))) (, ,)) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (DT the) (NN analysis))))) (. .)))
15630069	7	(S1 (S (NP (JJ MAIN) (NN OUTCOME)) (VP (VBZ MEASURES) (: :) (S (VP (VP (VBG Fasting) (NP (NN plasma) (NN Doc_15630069_1329_1336_Chemical))) (CC and) (VP (VBG fasting) (NP (NP (NN serum) (NN insulin) (NNS levels)) (, ,) (NP (NN insulin) (NN sensitivity) (NN index)) (, ,) (NP (NP (NN homeostasis) (NN model) (NN assessment)) (PP (IN of) (NP (NN insulin) (NN resistance)))) (, ,) (CC and) (NP (JJ Doc_15630069_1454_1461_Chemical) (NN effectiveness))))))) (. .)))
15630069	8	(S1 (S (NP (NP (DT The) (JJ mean) (JJ +/-) (NN SD) (NN duration)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (DT the) (VBN identified) (JJ atypical) (NN antipsychotic) (NN agent)))) (VP (AUX was) (NP (NP (NP (NP (CD 68.3) (NN +/-)) (NP (CD 28.9) (NNS months))) (PRN (-LRB- -LRB-) (NP (NNP Doc_15630069_1599_1608_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (CD 29.5) (NN +/-)) (NP (CD 17.5) (NNS months))) (PRN (-LRB- -LRB-) (NP (NNP Doc_15630069_1633_1643_Chemical)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (CD 40.9) (NN +/-)) (NP (NP (CD 33.7)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15630069_1665_1676_Chemical)) (-RRB- -RRB-)))))) (. .)))
15630069	9	(S1 (S (NP (JJ Fasting) (NN serum) (NN insulin) (NNS concentrations)) (VP (VBD differed) (PP (IN among) (NP (NP (NNS groups)) (-LRB- -LRB-) (NP (NP (NNP F) (-LRB- -LRB-) (CD 33) (-RRB- -RRB-) (SYM =) (CD 3.35)) (: ;) (NP (NN P)) (X (SYM =)) (CD .047)) (-RRB- -RRB-) (-LRB- -LRB-) (NP (NNP Doc_15630069_1764_1773_Chemical>Doc_15630069_1774_1784_Chemical>Doc_15630069_1785_1796_Chemical)) (-RRB- -RRB-))) (PP (IN with) (NP (NP (JJ significant) (NNS differences)) (PP (IN between) (NP (NP (NP (NNP Doc_15630069_1835_1844_Chemical) (CC and) (NNP Doc_15630069_1849_1860_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP t) (-LRB- -LRB-) (CD 33) (-RRB- -RRB-) (SYM =) (CD 2.32)) (: ;) (NP (NNP P)) (X (SYM =)) (CD .03)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_15630069_1889_1899_Chemical) (CC and) (NNP Doc_15630069_1904_1915_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP t) (-LRB- -LRB-) (CD 33) (-RRB- -RRB-) (SYM =) (CD 2.15)) (: ;) (NP (NNP P)) (X (SYM =)) (CD .04)) (-RRB- -RRB-)))))))) (. .)))
15630069	10	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (NN difference)) (PP (IN in) (NP (NP (NN insulin) (NN sensitivity) (NN index)) (PP (IN among) (NP (NP (NNS groups)) (PRN (-LRB- -LRB-) (NP (NP (NP (NNP F) (-LRB- -LRB-) (CD 33) (-RRB- -RRB-) (SYM =) (CD 10.66)) (: ;) (NP (CD P<.001)) (-RRB- -RRB-) (-LRB- -LRB-) (NP (NNP Doc_15630069_2043_2052_Chemical<Doc_15630069_2053_2063_Chemical<Doc_15630069_2064_2075_Chemical)) (-RRB- -RRB-)) (, ,) (PP (IN with) (NP (NP (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NNP Doc_15630069_2105_2114_Chemical) (CC and) (NNP Doc_15630069_2119_2129_Chemical) (VBG exhibiting) (JJ significant) (NN insulin) (NN resistance)) (PP (VBN compared) (PP (IN with) (NP (NP (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_15630069_2217_2228_Chemical)) (-LRB- -LRB-) (NP (NP (NNP Doc_15630069_2230_2239_Chemical) (NNP vs) (NNP Doc_15630069_2243_2254_Chemical)) (, ,) (NP (NNP t) (-LRB- -LRB-) (CD 33) (-RRB- -RRB-) (SYM =) (CD -4.29))) (: ;) (NP (NNP P<.001)) (: ;) (NP (NP (NNP Doc_15630069_2279_2289_Chemical) (NNP vs) (NNP Doc_15630069_2293_2304_Chemical)) (, ,) (NP (NNP t) (-LRB- -LRB-) (CD 33) (-RRB- -RRB-) (SYM =) (CD -3.62)))))))))))))))))) (: ;) (NP (QP (CD P) (SYM =) (CD .001) (CD -LSB-P<.001)) (NNS -RSB-)) (-RRB- -RRB-)))))))) (. .)))
15630069	11	(S1 (S (NP (NP (DT The) (NN homeostasis) (NN model) (NN assessment)) (PP (IN of) (NP (NN insulin) (NN resistance)))) (ADVP (RB also)) (VP (VBD differed) (ADVP (RB significantly)) (PP (IN among) (NP (NP (NNS groups)) (PRN (-LRB- -LRB-) (NP (NP (NP (NNP F)) (-LRB- -LRB-) (NP (CD 33)) (-RRB- -RRB-) (SBAR (S (VP (SYM =) (NP (CD 4.92)))))) (: ;) (NP (NNP P) (SYM =) (CD .01)) (-RRB- -RRB-) (-LRB- -LRB-) (NP (NNP Doc_15630069_2462_2471_Chemical>Doc_15630069_2472_2482_Chemical>Doc_15630069_2483_2494_Chemical)) (-RRB- -RRB-) (-LRB- -LRB-) (NP (NP (NNP Doc_15630069_2497_2506_Chemical) (NNP vs) (NNP Doc_15630069_2510_2521_Chemical)) (, ,) (NP (NNP t) (-LRB- -LRB-) (CD 33) (-RRB- -RRB-) (SYM =) (CD 2.94))) (: ;) (NP (NNP P) (SYM =) (CD .006)) (: ;) (NP (NP (NNP Doc_15630069_2547_2557_Chemical) (NNP vs) (NNP Doc_15630069_2561_2572_Chemical)) (, ,) (NP (NNP t) (-LRB- -LRB-) (CD 33) (-RRB- -RRB-) (SYM =) (CD 2.42))) (: ;) (NP (NNP P)) (X (SYM =)) (CD .02)) (-RRB- -RRB-))))) (. .)))
15630069	12	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (NN difference)) (PP (IN among) (NP (NP (NNS groups)) (PP (IN in) (NP (NP (JJ Doc_15630069_2649_2656_Chemical) (NN effectiveness)) (-LRB- -LRB-) (NP (NP (NNP F) (-LRB- -LRB-) (CD 30) (-RRB- -RRB-) (SYM =) (CD 4.18)) (: ;) (NP (NNP P)) (X (SYM =)) (CD .02)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NNP Doc_15630069_2696_2705_Chemical<Doc_15630069_2706_2716_Chemical<Doc_15630069_2717_2728_Chemical)) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (JJ significant) (NNS differences)) (PP (IN between) (NP (NP (NP (NNP Doc_15630069_2767_2776_Chemical) (CC and) (NNP Doc_15630069_2781_2792_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP t) (-LRB- -LRB-) (CD 30) (-RRB- -RRB-) (SYM =) (CD -2.59)) (: ;) (NP (NNP P)) (X (SYM =)) (CD .02)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_15630069_2822_2832_Chemical) (CC and) (NNP Doc_15630069_2837_2848_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP t) (-LRB- -LRB-) (CD 30) (-RRB- -RRB-) (SYM =) (CD -2.34)) (, ,) (NP (NNP P) (SYM =) (CD .03)) (-RRB- -RRB-))))))))) (. .)))
15630069	13	(S1 (S (NP (DT Both) (JJ nonobese) (JJ Doc_15630069_2902_2911_Chemical-) (CC and) (JJ Doc_15630069_2917_2927_Chemical-treated) (NNS groups)) (VP (VBD displayed) (NP (NP (JJ significant) (NN insulin) (NN resistance)) (CC and) (NP (NP (NN impairment)) (PP (IN of) (NP (JJ Doc_15630069_3002_3009_Chemical) (NN effectiveness))))) (PP (VBN compared) (PP (IN with) (NP (JJ Doc_15630069_3038_3049_Chemical-treated) (NNS subjects))))) (. .)))
15630069	14	(S1 (S (NP (NP (NNS Patients)) (VP (VBG taking) (NP (NP (NNP Doc_15630069_3084_3093_Chemical)) (CC and) (NP (NNP Doc_15630069_3098_3108_Chemical))))) (VP (MD must) (VP (AUX be) (VP (VBN examined) (PP (IN for) (NP (NP (NN insulin) (NN resistance)) (CC and) (NP (PRP$ its) (NNS consequences))))))) (. .)))
1563460	0	(S1 (NP (NP (JJ Thoracic) (JJ Doc_1563460_9_21_Disease) (ADJP (JJ secondary) (TO to) (JJ Doc_1563460_35_43_Chemical)) (NN anticoagulant) (NN therapy)) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
1563460	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (JJ thoracic) (NN Doc_1563460_101_113_Disease) (JJ secondary))) (PP (TO to) (NP (JJ anticoagulant) (NN therapy)))) (VP (AUX is) (VP (VBN presented))) (. .)))
1563460	2	(S1 (S (NP (NP (JJ Clinical) (NNS features)) (, ,) (ADJP (JJ similar) (PP (TO to) (NP (CD 2) (JJ other) (ADJP (RB previously) (VBN reported)) (NNS cases)))) (, ,)) (VP (AUX are) (VP (VBN discussed))) (. .)))
1563460	3	(S1 (S (NP (NP (DT A) (JJ high) (NN index)) (PP (IN of) (NP (NN suspicion)))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (DT a) (JJ quick) (JJ diagnostic) (NN procedure)) (CC and) (NP (JJ successful) (JJ decompressive) (NN surgery)))))) (. .)))
1564030	0	(S1 (S (NP (NN Doc_1564030_0_5_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ Doc_1564030_22_32_Chemical) (NN treatment)) (PP (IN in) (NP (NNS adolescents)))))) (. .)))
1564030	1	(S1 (S (NP (NP (NNP Doc_1564030_59_69_Chemical)) (, ,) (NP (DT a) (JJ selective) (JJ Doc_1564030_83_92_Chemical) (NN reuptake) (NN inhibitor)) (, ,)) (VP (AUX is) (VP (VBG gaining) (NP (JJ increased) (NN acceptance)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ adolescent) (NN Doc_1564030_176_186_Disease))))))) (. .)))
1564030	2	(S1 (S (S (UCP (ADJP (RB Generally) (JJ safe)) (CC and) (VP (ADVP (RB well)) (VBN tolerated) (PP (IN by) (NP (NNS adults)))))) (, ,) (NP (NNP Doc_1564030_233_243_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (S (VP (TO to) (VP (VB induce) (NP (NN Doc_1564030_272_277_Disease)))))))) (. .)))
1564030	3	(S1 (S (NP (NP (DT The) (NNS cases)) (PP (IN of) (NP (NP (CD five) (JJ Doc_1564030_297_306_Disease) (NNS adolescents)) (, ,) (NP (NP (CD 14-16) (NNS years)) (PP (IN of) (NP (NN age)))) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NN Doc_1564030_354_359_Disease)) (PP (IN during) (NP (NP (NN pharmacotherapy)) (PP (IN with) (NP (NNP Doc_1564030_388_398_Chemical)))))))) (, ,)))) (VP (AUX are) (VP (VBN reported) (ADVP (RB here)))) (. .)))
1564030	4	(S1 (S (NP (NP (JJ Apparent) (NN risk) (NNS factors)) (PP (IN for) (NP (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_1564030_464_469_Disease)))) (CC or) (NP (NP (NNS hypomania)) (PP (IN during) (NP (NP (JJ Doc_1564030_490_500_Chemical) (NN pharmacotherapy)) (PP (IN in) (NP (DT this) (NN population))))))))) (VP (AUX were) (NP (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (JJ attention-deficit) (NNP Doc_1564030_578_600_Disease)) (CC and) (NP (JJ affective) (NNP Doc_1564030_615_644_Disease)))) (PP (IN with) (NP (JJ Doc_1564030_650_659_Disease) (NNS features)))) (: ;) (NP (NP (DT a) (NN family) (NN history)) (PP (IN of) (NP (NP (NNP Doc_1564030_690_708_Disease)) (, ,) (RB especially) (NP (NNP Doc_1564030_721_737_Disease))))) (: ;) (CC and) (NP (NP (DT a) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_1564030_758_774_Disease)))))) (. .)))
1564030	5	(S1 (S (NP (JJ Further) (NN study)) (VP (AUX is) (VP (VBN needed) (S (VP (VP (TO to) (VP (VB determine) (NP (DT the) (JJ optimal) (NN dosage)))) (CC and) (VP (TO to) (VP (VB identify) (NP (NP (NN risk) (NNS factors)) (SBAR (WHNP (WDT that)) (S (VP (VBP increase) (NP (NP (JJ individual) (NN vulnerability)) (PP (TO to) (NP (NP (JJ Doc_1564030_903_913_Chemical) (VBN induced) (NN Doc_1564030_922_927_Disease)) (PP (IN in) (NP (NNS adolescents)))))))))))))))) (. .)))
15696449	0	(S1 (NP (NP (NN Doc_15696449_0_25_Disease)) (PP (IN after) (NP (NP (JJ high-dose) (NN melphalan)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_15696449_69_97_Disease))))))) (PP (IN during) (NP (NN stem) (NN cell) (NN transplantation))) (. .)))
15696449	1	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (NNP Doc_15696449_158_186_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15696449_188_190_Disease)) (-RRB- -RRB-))))) (VP (AUX have) (NP (DT a) (JJ poor) (NN prognosis))) (. .)))
15696449	2	(S1 (S (NP (NP (JJ Median) (NN survival) (NN time)) (PP (IN from) (NP (JJ standard) (NNS treatments)))) (VP (AUX is) (NP (QP (RB only) (CD 17)) (NNS months))) (. .)))
15696449	3	(S1 (S (S (NP (NP (JJ High-dose) (JJ intravenous) (NN Doc_15696449_302_311_Chemical)) (VP (VBN followed) (PP (IN by) (NP (NP (JJ peripheral) (NN blood) (NN stem) (NN cell) (NN transplant)) (PRN (-LRB- -LRB-) (NP (NN PBSCT)) (-RRB- -RRB-)))))) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (NP (DT the) (ADJP (RBS most) (JJ promising)) (NN therapy))))))) (, ,) (CC but) (S (NP (NN treatment) (NN mortality)) (VP (MD can) (VP (AUX be) (ADJP (JJ high))))) (. .)))
15696449	4	(S1 (S (NP (DT The) (NNS authors)) (VP (AUX have) (VP (VBN noted) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_15696449_491_516_Disease)))) (PP (ADVP (RB immediately)) (IN after) (NP (JJ melphalan) (NN conditioning))))) (. .)))
15696449	5	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN undertaken) (S (VP (TO to) (VP (VP (ADVP (RB further)) (VB examine) (NP (PRP$ its) (NN risk) (NNS factors))) (CC and) (VP (VB impact) (PP (IN on) (NP (NN posttransplant) (NN mortality))))))))) (. .)))
15696449	6	(S1 (S (NP (NP (JJ Consecutive) (JJ Doc_15696449_682_684_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NN PBSCT)))))) (VP (AUX were) (VP (VBN studied) (ADVP (RB retrospectively)))) (. .)))
15696449	7	(S1 (S (NP (NP (NN Doc_15696449_744_769_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15696449_771_774_Disease)) (-RRB- -RRB-)) (PP (IN after) (NP (JJ high-dose) (NN melphalan)))) (VP (AUX was) (VP (VBN defined) (PP (IN by) (NP (NP (DT a) (JJ minimum) (NN increase)) (PP (IN of) (NP (NP (CD 0.5) (NNS mg/dL)) (PRN (-LRB- -LRB-) (NP (CD 44) (NNS micromol/L)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (DT the) (JJ serum) (JJ Doc_15696449_878_888_Chemical) (NN level)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (NP (NP (QP (JJR greater) (IN than) (CD 50)) (NN %)) (PP (IN of) (NP (NN baseline)))) (PP (ADVP (RB immediately)) (IN after) (NP (NN conditioning)))))))))))) (. .)))
15696449	8	(S1 (S (NP (NN Urine) (NN sediment) (NN score)) (VP (AUX was) (NP (NP (DT the) (NN sum)) (PP (IN of) (NP (NP (DT the) (JJ individual) (NNS types)) (PP (IN of) (NP (NN sediment))) (VP (VBN identified) (PP (IN on) (NP (NN urine) (NN microscopy)))))))) (. .)))
15696449	9	(S1 (S (PP (IN Of) (NP (NP (DT the) (CD 80) (NNS patients)) (VP (VBN studied)))) (, ,) (NP (NNP Doc_15696449_1102_1105_Disease)) (VP (VBD developed) (PP (IN in) (NP (NP (CD 18.8) (NN %)) (PP (IN of) (NP (DT the) (NNS patients))))) (PP (IN after) (NP (JJ high-dose) (NN melphalan)))) (. .)))
15696449	10	(S1 (S (NP (JJ Univariate) (NN analysis)) (VP (VBN identified) (NP (NP (NN age)) (, ,) (NP (NNP Doc_15696449_1204_1219_Disease)) (, ,) (NP (JJ heavy) (NN Doc_15696449_1227_1238_Disease)) (, ,) (NP (JJ diuretic) (NN use)) (, ,) (CC and) (NP (NP (NN urine) (NN sediment) (NN score)) (PRN (-LRB- -LRB-) (NP (NN >3)) (-RRB- -RRB-)))) (PP (IN as) (NP (NN risk) (NNS factors)))) (. .)))
15696449	11	(S1 (S (NP (NP (NN Age)) (CC and) (NP (NN urine) (NN sediment) (NN score))) (VP (VBD remained) (ADVP (RB independently)) (NP (JJ significant) (NN risk) (NNS factors)) (PP (IN in) (NP (DT the) (JJ multivariate) (NN analysis)))) (. .)))
15696449	12	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NNP Doc_15696449_1425_1428_Disease)) (PP (IN after) (NP (JJ high-dose) (NN melphalan))))))) (VP (VP (VBD underwent) (NP (NN dialysis)) (ADVP (RBR more) (RB often)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.007)) (-RRB- -RRB-))) (, ,) (CC and) (VP (AUX had) (NP (NP (DT a) (ADJP (RBR worse) (JJ 1-year)) (NN survival)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (SYM =) (NP (CD 0.03)))) (-RRB- -RRB-))))) (. .)))
15696449	13	(S1 (S (NP (NP (DT The) (NN timing)) (PP (IN of) (NP (NNP Doc_15696449_1568_1580_Disease)))) (ADVP (RB strongly)) (VP (VBZ suggests) (NP (NN melphalan)) (PP (IN as) (NP (DT the) (JJ causative) (NN agent)))) (. .)))
15696449	14	(S1 (S (NP (JJ Ongoing) (NN Doc_15696449_1641_1655_Disease)) (VP (MD may) (VP (AUX be) (NP (NP (DT a) (NN prerequisite)) (PP (IN for) (NP (NNP Doc_15696449_1682_1694_Disease)))) (PP (IN by) (NP (NN melphalan))) (SBAR (IN as) (S (VP (VBN evidenced) (PP (IN by) (NP (DT the) (JJ active) (JJ urinary) (NN sediment)))))))) (. .)))
15696449	15	(S1 (S (NP (NP (NN Development)) (PP (IN of) (NP (NNP Doc_15696449_1768_1771_Disease)))) (ADVP (RB adversely)) (VP (VBD affected) (NP (DT the) (NN outcome)) (PP (IN after) (NP (NN PBSCT)))) (. .)))
15696449	16	(S1 (S (NP (JJ Effective) (JJ preventive) (NNS measures)) (VP (MD may) (VP (VB help) (VP (VB decrease) (NP (NP (DT the) (NN treatment) (NN mortality)) (PP (IN of) (NP (NN PBSCT))) (PP (IN in) (NP (JJ Doc_15696449_1900_1902_Disease) (NNS patients))))))) (. .)))
15815446	0	(S1 (NP (NP (NP (JJ Focal) (NN Doc_15815446_6_23_Disease)) (PP (IN in) (NP (NNS rats)))) (: :) (NP (NP (NN effect)) (PP (IN of) (NP (NNP Doc_15815446_43_56_Chemical-induced) (NNP Doc_15815446_65_77_Disease))) (PP (IN during) (NP (NN reperfusion)))) (. .)))
15815446	1	(S1 (S (PP (IN After) (NP (NP (CD 180) (NN min)) (PP (IN of) (NP (NNP Doc_15815446_115_157_Disease))) (PP (IN in) (NP (ADJP (RB spontaneously) (JJ Doc_15815446_175_187_Disease)) (NNS rats))))) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_15815446_208_221_Chemical-induced) (NNP Doc_15815446_230_242_Disease))) (PP (IN on) (NP (NP (NNP Doc_15815446_246_267_Disease)) (CC and) (NP (JJ blood-brain) (NN barrier) (NN permeability))))) (VP (AUX was) (VP (VBN determined))) (. .)))
15815446	2	(S1 (S (S (NP (NN Blood) (NN pressure)) (VP (AUX was) (VP (VBN manipulated) (PP (IN by) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ following) (NNS schedules)) (PP (IN during) (NP (NP (CD 120) (NN min)) (PP (IN of) (NP (NN reperfusion)))))))))))) (: :) (S (NP (NP (NNP Control)) (, ,) (NP (NP (JJ normotensive) (NN reperfusion)) (: ;) (NP (NP (NN 90/Doc_15815446_455_467_Disease)) (PRN (-LRB- -LRB-) (NP (NN 90/HTN)) (-RRB- -RRB-)))) (, ,)) (NP (NN blood) (NN pressure)) (VP (AUX was) (VP (VBN increased) (PP (IN by) (NP (CD 35) (NN mm))) (NP (NNP Hg)) (PP (IN during) (NP (NP (DT the) (JJ initial) (CD 90) (NN min)) (PP (IN of) (NP (NP (NN reperfusion) (RB only)) (: ;) (NP (NP (NN 15/Doc_15815446_569_581_Disease)) (PRN (-LRB- -LRB-) (NP (CD 15/HTN)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ normotensive) (NN reperfusion)) (PP (IN for) (NP (NP (CD 30) (NN min)) (VP (VBN followed) (PP (IN by) (NP (NP (NP (CD 15) (NN min)) (PP (IN of) (NP (NNP Doc_15815446_650_662_Disease)))) (CC and) (NP (NP (CD 75) (NN min)) (PP (IN of) (NP (NN normotension))))))))))))))))) (. .)))
15815446	3	(S1 (S (NP (NP (NNP Part) (NNP A)) (, ,) (PP (IN for) (NP (CD eight) (NNS rats))) (PP (IN in) (NP (DT each) (NN group) (NN Doc_15815446_728_740_Disease)))) (VP (AUX was) (VP (VBN evaluated) (PP (IN by) (S (VP (VBG staining) (NP (NP (NN tissue)) (VP (VBG using) (SBAR (S (NP (NNP Doc_15815446_780_815_Chemical) (CC and) (NNP Doc_15815446_820_825_Disease)) (VP (AUX was) (VP (VBN evaluated) (PP (IN by) (NP (NN microgravimetry)))))))))))))) (. .)))
15815446	4	(S1 (S (NP (NP (NNP Part) (NNP B)) (, ,) (PP (IN for) (NP (CD eight) (JJ different) (NNS rats))) (PP (IN in) (NP (DT each) (NN group) (NN blood-brain) (NN barrier) (NN permeability)))) (VP (AUX was) (VP (VBN evaluated) (PP (IN by) (S (VP (VBG measuring) (NP (NP (DT the) (NN amount) (CC and) (NN extent)) (PP (IN of) (NP (NP (NN extravasation)) (PP (IN of) (NP (NNP Evans) (NNP Blue) (NN dye))))))))))) (. .)))
15815446	5	(S1 (S (NP (NP (NN Doc_15815446_1025_1037_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN percentage)) (PP (IN of) (NP (DT the) (JJ ischemic) (NN hemisphere)))) (-RRB- -RRB-))) (VP (AUX was) (ADJP (ADJP (NP (NP (JJR less)) (PP (IN in) (NP (NP (NP (DT the) (JJ 15/HTN) (NN group)) (PRN (-LRB- -LRB-) (NP (CD 16) (NN +/-) (CD 6)) (, ,) (NP (JJ mean) (JJ +/-) (NN SD)) (-RRB- -RRB-))) (CC versus) (NP (NP (DT the) (JJ 90/HTN) (NN group)) (PRN (-LRB- -LRB-) (NP (QP (CD 30) (CD +/-)) (CD 6)) (-RRB- -RRB-)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (PP (IN in) (NP (NN turn)))))))))) (JJR less)) (PP (IN than) (NP (DT the) (NN control) (NN group)))) (PRN (-LRB- -LRB-) (NP (QP (CD 42) (CD +/-)) (CD 5)) (-RRB- -RRB-))) (. .)))
15815446	6	(S1 (S (NP (JJ Specific) (NN gravity)) (VP (VP (AUX was) (ADJP (JJR greater)) (PP (IN in) (NP (NP (NP (DT the) (JJ 15/HTN) (NN group)) (PRN (-LRB- -LRB-) (NP (QP (CD 1.043) (CD +/-)) (CD 0.002)) (-RRB- -RRB-))) (CC versus) (NP (NP (DT the) (NN 90/HTN)) (PRN (-LRB- -LRB-) (NP (QP (CD 1.036) (CD +/-)) (CD 0.003)) (-RRB- -RRB-)))))) (CC and) (VP (VBP control) (NP (PRN (-LRB- -LRB-) (NP (QP (CD 1.037) (CD +/-)) (CD 0.003)) (-RRB- -RRB-)) (NNS groups)))) (. .)))
15815446	7	(S1 (S (NP (NP (NN Doc_15815446_1366_1376_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (JJ mug) (NN g-1)) (PP (IN of) (NP (NN brain) (NN tissue)))) (-RRB- -RRB-))) (VP (AUX was) (ADJP (JJR greater)) (PP (IN in) (NP (NP (NP (DT the) (JJ 90/HTN) (NN group)) (PRN (-LRB- -LRB-) (NP (QP (CD 24.4) (CD +/-)) (CD 6.0)) (-RRB- -RRB-))) (CC versus) (NP (NP (DT the) (NN control) (NN group)) (PRN (-LRB- -LRB-) (NP (QP (CD 12.3) (CD +/-)) (CD 4.1)) (-RRB- -RRB-)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (PP (IN in) (NP (NP (NN turn)) (ADJP (ADJP (JJR greater)) (PP (IN than) (NP (NP (DT the) (JJ 15/HTN) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (CD 7.3) (NNS +/-)) (NP (CD 3.2))) (-RRB- -RRB-)))))))))))))) (. .)))
15815446	8	(S1 (S (S (NP (DT This) (NN study)) (VP (VBZ supports) (NP (NP (DT a) (NN hypothesis)) (SBAR (WHNP (IN that)) (S (PP (IN during) (NP (NN reperfusion))) (, ,) (NP (NP (DT a) (JJ short) (NN interval)) (PP (IN of) (NP (NNP Doc_15815446_1632_1644_Disease)))) (VP (VBZ decreases) (NP (NP (NNP Doc_15815446_1655_1667_Disease)) (CC and) (NP (NNP Doc_15815446_1672_1677_Disease))))))))) (: ;) (CC and) (S (NP (DT that) (JJ sustained) (NN Doc_15815446_1698_1710_Disease)) (VP (VBZ increases) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ vasogenic) (NNP Doc_15815446_1743_1748_Disease)))))) (. .)))
15817013	0	(S1 (FRAG (S (NP (NNS People)) (VP (VBN aged) (PP (IN over) (NP (CD 75))) (PP (IN in) (NP (NNP Doc_15817013_23_42_Disease))) (PP (IN on) (NP (NNP Doc_15817013_46_54_Chemical))))) (: :) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NP (JJ major) (NNP Doc_15817013_74_84_Disease)) (CC and) (NP (NNP Doc_15817013_89_95_Disease)))) (PP (IN in) (NP (NP (QP (JJR more) (IN than) (CD 500)) (NNS patient-years)) (PP (IN of) (NP (NN follow-up)))))) (. .)))
15817013	1	(S1 (FRAG (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ major) (NNP Doc_15817013_189_199_Disease) (CC and) (NNP Doc_15817013_204_210_Disease))) (PP (IN in) (NP (NP (NNS people)) (VP (VBN aged) (NP (NP (CD 76)) (CC and) (NP (NP (JJR older)) (PP (IN with) (NP (NNP Doc_15817013_244_263_Disease))))) (PP (IN on) (NP (JJ adjusted-dose) (NNP Doc_15817013_281_289_Chemical)))) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX been) (ADVP (RB recently)) (VP (AUX been) (VP (VBN admitted) (PP (TO to) (NP (NN hospital))))))))))))))) (. .)))
15817013	2	(S1 (FRAG (NP (DT A) (JJ retrospective) (JJ observational) (NN cohort) (NN study)) (. .)))
15817013	3	(S1 (S (NP (DT A) (JJ major) (NN healthcare) (NN network)) (VP (VBG involving) (NP (CD four) (JJ tertiary) (NNS hospitals))) (. .)))
15817013	4	(S1 (S (NP (NP (QP (CD Two) (CD hundred)) (JJ thirty-five) (NNS patients)) (VP (VBN aged) (NP (NP (NP (CD 76) (CC and) (JJR older)) (VP (VBN admitted) (PP (TO to) (NP (NP (DT a) (JJ major) (NN healthcare) (NN network)) (PP (IN between) (NP (NNP July) (CD 1) (, ,) (CD 2001))))))) (, ,) (CC and) (NP (NNP June) (CD 30) (, ,) (CD 2002)) (, ,)) (PP (IN with) (NP (NNP Doc_15817013_612_631_Disease))) (PP (IN on) (NP (NNP Doc_15817013_635_643_Chemical))))) (VP (AUX were) (VP (VBD enrolled))) (. .)))
15817013	5	(S1 (S (NP (NP (NN Information)) (VP (VBG regarding) (NP (NP (JJ major) (JJ Doc_15817013_701_709_Disease) (NNS episodes)) (, ,) (NP (NN Doc_15817013_720_727_Disease)) (, ,) (CC and) (NP (JJ Doc_15817013_733_741_Chemical) (NN use))))) (VP (AUX was) (VP (VBN obtained) (PP (IN from) (NP (NP (NNS patients)) (, ,) (NP (NNS relatives)) (, ,) (NP (JJ primary) (NNS physicians)) (, ,) (CC and) (NP (JJ medical) (NNS records)))))) (. .)))
15817013	6	(S1 (S (NP (NP (NP (QP (CD Two) (CD hundred)) (JJ twenty-eight) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 42) (NN %) (NNS men)) (-RRB- -RRB-))) (PP (IN with) (NP (NP (DT a) (JJ mean) (NN age)) (PP (IN of) (NP (CD 81.1))))) (PRN (-LRB- -LRB-) (NP (NN range) (CD 76-94)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (DT the) (NN analysis))))) (. .)))
15817013	7	(S1 (S (NP (NP (JJ Total) (NN follow-up)) (PP (IN on) (NP (NNP Doc_15817013_967_975_Chemical)))) (VP (AUX was) (NP (NP (CD 530) (NNS years)) (PRN (-LRB- -LRB-) (NP (JJ mean) (CD 28) (NNS months)) (-RRB- -RRB-)))) (. .)))
15817013	8	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (CD 53) (JJ major) (NN Doc_15817013_1028_1039_Disease)) (, ,) (PP (IN for) (NP (NP (DT an) (JJ annual) (NN rate)) (PP (IN of) (NP (CD 10.0) (NN %))))) (, ,) (PP (VBG including) (NP (NP (CD 24) (PRN (-LRB- -LRB-) (NP (CD 45.3) (NN %)) (-RRB- -RRB-)) (JJ life-threatening)) (CC and) (NP (CD five) (PRN (-LRB- -LRB-) (NP (CD 9.4) (NN %)) (-RRB- -RRB-)) (JJ fatal) (NN Doc_15817013_1130_1136_Disease)))))) (. .)))
15817013	9	(S1 (S (NP (NP (DT The) (JJ Doc_15817013_1142_1155_Disease) (NN rate)) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (NNP Doc_15817013_1181_1189_Chemical)))))) (VP (AUX was) (NP (CD 2.6) (NN %))) (. .)))
15817013	10	(S1 (S (S (NP (NP (DT The) (NN rate)) (PP (IN of) (NP (JJ major) (NNP Doc_15817013_1230_1240_Disease)))) (VP (AUX was) (UCP (ADJP (JJ high) (PP (IN in) (NP (DT this) (JJ old) (, ,) (JJ frail) (NN group)))) (, ,) (CC but) (VP (VBG excluding) (NP (NNS fatalities)))) (, ,) (S (VP (VBN resulted) (PP (IN in) (NP (DT no) (JJ long-term) (NNS sequelae))))))) (, ,) (CC and) (S (NP (NP (DT the) (JJ Doc_15817013_1345_1351_Disease) (NN rate)) (PP (IN on) (NP (NNP Doc_15817013_1360_1368_Chemical)))) (VP (AUX was) (ADJP (JJ low)) (, ,) (S (VP (VBG demonstrating) (SBAR (WHADVP (WRB how)) (S (NP (JJ effective) (JJ Doc_15817013_1406_1414_Chemical) (NN treatment)) (VP (AUX is)))))))) (. .)))
15859361	0	(S1 (S (NP (NP (NN Safety)) (PP (IN of) (NP (NNP Doc_15859361_10_19_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ adverse) (NN skin) (NNS reactions)) (PP (TO to) (NP (NP (NP (NNP Doc_15859361_63_76_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15859361_78_89_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_15859361_95_105_Chemical))))))))) (VP (VBN associated) (PP (CC or) (PP (RB not) (IN with) (NP (JJ common) (JJ non-steroidal) (JJ anti-inflammatory) (NNS drugs))))) (. .)))
15859361	1	(S1 (S (NP (NP (NP (NNP Doc_15859361_187_200_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15859361_202_213_Chemical--Doc_15859361_215_216_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_15859361_222_232_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15859361_234_235_Chemical)) (-RRB- -RRB-)))) (VP (AUX are) (ADVP (RB widely)) (VP (VBN used) (NP (JJ analgesic-antipyretic/anti-inflammatory) (NNS drugs)))) (. .)))
15859361	2	(S1 (S (NP (NP (DT The) (NN rate)) (PP (IN of) (NP (JJ adverse) (NN Doc_15859361_320_336_Disease) (NNS reactions))) (PP (TO to) (NP (DT these) (NNS agents)))) (VP (AUX is) (ADVP (RB generally)) (ADJP (JJ low))) (. .)))
15859361	3	(S1 (S (PP (IN On) (NP (DT the) (NN contrary))) (NP (NP (JJ non-steroidal) (JJ anti-inflammatory) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNP NSAIDs)) (-RRB- -RRB-))) (VP (AUX are) (ADVP (RB commonly)) (VP (VBN involved) (PP (IN in) (NP (JJ such) (NNS reactions))))) (. .)))
15859361	4	(S1 (S (NP (NP (NNP Doc_15859361_485_494_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP CE)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (JJ novel) (NN drug)) (, ,) (PP (IN with) (NP (NP (JJ high) (NN selectivity)) (CC and) (NP (NP (NN affinity)) (PP (IN for) (NP (JJ COX-2) (NN enzyme)))))))) (. .)))
15859361	5	(S1 (S (NP (PRP We)) (VP (VBN evaluated) (NP (NP (DT the) (NN tolerability)) (PP (IN of) (NP (NNS CE)))) (PP (IN in) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (VBN documented) (NN history)) (PP (IN of) (NP (NP (JJ adverse) (JJ cutaneous) (NNS reactions)) (PP (TO to) (NP (NNP P) (CC and) (NNP Doc_15859361_704_705_Chemical))) (VP (VBN associated) (FRAG (CC or) (RB not) (PP (TO to) (NP (JJ classic) (NNS NSAIDs)))))))))))))) (. .)))
15859361	6	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (CD 9) (NNS patients)) (PP (IN with) (NP (NNP Doc_15859361_779_795_Disease)))) (PP (TO to) (NP (NP (NNP P)) (CC and) (NP (NNP Doc_15859361_805_806_Chemical)))) (PP (IN with) (CC or) (PP (IN without) (NP (NP (JJ associated) (NNS reactions)) (PP (TO to) (NP (JJ classic) (NNS NSAIDs))))))) (. .)))
15859361	7	(S1 (S (NP (NP (DT The) (NN diagnosis)) (PP (IN of) (NP (NP (NNS P)) (CC and) (NP (JJ Doc_15859361_886_887_Chemical-induced) (NN skin) (NNS reactions))))) (VP (AUX was) (VP (VBN based) (PP (IN in) (NP (NN vivo) (NN challenge))))) (. .)))
15859361	8	(S1 (S (NP (DT The) (NN placebo)) (VP (AUX was) (ADVP (RB blindly)) (VP (VBN administered) (PP (IN at) (NP (NP (DT the) (NN beginning)) (PP (IN of) (NP (DT each) (NN challenge))))))) (. .)))
15859361	9	(S1 (S (PP (IN After) (NP (CD three) (NNS days))) (, ,) (NP (NP (DT a) (JJ cumulative) (NN dosage)) (PP (IN of) (NP (NP (CD 200) (NNS mg)) (PP (IN of) (NP (NN CE))))) (PP (IN in) (NP (JJ refracted) (NNS doses)))) (VP (AUX were) (VP (VBN given))) (. .)))
15859361	10	(S1 (S (PP (IN After) (NP (CD 2-3) (NNS days))) (, ,) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (CD 200) (NNS mg)))) (VP (AUX was) (VP (VBN administered))) (. .)))
15859361	11	(S1 (S (NP (DT All) (NNS patients)) (VP (VP (AUX were) (VP (VBN observed) (PP (IN for) (NP (NP (CD 6) (NNS hours)) (PP (IN after) (NP (DT each) (NN challenge))))))) (, ,) (CC and) (VP (VBD controlled) (ADVP (RB again)) (PP (IN after) (NP (NP (CD 24) (NNS hours)) (SBAR (S (VP (TO to) (VP (VB exclude) (NP (JJ delayed) (NNS reactions)))))))))) (. .)))
15859361	12	(S1 (S (NP (DT The) (NN challenge)) (VP (AUX was) (VP (VBN considered) (ADJP (JJ positive)) (SBAR (IN if) (S (NP (NP (QP (CD one) (CC or) (JJR more))) (PP (IN of) (NP (DT the) (NN following)))) (VP (VBD appeared) (: :) (NP (NP (NN erythema)) (, ,) (NP (NN rush)) (CC or) (NP (NNP Doc_15859361_1381_1390_Disease-Doc_15859361_1391_1401_Disease)))))))) (. .)))
15859361	13	(S1 (S (S (NP (DT No) (NN reaction)) (VP (AUX was) (VP (VBN observed) (PP (IN with) (NP (NN placebo)))))) (CC and) (S (NP (NP (CD eight) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 88.8) (NN %)) (-RRB- -RRB-))) (VP (VBD tolerated) (NP (CD CE)))) (. .)))
15859361	14	(S1 (S (NP (QP (RB Only) (CD one)) (NN patient)) (VP (VBD developed) (NP (NP (DT a) (JJ moderate) (NN Doc_15859361_1529_1539_Disease)) (PP (IN of) (NP (DT the) (NNS lips))))) (. .)))
15859361	15	(S1 (S (NP (NP (QP (RB Only) (CD one)) (JJ Doc_15859361_1574_1590_Disease) (NN reaction)) (PP (TO to) (NP (NN CE)))) (VP (AUX was) (VP (VBN documented) (PP (IN among) (NP (NP (CD 9) (NNS P)) (CC and) (NP (JJ Doc_15859361_1635_1636_Chemical-highly) (JJ NSAIDs) (NN intolerant) (NNS patients)))))) (. .)))
15859361	16	(S1 (S (ADVP (RB Thus)) (, ,) (NP (PRP we)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NN CE)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB reasonably) (JJ safe)) (NN alternative)) (SBAR (S (VP (TO to) (VP (AUX be) (VP (VBN used) (PP (IN in) (NP (NP (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (AUX do) (RB not) (VP (VB tolerate) (NP (NP (NNP P)) (CC and) (NP (NNP Doc_15859361_1780_1781_Chemical))))))))))))))))))) (. .)))
15882284	0	(S1 (NP (NP (JJ Case-control) (NN study)) (PP (IN of) (NP (NP (JJ regular) (JJ analgesic) (CC and) (JJ nonsteroidal) (NN anti-inflammatory) (NN use)) (CC and) (NP (NN Doc_15882284_83_106_Disease)))) (. .)))
15882284	1	(S1 (S (NP (NP (NNS Studies)) (PP (IN on) (NP (NP (DT the) (NN association)) (PP (IN between) (NP (NP (DT the) (JJ long-term) (NN use)) (PP (IN of) (NP (NP (NP (NP (NNP Doc_15882284_176_183_Chemical)) (CC and) (NP (JJ other) (JJ analgesic) (CC and) (JJ nonsteroidal) (NN anti-inflammatory) (NNS drugs))) (PRN (-LRB- -LRB-) (NP (NNP NSAIDs)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_15882284_258_281_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15882284_283_287_Disease)) (-RRB- -RRB-)))))))))) (VP (AUX have) (VP (VBN given) (NP (JJ conflicting) (NNS results)))) (. .)))
15882284	2	(S1 (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB examine) (NP (DT this) (NN association)))))) (, ,) (NP (NP (DT a) (JJ case-control) (NN study)) (PP (IN with) (NP (NP (NN incident) (NNS cases)) (PP (IN of) (NP (NNP Doc_15882284_403_407_Disease)))))) (VP (AUX was) (VP (VBN carried) (PRT (RP out)))) (. .)))
15882284	3	(S1 (S (NP (DT The) (NNS cases)) (VP (AUX were) (NP (NP (DT all) (NNS patients)) (VP (VBG entering) (NP (DT the) (JJ local) (NN dialysis) (NN program)))) (PP (IN because) (IN of) (NP (NP (NNP Doc_15882284_509_513_Disease)) (PP (IN in) (NP (NP (DT the) (NN study) (NN area)) (PP (IN between) (NP (NP (NNP June) (CD 1) (, ,) (CD 1995)) (CC and) (NP (NNP November) (CD 30) (, ,) (CD 1997))))))))) (. .)))
15882284	4	(S1 (S (NP (PRP They)) (VP (AUX were) (VP (VBN classified) (PP (VBG according) (PP (TO to) (NP (NP (DT the) (VBG underlying) (NN disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX had) (ADVP (RB presumably)) (VP (VBN led) (NP (PRP them)) (PP (TO to) (NP (NN Doc_15882284_667_671_Disease)))))))))))) (. .)))
15882284	5	(S1 (S (NP (NNS Controls)) (VP (AUX were) (NP (NP (NNS patients)) (VP (VBN admitted) (PP (TO to) (NP (NP (DT the) (JJ same) (NNS hospitals)) (PP (IN from) (SBAR (WHADVP (WRB where)) (S (NP (DT the) (NNS cases)) (VP (VBD arose))))) (, ,) (VP (ADVP (RB also)) (VBN matched) (PP (IN by) (NP (NP (NN age)) (CC and) (NP (NN sex)))))))))) (. .)))
15882284	6	(S1 (S (NP (NNS Odds) (NNS ratios)) (VP (AUX were) (VP (VBN calculated) (S (VP (VBG using) (NP (NP (DT a) (JJ conditional) (NN logistic) (NN model)) (, ,) (PP (VBG including) (NP (NP (JJ potential) (JJ confounding) (NNS factors)) (, ,) (PP (DT both) (PP (IN for) (NP (DT the) (JJ whole) (NN study) (NN population))) (CC and) (PP (IN for) (NP (DT the) (JJ various) (JJ underlying) (NNS diseases))))))))))) (. .)))
15882284	7	(S1 (S (NP (NP (QP (CD Five) (CD hundred) (CC and) (CD eighty-three)) (NNS cases)) (CC and) (NP (CD 1190) (NNS controls))) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (DT the) (NN analysis))))) (. .)))
15882284	8	(S1 (S (NP (NP (JJ Long-term) (NN use)) (PP (IN of) (NP (DT any) (JJ analgesic)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (JJ overall) (NNS odds) (NN ratio)) (PP (IN of) (NP (CD 1.22))))) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (CD CI) (, ,) (CD 0.89-1.66)) (-RRB- -RRB-)))) (. .)))
15882284	9	(S1 (S (PP (IN For) (NP (NP (JJ specific) (NNS groups)) (PP (IN of) (NP (NNS drugs))))) (, ,) (NP (DT the) (NNS risks)) (VP (AUX were) (NP (NP (NP (CD 1.56)) (PRN (-LRB- -LRB-) (NP (CD 1.05-2.30)) (-RRB- -RRB-)) (PP (IN for) (NP (NNP Doc_15882284_1228_1235_Chemical)))) (, ,) (NP (NP (CD 1.03)) (PRN (-LRB- -LRB-) (NP (CD 0.60-1.76)) (-RRB- -RRB-)) (PP (IN for) (NP (NNP Doc_15882284_1258_1269_Chemical)))) (, ,) (NP (NP (CD 0.80)) (PRN (-LRB- -LRB-) (NP (CD 0.39-1.63)) (-RRB- -RRB-)) (PP (IN for) (NP (NNP Doc_15882284_1292_1303_Chemical)))) (, ,) (CC and) (NP (NP (CD 0.94)) (PRN (-LRB- -LRB-) (NP (CD 0.57-1.56)) (-RRB- -RRB-)) (PP (IN for) (NP (JJ Doc_15882284_1330_1340_Chemical) (NNS NSAIDs)))))) (. .)))
15882284	10	(S1 (S (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (NNP Doc_15882284_1361_1365_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_15882284_1382_1389_Chemical))))) (VP (AUX was) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (JJ cumulated) (NN dose) (CC and) (NN duration)) (PP (IN of) (NP (NN use)))))))) (, ,) (CC and) (S (NP (PRP it)) (VP (AUX was) (ADJP (RB particularly) (JJ high)) (PP (IN among) (NP (NP (DT the) (NN subset)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ vascular) (NNP Doc_15882284_1517_1528_Disease))))))) (PP (IN as) (NP (JJ underlying) (NN disease) (NN -LSB-2.35) (PRN (-LRB- -LRB-) (NP (CD 1.17-4.72)) (-RRB- -RRB-)) (NN -RSB-))))) (. .)))
15882284	11	(S1 (S (NP (PRP$ Our) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ long-term) (NN use)) (PP (IN of) (NP (NP (JJ Doc_15882284_1623_1633_Chemical) (JJ analgesic) (NNS drugs)) (CC and) (NP (NNS NSAIDs))))) (VP (AUX is) (RB not) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NN Doc_15882284_1705_1709_Disease)))))))))) (. .)))
15882284	12	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ chronic) (NN use)) (PP (IN of) (NP (NNP Doc_15882284_1739_1746_Chemical)))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_15882284_1772_1776_Disease)))))) (. .)))
15953230	0	(S1 (NP (NP (NP (CD Two) (NNS cases)) (PP (IN of) (NP (NNP Doc_15953230_13_24_Chemical) (NNP Doc_15953230_25_33_Disease)))) (: :) (NP (NP (DT a) (NN cause)) (PP (IN for) (NP (NNP Doc_15953230_47_68_Disease)))) (. .)))
15953230	1	(S1 (S (NP (NP (CD Two) (NNS cases)) (PP (IN of) (NP (JJ deliberate) (NN self-poisoning))) (PP (IN with) (NP (NP (CD 5) (NNP g)) (CC and) (NP (NP (NP (CD 3.6) (NNP g)) (PP (IN of) (NP (NNP Doc_15953230_131_142_Chemical)))) (, ,) (ADVP (RB respectively)) (, ,))))) (VP (AUX are) (VP (VBN reported))) (. .)))
15953230	2	(S1 (S (PP (IN In) (NP (DT both) (NNS cases))) (, ,) (NP (NP (NN Doc_15953230_187_202_Disease)) (CC and) (NP (NN hypocalcaemia))) (VP (AUX were) (VP (VBN noted))) (. .)))
15953230	3	(S1 (S (NP (DT The) (NNP Doc_15953230_237_252_Disease)) (VP (VBD appeared) (S (VP (TO to) (VP (VB respond) (PP (TO to) (NP (NP (NN administration)) (PP (IN of) (NP (CD i.v.) (NN Doc_15953230_299_316_Chemical))))))))) (. .)))
15987266	0	(S1 (NP (NP (NP (JJ Growth-associated) (NN protein)) (NP (CD 43) (NN expression))) (PP (IN in) (NP (NP (JJ hippocampal) (JJ molecular) (NN layer)) (PP (IN of) (NP (NP (JJ chronic) (JJ Doc_15987266_82_91_Disease) (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_15987266_110_123_Chemical)))))))) (. .)))
15987266	1	(S1 (S (NP (CD GAP43)) (VP (AUX has) (VP (AUX been) (VP (VBN thought) (S (VP (TO to) (VP (AUX be) (VP (VBN linked) (PP (IN with) (NP (NP (NNP Doc_15987266_175_196_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15987266_198_201_Disease)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (JJ various) (JJ experimental) (NNS models)) (PP (IN of) (NP (NN Doc_15987266_237_245_Disease)))))))))))) (. .)))
15987266	2	(S1 (S (VP (TO To) (VP (VB investigate) (SBAR (WHADVP (WRB how)) (S (NP (NP (CD GAP43) (NN expression)) (PRN (-LRB- -LRB-) (NP (NNP GAP43-ir)) (-RRB- -RRB-))) (VP (VBZ correlates) (SBAR (S (PP (IN with) (NP (NNP Doc_15987266_310_313_Disease))) (, ,) (NP (PRP we)) (VP (VBD assessed) (NP (NP (NP (NP (DT the) (NN intensity)) (PRN (-LRB- -LRB-) (NP (NN densitometry)) (-RRB- -RRB-))) (CC and) (NP (NP (NN extension)) (PRN (-LRB- -LRB-) (NP (NN width)) (-RRB- -RRB-)))) (PP (IN of) (NP (NN GAP43-ir)))) (PP (IN in) (NP (NP (DT the) (JJ inner) (JJ molecular) (NN layer)) (PP (IN of) (NP (NP (DT the) (JJ dentate) (NN gyrus)) (PRN (-LRB- -LRB-) (NP (NNP IML)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NNS rats)) (ADJP (JJ subject) (PP (TO to) (NP (NP (NNP Doc_15987266_465_483_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_15987266_495_506_Chemical)))) (PRN (-LRB- -LRB-) (NP (NNP Pilo)) (-RRB- -RRB-)))) (, ,) (ADJP (RB previously) (VBN injected)) (CC or) (RB not) (PP (IN with) (NP (NP (NNP Doc_15987266_547_560_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_15987266_562_565_Chemical)) (-RRB- -RRB-))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VB inhibit) (NP (NNP Doc_15987266_600_603_Disease)))))))))))))))))))))) (. .)))
15987266	3	(S1 (S (NP (NN Doc_15987266_614_617_Chemical)) (VP (AUX was) (VP (VBN injected) (PP (IN before) (NP (DT the) (NNP Pilo) (NN injection))) (PP (IN in) (NP (JJ adult) (JJ Wistar) (NNS rats))))) (. .)))
15987266	4	(S1 (S (NP (DT The) (NNP Pilo) (NN group)) (VP (AUX was) (VP (VBN injected) (PP (IN with) (NP (DT the) (JJ same) (NNS drugs))) (, ,) (PP (IN except) (PP (IN for) (NP (NNP Doc_15987266_739_742_Chemical)))))) (. .)))
15987266	5	(S1 (S (S (NP (NNS Animals)) (VP (AUX were) (VP (VBN killed) (PP (IN between) (NP (CD 30) (CC and) (CD 60) (NNS days))) (ADVP (RB later))))) (, ,) (CC and) (S (NP (NN brain) (NNS sections)) (VP (AUX were) (VP (VBN processed) (PP (IN for) (NP (CD GAP43) (NN immunohistochemistry)))))) (. .)))
15987266	6	(S1 (S (NP (NN Densitometry)) (VP (VBD showed) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (VBG regarding) (NP (NP (NN GAP43-ir)) (PP (IN in) (NP (DT the) (NNP IML))))) (PP (IN between) (NP (NP (NNP Pilo)) (, ,) (NP (NNP Doc_15987266_959_962_Chemical+Pilo)) (, ,) (CC and) (NP (NN control) (NNS groups)))))) (. .)))
15987266	7	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (NP (DT the) (NN width)) (PP (IN of) (NP (NP (DT the) (JJ GAP43-ir) (NN band)) (PP (IN in) (NP (DT the) (NN IML)))))))) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NNP Doc_15987266_1067_1070_Chemical+Pilo)) (CC and) (NP (NN control) (NNS animals))) (VP (AUX had) (NP (NP (DT a) (ADJP (RB significantly) (JJR larger)) (NN band)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.03)) (-RRB- -RRB-))) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NP (DT that)) (PP (IN in) (NP (DT the) (NNP Pilo) (NN group)))))))))))) (. .)))
15987266	8	(S1 (S (NP (PRP$ Our) (JJ current) (NN finding) (SBAR (IN that) (S (NP (NP (NNS animals)) (PP (IN in) (NP (DT the) (NNP Doc_15987266_1233_1236_Chemical+Pilo) (NN group)))) (VP (AUX have) (NP (NP (DT a) (JJ GAP43-ir) (NN band)) (PP (IN in) (NP (DT the) (NNP IML))) (, ,) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NNS controls)))))) (, ,)))))) (VP (VBZ reinforces) (NP (NP (JJ prior) (NN data)) (PP (IN on) (NP (NP (DT the) (NN blockade)) (PP (IN of) (NP (NNP Doc_15987266_1351_1354_Disease))) (PP (IN in) (NP (DT these) (NNS animals))))))) (. .)))
15987266	9	(S1 (S (NP (NP (DT The) (NN change)) (PP (IN in) (NP (JJ GAP43-ir) (NN present))) (PP (IN in) (NP (JJ Pilo-treated) (NNS animals)))) (VP (AUX was) (NP (NP (DT a) (VBG thinning)) (PP (IN of) (NP (DT the) (NN band))) (PP (TO to) (NP (NP (DT a) (ADJP (RB very) (JJ narrow)) (NN layer)) (PP (ADVP (RB just)) (IN above) (NP (NP (DT the) (JJ granule) (NN cell) (NN layer)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (ADJP (JJ likely) (S (VP (TO to) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN loss)) (PP (IN of) (NP (NP (JJ hilar) (NN cell) (NNS projections)) (SBAR (WHNP (WDT that)) (S (VP (VBP express) (NP (CD GAP-43))))))))))))))))))))))) (. .)))
15991002	0	(S1 (S (NP (NP (JJ Doc_15991002_0_8_Chemical) (NNS antagonizes)) (ADJP (ADJP (JJ Doc_15991002_21_29_Chemical-)) (CC but) (ADJP (RB not) (JJ Doc_15991002_39_57_Chemical-induced)))) (VP (VBP anxiogenic) (NP (NP (NN effect)) (PP (IN in) (NP (NNS mice))))) (. .)))
15991002	1	(S1 (S (NP (NP (NNP Doc_15991002_104_112_Chemical)) (CC and) (NP (NNP Doc_15991002_117_125_Chemical))) (VP (AUX are) (ADVP (RB widely)) (VP (VBN consumed) (NP (JJ licit) (JJ psychoactive) (NNS drugs)) (NP (NNP worldwide)))) (. .)))
15991002	2	(S1 (S (NP (NN Epidemiological) (NNS studies)) (VP (VBD showed) (SBAR (IN that) (S (NP (PRP they)) (VP (AUX were) (ADVP (RB generally)) (VP (VBN used) (ADVP (RB concurrently))))))) (. .)))
15991002	3	(S1 (S (SBAR (IN Although) (S (NP (NP (DT some) (NNS studies)) (PP (IN in) (NP (JJ experimental) (NNS animals)))) (VP (VBP indicate) (NP (NP (JJ clear) (JJ pharmacological) (NNS interactions)) (PP (IN between) (NP (PRP them))))))) (, ,) (NP (DT no) (NNS studies)) (VP (AUX have) (VP (VBN shown) (NP (NP (DT a) (JJ specific) (NN interaction)) (PP (IN on) (NP (JJ Doc_15991002_409_416_Disease) (NNS responses)))))) (. .)))
15991002	4	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ investigates) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_15991002_486_494_Chemical))) (PP (IN on) (NP (NP (NNP Doc_15991002_498_505_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_15991002_517_525_Chemical)) (CC and) (NP (NP (DT another) (JJ anxiogenic) (NN drug)) (, ,) (NP (NNP Doc_15991002_555_573_Chemical)) (, ,)))) (PP (IN in) (NP (NNS mice)))))))) (. .)))
15991002	5	(S1 (S (NP (DT The) (JJ elevated) (JJ plus-maze) (-LRB- -LRB-) (NN EPM) (-RRB- -RRB-) (NN test)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNS drugs)))) (PP (IN on) (NP (NNP Doc_15991002_663_670_Disease)))))))) (. .)))
15991002	6	(S1 (S (NP (NP (NN Adult) (NN male) (NNP Swiss) (NNP Webster) (NNS mice)) (PRN (-LRB- -LRB-) (NP (JJ 25-32) (NNP g)) (-RRB- -RRB-))) (VP (AUX were) (VP (VP (VBN given) (NP (NP (NNP Doc_15991002_732_740_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.05-0.25) (NN mg/kg)) (NP (NNP s.c.))) (-RRB- -RRB-)))) (CC or) (VP (VBN saline) (NP (CD 10) (NN min)) (PP (IN before) (NP (NP (NP (NNP Doc_15991002_788_796_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 70) (CD mg/kg)) (NN i.p.)) (-RRB- -RRB-))) (CC or) (NP (NNP Doc_15991002_816_834_Chemical) (PRN (-LRB- -LRB-) (NP (QP (CD 15) (CC and) (CD 30)) (JJ mg/kg) (NNS i.p.)) (-RRB- -RRB-)) (NNS injections))))))) (. .)))
15991002	7	(S1 (S (PP (IN After) (NP (CD 15) (NN min))) (, ,) (NP (NNS mice)) (VP (AUX were) (VP (VBN evaluated) (PP (IN for) (NP (NP (PRP$ their) (NN open-) (CC and) (NN closed-arm) (NN time)) (CC and) (NP (NP (NNS entries)) (PP (IN on) (NP (NP (DT the) (NNS EPM)) (PP (IN for) (NP (DT a) (JJ 10-min) (NN session)))))))))) (. .)))
15991002	8	(S1 (S (NP (NN Locomotor) (NN activity)) (VP (AUX was) (VP (VBN recorded) (PP (IN for) (NP (JJ individual) (NNS groups))) (PP (IN by) (S (VP (VBG using) (NP (NP (DT the) (JJ same) (NN treatment) (NN protocol)) (PP (IN with) (NP (DT the) (JJ EPM) (NN test))))))))) (. .)))
15991002	9	(S1 (S (NP (NP (NNP Doc_15991002_1104_1112_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.05-0.25) (NN mg/kg)) (-RRB- -RRB-)) (NP (PRP itself))) (VP (AUX did) (RB not) (VP (VB produce) (NP (DT any) (JJ significant) (NN effect)) (PP (IN in) (NP (DT the) (JJ EPM) (NN test))) (, ,) (SBAR (IN whereas) (S (NP (NP (NP (NNP Doc_15991002_1202_1210_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 70) (NN mg/kg)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_15991002_1226_1244_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN mg/kg)) (-RRB- -RRB-)))) (VP (VBD produced) (NP (NP (DT an) (JJ anxiogenic) (NN effect)) (, ,) (ADJP (JJ apparent) (PP (IN with) (NP (NP (NNS decreases)) (PP (IN in) (NP (NP (JJ open-arm) (NN time)) (CC and) (NP (NN entry))))))))))))) (. .)))
15991002	10	(S1 (S (NP (JJ Doc_15991002_1339_1347_Chemical) (PRN (-LRB- -LRB-) (NP (CD 0.25) (NN mg/kg)) (-RRB- -RRB-)) (NN pretreatment)) (VP (VBD blocked) (NP (DT the) (ADJP (ADJP (JJ Doc_15991002_1386_1394_Chemical-)) (CC but) (ADJP (RB not) (JJ Doc_15991002_1404_1422_Chemical-induced))) (NN Doc_15991002_1431_1438_Disease))) (. .)))
15991002	11	(S1 (S (NP (NP (NP (NN Administration)) (PP (IN of) (NP (DT each) (NN drug)))) (CC and) (NP (PRP$ their) (NNS combinations))) (VP (AUX did) (RB not) (VP (VB produce) (NP (NP (DT any) (NN effect)) (PP (IN on) (NP (NN locomotor) (NN activity)))))) (. .)))
15991002	12	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (JJ antagonistic) (NN effect)) (PP (IN of) (NP (NNP Doc_15991002_1606_1614_Chemical))) (PP (IN on) (NP (NNP Doc_15991002_1618_1626_Chemical-induced) (NNP Doc_15991002_1635_1642_Disease)))) (VP (AUX is) (ADJP (JJ specific) (PP (TO to) (NP (NNP Doc_15991002_1658_1666_Chemical)))) (, ,) (PP (RB instead) (IN of) (NP (DT a) (JJ non-specific) (JJ anxiolytic) (NN effect))))))) (. .)))
15991002	13	(S1 (S (ADVP (RB Thus)) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB extend) (NP (NP (DT the) (JJ current) (NNS findings)) (PP (IN on) (NP (DT the) (NN interaction))) (PP (IN between) (NP (NP (NNP Doc_15991002_1781_1789_Chemical)) (CC and) (NP (NNP Doc_15991002_1794_1802_Chemical))))))) (. .)))
16034922	0	(S1 (NP (NP (JJ Long) (NN term) (NN hormone) (NN therapy)) (PP (IN for) (NP (JJ perimenopausal) (CC and) (JJ postmenopausal) (NNS women))) (. .)))
16034922	1	(S1 (S (NP (NP (NN Hormone) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NN HT)) (-RRB- -RRB-))) (VP (AUX is) (ADVP (RB widely)) (VP (VBN used) (PP (IN for) (S (VP (VBG controlling) (NP (JJ menopausal) (NNS symptoms))))))) (. .)))
16034922	2	(S1 (S (S (NP (PRP It)) (VP (AUX has) (ADVP (RB also)) (VP (AUX been) (VP (VBN used) (PP (IN for) (NP (NP (DT the) (NN management) (CC and) (NN prevention)) (PP (IN of) (NP (NP (NNP Doc_16034922_215_237_Disease)) (, ,) (NP (NNP Doc_16034922_239_251_Disease)) (CC and) (NP (NNP Doc_16034922_256_264_Disease)))) (PP (IN in) (NP (JJR older) (NNS women))))))))) (CC but) (S (NP (NP (DT the) (NN evidence)) (VP (VBG supporting) (NP (NP (PRP$ its) (NN use)) (PP (IN for) (NP (DT these) (NNS indications)))))) (VP (AUX is) (ADJP (RB largely) (JJ observational)))) (. .)))
16034922	3	(S1 (FRAG (S (VP (TO To) (VP (VB assess) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NP (JJ long-term) (NNS HT)) (PP (IN on) (NP (NN mortality)))) (, ,) (NP (NP (NNP Doc_16034922_427_440_Disease)) (, ,) (NP (NNP Doc_16034922_442_464_Disease)) (, ,) (NP (NNP Doc_16034922_466_472_Disease)) (, ,) (NP (JJ transient) (JJ ischaemic) (NNS attacks)) (, ,) (NP (NNP Doc_16034922_503_516_Disease) (, ,) (NNP Doc_16034922_518_535_Disease) (, ,) (NNP Doc_16034922_537_551_Disease) (, ,) (NNP Doc_16034922_553_571_Disease) (, ,) (NNP Doc_16034922_573_592_Disease)) (, ,) (NP (NN cognitive) (NN function)) (, ,) (NP (NNP Doc_16034922_614_622_Disease)) (, ,) (NP (NNP Doc_16034922_624_633_Disease)) (CC and) (NP (NP (NN quality)) (PP (IN of) (NP (NN life))))))))))) (. .)))
16034922	4	(S1 (NP (NP (NN SEARCH) (NN STRATEGY)) (: :) (S (NP (PRP We)) (VP (VBD searched) (NP (DT the) (JJ following) (NNS databases)) (ADVP (RB up) (PP (TO to) (NP (NNP November) (CD 2004)))) (: :) (NP (NP (DT the) (NNP Cochrane) (NNP Doc_16034922_742_761_Disease) (CC and) (NNP Subfertility) (NNP Group) (NNS Trials)) (NP (NP (NNP Register)) (, ,) (NP (NP (NP (NNP Cochrane) (NNP Central) (NNP Register)) (PP (IN of) (NP (JJ Controlled) (NNS Trials)))) (PRN (-LRB- -LRB-) (NP (NNP CENTRAL)) (-RRB- -RRB-))) (, ,) (NP (NNP MEDLINE)) (, ,) (NP (NNP EMBASE)) (, ,) (NP (JJ Biological) (NNS Abstracts)))))) (. .)))
16034922	5	(S1 (S (NP (NP (JJ Relevant) (JJ non-indexed) (NNS journals)) (CC and) (NP (NN conference) (NNS abstracts))) (VP (AUX were) (ADVP (RB also)) (VP (VBD searched))) (. .)))
16034922	6	(S1 (NP (NP (NN SELECTION) (NNS CRITERIA)) (: :) (NP (NP (JJ Randomised) (JJ double-blind) (NNS trials)) (PP (IN of) (NP (NP (NNS HT)) (PRN (-LRB- -LRB-) (NP (NP (NNS oestrogens)) (PP (IN with) (CC or) (IN without) (NP (NNP Doc_16034922_1059_1071_Chemical)))) (-RRB- -RRB-)))) (PP (IN versus) (NP (NN placebo))) (, ,) (VP (VBN taken) (PP (IN for) (NP (QP (IN at) (JJS least) (CD one)) (NN year))) (PP (IN by) (NP (JJ perimenopausal) (CC or) (JJ postmenopausal) (NNS women))))) (. .)))
16034922	7	(S1 (NP (NP (NP (NN DATA) (NN COLLECTION)) (CC AND) (NP (NN ANALYSIS))) (: :) (S (NP (NNP Fifteen) (NNS RCTs)) (VP (AUX were) (VP (VBN included)))) (. .)))
16034922	8	(S1 (S (S (NP (NNS Trials)) (VP (AUX were) (VP (VBN assessed) (PP (IN for) (NP (NN quality)))))) (CC and) (S (NP (CD two) (NN review) (NNS authors)) (VP (VBD extracted) (NP (NN data)) (ADVP (RB independently)))) (. .)))
16034922	9	(S1 (S (NP (PRP They)) (VP (VBD calculated) (NP (NN risk) (NNS ratios)) (PP (IN for) (NP (NP (JJ dichotomous) (NNS outcomes)) (CC and) (NP (JJ weighted) (JJ mean) (NNS differences)))) (PP (IN for) (NP (JJ continuous) (NNS outcomes)))) (. .)))
16034922	10	(S1 (S (NP (JJ Clinical) (NN heterogeneity)) (VP (VBN precluded) (NP (NN meta-analysis)) (PP (IN for) (NP (JJS most) (NNS outcomes)))) (. .)))
16034922	11	(S1 (NP (NP (JJ MAIN) (NNS RESULTS)) (: :) (NP (NP (DT All)) (SBAR (S (NP (DT the) (ADJP (RB statistically) (JJ significant)) (NNS results)) (VP (AUX were) (VP (VBN derived) (PP (IN from) (NP (DT the) (CD two) (JJS biggest) (NNS trials)))))))) (. .)))
16034922	12	(S1 (S (PP (IN In) (NP (ADJP (RB relatively) (JJ healthy)) (NNS women))) (, ,) (NP (VBN combined) (JJ continuous) (NNS HT)) (VP (ADVP (RB significantly)) (VBD increased) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NP (NP (NNP Doc_16034922_1664_1686_Disease)) (CC or) (NP (JJ coronary) (NN event))) (PRN (-LRB- -LRB-) (PP (IN after) (NP (NP (CD one) (NN year) (POS 's)) (NN use))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_16034922_1729_1735_Disease)) (PRN (-LRB- -LRB-) (PP (IN after) (NP (CD 3) (NNS years))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_16034922_1753_1766_Disease)) (PRN (-LRB- -LRB-) (PP (IN after) (NP (CD 5) (NNS years))) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_16034922_1787_1806_Disease)))))) (. .)))
16034922	13	(S1 (S (NP (JJ Long-term) (JJ Doc_16034922_1818_1827_Chemical-only) (NNS HT)) (ADVP (RB also)) (ADVP (RB significantly)) (VP (VBN increased) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NNP Doc_16034922_1877_1883_Disease)) (CC and) (NP (NNP Doc_16034922_1888_1907_Disease)))))) (. .)))
16034922	14	(S1 (S (ADVP (JJ Overall)) (, ,) (NP (NP (DT the) (ADJP (RB only) (RB statistically) (JJ significant)) (NNS benefits)) (PP (IN of) (NP (NNP HT)))) (VP (AUX were) (NP (NP (DT a) (VBN decreased) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_16034922_1998_2007_Disease)) (CC and) (NP (NNP Doc_16034922_2012_2024_Disease)))) (PP (IN with) (NP (JJ long-term) (NN use))))) (. .)))
16034922	15	(S1 (S (PP (IN Among) (NP (NP (ADJP (RB relatively) (JJ healthy)) (NNS women)) (PP (IN over) (NP (NP (CD 65) (NNS years)) (VP (VBG taking) (NP (JJ continuous) (JJ combined) (NNS HT))))))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_16034922_2188_2196_Disease))))))) (. .)))
16034922	16	(S1 (S (PP (IN Among) (NP (NP (NNS women)) (PP (IN with) (NP (NNP Doc_16034922_2215_2237_Disease))))) (, ,) (NP (NP (JJ long-term) (NN use)) (PP (IN of) (NP (JJ combined) (JJ continuous) (NNS HT)))) (VP (ADVP (RB significantly)) (VBN increased) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_16034922_2315_2337_Disease))))) (. .)))
16034922	17	(S1 (S (NP (DT No) (NNS trials)) (VP (VBD focussed) (ADVP (RB specifically)) (PP (IN on) (NP (JJR younger) (NNS women)))) (. .)))
16034922	18	(S1 (S (ADVP (RB However)) (, ,) (NP (CD one) (NN trial)) (VP (VBD analysed) (NP (NP (NP (NNS subgroups)) (PP (IN of) (NP (NP (CD 2839) (ADJP (RB relatively) (JJ healthy)) (QP (CD 50) (TO to) (CD 59)) (JJ year-old) (NNS women)) (VP (VBG taking) (NP (NP (JJ combined) (JJ continuous) (NN HT)) (CC and) (NP (NP (CD 1637)) (VP (VBG taking) (NP (JJ Doc_16034922_2524_2533_Chemical-only) (NNS HT))))))))) (, ,) (CC versus) (NP (JJ similar-sized) (NN placebo) (NNS groups)))) (. .)))
16034922	19	(S1 (S (S (NP (NP (DT The) (JJ only) (ADJP (RB significantly) (JJ increased)) (NN risk)) (VP (VBD reported))) (VP (AUX was) (PP (IN for) (NP (NNP Doc_16034922_2635_2657_Disease))) (PP (IN in) (NP (NP (NNS women)) (VP (VBG taking) (NP (JJ combined) (JJ continuous) (NNS HT))))))) (: ;) (S (NP (PRP$ their) (JJ absolute) (NN risk)) (VP (VBD remained) (ADJP (RB very) (JJ low)))) (. .)))
16034922	20	(S1 (NP (NP (NP (NNS AUTHORS) (POS ')) (NNS CONCLUSIONS)) (: :) (S (NP (NN HT)) (VP (AUX is) (RB not) (VP (VBN indicated) (PP (IN for) (NP (NP (DT the) (JJ routine) (NN management)) (PP (IN of) (NP (NN chronic) (NN disease)))))))) (. .)))
16034922	21	(S1 (S (NP (PRP We)) (VP (AUX need) (NP (NP (JJR more) (NN evidence)) (PP (IN on) (NP (NP (DT the) (NN safety)) (PP (IN of) (NP (NP (NNS HT)) (PP (IN for) (NP (JJ menopausal) (NN symptom) (NN control)))))))) (, ,) (SBAR (IN though) (S (NP (JJ short-term) (NN use)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (ADJP (RB relatively) (JJ safe)) (PP (IN for) (NP (JJ healthy) (JJR younger) (NNS women)))))))))) (. .)))
16083708	0	(S1 (NP (NP (NN Doc_16083708_0_25_Disease)) (: :) (NP (NP (DT an) (NN analysis)) (PP (IN of) (NP (NP (CD 461) (NNS incidences)) (VP (VBN submitted) (PP (TO to) (NP (DT the) (JJ Spanish) (NN registry))) (PP (IN over) (NP (DT a) (JJ 10-year) (NN period))))))) (. .)))
16083708	1	(S1 (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (: :) (S (NP (NP (NN Progress)) (PP (IN in) (NP (NP (NP (DT the) (NN understanding)) (PP (IN of) (NP (JJ susceptibility) (NNS factors))) (PP (TO to) (NP (NP (NNP Doc_16083708_192_217_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16083708_219_223_Disease)) (-RRB- -RRB-))))) (CC and) (NP (NN outcome) (NN predictability))))) (VP (AUX are) (VP (VBN hampered) (PP (IN by) (NP (NP (DT the) (NN lack)) (PP (IN of) (NP (NP (JJ systematic) (NNS programs)) (SBAR (S (VP (TO to) (VP (VB detect) (NP (JJ bona) (JJ fide) (NNS cases))))))))))))) (. .)))
16083708	2	(S1 (S (NP (DT A) (JJ cooperative) (NN network)) (VP (AUX was) (VP (VBN created) (PP (IN in) (NP (CD 1994))) (PP (IN in) (NP (NNP Spain))) (S (VP (TO to) (VP (VB identify) (NP (NP (DT all) (NNS suspicions)) (PP (IN of) (NP (NNP Doc_16083708_417_421_Disease)))) (PP (VBG following) (NP (DT a) (JJ prospective) (JJ structured) (NN report) (NN form)))))))) (. .)))
16083708	3	(S1 (S (NP (DT The) (NNP Doc_16083708_474_486_Disease)) (VP (AUX was) (VP (VBN characterized) (PP (VBG according) (PP (TO to) (NP (NP (NN hepatocellular)) (, ,) (NP (NN cholestatic)) (, ,) (CC and) (NP (JJ mixed) (NN laboratory) (NNS criteria)))) (CC and) (PP (TO to) (NP (JJ histologic) (NNS criteria)))) (SBAR (WHADVP (WRB when)) (FRAG (ADJP (JJ available)))))) (. .)))
16083708	4	(S1 (S (NP (NP (JJ Further) (NN evaluation)) (PP (IN of) (NP (NN causality) (NN assessment)))) (VP (AUX was) (ADVP (RB centrally)) (VP (VBN performed))) (. .)))
16083708	5	(S1 (S (PP (PP (IN Since) (NP (NNP April) (CD 1994))) (PP (TO to) (NP (NNP August) (CD 2004)))) (, ,) (NP (NP (QP (CD 461) (IN out) (IN of) (CD 570)) (VBN submitted) (NNS cases)) (, ,) (VP (VBG involving) (NP (CD 505) (NNS drugs))) (, ,)) (VP (AUX were) (VP (VBN deemed) (S (VP (TO to) (VP (AUX be) (VP (VBN related) (PP (TO to) (NP (NNP Doc_16083708_812_816_Disease))))))))) (. .)))
16083708	6	(S1 (S (NP (NP (DT The) (JJ antiinfective) (NN group)) (PP (IN of) (NP (NNS drugs)))) (VP (AUX was) (NP (NP (DT the) (ADJP (ADJP (ADVP (RBR more) (RB frequently)) (VBN incriminated)) (, ,) (ADJP (JJ Doc_16083708_889_900_Chemical-Doc_16083708_901_912_Chemical))) (NN accounting)) (PP (IN for) (NP (NP (DT the) (CD 12.8) (NN %)) (PP (IN of) (NP (DT the) (JJ whole) (NN series))))))) (. .)))
16083708	7	(S1 (S (NP (NP (DT The) (JJ hepatocellular) (NN pattern)) (PP (IN of) (NP (NN damage)))) (VP (AUX was) (NP (NP (DT the) (RBS most) (JJ common)) (PRN (-LRB- -LRB-) (NP (CD 58) (NN %)) (-RRB- -RRB-))) (, ,) (VP (AUX was) (ADVP (RB inversely)) (VP (VBN correlated) (PP (IN with) (NP (NP (NN age)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD .0001))) (-RRB- -RRB-)))))) (, ,) (CC and) (VP (AUX had) (NP (NP (DT the) (JJS worst) (NN outcome)) (PRN (-LRB- -LRB-) (NP (NNP Cox) (CD regression)) (, ,) (NP (NNP P) (QP (CD <) (CD .034))) (-RRB- -RRB-))))) (. .)))
16083708	8	(S1 (S (ADVP (RB Indeed)) (, ,) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NN liver) (NN transplantation) (CC and) (NN Doc_16083708_1175_1180_Disease))) (PP (IN in) (NP (DT this) (NN group)))) (VP (AUX was) (NP (CD 11.7) (NN %)) (SBAR (IN if) (S (NP (NNS patients)) (VP (AUX had) (NP (NNP Doc_16083708_1221_1229_Disease)) (PP (IN at) (NP (NN presentation)))))) (, ,) (SBAR (IN whereas) (S (NP (DT the) (JJ corresponding) (NN figure)) (VP (AUX was) (NP (CD 3.8) (NN %)) (PP (IN in) (NP (NP (JJ nonjaundiced) (NNS patients)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD .04))) (-RRB- -RRB-)))))))) (. .)))
16083708	9	(S1 (S (NP (NP (NNS Factors)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_16083708_1368_1393_Disease))))))) (VP (AUX were) (NP (NP (JJ female) (NN sex)) (PRN (-LRB- -LRB-) (NP (NP (QP (CC OR) (SYM =) (CD 25))) (: ;) (NP (NP (CD 95) (NN %)) (NP (NNS CI))) (: :) (NP (CD 4.1-151)) (: ;) (NP (NP (CD P) (NNS <)) (NP (CD .0001)))) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_16083708_1449_1470_Disease)) (PRN (-LRB- -LRB-) (NP (NP (QP (CC OR) (SYM =) (CD 7.9))) (: ;) (NP (NP (CD 95) (NN %)) (NP (NNS CI))) (: :) (NP (CD 1.6-37)) (: ;) (NP (NP (CD P) (NNS <)) (NP (CD .009)))) (-RRB- -RRB-)) (, ,) (CC and) (NP (NP (JJR higher) (NN baseline) (NN plasma) (JJ Doc_16083708_1536_1545_Chemical) (NN value)) (PRN (-LRB- -LRB-) (NP (NP (QP (CC OR) (SYM =) (CD 1.15))) (: ;) (NP (NP (CD 95) (NN %)) (NP (NNS CI))) (: :) (NP (CD 1.09-1.22)) (: ;) (NP (NP (CD P) (NNS <)) (NP (CD .0001)))) (-RRB- -RRB-))))) (. .)))
16083708	10	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (JJ drug-induced) (NN hepatocellular) (NN Doc_16083708_1650_1658_Disease)))) (VP (AUX have) (NP (NP (ADJP (CD 11.7) (NN %)) (NN chance)) (PP (IN of) (S (VP (VBG progressing) (PP (TO to) (NP (NP (NN Doc_16083708_1695_1700_Disease)) (CC or) (NP (NN transplantation))))))))) (. .)))
16083708	11	(S1 (S (NP (NN Doc_16083708_1721_1744_Chemical)) (VP (VBZ stands) (PRT (RP out)) (PP (IN as) (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (NN drug)) (VP (VBN related) (PP (TO to) (NP (NN Doc_16083708_1791_1795_Disease))))))) (. .)))
16092435	0	(S1 (NP (NP (JJ Morphological) (NN evaluation)) (PP (IN of) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_16092435_42_50_Chemical))))) (PP (IN on) (NP (NP (NNP Doc_16092435_54_64_Chemical-evoked) (NNP Doc_16092435_72_86_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
16092435	1	(S1 (S (NP (NP (DT The) (NN influence)) (PP (IN of) (NP (NNP Doc_16092435_113_121_Chemical))) (PP (IN on) (NP (NNP Doc_16092435_125_135_Chemical-induced) (NNP Doc_16092435_144_158_Disease))) (PP (IN in) (NP (NNS rats)))) (VP (AUX was) (VP (VBN studied))) (. .)))
16092435	2	(S1 (S (NP (NP (NN Doc_16092435_180_190_Chemical)) (PP (IN in) (NP (NP (DT the) (JJ cumulative) (NN dose)) (PP (IN of) (NP (CD 25) (NNS mg/kg)))))) (VP (VBD evoked) (NP (ADJP (RB fully) (VBN developed)) (NNP Doc_16092435_249_265_Disease))) (. .)))
16092435	3	(S1 (S (NP (NP (NN Doc_16092435_267_275_Chemical)) (PP (IN in) (NP (NP (DT the) (JJ multiple) (NNS doses)) (PP (IN of) (NP (CD 200) (NNS mg/kg)))))) (VP (AUX did) (RB not) (VP (VB influence) (NP (NNP Doc_16092435_329_332_Chemical) (NNP Doc_16092435_333_347_Disease)))) (. .)))
16112787	0	(S1 (FRAG (PP (IN In) (NP (NP (NN vivo) (NNS evidences)) (VP (VBG suggesting) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (JJ oxidative) (NN stress))) (PP (IN in) (NP (NP (NN pathogenesis)) (PP (IN of) (NP (JJ Doc_16112787_77_87_Chemical-induced) (NN nephrotoxicity))))))))) (: :) (NP (NP (NN protection)) (PP (IN by) (NP (NNP Doc_16112787_126_136_Chemical)))) (. .)))
16112787	1	(S1 (S (NP (NP (DT The) (NNS aims)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX were) (S (VP (TO to) (VP (VB examine) (NP (NP (NP (NP (NNP Doc_16112787_177_187_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16112787_189_192_Chemical)) (-RRB- -RRB-))) (JJ -induced) (JJ oxidative) (NN stress)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ promotes) (NP (NP (NN production)) (PP (IN of) (NP (NP (JJ reactive) (JJ Doc_16112787_256_262_Chemical) (NNS species)) (PRN (-LRB- -LRB-) (NP (NNP ROS)) (-RRB- -RRB-)))))) (CC and) (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (NNP Doc_16112787_308_318_Chemical)) (, ,) (NP (DT an) (JJ expectorant) (NN agent)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX has) (ADVP (RB also)) (NP (JJ antioxidant) (NNS properties)) (, ,) (PP (IN on) (NP (NP (NN kidney) (NN tissue)) (PP (IN against) (NP (NP (DT the) (JJ possible) (JJ Doc_16112787_419_422_Chemical-induced) (NN Doc_16112787_431_447_Disease)) (PP (IN in) (NP (NNS rats))))))))))))))))))))))) (. .)))
16112787	2	(S1 (S (NP (NNS Rats)) (VP (AUX were) (VP (VBN divided) (PP (IN into) (NP (NP (CD three) (NNS groups)) (: :) (NP (NP (NNP sham)) (, ,) (NP (NNP Doc_16112787_500_503_Chemical)) (CC and) (NP (NNP Doc_16112787_508_511_Chemical)) (CC plus) (NP (NNP Doc_16112787_517_527_Chemical))))))) (. .)))
16112787	3	(S1 (S (NP (NN Doc_16112787_529_532_Chemical)) (VP (AUX was) (VP (VBN administrated) (ADVP (RB intraperitoneally)) (PRN (-LRB- -LRB-) (NP (NN i.p.)) (-RRB- -RRB-)) (PP (IN with) (S (VP (VBG 200mgkg) (-LRB- -LRB-) (NP (NN -1)) (-RRB- -RRB-) (ADVP (RB twice) (RB daily)) (PP (IN for) (NP (CD 7) (NNS days)))))))) (. .)))
16112787	4	(S1 (S (NP (NN Doc_16112787_617_627_Chemical)) (VP (AUX was) (VP (VBN administered) (ADVP (RB orally)))) (. .)))
16112787	5	(S1 (S (NP (NP (JJ Doc_16112787_653_656_Chemical) (NN administration)) (PP (TO to) (NP (NN control) (NNS rats)))) (VP (VP (ADVP (RB significantly)) (VBD increased) (NP (NP (NP (JJ renal) (NNP Doc_16112787_718_733_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16112787_735_738_Chemical)) (-RRB- -RRB-))) (CC and) (NP (JJ urinary) (JJ Doc_16112787_752_760_Chemical-beta-d-glucosaminidase) (PRN (-LRB- -LRB-) (NP (NNP NAG)) (, ,) (NP (NP (DT a) (NN marker)) (PP (IN of) (NP (NNP Doc_16112787_802_822_Disease)))) (-RRB- -RRB-)) (NN excretion)))) (CC but) (VP (VBD decreased) (NP (NP (NP (JJ Doc_16112787_848_858_Chemical) (NN dismutase)) (PRN (-LRB- -LRB-) (NP (NNP SOD)) (-RRB- -RRB-))) (CC and) (NP (JJ catalase) (PRN (-LRB- -LRB-) (NP (NN CAT)) (-RRB- -RRB-)) (NNS activities))))) (. .)))
16112787	6	(S1 (S (NP (NP (JJ Doc_16112787_906_916_Chemical) (NN administration)) (PP (IN with) (NP (NP (JJ Doc_16112787_937_940_Chemical) (NNS injections)) (VP (VBN caused) (ADVP (RB significantly)))))) (VP (VBD decreased) (NP (NP (JJ renal) (JJ Doc_16112787_989_992_Chemical) (CC and) (JJ urinary) (NN NAG) (NN excretion)) (, ,) (CC and) (NP (JJ increased) (NN SOD) (NN activity)) (, ,) (CONJP (CC but) (RB not)) (NP (NP (NN CAT) (NN activity)) (PP (IN in) (NP (JJ renal) (NN tissue))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NP (NNP Doc_16112787_1104_1107_Chemical)) (ADVP (RB alone)))))))) (. .)))
16112787	7	(S1 (S (NP (NN Doc_16112787_1115_1125_Chemical)) (VP (VBD showed) (NP (NP (JJ histopathological) (NN protection)) (PP (IN against) (NP (JJ Doc_16112787_1170_1173_Chemical-induced) (NN nephrotoxicity))))) (. .)))
16112787	8	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (NP (DT a) (JJ significant) (NN dilatation)) (PP (IN of) (NP (JJ tubular) (NNS lumens)))) (, ,) (NP (JJ extensive) (JJ epithelial) (NN cell) (NN vacuolization)) (, ,) (NP (NN Doc_16112787_1294_1301_Disease)) (, ,) (NP (NN desquamation)) (, ,) (CC and) (NP (NNP Doc_16112787_1321_1329_Disease))) (PP (IN in) (NP (NP (NP (JJ Doc_16112787_1333_1336_Chemical-treated) (NNS rats)) (ADJP (ADJP (JJR more)) (PP (IN than) (NP (NP (DT those)) (PP (IN of) (NP (DT the) (NN control))))))) (CC and) (NP (DT the) (JJ Doc_16112787_1389_1399_Chemical) (NNS groups))))) (. .)))
16112787	9	(S1 (S (NP (NN Doc_16112787_1408_1418_Chemical)) (VP (VBD caused) (NP (DT a) (JJ marked) (NN Doc_16112787_1435_1476_Disease))) (. .)))
16112787	10	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (S (NP (JJ oxidative) (JJ tubular) (NN damage)) (VP (VBZ plays) (NP (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (DT the) (JJ Doc_16112787_1555_1558_Chemical-induced) (NN nephrotoxicity)))))) (CC and) (S (NP (NP (DT the) (NN modulation)) (PP (IN of) (NP (NP (JJ oxidative) (NN stress)) (PP (IN with) (NP (NNP Doc_16112787_1626_1636_Chemical)))))) (VP (VBZ reduces) (NP (DT the) (JJ Doc_16112787_1649_1652_Chemical-induced) (NN Doc_16112787_1661_1674_Disease)) (PP (DT both) (IN at) (NP (DT the) (JJ biochemical) (CC and) (JJ histological) (NNS levels))))))))) (. .)))
1615846	0	(S1 (NP (NP (JJ Doc_1615846_0_11_Chemical-Doc_1615846_12_22_Chemical) (NN therapy)) (PP (IN for) (NP (JJ primary) (NNP Doc_1615846_43_64_Disease))) (. .)))
1615846	1	(S1 (S (NP (NP (DT The) (JJ specific) (NN aim)) (PP (IN of) (NP (DT this) (NN retrospective)))) (, ,) (NP (JJ observational) (NN study)) (VP (AUX was) (S (VP (TO to) (VP (VB assess) (NP (NP (NN safety) (CC and) (NN efficacy)) (PP (IN of) (NP (NP (JJ long-term) (PRN (-LRB- -LRB-) (NP (CD 21) (NN months/patient)) (-RRB- -RRB-)) (, ,) (JJ open-label) (, ,) (JJ Doc_1615846_206_228_Chemical) (NN treatment)) (PP (IN in) (NP (NP (CD 80) (NNS patients)) (PP (IN with) (NP (NP (JJ primary) (JJ mixed) (NN Doc_1615846_273_287_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 68) (NN %)) (PP (IN of) (SBAR (WHNP (WP whom)) (S (VP (AUX had) (NP (NNP Doc_1615846_305_337_Disease))))))) (-RRB- -RRB-))))))))))))) (. .)))
1615846	2	(S1 (S (SBAR (IN Because) (S (NP (JJ ideal) (NN lipid) (NNS targets)) (VP (AUX were) (RB not) (VP (VBN reached) (PRN (-LRB- -LRB-) (NP (NN low-density) (NN lipoprotein) (PRN (-LRB- -LRB-) (NP (NNP LDL)) (-RRB- -RRB-)) (NNP Doc_1615846_416_427_Chemical)) (NP (NP (NP (NP (QP (JJR less) (IN than) (CD 130)) (NN mg/dl)) (, ,) (NP (NP (JJ high-density) (NN lipoprotein) (PRN (-LRB- -LRB-) (NP (NNP HDL)) (-RRB- -RRB-)) (NNP Doc_1615846_480_491_Chemical)) (ADJP (JJR greater) (PP (IN than) (NP (CD 35) (NN mg/dl))))) (, ,)) (CC or) (NP (JJ total) (NNP Doc_1615846_524_535_Chemical/HDL) (NNP Doc_1615846_540_551_Chemical))) (QP (RBR less) (IN than) (CD 4.5) (CD mg/dl))) (-RRB- -RRB-)) (PP (IN with) (NP (NP (NN diet)) (CC plus) (NP (DT a) (JJ single) (NN drug)))))))) (, ,) (NP (NNP Doc_1615846_603_614_Chemical) (PRN (-LRB- -LRB-) (NP (CD 1.2) (NN g/day)) (-RRB- -RRB-)) (JJ -Doc_1615846_627_637_Chemical) (PRN (-LRB- -LRB-) (NP (QP (RB primarily) (CD 20) (CC or) (CD 40) (CD mg))) (-RRB- -RRB-)) (NN treatment)) (VP (AUX was) (VP (VBN given))) (. .)))
1615846	3	(S1 (S (NP (JJ Follow-up) (NNS visits)) (VP (AUX were) (VP (VBN scheduled) (PP (IN with) (NP (JJ 2-drug) (NN therapy))) (NP (NP (QP (DT every) (CD 6) (TO to) (CD 8)) (NNS weeks)) (, ,) (NP (NP (DT an) (NN average)) (PP (IN of) (NP (NP (CD 10.3) (NNS visits)) (PP (IN per) (NP (NN patient))))))) (, ,) (SBAR (IN with) (S (NP (NP (CD 741) (NNS batteries)) (PP (IN of) (NP (NP (ADJP (CD 6) (NN liver)) (NN function) (NNS tests)) (CC and) (NP (CD 714) (JJ Doc_1615846_847_855_Chemical) (NN phosphokinase) (NNS levels))))) (VP (VBN measured)))))) (. .)))
1615846	4	(S1 (S (NP (NP (NP (QP (RB Only) (CD 1))) (PP (IN of) (NP (NP (DT the) (CD 4,446) (NN liver) (NN function) (NNS tests)) (PRN (-LRB- -LRB-) (NP (CD 0.02) (NN %)) (-RRB- -RRB-))))) (, ,) (NP (DT a) (JJ Doc_1615846_939_953_Chemical) (NN transferase)) (, ,)) (VP (AUX was) (ADJP (ADJP (JJR greater) (PP (IN than))) (CC or) (ADJP (JJ equal) (PP (TO to) (NP (NP (CD 3) (NNS times)) (NP (DT the) (JJ upper) (JJ normal) (NN limit))))))) (. .)))
1615846	5	(S1 (S (S (PP (IN Of) (NP (DT the) (CD 714) (JJ Doc_1615846_1039_1047_Chemical) (NN phosphokinase) (NNS levels))) (, ,) (NP (CD 9) (NN %)) (VP (AUX were) (ADJP (JJ high)))) (: ;) (S (NP (NP (QP (RB only) (CD 1))) (PRN (-LRB- -LRB-) (NP (CD 0.1) (NN %)) (-RRB- -RRB-))) (VP (AUX was) (ADVP (JJR greater) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (CD 3) (NNS times)))) (NP (DT the) (JJ upper) (JJ normal) (NN limit)))) (. .)))
1615846	6	(S1 (S (S (PP (IN With) (NP (JJ 2-drug) (NN therapy))) (, ,) (NP (VB mean) (NN total) (NNP Doc_1615846_1191_1202_Chemical)) (VP (VBD decreased) (NP (CD 22) (NN %)) (PP (IN from) (NP (QP (CD 255) (TO to) (CD 200)) (NNS mg/dl))))) (, ,) (S (NP (NNP Doc_1615846_1240_1252_Chemical) (NNS levels)) (VP (VBD decreased) (NP (CD 35) (NN %)) (PP (IN from) (NP (CD 236))) (PP (TO to) (NP (QP (CD 154) (CD mg/dl)))))) (, ,) (S (NP (NNP LDL) (NNP Doc_1615846_1301_1312_Chemical)) (VP (VBD decreased) (NP (CD 26) (NN %)) (PP (IN from) (NP (QP (CD 176) (TO to) (CD 131)) (NNS mg/dl))))) (, ,) (CC and) (S (NP (DT the) (JJ total) (NNP Doc_1615846_1364_1375_Chemical/HDL) (NNP Doc_1615846_1380_1391_Chemical) (NN ratio)) (VP (VBD decreased) (NP (CD 24) (NN %)) (PP (IN from) (NP (QP (CD 7.1) (TO to) (CD 5.4)))) (, ,) (UCP (ADVP (NP (DT all) (NN p)) (RBR less) (IN than)) (CC or) (ADJP (JJ equal) (PP (TO to) (NP (CD 0.0001))))))) (. .)))
1615846	7	(S1 (S (S (NP (NP (NN Doc_1615846_1465_1473_Disease)) (, ,) (ADJP (ADJP (JJ attributable) (PP (TO to) (NP (DT the) (NN drug) (NN combination)))) (CC and) (ADJP (JJ symptomatic) (RB enough) (S (VP (TO to) (VP (VB discontinue) (NP (PRP it))))))) (, ,)) (VP (VBD occurred) (PP (IN in) (NP (NP (NP (CD 3) (NN %)) (PP (IN of) (NP (NNS patients)))) (, ,) (CC and) (NP (NP (QP (IN in) (CD 1)) (NN %)) (PP (IN with) (NP (NP (JJ concurrent) (JJ high) (JJ Doc_1615846_1613_1621_Chemical) (NN phosphokinase)) (PRN (-LRB- -LRB-) (NP (CD 769) (NN U/liter)) (-RRB- -RRB-))))))))) (: ;) (S (NP (DT no) (NNS patients)) (VP (AUX had) (NP (NP (NNP Doc_1615846_1667_1681_Disease) (CC or) (NNP Doc_1615846_1685_1698_Disease.)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-)))))))
16309808	0	(S1 (SQ (AUX Does) (NP (NNP Doc_16309808_5_16_Chemical)) (VP (VB potentiate) (NP (JJ Doc_16309808_28_39_Chemical-associated) (NNP Doc_16309808_51_73_Disease))) (. ?)))
16309808	1	(S1 (S (NP (EX There)) (VP (AUX is) (ADVP (RB now)) (NP (NP (NN evidence)) (SBAR (S (VP (TO to) (VP (VB suggest) (NP (NP (DT a) (JJ central) (NN role)) (PP (IN for) (NP (DT the) (JJ dopaminergic) (NN system))) (PP (IN in) (NP (NP (NNP Doc_16309808_154_176_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16309808_178_181_Disease)) (-RRB- -RRB-))))))))))) (. .)))
16309808	2	(S1 (S (PP (IN For) (NP (NN example))) (, ,) (NP (NP (DT the) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_16309808_213_216_Disease)))) (VP (MD can) (VP (AUX be) (VP (ADVP (RB dramatically)) (VBN improved) (PP (IN by) (NP (NNP Doc_16309808_249_257_Chemical) (CC and) (NNP Doc_16309808_262_270_Chemical) (NNS agonists))) (, ,) (SBAR (IN whereas) (S (NP (JJ central) (NNP Doc_16309808_297_305_Chemical) (NNP D2) (NN receptor) (NNS antagonists)) (VP (MD can) (VP (VP (VB induce)) (CC or) (VP (VB aggravate) (NP (JJ Doc_16309808_354_357_Disease) (NNS symptoms)))))))))) (. .)))
16309808	3	(S1 (S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (, ,) (NP (EX there)) (VP (AUX is) (NP (NP (DT no) (JJ previous) (NN report)) (VP (VBG regarding) (SBAR (IN whether) (S (NP (NP (NNP Doc_16309808_432_443_Chemical)) (, ,) (NP (DT a) (JJ peripheral) (NNP Doc_16309808_458_466_Chemical) (NNP D2) (NN receptor) (NN antagonist)) (, ,)) (VP (MD can) (ADVP (RB also)) (VP (VP (VB induce)) (CC or) (VP (VB aggravate) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NN Doc_16309808_532_535_Disease)))))))))))) (. .)))
16309808	4	(S1 (S (NP (NP (NNP Doc_16309808_537_548_Chemical)) (, ,) (NP (NP (DT the) (JJ first) (NN noradrenergic)) (CC and) (NP (JJ specific) (JJ serotonergic) (NN antidepressant))) (PRN (-LRB- -LRB-) (NP (NNP Doc_16309808_616_621_Chemical)) (-RRB- -RRB-)) (, ,)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_16309808_649_652_Disease)) (PP (IN in) (NP (JJ several) (JJ recent) (NNS publications)))))))) (. .)))
16309808	5	(S1 (S (NP (DT The) (NNS authors)) (VP (VBP report) (ADVP (RB here)) (NP (NP (DT a) (JJ Doc_16309808_711_720_Disease) (NN patient) (NN comorbid)) (PP (IN with) (NP (NP (JJ postprandial) (NNP Doc_16309808_756_765_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_16309808_780_783_Disease)) (SBAR (IN after) (S (NP (NNP Doc_16309808_790_801_Chemical)) (VP (AUX had) (VP (AUX been) (VP (VBN added) (PP (TO to) (NP (PRP$ his) (JJ Doc_16309808_824_835_Chemical) (NN therapy))))))))))))))) (. .)))
16309808	6	(S1 (S (S (NP (PRP$ Our) (NN patient)) (VP (VBD started) (S (VP (TO to) (VP (AUX have) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NNP Doc_16309808_885_888_Disease)))) (SBAR (RB only) (IN after) (S (NP (PRP he)) (VP (AUX had) (VP (AUX been) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_16309808_925_936_Chemical))))))))))))) (, ,) (CC and) (S (NP (PRP$ his) (JJ Doc_16309808_946_949_Disease) (NNS symptoms)) (VP (VBN resolved) (ADVP (RB completely)) (PP (IN upon) (NP (NP (NN discontinuation)) (PP (IN of) (NP (PRP$ his) (NNP Doc_16309808_1007_1018_Chemical))))))) (. .)))
16309808	7	(S1 (S (NP (NP (PDT Such) (DT a) (JJ temporal) (NN relationship)) (PP (IN between) (NP (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_16309808_1068_1079_Chemical)))) (CC and) (NP (NP (DT the) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_16309808_1100_1103_Disease)))))) (PP (IN in) (NP (PRP$ our) (NN patient)))) (VP (AUX did) (RB not) (VP (VB support) (NP (NP (DT a) (JJ potentiating) (NN effect)) (PP (IN of) (NP (NNP Doc_16309808_1160_1170_Chemical))) (PP (IN on) (NP (JJ Doc_16309808_1174_1185_Chemical-associated) (NNP Doc_16309808_1197_1200_Disease)))))) (. .)))
16309808	8	(S1 (S (ADVP (RB However)) (, ,) (NP (NNS physicians)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP (NNP Doc_16309808_1262_1273_Chemical)) (VP (MD can) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_16309808_1297_1300_Disease))) (PP (IN in) (NP (NP (DT some) (NNS individuals)) (, ,) (ADVP (RB especially)) (NP (NP (DT those)) (VP (VBG receiving) (NP (JJ concomitant) (NNP Doc_16309808_1361_1369_Chemical) (NNP D2) (NN receptor) (NNS antagonists)))))))))))))))) (. .)))
16323982	0	(S1 (S (NP (JJ Antiandrogenic) (NN therapy)) (VP (MD can) (VP (VB cause) (NP (NN Doc_16323982_33_58_Disease)))) (. .)))
16323982	1	(S1 (FRAG (S (VP (TO To) (VP (VB study) (NP (NP (DT the) (NN change)) (PP (IN of) (NP (NN lipid) (NN metabolism)))) (PP (IN by) (NP (NP (JJ antiandrogen) (NN therapy)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_16323982_146_161_Disease)))))))))) (. .)))
16323982	2	(S1 (FRAG (NP (NNS MATERIALS) (CC AND) (NNS METHODS)) (: :) (S (NP (PRP We)) (VP (VBD studied) (PP (IN with) (NP (NP (DT a) (CD 2.5) (NNS years)) (ADJP (JJ follow-up) (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (NP (NP (NN plasma)) (NP (NP (NP (NNP Doc_16323982_246_258_Chemical) (PRN (-LRB- -LRB-) (NP (NNP C)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_16323982_264_277_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_16323982_279_281_Disease)) (-RRB- -RRB-))) (, ,) (NP (NP (NNS lipoproteins)) (PRN (-LRB- -LRB-) (NP (NNP LP)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNS apolipoproteins))) (PRN (-LRB- -LRB-) (NP (NNP Apo)) (-RRB- -RRB-))) (NNP B-100)) (, ,) (NP (NNP A-I)) (, ,) (CC and) (NP (NNP A-II) (FW pro) (FW fi) (FW les)))))))) (PP (IN in) (NP (NP (CD 24) (NNS patients)) (PP (IN of) (NP (NP (NP (NP (JJ mean) (NN age)) (NP (CD 60) (NNS years))) (PP (IN with) (NP (NP (NNP Doc_16323982_402_426_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN stage)) (: :) (NP (NNP T1cN0M0) (, ,) (NNP Gleason) (NN score)) (: :) (NP (CD 2-5))) (-RRB- -RRB-)))) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_16323982_486_505_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16323982_507_510_Chemical)) (-RRB- -RRB-)))))) (PP (IN without) (NP (JJ surgical) (NN management)))) (CC or) (NP (NN radiation) (NN therapy)))))))) (. .)))
16323982	3	(S1 (S (NP (NP (NP (JJ Significant) (NNS decreases)) (PP (IN of) (NP (NP (NNP HDL-C)) (, ,) (NP (NNP Apo) (NNP A-I)) (CC and) (NP (NNP Apo) (NNP A-II))))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (JJ Doc_16323982_643_655_Chemical) (NNS levels))) (PP (IN in) (NP (NNP VLDL))))) (VP (AUX were) (VP (VBN induced) (PP (IN by) (NP (NNP CPA))))) (. .)))
16323982	4	(S1 (S (PP (IN After) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (CD 2.5) (NNS years))) (PP (IN on) (NP (NN CPA) (NN treatment))))) (, ,) (NP (NP (CD four) (NNS patients)) (PP (IN out) (PP (IN of) (NP (NN twenty-four))))) (VP (AUX were) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (VP (VBN affected) (PP (IN by) (NP (NNP Doc_16323982_800_822_Disease))))))))) (. .)))
16323982	5	(S1 (S (NP (NP (NNP Ischaemic) (NNP Doc_16323982_847_872_Disease)) (PP (IN with) (NP (NP (DT an) (NN incidence) (NN rate)) (PP (IN of) (NP (CD 16.6) (NN %))) (SBAR (IN as) (S (VP (VBN caused) (PP (IN by) (NP (JJ prolonged) (NN CPA) (NN therapy))))))))) (VP (AUX is) (VP (VBN mediated) (PP (IN through) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NNP HDL) (NNP Doc_16323982_975_986_Chemical)) (, ,) (NP (NNP Apo) (NNP A-I)) (CC and) (NP (NNP Apo) (NNP A-II)))))) (ADVP (FW pro) (FW fi) (FW les)) (, ,) (ADJP (JJ other) (PP (IN than) (NP (NP (DT the) (JJ well-known) (JJ hyperglyceridemic) (NN effect)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_16323982_1082_1090_Chemical))))))))) (. .)))
16369751	0	(S1 (S (NP (NNP Doc_16369751_0_14_Chemical) (NNP Doc_16369751_15_29_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_16369751_41_66_Chemical)))) (. .)))
16369751	1	(S1 (S (NP (NN Doc_16369751_68_82_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ rare) (NN complication)) (VP (VBG occurring) (PP (IN during) (NP (NP (NNP Doc_16369751_123_137_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_16369751_139_143_Chemical)) (-RRB- -RRB-)) (NN treatment)) (PP (IN for) (NP (NNP Doc_16369751_159_171_Disease)))))))) (. .)))
16369751	2	(S1 (S (NP (PRP We)) (ADVP (RB herein)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 70-year-old) (NN man)) (PP (IN with) (NP (NNP Doc_16369751_225_229_Chemical-induced) (NNP Doc_16369751_238_252_Disease))))) (, ,) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NP (DT a) (JJ high) (NN serum) (NN level)) (PP (IN of) (NP (NP (NNP Doc_16369751_284_309_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16369751_311_315_Chemical)) (-RRB- -RRB-))))) (VP (AUX was) (VP (VBN observed))))))) (. .)))
16369751	3	(S1 (S (S (NP (NP (DT The) (NN patient)) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (JJ unresectable) (NN colon) (NN cancer)) (ADJP (JJ Doc_16369751_378_388_Disease) (PP (TO to) (NP (DT the) (NN liver) (CC and) (NN lung)))))))) (, ,)) (VP (AUX was) (VP (VBN referred) (PP (TO to) (NP (PRP us))) (PP (IN for) (NP (NN chemotherapy))) (PP (IN from) (NP (DT an) (VBN affiliated) (NN hospital)))))) (: ;) (S (NP (PRP he)) (VP (AUX had) (NP (DT no) (JJ cardiac) (NN history)))) (. .)))
16369751	4	(S1 (S (PP (IN After) (NP (NN admission))) (, ,) (NP (DT the) (NN patient)) (VP (VBD received) (NP (NP (DT a) (JJ continuous) (JJ intravenous) (NN infusion)) (PP (IN of) (NP (NP (NNP Doc_16369751_579_583_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1000) (NN mg/day)) (-RRB- -RRB-)))) (, ,) (SBAR (WHPP (IN during) (WHNP (WDT which))) (S (NP (NP (NNP Doc_16369751_612_627_Disease)) (PP (IN with) (NP (NNP Doc_16369751_633_658_Disease)))) (VP (VBD occurred) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (DT a) (JJ high) (NN serum) (JJ Doc_16369751_700_704_Chemical) (NN concentration)) (PP (IN of) (NP (CD 1955) (NN ng/ml)))))))))) (. .)))
16369751	5	(S1 (S (NP (CC Both) (NP (DT the) (NN Doc_16369751_743_758_Disease)) (CC and) (NP (DT the) (JJ electrocardiographic) (NNS changes))) (VP (VBD disappeared) (ADVP (RB spontaneously)) (PP (IN after) (NP (NP (DT the) (NN discontinuation)) (PP (IN of) (NP (NNP Doc_16369751_851_855_Chemical)))))) (. .)))
16369751	6	(S1 (S (SBAR (IN As) (S (NP (NP (DT the) (NN Doc_16369751_864_879_Disease)) (PP (IN in) (NP (DT this) (NN patient)))) (VP (AUX was) (VP (VBN considered) (S (VP (TO to) (VP (AUX have) (VP (AUX been) (ADJP (JJ due) (PP (TO to) (NP (JJ Doc_16369751_931_935_Chemical-induced) (NN Doc_16369751_944_958_Disease)))))))))))) (, ,) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_16369751_982_986_Chemical)))) (VP (AUX was) (VP (VBN abandoned))) (. .)))
16369751	7	(S1 (S (ADVP (RB Instead)) (, ,) (NP (NP (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_16369751_1034_1037_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (NN derivative)) (PP (IN of) (NP (NNP Doc_16369751_1055_1059_Chemical)))) (-RRB- -RRB-))))) (, ,) (PP (IN at) (NP (NP (CD 200) (NN mg/day)) (NP (RB twice) (DT a) (NN week)))) (, ,) (VP (AUX was) (VP (VBN instituted) (, ,) (SBAR (IN because) (S (NP (NNP S-1)) (VP (AUX has) (NP (NP (DT a) (JJ strong) (JJ inhibitory) (NN effect)) (PP (IN on) (NP (JJ Doc_16369751_1152_1169_Chemical) (NN dehydrogenase))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ catalyzes) (NP (NP (DT the) (NN degradative)) (PP (IN of) (NP (NNP Doc_16369751_1220_1224_Chemical)))) (PP (IN into) (NP (NNP Doc_16369751_1230_1234_Chemical)))))))))))) (. .)))
16369751	8	(S1 (S (NP (DT The) (JJ serum) (JJ Doc_16369751_1246_1250_Chemical) (NN concentration)) (ADVP (RB subsequently)) (VP (VBD decreased) (PP (TO to) (NP (QP (CD 352) (CD ng/ml)))) (, ,) (NP (NP (DT the) (JJ same)) (PP (IN as) (NP (NP (DT the) (NN value)) (VP (VBN measured) (PP (IN on) (NP (NP (DT the) (JJ first) (NN day)) (PP (IN of) (NP (JJ S-1) (NN administration)))))))))) (. .)))
16369751	9	(S1 (S (ADVP (RB Thereafter)) (, ,) (NP (DT no) (JJ cardiac) (NNS symptoms)) (VP (AUX were) (VP (VBN observed))) (. .)))
16369751	10	(S1 (S (NP (DT The) (NN patient)) (VP (VBD achieved) (NP (DT a) (JJ partial) (NN response)) (PP (NP (CD 6) (NNS months)) (IN after) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (DT the) (JJ S-1) (NN treatment)))))) (. .)))
16369751	11	(S1 (S (NP (NP (DT The) (NN experience)) (PP (IN of) (NP (DT this) (NN case)))) (, ,) (PP (ADVP (RB together)) (IN with) (NP (NP (DT a) (NN review)) (PP (IN of) (NP (DT the) (NN literature))))) (, ,) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP Doc_16369751_1597_1601_Chemical)) (VP (AUX is) (VP (VBN related) (PP (TO to) (NP (JJ Doc_16369751_1616_1620_Chemical-induced) (NN Doc_16369751_1629_1643_Disease)))))))) (. .)))
16369751	12	(S1 (S (NP (NN S-1)) (VP (MD may) (VP (AUX be) (VP (VBN administered) (ADVP (RB safely)) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_16369751_1693_1697_Chemical-induced) (NNP Doc_16369751_1706_1720_Disease)))))))) (. .)))
1655018	0	(S1 (NP (NP (NN Doc_1655018_0_24_Disease)) (PP (IN in) (NP (NNP Doc_1655018_28_44_Disease))) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_1655018_58_66_Chemical)) (CC and) (NP (NNP Doc_1655018_71_85_Chemical))))) (. .)))
1655018	1	(S1 (S (NP (NP (DT The) (NN case)) (PP (IN of) (NP (DT an) (JJ 11-year-old) (NN boy)))) (VP (AUX is) (VP (VBN reported) (SBAR (WHNP (WP who)) (S (VP (VP (AUX was) (VP (VBN known) (S (VP (TO to) (VP (AUX have) (NP (NN Doc_1655018_152_168_Disease)) (PP (IN for) (NP (CD 3) (NNS years)))))))) (CC and) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_1655018_202_211_Chemical)) (, ,) (NP (NNP Doc_1655018_213_228_Chemical)) (CC and) (NP (NNS transfusions))))))))))) (. .)))
1655018	2	(S1 (S (PP (NP (CD Two) (NNS weeks)) (IN before) (NP (PRP$ his) (NN Doc_1655018_268_273_Disease))) (NP (PRP he)) (VP (VP (AUX was) (VP (VBN readmitted) (PP (IN because) (IN of) (NP (NNP Doc_1655018_303_318_Disease))) (PP (IN with) (NP (NNP Doc_1655018_324_334_Disease))))) (CC and) (VP (VBD marked) (NP (NN Doc_1655018_346_377_Disease))) (CC and) (VP (VBD died) (PP (IN of) (NP (NNP Doc_1655018_390_418_Disease))))) (. .)))
1655018	3	(S1 (S (PP (IN At) (NP (NN autopsy))) (NP (FW peliosis) (CC and) (FW Doc_1655018_444_467_Disease)) (VP (AUX were) (VP (VBN found) (SBAR (WHNP (WDT which)) (S (ADVP (RB histologically)) (VP (VBD proved) (S (VP (TO to) (VP (AUX be) (NP (JJ well-differentiated) (NN Doc_1655018_533_557_Disease)))))))))) (. .)))
1655018	4	(S1 (S (NP (DT This) (NN case)) (VP (VBZ contributes) (PP (TO to) (NP (DT the) (JJ previous) (NNS observations))) (SBAR (IN that) (S (NP (NP (JJ non-metastasizing) (NN Doc_1655018_633_650_Disease)) (CC and) (NP (NN peliosis))) (VP (MD can) (VP (VB develop) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_1655018_693_701_Chemical-)) (CC and) (NP (JJ corticosteroid-treated) (NNP Doc_1655018_730_746_Disease))))))))))) (. .)))
16565833	0	(S1 (NP (NP (DT The) (NN influence)) (PP (IN of) (NP (DT the) (NN time) (NN interval))) (PP (IN between) (NP (NNP Doc_16565833_43_50_Chemical) (CC and) (NNP Doc_16565833_55_66_Chemical) (NN administration))) (PP (IN on) (NP (NP (DT the) (NN protection)) (PP (IN against) (NP (NP (NNP Doc_16565833_108_119_Chemical-induced) (NNP Doc_16565833_128_142_Disease)) (PP (IN in) (NP (NNS mice))))))) (. .)))
16565833	1	(S1 (S (PP (IN Despite) (NP (PRP$ its) (JJ well-known) (NN Doc_16565833_184_198_Disease))) (, ,) (NP (NP (DT the) (NNP Doc_16565833_204_228_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16565833_230_233_Chemical)) (-RRB- -RRB-))) (VP (VBZ continues) (S (VP (TO to) (VP (AUX be) (NP (DT an) (ADJP (ADJP (JJ effective)) (CC and) (ADJP (RB widely) (JJ used))) (NN chemotherapeutic) (NN agent)))))) (. .)))
16565833	2	(S1 (S (NP (JJ Doc_16565833_304_307_Chemical-induced) (NN Doc_16565833_316_330_Disease)) (ADVP (RB presumably)) (VP (VBZ results) (PP (IN from) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NP (JJ free) (NNS radicals)) (PP (IN by) (NP (NNP Doc_16565833_389_392_Chemical)))))))) (. .)))
16565833	3	(S1 (S (NP (JJ Reactive) (JJ Doc_16565833_403_409_Chemical) (NNS species)) (ADVP (RB particularly)) (VP (VBP affect) (NP (DT the) (JJ cardiac) (NNS myocytes)) (SBAR (IN because) (S (NP (DT these) (NNS cells)) (VP (VBP seem) (S (VP (TO to) (VP (AUX have) (NP (DT a) (ADJP (RB relatively) (JJ poor)) (NN antioxidant) (NN defense) (NN system))))))))) (. .)))
16565833	4	(S1 (S (NP (NP (DT The) (JJ semisynthetic) (NNP Doc_16565833_556_590_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16565833_592_599_Chemical)) (-RRB- -RRB-))) (VP (VBD showed) (NP (NN cardioprotection)) (PP (IN against) (NP (NNP Doc_16565833_633_636_Chemical-induced) (NNP Doc_16565833_645_659_Disease))) (PP (IN through) (NP (NP (PRP$ its) (JJ radical) (NN scavenging)) (CC and) (NP (NNP Doc_16565833_695_699_Chemical) (NN chelating) (NNS properties))))) (. .)))
16565833	5	(S1 (S (PP (IN Because) (IN of) (NP (NP (DT the) (ADJP (RB relatively) (JJ short)) (JJ final) (NN half-life)) (PP (IN of) (NP (NP (NNP Doc_16565833_773_780_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (RB about) (CD 30)) (NN min)) (-RRB- -RRB-)))))) (, ,) (NP (PRP it)) (VP (AUX is) (VP (VBN expected) (SBAR (IN that) (S (NP (NP (DT the) (NN time) (NN interval)) (PP (IN between) (NP (NP (NNP Doc_16565833_843_850_Chemical)) (CC and) (NP (NNP Doc_16565833_855_858_Chemical))))) (VP (MD might) (VP (AUX be) (PP (IN of) (NP (NN influence))) (PP (IN on) (NP (NP (DT the) (JJ cardioprotective) (NN effect)) (PP (IN of) (NP (NNP Doc_16565833_915_922_Chemical))))))))))) (. .)))
16565833	6	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT the) (NN aim)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (NP (DT this) (JJ possible) (NN effect)))))) (. .)))
16565833	7	(S1 (S (NP (NP (CD Six) (NNS groups)) (PP (IN of) (NP (QP (CD 6) (CD BALB/c)) (NNS mice)))) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NN saline)) (, ,) (NP (NP (NP (NP (NNP Doc_16565833_1068_1071_Chemical)) (ADVP (RB alone))) (CC or) (NP (NP (NNP Doc_16565833_1081_1084_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 4) (CD mg/kg)) (NN i.v.)) (-RRB- -RRB-)))) (VP (VBN preceded) (PP (IN by) (NP (NP (NNP Doc_16565833_1112_1119_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 500) (CD mg/kg)) (NN i.p.)) (-RRB- -RRB-)))) (PP (IN with) (NP (NP (DT an) (NN interval)) (PP (IN of) (NP (CD 10) (, ,) (CD 30) (, ,) (CD 60) (CC or) (CD 120) (NN min))))))))))) (. .)))
16565833	8	(S1 (S (PP (IN After) (NP (NP (NP (DT a) (JJ 6-week) (NN treatment) (NN period)) (CC and) (NP (JJ additional) (NN observation))) (PP (IN for) (NP (CD 2) (NNS weeks))))) (, ,) (NP (DT the) (NNS mice)) (VP (AUX were) (VP (VBN sacrificed))) (. .)))
16565833	9	(S1 (S (NP (PRP$ Their) (JJ cardiac) (NNS tissues)) (VP (AUX were) (VP (VBN processed) (PP (IN for) (NP (JJ light) (NN microscopy))) (, ,) (SBAR (WHPP (IN after) (WHNP (WDT which))) (S (NP (JJ cardiomyocyte) (NN damage)) (VP (AUX was) (VP (VBN evaluated) (PP (VBG according) (PP (TO to) (NP (NP (NNP Billingham)) (PRN (-LRB- -LRB-) (PP (IN in) (NP (NNP Doc_16565833_1412_1418_Disease) (NN Treat))) (NP (NP (NP (NNP Rep) (CD 62)) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-))) (: :) (NP (CD 865-872)) (, ,) (NP (CD 1978))) (-RRB- -RRB-))))))))))) (. .)))
16565833	10	(S1 (S (NP (JJ Microscopic) (NN evaluation)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_16565833_1503_1506_Chemical)))) (ADVP (RB alone)) (VP (VBN induced) (NP (JJ significant) (NN Doc_16565833_1533_1547_Disease)) (PP (IN in) (NP (NP (NN comparison)) (PP (TO to) (NP (NP (DT the) (JJ saline) (NN control) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP P<0.001)) (-RRB- -RRB-)))))))))) (. .)))
16565833	11	(S1 (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (JJ damaged) (NNS cardiomyocytes)))) (VP (AUX was) (ADVP (NP (NP (JJ 9.6-fold)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (QP (CD CI) (CD 4.4-21.0))) (-RRB- -RRB-))) (JJR higher)) (PP (IN in) (NP (NP (NNS mice)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_16565833_1706_1709_Chemical))) (ADVP (RB alone) (PP (IN than) (NP (NP (DT that)) (PP (IN in) (NP (NP (NNS animals)) (PP (IN of) (NP (DT the) (NN control) (NN group)))))))))))) (. .)))
16565833	12	(S1 (S (NP (NP (NP (DT The) (NN ratio)) (PP (IN of) (NP (NP (JJ aberrant) (NNS cardiomyocytes)) (PP (IN in) (NP (NP (NNS mice)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_16565833_1817_1820_Chemical)))))) (VP (VBN preceded) (PP (IN by) (NP (NNP Doc_16565833_1833_1840_Chemical))))))) (CC and) (NP (NP (DT those)) (PP (IN in) (NP (NP (NNS mice)) (VP (VBN treated) (PP (IN with) (NP (NN saline)))))))) (VP (VBD ranged) (PP (IN from) (NP (NP (QP (CD 1.6) (TO to) (CD 2.8))) (PRN (-LRB- -LRB-) (NP (NP (JJ mean) (CD 2.2)) (, ,) (NP (CD 95) (NN %) (QP (CD CI) (CD 1.2-4.1))) (, ,) (NP (CD P=0.019))) (-RRB- -RRB-))))) (. .)))
16565833	13	(S1 (S (NP (NP (DT The) (JJ mean) (JJ protective) (NN effect)) (PP (IN by) (S (VP (VBG adding) (NP (NNP Doc_16565833_1976_1983_Chemical)) (PP (IN before) (NP (NNP Doc_16565833_1991_1994_Chemical))))))) (VP (VBD led) (PP (TO to) (NP (NP (NP (DT a) (JJ significant) (JJ 4.4-fold) (NN reduction)) (PRN (-LRB- -LRB-) (NP (NNP P<0.001)) (, ,) (NP (CD 95) (NN %) (QP (CD CI) (CD 2.3-8.2))) (-RRB- -RRB-))) (PP (IN of) (NP (JJ abnormal) (NNS cardiomyocytes)))))) (. .)))
16565833	14	(S1 (S (NP (DT This) (JJ protective) (NN effect)) (VP (AUX did) (RB not) (VP (VB depend) (PP (IN on) (NP (NP (DT the) (NN time) (NN interval)) (PP (IN between) (NP (NP (NNP Doc_16565833_2156_2163_Chemical)) (CC and) (NP (NP (NNP Doc_16565833_2168_2171_Chemical) (NNP administration)) (PRN (-LRB- -LRB-) (NP (NNP P=0.345)) (-RRB- -RRB-))))))))) (. .)))
16565833	15	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (PP (IN in) (NP (DT an) (NN outpatient) (JJ clinical) (NN setting))) (NP (NNP Doc_16565833_2270_2277_Chemical)) (VP (MD may) (VP (AUX be) (VP (VBN administered) (PP (ADVP (RB shortly)) (IN before) (NP (NN Doc_16565833_2313_2316_Chemical))))))))) (. .)))
16723784	0	(S1 (NP (NP (JJ Clinical) (NN evaluation)) (PP (IN of) (NP (NP (JJ adverse) (NNS effects)) (PP (IN during) (NP (NNP Doc_16723784_46_54_Chemical) (NN administration))))) (PP (IN for) (NP (NP (NN Doc_16723784_74_93_Disease)) (CC and) (NP (NN flutter)))) (. .)))
16723784	1	(S1 (S (NP (NP (NNP Doc_16723784_119_141_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Bpd)) (-RRB- -RRB-))) (VP (AUX has) (VP (VBN attracted) (NP (NN attention)) (PP (IN as) (NP (NP (DT an) (JJ effective) (NN drug)) (PP (IN for) (NP (NP (NP (NNP Doc_16723784_197_216_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16723784_218_220_Disease)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_16723784_226_240_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16723784_242_245_Disease)) (-RRB- -RRB-))))))))) (. .)))
16723784	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (JJ serious) (JJ adverse) (NNS effects)) (, ,) (PP (VBG including) (NP (NP (NNP Doc_16723784_292_310_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16723784_312_315_Disease)) (-RRB- -RRB-)))) (, ,)) (VP (AUX have) (VP (AUX been) (VP (VBN reported)))) (. .)))
16723784	3	(S1 (FRAG (NP (NNS METHODS) (CC AND) (NNS RESULTS)) (: :) (S (NP (NP (JJ Adverse) (NNS effects)) (PP (IN of) (NP (NNP Bpd))) (VP (VBG requiring) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NN treatment)))))) (VP (AUX were) (VP (VBN evaluated)))) (. .)))
16723784	4	(S1 (S (NP (NNP Bpd)) (VP (AUX was) (VP (VBN administered) (PP (TO to) (NP (NP (NP (CD 459) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD 361) (NNS males)) (, ,) (ADJP (NP (CD 63+/-12) (NNS years)) (JJ old))) (-RRB- -RRB-))) (VP (VBG comprising) (NP (CD 378) (JJ Doc_16723784_520_522_Disease) (CC and) (CD 81) (JJ Doc_16723784_530_533_Disease) (NNS cases))))))) (. .)))
16723784	5	(S1 (S (NP (NP (JJ Mean) (JJ left) (NN ventricular) (NN ejection) (NN fraction)) (CC and) (NP (NP (JJ atrial) (NN dimension)) (PRN (-LRB- -LRB-) (NP (NN LAD)) (-RRB- -RRB-)))) (VP (AUX were) (NP (NP (CD 66+/-11) (NN %)) (CC and) (NP (NN 40+/-6) (NN mm))) (, ,) (ADVP (RB respectively))) (. .)))
16723784	6	(S1 (S (NP (JJ Adverse) (NNS effects)) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (NP (CD 19) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 4) (NN %)) (-RRB- -RRB-)))) (PP (IN during) (NP (NP (DT an) (JJ average) (NN follow-up)) (PP (IN of) (NP (CD 20) (NNS months))))))) (. .)))
16723784	7	(S1 (S (NP (EX There)) (VP (AUX was) (VP (VBN marked) (SBAR (S (NP (NNP Doc_16723784_760_775_Disease) (QP (JJR greater) (IN than) (CD 0.55))) (VP (VBZ s) (PP (IN in) (NP (NP (CD 13) (NNS patients)) (, ,) (NP (NNP Doc_16723784_812_823_Disease)))) (NP (NP (NP (QP (JJR less) (IN than) (CD 40)) (NN beats/min)) (PP (IN in) (NP (CD 6) (NNS patients)))) (, ,) (NP (NN dizziness)) (CC and) (NP (NP (JJ general) (NN fatigue)) (PP (IN in) (NP (NP (CD 1) (NN patient)) (NP (DT each))))))))))) (. .)))
16723784	8	(S1 (S (PP (IN In) (NP (NP (CD 4)) (PP (IN of) (NP (NP (CD 13) (NNS patients)) (PP (IN with) (NP (NNP Doc_16723784_936_951_Disease))))))) (, ,) (NP (NNP Doc_16723784_953_956_Disease)) (VP (VBD occurred)) (. .)))
16723784	9	(S1 (S (NP (NP (DT The) (JJ major) (VBG triggering) (NNS factors)) (PP (IN of) (NP (NNP Doc_16723784_999_1002_Disease)))) (VP (AUX were) (NP (NP (NN Doc_16723784_1008_1019_Disease)) (CC and) (NP (JJ sudden) (NN decrease))) (PP (IN in) (NP (NN heart) (NN rate)))) (. .)))
16723784	10	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (NNS differences)) (PP (IN in) (NP (NP (DT the) (JJ clinical) (NNS backgrounds)) (PP (IN of) (NP (DT the) (NNS patients))))) (PP (IN with) (CC and) (IN without) (NP (NNP Doc_16723784_1142_1145_Disease))) (ADJP (JJ other) (PP (IN than) (NP (NP (NP (NN LAD)) (CC and) (NP (NN age))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (ADJP (ADJP (JJR larger)) (CC and) (ADJP (JJR older))) (PP (IN in) (NP (NP (DT the) (NNS patients)) (PP (IN with) (NP (NNP Doc_16723784_1219_1222_Disease))))))))))))) (. .)))
16723784	11	(S1 (S (NP (NP (JJ Careful) (NN observation)) (PP (IN of) (NP (NP (JJ serum) (JJ Doc_16723784_1265_1274_Chemical) (NN concentration)) (CC and) (NP (DT the) (NNS ECG))))) (VP (MD should) (ADVP (RB always)) (VP (AUX be) (VP (AUX done) (PP (IN during) (NP (NNP Bpd) (NN administration))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (JJ elderly) (NNS patients)))))) (. .)))
16731636	0	(S1 (S (NP (NP (JJ Enhanced) (JJ Doc_16731636_9_22_Chemical-induced) (NN Doc_16731636_31_50_Disease)) (PP (IN in) (NP (NNP transgenic)))) (VP (NNS rats) (PP (IN with) (NP (JJ low) (NN brain) (NNS angiotensinogen)))) (. .)))
16731636	1	(S1 (S (NP (PRP We)) (VP (AUX have) (ADVP (RB previously)) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (DT a) (JJ permanent) (NN Doc_16731636_144_154_Disease)) (PP (IN in) (NP (NP (DT the) (NN brain) (NN renin-angiotensin) (NN system)) (PRN (-LRB- -LRB-) (NP (NNP RAS)) (-RRB- -RRB-))))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN sensitivity)) (PP (IN of) (NP (NP (DT the) (JJ baroreflex) (NN control)) (PP (IN of) (NP (NN heart) (NN rate)))))))))))) (. .)))
16731636	2	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (NP (PRP we)) (VP (VBN aimed) (PP (IN at) (S (VP (VBG studying) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (DT the) (NN brain) (NNS RAS))) (PP (IN in) (NP (DT the) (JJ cardiac) (NN reactivity)))) (PP (TO to) (NP (NP (DT the) (JJ beta-adrenoceptor) (PRN (-LRB- -LRB-) (NP (NN beta-AR)) (-RRB- -RRB-)) (NN agonist) (NNP Doc_16731636_406_419_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Iso)) (-RRB- -RRB-)))))))) (. .)))
16731636	3	(S1 (S (NP (NP (NNP Transgenic) (NNS rats)) (PP (IN with) (NP (NP (JJ low) (NN brain) (NNS angiotensinogen)) (PRN (-LRB- -LRB-) (NP (NNP TGR)) (-RRB- -RRB-))))) (VP (AUX were) (VP (VBN used))) (. .)))
16731636	4	(S1 (S (PP (IN In) (NP (VBN isolated) (NNS hearts))) (, ,) (NP (NNP Iso)) (VP (VBN induced) (NP (NP (DT a) (ADJP (RB significantly) (JJR greater)) (NN increase)) (PP (IN in) (NP (NP (JJ left) (NN ventricular) (PRN (-LRB- -LRB-) (NNP LV) (-RRB- -RRB-)) (NN pressure)) (CC and) (NP (NP (JJ maximal) (NN contraction)) (PRN (-LRB- -LRB-) (NP (NNP +dP/dt) (PRN (-LRB- -LRB-) (NP (NNP max)) (-RRB- -RRB-))) (-RRB- -RRB-))))) (PP (IN in) (NP (DT the) (NN TGR)))) (PP (IN than) (PP (IN in) (NP (DT the) (NNP Sprague-Dawley) (PRN (-LRB- -LRB-) (NP (NNP SD)) (-RRB- -RRB-)) (NNS rats))))) (. .)))
16731636	5	(S1 (S (NP (NP (NN Doc_16731636_677_691_Disease)) (VP (VBN induced) (PP (IN by) (NP (JJ Iso) (NN treatment))))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR higher) (PP (IN in) (NP (NN TGR)))) (PP (IN than) (PP (IN in) (NP (NP (JJ SD) (NNS rats)) (PRN (-LRB- -LRB-) (PP (IN in) (NP (NNP g) (NNP LV) (CD wt/100) (NNP g) (NN body) (NNS wt))) (, ,) (NP (NP (NP (NP (CD 0.28)) (ADJP (JJ +/-) (NP (CD 0.004)))) (CC vs.) (NP (NP (CD 0.24)) (ADJP (JJ +/-) (NP (CD 0.004))))) (, ,) (NP (RB respectively))) (-RRB- -RRB-))))))) (. .)))
16731636	6	(S1 (S (NP (NP (DT The) (JJR greater) (NN Doc_16731636_854_868_Disease)) (PP (IN in) (NP (JJ TGR) (NNS rats)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (ADJP (RBR more) (JJ pronounced)) (NN downregulation)) (PP (IN of) (NP (NP (NN beta-AR) (CC and) (NN upregulation)) (PP (IN of) (NP (CD LV) (JJ beta-AR) (JJ kinase-1) (NN mRNA) (NNS levels))))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT those)) (PP (IN in) (NP (JJ SD) (NNS rats)))))))) (. .)))
16731636	7	(S1 (S (NP (NP (DT The) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN heart) (NN rate)) (PRN (-LRB- -LRB-) (NP (NN HR)) (-RRB- -RRB-)) (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (JJ beta-AR) (NN antagonist) (NN Doc_16731636_1097_1107_Chemical)) (PP (IN in) (NP (JJ conscious) (NNS rats))))))))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN attenuated) (PP (IN in) (NP (NP (NNS TGR)) (PP (VBN compared) (PP (IN with) (NP (NP (JJ SD) (NNS rats)) (PRN (-LRB- -LRB-) (NP (CD -9.9) (NN +/-)) (NP (NP (CD 1.7) (NN %)) (PP (FW vs.) (NP (NP (CD -18.1) (NN +/-)) (NP (CD 1.5) (NN %))))) (-RRB- -RRB-))))))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ parasympathetic) (NN blockade)) (PP (IN by) (NP (NNP Doc_16731636_1270_1278_Chemical))))) (PP (IN on) (NP (NNP HR)))) (VP (AUX was) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS strains))))))))) (. .)))
16731636	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNS TGR)) (VP (AUX are) (ADJP (RBR more) (JJ sensitive) (PP (TO to) (NP (NP (JJ beta-AR) (JJ agonist-induced) (JJ cardiac) (NN inotropic) (NN response)) (CC and) (NP (NNP Doc_16731636_1423_1434_Disease))))) (, ,) (PP (ADVP (RB possibly)) (JJ due) (PP (TO to) (NP (NP (ADJP (RB chronically) (JJ low)) (JJ sympathetic) (NN outflow)) (VP (VBN directed) (PP (TO to) (NP (DT the) (NN heart))))))))))) (. .)))
16801510	0	(S1 (NP (NP (NP (JJ Drug-induced) (NN Doc_16801510_13_29_Disease)) (PP (IN in) (NP (NP (NN injection) (NN drug) (NNS users)) (VP (VBG receiving) (NP (NNP Doc_16801510_64_73_Chemical)))))) (: :) (NP (NP (JJ high) (NN frequency)) (PP (IN in) (NP (NP (VBN hospitalized) (NNS patients)) (CC and) (NP (NN risk) (NNS factors))))) (. .)))
16801510	1	(S1 (S (NP (JJ Drug-induced) (NN Doc_16801510_158_174_Disease)) (VP (AUX is) (NP (DT a) (JJ serious) (NN Doc_16801510_188_209_Disease))) (. .)))
16801510	2	(S1 (S (NP (NN Doc_16801510_211_220_Chemical)) (VP (VBZ prolongs) (NP (NP (DT the) (JJ QT) (NN interval)) (PP (IN in) (NP (NN vitro)))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner)))) (. .)))
16801510	3	(S1 (S (PP (IN In) (NP (DT the) (JJ inpatient) (NN setting))) (, ,) (NP (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (JJ QT) (JJ interval) (NN prolongation))) (PP (IN with) (NP (JJ Doc_16801510_356_365_Chemical) (NN treatment)))) (, ,) (NP (PRP$ its) (NN dose) (NN dependence)) (, ,) (CC and) (NP (NP (DT the) (NN importance)) (PP (IN of) (NP (NP (NNS cofactors)) (PP (JJ such) (IN as) (NP (JJ drug-drug) (NNS interactions))))))) (VP (VBP remain) (ADJP (JJ unknown))) (. .)))
16801510	4	(S1 (S (NP (PRP We)) (VP (VBD performed) (NP (DT a) (JJ systematic) (, ,) (JJ retrospective) (NN study)) (S (VP (VBG comparing) (NP (NP (NP (JJ active) (CC or) (JJ former) (JJ intravenous) (NN drug) (NNS users)) (VP (VBG receiving) (NP (NNP Doc_16801510_593_602_Chemical)))) (CC and) (NP (NP (DT those)) (VP (ADVP (RB not)) (VBG receiving) (NP (NNP Doc_16801510_627_636_Chemical)) (PP (IN among) (NP (NP (DT all) (NNS patients)) (VP (VBN hospitalized) (PP (IN over) (NP (NP (DT a) (JJ 5-year) (NN period)) (PP (IN in) (NP (DT a) (JJ tertiary) (NN care) (NN hospital)))))))))))))) (. .)))
16801510	5	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (CD 167) (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_16801510_753_762_Chemical)))))) (VP (VP (VBD fulfilled) (NP (DT the) (NN inclusion) (NNS criteria))) (CC and) (VP (AUX were) (VP (VBN compared) (PP (IN with) (NP (NP (DT a) (NN control) (NN group)) (PP (IN of) (NP (NP (CD 80) (NN injection) (NN drug) (NNS users)) (VP (RB not) (VBG receiving) (NP (NNP Doc_16801510_876_885_Chemical)))))))))) (. .)))
16801510	6	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (JJ Doc_16801510_902_911_Chemical) (NN dose))))) (, ,) (NP (CD 15) (ADJP (ADJP (JJ demographic)) (, ,) (ADJP (JJ biological)) (, ,) (CC and) (ADJP (JJ pharmacological))) (NNS variables)) (VP (AUX were) (VP (VBN considered) (PP (IN as) (NP (NP (JJ potential) (NN risk) (NNS factors)) (PP (IN for) (NP (NNP Doc_16801510_1022_1037_Disease))))))) (. .)))
16801510	7	(S1 (S (PP (IN Among) (NP (CD 167) (JJ Doc_16801510_1058_1067_Chemical) (NN maintenance) (NNS patients))) (, ,) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NNP Doc_16801510_1108_1124_Disease))) (PP (PP (TO to) (NP (NP (CD 0.50) (NN second)) (PRN (-LRB- -LRB-) (-LRB- -LRB-) (NN 1/2) (-RRB- -RRB-) (-RRB- -RRB-)))) (CC or) (ADVP (RB longer)))) (VP (AUX was) (NP (CD 16.2) (NN %)) (PP (VBN compared) (PP (IN with) (NP (NP (CD 0) (NN %)) (PP (IN in) (NP (CD 80) (NN control) (NNS subjects))))))) (. .)))
16801510	8	(S1 (S (NP (NP (NP (CD Six) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 3.6) (NN %)) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NNP Doc_16801510_1235_1244_Chemical) (NN group)))) (VP (VBD presented) (NP (NN Doc_16801510_1261_1280_Disease))) (. .)))
16801510	9	(S1 (S (NP (JJ QTc) (NN length)) (VP (VP (AUX was) (ADVP (RB weakly))) (CC but) (VP (ADVP (RB significantly)) (VBN associated) (PP (IN with) (NP (NP (JJ Doc_16801510_1338_1347_Chemical) (JJ daily) (NN dose)) (PRN (-LRB- -LRB-) (NP (NNP Spearman) (NN rank) (NN correlation) (NN coefficient)) (, ,) (NP (NP (CD 0.20)) (: ;) (NP (NNP P<.01))) (-RRB- -RRB-)))))) (. .)))
16801510	10	(S1 (S (NP (JJ Multivariate) (JJ regression) (NN analysis)) (VP (VBD allowed) (NP (NP (NN attribution)) (PP (IN of) (NP (NP (CD 31.8) (NN %)) (PP (IN of) (NP (NNP QTc) (CD variability)))))) (PP (TO to) (NP (NP (JJ Doc_16801510_1497_1506_Chemical) (NN dose)) (, ,) (NP (JJ cytochrome) (JJ P-450) (NN 3A4) (NN drug-drug) (NNS interactions)) (, ,) (NP (NNP Doc_16801510_1558_1569_Disease)) (, ,) (CC and) (NP (JJ altered) (NN liver) (NN function))))) (. .)))
16801510	11	(S1 (S (NP (NP (JJ QT) (JJ interval) (NN prolongation)) (PP (IN in) (NP (NP (JJ Doc_16801510_1640_1649_Chemical) (NN maintenance) (NNS patients)) (VP (VBN hospitalized) (PP (IN in) (NP (DT a) (JJ tertiary) (NN care) (NN center))))))) (VP (AUX is) (NP (DT a) (JJ frequent) (NN finding))) (. .)))
16801510	12	(S1 (S (NP (NP (JJ Doc_16801510_1733_1742_Chemical) (NN dose)) (, ,) (NP (NP (NN presence)) (PP (IN of) (NP (JJ cytochrome) (JJ P-450) (NN 3A4) (NNS inhibitors)))) (, ,) (NP (JJ Doc_16801510_1794_1803_Chemical) (NN level)) (, ,) (CC and) (NP (NN liver) (NN function))) (VP (VBP contribute) (PP (TO to) (NP (NNP Doc_16801510_1844_1859_Disease)))) (. .)))
16801510	13	(S1 (S (NP (NN Doc_16801510_1861_1877_Disease)) (VP (MD can) (VP (VB occur) (PP (IN with) (NP (NP (JJ low) (NNS doses)) (PP (IN of) (NP (NNP Doc_16801510_1906_1915_Chemical))))))) (. .)))
16810074	0	(S1 (NP (NP (NP (NNS Mechanisms)) (PP (IN of) (NP (NNP Doc_16810074_14_26_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_16810074_38_50_Chemical) (PRN (-LRB- -LRB-) (INTJ (UH NO)) (-RRB- -RRB-)) (NN deficiency))))) (: :) (NP (NP (NN focus)) (PP (IN on) (NP (JJ venous) (NN function)))) (. .)))
16810074	1	(S1 (S (NP (NP (NN Loss)) (PP (IN of) (NP (NP (JJ endothelial) (JJ cell-derived) (NN Doc_16810074_127_139_Chemical)) (PRN (-LRB- -LRB-) (NP (DT NO)) (-RRB- -RRB-)))) (PP (IN in) (NP (NNP Doc_16810074_148_160_Disease)))) (VP (AUX is) (NP (NP (DT a) (NN hallmark)) (PP (IN of) (NP (NNP Doc_16810074_178_198_Disease))))) (. .)))
16810074	2	(S1 (S (NP (NP (JJ Experimental) (NN Doc_16810074_213_225_Disease)) (VP (VBN created) (PP (IN by) (NP (NP (DT the) (NN removal)) (PP (IN of) (NP (DT NO))))))) (, ,) (ADVP (RB however)) (, ,) (VP (VBZ involves) (NP (NP (NNS mechanisms)) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (VBN decreased) (JJ arterial) (NN vasodilator) (NN activity))))))) (. .)))
16810074	3	(S1 (S (NP (DT These)) (VP (VBP include) (NP (NP (JJ augmented) (JJ endothelin-1) (PRN (-LRB- -LRB-) (JJ ET-1) (-RRB- -RRB-)) (NN release)) (, ,) (NP (JJ increased) (JJ sympathetic) (JJ nervous) (NN system) (NN activity)) (, ,) (CC and) (NP (JJ elevated) (NN tissue) (NN oxidative) (NN stress)))) (. .)))
16810074	4	(S1 (S (NP (PRP We)) (VP (VBN hypothesized) (SBAR (IN that) (S (NP (NNP Doc_16810074_500_530_Disease) (PRN (-LRB- -LRB-) (NP (NN venomotor)) (-RRB- -RRB-)) (NN tone)) (VP (VBZ plays) (NP (NP (DT a) (NN role)) (PP (IN in) (NP (NNP Doc_16810074_564_587_Chemical) (PRN (-LRB- -LRB-) (NP (NNP LNNA)) (-RRB- -RRB-)) (NNP Doc_16810074_595_607_Disease)))) (PP (IN through) (NP (DT these) (NNS mechanisms))))))) (. .)))
16810074	5	(S1 (S (NP (NNS Rats)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (DT the) (ADJP (RB NO) (JJ synthase)) (NN inhibitor) (NN Doc_16810074_683_687_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.5) (NN g/L)) (PP (IN in) (NP (NN drinking) (NN water)))) (-RRB- -RRB-)))) (PP (IN for) (NP (CD 2) (NNS weeks))))) (. .)))
16810074	6	(S1 (S (NP (NP (JJ Mean) (JJ arterial) (NN pressure)) (PP (IN of) (NP (JJ conscious) (NNS rats)))) (VP (AUX was) (NP (NP (NP (NP (CD 119) (NN +/-) (QP (CD 2) (CD mm))) (NP (NNP Hg))) (PP (IN in) (NP (NN control)))) (CC and) (NP (NP (NP (CD 194) (NN +/-)) (NP (CD 5) (JJ mm) (NNP Hg))) (PP (IN in) (NP (NP (JJ LNNA) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NNP P<0.05)) (-RRB- -RRB-))))))) (. .)))
16810074	7	(S1 (S (NP (NP (JJ Carotid) (NNS arteries)) (CC and) (NP (JJ vena) (NNS cava))) (VP (AUX were) (VP (VBN removed) (PP (IN for) (NP (NP (NN measurement)) (PP (IN of) (NP (JJ isometric) (NN contraction))))))) (. .)))
16810074	8	(S1 (S (NP (NP (JJ Maximal) (NN contraction)) (PP (TO to) (NP (NNP Doc_16810074_953_967_Chemical)))) (VP (AUX was) (ADVP (RB modestly)) (VP (VBN reduced) (PP (IN in) (NP (NP (NNS arteries)) (PP (IN from) (NP (NNP LNNA))))) (PP (VBN compared) (PP (IN with) (NP (NN control) (NNS rats)))) (SBAR (IN whereas) (S (NP (NP (DT the) (JJ maximum) (NN contraction)) (PP (TO to) (NP (NN ET-1)))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN reduced) (PRN (-LRB- -LRB-) (NP (CD 54) (NN %) (NN control)) (-RRB- -RRB-)))))))) (. .)))
16810074	9	(S1 (S (S (NP (NP (JJ Maximum) (NN contraction)) (PP (IN of) (NP (NP (FW vena) (FW cava)) (PP (TO to) (NP (NNP Doc_16810074_1155_1169_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 37) (NN %) (NN control)) (-RRB- -RRB-))))) (ADVP (RB also)) (VP (AUX was) (VP (VBN reduced)))) (CC but) (S (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (CD ET-1)))))) (VP (AUX was) (VP (VBN observed)))) (. .)))
16810074	10	(S1 (S (NP (NP (JJ Mean) (NN circulatory) (VBG filling) (NN pressure)) (, ,) (NP (NP (DT an) (ADJP (QP (IN in) (CD vivo))) (NN measure)) (PP (IN of) (NP (NN venomotor) (NN tone)))) (, ,)) (VP (AUX was) (RB not) (ADJP (JJ elevated)) (PP (IN in) (NP (NNP LNNA) (NNP Doc_16810074_1347_1359_Disease))) (PP (IN at) (NP (NP (QP (CD 1) (CC or) (CD 2)) (NNS weeks)) (PP (IN after) (NP (NNP LNNA)))))) (. .)))
16810074	11	(S1 (S (NP (NP (DT The) (NNP Doc_16810074_1392_1402_Chemical) (NN scavenger) (NNP Doc_16810074_1413_1419_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 30)) (, ,) (NP (CD 100)) (, ,) (CC and) (NP (NP (CD 300) (JJ micromol) (NNS kg)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)))) (, ,) (NP (NNP IV)) (-RRB- -RRB-))) (VP (VP (AUX did) (RB not) (VP (VB change) (NP (NP (JJ arterial) (NN pressure)) (PP (IN in) (NP (NN control) (NNS rats)))))) (CC but) (VP (VBD caused) (NP (NP (DT a) (JJ dose-dependent) (NN decrease)) (PP (IN in) (NP (NP (JJ LNNA) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NN -18) (NN +/-) (CD 8)) (, ,) (NP (NP (NP (CD -26) (NNS +/-)) (NP (CD 15))) (, ,) (CC and) (NP (NP (CD -54) (NNS +/-)) (NP (CD 11) (NN mm) (NNP Hg)))) (-RRB- -RRB-))))))) (. .)))
16810074	12	(S1 (S (ADVP (RB Similarly)) (, ,) (NP (NP (JJ ganglionic) (NN blockade)) (PP (IN with) (NP (NNP Doc_16810074_1641_1654_Chemical)))) (VP (VBD caused) (NP (NP (DT a) (ADJP (RB significantly) (JJR greater)) (NN fall)) (PP (IN in) (NP (NP (NNP LNNA) (NNP Doc_16810074_1699_1711_Disease) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NP (CD 76) (NNS +/-)) (NP (CD 9) (NN mm) (NNP Hg))) (-RRB- -RRB-))))) (PP (VBN compared) (PP (IN with) (NP (NP (NN control) (NNS rats)) (PRN (-LRB- -LRB-) (NP (CD 35) (JJ +/-) (CD 10) (RB mm) (NNP Hg)) (-RRB- -RRB-)))))) (. .)))
16810074	13	(S1 (S (NP (NP (JJ Carotid) (NN arteries)) (, ,) (NP (FW vena) (FW cava)) (, ,) (CC and) (NP (NP (JJ sympathetic) (NN ganglia)) (PP (IN from) (NP (NNP LNNA) (NNS rats))))) (VP (AUX had) (NP (NP (JJR higher) (NN basal) (NNS levels)) (PP (IN of) (NP (NNP Doc_16810074_1875_1885_Chemical)))) (PP (VBN compared) (PP (IN with) (NP (NP (DT those)) (PP (IN from) (NP (NN control) (NNS rats))))))) (. .)))
16810074	14	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (SBAR (IN while) (S (NP (DT NO) (NN deficiency)) (VP (VBZ increases) (NP (NP (NP (JJ oxidative) (NN stress)) (CC and) (NP (JJ sympathetic) (NN activity))) (PP (IN in) (NP (DT both) (JJ arterial) (CC and) (JJ venous) (NNS vessels))))))) (, ,) (NP (NP (DT the) (NN impact)) (PP (IN on) (NP (NNS veins)))) (VP (AUX does) (RB not) (VP (VB make) (NP (NP (DT a) (JJ major) (NN contribution)) (PP (TO to) (NP (NP (DT this) (NN form)) (PP (IN of) (NP (NNP Doc_16810074_2129_2141_Disease))))))))))) (. .)))
16867246	0	(S1 (NP (NP (NP (NP (NNP Association)) (PP (IN of) (NP (NN DRD2) (NNS polymorphisms)))) (CC and) (NP (NNP Doc_16867246_38_52_Chemical-induced) (NNP Doc_16867246_61_84_Disease))) (PP (IN in) (NP (JJ Chinese) (NNP Doc_16867246_96_109_Disease) (NNS patients))) (. .)))
16867246	1	(S1 (S (NP (NP (NN Doc_16867246_125_148_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16867246_150_153_Disease)) (-RRB- -RRB-))) (VP (AUX is) (VP (ADVP (RBS most) (RB commonly)) (VBN affected) (PP (IN by) (NP (NP (JJ typical) (JJ antipsychotic) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (AUX have) (NP (NP (DT a) (JJ high) (NN affinity)) (PP (IN with) (NP (DT the) (NNP D2) (NN receptor))))))))))) (. .)))
16867246	2	(S1 (S (ADVP (RB Recently)) (, ,) (NP (JJ many) (NN research) (NNS groups)) (VP (AUX have) (VP (VBN reported) (PP (IN on) (NP (NP (DT the) (JJ positive) (NN relationship)) (PP (IN between) (NP (NP (NP (DT the) (JJ genetic) (NNS variations)) (PP (IN in) (NP (DT the) (NN DRD2) (NN gene)))) (CC and) (NP (NP (DT the) (JJ therapeutic) (NN response)) (PP (IN in) (NP (NNP Doc_16867246_414_427_Disease) (NNS patients)))))))) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (NNS variations)) (PP (IN in) (NP (DT the) (NN receptor))))))))) (PP (IN in) (S (VP (VBG modulating) (NP (NN receptor) (NN expression))))))) (. .)))
16867246	3	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VB evaluate) (NP (NP (DT the) (NN role) (NN DRD2) (NNS plays)) (PP (IN in) (NP (NP (NNP Doc_16867246_576_590_Chemical-induced) (NNP Doc_16867246_599_602_Disease)) (PP (IN in) (NP (JJ Doc_16867246_606_619_Disease) (NNS patients))))))) (. .)))
16867246	4	(S1 (S (NP (PRP We)) (VP (VBD identified) (NP (NP (NP (CD seven) (NNS SNP)) (PRN (-LRB- -LRB-) (NP (JJ single) (NN nucleotide) (NN polymorphism)) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NP (JJ -141Cins>del) (, ,) (NNP TaqIB) (, ,) (NNP TaqID) (, ,) (NNP Ser311Cys) (, ,) (CD rs6275) (, ,) (CD rs6277)) (CC and) (NP (NNP TaqIA))) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NN DRD2) (NN gene)))) (PP (IN in) (NP (NP (NP (CD 146) (NNP Doc_16867246_785_798_Disease) (NNS inpatients)) (PRN (-LRB- -LRB-) (NP (NP (CD 59)) (PP (IN with) (NP (NP (NNP Doc_16867246_819_822_Disease)) (CC and) (NP (NP (CD 87)) (PP (IN without) (NP (NP (NNP Doc_16867246_838_841_Disease)) (VP (VBG according) (PP (TO to) (NP (DT the) (JJ Simpson-Angus) (NN Scale)))))))))) (-RRB- -RRB-))) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_16867246_893_907_Chemical))) (PP (IN after) (NP (CD 8) (NNS weeks))))))) (. .)))
16867246	5	(S1 (S (NP (NP (DT The) (NNS alleles)) (PP (IN of) (NP (DT all) (NNS loci)))) (VP (AUX were) (VP (VBN determined) (PP (IN by) (NP (NP (NNP PCR)) (PRN (-LRB- -LRB-) (NP (NN polymerase) (NN chain) (NN reaction)) (-RRB- -RRB-)))))) (. .)))
16867246	6	(S1 (S (NP (NP (NNP Polymorphisms) (NNP TaqID)) (, ,) (NP (NNP Ser311Cys)) (CC and) (NP (CD rs6277))) (VP (AUX were) (RB not) (ADJP (JJ polymorphic)) (PP (IN in) (NP (NP (DT the) (NN population)) (VP (VBN recruited) (PP (IN in) (NP (DT the) (JJ present) (NN study))))))) (. .)))
16867246	7	(S1 (S (NP (DT No) (JJ statistical) (NN significance)) (VP (AUX was) (VP (VBN found) (PP (PP (IN in) (NP (NP (NP (DT the) (JJ allele) (NN distribution)) (PP (IN of) (NP (NN -141Cins>del)))) (, ,) (NP (NP (NNP TaqIB)) (, ,) (NP (CD rs6275)) (CC and) (NP (NNP TaqIA))))) (CC or) (PP (IN in) (NP (NP (DT the) (VBN estimated) (NNS haplotypes)) (PRN (-LRB- -LRB-) (VP (VBD constituted) (PP (IN by) (NP (NP (NNP TaqIB)) (, ,) (NP (CD rs6275)) (CC and) (NP (NNP TaqIA))))) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (JJ linkage) (NN disequilibrium)) (PP (IN between) (NP (DT the) (CD two) (NNS groups))))))) (. .)))
16867246	8	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (AUX did) (RB not) (VP (VB lend) (NP (JJ strong) (NN support)) (PP (TO to) (NP (DT the) (NN view) (SBAR (IN that) (S (NP (NP (DT the) (JJ genetic) (NN variation)) (PP (IN of) (NP (DT the) (NN DRD2) (NN gene)))) (VP (VBZ plays) (NP (DT a) (JJ major) (NN role)) (PP (IN in) (NP (NP (DT the) (ADJP (RB individually) (JJ variable)) (JJ adverse) (NN effect)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_16867246_1531_1545_Chemical)))))) (, ,) (PP (ADVP (IN at) (JJS least)) (IN in) (NP (NP (JJ Chinese) (NNS patients)) (PP (IN with) (NP (NNP Doc_16867246_1581_1594_Disease)))))))))))) (. .)))
16867246	9	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBD confirmed) (NP (NP (DT a) (JJ previous) (NN study)) (PP (IN on) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NP (NNP DRD2)) (CC and) (NP (NNP Doc_16867246_1672_1675_Disease))) (PP (IN in) (NP (NNP Caucasians))))))))) (. .)))
16876986	0	(S1 (S (NP (JJ Physical) (NN training)) (VP (VBZ decreases) (NP (NN susceptibility)) (PP (TO to) (NP (NP (JJ subsequent) (JJ Doc_16876986_57_68_Chemical-induced) (NN Doc_16876986_77_85_Disease)) (PP (IN in) (NP (DT the) (NN rat)))))) (. .)))
16876986	1	(S1 (S (S (NP (JJ Regular) (NN motor) (NN activity)) (VP (AUX has) (NP (NP (JJ many) (NNS benefits)) (PP (IN for) (NP (ADJP (JJ mental) (CC and) (JJ physical)) (NN condition)))))) (CC but) (S (NP (NP (PRP$ its) (NNS implications)) (PP (IN for) (NP (NNP Doc_16876986_198_206_Disease)))) (VP (AUX are) (ADVP (RB still)) (ADJP (JJ controversial)))) (. .)))
16876986	2	(S1 (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB elucidate) (NP (DT this) (NN problem)))))) (, ,) (NP (PRP we)) (VP (AUX have) (VP (VBN studied) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ long-term) (NN physical) (NN activity))) (PP (IN on) (NP (NP (NN susceptibility)) (PP (TO to) (NP (JJ subsequent) (NN Doc_16876986_358_366_Disease)))))))) (. .)))
16876986	3	(S1 (S (NP (JJ Male) (JJ Wistar) (NNS rats)) (VP (AUX were) (VP (VBN subjected) (PP (TO to) (NP (VBN repeated) (NN training) (NNS sessions))) (PP (IN in) (NP (DT a) (NN treadmill) (CC and) (NN swimming) (NN pool))))) (. .)))
16876986	4	(S1 (S (ADVP (RB Thereafter)) (, ,) (NP (NNP Doc_16876986_476_484_Disease)) (VP (AUX were) (VP (VBN induced) (PP (IN by) (NP (NP (JJ Doc_16876986_501_512_Chemical) (NNS injections)) (PP (IN in) (NP (ADJP (ADJP (JJ trained)) (CC and) (ADJP (JJ non-trained))) (NN control) (NNS groups))))))) (. .)))
16876986	5	(S1 (S (PP (IN During) (NP (NP (DT the) (JJ acute) (NN period)) (PP (IN of) (NP (NNP Doc_16876986_594_612_Disease))))) (, ,) (NP (PRP we)) (VP (VBD measured) (NP (: :) (NP (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NP (DT the) (NN latency)) (PP (IN of) (NP (NP (DT the) (JJ first) (NN motor) (NN sign)) (, ,) (PRN (-LRB- -LRB-) (NP (LST (LS 2) (-RRB- -RRB-)) (NP (DT the) (NN intensity)) (PP (IN of) (NP (NNP Doc_16876986_689_697_Disease)))) (, ,) (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-)) (NP (DT the) (NN time)) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBD occurred) (PP (IN within) (NP (DT the) (JJ 6-h) (NN observation) (NN period))))))))) (, ,) (CC and) (PRN (-LRB- -LRB-) (NP (CD 4)) (-RRB- -RRB-)) (NP (DT the) (NN time))) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (JJ acute) (NN period)) (VP (VBD ended))))) (. .)))
16876986	6	(S1 (S (NP (PDT All) (DT these) (JJ behavioral) (NNS parameters)) (VP (VBD showed) (NP (NP (ADJP (RB statistically) (JJ significant)) (NNS changes)) (VP (VBG suggesting) (SBAR (IN that) (S (NP (JJ regular) (NN physical) (NNS exercises)) (VP (VP (VB decrease) (NP (NP (NN susceptibility)) (PP (TO to) (NP (ADJP (RB subsequently) (VBN induced)) (NNP Doc_16876986_974_982_Disease))))) (CC and) (VP (VB ameliorate) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (ADJP (RB experimentally) (VBN induced)) (NNP Doc_16876986_1035_1053_Disease))))))))))) (. .)))
16880771	0	(S1 (S (NP (NN Tonic) (NN dopaminergic) (NN stimulation) (NNS impairs)) (VP (VBP associative) (NP (NN learning)) (PP (IN in) (NP (JJ healthy) (NNS subjects)))) (. .)))
16880771	1	(S1 (S (NP (NNP Endogenous) (NNP Doc_16880771_92_100_Chemical)) (VP (VBZ plays) (NP (DT a) (JJ central) (NN role)) (PP (IN in) (NP (NP (NN salience)) (VP (VBG coding) (PP (IN during) (NP (JJ associative) (NN learning))))))) (. .)))
16880771	2	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (DT the) (JJ Doc_16880771_192_200_Chemical) (NN precursor) (NN levodopa)))) (VP (VBZ enhances) (NP (NP (NN learning)) (PP (IN in) (NP (NP (JJ healthy) (NNS subjects)) (CC and) (NP (JJ Doc_16880771_262_268_Disease) (NNS patients)))))) (. .)))
16880771	3	(S1 (S (PP (IN Because) (NP (NP (JJ Doc_16880771_287_295_Chemical) (NNS increases)) (CC both) (NP (NN phasic) (CC and) (NN tonic) (NN dopaminergic) (NN neurotransmission)))) (, ,) (NP (NP (DT the) (JJ critical) (NN mechanism)) (VP (VBG mediating) (NP (NP (DT the) (NN enhancement)) (PP (IN of) (NP (NN learning)))))) (VP (AUX is) (ADJP (JJ unresolved))) (. .)))
16880771	4	(S1 (S (NP (PRP We)) (ADVP (RB here)) (VP (VBD probed) (SBAR (WHADVP (WRB how)) (S (NP (JJ selective) (NN tonic) (NN dopaminergic) (NN stimulation)) (VP (VBZ affects) (NP (JJ associative) (NN learning)))))) (. .)))
16880771	5	(S1 (S (NP (CD Forty) (JJ healthy) (NNS subjects)) (VP (AUX were) (VP (VBN trained) (PP (IN in) (NP (NP (DT a) (JJ novel) (NN vocabulary)) (PP (IN of) (NP (CD 45) (JJ concrete) (NNS nouns))))) (PP (IN over) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (CD 5) (JJ consecutive) (NN training) (NNS days))) (PP (IN in) (NP (DT a) (JJ prospective) (, ,) (JJ randomized) (, ,) (JJ double-blind) (, ,) (JJ placebo-controlled) (NN design))))))) (. .)))
16880771	6	(S1 (S (NP (NNS Subjects)) (VP (VBD received) (NP (DT the) (ADJP (RB tonically) (JJ stimulating)) (NN Doc_16880771_767_775_Chemical-receptor) (NN agonist) (NNP Doc_16880771_793_802_Chemical) (PRN (-LRB- -LRB-) (NP (CD 0.1) (NN mg)) (-RRB- -RRB-)) (NNP vs) (NN placebo) (CD 120) (NN min)) (PP (IN before) (S (VP (VBG training) (PP (IN on) (NP (DT each) (NN training) (NN day))))))) (. .)))
16880771	7	(S1 (S (NP (DT The) (JJ Doc_16880771_873_881_Chemical) (JJ agonist) (ADJP (RB significantly) (JJ impaired)) (NN novel) (NN word) (NN learning)) (VP (VBD compared) (PP (TO to) (NP (NN placebo)))) (. .)))
16880771	8	(S1 (S (NP (DT This) (VBG learning) (NN decrement)) (VP (VBD persisted) (ADVP (RB up)) (PP (TO to) (NP (NP (DT the) (JJ last) (NN follow-up)) (ADJP (CD 4) (NNS weeks) (JJ post-training))))) (. .)))
16880771	9	(S1 (S (NP (NP (NNS Subjects)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_16880771_1058_1067_Chemical))))) (ADVP (RB also)) (VP (VBD showed) (NP (JJ restricted) (JJ emotional) (NNS responses)) (PP (VBN compared) (PP (TO to) (NP (DT the) (NN PLACEBO) (NN group))))) (. .)))
16880771	10	(S1 (S (NP (NP (DT The) (NN extent)) (PP (IN of) ('' ')) (VP (VBN flattened) ('' ') (NP (VB affect)) (PP (IN with) (NP (NNP Doc_16880771_1180_1189_Chemical))))) (VP (AUX was) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (NN degree)) (PP (IN of) (S (VP (VBG learning) (NP (NN inhibition))))))))) (. .)))
16880771	11	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN tonic) (NN occupation)) (PP (IN of) (NP (JJ Doc_16880771_1288_1296_Chemical) (NNS receptors)))) (VP (VBZ impairs) (NP (NN learning)) (PP (IN by) (NP (NP (NN competition)) (PP (IN with) (NP (JJ phasic) (JJ Doc_16880771_1351_1359_Chemical) (NNS signals))))))))) (. .)))
16880771	12	(S1 (S (ADVP (RB Thus)) (, ,) (NP (JJ phasic) (VBG signaling)) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (JJ critical) (NN mechanism)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NNP Doc_16880771_1436_1444_Chemical)) (VP (VBZ enhances) (NP (NP (JJ associative) (NN learning)) (PP (IN in) (NP (NP (JJ healthy) (NNS subjects)) (CC and) (NP (JJ Doc_16880771_1499_1505_Disease) (NNS patients))))))))))))) (. .)))
16906379	0	(S1 (S (NP (JJ Doc_16906379_0_11_Chemical-induced) (NNP Doc_16906379_20_30_Disease)) (VP (VBG fulfilling) (NP (NP (DT the) (NNS criteria)) (PP (IN of) (NP (NNP Doc_16906379_58_78_Disease))))) (. .)))
16906379	1	(S1 (S (NP (NP (DT A) (JJ 47-year-old) (NN man)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX been) (VP (VBG taking) (NP (NNP Doc_16906379_118_129_Chemical)) (PP (IN for) (NP (NNP Doc_16906379_134_157_Disease))))))))) (VP (VBD developed) (NP (NP (NNP Doc_16906379_168_173_Disease)) (, ,) (NP (NNP Doc_16906379_175_183_Disease)) (, ,) (NP (NNP Doc_16906379_185_199_Disease)) (, ,) (CC and) (NP (NNP Doc_16906379_205_220_Disease))) (, ,) (PP (IN with) (NP (NP (JJ elevated) (JJ C-reactive) (NN protein)) (PRN (-LRB- -LRB-) (NP (NNP CRP)) (-RRB- -RRB-))))) (. .)))
16906379	2	(S1 (S (NP (DT Neither) (NN myeloperoxidase-) (CC nor) (NN proteinase-3-antineutrophil) (NN cytoplasmic) (NN antibody)) (VP (AUX was) (ADJP (JJ positive))) (. .)))
16906379	3	(S1 (S (NP (DT These) (NNS manifestations)) (VP (VBD met) (NP (NP (DT the) (NNP American) (NNP College)) (PP (IN of) (NP (NNP Rheumatology) (CD 1990) (NNS criteria))) (PP (IN for) (NP (NP (DT the) (NN classification)) (PP (IN of) (NP (NNP Doc_16906379_456_476_Disease))))))) (. .)))
16906379	4	(S1 (S (NP (NN Stopping) (NN Doc_16906379_487_498_Chemical)) (VP (VBD led) (PP (TO to) (NP (NP (NP (NN amelioration)) (PP (IN of) (NP (NNS symptoms)))) (CC and) (NP (NP (NN normalization)) (PP (IN of) (NP (NN CRP) (NN level))))))) (. .)))
16906379	5	(S1 (S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (, ,) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ second) (NN case)) (PP (IN of) (NP (NP (NNP Doc_16906379_608_619_Chemical-induced) (NNP Doc_16906379_628_638_Disease)) (VP (VBG satisfying) (NP (DT the) (NNS criteria))))))) (. .)))
16906379	6	(S1 (S (NP (NP (NN Differential) (NN diagnosis)) (PP (IN for) (NP (JJ drug-induced) (NN disease)))) (VP (AUX is) (ADJP (JJ invaluable)) (ADVP (RB even)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ classical) (NN Doc_16906379_759_779_Disease)))))) (. .)))
16911931	0	(S1 (S (NP (NNP Intramuscular) (NNP Doc_16911931_14_25_Disease) (JJ immune) (NN globulin)) (VP (VBD combined) (PP (IN with) (NP (NNP Doc_16911931_56_66_Chemical))) (PP (IN in) (NP (NP (NN prevention)) (PP (IN of) (NP (NNP Doc_16911931_84_95_Disease) (NN recurrence))) (PP (IN after) (NP (NN liver) (NN transplantation)))))) (. .)))
16911931	1	(S1 (S (NP (NP (NP (NP (NNP Combined) (NNP Doc_16911931_157_168_Disease)) (NP (JJ immune) (NN globulin))) (PRN (-LRB- -LRB-) (NP (NNP HBIg)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_16911931_196_206_Chemical)) (PP (IN in) (NP (NP (NNS prophylaxis)) (PP (IN of) (NP (NP (DT the) (NN recurrence)) (PP (IN of) (NP (NNP Doc_16911931_243_254_Disease))) (PP (IN after) (NP (NN liver) (NN transplantation))))))))) (VP (AUX has) (VP (ADVP (RB significantly)) (VBN improved) (NP (NP (DT the) (NN survival)) (PP (IN of) (NP (JJ Doc_16911931_326_331_Chemical) (JJ positive) (NNS patients)))))) (. .)))
16911931	2	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN undertaken) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NNS outcomes)) (PP (IN of) (NP (NN liver) (NN transplantation))) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_16911931_445_462_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16911931_464_467_Disease)) (-RRB- -RRB-)))))))))))) (. .)))
16911931	3	(S1 (S (NP (NP (DT A) (JJ retrospective) (NN chart) (NN analysis)) (CC and) (NP (NP (DT a) (NN review)) (PP (IN of) (NP (DT the) (NN organ) (NN transplant) (NN database))))) (VP (VBD identified) (NP (NP (CD 51) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD 43) (NNS men)) (CC and) (NP (CD 8) (NNS women))) (-RRB- -RRB-))) (PP (VBN transplanted) (PP (IN for) (NP (NP (JJ benign) (JJ Doc_16911931_624_627_Disease-related) (JJ cirrhotic) (NNS diseases)) (PP (IN between) (NP (NP (NNP June) (CD 2002)) (CC and) (NP (NNP December) (CD 2004)))) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN survived) (NP (QP (JJR more) (IN than) (CD 3)) (NNS months)))))))))) (. .)))
16911931	4	(S1 (S (NP (NNP HBIg)) (VP (AUX was) (VP (VP (VBN administered) (ADVP (RB intravenously)) (PP (IN during) (NP (DT the) (JJ first) (NN week)))) (CC and) (ADVP (RB intramuscularly)) (ADVP (RB thereafter)))) (. .)))
16911931	5	(S1 (S (PP (IN At) (NP (NP (DT a) (JJ median) (NN follow-up)) (PP (IN of) (NP (CD 14.1) (NNS months))))) (, ,) (NP (NP (DT the) (JJ overall) (NN recurrence) (NN rate)) (PP (IN in) (NP (DT the) (CD 51) (NNS patients)))) (VP (AUX was) (NP (NP (CD 3.9) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 2/51)) (-RRB- -RRB-)))) (. .)))
16911931	6	(S1 (S (NP (DT The) (JJ overall) (NN patient) (NN survival)) (VP (AUX was) (NP (NP (CD 88.3) (NN %)) (, ,) (CC and) (NP (CD 82.4) (NN %))) (PP (IN after) (NP (QP (CD 1) (CC and) (CD 2)) (NNS years))) (, ,) (ADVP (RB respectively))) (. .)))
16911931	7	(S1 (S (NP (NP (DT A) (JJ daily) (JJ oral) (NN dose)) (PP (IN of) (NP (NP (CD 100) (NNS mg)) (ADJP (JJ Doc_16911931_1042_1052_Chemical) (PP (IN for) (NP (NP (CD 2) (NNS weeks)) (PP (IN before) (NP (NP (NN transplantation)) (PP (IN for) (NP (CD 10) (NNS patients))))))))))) (VP (VBD enabled) (NP (NP (NP (NP (NP (NP (CD 57.1) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 4/7)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 62.5) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 5/8)) (-RRB- -RRB-)))) (PP (IN of) (NP (NNP Doc_16911931_1143_1146_Disease-DNA) (CC and) (NNP Doc_16911931_1155_1160_Chemical)))) (NP (JJ positive) (NNS patients))) (ADVP (RB respectively))) (S (VP (TO to) (VP (VB convert) (S (VP (TO to) (VP (AUX be) (ADJP (JJ negative))))))))) (. .)))
16911931	8	(S1 (S (NP (JJ Intramuscular) (NN HBIg)) (VP (AUX was) (ADVP (RB well)) (VP (VBN tolerated) (PP (IN in) (NP (DT all) (NNS patients))))) (. .)))
16911931	9	(S1 (S (NP (NP (NN Doc_16911931_1286_1296_Chemical)) (VP (VBN combined) (PP (IN with) (NP (JJ intramuscular) (NN HBIg))))) (VP (MD can) (ADVP (RB effectively)) (VP (VB prevent) (NP (NN allograft)) (PP (IN from) (NP (NP (DT the) (NN recurrence)) (PP (IN of) (NP (NNP Doc_16911931_1387_1390_Disease))))) (PP (IN after) (NP (NN liver) (NN transplantation))))) (. .)))
16920333	0	(S1 (NP (NP (JJ Anticonvulsant) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_16920333_25_48_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16920333_50_59_Chemical)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (NNP Doc_16920333_64_72_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NN microperfusion)) (PP (IN of) (NP (NNP Doc_16920333_102_112_Chemical))))) (PP (IN in) (NP (NP (DT the) (NN hippocampus)) (PP (IN of) (NP (ADJP (RB freely) (JJ moving)) (NNS rats)))))))) (. .)))
16920333	1	(S1 (S (NP (NP (NNP Doc_16920333_155_178_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16920333_180_189_Chemical)) (, ,) (NP (NNP Doc_16920333_191_258_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (JJ novel) (JJ antiepileptic) (NN drug)) (, ,) (PP (ADVP (RB now)) (IN in) (NP (NN Phase) (NNP III) (JJ clinical) (NNS trials))) (, ,) (VP (VBN designed) (PP (IN with) (NP (NP (DT the) (NN aim)) (PP (IN of) (S (VP (VBG improving) (NP (NN efficacy) (CC and) (NN safety)) (PP (IN in) (NP (NP (NN comparison)) (PP (IN with) (NP (NP (DT the) (ADJP (RB structurally) (VBN related)) (NNS drugs)) (NP (NP (NP (NNP Doc_16920333_430_443_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16920333_445_448_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_16920333_454_467_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_16920333_469_472_Chemical)) (-RRB- -RRB-)))))))))))))))) (. .)))
16920333	2	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN studied) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ oral) (NN treatment)) (PP (IN with) (NP (NNP Doc_16920333_526_549_Chemical))))) (PP (IN on) (NP (NP (DT a) (JJ whole-animal) (NN model)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (JJ partial) (NN Doc_16920333_591_599_Disease)) (VP (MD can) (VP (AUX be) (VP (VBN elicited) (ADVP (RB repeatedly)) (PP (IN on) (NP (JJ different) (NNS days))) (PP (IN without) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NN threshold)) (CC or) (NP (JJ Doc_16920333_677_684_Disease) (NNS patterns)))))))))))))))) (. .)))
16920333	3	(S1 (S (PP (IN In) (NP (NP (DT the) (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NP (NN threshold) (NNS doses)) (PP (IN of) (NP (NNP Doc_16920333_742_752_Chemical)))))))) (, ,) (S (NP (NP (DT the) (JJ average) (NN number)) (PP (IN of) (NP (NNP Doc_16920333_776_784_Disease)))) (VP (AUX was) (NP (CD 2.3+/-1.2)))) (, ,) (CC and) (S (NP (JJ average) (NN Doc_16920333_812_819_Disease) (NN duration)) (VP (AUX was) (ADJP (ADJP (JJ 39.5+/-8.4s.) (JJ Pre-treatment)) (PP (IN with) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 30) (JJ mg/kg) (NNS 2h)))))) (SBAR (IN before) (S (NP (JJ Doc_16920333_894_904_Chemical) (NN microperfusion)) (VP (VBD prevented) (NP (NNP Doc_16920333_930_938_Disease)) (PP (IN in) (NP (NP (DT the) (CD 75) (NN %)) (PP (IN of) (NP (DT the) (NNS rats)))))))))) (. .)))
16920333	4	(S1 (S (NP (NP (JJR Lower) (NNS doses)) (PRN (-LRB- -LRB-) (NP (CD 3) (CC and) (CD 10mg/kg)) (-RRB- -RRB-))) (VP (AUX did) (RB not) (VP (VB suppress) (NP (NNP Doc_16920333_1008_1016_Disease)) (, ,) (ADVP (RB however)) (, ,) (SBAR (IN after) (S (NP (NP (NN administration)) (PP (IN of) (NP (NP (NNS 10mg/kg)) (, ,) (NP (NP (NP (JJ significant) (NNS reductions)) (PP (IN in) (NP (NNP Doc_16920333_1086_1094_Disease) (NN duration)))) (PRN (-LRB- -LRB-) (JJ 24.3+/-6.8s) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_16920333_1122_1129_Disease) (NN number)) (PRN (-LRB- -LRB-) (NP (CD 1.6+/-0.34)) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN found))))))) (. .)))
16920333	5	(S1 (S (NP (NP (DT No) (JJ adverse) (NNS effects)) (PP (IN of) (NP (NNP Doc_16920333_1184_1207_Chemical)))) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NN behavioral/EEG) (NNS patterns)) (VP (VBN studied)))) (, ,) (PP (VBG including) (NP (NN sleep/wakefulness) (NN cycle))) (, ,) (PP (IN at) (NP (NP (DT the) (NNS doses)) (VP (VBN studied)))))) (. .)))
17028363	0	(S1 (S (NP (NN Doc_17028363_0_19_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ prolonged) (NN intake)) (PP (IN of) (NP (NP (VBG slimming) (NNS pills)) (VP (VBG containing) (NP (NNP Doc_17028363_82_96_Chemical)))))))) (. .)))
17028363	1	(S1 (S (NP (JJ Chinese) (JJ herbal) (NN medicine) (NNS preparations)) (VP (VP (AUX are) (ADJP (RB widely) (JJ available))) (CC and) (VP (ADVP (RB often)) (VBN regarded) (PP (IN by) (NP (DT the) (NN public))) (PP (IN as) (NP (NP (JJ natural) (CC and) (JJ safe) (NNS remedies)) (PP (IN for) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (JJ medical) (NNS conditions))))))))) (. .)))
17028363	2	(S1 (S (NP (NP (NN Doc_17028363_255_266_Disease)) (VP (VBN caused) (PP (IN by) (NP (JJ Chinese) (NNS herbs))))) (VP (AUX has) (ADVP (RB previously)) (VP (AUX been) (VP (VBN reported) (, ,) (PP (ADVP (RB usually)) (VBG involving) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ aristolochic) (NNS acids)))))))) (. .)))
17028363	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (JJ 23-year-old) (NN woman)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_17028363_414_433_Disease)) (PP (VBG following) (NP (NP (JJ prolonged) (NN use)) (PP (IN of) (NP (NP (DT a) (JJ proprietary) (JJ Chinese) (JJ herbal) (VBG slimming) (NN pill)) (SBAR (WHNP (WDT that)) (S (VP (VBD contained) (NP (NP (JJ Doc_17028363_519_532_Chemical) (NNS derivatives)) (, ,) (VP (VBN extracted) (PP (IN from) (NP (NP (NNP Rhizoma) (NNP Rhei)) (PRN (-LRB- -LRB-) (NP (NN rhubarb)) (-RRB- -RRB-)))))))))))))))))) (. .)))
17028363	4	(S1 (S (NP (DT The) (NNP Doc_17028363_589_601_Disease)) (VP (AUX was) (ADVP (RB probably)) (VP (VBN aggravated) (PP (IN by) (NP (NP (DT the) (JJ concomitant) (NN intake)) (PP (IN of) (NP (NP (DT a) (JJ non-steroidal) (JJ anti-inflammatory) (NN drug)) (, ,) (NP (NNP Doc_17028363_695_705_Chemical)))))))) (. .)))
17028363	5	(S1 (S (NP (JJ Renal) (NN pathology)) (VP (AUX was) (NP (NP (DT that)) (PP (IN of) (NP (JJ hypocellular) (NNP Doc_17028363_748_769_Disease))))) (. .)))
17028363	6	(S1 (S (S (NP (JJ Spontaneous) (JJ renal) (NN recovery)) (VP (VBD occurred) (PP (IN upon) (NP (NP (NN cessation)) (PP (IN of) (NP (DT the) (VBG slimming) (NNS pills))))))) (, ,) (CC but) (S (NP (NP (JJ mild) (NN Doc_17028363_854_875_Disease)) (CC and) (NP (NNP Doc_17028363_880_895_Disease))) (VP (AUX was) (ADVP (RB still)) (ADJP (JJ evident)) (ADVP (NP (QP (RB histologically) (CD 4)) (NNS months)) (RB later)))) (. .)))
17028363	7	(S1 (S (SBAR (IN Although) (S (NP (NP (DT a) (JJ causal) (NN relationship)) (PP (IN between) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (DT an) (JJ Doc_17028363_998_1011_Chemical-containing) (JJ herbal) (NN agent)) (CC and) (NP (NNP Doc_17028363_1040_1052_Disease))))))) (VP (VBZ remains) (S (VP (TO to) (VP (AUX be) (VP (VBN proven)))))))) (, ,) (NP (JJ phytotherapy-associated) (JJ interstitial) (NN Doc_17028363_1112_1123_Disease)) (VP (MD should) (VP (AUX be) (VP (VBN considered) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP present) (PP (IN with) (NP (JJ unexplained) (NN Doc_17028363_1186_1199_Disease))))))))))) (. .)))
17035713	0	(S1 (NP (NP (NP (NN Doc_17035713_0_18_Chemical)) (PP (IN as) (NP (DT a) (JJ Doc_17035713_24_34_Chemical) (NN reagent)))) (: :) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (JJ critical) (JJ Doc_17035713_65_70_Chemical) (NNS groups))) (PP (IN in) (NP (NNP Doc_17035713_81_91_Chemical) (NNP Doc_17035713_92_103_Disease)))) (. .)))
17035713	1	(S1 (S (NP (NP (NNP Doc_17035713_105_123_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17035713_125_128_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (NP (DT a) (NN metabolite)) (PP (IN of) (NP (NP (DT the) (JJ alkylating) (NN agent) (NNP Doc_17035713_170_180_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17035713_182_185_Chemical)) (-RRB- -RRB-))))) (CC and) (NP (NP (ADJP (RB putatively) (JJ responsible) (PP (IN for) (NP (NNP Doc_17035713_218_230_Disease)))) (JJ following) (JJ anti-Doc_17035713_246_251_Disease) (NN therapy)) (PP (IN with) (NP (NNP Doc_17035713_265_268_Chemical)))))) (. .)))
17035713	2	(S1 (S (NP (NP (NN Depletion)) (PP (IN of) (NP (NNP Doc_17035713_283_293_Chemical) (PRN (-LRB- -LRB-) (NP (NNP SH)) (-RRB- -RRB-)) (NNS groups)))) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN from) (NP (NP (NN cell) (NN culture)) (, ,) (NP (NN animal)) (CC and) (NP (JJ clinical) (NNS studies))))))) (. .)))
17035713	3	(S1 (S (PP (IN In) (NP (DT this) (NN work))) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_17035713_399_402_Chemical))) (PP (IN on) (NP (NP (JJ human) (JJ proximal) (NN tubule) (NNS cells)) (PP (IN in) (NP (NP (JJ primary) (NN culture)) (PRN (-LRB- -LRB-) (NP (NN hRPTEC)) (-RRB- -RRB-))))))) (VP (AUX was) (VP (VBN investigated))) (. .)))
17035713	4	(S1 (S (NP (NP (NN Doc_17035713_480_488_Disease)) (PP (IN of) (NP (NNP Doc_17035713_492_495_Chemical)))) (VP (AUX was) (VP (VBN determined) (PP (IN by) (NP (NP (NN protein) (NN content)) (, ,) (NP (NN cell) (NN number)) (, ,) (NP (NN LDH) (NN release)) (, ,) (NP (JJ Doc_17035713_557_568_Chemical) (NN exclusion) (NN assay)) (CC and) (NP (JJ caspase-3) (NN activity)))))) (. .)))
17035713	5	(S1 (S (NP (NNP Free) (NNP Doc_17035713_614_620_Chemical)) (VP (AUX were) (VP (VBN measured) (PP (IN by) (NP (NP (DT the) (NN method)) (PP (IN of) (NP (NNP Ellman))))))) (. .)))
17035713	6	(S1 (S (NP (NN Doc_17035713_660_663_Chemical)) (VP (VBD reduced) (NP (NP (JJ hRPTEC) (NN cell) (NN number)) (CC and) (NP (NN protein))) (, ,) (S (VP (VBN induced) (NP (NP (NP (DT a) (NN loss)) (PP (IN in) (NP (JJ free) (JJ intracellular) (NN Doc_17035713_741_747_Chemical)))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NNP Doc_17035713_767_775_Disease) (NNS markers)))))))) (. .)))
17035713	7	(S1 (S (NP (NNP Doc_17035713_785_788_Chemical) (CONJP (CC but) (RB not)) (NNP Doc_17035713_797_805_Chemical)) (VP (VBD inhibited) (NP (NP (DT the) (JJ Doc_17035713_820_828_Chemical) (NNS proteases)) (ADJP (JJ caspase-3) (, ,) (JJ caspase-8) (CC and) (JJ cathepsin))) (SBAR (S (NP (NP (NNP B.) (NNP Caspase) (NN activation)) (PP (IN by) (NP (NNP Doc_17035713_899_908_Chemical)))) (VP (AUX was) (VP (VBD inhibited) (PP (IN by) (NP (NNP Doc_17035713_926_929_Chemical)))))))) (. .)))
17035713	8	(S1 (S (PP (IN In) (NP (NP (NNS cells)) (VP (VBN stained) (PP (IN with) (NP (NP (JJ fluorescent) (NNS dyes)) (VP (VBG targeting) (NP (NNS lysosomes)))))))) (, ,) (NP (NNP Doc_17035713_991_994_Chemical)) (VP (VBN induced) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (JJ lysosomal) (NN size)) (CC and) (NP (JJ lysosomal) (NN leakage)))))) (. .)))
17035713	9	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NNP Doc_17035713_1071_1074_Chemical))) (PP (IN on) (NP (NP (JJ Doc_17035713_1078_1086_Chemical) (NN protease) (NNS activities)) (CC and) (NP (NNP Doc_17035713_1111_1117_Chemical))))) (VP (MD could) (VP (AUX be) (VP (VBN reproduced) (PP (IN in) (NP (NN cell) (NN lysate)))))) (. .)))
17035713	10	(S1 (S (NP (NP (NN Acidification)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD slowed) (NP (NP (DT the) (NN reaction)) (PP (IN of) (NP (NNP Doc_17035713_1198_1201_Chemical)))) (PP (IN with) (NP (JJ Doc_17035713_1207_1212_Chemical) (NNS donors)))))) (, ,)) (VP (MD could) (ADVP (RB also)) (VP (VB attenuate) (NP (NP (NNS effects)) (PP (IN of) (NP (NNP Doc_17035713_1253_1256_Chemical))) (PP (IN on) (NP (NP (NNP Doc_17035713_1260_1268_Disease) (NNS markers)) (, ,) (NP (JJ Doc_17035713_1278_1283_Chemical) (NN depletion)) (CC and) (NP (NP (JJ Doc_17035713_1298_1306_Chemical) (NN protease) (NN inhibition)) (PP (IN in) (NP (NN living) (NNS cells))))))))) (. .)))
17035713	11	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NNP Doc_17035713_1350_1353_Chemical)) (ADVP (RB directly)) (VP (VBZ reacts) (PP (IN with) (NP (NP (JJ cellular) (NN protein)) (CC and) (NP (JJ non-protein) (NN Doc_17035713_1408_1414_Chemical)))) (, ,) (S (VP (VBG mediating) (NP (PRP$ its) (NN Doc_17035713_1430_1438_Disease)) (PP (IN on) (NP (NN hRPTEC)))))) (. .)))
17035713	12	(S1 (S (NP (DT This) (NN effect)) (VP (MD can) (VP (AUX be) (VP (VBN reduced) (PP (IN by) (NP (NN acidification)))))) (. .)))
17035713	13	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (JJ urinary) (NN acidification)) (VP (MD could) (VP (AUX be) (NP (NP (DT an) (NN option)) (SBAR (S (VP (TO to) (VP (VB prevent) (NP (NP (NNP Doc_17035713_1558_1561_Chemical) (NNP Doc_17035713_1562_1573_Disease)) (PP (IN in) (NP (NNS patients))))))))))) (. .)))
17042797	0	(S1 (S (NP (JJ Stereological) (NNS methods)) (VP (VBP reveal) (NP (NP (DT the) (JJ robust) (NN size) (CC and) (NN stability)) (PP (IN of) (NP (JJ ectopic) (JJ hilar) (NN granule) (NNS cells))) (PP (IN after) (NP (NP (NNP Doc_17042797_96_107_Chemical-induced) (NNP Doc_17042797_116_134_Disease)) (PP (IN in) (NP (DT the) (NN adult) (NN rat))))))) (. .)))
17042797	1	(S1 (S (S (S (VP (VBG Following) (NP (NN Doc_17042797_163_181_Disease)) (PP (IN in) (NP (DT the) (NN rat))))) (, ,) (NP (JJ dentate) (JJ granule) (NN cell) (NN neurogenesis)) (VP (VBZ increases) (ADVP (RB greatly)))) (, ,) (CC and) (S (NP (NP (JJ many)) (PP (IN of) (NP (DT the) (JJ new) (NNS neurons)))) (VP (VBP appear) (S (VP (TO to) (VP (VB develop) (ADVP (RB ectopically))))) (, ,) (PP (IN in) (NP (NP (DT the) (JJ hilar) (NN region)) (PP (IN of) (NP (DT the) (JJ hippocampal) (NN formation))))))) (. .)))
17042797	2	(S1 (S (NP (PRP It)) (VP (AUX has) (VP (AUX been) (VP (VBN suggested) (SBAR (IN that) (S (NP (DT the) (JJ ectopic) (JJ hilar) (NN granule) (NNS cells)) (VP (MD could) (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (JJ spontaneous) (NN Doc_17042797_451_459_Disease)) (SBAR (WHNP (WDT that)) (S (ADVP (RB ultimately)) (VP (VBP develop) (PP (IN after) (NP (NN Doc_17042797_490_508_Disease))))))))))))))) (. .)))
17042797	3	(S1 (S (ADVP (RB However)) (, ,) (NP (DT the) (NN population)) (VP (AUX has) (ADVP (RB never)) (VP (AUX been) (VP (VBN quantified) (, ,) (SBAR (IN so) (S (NP (PRP it)) (VP (AUX is) (ADJP (JJ unclear)) (SBAR (IN whether) (S (NP (PRP it)) (VP (AUX is) (ADJP (JJ substantial) (RB enough) (S (VP (TO to) (VP (AUX have) (NP (NP (DT a) (JJ strong) (NN influence)) (PP (IN on) (NP (NN epileptogenesis))))))))))))))))) (. .)))
17042797	4	(S1 (S (S (VP (TO To) (VP (VB quantify) (NP (DT this) (NN population))))) (, ,) (NP (NP (DT the) (JJ total) (NN number)) (PP (IN of) (NP (JJ ectopic) (JJ hilar) (NN granule) (NNS cells)))) (VP (AUX was) (VP (VBN estimated) (S (VP (VBG using) (NP (JJ unbiased) (NN stereology)) (PP (IN at) (NP (NP (JJ different) (NNS times)) (PP (IN after) (NP (JJ Doc_17042797_800_811_Chemical-induced) (NN Doc_17042797_820_838_Disease))))))))) (. .)))
17042797	5	(S1 (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (JJ hilar) (NNS neurons)))) (VP (VBP immunoreactive) (SBAR (IN for) (S (NP (NP (NNP Prox-1)) (, ,) (NP (DT a) (JJ granule-cell-specific) (NN marker)) (, ,)) (VP (AUX was) (VP (VBN estimated) (S (VP (VBG using) (NP (DT the) (JJ optical) (NN fractionator) (NN method))))))))) (. .)))
17042797	6	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (NN size)) (PP (IN of) (NP (DT the) (JJ hilar) (JJ ectopic) (NN granule) (NN cell) (NN population))) (PP (IN after) (NP (NNP Doc_17042797_1066_1084_Disease)))) (VP (AUX is) (ADJP (ADJP (JJ substantial)) (, ,) (CC and) (ADJP (JJ stable))) (PP (IN over) (NP (NN time))))))) (. .)))
17042797	7	(S1 (S (ADVP (RB Interestingly)) (, ,) (NP (NP (DT the) (NN size)) (PP (IN of) (NP (DT the) (NN population)))) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (VP (VBN correlated) (PP (IN with) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (JJ behavioral) (NNP Doc_17042797_1223_1231_Disease))))) (, ,) (SBAR (IN because) (S (NP (NP (NNS animals)) (PP (IN with) (NP (NP (ADJP (RBR more) (JJ ectopic)) (JJ granule) (NNS cells)) (PP (IN in) (NP (DT the) (NN hilus)))))) (VP (AUX have) (NP (ADJP (RBR more) (JJ frequent)) (JJ behavioral) (NN Doc_17042797_1324_1332_Disease)))))))))) (. .)))
17042797	8	(S1 (S (NP (DT The) (JJ hilar) (JJ ectopic) (NN granule) (NN cell) (NN population)) (VP (AUX does) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB vary) (ADVP (RB systematically)) (PP (IN across) (NP (DT the) (JJ septotemporal) (NNS axis)))))) (, ,) (SBAR (IN although) (S (NP (PRP it)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN volume)) (PP (IN of) (NP (DT the) (NN hilus))))))))))))) (. .)))
17042797	9	(S1 (S (NP (DT The) (NNS results)) (VP (VBP provide) (NP (JJ new) (NNP insight)) (PP (IN into) (NP (NP (DT the) (JJ potential) (NN role)) (PP (IN of) (NP (JJ ectopic) (JJ hilar) (NN granule) (NNS cells))) (PP (IN in) (NP (NP (DT the) (JJ Doc_17042797_1607_1618_Chemical) (NN model)) (PP (IN of) (NP (NNP Doc_17042797_1628_1650_Disease)))))))) (. .)))
17069550	0	(S1 (NP (NP (DT A) (JJ prospective) (, ,) (JJ open-label) (NN trial)) (PP (IN of) (NP (NNP Doc_17069550_35_46_Chemical))) (PP (IN in) (NP (NNP Doc_17069550_50_67_Disease))) (. .)))
17069550	1	(S1 (S (NP (NN Post-mortem) (NNS studies)) (VP (AUX have) (VP (VBN reported) (NP (NP (NNS abnormalities)) (PP (IN of) (NP (NP (DT the) (JJ cholinergic) (NN system)) (PP (IN in) (NP (NNP Doc_17069550_157_163_Disease)))))))) (. .)))
17069550	2	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NNP Doc_17069550_216_227_Chemical)) (, ,) (NP (NP (DT an) (JJ acetylcholinesterase) (NN inhibitor)) (CC and) (NP (JJ nicotinic) (NN receptor) (NN modulator))) (, ,))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (S (VP (VBG interfering) (NP (NNS behaviors)) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NNP Doc_17069550_356_362_Disease))))))))))))))) (. .)))
17069550	3	(S1 (S (NP (NP (JJ Thirteen) (JJ medication-free) (NNS children)) (PP (IN with) (NP (NP (NNP Doc_17069550_412_418_Disease)) (PRN (-LRB- -LRB-) (NP (NP (JJ mean) (NN age)) (, ,) (NP (CD 8.8) (JJ +/-) (CD 3.5) (NNS years))) (-RRB- -RRB-))))) (VP (VBD participated) (PP (IN in) (NP (NP (DT a) (JJ 12-week) (, ,) (JJ open-label) (NN trial)) (PP (IN of) (NP (NNP Doc_17069550_496_507_Chemical)))))) (. .)))
17069550	4	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN rated) (ADVP (RB monthly)) (PP (PP (IN by) (NP (NP (NNS parents)) (PP (IN on) (NP (NP (NP (DT the) (NNP Aberrant) (NN Behavior) (NNP Checklist)) (PRN (-LRB- -LRB-) (NP (NNP ABC)) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (NNPS Conners) (POS ')) (NN Parent) (NNP Rating) (NNP Scale-Revised)))))) (, ,) (CC and) (PP (IN by) (NP (NP (DT a) (NN physician)) (VP (VBG using) (NP (NP (NP (DT the) (NNS Children) (POS 's)) (NNP Psychiatric) (NNP Rating) (NNP Scale)) (CC and) (NP (DT the) (JJ Clinical) (JJ Global) (NNP Impressions) (NN scale))))))))) (. .)))
17069550	5	(S1 (S (NP (NNS Patients)) (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN reduction)) (PP (IN in) (NP (NP (NP (NP (JJ parent-rated) (NN Doc_17069550_808_820_Disease)) (CC and) (NP (JJ social) (NN withdrawal))) (PP (IN on) (NP (DT the) (NNP ABC)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ significant) (NNS improvements)) (PP (IN in) (NP (NP (JJ emotional) (NN lability) (CC and) (NN inattention)) (PP (IN on) (NP (NP (DT the) (NNPS Conners) (POS ')) (NN Parent) (NNP Rating) (NNP Scale--Revised)))))))))) (. .)))
17069550	6	(S1 (S (ADVP (RB Similarly)) (, ,) (NP (NN clinician) (NNS ratings)) (VP (VBD showed) (NP (NP (NNS reductions)) (PP (IN in) (NP (NP (DT the) (NN anger) (NN subscale)) (PP (IN of) (NP (NP (DT the) (NNS Children) (POS 's)) (NNP Psychiatric) (NNP Rating) (NN Scale))))))) (. .)))
17069550	7	(S1 (S (NP (NP (CD Eight)) (PP (IN of) (NP (CD 13) (NNS participants)))) (VP (AUX were) (VP (VBN rated) (PP (IN as) (NP (NNS responders))) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (PRP$ their) (NN improvement) (NNS scores))) (PP (IN on) (NP (DT the) (JJ Clinical) (NNP Global) (NNP Impressions) (NN scale))))))) (. .)))
17069550	8	(S1 (S (ADVP (RB Overall)) (, ,) (NP (NNP Doc_17069550_1229_1240_Chemical)) (VP (AUX was) (ADJP (JJ well-tolerated)) (, ,) (PP (IN with) (NP (NP (DT no) (JJ significant) (JJ adverse) (NNS effects)) (PP (ADVP (RB apart)) (IN from) (NP (NP (NNP Doc_17069550_1308_1317_Disease)) (PP (IN in) (NP (CD one) (NN patient)))))))) (. .)))
17069550	9	(S1 (S (PP (IN In) (NP (DT this) (JJ open) (NN trial))) (, ,) (NP (NNP Doc_17069550_1366_1377_Chemical)) (VP (VP (AUX was) (ADJP (JJ well-tolerated))) (CC and) (VP (VBN appeared) (S (VP (TO to) (VP (AUX be) (ADJP (JJ beneficial) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (S (VP (VBG interfering) (NP (NP (NNS behaviors)) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NP (NNP Doc_17069550_1487_1493_Disease)) (, ,) (ADVP (RB particularly)) (NP (NP (NN Doc_17069550_1508_1518_Disease)) (, ,) (NP (JJ behavioral) (NN dyscontrol)) (, ,) (CC and) (NP (NN inattention))))))))))))))))))) (. .)))
17069550	10	(S1 (S (NP (JJ Further) (JJ controlled) (NNS trials)) (VP (AUX are) (VP (VBN warranted))) (. .)))
17151160	0	(S1 (NP (NP (NP (JJ Randomized) (NN comparison)) (PP (IN of) (NP (NP (NNP Doc_17151160_25_35_Chemical)) (CC versus) (NP (NNP Doc_17151160_43_54_Chemical)))) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ first-episode) (NNP Doc_17151160_90_103_Disease)))))) (: :) (NP (JJ 4-month) (NNS outcomes)) (. .)))
17151160	1	(S1 (S (NP (DT The) (NNS authors)) (VP (VBD compared) (NP (NP (JJ 4-month) (NN treatment) (NNS outcomes)) (PP (IN for) (NP (NP (NNP Doc_17151160_186_196_Chemical)) (CC versus) (NP (NNP Doc_17151160_204_215_Chemical))))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ first-episode) (NNP Doc_17151160_247_260_Disease) (NN spectrum) (NNS disorders)))))) (. .)))
17151160	2	(S1 (S (NP (NP (QP (CD One) (CD hundred)) (CD twelve) (NNS subjects)) (-LRB- -LRB-) (NP (NP (NP (CD 70) (NN %)) (NP (NN male))) (: ;) (S (VP (VBP mean) (SBAR (S (NP (CD age=23.3) (NNS years) (NN -LSB-SD)) (VP (SYM =) (NP (CD 5.1) (NN -RSB-)) (-RRB- -RRB-) (PP (IN with) (NP (NP (NP (JJ first-episode) (NNP Doc_17151160_379_392_Disease)) (PRN (-LRB- -LRB-) (NP (CD 75) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_17151160_400_425_Disease) (PRN (-LRB- -LRB-) (NP (CD 17) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_17151160_433_460_Disease)))))))))) (PRN (-LRB- -LRB-) (NP (CD 8) (NN %)) (-RRB- -RRB-))) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_17151160_507_517_Chemical) (PRN (-LRB- -LRB-) (NP (CD 2.5-20) (NN mg/day)) (-RRB- -RRB-))) (CC or) (NP (NNP Doc_17151160_537_548_Chemical) (PRN (-LRB- -LRB-) (NP (JJ 1-6) (NN mg/day)) (-RRB- -RRB-)))))))) (. .)))
17151160	3	(S1 (S (NP (NN Response) (NNS rates)) (VP (AUX did) (RB not) (ADVP (RB significantly)) (VP (VBP differ) (PP (IN between) (NP (NP (NNP Doc_17151160_624_634_Chemical) (-LRB- -LRB-) (NP (NP (NP (CD 43.7) (NN %)) (, ,) (NP (NP (CD 95) (NN %)) (NP (CD CI=28.8) (NN %)))) (NP (CD -58.6) (NN %))) (-RRB- -RRB-)) (CC and) (NP (NNP Doc_17151160_667_678_Chemical) (-LRB- -LRB-) (NP (NP (NP (CD 54.3) (NN %)) (, ,) (NP (NP (CD 95) (NN %)) (NP (CD CI=39.9) (NN %)))) (NP (CD -68.7) (NN %))) (-RRB- -RRB-)))))) (. .)))
17151160	4	(S1 (S (PP (IN Among) (NP (NP (DT those) (VBG responding)) (PP (TO to) (NP (NN treatment))))) (, ,) (NP (NP (JJR more) (NNS subjects)) (PP (IN in) (NP (DT the) (NNP Doc_17151160_766_776_Chemical) (NN group))) (PRN (-LRB- -LRB-) (NP (NP (CD 40.9) (NN %)) (, ,) (NP (NP (NP (CD 95) (NN %)) (CD CI=16.8) (NN %)) (NP (CD -65.0) (NN %)))) (-RRB- -RRB-)) (PP (IN than) (PP (IN in) (NP (NP (DT the) (JJ Doc_17151160_823_834_Chemical) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (CD 18.9) (NN %)) (, ,) (NP (NP (NP (CD 95) (NN %)) (JJ CI=0) (NN %)) (NP (CD -39.2) (NN %)))) (-RRB- -RRB-)))))) (VP (AUX had) (NP (NP (JJ subsequent) (NNS ratings)) (VP (ADVP (RB not)) (VBG meeting) (NP (NN response) (NNS criteria))))) (. .)))
17151160	5	(S1 (S (NP (NP (JJ Negative) (NN symptom) (NNS outcomes)) (CC and) (NP (NP (NNS measures)) (PP (IN of) (NP (NP (NNP Doc_17151160_962_974_Disease)) (CC and) (NP (NNP Doc_17151160_979_988_Disease)))))) (VP (AUX did) (RB not) (VP (VB differ) (PP (IN between) (NP (NNS medications))))) (. .)))
17151160	6	(S1 (S (NP (JJ Extrapyramidal) (NN symptom) (NN severity) (NNS scores)) (VP (AUX were) (NP (CD 1.4)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (CD CI=1.2-1.6)) (-RRB- -RRB-)) (PP (IN with) (NP (NP (NNP Doc_17151160_1095_1106_Chemical)) (CC and) (NP (CD 1.2)))) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (CD CI=1.0-1.4)) (-RRB- -RRB-)) (PP (IN with) (NP (NNP Doc_17151160_1137_1147_Chemical)))) (. .)))
17151160	7	(S1 (S (S (NP (ADJP (RB Significantly) (JJR more)) (NNP Doc_17151160_1168_1179_Disease)) (VP (VBD occurred) (PP (IN with) (NP (NNP Doc_17151160_1194_1204_Chemical))) (PP (IN than) (PP (IN with) (NP (NNP Doc_17151160_1215_1226_Chemical)))))) (: :) (S (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN weight))) (PP (IN at) (NP (NP (CD 4) (NNS months)) (ADJP (JJ relative) (PP (TO to) (NP (NN baseline) (NN weight))))))) (VP (AUX was) (NP (NP (NP (NP (CD 17.3) (NN %)) (-LRB- -LRB-) (NP (NP (CD 95) (NN %)) (NP (CD CI=14.2) (NN %) (CD -20.5) (NN %))) (-RRB- -RRB-)) (PP (IN with) (NP (NNP Doc_17151160_1327_1337_Chemical)))) (CC and) (NP (NP (NP (CD 11.3) (NN %)) (-LRB- -LRB-) (NP (NP (NP (CD 95) (NN %)) (CD CI=8.4) (NN %)) (NP (CD -14.3) (NN %))) (-RRB- -RRB-)) (PP (IN with) (NP (NNP Doc_17151160_1373_1384_Chemical))))))) (. .)))
17151160	8	(S1 (S (NP (NP (NN Body) (NN mass) (NN index)) (PP (PP (IN at) (NP (NN baseline))) (CC and) (PP (IN at) (NP (CD 4) (NNS months))))) (VP (AUX was) (NP (NP (NP (NP (NP (NP (CD 24.3)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (CD CI=22.8-25.7)) (-RRB- -RRB-))) (CC versus) (NP (NP (CD 28.2)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (CD CI=26.7-29.7)) (-RRB- -RRB-)))) (PP (IN with) (NP (NNP Doc_17151160_1494_1504_Chemical)))) (CC and) (NP (NP (CD 23.9)) (-LRB- -LRB-) (NP (NP (CD 95) (NN %)) (NP (CD CI=22.5-25.3))) (-RRB- -RRB-) (FW versus) (NP (CD 26.7)) (-LRB- -LRB-) (NP (NP (CD 95) (NN %)) (NP (CD CI=25.2-28.2))) (-RRB- -RRB-))) (PP (IN with) (NP (NNP Doc_17151160_1569_1580_Chemical))))) (. .)))
17151160	9	(S1 (S (S (NP (NP (JJ Clinical) (NNS outcomes)) (PP (IN with) (NP (NNP Doc_17151160_1618_1629_Chemical)))) (VP (AUX were) (ADJP (JJ equal) (PP (TO to) (NP (NP (DT those)) (PP (IN with) (NP (NNP Doc_17151160_1655_1665_Chemical)))))))) (, ,) (CC and) (S (NP (NN response)) (VP (MD may) (VP (AUX be) (ADJP (RBR more) (JJ stable))))) (. .)))
17151160	10	(S1 (S (NP (NN Doc_17151160_1700_1710_Chemical)) (VP (MD may) (VP (AUX have) (NP (NP (DT an) (NN advantage)) (PP (IN for) (NP (NN motor) (NN side) (NNS effects)))))) (. .)))
17151160	11	(S1 (S (S (NP (DT Both) (NNS medications)) (VP (VBD caused) (NP (JJ substantial) (JJ rapid) (NN Doc_17151160_1799_1810_Disease)))) (, ,) (CC but) (S (NP (NNP Doc_17151160_1816_1827_Disease)) (VP (AUX was) (ADJP (JJR greater) (PP (IN with) (NP (NNP Doc_17151160_1845_1855_Chemical)))))) (. .)))
17159032	0	(S1 (NP (NP (JJ Early) (JJ paracentral) (NN Doc_17159032_18_35_Disease)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NNP Doc_17159032_55_73_Chemical))))) (. .)))
17159032	1	(S1 (S (VP (TO To) (VP (VB review) (NP (NP (DT the) (JJ natural) (UCP (NN history) (CC and) (JJ ocular) (CC and) (JJ systemic)) (JJ adverse) (NNS effects)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (NNP Doc_17159032_175_201_Chemical)) (SBAR (WHNP (WP who)) (S (VP (VBD attended) (NP (DT an) (JJ ophthalmic) (NN screening) (NN program)))))))))))) (. .)))
17159032	2	(S1 (NP (JJ Retrospective) (NN study) (. .)))
17159032	3	(S1 (S (NP (NP (NNS Records)) (PP (IN of) (NP (CD 262) (NNS patients))) (SBAR (WHNP (WP who)) (S (VP (VP (AUX were) (VP (VBG taking) (NP (NNP Doc_17159032_326_344_Chemical)))) (CC and) (VP (VBD screened) (PP (IN in) (NP (NP (DT the) (NNP Department)) (PP (IN of) (NP (NNP Ophthalmology)))))))))) (VP (AUX were) (VP (VBN reviewed))) (. .)))
17159032	4	(S1 (S (PP (IN Of) (NP (DT the) (CD 262) (NNS patients))) (, ,) (NP (NP (NP (CD 14)) (PRN (-LRB- -LRB-) (NP (CD 18) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (CD 76))) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN stopped) (NP (NN treatment)) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (DT the) (NN study)))))))))) (VP (VBD experienced) (NP (VBN documented) (JJ adverse) (NNS effects))) (. .)))
17159032	5	(S1 (S (NP (JJ Systemic) (JJ adverse) (NNS effects)) (VP (VBD occurred) (PP (IN in) (NP (NP (NP (CD 8) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 10.5) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ ocular) (JJ adverse) (NNS effects)) (PRN (, ,) (PP (IN in) (NP (CD 5))) (-LRB- -LRB-) (NP (CD 6.5) (NN %)) (-RRB- -RRB-)))))) (. .)))
17159032	6	(S1 (S (NP (NP (JJ Thirty-five) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 13.4) (NN %)) (-RRB- -RRB-))) (VP (AUX had) (NP (NP (NNP Doc_17159032_665_691_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VBN attributed) (PP (TO to) (NP (NP (JJ Doc_17159032_718_736_Chemical) (NN treatment)) (PP (IN in) (NP (NP (CD 4) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 1.5) (NN %)) (-RRB- -RRB-)))))))))))) (. .)))
17159032	7	(S1 (S (S (NP (NP (CD Three)) (PP (IN of) (NP (DT the) (CD 4) (NNS patients)))) (VP (AUX were) (VP (VBG taking) (NP (NP (QP (JJR less) (IN than) (CD 6.5)) (NN mg/kg)) (PP (IN per) (NP (NN day))))))) (CC and) (S (NP (DT all) (NNS patients)) (VP (AUX had) (NP (JJ normal) (JJ renal) (CC and) (NN liver) (NN function) (NN test) (NNS results)))) (. .)))
17159032	8	(S1 (S (S (NP (DT The) (JJ current) (NN study)) (VP (VP (VBD used) (NP (NP (DT a) (NN protocol)) (PP (IN of) (NP (NP (JJ visual) (NN acuity) (CC and) (NN color) (NN vision) (NN assessment)) (, ,) (NP (NN funduscopy)) (, ,) (CC and) (NP (NNP Humphrey) (CD 10-2) (JJ visual) (NN field) (NN testing)))))) (CC and) (VP (VBZ shows) (SBAR (IN that) (S (NP (JJ visual) (NN field) (NNS defects)) (VP (VBD appeared) (PP (IN before) (NP (NP (DT any) (JJ corresponding) (NNS changes)) (PP (IN in) (NP (DT any) (JJ other) (VBN tested) (JJ clinical) (NNS parameters))))))))))) (: ;) (S (S (NP (DT the) (NNS defects)) (VP (AUX were) (ADJP (JJ reproducible)))) (CC and) (S (NP (DT the) (NN test) (NNS parameters)) (VP (AUX were) (ADJP (JJ reliable))))) (. .)))
17159032	9	(S1 (S (NP (NP (NNS Patients)) (VP (VBG taking) (NP (NNP Doc_17159032_1248_1266_Chemical)))) (VP (MD can) (VP (VB demonstrate) (NP (NP (DT a) (JJ toxic) (NN reaction)) (PP (IN in) (NP (NP (DT the) (NNS retina)) (PP (IN despite) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ known) (NN risk) (NNS factors)))))))))) (. .)))
17159032	10	(S1 (S (NP (NP (NN Screening)) (, ,) (PP (VBG including) (NP (NNP Humphrey) (CD 10-2) (JJ visual) (NN field) (NN assessment))) (, ,)) (VP (AUX is) (VP (VP (VBN recommended) (NP (CD 2) (NNS years)) (PP (IN after) (NP (DT the) (JJ initial) (NN baseline)))) (CC and) (VP (ADVP (RB yearly)) (ADVP (RB thereafter))))) (. .)))
17223814	0	(S1 (S (NP (JJ Peri-operative)) (VP (VBP Doc_17223814_15_37_Disease) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (NN chemotherapy)) (PP (IN with) (NP (NP (NNP Doc_17223814_71_81_Chemical)) (CC and) (NP (NNP Doc_17223814_86_96_Chemical))))))))) (. .)))
17223814	1	(S1 (S (NP (NP (NP (DT A) (JJ 47-year-old) (NN woman)) (VP (VBN presented) (PP (IN for) (NP (NN mastectomy))))) (CC and) (NP (JJ immediate) (JJ latissimus) (NNS dorsi) (NN flap) (NN reconstruction))) (VP (AUXG having) (VP (AUX been) (VP (VBN diagnosed) (PP (IN with) (NP (JJ Doc_17223814_221_246_Disease) (NNS months))) (ADVP (RB previously))))) (. .)))
17223814	2	(S1 (S (PP (IN In) (NP (DT the) (JJ preceding) (NNS months))) (NP (PRP she)) (VP (AUX had) (VP (VBN received) (NP (JJ neo-adjuvant) (NN chemotherapy)) (PP (IN with) (NP (NP (NNP Doc_17223814_338_348_Chemical)) (, ,) (NP (NP (NNP Doc_17223814_350_360_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17223814_362_367_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_17223814_373_389_Chemical)))))) (. .)))
17223814	3	(S1 (S (S (NP (DT This)) (VP (AUX had) (VP (AUX been) (ADVP (RB apparently)) (ADJP (JJ uncomplicated))))) (CC and) (S (NP (PRP she)) (VP (AUX had) (VP (VBN maintained) (NP (NP (DT a) (ADJP (RB remarkably) (JJ high)) (NN level)) (PP (IN of) (NP (JJ physical) (NN activity))))))) (. .)))
17223814	4	(S1 (S (NP (PRP She)) (VP (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (ADJP (JJ bradycardic)) (PP (IN at) (NP (JJ pre-operative) (NN assessment)))))))) (CC but) (VP (AUX had) (NP (DT no) (JJ cardiac) (NNS symptoms)))) (. .)))
17223814	5	(S1 (S (S (NP (JJ Second) (NN degree) (NNP Mobitz) (NN type) (NNP II) (NNP Doc_17223814_617_639_Disease)) (VP (AUX was) (VP (VBN diagnosed) (PP (IN on) (NP (NN electrocardiogram)))))) (, ,) (CC and) (S (NP (JJ temporary) (JJ transvenous) (NN ventricular) (NN pacing)) (VP (VBD instituted) (PP (IN in) (NP (DT the) (JJ peri-operative) (NN period))))) (. .)))
17223814	6	(S1 (S (NP (PRP We)) (VP (VB discuss) (SBAR (SBAR (WHADVP (WRB how)) (S (NP (JJ evidence-based) (NNS guidelines)) (VP (MD would) (RB not) (VP (AUX have) (VP (AUX been) (ADJP (JJ helpful)) (PP (IN in) (NP (DT this) (NN case)))))))) (, ,) (CC and) (SBAR (WHADVP (WRB how)) (S (NP (NN chemotherapy)) (VP (MD can) (VP (VB exhibit) (NP (NP (JJ substantial) (NN Doc_17223814_890_904_Disease)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB develop) (PP (IN over) (NP (JJ many) (NNS years)))))))))))))) (. .)))
17223814	7	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (VBN received) (NP (NN chemotherapy)) (PP (IN at) (NP (DT any) (NN time)))))))) (VP (MD should) (VP (AUX have) (NP (DT a) (JJ pre-operative) (NN electrocardiogram)) (SBAR (RB even) (IN if) (S (NP (PRP they)) (VP (AUX are) (ADJP (JJ asymptomatic)))))))))) (. .)))
17255138	0	(S1 (S (S (NP (NP (NNS Risks) (CC and) (NNS benefits)) (PP (IN of) (NP (JJ COX-2) (NNS inhibitors)))) (NP (NNP vs) (JJ non-selective) (NNS NSAIDs))) (: :) (SINV (AUX does) (NP (PRP$ their) (JJ cardiovascular) (NN risk)) (VP (VB exceed) (NP (PRP$ their) (JJ gastrointestinal) (NN benefit)))) (. ?)))
17255138	1	(S1 (FRAG (NP (DT A) (NN retrospective) (NN cohort) (NN study)) (. .)))
17255138	2	(S1 (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (NP (NNP Doc_17255138_188_215_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17255138_217_220_Disease)) (-RRB- -RRB-)))) (PP (IN with) (NP (JJ COX-2) (NNS inhibitors)))) (VP (MD may) (VP (VB offset) (NP (PRP$ their) (NN gastrointestinal) (PRN (-LRB- -LRB-) (NP (NNP GI)) (-RRB- -RRB-)) (NN benefit)) (PP (VBN compared) (PP (IN with) (NP (NP (JJ non-selective) (PRN (-LRB- -LRB-) (NP (NNP NS)) (-RRB- -RRB-)) (JJ non-steroidal) (JJ anti-inflammatory) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNS NSAIDs)) (-RRB- -RRB-))))))) (. .)))
17255138	3	(S1 (S (NP (PRP We)) (VP (VBD aimed) (S (VP (TO to) (VP (VB compare) (NP (NP (DT the) (NNS risks)) (PP (IN of) (NP (NN hospitalization)))) (PP (IN for) (NP (NP (NP (NNP Doc_17255138_425_428_Disease) (CC and) (NNP Doc_17255138_433_444_Disease)) (PP (IN among) (NP (NP (JJ elderly) (NNS patients)) (VP (VBG using) (NP (JJ COX-2) (NNS inhibitors)))))) (, ,) (NP (NNP NS-NSAIDs)) (CC and) (NP (NNP Doc_17255138_506_519_Chemical)))))))) (. .)))
17255138	4	(S1 (S (NP (PRP We)) (VP (VBD conducted) (NP (DT a) (JJ retrospective) (NN cohort) (NN study)) (S (VP (VBG using) (NP (NP (JJ administrative) (NNS data)) (PP (IN of) (NP (NP (NNS patients) (NNS >)) (CC or) (NP (NP (CD =65) (NNS years)) (PP (IN of) (NP (NN age)))))) (SBAR (WHNP (WP who)) (S (VP (VBD filled) (NP (NP (DT a) (NN prescription)) (PP (IN for) (NP (NP (NNP NSAID)) (CC or) (NP (NNP Doc_17255138_671_684_Chemical))))) (PP (IN during) (NP (CD 1999-2002)))))))))) (. .)))
17255138	5	(S1 (S (NP (NNS Outcomes)) (VP (AUX were) (VP (VBN compared) (S (VP (VBG using) (NP (NP (NNP Cox) (NN regression) (NNS models)) (PP (IN with) (NP (JJ time-dependent) (NNS exposures)))))))) (. .)))
17255138	6	(S1 (S (NP (NP (NNS Person-years)) (PP (IN of) (NP (NN exposure))) (PP (IN among) (NP (NP (NNS non-users)) (PP (IN of) (NP (NNP Doc_17255138_838_845_Chemical)))))) (VP (AUX were) (: :) (NP (NP (NP (CD 75,761)) (PP (TO to) (NP (NNP Doc_17255138_862_875_Chemical)))) (, ,) (NP (NP (CD 42,671)) (PP (PP (TO to) (NP (NNP Doc_17255138_887_896_Chemical) (CD 65,860))) (PP (TO to) (NP (NNP Doc_17255138_907_916_Chemical))))) (, ,) (CC and) (NP (NP (CD 37,495)) (PP (TO to) (NP (NNS NS-NSAIDs)))))) (. .)))
17255138	7	(S1 (S (PP (IN Among) (NP (NP (NNS users)) (PP (IN of) (NP (NNP Doc_17255138_958_965_Chemical))))) (, ,) (NP (PRP they)) (VP (AUX were) (: :) (NP (NP (NP (CD 14,671)) (PP (TO to) (NP (NNP Doc_17255138_988_997_Chemical)))) (, ,) (NP (NP (CD 22,875)) (PP (TO to) (NP (NNP Doc_17255138_1009_1018_Chemical)))) (, ,) (NP (NP (CD 9,832)) (PP (TO to) (NP (NNS NS-NSAIDs)))) (CC and) (NP (NP (CD 38,048)) (PP (TO to) (NP (NNP Doc_17255138_1053_1066_Chemical)))))) (. .)))
17255138	8	(S1 (S (PP (IN Among) (NP (NP (NNS non-users)) (PP (IN of) (NP (NNP Doc_17255138_1087_1094_Chemical))))) (, ,) (NP (NP (NP (DT the) (VBN adjusted) (NN hazard) (NNS ratios)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (NN confidence) (NN interval)) (-RRB- -RRB-))) (PP (IN of) (NP (NN hospitalization))) (PP (IN for) (NP (NNP Doc_17255138_1172_1175_Disease/GI) (NNP vs))) (NP (DT the) (NNP Doc_17255138_1186_1199_Chemical) (PRN (-LRB- -LRB-) (PP (IN with) (NP (DT no) (NNP Doc_17255138_1209_1216_Chemical))) (-RRB- -RRB-)) (NN group))) (VP (AUX were) (: :) (FRAG (NP (NNP Doc_17255138_1230_1239_Chemical) (CD 1.27)) (PRN (-LRB- -LRB-) (NP (CD 1.13)) (, ,) (NP (CD 1.42)) (-RRB- -RRB-)) (, ,) (NP (NP (NP (NNP Doc_17255138_1259_1268_Chemical) (CD 0.93)) (PRN (-LRB- -LRB-) (NP (CD 0.83)) (, ,) (NP (CD 1.03)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_17255138_1288_1296_Chemical) (CD 1.59)) (PRN (-LRB- -LRB-) (NP (CD 1.31)) (, ,) (NP (CD 1.93)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_17255138_1316_1326_Chemical) (CD 1.17)) (PRN (-LRB- -LRB-) (NP (CD 0.99)) (, ,) (NP (CD 1.38)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_17255138_1349_1358_Chemical) (CD 1.05)) (PRN (-LRB- -LRB-) (NP (CD 0.74)) (, ,) (NP (CD 1.51)) (-RRB- -RRB-)))))) (. .)))
17255138	9	(S1 (S (PP (IN Among) (NP (NP (NNS users)) (PP (IN of) (NP (NNP Doc_17255138_1393_1400_Chemical))))) (, ,) (NP (PRP they)) (VP (AUX were) (: :) (NP (NP (NP (NNP Doc_17255138_1413_1422_Chemical) (CD 1.73)) (PRN (-LRB- -LRB-) (NP (CD 1.52)) (, ,) (NP (CD 1.98)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_17255138_1442_1451_Chemical) (CD 1.34)) (PRN (-LRB- -LRB-) (NP (CD 1.19)) (, ,) (NP (CD 1.52)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NP (NNP Doc_17255138_1471_1480_Chemical) (CD 1.51)) (PRN (-LRB- -LRB-) (NP (CD 0.95)) (, ,) (NP (CD 2.41)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_17255138_1500_1510_Chemical) (CD 1.69)) (PRN (-LRB- -LRB-) (NP (CD 1.35)) (, ,) (NP (CD 2.10)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_17255138_1530_1538_Chemical) (CD 1.35)) (PRN (-LRB- -LRB-) (NP (CD 0.97)) (, ,) (NP (CD 1.88)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_17255138_1561_1574_Chemical) (CD 1.29))) (-LRB- -LRB-) (CD 1.17) (, ,) (CD 1.42)) (-RRB- -RRB-))) (. .)))
17255138	10	(S1 (S (PP (IN Among) (NP (NP (NNS non-users)) (PP (IN of) (NP (NNP Doc_17255138_1625_1632_Chemical))))) (, ,) (NP (NNP Doc_17255138_1634_1642_Chemical)) (VP (VBD seemed) (S (VP (TO to) (VP (VB carry) (NP (NP (DT the) (JJS highest) (NN risk)) (PP (IN for) (NP (NN Doc_17255138_1680_1695_Disease)))))))) (. .)))
17255138	11	(S1 (S (NP (NP (DT The) (NNP Doc_17255138_1701_1704_Disease/Doc_17255138_1705_1716_Disease)) (PP (IN of) (NP (NNP Doc_17255138_1720_1729_Chemical)))) (VP (VP (AUX was) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_17255138_1753_1766_Chemical))))))) (CC and) (VP (VBD seemed) (S (VP (TO to) (VP (AUX be) (ADJP (ADJP (JJR better)) (PP (IN than) (NP (NP (DT those)) (PP (IN of) (NP (NP (NNP Doc_17255138_1805_1814_Chemical)) (CC and) (NP (NNS NS-NSAIDs)))))))))))) (. .)))
17255138	12	(S1 (S (PP (IN Among) (NP (NP (NNS users)) (PP (IN of) (NP (NNP Doc_17255138_1845_1852_Chemical))))) (, ,) (NP (PDT both) (NP (NNP Doc_17255138_1859_1868_Chemical)) (CC and) (NP (NNP Doc_17255138_1873_1881_Chemical))) (VP (VBD seemed) (S (VP (TO to) (VP (AUX be) (NP (DT the) (JJS least) (NN toxic)))))) (. .)))
17297207	0	(S1 (NP (NP (JJ Doc_17297207_0_7_Chemical-induced) (NN Doc_17297207_16_26_Disease)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (JJ severe) (NN Doc_17297207_52_59_Disease))))) (. .)))
17297207	1	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN reported) (SBAR (IN that) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ severe) (JJ Doc_17297207_109_116_Disease) (NN patient)) (PP (IN with) (NP (NNP Doc_17297207_130_138_Disease))))) (SBAR (WHNP (WP who)) (S (VP (VBD presented) (PP (IN with) (NP (NP (NNP Doc_17297207_158_168_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17297207_170_203_Disease)) (-RRB- -RRB-)))) (SBAR (IN while) (S (S (VP (VBG getting) (NP (JJ Doc_17297207_219_226_Chemical) (NN infusion)))) (VP (AUX was) (VP (VBN reported)))))))))))))) (. .)))
17297207	2	(S1 (S (NP (NP (DT A) (NN man)) (, ,) (ADJP (NP (CD 25) (NNS years)) (JJ old)) (, ,)) (VP (AUX was) (VP (VBN admitted) (PP (TO to) (NP (NN hospital))) (PP (IN with) (NP (NP (JJ high) (NN fever)) (, ,) (NP (NN chill)) (, ,) (NP (NP (NNP Doc_17297207_320_328_Disease)) (, ,) (NP (NNP Doc_17297207_330_338_Disease))))))) (. .)))
17297207	3	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (ADJP (RB fully) (JJ conscious)) (, ,) (NP (NP (NP (NN blood) (NN pressure)) (ADJP (CD 120/80) (NN mmHg))) (, ,) (NP (NP (NN pulse) (NN rate)) (NP (CD 100) (NN x/minute)) (, ,) (ADVP (JJ regular))))) (. .)))
17297207	4	(S1 (S (PP (IN On) (NP (NN admission))) (, ,) (NP (NN laboratory) (NN examination)) (VP (VBD showed) (SBAR (S (NP (NP (NNP Plasmodium) (NNP falciparum)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17297207_502_506_Chemical)) (-RRB- -RRB-)) (, ,) (NP (JJ total) (NNP Doc_17297207_515_524_Chemical) (CD 8.25) (NN mg/dL)) (, ,) (NP (JJ conjugated) (NNP Doc_17297207_548_557_Chemical) (CD 4.36) (NN mg/dL)) (, ,)) (VP (VBD unconjugated) (NP (NNP Doc_17297207_583_592_Chemical) (CD 3.89)) (ADVP (RB mg/dL)) (, ,) (SBAR (S (NP (NNP Doc_17297207_605_614_Chemical) (CD 3.52) (JJ meq/L) (NN Patient)) (VP (VP (AUX was) (VP (VBN diagnosed) (PP (IN as) (NP (NP (JJ severe) (NN Doc_17297207_658_665_Disease)) (PP (IN with) (NP (NNP Doc_17297207_671_679_Disease))))))) (CC and) (VP (VBD got) (NP (JJ Doc_17297207_688_695_Chemical) (NN infusion)) (PP (IN in) (NP (JJ Doc_17297207_708_716_Chemical) (ADJP (CD 5) (NN %)) (CD 500) (JJ mg/8) (NN hour))))))))))) (. .)))
17297207	5	(S1 (S (PP (IN On) (NP (DT the) (JJ second) (NN day))) (NP (DT the) (NN patient)) (VP (AUX had) (ADJP (JJ vomitus)) (, ,) (NP (NP (NAC (NNP Doc_17297207_778_786_Disease) (, ,) (NNP Doc_17297207_788_796_Disease) (, ,)) (NN loss)) (PP (IN of) (NP (NN hearing))))) (. .)))
17297207	6	(S1 (S (PP (IN After) (NP (NP (CD 30) (NNS hours)) (PP (IN of) (NP (JJ Doc_17297207_833_840_Chemical) (NN infusion))))) (NP (DT the) (NN patient)) (VP (VBD felt) (SBAR (S (NP (NP (NN palpitation)) (CC and) (NP (JJ electrocardiography) (PRN (-LRB- -LRB-) (NP (NNP ECG)) (-RRB- -RRB-)) (NN recording))) (VP (VBD showed) (SBAR (S (NP (NP (NNP Doc_17297207_926_959_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17297207_961_964_Disease)) (-RRB- -RRB-))) (VP (VBZ >) (NP (NP (CD 5) (NN x/minute)) (, ,) (NP (NP (NN trigemini)) (, ,) (NP (JJ constant) (JJ type--sinoatrial) (NN block)) (, ,) (NP (JJ positive) (NNP U) (NN wave))))))))))) (. .)))
17297207	7	(S1 (S (NP (PRP He)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_17297207_1061_1070_Chemical) (CD 50) (NNS mg)) (VP (ADVP (RB intravenously)) (VBN followed) (PP (IN by) (NP (NN infusion) (CD 1500) (NN mg)))))) (PP (IN in) (NP (NP (NNP Doc_17297207_1123_1131_Chemical) (ADJP (CD 5) (NN %)) (CD /24) (NN hour)) (CC and) (NP (JJ Doc_17297207_1147_1166_Chemical) (NN tablet)))))) (. .)))
17297207	8	(S1 (S (NP (JJ Doc_17297207_1175_1182_Chemical) (NN infusion)) (VP (VP (AUX was) (VP (VBN discontinued))) (CC and) (VP (VBD changed) (PP (IN with) (NP (JJ sulfate) (JJ Doc_17297207_1234_1241_Chemical) (NNS tablets))))) (. .)))
17297207	9	(S1 (S (S (S (ADVP (NP (CD Three) (NNS hours)) (RB later)) (NP (DT the) (NN patient)) (VP (VBD felt) (ADJP (JJR better)))) (, ,) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NNP Doc_17297207_1311_1314_Disease)))) (VP (VBD reduced) (PP (TO to) (NP (CD 4))) (: -) (NP (CD 5) (NN x/minute)))) (CC and) (S (PP (IN on) (NP (NP (DT the) (JJ third) (NN day)) (SBAR (S (NP (NNP ECG)) (VP (AUX was) (NP (JJ normal))))))) (, ,) (NP (JJ Doc_17297207_1378_1387_Chemical) (NN level)) (VP (AUX was) (NP (CD 3.34) (NN meq/L)))) (. .)))
17297207	10	(S1 (S (NP (PRP He)) (VP (AUX was) (VP (VBN discharged) (PP (IN on) (NP (NP (JJ 7th) (NN day)) (PP (IN in) (NP (JJ good) (NN condition))))))) (. .)))
17297207	11	(S1 (S (NP (NN Doc_17297207_1458_1465_Chemical)) (, ,) (PP (IN like) (NP (NNP Doc_17297207_1472_1481_Chemical))) (, ,) (VP (AUX is) (NP (NP (DT a) (NN chincona) (NN alkaloid)) (SBAR (WHNP (WDT that)) (S (VP (AUX has) (NP (JJ anti-arrhythmic) (NN property)) (, ,) (SBAR (IN although) (S (NP (PRP it)) (ADVP (RB also)) (ADJP (JJ pro-arrhythmic) (SBAR (IN that) (S (VP (MD can) (VP (VB cause) (NP (NNP Doc_17297207_1588_1607_Disease))))))))) (, ,) (PP (VBG including) (NP (NP (JJ severe) (NN Doc_17297207_1626_1636_Disease)) (PP (JJ such) (IN as) (NP (JJ multiple) (NNP Doc_17297207_1654_1657_Disease)))))))))) (. .)))
17297207	12	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (JJ parenteral) (NNP Doc_17297207_1688_1695_Chemical)))) (VP (MD must) (VP (AUX be) (VP (AUX done) (UCP (ADVP (RB carefully)) (CC and) (PP (IN with) (NP (NP (JJ good) (NN observation)) (PP (IN because) (IN of) (NP (PRP$ its) (JJ pro-arrhythmic) (NN effect)))))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (NP (JJR older) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (NP (NNP Doc_17297207_1821_1835_Disease) (CC or) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_17297207_1853_1873_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17297207_1875_1886_Disease)) (-RRB- -RRB-)) (SBAR (WHNP (WDT which)) (S (ADVP (RB frequently)) (VP (VBZ occurs) (ADJP (JJ due) (PP (TO to) (NP (NP (NP (NNP Doc_17297207_1919_1927_Disease)) (CC and) (CC or) (NP (NNP Doc_17297207_1935_1943_Disease))) (PP (IN in) (NP (NNP Doc_17297207_1947_1954_Disease) (NNS cases))))))))))))))))))) (. .)))
17346443	0	(S1 (NP (NP (NP (JJ Doc_17346443_0_13_Chemical-related) (NN Doc_17346443_22_42_Disease)) (CC and) (NP (NN utility))) (PP (IN of) (NP (NNP Doc_17346443_58_70_Chemical))) (PP (IN in) (NP (NP (DT a) (JJ Doc_17346443_76_90_Disease) (NN patient)) (PP (IN with) (NP (NP (JJ hepatic) (NN presentation)) (, ,) (NP (NNP Doc_17346443_126_133_Disease)) (CC and) (NP (JJ SPECT) (NNS abnormalities)))))) (. .)))
17346443	1	(S1 (S (NP (NN Doc_17346443_159_175_Disease)) (VP (AUX is) (NP (NP (DT an) (JJ autosomal) (JJ recessive) (NN disorder)) (PP (IN of) (NP (NP (JJ hepatic) (JJ Doc_17346443_222_228_Chemical) (NN metabolism)) (PP (IN with) (NP (NP (JJ consequent) (JJ Doc_17346443_256_262_Chemical) (NN accumulation)) (CC and) (NP (NNP Doc_17346443_280_288_Disease)))) (PP (IN in) (NP (NP (JJ many) (NNS tissues)) (CC and) (NP (JJ consequent) (NN hepatic)))))) (, ,) (ADJP (JJ neurologic) (CC and) (JJ Doc_17346443_344_365_Disease)))) (. .)))
17346443	2	(S1 (S (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_17346443_387_403_Disease)))) (PP (IN with) (NP (NNP Doc_17346443_409_430_Disease))))) (: ;) (S (ADVP (RB moreover)) (, ,) (PP (IN in) (NP (PRP$ our) (NN patient))) (, ,) (S (VP (VBG presenting) (ADVP (RB also)) (PP (IN with) (NP (NP (JJ high) (NNS levels)) (PP (IN of) (NP (NN state) (NN Doc_17346443_500_507_Disease))) (PP (IN without) (NP (NNP Doc_17346443_516_526_Disease))))))) (, ,) (NP (NN 99mTc-ECD-SPECT)) (VP (VBD showed) (NP (NP (JJ cortical) (NN hypoperfusion)) (PP (IN in) (NP (JJ frontal) (NNS lobes))) (, ,) (ADJP (RBR more) (JJ marked))) (PP (IN on) (NP (DT the) (JJ left) (JJ frontal) (NN lobe))))) (. .)))
17346443	3	(S1 (S (PP (IN During) (NP (NP (DT the) (NN follow-up)) (PP (IN of) (NP (PRP$ our) (NN patient))))) (, ,) (S (NP (NNP Doc_17346443_667_680_Chemical)) (VP (AUX was) (VP (VBN interrupted) (PP (IN after) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (DT a) (NNP Doc_17346443_723_743_Disease)))))))) (, ,) (CC and) (S (NP (NNP Doc_17346443_749_761_Chemical)) (VP (VBD permitted) (S (VP (TO to) (VP (VB continue) (NP (NP (DT the) (JJ successful) (NN treatment)) (PP (IN of) (NP (NP (DT the) (NN patient)) (PP (IN without) (NP (NNS side-effects))))))))))) (. .)))
17346443	4	(S1 (S (PP (IN In) (NP (PRP$ our) (NN case))) (NP (NP (DT the) (NN therapy)) (PP (IN with) (NP (NNP Doc_17346443_875_887_Chemical)))) (VP (VBD represented) (NP (NP (DT an) (JJ effective) (NN treatment)) (PP (IN for) (NP (NP (DT a) (JJ Doc_17346443_929_945_Disease) (NN patient)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (JJ Doc_17346443_963_976_Chemical-related) (NN side) (NNS effects)) (VP (VBD appeared)))))))) (. .)))
17346443	5	(S1 (S (S (NP (NP (DT The) (NN safety)) (PP (IN of) (NP (DT the) (NNP Doc_17346443_1026_1038_Chemical)))) (VP (VBD allowed) (S (NP (PRP us)) (VP (TO to) (VP (VB avoid) (NP (JJ other) (ADJP (RB potentially) (JJ toxic)) (NN chelating) (NNS drugs))))))) (: ;) (S (NP (DT this) (NN observation)) (VP (AUX is) (PP (IN in) (NP (NP (NN line)) (PP (IN with) (NP (NP (DT the) (VBG growing) (NN evidence)) (PP (IN on) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (DT the) (NN drug))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_17346443_1202_1218_Disease))))))))))))) (. .)))
17346443	6	(S1 (S (SBAR (IN Since) (S (NP (NP (JJS most)) (PP (IN of) (NP (NNP Doc_17346443_1234_1250_Disease) (JJ Doc_17346443_1251_1264_Chemical-treated) (NNS patients)))) (VP (AUX do) (RB not) (VP (VB seem) (S (VP (TO to) (VP (VB develop) (NP (DT this) (NN Doc_17346443_1310_1321_Disease))))))))) (, ,) (NP (PRP it)) (VP (MD could) (VP (AUX be) (ADJP (JJ conceivable) (SBAR (IN that) (S (NP (DT a) (JJ specific) (JJ genetic) (NN factor)) (VP (AUX is) (VP (VBN involved) (PP (IN in) (NP (NN drug) (NN response)))))))))) (. .)))
17346443	7	(S1 (S (NP (JJ Further) (NNS studies)) (VP (AUX are) (VP (VBN needed) (PP (PP (IN for) (NP (NP (DT a) (JJR better) (NN clarification)) (PP (IN of) (NP (JJ Doc_17346443_1465_1481_Disease) (NN therapy))))) (, ,) (CC and) (PP (IN in) (NP (JJ particular)))) (S (VP (TO to) (VP (VB differentiate) (NP (JJ specific) (NNS therapies)) (PP (IN for) (NP (JJ different) (JJ Doc_17346443_1559_1575_Disease) (NNS phenotypes)))))))) (. .)))
17351238	0	(S1 (S (NP (NP (DT A) (JJ dramatic) (NN drop)) (PP (IN in) (NP (NN blood)))) (VP (VBP pressure) (PP (VBG following) (NP (JJ prehospital) (JJ Doc_17351238_56_59_Chemical) (NN administration)))) (. .)))
17351238	1	(S1 (S (NP (NP (DT A) (NN male)) (PP (IN in) (NP (PRP$ his) (NNS sixties))) (PP (IN with) (NP (NP (DT no) (NN history)) (PP (IN of) (NP (JJ cardiac) (NN Doc_17351238_125_135_Disease)))))) (VP (VBD awoke) (PP (IN with) (NP (NNP Doc_17351238_147_157_Disease))) (PP (VBG following) (NP (DT an) (NN afternoon) (NN sleep)))) (. .)))
17351238	2	(S1 (S (NP (DT The) (NN patient)) (VP (AUX did) (RB not) (VP (NN self) (NN medicate))) (. .)))
17351238	3	(S1 (S (S (NP (NP (DT The) (NN patient) (POS 's)) (NNS observations)) (VP (AUX were) (PP (IN within) (NP (JJ normal) (NNS limits))))) (, ,) (S (NP (PRP he)) (VP (AUX was) (VP (VBN administered) (NP (NNP Doc_17351238_297_303_Chemical)) (PP (IN via) (NP (NP (DT a) (NN face) (NN mask)) (CC and) (NP (NP (NNP Doc_17351238_324_343_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17351238_345_348_Chemical)) (-RRB- -RRB-)))))))) (. .)))
17351238	4	(S1 (S (SBAR (NP (JJ Several) (NNS minutes)) (IN after) (S (NP (DT the) (JJ Doc_17351238_377_380_Chemical) (DT the) (NN patient)) (VP (VBD experienced) (NP (DT a) (JJ sudden) (NN drop)) (PP (IN in) (NP (NP (NN blood) (NN pressure)) (CC and) (NP (NN heart) (NN rate))))))) (, ,) (NP (DT this)) (VP (AUX was) (VP (VBN rectified) (PP (IN by) (NP (NP (NNP Doc_17351238_475_492_Chemical)) (CC and) (NP (DT a) (JJ fluid) (NN challenge)))))) (. .)))
17351238	5	(S1 (S (NP (EX There)) (VP (AUX was) (NP (DT no) (JJ further) (NN deterioration)) (PP (IN in) (NP (NP (DT the) (NN patient) (POS 's)) (NN condition))) (PP (IN during) (NP (NP (NN transport)) (PP (TO to) (NP (NN hospital)))))) (. .)))
17351238	6	(S1 (S (NP (EX There)) (VP (AUX are) (NP (NP (ADJP (RB very) (JJ few)) (VBN documented) (NN case)) (PP (IN like) (NP (NP (DT this)) (PP (IN in) (NP (DT the) (JJ prehospital) (JJ scientific) (NN literature))))))) (. .)))
17351238	7	(S1 (S (NP (DT The) (NN cause)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (JJ Bezold-Jarish) (JJ reflex) (, ,) (NN stimulation)) (PP (IN of) (NP (NP (DT the) (JJ ventricular) (NNS walls)) (SBAR (WHNP (WDT which)) (S (PP (IN in) (NP (NN turn))) (VP (VBZ decreases) (NP (JJ sympathetic) (NN outflow)) (PP (IN from) (NP (DT the) (JJ vasomotor) (NNP centre))))))))))))) (. .)))
17351238	8	(S1 (S (NP (NP (JJ Prehospital) (NN care) (NNS providers)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (VP (VBG managing) (NP (NP (DT any) (NN patient)) (PP (IN with) (NP (NP (DT a) (NN Doc_17351238_916_932_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBZ fails) (S (VP (TO to) (VP (VB recover) (PP (IN within) (NP (DT a) (JJ reasonable) (NN time) (NN frame))))))))))))))))) (VP (MD should) (VP (VP (VB consider) (NP (NP (DT the) (JJ Bezold-Jarisch)) (PP (JJ reflex) (IN as) (NP (DT the) (NN cause))))) (CC and) (VP (VB manage) (NP (DT the) (NN patient)) (ADVP (RB accordingly))))) (. .)))
1735570	0	(S1 (NP (NP (NN Chronic) (NN lesion)) (PP (IN of) (NP (JJ rostral) (JJ ventrolateral) (NN medulla))) (PP (IN in) (NP (ADJP (RB spontaneously) (JJ Doc_1735570_65_77_Disease)) (NNS rats))) (. .)))
1735570	1	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ chronic) (JJ selective) (JJ neuronal) (NN lesion)) (PP (IN of) (NP (JJ rostral) (JJ ventrolateral) (NN medulla))))) (PP (IN on) (NP (NP (NP (JJ mean) (JJ arterial) (NN pressure)) (, ,) (NP (NN heart) (NN rate)) (, ,) (CC and) (NP (JJ neurogenic) (NN tone))) (PP (IN in) (NP (JJ conscious) (, ,) (JJ unrestrained) (ADJP (RB spontaneously) (JJ Doc_1735570_277_289_Disease)) (NNS rats))))))) (. .)))
1735570	2	(S1 (S (NP (DT The) (NNS lesions)) (VP (AUX were) (VP (VBN placed) (PP (IN via) (NP (NP (JJ bilateral) (NNS microinjections)) (PP (IN of) (NP (CD 30) (CD nmol/200) (NNP nl) (NNP Doc_1735570_368_392_Chemical))))))) (. .)))
1735570	3	(S1 (S (NP (NP (DT The) (NN restimulation)) (PP (IN of) (NP (NP (DT this) (NN area)) (PP (IN with) (NP (NNP Doc_1735570_430_454_Chemical) (CD 15) (NN days) (NN postlesion)))))) (VP (VBD failed) (S (VP (TO to) (VP (VB produce) (NP (DT a) (JJ pressor) (NN response)))))) (. .)))
1735570	4	(S1 (S (ADVP (NP (CD One) (NN day)) (RB postlesion)) (, ,) (NP (DT the) (JJ resting) (JJ mean) (JJ arterial) (NN pressure)) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN decreased) (PP (IN in) (NP (JJ lesioned) (NNS rats))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NP (JJ sham) (NNS rats)) (PRN (-LRB- -LRB-) (NP (CD 100) (ADJP (JJ +/-) (NP (CD 7) (CC versus) (CD 173))) (JJ +/-) (CD 4) (NN mm) (NNP Hg)) (, ,) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))))))))) (. .)))
1735570	5	(S1 (S (ADVP (NP (CD Fifteen) (NNS days)) (RB later)) (, ,) (NP (DT the) (JJ lesioned) (NN group)) (ADVP (RB still)) (VP (VBD showed) (NP (NP (NNS values)) (ADJP (ADJP (RB significantly) (JJR lower) (PP (IN than) (NP (DT the) (NN sham) (NN group)))) (PRN (-LRB- -LRB-) (NP (QP (CD 150) (JJ +/-) (CD 6) (CC versus) (CD 167)) (JJ +/-) (CD 5) (RB mm) (NNP Hg)) (, ,) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))))) (. .)))
1735570	6	(S1 (S (NP (DT No) (JJ significant) (NN heart) (NN rate) (NNS differences)) (VP (AUX were) (VP (VBN observed) (PP (IN between) (NP (DT the) (NN sham) (CC and) (NN lesioned) (NNS groups))))) (. .)))
1735570	7	(S1 (S (NP (NP (DT The) (JJ ganglionic) (NN blocker) (NN Doc_1735570_961_973_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 5) (CD mg/kg)) (NN i.v.)) (-RRB- -RRB-))) (VP (VBD caused) (NP (NP (JJ similar) (NNS reductions)) (PP (IN in) (NP (NP (JJ mean) (JJ arterial) (NN pressure)) (PP (IN in) (NP (DT both) (JJ lesioned) (CC and) (JJ sham) (NNS groups))))))) (. .)))
1735570	8	(S1 (S (NP (DT The) (JJ Doc_1735570_1079_1091_Chemical-induced) (NN Doc_1735570_1100_1111_Disease)) (VP (AUX was) (VP (VBN accompanied) (PP (IN by) (NP (NP (NP (DT a) (JJ significant) (NN Doc_1735570_1145_1156_Disease)) (PP (IN in) (NP (NP (JJ lesioned) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NP (CD -32) (JJ +/-) (CD 13) (NNS beats)) (PP (IN per) (NP (NN minute)))) (-RRB- -RRB-))))) (CC but) (NP (DT a) (NAC (NNP Doc_1735570_1210_1221_Disease) (PP (IN in) (NP (NP (NP (JJ sham) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NP (CD +33) (JJ +/-) (CD 12) (NNS beats)) (PP (IN per) (NP (NN minute)))) (-RRB- -RRB-))) (NP (CD 1) (NN day))))) (NN postlesion)))))) (. .)))
1735570	9	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (JJ rostral) (JJ ventrolateral) (NN medulla) (NNS neurons)) (VP (VBP appear) (S (VP (TO to) (VP (VB play) (NP (DT a) (JJ significant) (NN role)) (PP (IN in) (S (VP (VBG maintaining) (NP (NN Doc_1735570_1381_1393_Disease)) (PP (IN in) (NP (JJ conscious) (ADJP (RB spontaneously) (JJ Doc_1735570_1421_1433_Disease)) (NNS rats)))))))))) (. .)))
1735570	10	(S1 (S (NP (NN Spinal) (CC or) (NN suprabulbar) (NNS structures)) (VP (MD could) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (JJ gradual) (NN recovery)) (PP (IN of) (NP (DT the) (NNP Doc_1735570_1526_1538_Disease))) (PP (IN in) (NP (DT the) (JJ lesioned) (NNS rats)))))))) (. .)))
17356399	0	(S1 (S (NP (NP (JJ Acute) (NNP Doc_17356399_6_20_Disease) (CC and) (NNP Doc_17356399_25_43_Disease)) (PP (IN after) (NP (NN multiagent)))) (VP (VB chemotherapy) (PP (VBG including) (NP (NP (NNP Doc_17356399_84_87_Chemical-asparaginase)) (CC and) (NP (JJ intrathecal) (NNP Doc_17356399_117_127_Chemical)))) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_17356399_149_177_Disease)))))) (. .)))
17356399	1	(S1 (S (NP (NP (DT A) (JJ 7-year-old) (NN girl)) (PP (IN with) (NP (NP (DT an) (JJ unusual) (NN reaction)) (PP (TO to) (NP (NN induction) (NN chemotherapy))))) (PP (IN for) (NP (NP (NN precursor) (NNP B-cell) (NNP Doc_17356399_269_297_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17356399_299_302_Disease)) (-RRB- -RRB-))))) (VP (AUX is) (VP (VBN described))) (. .)))
17356399	2	(S1 (S (NP (DT The) (NN patient)) (VP (VBD developed) (NP (NP (JJ acute) (NN Doc_17356399_346_360_Disease)) (VP (VBN evidenced) (PP (IN by) (NP (NP (JJ behavioral) (NNS changes)) (, ,) (NP (NN Doc_17356399_394_401_Disease)) (, ,) (NP (NN incontinence)) (, ,) (NP (NN Doc_17356399_417_438_Disease)) (, ,) (CC and) (NP (NP (JJ right-sided) (NN weakness)) (PP (IN with) (NP (JJ diffuse) (NNP Doc_17356399_478_496_Disease)))))))) (PP (IN on) (NP (JJ magnetic) (NN resonance) (NN angiography))) (PP (IN after) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (JJ intrathecal) (NNP Doc_17356399_571_581_Chemical)))))) (. .)))
17356399	3	(S1 (S (NP (NP (NNP Doc_17356399_583_594_Chemical)) (, ,) (NP (NNP Doc_17356399_596_609_Chemical)) (, ,) (CC and) (NP (NNP Doc_17356399_615_634_Chemical-asparaginase))) (VP (AUX were) (ADVP (RB also)) (VP (VBN administered) (PP (IN before) (NP (DT the) (NN episode))) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (NN induction) (NN therapy))))))) (. .)))
17356399	4	(S1 (S (S (NP (JJ Neurologic) (NN status)) (VP (VBD returned) (PP (TO to) (NP (NN baseline))) (PP (IN within) (NP (NP (CD 10) (NNS days)) (PP (IN of) (NP (DT the) (JJ acute) (NN event))))))) (, ,) (CC and) (S (NP (JJ magnetic) (NN resonance) (NN angiography) (NNS findings)) (VP (VBD returned) (PP (TO to) (NP (JJ normal))) (ADVP (NP (CD 4) (NNS months)) (RB later)))) (. .)))
17379047	0	(S1 (NP (NP (NP (NN Comparison)) (PP (IN of) (NP (JJ Doc_17379047_14_23_Chemical/Doc_17379047_24_43_Chemical) (NN combination) (NN therapy))) (PP (IN at) (NP (NP (NNS doses)) (ADVP (RB up) (PP (TO to) (NP (QP (CD 320/25) (CD mg))))) (PP (IN versus) (NP (NN monotherapy)))))) (: :) (NP (NP (DT a) (JJ double-blind) (, ,) (JJ placebo-controlled) (NN study)) (VP (VBN followed) (PP (IN by) (NP (NP (JJ long-term) (NN combination) (NN therapy)) (PP (IN in) (NP (NNP Doc_17379047_195_207_Disease) (NNS adults))))))) (. .)))
17379047	1	(S1 (S (S (NP (NP (CD One) (NN third)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN for) (NP (NNP Doc_17379047_262_274_Disease))))))) (VP (VB attain) (NP (NP (JJ adequate) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NNP BP)) (-RRB- -RRB-))) (NP (NN control)))) (, ,) (CC and) (S (NP (NN multidrug) (NNS regimens)) (VP (AUX are) (ADVP (RB often)) (VP (VBN required)))) (. .)))
17379047	2	(S1 (S (PP (VBN Given) (NP (NP (DT the) (JJ lifelong) (NN nature)) (PP (IN of) (NP (NNP Doc_17379047_392_404_Disease))))) (, ,) (NP (EX there)) (VP (AUX is) (NP (NP (DT a) (NN need)) (SBAR (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ long-term) (NN efficacy) (CC and) (NN tolerability)) (PP (IN of) (NP (NP (JJR higher) (NNS doses)) (PP (IN of) (NP (NN combination) (NN anti-Doc_17379047_510_522_Disease) (NNS therapies)))))))))))) (. .)))
17379047	3	(S1 (S (NP (DT This) (NN study)) (VP (VBD investigated) (NP (NP (DT the) (NN efficacy) (CC and) (NN tolerability)) (PP (IN of) (NP (NP (NP (NP (NP (NNP Doc_17379047_602_611_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17379047_613_616_Chemical)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_17379047_621_640_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17379047_642_646_Chemical)) (-RRB- -RRB-)))) (JJ -monotherapy) (CC and) (JJ higher-dose) (NNS combinations)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ essential) (NNP Doc_17379047_716_728_Disease))))))))) (. .)))
17379047	4	(S1 (S (NP (NP (DT The) (JJ first) (NN part)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (NP (DT an) (JJ 8-week) (, ,) (JJ multicenter) (, ,) (JJ randomized) (, ,) (JJ double-blind) (, ,) (ADJP (NN placebo) (VBN controlled)) (, ,) (JJ parallel-group) (NN trial))) (. .)))
17379047	5	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (JJ essential) (NNP Doc_17379047_888_900_Disease)))) (-LRB- -LRB-) (VP (VB mean) (SBAR (S (S (VP (VBG sitting) (NP (NP (JJ diastolic) (NNP BP) (NN -LSB-MSDBP) (NN -RSB-) (, ,) (CD >) (CC or) (CD =95) (NN mm) (NNP Hg)) (CC and) (NP (CD <110) (NNS mm))))) (NP (NNP Hg)) (-RRB- -RRB-) (VP (AUX were) (ADJP (ADJP (JJ randomized) (PP (TO to) (NP (NP (NP (CD 1)) (PP (IN of) (NP (NP (ADJP (CD 8) (NN treatment)) (NNS groups)) (: :) (NP (NP (NNP Doc_17379047_1012_1015_Chemical) (CD 160)) (CC or) (NP (NP (CD 320) (NNS mg)) (: ;) (NP (NP (NNP Doc_17379047_1031_1035_Chemical) (CD 12.5)) (CC or) (NP (NP (CD 25) (NNS mg)) (: ;) (NP (NNP Doc_17379047_1051_1054_Chemical/Doc_17379047_1055_1059_Chemical) (CD 160/12.5) (, ,) (CD 320/12.5))))))))) (, ,) (CC or) (NP (CD 320/25) (NN mg))))) (: ;) (CC or) (NN placebo)))))) (. .)))
17379047	6	(S1 (S (NP (NP (JJ Mean) (NNS changes)) (PP (IN in) (NP (NP (NN MSDBP) (CC and) (NN mean)) (VP (VBG sitting) (NP (NP (JJ systolic) (NNP BP)) (PRN (-LRB- -LRB-) (NP (NNP MSSBP)) (-RRB- -RRB-))))))) (VP (AUX were) (VP (VBN analyzed) (PP (IN at) (NP (DT the) (JJ 8-week) (NN core) (NN study) (NN end) (NN point))))) (. .)))
17379047	7	(S1 (S (NP (NP (JJ Doc_17379047_1215_1218_Chemical/Doc_17379047_1219_1223_Chemical) (NNS 320/12.5)) (CC and) (NP (CD 320/25) (NN mg))) (VP (AUX were) (ADVP (RB further)) (VP (VBN investigated) (PP (IN in) (NP (DT a) (JJ 54-week) (, ,) (JJ open-label) (NN extension))))) (. .)))
17379047	8	(S1 (S (NP (NN Response)) (VP (AUX was) (VP (VBN defined) (PP (IN as) (S (VP (VBG MSDBP) (NP (NP (NP (CD <90) (NN mm)) (NP (NNP Hg))) (CC or) (NP (DT a) (CD >) (CC or) (CD =10) (NN mm) (NNP Hg) (NN decrease))) (PP (VBN compared) (PP (TO to) (NP (NN baseline))))))))) (. .)))
17379047	9	(S1 (S (NP (NNP Control)) (VP (AUX was) (VP (VBN defined) (PP (IN as) (S (VP (VBG MSDBP) (NP (CD <90) (JJ mm) (NNP Hg)) (PP (VBN compared) (PP (IN with) (NP (NN baseline))))))))) (. .)))
17379047	10	(S1 (S (NP (NN Tolerability)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (S (VP (VBG monitoring) (NP (NP (NP (JJ adverse) (NNS events)) (PP (IN at) (NP (NP (NN randomization)) (CC and) (NP (DT all) (JJ subsequent) (NN study) (NNS visits))))) (CC and) (NP (NP (JJ regular) (NN evaluation)) (PP (IN of) (NP (NN hematology) (CC and) (NN blood) (NN chemistry)))))))))) (. .)))
17379047	11	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 1346) (NNS patients)))) (VP (AUX were) (VP (VBN randomized) (PP (IN into) (NP (NP (DT the) (JJ 8-week) (NN core) (NN study)) (PRN (-LRB- -LRB-) (NP (CD 734) (NNS men)) (, ,) (NP (NP (CD 612) (NNS women)) (: ;) (NP (NP (CD 924) (JJ white) (, ,) (ADJP (ADJP (CD 291) (NN black)) (, ,) (ADJP (CD 23) (JJ Asian)) (, ,) (ADJP (CD 108) (JJ other)) (PRN (: ;) (S (VP (VB mean) (NP (NP (NN age)) (, ,) (NP (CD 52.7) (NNS years))))) (: ;))) (NN mean) (NN weight)) (, ,) (NP (CD 92.6) (NNS kg)))) (-RRB- -RRB-)))))) (. .)))
17379047	12	(S1 (S (NP (DT All) (JJ active) (NNS treatments)) (VP (AUX were) (VP (VP (VBN associated) (PP (IN with) (NP (ADJP (RB significantly) (VBN reduced)) (NNS MSSBP)))) (CC and) (VP (VBN MSDBP) (PP (IN during) (NP (DT the) (NN core) (NN 8-week) (NN study)))) (, ,) (PP (IN with) (NP (NP (NP (DT each) (JJ monotherapy)) (VP (ADVP (RB significantly)) (VBG contributing) (PP (TO to) (NP (NP (DT the) (JJ overall) (NN effect)) (PP (IN of) (NP (NN combination) (NN therapy))))))) (PRN (-LRB- -LRB-) (NP (NNP Doc_17379047_2017_2020_Chemical) (CC and) (NNP Doc_17379047_2025_2029_Chemical)) (, ,) (NP (NNP P) (QP (CD <) (CD 0.001))) (-RRB- -RRB-)))))) (. .)))
17379047	13	(S1 (S (NP (DT Each) (NN combination)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (ADJP (RB significantly) (JJR greater)) (NNS reductions)) (PP (IN in) (NP (NP (NNP MSSBP)) (CC and) (NP (NNP MSDBP)))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (NNS monotherapies)) (CC and) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NP (DT all)) (, ,) (NP (NP (NN P)) (QP (CD <) (CD 0.001)))) (-RRB- -RRB-)))))))) (. .)))
17379047	14	(S1 (S (NP (NP (DT The) (JJ mean) (NN reduction)) (PP (IN in) (NP (CD MSSBP/MSDBP))) (PP (IN with) (NP (NNP Doc_17379047_2233_2236_Chemical/Doc_17379047_2237_2241_Chemical) (CD 320/25) (NNS mg)))) (VP (AUX was) (NP (CD 24.7/16.6) (JJ mm) (NNP Hg)) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (CD 5.9/7.0) (NN mm)) (NP (NNP Hg)) (PP (IN with) (NP (NN placebo))))))) (. .)))
17379047	15	(S1 (S (NP (NP (DT The) (NN reduction)) (PP (IN in) (NP (NNS MSSBP)))) (VP (AUX was) (ADJP (RB significantly) (JJR greater)) (PP (IN with) (NP (NNP Doc_17379047_2369_2372_Chemical/Doc_17379047_2373_2377_Chemical) (CD 320/25) (NNS mg))) (PP (VBN compared) (PP (IN with) (NP (NP (NNP Doc_17379047_2402_2405_Chemical/Doc_17379047_2406_2410_Chemical) (CD 160/12.5) (NNS mg)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.002))) (-RRB- -RRB-)))))) (. .)))
17379047	16	(S1 (S (NP (NP (NNS Rates)) (PP (IN of) (NP (NP (NN response)) (CC and) (NP (NNP BP) (NN control))))) (VP (AUX were) (ADJP (RB significantly) (JJR higher)) (PP (IN in) (NP (NP (DT the) (NNS groups)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NN combination) (NN treatment)) (PP (VBN compared) (PP (IN with) (NP (NP (DT those)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NN monotherapy)))))))))))))) (. .)))
17379047	17	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_17379047_2609_2620_Disease)))) (VP (AUX was) (ADJP (ADJP (JJR lower) (PP (IN with) (NP (NP (JJ Doc_17379047_2636_2639_Chemical/Doc_17379047_2640_2644_Chemical) (NNS combinations)) (PRN (-LRB- -LRB-) (NP (CD 1.8) (NN %) (CD -6.1) (NN %)) (-RRB- -RRB-))))) (PP (IN than) (PP (IN with) (NP (NP (JJ Doc_17379047_2680_2684_Chemical) (NNS monotherapies)) (PRN (-LRB- -LRB-) (NP (NP (CD 7.1) (NN %)) (NP (CD -13.3) (NN %))) (-RRB- -RRB-))))))) (. .)))
17379047	18	(S1 (S (NP (NP (DT The) (NN majority)) (PP (IN of) (NP (JJ adverse) (NNS events))) (PP (IN in) (NP (DT the) (NN core) (NN study)))) (VP (AUX were) (ADJP (IN of) (JJ mild) (PP (TO to) (NP (JJ moderate) (NN severity))))) (. .)))
17379047	19	(S1 (S (NP (NP (DT The) (NN efficacy) (CC and) (NN tolerability)) (PP (IN of) (NP (JJ Doc_17379047_2830_2833_Chemical/Doc_17379047_2834_2838_Chemical) (NNS combinations)))) (VP (AUX were) (VP (VBN maintained) (PP (IN during) (NP (NP (DT the) (NN extension)) (PRN (-LRB- -LRB-) (NP (CD 797) (NNS patients)) (-RRB- -RRB-)))))) (. .)))
17379047	20	(S1 (S (PP (IN In) (NP (DT this) (NN study) (NN population))) (, ,) (NP (NP (NN combination) (NNS therapies)) (PP (IN with) (NP (NNP Doc_17379047_2971_2974_Chemical/Doc_17379047_2975_2979_Chemical)))) (VP (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (ADJP (RB significantly) (JJR greater)) (NNP BP) (NNS reductions))) (PP (VBN compared) (PP (IN with) (NP (DT either) (NN monotherapy)))))) (, ,) (VP (AUX were) (VP (ADVP (RB well)) (VBN tolerated))) (, ,) (CC and) (VP (AUX were) (VP (VBN associated) (PP (IN with) (ADJP (ADJP (RBR less) (JJ Doc_17379047_3122_3133_Disease)) (PP (IN than) (NP (NP (NNP Doc_17379047_3139_3143_Chemical)) (ADVP (RB alone))))))))) (. .)))
17384765	0	(S1 (S (NP (JJ Succimer) (NN chelation)) (VP (VP (VBZ improves) (NP (NP (NN learning)) (, ,) (NP (NN attention)) (, ,) (CC and) (NP (JJ arousal) (NN regulation))) (PP (IN in) (NP (JJ lead-exposed) (NNS rats)))) (CC but) (VP (VBZ produces) (NP (JJ lasting) (NN Doc_17384765_114_134_Disease)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NN lead) (NN exposure))))))) (. .)))
17384765	1	(S1 (S (NP (EX There)) (VP (AUX is) (VP (VBG growing) (NP (NN pressure)) (SBAR (IN for) (S (NP (NNS clinicians)) (VP (TO to) (VP (VB prescribe) (NP (NN chelation) (NN therapy)) (PP (IN at) (NP (RB only) (RB slightly) (JJ elevated) (NN blood) (NN lead) (NNS levels))))))))) (. .)))
17384765	2	(S1 (S (ADVP (RB However)) (, ,) (NP (ADJP (RB very) (JJ few)) (NNS studies)) (VP (AUX have) (VP (VBN evaluated) (SBAR (SBAR (IN whether) (S (NP (NN chelation)) (VP (VBZ improves) (NP (NP (JJ cognitive) (NNS outcomes)) (PP (IN in) (NP (JJ Doc_17384765_387_389_Chemical-exposed) (NNS children))))))) (, ,) (CC or) (SBAR (IN whether) (S (NP (DT these) (NNS agents)) (VP (AUX have) (NP (NP (JJ adverse) (NNS effects)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB affect) (NP (NN brain) (NN development)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ Doc_17384765_505_507_Chemical) (NN exposure)))))))))))))))) (. .)))
17384765	3	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB answer) (NP (DT these) (NNS questions))))) (, ,) (S (VP (VBG using) (NP (NP (DT a) (JJ rodent) (NN model)) (PP (IN of) (NP (JJ early) (NN childhood)))) (NP (NP (NNP Doc_17384765_628_630_Chemical) (NN exposure) (CC and) (NN treatment)) (PP (IN with) (NP (NP (NN succimer)) (, ,) (NP (NP (DT a) (ADJP (RB widely) (VBN used)) (NN chelating) (NN agent)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ Doc_17384765_720_722_Chemical) (NN poisoning))))))))))))) (. .)))
17384765	4	(S1 (S (NP (JJ Doc_17384765_743_745_Chemical) (NN exposure)) (VP (VBD produced) (NP (NNP Doc_17384765_764_783_Disease)) (PP (IN in) (NP (NP (NN learning)) (, ,) (NP (NN attention)) (, ,) (NP (NN inhibitory) (NN control)) (, ,) (CC and) (NP (NN arousal) (NN regulation)))) (, ,) (S (VP (VBG paralleling) (NP (NP (DT the) (NNS areas)) (PP (IN of) (NP (NP (NN dysfunction)) (VP (VBN seen) (PP (IN in) (NP (JJ Doc_17384765_897_899_Chemical-exposed) (NNS children)))))))))) (. .)))
17384765	5	(S1 (S (NP (NP (JJR Succimer) (NN treatment)) (PP (IN of) (NP (DT the) (JJ Doc_17384765_944_946_Chemical-exposed) (NNS rats)))) (ADVP (RB significantly)) (VP (VBD improved) (NP (NP (NN learning)) (, ,) (NP (NN attention)) (, ,) (CC and) (NP (JJ arousal) (NN regulation))) (, ,) (SBAR (IN although) (S (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (DT the) (NN treatment)))) (VP (VBN varied) (PP (IN as) (NP (NP (NP (DT a) (NN function)) (PP (IN of) (NP (DT the) (JJ Doc_17384765_1095_1097_Chemical) (NN exposure) (NN level)))) (CC and) (NP (DT the) (JJ specific) (JJ functional) (NN deficit)))))))) (. .)))
17384765	6	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (JJR succimer) (NN treatment)) (PP (IN of) (NP (NP (NNS rats)) (VP (RB not) (ADVP (RB previously)) (VBN exposed) (PP (TO to) (NP (NNP Doc_17384765_1216_1218_Chemical))))))) (VP (VBD produced) (NP (NP (JJ lasting) (CC and) (JJ pervasive) (NN Doc_17384765_1250_1285_Disease)) (ADJP (JJ comparable) (PP (IN in) (NP (NN magnitude))) (PP (TO to) (NP (NP (DT that)) (VP (VBN produced) (PP (IN by) (NP (DT the) (JJR higher) (JJ Doc_17384765_1341_1343_Chemical) (NN exposure) (NN regimen))))))))) (. .)))
17384765	7	(S1 (S (NP (DT These)) (VP (AUX are) (NP (NP (DT the) (JJ first) (NN data)) (, ,) (PP (TO to) (NP (PRP$ our) (NN knowledge))) (, ,) (SBAR (S (VP (TO to) (VP (VB show) (SBAR (IN that) (S (NP (NP (NN treatment)) (PP (IN with) (NP (DT any) (VBG chelating) (NN agent)))) (VP (MD can) (VP (VB alleviate) (NP (NP (NN Doc_17384765_1481_1499_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_17384765_1507_1509_Chemical) (NN exposure))))))))))))))) (. .)))
17384765	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (PRP it)) (VP (MD may) (VP (AUX be) (ADJP (JJ possible)) (S (VP (TO to) (VP (VB identify) (NP (NP (DT a) (JJ succimer) (NN treatment) (NN protocol)) (SBAR (WHNP (WDT that)) (S (VP (VBZ improves) (NP (NP (JJ cognitive) (NNS outcomes)) (PP (IN in) (NP (JJ Doc_17384765_1645_1647_Chemical-exposed) (NNS children)))))))))))))))) (. .)))
17384765	9	(S1 (S (ADVP (RB However)) (, ,) (NP (PRP they)) (ADVP (RB also)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN succimer) (NN treatment)) (VP (MD should) (VP (AUX be) (VP (ADVP (RB strongly)) (VBN discouraged) (PP (IN for) (NP (NP (NNS children)) (SBAR (WHNP (WP who)) (S (VP (AUX do) (RB not) (VP (AUX have) (NP (NP (JJ elevated) (NN tissue) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_17384765_1803_1805_Chemical)) (CC or) (NP (JJ other) (JJ heavy) (NNS metals))))))))))))))))) (. .)))
17445520	0	(S1 (S (NP (NN Doc_17445520_0_8_Chemical)) (VP (VBP challenge) (NP (NN test)) (PP (IN in) (NP (NP (NNP Doc_17445520_27_41_Disease)) (CC and) (NP (NNP Doc_17445520_46_56_Disease)))) (PP (IN with) (NP (NNP Doc_17445520_62_75_Disease)))) (. .)))
17445520	1	(S1 (S (NP (PRP$ Our) (NN aim)) (VP (AUX was) (S (VP (TO to) (VP (VB observe) (SBAR (IN if) (S (NP (NP (NP (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_17445520_117_131_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17445520_133_135_Disease)) (-RRB- -RRB-))))) (CC and) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_17445520_155_190_Disease))))) (-LRB- -LRB-) (NP (NNP Doc_17445520_192_195_Disease)) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NP (NNP Diagnostic) (CC and) (NNP Statistical) (NNP Manual)) (PP (IN of) (NP (NNP Doc_17445520_235_251_Disease)))) (, ,) (NP (JJ Fourth) (NN Edition) (NNS criteria)) (-RRB- -RRB-))) (VP (VB respond) (PP (IN in) (NP (DT a) (JJ similar) (NN way))) (PP (TO to) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NNP Doc_17445520_323_336_Disease))))) (PP (IN by) (NP (DT an) (JJ oral) (JJ Doc_17445520_348_356_Chemical) (NN challenge) (NN test)))))))))) (. .)))
17445520	2	(S1 (S (NP (PRP We)) (ADVP (RB randomly)) (VP (VBD selected) (NP (CD 29) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_17445520_411_413_Disease)) (, ,) (NP (NP (NP (CD 27)) (PP (IN with) (NP (NNP Doc_17445520_423_426_Disease)))) (, ,) (NP (NP (CD 25)) (PP (IN with) (NP (NNP Doc_17445520_436_452_Disease))) (PP (IN without) (NP (NP (NNP Doc_17445520_461_474_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17445520_476_478_Disease)) (-RRB- -RRB-))))) (, ,) (CC and) (NP (CD 28) (JJ healthy) (NNS volunteers)))))) (. .)))
17445520	3	(S1 (S (NP (DT The) (NNS patients)) (VP (AUX had) (NP (NP (DT no) (JJ psychotropic) (NN drug)) (PP (IN for) (NP (ADVP (IN at) (JJS least)) (DT a) (JJ 4-week) (NN period))))) (. .)))
17445520	4	(S1 (S (PP (IN In) (NP (NP (DT a) (JJ randomized) (JJ double-blind) (NN experiment)) (VP (VBN performed) (PP (IN in) (NP (CD 2) (NNS occasions))) (ADVP (NP (CD 7) (NNS days)) (RB apart))))) (, ,) (S (NP (NP (CD 480) (JJ mg) (NNP Doc_17445520_662_670_Chemical)) (CC and) (NP (DT a) (NNP Doc_17445520_677_685_Chemical-free) (PRN (-LRB- -LRB-) (NP (NN placebo)) (-RRB- -RRB-)) (NN solution))) (VP (AUX were) (VP (VBN administered) (PP (IN in) (NP (DT a) (NN coffee) (NN form)))))) (CC and) (S (NP (NNP Doc_17445520_749_756_Disease) (NNS scales)) (VP (AUX were) (VP (VBN applied) (PP (IN before) (CC and) (IN after) (NP (DT each) (NN test)))))) (. .)))
17445520	5	(S1 (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (NP (NP (NP (CD 58.6) (NN %)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 17)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_17445520_848_850_Disease)))))) (, ,) (NP (NP (NP (NP (CD 44.4) (NN %)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 12)) (-RRB- -RRB-))) (PP (IN of) (NP (NNS patients)))) (PP (IN with) (NP (NNP Doc_17445520_884_887_Disease)))) (, ,) (NP (NP (NP (CD 12.0) (NN %)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 3)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_17445520_920_922_Disease)))))) (, ,) (CC and) (NP (NP (CD 7.1) (NN %)) (PRN (-LRB- -LRB-) (NP (NN n=) (CD 2)) (-RRB- -RRB-)) (SBAR (IN of) (S (NP (NN control) (NNS subjects)) (VP (AUX had) (NP (DT a) (JJ Doc_17445520_966_971_Disease) (NN attack)) (PP (IN after) (NP (NP (DT the) (JJ 480-mg) (JJ Doc_17445520_996_1004_Chemical) (NN challenge) (NN test)) (SBAR (S (-LRB- -LRB-) (NP (NNP chi) (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-) (-LRB- -LRB-) (CD 3)) (-RRB- -RRB-) (VP (SYM =) (NP (CD 16.22)))))))))))) (, ,) (NP (NNP P) (SYM =) (CD .001)) (-RRB- -RRB-))) (. .)))
17445520	6	(S1 (S (NP (NP (DT The) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_17445520_1069_1071_Disease)) (CC and) (NP (NNP Doc_17445520_1076_1079_Disease))))) (VP (AUX were) (ADJP (ADJP (RBR more) (JJ sensitive) (PP (TO to) (NP (NNP Doc_17445520_1103_1111_Chemical)))) (SBAR (IN than) (S (VP (AUX were) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_17445520_1136_1138_Disease)) (CC and) (NP (JJ healthy) (NNS volunteers)))))))))) (. .)))
17445520	7	(S1 (S (NP (DT No) (NNP Doc_17445520_1166_1171_Disease) (NN attack)) (VP (AUX was) (VP (VBN observed) (PP (IN after) (NP (DT the) (JJ Doc_17445520_1202_1210_Chemical-free) (NN solution) (NN intake))))) (. .)))
17445520	8	(S1 (S (NP (NP (DT The) (NNS patients)) (PP (IN with) (NP (NNP Doc_17445520_1251_1253_Disease)))) (VP (AUX had) (NP (DT a) (JJR lower) (NN heart) (NN rate)) (NP (NP (NN response)) (PP (TO to) (NP (DT the) (NN test))) (PP (IN than) (NP (NP (PDT all) (DT the) (JJ other) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ 2-way) (NN analysis)) (PP (IN of) (NP (NP (NN variance)) (, ,) (NP (NN group)))) (PP (IN by) (NP (NN time) (NN interaction))) (PP (IN with) (NP (JJ Greenhouse-Geisser) (NN correction)))) (: :) (NP (NNP F) (-LRB- -LRB-) (CD 3,762) (-RRB- -RRB-) (SYM =) (CD 2.85) (, ,) (CD P)) (X (SYM =)) (CD .026)) (-RRB- -RRB-)))))) (. .)))
17445520	9	(S1 (S (NP (PRP$ Our) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (EX there)) (VP (AUX is) (NP (NP (DT an) (NN association)) (PP (IN between) (NP (NP (NP (NNP Doc_17445520_1497_1510_Disease)) (, ,) (NP (NP (DT no) (NN matter)) (SBAR (WHNP (IN if)) (S (VP (VBN associated) (PP (IN with) (NP (NNP Doc_17445520_1541_1543_Disease) (CC or) (NNP Doc_17445520_1547_1550_Disease))))))) (, ,)) (CC and) (NP (NNP Doc_17445520_1556_1571_Disease)))) (PP (TO to) (NP (DT an) (JJ oral) (JJ Doc_17445520_1583_1591_Chemical) (NN challenge) (NN test)))))))) (. .)))
17484470	0	(S1 (NP (NP (NP (JJ Mitral) (NN annuloplasty)) (PP (IN as) (NP (DT a) (JJ ventricular) (NN restoration) (NN method))) (PP (IN for) (NP (DT the) (VBG failing) (NN left) (NN ventricle)))) (: :) (NP (DT a) (NN pilot) (NN study)) (. .)))
17484470	1	(S1 (NP (NP (NP (NN BACKGROUND) (CC AND) (NN AIM)) (PP (IN OF) (NP (DT THE) (NN STUDY)))) (: :) (S (S (NP (NP (JJ Undersized) (JJ mitral) (NN annuloplasty)) (PRN (-LRB- -LRB-) (NP (NN MAP)) (-RRB- -RRB-))) (VP (AUX is) (ADJP (JJ effective) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_17484470_203_225_Disease) (CC and) (NNP Doc_17484470_230_261_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17484470_263_265_Disease)) (-RRB- -RRB-))))))) (PP (IN since)) (, ,) (CONJP (RB as) (RB well) (IN as)) (VP (VBG addressing) (NP (DT the) (NNP Doc_17484470_300_302_Disease))))) (, ,) (S (NP (DT the) (NN MAP)) (VP (MD may) (ADVP (RB also)) (VP (VB reshape) (NP (DT the) (JJ dilated) (NN left) (NN ventricular) (PRN (-LRB- -LRB-) (NP (NNP LV)) (-RRB- -RRB-)) (NN base)))))) (. .)))
17484470	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ direct) (NNS benefits)) (PP (IN of) (NP (NP (DT this) (JJ possible)) (VP (VBG reshaping) (PP (IN on) (NP (CD LV) (NN function))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ underlying) (NNP Doc_17484470_469_471_Disease))))))))) (VP (VBP remain) (S (VP (ADVP (RB incompletely)) (VBN understood)))) (. .)))
17484470	3	(S1 (S (NP (DT The) (NN study) (NN aim)) (VP (AUX was) (S (VP (TO to) (VP (VB identify) (NP (DT these) (NNS benefits)) (PP (IN in) (NP (NP (DT a) (JJ canine) (NN model)) (PP (IN of) (NP (NN Doc_17484470_570_589_Disease))))))))) (. .)))
17484470	4	(S1 (S (NP (CD Six) (NNS dogs)) (VP (VBD underwent) (NP (NN MAP)) (PP (IN with) (NP (NP (DT a) (JJ prosthetic) (NN band)) (PP (IN on) (NP (DT the) (NN posterior) (NN mitral) (NN annulus))))) (, ,) (S (VP (VBG using) (NP (CD four) (NNP mattress) (NNS sutures))))) (. .)))
17484470	5	(S1 (S (NP (DT The) (NNS sutures)) (VP (VP (AUX were) (VP (VBN passed) (ADVP (RB individually)) (PP (IN through) (NP (CD four) (NNS tourniquets))))) (CC and) (VP (VBD exteriorized) (VP (VBN untied) (PP (IN via) (NP (DT the) (JJ left) (NN atriotomy)))))) (. .)))
17484470	6	(S1 (S (NP (JJ Sonomicrometry) (NNS crystals)) (VP (VP (AUX were) (VP (VBN implanted) (PP (IN around) (NP (DT the) (JJ mitral) (NN annulus))))) (CC and) (VP (VBD left) (NP (NN ventricle)) (S (VP (TO to) (VP (VB measure) (NP (NP (NN geometry)) (CC and) (NP (JJ regional) (NN function)))))))) (. .)))
17484470	7	(S1 (S (S (NP (NN Doc_17484470_945_964_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_17484470_980_991_Chemical)) (CC and) (NP (NN volume) (NN loading)))) (PP (IN after) (S (VP (VBG weaning) (PP (IN from) (NP (JJ cardiopulmonary) (NN bypass))))))))) (: ;) (S (NP (NP (DT an) (NN absence)) (PP (IN of) (NP (NNP Doc_17484470_1068_1070_Disease)))) (VP (AUX was) (VP (VBN confirmed) (PP (IN by) (NP (NN echocardiography)))))) (. .)))
17484470	8	(S1 (S (NP (NN MAP)) (VP (AUX was) (VP (VBN accomplished) (PP (IN by) (S (VP (VBG cinching) (NP (DT the) (NNS tourniquets))))))) (. .)))
17484470	9	(S1 (S (NP (NNS Data)) (VP (AUX were) (VP (VBN acquired) (PP (PP (IN at) (NP (NN baseline))) (, ,) (PP (IN after) (NP (NP (NN induction)) (PP (IN of) (NP (NNP Doc_17484470_1207_1226_Disease))))) (, ,) (CC and) (PP (IN after) (NP (NN MAP)))))) (. .)))
17484470	10	(S1 (S (NP (NN MAP)) (VP (VBD decreased) (NP (NP (JJ mitral) (NN annular) (NNS dimensions)) (PP (IN in) (NP (DT both) (JJ commissure-commissure) (CC and) (JJ septal-lateral) (NNS directions))))) (. .)))
17484470	11	(S1 (S (ADVP (RB Concomitantly)) (, ,) (NP (NP (DT the) (JJ diastolic) (NN diameter)) (PP (IN of) (NP (DT the) (NN LV) (NN base) (CC and) (NN LV) (NN sphericity)))) (VP (VBD decreased) (PP (PP (PRN (-LRB- -LRB-) (FW i.e.) (, ,) (ADJP (JJ improved)) (-RRB- -RRB-)) (IN from) (NP (NP (NP (CD 37.4) (NN +/-)) (NP (QP (CD 9.3) (TO to) (CD 35.9)) (JJ +/-) (CD 10) (NNS mm))) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.063)) (-RRB- -RRB-)))) (, ,) (CC and) (PP (IN from) (NP (NP (NP (QP (CD 67.9) (JJ +/-) (CD 18.6) (NN %) (TO to) (CD 65.3) (NN +/-))) (NP (CD 18.9) (NN %))) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.016)) (-RRB- -RRB-))))) (, ,) (ADVP (RB respectively))) (. .)))
17484470	12	(S1 (S (NP (NNS Decreases)) (VP (AUX were) (ADJP (JJ evident)) (PP (IN in) (NP (DT both) (JJ LV) (JJ end-diastolic) (NN pressure))) (PRN (-LRB- -LRB-) (PP (IN from) (NP (NP (NP (CD 17) (NN +/-)) (NP (QP (CD 7) (TO to) (CD 15)) (JJ +/-) (CD 6) (NNS mmHg))) (, ,) (NP (NNP p) (SYM =) (CD 0.0480)) (CC and) (NP (NP (NNP Doc_17484470_1674_1677_Chemical)) (PRN (-LRB- -LRB-) (NP (PP (IN from) (NP (CD 48) (NNS +/-))) (NP (NP (QP (CD 8) (TO to) (CD 45) (NN +/-))) (NP (CD 8) (NN ms)))) (, ,) (NP (NNP p) (CD <0.01)) (-RRB- -RRB-))))) (, ,)) (SBAR (IN while) (S (NP (NP (JJ fractional) (NN shortening)) (PP (IN at) (NP (DT the) (NN LV) (NN base)))) (VP (VBD increased) (PP (IN from) (NP (CD 7.7) (NN +/-))) (NP (CD 4.5) (NN %)) (PP (TO to) (NP (CD 9.4) (NN +/-))) (NP (CD 4.5) (NN %)) (PRN (-LRB- -LRB-) (FRAG (X (FW p) (SYM =)) (NP (CD 0.045))) (-RRB- -RRB-)))))) (. .)))
17484470	13	(S1 (S (PP (IN After) (NP (NN MAP))) (, ,) (NP (NNS increases)) (VP (AUX were) (VP (VBN identified) (PP (IN in) (NP (PDT both) (NP (NP (JJ cardiac) (NN output)) (PRN (-LRB- -LRB-) (NP (PP (IN from) (NP (CD 1.54) (NN +/-))) (NP (NP (QP (CD 0.57) (TO to) (CD 1.65) (NN +/-))) (NP (CD 0.57) (NN 1/min)))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Emax)) (PRN (-LRB- -LRB-) (NP (QP (IN from) (CD 1.86) (CD +/-)) (QP (CD 0.9) (TO to) (CD 2.41)) (JJ +/-) (CD 1.31) (NNS mmHg/ml)) (-RRB- -RRB-))))))) (. .)))
17484470	14	(S1 (S (NP (NP (DT The) (NNS data)) (VP (VBN acquired))) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ isolated) (NN MAP)) (VP (MD may) (VP (AUX have) (NP (JJ certain) (NNS benefits)) (PP (IN on) (NP (NP (CD LV) (NN dimension/function)) (PP (IN in) (NP (NNP Doc_17484470_2088_2107_Disease))))) (, ,) (PP (ADVP (RB even)) (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (NNP Doc_17484470_2132_2134_Disease.)) (SBAR (WHADVP (WRB However)) (, ,) (S (NP (JJ further) (NNS investigations)) (VP (AUX are) (VP (VBN warranted) (PP (IN in) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (NNP Doc_17484470_2196_2217_Disease)))))))))))))))))) (. .)))
17496739	0	(S1 (S (NP (JJ Doc_17496739_0_12_Chemical/Doc_17496739_13_23_Chemical-induced) (NNP Doc_17496739_32_39_Disease)) (ADVP (RB rapidly)) (VP (VBD reversed) (PP (IN by) (NP (JJ high) (NN flux) (NNS hemodialysis))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN on) (NP (JJ peritoneal) (NN dialysis)))))) (. .)))
17496739	1	(S1 (S (PP (IN Despite) (NP (NP (JJ popular) (NN use)) (PP (IN of) (NP (NNP Doc_17496739_143_155_Chemical))))) (, ,) (NP (NP (DT the) (JJ dire) (NN Doc_17496739_166_179_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_17496739_196_208_Chemical))))) (ADVP (RB still)) (VP (VBZ goes) (ADJP (JJ unrecognized)) (, ,) (PP (VBG leading) (PP (TO to) (NP (NP (DT a) (NN delay)) (PP (IN in) (NP (JJ appropriate) (NN management))))))) (. .)))
17496739	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (JJ 57-year-old) (NN woman)) (PP (IN with) (NP (NNP Doc_17496739_315_338_Disease))) (VP (VBG receiving) (NP (NP (JJ continuous) (JJ ambulatory) (JJ peritoneal) (NN dialysis)) (PRN (-LRB- -LRB-) (NP (NNP CAPD)) (-RRB- -RRB-)))) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (JJ slurred) (NN speech)) (, ,) (NP (NNP Doc_17496739_429_435_Disease)) (, ,) (NP (JJ bizarre) (NN behavior)) (, ,) (NP (JJ progressive) (JJ mental) (NN Doc_17496739_474_483_Disease)) (, ,) (CC and) (NP (NP (CD 2) (NNS episodes)) (PP (IN of) (NP (NP (JJ generalized) (NNP Doc_17496739_515_535_Disease)) (PRN (-LRB- -LRB-) (NP (NNP GTCS)) (-RRB- -RRB-)))))) (PP (IN after) (NP (NP (CD 5) (NNS doses)) (PP (IN of) (NP (NNP Doc_17496739_560_572_Chemical/Doc_17496739_573_583_Chemical))))) (PRN (-LRB- -LRB-) (NP (QP (CD 2) (CD g/250)) (NN mg)) (-RRB- -RRB-)) (SBAR (S (VP (AUX were) (VP (VBN given) (PP (IN for) (NP (NNP Doc_17496739_612_626_Disease))) (PP (IN with) (NP (JJ secondary) (NN Doc_17496739_642_651_Disease)))))))))))) (. .)))
17496739	3	(S1 (S (NP (DT The) (NN laboratory) (NNS data)) (VP (VBD revealed) (NP (NP (JJ normal) (NN plasma) (NN electrolyte)) (CC and) (NP (JJ Doc_17496739_712_719_Chemical) (NNS levels)) (CC but) (NP (NNP Doc_17496739_731_743_Disease)))) (. .)))
17496739	4	(S1 (S (NP (JJ Neurologic) (NNS examinations)) (VP (VBD showed) (NP (NNP Doc_17496739_776_786_Disease) (CC and) (NNP bilateral) (NNP Babinski) (NN sign))) (. .)))
17496739	5	(S1 (S (NP (NP (JJ Computed) (NN tomography)) (PP (IN of) (NP (NP (NN brain)) (CC and) (NP (NN electroencephalogram))))) (VP (AUX were) (ADJP (JJ unremarkable))) (. .)))
17496739	6	(S1 (S (PP (IN Despite) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ antiepileptic) (NNS agents))))) (, ,) (NP (DT another) (NNP GTCS) (NN episode)) (VP (VBD recurred) (PP (IN after) (NP (NP (DT the) (JJ sixth) (NN dose)) (PP (IN of) (NP (NNP Doc_17496739_984_996_Chemical/Doc_17496739_997_1007_Chemical)))))) (. .)))
17496739	7	(S1 (S (NP (NN Brain) (JJ magnetic) (NN resonance) (NN imaging)) (VP (AUX did) (RB not) (VP (VB demonstrate) (NP (NP (JJ acute) (NN Doc_17496739_1068_1078_Disease)) (CC and) (NP (JJ organic) (NN Doc_17496739_1091_1104_Disease))))) (. .)))
17496739	8	(S1 (S (NP (NP (NN Initiation)) (PP (IN of) (NP (JJ high-flux) (NNS hemodialysis)))) (ADVP (RB rapidly)) (VP (VBD reversed) (NP (DT the) (JJ neurologic) (NNS symptoms)) (PP (IN within) (NP (CD 4) (NNS hours)))) (. .)))
17496739	9	(S1 (S (NP (JJ Doc_17496739_1200_1212_Chemical-induced) (NNP Doc_17496739_1221_1235_Disease)) (VP (MD should) (VP (AUX be) (VP (VBN considered) (PP (IN in) (NP (NP (DT any) (JJ uremic) (NNS patients)) (PP (IN with) (NP (JJ unexplained) (JJ neurological) (NNS manifestations)))))))) (. .)))
17496739	10	(S1 (S (NP (NNP CAPD)) (VP (AUX is) (ADJP (JJ inefficient)) (PP (IN in) (S (VP (VBG removing) (NP (NNP Doc_17496739_1358_1370_Chemical))))) (, ,) (SBAR (IN whereas) (S (NP (NN hemodialysis)) (VP (MD can) (ADVP (RB rapidly)) (VP (VB terminate) (NP (DT the) (JJ Doc_17496739_1419_1431_Chemical-induced) (NN Doc_17496739_1440_1454_Disease))))))) (. .)))
17543491	0	(S1 (NP (NP (NN Frequency)) (PP (IN of) (NP (JJ transient) (JJ ipsilateral) (NNP Doc_17543491_35_55_Disease))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (JJ carotid) (NN endarterectomy)) (PP (IN under) (NP (JJ local) (NNS anesthesia)))))) (. .)))
17543491	1	(S1 (S (PP (ADVP (RB Especially)) (IN because) (IN of) (NP (NP (NNS improvements)) (PP (IN in) (NP (JJ clinical) (JJ neurologic) (NN monitoring))))) (, ,) (NP (NP (JJ carotid) (NN endarterectomy)) (VP (AUX done) (PP (IN under) (NP (JJ local) (NNS anesthesia))))) (VP (AUX has) (VP (VBN become) (NP (NP (DT the) (NN technique)) (PP (IN of) (NP (NN choice))) (PP (IN in) (NP (JJ several) (NNS centers)))))) (. .)))
17543491	2	(S1 (S (NP (NP (JJ Doc_17543491_314_355_Disease) (NNS due)) (PP (TO to) (NP (JJ local) (NNS anesthetics)))) (VP (AUX have) (VP (AUX been) (VP (VBN described) (, ,) (ADVP (RB however))))) (. .)))
17543491	3	(S1 (S (NP (JJ Such) (NNS complications)) (VP (AUX are) (ADJP (RBS most) (JJ important)) (PP (IN in) (NP (NP (NNS situations)) (SBAR (WHADVP (WRB where)) (S (NP (EX there)) (VP (AUX is) (NP (DT a) (JJ pre-existing) (NN Doc_17543491_493_516_Disease)))))))) (. .)))
17543491	4	(S1 (S (NP (PRP We)) (ADVP (RB therefore)) (VP (VBD examined) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ local) (NNS anesthesia))) (PP (IN on) (NP (JJ vocal) (NN cord) (NN function)))) (S (VP (TO to) (ADVP (RB better)) (VP (VB understand) (NP (PRP$ its) (JJ possible) (NNS consequences)))))) (. .)))
17543491	5	(S1 (S (NP (DT This) (JJ prospective) (NN study)) (VP (VBD included) (NP (NP (CD 28) (NNS patients)) (VP (VBG undergoing) (NP (NN carotid) (NN endarterectomy)) (PP (IN under) (NP (JJ local) (NNS anesthesia)))))) (. .)))
17543491	6	(S1 (S (NP (JJ Vocal) (NN cord) (NN function)) (VP (AUX was) (VP (VBN evaluated) (ADVP (RB before)) (, ,) (PP (PP (IN during)) (, ,) (CC and) (PP (IN after) (NP (NN surgery)))) (PRN (-LRB- -LRB-) (NP (NN postoperative) (NN day) (CD 1)) (-RRB- -RRB-)) (S (VP (VBG using) (NP (JJ flexible) (NN laryngoscopy)))))) (. .)))
17543491	7	(S1 (S (NP (NNP Anesthesia)) (VP (AUX was) (VP (VBN performed) (PP (IN by) (S (VP (VBG injecting) (NP (NP (QP (CD 20) (TO to) (CD 40)) (NN mL)) (PP (IN of) (NP (NP (NP (DT a) (NN mixture)) (PP (IN of) (NP (NP (JJ long-acting)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17543491_951_962_Chemical)) (-RRB- -RRB-))))) (CC and) (NP (JJ short-acting) (PRN (-LRB- -LRB-) (NP (NNP Doc_17543491_982_992_Chemical)) (-RRB- -RRB-)) (NN anesthetic)))))))))) (. .)))
17543491	8	(S1 (S (NP (DT All) (NNS patients)) (VP (AUX had) (NP (JJ normal) (JJ vocal) (NN cord) (NN function)) (ADVP (RB preoperatively))) (. .)))
17543491	9	(S1 (S (NP (NP (CD Twelve) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 43) (NN %)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN found) (S (VP (TO to) (VP (AUX have) (NP (JJ intraoperative) (JJ ipsilateral) (NN Doc_17543491_1143_1163_Disease))))))) (. .)))
17543491	10	(S1 (S (NP (PRP It)) (VP (VBD resolved) (PP (IN in) (NP (DT all) (NNS cases))) (NP (QP (CD <) (CC or) (CD =24)) (NNS hours))) (. .)))
17543491	11	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (JJ significant) (NNS differences)) (PP (IN in) (NP (NP (NN operating) (NN time)) (CC or) (NP (NP (NN volume) (CC or) (NN frequency)) (PP (IN of) (NP (JJ anesthetic) (NN administration))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ temporary) (NNP Doc_17543491_1341_1361_Disease))))))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT those)) (ADVP (IN without)))))) (. .)))
17543491	12	(S1 (S (NP (JJ Local) (NN anesthesia)) (VP (VBD led) (PP (TO to) (NP (JJ temporary) (NN ipsilateral) (NN Doc_17543491_1449_1469_Disease))) (PP (IN in) (NP (NP (RB almost) (NN half)) (PP (IN of) (NP (DT these) (NNS patients)))))) (. .)))
17543491	13	(S1 (S (SBAR (IN Because) (S (NP (JJ pre-existing) (NNP Doc_17543491_1525_1534_Disease)) (VP (AUX is) (PP (IN of) (NP (NP (DT a) (JJ relevant) (NN frequency)) (PRN (-LRB- -LRB-) (NP (QP (IN up) (TO to) (CD 3)) (NN %)) (-RRB- -RRB-))))))) (, ,) (NP (NP (DT a) (JJ preoperative) (NN evaluation)) (PP (IN of) (NP (JJ vocal) (NN cord)))) (VP (VBP function) (SBAR (IN before) (S (NP (NP (JJ carotid) (NN endarterectomy)) (PP (IN under) (NP (JJ local) (NNS anesthesia)))) (VP (AUX is) (VP (VBN recommended) (S (VP (TO to) (VP (VB avoid) (NP (JJ intraoperative) (NN Doc_17543491_1715_1734_Disease)))))))))) (. .)))
17543491	14	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ preoperative) (JJ contralateral) (NN Doc_17543491_1780_1800_Disease))))) (, ,) (NP (NP (NN surgery)) (PP (IN under) (NP (JJ general) (NNS anesthesia)))) (VP (MD should) (VP (AUX be) (VP (VBN considered)))) (. .)))
17554526	0	(S1 (NP (NP (NN Doc_17554526_0_25_Disease)) (PP (IN in) (NP (JJ regular) (JJ recreational) (JJ Doc_17554526_50_57_Chemical) (NNS users))) (. .)))
17554526	1	(S1 (S (NP (NP (DT The) (NN ability)) (SBAR (S (VP (TO to) (VP (VB read) (NP (JJ facial) (NNS expressions))))))) (VP (AUX is) (ADJP (JJ essential) (PP (IN for) (NP (JJ normal) (JJ human) (JJ social) (NN interaction))))) (. .)))
17554526	2	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB conduct) (NP (NP (DT the) (JJ first) (NN investigation)) (PP (IN of) (NP (NP (JJ facial) (NN expression) (NN recognition) (NN performance)) (PP (IN in) (NP (JJ recreational) (JJ Doc_17554526_297_304_Chemical) (NNS users)))))))))) (. .)))
17554526	3	(S1 (S (NP (NNS MATERIALS) (CC AND) (NNS METHODS)) (: :) (NP (NP (CD Three) (NNS groups)) (, ,) (VP (VBN comprised) (PP (IN of) (NP (NP (NP (CD 21) (JJ Doc_17554526_365_372_Chemical) (JJ naive) (NNS participants)) (PRN (-LRB- -LRB-) (NP (NNP CN)) (-RRB- -RRB-))) (, ,) (NP (NP (CD 30) (JJ occasional) (NNP Doc_17554526_413_420_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP OC)) (-RRB- -RRB-))) (, ,) (CC and) (NP (CD 48) (JJ regular) (JJ recreational) (NNP Doc_17554526_455_462_Chemical) (PRN (-LRB- -LRB-) (NP (NNP RC)) (-RRB- -RRB-)) (NNS users))))) (, ,)) (VP (AUX were) (VP (VBN compared))) (. .)))
17554526	4	(S1 (S (NP (NP (DT An) (JJ emotional) (JJ facial) (NN expression) (PRN (-LRB- -LRB-) (NP (NNP EFE)) (-RRB- -RRB-)) (NN task)) (VP (VBG consisting) (PP (IN of) (NP (NP (DT a) (ADJP (JJ male) (CC and) (JJ female)) (NN face)) (VP (VBG expressing) (NP (CD six) (JJ basic) (NNS emotions)))))) (PRN (-LRB- -LRB-) (NP (NP (NN happiness)) (, ,) (NP (NN surprise) (, ,) (NN sadness) (, ,) (NN anger)) (, ,) (NP (NN fear)) (, ,) (CC and) (NP (NN disgust))) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN administered))) (. .)))
17554526	5	(S1 (S (NP (NP (JJ Mean) (NN percent) (NN accuracy)) (CC and) (NP (NP (NNS latencies)) (PP (IN for) (NP (JJ correct) (NNS responses))) (PP (IN across) (NP (NP (CD eight) (NNS presentations)) (PP (IN of) (NP (DT each) (JJ basic) (NN emotion))))))) (VP (AUX were) (VP (VBN derived))) (. .)))
17554526	6	(S1 (S (S (NP (NNS Participants)) (VP (AUX were) (ADVP (RB also)) (VP (VBN assessed) (PP (IN with) (NP (DT the) (`` ``) (NNS Eyes) (NN task) ('' '') (S (VP (TO to) (VP (VB investigate) (NP (PRP$ their) (NN ability) (S (VP (TO to) (VP (VB recognize) (NP (ADJP (RBR more) (JJ complex)) (JJ emotional) (NNS states)))))))))))))) (CC and) (S (NP (DT the) (NN Symptom)) (ADJP (JJ CheckList-90-Revised) (S (VP (TO to) (VP (VB measure) (NP (NN psychopathology))))))) (. .)))
17554526	7	(S1 (S (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (NN group) (NNS differences)) (PP (IN in) (NP (NP (NN psychopathology)) (CC or) (NP (`` ``) (NX (NNS eyes) (NN task)) ('' '') (NN performance))))))) (, ,) (CC but) (S (NP (NP (DT the) (JJ RC) (NN group)) (, ,) (SBAR (WHNP (WP who)) (S (ADVP (RB otherwise)) (VP (AUX had) (NP (NP (JJ similar) (JJ illicit) (NN substance) (NN use) (NNS histories)) (PP (TO to) (NP (DT the) (NN OC) (NN group))))))) (, ,)) (VP (VBD exhibited) (NP (NNP Doc_17554526_1176_1210_Disease)) (PP (VBN compared) (PP (TO to) (NP (DT the) (NN OC) (CC and) (NN CN) (NNS groups)))))) (. .)))
17554526	8	(S1 (S (NP (DT The) (NN RC) (NN group)) (ADVP (RB also)) (VP (VP (ADVP (RB correctly)) (VBN identified) (NP (NP (NN anger)) (, ,) (NP (NN fear)) (, ,) (NP (NN happiness)) (, ,) (CC and) (NP (NN surprise))) (, ,) (ADVP (ADVP (RBR more) (RB slowly)) (PP (IN than) (NP (NN CN))))) (, ,) (CC but) (RB not) (VP (VBN OC) (NP (NNS participants)))) (. .)))
17554526	9	(S1 (S (NP (DT The) (NN OC) (NN group)) (VP (AUX was) (ADJP (ADJP (JJR slower)) (PP (IN than) (NP (NN CN)))) (SBAR (WHADVP (WRB when)) (S (ADVP (RB correctly)) (VP (VBG identifying) (NP (NN disgust)))))) (. .)))
17554526	10	(S1 (S (NP (NP (DT The) (JJ selective) (NN deficit)) (PP (IN in) (NP (NN fear) (NN recognition) (NN accuracy))) (VP (VBN manifested) (PP (IN by) (NP (DT the) (JJ RC) (NN group))))) (ADVP (RB cannot)) (VP (AUX be) (VP (VBN explained) (PP (IN by) (NP (NP (DT the) (JJ subacute) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_17554526_1561_1568_Chemical)) (, ,) (CC or) (NP (NNP Doc_17554526_1573_1580_Chemical)))))) (, ,) (SBAR (IN because) (S (NP (NP (ADJP (ADJP (JJ recent)) (CC and) (ADJP (RBR less) (JJ recent))) (NNS users)) (PP (IN of) (NP (NP (DT these) (NNS drugs)) (PP (IN within) (NP (DT this) (NN group)))))) (VP (AUX were) (ADJP (RB similarly) (JJ impaired))))))) (. .)))
17554526	11	(S1 (S (NP (NP (JJ Possible) (NNS parallels)) (PP (IN between) (NP (NP (JJ RC) (NNS users)) (CC and) (NP (NNP Doc_17554526_1717_1728_Disease)))) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (NNP Doc_17554526_1745_1770_Disease)) (, ,) (NP (NNP Doc_17554526_1772_1792_Disease)) (, ,) (CC and) (NP (NNS etiology))))))) (VP (AUX are) (VP (VBN discussed))) (. .)))
1756784	0	(S1 (NP (NP (NP (NN Damage)) (PP (IN of) (NP (NP (NN substantia) (NN nigra) (NNS pars) (NN reticulata)) (PP (IN during) (NP (NP (NNP Doc_1756784_50_61_Chemical-induced) (NNP Doc_1756784_70_88_Disease)) (PP (IN in) (NP (DT the) (NN rat)))))))) (: :) (NP (NP (JJ immunohistochemical) (NN study)) (PP (IN of) (NP (NP (NNS neurons)) (, ,) (NP (NNS astrocytes)) (CC and) (NP (JJ serum-protein) (NN extravasation))))) (. .)))
1756784	1	(S1 (S (NP (DT The) (NN substantia) (NN nigra)) (VP (AUX has) (NP (NP (DT a) (JJ gating) (NN function)) (VP (VBG controlling) (NP (NP (DT the) (NN spread)) (PP (IN of) (NP (JJ Doc_1756784_252_269_Disease) (NN activity))))))) (. .)))
1756784	2	(S1 (S (ADVP (RB Additionally)) (, ,) (PP (IN in) (NP (NP (NNS models)) (PP (IN of) (NP (JJ prolonged) (NNP Doc_1756784_317_335_Disease))))) (NP (NP (DT the) (NNS pars) (NN reticulata)) (PP (IN of) (NP (NP (NN substantia) (NNS nigra)) (PRN (-LRB- -LRB-) (NP (NNP SNR)) (-RRB- -RRB-))))) (VP (VBZ suffers) (PP (IN from) (NP (NP (DT a) (JJ massive) (NN lesion)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB arise) (PP (IN from) (NP (NP (DT a) (JJ massive) (JJ metabolic) (NN derangement) (CC and) (NN hyperexcitation)) (VP (VBG developing) (PP (IN in) (NP (DT the) (VBN activated) (NN SNR))))))))))))) (. .)))
1756784	3	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (NNP Doc_1756784_533_551_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NP (JJ systemic) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_1756784_589_600_Chemical)) (PP (IN in) (NP (NNS rats))))))))) (. .)))
1756784	4	(S1 (S (NP (NP (DT The) (NN neuropathology)) (PP (IN of) (NP (NNP SNR)))) (VP (AUX was) (VP (VBN investigated) (S (VP (VBG using) (NP (NN immunohistochemical) (NNS techniques)) (PP (IN with) (NP (NP (DT the) (JJ major) (NN emphasis)) (PP (IN on) (NP (NP (DT the) (NN time-course)) (PP (IN of) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NNS neurons)) (CC and) (NP (NNS astrocytes)))))))))))))) (. .)))
1756784	5	(S1 (S (S (NP (NP (NNS Animals)) (VP (VBG surviving) (NP (NP (CD 20)) (, ,) (NP (CD 30)) (, ,) (NP (CD 40)) (, ,) (NP (CD 60) (NN min)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (NP (CD 6) (NNS hours)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (CC and) (NP (CD 3) (NNS days))) (PP (IN after) (NP (NP (NN induction)) (PP (IN of) (NP (NNP Doc_1756784_860_878_Disease))))))) (VP (AUX were) (ADJP (JJ perfusion-fixed)))) (, ,) (CC and) (S (NP (NNS brains)) (VP (VBD processed) (PP (IN for) (NP (NP (JJ immunohistochemical) (NN staining)) (PP (IN of) (NP (NNP SNR))))))) (. .)))
1756784	6	(S1 (S (NP (NP (NN Nissl-staining) (CC and) (NNS antibodies)) (PP (IN against) (NP (NP (DT the) (JJ neuron-specific) (JJ Doc_1756784_1021_1028_Chemical-binding) (NN protein)) (, ,) (NP (NN parvalbumin)) (, ,)))) (VP (VBD served) (S (VP (TO to) (VP (VB detect) (NP (NNP Doc_1756784_1076_1091_Disease)) (PP (IN in) (NP (NNP SNR))))))) (. .)))
1756784	7	(S1 (S (NP (NP (NNS Antibodies)) (PP (PP (IN against) (NP (NP (DT the) (JJ astroglia-specific) (JJ cytoskeletal) (NN protein)) (, ,) (NP (NP (JJ glial) (JJ fibrillary) (NN acidic) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN GFAP)) (-RRB- -RRB-))) (, ,))) (CC and) (PP (IN against) (NP (NP (DT the) (JJ glial) (JJ Doc_1756784_1226_1233_Chemical-binding) (NN protein)) (, ,) (NP (JJ S-100) (NN protein)) (, ,))))) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN status)) (PP (IN of) (NP (NNS astrocytes))))))))) (. .)))
1756784	8	(S1 (S (NP (NP (NP (JJ Immunohistochemical) (NN staining)) (PP (IN for) (NP (NN serum-albumin)))) (CC and) (NP (NP (NNS immunoglobulins)) (PP (IN in) (NP (NN brain) (NN tissue))))) (VP (AUX was) (VP (VBN taken) (PP (IN as) (NP (NP (NN indicator)) (PP (IN of) (NP (NP (JJ blood-brain) (NN barrier) (NNS disturbances)) (CC and) (NP (JJ vasogenic) (NN Doc_1756784_1468_1473_Disease) (NN formation)))))))) (. .)))
1756784	9	(S1 (S (NP (JJ Immunohistochemical) (NN staining)) (VP (VBD indicated) (NP (NP (NN loss)) (PP (IN of) (S (VP (VBG GFAP-staining) (ADVP (RB already)) (PP (IN at) (NP (CD 30) (NN min))) (PP (IN after) (NP (NP (NN induction)) (PP (IN of) (NP (NNP Doc_1756784_1583_1591_Disease))))) (PP (IN in) (NP (NP (DT an) (JJ oval) (NN focus)) (VP (VBN situated) (PP (IN in) (NP (NP (DT the) (NN center)) (PP (IN of) (NP (NNP SNR))))) (SBAR (IN while) (S (VP (VBG sparing) (NP (JJ medial) (CC and) (JJ lateral) (NNS aspects))))))))))))) (. .)))
1756784	10	(S1 (S (NP (QP (IN At) (CD 1)) (NNP h) (EX there)) (VP (AUX was) (NP (NP (JJ additional) (NN vacuolation)) (PP (IN in) (NP (JJ S-100) (NN protein) (VBG staining))))) (. .)))
1756784	11	(S1 (S (PP (IN By) (NP (CD 2) (NNS hours))) (, ,) (S (NP (NN parvalbumin-staining)) (VP (VBD changed) (PP (IN in) (NP (NP (DT the) (JJ central) (NNS SNR)) (VP (VBG indicating) (NP (NNP Doc_1756784_1819_1834_Disease))))))) (, ,) (CC and) (S (NP (NNP Nissl-staining)) (VP (VBD visualized) (NP (DT some) (NN Doc_1756784_1871_1890_Disease)))) (. .)))
1756784	12	(S1 (S (NP (NP (NN Staining)) (PP (IN for) (NP (NNS serum-proteins)))) (VP (VBD occurred) (PP (IN in) (NP (DT a) (JJ patchy) (NN manner))) (PP (IN throughout) (NP (DT the) (NN forebrain))) (PP (IN during) (NP (DT the) (JJ first) (NNS hours)))) (. .)))
1756784	13	(S1 (S (PP (IN By) (NP (CD 6))) (NP (NNP h)) (, ,) (NP (JJ vasogenic) (NNP Doc_1756784_2015_2020_Disease)) (VP (VBD covered) (NP (DT the) (JJ lesioned) (NNS SNR))) (. .)))
1756784	14	(S1 (S (PP (IN By) (NP (CD 24))) (NP (NNP h)) (, ,) (NP (NP (NN glial)) (CC and) (NP (JJ neuronal) (NNS markers))) (VP (VBD indicated) (NP (NP (DT a) (JJ massive) (NN lesion)) (PP (IN in) (NP (NP (DT the) (NN center)) (PP (IN of) (NP (NNP SNR))))))) (. .)))
1756784	15	(S1 (S (PP (IN By) (NP (JJ 48-72) (NNP h))) (, ,) (S (NP (NP (NNS astrocytes)) (VP (VBG surrounding) (NP (DT the) (NN lesion)))) (VP (VBD increased) (PP (IN in) (NP (NN size))))) (, ,) (CC and) (S (NP (JJ polymorphic) (NN phagocytotic) (NNS cells)) (VP (VBD invaded) (NP (DT the) (VBN damaged) (NN area)))) (. .)))
1756784	16	(S1 (S (PP (IN In) (S (NP (NP (DT a) (JJ further) (NN group)) (PP (IN of) (NP (NNS animals)))) (VP (VBG surviving) (NP (QP (CD 1) (TO to) (CD 5)) (NNS days))))) (, ,) (NP (JJ conventional) (NNS paraffin-sections)) (VP (VBD confirmed) (NP (NP (DT the) (ADJP (JJ neuronal) (CC and) (JJ glial)) (NN damage)) (PP (IN of) (NP (NN SNR))))) (. .)))
1756784	17	(S1 (S (NP (NP (JJ Additional) (NN pathology)) (PP (IN of) (NP (JJ similar) (NN quality)))) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (DT the) (JJ globus) (NN pallidus))))) (. .)))
1756784	18	(S1 (S (SBAR (IN Since) (S (NP (NNS astrocytes)) (VP (AUX were) (ADVP (RB always)) (VP (VBN damaged) (PP (IN in) (NP (NN parallel))) (PP (IN with) (NP (NP (NNS neurons)) (PP (IN in) (NP (NNP SNR))))))))) (NP (PRP it)) (VP (AUX is) (VP (VBN proposed) (SBAR (IN that) (S (NP (NP (DT the) (ADJP (JJ anatomical) (CC and) (JJ functional)) (NN interrelationship)) (PP (IN between) (NP (NP (NNS neurons)) (CC and) (NP (NNS astrocytes))))) (VP (AUX is) (ADJP (RB particularly) (JJ tight)) (PP (IN in) (NP (NNP SNR)))))))) (. .)))
1756784	19	(S1 (S (NP (DT Both) (NN cell) (NNS elements)) (VP (MD may) (VP (VB suffer) (PP (IN in) (NP (NN common))) (PP (IN from) (NP (NP (NNP Doc_1756784_2707_2728_Disease)) (CC and) (NP (NNP Doc_1756784_2733_2761_Disease)))) (SBAR (IN as) (S (VP (VBP occur) (PP (IN during) (NP (JJ massive) (NN Doc_1756784_2786_2804_Disease)))))))) (. .)))
17572393	0	(S1 (S (NP (NP (JJ Neuroprotective) (NNS effects)) (PP (IN of) (NP (NNP Doc_17572393_27_36_Chemical))) (PP (IN upon) (NP (DT the) (NN offspring)))) (VP (VBP cerebellar) (NP (NN cortex)) (PP (IN in) (NP (NP (DT the) (NN rat) (NN model)) (PP (IN of) (NP (NNP Doc_17572393_94_98_Chemical-induced) (NNP Doc_17572393_107_125_Disease)))))) (. .)))
17572393	1	(S1 (S (NP (NN Doc_17572393_127_145_Disease)) (VP (AUX is) (NP (NP (DT a) (NN Doc_17572393_151_163_Disease)) (VP (VBN characterized) (PP (IN by) (NP (NP (NNS defects)) (PP (IN in) (NP (NP (NN proliferation)) (, ,) (NP (NN migration)) (CC and) (NP (NN maturation))))))))) (. .)))
17572393	2	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (VP (TO to) (VP (VB evaluate) (NP (DT the) (NNS alterations)) (PP (IN in) (NP (NP (NN offspring) (NN rat) (NN cerebellum)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ maternal) (NN exposure)) (PP (TO to) (NP (NP (NNP Doc_17572393_345_394_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17572393_396_400_Chemical)) (-RRB- -RRB-))))))))))) (CC and) (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ exogenous) (NNP Doc_17572393_446_455_Chemical))) (PP (IN upon) (NP (JJ cerebellar) (JJ Doc_17572393_472_476_Chemical-induced) (NN Doc_17572393_485_503_Disease)))))))) (, ,) (S (VP (VBG using) (NP (ADJP (JJ histological) (CC and) (JJ biochemical)) (NNS analyses)))))) (. .)))
17572393	3	(S1 (S (S (NP (JJ Pregnant) (NN Wistar) (NNS rats)) (VP (AUX were) (VP (VBN assigned) (PP (TO to) (NP (CD five) (NNS groups)))))) (: :) (S (ADJP (JJ intact-control) (, ,) (JJ saline-control) (, ,) (JJ Doc_17572393_633_642_Chemical-treated) (, ,) (JJ Doc_17572393_652_656_Chemical-exposed) (CC and) (JJ Doc_17572393_669_673_Chemical-exposed) (CC plus) (JJ Doc_17572393_687_696_Chemical))) (. .)))
17572393	4	(S1 (S (S (NP (NNS Rats)) (VP (AUX were) (VP (VBN exposed) (PP (TO to) (NP (NNP Doc_17572393_719_723_Chemical))) (PP (IN on) (NP (JJ embryonic) (NN day) (CD 15)))))) (CC and) (S (NP (NNP Doc_17572393_748_757_Chemical)) (VP (AUX was) (VP (VBN given) (PP (IN until) (NP (NN delivery)))))) (. .)))
17572393	5	(S1 (S (S (NP (NP (NN Immuno/histochemistry)) (CC and) (NP (NNP electron) (NN microscopy))) (VP (AUX were) (VP (VBN carried) (PRT (RP out)) (PP (IN on) (NP (DT the) (NN offspring) (NN cerebellum)))))) (, ,) (CC and) (S (NP (NP (NNS levels)) (PP (IN of) (NP (NNP Doc_17572393_890_905_Chemical) (CC and) (NNP Doc_17572393_910_920_Chemical) (NN dismutase)))) (VP (AUX were) (VP (VBN determined)))) (. .)))
17572393	6	(S1 (S (ADVP (RB Histopathologically)) (, ,) (S (NP (JJ typical) (NNS findings)) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NN cerebella)) (PP (IN from) (NP (DT the) (NN control) (NNS groups)))))))) (, ,) (CC but) (S (NP (NP (DT the) (NNS findings)) (ADJP (JJ consistent) (PP (IN with) (NP (JJ early) (JJ embryonic) (NN development))))) (VP (AUX were) (VP (VBN noted) (PP (IN in) (NP (JJ Doc_17572393_1117_1121_Chemical-exposed) (JJ Doc_17572393_1130_1148_Disease) (NN group)))))) (. .)))
17572393	7	(S1 (S (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ marked) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (JJ TUNEL) (JJ positive) (NNS cells)) (CC and) (NP (JJ nestin) (JJ positive) (NNS cells)))))) (PP (IN in) (NP (JJ Doc_17572393_1251_1255_Chemical-exposed) (NN group)))))) (, ,) (CC but) (S (NP (NP (DT a) (VBN decreased) (NN immunoreactivity)) (PP (TO to) (NP (NP (JJ glial) (JJ fibrillary) (NN acidic) (NN protein)) (, ,) (NP (NN synaptophysin)) (CC and) (NP (VBG transforming) (NN growth) (NN factor) (NNS beta1))))) (VP (AUX was) (ADJP (JJ observed)) (, ,) (S (VP (VBG indicating) (NP (DT a) (JJ delayed) (NN maturation)))))) (, ,) (CC and) (S (NP (NNP Doc_17572393_1442_1451_Chemical)) (VP (ADVP (RB significantly)) (VBD reversed) (NP (DT these) (NNS changes)))) (. .)))
17572393	8	(S1 (S (NP (NP (JJ Doc_17572393_1490_1505_Chemical) (NN level)) (PP (IN in) (NP (JJ Doc_17572393_1515_1519_Chemical-exposed) (NN group)))) (VP (AUX was) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (NP (DT those)) (PP (IN in) (NP (NP (NN control) (NNS groups)) (CC and) (NP (NP (JJ Doc_17572393_1578_1587_Chemical) (VBN decreased) (JJ Doc_17572393_1598_1613_Chemical) (NNS levels)) (PP (IN in) (NP (NP (NNP Doc_17572393_1624_1628_Chemical) (NNP group)) (PRN (-LRB- -LRB-) (NP (NNP P<0.01)) (-RRB- -RRB-)))))))))) (, ,) (SBAR (IN while) (S (NP (EX there)) (VP (AUX were) (NP (DT no) (JJ significant) (NNS differences)) (PP (IN in) (NP (NP (DT the) (JJ Doc_17572393_1696_1706_Chemical) (NN dismutase) (NNS levels)) (PP (IN between) (NP (DT these) (NNS groups))))))))) (. .)))
17572393	9	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (S (NP (NP (NN exposure)) (PP (IN of) (NP (NNS animals))) (PP (TO to) (NP (NNP Doc_17572393_1793_1797_Chemical))) (PP (IN during) (NP (NN pregnancy)))) (VP (VBZ leads) (PP (TO to) (NP (NP (JJ delayed) (NN maturation)) (PP (IN of) (NP (NN offspring) (NN cerebellum))))))) (CC and) (S (NP (NNP Doc_17572393_1871_1880_Chemical)) (VP (VBZ protects) (NP (DT the) (NN cerebellum)) (PP (IN against) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_17572393_1928_1932_Chemical)))))))))) (. .)))
1760851	0	(S1 (S (NP (NP (JJ Reduced) (NN Doc_1760851_8_22_Disease)) (PP (IN of) (NP (NNP Doc_1760851_26_37_Chemical)))) (VP (VP (VBN given) (PP (IN in) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (JJ Doc_1760851_59_92_Chemical) (NNS conjugates)))))) (: :) (CC and) (VP (NP (JJ experimental) (NN study)) (PP (IN in) (NP (DT the) (NN rat))))) (. .)))
1760851	1	(S1 (S (NP (DT A) (NN rat) (NN model)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ general) (JJ acute) (NNP Doc_1760851_191_199_Disease)) (CC and) (NP (NP (NP (DT the) (JJ late) (NNP Doc_1760851_213_227_Disease)) (PP (IN of) (NP (CD 4) (NN mg/kg) (NNP Doc_1760851_239_250_Chemical)))) (PRN (-LRB- -LRB-) (NP (NNP Doc_1760851_252_255_Chemical)) (-RRB- -RRB-)) (VP (VBN given) (PP (CC either) (PP (IN as) (NP (JJ free) (NN drug))) (CC or) (PP (IN in) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (CD three) (JJ Doc_1760851_307_340_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_1760851_342_346_Chemical)) (-RRB- -RRB-)) (NN copolymer) (NNS conjugates)))))))))))))) (. .)))
1760851	2	(S1 (S (PP (IN In) (NP (DT these) (JJ Doc_1760851_379_383_Chemical) (NNS copolymers))) (, ,) (NP (NNP Doc_1760851_396_399_Chemical)) (VP (AUX was) (ADVP (RB covalently)) (VP (VBN bound) (PP (IN via) (NP (NP (JJ peptide) (NNS linkages)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (ADJP (ADJP (ADJP (RB either) (JJ non-biodegradable)) (PRN (-LRB- -LRB-) (JJ Doc_1760851_478_485_Chemical) (-RRB- -RRB-))) (CC or) (ADJP (JJ degradable) (PP (IN by) (NP (NP (JJ lysosomal) (NNS proteinases)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1760851_527_542_Chemical)) (-RRB- -RRB-))))))))))))) (. .)))
1760851	3	(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (CD one) (JJ biodegradable) (NN conjugate)) (VP (VBG containing) (NP (NNP Doc_1760851_597_610_Chemical)))) (VP (AUX was) (VP (VBN used)))) (: ;) (S (NP (DT this) (NN residue)) (VP (AUX was) (VP (VBN targeted) (PP (TO to) (NP (DT the) (NN liver)))))) (. .)))
1760851	4	(S1 (S (PP (IN Over) (NP (NP (DT the) (JJ first) (CD 3) (NNS weeks)) (PP (IN after) (NP (NP (DT the) (JJ i.v.) (NN administration)) (PP (IN of) (NP (ADJP (JJ free) (CC and) (JJ polymer-bound)) (NNP Doc_1760851_740_743_Chemical))))))) (, ,) (NP (DT all) (NNS animals)) (VP (VBD showed) (NP (NP (DT a) (JJ transient) (NN reduction)) (PP (IN in) (NP (NN body) (NN weight))))) (. .)))
1760851	5	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ maximal) (NN reduction)) (PP (IN in) (NP (NP (NN body) (NN weight)) (VP (VBN seen) (PP (IN in) (NP (NP (NNS animals)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NP (JJ polymer-bound) (NNP Doc_1760851_892_895_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 4) (NN mg/kg)) (-RRB- -RRB-)))))))))))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR lower)) (PP (IN than) (SBAR (WHNP (WDT that)) (S (VP (VBD observed) (PP (IN in) (NP (NP (DT those)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NP (NP (JJ free) (NNP Doc_1760851_977_980_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 4) (NN mg/kg)) (-RRB- -RRB-))) (CC or) (NP (NP (DT a) (NN mixture)) (PP (IN of) (NP (DT the) (JJ unmodified) (NN parent) (JJ Doc_1760851_1029_1033_Chemical) (NN copolymer)))) (CC and) (NP (NP (JJ free) (NNP Doc_1760851_1053_1056_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 4) (NN mg/kg)) (: ;) (NP (NP (NN P)) (QP (JJR less) (IN than) (CD 0.01)))) (-RRB- -RRB-))))))))))))))) (. .)))
1760851	6	(S1 (S (S (PP (IN Throughout) (NP (NP (DT the) (NN study)) (PRN (-LRB- -LRB-) (NP (CD 20) (NNS weeks)) (-RRB- -RRB-)))) (, ,) (NP (NP (NNS deaths)) (VP (VBN related) (PP (TO to) (NP (NNP Doc_1760851_1137_1151_Disease))))) (VP (AUX were) (VP (VBN observed) (ADVP (RB only)) (PP (IN in) (NP (NP (NNS animals)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NP (DT either) (JJ free) (NN Doc_1760851_1208_1211_Chemical)) (CC or) (NP (NP (DT the) (NN mixture)) (PP (IN of) (NP (NP (JJ Doc_1760851_1230_1234_Chemical) (NN copolymer)) (CC and) (NP (JJ free) (NN Doc_1760851_1254_1257_Chemical)))))))))))))) (: ;) (S (PP (IN in) (NP (DT these) (NNS cases))) (, ,) (NP (JJ histological) (NNS investigations)) (VP (VBD revealed) (NP (NP (JJ marked) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN heart)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (ADJP (JJ consistent) (PP (IN with) (NP (NNP Doc_1760851_1366_1369_Chemical-induced) (NNP Doc_1760851_1378_1392_Disease)))))))))))) (. .)))
1760851	7	(S1 (S (NP (NP (JJ Sequential) (NNS measurements)) (PP (IN of) (NP (NP (NP (JJ cardiac) (NN output)) (PP (IN in) (NP (VBG surviving) (NNS animals))) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (DT either) (JJ free) (NNP Doc_1760851_1483_1486_Chemical)))))) (CC or) (NP (NP (DT the) (NN mixture)) (PP (IN of) (NP (NP (JJ Doc_1760851_1505_1509_Chemical) (NN copolymer)) (CC and) (NP (JJ free) (NN Doc_1760851_1529_1532_Chemical)))))))) (VP (VBD showed) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (QP (RB approximately) (CD 30)) (NN %)))) (PP (IN in) (NP (NP (NN function)) (VP (VBG beginning) (PP (IN at) (NP (NP (DT the) (JJ 4th) (NN week)) (PP (IN after) (NP (NN drug) (NN administration))))))))) (. .)))
1760851	8	(S1 (S (NP (NP (DT The) (NN heart) (NN rate)) (PP (IN in) (NP (DT these) (NNS animals)))) (VP (AUX was) (ADJP (ADJP (NP (QP (RB approximately) (CD 12)) (NN %)) (JJR lower)) (PP (IN than) (NP (NP (DT that)) (VP (VBN measured) (PP (IN in) (NP (NP (JJ age-matched) (NN control) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))))))))) (. .)))
1760851	9	(S1 (S (NP (NP (NNS Animals)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (VP (VBN given) (NP (NP (DT the) (JJ Doc_1760851_1793_1797_Chemical) (NN copolymer) (NNS conjugates)) (VP (VBG containing) (NP (NNP Doc_1760851_1830_1833_Chemical))))))))) (VP (VBD exhibited) (NP (DT no) (JJ significant) (NN change)) (PP (IN in) (NP (JJ cardiac) (NN output))) (PP (IN throughout) (NP (NP (DT the) (NN study)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))))) (. .)))
1760851	10	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (DT no) (JJ significant) (NN histological) (NN change)) (VP (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (NN heart)) (PP (IN of) (NP (NP (NNS animals)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NNP Doc_1760851_2024_2027_Chemical)) (PP (IN in) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (JJ Doc_1760851_2043_2047_Chemical) (NN copolymer) (NNS conjugates)))))))))))))) (CC and) (VP (AUX were) (VP (VBN killed) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT the) (NN study)))))))) (. .)))
1760851	11	(S1 (S (ADVP (RB However)) (, ,) (NP (DT these) (NNS animals)) (VP (AUX had) (VP (VBN shown) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NN heart) (NN rate))) (VP (VBG beginning) (PP (IN at) (NP (NP (CD 8) (NNS weeks)) (PP (IN after) (NP (NP (NN drug) (NN administration)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-))))))) (. .)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 400) (NNS WORDS))))) (-RRB- -RRB-))))))
17721298	0	(S1 (S (NP (JJ Corneal) (NN Doc_17721298_8_14_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ aerosolized) (NN crack) (NN Doc_17721298_49_56_Chemical) (NN use)))) (. .)))
17721298	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (CD 4) (NNS cases)) (PP (IN of) (NP (NP (JJ corneal) (NN Doc_17721298_100_106_Disease)) (VP (VBN associated) (PP (IN with) (NP (NN Doc_17721298_123_133_Disease)))))))) (. .)))
17721298	2	(S1 (S (NP (NP (DT The) (NNS pathogenesis)) (PP (IN of) (NP (NP (DT these) (NN Doc_17721298_161_167_Disease) (CC and) (NN management)) (PP (IN of) (NP (DT these) (NNS patients)))))) (VP (AUX are) (ADVP (RB also)) (VP (VBN reviewed))) (. .)))
17721298	3	(S1 (S (NP (NP (NN Review)) (PP (IN of) (NP (NP (DT all) (NNS cases)) (PP (IN of) (NP (JJ corneal) (NNP Doc_17721298_260_266_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_17721298_283_293_Disease))))))) (VP (VBN seen) (PP (IN at) (NP (PRP$ our) (NN institution))) (PP (PP (IN from) (NP (NNP July) (CD 2006))) (PP (TO to) (NP (NNP December) (CD 2006))))) (. .)))
17721298	4	(S1 (S (NP (NP (CD Four) (NNS patients)) (PP (IN with) (NP (JJ corneal) (NNP Doc_17721298_387_393_Disease))) (VP (VBN associated) (PP (IN with) (NP (NN crack) (JJ Doc_17721298_416_423_Chemical) (NN use))))) (VP (AUX were) (VP (VBN reviewed))) (. .)))
17721298	5	(S1 (S (S (NP (DT All) (JJ corneal) (NN Doc_17721298_455_461_Disease)) (VP (AUX were) (VP (VBN cultured)))) (, ,) (CC and) (S (NP (DT the) (NNS patients)) (VP (AUX were) (VP (VBN admitted) (PP (TO to) (NP (DT the) (NN hospital))) (PP (IN for) (NP (JJ intensive) (JJ topical) (JJ antibiotic) (NN treatment)))))) (. .)))
17721298	6	(S1 (S (NP (DT Each) (NN patient)) (VP (VBD received) (NP (NP (JJ comprehensive) (NN health) (NN care)) (, ,) (PP (VBG including) (NP (UCP (JJ medical) (CC and) (NN substance)) (NN abuse) (NNS consultations))))) (. .)))
17721298	7	(S1 (S (S (NP (JJ Streptococcal) (NNS organisms)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (CD 3) (NNS cases)))))) (CC and) (S (NP (NNP Capnocytophaga) (CC and) (NNP Brevibacterium)) (VP (VBD casei) (PP (IN in) (NP (CD 1) (NN patient))))) (. .)))
17721298	8	(S1 (S (NP (DT The) (NNP Doc_17721298_778_788_Disease)) (VP (VBD responded) (PP (TO to) (NP (JJ antibiotic) (NN treatment)))) (. .)))
17721298	9	(S1 (S (NP (CD Two) (NNS patients)) (VP (VBD needed) (NP (NP (DT a) (JJ lateral) (NN tarsorrhaphy)) (PP (IN for) (NP (JJ persistent) (JJ epithelial) (NNS defects))))) (. .)))
17721298	10	(S1 (S (NP (JJ Aerosolized) (NN crack) (NN Doc_17721298_933_940_Chemical) (NN use)) (VP (MD can) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ corneal) (NN Doc_17721298_995_1001_Disease)))))))) (. .)))
17721298	11	(S1 (S (NP (NN Doc_17721298_1003_1013_Disease)) (VP (VBZ provides) (NP (NP (JJ additional) (NNS challenges)) (PP (IN for) (NP (NN management))))) (. .)))
17721298	12	(S1 (S (NP (NP (NP (RB Not) (JJ only) (NN treatment)) (PP (IN of) (NP (NP (PRP$ their) (JJ Doc_17721298_1089_1099_Disease)) (CONJP (CC but) (RB also)) (NP (NP (DT the) (JJ overall) (JJ poor) (NN health)) (PP (IN of) (NP (DT the) (NNS patients))))))) (CC and) (NP (NP (VBN increased) (NN risk)) (PP (IN of) (NP (NN noncompliance))))) (VP (AUX need) (S (VP (TO to) (VP (AUX be) (VP (VBN addressed)))))) (. .)))
17721298	13	(S1 (S (NP (JJ Comprehensive) (NN care)) (VP (MD may) (VP (VB provide) (NP (DT the) (NN patient)) (NP (DT the) (NN opportunity) (S (VP (TO to) (VP (VP (VB discontinue) (NP (PRP$ their) (NN substance) (NN abuse))) (, ,) (VP (VB improve) (NP (PRP$ their) (JJ overall) (NN health))) (, ,) (CC and) (VP (VB prevent) (NP (JJ future) (JJ corneal) (NNS complications))))))))) (. .)))
1779253	0	(S1 (NP (NP (NP (JJ Topical) (ADJP (CD 0.025) (NN %)) (NN Doc_1779253_15_24_Chemical)) (PP (IN in) (NP (JJ chronic) (NNP Doc_1779253_36_59_Disease)))) (: :) (NP (NP (NN efficacy)) (, ,) (NP (NP (NNS predictors)) (PP (IN of) (NP (NP (NN response)) (CC and) (NP (JJ long-term) (NN course)))))) (. .)))
1779253	1	(S1 (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB evaluate) (NP (DT the) (NN efficacy)))))) (, ,) (NP (NP (NP (NP (JJ time-course)) (PP (IN of) (NP (NN action)))) (CC and) (NP (NP (NNS predictors)) (PP (IN of) (NP (NP (NN response)) (PP (TO to) (NP (JJ topical) (NNP Doc_1779253_211_220_Chemical))))))) (, ,) (NP (NP (CD 39) (NNS patients)) (PP (IN with) (NP (NP (JJ chronic) (NNP Doc_1779253_247_270_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1779253_272_275_Disease)) (-RRB- -RRB-))))) (, ,) (NP (NP (JJ median) (NN duration)) (NP (CD 24) (NNS months))) (, ,)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (ADJP (CD 0.025) (NN %)) (JJ Doc_1779253_330_339_Chemical) (NN cream))) (PP (IN for) (NP (CD 8) (NNS weeks))))) (. .)))
1779253	2	(S1 (S (PP (IN During) (NP (NN therapy))) (NP (DT the) (NNS patients)) (VP (VBD rated) (NP (PRP$ their) (NN Doc_1779253_399_403_Disease)) (PP (IN on) (NP (NP (NP (DT a) (JJ visual) (NN analogue) (NN scale)) (PRN (-LRB- -LRB-) (NP (NNP VAS)) (-RRB- -RRB-))) (CC and) (NP (DT a) (JJ verbal) (NN outcome) (NN scale))))) (. .)))
1779253	3	(S1 (S (NP (DT A) (JJ follow-up) (NN investigation)) (VP (AUX was) (VP (VBN performed) (SBAR (NP (CD 10-12) (NNS months)) (IN after) (S (VP (VB study) (NP (NN onset)) (PP (IN on) (NP (NP (DT the) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN improved)))))))))))) (. .)))
1779253	4	(S1 (S (S (NP (NP (NNP Nineteen) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 48.7) (NN %)) (-RRB- -RRB-))) (ADVP (RB substantially)) (VP (VBD improved) (PP (IN after) (NP (DT the) (JJ 8-week) (NN trial))))) (: ;) (S (NP (NP (NP (NP (NP (CD 5) (-LRB- -LRB-) (NP (CD 12.8) (NN %)) (-RRB- -RRB-) (JJ discontinued) (NN therapy)) (ADJP (JJ due) (PP (TO to) (NP (NP (NNS side-effects)) (PP (JJ such) (IN as) (NP (NP (JJ intolerable) (JJ Doc_1779253_714_723_Chemical-induced) (NNP Doc_1779253_732_750_Disease)) (PRN (-LRB- -LRB-) (NP (CD 4)) (-RRB- -RRB-)))))))) (CC or) (NP (NNP Doc_1779253_758_766_Disease))) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (: ;) (CD 15)) (PRN (-LRB- -LRB-) (NP (CD 38.5) (NN %)) (-RRB- -RRB-))) (VP (VBD reported) (NP (DT no) (NN benefit)))) (. .)))
1779253	5	(S1 (S (NP (NP (DT The) (NN decrease)) (PP (IN in) (NP (NN VAS) (NNS ratings)))) (VP (AUX was) (ADJP (JJ significant)) (PP (IN after) (NP (NP (CD 2) (NNS weeks)) (PP (IN of) (NP (JJ continuous) (NN application)))))) (. .)))
1779253	6	(S1 (S (S (PP (IN Of) (NP (DT the) (NNS responders))) (NP (CD 72.2) (NN %)) (VP (AUX were) (ADVP (RB still)) (VP (VBN improved) (PP (IN at) (NP (DT the) (NN follow-up)))))) (: ;) (S (NP (NP (RB only) (NN one-third)) (PP (IN of) (NP (PRP them)))) (VP (AUX had) (VP (VBN continued) (NP (NN application)) (ADVP (RB irregularly))))) (. .)))
1779253	7	(S1 (S (NP (NN Treatment) (NN effect)) (VP (AUX was) (RB not) (ADJP (JJ dependent) (PP (IN on) (NP (NP (NP (NN patient) (POS 's)) (NN age)) (, ,) (NP (NP (NP (NN duration)) (CC or) (NP (NN localization))) (PP (IN of) (NP (NNP Doc_1779253_1094_1097_Chemical) (PRN (-LRB- -LRB-) (S (NP (JJ trigeminal) (NN involvement)) (VP (AUX was) (VP (VBN excluded)))) (-RRB- -RRB-)) (, ,) (NNP Doc_1779253_1137_1156_Disease) (CC or) (NNP Doc_1779253_1160_1164_Disease) (NN character)))))))) (. .)))
1779253	8	(S1 (S (NP (NN Treatment) (NN response)) (VP (AUX was) (RB not) (VP (VBN correlated) (PP (IN with) (NP (NP (DT the) (NN incidence) (, ,) (NN time-course) (CC or) (NN severity)) (PP (IN of) (NP (JJ Doc_1779253_1261_1270_Chemical-induced) (NN burning))))))) (. .)))
1779253	9	(S1 (S (SBAR (IN If) (S (VP (VBN confirmed) (PP (IN in) (NP (JJ controlled) (NNS trials)))))) (, ,) (NP (NP (DT the) (JJ long-term) (NNS results)) (PP (IN of) (NP (DT this) (JJ open) (, ,) (JJ non-randomized) (NN study)))) (VP (MD might) (VP (VB indicate) (SBAR (IN that) (S (NP (NP (DT the) (JJ analgesic) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_1779253_1424_1433_Chemical)) (PP (IN in) (NP (NNP Doc_1779253_1437_1440_Disease)))))) (VP (AUX is) (VP (VBN mediated) (PP (IN by) (NP (DT both) (NN interference))) (PP (IN with) (NP (NP (NP (JJ neuropeptide) (NN metabolism)) (CC and) (NP (NP (JJ morphological) (NNS changes)) (PRN (-LRB- -LRB-) (ADVP (RB perhaps)) (NP (NN degeneration)) (-RRB- -RRB-)))) (PP (IN of) (NP (JJ nociceptive) (NNS afferents))))))))))) (. .)))
17828434	0	(S1 (NP (NP (JJ Doc_17828434_0_24_Chemical) (-LRB- -LRB-) (NN MIP) (-RRB- -RRB-) (NN synthase) (NN inhibition)) (: :) (NP (NP (NN in-vivo) (NN study)) (PP (IN in) (NP (NNS rats)))) (. .)))
17828434	1	(S1 (S (NP (NP (NNP Doc_17828434_75_82_Chemical)) (CC and) (NP (NNP Doc_17828434_87_96_Chemical))) (VP (VP (AUX are) (NP (DT the) (JJ prototypic) (NN mood) (NNS stabilizers))) (CC and) (VP (AUX have) (NP (NP (JJ diverse) (NNS structures)) (CC and) (NP (NNS targets))))) (. .)))
17828434	2	(S1 (S (NP (DT Both) (NNS drugs)) (VP (VBP influence) (NP (JJ Doc_17828434_195_203_Chemical) (NN metabolism))) (. .)))
17828434	3	(S1 (S (S (NP (JJ Doc_17828434_216_223_Chemical) (NNS inhibits)) (VP (VBP IMPase))) (CC and) (S (NP (NNP Doc_17828434_244_253_Chemical)) (VP (VBZ inhibits) (NP (NN MIP) (NN synthase)))) (. .)))
17828434	4	(S1 (S (NP (DT This) (NN study)) (VP (VBZ shows) (SBAR (IN that) (S (NP (NN MIP) (NN synthase) (NN inhibition)) (VP (AUX does) (RB not) (VP (VP (VB replicate)) (CC or) (VP (VB augment) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_17828434_368_375_Chemical)))) (PP (IN in) (NP (DT the) (NNP Doc_17828434_383_391_Chemical) (JJ sensitive) (JJ Doc_17828434_402_413_Chemical-induced) (JJ Doc_17828434_422_430_Disease) (NN model))))))))) (. .)))
17828434	5	(S1 (S (NP (NP (DT This) (NN lack)) (PP (IN of) (NP (NNS effects)))) (VP (MD may) (VP (VB stem) (PP (IN from) (NP (NP (DT the) (JJ low) (NN contribution)) (PP (IN of) (NP (NN de-novo) (NN synthesis))) (PP (PP (TO to) (NP (JJ cellular) (JJ Doc_17828434_527_535_Chemical) (NN supply))) (CC or) (PP (TO to) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (DT the) (NN de-novo) (NN synthesis))) (PP (IN by) (NP (NP (NNP Doc_17828434_592_599_Chemical)) (NP (PRP itself))))))))))) (. .)))
17879100	0	(S1 (S (NP (JJ Non-steroidal) (NN anti-inflammatory)) (VP (VBD drugs-associated) (NP (NP (JJ acute) (NN Doc_17879100_55_77_Disease)) (PP (IN with) (NP (JJ granular) (JJ tubular) (NN basement) (NN membrane) (NNS deposits))))) (. .)))
17879100	1	(S1 (S (S (NP (NP (NN Doc_17879100_128_163_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17879100_165_169_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT an) (JJ important) (NN cause)) (PP (IN of) (NP (NNP Doc_17879100_196_215_Disease))) (VP (VBG resulting) (PP (IN from) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS insults))))))) (, ,) (PP (VBG including) (NP (JJ immune) (JJ complex-mediated) (NN tubulo-Doc_17879100_294_313_Disease))))) (, ,) (CC but) (S (NP (NP (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (JJ non-steroidal) (JJ anti-inflammatory) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NNS NSAIDs)) (-RRB- -RRB-))))) (VP (AUX are) (NP (DT a) (ADJP (RB far) (RBR more) (JJ frequent)) (NN cause)))) (. .)))
17879100	2	(S1 (S (ADVP (RB Overall)) (, ,) (PP (IN as) (NP (DT an) (NN entity))) (, ,) (NP (NNP Doc_17879100_434_438_Disease)) (VP (VBZ remains) (ADJP (JJ under-diagnosed)) (, ,) (SBAR (IN as) (S (NP (NNS symptoms)) (VP (VB resolve) (ADVP (RB spontaneously)) (SBAR (IN if) (S (NP (DT the) (NN medication)) (VP (AUX is) (VP (VBN stopped))))))))) (. .)))
17879100	3	(S1 (S (NP (PRP We)) (VP (VBP report) (PP (IN on) (NP (NP (DT a) (JJ 14-year-old) (NN boy)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_17879100_573_592_Disease) (CD 2) (NNS weeks)) (PP (IN after) (NP (JJ aortic) (NN valve) (NN surgery))))))))) (. .)))
17879100	4	(S1 (S (NP (PRP He)) (VP (AUX was) (VP (VP (VBN put) (PP (IN on) (NP (NNP Doc_17879100_643_650_Chemical))) (PP (VBG following) (NP (NN surgery)))) (CC and) (VP (VBD took) (NP (NNP Doc_17879100_678_687_Chemical)) (PP (IN for) (NP (NN fever))) (PP (IN for) (NP (RB nearly) (DT a) (NN week))) (ADVP (RB prior) (PP (TO to) (NP (NN presentation))))))) (. .)))
17879100	5	(S1 (S (NP (PRP He)) (ADVP (RB then)) (VP (VP (VBD presented) (PP (TO to) (NP (DT the) (NN emergency) (NN department) (NN feeling))) (ADVP (RB quite) (RB ill))) (CC and) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX have) (NP (NP (DT a) (NN blood) (NNP Doc_17879100_833_846_Chemical) (PRN (-LRB- -LRB-) (NP (NNP BUN)) (-RRB- -RRB-)) (NN concentration)) (PP (IN of) (NP (NP (QP (IN of) (CD 147)) (NNS mg/dl)) (, ,) (NP (NP (NP (NNP Doc_17879100_884_894_Chemical)) (PP (IN of) (NP (CD 15.3) (NN mg/dl)))) (CC and) (NP (NP (JJ serum) (NNP Doc_17879100_919_928_Chemical)) (PP (IN of) (NP (CD 8.7) (NN mEq/l)))))))))))))) (. .)))
17879100	6	(S1 (S (NP (NN Dialysis)) (VP (AUX was) (ADVP (RB immediately)) (VP (VBN initiated))) (. .)))
17879100	7	(S1 (S (NP (DT A) (NN kidney) (NN biopsy)) (VP (VBD showed) (NP (NP (JJ inflammatory) (VB infiltrate)) (ADJP (JJ consistent) (PP (IN with) (NP (NNP Doc_17879100_1042_1046_Disease)))))) (. .)))
17879100	8	(S1 (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (NP (DT the) (JJ tubular) (NN basement) (NN membrane)) (PRN (-LRB- -LRB-) (NP (NNP TBM)) (-RRB- -RRB-)))) (, ,) (NP (NP (ADJP (RB very) (JJ intense)) (JJ granular) (NNS deposits)) (PP (IN of) (NP (NP (JJ polyclonal) (NNP IgG)) (CC and) (NP (NNP C3))))) (VP (AUX were) (VP (VBN noted))) (. .)))
17879100	9	(S1 (S (NP (PRP He)) (VP (VP (VBD needed) (NP (NN dialysis)) (PP (IN for) (NP (CD 2) (NNS weeks)))) (CC and) (VP (AUX was) (VP (VBN treated) (ADVP (RB successfully)) (PP (IN with) (NP (NNP Doc_17879100_1230_1238_Chemical))) (PP (IN for) (NP (CD 6) (NNS months)))))) (. .)))
17879100	10	(S1 (S (NP (NP (PRP$ His) (JJ renal) (NN recovery)) (CC and) (NP (NP (NN disappearance)) (PP (IN of) (NP (NNP Doc_17879100_1293_1304_Disease))))) (VP (VBD took) (NP (DT a) (NN year))) (. .)))
17879100	11	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (DT this)) (VP (AUX is) (NP (NP (DT a) (JJ first) (NN report)) (PP (IN of) (NP (JJ NSAIDs-associated) (NNP Doc_17879100_1377_1381_Disease))) (, ,) (VP (VBG showing) (NP (NP (NNS deposits)) (PP (IN of) (NP (JJ granular) (JJ immune) (NN complex)))) (PP (CONJP (RB present) (RB only)) (PP (IN in) (NP (DT the) (NN TBM))) (CC and) (PP (RB not) (IN in) (NP (DT the) (NN glomeruli))))))) (. .)))
17879217	0	(S1 (S (NP (JJ Doc_17879217_0_10_Chemical-associated) (NN segmental)) (VP (VBD necrotizing) (NP (NNP Doc_17879217_44_62_Disease)) (PP (IN in) (NP (NNP Doc_17879217_66_93_Disease)))) (. .)))
17879217	1	(S1 (S (NP (JJ Segmental) (NN necrotising) (NN Doc_17879217_117_135_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN as) (NP (NP (NN complication)) (PP (IN of) (NP (NP (JJ Doc_17879217_173_183_Chemical) (NN therapy)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN treatment)) (PP (IN for) (NP (NNP Doc_17879217_228_240_Disease))))))))))))) (. .)))
17879217	2	(S1 (S (NP (NP (JJ Changing) (NN epidemiology)) (PP (IN of) (NP (NP (NNP Doc_17879217_267_277_Disease)) (PP (JJ such) (IN as) (NP (NP (NNP Doc_17879217_286_308_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_17879217_310_312_Disease)) (-RRB- -RRB-))))))) (VP (AUX has) (VP (VBN led) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_17879217_351_361_Chemical))) (PP (IN for) (NP (NNP Doc_17879217_366_391_Disease))))))))) (. .)))
17879217	3	(S1 (S (NP (PRP We)) (VP (VP (VBP describe) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Staphylococcal) (NNP Doc_17879217_445_447_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_17879217_462_481_Disease)) (ADVP (JJ secondary) (PP (TO to) (NP (DT a) (JJ segmental) (NN necrotising) (NN Doc_17879217_519_537_Disease)))) (SBAR (IN while) (S (VP (AUXG being) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17879217_563_573_Chemical)))))))))))))))) (, ,) (CC and) (VP (VBP review) (NP (NP (DT the) (NN literature)) (VP (VBG regarding) (NP (NP (DT this) (NN complication)) (PP (IN of) (NP (JJ Doc_17879217_632_642_Chemical) (NN therapy)))))))) (. .)))
17954033	0	(S1 (NP (NP (NN Rate)) (PP (IN of) (NP (NP (JJ YMDD) (NN motif) (NNS mutants)) (PP (IN in) (NP (NP (JJ Doc_17954033_30_40_Chemical-untreated) (JJ Iranian) (NNS patients)) (PP (IN with) (NP (JJ chronic) (NNP Doc_17954033_81_108_Disease))))))) (. .)))
17954033	1	(S1 (S (NP (NN Doc_17954033_122_132_Chemical)) (VP (AUX is) (VP (VBN used) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ chronic) (NNP Doc_17954033_170_181_Disease) (NNS patients))))))) (. .)))
17954033	2	(S1 (S (NP (JJ Recent) (NNS studies)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (JJ YMDD) (NN motif) (NNS mutants)) (PRN (-LRB- -LRB-) (NP (JJ resistant) (JJ Doc_17954033_251_262_Disease) (NN virus)) (-RRB- -RRB-))) (VP (VBP occur) (PP (IN as) (NP (NP (JJ natural) (JJ genome) (NN variability)) (PP (IN in) (NP (JJ Doc_17954033_309_319_Chemical-untreated) (JJ chronic) (NN Doc_17954033_338_349_Disease) (NNS patients))))))))) (. .)))
17954033	3	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (NP (PRP we)) (VP (VBD aimed) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NP (JJ YMDD) (NN motif) (NNS mutants)) (PP (IN in) (NP (NP (JJ Doc_17954033_430_440_Chemical-untreated) (NN chronic) (NN Doc_17954033_459_470_Disease) (NNS patients)) (PP (IN in) (NP (NNP Iran)))))))))))) (. .)))
17954033	4	(S1 (S (NP (NP (NP (NNS PATIENTS)) (CC AND) (NP (NNS METHODS))) (: :) (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (CD 77) (JJ chronic) (NNP Doc_17954033_533_544_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (RB not) (VP (AUX been) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_17954033_584_594_Chemical)))))))))))) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (DT the) (NN study))))) (. .)))
17954033	5	(S1 (S (NP (NP (NN Serum) (NNS samples)) (PP (IN from) (NP (NNS patients)))) (VP (AUX were) (VP (VBN tested) (PP (IN by) (NP (NP (NN polymerase) (NN chain) (NN reaction-restriction) (NN fragment) (NN length) (NN polymorphism)) (PRN (-LRB- -LRB-) (NP (NN PCR-RFLP)) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (NN detection)) (PP (IN of) (NP (JJ YMDD) (NN motif) (NNS mutants))))))) (. .)))
17954033	6	(S1 (S (NP (DT All) (NNS patients)) (VP (AUX were) (ADVP (RB also)) (VP (VBN tested) (PP (IN for) (NP (NP (NN liver) (NNS enzymes)) (, ,) (ADJP (ADJP (JJ anti-HCV)) (, ,) (ADJP (JJ Doc_17954033_840_845_Chemical)) (, ,) (CC and) (ADJP (JJ anti-HBe))))))) (. .)))
17954033	7	(S1 (S (PP (IN Of) (NP (NP (DT the) (CD 77) (NNS patients)) (VP (VBD enrolled) (PP (IN in) (NP (DT the) (NN study)))))) (, ,) (S (NP (CD 73) (NN %)) (VP (AUX were) (ADJP (JJ male)))) (CC and) (S (NP (CD 27) (NN %)) (VP (AUX were) (ADJP (JJ female)))) (. .)))
17954033	8	(S1 (S (NP (NP (JJ Mean) (NN ALT)) (CC and) (NP (NNP AST) (NNS levels))) (VP (AUX were) (NP (QP (CD 124.4+/-73.4) (CC and) (CD 103.1+/-81)) (NNS IU/l)) (, ,) (ADVP (RB respectively))) (. .)))
17954033	9	(S1 (S (NP (NN Doc_17954033_1024_1029_Chemical)) (VP (AUX was) (ADJP (ADJP (JJ positive) (PP (IN in) (NP (CD 40) (NN %)))) (CC and) (ADJP (JJ anti-HBe) (PP (IN in) (NP (NP (CD 60) (NN %)) (PP (IN of) (NP (DT the) (NNS patients)))))))) (. .)))
17954033	10	(S1 (S (NP (NN Anti-HCV)) (VP (AUX was) (ADJP (JJ negative)) (PP (IN in) (NP (NP (DT all)) (PP (IN of) (NP (PRP them)))))) (. .)))
17954033	11	(S1 (S (NP (JJ YMDD) (NN motif) (NNS mutants)) (VP (AUX were) (RB not) (VP (VBN detected) (PP (IN in) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (NNS patients))))) (PP (IN despite) (NP (NP (DT the) (NN liver) (NN enzyme) (NNS levels)) (CC and) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NNP Doc_17954033_1237_1242_Chemical)) (CC or) (NP (NN anti-HBe))))))))) (. .)))
17954033	12	(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (JJ natural) (NN occurrence)) (PP (IN of) (NP (JJ YMDD) (NN motif) (NNS mutants))) (PP (IN in) (NP (NP (JJ Doc_17954033_1325_1335_Chemical-untreated) (NNS patients)) (PP (IN with) (NP (JJ chronic) (NNP Doc_17954033_1368_1379_Disease)))))) (VP (AUX has) (VP (AUX been) (VP (VBN reported)))))) (, ,) (NP (DT these) (NNS mutants)) (VP (AUX were) (RB not) (VP (VBN detected) (PP (IN in) (NP (JJ Iranian) (JJ Doc_17954033_1442_1452_Chemical-untreated) (JJ chronic) (NN Doc_17954033_1471_1482_Disease) (NNS patients))))) (. .)))
18025637	0	(S1 (NP (NNP Doc_18025637_0_29_Disease) (CC and) (NNP Doc_18025637_34_44_Chemical) (. .)))
18025637	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NNP Doc_18025637_56_85_Disease))) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_18025637_102_112_Chemical-induced) (JJ secondary) (NN Doc_18025637_131_143_Disease))))) (VP (AUX is) (VP (VBN described))) (. .)))
18025637	2	(S1 (S (SBAR (IN Although) (S (NP (NP (DT an) (JJ infrequent) (NN complication)) (PP (IN of) (NP (JJ selective) (NNP Doc_18025637_207_216_Chemical)))) (VP (VBD reuptake) (NP (JJ inhibitor) (NN therapy))))) (, ,) (NP (PRP it)) (VP (AUX is) (ADJP (JJ important)) (SBAR (IN that) (S (NP (NNS ophthalmologists)) (VP (AUX are) (ADJP (JJ aware) (SBAR (IN that) (S (NP (DT these) (NNS agents)) (VP (MD can) (VP (VB cause) (NP (NN Doc_18025637_321_333_Disease)) (SBAR (IN because) (S (NP (NP (DT this) (NN class)) (PP (IN of) (NP (NNS drugs)))) (VP (AUX is) (ADVP (RB widely)) (VP (VBN prescribed)))))))))))))) (. .)))
18165598	0	(S1 (S (NP (NP (DT The) (NN differential) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_18165598_28_39_Chemical)) (CC and) (NP (NNP Doc_18165598_44_53_Chemical)))) (PP (IN on) (NP (JJ Doc_18165598_57_73_Chemical) (NN release)))) (, ,) (VP (VBP cyclooxygenase) (NP (NP (NN gene) (NN expression)) (CC and) (NP (NNP Doc_18165598_118_122_Disease))) (PP (IN in) (NP (DT a) (JJ clinical) (NNP Doc_18165598_137_141_Disease) (NN model)))) (. .)))
18165598	1	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (S (VP (VBG blocking) (NP (JJ nociceptive) (NN input)) (PP (IN from) (NP (JJ surgical) (NNS sites)))))))) (, ,) (NP (JJ long-acting) (JJ local) (NNS anesthetics)) (VP (MD might) (ADVP (RB directly)) (VP (VBP modulate) (NP (NN Doc_18165598_278_290_Disease)))) (. .)))
18165598	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (PRP we)) (VP (VP (VBP describe) (NP (NP (DT the) (JJ proinflammatory) (NNS effects)) (PP (IN of) (NP (NNP Doc_18165598_357_368_Chemical))) (PP (IN on) (NP (JJ local) (NNP Doc_18165598_378_394_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_18165598_396_400_Chemical)) (-RRB- -RRB-)) (NN production))))) (CC and) (VP (VBP cyclooxygenase) (NP (NP (-LRB- -LRB-) (NNP COX) (-RRB- -RRB-) (NN gene) (NN expression)) (SBAR (WHNP (WDT that)) (S (VP (VBZ increases) (NP (NNP Doc_18165598_469_487_Disease)) (PP (IN in) (NP (JJ human) (NNS subjects))))))))) (. .)))
18165598	3	(S1 (S (NP (NP (NP (NNS Subjects)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 114)) (-RRB- -RRB-))) (VP (VBG undergoing) (NP (NP (NN extraction)) (PP (IN of) (NP (JJ impacted) (JJ third) (NNS molars)))))) (VP (VP (VBD received) (NP (NP (DT either) (ADJP (CD 2) (NN %)) (JJ Doc_18165598_601_610_Chemical)) (CC or) (NP (ADJP (CD 0.5) (NN %)) (JJ Doc_18165598_619_630_Chemical))) (PP (IN before) (NP (NP (NN surgery)) (CC and) (NP (NP (DT either) (JJ Doc_18165598_657_666_Chemical) (CD 50) (NN mg)) (CC or) (NP (NN placebo))))) (NP (QP (RB orally) (CD 90)) (NN min)) (PP (IN before) (NP (NN surgery)))) (CC and) (VP (PP (IN for) (NP (DT the) (JJ following) (CD 48) (NNP h.) (JJ Oral) (NN mucosal) (NNS biopsies))) (AUX were) (VP (VBN taken) (PP (IN before) (NP (NP (NN surgery)) (CC and) (NP (NP (CD 48)) (NP (NNP h))))) (PP (IN after) (NP (NN surgery)))))) (. .)))
18165598	4	(S1 (S (PP (IN After) (NP (NN extraction))) (, ,) (NP (DT a) (NN microdialysis) (NN probe)) (VP (AUX was) (VP (VBN placed) (PP (IN at) (NP (NP (DT the) (JJ surgical) (NN site)) (PP (IN for) (NP (ADJP (JJ Doc_18165598_889_893_Chemical) (CC and) (JJ Doc_18165598_898_912_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18165598_914_918_Chemical)) (-RRB- -RRB-)) (NNS measurements))))))) (. .)))
18165598	5	(S1 (S (NP (DT The) (NNP Doc_18165598_947_958_Chemical/Doc_18165598_959_968_Chemical) (NN group)) (VP (VBD reported) (ADVP (RB significantly)) (NP (NNP Doc_18165598_998_1007_Disease)) (, ,) (SBAR (IN as) (S (VP (VBN assessed) (PP (IN by) (NP (DT a) (JJ visual) (NN analog) (NN scale))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (JJ other) (CD three) (NN treatment) (NNS groups)) (PP (IN over) (NP (NP (DT the) (JJ first) (CD 4) (NNP h.)) (SBAR (WHADVP (WRB However)) (, ,) (S (NP (DT the) (NNP Doc_18165598_1127_1138_Chemical/placebo) (NN group)) (VP (VBD reported) (NP (ADJP (RB significantly) (JJR more)) (NN Doc_18165598_1181_1185_Disease)) (PP (IN at) (NP (CD 24) (NNP h) (CC and) (NNP Doc_18165598_1198_1202_Chemical) (NNS levels))) (PP (IN during) (NP (DT the) (JJ first) (CD 4))) (SBAR (S (NP (NNP h)) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN than) (NP (DT the) (JJ other) (CD three) (NN treatment) (NNS groups))))))))))))))))))) (. .)))
18165598	6	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NNP Doc_18165598_1306_1317_Chemical)) (ADVP (RB significantly)) (VP (VBD increased) (NP (JJ COX-2) (NN gene) (NN expression)) (PP (IN at) (NP (CD 48))) (NP (NNP h)) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (DT the) (NNP Doc_18165598_1393_1402_Chemical/placebo) (NN group))))))) (. .)))
18165598	7	(S1 (S (NP (NN Doc_18165598_1418_1429_Chemical) (NNS levels)) (VP (AUX were) (RB not) (VP (ADVP (RB significantly)) (VBN affected) (PP (IN by) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (NNS treatments))))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NP (DT the) (NNS effects)) (VP (VBN seen))) (VP (AUX were) (ADJP (ADJP (JJ attributable) (PP (TO to) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN COX-2)))))) (, ,) (CC but) (ADJP (RB not) (JJ COX-1)))))))))) (. .)))
18165598	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_18165598_1625_1636_Chemical)) (VP (VBZ stimulates) (NP (JJ COX-2) (NN gene) (NN expression)) (PP (IN after) (NP (NP (NP (NNP Doc_18165598_1676_1689_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (JJR higher) (NNP Doc_18165598_1723_1727_Chemical) (NN production)))))))) (CC and) (NP (NNP Doc_18165598_1743_1747_Disease)))) (PP (IN after) (NP (DT the) (JJ local) (JJ anesthetic) (NN effect) (NNS dissipates))))))) (. .)))
18189308	0	(S1 (FRAG (NP (NP (NP (JJ p75NTR) (NN expression)) (PP (IN in) (NP (NN rat) (NN urinary) (NN bladder) (JJ sensory) (NNS neurons)))) (CC and) (NP (NP (JJ spinal) (NN cord)) (PP (IN with) (NP (NNP Doc_18189308_78_94_Chemical-induced) (NNP Doc_18189308_103_111_Disease))))) (. .)))
18189308	1	(S1 (S (NP (NP (DT A) (NN role)) (PP (IN for) (NP (NP (NN nerve) (NN growth) (NN factor)) (PRN (-LRB- -LRB-) (NP (NNP NGF)) (-RRB- -RRB-)))) (PP (IN in) (S (VP (VBG contributing) (PP (TO to) (NP (NP (VBN increased) (NN voiding) (NN frequency)) (CC and) (NP (JJ altered) (NN sensation)))) (PP (IN from) (NP (DT the) (JJ urinary) (NN bladder))))))) (VP (AUX has) (VP (AUX been) (VP (VBN suggested)))) (. .)))
18189308	2	(S1 (S (NP (JJ Previous) (NNS studies)) (VP (AUX have) (VP (VBN examined) (NP (NP (DT the) (NN expression) (CC and) (NN regulation)) (PP (IN of) (NP (NP (JJ Doc_18189308_328_336_Chemical) (NN kinase) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NNP Trks)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NN micturition) (NNS reflexes)) (PP (IN with) (NP (NNP Doc_18189308_390_418_Disease)))))))) (. .)))
18189308	3	(S1 (S (NP (DT The) (JJ present) (NNS studies)) (VP (VB examine) (NP (NP (DT the) (NN expression) (CC and) (NN regulation)) (PP (IN of) (NP (DT another) (NN receptor))) (VP (VBN known) (PP (TO to) (NP (NP (NN bind) (CD NGF)) (, ,) (NP (NP (CD p75)) (PRN (-LRB- -LRB-) (NP (NNP NTR)) (-RRB- -RRB-))) (, ,))))) (PP (IN after) (NP (NP (JJ various) (NNS durations)) (PP (IN of) (NP (NNP Doc_18189308_554_574_Disease))) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_18189308_586_602_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18189308_604_607_Chemical)) (-RRB- -RRB-)))))))) (. .)))
18189308	4	(S1 (S (NP (JJ Doc_18189308_610_613_Chemical-induced) (NNP Doc_18189308_622_630_Disease)) (VP (VBD increased) (PRN (-LRB- -LRB-) (NP (NP (JJ P) (NN <)) (CC or) (NP (SYM =) (CD 0.001))) (-RRB- -RRB-)) (NP (NP (CD p75) (-LRB- -LRB-) (NN NTR) (-RRB- -RRB-) (NN expression)) (PP (IN in) (NP (NP (DT the) (JJ superficial) (ADJP (JJ lateral) (CC and) (JJ medial)) (JJ dorsal) (NN horn)) (PP (IN in) (NP (ADJP (JJ L1-L2) (CC and) (JJ L6-S1)) (NN spinal) (NNS segments))))))) (. .)))
18189308	5	(S1 (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (NP (CD p75) (PRN (-LRB- -LRB-) (NP (NNP NTR)) (-RRB- -RRB-)) (JJ -immunoreactive) (-LRB- -LRB-) (JJ -IR) (-RRB- -RRB-) (NNS cells)) (PP (IN in) (NP (NP (DT the) (JJ lumbosacral) (JJ dorsal) (NN root) (NN ganglia)) (PRN (-LRB- -LRB-) (NP (NNP DRG)) (-RRB- -RRB-))))))) (ADVP (RB also)) (VP (VBN increased) (PRN (-LRB- -LRB-) (NP (NNP P) (NNP <) (CC or) (SYM =) (CD 0.05)) (-RRB- -RRB-)) (PP (IN with) (NP (NP (JJ Doc_18189308_895_898_Chemical-induced) (NNP Doc_18189308_907_915_Disease)) (PRN (-LRB- -LRB-) (ADJP (JJ acute) (, ,) (JJ intermediate) (, ,) (CC and) (JJ chronic)) (-RRB- -RRB-))))) (. .)))
18189308	6	(S1 (S (NP (JJ Quantitative) (, ,) (JJ real-time) (NN polymerase) (NN chain) (NN reaction)) (ADVP (RB also)) (VP (VBD demonstrated) (NP (NP (JJ significant) (NNS increases)) (PRN (-LRB- -LRB-) (NP (NNP P) (NNP <) (CC or) (SYM =) (CD 0.01)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (CD p75) (-LRB- -LRB-) (NN NTR) (-RRB- -RRB-) (NN mRNA)) (PP (IN in) (NP (NNP DRG))) (PP (IN with) (NP (ADJP (JJ intermediate) (CC and) (JJ chronic)) (NNP Doc_18189308_1112_1115_Chemical-induced) (NNP Doc_18189308_1124_1132_Disease)))))) (. .)))
18189308	7	(S1 (S (NP (NP (JJ Retrograde) (JJ dye-tracing) (NNS techniques)) (PP (IN with) (NP (NNP Fastblue)))) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB identify) (NP (JJ presumptive) (NN bladder) (NN afferent) (NNS cells)) (PP (IN in) (NP (DT the) (JJ lumbosacral) (NN DRG)))))))) (. .)))
18189308	8	(S1 (S (PP (IN In) (NP (NP (NN bladder) (NN afferent) (NNS cells)) (PP (IN in) (NP (NNP DRG))))) (, ,) (NP (CD p75) (-LRB- -LRB-) (NN NTR) (-RRB- -RRB-) (NN -IR)) (VP (AUX was) (ADVP (RB also)) (VP (VBN increased) (PRN (-LRB- -LRB-) (NP (NP (JJ P) (NN <)) (CC or) (NP (SYM =) (CD 0.01))) (-RRB- -RRB-)) (PP (IN with) (NP (NNP Doc_18189308_1349_1357_Disease))))) (. .)))
18189308	9	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (CD p75) (-LRB- -LRB-) (NNP NTR) (-RRB- -RRB-) (NN -IR)) (PP (IN in) (NP (NNP DRG) (NN cell) (NNS bodies))))))))) (, ,) (NP (NP (NP (NNS increases)) (PRN (-LRB- -LRB-) (NP (NNP P) (NNP <) (CC or) (SYM =) (CD 0.001)) (-RRB- -RRB-))) (PP (IN in) (NP (NN pericellular))) (PRN (-LRB- -LRB-) (VP (VBG encircling) (NP (NNP DRG) (NNS cells))) (-RRB- -RRB-)) (NP (CD p75) (-LRB- -LRB-) (NNP NTR) (-RRB- -RRB-) (NN -IR)) (PP (IN in) (NP (NNP DRG)))) (ADVP (RB also)) (VP (VBD increased)) (. .)))
18189308	10	(S1 (S (NP (JJ Confocal) (NNS analyses)) (VP (VBD demonstrated) (SBAR (S (NP (DT that) (JJ pericellular) (CD p75) (-LRB- -LRB-) (NN NTR) (-RRB- -RRB-) (NN -IR)) (VP (AUX was) (RB not) (VP (VBN colocalized) (PP (IN with) (NP (NP (DT the) (JJ glial) (NN marker)) (, ,) (NP (NP (JJ glial) (JJ fibrillary) (NN acidic) (NN protein)) (PRN (-LRB- -LRB-) (NP (NN GFAP)) (-RRB- -RRB-)))))))))) (. .)))
18189308	11	(S1 (S (NP (DT These) (NNS studies)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (CD p75) (-LRB- -LRB-) (NN NTR) (-RRB- -RRB-) (NN expression)) (PP (IN in) (NP (NN micturition) (NNS reflexes)))) (VP (AUX is) (ADJP (JJ present)) (UCP (ADVP (RB constitutively)) (CC and) (VP (VBN modified) (PP (IN by) (NP (NNP Doc_18189308_1781_1801_Disease))))))))) (. .)))
18189308	12	(S1 (S (NP (NP (DT The) (JJ functional) (NN significance)) (PP (IN of) (NP (NP (CD p75) (-LRB- -LRB-) (NN NTR) (-RRB- -RRB-) (NN expression)) (PP (IN in) (NP (NN micturition) (NNS reflexes)))))) (VP (VBZ remains) (S (VP (TO to) (VP (AUX be) (VP (VBN determined)))))) (. .)))
18340638	0	(S1 (FRAG (NP (JJ Doc_18340638_0_12_Chemical-induced) (JJ suicidal) (NN erythrocyte) (NN death)) (. .)))
18340638	1	(S1 (S (NP (NN Doc_18340638_61_73_Chemical)) (VP (AUX is) (ADVP (RB widely)) (VP (VBN used) (PP (IN as) (NP (DT an) (JJ immunosuppressive) (NN drug))))) (. .)))
18340638	2	(S1 (S (NP (NP (DT The) (JJ side) (NNS effects)) (PP (IN of) (NP (NNP Doc_18340638_139_151_Chemical)))) (VP (VBP include) (NP (NP (NNP Doc_18340638_160_166_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX has) (VP (AUX been) (VP (VBN attributed) (PP (TO to) (NP (NN Doc_18340638_197_220_Disease)))))))))) (. .)))
18340638	3	(S1 (S (ADVP (RB Alternatively)) (, ,) (NP (NNP Doc_18340638_237_243_Disease)) (VP (MD could) (VP (VB result) (PP (IN from) (NP (NP (VBN accelerated) (JJ suicidal) (NN erythrocyte) (NN death)) (CC or) (NP (NP (NN eryptosis)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN characterized) (PP (IN by) (NP (NP (NN exposure)) (PP (IN of) (NP (NP (NNP Doc_18340638_353_371_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP PS)) (-RRB- -RRB-)))))) (PP (PP (IN at) (NP (DT the) (JJ erythrocyte) (NN surface))) (CC and) (PP (IN by) (NP (NN cell) (NN shrinkage))))))))))))) (. .)))
18340638	4	(S1 (S (NP (DT The) (JJ present) (NNS experiments)) (VP (VBD explored) (SBAR (IN whether) (S (NP (NNP Doc_18340638_477_489_Chemical)) (VP (VBZ influences) (NP (NN eryptosis)))))) (. .)))
18340638	5	(S1 (S (PP (VBG According) (PP (TO to) (NP (JJ annexin) (NN V) (VBG binding)))) (, ,) (NP (NP (NNS erythrocytes)) (PP (IN from) (NP (NNS patients)))) (ADVP (RB indeed)) (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN of) (NP (NNP PS) (NN exposure)))) (PP (IN within) (NP (NP (CD 1) (NN week)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_18340638_655_667_Chemical)))))) (. .)))
18340638	6	(S1 (S (PP (IN In) (NP (DT a) (JJ second) (NN series))) (, ,) (NP (NP (JJ cytosolic) (JJ Doc_18340638_699_703_Chemical) (NN activity)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18340638_714_719_Chemical) (NN fluorescence)) (-RRB- -RRB-)) (, ,) (NP (NN cell) (NN volume)) (PRN (-LRB- -LRB-) (NP (JJ forward) (NN scatter)) (-RRB- -RRB-)) (, ,) (CC and) (NP (NP (NN PS-exposure)) (PRN (-LRB- -LRB-) (S (NP (NN annexin) (NNS V)) (VP (VBG binding))) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN determined) (PP (IN by) (NP (NP (JJ FACS) (NN analysis)) (PP (IN in) (NP (NP (NNS erythrocytes)) (PP (IN from) (NP (JJ healthy) (NNS volunteers))))))))) (. .)))
18340638	7	(S1 (S (NP (NP (NN Exposure)) (PP (TO to) (NP (NP (NNP Doc_18340638_897_909_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD >) (CC or) (CD =2)) (NN microg/mL)) (-RRB- -RRB-)))) (PP (IN for) (NP (CD 48) (NNS hours)))) (VP (VP (VBD increased) (NP (NP (JJ cytosolic) (JJ Doc_18340638_963_967_Chemical) (NN activity)) (CC and) (NP (JJ annexin) (NN V) (VBG binding)))) (CC and) (VP (VBD decreased) (ADVP (RB forward)) (NP (NN scatter)))) (. .)))
18340638	8	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_18340638_1044_1056_Chemical))) (PP (IN on) (NP (NP (DT both) (JJ annexin) (NNS V)) (ADJP (ADJP (JJ binding)) (CC and) (ADJP (RB forward) (JJR scatter)))))) (VP (AUX was) (ADVP (RB significantly)) (VP (VBN blunted) (PP (IN in) (NP (NP (DT the) (JJ nominal) (NN absence)) (PP (IN of) (NP (JJ extracellular) (NNP Doc_18340638_1169_1173_Chemical))))))) (. .)))
18340638	9	(S1 (S (NP (NN Doc_18340638_1188_1200_Chemical)) (VP (VBZ triggers) (NP (JJ suicidal) (JJ erythrocyte) (NN death)) (, ,) (S (NP (DT an) (NN effect)) (ADVP (RB presumably)) (VP (VBG contributing) (PP (TO to) (NP (NNP Doc_18340638_1275_1287_Chemical-induced) (NNP Doc_18340638_1296_1302_Disease)))))) (. .)))
18341442	0	(S1 (NP (NP (JJ Doc_18341442_0_13_Chemical)) (PP (IN as) (NP (NP (DT an) (NN adjunct)) (PP (TO to) (NP (NP (JJ Doc_18341442_31_44_Chemical) (NN treatment)) (PP (IN in) (NP (NP (NNS cats)) (PP (IN with) (NP (VBN suspected) (NNP Doc_18341442_78_97_Disease))))))))) (. .)))
18341442	1	(S1 (S (S (VP (TO To) (VP (VB assess) (NP (NNS pharmacokinetics))))) (, ,) (NP (NP (NN efficacy)) (, ,) (CC and) (NP (NN tolerability)) (PP (IN of) (NP (JJ oral) (NNP Doc_18341442_173_186_Chemical)))) (VP (VBN administered) (PP (IN as) (NP (NP (DT an) (NN adjunct)) (PP (TO to) (NP (NP (JJ Doc_18341442_217_230_Chemical) (NN treatment)) (PP (IN in) (NP (NP (NNS cats)) (PP (IN with) (NP (ADJP (RB poorly) (VBN controlled)) (VBN suspected) (NNP Doc_18341442_282_301_Disease)))))))))) (. .)))
18341442	2	(S1 (NP (NP (NN DESIGN-Open-label)) (, ,) (NP (JJ noncomparative) (JJ clinical) (NN trial)) (. .)))
18341442	3	(S1 (S (NP (CD 12) (NNS cats)) (VP (VBD suspected) (S (VP (TO to) (VP (AUX have) (NP (NP (NN Doc_18341442_388_407_Disease)) (SBAR (SBAR (WHNP (WDT that)) (S (VP (AUX was) (ADVP (RB poorly)) (VP (VBN controlled) (PP (IN with) (NP (NNP Doc_18341442_440_453_Chemical))))))) (CC or) (SBAR (WHNP (WDT that)) (S (VP (AUX had) (NP (JJ unacceptable) (JJ adverse) (NNS effects)) (SBAR (WHADVP (WRB when)) (S (VP (VBN treated) (PP (IN with) (NP (NNP Doc_18341442_513_526_Chemical))))))))))))))) (. .)))
18341442	4	(S1 (S (NP (NNS Cats)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_18341442_563_576_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN mg/kg) (CD -LSB-9.1) (NN mg/lb) (NN -RSB-)) (, ,) (NP (NP (NNP PO)) (, ,) (NP (NNP q) (CD 8) (NNP h))) (-RRB- -RRB-)))))) (. .)))
18341442	5	(S1 (S (PP (IN After) (NP (NP (DT a) (NN minimum)) (PP (IN of) (NP (NP (CD 1) (NN week)) (PP (IN of) (NP (NN treatment))))))) (, ,) (S (NP (JJ serum) (JJ Doc_18341442_658_671_Chemical) (NNS concentrations)) (VP (AUX were) (VP (VBN measured) (ADVP (RB before))))) (CC and) (S (NP (NP (CD 2)) (, ,) (NP (CD 4)) (, ,) (CC and) (NP (NP (CD 6) (NNS hours)) (PP (IN after) (NP (NN drug) (NN administration)))) (, ,) (CC and) (NP (NN maximum) (CC and) (NN minimum) (NN serum) (NNS concentrations) (CC and) (NN elimination) (NN half-life))) (VP (AUX were) (VP (VBN calculated)))) (. .)))
18341442	6	(S1 (S (S (NP (NP (NN Doc_18341442_845_852_Disease) (NNS frequencies)) (PP (IN before) (CC and) (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ Doc_18341442_896_909_Chemical) (NN treatment)))))) (VP (AUX were) (VP (VBN compared)))) (, ,) (CC and) (S (NP (JJ adverse) (NNS effects)) (VP (AUX were) (VP (VBN recorded)))) (. .)))
18341442	7	(S1 (S (S (NP (JJ Median) (NN maximum) (NN serum) (JJ Doc_18341442_1000_1013_Chemical) (NN concentration)) (VP (AUX was) (NP (CD 25.5) (NN microg/mL)))) (, ,) (S (NP (JJ median) (NN minimum) (NN serum) (JJ Doc_18341442_1069_1082_Chemical) (NN concentration)) (VP (AUX was) (NP (CD 8.3) (NN microg/mL)))) (, ,) (CC and) (S (NP (JJ median) (NN elimination) (NN half-life)) (VP (AUX was) (NP (CD 2.9) (NNS hours)))) (. .)))
18341442	8	(S1 (S (S (NP (JJ Median) (NNP Doc_18341442_1171_1178_Disease) (NN frequency)) (ADVP (RB prior) (PP (TO to) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_18341442_1213_1226_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 2.1) (NN Doc_18341442_1232_1240_Disease/mo)) (-RRB- -RRB-))))))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN than) (NP (JJ median) (JJ Doc_18341442_1282_1289_Disease) (NN frequency)))) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (JJ Doc_18341442_1320_1333_Chemical) (NN treatment)) (PRN (-LRB- -LRB-) (NP (CD 0.42) (NN Doc_18341442_1350_1358_Disease/mo)) (-RRB- -RRB-)))))))) (, ,) (CC and) (S (NP (NP (CD 7)) (PP (IN of) (NP (CD 10) (NNS cats)))) (VP (AUX were) (VP (VBN classified) (PP (IN as) (S (VP (AUXG having) (VP (VBN responded) (PP (TO to) (NP (NP (JJ Doc_18341442_1420_1433_Chemical) (NN treatment)) (PRN (-LRB- -LRB-) (NP (NN ie)) (, ,) (NP (NP (NN reduction)) (PP (IN in) (NP (NP (JJ Doc_18341442_1462_1469_Disease) (NN frequency)) (PP (IN of) (NP (CD >or=50) (NN %)))))) (-RRB- -RRB-))))))))))) (. .)))
18341442	9	(S1 (S (NP (CD Two) (NNS cats)) (VP (AUX had) (NP (NP (JJ transient) (NN lethargy)) (CC and) (NP (NN inappetence)))) (. .)))
18341442	10	(S1 (NP (NP (NP (NNS CONCLUSIONS)) (CC AND) (NP (JJ CLINICAL) (NN RELEVANCE))) (: :) (NP (NP (NNS Results)) (VP (VBN suggested) (SBAR (IN that) (S (NP (NNP Doc_18341442_1601_1614_Chemical)) (VP (VP (AUX is) (ADVP (RB well)) (VP (VBN tolerated) (PP (IN in) (NP (NNS cats))))) (CC and) (VP (MD may) (VP (AUX be) (ADJP (JJ useful) (PP (IN as) (NP (NP (DT an) (NN adjunct)) (PP (TO to) (NP (NP (JJ Doc_18341442_1676_1689_Chemical) (NN treatment)) (PP (IN in) (NP (NP (NNS cats)) (PP (IN with) (NP (NNP Doc_18341442_1713_1732_Disease))))))))))))))))) (. .)))
1837756	0	(S1 (NP (NP (JJ Doc_1837756_0_9_Chemical) (JJ reuptake) (NNS inhibitors)) (, ,) (NP (NN Doc_1837756_31_39_Disease)) (, ,) (CC and) (NP (DT the) (JJ ventral) (JJ basal) (NN ganglia)) (. .)))
1837756	1	(S1 (S (NP (NNS Antidepressants)) (VP (AUX have) (ADVP (RB previously)) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (JJ paranoid) (NNS reactions)) (PP (IN in) (NP (JJ Doc_1837756_147_158_Disease) (NNS patients)))))))) (. .)))
1837756	2	(S1 (S (NP (NP (CD Five) (NNS cases)) (PP (IN of) (NP (JJ paranoid) (NN exacerbation))) (PP (IN with) (NP (DT the) (JJ Doc_1837756_214_223_Chemical) (JJ reuptake) (NNS inhibitors))) (NP (NP (NNP Doc_1837756_244_254_Chemical)) (CC and) (NP (NNP Doc_1837756_259_272_Chemical)))) (VP (AUX are) (VP (VBN reported) (ADVP (RB here)))) (. .)))
1837756	3	(S1 (S (NP (NP (NNS Elements)) (ADJP (JJ common) (PP (TO to) (NP (DT these) (NNS cases))))) (VP (VBD included) (NP (NP (NP (DT a) (NN history)) (PP (IN of) (NP (JJ paranoid) (NN symptomatology)))) (CC and) (NP (NP (DT the) (JJ concomitant) (NN occurrence)) (PP (IN of) (NP (NN Doc_1837756_403_436_Disease)))))) (. .)))
1837756	4	(S1 (S (NP (NP (JJ Complicated) (NNP Doc_1837756_450_470_Disease)) (PRN (-LRB- -LRB-) (PP (VBG including) (NP (NP (NP (NN atypicality)) (PP (IN of) (NP (NN course)))) (CC and) (NP (NP (NP (NN symptomatology)) (, ,) (NP (NP (NN chronicity)) (, ,) (NP (NNP Doc_1837756_536_545_Disease) (, ,) (NNP Doc_1837756_547_557_Disease)) (, ,)) (CC and) (NP (JJ secondary) (NN onset))) (PP (IN in) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (DT a) (JJ primary) (NN Doc_1837756_606_615_Disease)))))))) (-RRB- -RRB-))) (VP (MD may) (VP (VB present) (NP (JJ particular) (NN vulnerability)) (PP (TO to) (NP (NP (JJ paranoid) (NNS exacerbations)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_1837756_696_705_Chemical) (JJ reuptake) (NNS inhibitors)))))))) (. .)))
1837756	5	(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (NN pharmacology) (CC and) (NN neurobiology)) (PP (IN of) (NP (NNP Doc_1837756_773_781_Disease)))) (VP (VBP remain) (ADJP (JJ cryptic))))) (, ,) (NP (NP (JJ several) (NNS mechanisms)) (, ,) (PP (VBG including) (NP (NP (JJ 5HT3) (JJ receptor-mediated) (JJ Doc_1837756_851_859_Chemical) (NN release)) (, ,) (NP (JJ beta-noradrenergic) (NN receptor) (NN downregulation)) (, ,) (CC or) (NP (NP (NP (JJ GABAB) (NN receptor) (NN upregulation)) (VP (VBG acting) (PP (IN in) (NP (NP (DT the) (NN vicinity)) (PP (IN of) (NP (DT the) (JJ ventral) (JJ basal) (NN ganglia))))))) (PRN (-LRB- -LRB-) (PP (ADVP (RB possibly)) (IN in) (NP (NP (JJ lateral) (NN orbitofrontal)) (CC or) (NP (NNP anterior) (NN cingulate) (NNS circuits)))) (-RRB- -RRB-))))) (, ,)) (VP (MD might) (VP (VB apply) (PP (TO to) (NP (DT this) (NN phenomenon))))) (. .)))
1837756	6	(S1 (S (NP (DT These) (NNS cases)) (VP (VP (VB call) (NP (NP (NN attention)) (PP (TO to) (NP (NP (JJ possible) (JJ paranoid) (NNS exacerbations)) (PP (IN with) (NP (NP (JJ Doc_1837756_1163_1172_Chemical) (JJ reuptake) (NNS blockers)) (PP (IN in) (NP (JJ select) (NNS patients))))))))) (CC and) (VP (VB raise) (NP (NP (JJ neurobiological) (NNS considerations)) (VP (VBG regarding) (NP (NNP Doc_1837756_1261_1269_Disease)))))) (. .)))
18399341	0	(S1 (NP (NP (JJ Clinical) (NN comparison)) (PP (IN of) (NP (NP (JJ cardiorespiratory) (NNS effects)) (PP (IN during) (NP (JJ unilateral) (CC and) (JJ conventional) (NN spinal) (NN anaesthesia))))) (. .)))
18399341	1	(S1 (S (NP (JJ Spinal) (NN anaesthesia)) (VP (VP (AUX is) (ADVP (RB widely)) (VP (VBN employed) (PP (IN in) (NP (JJ clinical) (NN practice))))) (CC but) (VP (AUX has) (NP (NP (DT the) (JJ main) (NN drawback)) (PP (IN of) (NP (JJ post-spinal) (NN Doc_18399341_216_233_Disease)))))) (. .)))
18399341	2	(S1 (S (NP (NNS Efforts)) (VP (MD must) (ADVP (RB therefore)) (VP (VB continue) (S (VP (TO to) (VP (AUX be) (VP (VBN made) (S (VP (TO to) (VP (VB obviate) (NP (DT this) (NN setback) (NN OBJECTIVE))))))))) (: :) (S (VP (TO To) (VP (VB evaluate) (NP (DT the) (ADJP (JJ cardiovascular) (CC and) (JJ respiratory)) (NNS changes)) (PP (IN during) (NP (JJ unilateral) (CC and) (JJ conventional) (NN spinal) (NN anaesthesia)))))))) (. .)))
18399341	3	(S1 (S (PP (IN With) (NP (JJ ethical) (NN approval))) (, ,) (NP (PRP we)) (VP (VBD studied) (NP (NP (NP (NP (CD 74) (NNP American) (NNP Society)) (PP (IN of) (NP (NNP Anesthesiologists)))) (PRN (-LRB- -LRB-) (NP (NNP ASA)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ physical) (NN status) (NN class)) (NP (QP (CD 1) (CC and) (CD 2)) (NNS patients)) (VP (VBN scheduled) (PP (IN for) (NP (JJ elective) (JJ unilateral) (JJR lower) (NN limb) (NN surgery))))))) (. .)))
18399341	4	(S1 (S (NP (NNS Patients)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN allocated) (PP (IN into) (NP (NP (NP (CD one)) (PP (IN of) (NP (CD two) (NNS groups)))) (: :) (NP (NP (NN lateral)) (CC and) (NP (JJ conventional) (JJ spinal) (NN anaesthesia) (NNS groups))))))) (. .)))
18399341	5	(S1 (S (PP (IN In) (NP (NP (DT the) (JJ lateral) (NN position)) (PP (IN with) (NP (JJ operative) (NN side) (RP down))))) (, ,) (NP (NNS patients)) (VP (VBD recived) (NP (NP (QP (CD 10) (CD mg)) (PRN (-LRB- -LRB-) (NNS 2mls) (-RRB- -RRB-))) (PP (IN of) (NP (ADJP (CD 0.5) (NN %)) (JJ hyperbaric) (NN Doc_18399341_815_826_Chemical)))) (PP (IN through) (NP (DT a) (JJ 25-gauge) (NN spinal) (NN needle)))) (. .)))
18399341	6	(S1 (S (NP (NP (NNS Patients)) (PP (IN in) (NP (DT the) (JJ unilateral) (NN group)))) (VP (AUX were) (VP (VBN maintained) (PP (IN in) (NP (DT the) (JJ lateral) (NN position))) (PP (IN for) (NP (NP (CD 15) (NNS minutes)) (VP (VBG following) (NP (NN spinal) (NN injection))))) (SBAR (IN while) (S (NP (NP (DT those)) (PP (IN in) (NP (DT the) (JJ conventional) (NN group)))) (VP (AUX were) (VP (VBN turned) (NP (NN supine)) (PP (ADVP (RB immediately)) (IN after) (NP (NN injection))))))))) (. .)))
18399341	7	(S1 (S (NP (NP (NN Blood) (NN pressure)) (, ,) (NP (NN heart) (NN rate)) (, ,) (NP (NN respiratory) (NN rate)) (CC and) (NP (JJ Doc_18399341_1111_1117_Chemical) (NN saturation))) (VP (AUX were) (VP (VBN monitored) (PP (IN over) (NP (CD 1) (NN hour))))) (. .)))
18399341	8	(S1 (S (NP (NP (NP (NP (CD Three) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 8.1) (NN %)) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (JJ unilateral) (NN group)))) (CC and) (NP (NP (CD 5)) (PRN (-LRB- -LRB-) (NP (CD 13.5) (NN %)) (-RRB- -RRB-)))) (PP (IN in) (NP (DT the) (JJ conventional) (NN group)))) (VP (VBD developed) (NP (NNP Doc_18399341_1262_1273_Disease) (, ,) (NNP P=) (CD 0.71))) (. .)))
18399341	9	(S1 (S (NP (NP (NP (CD Four) (PRN (-LRB- -LRB-) (NP (CD 10.8) (NN %)) (-RRB- -RRB-)) (NNS patients)) (PP (IN in) (NP (DT the) (JJ conventional) (NN group) (CC and) (CD 1))) (PRN (-LRB- -LRB-) (NP (CD 2.7) (NN %)) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (JJ unilateral) (NN group)))) (, ,) (NP (NNP P=) (CD 0.17))) (VP (VBN required) (NP (JJ Doc_18399341_1387_1398_Chemical) (NN infusion)) (S (VP (TO to) (VP (VB treat) (NP (NNP Doc_18399341_1417_1428_Disease)))))) (. .)))
18399341	10	(S1 (S (NP (NP (NNS Patients)) (PP (IN in) (NP (DT the) (JJ conventional) (NN group)))) (VP (AUX had) (NP (NP (ADJP (RB statistically) (JJ significant)) (JJR greater) (NN fall)) (PP (IN in) (NP (NP (DT the) (JJ systolic) (NN blood) (NNS pressures)) (PP (IN at) (NP (CD 15) (, ,) (CD 30) (CC and) (CD 45) (NNS minutes)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NP (DT the) (NN baseline)) (PRN (-LRB- -LRB-) (NP (NNP P=) (CD 0.003) (, ,) (CD 0.001) (CC and) (CD 0.004)) (-RRB- -RRB-)))))))) (. .)))
18399341	11	(S1 (S (NP (NP (NP (DT The) (JJ mean) (NN respiratory) (NN rate)) (CC and) (NP (JJ Doc_18399341_1654_1660_Chemical) (NNS saturations))) (PP (IN in) (NP (DT the) (CD two) (NNS groups)))) (VP (AUX were) (ADJP (JJ similar))) (. .)))
18399341	12	(S1 (S (PP (VBN Compared) (PP (TO to) (NP (JJ conventional) (NN spinal) (NN anaesthesia)))) (, ,) (NP (JJ unilateral) (NN spinal) (NN anaesthesia)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (JJR fewer) (NNP Doc_18399341_1818_1846_Disease))))) (. .)))
18399341	13	(S1 (S (ADVP (RB Also)) (, ,) (NP (NP (DT the) (NN type)) (PP (IN of) (NP (JJ spinal) (NN block)))) (VP (VBD instituted) (VP (VBN affected) (PP (IN neither) (NP (NP (DT the) (NN respiratory) (NN rate)) (CC nor) (NP (DT the) (JJ arterial) (JJ Doc_18399341_1945_1951_Chemical) (NN saturation)))))) (. .)))
18422462	0	(S1 (NP (NP (NN Spectrum)) (PP (IN of) (NP (JJ adverse) (NNS events))) (PP (IN after) (NP (NP (JJ generic) (NNS HAART)) (PP (IN in) (NP (JJ southern) (NNP Indian) (NNP Doc_18422462_66_78_Disease) (NNS patients))))) (. .)))
18422462	1	(S1 (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (ADJP (RB clinically) (JJ significant)) (JJ adverse) (NNS events)) (PP (IN after) (NP (ADJP (JJ long-term) (, ,) (JJ fixed-dose) (, ,) (JJ generic)) (ADJP (RB highly) (JJ active)) (JJ antiretroviral) (NN therapy) (PRN (-LRB- -LRB-) (NNP HAART) (-RRB- -RRB-)) (NN use))))) (PP (IN among) (NP (NP (NNP Doc_18422462_249_261_Disease) (NNS individuals)) (PP (IN in) (NP (NNP South) (NNP India))))))))) (, ,) (NP (PRP we)) (VP (VBD examined) (NP (NP (DT the) (NNS experiences)) (PP (IN of) (NP (NP (CD 3154) (JJ Doc_18422462_326_338_Disease) (NNS individuals)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (DT a) (NN minimum)) (PP (IN of) (NP (NP (CD 3) (NNS months)) (PP (IN of) (NP (NP (JJ generic) (NN HAART)) (PP (IN between) (NP (NP (NNP February) (CD 1996)) (CC and) (NP (NNP December) (CD 2006)))))))) (PP (IN at) (NP (NP (DT a) (NNP Doc_18422462_448_481_Disease)) (PP (IN in) (NP (NNP South) (NNP India)))))))))))) (. .)))
18422462	2	(S1 (S (NP (DT The) (RBS most) (JJ common) (NNS regimens)) (VP (AUX were) (NP (NP (NP (NP (NP (NNP Doc_18422462_528_531_Chemical) (NNP +) (NNP Doc_18422462_534_537_Chemical) (NNP +) (NNP Doc_18422462_540_550_Chemical)) (-LRB- -LRB-) (NP (NNP Doc_18422462_552_555_Chemical)) (-RRB- -RRB-) (-LRB- -LRB-) (NP (CD 54.8) (NN %)) (-RRB- -RRB-)) (, ,) (NP (NP (NP (NP (NNP Doc_18422462_566_576_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18422462_578_581_Chemical)) (-RRB- -RRB-))) (NNP +) (NNP Doc_18422462_585_588_Chemical) (NNP +) (NNP Doc_18422462_591_594_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 14.5) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_18422462_604_607_Chemical) (NNP +) (NNP Doc_18422462_610_613_Chemical) (NNP +) (NNP Doc_18422462_616_625_Chemical)) (-LRB- -LRB-) (NP (NNP Doc_18422462_627_630_Chemical)) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (CD 20.1) (NN %)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_18422462_645_648_Chemical) (NNP +) (NNP Doc_18422462_651_654_Chemical) (NNP +) (NNP Doc_18422462_657_660_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5.4) (NN %)) (-RRB- -RRB-))))) (. .)))
18422462	3	(S1 (S (NP (NP (DT The) (ADJP (RBS most) (JJ common)) (JJ adverse) (NNS events)) (CC and) (NP (NP (JJ median) (NN CD4)) (PP (IN at) (NP (NP (NN time)) (PP (IN of) (NP (NN event))))))) (VP (AUX were) (NP (NP (NP (NNP Doc_18422462_737_741_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 15.2) (NN %)) (: ;) (NP (NP (NN CD4)) (, ,) (NP (CD 285) (NN cells/microL)))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_18422462_777_798_Disease)) (PRN (-LRB- -LRB-) (NP (QP (CD 9.0) (NN %) (CC and) (CD 348) (NN cells/microL))) (-RRB- -RRB-))))) (. .)))
18422462	4	(S1 (S (NP (NP (ADJP (RB Clinically) (JJ significant)) (NNP Doc_18422462_851_857_Disease)) (PRN (-LRB- -LRB-) (NP (NN hemoglobin) (NN <7) (NNS g/dL)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (CD 5.4) (NN %)) (PP (IN of) (NP (NP (NP (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NNP CD4)) (, ,) (NP (CD 165) (NN cells/microL))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_18422462_940_949_Disease)) (PRN (-LRB- -LRB-) (NP (NP (JJ clinical) (NNP Doc_18422462_960_968_Disease)) (PP (IN with) (NP (NP (NP (JJ Doc_18422462_974_981_Chemical) (NN aminotransferase) (NN >)) (NP (QP (CD 5) (NNS times)) (JJ upper) (NNS limits))) (PP (IN of) (NP (JJ normal)))))) (-RRB- -RRB-))))))) (PP (IN in) (NP (NP (CD 3.5) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PRN (-LRB- -LRB-) (NP (NNP CD4)) (, ,) (NP (CD 260) (NN cells/microL)) (-RRB- -RRB-)))))))) (. .)))
18422462	5	(S1 (S (NP (NNS Women)) (VP (AUX were) (ADJP (ADVP (RB significantly) (RBR more)) (JJ likely) (S (VP (TO to) (VP (VB experience) (NP (NNP Doc_18422462_1129_1144_Disease)))))) (, ,) (SBAR (IN while) (S (NP (NNS men)) (VP (AUX were) (ADJP (ADVP (RB significantly) (RBR more)) (JJ likely) (S (VP (TO to) (VP (VB experience) (NP (NNP Doc_18422462_1201_1231_Disease)))))) (PRN (-LRB- -LRB-) (NP (QP (CD p) (CD <)) (CD 0.05)) (-RRB- -RRB-)))))) (. .)))
18422462	6	(S1 (S (PP (IN Among) (NP (NP (DT the) (NNS patients)) (PP (IN with) (NP (NP (CD 1) (NN year)) (PP (IN of) (NP (NN follow-up))))))) (, ,) (NP (JJ Doc_18422462_1289_1292_Chemical) (NN therapy)) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN associated) (PP (IN with) (S (VP (VBG developing) (NP (NNP Doc_18422462_1346_1350_Disease) (CC and) (NNP Doc_18422462_1355_1358_Chemical) (NN therapy)) (PP (IN with) (S (VP (VBG developing) (NP (NP (NN Doc_18422462_1383_1404_Disease)) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.05))) (-RRB- -RRB-))))))))))) (. .)))
18422462	7	(S1 (S (NP (NP (NNP Doc_18422462_1417_1423_Disease)) (CC and) (NP (NNP Doc_18422462_1428_1437_Disease))) (ADVP (RB often)) (VP (VBP occur) (PP (IN within) (NP (NP (CD 12) (NNS weeks)) (PP (IN of) (NP (JJ initiating) (JJ generic) (NNS HAART)))))) (. .)))
18422462	8	(S1 (S (NP (NP (JJ Frequent) (CC and) (JJ early) (NN monitoring)) (PP (IN for) (NP (DT these) (NNP Doc_18422462_1535_1545_Disease)))) (VP (AUX is) (VP (VBN warranted) (PP (IN in) (NP (VBG developing) (NNS countries))) (SBAR (WHADVP (WRB where)) (S (NP (JJ generic) (NN HAART)) (VP (AUX is) (ADVP (RB increasingly)) (ADJP (JJ available))))))) (. .)))
18450790	0	(S1 (NP (NP (NP (NN Doc_18450790_0_11_Chemical)) (CC and) (NP (JJ sensory) (NN Doc_18450790_24_37_Disease))) (: :) (NP (DT a) (JJ neurophysiological) (NN study)) (. .)))
18450790	1	(S1 (S (NP (JJ Recent) (NNS studies)) (VP (VBD confirmed) (NP (NP (DT a) (JJ high) (NN incidence)) (PP (IN of) (NP (NNP Doc_18450790_124_149_Disease))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (JJ different) (NNS doses)) (PP (IN of) (NP (NNP Doc_18450790_194_205_Chemical)))))))))) (. .)))
18450790	2	(S1 (S (NP (NP (DT The) (NN study) (POS 's)) (NNS aims)) (VP (AUX were) (S (VP (TO to) (VP (VP (VB measure) (NP (NP (NNS variations)) (PP (IN in) (NP (JJ sural) (NN nerve) (JJ sensory) (NN action) (NN potential)))) (PRN (-LRB- -LRB-) (VB SAP) (-RRB- -RRB-)) (VP (VB amplitude) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ refractory) (NNP Doc_18450790_335_364_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18450790_366_369_Disease)) (-RRB- -RRB-)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_18450790_384_395_Chemical)))))))))) (CC and) (VP (VB use) (NP (DT these) (NNS findings)) (S (VP (TO to) (VP (VB identify) (NP (NP (DT the) (NNP Doc_18450790_435_445_Disease) (NN potential)) (PP (IN of) (NP (NP (NNP Doc_18450790_459_470_Chemical)) (CC and) (NP (NP (DT the) (NN recovery) (NN capacity)) (PP (IN of) (NP (JJ sensory) (NNS fibres))) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NN treatment))))))))))))))))) (. .)))
18450790	3	(S1 (NP (NNS PATIENTS) (CC AND) (NNS METHODS) (: :) (NP (NP (NP (ADJP (JJ Clinical) (CC and) (JJ electrophysiological)) (NNS data)) (PP (IN in) (NP (NP (CD 12) (JJ female) (NNS patients)) (PP (IN with) (NP (NNP Doc_18450790_639_642_Disease))) (PP (IN during) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_18450790_665_676_Chemical)))))) (CC and) (NP (NP (QP (IN up) (TO to) (CD 47)) (NNS months)) (SBAR (IN after) (S (NP (NP (NN discontinuation)) (PP (IN of) (NP (NN treatment)))) (VP (AUX were) (VP (VBN analysed))))))) (. .)))
18450790	4	(S1 (S (S (NP (JJ Sural) (NN nerve)) (VP (VB SAP) (NP (JJ amplitude) (NN reduction) (NN >)))) (CC or) (S (NP (CD =40) (NN %)) (VP (AUX was) (NP (NP (DT the) (NNS criteria)) (PP (IN for) (S (VP (VBG discontinuing) (NP (NN therapy)))))))) (. .)))
18450790	5	(S1 (S (PP (IN During) (NP (NN treatment))) (, ,) (NP (CD 11) (NNS patients)) (VP (VBD showed) (NP (DT a) (NN Doc_18450790_885_923_Disease)) (PP (VBN compared) (PP (TO to) (NP (NP (JJ baseline) (NNS values)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 9)) (PP (IN with) (NP (DT a) (NN reduction) (NN >)))) (CC or) (NP (NP (CD =50) (NN %)) (CC and) (NP (QP (CD 2) (CD <50)) (NN %)))) (-RRB- -RRB-)))))) (. .)))
18450790	6	(S1 (S (NP (CD One) (NN patient)) (VP (VBD showed) (NP (NP (DT no) (NNS changes)) (PP (IN in) (NP (VB SAP) (NN amplitude))))) (. .)))
18450790	7	(S1 (S (NP (CD Five) (NNS patients)) (VP (VBD complained) (PP (IN of) (NP (NP (NNS paresthesias)) (CC and) (NP (NN leg) (NNS cramps))))) (. .)))
18450790	8	(S1 (S (PP (IN After) (NP (JJ Doc_18450790_1106_1117_Chemical) (NN treatment))) (, ,) (NP (NN sural)) (VP (VB SAP) (NP (NP (NN amplitude)) (VP (VBN recovered) (PP (IN in) (NP (CD 3) (NNS patients)))))) (. .)))
18450790	9	(S1 (S (PP (IN At) (NP (NP (NN detection)) (PP (IN of) (NP (NNP Doc_18450790_1190_1228_Disease))))) (, ,) (NP (DT the) (JJ median) (JJ Doc_18450790_1241_1252_Chemical) (JJ cumulative) (NN dose)) (VP (AUX was) (NP (CD 21.4) (NNP g))) (. .)))
18450790	10	(S1 (S (NP (DT The) (NN threshold) (NN Doc_18450790_1295_1312_Disease)) (VP (AUX is) (ADJP (ADJP (JJR lower)) (SBAR (IN than) (S (ADVP (RB previously)) (VP (VBN reported)))))) (. .)))
18450790	11	(S1 (S (S (NP (JJ Sural) (NN nerve)) (VP (VB SAP) (NP (JJ amplitude) (NN reduction)))) (VP (AUX is) (NP (NP (NP (DT a) (ADJP (JJ reliable) (CC and) (JJ sensitive)) (NN marker)) (PP (IN of) (NP (NN degeneration)))) (CC and) (NP (NP (NN recovery)) (PP (IN of) (NP (JJ sensory) (NNS fibres)))))) (. .)))
18450790	12	(S1 (S (NP (DT This) (JJ electrophysiological) (NN parameter)) (VP (VP (VBZ provides) (NP (NP (NN information)) (PP (IN about) (NP (NP (JJ subclinical) (JJ Doc_18450790_1555_1565_Disease) (NN potential)) (PP (IN of) (NP (NNP Doc_18450790_1579_1590_Chemical))))))) (CC but) (VP (AUX is) (RB not) (ADJP (JJ helpful) (PP (IN in) (S (VP (VBG predicting) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (JJ sensory) (NNS symptoms)))))))))) (. .)))
1858969	0	(S1 (NP (NP (CD Five) (NNS cases)) (PP (IN of) (NP (NNP Doc_1858969_14_26_Disease))) (PP (IN during) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_1858969_47_54_Disease)) (PP (IN with) (NP (NNP Doc_1858969_60_78_Chemical))))))) (. .)))
1858969	1	(S1 (S (NP (NP (CD Five) (NNS cases)) (PP (IN of) (NP (NNP Doc_1858969_94_106_Disease))) (VP (VBG following) (NP (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_1858969_132_150_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1858969_152_155_Chemical)) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (NP (JJ Congolese) (NNS patients)) (PP (IN with) (NP (NNP Doc_1858969_198_216_Disease))))))) (. .)))
1858969	2	(S1 (S (S (NP (CD Two) (NNS cases)) (VP (AUX had) (NP (DT a) (JJ fatal) (NN outcome)))) (CC and) (S (NP (NN one)) (VP (VBD resulted) (PP (IN in) (NP (JJ severe) (NNS sequelae))))) (. .)))
1858969	3	(S1 (S (NP (DT The) (JJ notable) (NN fact)) (VP (AUX was) (SBAR (IN that) (S (NP (DT this) (NN complication)) (VP (VBD occurred) (PP (IN in) (NP (NP (CD three) (NNS patients)) (VP (VBN hospitalized) (PP (IN before) (NP (NP (NP (NN treatment)) (VP (VBD began)) (, ,) (SBAR (WHPP (IN with) (WHNP (WP whom))) (S (NP (ADJP (RB particularly) (JJ strict)) (JJ therapeutic) (NNS precautions)) (VP (AUX were) (VP (VBN taken)))))) (, ,) (NP (NP (FW i.e.)) (, ,) (NP (NP (NP (JJ initial) (NN dose)) (NP (QP (JJR less) (IN than) (CD 10)) (NNS mg))) (PP (IN of) (NP (NNP DEC) (, ,) (ADJP (RB very) (JJ gradual)) (NN dose) (NNS increases)))) (, ,)) (CC and) (NP (JJ associated) (JJ anti-allergic) (NN treatment))))))))))) (. .)))
1858969	4	(S1 (S (NP (NP (DT This) (NN type)) (PP (IN of) (NP (JJ drug-induced) (NN complication)))) (VP (MD may) (RB not) (VP (AUX be) (ADJP (RB that) (JJ uncommon)) (PP (IN in) (NP (ADJP (RB highly) (JJ endemic)) (NNS regions))))) (. .)))
1858969	5	(S1 (S (NP (PRP It)) (VP (VBZ occurs) (UCP (ADVP (RB primarily)) (, ,) (CC but) (RB not) (ADVP (RB exclusively))) (, ,) (PP (IN in) (NP (NP (NNS subjects)) (VP (VBG presenting) (PP (IN with) (NP (DT a) (JJ high) (NN microfilarial) (NN load))))))) (. .)))
1858969	6	(S1 (S (NP (NP (DT The) (NN relationship)) (PP (IN between) (NP (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP Doc_1858969_802_814_Disease)))) (CC and) (NP (NP (DT the) (NN decrease)) (PP (IN in) (NP (NNS microfilaremia))))))) (VP (AUX is) (ADJP (JJ evident))) (. .)))
1858969	7	(S1 (S (NP (DT The) (JJ pathophysiological) (NNS mechanisms)) (VP (AUX are) (VP (VBN discussed) (PP (IN in) (NP (NP (NP (DT the) (NN light)) (PP (IN of) (NP (DT these) (NNS observations)))) (CC and) (NP (NP (DT the) (JJ few) (JJ other) (NNS comments)) (PP (IN on) (NP (NP (DT this) (NN subject)) (VP (VBN published) (PP (IN in) (NP (DT the) (NN literature))))))))))) (. .)))
18801087	0	(S1 (NP (NP (NP (NP (JJ Doc_18801087_0_10_Chemical-related) (JJ pulmonary) (NN mass)) (CC and) (NP (JJ unique) (NN Doc_18801087_45_74_Disease))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_18801087_93_115_Disease)))))) (: :) (NP (NP (JJ Diagnostic) (NN pitfall)) (CC and) (NP (JJ new) (NNS findings))) (. .)))
18801087	1	(S1 (S (S (NP (NN Doc_18801087_154_164_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ anti-arrhythmic) (NN drug)) (PP (IN for) (NP (JJ life-threatening) (NN Doc_18801087_213_224_Disease)))))) (, ,) (CC but) (S (NP (JJ various) (JJ adverse) (NNS effects)) (VP (AUX have) (VP (AUX been) (VP (VBN reported))))) (. .)))
18801087	2	(S1 (S (NP (JJ Reported) (NN herein)) (VP (AUX is) (NP (NP (DT an) (JJ autopsy) (NN case)) (PP (IN of) (NP (NNP Doc_18801087_312_334_Disease)))) (, ,) (PP (IN in) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NP (NP (DT a) (NN lung) (NN mass)) (PRN (-LRB- -LRB-) (NP (NP (CD 1.5) (NN cm)) (PP (IN in) (NP (NN diameter)))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_18801087_400_411_Disease)) (PRN (-LRB- -LRB-) (NP (CD 2.76) (NN g/day)) (-RRB- -RRB-)))) (PP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_18801087_446_456_Chemical))) (PP (IN for) (NP (DT a) (JJ long) (NN time))))))))))) (. .)))
18801087	3	(S1 (S (S (NP (DT The) (NN lung) (NN mass)) (VP (AUX was) (ADJP (RB highly) (VBN suspected) (S (VP (TO to) (VP (AUX be) (ADJP (JJ Doc_18801087_515_526_Disease)) (PP (IN on) (NP (NN CT) (CC and) (NN positron) (NN emission) (NN tomography))))))))) (, ,) (CC but) (S (NP (RB histologically) (DT the) (NN lesion)) (VP (AUX was) (VP (VBN composed) (PP (IN of) (NP (NP (JJ lymphoplasmacytic) (NNS infiltrates)) (PP (IN in) (NP (NP (NN alveolar) (NNS walls)) (CC and) (NP (NP (JJ intra-alveolar) (NN accumulation)) (PP (IN of) (NP (NP (JJ foamy) (NNS macrophages)) (VP (VBG containing) (NP (JJ characteristic) (JJ myelinoid) (NNS bodies)))))))))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (PRP it)) (VP (AUX was) (NP (DT an) (JJ Doc_18801087_784_794_Chemical-related) (NN lesion)))))))))) (. .)))
18801087	4	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (S (NP (DT the) (NN lung) (NN tissue)) (VP (AUX had) (ADVP (RB unevenly)) (VP (VBN distributed) (NP (JJ Doc_18801087_865_876_Chemical) (NN deposition))))) (, ,) (CC and) (S (NP (JJ abnormally) (JJ tortuous) (NNS capillaries)) (VP (AUX were) (VP (VBN seen) (PP (PP (IN in) (NP (DT the) (NN mass))) (CC and) (PP (IN in) (NP (NP (ADJP (RB heavily) (JJ hemosiderotic)) (NN lung) (NNS portions)) (PP (IN outside) (NP (DT the) (NN mass))))))))) (. .)))
18801087	5	(S1 (S (PP (IN In) (NP (DT the) (NNS kidneys))) (, ,) (NP (NNS glomeruli)) (VP (AUX had) (NP (NP (JJ membrane) (NNS spikes)) (, ,) (NP (NP (JJ prominent) (VBG swelling)) (PP (IN of) (NP (NP (NNS podocytes)) (CC and) (NP (JJ subepithelial) (NNS deposits))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (ADJP (ADJP (RB sometimes) (JJ large)) (CC and) (ADJP (JJ hump-like)))))))) (. .)))
18801087	6	(S1 (S (NP (NP (NP (NNP Doc_18801087_1157_1176_Disease)) (, ,) (NP (NNP Doc_18801087_1178_1193_Disease)) (, ,) (NP (NNP Doc_18801087_1195_1214_Disease)) (CC or) (NP (JJ other) (NNS diseases))) (PP (IN with) (NP (NP (DT a) (JJ known) (NN relationship)) (PP (TO to) (NP (NNP Doc_18801087_1262_1291_Disease)))))) (VP (AUX were) (RB not) (VP (VBN found))) (. .)))
18801087	7	(S1 (S (NP (DT The) (JJ present) (NN case)) (VP (VP (VBZ highlights) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP (NP (NN differential) (NN diagnosis)) (PP (IN between) (NP (NP (DT an) (JJ Doc_18801087_1391_1401_Chemical-related) (NN Doc_18801087_1410_1426_Disease)) (CC and) (NP (DT a) (NN Doc_18801087_1433_1441_Disease))))) (VP (MD can) (VP (AUX be) (ADJP (RB very) (JJ difficult)) (ADVP (RB radiologically)))))))) (, ,) (CC and) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP Doc_18801087_1498_1527_Disease)) (VP (MD might) (VP (AUX be) (NP (NP (DT another) (JJ possible) (NN complication)) (PP (IN of) (NP (JJ Doc_18801087_1570_1580_Chemical) (NN treatment)))))))))) (. .)))
18945509	0	(S1 (NP (NP (NP (NN Risk)) (PP (IN of) (NP (NNP Doc_18945509_8_31_Disease))) (VP (VBN associated) (PP (IN with) (NP (NP (JJ initial) (JJ Doc_18945509_56_69_Chemical) (NN treatment)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_18945509_97_101_Disease) (CD 2) (NN Doc_18945509_104_112_Disease))))))))) (: :) (NP (DT a) (VBN matched) (JJ case-control) (NN study)) (. .)))
18945509	1	(S1 (S (NP (DT This) (NN study)) (VP (VBD sought) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (JJ developing) (NNP Doc_18945509_201_224_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_18945509_226_229_Disease)) (-RRB- -RRB-)))) (VP (VBN associated) (PP (IN with) (NP (NP (JJ initial) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_18945509_268_272_Disease) (CD 2) (NNP Doc_18945509_275_283_Disease)) (PP (IN with) (NP (JJ different) (NNP Doc_18945509_299_313_Chemical))))))))))))) (. .)))
18945509	2	(S1 (S (PP (IN In) (NP (NNP Doc_18945509_327_331_Disease) (CD 2) (NNP Doc_18945509_334_342_Disease) (NNS patients))) (, ,) (NP (NP (NNS cases)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_18945509_373_376_Disease)))))) (VP (AUX were) (VP (VBN compared) (ADVP (RB retrospectively)) (PP (IN with) (NP (NP (NNS controls)) (SBAR (WHNP (WDT that)) (S (VP (AUX did) (RB not)))))))) (. .)))
18945509	3	(S1 (S (NP (NP (DT The) (JJ 20-year) (NN risk)) (PP (IN of) (NP (NNP Doc_18945509_455_458_Disease))) (PP (IN at) (NP (NP (NN diagnosis)) (PP (IN of) (NP (NNP Doc_18945509_475_483_Disease)))))) (, ,) (S (VP (VBG using) (NP (DT the) (JJ UKPDS) (NN risk) (NN engine)))) (, ,) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB match) (NP (NP (NNS cases)) (PP (IN with) (NP (NNS controls))))))))) (. .)))
18945509	4	(S1 (S (NP (NP (DT The) (CD 76) (NNS cases)) (PP (IN of) (NP (NNP Doc_18945509_578_581_Disease)))) (VP (AUX were) (PP (VBN compared) (PP (IN with) (NP (CD 152) (NNS controls))))) (. .)))
18945509	5	(S1 (S (NP (NP (DT The) (NN hazard)) (PP (IN of) (S (VP (VBG developing) (NP (NP (NNP Doc_18945509_640_643_Disease)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (NN CI)) (-RRB- -RRB-)))))) (VP (VBN associated) (PP (IN with) (NP (JJ initial) (NN treatment))))) (VP (VP (VBD increased) (PP (IN by) (NP (NP (NP (NP (JJ 2.4-fold)) (PRN (-LRB- -LRB-) (NP (CD 1.3-4.3)) (, ,) (NP (NNP P=0.004)) (-RRB- -RRB-))) (PP (IN with) (NP (NNP Doc_18945509_733_746_Chemical)))) (: ;) (NP (NP (NP (JJ 2-fold)) (PRN (-LRB- -LRB-) (NP (CD 0.9-4.6)) (, ,) (NP (NNP P=0.099)) (-RRB- -RRB-))) (PP (IN with) (NP (NNP Doc_18945509_779_788_Chemical)))) (: ;) (NP (NP (JJ 2.9-fold)) (PRN (-LRB- -LRB-) (NP (CD 1.6-5.1)) (, ,) (NP (NNP P=0.000)) (-RRB- -RRB-))))) (PP (IN with) (NP (DT either)))) (, ,) (CC and) (VP (AUX was) (ADJP (JJ unchanged)) (PP (IN with) (NP (NNP Doc_18945509_854_863_Chemical))))) (. .)))
18945509	6	(S1 (S (NP (DT The) (NN hazard)) (VP (VBD decreased) (NP (NP (NP (NP (JJ 0.3-fold)) (PRN (-LRB- -LRB-) (NP (CD 0.7-1.7)) (, ,) (NP (NNP P=0.385)) (-RRB- -RRB-))) (PP (IN with) (NP (NP (NNP Doc_18945509_919_930_Chemical)) (, ,) (NP (NP (NN 0.4-fold)) (PRN (-LRB- -LRB-) (NP (CD 0.7-1.3)) (, ,) (NP (NNP P=0.192)) (-RRB- -RRB-)) (PP (IN with) (NP (NNP Doc_18945509_965_975_Chemical)))) (, ,)))) (CC and) (NP (NP (JJ 0.4-fold)) (PRN (-LRB- -LRB-) (NP (CD 0.7-1.1)) (, ,) (NP (NNP P=0.09)) (-RRB- -RRB-)))) (PP (IN with) (NP (DT either)))) (. .)))
18945509	7	(S1 (S (NP (NP (JJ Initiating) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_18945509_1058_1062_Disease) (CD 2) (NNP Doc_18945509_1065_1073_Disease)) (PP (IN with) (NP (NNP Doc_18945509_1079_1092_Chemical) (CC or) (NNP Doc_18945509_1096_1105_Chemical)))))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (VBN increased) (NN risk)) (PP (IN of) (NP (NNP Doc_18945509_1143_1146_Disease))) (PP (IN in) (NP (NP (NN comparison)) (PP (TO to) (NP (NNP Doc_18945509_1164_1174_Chemical) (CC or) (NNP Doc_18945509_1178_1189_Chemical))))))))) (. .)))
18945509	8	(S1 (S (SBAR (IN If) (S (VP (VBN confirmed)))) (, ,) (S (S (NP (DT this)) (VP (MD may) (VP (AUX be) (ADJP (JJ important)) (SBAR (IN because) (S (NP (JJS most) (NNP Indian) (NNS patients)) (VP (VBP receive) (NP (DT the) (JJR cheaper) (JJR older) (NNS sulphonylureas)))))))) (, ,) (CC and) (S (NP (JJ present) (NNS guidelines)) (VP (AUX do) (RB not) (VP (VB distinguish) (PP (IN between) (NP (JJ individual) (NNS agents))))))) (. .)))
18987260	0	(S1 (NP (NP (JJ Reduced) (NN progression)) (PP (IN of) (NP (NNP Doc_18987260_23_33_Chemical) (NNP Doc_18987260_34_45_Disease))) (PP (IN in) (NP (NP (ADJP (RB spontaneously) (JJ Doc_18987260_63_75_Disease)) (NNS rats)) (VP (VBN treated) (PP (IN by) (NP (NNP Doc_18987260_92_100_Chemical)))))) (. .)))
18987260	1	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (JJ antihypertensive) (NNS effects)) (PP (IN of) (NP (NP (NP (JJ angiotensin) (NNP II) (JJ type-1) (NN receptor) (NN blocker)) (, ,) (NP (NNP Doc_18987260_226_234_Chemical)) (, ,)) (CC and) (NP (NP (PRP$ its) (NN potential)) (PP (IN in) (NP (VBG slowing) (NNP Doc_18987260_265_295_Disease))) (PP (IN in) (NP (NP (ADJP (RB spontaneously) (JJ Doc_18987260_313_325_Disease)) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NNP SHR)) (-RRB- -RRB-))))))) (PP (IN with) (NP (NNP Doc_18987260_342_352_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_18987260_354_357_Chemical)) (-RRB- -RRB-)) (NNP Doc_18987260_359_370_Disease)))))))) (. .)))
18987260	2	(S1 (S (NP (JJ Six-month-old) (NN female) (NNS SHR)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN selected) (PP (IN in) (NP (CD six) (NNS groups))))) (. .)))
18987260	3	(S1 (S (NP (NP (CD Two) (NN control) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NP (NNP SH)) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_18987260_471_477_Chemical)) (-RRB- -RRB-))) (VP (VBD received) (NP (NN vehicle))) (. .)))
18987260	4	(S1 (S (NP (NP (NP (NNS Groups) (NNP Doc_18987260_504_507_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NP (NNP Doc_18987260_512_515_Chemical+LOS)) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_18987260_527_530_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 12)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_18987260_540_543_Chemical+LOS)) (PRN (-LRB- -LRB-) (NP (CD 12)) (-RRB- -RRB-)))) (VP (VBD received) (NP (NP (NNP Doc_18987260_561_564_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2) (CD mg/kg/b.w.)) (NN i.v.)) (-RRB- -RRB-))) (ADVP (RB twice)) (PP (IN in) (NP (DT a) (JJ 3-week) (NN interval)))) (. .)))
18987260	5	(S1 (S (NP (NP (NNP Group) (NNP Doc_18987260_619_622_Chemical+LOS)) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-))) (VP (VBD received) (NP (NP (NNP Doc_18987260_639_647_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 10) (NN mg/kg/b.w./day)) (PP (IN by) (NP (NNS gavages)))) (-RRB- -RRB-))) (PP (IN for) (NP (NP (CD 6) (NNS weeks)) (CC and) (NP (NP (NN group) (NNS Doc_18987260_701_704_Chemical+LOS)) (PRN (-LRB- -LRB-) (NP (CD 12)) (-RRB- -RRB-))))) (PP (IN for) (NP (CD 12) (NNS weeks))) (PP (IN after) (NP (NP (JJ second) (NN injection)) (PP (IN of) (NP (NNP Doc_18987260_752_755_Chemical)))))) (. .)))
18987260	6	(S1 (S (NP (NNS Animals)) (VP (AUX were) (VP (VBN killed) (PP (IN after) (NP (QP (CD 6) (CC or) (CD 12)) (NNS weeks))) (, ,) (ADVP (RB respectively)))) (. .)))
18987260	7	(S1 (S (S (NP (JJ Haemodynamic) (NNS measurements)) (VP (AUX were) (VP (VBN performed) (PP (IN on) (NP (JJ anaesthetized) (NNS animals)))))) (, ,) (S (NP (NN blood) (CC and) (NN urine) (NNS samples)) (VP (AUX were) (VP (VBN taken) (PP (IN for) (NP (JJ biochemical) (NN analysis)))))) (CC and) (S (NP (DT the) (JJ left) (NN kidney)) (VP (AUX was) (VP (VBN processed) (PP (IN for) (NP (JJ morphological) (NNS studies)))))) (. .)))
18987260	8	(S1 (S (NP (JJ Short-term) (JJ Doc_18987260_1020_1028_Chemical) (NN treatment)) (, ,) (PP (IN besides) (NP (JJ antihypertensive) (NN effect))) (, ,) (VP (VP (VBD improved) (NP (JJ glomerular) (NN filtration) (NN rate))) (CC and) (VP (VBD ameliorated) (NP (NP (NN Doc_18987260_1125_1143_Disease)) (VP (VBG resulting) (PP (IN in) (NP (VBN decreased) (NN Doc_18987260_1167_1178_Disease))))))) (. .)))
18987260	9	(S1 (S (NP (NP (JJ Prolonged) (NN treatment)) (PP (IN with) (NP (NNP Doc_18987260_1205_1213_Chemical)))) (VP (VBD showed) (NP (NP (JJ further) (NN reduction)) (PP (IN of) (NP (NNP Doc_18987260_1242_1260_Disease))) (VP (VBN associated) (PP (IN with) (NP (NP (JJ reduced) (NN progression)) (PP (IN of) (NP (NP (NNP Doc_18987260_1300_1315_Disease)) (CC and) (NP (JJ interstitial) (NNP Doc_18987260_1333_1341_Disease)))))))) (, ,) (S (ADVP (RB thus)) (VP (VBG preventing) (NP (JJ heavy) (NNP Doc_18987260_1365_1376_Disease) (CC and) (NNP Doc_18987260_1381_1402_Disease))))) (. .)))
18987260	10	(S1 (S (NP (NN Doc_18987260_1404_1412_Chemical)) (VP (VP (VBD reduced) (NP (NN uraemia))) (CC and) (VP (VBD increased) (NP (JJ Doc_18987260_1443_1447_Chemical) (NN clearance)) (PP (IN in) (NP (NP (JJ advanced) (NNP Doc_18987260_1470_1473_Chemical) (NNP Doc_18987260_1474_1485_Disease)) (PP (IN in) (NP (NNP SHR))))))) (. .)))
18987260	11	(S1 (S (NP (JJ Histological) (NN examination)) (VP (VBD showed) (SBAR (IN that) (S (NP (NNP Doc_18987260_1531_1539_Chemical)) (VP (MD could) (VP (VB prevent) (NP (NP (NNP Doc_18987260_1554_1569_Disease)) (, ,) (NP (NNP Doc_18987260_1571_1596_Disease)) (CC and) (NP (NNP Doc_18987260_1601_1609_Disease))) (PP (IN in) (NP (NNP Doc_18987260_1613_1616_Chemical) (NNP Doc_18987260_1617_1628_Disease)))))))) (. .)))
18987260	12	(S1 (S (NP (NN Doc_18987260_1642_1650_Chemical)) (VP (VBZ reduces) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NP (NN progression)) (PP (IN of) (NP (JJ Doc_18987260_1686_1689_Chemical-induced) (NNP Doc_18987260_1698_1732_Disease))) (PP (TO to) (NP (NNP Doc_18987260_1736_1759_Disease))))) (PP (IN in) (NP (NNP SHR))))) (. .)))
19020118	0	(S1 (NP (NP (NP (DT The) (NNS risks)) (PP (IN of) (NP (NP (NN aprotinin)) (CC and) (NP (NN Doc_19020118_27_42_Chemical)))) (PP (IN in) (NP (JJ cardiac) (NN surgery)))) (: :) (NP (NP (DT a) (JJ one-year) (NN follow-up)) (PP (IN of) (NP (CD 1188) (JJ consecutive) (NNS patients)))) (. .)))
19020118	1	(S1 (S (NP (PRP$ Our) (NN aim)) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (NP (NP (JJ postoperative) (NNS complications)) (CC and) (NP (NN mortality))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NN aprotinin))))) (PP (VBN compared) (PP (TO to) (NP (NP (NNP Doc_19020118_241_256_Chemical)) (PP (IN in) (NP (DT an) (JJ unselected) (, ,) (JJ consecutive) (NN cohort)))))))))) (. .)))
19020118	2	(S1 (S (NP (NP (JJ Perioperative) (NNS data)) (PP (IN from) (NP (JJ consecutive) (JJ cardiac) (NN surgery) (NNS patients)))) (VP (AUX were) (ADVP (RB prospectively)) (VP (VBN collected) (PP (IN between) (NP (NP (NNP September) (CD 2005)) (CC and) (NP (NNP June) (CD 2006)))) (PP (IN in) (NP (NP (DT a) (JJ university-affiliated) (NN clinic)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 1188)) (-RRB- -RRB-)))))) (. .)))
19020118	3	(S1 (S (S (PP (IN During) (NP (DT the) (JJ first) (CD 5) (NN mo))) (, ,) (NP (CD 596) (NNS patients)) (VP (VBD received) (NP (NP (NN aprotinin)) (PRN (-LRB- -LRB-) (NP (NNP Group) (NNP A)) (-RRB- -RRB-))))) (: ;) (S (PP (IN in) (NP (DT the) (JJ next) (CD 5) (NN mo))) (, ,) (NP (CD 592) (NNS patients)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_19020118_592_607_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Group) (NNP T)) (-RRB- -RRB-))))))) (. .)))
19020118	4	(S1 (S (PP (IN Except) (PP (IN for) (NP (JJ antifibrinolytic) (NN therapy)))) (, ,) (NP (DT the) (JJ anesthetic) (CC and) (JJ surgical) (NNS protocols)) (VP (VBD remained) (ADJP (JJ unchanged))) (. .)))
19020118	5	(S1 (S (NP (DT The) (JJ pre-) (CC and) (JJ intraoperative) (NNS variables)) (VP (AUX were) (ADJP (JJ comparable)) (PP (IN between) (NP (DT the) (NN treatment) (NNS groups)))) (. .)))
19020118	6	(S1 (S (ADVP (RB Postoperatively)) (, ,) (NP (NP (DT a) (ADJP (RB significantly) (JJR higher)) (NN incidence)) (PP (IN of) (NP (NNP Doc_19020118_860_868_Disease)))) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NNP Group) (NNP T))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 4.6) (NN %)) (NNP vs) (CD 1.2) (NN %)) (, ,) (NP (NNP P) (NNP <) (CD 0.001))) (-RRB- -RRB-)))) (. .)))
19020118	7	(S1 (S (NP (DT This) (NN difference)) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ significant)) (PP (IN in) (NP (NP (NP (NP (DT the) (JJ primary) (NN valve) (NN surgery)) (CC and) (NP (DT the) (JJ high) (NN risk) (NN surgery))) (NNS subgroups)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD 7.9) (NN %)) (NNP vs) (CD 1.2) (NN %)) (, ,) (NP (NNP P) (SYM =) (CD 0.003))) (: ;) (NP (NP (CD 7.3) (NN %)) (NNP vs) (CD 2.4) (NN %))) (, ,) (NP (NP (NNS P)) (VP (SYM =) (NP (NP (CD 0.035)) (, ,) (ADVP (RB respectively))))) (-RRB- -RRB-))))) (. .)))
19020118	8	(S1 (S (NP (NP (NP (JJ Persistent) (NNP Doc_19020118_1096_1115_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 7.9) (NN %)) (NNP vs) (CD 2.3) (NN %)) (, ,) (NP (NNP P) (SYM =) (CD 0.020))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_19020118_1146_1159_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 9.7) (NN %)) (NNP vs) (CD 1.7) (NN %)) (, ,) (NP (NNP P) (SYM =) (CD 0.002))) (-RRB- -RRB-)))) (VP (AUX were) (ADVP (RB also)) (ADJP (RBR more) (JJ common) (PP (IN in) (NP (NNP Group) (NNP T)))) (, ,) (PP (IN in) (NP (DT the) (JJ primary) (NN valve) (NN surgery) (NN subgroup)))) (. .)))
19020118	9	(S1 (S (PP (IN On) (NP (DT the) (NN contrary))) (, ,) (PP (IN among) (NP (JJ primary) (JJ coronary) (NN artery) (NN bypass) (NN surgery) (NNS patients))) (, ,) (NP (EX there)) (VP (AUX were) (ADJP (RBR more) (JJ acute)) (NP (NP (NNP Doc_19020118_1353_1375_Disease)) (CC and) (NP (NNP Doc_19020118_1380_1397_Disease))) (PP (IN in) (NP (NP (NNP Group) (NNP A)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NP (NP (CD 5.8) (NN %)) (NNP vs) (CD 2.0) (NN %)) (, ,) (NP (NNP P) (SYM =) (CD 0.027))) (: ;) (NP (CD 22.5) (NN %))) (NNP vs)) (ADJP (CD 15.2) (NN %))) (, ,) (NP (NP (NNP P) (SYM =)) (NP (NP (CD 0.036)) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))))) (. .)))
19020118	10	(S1 (S (NP (DT The) (JJ 1-yr) (NN mortality)) (VP (AUX was) (ADJP (RB significantly) (JJR higher)) (PP (IN after) (S (VP (VBG aprotinin) (NP (NN treatment)) (PP (IN in) (NP (NP (DT the) (JJ high) (NN risk) (NN surgery) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 17.7) (NN %)) (NNP vs) (CD 9.8) (NN %)) (, ,) (NP (NNP P) (SYM =) (CD 0.034))) (-RRB- -RRB-)))))))) (. .)))
19020118	11	(S1 (S (NP (DT Both) (JJ antifibrinolytic) (NNS drugs)) (VP (VBP bear) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ adverse) (NN outcome))) (PP (VBG depending) (PP (IN on) (NP (NP (DT the) (NN type)) (PP (IN of) (NP (JJ cardiac) (NN surgery)))))))) (. .)))
19020118	12	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN aprotinin)))) (VP (MD should) (VP (AUX be) (VP (VBN avoided) (PP (IN in) (NP (NP (JJ coronary) (NN artery) (NN bypass) (NN graft)) (CC and) (NP (JJ high) (NN risk) (NNS patients)))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_19020118_1849_1864_Chemical)))) (VP (AUX is) (RB not) (VP (VBN recommended) (PP (IN in) (NP (NN valve) (NN surgery)))))))))) (. .)))
1905439	0	(S1 (S (NP (NP (NN Delirium)) (PP (IN in) (NP (DT an) (JJ elderly) (NN woman)))) (ADVP (RB possibly)) (VP (VBN associated) (PP (IN with) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_1905439_72_83_Chemical)))))) (. .)))
1905439	1	(S1 (S (NP (NN Doc_1905439_85_96_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (JJ adverse) (NNS reactions)) (, ,) (PP (VBG including) (NP (NP (NNP Doc_1905439_151_176_Disease)) (, ,) (NP (JJ gynecologic) (NNS problems)) (, ,) (CC and) (NP (NNP Doc_1905439_204_212_Disease))))))))) (. .)))
1905439	2	(S1 (S (NP (NP (NNS Changes)) (PP (IN in) (NP (JJ mental) (NN status)))) (, ,) (ADVP (RB however)) (, ,) (VP (AUX have) (RB not) (VP (AUX been) (VP (VBN reported)))) (. .)))
1905439	3	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (NN case)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (DT an) (JJ 89-year-old) (NN woman)) (PP (IN in) (NP (DT a) (JJ long-term) (NN care) (NN facility)))) (VP (VBD became) (NP (NNP Doc_1905439_357_365_Disease)) (PP (IN after) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (JJ Doc_1905439_390_401_Chemical) (NN therapy)))))))))) (. .)))
1905439	4	(S1 (S (NP (NP (NP (DT The) (NN patient) (POS 's)) (NN change)) (PP (IN in) (NP (JJ mental) (NN status)))) (VP (AUX was) (ADVP (RB first)) (VP (VBN reported) (NP (CD nine) (NNS days)) (PP (IN after) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NN therapy))))))) (. .)))
1905439	5	(S1 (S (S (NP (PRP$ Her) (NNP Doc_1905439_515_523_Disease)) (VP (ADVP (RB significantly)) (VBN improved) (SBAR (IN after) (S (NP (NNP Doc_1905439_553_564_Chemical)) (VP (AUX was) (VP (VBN discontinued))))))) (CC and) (S (NP (PRP$ her) (JJ mental) (NN status)) (VP (VBD returned) (PP (TO to) (NP (JJ normal))) (PP (IN within) (NP (DT a) (NN week))))) (. .)))
1905439	6	(S1 (S (SBAR (IN Because) (S (NP (NP (DT no) (JJ other) (NNS factors)) (VP (VBN related) (PP (TO to) (NP (DT this) (NN patient))))) (VP (VBD changed) (ADVP (RB significantly))))) (, ,) (NP (NP (DT the) (NN Doc_1905439_714_722_Disease)) (VP (VBN experienced) (PP (IN by) (NP (DT this) (NN patient))))) (ADVP (RB possibly)) (VP (VBD resulted) (PP (IN from) (NP (JJ Doc_1905439_774_785_Chemical) (NN therapy)))) (. .)))
19108278	0	(S1 (NP (NP (NP (NP (DT The) (JJ biological) (NNS properties)) (PP (IN of) (NP (NP (DT the) (JJ optical) (NNS isomers)) (PP (IN of) (NP (NNP Doc_19108278_52_63_Chemical)))))) (CC and) (NP (NP (PRP$ their) (NNS effects)) (PP (IN on) (NP (NNP Doc_19108278_85_104_Disease.) (CD 1))))) (. .)))
19108278	1	(S1 (S (NP (NP (DT The) (JJ optical) (NNS isomers)) (PP (IN of) (NP (NNP Doc_19108278_132_143_Chemical)))) (VP (AUX have) (VP (AUX been) (VP (VBN compared) (PP (IN for) (NP (NP (PRP$ their) (NN beta-blocking)) (CC and) (NP (NN antiarrhythmic) (CD activities.2))))))) (. .)))
19108278	2	(S1 (S (PP (IN In) (S (VP (VBG blocking) (NP (NP (DT the) (JJ positive) (JJ inotropic) (CC and) (JJ chronotropic) (NNS responses)) (PP (TO to) (NP (NNP Doc_19108278_285_297_Chemical))))))) (, ,) (NP (NNP Doc_19108278_299_314_Chemical)) (VP (AUX had) (NP (QP (JJR less) (IN than) (CD one)) (JJ hundredth)) (NP (NP (DT the) (NN potency)) (PP (IN of) (NP (NNP Doc_19108278_358_373_Chemical))))) (. .)))
19108278	3	(S1 (S (PP (IN At) (NP (NP (NN dose) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_19108278_393_408_Chemical)) (SBAR (WHNP (WDT which)) (S (VP (VBD attenuated) (NP (NP (DT the) (NNS responses)) (PP (TO to) (NP (NNP Doc_19108278_443_455_Chemical))))))))))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (NN prolongation)) (PP (IN of) (NP (NP (DT the) (NNP PR) (NN interval)) (PP (IN of) (NP (DT the) (CD electrocardiogram.3))))))) (. .)))
19108278	4	(S1 (S (NP (NP (DT The) (JJ metabolic) (NNS responses)) (PP (TO to) (NP (NNP Doc_19108278_568_580_Chemical))) (PP (IN in) (NP (NP (NNS dogs)) (PRN (-LRB- -LRB-) (NP (NP (DT an) (NN increase)) (PP (IN in) (S (VP (VBG circulating) (NP (NNP Doc_19108278_617_624_Chemical) (, ,) (NNP Doc_19108278_626_633_Chemical) (CC and) (NNP Doc_19108278_638_654_Chemical)))))) (-RRB- -RRB-))))) (VP (AUX were) (DT all) (VP (VBN blocked) (PP (IN by) (NP (NP (NNP Doc_19108278_676_691_Chemical.) (NNP Doc_19108278_693_708_Chemical)) (SBAR (S (VP (VP (AUX had) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (JJ Doc_19108278_726_736_Chemical) (NN mobilization))))) (CC but) (VP (ADVP (RB significantly)) (VBD reduced) (NP (DT the) (NNS increments)) (PP (IN in) (NP (DT both) (NNP Doc_19108278_799_806_Chemical) (CC and) (NNP Doc_19108278_811_818_Chemical.4))))))))))) (. .)))
19108278	5	(S1 (S (NP (NP (DT Both) (NNS isomers)) (PP (IN of) (NP (NNP Doc_19108278_838_849_Chemical)))) (VP (VBN possessed) (NP (JJ similar) (NN depressant) (NN potency)) (PP (IN on) (NP (NP (VBN isolated) (NN Doc_19108278_899_912_Disease)) (VP (VBN taken) (PP (IN from) (NP (CD guinea-pigs.5))))))) (. .)))
19108278	6	(S1 (S (NP (NP (DT The) (NNS isomers)) (PP (IN of) (NP (NNP Doc_19108278_954_965_Chemical)))) (VP (VBD exhibited) (NP (JJ similar) (JJ local) (NN anaesthetic) (NNS potencies)) (PP (IN on) (NP (DT an) (VBN isolated) (NN frog) (NN nerve) (NN preparation))) (PP (IN at) (NP (NP (DT a) (NN level)) (ADVP (NP (QP (RB approximately) (CD three)) (NNS times)) (IN that)) (PP (IN of) (NP (NNP Doc_19108278_1095_1103_Chemical)))))) (. .)))
19108278	7	(S1 (S (NP (DT The) (JJ racemic) (NN compound)) (VP (AUX was) (ADJP (ADVP (RB significantly) (RBR less)) (JJ potent) (PP (IN than) (NP (DT either) (CD isomer.6))))) (. .)))
19108278	8	(S1 (S (S (NP (NP (DT Both) (NNS isomers)) (PP (IN of) (NP (NNP Doc_19108278_1194_1205_Chemical)))) (VP (AUX were) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG preventing) (NP (JJ Doc_19108278_1233_1243_Chemical-induced) (NNP Doc_19108278_1252_1271_Disease)) (PP (IN in) (NP (NP (NNS cats)) (VP (VBN anaesthetized) (PP (IN with) (NP (NNP Doc_19108278_1299_1308_Chemical)))))))))))) (, ,) (CC but) (S (NP (NP (DT the) (JJ mean) (NN dose)) (PP (IN of) (NP (NNP Doc_19108278_1331_1346_Chemical)))) (VP (AUX was) (NP (CD 0.09+/-0.02) (NN mg/kg)) (SBAR (IN whereas) (S (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_19108278_1385_1400_Chemical)))) (VP (AUX was) (NP (CD 4.2+/-1.2) (NN mg/kg))))))) (. .)))
19108278	9	(S1 (S (PP (IN At) (NP (NP (DT the) (JJ effective) (NN dose) (NN level)) (PP (IN of) (NP (NNP Doc_19108278_1453_1468_Chemical))))) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (NN prolongation)) (PP (IN of) (NP (NP (DT the) (NNP PR) (NN interval)) (PP (IN of) (NP (DT the) (NN electrocardiogram))))))) (. .)))
19108278	10	(S1 (S (NP (NP (NN Blockade)) (PP (IN of) (NP (NNP Doc_19108278_1563_1574_Disease))) (PP (IN with) (NP (DT both) (NNS isomers)))) (VP (AUX was) (ADJP (JJ surmountable)) (PP (IN by) (S (VP (VBG increasing) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (CD Doc_19108278_1636_1646_Chemical.7)))))))) (. .)))
19108278	11	(S1 (S (NP (NP (DT Both) (NNS isomers)) (PP (IN of) (NP (NNP Doc_19108278_1666_1677_Chemical)))) (VP (AUX were) (ADVP (RB also)) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG reversing) (NP (NP (NN Doc_19108278_1709_1732_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_19108278_1743_1750_Chemical))) (PP (IN in) (NP (NP (JJ anaesthetized) (NNS cats)) (CC and) (NP (NNS dogs))))))))))) (. .)))
19108278	12	(S1 (S (NP (NP (DT The) (NN dose)) (PP (IN of) (NP (NNP Doc_19108278_1795_1810_Chemical)))) (VP (AUX was) (ADJP (ADJP (ADJP (RB significantly) (JJR smaller)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_19108278_1850_1865_Chemical))))) (PP (IN in) (NP (DT both) (NNS species)))) (CC but) (ADJP (ADJP (RB much) (JJR higher)) (PP (IN than) (NP (NP (DT that)) (VP (VBN required) (S (VP (TO to) (VP (VB produce) (NP (NP (NN evidence)) (PP (IN of) (NP (CD beta-blockade.8))))))))))))) (. .)))
19108278	13	(S1 (S (NP (NP (DT The) (NNS implications)) (PP (IN of) (NP (DT these) (NNS results)))) (VP (AUX are) (VP (VBN discussed))) (. .)))
19139825	0	(S1 (NP (NP (NP (NN Doc_19139825_0_9_Chemical)) (PP (IN in) (NP (NN combination))) (PP (IN with) (NP (NN radiotherapy))) (PP (IN in) (NP (JJ unresectable) (NNP Doc_19139825_59_71_Disease)))) (: :) (NP (DT a) (NN phase) (CD 2) (NN study)) (. .)))
19139825	1	(S1 (S (S (VP (VBG Improving) (NP (JJ Doc_19139825_100_112_Disease) (NN multiforme) (PRN (-LRB- -LRB-) (NP (NNP GBM)) (-RRB- -RRB-)) (NN treatment)) (PP (IN with) (NP (NN radio-chemotherapy))))) (VP (VBZ remains) (NP (DT a) (NN challenge))) (. .)))
19139825	2	(S1 (S (NP (NN Doc_19139825_185_194_Chemical)) (VP (AUX is) (NP (DT an) (JJ attractive) (NN option)) (SBAR (IN as) (S (NP (PRP it)) (VP (NNS exhibits) (NP (NP (NP (NN growth) (NN inhibition)) (PP (IN of) (NP (JJ human) (NN Doc_19139825_261_267_Disease)))) (CONJP (RB as) (RB well) (IN as)) (NP (NN brain) (NN penetration))))))) (. .)))
19139825	3	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBD assessed) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (JJ radiotherapy) (PRN (-LRB- -LRB-) (NP (CD 60) (NNP Gy/30) (CD fractions/40) (NNS days)) (-RRB- -RRB-)) (CC and) (NNP Doc_19139825_390_399_Chemical)))) (PRN (-LRB- -LRB-) (S (NP (NP (CD 0.9) (NNS mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (VP (VBP /day) (PP (IN on) (NP (NP (NNS days)) (ADJP (JJ 1-5) (PP (IN on) (NP (NP (NNS weeks)) (CD 1) (, ,) (CD 3) (CC and) (CD 5)))))))) (-RRB- -RRB-)) (PP (IN in) (NP (NP (CD 50) (NNS adults)) (PP (IN with) (NP (ADJP (RB histologically) (VBN proven) (CC and) (JJ untreated)) (NNS GBM)))))) (. .)))
19139825	4	(S1 (S (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (JJ non-hematological) (NNP Doc_19139825_544_554_Disease)))) (VP (AUX was) (ADJP (JJ low)))) (CC and) (S (NP (NN grade) (NN 3-4) (NN hematological) (NNP Doc_19139825_591_601_Disease)) (VP (AUX were) (VP (VBN reported) (PP (IN in) (NP (NP (CD 20) (NNS patients)) (PRN (-LRB- -LRB-) (ADVP (RB mainly)) (NP (NP (NNP Doc_19139825_639_650_Disease)) (CC and) (NP (NNP Doc_19139825_655_666_Disease))) (-RRB- -RRB-))))))) (. .)))
19139825	5	(S1 (S (NP (NP (JJ Partial) (NN response)) (CC and) (NP (NN stabilization) (NNS rates))) (VP (AUX were) (NP (NP (CD 2) (NN %)) (CC and) (NP (CD 32) (NN %))) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN with) (NP (NP (DT an) (JJ overall) (NN time)) (PP (TO to) (NP (NP (NN progression)) (PP (IN of) (NP (CD 12) (NNS weeks)))))))) (. .)))
19139825	6	(S1 (S (NP (JJ One-year) (JJ overall) (NN survival) (PRN (-LRB- -LRB-) (NP (NN OS)) (-RRB- -RRB-)) (NN rate)) (VP (AUX was) (NP (CD 42) (NN %)) (, ,) (PP (IN with) (NP (NP (DT a) (JJ median) (NN OS)) (PP (IN of) (NP (CD 40) (NNS weeks)))))) (. .)))
19139825	7	(S1 (S (NP (NP (NN Doc_19139825_865_874_Chemical)) (PP (IN in) (NP (NN combination))) (PP (IN with) (NP (NN radiotherapy)))) (VP (AUX was) (ADVP (RB well)) (VP (VBN tolerated))) (. .)))
19139825	8	(S1 (S (ADVP (RB However)) (, ,) (SBAR (IN while) (S (NP (NP (NN response)) (CC and) (NP (NN stabilization))) (VP (VBD concerned) (NP (NP (NN one-third)) (PP (IN of) (NP (DT the) (NNS patients))))))) (, ,) (NP (DT the) (NN study)) (VP (AUX did) (RB not) (VP (VB show) (NP (NP (VBN increased) (NNS benefits)) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (NN survival)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ unresectable) (NNS GBM)))))))))))) (. .)))
19154241	0	(S1 (NP (NP (NP (JJ Long-term) (JJ Doc_19154241_10_17_Chemical) (NN therapy)) (VP (VBG leading) (PP (TO to) (NP (NNP Doc_19154241_37_56_Disease))))) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
19154241	1	(S1 (S (NP (DT This) (NN paper)) (VP (VBZ reviews) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ chronic) (JJ Doc_19154241_123_130_Chemical) (NN therapy))) (PP (IN on) (NP (NP (JJ serum) (JJ Doc_19154241_148_155_Chemical) (NN level) (CC and) (NN parathyroid) (NNS glands)) (, ,) (NP (PRP$ its) (NNS pathogenesis)) (, ,) (CC and) (NP (NN treatment) (NNS options)))))) (. .)))
19154241	2	(S1 (S (NP (PRP We)) (VP (VBD examined) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ Doc_19154241_253_260_Chemical-treated) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN recurrent) (NP (NNP Doc_19154241_295_308_Disease)) (S (VP (TO to) (ADVP (RB better)) (VP (VB understand) (NP (DT the) (NN disease) (NN process))))))))))))) (. .)))
19154241	3	(S1 (S (NP (NN Doc_19154241_363_390_Disease)) (VP (AUX is) (NP (NP (DT a) (ADJP (ADJP (JJ rare)) (CC but) (ADJP (RB potentially) (JJ life-threatening))) (NN side) (NN effect)) (PP (IN of) (NP (JJ long-term) (JJ Doc_19154241_459_466_Chemical) (NN therapy))))) (. .)))
19154241	4	(S1 (S (NP (NP (JJ Careful) (NN patient) (NN selection)) (CC and) (NP (JJ long-term) (NN follow-up))) (VP (MD can) (VP (VB reduce) (NP (NN morbidity)))) (. .)))
19154241	5	(S1 (NP (NP (JJ PRACTICAL) (NNS IMPLICATIONS)) (: :) (NP (NP (QP (RB As) (JJ much) (IN as) (CD 15)) (NN %)) (PP (IN of) (NP (NP (JJ Doc_19154241_590_597_Chemical-treated) (NNS patients)) (VP (VBN become) (NP (NN hypercalcemic)))))) (. .)))
19154241	6	(S1 (S (PP (IN By) (S (ADVP (RB routinely)) (VP (VBG monitoring) (NP (JJ serum) (JJ Doc_19154241_667_674_Chemical) (NNS levels))))) (, ,) (NP (NN healthcare) (NNS providers)) (VP (MD can) (VP (VB improve) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (NP (NN life)) (PP (IN of) (NP (DT this) (JJ patient) (NN group)))))))) (. .)))
19178808	0	(S1 (NP (NP (NN Comparison)) (PP (IN of) (NP (JJ laryngeal) (NN mask))) (PP (IN with) (NP (NP (JJ endotracheal) (NN tube)) (PP (IN for) (NP (NN anesthesia))) (PP (IN in) (NP (JJ endoscopic) (JJ sinus) (NN surgery))))) (. .)))
19178808	1	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB compare) (NP (JJ surgical) (NNS conditions)) (, ,) (PP (VBG including) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NP (NNP Doc_19178808_194_217_Disease)) (PP (IN as) (S (PP (RB well) (IN as) (NP (JJ intraoperative) (NN blood) (NN pressure))) (, ,) (PP (IN during) (NP (JJ functional) (JJ endoscopic) (NN sinus) (NN surgery))) (-LRB- -LRB-) (NP (NNP FESS)) (-RRB- -RRB-) (VP (VBG using) (NP (NP (NP (JJ flexible) (VBN reinforced) (JJ laryngeal) (NN mask) (NN airway)) (PRN (-LRB- -LRB-) (NP (NNP FRLMA)) (-RRB- -RRB-))) (CC versus) (NP (NP (JJ endotracheal) (NN tube)) (PRN (-LRB- -LRB-) (NP (NNP ETT)) (-RRB- -RRB-)))) (PP (IN in) (S (VP (VBG maintaining) (NP (NP (JJ controlled) (NNP Doc_19178808_423_434_Disease) (NNS anesthesia)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ Doc_19178808_457_465_Chemical-Doc_19178808_466_478_Chemical) (JJ total) (NN i.v.) (NNS anesthesia)) (PRN (-LRB- -LRB-) (NP (NNP TIVA)) (-RRB- -RRB-)))))))))))))))))))) (. .)))
19178808	2	(S1 (NP (NP (NP (CD Sixty) (JJ normotensive) (NNP American) (NNP Society)) (PP (IN of) (NP (NNP Anesthesiologists) (NNP I-II) (NN adult) (NNS patients))) (VP (VBG undergoing) (NP (NN FESS) (SBAR (IN under) (S (NP (NP (JJ controlled) (JJ Doc_19178808_628_639_Disease) (NNS anesthesia)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_19178808_661_669_Chemical-Doc_19178808_670_682_Chemical-TIVA))))) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (IN into) (NP (CD two) (NNS groups)))))))))) (: :) (NP (NP (NN group) (NN I)) (, ,) (NP (NNP FRLMA))) (: ;) (NP (NP (NN group) (NNP II)) (, ,) (NP (NNP ETT))) (. .)))
19178808	3	(S1 (S (S (NP (NN Doc_19178808_759_769_Disease)) (VP (AUX was) (VP (VBN measured)))) (CC and) (S (NP (NP (DT the) (NN visibility)) (PP (IN of) (NP (DT the) (JJ operative) (NN field)))) (VP (AUX was) (VP (VBN evaluated) (PP (VBG according) (PP (TO to) (NP (DT a) (JJ six-point) (NN scale))))))) (. .)))
19178808	4	(S1 (S (NP (JJ Controlled) (NN Doc_19178808_891_902_Disease)) (VP (AUX was) (VP (VBN achieved) (PP (IN within) (NP (NP (DT a) (JJR shorter) (NN period)) (VP (VBG using) (NP (NP (JJ laryngeal) (NN mask)) (VP (VBG using) (NP (NP (NP (JJR lower) (NNS rates)) (PP (IN of) (NP (JJ Doc_19178808_982_994_Chemical) (NN infusion)))) (CC and) (NP (NP (JJR lower) (JJ total) (NN dose)) (PP (IN of) (NP (NNP Doc_19178808_1028_1040_Chemical)))))))))))) (. .)))
19178808	5	(S1 (S (PP (IN In) (NP (NN summary))) (, ,) (NP (PRP$ our) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN airway) (NN management)) (VP (VBG using) (NP (NN FRLMA)) (PP (IN during) (NP (VBN controlled) (NNP Doc_19178808_1140_1151_Disease) (NN anesthesia))))) (VP (VP (VBD provided) (NP (JJR better) (JJ surgical) (NNS conditions)) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (NN quality)) (PP (IN of) (NP (NP (JJ operative) (NN field)) (CC and) (NP (NNP Doc_19178808_1242_1252_Disease))))))))) (CC and) (VP (VBD allowed) (PP (IN for) (NP (NP (JJ convenient) (VBN induced) (NN Doc_19178808_1288_1299_Disease)) (PP (IN with) (NP (NP (JJ low) (NNS doses)) (PP (IN of) (NP (NNP Doc_19178808_1318_1330_Chemical))))))) (PP (IN during) (NP (NNP TIVA))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (NN FESS)))))))))) (. .)))
19184102	0	(S1 (S (VP (VB Doc_19184102_0_32_Disease) (PP (IN during) (NP (JJ Doc_19184102_40_49_Chemical) (NN therapy)))) (. .)))
19184102	1	(S1 (S (S (NP (NP (NN Doc_19184102_59_72_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19184102_74_77_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (ADJP (JJ effective) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (JJ many) (NNS types)) (PP (IN of) (NP (NNP Doc_19184102_127_135_Disease)))))))))) (, ,) (CC but) (S (NP (PRP$ its) (NN use)) (VP (MD can) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN body) (NN weight))))))))) (. .)))
19184102	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (NNP Doc_19184102_220_252_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19184102_254_259_Disease)) (-RRB- -RRB-)))) (VP (VBG arising) (PP (IN in) (NP (NP (DT a) (NN child)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NN Doc_19184102_294_301_Disease)) (PP (IN during) (NP (JJ Doc_19184102_309_312_Chemical) (NN treatment))))))))))) (. .)))
19184102	3	(S1 (S (NP (NN Laboratory) (NNS data)) (VP (VBD revealed) (NP (NP (NN Doc_19184102_349_365_Disease)) (PP (IN with) (NP (NN insulin) (NN resistance))))) (. .)))
19184102	4	(S1 (S (S (PP (IN After) (NP (NP (DT the) (NN withdrawal)) (PP (IN of) (NP (JJ Doc_19184102_415_418_Chemical) (NN therapy))))) (, ,) (NP (PRP$ our) (NN patient)) (VP (VBD showed) (NP (NP (DT a) (JJ significant) (NN Doc_19184102_461_472_Disease)) (, ,) (NP (NP (DT a) (NN decrease)) (PP (IN of) (NP (NN body) (NN mass) (NN index)))) (, ,) (CC and) (NP (NP (NN normalization)) (PP (IN of) (NP (NN metabolic) (CC and) (NN endocrine) (NNS parameters))))))) (: ;) (S (ADVP (RB moreover)) (, ,) (NP (NN ultrasound) (NNS measurements)) (VP (VBD showed) (NP (DT a) (JJ complete) (NN normalization)))) (. .)))
19184102	5	(S1 (S (S (NP (DT The) (JJ present) (NN case)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (NNP Doc_19184102_660_667_Disease)) (, ,) (NP (NNP Doc_19184102_669_685_Disease)) (, ,) (NP (NN insulin) (NN resistance)) (, ,) (CC and) (NP (NP (JJ long-term) (NN treatment)) (PP (IN with) (NP (NNP Doc_19184102_736_739_Chemical))))) (VP (MD may) (VP (AUX be) (DT all) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_19184102_786_791_Disease)))))))))))) (: ;) (S (NP (DT this) (NN side) (NN effect)) (VP (AUX is) (ADJP (JJ reversible)) (PP (IN after) (NP (JJ Doc_19184102_830_833_Chemical) (NN withdrawal))))) (. .)))
19263707	0	(S1 (S (NP (NN Doc_19263707_0_11_Chemical)) (VP (VBN induced) (NP (NNP ANCA) (JJ positive) (NN Doc_19263707_34_44_Disease))) (. .)))
19263707	1	(S1 (S (NP (NP (JJ Anti-thyroid) (NNS drugs)) (, ,) (PP (IN like) (NP (NP (NP (NNP Doc_19263707_71_82_Chemical)) (CC and) (NP (NNP Doc_19263707_87_103_Chemical))) (PRN (-LRB- -LRB-) (NP (NNP Doc_19263707_105_108_Chemical)) (-RRB- -RRB-))))) (VP (AUX are) (ADVP (RB commonly)) (VP (VBN prescribed) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_19263707_155_170_Disease))))))) (. .)))
19263707	2	(S1 (S (NP (NN One)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (NP (DT the) (JJ side) (NNS effects)) (PP (IN of) (NP (JJ antithyroid) (NNS medications)))))))) (. .)))
19263707	3	(S1 (S (NP (NP (JJ Antineutrophil) (JJ cytoplasmic) (NN antibody)) (PRN (-LRB- -LRB-) (NP (NNP ANCA)) (-RRB- -RRB-))) (VP (VBD --associated) (SBAR (S (NP (NNP Doc_19263707_295_305_Disease)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB potentially) (JJ life-threatening)) (JJ adverse) (NN effect)) (PP (IN of) (NP (NNS antithyroidmedications)))))))) (. .)))
19263707	4	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_19263707_407_422_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (ADJP (NNP ANCA) (JJ positive)) (JJ Doc_19263707_451_462_Chemical) (VBN induced) (NN Doc_19263707_471_481_Disease))))))))) (. .)))
19263707	5	(S1 (S (NP (DT The) (NN episode)) (VP (AUX was) (VP (VBN characterized) (PP (IN by) (NP (NP (DT a) (JJ vasculitic) (NN Doc_19263707_529_538_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ large) (JJ joint) (NN Doc_19263707_567_576_Disease)) (, ,) (NP (NNP Doc_19263707_578_585_Disease) (CC and) (NNP Doc_19263707_590_601_Disease)) (CC but) (NP (DT no) (NNP Doc_19263707_609_639_Disease))))))))) (. .)))
19263707	6	(S1 (S (NP (PRP He)) (VP (VP (AUX was) (VP (VBN referred) (PP (TO to) (NP (PRP us))) (PP (IN for) (NP (JJ neurological) (NN evaluation))) (SBAR (IN because) (S (NP (PRP he)) (VP (AUX had) (NP (NN difficulty)) (PP (IN in) (S (VP (VBG getting) (PRT (RP up)) (PP (IN from) (S (VP (VBG squatting) (NP (NN position))))))))))))) (CC and) (VP (AUX was) (VP (VBN suspected) (S (VP (TO to) (VP (AUX have) (NP (NN Doc_19263707_781_789_Disease)))))))) (. .)))
19263707	7	(S1 (S (NP (NP (NNP Doc_19263707_791_802_Chemical)) (CC and) (NP (NNP Doc_19263707_807_818_Chemical))) (VP (AUX have) (NP (NP (DT a) (JJR lower) (NN incidence)) (PP (IN of) (NP (JJ reported) (NNP ANCA) (JJ positive) (NN side) (NNS effects))) (PP (IN than) (NP (NN PUT))))) (. .)))
19263707	8	(S1 (S (PP (TO To) (NP (NP (DT the) (JJS best)) (PP (IN of) (NP (PRP$ our) (NN knowledge))))) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN ANCA) (JJ positive) (JJ Doc_19263707_952_963_Chemical) (VBN induced) (NN Doc_19263707_972_982_Disease) (NN case)) (VP (VBN reported) (PP (IN from) (NP (NNP India)))))) (. .)))
19293073	0	(S1 (NP (NP (NP (NN Doc_19293073_0_7_Chemical)) (PP (IN for) (NP (NP (DT the) (JJ primary) (NN prevention)) (PP (IN of) (NP (JJ cardiovascular) (NNS events)))))) (: :) (NP (NP (DT an) (NN update)) (PP (IN of) (NP (DT the) (NN evidence))) (PP (IN for) (NP (DT the) (NNP U.S.) (NNP Preventive) (NNPS Services) (NNP Task) (NNP Force)))) (. .)))
19293073	1	(S1 (S (NP (NP (NNP Doc_19293073_144_166_Disease)) (CC and) (NP (NNP Doc_19293073_171_194_Disease))) (VP (AUX are) (NP (NP (JJ leading) (NNS causes)) (PP (IN of) (NP (NNP Doc_19293073_217_222_Disease))) (PP (IN in) (NP (DT the) (NNP United) (NNPS States))))) (. .)))
19293073	2	(S1 (S (PP (IN In) (NP (CD 2002))) (, ,) (NP (NP (DT the) (NNP U.S.) (NNP Preventive) (NNPS Services) (NNP Task) (NNP Force)) (PRN (-LRB- -LRB-) (NP (NNP USPSTF)) (-RRB- -RRB-))) (ADVP (RB strongly)) (VP (VBD recommended) (SBAR (IN that) (S (NP (NNS clinicians)) (VP (VB discuss) (NP (NNP Doc_19293073_348_355_Chemical)) (PP (IN with) (NP (NP (NNS adults)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (PP (IN at) (NP (NP (JJ increased) (NN risk)) (PP (IN for) (NP (NNP Doc_19293073_398_420_Disease)))))))))))))) (. .)))
19293073	3	(S1 (FRAG (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (NNS benefits) (CC and) (NNS harms)) (PP (IN of) (S (VP (VBG taking) (NP (NNP Doc_19293073_477_484_Chemical)) (PP (IN for) (NP (NP (DT the) (JJ primary) (NN prevention)) (PP (IN of) (NP (NP (NNP Doc_19293073_515_537_Disease)) (, ,) (NP (NNP Doc_19293073_539_546_Disease)) (, ,) (CC and) (NP (NNP Doc_19293073_552_557_Disease))))))))))))) (. .)))
19293073	4	(S1 (NP (NP (NNS DATA) (NNS SOURCES)) (: :) (NP (NP (NP (NNP MEDLINE) (CC and) (NNP Cochrane) (NNP Library)) (PRN (-LRB- -LRB-) (NP (NP (NN search) (NNS dates)) (, ,) (NP (NP (CD 1) (NNP January) (CD 2001) (TO to) (CD 28)) (NP (NNP August) (CD 2008)))) (-RRB- -RRB-))) (, ,) (NP (JJ recent) (JJ systematic) (NNS reviews)) (, ,) (NP (NP (NN reference) (NNS lists)) (PP (IN of) (NP (VBN retrieved) (NNS articles)))) (, ,) (CC and) (NP (NP (NNS suggestions)) (PP (IN from) (NP (NNS experts))))) (. .)))
19293073	5	(S1 (FRAG (NP (NN STUDY) (NN SELECTION)) (: :) (S (NP (NP (NP (JJ English-language) (JJ randomized) (, ,) (JJ controlled) (NNS trials)) (PRN (-LRB- -LRB-) (NNS RCTs) (-RRB- -RRB-)) (: ;) (NP (JJ case-control) (NNS studies)) (: ;) (NP (NNS meta-analyses)) (: ;)) (CC and) (NP (NP (JJ systematic) (NNS reviews)) (PP (IN of) (NP (NNP Doc_19293073_883_890_Chemical))) (PP (IN versus) (NP (NP (NN control)) (PP (IN for) (NP (NP (DT the) (JJ primary) (NN prevention)) (PP (IN of) (NP (NP (NNP Doc_19293073_936_958_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19293073_960_963_Disease)) (-RRB- -RRB-)))))))))) (VP (AUX were) (VP (VBN selected) (S (VP (TO to) (VP (VB answer) (NP (NP (DT the) (JJ following) (NNS questions)) (: :) (S (NP (NNP Does) (NNP Doc_19293073_1019_1026_Chemical)) (VP (VB decrease) (NP (NP (NP (JJ coronary) (NN heart) (NNS events)) (, ,) (NP (NP (NNP Doc_19293073_1059_1066_Disease)) (, ,) (NP (NP (NNP Doc_19293073_1068_1073_Disease)) (PP (IN from) (NP (JJ coronary) (NN heart) (NNS events)))) (CC or) (NP (NNP Doc_19293073_1104_1110_Disease))) (, ,)) (CC or) (NP (JJ all-cause) (NN mortality))) (PP (IN in) (NP (NP (NNS adults)) (PP (IN without) (NP (JJ known) (NNP Doc_19293073_1159_1162_Disease)))))))))))))) (. ?)))
19293073	6	(S1 (SQ (AUX Does) (NP (NNP Doc_19293073_1169_1176_Chemical)) (VP (VB increase) (NP (NP (NNP Doc_19293073_1186_1211_Disease)) (CC or) (NP (NNP Doc_19293073_1215_1234_Disease)))) (. ?)))
19293073	7	(S1 (NP (NN DATA) (NN EXTRACTION) (: :) (S (NP (DT All) (NNS studies)) (VP (AUX were) (VP (VP (VBN reviewed)) (, ,) (VP (VBN abstracted)) (, ,) (CC and) (VP (VBN rated) (PP (IN for) (NP (NN quality))) (PP (IN by) (S (VP (VBG using) (NP (JJ predefined) (JJ USPSTF) (NNS criteria))))))))) (. .)))
19293073	8	(S1 (FRAG (NP (NN DATA) (NN SYNTHESIS)) (: :) (S (NP (NP (JJ New) (NN evidence)) (PP (IN from) (NP (NP (CD 1) (JJ good-quality) (NN RCT)) (, ,) (NP (CD 1) (JJ good-quality) (NN meta-analysis)) (, ,) (CC and) (NP (NP (CD 2) (JJ fair-quality) (NNS subanalyses)) (PP (IN of) (NP (NNS RCTs))))))) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (JJ Doc_19293073_1492_1499_Chemical) (NN use)) (VP (VBZ reduces) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (JJ Doc_19293073_1526_1529_Disease) (NNS events)) (PP (IN in) (NP (NNS patients)))))) (PP (IN without) (NP (JJ known) (NN Doc_19293073_1563_1566_Disease)))))))) (. .)))
19293073	9	(S1 (S (NP (NP (NNS Men)) (PP (IN in) (NP (DT these) (NNS studies)))) (VP (VBD experienced) (SBAR (S (NP (JJR fewer) (NN Doc_19293073_1607_1629_Disease) (CC and) (NNS women)) (VP (VBD experienced) (NP (JJR fewer) (NN Doc_19293073_1658_1674_Disease)))))) (. .)))
19293073	10	(S1 (S (NP (NNP Doc_19293073_1676_1683_Chemical)) (VP (AUX does) (RB not) (VP (VB seem) (S (VP (TO to) (VP (VB affect) (NP (NP (NP (JJ Doc_19293073_1708_1711_Disease) (NN mortality)) (CC or) (NP (JJ all-cause) (NN mortality))) (PP (IN in) (NP (DT either) (NNS men) (CC or) (NNS women))))))))) (. .)))
19293073	11	(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NNP Doc_19293073_1780_1787_Chemical))) (PP (IN for) (NP (NN primary) (NN prevention)))) (VP (VBZ increases) (NP (NP (DT the) (NN risk)) (PP (IN for) (NP (NP (JJ major) (JJ Doc_19293073_1840_1848_Disease) (NNS events)) (, ,) (RB primarily) (NP (JJ Doc_19293073_1867_1892_Disease) (NNS events)) (, ,) (PP (IN in) (NP (DT both) (NNS men) (CC and) (NNS women))))))) (. .)))
19293073	12	(S1 (S (NP (NNS Men)) (VP (AUX have) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN for) (NP (NP (NNP Doc_19293073_1955_1974_Disease)) (PP (IN with) (NP (JJ Doc_19293073_1980_1987_Chemical) (NN use))))))) (. .)))
19293073	13	(S1 (S (NP (NP (DT A) (JJ new) (NN RCT)) (CC and) (NP (NN meta-analysis))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN risk)) (PP (IN for) (NP (NNP Doc_19293073_2047_2066_Disease))) (PP (IN in) (NP (NNS women)))) (VP (AUX is) (RB not) (ADVP (RB statistically)) (VP (ADVP (RB significantly)) (VBN increased)))))) (. .)))
19293073	14	(S1 (S (NP (NP (JJ New) (NN evidence)) (PP (IN on) (NP (NNP Doc_19293073_2151_2158_Chemical))) (PP (IN for) (NP (NP (DT the) (JJ primary) (NN prevention)) (PP (IN of) (NP (NNP Doc_19293073_2189_2192_Disease)))))) (VP (AUX is) (VP (VBN limited))) (. .)))
19293073	15	(S1 (S (NP (NP (DT The) (NN dose)) (PP (IN of) (NP (NNP Doc_19293073_2217_2224_Chemical)))) (VP (VBD used) (PP (IN in) (NP (NP (DT the) (NNS RCTs)) (VP (VBN varied)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD prevented) (NP (NP (DT the) (NN estimation)) (PP (IN of) (NP (DT the) (ADJP (RBS most) (JJ appropriate)) (NN dose))) (PP (IN for) (NP (JJ primary) (NN prevention)))))))))) (. .)))
19293073	16	(S1 (S (NP (NP (JJ Several)) (PP (IN of) (NP (DT the) (NNS RCTs)))) (VP (AUX were) (VP (VBN conducted) (PP (IN within) (NP (NP (NNS populations)) (PP (IN of) (NP (NN health) (NNS professionals))) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB potentially)) (VP (VBZ limits) (NP (NN generalizability))))))))) (. .)))
19293073	17	(S1 (S (NP (NN Doc_19293073_2468_2475_Chemical)) (VP (VBZ reduces) (NP (NP (DT the) (NN risk)) (PP (IN for) (NP (NNP Doc_19293073_2497_2518_Disease))) (PP (IN in) (NP (NP (NNS men) (CC and) (NNP Doc_19293073_2530_2537_Disease)) (PP (IN in) (NP (NNS women))))))) (. .)))
19293073	18	(S1 (S (NP (JJ Doc_19293073_2548_2555_Chemical) (NN use)) (VP (VBZ increases) (NP (NP (DT the) (NN risk)) (PP (IN for) (NP (JJ serious) (JJ Doc_19293073_2591_2599_Disease) (NNS events))))) (. .)))
19338378	0	(S1 (X (S (VP (VBG Reducing) (NP (NP (NN harm)) (VP (VBN associated) (PP (IN with) (NP (NN anticoagulation))))))) (: :) (NP (NP (JJ practical) (NNS considerations)) (PP (IN of) (NP (NP (JJ Doc_19338378_75_85_Chemical) (NN therapy)) (PP (IN in) (NP (JJ Doc_19338378_97_104_Chemical-induced) (NNS thrombocytopenia)))))) (. .)))
19338378	1	(S1 (S (NP (NNP Doc_19338378_131_141_Chemical)) (VP (AUX is) (NP (NP (DT a) (ADJP (RB hepatically) (VBN metabolized)) (, ,) (JJ direct) (NN thrombin) (NN inhibitor)) (VP (VBN used) (PP (PP (IN for) (NP (NP (NN prophylaxis) (CC or) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_19338378_235_245_Disease)) (PP (IN in) (NP (NP (JJ Doc_19338378_249_256_Chemical-induced) (NNS thrombocytopenia)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19338378_283_286_Disease)) (-RRB- -RRB-)))))))) (CC and) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (CC or) (PP (IN at) (NP (NP (NN risk)) (PP (IN of) (NP (NNP Doc_19338378_324_327_Disease))) (VP (VBG undergoing) (NP (NP (JJ percutaneous) (JJ coronary) (NN intervention)) (PRN (-LRB- -LRB-) (NP (NNP PCI)) (-RRB- -RRB-))))))))))))) (. .)))
19338378	2	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN review)))) (VP (AUX is) (S (VP (TO to) (VP (VB summarize) (NP (NP (JJ practical) (NNS considerations)) (PP (IN of) (NP (NP (JJ Doc_19338378_454_464_Chemical) (NN therapy)) (PP (IN in) (NP (NNP Doc_19338378_476_479_Disease)))))))))) (. .)))
19338378	3	(S1 (S (NP (NP (DT The) (PRP US) (JJ FDA-recommended) (JJ Doc_19338378_504_514_Chemical) (NN dose)) (PP (IN in) (NP (NNP Doc_19338378_523_526_Disease)))) (VP (AUX is) (NP (NP (CD 2) (NN microg/kg/min)) (PRN (-LRB- -LRB-) (VP (VBN reduced) (PP (IN in) (NP (NP (NNS patients)) (PP (PP (IN with) (NP (NNP Doc_19338378_572_590_Disease))) (CC and) (PP (IN in) (NP (JJ paediatric) (NNS patients))))))) (-RRB- -RRB-))) (, ,) (S (VP (VBN adjusted) (S (VP (TO to) (VP (VB achieve) (NP (NP (NP (VBN activated) (JJ partial) (NN thromboplastin) (NNS times)) (PRN (-LRB- -LRB-) (NNS aPTTs) (-RRB- -RRB-))) (NP (NP (JJ 1.5-3) (NNS times) (NN baseline)) (PRN (-LRB- -LRB-) (NP (RB not) (CD >100) (NNS seconds)) (-RRB- -RRB-)))))))))) (. .)))
19338378	4	(S1 (S (NP (JJ Contemporary) (NNS experiences)) (VP (VBP indicate) (SBAR (IN that) (S (NP (VBN reduced) (NNS doses)) (VP (VP (AUX are) (ADVP (RB also)) (VP (VBN needed) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNS conditions)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ hepatic) (NN hypoperfusion)) (, ,) (NP (NNP e.g.) (NNP Doc_19338378_869_882_Disease))))))))))) (, ,) (CC yet) (VP (AUX are) (ADJP (JJ unnecessary) (PP (IN for) (NP (NNP Doc_19338378_908_925_Disease) (, ,) (NN adult) (NN age) (, ,) (NN sex) (, ,) (NN race/ethnicity) (CC or) (NN Doc_19338378_961_968_Disease))))))))) (. .)))
19338378	5	(S1 (S (NP (JJ Doc_19338378_970_980_Chemical) (CD 0.5-1.2) (NN microg/kg/min)) (ADVP (RB typically)) (VP (VBZ supports) (NP (JJ therapeutic) (NNS aPTTs))) (. .)))
19338378	6	(S1 (S (NP (NP (DT The) (JJ FDA-recommended) (NN dose)) (PP (IN during) (NP (NNP PCI)))) (VP (AUX is) (NP (NP (CD 25) (NN microg/kg/min)) (PRN (-LRB- -LRB-) (NP (QP (CD 350) (CD microg/kg)) (JJ initial) (NNS bolus)) (-RRB- -RRB-))) (, ,) (S (VP (VBN adjusted) (S (VP (TO to) (VP (VB achieve) (NP (NP (VBN activated) (VBG clotting) (NNS times)) (PRN (-LRB- -LRB-) (NP (NNS ACTs)) (-RRB- -RRB-)) (PP (IN of) (NP (JJ 300-450) (NNP sec)))))))))) (. .)))
19338378	7	(S1 (S (S (PP (IN For) (NP (NNP PCI))) (, ,) (NP (NNP Doc_19338378_1205_1215_Chemical)) (VP (AUX has) (RB not) (VP (AUX been) (VP (VBN investigated) (PP (IN in) (NP (NNP Doc_19338378_1245_1265_Disease) (NNS patients))))))) (: ;) (S (S (NP (NN dose) (NN adjustment)) (VP (AUX is) (ADJP (JJ unnecessary) (PP (IN for) (NP (NP (NN adult) (NN age)) (, ,) (NP (NN sex)) (, ,) (NP (NN race/ethnicity)) (CC or) (NP (NNP Doc_19338378_1345_1352_Disease))))))) (, ,) (CC and) (S (NP (JJR lesser) (NNS doses)) (VP (MD may) (VP (AUX be) (ADJP (JJ adequate) (PP (IN with) (NP (JJ concurrent) (NN glycoprotein) (NN IIb/IIIa) (NN inhibition)))))))) (. .)))
19338378	8	(S1 (S (S (NP (NN Doc_19338378_1437_1447_Chemical)) (VP (VBZ prolongs) (NP (DT the) (JJ International) (JJ Normalized) (NN Ratio)))) (, ,) (CC and) (S (NP (NP (JJ published) (NNS approaches)) (PP (IN for) (S (VP (VBG monitoring) (NP (DT the) (JJ Doc_19338378_1537_1547_Chemical-to-Doc_19338378_1551_1559_Chemical) (NN transition)))))) (VP (MD should) (VP (AUX be) (VP (VBN followed))))) (. .)))
19338378	9	(S1 (S (NP (NP (NN Doc_19338378_1591_1605_Disease)) (PP (IN with) (NP (NNP Doc_19338378_1611_1621_Chemical)))) (VP (AUX is) (NP (CD 0-10) (NN %)) (PP (IN in) (NP (NP (DT the) (JJ non-interventional) (NN setting)) (CC and) (NP (NP (CD 0-5.8) (NN %)) (ADVP (RB periprocedurally)))))) (. .)))
19338378	10	(S1 (S (S (NP (NN Doc_19338378_1694_1704_Chemical)) (VP (AUX has) (NP (DT no) (JJ specific) (NN antidote)))) (, ,) (CC and) (S (SBAR (IN if) (S (NP (JJ excessive) (NN anticoagulation)) (VP (VBZ occurs)))) (, ,) (NP (JJ Doc_19338378_1772_1782_Chemical) (NN infusion)) (VP (MD should) (VP (AUX be) (VP (VP (VBN stopped)) (CC or) (VP (VBN reduced)))))) (. .)))
19338378	11	(S1 (S (NP (NP (JJ Improved) (NN familiarity)) (PP (IN of) (NP (NP (NN healthcare) (NNS professionals)) (PP (IN with) (NP (NP (JJ Doc_19338378_1876_1886_Chemical) (NN therapy)) (PP (IN in) (NP (NNP Doc_19338378_1898_1901_Disease)))))))) (, ,) (PP (VBG including) (PP (IN in) (NP (JJ special) (NNS populations))) (CC and) (PP (IN during) (NP (NNP PCI)))) (, ,) (VP (MD may) (VP (VB facilitate) (NP (NP (NP (NN reduction)) (PP (IN of) (NP (NP (NN harm)) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_19338378_2001_2004_Disease)) (PRN (-LRB- -LRB-) (NP (QP (CD e.g.) (JJR fewer)) (NNP Doc_19338378_2017_2027_Disease)) (-RRB- -RRB-)))))))) (CC or) (NP (NP (PRP$ its) (NN treatment)) (PRN (-LRB- -LRB-) (VP (VBG e.g.) (NP (JJR fewer) (JJ Doc_19338378_2058_2068_Chemical) (NN medication) (NNS errors))) (-RRB- -RRB-)))))) (. .)))
19392810	0	(S1 (S (NP (NP (NN Doc_19392810_0_14_Disease)) (CC and) (NP (NN brain))) (VP (VBP Doc_19392810_25_40_Disease) (PP (IN in) (NP (NP (DT a) (JJ Doc_19392810_46_52_Chemical-dependent) (NN male)) (PP (IN under) (NP (JJ Doc_19392810_74_83_Chemical) (NN maintenance) (NN therapy)))))) (. .)))
19392810	1	(S1 (S (NP (EX There)) (VP (AUX are) (NP (NP (JJ several) (NNS complications)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_19392810_164_170_Chemical) (NN abuse)))) (, ,) (SBAR (WHNP (DT some) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (AUX are) (ADJP (JJ life-threatening))))))) (. .)))
19392810	2	(S1 (S (NP (NN Doc_19392810_214_223_Chemical)) (VP (MD may) (VP (VB aggravate) (NP (DT this) (NN problem)))) (. .)))
19392810	3	(S1 (NP (NP (DT A) (JJ clinical) (NN case) (NN description)) (. .)))
19392810	4	(S1 (S (NP (DT A) (JJ 33-year-old) (NN man)) (VP (VBD presented) (PP (IN with) (NP (NP (NN Doc_19392810_331_345_Disease)) (CC and) (NP (JJ cerebral) (NN Doc_19392810_359_374_Disease)))) (PP (IN after) (NP (JJ intravenous) (NNP Doc_19392810_393_399_Chemical)))) (. .)))
19392810	5	(S1 (S (NP (PRP He)) (VP (VP (AUX had) (VP (VBN used) (NP (NNP Doc_19392810_413_419_Chemical)) (PP (IN since) (NP (NN age) (CD 20))))) (, ,) (CC and) (VP (AUX had) (VP (VBN used) (NP (QP (CD 150) (CD mg)) (JJ Doc_19392810_454_463_Chemical) (NN daily)) (PP (IN for) (NP (CD 6) (NNS months)))))) (. .)))
19392810	6	(S1 (S (NP (PRP He)) (VP (VP (AUX was) (VP (VBN found) (NP (NN unconsciousness)) (PP (IN at) (NP (NN home))))) (CC and) (VP (AUX was) (VP (VBN sent) (PP (TO to) (NP (PRP$ our) (NN hospital)))))) (. .)))
19392810	7	(S1 (S (PP (IN In) (NP (DT the) (NN ER))) (, ,) (NP (PRP$ his) (NN opiate) (NN level)) (VP (AUX was) (NP (CD 4497) (NN ng/ml))) (. .)))
19392810	8	(S1 (S (PP (IN In) (NP (DT the) (NNP ICU))) (, ,) (NP (PRP we)) (VP (VBD found) (NP (NP (NNP Doc_19392810_616_630_Disease)) (, ,) (NP (NNP Doc_19392810_632_651_Disease)) (CC and) (NP (NNP Doc_19392810_656_681_Disease)))) (. .)))
19392810	9	(S1 (S (PP (IN After) (NP (NP (NN transfer)) (PP (TO to) (NP (DT an) (JJ internal) (NN ward))))) (, ,) (NP (PRP we)) (VP (VBD noted) (NP (NP (NP (NN Doc_19392810_728_735_Disease)) (CC and) (NP (NN weakness))) (PP (IN of) (NP (PRP$ his) (JJ left) (NNS limbs))))) (. .)))
19392810	10	(S1 (S (PP (IN After) (NP (NNP MRI))) (, ,) (NP (PRP we)) (VP (VBD found) (NP (JJ cerebral) (NNP Doc_19392810_797_816_Disease))) (. .)))
19392810	11	(S1 (S (NP (NP (DT Those)) (VP (VBG using) (NP (NP (NNP Doc_19392810_842_851_Chemical)) (CC and) (NP (NNP Doc_19392810_856_862_Chemical))))) (ADVP (RB simultaneously)) (VP (MD may) (VP (VB increase) (NP (NP (NN risk)) (PP (IN of) (NP (NP (NNP Doc_19392810_899_913_Disease)) (CC and) (NP (NNP Doc_19392810_918_933_Disease))))))) (. .)))
19392810	12	(S1 (S (NP (NP (NNS Patients)) (PP (IN under) (NP (JJ Doc_19392810_950_959_Chemical) (NN maintenance) (NN therapy)))) (VP (MD should) (VP (AUX be) (VP (VBN warned) (PP (VBG regarding) (NP (DT these) (JJ serious) (JJ adverse) (NNS events)))))) (. .)))
19392810	13	(S1 (S (NP (NP (NNS Hypotheses)) (PP (IN of) (NP (NNP Doc_19392810_1051_1057_Chemical-related) (NNP Doc_19392810_1066_1080_Disease) (CC and) (NNP Doc_19392810_1085_1091_Disease))) (PP (IN in) (NP (JJ Doc_19392810_1095_1101_Chemical) (NNS abusers)))) (VP (AUX are) (VP (VBN discussed))) (. .)))
19419794	0	(S1 (S (VP (VP (VBD Increased) (NP (NN vulnerability)) (PP (TO to) (NP (JJ Doc_19419794_27_44_Chemical) (NN lesion)))) (CC and) (VP (VBD reduced) (NP (NP (NN development)) (PP (IN of) (NP (NNP Doc_19419794_79_90_Disease)))) (PP (IN in) (NP (NP (NNS mice)) (VP (VBG lacking) (NP (JJ CB1) (JJ cannabinoid) (NNS receptors))))))) (. .)))
19419794	1	(S1 (S (NP (NP (NP (NN Motor) (NN impairment)) (, ,) (NP (JJ Doc_19419794_152_160_Chemical) (PRN (-LRB- -LRB-) (NP (NNP DA)) (-RRB- -RRB-)) (JJ neuronal) (NN activity)) (CC and) (NP (NNP Doc_19419794_188_201_Chemical) (-LRB- -LRB-) (NN PENK) (-RRB- -RRB-) (NN gene) (NN expression))) (PP (IN in) (NP (NP (DT the) (JJ caudate-putamen)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19419794_249_252_Chemical)) (-RRB- -RRB-))))) (VP (AUX were) (VP (VBN measured) (PP (IN in) (NP (ADJP (JJ Doc_19419794_271_277_Chemical-lesioned) (CC and) (VBN treated)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19419794_300_318_Chemical)) (-RRB- -RRB-)) (NNP CB1) (NNP KO) (CC and) (NNP WT) (NNS mice))))) (. .)))
19419794	2	(S1 (S (NP (NP (DT A) (NN lesion)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_19419794_360_366_Chemical))))) (VP (VBD produced) (NP (JJR more) (JJ severe) (NN motor) (NN deterioration)) (PP (IN in) (NP (NP (NNP CB1) (NNP KO) (NNS mice)) (VP (VBN accompanied) (PP (IN by) (NP (NP (NP (JJR more) (NN loss)) (PP (IN of) (NP (NN DA) (NNS neurons)))) (CC and) (NP (NP (VBN increased) (NN PENK) (NN gene) (NN expression)) (PP (IN in) (NP (DT the) (NNP CPu)))))))))) (. .)))
19419794	3	(S1 (S (NP (NN Oxidative/nitrosative) (CC and) (NN neuroinflammatory) (NNS parameters)) (VP (AUX were) (VP (VBN estimated) (PP (IN in) (NP (NP (DT the) (NN CPu) (CC and) (NN cingulate) (NN cortex)) (PRN (-LRB- -LRB-) (NP (NNP Cg)) (-RRB- -RRB-)))))) (. .)))
19419794	4	(S1 (S (NP (NNP CB1) (NNP KO) (NNS mice)) (VP (VBD exhibited) (NP (NP (JJR higher) (JJ Doc_19419794_646_649_Chemical) (NNS levels)) (CC and) (NP (NN iNOS) (NN protein) (NN expression))) (PP (IN in) (NP (DT the) (NNP CPu) (CC and) (NNP Doc_19419794_700_702_Chemical))) (PP (VBN compared) (PP (TO to) (NP (JJ WT) (NNS mice))))) (. .)))
19419794	5	(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NNP Doc_19419794_739_757_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 12) (NNS weeks)) (-RRB- -RRB-))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJR less) (JJ severe) (NN Doc_19419794_793_804_Disease)) (PP (IN in) (NP (NNP CB1) (NNP KO))))) (PP (IN than) (PP (IN in) (NP (JJ WT) (NNS mice))))) (. .)))
19419794	6	(S1 (S (NP (DT The) (NNS results)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (DT the) (NN lack)) (PP (IN of) (NP (JJ cannabinoid) (NN CB1) (NNS receptors)))) (VP (VP (VBD increased) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NP (NNP Doc_19419794_922_938_Disease)) (CC and) (NP (NN DA) (NN lesion)))))) (, ,) (CC and) (VP (VBD reduced) (NP (JJ Doc_19419794_966_972_Chemical-induced) (NN Doc_19419794_981_992_Disease))))))) (. .)))
19419794	7	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN activation)) (PP (IN of) (NP (JJ CB1) (NNS receptors)))) (VP (VBZ offers) (NP (NN neuroprotection)) (PP (IN against) (NP (NP (JJ dopaminergic) (NN lesion)) (CC and) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ Doc_19419794_1123_1129_Chemical-induced) (NN Doc_19419794_1138_1149_Disease)))))))))) (. .)))
1943082	0	(S1 (S (NP (NN Hepatocellular)) (VP (VBP oxidant) (NP (NN stress)) (PP (VBG following) (NP (NN Doc_1943082_40_78_Disease)))) (. .)))
1943082	1	(S1 (S (NP (NP (NN Reperfusion)) (PP (IN of) (NP (JJ ischemic) (NN intestine) (NNS results))) (PP (IN in) (NP (JJ acute) (NNP Doc_1943082_131_148_Disease)))) (VP (VBD characterized) (PP (IN by) (NP (JJ hepatocellular) (JJ enzyme) (NN release))) (PP (IN into) (NP (NP (NN plasma) (, ,) (NN reduction)) (PP (IN in) (NP (NP (JJ bile) (NN flow) (NN rate)) (, ,) (CC and) (NP (NN neutrophil) (NN sequestration)))) (PP (IN within) (NP (DT the) (NN liver)))))) (. .)))
1943082	2	(S1 (S (NP (NP (DT The) (NN pathophysiology)) (VP (VBG underlying) (NP (DT this) (JJ acute) (NN Doc_1943082_327_341_Disease)))) (VP (AUX is) (ADJP (JJ unknown))) (. .)))
1943082	3	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN undertaken) (S (VP (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NNS oxidants)) (VP (AUX are) (VP (VBN associated) (PP (IN with) (NP (DT the) (NNP Doc_1943082_434_448_Disease))))))))) (CC and) (VP (TO to) (VP (VB determine) (NP (NP (DT the) (JJ relative) (NN value)) (PP (IN of) (NP (NP (JJ several) (JJ indirect) (NNS methods)) (PP (IN of) (S (VP (VBG assessing) (NP (JJ oxidant) (NN exposure)) (PP (IN in) (NP (NN vivo))))))))))))))) (. .)))
1943082	4	(S1 (S (NP (NNS Rats)) (VP (AUX were) (VP (VBN subjected) (PP (TO to) (NP (DT a) (JJ standardized) (NN Doc_1943082_590_628_Disease))))) (. .)))
1943082	5	(S1 (S (NP (JJ Hepatic) (NN tissue)) (VP (AUX was) (ADJP (ADJP (JJ assayed) (PP (IN for) (NP (NN lipid) (NN peroxidation) (NNS products)))) (CC and) (ADJP (ADJP (JJ oxidized)) (CC and) (ADJP (JJ Doc_1943082_706_725_Chemical))))) (. .)))
1943082	6	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (JJ hepatic) (NN tissue) (NN total) (NNP Doc_1943082_771_782_Chemical) (JJ following) (NN Doc_1943082_793_831_Disease))))) (. .)))
1943082	7	(S1 (S (NP (NP (JJ Oxidized) (NNP Doc_1943082_842_853_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_1943082_855_859_Chemical)) (-RRB- -RRB-))) (VP (VBD increased) (ADVP (RB significantly)) (PP (VBG following) (NP (NP (QP (CD 30) (CC and) (CD 60)) (NN min)) (PP (IN of) (NP (NN reperfusion)))))) (. .)))
1943082	8	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN increase)) (PP (IN in) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (NNS products)) (PP (IN of) (NP (NP (NN lipid) (NN peroxidation)) (VP (VBN associated) (PP (IN with) (NP (DT this) (NN injury)))))))))))) (. .)))
1943082	9	(S1 (S (NP (NP (DT An) (NN increase)) (PP (IN in) (NP (NNP Doc_1943082_1036_1040_Chemical))) (PP (IN within) (NP (JJ hepatic) (NN tissue))) (PP (IN during) (NP (JJ intestinal) (NN reperfusion)))) (VP (VBZ suggests) (NP (NP (NN exposure)) (PP (IN of) (NP (NNS hepatocytes))) (PP (TO to) (NP (DT an) (JJ oxidant) (NN stress))))) (. .)))
1943082	10	(S1 (S (NP (NP (DT The) (NN lack)) (PP (IN of) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (NNS products)) (PP (IN of) (NP (NN lipid) (NN peroxidation)))))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (DT the) (JJ oxidant) (NN stress)) (VP (AUX is) (PP (IN of) (NP (JJ insufficient) (NN magnitude))) (S (VP (TO to) (VP (VB result) (PP (IN in) (NP (JJ irreversible) (NN injury))) (S (VP (TO to) (VP (VB hepatocyte) (NP (NN cell) (NNS membranes)))))))))))) (. .)))
1943082	11	(S1 (S (NP (DT These) (NNS data)) (ADVP (RB also)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NN measurement)) (PP (IN of) (NP (NN tissue) (NN Doc_1943082_1397_1401_Chemical)))) (VP (MD may) (VP (AUX be) (NP (NP (DT a) (ADJP (RBR more) (JJ sensitive)) (NN indicator)) (PP (IN of) (NP (JJ oxidant) (NN stress))) (PP (IN than) (NP (NP (NN measurement)) (PP (IN of) (NP (NP (NNS products)) (PP (IN of) (NP (NN lipid) (NN peroxidation))))))))))))) (. .)))
19447152	0	(S1 (NP (NP (NP (NN Animal) (NN model)) (PP (IN of) (NP (NNP Doc_19447152_16_21_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_19447152_33_40_Chemical))))) (: :) (NP (NP (NN Evidence)) (PP (IN of) (NP (JJ oxidative) (NN stress))) (PP (IN in) (NP (NP (JJ submitochondrial) (NNS particles)) (PP (IN of) (NP (DT the) (NN rat) (NN brain)))))) (. .)))
19447152	1	(S1 (S (NP (NP (DT The) (JJ intracerebroventricular) (PRN (-LRB- -LRB-) (NP (NNP ICV)) (-RRB- -RRB-)) (NN administration)) (PP (IN of) (NP (NNP Doc_19447152_171_178_Chemical))) (PRN (-LRB- -LRB-) (NP (DT a) (JJ Doc_19447152_182_187_Chemical/Doc_19447152_188_192_Chemical-ATPase) (NN inhibitor)) (-RRB- -RRB-)) (PP (IN in) (NP (NNS rats)))) (VP (AUX has) (VP (AUX been) (VP (VBN suggested) (S (VP (TO to) (VP (VB mimic) (NP (NP (DT some) (NNS symptoms)) (PP (IN of) (NP (JJ human) (NN Doc_19447152_270_283_Disease)))))))))) (. .)))
19447152	2	(S1 (S (NP (JJ Clinical) (NNS studies)) (VP (AUX have) (VP (VBN shown) (SBAR (IN that) (S (NP (NNP Doc_19447152_318_334_Disease)) (VP (MD may) (VP (AUX be) (VP (VBN related) (PP (TO to) (NP (NN Doc_19447152_353_378_Disease)))))))))) (. .)))
19447152	3	(S1 (S (ADVP (RB Herein)) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (JJ behavioral) (CC and) (JJ biochemical) (NNS effects)) (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (JJ ICV) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_19447152_480_487_Chemical)) (PP (IN in) (NP (NNS rats)))))))))) (. .)))
19447152	4	(S1 (S (S (VP (TO To) (VP (VB achieve) (NP (DT this) (NN aim))))) (, ,) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ Doc_19447152_533_540_Chemical) (NN injection)))) (PP (ADVP (RB immediately)) (IN after) (NP (NP (QP (CC and) (CD 7)) (NNS days)) (VP (VBG following) (NP (NP (DT a) (JJ single) (NNP Doc_19447152_599_602_Chemical) (NN administration)) (PRN (-LRB- -LRB-) (PP (IN at) (NP (NP (NNS concentrations)) (PP (IN of) (NP (NP (NP (CD 10)) (PRN (-LRB- -LRB-) (JJ -2) (-RRB- -RRB-))) (CC and) (NP (CD 10) (-LRB- -LRB-) (NN -3) (-RRB- -RRB-) (NNP M)))))) (-RRB- -RRB-))) (PP (IN on) (NP (NN locomotion)))))) (VP (AUX was) (VP (VBN measured) (S (VP (VBG using) (NP (DT the) (JJ open-field) (NN test)))))) (. .)))
19447152	5	(S1 (S (ADVP (RB Additionally)) (, ,) (NP (NP (NP (JJ Doc_19447152_728_747_Chemical) (JJ reactive) (NNS substances)) (PRN (-LRB- -LRB-) (NP (NNP TBARSs)) (-RRB- -RRB-))) (CC and) (NP (JJ Doc_19447152_781_791_Chemical) (NN production))) (VP (AUX were) (VP (VBN measured) (PP (IN in) (NP (NP (JJ submitochondrial) (NNS particles)) (PP (IN of) (NP (DT the) (JJ prefrontal) (NN cortex) (, ,) (NN hippocampus) (, ,) (NN striatum) (CC and) (NN amygdala))))))) (. .)))
19447152	6	(S1 (S (NP (PRP$ Our) (NNS findings)) (VP (VBD demonstrated) (SBAR (IN that) (S (S (NP (NP (NP (NNP Doc_19447152_940_947_Chemical)) (PP (IN at) (NP (CD 10))) (PRN (-LRB- -LRB-) (NP (NN -2)) (-RRB- -RRB-))) (CC and) (NP (CD 10) (-LRB- -LRB-) (NN -3) (-RRB- -RRB-) (NNP M))) (VP (VBN induced) (NP (NN hyperlocomotion)) (PP (IN in) (NP (NNS rats))))) (, ,) (CC and) (S (NP (DT this) (NN response)) (VP (VBD remained) (PRT (RP up)) (PP (TO to) (NP (NP (CD 7) (NNS days)) (VP (VBG following) (NP (DT a) (JJ single) (NN ICV) (NN injection)))))))))) (. .)))
19447152	7	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP we)) (VP (VBD observed) (SBAR (IN that) (S (NP (NP (DT the) (JJ persistent) (NN increase)) (PP (IN in) (NP (DT the) (NN rat) (JJ spontaneous) (NN locomotion)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NP (VBN increased) (NNS TBARS) (NNS levels)) (CC and) (NP (JJ Doc_19447152_1211_1221_Chemical) (NN generation))) (PP (IN in) (NP (NP (JJ submitochondrial) (NNS particles)) (PP (IN in) (NP (NP (DT the) (JJ prefrontal) (NN cortex)) (, ,) (NP (NN striatum)) (CC and) (NP (NN amygdala))))))))))))) (. .)))
19447152	8	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (JJ Doc_19447152_1327_1334_Chemical-induced) (JJ Doc_19447152_1343_1348_Disease-like) (NN behavior)) (VP (MD may) (VP (VB provide) (NP (NP (DT a) (JJ useful) (NN animal) (NN model)) (SBAR (S (VP (TO to) (VP (VB test) (NP (NP (DT the) (NN hypothesis)) (PP (IN of) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (NP (JJ oxidative) (NN stress)) (PP (IN in) (NP (NNP Doc_19447152_1462_1478_Disease))))))))))))))) (. .)))
19515070	0	(S1 (NP (NP (JJ Intraoperative) (NN dialysis)) (PP (IN during) (NP (NP (NN liver) (NN transplantation)) (PP (IN with) (NP (NNP Doc_19515070_58_75_Chemical))))) (. .)))
19515070	1	(S1 (S (NP (NP (NN Liver) (NN transplantation)) (PP (IN for) (NP (NP (ADJP (RB acutely) (JJ ill)) (NNS patients)) (PP (IN with) (NP (NNP Doc_19515070_129_152_Disease)))))) (VP (VBZ carries) (NP (NP (JJ high) (NN intraoperative)) (CC and) (NP (JJ immediate) (JJ postoperative) (NNS risks)))) (. .)))
19515070	2	(S1 (S (S (NP (DT These)) (VP (AUX are) (VP (VBN increased) (PP (IN with) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ concomitant) (NNP Doc_19515070_269_288_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19515070_290_293_Disease)) (-RRB- -RRB-))))))))) (CC and) (S (NP (JJ intraoperative) (NN dialysis)) (VP (AUX is) (ADVP (RB sometimes)) (VP (VBN required) (S (VP (TO to) (VP (VB allow) (S (NP (DT the) (NN transplant)) (VP (TO to) (VP (VB proceed)))))))))) (. .)))
19515070	3	(S1 (S (NP (NP (DT The) (NNS derangements)) (PP (IN in) (NP (NP (DT the) (NN procoagulant) (CC and) (NN anticoagulant) (NNS pathways)) (PP (IN during) (NP (NNP Doc_19515070_452_475_Disease)))))) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NP (NNS difficulties)) (PP (IN with) (NP (NN anticoagulation))))) (PP (IN during) (NP (NN dialysis))) (, ,) (SBAR (ADVP (RB especially)) (WHADVP (WRB when)) (S (VP (VBN continued) (PP (IN in) (NP (DT the) (NN operating) (NN room)))))))) (. .)))
19515070	4	(S1 (S (S (NP (JJ Systemic) (NN anticoagulation)) (VP (AUX is) (ADJP (JJ unsafe) (CC and) (JJ regional)))) (S (NP (NP (JJ Doc_19515070_636_643_Chemical) (NN anticoagulation)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (DT a) (JJ functional) (NN liver)))))) (VP (VBZ carries) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_19515070_717_724_Chemical) (NNP Doc_19515070_725_733_Disease)))))) (. .)))
19515070	5	(S1 (S (ADVP (JJ Doc_19515070_735_752_Chemical)) (, ,) (NP (NP (DT a) (JJ new) (NN dialysate)) (PP (IN with) (NP (NNP Doc_19515070_775_786_Chemical)))) (VP (MD can) (VP (AUX be) (VP (VBN used) (PP (IN for) (NP (NN anticoagulation))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP cannot) (VP (VB tolerate) (NP (NP (NNP Doc_19515070_851_858_Chemical)) (CC or) (NP (JJ regional) (NNP Doc_19515070_871_878_Chemical)))))))))))) (. .)))
19515070	6	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 40-year-old) (NN female)) (PP (IN with) (NP (NP (NNP Doc_19515070_926_939_Chemical-induced) (NNP Doc_19515070_948_971_Disease)) (PP (IN with) (NP (NP (JJ associated) (NNP Doc_19515070_988_991_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (JJ intraoperative) (JJ dialytic) (NN support)) (PP (IN during) (NP (NP (NN liver) (NN transplantation)) (VP (VBN anticoagulated) (PP (IN with) (NP (NNP Doc_19515070_1087_1104_Chemical))) (PP (IN during) (NP (DT the) (JJ entire) (NN procedure))))))))))))))))) (. .)))
19515070	7	(S1 (S (NP (DT The) (NN patient)) (VP (VP (VBD tolerated) (NP (DT the) (NN procedure) (NN well)) (PP (IN without) (NP (NP (DT any) (NNS signs)) (PP (IN of) (NP (NNP Doc_19515070_1196_1203_Chemical) (NNP Doc_19515070_1204_1212_Disease)))))) (CC and) (VP (VBD maintained) (NP (JJ adequate) (NN anticoagulation)) (PP (IN for) (NP (NP (NN patency)) (PP (IN of) (NP (DT the) (NN dialysis) (NN circuit))))))) (. .)))
19515070	8	(S1 (S (NP (JJ Doc_19515070_1290_1297_Chemical) (NN dialysate)) (VP (AUX is) (NP (NP (DT a) (JJ safe) (NN alternative)) (PP (IN for) (NP (NP (JJ intradialytic) (NN support)) (PP (IN of) (NP (NP (NN liver) (NN transplantation)) (PP (IN in) (NP (NNP Doc_19515070_1384_1407_Disease))))))))) (. .)))
19531695	0	(S1 (NP (NP (NP (NN Doc_19531695_0_8_Disease)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (JJ toxic) (JJ Doc_19531695_33_43_Chemical) (NN plasma) (NNS concentrations)))))) (: :) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (DT a) (JJ pharmacokinetic) (NN drug) (NN interaction))) (PP (IN with) (NP (NNP Doc_19531695_119_129_Chemical)))) (. .)))
19531695	1	(S1 (FRAG (S (VP (TO To) (VP (VB describe) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (NNP Doc_19531695_164_174_Chemical-induced) (NNP Doc_19531695_183_191_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJ pharmacokinetic) (NN drug) (NN interaction)) (PP (IN with) (NP (NNP Doc_19531695_248_258_Chemical)))))))))))) (. .)))
19531695	2	(S1 (NP (NP (NN CASE) (NN SUMMARY)) (: :) (NP (NP (DT A) (JJ 69-year-old) (JJ white) (NN female)) (VP (VBN presented) (PP (TO to) (NP (DT the) (NN emergency) (NN department))) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (NNP Doc_19531695_357_366_Disease)) (CC and) (NP (NNP Doc_19531695_371_379_Disease)))))) (PP (IN over) (NP (DT the) (JJ past) (JJ several) (NNS days))))) (. .)))
19531695	3	(S1 (S (PP (IN On) (NP (NN admission))) (NP (DT the) (NN patient)) (VP (AUX was) (VP (VBG taking) (NP (NNP Doc_19531695_444_454_Chemical) (UCP (ADJP (QP (CD 12) (CD mg)) (RB twice) (JJ daily)) (, ,) (ADJP (NP (NNP Doc_19531695_474_482_Chemical) (CD 2)) (JJ mg/day)) (, ,) (ADJP (NP (NNP Doc_19531695_493_503_Chemical) (CD 1)) (JJ mg/day)) (, ,) (ADJP (NP (NNP Doc_19531695_514_527_Chemical) (CD 100)) (JJ microg/day)) (, ,) (ADJP (NP (NNP Doc_19531695_544_556_Chemical) (CD 40)) (JJ mg/day)) (, ,) (ADJP (NP (NNP Doc_19531695_568_578_Chemical) (CD 40)) (JJ mg/day)) (, ,) (CC and) (NP (NNP Doc_19531695_594_604_Chemical) (CD 100))) (NNS mg)) (ADVP (RB twice) (RB daily)))) (. .)))
19531695	4	(S1 (S (NP (NN Doc_19531695_625_635_Chemical)) (VP (AUX had) (VP (AUX been) (VP (VBN started) (ADVP (NP (CD 2) (NNS weeks)) (RB prior)) (PP (IN for) (NP (NN Doc_19531695_671_690_Disease)))))) (. .)))
19531695	5	(S1 (S (NP (NP (NN Laboratory) (NN test) (NNS findings)) (PP (IN on) (NP (NN admission)))) (VP (AUX were) (ADJP (JJ notable) (PP (ADVP (RB only)) (IN for) (NP (NP (DT a) (JJ Doc_19531695_754_764_Chemical) (NN plasma) (NN concentration)) (PP (IN of) (NP (CD 1360) (NN microg/L)))))) (PRN (-LRB- -LRB-) (NP (NN reference) (NN range) (CD 200-1000)) (-RRB- -RRB-))) (. .)))
19531695	6	(S1 (S (NP (NP (DT A) (JJ metabolic) (NN drug) (NN interaction)) (PP (IN between) (NP (NP (NNP Doc_19531695_868_878_Chemical)) (CC and) (NP (NNP Doc_19531695_883_893_Chemical)))) (, ,) (SBAR (WHNP (WDT which)) (S (NP (DT the) (NN patient)) (VP (AUX had) (VP (AUX been) (VP (VBG taking) (PP (IN for) (NP (QP (JJR more) (IN than) (CD 5)) (NNS years)))))))) (, ,)) (VP (AUX was) (VP (VBN considered))) (. .)))
19531695	7	(S1 (S (S (NP (NN Doc_19531695_968_978_Chemical)) (VP (AUX was) (VP (VBN discontinued)))) (CC and) (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NNP Doc_19531695_1012_1022_Chemical)))) (VP (AUX was) (VP (VBN reduced) (PP (TO to) (NP (CD 50) (NN mg))) (ADVP (RB twice) (RB daily))))) (. .)))
19531695	8	(S1 (S (NP (PRP$ Her) (NNP Doc_19531695_1061_1069_Disease)) (VP (VBN resolved) (ADVP (NP (CD 3) (NNS days)) (RB later))) (. .)))
19531695	9	(S1 (S (NP (NP (ADJP (ADJP (JJ Doc_19531695_1105_1115_Chemical)) (CC and) (ADJP (RB pharmacologically) (JJ similar))) (NNS agents)) (SBAR (WHNP (WDT that)) (S (VP (VBP interact) (PP (IN with) (NP (NNP Doc_19531695_1172_1178_Chemical) (NNS channels))))))) (VP (MD may) (VP (VB cause) (NP (NP (NN Doc_19531695_1198_1206_Disease)) (PP (IN in) (NP (JJ susceptible) (NNS patients)))))) (. .)))
19531695	10	(S1 (S (NP (NP (DT A) (JJ MEDLINE) (NN search)) (PRN (-LRB- -LRB-) (NP (JJ 1966-January) (CD 2009)) (-RRB- -RRB-))) (VP (VBD revealed) (NP (CD one)) (PP (IN in) (NP (NP (NN vivo) (JJ pharmacokinetic) (NN study)) (PP (IN on) (NP (NP (NP (DT the) (NN interaction)) (PP (IN between) (NP (NP (NP (NNP Doc_19531695_1339_1349_Chemical)) (, ,) (NP (DT a) (JJ CYP2D6) (NN substrate)) (, ,)) (CC and) (NP (NP (NNP Doc_19531695_1375_1385_Chemical)) (, ,) (NP (DT a) (JJ CYP2D6) (NN inhibitor)) (, ,))))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (ADJP (CD 3) (NN case)) (NNS reports)) (PP (IN of) (NP (JJ Doc_19531695_1436_1446_Chemical-induced) (NNP Doc_19531695_1455_1463_Disease))))))))) (. .)))
19531695	11	(S1 (S (S (PP (VBG According) (PP (TO to) (NP (DT the) (NNP Naranjo) (NN probability) (NN scale)))) (, ,) (NP (NNP Doc_19531695_1509_1519_Chemical)) (VP (AUX was) (NP (NP (DT the) (JJ probable) (NN cause)) (PP (IN of) (NP (NP (DT the) (NN patient) (POS 's)) (NNP Doc_19531695_1560_1568_Disease)))))) (: ;) (S (NP (DT the) (NNP Horn) (NNP Drug) (NNP Interaction) (NN Probability) (NN Scale)) (VP (VBZ indicates) (NP (NP (DT a) (JJ possible) (JJ pharmacokinetic) (NN drug) (NN interaction)) (PP (IN between) (NP (NP (NNP Doc_19531695_1676_1686_Chemical)) (CC and) (NP (NNP Doc_19531695_1691_1701_Chemical))))))) (. .)))
19531695	12	(S1 (S (NP (JJ Supratherapeutic) (JJ Doc_19531695_1733_1743_Chemical) (NN plasma) (NNS concentrations)) (VP (MD may) (VP (VB cause) (NP (NN Doc_19531695_1776_1784_Disease)))) (. .)))
19531695	13	(S1 (S (SBAR (IN Because) (S (NP (NNP Doc_19531695_1794_1802_Disease)) (VP (MD may) (VP (VB occur) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_19531695_1818_1828_Chemical)) (VP (AUX is) (VP (VBN prescribed) (PP (IN with) (NP (NP (NNP Doc_19531695_1848_1858_Chemical)) (CC and) (NP (JJ other) (JJ potent) (NN CYP2D6) (NNS inhibitors)))))))))))) (, ,) (NP (NNP Doc_19531695_1895_1905_Chemical) (NN plasma) (NNS concentrations)) (VP (MD should) (VP (AUX be) (VP (VBN monitored) (ADVP (RB closely)) (PP (IN with) (NP (NP (NN commencement)) (PP (IN of) (NP (JJ CYP2D6) (NNS inhibitors)))))))) (. .)))
19549709	0	(S1 (S (NP (NP (NN Efficacy)) (PP (IN of) (NP (NP (NNP Doc_19549709_12_22_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19549709_24_30_Chemical)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ advanced) (NNP Doc_19549709_58_63_Disease)))))) (ADVP (RB previously)) (VP (VBN treated) (PP (PP (IN with) (NP (NP (NN chemotherapy)) (ADVP (RB alone)))) (CC or) (PP (IN with) (NP (ADJP (JJ chemotherapy) (CC and) (JJ EGFR)) (NNS inhibitors))))) (. .)))
19549709	1	(S1 (S (NP (NN Treatment) (NNS options)) (VP (AUX are) (ADJP (JJ scarce)) (PP (IN in) (NP (JJ pretreated) (JJ advanced) (NNP Doc_19549709_213_239_Disease) (PRN (-LRB- -LRB-) (NP (NNP Doc_19549709_241_246_Disease)) (-RRB- -RRB-)) (NNS patients)))) (. .)))
19549709	2	(S1 (S (NP (NP (NNP Doc_19549709_258_264_Chemical)) (, ,) (NP (NP (DT an) (JJ oral) (NN inhibitor)) (PP (IN of) (NP (NP (DT the) (JJ mammalian) (NN target)) (PP (IN of) (NP (NP (NNP Doc_19549709_311_320_Chemical)) (PRN (-LRB- -LRB-) (NP (NN mTOR)) (-RRB- -RRB-))))))) (, ,)) (VP (AUX has) (VP (VBN shown) (NP (NN phase)) (S (NP (PRP I)) (VP (NN efficacy) (PP (IN in) (NP (NNP Doc_19549709_359_364_Disease))))))) (. .)))
19549709	3	(S1 (S (NP (NP (NNP Stage) (NNP IIIb) (CC or) (NNP IV) (NNP Doc_19549709_392_397_Disease) (NNS patients)) (, ,) (PP (IN with) (NP (NP (QP (CD two) (CC or) (JJR fewer)) (JJ prior) (JJ chemotherapy) (NNS regimens)) (, ,) (NP (NP (CD one) (NNP Doc_19549709_459_467_Chemical)) (VP (VBN based) (PRN (-LRB- -LRB-) (NP (NN stratum) (CD 1)) (-RRB- -RRB-)))) (CC or) (NP (NP (DT both) (ADJP (JJ chemotherapy) (CC and) (JJ epidermal)) (NN growth) (NN factor) (NN receptor) (NNP Doc_19549709_544_552_Chemical) (JJ kinase) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (NN stratum) (CD 2)) (-RRB- -RRB-))))) (, ,)) (VP (VBD received) (NP (NNP Doc_19549709_593_599_Chemical) (CD 10) (NN mg/day)) (PP (IN until) (NP (ADJP (JJ progression) (CC or) (JJ unacceptable)) (NNP Doc_19549709_644_652_Disease)))) (. .)))
19549709	4	(S1 (S (NP (JJ Primary) (NN objective)) (VP (AUX was) (NP (NP (JJ overall) (NN response) (NN rate)) (PRN (-LRB- -LRB-) (NP (NNP ORR)) (-RRB- -RRB-)))) (. .)))
19549709	5	(S1 (S (NP (NP (NNS Analyses)) (PP (IN of) (NP (NP (NNS markers)) (VP (VBN associated) (PP (IN with) (NP (DT the) (NN mTOR) (NN pathway))))))) (VP (AUX were) (VP (VBN carried) (PRT (RP out)) (PP (IN on) (NP (NP (JJ archival) (NN Doc_19549709_787_792_Disease)) (PP (IN from) (NP (NP (DT a) (NN subgroup)) (VP (VBG using) (NP (NP (NP (NN immunohistochemistry)) (PRN (-LRB- -LRB-) (NP (NNP IHC)) (-RRB- -RRB-))) (CC and) (NP (JJ direct) (NN mutation) (NN sequencing)))))))))) (. .)))
19549709	6	(S1 (S (NP (JJ Eighty-five) (NNS patients)) (VP (AUX were) (VP (VBD enrolled) (, ,) (NP (NP (NP (CD 42)) (PP (IN in) (NP (NN stratum) (CD 1)))) (CC and) (NP (NP (CD 43)) (PP (IN in) (NP (NN stratum))))))) (. .)))
19549709	7	(S1 (S (NP (NNP ORR)) (VP (AUX was) (NP (NP (CD 4.7) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (CD 7.1) (NN %) (QP (RB stratum) (CD 1))) (: ;) (NP (NP (ADJP (CD 2.3) (NN %)) (NN stratum)) (NP (CD 2)))) (-RRB- -RRB-)))) (. .)))
19549709	8	(S1 (S (NP (JJ Overall) (NN disease) (NN control) (NN rate)) (VP (AUX was) (NP (CD 47.1) (NN %))) (. .)))
19549709	9	(S1 (S (NP (NP (JJ Median) (JJ progression-free) (NNS survivals)) (PRN (-LRB- -LRB-) (NP (NN PFSs)) (-RRB- -RRB-))) (VP (AUX were) (NP (NP (NP (CD 2.6)) (PRN (-LRB- -LRB-) (NP (NN stratum) (CD 1)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 2.7) (NNS months)) (PRN (-LRB- -LRB-) (NP (NN stratum) (CD 2)) (-RRB- -RRB-))))) (. .)))
19549709	10	(S1 (S (NP (NP (JJ Common) (NNS >)) (CC or) (NP (NN =grade) (CD 3) (NNS events))) (VP (AUX were) (NP (NP (NN fatigue)) (, ,) (NP (NP (NNP Doc_19549709_1173_1180_Disease)) (, ,) (NP (NNP Doc_19549709_1182_1192_Disease)) (, ,) (NP (NNP Doc_19549709_1194_1200_Disease)) (, ,) (CC and) (NP (NNP Doc_19549709_1206_1222_Disease))))) (. .)))
19549709	11	(S1 (S (NP (NP (NN Doc_19549709_1224_1235_Disease)) (, ,) (ADJP (ADVP (RB probably) (CC or) (RB possibly)) (VBN related)) (, ,) (ADVP (RB mainly)) (NP (NN grade) (NN 1/2)) (, ,)) (VP (VBD occurred) (PP (IN in) (NP (CD 25) (NN %)))) (. .)))
19549709	12	(S1 (S (NP (NP (NNP Cox) (NN regression) (NN analysis)) (PP (IN of) (NP (JJ IHC) (NNS scores)))) (VP (VBD found) (SBAR (IN that) (S (NP (NP (JJ only) (JJ phospho) (NN AKT)) (PRN (-LRB- -LRB-) (NP (NN pAKT)) (-RRB- -RRB-))) (VP (AUX was) (NP (NP (DT a) (JJ significant) (JJ independent) (NN predictor)) (PP (IN of) (NP (JJR worse) (NNS PFS)))))))) (. .)))
19549709	13	(S1 (S (NP (JJ Doc_19549709_1442_1448_Chemical) (CD 10) (NN mg/day)) (VP (AUX was) (VP (ADVP (RB well)) (VBN tolerated) (, ,) (S (VP (VBG showing) (NP (JJ modest) (JJ clinical) (NN activity)) (PP (IN in) (NP (JJ pretreated) (NN Doc_19549709_1526_1531_Disease))))))) (. .)))
19549709	14	(S1 (S (NP (NP (NP (NN Evaluation)) (PP (IN of) (NP (NNP Doc_19549709_1547_1553_Chemical)))) (CC plus) (NP (NP (JJ standard) (NN therapy)) (PP (IN for) (NP (JJ metastatic) (NN Doc_19549709_1591_1596_Disease))))) (VP (VBZ continues)) (. .)))
19553912	0	(S1 (NP (NP (NN Doc_19553912_0_21_Disease)) (: :) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNP Doc_19553912_35_44_Chemical)))) (. .)))
19553912	1	(S1 (S (NP (NN Doc_19553912_46_67_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ common) (NN problem)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB hinder) (NP (NP (NP (NNS patients) (POS ')) (NN quality)) (PP (IN of) (NP (NN life)))))))))) (. .)))
19553912	2	(S1 (S (NP (PRP It)) (VP (VP (VBZ occurs) (PP (IN in) (NP (CD 12))) (PP (TO to) (NP (NP (CD 76) (NN %)) (PP (IN of) (NP (NNS patients)))))) (, ,) (CC and) (VP (AUX is) (ADJP (RBS most) (JJ common) (PP (IN in) (NP (DT the) (JJ immediate) (JJ posttransplant) (NN period)))))) (. .)))
19553912	3	(S1 (S (NP (NP (DT A) (NN variety)) (PP (IN of) (NP (NNS factors)))) (VP (AUX have) (VP (AUX been) (VP (VBN identified) (SBAR (IN that) (S (VP (VBP increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NNP Doc_19553912_294_315_Disease)) (, ,) (SBAR (WHPP (IN of) (WHNP (WDT which))) (S (NP (NP (DT the) (NN level)) (PP (IN of) (NP (JJ renal) (NN function)))) (VP (AUX is) (ADJP (RBS most) (JJ important)))))))))))))) (. .)))
19553912	4	(S1 (S (NP (NP (NNP Doc_19553912_373_382_Chemical)) (, ,) (NP (NP (DT a) (JJ mammalian) (NN target)) (PP (IN of) (NP (JJ Doc_19553912_406_415_Chemical) (NN inhibitor)))) (, ,)) (VP (AUX has) (VP (AUX been) (VP (VBN implicated) (PP (IN as) (S (VP (VBG playing) (NP (DT a) (JJ special) (NN role)) (PP (IN in) (NP (NN Doc_19553912_476_497_Disease))))))))) (. .)))
19553912	5	(S1 (S (NP (DT This) (NN review)) (VP (VBZ considers) (NP (NP (NN Doc_19553912_521_527_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_19553912_544_553_Chemical)))) (, ,) (PP (VBG including) (NP (NP (PRP$ its) (NN presentation)) (, ,) (NP (NNS mechanisms)) (, ,) (CC and) (NP (NN management)))))) (. .)))
19655282	0	(S1 (NP (NP (JJ Coronary) (JJ computerized) (NN tomography) (NN angiography)) (PP (IN for) (NP (NP (JJ rapid) (NN discharge)) (PP (IN of) (NP (NP (JJ low-risk) (NNS patients)) (PP (IN with) (NP (NNP Doc_19655282_91_98_Chemical-associated) (NNP Doc_19655282_110_120_Disease))))))) (. .)))
19655282	1	(S1 (S (NP (NP (JJS Most) (NNS patients)) (VP (VBG presenting) (PP (TO to) (NP (NP (NN emergency) (NNS departments)) (PRN (-LRB- -LRB-) (NP (NNP EDs)) (-RRB- -RRB-)))) (PP (IN with) (NP (JJ Doc_19655282_195_202_Chemical-associated) (NNP Doc_19655282_214_224_Disease))))) (VP (VP (AUX are) (VP (VBN admitted) (PP (IN for) (NP (QP (IN at) (JJS least) (CD 12)) (NNS hours))))) (CC and) (VP (VBP receive) (NP (DT a) (`` ``) (S (VP (VB rule) (PRT (RP out)) (NP (JJ acute) (NNP Doc_19655282_290_307_Disease)))) ('' '') (NN protocol)) (, ,) (ADVP (RB often)) (PP (IN with) (NP (NP (JJ noninvasive) (NN testing)) (PP (ADVP (RB prior)) (TO to) (NP (NN discharge))))))) (. .)))
19655282	2	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN without) (NP (JJ Doc_19655282_390_397_Chemical) (NN use))))) (, ,) (NP (NP (JJ coronary) (JJ computerized) (NN tomography) (NN angiography)) (PRN (-LRB- -LRB-) (NP (NNP CTA)) (-RRB- -RRB-))) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (AUX be) (ADJP (JJ useful) (PP (IN for) (S (VP (VBG identifying) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NNS patients)))) (PP (IN at) (NP (NP (JJ low) (NN risk)) (PP (IN for) (NP (NP (NNP Doc_19655282_534_548_Disease)) (SBAR (WHNP (WP who)) (S (VP (MD can) (VP (AUX be) (ADVP (RB safely)) (VP (VBN discharged)))))))))))))))))))) (. .)))
19655282	3	(S1 (S (NP (PRP It)) (VP (AUX is) (ADJP (JJ unclear)) (SBAR (IN whether) (S (NP (DT a) (JJ coronary) (NN CTA) (NN strategy)) (VP (MD would) (VP (AUX be) (ADJP (JJ efficacious)) (PP (IN in) (NP (NNP Doc_19655282_649_656_Chemical-associated) (NNP Doc_19655282_668_678_Disease))) (, ,) (SBAR (IN as) (S (NP (NNP Doc_19655282_683_701_Disease)) (VP (MD may) (VP (VB account) (PP (IN for) (NP (NP (DT some)) (PP (IN of) (NP (DT the) (NNP Doc_19655282_730_738_Disease)))))))))))))) (. .)))
19655282	4	(S1 (S (NP (PRP We)) (VP (VBD studied) (SBAR (IN whether) (S (NP (NP (DT a) (JJ negative) (JJ coronary) (NN CTA)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_19655282_800_807_Chemical-associated) (NNP Doc_19655282_819_829_Disease)))))) (VP (MD could) (VP (VB identify) (NP (NP (DT a) (NN subset)) (ADJP (JJ safe) (PP (IN for) (NP (NN discharge)))))))))) (. .)))
19655282	5	(S1 (S (NP (PRP We)) (ADVP (RB prospectively)) (VP (VBN evaluated) (NP (NP (DT the) (NN safety)) (PP (IN of) (NP (NP (JJ coronary) (NNS CTA)) (PP (IN for) (NP (NP (JJ low-risk) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD presented) (PP (TO to) (NP (DT the) (NNP ED))) (PP (IN with) (NP (NP (JJ cocaineassociated) (NNP Doc_19655282_1006_1016_Disease)) (PRN (-LRB- -LRB-) (NP (JJ self-reported) (CC or) (JJ positive) (NN urine) (NN test)) (-RRB- -RRB-))))))))))))) (. .)))
19655282	6	(S1 (S (NP (JJ Consecutive) (NNS patients)) (VP (VP (VBD received) (NP (DT either) (JJ immediate) (JJ coronary) (NN CTA)) (PP (IN in) (NP (DT the) (NNP ED))) (PRN (-LRB- -LRB-) (PP (IN without) (NP (JJ serial) (NNS markers))) (-RRB- -RRB-))) (CC or) (VP (VBD underwent) (NP (JJ coronary) (NNS CTA)) (PP (IN after) (NP (NP (DT a) (JJ brief) (NN observation) (NN period)) (PP (IN with) (NP (JJ serial) (JJ cardiac) (NN marker) (NNS measurements))))))) (. .)))
19655282	7	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (JJ negative) (JJ coronary) (NNS CTA)) (PRN (-LRB- -LRB-) (NP (JJ maximal) (NN stenosis)) (NP (QP (JJR less) (IN than) (CD 50)) (NN %)) (-RRB- -RRB-))))) (VP (AUX were) (VP (VBN discharged))) (. .)))
19655282	8	(S1 (S (NP (DT The) (JJ main) (NN outcome)) (VP (AUX was) (NP (NP (JJ 30-day) (JJ cardiovascular) (NN Doc_19655282_1381_1386_Disease)) (CC or) (NP (NNP Doc_19655282_1390_1411_Disease)))) (. .)))
19655282	9	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 59) (NNS patients))) (PP (IN with) (NP (NNP Doc_19655282_1450_1457_Chemical-associated) (NNP Doc_19655282_1469_1479_Disease)))) (VP (AUX were) (VP (VBN evaluated))) (. .)))
19655282	10	(S1 (S (NP (NNS Patients)) (VP (VP (AUX had) (NP (NP (DT a) (JJ mean) (NN age)) (PP (IN of) (NP (CD 45.6) (JJ +/-) (CD 6.6) (NNS yrs))))) (CC and) (VP (AUX were) (NP (ADJP (CD 86) (NN %)) (JJ black))) (, ,) (NP (ADJP (CD 66) (NN %)) (NN male))) (. .)))
19655282	11	(S1 (S (S (NP (JJ Seventy-nine) (NN percent)) (VP (AUX had) (NP (NP (DT a) (JJ normal)) (CC or) (NP (JJ nonspecific) (NN ECG))))) (CC and) (S (NP (CD 85) (NN %)) (VP (AUX had) (NP (DT a) (NNP TIMI) (NN score) (NN <2)))) (. .)))
19655282	12	(S1 (S (NP (CD Twenty) (NNS patients)) (VP (VBD received) (NP (JJ coronary) (NN CTA)) (ADVP (RB immediately)) (PP (IN in) (NP (NP (DT the) (NNP ED)) (, ,) (SBAR (WHNP (CD 18) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (AUX were) (VP (VBN discharged) (PP (VBG following) (NP (NP (NN CTA)) (PRN (-LRB- -LRB-) (NP (CD 90) (NN %)) (-RRB- -RRB-))))))))))) (. .)))
19655282	13	(S1 (S (NP (NNP Thirty-nine)) (VP (VBD received) (NP (JJ coronary) (NN CTA)) (PP (IN after) (NP (DT a) (JJ brief) (NN observation) (NN period))) (, ,) (PP (IN with) (NP (NP (CD 37) (VBN discharged) (NN home) (VBG following) (NNS CTA)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %)) (-RRB- -RRB-))))) (. .)))
19655282	14	(S1 (S (NP (CD Six) (NNS patients)) (VP (AUX had) (VP (NNP Doc_19655282_1891_1908_Disease) (NP (CD >or=50) (NN %)))) (. .)))
19655282	15	(S1 (S (PP (IN During) (NP (DT the) (JJ 30-day) (JJ follow-up) (NN period))) (, ,) (NP (NP (DT no) (NNS patients)) (VP (VBN died) (PP (IN of) (NP (NP (NP (DT a) (JJ cardiovascular) (NN event)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 0) (NN %)) (: ;) (NP (ADJP (CD 95) (NN %)) (NN CI))) (, ,) (NP (CD 0-6.1) (NN %))) (-RRB- -RRB-))) (CC and) (NP (DT no) (NN patient)))))) (VP (VBD sustained) (NP (NP (DT a) (JJ nonfatal) (NN Doc_19655282_2054_2075_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 0) (NN %)) (: ;) (NP (ADJP (CD 95) (NN %)) (NNS CI))) (, ,) (NP (CD 0-6.1) (NN %))) (-RRB- -RRB-)))) (. .)))
19655282	16	(S1 (S (SBAR (IN Although) (S (NP (NNP Doc_19655282_2120_2127_Chemical-associated) (NNP Doc_19655282_2139_2158_Disease)) (VP (MD can) (VP (VB result) (PP (IN from) (NP (JJ coronary) (NN vasoconstriction))))))) (, ,) (NP (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_19655282_2216_2223_Chemical))) (VP (VBN associated) (NP (NNP Doc_19655282_2235_2245_Disease)))) (, ,) (NP (DT a) (JJ non-ischemic) (NN ECG)) (, ,) (CC and) (NP (DT a) (NNP TIMI) (NN risk) (NN score))) (ADVP (RB <2)) (VP (MD may) (VP (AUX be) (VP (ADVP (RB safely)) (VBN discharged) (PP (IN from) (NP (DT the) (NNP ED))) (PP (IN after) (NP (NP (DT a) (JJ negative) (JJ coronary) (NN CTA)) (PP (IN with) (NP (NP (DT a) (JJ low) (NN risk)) (PP (IN of) (NP (JJ 30-day) (JJ adverse) (NNS events)))))))))) (. .)))
19681452	0	(S1 (NP (NP (NNP Bilateral) (NNP Doc_19681452_10_33_Disease)) (PP (IN of) (NP (DT the) (JJ globus) (NN pallidus))) (PP (IN after) (NP (NNP Doc_19681452_63_70_Chemical) (CC and) (NNP Doc_19681452_75_82_Chemical) (NN intoxication))) (. .)))
19681452	1	(S1 (S (NP (NN Doc_19681452_97_104_Chemical)) (VP (AUX is) (NP (NP (DT a) (NN risk) (NN factor)) (PP (IN for) (NP (DT both) (JJ ischemic) (CC and) (NNP Doc_19681452_144_163_Disease))))) (. .)))
19681452	2	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 31-year-old) (NN man)) (PP (IN with) (NP (NP (JJ bilateral) (NNP Doc_19681452_221_229_Disease)) (PP (IN of) (NP (NP (DT the) (JJ globus) (NN pallidus)) (PP (IN after) (NP (NP (JJ excessive) (NN Doc_19681452_269_276_Chemical)) (CC and) (NP (JJ intranasal) (JJ Doc_19681452_292_299_Chemical) (NN use)))))))))))) (. .)))
19681452	3	(S1 (S (NP (JJ Drug-related) (JJ globus) (NN pallidus) (NN Doc_19681452_334_345_Disease)) (VP (AUX are) (ADVP (RBS most) (RB often)) (VP (VBN associated) (PP (IN with) (NP (NN heroin))))) (. .)))
19681452	4	(S1 (S (NP (NP (NN Doc_19681452_385_417_Disease)) (PP (IN after) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_19681452_435_442_Chemical)))))) (, ,) (PP (IN without) (NP (JJ concurrent) (JJ Doc_19681452_463_469_Chemical) (NN use))) (, ,) (VP (AUX have) (ADVP (RB never)) (VP (AUX been) (VP (VBN reported)))) (. .)))
19681452	5	(S1 (S (PP (IN In) (NP (PRP$ our) (NN patient))) (, ,) (NP (NP (JJ transient) (NNP Doc_19681452_527_545_Disease) (CC or) (NNP Doc_19681452_549_572_Disease)) (VP (VBN related) (PP (TO to) (NP (NNP Doc_19681452_584_591_Chemical) (NN and/or) (JJ Doc_19681452_599_606_Chemical) (NN use))))) (VP (AUX were) (NP (NP (DT the) (ADJP (RBS most) (JJ likely)) (NNS causes)) (PP (IN of) (NP (NNP Doc_19681452_642_664_Disease))))) (. .)))
19715529	0	(S1 (S (NP (JJ Late) (NN fulminant)) (VP (VBP posterior) (NP (JJ reversible) (JJ Doc_19715529_36_50_Disease) (NN syndrome)) (PP (IN after) (NP (NN liver) (NN transplant)))) (. .)))
19715529	1	(S1 (S (NP (NNP Posterior) (NNP Doc_19715529_106_125_Disease)) (PP (JJ due) (TO to) (NP (JJ calcineurin-inhibitor-related) (NNP Doc_19715529_163_176_Disease))) (VP (AUX is) (NP (NP (DT a) (ADJP (JJ rare) (CC but) (JJ severe)) (NN complication)) (SBAR (WHNP (WDT that)) (S (VP (VBZ results) (PP (IN from) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (JJ immunosuppressive) (NNS agents)) (PRN (-LRB- -LRB-) (ADVP (RB primarily)) (NP (NP (DT those)) (VP (VBN administered) (PP (IN after) (NP (DT a) (NN liver) (CC or) (NN kidney) (NN transplant))))) (-RRB- -RRB-))))))))))) (. .)))
19715529	2	(S1 (S (NP (NP (DT The) (JJ pathophysiologic) (NNS mechanisms)) (PP (IN of) (NP (DT that) (NN disorder)))) (VP (VBP remain) (ADJP (JJ unknown))) (. .)))
19715529	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 46-year-old) (NN woman)) (SBAR (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (DT a) (NN liver) (NN transplant)) (PP (IN in) (NP (PRP$ our) (NN center)))) (PP (IN as) (NP (NN treatment))) (PP (IN for) (NP (NNP Doc_19715529_512_531_Disease)))))) (CC and) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NP (RB either) (DT a) (JJ fulminant) (NN course)) (PP (IN of) (NP (NN posterior) (NN Doc_19715529_583_602_Disease) (CC or) (NN posterior) (JJ reversible) (NN Doc_19715529_627_641_Disease) (NN syndrome)))) (VP (VBD developed) (NP (CD 110) (NNS days)) (PP (IN after) (NP (NN transplant))))))))))) (. .)))
19715529	4	(S1 (S (PP (IN After) (NP (NP (DT an) (ADJP (RB initially) (JJ uneventful)) (NN course)) (PP (IN after) (NP (DT the) (NN transplant))))) (, ,) (NP (DT the) (NN patient)) (ADVP (RB rapidly)) (VP (VBD fell) (PP (IN into) (NP (JJ deep) (NN Doc_19715529_782_786_Disease)))) (. .)))
19715529	5	(S1 (S (NP (NP (NNP Cerebral) (NNP MRI)) (VP (VB scan))) (VP (VBD showed) (NP (NP (JJ typical) (NNS signs)) (PP (IN of) (NP (NN enhancement)))) (PP (IN in) (NP (DT the) (NN pontine) (CC and) (NN posterior) (NNS regions)))) (. .)))
19715529	6	(S1 (S (S (VP (VBG Switching) (NP (NP (DT the) (JJ immunosuppressive) (NN regimen)) (PP (IN from) (NP (NNP Doc_19715529_934_944_Chemical)))) (PP (TO to) (NP (NNP Doc_19715529_948_960_Chemical))))) (VP (AUX did) (RB not) (VP (VB improve) (NP (DT the) (JJ clinical) (NN situation)))) (. .)))
19715529	7	(S1 (S (NP (NP (DT The) (NN termination)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (DT any) (JJ calcineurin) (NN inhibitor)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ complete) (NN resolution)) (PP (IN of) (NP (DT that) (NN complication)))))) (. .)))
19715529	8	(S1 (S (NP (NP (JJ Posterior) (JJ reversible) (NN Doc_19715529_1151_1165_Disease) (NN syndrome)) (PP (IN after) (NP (NN liver) (NN transplant)))) (VP (AUX is) (ADJP (JJ rare))) (. .)))
19715529	9	(S1 (S (NP (PRP We)) (VP (VBP recommend) (NP (NP (NP (DT a) (JJ complete) (NN cessation)) (PP (IN of) (NP (DT any) (JJ calcineurin) (NN inhibitor)))) (CONJP (RB rather) (IN than)) (NP (DT a) (NN dose) (NN reduction)))) (. .)))
19728177	0	(S1 (S (NP (NP (JJ Prolonged) (NN Doc_19728177_10_21_Disease)) (PP (IN as) (NP (NP (DT a) (NN bridge)) (PP (TO to) (NP (NN recovery))))) (PP (IN for) (NP (NP (NNP Doc_19728177_50_64_Disease)) (CC and) (NP (NNP Doc_19728177_69_94_Disease))))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_19728177_111_136_Disease)))) (. .)))
19728177	1	(S1 (S (VP (TO To) (VP (VP (VB review) (NP (NP (JJ evidence-based) (NN treatment) (NNS options)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_19728177_210_224_Disease) (NN complicating) (NNP Doc_19728177_238_263_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19728177_265_268_Disease)) (-RRB- -RRB-)))))))) (CC and) (VP (VB discuss) (NP (NP (DT the) (JJ potential) (NNS applications)) (PP (IN of) (NP (NNP Doc_19728177_312_323_Disease))))))) (. .)))
19728177	2	(S1 (NP (NP (NP (NP (JJ Case-based) (NNS observations)) (PP (IN from) (NP (DT a) (JJ medical) (JJ intensive) (NN care) (NN unit)))) (PRN (-LRB- -LRB-) (NP (NNP MICU)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (DT a) (JJ tertiary) (NN care) (NN facility)) (PP (IN in) (NP (NP (DT a) (JJ 27-year-old) (NN female)) (PP (IN with) (NP (NNP Doc_19728177_456_459_Disease))) (PP (IN from) (NP (NP (NNP Doc_19728177_465_478_Chemical)) (CC and) (NP (JJ resultant) (NNP Doc_19728177_493_507_Disease)))))))) (. .)))
19728177	3	(S1 (S (NP (PRP$ Our) (NN patient)) (VP (AUX was) (VP (VBN admitted) (PP (TO to) (NP (DT the) (NN MICU))) (PP (IN after) (S (VP (AUXG being) (VP (VBN found) (S (ADJP (JJ unresponsive) (PP (IN with) (NP (NP (JJ presumed) (NN Doc_19728177_600_608_Disease)) (PP (IN from) (NP (NNP Doc_19728177_614_627_Chemical))) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN ingested) (PP (IN over) (NP (DT a) (JJ 2-day) (NN period))))))))))))))))) (. .)))
19728177	4	(S1 (S (NP (DT The) (NN patient)) (VP (AUX had) (VP (VBN depressed) (PP (IN of) (NP (NP (JJ mental) (NN status)) (VP (VBG lasting) (NP (QP (IN at) (JJS least) (CD 24)) (NNP h)) (PP (ADVP (RB prior)) (TO to) (NP (NN admission)))))))) (. .)))
19728177	5	(S1 (S (NP (JJ Initial) (NN evaluation)) (VP (VBD confirmed) (NP (NNP Doc_19728177_782_785_Chemical)) (PP (IN from) (NP (NP (NNP Doc_19728177_791_804_Chemical)) (CC and) (NP (NNP Doc_19728177_809_823_Disease))))) (. .)))
19728177	6	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (JJ Doc_19728177_854_866_Disease) (NN therapy)) (, ,) (NP (NN hyperventilation)) (, ,) (NP (NN sedation)) (, ,) (CC and) (NP (NN chemical) (NN Doc_19728177_917_926_Disease)))))) (. .)))
19728177	7	(S1 (S (NP (PRP$ Her) (JJ intracranial) (NN pressure)) (VP (VBD remained) (ADJP (JJ elevated)) (PP (IN despite) (NP (JJ maximal) (JJ medical) (NN therapy)))) (. .)))
19728177	8	(S1 (S (NP (PRP We)) (ADVP (RB then)) (VP (VBD initiated) (NP (NP (NN Doc_19728177_1023_1046_Disease)) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN continued) (PP (IN for) (NP (CD 5) (NN days))))))))) (. .)))
19728177	9	(S1 (S (PP (IN At) (NP (NN re-warming))) (, ,) (NP (NN patient)) (VP (AUX had) (NP (NP (NN resolution)) (PP (IN of) (NP (PRP$ her) (NNP Doc_19728177_1124_1138_Disease) (CC and) (NNP Doc_19728177_1143_1168_Disease))))) (. .)))
19728177	10	(S1 (S (PP (IN At) (NP (NN discharge))) (, ,) (NP (PRP she)) (VP (AUX had) (NP (NP (JJ complete) (NN recovery)) (PP (IN of) (NP (ADJP (ADJP (JJ neurological)) (CC and) (ADJP (JJ hepatic))) (NNS functions))))) (. .)))
19728177	11	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_19728177_1278_1281_Disease) (CC and) (NNP Doc_19728177_1286_1300_Disease))) (PP (IN from) (NP (NNP Doc_19728177_1306_1319_Chemical) (NNP Doc_19728177_1320_1328_Disease))))) (, ,) (NP (JJ prolonged) (NNP Doc_19728177_1340_1363_Disease)) (VP (MD could) (ADVP (RB potentially)) (VP (AUX be) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (NN life) (NN saving) (NN therapy)) (CC and) (NP (NP (DT a) (NN bridge)) (PP (TO to) (NP (NP (NN hepatic)) (CC and) (NP (NN neurological) (NN recovery)))))))))) (. .)))
19728177	12	(S1 (S (NP (NP (DT A) (JJ clinical) (NN trial)) (PP (IN of) (NP (NNP Doc_19728177_1486_1497_Disease))) (PP (IN in) (NP (NNS patients))) (PP (IN with) (NP (DT this) (NN condition)))) (VP (AUX is) (VP (VBN warranted))) (. .)))
19815465	0	(S1 (S (NP (NN Doc_19815465_0_28_Disease)) (VP (AUX are) (RB not) (ADJP (JJ specific) (TO to) (JJ Doc_19815465_49_59_Chemical))) (. .)))
19815465	1	(S1 (S (NP (DT This) (NN study)) (VP (VBD investigated) (NP (NP (DT the) (NN Doc_19815465_89_103_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (JJ antiepileptic) (NN drug) (NNP Doc_19815465_143_153_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP VGB)) (-RRB- -RRB-))))))) (. .)))
19815465	2	(S1 (S (NP (NP (QP (CD Two) (CD hundred)) (CD four) (NNS people)) (PP (IN with) (NP (NNP Doc_19815465_190_198_Disease)))) (VP (AUX were) (VP (VBN grouped) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (JJ antiepileptic) (NN drug) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NP (JJ current)) (, ,) (NP (JJ previous)) (, ,) (CC or) (NP (NP (DT no) (NN exposure)) (PP (TO to) (NP (NNS VGB))))) (-RRB- -RRB-)))))))) (. .)))
19815465	3	(S1 (S (NP (NNS Groups)) (VP (AUX were) (VP (VBN matched) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (NN age)) (, ,) (NP (NN gender)) (, ,) (CC and) (NP (NN Doc_19815465_352_359_Disease) (NN frequency)))))))) (. .)))
19815465	4	(S1 (S (NP (DT All) (NNS patients)) (VP (VBD underwent) (NP (NP (JJ objective) (NN assessment)) (PP (IN of) (NP (NP (NP (JJ electrophysiological) (NN function)) (PRN (-LRB- -LRB-) (NP (JJ wide-field) (JJ multifocal) (NN electroretinography)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ conventional) (JJ visual) (NN field) (NN testing)) (PRN (-LRB- -LRB-) (NP (JJ static) (NN perimetry)) (-RRB- -RRB-))))))) (. .)))
19815465	5	(S1 (S (NP (NN Doc_19815465_550_585_Disease)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (NP (CD 59) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (VP (ADVP (RB currently)) (VBG taking) (NP (NN VGB)))))) (, ,) (NP (NP (CD 43) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (ADVP (RB previously)) (VP (VBD took) (NP (NN VGB)))))))) (, ,) (CC and) (NP (NP (CD 24) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT no) (NN exposure)) (PP (TO to) (NP (CD VGB)))))))))))) (. .)))
19815465	6	(S1 (S (NP (NP (NN Assessment)) (PP (IN of) (NP (JJ retinal) (NN function)))) (VP (VBD revealed) (NP (NP (JJ abnormal) (NNS responses)) (PP (PP (IN in) (NP (NP (NP (CD 48) (NN %)) (PP (IN of) (NP (JJ current) (NN VGB) (NNS users)))) (CC and) (NP (NP (CD 22) (NN %)) (PP (IN of) (NP (JJ prior) (NN VGB) (NNS users)))))) (, ,) (CC but) (PP (IN in) (NP (NP (NN none)) (PP (IN of) (NP (NP (DT the) (NNS patients)) (PP (IN without) (NP (NP (JJ previous) (NN exposure)) (PP (TO to) (NP (CD VGB)))))))))))) (. .)))
19815465	7	(S1 (S (NP (NNP Bilateral) (NNP Doc_19815465_913_939_Disease)) (VP (AUX are) (ADJP (JJ common) (PP (IN in) (NP (DT the) (VBN treated) (NNP Doc_19815465_966_974_Disease) (NN population)))) (, ,) (ADVP (RB irrespective) (PP (IN of) (NP (NN drug) (NN history))))) (. .)))
19815465	8	(S1 (S (NP (NP (NN Assessment)) (PP (IN by) (NP (JJ conventional) (JJ static) (NN perimetry)))) (VP (MD may) (RB neither) (VP (AUX be) (ADJP (RB sufficiently) (JJ sensitive) (CC nor) (JJ specific)) (S (VP (TO to) (ADVP (RB reliably)) (VP (VB identify) (NP (NP (NN Doc_19815465_1133_1149_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNS VGB)))))))))) (. .)))
19841052	0	(S1 (NP (NP (NN Smoking)) (PP (IN of) (NP (NP (NN crack) (NN Doc_19841052_17_24_Chemical)) (PP (IN as) (NP (DT a) (NN risk) (NN factor))))) (PP (IN for) (NP (NNP Doc_19841052_46_59_Disease))) (PP (IN among) (NP (NP (NNS people)) (SBAR (WHNP (WP who)) (S (VP (VBP use) (NP (NN injection) (NNS drugs))))))) (. .)))
19841052	1	(S1 (S (NP (JJ Little)) (VP (AUX is) (VP (VBN known) (PP (IN about) (NP (NP (DT the) (JJ possible) (NN role)) (SBAR (WHNP (IN that)) (S (NP (NN smoking) (NN crack) (NNP Doc_19841052_169_176_Chemical)) (VP (AUX has) (PP (IN on) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_19841052_201_214_Disease)))))))))))) (. .)))
19841052	2	(S1 (S (PP (VBN Given) (NP (NP (DT the) (VBG increasing) (NN use)) (PP (IN of) (NP (NN crack) (NN Doc_19841052_250_257_Chemical))))) (, ,) (NP (PRP we)) (VP (VBD sought) (S (VP (TO to) (VP (VB examine) (SBAR (IN whether) (S (NP (NP (NN use)) (PP (IN of) (NP (DT this) (JJ illicit) (NN drug)))) (VP (AUX has) (VP (VBN become) (NP (NP (DT a) (NN risk) (NN factor)) (PP (IN for) (NP (NN Doc_19841052_342_355_Disease)))))))))))) (. .)))
19841052	3	(S1 (S (NP (PRP We)) (VP (VBD included) (NP (NP (NNS data)) (PP (IN from) (NP (NP (NNS people)) (VP (VBG participating) (PP (IN in) (NP (DT the) (NNP Vancouver) (NN Injection) (NN Drug) (NNS Users) (NN Study)))) (SBAR (WHNP (WP who)) (S (VP (VBD reported) (SBAR (S (NP (VBG injecting) (JJ illicit) (NNS drugs)) (ADVP (IN at) (JJS least) (RB once) (PP (IN in) (NP (NP (DT the) (NN month)) (PP (IN before) (NP (NN enrolment))) (, ,) (VP (VBN lived) (PP (IN in) (NP (DT the) (JJR greater) (NNP Vancouver) (NN area)))) (, ,)))) (VP (VP (AUX were) (ADJP (JJ HIV-negative)) (PP (IN at) (NP (NN enrolment)))) (CC and) (VP (VBD completed) (NP (QP (IN at) (JJS least) (CD 1)) (JJ follow-up) (NN study) (NN visit))))))))))))) (. .)))
19841052	4	(S1 (S (VP (TO To) (VP (VB determine) (PP (IN whether) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NNP HIV) (NN seroconversion)) (PP (IN among) (NP (NP (JJ daily) (NNS smokers)) (PP (IN of) (NP (NN crack))) (S (S (NP (NNP Doc_19841052_732_739_Chemical)) (VP (VBD changed) (PP (IN over) (NP (NN time))))) (, ,) (NP (PRP we)) (VP (VP (VBD used) (NP (NNP Cox) (JJ proportional) (NNS hazards) (NN regression))) (CC and) (VP (VBN divided) (NP (DT the) (NN study)) (PP (IN into) (NP (NP (CD 3) (NNS periods)) (: :) (NP (NP (NP (NP (NP (NP (NNP May) (CD 1)) (, ,) (NP (JJ 1996-Nov.) (CD 30)) (, ,) (NP (CD 1999)) (PRN (-LRB- -LRB-) (NP (NN period) (CD 1)) (-RRB- -RRB-)) (, ,) (NP (NNP Dec.) (CD 1)) (, ,)) (JJ 1999-Nov.) (CD 30) (, ,) (CD 2002)) (PRN (-LRB- -LRB-) (NP (NN period) (CD 2)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNP Dec.) (CD 1)) (, ,) (NP (JJ 2002-Dec.) (CD 30)) (, ,) (NP (CD 2005))) (PRN (-LRB- -LRB-) (NP (NN period) (CD 3)) (-RRB- -RRB-)))))))))))))))) (. .)))
19841052	5	(S1 (S (ADVP (JJ Overall)) (, ,) (NP (CD 1048) (JJ eligible) (NN injection) (NN drug) (NNS users)) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (PRP$ our) (NN study))))) (. .)))
19841052	6	(S1 (S (PP (IN Of) (NP (DT these))) (, ,) (NP (CD 137)) (VP (VBD acquired) (NP (NNP Doc_19841052_1065_1078_Disease)) (PP (IN during) (NP (NN follow-up)))) (. .)))
19841052	7	(S1 (S (NP (NP (DT The) (JJ mean) (NN proportion)) (PP (IN of) (NP (NP (NNS participants)) (SBAR (WHNP (WP who)) (S (VP (VBD reported) (NP (NP (JJ daily) (NN smoking)) (PP (IN of) (NP (NN crack) (NN Doc_19841052_1169_1176_Chemical)))))))))) (VP (VBD increased) (PP (IN from) (NP (CD 11.6) (NN %))) (PP (IN in) (NP (NN period))) (NP (QP (CD 1) (TO to) (CD 39.7)) (NN %)) (PP (IN in) (NP (NN period) (CD 3)))) (. .)))
19841052	8	(S1 (S (PP (IN After) (S (VP (VBG adjusting) (PP (IN for) (NP (JJ potential) (NNS confounders)))))) (, ,) (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP HIV)))) (NP (NP (NN seroconversion)) (PP (IN among) (NP (NP (NNS participants)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (NP (NP (JJ daily) (NNS smokers)) (PP (IN of) (NP (NN crack) (NNP Doc_19841052_1371_1378_Chemical))) (VP (VBN increased) (PP (IN over) (NP (NP (NN time)) (PRN (-LRB- -LRB-) (NP (NN period) (CD 1)) (: :) (NP (NP (NP (NN hazard) (NN ratio)) (JJ -LSB-HR) (JJ -RSB-) (CD 1.03)) (, ,) (NP (NP (NP (ADJP (CD 95) (NN %)) (NN confidence)) (JJ interval) (JJ -LSB-CI) (NN -RSB-)) (NP (NP (CD 0.57-1.85)) (: ;) (NP (NN period) (CD 2)) (: :) (NP (NP (QP (CD HR) (CD 1.68))) (, ,) (NP (NP (NP (CD 95) (NN %)) (NP (CD CI) (NN 1.01-2.80))) (: ;) (CC and) (NP (NN period) (CD 3)))) (: :) (NP (QP (CD HR) (CD 2.74))))) (, ,) (NP (NP (CD 95) (NN %)) (NP (NNP CI) (CD 1.06-7.11)))) (-RRB- -RRB-))))))))))))))) (. .)))
19841052	9	(S1 (S (NP (NP (NN Smoking)) (PP (IN of) (NP (NN crack) (NN Doc_19841052_1586_1593_Chemical)))) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (NP (NP (DT an) (JJ independent) (NN risk) (NN factor)) (PP (IN for) (NP (NP (NNP HIV) (NN seroconversion)) (PP (IN among) (NP (NP (NNS people)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (NP (NN injection) (NN drug) (NNS users))))))))))))))) (. .)))
19841052	10	(S1 (S (NP (DT This) (NN finding)) (VP (VBZ points) (PP (TO to) (NP (NP (DT the) (JJ urgent) (NN need)) (PP (IN for) (NP (NP (JJ evidence-based) (JJ public) (NN health) (NNS initiatives)) (VP (VBN targeted) (PP (IN at) (NP (NP (NNS people)) (SBAR (WHNP (WP who)) (S (VP (VBP smoke) (NP (NN crack) (NN Doc_19841052_1823_1830_Chemical))))))))))))) (. .)))
19914299	0	(S1 (S (NP (NN Doc_19914299_0_10_Chemical)) (VP (VBZ improves) (NP (NP (DT the) (NN Doc_19914299_24_39_Disease)) (VP (VBN caused) (PP (IN by) (NP (DT the) (JJ chemotherapy) (NN agent) (NN Doc_19914299_73_87_Chemical)))))) (. .)))
19914299	1	(S1 (S (NP (NP (JJ Doc_19914299_89_95_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (AUX been) (VP (VBN treated) (PP (IN with) (NP (JJ systemic) (JJ adjuvant) (NN chemotherapy))))))))) (VP (AUX have) (VP (VBN described) (S (VP (VBG experiencing) (NP (NNS deteriorations)) (PP (IN in) (NP (NN cognition))))))) (. .)))
19914299	2	(S1 (S (NP (NP (DT A) (ADJP (RB widely) (VBN used)) (JJ chemotherapeutic) (NN agent)) (, ,) (NP (NP (NNP Doc_19914299_258_272_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19914299_274_278_Chemical)) (-RRB- -RRB-))) (, ,)) (VP (VP (ADVP (RB readily)) (VBZ crosses) (NP (DT the) (JJ blood-brain) (NN barrier))) (CC and) (ADVP (RB so)) (VP (MD could) (VP (AUX have) (NP (NP (DT a) (JJ direct) (NN effect)) (PP (IN on) (NP (NN brain) (NN function))))))) (. .)))
19914299	3	(S1 (S (PP (IN In) (NP (NN particular))) (NP (DT this) (JJ anti) (JJ mitotic) (NN drug)) (VP (MD could) (VP (VB reduce) (NP (NN cell) (NN proliferation)) (PP (IN in) (NP (NP (DT the) (JJ neurogenic) (NNS regions)) (PP (IN of) (NP (DT the) (NN adult) (NN brain))))))) (. .)))
19914299	4	(S1 (S (PP (IN In) (NP (NN contrast))) (NP (NNS reports)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ hippocampal) (JJ dependent) (NN neurogenesis)) (CC and) (NP (NN cognition))) (VP (AUX are) (VP (VBN enhanced) (PP (IN by) (NP (DT the) (NNP SSRI) (NN antidepressant) (NN Doc_19914299_612_622_Chemical)))))))) (. .)))
19914299	5	(S1 (S (PP (IN In) (NP (DT this) (NN investigation))) (NP (NP (DT the) (JJ behavioural) (NNS effects)) (PP (PP (IN of) (NP (NP (JJ chronic) (PRN (-LRB- -LRB-) (NP (CD two) (NN week)) (-RRB- -RRB-)) (NN treatment)) (PP (IN with) (NP (NNP Doc_19914299_707_711_Chemical))))) (CC and) (PRN (-LRB- -LRB-) (NP (CD three) (NNS weeks)) (-RRB- -RRB-)) (PP (IN with) (NP (NNP Doc_19914299_735_745_Chemical))) (CC either) (ADVP (RB separately)) (CC or) (PP (IN in) (NP (NN combination)))) (PP (IN with) (NP (NNP Doc_19914299_787_791_Chemical)))) (VP (AUX were) (VP (VBN tested) (PP (IN on) (NP (JJ adult) (NNP Lister) (JJ hooded) (NNS rats))))) (. .)))
19914299	6	(S1 (S (NP (JJ Behavioural) (NNS effects)) (VP (AUX were) (VP (VBN tested) (S (VP (VBG using) (NP (NP (DT a) (NN context)) (ADJP (JJ dependent) (PP (VBN conditioned) (NP (NP (JJ emotional) (NN response) (NN test)) (PRN (-LRB- -LRB-) (NP (NN CER)) (-RRB- -RRB-))))) (SBAR (WHNP (WDT which)) (S (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_19914299_972_976_Chemical))))) (VP (AUX had) (NP (NP (DT a) (JJ significant) (NN reduction)) (PP (IN in) (NP (NN freezing) (NN time)))) (PP (VBN compared) (PP (TO to) (NP (NNS controls))))))))))))))) (. .)))
19914299	7	(S1 (S (NP (NP (DT A) (JJ separate) (NN group)) (PP (IN of) (NP (NNS animals)))) (VP (AUX was) (VP (VBN tested) (S (VP (VBG using) (NP (NP (DT a) (JJ hippocampal) (JJ dependent) (JJ spatial) (NN working) (NN memory) (NN test)) (, ,) (NP (NP (DT the) (NN object) (NN location) (NN recognition) (NN test)) (PRN (-LRB- -LRB-) (NP (NNP OLR)) (-RRB- -RRB-)))))))) (. .)))
19914299	8	(S1 (S (S (NP (NP (NNS Animals)) (VP (VBN treated) (ADVP (RB only)) (PP (IN with) (NP (NNP Doc_19914299_1212_1216_Chemical))))) (VP (VBD showed) (NP (JJ significant) (NNS deficits)) (PP (IN in) (NP (PRP$ their) (NN ability) (S (VP (TO to) (VP (VB carry) (PRT (RP out)) (NP (DT the) (JJ OLR) (NN task))))))))) (CC but) (S (NP (NP (NNP co) (NN administration)) (PP (IN of) (NP (NNP Doc_19914299_1313_1323_Chemical)))) (VP (VBD improved) (SBAR (S (NP (PRP$ their) (FW performance.) (NNP Doc_19914299_1352_1356_Chemical) (NN chemotherapy)) (VP (VBD caused) (NP (NP (DT a) (JJ significant) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (VBG proliferating) (NNS cells)) (PP (IN in) (NP (NP (DT the) (JJ sub) (JJ granular) (NN zone)) (PP (IN of) (NP (DT the) (JJ dentate) (NN gyrus))) (PP (VBN compared) (PP (TO to) (NP (NNS controls)))))))))))))))) (. .)))
19914299	9	(S1 (S (NP (DT This) (NN reduction)) (VP (AUX was) (VP (VBN eliminated) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_19914299_1541_1551_Chemical)) (VP (AUX was) (NP (NP (NNP co)) (VP (VBN administered) (PP (IN with) (NP (NN Doc_19914299_1577_1581_Chemical)))))))))) (. .)))
19914299	10	(S1 (S (NP (NP (NN Doc_19914299_1583_1593_Chemical)) (PP (IN on) (NP (PRP$ its) (JJ own)))) (VP (AUX had) (NP (DT no) (NN effect)) (PP (IN on) (S (VP (VBG proliferating) (NP (NP (NN cell) (NN number)) (CC or) (NP (NN behaviour))))))) (. .)))
19914299	11	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (NNP Doc_19914299_1690_1694_Chemical)) (VP (MD can) (ADVP (RB negatively)) (VP (VP (VB affect) (NP (DT both) (NN cell) (NN proliferation))) (CC and) (VP (VB Doc_19914299_1745_1781_Disease)))))) (CC and) (SBAR (IN that) (S (NP (DT these) (NNS deficits)) (VP (MD can) (VP (AUX be) (VP (VBN reversed) (PP (IN by) (NP (NP (DT the) (JJ simultaneous) (NN administration)) (PP (IN of) (NP (DT the) (JJ antidepressant) (NN Doc_19914299_1879_1889_Chemical)))))))))))) (. .)))
19920070	0	(S1 (S (NP (NP (JJ Liver-specific) (NN ablation)) (PP (IN of) (NP (JJ integrin-linked) (NN kinase))) (PP (IN in) (NP (NNS mice)))) (VP (VBZ results) (PP (IN in) (NP (NP (JJ enhanced) (CC and) (JJ prolonged) (NN cell) (NN proliferation)) (CC and) (NP (NNP Doc_19920070_115_127_Disease)))) (PP (IN after) (NP (NNP Doc_19920070_134_147_Chemical) (NN administration)))) (. .)))
19920070	1	(S1 (S (NP (PRP We)) (VP (AUX have) (ADVP (RB recently)) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (NN disruption)) (PP (IN of) (NP (NP (JJ extracellular) (NNP matrix) (PRN (-LRB- -LRB-) (NP (NNP ECM)) (-RRB- -RRB-)) (NN /integrin)) (VP (VBG signaling) (PP (IN via) (NP (NP (NN elimination)) (PP (IN of) (NP (NP (JJ integrin-linked) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN ILK)) (-RRB- -RRB-))))))))) (PP (IN in) (NP (NNS hepatocytes)))) (VP (VBZ interferes) (PP (IN with) (NP (NP (NNS signals)) (VP (VBG leading) (PP (TO to) (NP (NP (NN termination)) (PP (IN of) (NP (NNP Doc_19920070_372_390_Disease))))))))))))) (. .)))
19920070	2	(S1 (S (NP (DT This) (NN study)) (VP (VBZ investigates) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN ILK))) (PP (IN in) (NP (NP (NNP Doc_19920070_435_452_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_19920070_464_477_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_19920070_479_481_Chemical)) (-RRB- -RRB-))))))))) (. .)))
19920070	3	(S1 (NP (NP (NP (NP (NN Wild-type)) (PRN (-LRB- -LRB-) (NP (NN WT)) (-RRB- -RRB-))) (CC and) (NP (NN ILK))) (: :) (S (NP (JJ liver-/-) (NNS mice)) (VP (AUX were) (VP (VBN given) (NP (NP (NNP Doc_19920070_532_534_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.1) (NN %)) (PP (IN in) (NP (NN drinking) (NN water)))) (-RRB- -RRB-))) (PP (IN for) (NP (CD 10) (NNS days)))))) (. .)))
19920070	4	(S1 (S (NP (NNS Livers)) (VP (AUX were) (VP (VBN harvested) (PRT (RP on)) (NP (NP (CD 2)) (, ,) (NP (CD 5)) (, ,) (CC and) (NP (CD 10) (NN days))) (PP (IN during) (NP (NNP Doc_19920070_623_625_Chemical) (NN administration))))) (. .)))
19920070	5	(S1 (S (PP (IN In) (NP (DT the) (JJ hepatocyte-specific) (JJ ILK/liver-/-) (NNS mice))) (, ,) (NP (DT the) (NN liver) (: :) (NN body) (NN weight) (NN ratio)) (VP (AUX was) (ADVP (RBR more) (IN than) (RB double) (RB as)) (PP (VBN compared) (PP (TO to) (NP (NP (CD 0) (NNP h)) (PP (IN at) (NP (NN day) (CD 2))) (PRN (-LRB- -LRB-) (NP (CD 2.5) (NNS times)) (-RRB- -RRB-))))) (, ,) (SBAR (IN while) (S (PP (IN at) (NP (NNS days) (CD 5) (CC and) (CD 10))) (, ,) (NP (PRP it)) (VP (AUX was) (ADJP (JJ enlarged) (NP (CD three) (NNS times))))))) (. .)))
19920070	6	(S1 (S (PP (IN In) (NP (DT the) (JJ WT) (NNS mice))) (, ,) (NP (DT the) (NN increase)) (VP (AUX was) (SBAR (IN as) (S (VP (VP (VBN expected) (PP (IN from) (NP (JJ previous) (NN literature))) (PRN (-LRB- -LRB-) (NP (CD 1.8) (NNS times)) (-RRB- -RRB-))) (CC and) (VP (VBZ seems) (S (VP (TO to) (VP (AUX have) (VP (VBN leveled) (PRT (RP off)) (PP (IN after) (NP (NN day) (CD 2)))))))))))) (. .)))
19920070	7	(S1 (S (NP (EX There)) (VP (AUX were) (ADVP (RB slightly)) (VP (VBN increased) (NP (VBG proliferating) (NN cell) (JJ nuclear) (NN antigen-positive) (NNS cells)) (PP (IN in) (NP (DT the) (JJ ILK/liver-/-) (NNS animals))) (PP (IN at) (NP (NN day) (CD 2))) (SBAR (IN as) (S (VP (VBN compared) (S (VP (TO to) (VP (VB WT) (PP (IN after) (NP (NNP Doc_19920070_1097_1099_Chemical) (NN administration))))))))))) (. .)))
19920070	8	(S1 (S (PP (IN In) (NP (DT the) (JJ WT) (NNS animals))) (, ,) (NP (DT the) (JJ proliferative) (NN response)) (VP (AUX had) (VP (VBN come) (ADVP (RB back)) (PP (TO to) (NP (JJ normal))) (PP (IN by) (NP (NNS days) (CD 5) (CC and) (CD 10))))) (. .)))
19920070	9	(S1 (S (NP (NP (NNS Hepatocytes)) (PP (IN of) (NP (DT the) (JJ ILK/liver-/-) (NNS mice)))) (VP (VBD continued) (S (VP (TO to) (VP (VBP proliferate) (PRT (RP up)) (PP (IN until) (NP (NN day) (CD 10))))))) (. .)))
19920070	10	(S1 (S (NP (JJ ILK/liver-/-) (NNS mice)) (ADVP (RB also)) (VP (VBD showed) (NP (NP (VBN increased) (NN expression)) (PP (IN of) (NP (NP (JJ key) (NNS genes)) (VP (VBN involved) (PP (IN in) (NP (JJ hepatocyte) (NN proliferation))) (PP (IN at) (NP (NP (JJ different) (NN time) (NNS points)) (PP (IN during) (NP (NNP Doc_19920070_1416_1418_Chemical) (NN administration)))))))))) (. .)))
19920070	11	(S1 (S (PP (IN In) (NP (NN summary))) (, ,) (NP (NNP ECM) (NNS proteins)) (VP (VB communicate) (PP (IN with) (NP (NP (DT the) (VBG signaling) (NN machinery)) (PP (IN of) (NP (NP (VBG dividing) (NNS cells)) (PP (IN via) (NP (NN ILK))))))) (S (VP (TO to) (VP (VB regulate) (NP (NP (NN hepatocyte) (NN proliferation) (CC and) (NN termination)) (PP (IN of) (NP (DT the) (JJ proliferative) (NN response)))))))) (. .)))
19920070	12	(S1 (S (NP (NP (NN Lack)) (PP (IN of) (NP (NN ILK))) (PP (IN in) (NP (DT the) (NNS hepatocytes)))) (VP (VBZ imparts) (NP (NP (VBN prolonged) (JJ proliferative) (NN response)) (PP (CONJP (RB not) (RB only)) (PP (TO to) (NP (NP (NNS stimuli)) (ADJP (JJ related) (PP (TO to) (NP (NNP Doc_19920070_1714_1732_Disease)))))) (CONJP (CC but) (RB also)) (PP (TO to) (NP (NP (JJ xenobiotic) (NN chemical) (NNS mitogens)) (, ,) (PP (JJ such) (IN as) (NP (NNP Doc_19920070_1783_1785_Chemical)))))))) (. .)))
19967075	0	(S1 (NP (NP (VBN Decreased) (NN Expression)) (PP (IN of) (NP (NNP Doc_19967075_24_26_Chemical/Doc_19967075_27_28_Chemical-ATPase) (, ,) (NNP NHE3) (, ,) (NNP NBC1) (, ,) (NNP AQP1) (CC and) (NNP Doc_19967075_58_61_Disease))) (PP (IN in) (NP (NNP Doc_19967075_65_75_Chemical-induced) (NNP Doc_19967075_84_95_Disease))) (. .)))
19967075	1	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN aimed) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (EX there)) (VP (AUX is) (NP (NP (DT an) (JJ altered) (NN regulation)) (PP (IN of) (NP (JJ tubular) (NNS transporters))) (PP (IN in) (NP (JJ Doc_19967075_204_214_Chemical-induced) (NN Doc_19967075_223_234_Disease)))))))))))) (. .)))
19967075	2	(S1 (S (S (NP (NP (JJ Sprague-Dawley) (NN male) (NNS rats)) (PRN (-LRB- -LRB-) (NP (CD 200~250) (NNP g)) (-RRB- -RRB-))) (VP (AUX were) (ADVP (RB subcutaneously)) (VP (VBN injected) (PP (IN with) (NP (NNP Doc_19967075_307_317_Chemical))) (PRN (-LRB- -LRB-) (NP (NP (CD 100) (NNS mg/kg)) (PP (IN per) (NP (NN day)))) (-RRB- -RRB-)) (PP (IN for) (NP (CD 7) (NNS days)))))) (, ,) (CC and) (S (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ tubular) (NNS transporters)))) (VP (AUX was) (VP (VBN determined) (PP (IN by) (NP (NN immunoblotting) (CC and) (NN immunohistochemistry)))))) (. .)))
19967075	3	(S1 (S (NP (NP (DT The) (NN mRNA) (CC and) (NN protein) (NN expression)) (PP (IN of) (NP (NNP Doc_19967075_487_490_Disease)))) (VP (AUX was) (ADVP (RB also)) (VP (VBN determined))) (. .)))
19967075	4	(S1 (S (NP (JJ Doc_19967075_512_522_Chemical-treated) (NNS rats)) (VP (VBD exhibited) (ADVP (RB significantly)) (NP (VBN decreased) (JJ Doc_19967075_570_580_Chemical) (NN clearance)) (PP (IN along) (PP (IN with) (NP (VBN increased) (NN plasma) (NN Doc_19967075_619_629_Chemical) (NNS levels))))) (. .)))
19967075	5	(S1 (S (ADVP (RB Accordingly)) (, ,) (NP (NP (DT the) (JJ fractional) (NN excretion)) (PP (IN of) (NP (NNP Doc_19967075_679_685_Chemical)))) (VP (VBD increased)) (. .)))
19967075	6	(S1 (S (NP (NN Urine) (NN volume)) (VP (AUX was) (VP (VBN increased) (, ,) (SBAR (IN while) (S (NP (NP (NN urine) (NN osmolality)) (CC and) (NP (JJ free) (NN water) (NN reabsorption))) (VP (AUX were) (VP (VBN decreased))))))) (. .)))
19967075	7	(S1 (S (NP (NN Immunoblotting) (CC and) (NN immunohistochemistry)) (VP (VBD revealed) (NP (NP (VBN decreased) (NN expression)) (PP (IN of) (NP (NP (NNP Doc_19967075_865_870_Chemical/Doc_19967075_871_875_Chemical-ATPase)) (, ,) (NP (NNP NHE3)) (, ,) (NP (NNP NBC1)) (, ,) (CC and) (NP (NNP AQP1))))) (PP (IN in) (NP (NP (DT the) (NN kidney)) (PP (IN of) (NP (JJ Doc_19967075_922_932_Chemical-treated) (NNS rats)))))) (. .)))
19967075	8	(S1 (S (NP (NP (DT The) (NN expression)) (PP (IN of) (NP (NP (NNS OAT1)) (CC and) (NP (NNS OAT3))))) (VP (AUX was) (ADVP (RB also)) (VP (VBN decreased))) (. .)))
19967075	9	(S1 (S (NP (JJ Doc_19967075_999_1009_Chemical-induced) (NN Doc_19967075_1018_1029_Disease)) (VP (MD may) (VP (PP (ADVP (IN at) (JJS least)) (IN in) (NP (NN part))) (AUX be) (ADVP (RB causally)) (VP (VBN related) (PP (IN with) (NP (NP (DT a) (VBN decreased) (NN expression)) (PP (IN of) (NP (NNP Doc_19967075_1102_1107_Chemical/Doc_19967075_1108_1112_Chemical-ATPase) (, ,) (NNP NHE3) (, ,) (NNP NBC1) (, ,) (NNP AQP1) (CC and) (NNP Doc_19967075_1142_1145_Disease)))))))) (. .)))
20009434	0	(S1 (S (VP (VB Doc_20009434_0_19_Disease) (PP (IN after) (NP (JJ high-dose) (JJ Doc_20009434_36_48_Chemical) (NN therapy))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NN ileostomy)))))) (. .)))
20009434	1	(S1 (S (NP (NP (JJ High-dose) (NNP Doc_20009434_96_108_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP HD-Doc_20009434_113_116_Chemical)) (-RRB- -RRB-))) (VP (VP (AUX is) (NP (NP (DT an) (JJ important) (NN treatment)) (PP (IN for) (NP (NNP Doc_20009434_148_164_Disease))))) (, ,) (CC but) (VP (MD can) (VP (VB cause) (NP (NP (NN hepatic)) (CC and) (NP (NNP Doc_20009434_192_206_Disease))) (SBAR (WHADVP (WRB when)) (S (NP (PRP$ its) (NN clearance)) (VP (AUX is) (VP (VBN delayed)))))))) (. .)))
20009434	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_20009434_258_277_Disease)))) (PP (IN after) (NP (JJ Doc_20009434_284_290_Chemical) (NN therapy))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NN ileostomy))))) (, ,) (S (NP (DT The) (NN patient)) (VP (AUX was) (NP (NP (DT a) (JJ 3-year-old) (NN boy)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN received) (NP (NP (DT a) (JJ living-related) (NN liver) (NN transplantation)) (PP (IN for) (NP (NNP Doc_20009434_421_447_Disease)))))))))))) (. .)))
20009434	3	(S1 (S (PP (IN At) (NP (NN day) (CD 833))) (PP (IN after) (NP (DT the) (NN transplantation))) (, ,) (NP (PRP he)) (VP (AUX was) (VP (VBN diagnosed) (PP (IN with) (NP (NP (NNP Doc_20009434_509_513_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20009434_515_564_Disease)) (, ,) (NP (NNP Doc_20009434_566_597_Disease)) (-RRB- -RRB-)))))) (. .)))
20009434	4	(S1 (S (PP (IN During) (NP (NN induction) (NN therapy))) (, ,) (NP (PRP he)) (NP (NP (NN Doc_20009434_629_655_Disease)) (CC and) (NP (NN ileostomy))) (VP (AUX was) (VP (VBN performed))) (. .)))
20009434	5	(S1 (S (NP (JJ Subsequent) (JJ HD-Doc_20009434_699_702_Chemical) (NN therapy)) (VP (VBD caused) (NP (NP (NN Doc_20009434_718_737_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBD required) (NP (JJ continuous) (NN hemodialysis))))))) (. .)))
20009434	6	(S1 (S (NP (PRP We)) (VP (VBD supposed) (NP (DT that) (JJ Doc_20009434_794_819_Disease) (NN due)) (PP (TO to) (NP (JJ substantial) (NN drainage))) (PP (IN from) (NP (NP (DT the) (NN ileostoma)) (VP (VBN caused) (NP (NNP Doc_20009434_874_896_Disease)))))) (. .)))
20009434	7	(S1 (S (PP (IN After) (NP (NP (NN recovery)) (PP (IN of) (NP (PRP$ his) (JJ renal) (NN function))))) (, ,) (NP (PRP we)) (VP (MD could) (ADVP (RB safely)) (VP (VB treat) (NP (NP (DT the) (NN patient)) (PP (IN with) (NP (JJ HD-Doc_20009434_978_981_Chemical) (NN therapy)))) (PP (IN by) (S (VP (VBG controlling) (NP (NP (NN drainage)) (PP (IN from) (NP (NN ileostoma))) (PP (IN with) (NP (JJ total) (JJ parenteral) (NN nutrition))))))))) (. .)))
20024739	0	(S1 (NP (NP (JJ Longitudinal) (NN association)) (PP (IN of) (NP (JJ Doc_20024739_28_35_Chemical) (NN use))) (PP (IN with) (NP (NP (NNP Doc_20024739_45_68_Disease)) (CC and) (NP (NNP Doc_20024739_73_111_Disease)))) (. .)))
20024739	1	(S1 (S (NP (PRP We)) (VP (VBN evaluated) (NP (NP (NP (DT the) (NN association)) (PP (IN of) (NP (NP (JJ Doc_20024739_145_152_Chemical) (NN consumption)) (CC and) (NP (NN Doc_20024739_169_179_Disease))))) (, ,) (CC and) (NP (NP (PRP$ their) (NNS effects)) (PP (IN on) (NP (NP (NNP Doc_20024739_202_225_Disease)) (PP (IN among) (NP (NP (NNS women)) (PP (IN with) (NP (NNP Doc_20024739_243_246_Disease)))))))))) (. .)))
20024739	2	(S1 (S (NP (DT The) (NN study)) (VP (VBD included) (NP (NP (CD 871) (NNS women)) (PP (IN with) (NP (NNP Doc_20024739_282_285_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN recruited) (PP (IN from) (NP (CD 1993-1995))) (PP (IN in) (NP (CD four) (NNP US) (NNS cities))))))))) (. .)))
20024739	3	(S1 (S (NP (DT The) (NNS participants)) (VP (AUX had) (NP (NP (JJ physical) (NN examination)) (, ,) (NP (JJ medical) (NN record) (NN extraction)) (, ,) (CC and) (NP (NN venipuncture)) (, ,) (NP (JJ CD4+T-cell) (NNS counts) (NN determination)) (, ,) (NP (NP (NN measurement)) (PP (IN of) (NP (NP (JJ Doc_20024739_475_485_Disease) (NNS symptoms)) (PRN (-LRB- -LRB-) (PP (VBG using) (NP (NP (DT the) (JJ self-report) (NNP Center)) (PP (IN for) (NP (NNP Epidemiological) (NNP Studies-Doc_20024739_553_563_Disease) (NNP Scale))))) (-RRB- -RRB-))))) (, ,) (CC and) (NP (JJ Doc_20024739_576_583_Chemical) (NN use) (NN assessment))) (PP (PP (IN at) (NP (NN enrollment))) (, ,) (CC and) (ADVP (RB semiannually)) (PP (IN until) (NP (NNP March) (CD 2000))))) (. .)))
20024739	4	(S1 (S (NP (NP (JJ Multilevel) (JJ random) (NN coefficient) (NN ordinal) (NNS models)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ multilevel) (NNS models)) (PP (IN with) (NP (JJ joint) (NNS responses))))) (VP (AUX were) (VP (VBN used) (PP (IN in) (NP (DT the) (NN analysis))))) (. .)))
20024739	5	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (JJ significant) (NN association)) (PP (IN between) (NP (NP (NN level)) (PP (IN of) (NP (NP (JJ Doc_20024739_825_832_Chemical) (NN use)) (CC and) (NP (JJ CD4+) (JJ T-cell) (NNS counts)))))))) (. .)))
20024739	6	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NNS participants)) (VP (AUX were) (ADJP (JJ stratified) (PP (IN by) (NP (JJ antiretroviral) (NN therapy) (PRN (-LRB- -LRB-) (NP (NN ART)) (-RRB- -RRB-)) (NN use))))))) (, ,) (NP (NP (DT the) (NN association)) (PP (IN between) (NP (NP (NNP Doc_20024739_956_963_Chemical)) (CC and) (NP (NNP CD4+) (NNP T-cell))))) (VP (AUX did) (RB not) (VP (VB reach) (NP (JJ statistical) (NN significance)))) (. .)))
20024739	7	(S1 (S (NP (NP (DT The) (NN association)) (PP (IN between) (NP (NP (JJ Doc_20024739_1044_1051_Chemical) (NN consumption)) (CC and) (NP (NN Doc_20024739_1068_1078_Disease))))) (VP (AUX was) (ADJP (JJ significant)) (PRN (-LRB- -LRB-) (NP (CD p<0.001)) (-RRB- -RRB-))) (. .)))
20024739	8	(S1 (S (NP (NN Doc_20024739_1106_1116_Disease)) (VP (AUX had) (NP (NP (DT a) (JJ significant) (JJ negative) (NN effect)) (PP (IN on) (NP (JJ CD4+) (JJ T-cell) (NNS counts)))) (PP (IN over) (NP (NN time))) (ADVP (RB regardless) (PP (IN of) (NP (NN ART) (NN use))))) (. .)))
20024739	9	(S1 (S (NP (PRP$ Our) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ Doc_20024739_1232_1239_Chemical) (NN consumption)) (VP (AUX has) (NP (NP (DT a) (JJ direct) (NN association)) (PP (IN with) (NP (NN Doc_20024739_1282_1292_Disease)))))))) (. .)))
20024739	10	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NNP Doc_20024739_1304_1314_Disease)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_20024739_1334_1357_Disease))))) (. .)))
20024739	11	(S1 (S (NP (PRP$ Our) (NNS findings)) (VP (AUX have) (NP (NP (NNS implications)) (PP (IN for) (NP (NP (DT the) (NN provision)) (PP (IN of) (NP (NNP Doc_20024739_1411_1418_Chemical))))) (SBAR (S (VP (VBP use) (NP (NP (NNS interventions)) (CC and) (NP (JJ psychological) (NNS resources))) (S (VP (TO to) (VP (VB improve) (NP (NP (DT the) (NN health)) (PP (IN of) (NP (NP (NNS women)) (PP (IN with) (NP (NNP Doc_20024739_1501_1504_Disease)))))))))))))) (. .)))
20034406	0	(S1 (S (NP (NP (JJ Chemokine) (NNS CCL2)) (CC and) (NP (PRP$ its) (NN receptor) (NNS CCR2))) (VP (AUX are) (VP (VBN increased) (PP (IN in) (NP (NP (DT the) (NNS hippocampus)) (VP (VBG following) (NP (JJ Doc_20034406_80_91_Chemical-induced) (NNP Doc_20034406_100_118_Disease))))))) (. .)))
20034406	1	(S1 (S (NP (NN Neuroinflammation)) (VP (VP (VBZ occurs) (PP (IN after) (NP (NNP Doc_20034406_163_171_Disease)))) (CC and) (VP (AUX is) (VP (VBN implicated) (PP (IN in) (NP (NN epileptogenesis)))))) (. .)))
20034406	2	(S1 (S (S (NP (NN CCR2)) (VP (AUX is) (NP (NP (DT a) (NN chemokine) (NN receptor)) (PP (IN for) (NP (NN CCL2)))))) (CC and) (S (NP (PRP$ their) (NN interaction) (NNS mediates)) (VP (VBP monocyte) (NP (NN infiltration)) (PP (IN in) (NP (NP (DT the) (JJ neuroinflammatory) (NN cascade)) (VP (VBN triggered) (PP (IN in) (NP (JJ different) (NNP Doc_20034406_357_374_Disease)))))))) (. .)))
20034406	3	(S1 (S (PP (IN In) (NP (DT this) (NN work))) (NP (NP (NNS CCR2)) (CC and) (NP (JJ CCL2) (NN expression))) (VP (AUX were) (VP (VBN examined) (PP (VBG following) (NP (NP (NP (NNP Doc_20034406_438_456_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20034406_458_460_Disease)) (-RRB- -RRB-))) (VP (VBN induced) (PP (IN by) (NP (JJ Doc_20034406_473_484_Chemical) (NN injection)))))))) (. .)))
20034406	4	(S1 (S (NP (NN Doc_20034406_505_507_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (JJ Doc_20034406_523_534_Chemical) (NN injection))))) (. .)))
20034406	5	(S1 (S (NP (NN Control) (NNS rats)) (VP (AUX were) (VP (VBN injected) (PP (IN with) (NP (NP (NN saline)) (PP (RB instead) (IN of) (NP (NNP Doc_20034406_596_607_Chemical))))))) (. .)))
20034406	6	(S1 (S (PP (NP (CD Five) (NNS days)) (IN after) (NP (NN Doc_20034406_625_627_Disease))) (, ,) (NP (NP (CD CCR2) (NN staining)) (PP (IN in) (NP (NP (NNS neurons)) (CC and) (NP (JJ glial) (NNS cells))))) (VP (AUX was) (VP (VBN examined) (S (VP (VBG using) (NP (JJ imunohistochemical) (NNS analyses)))))) (. .)))
20034406	7	(S1 (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (CD CCR2) (JJ positive) (NNS cells)))) (VP (AUX was) (VP (VBN determined) (S (VP (VBG using) (NP (NN stereology) (NNS probes)) (PP (IN in) (NP (DT the) (NN hippocampus))))))) (. .)))
20034406	8	(S1 (S (NP (NP (JJ CCL2) (NN expression)) (PP (IN in) (NP (DT the) (NN hippocampus)))) (VP (AUX was) (VP (VBN examined) (PP (IN by) (NP (JJ molecular) (NN assay))))) (. .)))
20034406	9	(S1 (S (NP (VBN Increased) (NN CCR2)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (DT the) (NN hippocampus))) (PP (IN after) (NP (NN Doc_20034406_941_943_Disease))))) (. .)))
20034406	10	(S1 (S (NP (NN Doc_20034406_945_953_Disease)) (ADVP (RB also)) (VP (VBD resulted) (PP (IN in) (NP (NP (NNS alterations)) (PP (TO to) (NP (NP (DT the) (NN cell) (NNS types)) (VP (VBG expressing) (NP (NN CCR2)))))))) (. .)))
20034406	11	(S1 (S (NP (NP (JJ Increased) (NNS numbers)) (PP (IN of) (NP (NP (NNS neurons)) (SBAR (WHNP (WDT that)) (S (VP (VBD expressed) (NP (NN CCR2)))))))) (VP (AUX was) (VP (VBN observed) (PP (VBG following) (NP (NN Doc_20034406_1090_1092_Disease))))) (. .)))
20034406	12	(S1 (S (NP (JJ Microglial) (NNS cells)) (VP (AUX were) (ADVP (RBR more) (RB closely)) (VP (VBN apposed) (PP (TO to) (NP (DT the) (JJ CCR2-labeled) (NNS cells))) (PP (IN in) (NP (JJ Doc_20034406_1166_1168_Disease) (NNS rats))))) (. .)))
20034406	13	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NNS rats)) (SBAR (WHNP (WDT that)) (S (VP (VBD experienced) (NP (NNP Doc_20034406_1210_1212_Disease)))))) (VP (VBD exhibited) (NP (NN CCR2-labeling)) (PP (IN in) (NP (NP (NNS populations)) (PP (IN of) (NP (JJ hypertrophied) (NNS astrocytes))))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (NP (NN CA1)) (CC and) (NP (JJ dentate) (NN gyrus))))) (. .)))
20034406	14	(S1 (S (NP (DT These) (CD CCR2+) (NNS astroctytes)) (VP (AUX were) (RB not) (VP (VBN observed) (PP (IN in) (NP (NN control) (NNS rats))))) (. .)))
20034406	15	(S1 (S (NP (NP (NN Examination)) (PP (IN of) (NP (CD CCL2) (NN expression)))) (VP (VBD showed) (SBAR (IN that) (S (NP (PRP it)) (VP (AUX was) (ADJP (JJ elevated)) (PP (IN in) (NP (DT the) (JJ hippocampus) (JJ following) (NN Doc_20034406_1465_1467_Disease))))))) (. .)))
20034406	16	(S1 (S (NP (DT The) (NNS data)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NNS CCR2)) (CC and) (NP (NNS CCL2))) (VP (AUX are) (VP (VBN up-regulated) (PP (IN in) (NP (NP (DT the) (NN hippocampus)) (PP (IN after) (NP (JJ Doc_20034406_1556_1567_Chemical-induced) (NNP Doc_20034406_1576_1578_Disease)))))))))) (. .)))
20034406	17	(S1 (S (NP (JJ Doc_20034406_1580_1588_Disease)) (ADVP (RB also)) (VP (VBP result) (PP (IN in) (NP (NP (NNS changes)) (PP (TO to) (NP (NP (ADJP (CD CCR2) (NN receptor)) (NN expression)) (PP (IN in) (NP (NP (NNS neurons)) (CC and) (NP (NNS astrocytes))))))))) (. .)))
20034406	18	(S1 (S (NP (DT These) (NNS changes)) (VP (MD might) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (JJ detrimental) (NN neuroplasticity)) (CC and) (NP (NP (JJ neuroinflammatory) (NNS changes)) (SBAR (WHNP (WDT that)) (S (VP (VBP occur) (PP (VBG following) (NP (NN Doc_20034406_1781_1789_Disease)))))))))))) (. .)))
20046642	0	(S1 (S (NP (JJ Metallothionein) (NN induction)) (VP (VBZ reduces) (NP (NP (JJ caspase-3) (NN activity)) (CC and) (NP (NP (NN TNFalpha) (NNS levels)) (PP (IN with) (NP (NP (NNP Doc_20046642_78_112_Disease)) (CC and) (NP (JJ intact) (JJ hippocampal) (NNS neurons)))) (PP (IN in) (NP (JJ Doc_20046642_147_157_Chemical-treated) (NNS rats)))))) (. .)))
20046642	1	(S1 (S (NP (JJ Hippocampal) (NN integrity)) (VP (AUX is) (ADJP (JJ essential)) (PP (IN for) (NP (JJ cognitive) (NNS functions)))) (. .)))
20046642	2	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NP (NP (NN induction)) (PP (IN of) (NP (NP (NN metallothionein)) (PRN (-LRB- -LRB-) (NP (NN MT)) (-RRB- -RRB-)))) (PP (IN by) (NP (NNP Doc_20046642_288_295_Chemical)))) (CC and) (NP (NP (PRP$ its) (NN role)) (PP (IN in) (NP (NN neuroprotection))))) (VP (AUX has) (VP (AUX been) (VP (VBN documented)))) (. .)))
20046642	3	(S1 (S (NP (NP (DT The) (JJ present) (NN study)) (VP (VBN aimed) (S (VP (TO to) (VP (VB explore) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (CD MT) (NN induction))) (PP (IN on) (NP (NP (NNP Doc_20046642_414_424_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20046642_426_430_Chemical)) (-RRB- -RRB-)))))))))) (VP (VBD -induced) (NP (JJ hippocampal) (NN Doc_20046642_452_473_Disease)) (PP (IN in) (NP (NNS rats)))) (. .)))
20046642	4	(S1 (S (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 60) (JJ male) (NNP Wistar) (NN albino) (NNS rats)))) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN divided) (PP (IN into) (NP (NP (CD four) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NN 15/group)) (-RRB- -RRB-))))))) (: :) (S (NP (NP (DT The) (NN control) (NN group)) (VP (VBN injected) (PP (IN with) (NP (NP (JJ single) (NNS doses)) (PP (IN of) (NP (NP (JJ normal) (NN saline)) (PRN (-LRB- -LRB-) (NP (NN i.c.v)) (-RRB- -RRB-)))))))) (VP (VBD followed) (NP (CD 24) (NNP h)) (ADVP (RB later)) (PP (IN by) (NP (NNP Doc_20046642_665_669_Chemical) (JJ solvent) (PRN (-LRB- -LRB-) (NP (CD i.v)) (-RRB- -RRB-)))))) (. .)))
20046642	5	(S1 (S (NP (NP (DT The) (JJ second) (NN group)) (VP (VBN administered) (ADJP (JJ Doc_20046642_715_722_Chemical) (PRN (-LRB- -LRB-) (FRAG (NP (QP (CD 0.1) (CD micromol/10)) (JJ microl) (JJ normal) (NN saline)) (, ,) (NP (NN i.c.v)) (, ,) (ADVP (RB once))) (-RRB- -RRB-)) (ADVP (RB then)) (ADJP (JJ Doc_20046642_780_784_Chemical) (JJ solvent)) (PRN (-LRB- -LRB-) (JJ i.v) (-RRB- -RRB-))) (PP (IN after) (NP (CD 24) (NNP h.) (NNP Third) (NN group))))) (VP (VBD received) (NP (NP (NNP Doc_20046642_832_836_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 20) (NNS mg/kg)) (, ,) (NP (CD i.v))) (, ,) (RB once) (-RRB- -RRB-))) (NP (CD 24) (NNP h)) (PP (IN after) (NP (NN injection))) (PP (IN with) (NP (NP (JJ normal) (NN saline)) (PRN (-LRB- -LRB-) (NP (NN i.c.v)) (-RRB- -RRB-))))) (. .)))
20046642	6	(S1 (S (NP (JJ Fourth) (NN group)) (VP (VBD received) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NNP Doc_20046642_947_954_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 0.1) (ADJP (CD micromol/10) (NN microl)) (JJ normal) (NN saline)) (, ,) (NP (CD i.c.v)) (-RRB- -RRB-)) (ADJP (ADJP (RB then) (JJ Doc_20046642_1006_1010_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 20) (NNS mg/kg)) (, ,) (NP (NP (CD i.v)) (, ,) (NP (RB once)))) (-RRB- -RRB-)))) (PP (IN after) (NP (CD 24) (NNP h)))) (. .)))
20046642	7	(S1 (S (NP (DT The) (VBN obtained) (NNS data)) (VP (VBD revealed) (SBAR (S (NP (DT that) (NNP Doc_20046642_1077_1081_Chemical) (NN administration)) (VP (VBD resulted) (PP (IN in) (NP (NP (NN deterioration)) (PP (IN of) (NP (NP (NN learning)) (CC and) (NP (NP (JJ short-term) (NN memory)) (PRN (-LRB- -LRB-) (NP (NN STM)) (-RRB- -RRB-))))))) (, ,) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (S (VP (VBG using) (NP (NP (JJ radial) (NN arm) (NN water) (NN maze)) (, ,) (VP (VBN accompanied) (PP (IN with) (NP (NP (VBN decreased) (JJ hippocampal) (JJ Doc_20046642_1247_1258_Chemical) (FW reductase) (PRN (-LRB- -LRB-) (NP (NNP GR)) (-RRB- -RRB-)) (NN activity)) (CC and) (NP (NNP Doc_20046642_1287_1306_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_20046642_1308_1311_Chemical)) (-RRB- -RRB-)) (NN content)))))))))))))))) (. .)))
20046642	8	(S1 (S (ADVP (RB Also)) (, ,) (NP (NNP Doc_20046642_1328_1332_Chemical) (NN administration)) (VP (VBD increased) (NP (NP (NP (JJ serum) (NNP Doc_20046642_1364_1369_Disease) (NNP Doc_20046642_1370_1378_Disease) (NN factor-alpha)) (PRN (-LRB- -LRB-) (NP (NNP TNFalpha)) (-RRB- -RRB-)) (, ,) (NP (JJ hippocampal) (NN MT)) (CC and) (NP (NNP Doc_20046642_1423_1438_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_20046642_1440_1443_Chemical)) (-RRB- -RRB-)) (NNS contents))) (CONJP (RB as) (RB well) (IN as)) (NP (JJ caspase-3) (NN activity))) (PP (IN in) (NP (NN addition))) (PP (TO to) (NP (JJ histological) (NNS alterations)))) (. .)))
20046642	9	(S1 (S (NP (JJ Doc_20046642_1525_1532_Chemical) (NN pretreatment)) (VP (VP (VBN counteracted) (NP (NP (JJ Doc_20046642_1559_1563_Chemical-induced) (NN inhibition)) (PP (IN of) (NP (NP (NN GR) (CC and) (NN depletion)) (PP (IN of) (NP (NNP Doc_20046642_1606_1609_Chemical))))))) (CC and) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (JJ significant) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_20046642_1665_1668_Chemical)) (CC and) (NP (NNP TNFalpha))))))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NN caspase-3)))))))) (. .)))
20046642	10	(S1 (S (NP (DT The) (JJ histological) (NNS features)) (VP (AUX were) (VP (VBN improved) (PP (IN in) (NP (NP (NN hippocampus)) (PP (IN of) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_20046642_1796_1803_Chemical) (NNP +) (NNP Doc_20046642_1806_1810_Chemical)))))))) (PP (VBN compared) (PP (TO to) (NP (JJ only) (JJ Doc_20046642_1828_1832_Chemical-treated) (NNS animals)))))) (. .)))
20046642	11	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN MT) (NN induction) (NNS halts)) (VP (VBD Doc_20046642_1884_1888_Chemical-induced) (NP (JJ hippocampal) (NNP Doc_20046642_1909_1917_Disease)) (SBAR (IN as) (S (NP (PRP it)) (VP (VP (VBD prevented) (NP (NP (JJ GR) (NN inhibition)) (CC and) (NP (JJ Doc_20046642_1952_1955_Chemical) (NN depletion)))) (CC and) (VP (VBN counteracted) (NP (NP (DT the) (VBN increased) (NNS levels)) (PP (IN of) (NP (NNP TNFalpha) (, ,) (NNP Doc_20046642_2017_2020_Chemical) (CC and) (JJ caspase-3) (NN activity)))) (PP (IN with) (NP (NP (JJ subsequent) (NN preservation)) (PP (IN of) (NP (NN cognition)))))))))) (. .)))
20129423	0	(S1 (NP (NP (JJ Fatal) (JJ Doc_20129423_6_19_Chemical) (VBN induced) (JJ fulminant) (NNP Doc_20129423_38_50_Disease) (PRN (-LRB- -LRB-) (NP (NNP Doc_20129423_52_68_Disease)) (-RRB- -RRB-)) (NNP Doc_20129423_70_81_Disease)) (: :) (NP (NP (NN emphasis)) (PP (IN on) (NP (NP (JJ anatomical) (CC and) (JJ histological) (NNS characteristics)) (, ,) (NP (NNS mechanisms)) (CC and) (NP (NP (NNP genetics)) (PP (IN of) (NP (NP (NN drug) (NN Doc_20129423_172_188_Disease)) (CC and) (NP (NN differential) (NN diagnosis)))))))) (. .)))
20129423	1	(S1 (S (NP (NP (DT The) (ADJP (RBS most) (JJ severe)) (JJ adverse) (NNS reactions)) (PP (TO to) (NP (NNP Doc_20129423_254_267_Chemical)))) (VP (AUX have) (VP (AUX been) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (JJ haemopoietic) (NN system)) (, ,) (NP (DT the) (NN liver)) (CC and) (NP (DT the) (JJ cardiovascular) (NN system))))))) (. .)))
20129423	2	(S1 (S (NP (NP (DT A) (ADJP (ADJP (RB frequently) (JJ fatal)) (, ,) (IN although) (ADJP (RB exceptionally) (JJ rare))) (NN side) (NN effect)) (PP (IN of) (NP (NNP Doc_20129423_419_432_Chemical)))) (VP (AUX is) (NP (NNP Doc_20129423_436_447_Disease) (NNP Doc_20129423_448_460_Disease) (PRN (-LRB- -LRB-) (NP (NNP Doc_20129423_462_478_Disease)) (-RRB- -RRB-)) (NNP Doc_20129423_480_491_Disease))) (. .)))
20129423	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_20129423_513_541_Disease) (JJ secondary))) (PP (TO to) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_20129423_573_586_Chemical))))))) (. .)))
20129423	4	(S1 (S (S (NP (JJ Acute) (NN Doc_20129423_594_622_Disease)) (VP (AUX was) (RB not) (VP (VBN suspected) (ADVP (RB clinically))))) (, ,) (CC and) (S (NP (DT the) (NN diagnosis)) (VP (AUX was) (VP (VBN made) (NP (NN post-mortem))))) (. .)))
20129423	5	(S1 (S (NP (NN Histology)) (VP (VBD revealed) (NP (NP (NN diffuse) (NN infiltration)) (PP (IN of) (NP (DT the) (NN myocardium))) (PP (IN by) (NP (NP (NNS eosinophils) (CC and) (NNS lymphocytes)) (PP (IN with) (NP (JJ myocyte) (NN damage))))))) (. .)))
20129423	6	(S1 (S (ADVP (RB Clinically)) (, ,) (NP (NNP Doc_20129423_815_820_Disease)) (VP (AUX was) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_20129423_832_849_Disease))))) (. .)))
20129423	7	(S1 (S (PP (TO To) (NP (NP (JJS best)) (PP (IN of) (NP (PRP$ our) (NN knowledge))))) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ second) (NN case)) (PP (IN of) (NP (NP (JJ fatal) (JJ Doc_20129423_909_922_Chemical) (VBN induced) (NN Doc_20129423_931_942_Disease)) (VP (VBN reported) (PP (IN in) (NP (JJ English) (NN literature)))))))) (. .)))
20169779	0	(S1 (NP (NP (NN Doc_20169779_0_26_Disease)) (PP (IN in) (NP (NP (DT the) (JJ Doc_20169779_34_38_Chemical) (NN marmoset) (NN model)) (PP (IN of) (NP (NNP Doc_20169779_57_76_Disease))))) (. .)))
20169779	1	(S1 (S (NP (NN Doc_20169779_90_115_Disease)) (VP (AUX are) (ADVP (RB increasingly)) (VP (VBN recognised) (PP (IN as) (NP (NP (DT a) (JJ significant) (NN problem)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_20169779_186_205_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20169779_207_209_Disease)) (-RRB- -RRB-)))))))))) (. .)))
20169779	2	(S1 (S (NP (DT These) (NNS symptoms)) (VP (MD may) (VP (AUX be) (ADJP (JJ due) (S (VP (TO to) (VP (POS ') (NP (NN sensitisation)) ('' ') (PP (VBG following) (NP (NP (JJ repeated) (JJ Doc_20169779_276_284_Chemical) (NN treatment)) (CC or) (NP (NP (DT a) (JJ direct) (NN effect)) (PP (IN of) (NP (NNP Doc_20169779_317_325_Chemical))) (PP (IN on) (NP (DT the) (NN disease) (NN state)))))))))))) (. .)))
20169779	3	(S1 (S (NP (DT The) (JJ Doc_20169779_352_360_Chemical-treated) (JJ Doc_20169779_369_373_Chemical-lesioned) (NN marmoset)) (VP (AUX was) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (NNP Doc_20169779_415_440_Disease))) (PP (IN in) (NP (JJ Doc_20169779_444_446_Disease) (NNS patients))))))) (. .)))
20169779	4	(S1 (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP compare) (NP (NP (DT the) (NN time) (NN course)) (PP (IN of) (NP (NP (JJ Doc_20169779_492_500_Chemical-induced) (NN motor) (NNS fluctuations)) (CC and) (NP (JJ Doc_20169779_532_548_Disease-like) (NNS behaviors))))) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NN duration)) (PP (IN of) (NP (NP (NN treatment) (CC and) (NN onset)) (PP (IN of) (NP (NNS symptoms)))))))))))) (. .)))
20169779	5	(S1 (S (NP (NNS Marmosets)) (VP (AUX were) (VP (VBN administered) (NP (NP (NNP Doc_20169779_684_728_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 2.0) (RB mg/kg) (NNP s.c.)) (-RRB- -RRB-))) (PP (IN for) (NP (CD five) (NNS days))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (JJ stable) (NN Doc_20169779_781_793_Disease))))))) (. .)))
20169779	6	(S1 (S (NP (NP (NNP Doc_20169779_795_803_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 15) (NNS mg/kg) (CC and) (NNP Doc_20169779_818_829_Chemical)) (, ,) (NP (CD 3.75) (NN mg/kg))) (-RRB- -RRB-)) (PP (IN p.o.) (NP (NN b.i.d))) (, ,)) (VP (AUX was) (VP (VBN administered) (PP (IN for) (NP (CD 30) (NNS days))))) (. .)))
20169779	7	(S1 (S (NP (NNS Animals)) (VP (AUX were) (VP (VBN evaluated) (PP (IN for) (NP (NNP Doc_20169779_912_935_Disease) (, ,) (NNP Doc_20169779_937_947_Disease) (CC and) (NP (NP (NP (NP (JJ on-time) (-LRB- -LRB-) (NN motor) (NNS fluctuations) (-RRB- -RRB-)) (CC and) (NP (NP (JJ Doc_20169779_985_1001_Disease-like) (NNS behaviors)) (PP (IN on) (NP (NNP Day) (CD 0))))) (PRN (-LRB- -LRB-) (RB prior) (PP (TO to) (NP (NNP Doc_20169779_1036_1044_Chemical))) (-RRB- -RRB-))) (CC and) (NP (PP (IN on) (NP (NP (NNS Days) (CD 1) (, ,) (CD 7) (, ,) (CD 13) (, ,) (CD 27) (CC and) (CD 30)) (PP (IN of) (NP (NN treatment) (VBG using) (NN post))))) (NP (FW hoc) (FW DVD) (NN analysis)) (PP (IN by) (NP (DT a) (JJ trained) (NN rater))) (, ,) (ADJP (JJ blind) (PP (TO to) (NP (DT the) (NN treatment) (NN day)))))))))) (. .)))
20169779	8	(S1 (S (NP (DT The) (JJ Doc_20169779_1180_1196_Disease-like) (NN behavior) (NN rating) (NN scale)) (VP (VBD demonstrated) (NP (NP (JJ high) (NN interrater) (NN reliability)) (PP (IN between) (NP (NP (CD three) (JJ trained) (NNS raters)) (PP (IN of) (NP (VBG differing) (JJ professional) (NNS backgrounds))))))) (. .)))
20169779	9	(S1 (S (SBAR (IN As) (S (VP (VBN anticipated)))) (, ,) (NP (NNS animals)) (VP (VBD exhibited) (NP (NP (DT a) (JJ progressive) (NN increase)) (PP (IN in) (NP (NP (JJ Doc_20169779_1393_1401_Chemical-induced) (NN motor) (NNS fluctuations)) (, ,) (NP (NNP Doc_20169779_1430_1440_Disease)) (CC and) (NP (NN wearing-off)))) (, ,) (SBAR (WHNP (WDT that)) (S (VP (VBD correlated) (PP (IN with) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (JJ Doc_20169779_1495_1503_Chemical) (NN therapy)))))))))) (. .)))
20169779	10	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (S (NP (JJ Doc_20169779_1526_1534_Chemical-induced) (JJ Doc_20169779_1543_1559_Disease-like) (NNS behaviors)) (VP (AUX were) (ADJP (JJ present)) (PP (IN on) (NP (NP (NNP Day) (CD 1)) (PP (IN of) (NP (JJ Doc_20169779_1600_1608_Chemical) (NN treatment))))))) (CC and) (S (NP (PRP$ their) (NN severity)) (VP (AUX did) (RB not) (VP (VB correlate) (PP (IN with) (NP (NP (NN duration)) (PP (IN of) (NP (NN treatment)))))))) (. .)))
20169779	11	(S1 (S (NP (DT The) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNP Doc_20169779_1719_1745_Disease)) (PP (IN in) (NP (NNP Doc_20169779_1749_1751_Disease)))) (VP (AUX are) (ADJP (RBR more) (JJ likely)) (NP (NP (DT an) (NN interaction)) (PP (IN between) (NP (NP (NNP Doc_20169779_1791_1799_Chemical)) (CC and) (NP (NP (DT the) (NN disease) (NN state)) (PP (IN than) (NP (NP (DT a) (NN consequence)) (PP (IN of) (NP (NN sensitisation))) (PP (TO to) (NP (VBN repeated) (JJ dopaminergic) (NN therapy))))))))))))) (. .)))
20192893	0	(S1 (NP (NP (NN Contrast) (NN medium) (NN nephrotoxicity)) (PP (IN after) (NP (NP (JJ renal) (NN artery)) (CC and) (NP (JJ coronary) (NN angioplasty)))) (. .)))
20192893	1	(S1 (S (NP (NP (NN Doc_20192893_88_105_Disease)) (VP (VBN induced) (PP (IN by) (NP (JJ iodinated) (NN contrast) (NN medium) (PRN (-LRB- -LRB-) (NP (NNP CM)) (-RRB- -RRB-)) (NN administration))))) (VP (MD can) (VP (VB minimize) (NP (NP (DT the) (NN benefit)) (PP (IN of) (NP (DT the) (JJ interventional) (NN procedure))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (NP (JJ renal) (NN angioplasty)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20192893_262_266_Chemical)) (-RRB- -RRB-))))))))) (. .)))
20192893	2	(S1 (FRAG (S (VP (TO To) (VP (VB compare) (NP (DT the) (NN susceptibility)) (PP (TO to) (NP (NP (JJ nephrotoxic) (NN effect)) (PP (IN of) (NP (NP (NNS CM)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (NNP Doc_20192893_359_363_Chemical)) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN submitted) (S (VP (TO to) (VP (VB percutaneous) (NP (NP (JJ coronary) (NN intervention)) (PRN (-LRB- -LRB-) (NP (NNP PCI)) (-RRB- -RRB-))))))))))))))))))))) (. .)))
20192893	3	(S1 (S (NP (NN MATERIAL) (CC AND) (NNS METHODS)) (: :) (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (CD 33) (NNS patients)) (VP (ADVP (RB successfully)) (VBN treated) (PP (IN with) (NP (NNP Doc_20192893_512_516_Chemical))) (PRN (-LRB- -LRB-) (S (NP (NP (JJ Doc_20192893_518_522_Chemical) (NN group)) (, ,) (NP (NP (JJ mean) (NN age)) (NP (CD 70+/-12) (NNS years))) (, ,) (NP (CD 23) (NN female)) (, ,) (NP (JJ basal) (JJ Doc_20192893_571_581_Chemical) (NN 1.46+/-0.79)) (, ,)) (VP (VBP range) (NP (CD 0.7-4.9) (NN mg/dl)))) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN compared) (PP (IN with) (NP (NP (CD 33) (NNS patients)) (VP (VBG undergoing) (NP (NP (NP (JJ successful) (NNP PCI)) (PRN (-LRB- -LRB-) (NP (NNP PCI) (NN group)) (-RRB- -RRB-))) (, ,) (VP (VBN matched) (PP (IN for) (NP (NP (JJ basal) (NN Doc_20192893_704_714_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1.44+/-0.6)) (, ,) (NP (NP (NN range)) (NP (CD 0.7-3.4) (NNS mg/dl))) (-RRB- -RRB-)) (, ,) (NP (NN gender)) (, ,) (CC and) (NP (NN age))))))))))) (. .)))
20192893	4	(S1 (S (PP (IN In) (NP (DT both) (NNS groups))) (NP (JJ postprocedural) (PRN (-LRB- -LRB-) (NP (CD 48) (NNP h)) (-RRB- -RRB-)) (NN serum) (NNP Doc_20192893_810_820_Chemical)) (VP (AUX was) (VP (VBN measured))) (. .)))
20192893	5	(S1 (S (NP (JJ Postprocedural) (JJ Doc_20192893_859_869_Chemical) (NN level)) (VP (VP (VBD decreased) (ADVP (RB nonsignificantly)) (PP (IN in) (NP (NP (DT the) (JJ Doc_20192893_910_914_Chemical) (NN group)) (PRN (-LRB- -LRB-) (NP (QP (CD 1.46+/-0.8) (CC vs.) (CD 1.34+/-0.5)) (NNS mg/dl)) (, ,) (NP (NNPS P=NS)) (-RRB- -RRB-))))) (CC and) (VP (VBD increased) (ADVP (RB significantly)) (PP (IN in) (NP (NP (DT the) (NNP PCI) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 1.44+/-0.6) (CC vs.) (CD 1.57+/-0.7)) (NNS mg/dl)) (, ,) (NP (NNP P<0.02))) (-RRB- -RRB-)))))) (. .)))
20192893	6	(S1 (S (NP (NP (NNS Changes)) (PP (IN in) (NP (JJ serum) (NNP Doc_20192893_1066_1076_Chemical))) (PP (IN after) (NP (NP (NN intervention)) (PRN (-LRB- -LRB-) (NP (NN after-before)) (-RRB- -RRB-))))) (VP (AUX were) (ADJP (RB significantly) (JJ different) (PP (IN between) (NP (DT the) (NNP Doc_20192893_1152_1156_Chemical) (CC and) (NNP PCI) (NNS groups)))) (PRN (-LRB- -LRB-) (NP (CD -0.12+/-0.5) (CC vs.) (CD 0.13+/-0.3) (, ,) (CD P=0.014)) (-RRB- -RRB-))) (. .)))
20192893	7	(S1 (S (NP (DT This) (NN difference)) (VP (AUX was) (RB not) (ADJP (JJ related) (PP (PP (TO to) (NP (RB either) (DT a) (JJ different) (JJ clinical) (NN risk) (NN profile))) (CC or) (PP (TO to) (NP (NP (DT the) (NN volume)) (PP (IN of) (NP (NP (NNS CM)) (VP (VBN administered))))))))) (. .)))
20192893	8	(S1 (S (PP (IN In) (NP (DT this) (JJ preliminary) (NN study))) (NP (NP (NNS patients)) (VP (VBN submitted) (PP (TO to) (NP (NNP Doc_20192893_1384_1388_Chemical))))) (VP (VBD showed) (NP (NP (DT a) (JJR lower) (NN susceptibility)) (SBAR (S (VP (TO to) (VP (VB Doc_20192893_1422_1434_Disease) (VP (VBN induced) (PP (IN by) (NP (NP (NN CM) (NN administration)) (PP (IN than) (NP (NNP PCI) (NNS patients)))))))))))) (. .)))
20192893	9	(S1 (S (NP (NP (DT The) (NN effectiveness)) (PP (IN of) (NP (NNP Doc_20192893_1504_1508_Chemical))) (PP (IN on) (NP (JJ renal) (NN function)))) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (VP (ADVP (RB barely)) (VBN influenced) (PP (IN by) (NP (NN Doc_20192893_1560_1571_Disease)))))))) (. .)))
2021990	0	(S1 (S (NP (NN Doc_2021990_0_15_Chemical)) (VP (VBZ prevents) (NP (NP (DT the) (JJ haemodynamic) (NNS changes)) (PP (IN of) (NP (NNP Doc_2021990_53_63_Chemical))) (PP (IN in) (NP (NN ICU) (NNS patients))))) (. .)))
2021990	1	(S1 (S (NP (NP (NNP Doc_2021990_81_91_Chemical)) (, ,) (NP (DT a) (NP (NP (NNP Doc_2021990_95_104_Chemical) (CD 2)) (PRN (-LRB- -LRB-) (NP (NNP H2)) (-RRB- -RRB-))) (NN antagonist)) (, ,)) (VP (VBZ produces) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (JJ arterial) (NN pressure)) (ADJP (RB due) (PP (TO to) (NP (NN vasodilatation))))))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (ADJP (RB critically) (JJ ill)) (NNS patients)))) (. .)))
2021990	2	(S1 (S (NP (DT This)) (VP (MD may) (VP (AUX be) (SBAR (IN because) (S (NP (NNP Doc_2021990_247_257_Chemical)) (VP (VBZ acts) (PP (IN as) (NP (DT a) (JJ Doc_2021990_268_277_Chemical) (NN agonist)))))))) (. .)))
2021990	3	(S1 (S (NP (PRP We)) (, ,) (ADVP (RB therefore)) (, ,) (VP (VBD investigated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (DT the) (NP (NP (NNP Doc_2021990_334_343_Chemical) (CD 1)) (PRN (-LRB- -LRB-) (NP (NNP H1)) (-RRB- -RRB-))) (NN receptor) (NN antagonist)) (, ,) (NP (NNP Doc_2021990_371_386_Chemical)) (, ,))) (PP (IN on) (NP (NP (DT the) (JJ haemodynamic) (NNS changes)) (VP (VBN observed) (PP (IN after) (NP (NNP Doc_2021990_431_441_Chemical))) (PP (IN in) (NP (NN ICU) (NNS patients)))))))) (. .)))
2021990	4	(S1 (S (NP (DT Each) (NN patient)) (VP (AUX was) (VP (VBN studied) (PP (IN on) (NP (CD two) (JJ separate) (NNS days))))) (. .)))
2021990	5	(S1 (S (PP (IN In) (NP (DT a) (JJ random) (NN fashion))) (, ,) (NP (PRP they)) (VP (VBD received) (NP (NNP Doc_2021990_541_551_Chemical) (CD 200)) (NP (JJ mg) (NNP iv)) (PP (PP (IN on) (NP (CD one) (NN day))) (, ,) (CC and) (PP (IN on) (NP (DT the) (JJ other)))) (, ,) (NP (NP (DT a) (NN pretreatment)) (PP (IN of) (NP (NNP Doc_2021990_610_625_Chemical) (CD 40))) (PP (VBG mg) (NP (NAC (NNP iv) (PP (IN with) (NP (NNP Doc_2021990_640_650_Chemical) (CD 200) (NNS mg)))) (NNP iv))))) (. .)))
2021990	6	(S1 (S (PP (IN In) (NP (DT the) (JJ non-pretreatment) (NN group))) (, ,) (NP (NP (JJ mean) (JJ arterial) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN MAP)) (-RRB- -RRB-))) (VP (VBD decreased) (PP (IN from) (NP (NP (QP (CD 107.4) (JJ +/-) (CD 8.4) (NN mmHg) (TO to) (CD 86.7)) (JJ +/-) (CD 11.4) (NNS mmHg)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-)) (NP (CD two) (NNS minutes)))) (PP (IN after) (NP (NNP Doc_2021990_815_825_Chemical)))) (. .)))
2021990	7	(S1 (S (ADVP (RB Also)) (, ,) (NP (NP (JJ systemic) (JJ vascular) (NN resistance)) (PRN (-LRB- -LRB-) (NP (NN SVR)) (-RRB- -RRB-))) (VP (VBD decreased) (PP (IN during) (NP (NP (DT the) (JJ eight-minute) (NN observation) (NN period)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-))))) (. .)))
2021990	8	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (PP (IN in) (NP (DT the) (JJ pretreatment) (NN group))) (, ,) (NP (JJ little) (NN haemodynamic) (NN change)) (VP (AUX was) (VP (VBN seen))) (. .)))
2021990	9	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (DT an) (NNP H1) (NN antagonist)) (VP (MD may) (VP (AUX be) (ADJP (JJ useful) (PP (IN in) (S (VP (VBG preventing) (NP (NP (NNP Doc_2021990_1080_1091_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP iv) (NNP Doc_2021990_1105_1115_Chemical))))))))) (, ,) (SBAR (IN since) (S (NP (NP (DT the) (JJ vasodilating) (NN activity)) (PP (IN of) (NP (NNP Doc_2021990_1152_1162_Chemical)))) (VP (AUX is) (VP (VBN mediated) (, ,) (PP (IN in) (NP (NN part))) (, ,) (PP (IN through) (NP (DT the) (JJ H1) (NN receptor)))))))))))) (. .)))
20408947	0	(S1 (NP (NP (NP (NNP Medical) (CC and) (NNP Doc_20408947_12_23_Disease) (NNS outcomes)) (PP (IN for) (NP (NP (NNS patients)) (VP (VBN transplanted) (PP (IN for) (NP (JJ Doc_20408947_63_76_Chemical-induced) (NN Doc_20408947_85_104_Disease))))))) (: :) (NP (DT a) (JJ case-control) (NN study)) (. .)))
20408947	1	(S1 (S (NP (JJ Doc_20408947_140_153_Chemical-induced) (NN hepatotoxicity)) (VP (AUX is) (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (NN cause)) (PP (IN of) (NP (NP (NNP Doc_20408947_205_224_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20408947_226_229_Disease)) (-RRB- -RRB-)))) (PP (IN in) (NP (DT the) (NNP UK))))) (. .)))
20408947	2	(S1 (S (NP (NNS Patients)) (ADVP (RB often)) (VP (VBP consume) (NP (DT the) (NN drug)) (PP (PP (IN with) (NP (JJ suicidal) (NN intent))) (CC or) (PP (IN with) (NP (NP (DT a) (NN background)) (PP (IN of) (NP (NN substance) (NN dependence))))))) (. .)))
20408947	3	(S1 (FRAG (NP (NNS AIMS) (CC AND) (NNS METHODS)) (: :) (S (NP (PRP We)) (VP (VBD compared) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NNP Doc_20408947_387_408_Disease) (, ,) (NNP Doc_20408947_410_421_Disease) (JJ co-morbidity) (, ,) (ADJP (JJ medical) (CC and) (JJ psychosocial)) (NNS outcomes))) (PP (IN of) (NP (NP (DT all) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN undergone) (NP (NP (NN liver) (NN transplantation)) (PRN (-LRB- -LRB-) (NP (NNP LT)) (-RRB- -RRB-))) (ADVP (RB emergently)) (PP (IN between) (NP (NP (CD 1999-2004)) (PP (IN for) (NP (JJ Doc_20408947_564_577_Chemical-induced) (NNP Doc_20408947_586_589_Disease))))))))) (PRN (-LRB- -LRB-) (NP (CD n=36)) (-RRB- -RRB-))))) (PP (IN with) (NP (NP (JJ age-) (CC and) (JJ sex-matched) (NNS patients)) (VP (VBG undergoing) (NP (NP (NP (JJ emergent) (NNS LT)) (PP (IN for) (NP (NP (JJ non-Doc_20408947_663_676_Chemical-induced) (NNP Doc_20408947_685_688_Disease)) (PRN (-LRB- -LRB-) (NP (CD n=35)) (-RRB- -RRB-))))) (CC and) (NP (NP (JJ elective) (NNS LT)) (PP (IN for) (NP (NP (NNP Doc_20408947_716_737_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20408947_739_742_Disease)) (, ,) (NP (CD n=34)) (-RRB- -RRB-))))))))))) (. .)))
20408947	4	(S1 (S (NP (JJ Doc_20408947_760_773_Chemical-induced) (NNP Doc_20408947_782_785_Disease) (NNS patients)) (VP (VBG undergoing) (SBAR (S (NP (NNP LT)) (VP (AUX had) (NP (NP (NP (DT a) (JJR greater) (NN severity)) (PP (IN of) (NP (NP (JJ pre-LT) (NN illness)) (VP (VBN reflected) (PP (IN by) (NP (NP (JJR higher) (JJ Acute) (NNP Physiology)) (CC and) (NP (JJ Chronic) (NN Health) (NN Evaluation) (NNP II) (NNS scores)))))))) (CC and) (NP (NP (NN requirement)) (PP (IN for) (NP (NN organ) (NN support))))) (PP (VBN compared) (PP (IN with) (NP (DT the) (JJ other) (CD two) (NNS groups)))))))) (. .)))
20408947	5	(S1 (S (NP (CD Twenty) (ADJP (PRN (-LRB- -LRB-) (NP (CD 56) (NN %)) (-RRB- -RRB-)) (JJ Doc_20408947_1010_1023_Chemical-induced)) (NNP Doc_20408947_1032_1035_Disease) (NNS patients)) (VP (AUX had) (NP (DT a) (JJ formal) (NN Doc_20408947_1058_1079_Disease)) (SBAR (IN before) (S (NP (NP (NP (NNP LT)) (PRN (-LRB- -LRB-) (NP (JJ non-Doc_20408947_1095_1108_Chemical-induced) (NNP Doc_20408947_1117_1120_Disease=0/35)) (, ,) (NP (NP (NNP Doc_20408947_1127_1130_Disease=2/34)) (: ;) (NP (NP (CD P<0.01)) (PP (IN for) (NP (DT all))))) (-RRB- -RRB-))) (CC and) (NP (NP (CD nine)) (PRN (-LRB- -LRB-) (NP (CD 25) (NN %)) (-RRB- -RRB-)))) (VP (AUX had) (NP (DT a) (JJ previous) (NN suicide) (NN attempt)))))) (. .)))
20408947	6	(S1 (S (PP (IN During) (NP (NP (NN follow-up)) (PRN (-LRB- -LRB-) (NP (QP (JJ median) (CD 5)) (NNS years)) (-RRB- -RRB-)))) (, ,) (NP (EX there)) (VP (AUX were) (NP (NP (DT no) (JJ significant) (NNS differences)) (PP (IN in) (NP (NP (NP (NN rejection)) (PRN (-LRB- -LRB-) (ADJP (JJ acute) (CC and) (JJ chronic)) (-RRB- -RRB-))) (, ,) (NP (NN graft) (NN failure)) (CC or) (NP (NN survival)))) (PP (IN between) (NP (NP (DT the) (NNS groups)) (PRN (-LRB- -LRB-) (NP (JJ Doc_20408947_1353_1366_Chemical-induced) (NNP Doc_20408947_1375_1378_Disease) (CD 1) (NN year) (CD 87) (NN %)) (, ,) (NP (NP (CD 5) (NNS years)) (NP (NP (CD 75) (NN %)) (: ;) (NP (NP (JJ non-Doc_20408947_1408_1421_Chemical-induced) (NNP Doc_20408947_1430_1433_Disease) (CD 88) (NN %)) (, ,) (NP (CD 78) (NN %))) (: ;) (NP (NNP Doc_20408947_1444_1447_Disease) (CD 93) (NN %)))) (, ,) (NP (NP (CD 82) (NN %)) (: :) (NP (CD P>0.6) (NN log) (NN rank))) (-RRB- -RRB-)))))) (. .)))
20408947	7	(S1 (S (NP (CD Two) (JJ Doc_20408947_1479_1492_Chemical-induced) (NNP Doc_20408947_1501_1504_Disease) (NNS patients)) (VP (VBD reattempted) (NP (NP (NN suicide) (NN post-LT)) (PRN (-LRB- -LRB-) (NP (NP (NN one)) (VP (VBN died) (S (ADJP (NP (CD 8) (NNS years)) (JJ post-LT))))) (-RRB- -RRB-)))) (. .)))
20408947	8	(S1 (S (PP (IN Despite) (NP (NP (DT a) (JJ high) (NN prevalence)) (PP (IN of) (NP (NNP Doc_20408947_1612_1623_Disease) (NN disturbance))))) (, ,) (NP (NP (NNS outcomes)) (PP (IN for) (NP (NP (NNS patients)) (VP (VBN transplanted) (ADVP (RB emergently)) (PP (IN for) (NP (JJ Doc_20408947_1687_1700_Chemical-induced) (NN Doc_20408947_1709_1712_Disease))))))) (VP (AUX were) (ADJP (JJ comparable) (PP (TO to) (NP (NP (DT those)) (VP (VBN transplanted) (PP (PP (IN for) (NP (JJ non-Doc_20408947_1759_1772_Chemical-induced) (NNP Doc_20408947_1781_1784_Disease))) (CC and) (ADVP (RB electively)) (PP (IN for) (NP (NNP Doc_20408947_1804_1807_Disease))))))))) (. .)))
20408947	9	(S1 (S (NP (NP (JJ Multidisciplinary) (NNS approaches)) (PP (IN with) (NP (JJ long-term) (JJ Doc_20408947_1853_1864_Disease) (NN follow-up)))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (NP (JJ low) (JJ post-transplant) (NN suicide) (NNS rates)) (VP (VBN seen))) (CC and) (NP (NP (JJ low) (NNS rates)) (PP (IN of) (NP (NN graft) (NN loss)))))) (PP (IN because) (IN of) (NP (NN non-compliance))))) (. .)))
20431083	0	(S1 (NP (NP (NP (JJ Antithrombotic) (NN drug) (NN use)) (, ,) (NP (NN cerebral) (NNS microbleeds)) (, ,) (CC and) (NP (NN Doc_20431083_51_75_Disease))) (: :) (NP (NP (DT a) (JJ systematic) (NN review)) (PP (IN of) (NP (VBN published) (CC and) (JJ unpublished) (NNS studies)))) (. .)))
20431083	1	(S1 (NP (NP (NP (NN BACKGROUND)) (CC AND) (NP (NN PURPOSE))) (: :) (S (S (NP (NP (NNP Doc_20431083_159_179_Disease)) (PRN (-LRB- -LRB-) (NP (NNP MB)) (-RRB- -RRB-))) (VP (AUX are) (NP (NP (JJ potential) (NN risk) (NNS factors)) (PP (IN for) (NP (NP (NNP Doc_20431083_216_240_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20431083_242_245_Disease)) (-RRB- -RRB-))))))) (, ,) (CC but) (S (NP (PRP it)) (VP (AUX is) (ADJP (JJ unclear)) (SBAR (IN if) (S (NP (PRP they)) (VP (AUX are) (NP (NP (DT a) (NN contraindication)) (PP (TO to) (S (VP (VBG using) (NP (JJ antithrombotic) (NNS drugs)))))))))))) (. .)))
20431083	2	(S1 (S (NP (NNS Insights)) (VP (MD could) (VP (AUX be) (VP (VBN gained) (PP (IN by) (S (VP (VBG pooling) (NP (NNS data)) (PP (IN on) (NP (NP (CD MB) (NN frequency)) (ADJP (JJ stratified) (PP (IN by) (NP (NP (JJ antithrombotic) (NN use)) (PP (IN in) (NP (NP (NNS cohorts)) (PP (IN with) (NP (NP (NNP Doc_20431083_434_437_Disease)) (CC and) (NP (NP (NP (NP (NNP Doc_20431083_442_457_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20431083_459_461_Disease)) (-RRB- -RRB-))) (NP (JJ /transient) (JJ Doc_20431083_473_481_Disease) (NN attack))) (PRN (-LRB- -LRB-) (NP (NNP Doc_20431083_490_493_Disease)) (-RRB- -RRB-)))))))))))))))))) (. .)))
20431083	3	(S1 (S (NP (PRP We)) (VP (VBD performed) (NP (NP (DT a) (JJ systematic) (NN review)) (PP (IN of) (NP (NP (VBN published) (CC and) (JJ unpublished) (NNS data)) (PP (IN from) (NP (NP (NNS cohorts)) (PP (IN with) (NP (NNP Doc_20431083_590_596_Disease) (CC or) (NNP Doc_20431083_600_603_Disease)))))))) (S (VP (TO to) (VP (VB compare) (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NP (NP (CD MB)) (PP (IN in) (NP (PRN (: :) (-LRB- -LRB-) (CD 1) (-RRB- -RRB-)) (JJ antithrombotic) (NNS users)))) (NNP vs) (NP (NP (NP (JJ nonantithrombotic) (NNS users)) (PP (IN with) (NP (NNP Doc_20431083_695_698_Disease)))) (: ;) (NP (NP (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (JJ antithrombotic) (NNS users)) (NP (NNP vs) (NNS nonusers)) (PP (IN with) (NP (NNP Doc_20431083_742_744_Disease/Doc_20431083_745_748_Disease)))) (: ;) (CC and) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-))) (NNP Doc_20431083_758_761_Disease) (NNP vs) (NNP Doc_20431083_765_773_Disease) (NNS events)) (ADJP (JJ stratified) (PP (IN by) (NP (JJ antithrombotic) (NN use)))))))))) (. .)))
20431083	4	(S1 (S (NP (PRP We)) (ADVP (RB also)) (VP (VBD analyzed) (NP (ADJP (VBN published) (CC and) (JJ unpublished)) (JJ follow-up) (NNS data)) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_20431083_898_901_Disease))) (PP (IN in) (NP (NP (JJ antithrombotic) (NNS users)) (PP (IN with) (NP (NNS MB)))))))))) (. .)))
20431083	5	(S1 (S (PP (IN In) (NP (NP (DT a) (VBN pooled) (NN analysis)) (PP (IN of) (NP (NP (CD 1460) (NN Doc_20431083_973_976_Disease)) (CC and) (NP (CD 3817) (NN Doc_20431083_986_988_Disease/Doc_20431083_989_992_Disease)))))) (, ,) (S (NP (NNS MB)) (VP (AUX were) (ADJP (RBR more) (JJ frequent)) (PP (IN in) (NP (NP (NNP Doc_20431083_1019_1022_Disease) (NNP vs) (NNP Doc_20431083_1026_1028_Disease/Doc_20431083_1029_1032_Disease)) (PP (IN in) (NP (DT all) (NN treatment) (NNS groups))))))) (, ,) (CC but) (S (NP (DT the) (NN excess)) (VP (VBN increased) (PP (IN from) (NP (NP (CD 2.8)) (PRN (-LRB- -LRB-) (NP (NP (NNS odds) (NN ratio)) (: ;) (NP (NN range))) (, ,) (NP (CD 2.3-3.5)) (-RRB- -RRB-)))) (PP (IN in) (NP (JJ nonantithrombotic) (NNS users))) (PP (TO to) (NP (NP (CD 5.7)) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (CD 3.4-9.7)) (-RRB- -RRB-)) (PP (IN in) (NP (NP (NP (JJ antiplatelet) (NNS users)) (CC and) (NP (NP (CD 8.0)) (PRN (-LRB- -LRB-) (NP (NN range)) (, ,) (NP (CD 3.5-17.8)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NNP Doc_20431083_1223_1231_Chemical) (NNS users)) (PRN (-LRB- -LRB-) (NP (NNP P) (CD difference=0.01)) (-RRB- -RRB-)))))))))) (. .)))
20431083	6	(S1 (S (NP (EX There)) (VP (AUX was) (ADVP (RB also)) (NP (NP (NP (DT an) (NN excess)) (PP (IN of) (NP (NP (NNS MB)) (PP (IN in) (NP (NP (JJ Doc_20431083_1293_1301_Chemical) (NNS users)) (SBAR (S (NP (NNP vs)) (VP (VBZ nonusers) (PP (IN with) (NP (NNP Doc_20431083_1325_1328_Disease)))))))))) (PRN (-LRB- -LRB-) (CC OR) (, ,) (NP (NP (CD 2.7)) (: ;) (NP (CD 95) (NN %) (CD CI) (, ,) (CD 1.6-4.4)) (: ;) (NP (CD P<0.001))) (-RRB- -RRB-))) (CC but) (NP (NP (NN none)) (PP (IN in) (NP (NP (JJ Doc_20431083_1377_1385_Chemical) (NNS users)) (PP (IN with) (NP (NNP Doc_20431083_1397_1399_Disease/Doc_20431083_1400_1403_Disease))))) (PRN (-LRB- -LRB-) (CC OR) (, ,) (NP (NP (CD 1.3)) (: ;) (NP (CD 95) (NN %) (CD CI) (, ,) (CD 0.9-1.7)) (: ;) (NP (CD P=0.33)) (: ;) (NP (QP (CD P) (CD difference=0.01)))) (-RRB- -RRB-))))) (. .)))
20431083	7	(S1 (S (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJR smaller) (NN excess)) (PP (IN of) (S (VP (VBG MB) (PP (IN in) (NP (NN antiplatelet) (NNS users))) (NP (NP (NNP vs) (NNS nonusers)) (PP (IN with) (NP (NP (NNP Doc_20431083_1531_1534_Disease)) (PRN (-LRB- -LRB-) (CC OR) (, ,) (NP (NP (CD 1.7)) (: ;) (NP (CD 95) (NN %) (CD CI) (, ,) (CD 1.3-2.3)) (: ;) (NP (CD P<0.001))) (-RRB- -RRB-))))))))))) (, ,) (CC but) (S (NP (NNS findings)) (VP (AUX were) (ADJP (JJ similar) (PP (IN for) (NP (NP (JJ antiplatelet) (NNS users)) (PP (IN with) (NP (NNP Doc_20431083_1626_1628_Disease/Doc_20431083_1629_1632_Disease)))))) (PRN (-LRB- -LRB-) (CC OR) (, ,) (NP (NP (CD 1.4)) (: ;) (NP (CD 95) (NN %) (CD CI) (, ,) (CD 1.2-1.7)) (: ;) (NP (CD P<0.001)) (: ;) (NP (QP (CD P) (CD difference=0.25)))) (-RRB- -RRB-)))) (. .)))
20431083	8	(S1 (S (PP (IN In) (NP (NP (VBN pooled) (JJ follow-up) (NNS data)) (PP (IN for) (NP (CD 768) (JJ antithrombotic) (NNS users))))) (, ,) (NP (NP (NN presence)) (PP (IN of) (NP (NN MB))) (PP (IN at) (NP (NN baseline)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (ADJP (RB substantially) (JJ increased)) (NN risk)) (PP (IN of) (NP (NP (JJ subsequent) (NNP Doc_20431083_1836_1839_Disease)) (PRN (-LRB- -LRB-) (CC OR) (, ,) (NP (NP (CD 12.1)) (: ;) (NP (CD 95) (NN %) (CD CI) (, ,) (CD 3.4-42.5)) (: ;) (NP (NNP P<0.001))) (-RRB- -RRB-)))))))) (. .)))
20431083	9	(S1 (S (NP (NP (DT The) (NN excess)) (PP (IN of) (NP (NP (NN MB)) (PP (IN in) (NP (NP (JJ Doc_20431083_1912_1920_Chemical) (NNS users)) (PP (IN with) (NP (NNP Doc_20431083_1932_1935_Disease))))) (PP (VBN compared) (PP (TO to) (NP (JJ other) (NNS groups))))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNS MB)) (VP (VBP increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ Doc_20431083_1999_2007_Chemical-associated) (NN Doc_20431083_2019_2022_Disease)))))))) (. .)))
20431083	10	(S1 (S (S (NP (JJ Limited) (JJ prospective) (NNS data)) (VP (VBP corroborate) (NP (DT these) (NNS findings)))) (, ,) (CC but) (S (NP (JJR larger) (JJ prospective) (NNS studies)) (VP (AUX are) (ADVP (RB urgently)) (VP (VBN required)))) (. .)))
20447294	0	(S1 (NP (NP (NNS Studies)) (PP (IN of) (NP (NP (NN synergy)) (PP (IN between) (NP (NP (NNP Doc_20447294_27_35_Chemical)) (CC and) (NP (NP (DT a) (JJ novel) (JJ Doc_20447294_48_54_Chemical) (NN channel) (NN blocker)) (, ,) (NP (NNP Doc_20447294_72_79_Chemical)) (, ,)))) (PP (IN in) (NP (NP (NN rat) (NNS models)) (PP (IN of) (NP (NNP Doc_20447294_98_131_Disease))))))) (. .)))
20447294	1	(S1 (S (NP (DT This) (NN study)) (VP (VBD determined) (NP (NP (DT the) (JJ antihyperalgesic) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_20447294_197_204_Chemical)) (, ,) (NP (NP (DT a) (JJ Doc_20447294_208_214_Chemical) (NN channel) (NN blocker)) (PP (IN with) (NP (NP (JJ antioxidant) (NNS properties)) (VP (VBN given) (UCP (ADVP (RB alone)) (CC and) (PP (IN in) (NP (NP (NNS combinations)) (PP (IN with) (NP (NP (NNP Doc_20447294_296_304_Chemical)) (PP (IN in) (NP (NP (NN rat) (NNS models)) (PP (IN of) (NP (NNP Doc_20447294_322_355_Disease)))))))))))))))))) (. .)))
20447294	2	(S1 (S (S (NP (NP (NN Dose) (NN response) (NNS curves)) (PP (IN for) (NP (NP (JJ nonsedating) (NNS doses)) (PP (IN of) (NP (NNP Doc_20447294_411_419_Chemical) (CC and) (NNP Doc_20447294_424_431_Chemical))))) (VP (VBN given) (ADVP (ADVP (RB intraperitoneally) (RB alone)) (CC and) (ADVP (RB together))) (PP (IN in) (NP (NNS combinations))))) (VP (AUX were) (VP (VBN constructed) (PP (IN for) (NP (NP (JJ antihyperalgesic) (NN effect)) (VP (VBG using) (NP (NP (NN paw) (NN withdrawal)) (PP (IN from) (NP (JJ noxious) (NN heat)))) (PP (IN in) (NP (CD two) (NNP Doc_20447294_582_590_Disease) (NNS models))))))))) (: :) (S (NP (NP (JJ carrageenan-induced) (NN paw) (NNP Doc_20447294_623_635_Disease) (CC and) (NNP Doc_20447294_640_654_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20447294_656_659_Chemical)) (-RRB- -RRB-))) (VP (VBD -induced) (NP (NNP Doc_20447294_669_688_Disease)))) (. .)))
20447294	3	(S1 (S (NP (DT The) (NN maximum) (NN nonsedating) (NNS doses)) (VP (AUX were) (: :) (NP (NP (NNP Doc_20447294_735_743_Chemical)) (, ,) (NP (NP (CD 3.2) (NN mg/kg)) (: ;) (NP (NNP Doc_20447294_756_763_Chemical) (CD 10.0) (NN mg/kg)) (: ;) (NP (NP (QP (CD 5.0) (CD mg/kg)) (NN Doc_20447294_786_793_Chemical)) (PP (IN with) (NP (NNP Doc_20447294_799_807_Chemical) (CD 3.2))) (VP (VBN mg/kg) (PP (IN in) (NP (NN combination)))))))) (. .)))
20447294	4	(S1 (S (NP (DT The) (NNS doses)) (VP (VBD calculated) (S (VP (TO to) (VP (VB cause) (NP (NP (CD 50) (NN %) (NN reversal)) (PP (IN of) (NP (NP (NP (NNP Doc_20447294_880_892_Disease)) (PRN (-LRB- -LRB-) (CD ED50) (-RRB- -RRB-)) (SBAR (S (VP (AUX were) (NP (NP (NP (NP (NP (NP (NP (CD 7.54)) (PRN (-LRB- -LRB-) (NP (CD 1.81)) (-RRB- -RRB-))) (CC and) (NP (CD 4.83))) (PRN (-LRB- -LRB-) (NP (CD 1.54)) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (JJ carrageenan) (NN model)))) (CC and) (NP (NP (CD 44.18)) (PRN (-LRB- -LRB-) (NP (CD 1.37)) (-RRB- -RRB-)))) (CC and) (NP (CD 9.14))) (PRN (-LRB- -LRB-) (NP (CD 1.24)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (DT the) (JJ Doc_20447294_998_1001_Chemical-induced) (NNP Doc_20447294_1010_1020_Disease) (NN model)) (PP (IN for) (NP (NNP Doc_20447294_1031_1038_Chemical) (CC and) (NNP Doc_20447294_1043_1051_Chemical))))) (, ,) (ADVP (RB respectively)))))) (PRN (-LRB- -LRB-) (NP (NP (NN mg/kg)) (: ;) (S (VP (VBP mean)))) (, ,) (NP (NNP SEM)) (-RRB- -RRB-))))))))) (. .)))
20447294	5	(S1 (S (NP (DT These) (NNS values)) (VP (AUX were) (ADJP (ADJP (JJR greater)) (PP (IN than) (NP (DT the) (JJ maximum) (JJ nonsedating) (NNS doses))))) (. .)))
20447294	6	(S1 (S (S (NP (NP (DT The) (CD ED50) (NNS values)) (PP (IN for) (NP (NP (NNP Doc_20447294_1168_1176_Chemical)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN in) (NP (NN combination))) (PP (IN with) (NP (NP (NNP Doc_20447294_1208_1215_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg/kg)) (-RRB- -RRB-)))))))))) (VP (AUX were) (ADJP (JJR less) (PP (IN than) (NP (DT the) (JJ maximum) (NN nonsedating) (NN dose)))))) (: :) (S (NP (NP (NP (CD 0.56)) (PRN (-LRB- -LRB-) (NP (CD 1.55)) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (JJ carrageenan) (NN model)))) (CC and) (NP (NP (CD 1.37)) (PRN (-LRB- -LRB-) (NP (CD 1.23)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (DT the) (NNP Doc_20447294_1331_1341_Disease) (NN model)) (PRN (-LRB- -LRB-) (NP (CD mg/kg)) (: ;) (S (VP (VB mean))) (, ,) (NP (NNP SEM)) (-RRB- -RRB-))))) (. .)))
20447294	7	(S1 (S (NP (NP (DT The) (NN antinociception)) (PP (IN after) (NP (NP (NNP Doc_20447294_1394_1402_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 3.2) (NN mg/kg)) (-RRB- -RRB-))))) (VP (AUX was) (VP (VBN increased) (PP (IN by) (NP (NP (NN co-administration)) (PP (IN with) (NP (NNP Doc_20447294_1455_1462_Chemical))))) (PP (IN from) (NP (NP (QP (CD 28.0) (CC and) (CD 31.7) (NN %) (TO to) (CD 114.6) (CC and) (CD 56.9) (NN %)) (NN reversal)) (PP (IN of) (NP (NP (NP (NNP Doc_20447294_1514_1526_Disease)) (PP (IN in) (NP (DT the) (JJ inflammatory) (CC and) (JJ neuropathic) (NNS models))) (, ,) (ADVP (RB respectively))) (PRN (-LRB- -LRB-) (NP (NP (NNP P) (NNP <) (CD 0.01)) (: ;) (NP (NP (JJ one-way) (NN analysis)) (PP (IN of) (NP (NP (RB variance-significantly) (JJR greater)) (PP (IN than) (NP (NP (DT either) (NN drug)) (VP (VBN given) (ADVP (RB alone))))))))) (-RRB- -RRB-)))))))) (. .)))
20447294	8	(S1 (S (NP (NP (DT The) (JJ maximum) (JJ antihyperalgesic) (NN effect)) (ADJP (JJ achievable) (PP (IN with) (NP (NP (JJ nonsedating) (NNS doses)) (PP (IN of) (NP (NNP Doc_20447294_1763_1771_Chemical))))))) (VP (MD may) (VP (AUX be) (VP (VBN increased) (ADVP (RB significantly)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN drug)) (VP (AUX is) (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NNP Doc_20447294_1845_1852_Chemical)))))))))))) (. .)))
20495512	0	(S1 (NP (NP (JJ Doc_20495512_0_7_Chemical-induced) (NN thrombocytopenia)) (: :) (NP (DT a) (JJ practical) (NN review)) (. .)))
20495512	1	(S1 (S (NP (NP (JJ Doc_20495512_54_61_Chemical-induced) (NN thrombocytopenia)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20495512_88_91_Disease)) (-RRB- -RRB-))) (VP (VBZ remains) (ADJP (JJ under-recognized)) (PP (IN despite) (NP (PRP$ its) (ADJP (RB potentially) (JJ devastating)) (NNS outcomes)))) (. .)))
20495512	2	(S1 (S (NP (PRP It)) (VP (VBZ begins) (SBAR (WHADVP (WRB when)) (S (NP (JJ Doc_20495512_179_186_Chemical) (NN exposure)) (VP (VBZ stimulates) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NP (NP (JJ Doc_20495512_224_231_Chemical-platelet) (NN factor)) (NP (CD 4) (NNS antibodies))) (, ,) (SBAR (WHNP (WDT which)) (S (PP (IN in) (NP (NN turn))) (VP (VBZ triggers) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (JJ procoagulant) (NN platelet) (NNS particles)))))))))))))) (. .)))
20495512	3	(S1 (S (NP (NP (NNP Doc_20495512_333_343_Disease) (CC and) (NNP Doc_20495512_348_364_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBP follow))))) (VP (VBP comprise) (NP (NP (DT the) (CD 2) (NN hallmark) (NNS traits)) (PP (IN of) (NP (NNP Doc_20495512_411_414_Disease)))) (, ,) (SBAR (IN with) (S (NP (DT the) (NN former)) (ADJP (RB largely) (JJ responsible) (PP (IN for) (NP (JJ significant) (NN Doc_20495512_468_490_Disease))))))) (. .)))
20495512	4	(S1 (S (NP (NP (DT The) (NN prevalence)) (PP (IN of) (NP (NNP Doc_20495512_510_513_Disease)))) (VP (VBZ varies) (PP (IN among) (NP (JJ several) (NNS subgroups))) (, ,) (PP (IN with) (NP (NP (JJR greater) (NN incidence)) (PP (IN in) (NP (JJ surgical) (RB as))) (PP (VBN compared) (PP (IN with) (NP (JJ medical) (NNS populations))))))) (. .)))
20495512	5	(S1 (S (NP (NN Doc_20495512_619_622_Disease)) (VP (VP (MD must) (VP (AUX be) (VP (VBN acknowledged) (PP (IN for) (NP (NP (PRP$ its) (JJ intense) (NN predilection)) (PP (IN for) (NP (NNP Doc_20495512_677_687_Disease)))))))) (CC and) (VP (VBD suspected) (SBAR (WHADVP (WRB whenever)) (S (NP (NNP Doc_20495512_711_721_Disease)) (VP (VBZ occurs) (PP (IN after) (NP (NNP Doc_20495512_735_742_Chemical) (NN exposure)))))))) (. .)))
20495512	6	(S1 (S (NP (NP (JJ Early) (NN recognition)) (SBAR (WHNP (WDT that)) (S (VP (VBZ incorporates) (NP (DT the) (JJ clinical) (CC and) (JJ serologic) (NNS clues)))))) (VP (AUX is) (NP (NP (ADJP (JJ paramount) (TO to) (JJ timely)) (NN institution)) (PP (IN of) (NP (NN treatment)))) (, ,) (SBAR (IN as) (S (NP (PRP$ its) (NN delay)) (VP (MD may) (VP (VB result) (PP (IN in) (NP (JJ catastrophic) (NNS outcomes)))))))) (. .)))
20495512	7	(S1 (S (NP (NP (DT The) (NN treatment)) (PP (IN of) (NP (NNP Doc_20495512_938_941_Disease)))) (VP (NNS mandates) (NP (NP (NP (DT an) (JJ immediate) (NN cessation)) (PP (IN of) (NP (DT all) (JJ Doc_20495512_981_988_Chemical) (NN exposure)))) (CC and) (NP (NP (DT the) (NN institution)) (PP (IN of) (NP (DT an) (JJ antithrombotic) (NN therapy))))) (, ,) (S (ADVP (RBS most) (RB commonly)) (VP (VBG using) (NP (DT a) (JJ direct) (NN thrombin) (NN inhibitor))))) (. .)))
20495512	8	(S1 (S (NP (NP (JJ Current) (`` ``) (JJ diagnostic) ('' '') (NNS tests)) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB primarily)) (VP (VBP include) (NP (ADJP (ADJP (JJ functional)) (CC and) (ADJP (JJ antigenic))) (NNS assays))))) (, ,)) (VP (AUX have) (NP (NP (JJR more)) (PP (IN of) (NP (DT a) (NN confirmatory))) (PP (IN than) (NP (NP (JJ diagnostic) (NN role)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NNP Doc_20495512_1252_1255_Disease))))))))) (. .)))
20495512	9	(S1 (S (NP (JJ Special) (NN attention)) (VP (MD must) (VP (AUX be) (VP (VBN paid) (PP (TO to) (NP (NP (JJ cardiac) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (ADVP (RB often)) (VP (VBN exposed) (PP (TO to) (NP (JJ Doc_20495512_1333_1340_Chemical) (JJ multiple) (NNS times))) (PP (IN during) (NP (NP (PRP$ their) (NN course)) (PP (IN of) (NP (NN treatment)))))))))))))) (. .)))
20495512	10	(S1 (S (NP (JJ Direct) (NN thrombin) (NNS inhibitors)) (VP (AUX are) (ADJP (JJ appropriate)) (, ,) (NP (NP (JJ evidence-based) (NNS alternatives)) (PP (TO to) (NP (NNP Doc_20495512_1465_1472_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_20495512_1503_1506_Disease))))) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX need) (S (VP (TO to) (VP (VB undergo) (NP (JJ percutaneous) (JJ coronary) (NN intervention)))))))))))) (. .)))
20495512	11	(S1 (S (SBAR (IN As) (S (NP (NNP Doc_20495512_1567_1574_Chemical)) (VP (VBZ remains) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (ADJP (ADVP (RBS most) (RB frequently)) (VBN used)) (NNS medications)))) (NP (NN today)) (PP (IN with) (NP (NN potential))) (PP (IN for) (NP (NNP Doc_20495512_1652_1655_Disease))) (PP (IN with) (NP (DT every) (JJ Doc_20495512_1667_1674_Chemical) (NN exposure)))))) (, ,) (NP (NP (DT a) (JJ close) (NN vigilance)) (PP (IN of) (NP (NN platelet) (NNS counts)))) (VP (MD must) (VP (AUX be) (ADJP (JJ practiced)) (SBAR (WHADVP (WRB whenever)) (S (NP (NNP Doc_20495512_1749_1756_Chemical)) (VP (AUX is) (VP (VBN initiated))))))) (. .)))
20513036	0	(S1 (NP (NP (NNP Abductor) (NNP Doc_20513036_9_18_Disease)) (PP (IN after) (NP (NP (JJ botox) (NN injection)) (PP (IN for) (NP (NNP Doc_20513036_45_73_Disease))))) (. .)))
20513036	1	(S1 (NP (NP (NN OBJECTIVES/HYPOTHESIS)) (: :) (S (NP (NP (JJ Botulinum) (NN toxin) (PRN (-LRB- -LRB-) (NP (NNP Botox)) (-RRB- -RRB-)) (NNS injections)) (PP (IN into) (NP (DT the) (JJ thyroarytenoid) (NNS muscles)))) (VP (AUX are) (NP (NP (DT the) (JJ current) (NN standard)) (PP (IN of) (NP (NN care))) (PP (IN for) (NP (NP (NNP Doc_20513036_202_230_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20513036_232_236_Disease)) (-RRB- -RRB-))))))) (. .)))
20513036	2	(S1 (S (NP (JJ Reported) (JJ adverse) (NNS effects)) (VP (VBP include) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (NP (NN breathiness)) (, ,) (NP (NN Doc_20513036_297_308_Disease)) (, ,) (CC and) (NP (NP (NN difficulty)) (PP (IN with) (NP (VBG swallowing) (NNS liquids)))))))) (. .)))
20513036	3	(S1 (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP report) (NP (NP (JJ multiple) (NNS cases)) (PP (IN of) (NP (NNP Doc_20513036_383_411_Disease)))) (PP (VBG following) (NP (NP (NNP Botox) (NNS injections)) (PP (IN for) (NP (NP (NNP Doc_20513036_443_447_Disease)) (, ,) (NP (NP (DT a) (NN complication)) (ADJP (RB previously) (JJ unreported)))))))) (. .)))
20513036	4	(S1 (NP (NP (NN STUDY) (NN DESIGN)) (: :) (NP (NN Retrospective) (NN case) (NN series)) (. .)))
20513036	5	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NNP Botox) (NNS injections)) (PP (IN for) (NP (NP (JJ spasmodic) (NN Doc_20513036_591_600_Disease)) (PP (IN between) (NP (NP (NNP January) (CD 2000)) (CC and) (NP (NNP October) (CD 2009)))))))))) (VP (AUX were) (VP (VBN evaluated))) (. .)))
20513036	6	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NNP Doc_20513036_669_673_Disease)))) (VP (AUX were) (VP (VBN identified))) (. .)))
20513036	7	(S1 (S (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (NNS treatments)))) (VP (VBD received))) (CC and) (S (NP (JJ adverse) (NNS effects)) (VP (AUX were) (VP (VBN noted)))) (. .)))
20513036	8	(S1 (S (PP (IN For) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_20513036_775_803_Disease))))) (, ,) (NP (NP (NP (NN age)) (, ,) (NP (NN sex)) (, ,) (NP (NNP Doc_20513036_815_824_Disease) (NNP Botox) (NN dose)) (, ,) (NP (JJ prior) (JJ Botox) (NN dose)) (, ,) (CC and) (NP (NN course))) (VP (VBG following) (NP (NNP Doc_20513036_876_885_Disease)))) (VP (AUX were) (VP (VBN noted))) (. .)))
20513036	9	(S1 (S (PP (IN From) (NP (NP (DT a) (NN database)) (PP (IN of) (NP (NP (CD 452) (NNS patients)) (VP (VBG receiving) (NP (NNP Botox))))))) (, ,) (NP (CD 352) (NNS patients)) (VP (AUX had) (VP (AUX been) (VP (VBN diagnosed) (PP (IN with) (NP (NN Doc_20513036_993_997_Disease)))))) (. .)))
20513036	10	(S1 (S (PP (IN Of) (NP (DT these) (CD 352) (NNS patients))) (, ,) (S (NP (CD eight) (NNS patients)) (VP (VBD suffered) (NP (NN Doc_20513036_1046_1074_Disease)))) (, ,) (CC and) (S (NP (CD two)) (VP (VBD suffered) (NP (DT this) (NN complication)) (ADVP (RB twice)))) (. .)))
20513036	11	(S1 (S (NP (DT All) (JJ affected) (NNS patients)) (VP (AUX were) (NP (NNS females)) (PP (IN over) (NP (NP (DT the) (NN age)) (PP (IN of) (NP (CD 50) (NNS years)))))) (. .)))
20513036	12	(S1 (S (NP (JJS Most) (NNS patients)) (VP (VP (AUX had) (VP (VBN received) (NP (NP (NNS treatments)) (PP (ADVP (RB prior)) (TO to) (NP (NNP Doc_20513036_1226_1244_Disease)))))) (CC and) (VP (VBD continued) (NP (NN receiving)) (PP (IN after) (NP (NNP Doc_20513036_1275_1284_Disease))))) (. .)))
20513036	13	(S1 (S (S (NP (CD Seven) (NNS patients)) (VP (VBD recovered) (PP (IN after) (NP (NP (DT a) (JJ brief) (NN period)) (PP (IN of) (NP (NN activity) (NNS restrictions))))))) (, ,) (CC and) (S (NP (NN one)) (VP (VBD underwent) (NP (DT a) (NN tracheotomy)))) (. .)))
20513036	14	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_20513036_1408_1426_Disease))) (PP (IN after) (NP (NNP Botox) (NN injection))) (PP (IN for) (NP (NNP Doc_20513036_1453_1457_Disease)))) (VP (AUX was) (NP (CD 0.34) (NN %))) (. .)))
20513036	15	(S1 (S (NP (NNP Bilateral) (NNP Doc_20513036_1492_1510_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ rare) (NN complication)) (PP (IN of) (NP (NNP Botox) (NNS injections))) (PP (IN for) (NP (NNP Doc_20513036_1558_1562_Disease)))) (, ,) (S (VP (VBG causing) (NP (NN difficulty)) (PP (IN with) (S (VP (VBG breathing) (PP (IN upon) (NP (NN exertion))))))))) (. .)))
20513036	16	(S1 (S (NP (NP (DT The) (JJ likely) (NN mechanism)) (PP (IN of) (NP (NNP Doc_20513036_1637_1646_Disease)))) (VP (AUX is) (NP (NP (NN diffusion)) (PP (IN of) (NP (NNP Botox)))) (PP (IN around) (NP (NP (DT the) (JJ muscular) (NN process)) (PP (IN of) (NP (NP (DT the) (NN arytenoid)) (PP (TO to) (NP (DT the) (NN posterior) (NN cricoarytenoid) (NNS muscles)))))))) (. .)))
20513036	17	(S1 (S (S (NP (DT The) (NNP Doc_20513036_1759_1768_Disease)) (VP (AUX is) (ADJP (JJ temporary)))) (, ,) (CC and) (S (NP (NP (NN watchful)) (VP (VBG waiting) (PP (IN with) (NP (NP (NN restriction)) (PP (IN of) (NP (NN activity))))))) (VP (AUX is) (NP (DT the) (VBN recommended) (NN management)))) (. .)))
20566328	0	(S1 (S (NP (NNP Doc_20566328_0_24_Disease)) (VP (VBZ contributes) (PP (TO to) (NP (NNP Doc_20566328_40_47_Chemical-induced) (NNP Doc_20566328_56_75_Disease))) (: :) (NP (NP (NN Prevention)) (PP (IN by) (NP (DT the) (JJ targeted) (JJ antioxidant) (NNS MitoQ))))) (. .)))
20566328	1	(S1 (S (NP (NP (DT The) (NN goal)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB assess) (NP (NP (JJ mitochondrial) (NN function)) (CC and) (NP (JJ ROS) (NN production))) (PP (IN in) (NP (NP (DT an) (JJ experimental) (NN model)) (PP (IN of) (NP (JJ Doc_20566328_230_237_Chemical-induced) (NNP Doc_20566328_246_265_Disease))))))))) (. .)))
20566328	2	(S1 (S (NP (PRP We)) (VP (VBN hypothesized) (SBAR (IN that) (S (NP (JJ Doc_20566328_288_295_Chemical) (NN abuse)) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (JJ altered) (JJ mitochondrial) (NN function)) (SBAR (WHNP (WDT that)) (S (PP (IN in) (NP (NN turn))) (VP (MD may) (VP (VB cause) (NP (NN Doc_20566328_368_396_Disease))))))))))))) (. .)))
20566328	3	(S1 (S (NP (NP (CD Seven) (NNS days)) (PP (IN of) (NP (NNP Doc_20566328_412_419_Chemical) (NN administration))) (PP (TO to) (NP (NNS rats)))) (VP (VBD led) (PP (TO to) (NP (NP (DT an) (VBN increased) (JJ Doc_20566328_463_469_Chemical) (NN consumption)) (VP (VBD detected) (PP (IN in) (NP (JJ cardiac) (NNS fibers))) (, ,) (ADVP (RB specifically)) (PP (IN through) (NP (NP (JJ complex) (NNP I)) (CC and) (NP (JJ complex) (NNP III)))))))) (. .)))
20566328	4	(S1 (S (NP (NN ROS) (NNS levels)) (VP (AUX were) (VP (VBN increased) (, ,) (PP (ADVP (RB specifically)) (IN in) (NP (JJ interfibrillar) (NNS mitochondria))))) (. .)))
20566328	5	(S1 (S (PP (IN In) (NP (NN parallel))) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (JJ Doc_20566328_666_669_Chemical) (NN synthesis)))) (, ,) (SBAR (IN whereas) (S (NP (DT no) (NN difference)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (JJ subsarcolemmal) (NN mitochondria)))))))) (. .)))
20566328	6	(S1 (S (NP (NP (DT This) (JJ uncoupling) (NN effect)) (PP (IN on) (NP (JJ oxidative) (NN phosphorylation)))) (VP (AUX was) (ADJP (RB not) (JJ detectable)) (PP (IN after) (NP (NP (JJ short-term) (NN exposure)) (PP (TO to) (NP (NNP Doc_20566328_848_855_Chemical))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (DT these) (NNP Doc_20566328_879_906_Disease)) (VP (AUX were) (NP (NP (DT a) (JJ late)) (PP (RB rather) (IN than) (NP (NP (DT a) (JJ primary) (NN event)) (PP (IN in) (NP (NP (DT the) (JJ pathological) (NN response)) (PP (TO to) (NP (NNP Doc_20566328_979_986_Chemical)))))))))))))) (. .)))
20566328	7	(S1 (S (NP (NP (NNP MitoQ)) (, ,) (NP (DT a) (JJ mitochondrial-targeted) (NN antioxidant)) (, ,)) (VP (AUX was) (VP (VBN shown) (S (VP (TO to) (VP (ADVP (RB completely)) (VB prevent) (NP (NP (DT these) (NNP Doc_20566328_1071_1098_Disease)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NNP Doc_20566328_1110_1129_Disease)) (VP (VBD characterized) (ADVP (RB here)) (PP (IN by) (NP (NP (DT a) (NN Doc_20566328_1154_1175_Disease)) (VP (VBN studied) (PP (IN with) (NP (NP (DT a) (NN conductance) (NN catheter)) (SBAR (S (VP (TO to) (VP (VB obtain) (NP (JJ pressure-volume) (NNS data))))))))))))))))))) (. .)))
20566328	8	(S1 (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (DT these) (NNS results)) (VP (VP (VBP extend) (NP (JJ previous) (NNS studies))) (CC and) (VP (VB demonstrate) (SBAR (IN that) (S (NP (NNP Doc_20566328_1319_1326_Chemical-induced) (NNP Doc_20566328_1335_1354_Disease)) (VP (MD may) (VP (AUX be) (ADJP (JJ due) (PP (TO to) (NP (DT a) (NN Doc_20566328_1371_1391_Disease)))))))))) (. .)))
20589632	0	(S1 (NP (NP (JJ Doc_20589632_0_12_Chemical-induced) (JJ immune) (NN Doc_20589632_28_44_Disease)) (PP (IN in) (NP (NP (DT a) (JJ pediatric) (NN oncology) (NN patient)) (VP (VBG presenting) (PP (IN as) (NP (DT an) (NN Doc_20589632_94_130_Disease)))))) (. .)))
20589632	1	(S1 (NP (NP (DT A) (JJ 10-year-old) (NN male)) (PP (IN with) (NP (NNP Doc_20589632_156_170_Disease))) (VP (VBN presented) (PP (IN with) (NP (NNP Doc_20589632_186_210_Disease)))) (. .)))
20589632	2	(S1 (S (PP (IN During) (NP (JJ red) (NN cell) (NN transfusion))) (, ,) (NP (PRP he)) (VP (VBD developed) (NP (NN Doc_20589632_254_268_Disease))) (. .)))
20589632	3	(S1 (S (NP (NN Transfusion) (NN reaction)) (ADVP (RB workup)) (VP (AUX was) (ADJP (JJ negative))) (. .)))
20589632	4	(S1 (S (NP (NN Doc_20589632_312_348_Disease)) (VP (AUX was) (VP (VBN suspected) (PP (IN because) (IN of) (NP (NP (JJ positive) (JJ direct) (NN antiglobulin) (NN test)) (, ,) (NP (JJ negative) (NN eluate)) (, ,) (CC and) (NP (NP (NNS microspherocytes)) (PP (IN on) (NP (NP (JJ smear) (NN pre-)) (CC and) (NP (NN post-transfusion))))))))) (. .)))
20589632	5	(S1 (S (NP (NP (NN Drug) (NNS studies)) (VP (VBG using) (NP (DT the) (JJ indirect) (NN antiglobulin) (NN test)))) (VP (AUX were) (ADJP (ADJP (RB strongly) (JJ positive) (PP (IN with) (NP (NNP Doc_20589632_561_573_Chemical)))) (CC and) (ADJP (JJ Doc_20589632_578_590_Chemical-Doc_20589632_591_607_Chemical)) (CC but) (ADJP (JJ negative) (PP (IN with) (NP (NNP Doc_20589632_626_642_Chemical)))))) (. .)))
20589632	6	(S1 (S (NP (DT The) (NN patient)) (VP (VBD recovered) (PP (IN after) (S (VP (VBG discontinuing) (NP (DT the) (NN drug))))) (, ,) (PP (IN with) (NP (NP (DT no) (NN recurrence)) (PP (IN in) (NP (CD 2) (NNS years)))))) (. .)))
20589632	7	(S1 (S (NP (NP (JJ Other) (NNS causes)) (PP (IN of) (NP (NNP Doc_20589632_743_749_Disease)))) (VP (MD should) (VP (AUX be) (VP (VBN considered) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ worse-than-expected) (NN Doc_20589632_808_814_Disease)) (PP (IN after) (NP (NN chemotherapy)))))))))) (. .)))
20589632	8	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN Doc_20589632_848_857_Disease)) (PP (IN during) (NP (NN transfusion)))) (VP (AUX is) (RB not) (ADVP (RB always)) (NP (DT a) (NN transfusion) (NN reaction))) (. .)))
20595935	0	(S1 (NP (NP (NP (JJ Doc_20595935_0_9_Chemical) (NN stimulation) (NN test)) (PP (IN in) (NP (NNP Doc_20595935_30_48_Disease)))) (: :) (NP (NP (NN loss)) (PP (IN of) (NP (NN prolactin) (NN response))) (PP (IN in) (NP (ADJP (JJ anatomic) (CC or) (JJ functional)) (NN stalk) (NN effect)))) (. .)))
20595935	1	(S1 (S (NP (JJ Doc_20595935_122_131_Chemical) (NN stimulation) (NN test)) (VP (AUX was) (ADVP (RB previously)) (VP (VBN investigated) (PP (IN as) (NP (NP (DT a) (NN tool)) (PP (PP (IN for) (NP (NP (NN differential) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_20595935_217_235_Disease))))) (, ,) (CC but) (PP (IN with) (NP (JJ conflicting) (NNS results)))))))) (. .)))
20595935	2	(S1 (S (NP (NN Macroprolactinemia)) (VP (AUX was) (ADVP (RB never)) (VP (VBN considered) (PP (IN in) (NP (DT those) (JJ previous) (NNS studies))))) (. .)))
20595935	3	(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBD aimed) (S (VP (TO to) (VP (VB re-investigate) (NP (NP (DT the) (JJ diagnostic) (NN value)) (PP (IN of) (NP (NNP Doc_20595935_391_400_Chemical)))) (PP (IN in) (NP (NP (DT a) (NN population)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (DT all) (VP (VBN screened) (PP (IN for) (NP (NN macroprolactinemia))))))))))))) (. .)))
20595935	4	(S1 (S (NP (NP (JJ Prolactin) (NNS responses)) (PP (TO to) (NP (NP (NNP Doc_20595935_486_495_Chemical)) (PP (IN in) (NP (NP (CD 65) (JJ female) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NN age)) (: :) (NP (CD 29.9) (JJ +/-) (CD 8.1) (NNS years))) (-RRB- -RRB-)))))) (PP (IN with) (NP (NNP Doc_20595935_549_567_Disease)))) (VP (AUX were) (VP (VBN tested) (PP (IN in) (NP (DT a) (JJ descriptive) (, ,) (VBN matched) (NN case-control) (NN study))))) (. .)))
20595935	5	(S1 (S (S (NP (JJ Doc_20595935_635_644_Chemical) (CD 80) (NN mg)) (, ,) (NP (NN p.o.)) (VP (AUX was) (VP (VBN administered)))) (, ,) (CC and) (S (ADVP (RB then)) (NP (NN PRL) (NNS levels)) (VP (AUX were) (VP (VBN measured) (PP (IN at) (NP (JJ 8th) (CC and) (JJ 16th) (NNS hours))) (, ,) (PP (IN by) (NP (JJ immunometric) (NN chemiluminescence)))))) (. .)))
20595935	6	(S1 (S (NP (JJ Doc_20595935_767_776_Chemical) (NN responsiveness)) (VP (AUX was) (VP (VBN determined) (PP (IN by) (NP (NP (JJ peak) (NN percent) (NN change)) (PP (IN in) (NP (NP (JJ basal) (NN prolactin) (NNS levels)) (PRN (-LRB- -LRB-) (NP (NNP PRL)) (-RRB- -RRB-)))))))) (. .)))
20595935	7	(S1 (S (NP (NNP Doc_20595935_872_881_Chemical)) (VP (ADVP (RB significantly)) (VBD increased) (NP (NP (NN PRL) (NNS levels)) (PP (PP (IN in) (NP (NP (NP (JJ healthy) (NNS controls)) (PRN (-LRB- -LRB-) (NP (NNP N.) (CD 8)) (, ,) (NP (NNP PRL)) (: :) (NP (CD 183) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NNP Doc_20595935_956_973_Disease)) (PRN (-LRB- -LRB-) (NP (NNP N.) (CD 8)) (, ,) (NP (NNP PRL)) (: :) (NP (CD 7) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_20595935_991_1008_Disease)) (PRN (-LRB- -LRB-) (NP (NNP N.) (CD 19)) (, ,) (NP (NNP PRL)) (: :) (NP (CD 21) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (NNS macroprolactinemia)) (PRN (-LRB- -LRB-) (NP (NNP N.) (CD 23)) (, ,) (NP (NNP PRL)) (: :) (NP (CD 126) (NN %)) (-RRB- -RRB-)))) (, ,))) (CC but) (PP (RB not) (IN in) (NP (NP (NP (NN pseudoprolactinoma)) (PRN (-LRB- -LRB-) (NP (NNP N.) (CD 8)) (, ,) (NP (NP (NN PRL)) (: :) (NP (CD 0.8) (NN %))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ Doc_20595935_1120_1131_Chemical-induced) (NNP Doc_20595935_1140_1158_Disease)) (PRN (-LRB- -LRB-) (NP (NNP N.) (CD 7)) (, ,) (NP (NP (NNP PRL)) (: :) (NP (CD 3) (NN %))) (-RRB- -RRB-)))))))) (. .)))
20595935	8	(S1 (S (NP (JJ ROC) (NN curve) (NN analysis)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (NN unresponsiveness)) (PP (TO to) (NP (NNP Doc_20595935_1229_1238_Chemical)))) (VP (VBD defined) (PP (IN as) (NP (NNP PRL))) (NP (CD <7) (NN %)) (, ,) (S (NP (NP (JJ discriminated) (ADJP (JJ anatomical) (CC or) (JJ functional)) (NN stalk) (NN effect)) (PRN (-LRB- -LRB-) (NP (NP (NN sensitivity)) (: :) (NP (NP (CD 74) (NN %)) (, ,) (NP (NN specificity))) (: :) (NP (NP (CD 73) (NN %)) (, ,) (NP (NNP AUC))) (: :) (NP (NP (CD 0.855+/-0.04)) (, ,) (NP (NNP P) (CD <0.001) (, ,) (CD CI))) (: :) (NP (CD 0.768-0.942))) (-RRB- -RRB-))) (VP (VBN associated) (PP (IN with) (NP (NP (NN pseudoprolactinoma)) (CC or) (NP (NP (NNP Doc_20595935_1432_1443_Chemical-induced) (NNP Doc_20595935_1452_1470_Disease)) (, ,) (ADVP (RB respectively))))))))))) (. .)))
20595935	9	(S1 (S (NP (JJ Doc_20595935_1498_1507_Chemical) (NN responsiveness)) (VP (AUX is) (RB not) (NP (NP (DT a) (JJ reliable) (NN finding)) (PP (IN for) (NP (NP (DT the) (NN differential) (NN diagnosis)) (PP (IN of) (NP (NN Doc_20595935_1583_1601_Disease))))))) (. .)))
20595935	10	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (JJ Doc_20595935_1612_1621_Chemical) (JJ unresponsiveness) (NNS discriminates) (NN stalk) (NN effect)) (PRN (-LRB- -LRB-) (FW i.e.) (, ,))) (ADVP (RB anatomically) (CC or) (RB functionally)) (VP (VBD inhibited) (NP (JJ dopaminergic) (NN tonus) (-RRB- -RRB-)) (PP (IN from) (NP (NP (JJ other) (NNS causes)) (PP (IN of) (NP (NNP Doc_20595935_1753_1771_Disease))))) (PP (IN with) (NP (NP (VBG varying) (NNS degrees)) (PP (IN of) (NP (NN responsiveness)))))) (. .)))
20682692	0	(S1 (S (NP (NP (NN Blockade)) (PP (IN of) (NP (JJ endothelial-mesenchymal) (NN transition))) (PP (IN by) (NP (DT a) (JJ Smad3) (NN inhibitor)))) (VP (VBZ delays) (NP (NP (DT the) (JJ early) (NN development)) (PP (IN of) (NP (JJ Doc_20682692_100_114_Chemical-induced) (NN Doc_20682692_123_143_Disease))))) (. .)))
20682692	1	(S1 (S (NP (DT A) (JJ multicenter) (, ,) (JJ controlled) (NN trial)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (JJ early) (NN blockade)) (PP (IN of) (NP (DT the) (JJ renin-Doc_20682692_228_239_Chemical) (NN system))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN type) (CD 1) (NNP Doc_20682692_271_279_Disease) (CC and) (NNP normoalbuminuria)))))) (VP (AUX did) (RB not) (VP (VB retard) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NNP Doc_20682692_335_346_Disease)))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NP (JJ other) (NN mechanism)) (PRN (-LRB- -LRB-) (PRP s) (-RRB- -RRB-))) (VP (AUX are) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NP (JJ early) (NNP Doc_20682692_425_445_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20682692_447_467_Disease)) (-RRB- -RRB-))))))))))))))))) (. .)))
20682692	2	(S1 (S (NP (PRP We)) (VP (AUX have) (ADVP (RB previously)) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (NN endothelial-mesenchymal-transition)) (PRN (-LRB- -LRB-) (NP (NNP EndoMT)) (-RRB- -RRB-))) (VP (VBZ contributes) (PP (TO to) (NP (NP (DT the) (JJ early) (NN development)) (PP (IN of) (NP (NNP Doc_20682692_591_618_Disease))))) (ADVP (RB independently) (PP (IN of) (NP (NP (NN microalbuminuria)) (PP (IN in) (NP (NP (NNS mice)) (PP (IN with) (NP (JJ Doc_20682692_666_680_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_20682692_682_685_Chemical)) (-RRB- -RRB-)) (JJ -induced) (NN Doc_20682692_695_703_Disease))))))))))))) (. .)))
20682692	3	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (PRP we)) (VP (VBN hypothesized) (SBAR (IN that) (S (S (VP (VBG blocking) (NP (NNP EndoMT)))) (VP (VBZ reduces) (NP (NP (DT the) (JJ early) (NN development)) (PP (IN of) (NP (NN Doc_20682692_797_817_Disease)))))))) (. .)))
20682692	4	(S1 (NP (NP (NP (NN RESEARCH) (NN DESIGN)) (CC AND) (NP (NNS METHODS))) (: :) (S (NP (NNP EndoMT)) (VP (AUX was) (VP (VBN induced) (PP (IN in) (NP (NP (NP (NP (DT a) (NN mouse)) (JJ pancreatic) (JJ microvascular) (JJ endothelial) (NN cell) (NN line)) (PRN (-LRB- -LRB-) (NP (NNP MMEC)) (-RRB- -RRB-)) (PP (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ advanced) (NN glycation) (NN end) (NNS products)) (PRN (-LRB- -LRB-) (NP (NNPS AGEs)) (-RRB- -RRB-)))))) (CC and) (PP (IN in) (NP (DT the) (JJ endothelial) (JJ lineage-traceble) (NN mouse) (NN line))) (NP (NNP Tie2-Cre)))) (: ;) (NP (NNP Loxp-EGFP)))) (PP (IN by) (NP (NP (NN administration)) (PP (IN of) (NP (NNS AGEs))))) (, ,) (PP (IN with) (NP (NP (JJ nonglycated) (NN mouse) (NN albumin)) (VP (VBG serving) (PP (IN as) (NP (DT a) (NN control))))))))) (. .)))
20682692	5	(S1 (S (NP (NNP Phosphorylated) (NNP Smad3)) (VP (AUX was) (VP (VBN detected) (PP (IN by) (NP (NP (NN immunoprecipitation/Western) (VBG blotting)) (CC and) (NP (JJ confocal) (NN microscopy)))))) (. .)))
20682692	6	(S1 (S (NP (NP (VBG Blocking) (NNS studies)) (VP (VBG using) (NP (NN receptor)) (PP (IN for) (NP (NP (NN AGE) (NN siRNA)) (CC and) (NP (NP (DT a) (JJ specific) (NN inhibitor)) (PP (IN of) (NP (NP (NNP Smad3)) (PRN (-LRB- -LRB-) (NP (NNP SIS3)) (-RRB- -RRB-))))))))) (VP (AUX were) (VP (VBN performed) (PP (PP (IN in) (NP (NNS MMECs))) (CC and) (PP (IN in) (NP (NP (NNP Doc_20682692_1357_1360_Chemical-induced) (NNP Doc_20682692_1369_1389_Disease)) (PP (IN in) (NP (NNP Tie2-Cre)))))) (: ;) (NP (JJ Loxp-EGFP) (NNS mice)))) (. .)))
20682692	7	(S1 (S (NP (NP (JJ Confocal) (NN microscopy)) (CC and) (NP (JJ real-time) (NN PCR))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NNS AGEs)) (VP (VBN induced) (NP (NNP EndoMT)) (PP (PP (IN in) (NP (NNP MMECs))) (CC and) (PP (IN in) (NP (NNP Tie2-Cre)))) (: ;) (NP (JJ Loxp-EGFP) (NNS mice)))))) (. .)))
20682692	8	(S1 (S (NP (NNP Immunoprecipitation/Western) (VBG blotting)) (VP (VBD showed) (SBAR (IN that) (S (NP (NNP Smad3)) (VP (VP (AUX was) (VP (VBN activated) (PP (IN by) (NP (NNS AGEs))))) (CC but) (VP (AUX was) (VP (VBD inhibited) (PP (IN by) (S (VP (VBG SIS3) (PP (PP (IN in) (NP (NNS MMECs))) (CC and) (PP (IN in) (NP (JJ Doc_20682692_1663_1666_Chemical-induced) (NN Doc_20682692_1675_1695_Disease))))))))))))) (. .)))
20682692	9	(S1 (S (NP (NP (JJ Confocal) (NN microscopy)) (CC and) (NP (JJ real-time) (NN PCR))) (VP (ADVP (RB further)) (VBD demonstrated) (SBAR (IN that) (S (NP (NNP SIS3)) (VP (VBD abrogated) (NP (NP (NNP EndoMT)) (, ,) (NP (NNP Doc_20682692_1784_1806_Disease)) (, ,) (CC and) (NP (NP (JJ retarded) (NN progression)) (PP (IN of) (NP (NNP Doc_20682692_1836_1847_Disease))))))))) (. .)))
20682692	10	(S1 (S (NP (NN EndoMT)) (VP (AUX is) (NP (NP (DT a) (JJ novel) (NN pathway)) (VP (VBG leading) (PP (TO to) (NP (NP (JJ early) (NN development)) (PP (IN of) (NP (NNP Doc_20682692_1920_1940_Disease)))))))) (. .)))
20682692	11	(S1 (S (NP (NP (NN Blockade)) (PP (IN of) (NP (NNP EndoMT))) (PP (IN by) (NP (NN SIS3)))) (VP (MD may) (VP (VB provide) (NP (NP (DT a) (JJ new) (NN strategy)) (SBAR (S (VP (TO to) (VP (VB retard) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NP (NNP Doc_20682692_2025_2045_Disease)) (CC and) (NP (JJ other) (NNP Doc_20682692_2056_2078_Disease)))))))))))) (. .)))
20828385	0	(S1 (NP (NP (NP (NN Cytostatic)) (CC and) (NP (JJ anti-angiogenic) (NNS effects))) (PP (IN of) (NP (NP (NNP Doc_20828385_42_54_Chemical)) (PP (IN in) (NP (NNP Doc_20828385_58_89_Disease))))) (. .)))
20828385	1	(S1 (S (NP (NP (NNP Doc_20828385_91_111_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_20828385_113_116_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (ADJP (ADJP (JJ rare)) (CC and) (ADJP (JJ aggressive))) (NN type)) (PP (IN of) (NP (JJ B-cell) (NN non-Doc_20828385_162_180_Disease))))) (. .)))
20828385	2	(S1 (S (S (NP (NNS Patients)) (VP (VBP become) (ADJP (RB progressively) (JJ refractory) (PP (TO to) (NP (JJ conventional) (NNS chemotherapy)))))) (, ,) (CC and) (S (NP (PRP$ their) (NN prognosis)) (VP (AUX is) (ADJP (JJ poor)))) (. .)))
20828385	3	(S1 (S (ADVP (RB However)) (, ,) (NP (DT a) (ADJP (CD 38) (NN %)) (NN remission) (NN rate)) (VP (AUX has) (VP (AUX been) (ADVP (RB recently)) (VP (VBN reported) (PP (IN in) (NP (NP (JJ refractory) (NN Doc_20828385_353_356_Disease)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_20828385_370_382_Chemical)) (, ,) (NP (NP (DT a) (JJ mTOR) (NN inhibitor.Here)) (SBAR (S (NP (PRP we)) (VP (AUX had) (NP (DT the) (NN opportunity) (S (VP (TO to) (VP (VB study) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ refractory) (NNP Doc_20828385_459_462_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (NP (NP (NNP Doc_20828385_471_476_Disease) (NN regression)) (NP (CD two) (NNS months))) (PP (IN after) (NP (JJ Doc_20828385_505_517_Chemical) (NN treatment)))) (, ,) (CC and) (NP (NP (DT a) (JJ progression-free) (NN survival)) (PP (IN of) (NP (CD 10) (NNS months))))))))))))))))))))))))) (. .)))
20828385	4	(S1 (S (PP (IN In) (NP (DT this) (NN case))) (, ,) (NP (NN lymph) (NN node) (NNS biopsies)) (VP (AUX were) (VP (VBN performed) (ADVP (ADVP (RB before)) (CC and) (NP (CD six) (NNS months))) (PP (IN after) (NP (JJ Doc_20828385_652_664_Chemical) (NN therapy))))) (. .)))
20828385	5	(S1 (S (NP (NP (NN Comparison)) (PP (IN of) (NP (DT the) (CD two) (NNS biopsies)))) (VP (VBD showed) (SBAR (IN that) (S (NP (NNP Doc_20828385_717_729_Chemical)) (VP (VP (VBD inhibited) (NP (NNP Doc_20828385_740_745_Disease) (NN cell) (NN proliferation)) (PP (IN through) (NP (NN cell) (NN cycle) (NN arrest)))) (, ,) (CC but) (VP (AUX did) (RB not) (VP (VB induce) (NP (NP (DT any) (NN change)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (JJ apoptotic) (NN Doc_20828385_849_854_Disease) (NNS cells)))))))))))) (. .)))
20828385	6	(S1 (S (ADVP (RB Apart) (PP (IN from) (NP (DT this) (JJ cytostatic) (NN effect)))) (, ,) (NP (NNP Doc_20828385_897_909_Chemical)) (VP (AUX had) (NP (NP (DT an) (JJ antiangiogenic) (NN effect)) (PP (IN with) (NP (NN decrease))) (PP (PP (IN of) (NP (NNP Doc_20828385_956_961_Disease) (NN microvessel) (NN density))) (CC and) (PP (IN of) (NP (CD VEGF) (NN expression)))))) (. .)))
20828385	7	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (JJ numerous) (JJ patchy) (, ,) (JJ well-limited) (JJ fibrotic) (NNS areas)) (, ,) (ADJP (JJ compatible) (PP (IN with) (NP (JJ post-Doc_20828385_1083_1091_Disease) (NN tissue) (NN repair)))) (, ,)) (VP (AUX were) (VP (VBN found) (PP (IN after) (NP (JJ 6-month) (JJ Doc_20828385_1132_1144_Chemical) (NN therapy))))) (. .)))
20828385	8	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NNP Doc_20828385_1160_1172_Chemical)) (VP (VBD reduced) (NP (NNP Doc_20828385_1181_1186_Disease) (NN burden)) (PP (IN through) (NP (NP (VBN associated) (UCP (JJ cytostatic) (CC and) (JJ anti-angiogenic)) (NNS effects.This)) (SBAR (S (NP (NP (JJ dual) (NN effect)) (PP (IN of) (NP (NNP Doc_20828385_1272_1284_Chemical))) (PP (IN on) (NP (NNP Doc_20828385_1288_1293_Disease) (NN tissue)))) (VP (MD could) (VP (VB contribute) (PP (TO to) (NP (NP (PRP$ its) (ADJP (RB recently) (VBN reported)) (NN efficiency)) (PP (IN in) (NP (NP (JJ refractory) (NNP Doc_20828385_1368_1371_Disease) (NN resistant)) (PP (TO to) (NP (JJ conventional) (NN chemotherapy)))))))))))))) (. .)))
2083961	0	(S1 (NP (NP (NN Doc_2083961_0_19_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_2083961_27_37_Chemical)))) (. .)))
2083961	1	(S1 (S (NP (NP (DT A) (JJ 23-year-old) (NN male) (NN patient)) (PP (IN with) (NP (ADJP (RB bacteriologically) (VBN proven)) (NNP Doc_2083961_96_118_Disease)))) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (DT the) (JJ various) (NNS regimens)) (PP (IN of) (NP (NN antituberculosis) (NNS drugs))))) (PP (IN for) (NP (QP (RB nearly) (CD 15)) (NNS months))))) (. .)))
2083961	2	(S1 (S (NP (NNP Doc_2083961_205_215_Chemical)) (VP (AUX was) (VP (VBN administered) (ADVP (RB thrice)) (PP (IN as) (NP (NP (NP (CD one)) (PP (IN of) (NP (DT the) (JJ 3-4) (NN drug) (NN regimen)))) (CC and) (NP (NP (DT each) (NN time)) (SBAR (S (NP (PRP he)) (VP (VBD developed) (NP (NP (JJ untoward) (JJ side) (NNS effects)) (PP (IN like) (NP (NP (NNP Doc_2083961_325_331_Disease)) (, ,) (NP (NNP Doc_2083961_333_341_Disease)) (CC and) (NP (NN fever)))) (PP (IN with) (NP (NNS chills) (CC and) (NNP Doc_2083961_368_374_Disease)))))))))))) (. .)))
2083961	3	(S1 (S (NP (DT The) (JJ last) (JJ such) (NN episode)) (VP (AUX was) (PP (IN of) (NP (NNP Doc_2083961_405_424_Disease))) (PP (IN at) (SBAR (WHNP (WDT which)) (S (VP (VBP stage) (SBAR (S (NP (DT the) (NN patient)) (VP (AUX was) (VP (VBN seen) (PP (IN by) (NP (NP (DT the) (NNS authors)) (PP (IN of) (NP (DT this) (NN report)))))))))))))) (. .)))
2083961	4	(S1 (S (NP (DT The) (NN patient)) (, ,) (ADVP (RB however)) (, ,) (VP (VBD made) (NP (DT a) (JJ full) (NN recovery))) (. .)))
20859899	0	(S1 (S (NP (NN Doc_20859899_0_7_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_20859899_18_30_Disease))) (PP (IN during) (NP (NP (NN use)) (PP (IN of) (NP (NP (DT a) (VBN combined) (NN therapy)) (PP (IN with) (NP (NP (DT the) (JJ Doc_20859899_73_84_Chemical-converting) (NN enzyme) (NN inhibitor)) (CC and) (NP (NNP Doc_20859899_117_131_Chemical))))))))) (. .)))
20859899	1	(S1 (S (NP (NP (DT A) (CD 76) (JJ year-old) (NN woman)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (JJ coronary) (NN artery) (NN bypass) (NN grafting)) (CC and) (NP (JJ prior) (NN Doc_20859899_213_234_Disease))))))) (VP (AUX was) (VP (VBN transferred) (PP (TO to) (NP (DT the) (NN emergency) (NN room))) (PP (IN with) (NP (NNP Doc_20859899_278_299_Disease))) (PP (JJ due) (TO to) (NP (NP (JJ marked) (NN Doc_20859899_314_325_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_20859899_336_348_Disease)))))))) (. .)))
20859899	2	(S1 (S (S (NP (NP (DT The) (NN concentration)) (PP (IN of) (NP (JJ serum) (NNP Doc_20859899_377_386_Chemical)))) (VP (AUX was) (ADJP (JJ high)))) (, ,) (CC and) (S (NP (JJ normal) (JJ sinus) (NN rhythm)) (VP (AUX was) (VP (VBN restored) (PP (IN after) (NP (NP (NN correction)) (PP (IN of) (NP (DT the) (JJ serum) (JJ Doc_20859899_464_473_Chemical) (NN level)))))))) (. .)))
20859899	3	(S1 (S (NP (NP (DT The) (NN cause)) (PP (IN of) (NP (NNP Doc_20859899_494_506_Disease)))) (VP (AUX was) (VP (VBN considered) (S (VP (TO to) (VP (AUX be) (NP (NP (JJ several) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_20859899_545_559_Chemical)) (, ,) (NP (NP (DT an) (JJ Doc_20859899_564_575_Chemical) (NN antagonist)) (, ,) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (NP (DT the) (JJ long-term) (NN intake)) (PP (IN of) (NP (NP (NNP Doc_20859899_627_635_Chemical)) (, ,) (NP (DT an) (NNP ACE) (NN inhibitor))))))))))))))))) (. .)))
20859899	4	(S1 (S (NP (DT This) (NN case)) (VP (AUX is) (NP (NP (DT a) (JJ good) (NN example)) (PP (IN of) (NP (NP (JJ electrolyte) (NN imbalance)) (VP (VBG causing) (NP (JJ acute) (JJ life-threatening) (NN Doc_20859899_739_753_Disease))))))) (. .)))
20859899	5	(S1 (S (NP (NNS Clinicians)) (VP (MD should) (VP (AUX be) (ADJP (JJ alert) (PP (TO to) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NNP Doc_20859899_804_816_Disease))) (, ,) (UCP (PP (ADVP (RB especially)) (IN in) (NP (NP (JJ elderly) (NNS patients)) (VP (VBG using) (NP (NN ACE/ARB)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ Doc_20859899_883_892_Chemical) (VBG sparing) (NNS agents)))))))) (CC and) (SBAR (WHNP (WP who)) (S (VP (AUX have) (NP (JJ mild) (NN Doc_20859899_926_943_Disease))))))))))) (. .)))
20927253	0	(S1 (NP (NP (NNP Diffuse) (NNP Doc_20927253_8_21_Disease)) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_20927253_46_57_Chemical))))) (. .)))
20927253	1	(S1 (S (S (NP (NN Doc_20927253_71_83_Disease)) (VP (AUX is) (VP (VBN caused) (PP (IN by) (NP (NP (NN bone) (NN resorption)) (PP (IN in) (NP (NP (NN excess)) (PP (IN of) (NP (NN bone) (NN formation)))))))))) (, ,) (CC and) (S (NP (NNP Doc_20927253_146_161_Chemical) (, ,)) (VP (AUX are) (VP (VBN used) (S (VP (TO to) (VP (VB inhibit) (NP (NN bone) (NN resorption)))))))) (. .)))
20927253	2	(S1 (S (NP (NP (NNP Doc_20927253_200_211_Chemical)) (, ,) (NP (DT a) (NN Doc_20927253_215_228_Chemical)) (, ,)) (VP (AUX is) (ADJP (JJ effective) (PP (IN for) (NP (NP (CC both) (DT the) (NN treatment) (CC and) (NN prevention)) (PP (IN of) (NP (NNP Doc_20927253_284_296_Disease))) (PP (IN in) (NP (JJ postmenopausal) (NNS women))))))) (. .)))
20927253	3	(S1 (S (NP (NN Side) (NNS effects)) (VP (AUX are) (ADJP (ADJP (RB relatively) (JJ few)) (CC and) (ADJP (RB prominently) (JJ gastrointestinal)))) (. .)))
20927253	4	(S1 (S (NP (NN Doc_20927253_388_408_Disease)) (VP (MD may) (VP (AUX be) (NP (NP (DT an) (JJ important) (NN side) (NN effect)) (PP (IN in) (NP (DT these) (NNS patients)))))) (. .)))
20927253	5	(S1 (S (NP (PRP We)) (VP (VBD presented) (NP (NP (DT a) (NN patient)) (VP (VBN admitted) (PP (TO to) (NP (NP (PRP$ our) (JJ out-patient) (NN clinic)) (PP (IN with) (NP (JJ diffuse) (NNP Doc_20927253_531_544_Disease))))) (PP (IN after) (NP (NP (CD three) (JJ consecutive) (NN administration)) (PP (IN of) (NP (NNP Doc_20927253_587_598_Chemical)))))))) (. .)))
20927253	6	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (S (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_20927253_643_655_Disease)))) (VP (MD can) (VP (VB report) (NP (NNP Doc_20927253_667_671_Disease))))) (, ,) (CC and) (S (NP (NNP Doc_20927253_677_691_Chemical-related) (NNP Doc_20927253_700_704_Disease)) (VP (MD should) (ADVP (RB also)) (VP (AUX be) (VP (VBN considered) (PP (IN before) (S (VP (VBG ascribing) (NP (DT this) (NN complaint)) (PP (TO to) (NP (NN Doc_20927253_766_778_Disease))))))))))))) (. .)))
20959502	0	(S1 (NP (NP (NP (JJ Cerebrospinal) (NN fluid) (NN penetration)) (PP (IN of) (NP (JJ high-dose) (NNP Doc_20959502_45_55_Chemical))) (PP (IN in) (NP (VBN suspected) (NN Staphylococcus) (NN aureus)))) (NP (NNP Doc_20959502_91_101_Disease)) (. .)))
20959502	1	(S1 (S (S (VP (TO To) (VP (VB report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_20959502_134_145_Chemical-sensitive) (NNP Doc_20959502_156_195_Disease)))) (PP (IN with) (NP (NP (VBN suspected) (NNP MSSA) (NNP Doc_20959502_216_226_Disease)) (VP (VBN treated) (PP (IN with) (NP (JJ high-dose) (NNP Doc_20959502_250_260_Chemical))))))))) (VP (VBD assessed) (PP (IN with) (NP (NP (JJ concurrent) (NN serum)) (CC and) (NP (JJ cerebrospinal) (NN fluid) (PRN (-LRB- -LRB-) (NP (NNP CSF)) (-RRB- -RRB-)) (NNS concentrations))))) (. .)))
20959502	2	(S1 (NP (NP (NN CASE) (NN SUMMARY)) (: :) (NP (NP (DT A) (JJ 54-year-old) (NN male)) (VP (VBN presented) (PP (TO to) (NP (NP (DT the) (NN emergency) (NN department)) (PP (IN with) (NP (NP (JJ generalized) (NN weakness)) (CC and) (NP (JJ presumed) (JJ health-care-associated) (NN Doc_20959502_471_480_Disease)))) (VP (VBN shown) (PP (IN on) (NP (NN chest) (NN radiograph)))))))) (. .)))
20959502	3	(S1 (S (NP (NN Treatment)) (VP (AUX was) (ADVP (RB empirically)) (VP (VBN initiated) (PP (IN with) (NP (NP (NNP Doc_20959502_549_559_Chemical)) (, ,) (NP (NNP Doc_20959502_561_573_Chemical)) (, ,) (CC and) (NP (NNP Doc_20959502_579_591_Chemical/Doc_20959502_592_602_Chemical)))))) (. .)))
20959502	4	(S1 (S (NP (NN Blood) (NNS cultures)) (VP (VBD revealed) (NP (NP (NNP S.) (NN aureus)) (ADJP (JJ susceptible) (PP (TO to) (NP (NNP Doc_20959502_653_662_Chemical)))))) (. .)))
20959502	5	(S1 (S (NP (JJ Empiric) (JJ antibiotic) (NN treatment)) (VP (AUX was) (VP (VBN narrowed) (S (VP (TO to) (VP (VB nafcillin) (PP (IN on) (NP (NN day) (CD 4)))))))) (. .)))
20959502	6	(S1 (S (PP (IN On) (NP (NN day) (CD 8))) (, ,) (NP (DT the) (NN patient)) (VP (VBD developed) (NP (NP (NNP Doc_20959502_761_780_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ serum) (NNP Doc_20959502_788_798_Chemical)) (QP (CD 1.9) (CD mg/dL))) (, ,) (VP (VBN increased) (PP (IN from) (NP (NP (QP (CD 1.2) (CD mg/dL)) (DT the) (JJ previous) (NN day)) (CC and) (NP (NP (CD 0.8) (NN mg/dL)) (PP (IN on) (NP (NN admission)))))))) (-RRB- -RRB-)))) (. .)))
20959502	7	(S1 (S (NP (NP (DT The) (NN patient) (POS 's)) (NNP Glasgow) (NNP Doc_20959502_903_907_Disease) (NN Score)) (VP (AUX was) (NP (CD 3)) (, ,) (PP (IN with) (NP (NP (JJ normal) (NNS findings)) (VP (VBN shown) (PP (IN on) (NP (NP (JJ computed) (NN tomography) (VB scan)) (PP (IN of) (NP (NP (DT the) (JJ head) (CD 72) (NNS hours)) (VP (VBG following) (NP (NP (DT an) (NN episode)) (PP (IN of) (NP (NNP Doc_20959502_1021_1035_Disease)))) (PP (IN on) (NP (NN day) (CD 10)))))))))))) (. .)))
20959502	8	(S1 (S (NP (DT The) (NN patient)) (VP (VBD experienced) (S (VP (VBG relapsing) (NP (NNP MSSA) (NNP Doc_20959502_1086_1096_Disease)) (PP (IN on) (NP (NN day) (CD 9))))) (, ,) (S (VP (VBG increasing) (NP (NP (DT the) (NN suspicion)) (PP (IN for) (NP (DT a) (JJ central) (JJ nervous) (NN system) (PRN (-LRB- -LRB-) (NP (NNP CNS)) (-RRB- -RRB-)) (NNP Doc_20959502_1167_1176_Disease))))))) (. .)))
20959502	9	(S1 (S (S (NP (NNP Doc_20959502_1178_1187_Chemical)) (VP (AUX was) (VP (VBN discontinued)))) (CC and) (S (NP (NNP Doc_20959502_1209_1219_Chemical) (CD 9) (JJ mg/kg) (NN daily)) (VP (VP (AUX was) (VP (VBN initiated) (PP (IN for) (NP (JJ suspected) (NNP Doc_20959502_1262_1272_Disease))))) (CC and) (VP (AUX was) (VP (VBN continued) (PP (IN until) (NP (NP (NP (DT the) (NN patient) (POS 's)) (NN Doc_20959502_1311_1316_Disease)) (PP (IN on) (NP (NN day) (CD 16))))))))) (. .)))
20959502	10	(S1 (S (NP (NP (JJ Doc_20959502_1328_1338_Chemical) (NN serum)) (CC and) (NP (NNP CSF) (NN trough) (NNS concentrations))) (VP (AUX were) (NP (NP (CD 11.21) (NN ug/mL)) (CC and) (NP (CD 0.52) (NN ug/mL))) (, ,) (ADVP (RB respectively)) (, ,) (PP (RB prior) (PP (TO to) (NP (DT the) (JJ third) (NN dose))))) (. .)))
20959502	11	(S1 (S (S (NP (JJ Lumbar) (NN puncture) (NNS results)) (VP (AUX were) (ADJP (JJ inconclusive)))) (CC and) (S (NP (DT no) (JJ further) (NN blood) (NNS cultures)) (VP (AUX were) (ADJP (JJ positive)) (PP (IN for) (NP (NNP MSSA))))) (. .)))
20959502	12	(S1 (S (NP (JJ Doc_20959502_1543_1551_Chemical) (NN kinase) (NNS levels)) (VP (VP (AUX were) (ADJP (JJ normal) (PP (ADVP (RB prior)) (TO to) (NP (JJ Doc_20959502_1587_1597_Chemical) (NN therapy))))) (CC and) (VP (AUX were) (RB not) (VP (VBN reassessed)))) (. .)))
20959502	13	(S1 (S (NP (NNP Doc_20959502_1643_1653_Chemical)) (VP (AUX was) (VP (VBN initiated) (PP (IN in) (NP (NP (PRP$ our) (ADJP (JJ patient) (JJ secondary) (TO to) (JJ possible)) (JJ Doc_20959502_1705_1714_Chemical-induced) (JJ acute) (NN Doc_20959502_1729_1751_Disease)) (CC and) (NP (NN relapsing) (NN Doc_20959502_1766_1776_Disease)))))) (. .)))
20959502	14	(S1 (S (PP (IN At) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 9) (NN mg/kg))))) (, ,) (NP (NP (JJ resultant) (NN penetration)) (PP (IN of) (NP (CD 5) (NN %)))) (VP (AUX was) (ADJP (ADJP (ADJP (JJR higher)) (PP (IN than) (PP (IN in) (NP (JJ previous) (NNS reports))))) (, ,) (ADJP (RBR more) (JJ consistent) (PP (IN with) (NP (JJ inflamed) (NNS meninges)))))) (. .)))
20959502	15	(S1 (S (NP (NNP High-dose) (NNP Doc_20959502_1928_1938_Chemical)) (VP (MD may) (VP (AUX be) (NP (NP (DT an) (JJ alternative) (NN option)) (PP (IN for) (NP (NP (NNP MSSA) (NNP Doc_20959502_1977_1987_Disease)) (PP (IN with) (CC or) (PP (IN without) (NP (NP (DT a) (JJ CNS) (NN source)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (VP (VBN failed)) (CC or) (VP (VBD cannot) (VP (VB tolerate) (NP (JJ standard) (NN therapy)))))))))))))))))) (. .)))
20959502	16	(S1 (S (NP (NP (JJ Further) (JJ clinical) (NN evaluation)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (VBN confirmed) (NNP Doc_20959502_2137_2147_Disease)))))) (VP (AUX is) (VP (VBN warranted))) (. .)))
21195121	0	(S1 (S (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NNP Doc_21195121_12_24_Chemical))) (PP (IN in) (NP (NNP Doc_21195121_28_39_Disease)))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_21195121_51_58_Chemical))) (PP (IN in) (NP (NNS rats)))) (. .)))
21195121	1	(S1 (S (NP (NN Doc_21195121_68_75_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ Doc_21195121_82_96_Chemical) (NN pesticide)) (CC and) (NP (NN scabicide)))) (. .)))
21195121	2	(S1 (S (NP (PRP It)) (VP (VBZ evokes) (S (NP (NNP Doc_21195121_132_143_Disease)) (ADVP (RB mainly)) (VP (NN trough) (NP (NP (DT the) (NN blockage)) (PP (IN of) (NP (JJ Doc_21195121_174_178_Chemical) (PRN (-LRB- -LRB-) (NP (DT A)) (-RRB- -RRB-)) (NNS receptors))))))) (. .)))
21195121	3	(S1 (S (NP (NP (NP (NNP Doc_21195121_193_205_Chemical)) (PRN (-LRB- -LRB-) (INTJ (UH NO)) (-RRB- -RRB-))) (, ,) (NP (JJ gaseous) (NN neurotransmitter)) (, ,)) (VP (AUX has) (NP (NP (NN contradictor) (NN role)) (PP (IN in) (NP (NP (NNS epileptogenesis)) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ opposite) (NNS effects)) (PP (IN of) (NP (NP (NP (NNP Doc_21195121_306_316_Chemical)) (, ,) (NP (NP (NN precursor)) (PP (IN of) (NP (NP (DT NO) (NNS syntheses)) (PRN (-LRB- -LRB-) (NP (NNP NOS)) (-RRB- -RRB-))))) (, ,)) (CC and) (NP (NP (NNP Doc_21195121_355_361_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP NOS) (NN inhibitor)) (-RRB- -RRB-)) (VP (VBN observed) (PP (IN in) (NP (JJ different) (NNP Doc_21195121_400_408_Disease) (NNS models)))))))))))))) (. .)))
21195121	4	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (JJ current) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP NO))) (PP (IN on) (NP (NP (DT the) (JJ behavioral) (CC and) (JJ EEG) (NNS characteristics)) (PP (IN of) (NP (NP (NNP Doc_21195121_526_533_Chemical-induced) (NNP Doc_21195121_542_550_Disease)) (PP (IN in) (NP (JJ male) (NNP Wistar) (NN albino) (NNS rats)))))))))))) (. .)))
21195121	5	(S1 (S (NP (NP (DT The) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_21195121_601_611_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 600)) (, ,) (NP (CD 800)) (CC and) (NP (CD 1000) (NN mg/kg))) (, ,) (NP (NNP i.p.)) (-RRB- -RRB-)) (PP (IN in) (NP (JJ dose-dependent) (NN manner)))))) (VP (VP (ADVP (RB significantly)) (VBD increased) (NP (NNP Doc_21195121_693_703_Disease) (NN incidence) (CC and) (NN severity))) (CC and) (VP (VBN shortened) (NP (NN latency) (NN time)) (PP (TO to) (NP (NP (JJ first) (NN Doc_21195121_763_773_Disease)) (VP (VBN elicited) (PP (IN by) (NP (NP (JJR lower) (JJ Doc_21195121_792_799_Chemical) (NN dose)) (PRN (-LRB- -LRB-) (NP (NP (CD 4) (NN mg/kg)) (, ,) (NP (NNP i.p.))) (-RRB- -RRB-))))))))) (. .)))
21195121	6	(S1 (S (PP (IN On) (NP (DT the) (NN contrary))) (, ,) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NP (NNP Doc_21195121_857_863_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 500) (, ,) (CD 700) (CC and) (CD 900) (NNS mg/kg)) (, ,) (NP (NNP i.p.)) (-RRB- -RRB-))))) (VP (VBD decreased) (NP (NP (NNP Doc_21195121_905_915_Disease) (NN incidence) (CC and) (NN severity)) (CC and) (NP (VBN prolonged) (NN latency) (NN time))) (PP (TO to) (NP (NNP Doc_21195121_969_979_Disease))) (PP (VBG following) (NP (NP (NN injection)) (PP (IN with) (NP (NP (DT a) (JJ Doc_21195121_1007_1017_Disease) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_21195121_1026_1033_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 8) (NN mg/kg)) (, ,) (NP (NNP i.p.))) (-RRB- -RRB-))))))))) (. .)))
21195121	7	(S1 (S (NP (NNP EEG) (NNS analyses)) (VP (VBD showed) (NP (NP (NP (NN increase)) (PP (IN of) (NP (NP (NN number) (CC and) (NN duration)) (PP (IN of) (NP (NP (JJ ictal) (NNS periods)) (PP (IN in) (NP (NP (NNP EEG)) (PP (IN of) (NP (NNS rats))))) (VP (VBG receiving) (NP (NNP Doc_21195121_1145_1155_Chemical)) (ADVP (RB prior) (PP (TO to) (NP (NNP Doc_21195121_1165_1172_Chemical)))))))))) (CC and) (NP (NP (NN decrease)) (PP (IN of) (NP (NP (DT this) (NN number)) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN pretreated) (PP (IN with) (NP (NNP Doc_21195121_1225_1231_Chemical))))))))))) (. .)))
21195121	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP support) (NP (NP (DT the) (NN conclusion)) (SBAR (WHNP (WDT that)) (S (ADVP (RB NO)) (VP (VBZ plays) (NP (NP (DT a) (NN role)) (PP (IN of) (NP (JJ endogenous) (NN convulsant))) (PP (IN in) (NP (NP (NN rat) (NN model)) (PP (IN of) (NP (NNP Doc_21195121_1332_1339_Chemical) (NNP Doc_21195121_1340_1348_Disease))))))))))) (. .)))
2131034	0	(S1 (NP (NP (NP (NP (JJ Severe) (NN Doc_2131034_7_21_Disease)) (CC and) (NP (NN motor) (NN loss))) (PP (IN after) (NP (JJ intrathecal) (NN thiotepa) (NN combination) (NNS chemotherapy)))) (: :) (NP (NP (NN description)) (PP (IN of) (NP (CD two) (NNS cases)))) (. .)))
2131034	1	(S1 (S (NP (NP (CD Two) (NNS cases)) (PP (IN of) (NP (JJ severe) (JJ delayed) (NN Doc_2131034_144_163_Disease))) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (JJ intrathecal) (PRN (-LRB- -LRB-) (NP (PRP IT)) (-RRB- -RRB-)) (NN combination) (NN chemotherapy)) (PP (VBG including) (NP (NP (NNP Doc_2131034_249_257_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP TSPA)) (-RRB- -RRB-)))))))))) (VP (AUX are) (VP (VBN presented))) (. .)))
2131034	2	(S1 (S (NP (DT Both) (NNS cases)) (VP (VBD developed) (NP (NNP Doc_2131034_301_318_Disease)) (PP (IN with) (NP (NN motor) (NN predominance))) (PP (IN in) (NP (DT the) (JJR lower) (NNS extremities))) (SBAR (NP (QP (CD 1) (CC and) (CD 6)) (NNS months)) (IN after) (S (NP (PRP IT)) (ADVP (JJ chemotherapy)) (VP (AUX was) (VP (VBN administered)))))) (. .)))
2131034	3	(S1 (S (NP (NN Doc_2131034_423_444_Disease)) (VP (AUX have) (VP (AUX been) (VP (VBN described) (PP (IN with) (NP (NP (NNP Doc_2131034_470_485_Chemical)) (, ,) (NP (NNP Doc_2131034_487_510_Chemical)) (CC and) (NP (NNP Doc_2131034_515_522_Chemical))))))) (. .)))
2131034	4	(S1 (S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (, ,) (ADVP (RB however)) (, ,) (NP (NP (NNP Doc_2131034_551_568_Disease) (JJ following) (NN administration)) (PP (IN of) (NP (DT these) (CD three) (NNS agents)))) (VP (AUX has) (RB not) (VP (AUX been) (VP (ADVP (RB previously)) (VBN described)))) (. .)))
2131034	5	(S1 (S (PP (IN In) (NP (NP (NN spite)) (PP (IN of) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (NNP Doc_2131034_677_681_Chemical)) (VP (AUX is) (NP (DT a) (ADJP (JJ useful) (NP (PRP IT))) (NN agent))))))))) (, ,) (NP (NP (PRP$ its) (NN combination)) (PP (IN with) (NP (NP (NNP Doc_2131034_725_728_Chemical)) (, ,) (NP (NNP Doc_2131034_730_735_Chemical)) (CC and) (NP (NNS radiotherapy))))) (VP (MD could) (VP (VB cause) (NP (JJ severe) (NN Doc_2131034_772_785_Disease)))) (. .)))
2131034	6	(S1 (S (NP (DT This) (JJ unexpected) (NN complication)) (VP (VBZ indicates) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (JJ further) (NN toxicology) (NN research)) (PP (IN on) (NP (NN IT-TSPA))))))) (. .)))
2173761	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NP (NNP cromakalim)) (CC and) (NP (NNP Doc_2173761_26_35_Chemical)))) (PP (IN on) (NP (NP (JJ large) (NN epicardial)) (CC and) (NP (NP (JJ small) (JJ coronary) (NNS arteries)) (PP (IN in) (NP (JJ conscious) (NNS dogs)))))) (. .)))
2173761	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NP (JJ i.v.) (JJ bolus) (NN administration)) (PP (IN of) (NP (NN cromakalim))) (PRN (-LRB- -LRB-) (NP (JJ 1-10) (NN micrograms/kg)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_2173761_183_192_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 3-100) (NNS micrograms/kg)) (-RRB- -RRB-))))) (PP (PP (IN on) (NP (NP (JJ large) (-LRB- -LRB-) (JJ circumflex) (NN artery) (-RRB- -RRB-)) (CC and) (NP (JJ small) (JJ coronary) (NNS arteries)))) (CC and) (PP (IN on) (NP (JJ systemic) (NNS hemodynamics))))) (VP (AUX were) (VP (VP (VBN investigated) (PP (IN in) (NP (ADJP (RB chronically) (VBN instrumented)) (JJ conscious) (NNS dogs)))) (CC and) (VP (VBN compared) (PP (TO to) (NP (NP (DT those)) (PP (IN of) (NP (NP (NNP Doc_2173761_387_400_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ 0.03-10) (NN micrograms/kg)) (-RRB- -RRB-))))))))) (. .)))
2173761	2	(S1 (S (NP (NP (NNP Doc_2173761_426_439_Chemical)) (, ,) (NP (QP (IN up) (TO to) (CD 0.3)) (NN micrograms/kg)) (, ,)) (ADVP (RB selectively)) (VP (VBD increased) (NP (NP (JJ circumflex) (NN artery) (NN diameter)) (PRN (-LRB- -LRB-) (NP (NNP CxAD)) (-RRB- -RRB-))) (PP (IN without) (S (VP (ADVP (RB simultaneously)) (VBG affecting) (NP (DT any) (JJ other) (NN Doc_2173761_565_606_Disease)))))) (. .)))
2173761	3	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NP (NP (NNP cromakalim)) (CC and) (NP (NNP Doc_2173761_636_645_Chemical))) (PP (IN at) (NP (DT all) (NNS doses)))) (CC and) (NP (NP (NNP Doc_2173761_663_676_Chemical)) (PP (IN at) (NP (NP (NNS doses)) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (CD 0.3) (NN micrograms/kg)))))))) (VP (VP (ADVP (RB simultaneously) (CC and) (RB dose-dependently)) (VBD increased) (NP (NP (NNP CxAD)) (, ,) (NP (NP (JJ coronary) (NN blood) (NN flow)) (CC and) (NP (NN heart) (NN rate))))) (CC and) (VP (VBD decreased) (NP (NP (JJ coronary) (JJ vascular) (NN resistance)) (CC and) (NP (JJ aortic) (NN pressure))))) (. .)))
2173761	4	(S1 (S (NP (NNP Cromakalim)) (VP (AUX was) (ADJP (RB approximately) (JJ 8-) (TO to) (JJ 9.5-fold) (ADJP (RBR more) (JJ potent)) (PP (IN than) (NP (NNP Doc_2173761_928_937_Chemical)))) (PP (IN in) (NP (VBG increasing) (NNP CxAD)))) (. .)))
2173761	5	(S1 (S (S (NP (NP (NP (NP (NP (NNP Vasodilation)) (PP (IN of) (NP (JJ large) (CC and) (JJ small) (JJ coronary) (NNS vessels)))) (CC and) (NP (NNP Doc_2173761_1011_1022_Disease))) (VP (VBN induced) (PP (IN by) (NP (NN cromakalim))))) (CC and) (NP (NNP Doc_2173761_1049_1058_Chemical))) (VP (AUX were) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (JJ prior) (JJ combined) (NN beta) (NN adrenergic)) (CC and) (NP (JJ muscarinic) (NNS receptors) (NN blockade))))))) (CC but) (S (NP (JJ drug-induced) (NN Doc_2173761_1162_1173_Disease)) (VP (AUX was) (VP (VBN abolished)))) (. .)))
2173761	6	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (JJ circumflex) (NN artery) (NN blood) (NN flow)) (VP (AUX was) (VP (VBN maintained) (S (ADJP (JJ constant))))))) (, ,) (NP (NP (DT the) (NNS increases)) (PP (IN in) (NP (NP (NP (NP (NNP CxAD)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2173761_1281_1291_Chemical))))) (PRN (-LRB- -LRB-) (NP (CD 10) (NN micrograms/kg)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_2173761_1312_1321_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN micrograms/kg)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_2173761_1345_1358_Chemical)))) (PRN (-LRB- -LRB-) (NP (CD 10) (NN micrograms/kg)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN reduced) (PP (IN by) (NP (CD 68) (NN +/-))) (NP (NP (CD 7)) (, ,) (NP (NP (CD 54) (NN +/-)) (NP (QP (CD 9) (CC and) (CD 1) (CD +/-) (CD 1)) (NN %)) (, ,) (ADVP (RB respectively)))))) (. .)))
2173761	7	(S1 (S (ADVP (RB Thus)) (, ,) (SBAR (IN whereas) (S (NP (NNP Doc_2173761_1455_1468_Chemical)) (ADVP (RB preferentially) (CC and) (RB flow-independently)) (VP (VBZ dilates) (NP (JJ large) (JJ coronary) (NNS arteries))))) (, ,) (NP (NP (ADJP (JJ cromakalim) (CC and) (JJ Doc_2173761_1555_1571_Chemical)) (ADJP (DT both) (JJ large) (CC and) (JJ small)) (JJ coronary) (NNS arteries)) (CC and) (NP (DT this) (NN effect))) (VP (AUX is) (RB not) (ADJP (JJ dependent) (PP (IN upon) (NP (NP (DT the) (JJ simultaneous) (JJ beta) (JJ adrenoceptors-mediated) (NN rise)) (PP (IN in) (NP (JJ myocardial) (JJ metabolic) (NN demand))))))) (. .)))
2173761	8	(S1 (S (ADVP (RB Finally)) (, ,) (NP (NP (NP (CD two) (NNS mechanisms)) (ADVP (IN at) (JJS least))) (, ,) (NP (NP (JJ direct) (NN vasodilation)) (CC and) (NP (NN flow) (NN dependency))) (, ,)) (VP (AUX are) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (ADJP (JJ cromakalim-) (CC and) (JJ Doc_2173761_1842_1851_Chemical-induced)) (NN increase)) (PP (IN in) (NP (NNP CxAD))))))) (. .)))
2217015	0	(S1 (NP (NP (NNP Doc_2217015_0_14_Chemical-induced) (NNP Doc_2217015_23_34_Disease) (CC and) (NNP Doc_2217015_39_52_Disease)) (PP (IN in) (NP (NP (JJ elderly) (NNS females)) (PP (IN with) (NP (NNP Doc_2217015_77_91_Disease))))) (. .)))
2217015	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (NP (JJ Doc_2217015_103_117_Chemical-induced) (JJ non-oliguric) (NN Doc_2217015_139_152_Disease)) (CC and) (NP (JJ severe) (NN Doc_2217015_164_175_Disease))) (VP (VBG occurring) (ADVP (RB simultaneously)) (PP (IN in) (NP (CD two) (JJ elderly) (NNS females)))))) (. .)))
2217015	2	(S1 (S (NP (DT The) (NNP Doc_2217015_229_240_Disease)) (VP (AUX was) (ADJP (JJ due) (PP (TO to) (NP (NP (NN maturation) (NN arrest)) (PP (IN of) (NP (DT the) (VBN myeloid) (NN series))) (PP (IN in) (NP (CD one) (NN patient))))))) (. .)))
2217015	3	(S1 (S (S (NP (DT Both) (NNS patients)) (VP (AUX were) (ADJP (JJ Doc_2217015_327_343_Disease)))) (, ,) (CC but) (S (NP (PRP it)) (VP (AUX is) (RB not) (ADJP (JJ clear)) (SBAR (IN whether) (S (NP (DT this)) (VP (AUX was) (NP (NP (DT a) (JJ predisposing) (NN factor)) (PP (TO to) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT these) (JJ adverse) (NNS reactions))))))))))) (. .)))
2217015	4	(S1 (S (ADVP (RB However)) (, ,) (NP (PRP it)) (VP (MD would) (VP (VB seem) (ADJP (JJ prudent)) (S (RB not) (VP (TO to) (VP (VB use) (NP (NP (NN Doc_2217015_493_507_Chemical)) (PP (IN in) (NP (NNP Doc_2217015_511_522_Disease) (NNS patients)))) (SBAR (IN until) (S (NP (DT the) (NNP Doc_2217015_542_556_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN corrected))))))))))) (. .)))
2239937	0	(S1 (NP (NP (NN Etiology)) (PP (IN of) (NP (NNP Doc_2239937_12_25_Disease))) (PP (IN in) (NP (NP (NN hemodialysis) (NNS patients)) (PP (IN on) (NP (JJ Doc_2239937_54_71_Chemical) (NN therapy))))) (. .)))
2239937	1	(S1 (S (NP (NP (NP (CD Fourteen)) (PP (IN of) (NP (CD 39) (NN dialysis) (NNS patients)))) (PRN (-LRB- -LRB-) (NP (CD 36) (NN %)) (-RRB- -RRB-))) (VP (VBD became) (ADJP (JJ hypercalcemic)) (PP (IN after) (S (VP (VBG switching) (PP (TO to) (NP (NNP Doc_2239937_160_177_Chemical))) (PP (IN as) (NP (PRP$ their) (JJ principal) (JJ Doc_2239937_197_206_Chemical) (NN binder))))))) (. .)))
2239937	2	(S1 (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB identify) (NP (NP (NN risk) (NNS factors)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_2239937_284_297_Disease))))))))))) (, ,) (NP (NP (JJ indirect) (NNS parameters)) (PP (IN of) (NP (NP (JJ intestinal) (JJ Doc_2239937_333_340_Chemical) (NN reabsorption)) (CC and) (NP (NN bone) (NN turnover) (NN rate)))) (PP (IN in) (NP (DT these) (CD 14) (NNS patients)))) (VP (AUX were) (VP (VBN compared) (PP (IN with) (NP (NP (NNS results)) (PP (IN in) (NP (NP (CD 14) (JJ eucalcemic) (NNS patients)) (VP (VBN matched) (PP (IN for) (NP (NP (NN age) (, ,) (NN sex) (, ,) (NN length)) (PP (IN of) (NP (NN time))) (PP (IN on) (NP (NP (NN dialysis) (, ,) (CC and) (NN etiology)) (PP (IN of) (NP (NNP Doc_2239937_517_530_Disease)))))))))))))) (. .)))
2239937	3	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (S (VP (VBG experiencing) (NP (NP (JJ hypercalcemic) (NNS episodes)) (PP (IN with) (NP (NP (JJ peak) (NNP Doc_2239937_593_600_Chemical) (NNS values)) (PP (IN of) (NP (NP (QP (CD 2.7) (TO to) (CD 3.8) (CD mmol/L))) (PRN (-LRB- -LRB-) (NP (QP (CD 10.7) (TO to) (CD 15.0) (CD mg/dL))) (-RRB- -RRB-)))))))))))) (, ,) (NP (NP (NNS patients)) (PP (IN in) (NP (DT the) (JJ hypercalcemic) (NN group)))) (VP (VBD exhibited) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (DT the) (JJ mean) (NNP Doc_2239937_732_739_Chemical) (NN concentration)) (VP (VBN obtained) (PP (IN during) (NP (NP (CD 6) (NNS months)) (PP (IN before) (NP (DT the) (NN switch))))))))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (JJ mean) (NN value)) (VP (VBN obtained) (PP (IN during) (NP (NP (DT the) (CD 7) (NNS months)) (PP (IN of) (NP (NP (NN observation)) (PP (IN after) (NP (NP (DT the) (NN switch)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 2.4) (JJ +/-) (CD 0.03) (TO to) (CD 2.5)) (JJ +/-) (CD 0.03) (NNS mmol/L)) (NP (NP (QP (CD -LSB-9.7) (JJ +/-) (CD 0.2) (TO to) (CD 10.2) (NN +/-))) (NP (CD 0.1) (CD mg/dL) (NN -RSB-)))) (, ,) (NP (NNP P) (SYM =) (CD 0.006)) (-RRB- -RRB-))))))))))))) (. .)))
2239937	4	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (JJ eucalcemic) (NNS patients)) (VP (VBD exhibited) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NP (JJ mean) (JJ Doc_2239937_1035_1042_Chemical) (NNS values)) (PP (IN over) (NP (NP (DT the) (JJ same) (NN time) (NN period)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 2.3) (JJ +/-) (CD 0.05) (TO to) (CD 2.3)) (JJ +/-) (CD 0.05) (NNS mmol/L)) (NP (NP (QP (CD -LSB-9.2) (JJ +/-) (CD 0.2) (TO to) (CD 9.2) (NN +/-))) (NP (CD 0.2) (CD mg/dL) (NN -RSB-)))) (-RRB- -RRB-)))))))) (. .)))
2239937	5	(S1 (S (NP (NP (NP (JJ Doc_2239937_1150_1155_Chemical) (NN dosage)) (, ,) (NP (JJ calculated) (JJ dietary) (JJ Doc_2239937_1183_1190_Chemical) (NN intake)) (, ,) (CC and) (NP (VBG circulating) (NNS levels))) (PP (IN of) (NP (JJ Doc_2239937_1225_1234_Chemical) (NNS metabolites)))) (VP (AUX were) (ADJP (JJ similar)) (PP (IN in) (NP (DT both) (NNS groups)))) (. .)))
2239937	6	(S1 (S (NP (NP (JJ Physical) (NN activity) (NN index)) (CC and) (NP (NN predialysis) (NN serum) (NN Doc_2239937_1322_1333_Chemical) (NNS levels))) (ADVP (RB also)) (VP (AUX were) (ADJP (JJ similar)) (PP (IN in) (NP (DT both) (NNS groups)))) (. .)))
2239937	7	(S1 (S (ADVP (RB However)) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (NN difference)) (PP (IN in) (NP (NP (NNS parameters)) (VP (VBG reflecting) (NP (NN bone) (NN turnover) (NNS rates))))) (PP (IN between) (NP (NP (NNS groups.)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-))))))))
22836123	0	(S1 (NP (NP (NP (NNP Late-onset) (NNP Doc_22836123_11_35_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_22836123_47_57_Chemical)) (CC and) (NP (NNP Doc_22836123_62_74_Chemical)))))) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
22836123	1	(S1 (S (NP (NP (NN Doc_22836123_91_115_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_22836123_117_120_Disease)) (-RRB- -RRB-))) (VP (VP (AUX is) (NP (NP (DT a) (JJ rare) (NN complication)) (PP (IN of) (NP (NP (NNP Doc_22836123_148_166_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_22836123_168_171_Disease)) (-RRB- -RRB-)))))) (CC but) (VP (MD can) (VP (AUX be) (ADJP (JJ severe) (RB enough) (S (VP (TO to) (VP (VB require) (ADJP (ADJP (JJ temporary)) (CC or) (ADJP (JJ permanent))) (NP (JJ renal) (NN replacement) (NN therapy))))))))) (. .)))
22836123	2	(S1 (S (NP (ADJP (JJ Moderate) (TO to) (JJ high)) (NN dose) (JJ Doc_22836123_281_295_Chemical) (NN use)) (VP (AUX is) (VP (VBN recognized) (PP (IN as) (NP (NP (DT a) (JJ major) (NN risk) (NN factor)) (PP (IN for) (NP (NNP Doc_22836123_341_344_Disease))))))) (. .)))
22836123	3	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (EX there)) (VP (AUX have) (VP (AUX been) (NP (NP (NNS reports)) (PP (IN of) (NP (NNP Doc_22836123_386_412_Disease))) (VP (VBD precipitated) (PP (IN by) (NP (NNP Doc_22836123_429_441_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_22836123_459_462_Disease))))))))) (. .)))
22836123	4	(S1 (S (PP (IN In) (NP (DT this) (NN article))) (, ,) (NP (PRP we)) (VP (VBP report) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_22836123_506_509_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_22836123_521_531_Chemical)) (CC and) (NP (NNP Doc_22836123_536_551_Chemical))))))))) (. .)))
22836123	5	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN work)))) (VP (AUX is) (S (VP (TO to) (VP (VB call) (NP (NN attention)) (PP (TO to) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ Doc_22836123_610_620_Chemical) (NN use))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_22836123_642_645_Disease))))))))))) (. .)))
2320485	0	(S1 (NP (NP (JJ Doc_2320485_0_10_Chemical-induced) (NNP Doc_2320485_19_35_Disease)) (PP (IN in) (NP (NP (DT a) (CD 15) (NN year)) (VP (ADVP (JJ old)) (VBG presenting) (PP (IN as) (NP (NN near-Doc_2320485_72_79_Disease)))))) (. .)))
2320485	1	(S1 (S (NP (NN Doc_2320485_81_91_Chemical)) (VP (AUX is) (NP (NP (DT an) (JJ antihypertensive) (NN medication)) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADJP (JJ available)) (UCP (ADVP (RB generically)) (CC and) (PP (IN under) (NP (NP (DT the) (NN trade) (NN name)) (NP (NNP Aldomet)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (VP (VP (ADVP (RB widely)) (VBN prescribed) (PP (IN in) (NP (DT the) (NN adult) (NN population)))) (CC and) (VP (ADVP (RB infrequently)) (VBN used) (PP (IN in) (NP (NNS children)))))))))))))))) (. .)))
2320485	2	(S1 (S (NP (NN Doc_2320485_275_285_Chemical)) (VP (VBZ causes) (NP (NP (DT an) (NN Doc_2320485_296_323_Disease)) (PP (IN in) (NP (NP (DT a) (JJ small) (NN percentage)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP take) (NP (DT the) (NN drug))))))))))) (. .)))
2320485	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_2320485_397_407_Chemical-induced) (NNP Doc_2320485_416_432_Disease)))) (PP (IN in) (NP (NP (DT a) (JJ 15-year-old) (NN boy)) (SBAR (WHNP (WP who)) (S (VP (VBD presented) (PP (TO to) (NP (DT the) (NN emergency) (NN department))) (PP (IN with) (NP (NN near-Doc_2320485_506_513_Disease))))))))) (. .)))
2320485	4	(S1 (S (NP (DT The) (NN boy)) (VP (AUX had) (VP (AUX been) (VP (VBN treated) (PP (IN with) (NP (JJ intravenous) (NN Doc_2320485_557_567_Chemical))) (PP (IN during) (NP (NP (DT a) (JJ Doc_2320485_577_583_Disease) (NN admission)) (PP (ADVP (NP (CD seven) (NNS weeks)) (RB prior)) (TO to) (NP (NN presentation)))))))) (. .)))
2320485	5	(S1 (S (NP (NN Evaluation)) (VP (VBD revealed) (NP (NP (NP (DT a) (NN hemoglobin)) (PP (IN of) (NP (CD three) (NNS grams)))) (, ,) (NP (NP (NP (CD 3+) (NNS Coombs) (POS ')) (NN test)) (PP (IN with) (NP (NP (JJ polyspecific) (JJ anti-human) (NN globulin)) (CC and) (NP (JJ monospecific) (NNP IgG) (NNS reagents))))) (, ,) (CC and) (NP (DT a) (JJ warm) (VBG reacting) (NN autoantibody)))) (. .)))
2320485	6	(S1 (S (NP (NP (NN Transfusion)) (CC and) (NP (JJ Doc_2320485_813_827_Chemical) (NN therapy))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ complete) (NN recovery)) (PP (IN of) (NP (DT the) (NN patient)))))) (. .)))
2320485	7	(S1 (S (NP (NP (NN Emergency) (NNS physicians)) (VP (VBG treating) (NP (NNS children)))) (VP (MD must) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (DT this) (NN syndrome)))) (PP (IN in) (NP (NN order))) (S (VP (TO to) (VP (VP (VB diagnose)) (CC and) (VP (VB treat) (NP (PRP it)) (ADVP (RB correctly)))))))) (. .)))
2320485	8	(S1 (S (NP (NP (DT A) (JJ brief) (NN review)) (PP (IN of) (NP (ADJP (ADJP (JJ autoimmune)) (CC and) (ADJP (JJ drug-induced))) (NNP Doc_2320485_1045_1062_Disease)))) (VP (AUX is) (VP (VBN provided))) (. .)))
23433219	0	(S1 (NP (NP (NP (DT The) (NN risk)) (CC and) (NP (JJ associated) (NNS factors))) (PP (IN of) (NP (NNP Doc_23433219_35_50_Chemical) (NNP Doc_23433219_51_60_Disease))) (PP (IN in) (NP (NP (JJ Doc_23433219_64_79_Chemical-dependent) (NNS patients)) (PP (IN in) (NP (NNP Malaysia))))) (. .)))
23433219	1	(S1 (S (NP (NP (DT The) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (NN lifetime)) (CC and) (NP (JJ current) (JJ Doc_23433219_201_216_Chemical-induced) (NN Doc_23433219_225_234_Disease)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ Doc_23433219_252_267_Chemical) (NN dependence)))))))))) (. .)))
23433219	2	(S1 (S (NP (NP (DT The) (NN association)) (PP (IN between) (NP (NP (JJ psychiatric) (NN co-morbidity)) (CC and) (NP (JJ Doc_23433219_333_348_Chemical-induced) (NN Doc_23433219_357_366_Disease))))) (VP (AUX was) (ADVP (RB also)) (VP (VBN studied))) (. .)))
23433219	3	(S1 (S (NP (DT This)) (VP (AUX was) (NP (NP (DT a) (JJ cross-sectional) (NN study)) (VP (VBN conducted) (ADVP (RB concurrently)) (PP (IN at) (NP (NP (DT a) (NN teaching) (NN hospital)) (CC and) (NP (NP (DT a) (NN drug) (NN rehabilitation) (NN center)) (PP (IN in) (NP (NNP Malaysia))))))))) (. .)))
23433219	4	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_23433219_550_565_Chemical))) (VP (VBN based) (PP (IN on) (NP (NNP DSM-IV))))))) (VP (AUX were) (VP (VBN interviewed) (S (VP (VBG using) (NP (NP (DT the) (NNP Mini) (NNP International) (NNP Neuropsychiatric) (NN Interview)) (PRN (-LRB- -LRB-) (NP (NNP M.I.N.I.)) (-RRB- -RRB-))) (PP (IN for) (NP (NP (JJ Doc_23433219_670_685_Chemical-induced) (NNP Doc_23433219_694_703_Disease)) (CC and) (NP (JJ other) (NNP Doc_23433219_714_742_Disease)))))))) (. .)))
23433219	5	(S1 (S (NP (NP (DT The) (NN information)) (PP (IN on) (NP (NP (JJ sociodemographic) (NN background)) (CC and) (NP (NN drug) (NN use) (NN history))))) (VP (AUX was) (VP (VBN obtained) (PP (IN from) (NP (NP (NN interview)) (CC or) (NP (JJ medical) (NNS records)))))) (. .)))
23433219	6	(S1 (S (PP (IN Of) (NP (CD 292) (NNS subjects))) (, ,) (NP (NP (NP (CD 47.9) (NN %)) (PP (IN of) (NP (NP (DT the) (NNS subjects)) (SBAR (S (VP (AUX had) (NP (NP (DT a) (JJ past) (NN history)) (PP (IN of) (NP (NNP Doc_23433219_930_948_Disease)))))))))) (CC and) (NP (NP (CD 13.0) (NN %)) (PP (IN of) (NP (DT the) (NNS patients))))) (VP (AUX were) (VP (AUXG having) (NP (JJ current) (NN Doc_23433219_995_1013_Disease)))) (. .)))
23433219	7	(S1 (S (NP (NP (NP (JJ Co-morbid) (JJ major) (NNP Doc_23433219_1031_1050_Disease)) (PRN (-LRB- -LRB-) (NP (CD OR=7.18)) (, ,) (NP (CD 95) (CD CI=2.612-19.708)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_23433219_1082_1098_Disease) (PRN (-LRB- -LRB-) (NP (CD OR=13.807)) (, ,) (NP (CD 95) (CD CI=5.194-36.706)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_23433219_1132_1163_Disease) (PRN (-LRB- -LRB-) (NP (CD OR=12.619)) (, ,) (NP (CD 95) (CD CI=6.702-23.759)) (-RRB- -RRB-))) (CC and) (NP (JJ heavy) (JJ Doc_23433219_1206_1221_Chemical) (NNS uses))) (VP (AUX were) (VP (ADVP (RB significantly)) (VBN associated) (PP (IN with) (NP (NN lifetime) (NNP Doc_23433219_1271_1286_Chemical-induced) (NNP Doc_23433219_1295_1304_Disease))) (SBAR (IN after) (S (VP (VBN adjusted) (PP (IN for) (NP (JJ other) (NNS factors)))))))) (. .)))
23433219	8	(S1 (S (NP (NP (NP (NNP Major) (NNP Doc_23433219_1345_1364_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NNP OR=2.870)) (, ,) (NP (CD CI=1.154-7.142))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_23433219_1396_1427_Disease)) (PRN (-LRB- -LRB-) (NP (CD OR=3.299)) (, ,) (NP (CD 95) (CD CI=1.375-7.914)) (-RRB- -RRB-)))) (VP (AUX were) (NP (NP (DT the) (JJ only) (NNS factors)) (VP (VBN associated) (PP (IN with) (NP (JJ current) (NN Doc_23433219_1504_1513_Disease)))))) (. .)))
23433219	9	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ high) (NN risk)) (PP (IN of) (NP (NNP Doc_23433219_1552_1561_Disease))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ Doc_23433219_1579_1594_Chemical) (NN dependence))))))) (. .)))
23433219	10	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ co-morbid) (JJ affective) (NN disorderDoc_23433219_1658_1682_Disease)) (, ,) (CC and) (NP (JJ heavy) (JJ Doc_23433219_1694_1709_Chemical) (NN use)))))) (. .)))
23433219	11	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NP (DT all) (NNS cases)) (PP (IN of) (NP (JJ Doc_23433219_1751_1766_Chemical) (NN dependence)))) (VP (MD should) (VP (AUX be) (VP (VBN screened) (PP (IN for) (NP (NN Doc_23433219_1801_1819_Disease)))))))))) (. .)))
23535177	0	(S1 (NP (NP (NP (JJ Cerebellar) (JJ sensory) (NN processing) (NNS alterations)) (NP (NN impact) (NN motor) (JJ cortical) (NN plasticity)) (PP (IN in) (NP (NNP Doc_23535177_78_97_Disease)))) (: :) (NP (NP (NNS clues)) (PP (IN from) (NP (NNP Doc_23535177_110_120_Disease) (NNS patients)))) (. .)))
23535177	1	(S1 (S (NP (NP (DT The) (NN plasticity)) (PP (IN of) (NP (NP (JJ primary) (NN motor) (NN cortex)) (PRN (-LRB- -LRB-) (NP (NNP M1)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NP (NNP Doc_23535177_192_211_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_23535177_213_215_Disease)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ Doc_23535177_221_229_Chemical-induced) (NNS dyskinesias)) (PRN (-LRB- -LRB-) (NP (NNP Doc_23535177_251_255_Disease)) (-RRB- -RRB-)))))))) (VP (AUX is) (ADVP (RB severely)) (ADJP (JJ impaired))) (. .)))
23535177	2	(S1 (S (NP (PRP We)) (ADVP (RB recently)) (VP (VBD reported) (PP (IN in) (NP (JJ young) (JJ healthy) (NNS subjects))) (SBAR (IN that) (S (NP (JJ inhibitory) (NN cerebellar) (NN stimulation)) (VP (VBD enhanced) (NP (NP (DT the) (JJ sensorimotor) (NN plasticity)) (PP (IN of) (NP (NNP M1))) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NP (VBN paired) (JJ associative) (NN stimulation)) (PRN (-LRB- -LRB-) (NP (NNP PAS)) (-RRB- -RRB-))))))))))))) (. .)))
23535177	3	(S1 (S (NP (DT This) (NN study)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (NP (DT the) (JJ deficient) (NN sensorimotor) (NN M1) (NN plasticity)) (PP (IN in) (NP (NP (CD 16) (NNS patients)) (PP (IN with) (NP (NNP Doc_23535177_556_560_Disease)))))) (VP (MD could) (VP (AUX be) (VP (VBN reinstated) (PP (IN by) (NP (NP (DT a) (JJ single) (NN session)) (PP (IN of) (NP (NP (JJ real) (JJ inhibitory) (NN cerebellar) (NN stimulation)) (CONJP (CC but) (RB not)) (NP (NN sham) (NN stimulation)))))))))))) (. .)))
23535177	4	(S1 (S (NP (DT This)) (VP (AUX was) (ADJP (JJ evident)) (SBAR (WHADVP (RB only) (WRB when)) (S (NP (DT a) (JJ sensory) (NN component)) (VP (AUX was) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NN plasticity))))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (JJ cerebellar) (JJ sensory) (NN processing) (NN function)) (VP (AUX is) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN resurgence)) (PP (IN of) (NP (JJ M1) (NN plasticity)))))))))))))))) (. .)))
23535177	5	(S1 (S (NP (NP (DT The) (NN benefit)) (PP (IN of) (NP (JJ inhibitory) (NN cerebellar) (NN stimulation))) (PP (IN on) (NP (NNP Doc_23535177_916_920_Disease)))) (VP (AUX is) (VP (VBN known))) (. .)))
23535177	6	(S1 (S (S (VP (TO To) (VP (VB explore) (SBAR (IN whether) (S (NP (DT this) (NN benefit)) (VP (AUX is) (VP (VBN linked) (PP (TO to) (NP (NP (DT the) (NN restoration)) (PP (IN of) (NP (NP (NN sensorimotor) (NN plasticity)) (PP (IN of) (NP (NNP M1)))))))))))))) (, ,) (NP (PRP we)) (VP (VBD conducted) (NP (NP (DT an) (JJ additional) (NN study)) (VP (VBG looking) (PP (IN at) (NP (NP (NP (NNS changes)) (PP (IN in) (NP (NNP Doc_23535177_1081_1085_Disease)))) (CC and) (NP (JJ PAS-induced) (NN plasticity)))))) (PP (IN after) (NP (NP (CD 10) (NNS sessions)) (PP (IN of) (NP (DT either) (JJ bilateral) (, ,) (JJ real) (JJ inhibitory) (NN cerebellar) (NN stimulation) (CC or) (NN sham) (NN stimulation)))))) (. .)))
23535177	7	(S1 (S (S (NP (JJ Only) (UCP (JJ real) (CC and) (RB not)) (NN sham) (NN stimulation)) (VP (AUX had) (NP (DT an) (JJ antidyskinetic) (NN effect)))) (CC and) (S (NP (PRP it)) (VP (AUX was) (VP (VBN paralleled) (PP (IN by) (NP (NP (DT a) (NN resurgence)) (PP (IN in) (NP (NP (DT the) (JJ sensorimotor) (NN plasticity)) (PP (IN of) (NP (NNP M1)))))))))) (. .)))
23535177	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NNS alterations)) (PP (IN in) (NP (JJ cerebellar) (JJ sensory) (NN processing) (NN function))) (, ,) (VP (VBG occurring) (NP (NP (ADJP (JJ secondary) (TO to) (JJ abnormal)) (JJ basal) (NN ganglia) (NNS signals)) (VP (VBG reaching) (NP (PRP it))))) (, ,)) (VP (MD may) (VP (AUX be) (NP (NP (DT an) (JJ important) (NN element)) (VP (VBG contributing) (PP (TO to) (NP (NP (NP (DT the) (JJ maladaptive) (NN sensorimotor) (NN plasticity)) (PP (IN of) (NP (NNP M1)))) (CC and) (NP (NP (DT the) (NN emergence)) (PP (IN of) (NP (NNP Doc_23535177_1612_1642_Disease))))))))))))) (. .)))
2358093	0	(S1 (NP (NP (DT The) (JJ long-term) (NN safety)) (PP (IN of) (NP (NNP Doc_2358093_24_31_Chemical))) (PP (IN in) (NP (NP (NNS women)) (PP (IN with) (NP (NNP Doc_2358093_46_67_Disease))))) (. .)))
2358093	1	(S1 (S (SBAR (IN Although) (S (NP (NP (NP (DT the) (JJ short-term) (NN safety)) (PRN (-LRB- -LRB-) (FRAG (ADVP (RBR less) (IN than) (CC or) (JJ equal) (PP (TO to) (NP (CD 6) (NNS months))))) (-RRB- -RRB-))) (PP (IN of) (NP (NNP Doc_2358093_136_143_Chemical)))) (VP (AUX has) (VP (AUX been) (VP (VBN established) (PP (IN in) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS settings)))))))))) (, ,) (NP (DT no) (NN information)) (VP (VBZ exists) (PP (IN as) (PP (TO to) (NP (PRP$ its) (JJ long-term) (NN safety))))) (. .)))
2358093	2	(S1 (S (NP (PRP We)) (ADVP (RB therefore)) (VP (VBD investigated) (NP (NP (DT the) (JJ long-term) (NN safety)) (PP (IN of) (NP (NNP Doc_2358093_291_298_Chemical)))) (PP (IN by) (S (VP (VBG performing) (NP (NP (DT a) (JJ retrospective) (NN chart) (NN review)) (PP (IN of) (NP (NP (CD 60) (JJ female) (NNS patients)) (PP (IN with) (NP (NNP Doc_2358093_369_390_Disease))) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_2358093_404_411_Chemical))) (PP (IN for) (NP (NP (DT a) (JJ continuous) (NN period)) (PP (IN of) (NP (CD 6) (NNS months) (QP (CC or) (JJR longer)))))))))))))) (. .)))
2358093	3	(S1 (S (S (NP (NP (DT The) (JJ mean) (NN age)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX was) (NP (CD 35.2) (NNS years)))) (CC and) (S (NP (NP (DT the) (JJ mean) (NN duration)) (PP (IN of) (NP (NN therapy)))) (VP (AUX was) (NP (CD 59.7) (NNS months)))) (. .)))
2358093	4	(S1 (S (NP (RB Virtually) (DT all) (NNS patients)) (VP (VBD experienced) (NP (QP (CD one) (CC or) (JJR more)) (JJ adverse) (NNS reactions))) (. .)))
2358093	5	(S1 (S (NP (NP (NP (NNP Doc_2358093_619_642_Disease)) (PRN (-LRB- -LRB-) (NP (CD 79) (NN %)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_2358093_650_661_Disease)) (PRN (-LRB- -LRB-) (NP (CD 60) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (NN muscle) (NN cramps/Doc_2358093_683_691_Disease)) (PRN (-LRB- -LRB-) (NP (CD 40) (NN %)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ transaminase) (NNS elevations)) (PRN (-LRB- -LRB-) (NP (CD 40) (NN %)) (-RRB- -RRB-)))) (VP (AUX were) (NP (DT the) (JJS most) (JJ common) (JJ adverse) (NNS reactions))) (. .)))
2358093	6	(S1 (S (NP (DT The) (NN drug)) (VP (AUX was) (VP (VBN discontinued) (PP (JJ due) (TO to) (NP (JJ adverse) (NNS reactions))) (PP (IN in) (NP (CD 8) (NNS patients))))) (. .)))
2358093	7	(S1 (S (NP (DT No) (NN patient)) (VP (AUX has) (VP (VP (VBN died)) (CC or) (VP (VBD suffered) (NP (NP (DT any) (JJ apparent) (JJ long-term) (NN sequelae)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (ADJP (RB directly) (JJ attributable) (PP (TO to) (NP (DT the) (NN drug))))))))))) (. .)))
2358093	8	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (, ,) (PP (IN despite) (NP (NP (DT a) (ADJP (RB relatively) (JJ high)) (NN incidence)) (PP (IN of) (NP (JJ adverse) (NNS reactions))))) (, ,) (NP (NNP Doc_2358093_1024_1031_Chemical)) (VP (AUX has) (VP (VBN proven) (S (VP (TO to) (VP (AUX be) (ADJP (RB remarkably) (JJ safe)) (PP (IN over) (NP (DT the) (NN long-term))) (PP (IN in) (NP (NP (DT this) (NN group)) (PP (IN of) (NP (NNS patients))))))))))))) (. .)))
23666265	0	(S1 (NP (NP (DT The) (NN function)) (PP (IN of) (NP (NP (JJ P2X3) (NN receptor)) (CC and) (NP (JJ NK1) (NN receptor) (NNS antagonists)))) (PP (IN on) (NP (NP (NNP Doc_23666265_62_78_Chemical-induced) (NNP Doc_23666265_87_95_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
23666265	1	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT the) (NN study)))) (VP (AUX is) (S (VP (TO to) (VP (VB explore) (NP (NP (DT the) (NN function)) (PP (IN of) (NP (NP (NNP P2X3) (CC and) (NNP NK1) (NNS receptors)) (SBAR (S (NP (NP (NNS antagonists)) (PP (IN on) (NP (NP (NNP Doc_23666265_207_223_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_23666265_225_228_Chemical)) (-RRB- -RRB-))))) (VP (VBD -induced) (NP (NNP Doc_23666265_238_246_Disease)) (PP (IN in) (NP (NNS rats))))))))))))) (. .)))
23666265	2	(S1 (S (NP (CD Sixty) (JJ female) (NNP Sprague-Dawley) (PRN (-LRB- -LRB-) (NP (NNP SD)) (-RRB- -RRB-)) (NNS rats)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN divided) (PP (IN into) (NP (CD three) (NNS groups))))) (. .)))
23666265	3	(S1 (S (NP (NP (DT The) (NNS rats)) (PP (IN in) (NP (DT the) (NN control) (NN group)))) (VP (AUX were) (VP (ADVP (RB intraperitoneally) (PRN (-LRB- -LRB-) (NP (CD i.p.)) (-RRB- -RRB-))) (VBN injected) (PP (IN with) (NP (NP (NP (NP (NP (CD 0.9) (NN %)) (NN saline)) (PRN (-LRB- -LRB-) (NP (CD 4) (NNS ml/kg)) (-RRB- -RRB-)) (: ;) (S (S (NP (NP (DT the) (NNS rats)) (PP (IN in) (NP (DT the) (NN model) (NN group)))) (VP (AUX were) (ADVP (RB i.p.)) (VP (VBN injected) (PP (IN with) (NP (NP (NNP CYP)) (PRN (-LRB- -LRB-) (NP (CD 150) (NNS mg/kg)) (-RRB- -RRB-))))))) (: ;) (CC and) (S (NP (NP (DT the) (NNS rats)) (PP (IN in) (NP (DT the) (NN intervention) (NN group)))) (VP (AUX were) (ADVP (RB i.p.)) (VP (VBN injected) (PP (IN with) (NP (NNP CYP))) (PP (IN with) (NP (RB subsequently) (NN perfusion)))))))) (PP (IN of) (NP (NN bladder))) (PP (IN with) (NP (NP (NNP P2X3) (CC and) (NNP NK1) (NNS receptors) (POS ')) (NNS antagonists)))) (, ,) (NP (NNP Doc_23666265_658_665_Chemical) (CC and) (NNP Doc_23666265_670_678_Chemical)))))) (. .)))
23666265	4	(S1 (S (NP (NP (JJ Spontaneous) (NN Doc_23666265_692_706_Disease)) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNS CYP)))))) (VP (AUX were) (VP (VBN observed))) (. .)))
23666265	5	(S1 (S (NP (NP (JJ Urodynamic) (NNS parameters)) (, ,) (NP (NP (NN bladder) (JJ pressure-volume) (NN curve)) (, ,) (NP (NP (NN maximum) (VBG voiding) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NNP MVP)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN maximum) (JJ cystometric) (NN capacity)) (PRN (-LRB- -LRB-) (NP (NNP MCC)) (-RRB- -RRB-)))) (, ,)) (VP (AUX were) (VP (VBN recorded))) (. .)))
23666265	6	(S1 (S (NP (NP (JJ Pathological) (NNS changes)) (PP (IN in) (NP (NN bladder) (NN tissue)))) (VP (AUX were) (VP (VBN observed))) (. .)))
23666265	7	(S1 (S (NP (NN Immunofluorescence)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB detect) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NNP P2X3) (CC and) (NNP NK1) (NNS receptors))) (PP (IN in) (NP (NN bladder))))))))) (. .)))
23666265	8	(S1 (S (NP (JJ Doc_23666265_1053_1069_Chemical) (NN treatment)) (VP (VBD increased) (NP (DT the) (JJ spontaneous) (JJ Doc_23666265_1106_1120_Disease) (NNS scores))) (. .)))
23666265	9	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_23666265_1146_1165_Disease))) (PP (IN during) (NP (NP (NN urine) (NN storage) (NN period)) (PP (IN of) (NP (NN model) (NN group)))))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN than) (NP (NP (NP (NN intervention) (NN group)) (PRN (-LRB- -LRB-) (S (NP (NNP X) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (SYM =) (CD 7.619) (, ,) (CD P)) (VP (SYM =) (NP (CD 0.007)))) (-RRB- -RRB-))) (CC and) (NP (NP (NN control) (NN group)) (PRN (-LRB- -LRB-) (S (NP (NNP X) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (SYM =) (CD 13.755) (, ,) (CD P)) (VP (SYM =) (NP (CD 0.000)))) (-RRB- -RRB-))))))) (. .)))
23666265	10	(S1 (S (NP (NP (NN MCC)) (PP (IN in) (NP (DT the) (NN model) (NN group)))) (VP (AUX was) (ADJP (ADJP (JJR lower)) (PP (IN than) (NP (NP (DT the) (NN control) (CC and) (NN intervention) (NNS groups)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.01))) (-RRB- -RRB-)))))) (. .)))
23666265	11	(S1 (S (NP (NP (JJ Histological) (NNS changes)) (ADJP (JJ evident) (PP (IN in) (NP (NN model) (CC and) (NN intervention) (NNS groups))))) (NP (NP (NNS rats) (POS ')) (NN bladder)) (VP (VBD included) (NP (NP (NN Doc_23666265_1501_1506_Disease)) (, ,) (NP (NN vasodilation)) (, ,) (CC and) (NP (NP (NN infiltration)) (PP (IN of) (NP (JJ inflammatory) (NNS cells)))))) (. .)))
23666265	12	(S1 (S (PP (IN In) (NP (NN model) (NN group))) (, ,) (S (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NNP P2X3) (NN receptor)))) (VP (VBD increased) (PP (IN in) (NP (NP (NN urothelium)) (CC and) (NP (NN suburothelium)))))) (, ,) (CC and) (S (NP (JJ NK1) (NN receptor)) (VP (VBD increased) (PP (IN in) (NP (NN suburothelium))) (, ,) (SBAR (IN while) (S (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (PRP them))) (PP (IN in) (NP (NN intervention) (NN group)))) (VP (AUX was) (ADJP (JJR lower))))))) (. .)))
23666265	13	(S1 (S (PP (IN In) (NP (JJ CYP-induced) (NNP Doc_23666265_1788_1796_Disease))) (, ,) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NNP P2X3) (CC and) (NNP NK1) (NNS receptors)))) (VP (VBD increased) (PP (IN in) (NP (JJ urothelium) (NN and/or) (NN suburothelium)))) (. .)))
23666265	14	(S1 (S (NP (NP (NN Perfusion)) (PP (IN of) (NP (NN bladder))) (PP (IN with) (NP (NP (NNP P2X3)) (CC and) (NP (JJ NK1) (NNS receptors) (NNS antagonists))))) (VP (VBD ameliorated) (NP (DT the) (NN bladder) (NN function))) (. .)))
2383364	0	(S1 (NP (NP (NP (JJ Patient) (NN tolerance) (NN study)) (PP (IN of) (NP (JJ topical) (NNP Doc_2383364_35_64_Chemical)))) (: :) (NP (NP (DT a) (JJ new) (JJ topical) (NN agent)) (PP (IN for) (NP (NNS burns)))) (. .)))
2383364	1	(S1 (S (NP (JJ Effective) (JJ topical) (NN antimicrobial) (NNS agents)) (VP (VB decrease) (NP (NP (NN Doc_2383364_145_154_Disease)) (CC and) (NP (NN mortality))) (PP (IN in) (NP (VB burn) (NNS patients)))) (. .)))
2383364	2	(S1 (S (S (NP (NP (NP (NNP Doc_2383364_187_214_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2383364_216_219_Chemical)) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ new) (JJ broad-spectrum) (JJ antimicrobial) (NN agent)) (, ,)) (VP (AUX has) (VP (AUX been) (VP (VBN evaluated) (PP (IN as) (NP (NP (DT a) (JJ topical)) (VP (VB burn) (S (VP (VB wound) (S (VP (VBG dressing) (PP (IN in) (NP (NN cream) (NN form)))))))))))))) (, ,) (CC but) (S (NP (JJ preliminary) (JJ clinical) (NNS trials)) (VP (VBD reported) (SBAR (IN that) (S (NP (PRP it)) (VP (AUX was) (ADJP (JJ painful)) (PP (IN upon) (NP (NN application)))))))) (. .)))
2383364	3	(S1 (S (NP (DT This) (NN study)) (VP (VBD compared) (NP (NP (JJ various) (NNS concentrations)) (PP (IN of) (NP (NNP Doc_2383364_456_459_Chemical)))) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (DT a) (JJ tolerable) (NN concentration)) (VP (MD could) (VP (AUX be) (VP (VBN identified) (PP (IN with) (NP (NP (NN retention)) (PP (IN of) (NP (JJ antimicrobial) (NN efficacy)))))))))))))) (. .)))
2383364	4	(S1 (S (NP (NP (JJ Twenty-nine) (VBP burn) (NNS patients)) (, ,) (NP (NP (DT each)) (PP (IN with) (NP (NNP Doc_2383364_601_618_Disease))) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (AUX be) (VP (ADVP (RB separately)) (VBN treated))))))) (, ,)) (VP (AUX were) (VP (VBN given) (NP (NP (NNS pairs)) (PP (IN of) (NP (NNS treatments)))) (PP (IN at) (NP (NP (JJ successive) (JJ 12-h) (NNS intervals)) (PP (IN over) (NP (DT a) (JJ 3-day) (NN period))))))) (. .)))
2383364	5	(S1 (S (NP (PRP One)) (VP (VBP burn) (SBAR (S (NP (NN site)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (DT each)) (PP (IN of) (NP (CD four) (JJ different) (NNP Doc_2383364_789_792_Chemical) (NNS concentrations))))) (, ,) (PP (IN from) (NP (NP (NP (NP (CD 0.25)) (PP (IN per) (NP (NP (NP (NN cent)) (PP (TO to) (NP (CD 2))) (PP (IN per) (NP (NN cent)))) (, ,) (NP (PRP$ their) (NN vehicle)) (, ,)))) (CC and) (NP (NP (CD 1)) (PP (IN per) (NP (NN cent) (NNP Doc_2383364_873_893_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_2383364_895_899_Chemical)) (-RRB- -RRB-)) (NN cream))))) (, ,) (NP (NP (DT an) (JJ antimicrobial) (NN agent)) (VP (ADVP (RB frequently)) (VBN used) (PP (IN for) (NP (NP (JJ topical) (NN treatment)) (PP (IN of) (NP (VB burn) (NNS wounds)))))))))))))) (. .)))
2383364	6	(S1 (S (NP (DT The) (JJ other) (NN site)) (VP (AUX was) (ADVP (RB always)) (VP (VBN treated) (PP (IN with) (NP (JJ Doc_2383364_1024_1028_Chemical) (NN cream))))) (. .)))
2383364	7	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ direct) (NN relationship)) (PP (IN between) (NP (NP (JJ Doc_2383364_1076_1079_Chemical) (NN concentration)) (CC and) (NP (NP (NP (NNS patients) (POS ')) (NNS ratings)) (PP (IN of) (NP (NNP Doc_2383364_1119_1123_Disease))) (PP (IN on) (NP (DT an) (JJ analogue) (NN scale)))))))) (. .)))
2383364	8	(S1 (S (S (NP (NP (DT The) (CD 0.25)) (PP (IN per) (NP (NN cent) (NN Doc_2383364_1164_1167_Chemical) (NN cream)))) (VP (AUX was) (ADVP (JJS closest) (PP (TO to) (NP (NNP Doc_2383364_1189_1193_Chemical)))) (PP (IN in) (NP (NNP Doc_2383364_1197_1201_Disease) (NN tolerance))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (NN none)) (PP (IN of) (NP (DT the) (NNS treatments)))) (VP (VBD differed) (ADVP (RB statistically)) (PP (PP (IN from) (NP (NNP Doc_2383364_1273_1277_Chemical))) (CC or) (PP (IN from) (NP (DT each) (JJ other)))))) (. .)))
2383364	9	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN ease)) (PP (IN of) (NP (NP (NN application)) (PP (IN of) (NP (JJ Doc_2383364_1334_1337_Chemical) (NNS creams)))))) (VP (AUX was) (ADJP (ADJP (RBR less) (JJ satisfactory)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_2383364_1380_1384_Chemical))))))) (. .)))
2383364	10	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN concluded) (SBAR (IN that) (S (S (NP (NP (NNS formulations)) (PP (IN at) (CC or) (IN below) (NP (CD 0.5))) (PP (IN per) (NP (NN cent) (NN Doc_2383364_1446_1449_Chemical)))) (VP (MD may) (VP (VB prove) (ADJP (JJ acceptable)) (PP (IN for) (NP (NN wound) (NN care)))))) (, ,) (CC but) (S (NP (DT the) (NN vehicle) (NN system)) (VP (VBZ needs) (NP (JJ pharmaceutical) (NN improvement)) (S (VP (TO to) (VP (VB render) (S (NP (PRP it)) (ADJP (ADJP (RBR more) (JJ tolerable)) (CC and) (ADJP (JJR easier) (SBAR (S (VP (TO to) (VP (VB use))))))))))))))))) (. .)))
23846525	0	(S1 (FRAG (S (NP (JJ Acute) (NN Doc_23846525_6_15_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_23846525_32_43_Chemical))))) (: :) (NP (NP (DT a) (NN case) (NN report)) (CC and) (NP (NP (NN review)) (PP (IN of) (NP (DT the) (NN literature))))) (. .)))
23846525	1	(S1 (S (S (NP (JJ Drug-induced) (NN hepatotoxicity)) (VP (AUX is) (NP (NP (DT a) (JJ common) (NN cause)) (PP (IN of) (NP (JJ acute) (NNP Doc_23846525_144_153_Disease)))))) (, ,) (CC and) (S (NP (NP (DT the) (NN recognition)) (PP (IN of) (NP (DT the) (JJ responsible) (NN drug)))) (VP (MD may) (VP (AUX be) (ADJP (JJ difficult))))) (. .)))
23846525	2	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ Doc_23846525_239_250_Chemical-related) (JJ acute) (NN Doc_23846525_265_274_Disease))))) (. .)))
23846525	3	(S1 (S (NP (DT The) (NN diagnosis)) (VP (AUX is) (VP (ADVP (RB strongly)) (VBN suggested) (PP (IN by) (NP (NP (DT an) (JJ accurate) (JJ medical) (NN history)) (CC and) (NP (NN liver) (NN biopsy)))))) (. .)))
23846525	4	(S1 (S (NP (NP (NNS Reports)) (PP (IN about) (NP (NP (NNS cases)) (PP (IN of) (NP (NN hepatotoxicity))) (ADJP (RB due) (PP (TO to) (NP (NNP Doc_23846525_406_417_Chemical))))))) (VP (AUX are) (VP (VBG increasing) (PP (IN in) (NP (DT the) (JJ last) (JJ few) (NNS years))) (, ,) (PP (IN after) (NP (NP (DT the) (VBN increased) (NN use)) (PP (IN of) (NP (DT this) (NN drug))))))) (. .)))
23846525	5	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (PRP we)) (VP (VBP believe) (SBAR (IN that) (S (NP (NNS physicians)) (VP (MD should) (ADVP (RB carefully)) (VP (VB consider) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ drug-induced) (NN Doc_23846525_587_601_Disease)))) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_23846525_607_618_Chemical)) (VP (AUX is) (VP (VBN prescribed)))))))))) (. .)))
23864035	0	(S1 (NP (NP (NP (NP (NNP Doc_23864035_0_10_Chemical)) (CC and) (NP (NNP Doc_23864035_15_28_Chemical))) (PP (IN as) (NP (NN salvage) (NN therapy))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ relapsed/refractory) (NNP Doc_23864035_85_101_Disease)))))) (: :) (NP (NP (NN analysis)) (PP (IN of) (NP (JJ long-term) (JJ clinical) (NNS outcomes)))) (. .)))
23864035	1	(S1 (S (NP (NP (JJ Doc_23864035_144_154_Chemical) (PRN (-LRB- -LRB-) (NP (NN bort)) (-RRB- -RRB-)) (NN -Doc_23864035_162_175_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_23864035_177_180_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT an) (JJ effective) (NN therapy)) (PP (IN for) (NP (NP (JJ relapsed/refractory) (PRN (-LRB- -LRB-) (NP (NNP R/R)) (-RRB- -RRB-)) (NNP Doc_23864035_236_252_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_23864035_254_256_Disease)) (-RRB- -RRB-)))))) (. .)))
23864035	2	(S1 (S (NP (DT This) (NN retrospective) (NN study)) (VP (VBD investigated) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NN bort)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (NP (QP (CD 1.3) (CD mg/m))) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-) (PP (IN on) (NP (NNS days) (CD 1) (, ,) (CD 4) (, ,) (CD 8) (, ,) (CC and) (CD 11))) (NP (DT every) (CD 3) (NNS weeks)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_23864035_377_380_Chemical))) (-LRB- -LRB-) (NP (CD 20) (NN mg)) (PP (IN on) (NP (NP (DT the) (NN day)) (PP (IN of))))) (CC and) (NP (NP (DT the) (NN day)) (PP (IN after) (NP (NN bort))))) (-RRB- -RRB-))))) (PP (IN as) (NP (NP (NN salvage) (NN treatment)) (PP (IN in) (NP (NP (CD 85) (NNS patients)) (PP (IN with) (NP (NNP R/R) (NNP Doc_23864035_471_473_Disease))))))) (PP (IN after) (NP (NP (JJ prior) (JJ autologous) (NN stem) (NN cell) (NN transplantation)) (CC or) (NP (JJ conventional) (NN chemotherapy))))) (. .)))
23864035	3	(S1 (S (NP (NP (DT The) (JJ median) (NN number)) (PP (IN of) (NP (NP (JJ prior) (NNS lines)) (PP (IN of) (NP (NN therapy)))))) (VP (AUX was) (NP (CD 2))) (. .)))
23864035	4	(S1 (S (NP (NP (JJ Eighty-seven) (NN percent)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (AUX had) (VP (VBN received) (NP (NP (JJ immunomodulatory) (NNS drugs)) (VP (VBN included) (PP (IN in) (NP (NP (DT some) (NN line)) (PP (IN of) (NP (NN therapy))) (PP (IN before) (NP (NN bort-Doc_23864035_722_725_Chemical))))))))) (. .)))
23864035	5	(S1 (S (NP (NP (DT The) (JJ median) (NN number)) (PP (IN of) (NP (JJ bort-Doc_23864035_753_756_Chemical) (NNS cycles)))) (VP (AUX was) (NP (CD 6)) (, ,) (PP (IN up) (PP (TO to) (NP (NP (DT a) (NN maximum)) (PP (IN of) (NP (CD 12) (NNS cycles))))))) (. .)))
23864035	6	(S1 (S (PP (IN On) (NP (DT an) (JJ intention-to-treat) (NN basis))) (, ,) (NP (NP (CD 55) (NN %)) (PP (IN of) (NP (NP (DT the) (NNS patients)) (VP (VBN achieved) (PP (IN at) (NP (NP (RBS least) (JJ partial) (NN response)) (, ,) (PP (VBG including) (NP (NP (ADJP (CD 19) (NN %)) (NNS CR)) (CC and) (NP (CD 35) (NN %)))))))))) (VP (VBD achieved) (NP (ADJP (ADVP (IN at) (JJS least)) (RB very) (JJ good)) (JJ partial) (NN response))) (. .)))
23864035	7	(S1 (S (NP (NP (NP (JJ Median) (NNS durations)) (PP (IN of) (NP (NN response)))) (, ,) (NP (NP (NN time)) (PP (TO to) (NP (JJ next) (NN therapy)))) (CC and) (NP (JJ treatment-free) (NN interval))) (VP (AUX were) (NP (NP (CD 8)) (, ,) (NP (CD 11.2)) (, ,) (CC and) (NP (CD 5.1) (NNS months))) (, ,) (ADVP (RB respectively))) (. .)))
23864035	8	(S1 (S (NP (DT The) (ADJP (RBS most) (JJ relevant)) (JJ adverse) (NN event)) (VP (AUX was) (NP (NP (NNP Doc_23864035_1122_1143_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (VBD occurred) (PP (IN in) (NP (NP (CD 78) (NN %)) (PP (IN of) (NP (NP (DT the) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NNP grade) (NNP II)) (, ,) (NP (NP (NP (CD 38) (NN %)) (: ;) (NP (NN grade))) (NNP III))) (, ,) (NP (CD 21) (NN %)) (-RRB- -RRB-))))))) (CC and) (VP (VBD led) (PP (TO to) (NP (NP (NN treatment) (NN discontinuation)) (PP (IN in) (NP (CD 6) (NN %))))))))))) (. .)))
23864035	9	(S1 (S (SBAR (IN With) (S (NP (DT a) (JJ median)) (VP (VBP follow) (PRT (RP up)) (PP (IN of) (NP (CD 22) (NNS months)))))) (, ,) (NP (NP (JJ median) (NN time)) (PP (TO to) (NP (NP (NN progression)) (, ,) (NP (NP (JJ progression-free) (NN survival)) (PRN (-LRB- -LRB-) (NP (NNS PFS)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_23864035_1365_1381_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_23864035_1383_1385_Disease)) (-RRB- -RRB-)))))) (VP (AUX were) (NP (NP (CD 8.9)) (, ,) (NP (CD 8.7)) (, ,) (CC and) (NP (CD 22) (NNS months))) (, ,) (ADVP (RB respectively))) (. .)))
23864035	10	(S1 (S (NP (NP (JJ Prolonged) (NNS PFS)) (CC and) (NP (NNP Doc_23864035_1449_1451_Disease))) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (VP (VP (VBG achieving) (NP (NN CR))) (CC and) (VP (VBG receiving) (NP (NP (JJ bort-Doc_23864035_1510_1513_Chemical) (DT a) (JJ single) (NN line)) (PP (IN of) (NP (JJ prior) (NN therapy)))))))))) (. .)))
23864035	11	(S1 (S (NP (NN Doc_23864035_1546_1554_Chemical)) (VP (AUX was) (NP (NP (DT an) (JJ effective) (NN salvage) (NN treatment)) (PP (IN for) (NP (NNP Doc_23864035_1594_1596_Disease) (NNS patients)))) (, ,) (PP (ADVP (RB particularly)) (IN for) (NP (NP (DT those)) (PP (IN in) (NP (JJ first) (NN relapse)))))) (. .)))
23871786	0	(S1 (S (NP (NP (JJ Pubertal) (NN exposure)) (PP (TO to) (NP (NNP Doc_23871786_21_32_Chemical)))) (VP (VP (VBZ increases) (NP (JJ Doc_23871786_43_50_Disease-like) (NN behavior))) (CC and) (VP (VBZ decreases) (NP (NP (NN acetylcholinesterase) (NN activity)) (PP (IN of) (NP (NN hippocampus))) (PP (IN in) (NP (NN adult) (NN male) (NNS mice)))))) (. .)))
23871786	1	(S1 (S (NP (NP (DT The) (JJ negative) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_23871786_168_179_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_23871786_181_184_Chemical)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (NN neurodevelopment)) (CC and) (NP (NNS behaviors))))) (VP (AUX have) (VP (AUX been) (ADJP (RB well) (VBN established)))) (. .)))
23871786	2	(S1 (S (NP (NP (NN Acetylcholinesterase)) (PRN (-LRB- -LRB-) (NP (NN AChE)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (JJ regulatory) (NN enzyme)) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN involved) (PP (IN in) (NP (JJ Doc_23871786_320_327_Disease-like) (NN behavior))))))))) (. .)))
23871786	3	(S1 (S (NP (DT This) (NN study)) (VP (VBD investigated) (NP (NP (JJ behavioral) (NNS phenotypes) (CC and) (NN AChE) (NN activity)) (PP (IN in) (NP (NP (JJ male) (NNS mice)) (VP (VBG following) (NP (JJ Doc_23871786_430_433_Chemical) (NN exposure)) (PP (IN during) (NP (NN puberty)))))))) (. .)))
23871786	4	(S1 (S (PP (IN On) (NP (JJ postnatal) (NN day))) (PRN (-LRB- -LRB-) (VB PND) (-RRB- -RRB-)) (NP (CD 35) (, ,) (JJ male) (NNS mice)) (VP (AUX were) (VP (VBN exposed) (S (VP (TO to) (VP (VB 50mg) (NP (NP (JJ Doc_23871786_517_520_Chemical/kg) (NN diet)) (PP (IN per) (NP (NN day)))) (PP (IN for) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (CD 35) (NNS days)))))))))) (. .)))
23871786	5	(S1 (S (PP (IN On) (NP (CD PND71))) (, ,) (NP (DT a) (JJ behavioral) (NN assay)) (VP (AUX was) (VP (VBN performed) (S (VP (VBG using) (NP (NP (NP (DT the) (JJ elevated) (NN plus) (NN maze)) (PRN (-LRB- -LRB-) (NP (NN EPM)) (-RRB- -RRB-))) (CC and) (NP (DT the) (NN light/dark) (NN test))))))) (. .)))
23871786	6	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN AChE) (NN activity)) (VP (AUX was) (VP (VBN measured) (PP (IN in) (NP (NP (DT the) (JJ prefrontal) (NN cortex)) (, ,) (NP (NNP Doc_23871786_731_743_Disease)) (, ,) (NP (NN cerebellum)) (CC and) (NP (NN hippocampus)))))) (. .)))
23871786	7	(S1 (S (NP (NP (NNS Results)) (PP (IN from) (NP (PRP$ our) (JJ behavioral) (NN phenotyping)))) (VP (VBD indicated) (SBAR (IN that) (S (NP (JJ Doc_23871786_828_835_Disease-like) (NN behavior)) (VP (AUX was) (VP (VBN increased) (PP (IN in) (NP (NP (NNS mice)) (VP (VBN exposed) (PP (TO to) (NP (NN Doc_23871786_883_886_Chemical))))))))))) (. .)))
23871786	8	(S1 (S (NP (NN AChE) (NN activity)) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN decreased) (PP (IN in) (NP (NP (DT the) (NN hippocampus)) (PP (IN of) (NP (NP (NNS mice)) (PP (IN with) (NP (NNP Doc_23871786_962_965_Chemical))))) (PP (VBN compared) (PP (TO to) (NP (NN control) (NNS mice)))))) (, ,) (SBAR (IN whereas) (S (NP (DT no) (NN difference)) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NP (DT the) (JJ prefrontal) (NN cortex)) (, ,) (NP (NN Doc_23871786_1050_1062_Disease)) (CC and) (NP (NN cerebellum)))))))))) (. .)))
23871786	9	(S1 (S (NP (PRP$ Our) (NNS findings)) (VP (VBD showed) (SBAR (IN that) (S (NP (JJ pubertal) (JJ Doc_23871786_1113_1116_Chemical) (NN exposure)) (VP (VBD increased) (NP (NP (JJ Doc_23871786_1136_1143_Disease-like) (NN behavior)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (VBN decreased) (NN AChE) (NN activity)) (PP (IN of) (NP (DT the) (NN hippocampus))) (PP (IN in) (NP (NN adult) (NN male) (NNS mice))))))))))))))) (. .)))
23871786	10	(S1 (S (NP (JJ Further) (NNS studies)) (VP (AUX are) (ADJP (JJ necessary) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (JJ cholinergic) (VBG signaling)) (PP (IN of) (NP (NP (DT the) (NNS hippocampus)) (PP (IN in) (NP (JJ PBE) (VBN induced) (JJ Doc_23871786_1356_1363_Disease-like) (NNS behaviors))))))))))) (. .)))
23872883	0	(S1 (S (NP (NP (JJ Biochemical) (NNS effects)) (PP (IN of) (NP (NNP Solidago) (NN virgaurea)))) (VP (VB extract) (PP (IN on) (NP (JJ experimental) (NN Doc_23872883_66_80_Disease)))) (. .)))
23872883	1	(S1 (S (NP (NP (NNP Doc_23872883_82_105_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_23872883_107_111_Disease)) (-RRB- -RRB-))) (VP (AUX are) (NP (NP (DT the) (JJ major) (NN health) (NN problem)) (PP (IN of) (NP (JJ advanced) (CONJP (RB as) (RB well) (IN as)) (NP (VBG developing) (NNS countries)) (PP (IN of) (NP (DT the) (NN world))))))) (. .)))
23872883	2	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (S (NP (NP (DT the) (JJ protective) (NN effect)) (PP (IN of) (NP (DT the) (NNP Solidago) (NN virgaurea)))) (VP (VB extract) (PP (IN on) (NP (NP (JJ Doc_23872883_307_320_Chemical-induced) (NN Doc_23872883_329_343_Disease)) (PP (IN in) (NP (NNS rats))))))))))) (. .)))
23872883	3	(S1 (S (NP (NP (DT The) (JJ subcutaneous) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_23872883_383_396_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN mg/kg)) (-RRB- -RRB-)))) (PP (IN into) (NP (NNS rats)))) (ADVP (RB twice)) (PP (IN at) (NP (DT an) (NN interval))) (PP (IN of) (NP (CD 24))) (NP (NNP h)) (, ,) (PP (IN for) (NP (CD two) (JJ consecutive) (NNS days))) (, ,) (VP (VBD led) (PP (TO to) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (JJ serum) (JJ Doc_23872883_513_520_Chemical) (NN dehydrogenase)) (, ,) (NP (JJ Doc_23872883_536_544_Chemical) (NN phosphokinase)) (, ,) (NP (JJ Doc_23872883_560_567_Chemical) (NN transaminase)) (, ,) (NP (JJ Doc_23872883_582_591_Chemical) (NN transaminase)) (, ,) (CC and) (NP (NP (JJ Doc_23872883_610_621_Chemical-converting) (JJ enzyme) (NNS activities)) (, ,) (NP (NP (JJ total) (NNP Doc_23872883_658_669_Chemical)) (, ,) (NP (NNP Doc_23872883_671_684_Chemical)) (, ,) (NP (JJ free) (NN serum) (NNP Doc_23872883_697_707_Chemical)) (, ,) (NP (NP (JJ cardiac) (NN tissue) (NNP Doc_23872883_724_739_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_23872883_741_744_Chemical)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ Doc_23872883_751_763_Chemical) (NNS levels)) (CC and) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NP (NNS levels)) (PP (IN of) (NP (NNP Doc_23872883_811_822_Chemical) (CC and) (NNP Doc_23872883_827_837_Chemical) (NN dismutase))))))))))) (PP (IN in) (NP (JJ cardiac) (NN tissue))))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NP (DT the) (JJ normal) (NN control) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP P) (NNP <) (CD 0.05)) (-RRB- -RRB-)))))))) (. .)))
23872883	4	(S1 (S (NP (NP (NN Pretreatment)) (PP (IN with) (NP (NNP S.) (NN virgaurea)))) (VP (VB extract) (PP (IN for) (NP (CD 5) (NNS weeks))) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NP (CD 250) (NNS mg/kg)) (VP (VBN followed) (PP (IN by) (NP (JJ Doc_23872883_1004_1017_Chemical) (NN injection))) (PP (ADVP (RB significantly)) (VBN prevented) (NP (DT the) (JJ observed) (NNS alterations))))))))) (. .)))
23872883	5	(S1 (S (NP (NP (NP (NNP Doc_23872883_1078_1087_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 50) (NN mg/kg/day)) (, ,) (NP (VBN given) (NN orally))) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NP (JJ Doc_23872883_1134_1145_Chemical-converting) (NN enzyme)) (VP (VBN used) (PP (IN as) (NP (DT a) (JJ standard) (JJ cardioprotective) (NN drug))))))) (, ,)) (VP (AUX was) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (JJ positive) (NN control)) (PP (IN in) (NP (DT this) (NN study))))))) (. .)))
23872883	6	(S1 (S (NP (NP (DT The) (NNS data)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP S.) (NN virgaurea)) (VP (VB extract) (NP (NNS exerts)) (NP (PRP$ its) (JJ protective) (NN effect)) (PP (IN by) (S (VP (VP (VBG decreasing) (NP (JJ Doc_23872883_1359_1362_Chemical) (NN level))) (CC and) (VP (VBG increasing) (NP (NP (DT the) (JJ antioxidant) (NN status)) (PP (IN in) (NP (JJ Doc_23872883_1410_1423_Chemical-treated) (NNS rats)))))))))))) (. .)))
23872883	7	(S1 (S (NP (DT The) (NN study)) (VP (VBZ emphasizes) (S (NP (NP (DT the) (JJ beneficial) (NN action)) (PP (IN of) (NP (NNP S.) (NN virgaurea)))) (VP (VB extract) (PP (IN as) (NP (DT a) (JJ cardioprotective) (NN agent)))))) (. .)))
23892921	0	(S1 (NP (NP (NP (`` ``) (JJ Real-world) ('' '') (NNS data)) (PP (IN on) (NP (NP (DT the) (NN efficacy) (CC and) (NN safety)) (PP (IN of) (NP (NP (NNP Doc_23892921_48_60_Chemical)) (CC and) (NP (NNP Doc_23892921_65_78_Chemical)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ relapsed/refractory) (JJ multiple) (NNP Doc_23892921_125_132_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN treated) (PP (VBG according) (PP (TO to) (NP (DT the) (JJ standard) (JJ clinical) (NN practice))))))))))))) (: :) (NP (NP (DT a) (NN study)) (PP (IN of) (NP (DT the) (JJ Greek) (NNP Myeloma) (NNP Study) (NNP Group)))) (. .)))
23892921	1	(S1 (S (S (NP (NP (NNP Doc_23892921_237_249_Chemical) (CC and) (NNP Doc_23892921_254_267_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP RD)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (NN standard)) (PP (IN of) (NP (NN care))) (PP (IN for) (NP (NP (JJ relapsed/refractory) (JJ multiple) (NNP Doc_23892921_328_335_Disease)) (PRN (-LRB- -LRB-) (NP (NNP RRMM)) (-RRB- -RRB-))))))) (, ,) (CC but) (S (NP (EX there)) (VP (AUX is) (VP (VBN limited) (NP (NP (VBN published) (NNS data)) (PP (IN on) (NP (NP (PRP$ its) (NN efficacy) (CC and) (NN safety)) (PP (IN in) (NP (NP (DT the) (`` ``) (JJ real) (NN world) ('' '')) (PRN (-LRB- -LRB-) (NP (NNP RW)) (-RRB- -RRB-))))))) (, ,) (PP (VBG according) (PP (TO to) (NP (NP (DT the) (NNP International) (NNP Society)) (PP (IN of) (NP (NP (NNPS Pharmacoeconomics)) (CC and) (NP (NP (NNS Outcomes)) (NP (NNP Research) (NN definition))))))))))) (. .)))
23892921	2	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (QP (CD 212) (CD RRMM)) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NNP RD)) (PP (IN in) (NP (NN RW)))))))) (. .)))
23892921	3	(S1 (S (NP (JJ Objective) (NN response) (PRN (-LRB- -LRB-) (NP (NP (NN >PR)) (PRN (-LRB- -LRB-) (NP (JJ partial) (NN response)) (-RRB- -RRB-))) (-RRB- -RRB-)) (NN rate)) (VP (AUX was) (NP (NP (CD 77.4) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ complete) (NN response)) (PRN (-LRB- -LRB-) (NP (NNP CR)) (-RRB- -RRB-))) (, ,) (NP (CD 20.2) (NN %))) (-RRB- -RRB-)))) (. .)))
23892921	4	(S1 (S (NP (NP (NP (JJ Median) (NN time)) (PP (TO to) (NP (JJ first)))) (CC and) (NP (JJS best) (NN response))) (VP (AUX was) (NP (QP (CD 2) (CC and) (CD 5)) (NNS months)) (, ,) (ADVP (RB respectively))) (. .)))
23892921	5	(S1 (S (NP (JJ Median) (NN time)) (VP (TO to) (VP (VB CR) (SBAR (WHADVP (WRB when)) (S (NP (NNP RD)) (VP (AUX was) (VP (VBN given) (PP (IN as) (NP (NP (NP (ADJP (JJ 2nd) (CC or) (JJ >2)) (PRN (-LRB- -LRB-) (NP (NN nd)) (-RRB- -RRB-)) (NN -line) (NN treatment)) (NP (QP (IN at) (CD 4) (CC and) (CD 11)) (NNS months))) (, ,) (ADVP (RB respectively)))))))))) (. .)))
23892921	6	(S1 (S (NP (NP (NN Quality)) (PP (IN of) (NP (NN response)))) (VP (AUX was) (ADJP (JJ independent) (PP (IN of) (NP (NP (NP (JJ previous) (NNS lines)) (PP (IN of) (NP (NNS therapies)))) (CC or) (NP (NP (JJ previous) (NN exposure)) (PP (TO to) (NP (NP (NNP Doc_23892921_939_950_Chemical)) (CC or) (NP (NNP Doc_23892921_954_964_Chemical))))))))) (. .)))
23892921	7	(S1 (S (S (NP (NP (JJ Median) (NN duration)) (PP (IN of) (NP (NN response)))) (VP (AUX was) (NP (CD 34.4) (NNS months)))) (, ,) (CC and) (S (NP (PRP it)) (VP (AUX was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NNP RD)) (PP (IN until) (NP (NN progression)))))) (PRN (-LRB- -LRB-) (RB not) (VP (VBN reached) (PP (IN versus) (NP (NP (CD 19) (NNS months)) (, ,) (NP (NNP p) (NNP <) (CD 0.001))))) (-RRB- -RRB-)))))) (. .)))
23892921	8	(S1 (S (NP (NP (NN Improvement)) (PP (IN of) (NP (JJ humoral) (NN immunity)))) (VP (VBD occurred) (PP (PP (IN in) (NP (NP (CD 60) (NN %)) (PP (IN of) (NP (NP (NNS responders)) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.001))) (-RRB- -RRB-)))))) (CC and) (PP (IN in) (NP (NP (DT the) (NN majority)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD achieved) (NP (JJ stable) (NN disease))))))))))) (. .)))
23892921	9	(S1 (S (NP (JJ Adverse) (NNS events)) (VP (AUX were) (VP (VBN reported) (PP (IN in) (NP (NP (NP (CD 68.9) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NN myelosuppression)) (PP (IN in) (NP (CD 49.4) (NN %)))) (-RRB- -RRB-))))) (CC and) (NP (NP (CD 12.7) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN needed) (NP (NN hospitalization)))))))))) (. .)))
23892921	10	(S1 (S (NP (NN Doc_23892921_1381_1402_Disease)) (VP (AUX was) (VP (VBN observed) (ADVP (RB only)) (PP (IN in) (NP (NP (NP (CD 2.5) (NN %)) (PP (IN of) (NP (NNS patients)))) (CC and) (NP (NN Doc_23892921_1446_1466_Disease)))) (PP (IN in) (NP (CD 5.7) (NN %))))) (. .)))
23892921	11	(S1 (S (NP (NN Dose) (NNS reductions)) (VP (AUX were) (VP (VBN needed) (PP (IN in) (NP (NP (NP (CD 31) (NN %)) (PP (IN of) (NP (NNS patients)))) (CC and) (NP (NP (JJ permanent) (NN discontinuation)) (PP (IN in) (NP (CD 38.9) (NN %)))))))) (. .)))
23892921	12	(S1 (S (NP (NP (JJ Median) (NN time)) (PP (TO to) (NP (NN treatment) (NN discontinuation)))) (VP (AUX was) (NP (CD 16.8) (NNS months))) (. .)))
23892921	13	(S1 (S (NP (NP (NP (NN Performance) (NN status)) (PRN (-LRB- -LRB-) (NP (NNP PS)) (-RRB- -RRB-))) (CC and) (NP (JJ initial) (JJ Doc_23892921_1660_1672_Chemical) (NN dose))) (VP (VBD predicted) (PP (IN for) (NP (NN treatment) (NN discontinuation)))) (. .)))
23892921	14	(S1 (S (NP (JJ Extra-medullary) (NNS relapses)) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 3.8) (NN %)) (PP (IN of) (NP (NNS patients)))))) (. .)))
23892921	15	(S1 (S (S (NP (PRP$ Our) (NN study)) (VP (VBZ confirms) (SBAR (IN that) (S (NP (NNP RD)) (VP (AUX is) (ADJP (JJ effective) (CC and) (JJ safe)) (PP (IN in) (NP (CD RRMM))) (PP (IN in) (NP (DT the) (NN RW)))))))) (: ;) (S (NP (PRP it)) (VP (VBZ produces) (NP (JJ durable) (NNS responses)) (PP (ADVP (RB especially)) (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VP (VBP continue) (PP (IN on) (NP (NN treatment))) (PP (IN till) (NP (NN progression)))) (CC and) (VP (VBZ improves) (NP (JJ humoral) (NN immunity)) (PP (ADVP (RB even)) (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ stable) (NN disease))))))))))))) (. .)))
23949582	0	(S1 (NP (NP (NP (DT The) (JJ cytogenetic) (NN action)) (PP (IN of) (NP (NP (NNP Doc_23949582_26_36_Chemical)) (, ,) (NP (NNP Doc_23949582_38_43_Chemical)) (, ,) (CC and) (NP (PRP$ their) (NN combination)))) (PP (IN on) (NP (JJ peripheral) (NN rabbit) (NNS lymphocytes)))) (: :) (NP (DT an) (ADJP (FW in) (FW vivo/in)) (NN vitro) (NN cytogenetic) (NN study)) (. .)))
23949582	1	(S1 (S (NP (NP (NNP Doc_23949582_140_150_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_23949582_152_155_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT an) (JJ alkylating) (JJ Doc_23949582_174_182_Chemical) (NN mustard)) (, ,) (VP (VBN administrated) (PP (IN as) (NP (DT an) (JJ antineoplasmic) (NN agent)))))) (. .)))
23949582	2	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN characterized) (PP (IN by) (NP (PRP$ its) (JJ intense) (NN urotoxic) (NN action))) (, ,) (PP (VBG leading) (PP (TO to) (NP (NNP Doc_23949582_297_317_Disease)))))) (. .)))
23949582	3	(S1 (S (NP (NP (DT This) (NN side) (NN effect)) (PP (IN of) (NP (NNP Doc_23949582_339_342_Chemical)))) (VP (VBZ raises) (NP (NP (DT the) (NN requirement)) (PP (IN for) (NP (DT the) (NN co-administration))) (PP (IN with) (NP (NNP Doc_23949582_397_429_Chemical)))) (PRN (-LRB- -LRB-) (NP (NNP Doc_23949582_431_436_Chemical)) (-RRB- -RRB-)) (S (VP (VBG aiming) (S (VP (TO to) (VP (VB avoid) (CC or) (VB minimize) (NP (DT this) (NN effect)))))))) (. .)))
23949582	4	(S1 (S (NP (NP (NNP Doc_23949582_479_482_Chemical)) (CC and) (NP (NNP Doc_23949582_487_492_Chemical))) (VP (AUX were) (VP (VBN administrated) (ADVP (RB separately)) (PP (IN on) (NP (NP (NP (NN rabbit) (POS 's)) (NNS lymphocytes)) (PP (IN in) (NP (NN vivo))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (ADVP (RB later)) (VP (VBN developed) (PP (IN in) (NP (NN vitro))))))))))) (. .)))
23949582	5	(S1 (S (NP (NP (JJ Cytogenetic) (NNS markers)) (PP (IN for) (NP (NP (NP (JJ sister) (JJ chromatid) (NNS exchanges)) (PRN (-LRB- -LRB-) (NP (NNP SCEs)) (-RRB- -RRB-))) (, ,) (NP (NP (NN proliferation) (NN rate) (NN index)) (PRN (-LRB- -LRB-) (NP (NNP PRI)) (-RRB- -RRB-))) (CC and) (NP (NNP Mitotic) (NNP Index))))) (VP (AUX were) (VP (VBN recorded))) (. .)))
23949582	6	(S1 (S (NP (NP (NP (NNP Doc_23949582_716_721_Chemical) (POS 's)) (NN action)) (, ,) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NNP Doc_23949582_752_755_Chemical)))))) (VP (VBZ reduces) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NNS SCEs)))) (, ,) (PP (IN in) (NP (NP (NN comparison)) (PP (IN with) (NP (NP (DT the) (JJ SCEs) (NNS recordings)) (VP (VBN obtained) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_23949582_840_843_Chemical)) (VP (AUX is) (VP (VBN administered) (ADVP (RB alone)))))))))))) (. .)))
23949582	7	(S1 (S (PP (IN In) (NP (NP (NN addition)) (PP (TO to) (NP (DT this))))) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (JJ high) (NNS concentrations)) (PP (IN of) (NP (NNP Doc_23949582_916_921_Chemical)))) (VP (AUX were) (VP (VBN administered))))) (NP (NP (RB alone) (JJ significant) (NNS reductions)) (PP (IN of) (NP (DT the) (NNP PRI)))) (VP (AUX were) (VP (VBN noted) (, ,) (PP (IN than) (PP (IN with) (NP (NP (JJ Doc_23949582_1002_1005_Chemical) (NN acting)) (PP (IN at) (NP (NP (DT the) (JJ same) (NN concentration)) (PP (IN on) (NP (DT the) (NNS lymphocytes)))))))))) (. .)))
23949582	8	(S1 (S (NP (NN Doc_23949582_1059_1064_Chemical)) (ADVP (RB significantly)) (VP (VBZ reduces) (NP (NP (NNP Doc_23949582_1087_1090_Chemical) (POS 's)) (NN genotoxicity)) (, ,) (SBAR (IN while) (S (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN in) (NP (JJ high) (NNS concentrations)))))) (NP (PRP it)) (VP (VBZ acts) (PP (IN in) (NP (NP (DT an) (JJ inhibitory) (NN fashion)) (PP (IN on) (NP (NP (DT the) (JJ cytostatic) (NN action)) (PP (IN of) (NP (DT the) (NN drug))))))))))) (. .)))
23952588	0	(S1 (NP (NP (NP (NN Risk) (NNS factors)) (CC and) (NP (NNS predictors))) (PP (IN of) (NP (JJ Doc_23952588_31_39_Chemical-induced) (NNP Doc_23952588_48_58_Disease))) (PP (IN among) (NP (NP (JJ multiethnic) (NNS Malaysians)) (PP (IN with) (NP (NNP Doc_23952588_93_112_Disease))))) (. .)))
23952588	1	(S1 (S (NP (NP (JJ Chronic) (JJ pulsatile) (JJ Doc_23952588_132_140_Chemical) (NN therapy)) (PP (IN for) (NP (NP (NNP Doc_23952588_153_172_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_23952588_174_176_Disease)) (-RRB- -RRB-))))) (VP (VBZ leads) (PP (TO to) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NN motor) (NNS fluctuations)) (CC and) (NP (NN Doc_23952588_229_239_Disease))))))) (. .)))
23952588	2	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (DT the) (NN prevalence) (CC and) (NNS predictors)) (PP (IN of) (NP (NNP Doc_23952588_285_293_Chemical-induced) (NNP Doc_23952588_302_312_Disease))) (PP (IN among) (NP (NP (JJ multiethnic) (JJ Malaysian) (NNS patients)) (PP (IN with) (NP (NNP Doc_23952588_355_357_Disease))))))) (. .)))
23952588	3	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT a) (JJ cross-sectional) (NN study)) (VP (VBG involving) (NP (NP (CD 95) (NNS patients)) (PP (IN with) (NP (NNP Doc_23952588_427_429_Disease)))) (PP (IN on) (NP (NP (JJ uninterrupted) (JJ Doc_23952588_447_455_Chemical) (NN therapy)) (PP (IN for) (NP (QP (IN at) (JJS least) (CD 6)) (NNS months)))))))) (. .)))
23952588	4	(S1 (S (NP (NP (DT The) (NN instrument)) (VP (VBN used))) (VP (AUX was) (NP (DT the) (JJ UPDRS) (NNS questionnaires))) (. .)))
23952588	5	(S1 (S (NP (NP (DT The) (NNS predictors)) (PP (IN of) (NP (NNP Doc_23952588_555_565_Disease)))) (VP (AUX were) (VP (VBN determined) (S (VP (VBG using) (NP (JJ multivariate) (JJ logistic) (NN regression) (NN analysis)))))) (. .)))
23952588	6	(S1 (S (NP (DT The) (JJ mean) (NN age)) (VP (AUX was) (NP (QP (CD 65.6) (CD +) (CD 8.5)) (NNS years))) (. .)))
23952588	7	(S1 (S (NP (DT The) (JJ mean) (NN onset) (NN age)) (VP (AUX was) (NP (CD 58.5) (NN +) (CD 9.8) (NNS years))) (. .)))
23952588	8	(S1 (S (NP (DT The) (JJ median) (NN disease) (NN duration)) (VP (AUX was) (NP (CD 6) (-LRB- -LRB-) (CD 7) (-RRB- -RRB-) (NNS years))) (. .)))
23952588	9	(S1 (S (NP (NN Doc_23952588_761_771_Disease)) (VP (AUX was) (ADJP (JJ present) (PP (IN in) (NP (CD 44) (NN %)))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 42)) (-RRB- -RRB-)) (PP (IN with) (NP (NP (JJ median) (JJ Doc_23952588_812_820_Chemical) (NN therapy)) (PP (IN of) (NP (CD 3) (NNS years)))))) (. .)))
23952588	10	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (ADJP (CD 64.3) (NN %)) (NNPS Chinese)) (, ,) (NP (ADJP (CD 31) (NN %)) (NNP Malays)) (, ,) (CC and) (NP (ADJP (CD 3.7) (NN %)) (NNPS Indians)) (CC and) (NP (JJ other) (JJ ethnic) (NNS groups)))) (. .)))
23952588	11	(S1 (S (NP (NP (JJ Eighty-one) (NN percent)) (PP (IN of) (NP (NNS patients))) (PP (IN with) (NP (NNP Doc_23952588_957_967_Disease)))) (VP (AUX had) (NP (JJ clinical) (NNS fluctuations))) (. .)))
23952588	12	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NNP Doc_23952588_1009_1019_Disease)))) (VP (AUX had) (NP (NP (JJR lower) (NN onset) (NN age)) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.001))) (-RRB- -RRB-)) (, ,) (NP (NP (JJR longer) (NN duration)) (PP (IN of) (NP (JJ Doc_23952588_1073_1081_Chemical) (NN therapy)))) (PRN (-LRB- -LRB-) (NP (QP (CD p) (CD <)) (CD 0.001)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_23952588_1104_1127_Disease)) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.001))) (-RRB- -RRB-)) (, ,) (NP (RBR higher) (JJ total) (JJ daily) (JJ Doc_23952588_1161_1169_Chemical) (NN dose)) (PRN (-LRB- -LRB-) (NP (QP (CD p) (CD <)) (CD 0.001)) (-RRB- -RRB-)) (, ,) (CC and) (NP (JJR higher) (JJ total) (NNS UPDRS) (NNS scores)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.005)) (-RRB- -RRB-)) (PP (IN than) (NP (NP (NNS patients)) (PP (IN without) (NP (NNP Doc_23952588_1254_1264_Disease))))))) (. .)))
23952588	13	(S1 (S (NP (NP (DT The) (CD three) (JJ significant) (NNS predictors)) (PP (IN of) (NP (NNP Doc_23952588_1302_1312_Disease)))) (VP (AUX were) (NP (NP (NN duration)) (PP (IN of) (NP (NP (NN Doc_23952588_1330_1338_Chemical) (NN therapy)) (, ,) (NP (NN onset) (NN age)) (, ,) (CC and) (NP (JJ total) (JJ daily) (JJ Doc_23952588_1375_1383_Chemical) (NN dose)))))) (. .)))
23952588	14	(S1 (S (NP (NP (DT The) (NN prevalence)) (PP (IN of) (NP (NNP Doc_23952588_1421_1429_Chemical-induced) (NNP Doc_23952588_1438_1448_Disease))) (PP (IN in) (NP (PRP$ our) (NNS patients)))) (VP (AUX was) (NP (CD 44) (NN %))) (. .)))
23952588	15	(S1 (S (NP (DT The) (RBS most) (JJ significant) (NNS predictors)) (VP (AUX were) (NP (NP (NP (NN duration)) (PP (IN of) (NP (JJ Doc_23952588_1523_1531_Chemical) (NN therapy)))) (, ,) (NP (JJ total) (JJ daily) (JJ Doc_23952588_1553_1561_Chemical) (NN dose)) (, ,) (CC and) (NP (NN onset) (NN age)))) (. .)))
2400986	0	(S1 (NP (NP (NP (JJ Dose-dependent) (NN Doc_2400986_15_28_Disease)) (PP (IN of) (NP (JJ high-dose) (NNP Doc_2400986_42_50_Chemical))) (PP (IN in) (NP (NNS children)))) (: :) (NP (DT a) (ADJP (JJ clinical) (CC and) (JJ pharmacological)) (NN study)) (. .)))
2400986	1	(S1 (S (S (NP (NN Doc_2400986_102_110_Chemical)) (VP (AUX is) (VP (VBN known) (S (VP (TO to) (VP (AUX be) (ADJP (JJ Doc_2400986_126_136_Disease)) (PP (IN in) (NP (NP (NNS animals)) (CC and) (NP (NNS humans)))))))))) (, ,) (CC but) (S (NP (PRP$ its) (JJ acute) (NN Doc_2400986_174_187_Disease)) (VP (VBZ remains) (ADJP (RB poorly) (VBN characterized)) (PP (IN in) (NP (NNS children))))) (. .)))
2400986	2	(S1 (S (S (NP (PRP We)) (VP (VBP report) (ADVP (RB here)) (NP (NP (DT a) (JJ retrospective) (NN study)) (PP (IN of) (NP (NP (CD 123) (NNS children)) (PRN (-LRB- -LRB-) (NP (JJ median) (NN age)) (, ,) (NP (CD 6.5) (NNS years)) (-RRB- -RRB-)))) (VP (VBG receiving) (NP (JJ high-dose) (NNP Doc_2400986_327_335_Chemical)) (PP (IN in) (NP (VBN combined) (NN chemotherapy))) (PP (IN before) (NP (NP (NN bone) (NN marrow) (NN transplantation)) (PP (IN for) (NP (JJ malignant) (JJ solid) (NN Doc_2400986_416_422_Disease))))))))) (, ,) (NP (NNP Doc_2400986_424_436_Disease)) (VP (VBN excluded)) (. .)))
2400986	3	(S1 (S (NP (NN Doc_2400986_447_455_Chemical)) (VP (AUX was) (VP (VBN given) (ADVP (RB p.o.)) (, ,) (NP (NP (DT every) (CD 6) (NNS hours)) (PP (IN for) (NP (NP (CD 16) (NNS doses)) (PP (IN over) (NP (CD 4) (NN days)))))))) (. .)))
2400986	4	(S1 (S (S (NP (CD Two) (JJ total) (NNS doses)) (VP (AUX were) (ADVP (RB consecutively)) (VP (VBN used)))) (: :) (S (NP (NP (QP (CD 16) (CD mg/kg))) (, ,) (ADVP (RB then) (NP (CD 600) (NN mg/m2))))) (. .)))
2400986	5	(S1 (S (NP (NP (DT The) (NN dose) (NN calculation)) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NN body) (NN surface) (NN area)))))) (VP (VBZ results) (PP (IN in) (NP (NP (JJR higher) (NNS doses)) (PP (IN in) (NP (JJ young) (NNS children))))) (PP (IN than) (PP (IN in) (NP (NP (JJR older) (NNS patients)) (PRN (-LRB- -LRB-) (NP (QP (CD 16) (TO to) (CD 28)) (NNS mg/kg)) (-RRB- -RRB-)))))) (. .)))
2400986	6	(S1 (S (S (NP (NN Ninety-six) (NNS patients)) (VP (AUX were) (RB not) (VP (VBN given) (NP (JJ anticonvulsive) (NN prophylaxis))))) (: ;) (S (NP (NP (CD 7)) (PRN (-LRB- -LRB-) (NP (CD 7.5) (NN %)) (-RRB- -RRB-))) (VP (VBD developed) (NP (NNP Doc_2400986_799_807_Disease)) (PP (IN during) (NP (NP (DT the) (CD 4) (NNS days)) (PP (PP (IN of) (NP (DT the) (JJ Doc_2400986_833_841_Chemical) (NN course))) (CC or) (PP (IN within) (NP (NP (CD 24) (NNP h)) (PP (IN after) (NP (DT the) (JJ last) (NN dosing)))))))))) (. .)))
2400986	7	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (DT the) (JJ total) (NNP Doc_2400986_902_910_Chemical) (NN dose)) (VP (AUX was) (VP (VBN taken) (PP (IN into) (NP (NN account))))))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (NN difference)) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NNP Doc_2400986_987_1000_Disease) (NN incidence))))) (PP (IN among) (NP (NP (NP (NNS patients)) (PP (IN under) (NP (NP (CD 16) (NNS mg/kg)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 1)) (PP (IN of) (NP (CD 57)))) (, ,) (NP (CD 1.7) (NN %))) (-RRB- -RRB-))))) (CC and) (NP (NP (NNS patients)) (PP (IN under) (NP (NP (NP (CD 600) (NNS mg/m2)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 6)) (PP (IN of) (NP (CD 39)))) (, ,) (NP (CD 15.4) (NN %))) (-RRB- -RRB-))) (-LRB- -LRB-) (PP (VBG P) (NP (QP (JJR less) (IN than) (CD 0.02)))) (-RRB- -RRB-)))))))) (. .)))
2400986	8	(S1 (S (S (NP (JJ Twenty-seven) (NNS patients)) (VP (AUX were) (VP (VBN given) (NP (NP (DT a) (JJ 600-mg/m2) (JJ Doc_2400986_1168_1176_Chemical) (JJ total) (NN dose)) (PP (IN with) (NP (NP (JJ continuous) (NN i.v.) (NN infusion)) (PP (IN of) (NP (NNP Doc_2400986_1221_1231_Chemical))))))))) (: ;) (S (NP (NN none)) (VP (AUX had) (NP (DT any) (JJ neurological) (NNS symptoms)))) (. .)))
2400986	9	(S1 (S (S (NP (JJ Doc_2400986_1269_1277_Chemical) (NNS levels)) (VP (AUX were) (VP (VBN measured) (PP (IN by) (NP (NP (NP (DT a) (NN gas) (NN chromatographic-mass) (NN spectrometry) (NN assay)) (PP (IN in) (NP (NP (DT the) (NN plasma) (CC and) (NN cerebrospinal) (NN fluid)) (PP (IN of) (NP (NP (CD 9) (NNS children)) (PP (IN without) (NP (NNP Doc_2400986_1408_1438_Disease))) (PP (IN under) (NP (NP (CD 600) (NNS mg/m2)) (ADJP (JJ Doc_2400986_1455_1463_Chemical) (PP (IN with) (NP (NNP Doc_2400986_1469_1479_Chemical))))))))))) (: :) (NP (JJ Doc_2400986_1480_1488_Chemical) (JJ cerebrospinal) (NN fluid))))))) (: :) (S (NP (NN plasma) (NN ratio)) (VP (AUX was) (NP (CD 1.39)))) (. .)))
2400986	10	(S1 (S (S (NP (DT This)) (VP (AUX was) (ADJP (RB significantly) (JJ different)) (PRN (-LRB- -LRB-) (NP (QP (RB P) (JJR less) (IN than) (CD 0.02))) (-RRB- -RRB-)) (PP (IN from) (NP (DT the) (JJ cerebrospinal) (NN fluid))))) (: :) (S (NP (NN plasma) (NN ratio)) (ADVP (RB previously)) (VP (VBD defined) (PP (IN in) (NP (NP (NNS children)) (VP (VBG receiving) (NP (NP (DT a) (JJ 16-mg/kg) (JJ total) (NN dose)) (PP (IN of) (NP (NNP Doc_2400986_1692_1700_Chemical))))))))) (. .)))
2400986	11	(S1 (S (NP (DT This) (NN study)) (VP (VBZ shows) (SBAR (IN that) (S (NP (NNP Doc_2400986_1724_1732_Chemical) (NNP Doc_2400986_1733_1746_Disease)) (VP (AUX is) (UCP (ADJP (JJ dose-dependent) (PP (IN in) (NP (NNS children)))) (CC and) (VP (ADVP (RB efficiently)) (VBN prevented) (PP (IN by) (NP (NNP Doc_2400986_1806_1816_Chemical))))))))) (. .)))
2400986	12	(S1 (S (NP (NP (NP (DT A) (JJ Doc_2400986_1820_1828_Chemical) (NN dose)) (VP (VBN calculated) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NN body) (NN surface) (NN area))))))) (, ,) (VP (VBG resulting) (PP (IN in) (NP (NP (JJR higher) (NNS doses)) (PP (IN in) (NP (JJ young) (NNS children)))))) (, ,)) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (NNP Doc_2400986_1941_1964_Disease))) (, ,) (ADVP (RB close) (PP (TO to) (NP (NP (JJ Doc_2400986_1975_1988_Disease) (NN incidence)) (VP (VBN observed) (PP (IN in) (NP (NNS adults))))))))) (. .)))
2400986	13	(S1 (S (SBAR (IN Since) (S (NP (NN plasma) (NN pharmacokinetic) (NNS studies)) (VP (VBD showed) (NP (NP (DT a) (JJR faster) (NNP Doc_2400986_2072_2080_Chemical) (NN clearance)) (PP (IN in) (NP (NNS children)))) (PP (IN than) (PP (IN in) (NP (NNS adults))))))) (, ,) (NP (DT this) (JJ new) (NN dose)) (VP (MD may) (VP (JJ approximate) (ADVP (RBR more) (RB closely)) (NP (NP (DT the) (JJ adult) (JJ systemic) (NN exposure)) (VP (VBN obtained) (PP (IN after) (NP (DT the) (JJ usual) (JJ 16-mg/kg) (NN total) (NN dose))))) (, ,) (PP (IN with) (NP (NP (JJ potential) (NNS inferences)) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (NN anticancer)) (CC or) (NP (JJ myeloablative) (NNS effects)))))))))) (. .)))
2400986	14	(S1 (S (NP (NP (DT The) (JJ Doc_2400986_2315_2323_Chemical) (NN dose)) (PP (IN in) (NP (NP (NNS children)) (CC and) (NP (NNS infants)))) (VP (VBG undergoing) (NP (NN bone) (NN marrow) (NN transplantation)))) (VP (MD should) (VP (AUX be) (VP (VBN reconsidered) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (JJ pharmacokinetic) (NNS studies)))))))) (. .)))
24040781	0	(S1 (NP (NP (NP (DT An) (JJ unexpected) (NN diagnosis)) (PP (IN in) (NP (NP (DT a) (JJ renal-transplant) (NN patient)) (PP (IN with) (NP (NNP Doc_24040781_59_70_Disease))) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_24040781_84_94_Chemical))))))) (: :) (NP (NNP Doc_24040781_96_110_Disease)) (. .)))
24040781	1	(S1 (S (NP (NN Doc_24040781_112_123_Disease)) (VP (AUX is) (NP (NP (DT an) (VBN expected) (NN complication)) (PP (IN in) (NP (NP (NN transplant) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (JJ mammalian) (NN target)) (PP (IN of) (NP (NP (JJ Doc_24040781_208_217_Chemical) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (JJ mTOR-i)) (-RRB- -RRB-))))))))))) (. .)))
24040781	2	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ clinical) (NN suspicion)) (VP (MD should) (ADVP (RB always)) (VP (AUX be) (VP (VBN supported) (PP (IN by) (NP (JJ histological) (NN evidence))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB investigate) (NP (NP (JJ potential) (JJ alternate) (NNS diagnoses)) (PP (JJ such) (IN as) (NP (NP (JJ acute) (CC or) (NN chronic) (NN rejection)) (, ,) (NP (JJ interstitial) (NNP Doc_24040781_422_430_Disease) (CC and) (NNP Doc_24040781_435_450_Disease)) (, ,) (CC or) (NP (NN recurrent)) (CC or) (NP (JJ de) (NN novo) (NN Doc_24040781_476_490_Disease)))))))))))) (. .)))
24040781	3	(S1 (S (PP (IN In) (NP (DT this) (NN case))) (NP (PRP we)) (VP (VBP report) (NP (NP (DT the) (JJ unexpected) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_24040781_543_554_Disease)))) (PP (IN in) (NP (NP (DT a) (JJ renal-transplant) (NN patient)) (PP (IN with) (NP (NP (JJ pre-transplant) (NN Doc_24040781_605_626_Disease)) (PP (IN of) (NP (JJ undetermined) (NN significance))) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_24040781_670_681_Disease)) (PP (IN after) (NP (NP (NN conversion)) (PP (IN from) (NP (NNP Doc_24040781_704_714_Chemical))) (PP (TO to) (NP (NNP Doc_24040781_718_728_Chemical))))))))))))) (. .)))
24055495	0	(S1 (S (NP (JJ Long-term) (JJ oral) (JJ Doc_24055495_15_24_Chemical) (NN treatment)) (VP (VBZ prevents) (NP (NN Doc_24055495_44_62_Disease)) (PP (IN in) (NP (NP (JJ male) (JJ Wistar) (NNS rats)) (VP (VBN treated) (ADVP (RB intracerebroventricularly)) (PP (IN with) (NP (NNP Doc_24055495_122_136_Chemical))))))) (. .)))
24055495	1	(S1 (S (NP (JJ Basic) (CC and) (JJ clinical) (NN research)) (VP (AUX has) (VP (VBN demonstrated) (S (PP (IN that) (S (NP (NP (NNP Doc_24055495_188_196_Disease)) (PP (IN of) (NP (JJ sporadic) (NNP Doc_24055495_209_228_Disease) (PRN (-LRB- -LRB-) (JJ sAD) (-RRB- -RRB-)) (NN type)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (NN dysfunction)) (PP (IN of) (NP (NP (DT the) (JJ insulin-receptor) (PRN (-LRB- -LRB-) (NP (NNP IR)) (-RRB- -RRB-)) (NN system)) (VP (VBN followed) (PP (IN by) (NP (NP (VBN decreased) (JJ Doc_24055495_329_336_Chemical) (NN transport)) (PP (IN via) (NP (NP (JJ Doc_24055495_351_358_Chemical) (NN transporter) (NNS GLUT4)) (CC and) (NP (NP (VBN decreased) (JJ Doc_24055495_391_398_Chemical) (NN metabolism)) (PP (IN in) (NP (NN brain) (NNS cells)))))))))))))))))))) (. .)))
24055495	2	(S1 (S (NP (NP (DT An) (JJ alternative) (NN source)) (PP (IN of) (NP (NN energy)))) (VP (AUX is) (NP (NP (NNP Doc_24055495_461_472_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (DT the) (NNP Doc_24055495_478_479_Chemical-4-epimer)) (PP (IN of) (NP (NNP Doc_24055495_492_501_Chemical)))) (-RRB- -RRB-)) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN transported) (PP (IN into) (NP (DT the) (NN brain))) (PP (IN by) (NP (NP (JJ insulin-independent) (NN GLUT3) (NN transporter)) (SBAR (WHADVP (WRB where)) (S (NP (PRP it)) (VP (MD might) (VP (AUX be) (VP (VBN metabolized) (PP (TO to) (NP (NNP Doc_24055495_613_620_Chemical))) (PP (IN via) (NP (DT the) (NNP Leloir) (NN pathway)))))))))))))))) (. .)))
24055495	3	(S1 (S (S (NP (NP (ADJP (RB Exclusively) (JJ parenteral)) (JJ daily) (NNS injections)) (PP (IN of) (NP (NNP Doc_24055495_688_697_Chemical)))) (VP (VP (VB induce) (NP (NP (NN memory) (NN deterioration)) (PP (IN in) (NP (NNS rodents))))) (CC and) (VP (AUX are) (VP (VBN used) (S (VP (TO to) (VP (VB generate) (NP (NN animal) (VBG aging) (NN model))))))))) (, ,) (CC but) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ oral) (JJ Doc_24055495_806_815_Chemical) (NN treatment))) (PP (IN on) (NP (JJ cognitive) (NNS functions)))) (VP (AUX have) (ADVP (RB never)) (VP (AUX been) (VP (VBN tested))))) (. .)))
24055495	4	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN investigated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ continuous) (JJ daily) (JJ oral) (NNP Doc_24055495_931_940_Chemical) (PRN (-LRB- -LRB-) (NP (CD 200) (NN mg/kg/day)) (-RRB- -RRB-)) (NN treatment))) (PP (IN on) (NP (NP (NNP Doc_24055495_970_988_Disease)) (PP (IN in) (NP (NP (JJ Doc_24055495_992_1006_Chemical-induced) (PRN (-LRB- -LRB-) (NP (NNP Doc_24055495_1016_1019_Chemical-icv)) (-RRB- -RRB-)) (NN rat) (NN model)) (PP (IN of) (NP (JJ sAD))))) (, ,) (VP (VBN tested) (PP (IN by) (NP (NP (NNP Morris) (NNP Water) (NN Maze)) (CC and) (NP (NNP Passive) (NNP Avoidance) (NN test))))) (, ,) (ADVP (RB respectively))))))) (. .)))
24055495	5	(S1 (S (NP (NP (CD One) (NN month)) (PP (IN of) (NP (JJ oral) (JJ Doc_24055495_1131_1140_Chemical) (NN treatment)))) (VP (VBD initiated) (ADVP (RB immediately)) (PP (IN after) (NP (DT the) (NNP Doc_24055495_1183_1186_Chemical-icv) (NN administration))) (, ,) (S (VP (ADVP (RB successfully)) (VBN prevented) (NP (NP (NN development)) (PP (IN of) (NP (DT the) (JJ Doc_24055495_1249_1252_Chemical-icv-induced) (NNP Doc_24055495_1265_1283_Disease))))))) (. .)))
24055495	6	(S1 (S (NP (NP (JJ Beneficial) (NN effect)) (PP (IN of) (NP (JJ oral) (NNP Doc_24055495_1311_1320_Chemical)))) (VP (AUX was) (ADJP (JJ independent) (PP (PP (IN of) (NP (DT the) (NN rat) (NN age))) (CC and) (PP (IN of) (NP (NP (DT the) (JJ Doc_24055495_1363_1372_Chemical) (NN dose)) (VP (VBG ranging) (PP (IN from) (NP (QP (CD 100) (TO to) (CD 300)) (NN mg/kg/day))))))))) (. .)))
24055495	7	(S1 (S (ADVP (RB Additionally)) (, ,) (NP (JJ oral) (JJ Doc_24055495_1432_1441_Chemical) (NN administration)) (VP (VBD led) (PP (TO to) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (NNP Doc_24055495_1482_1491_Chemical))) (PP (IN in) (NP (DT the) (NN blood)))))) (. .)))
24055495	8	(S1 (S (NP (NP (DT The) (NN increase)) (PP (IN of) (NP (JJ Doc_24055495_1522_1531_Chemical) (NN concentration))) (PP (IN in) (NP (DT the) (JJ cerebrospinal) (NN fluid)))) (VP (AUX was) (ADJP (ADJP (NP (JJ several) (NNS times)) (JJR lower) (PP (IN after) (NP (JJ oral)))) (PP (IN than) (PP (IN after) (NP (NP (JJ parenteral) (NN administration)) (PP (IN of) (NP (DT the) (JJ same) (JJ Doc_24055495_1657_1666_Chemical) (NN dose)))))))) (. .)))
24055495	9	(S1 (S (NP (JJ Oral) (JJ Doc_24055495_1678_1687_Chemical) (NN exposure)) (VP (VP (MD might) (VP (AUX have) (NP (NP (JJ beneficial) (NNS effects)) (PP (IN on) (NP (NP (NN learning)) (CC and) (NP (NN memory) (NN ability))))))) (CC and) (VP (MD could) (VP (AUX be) (PP (IN worth) (S (VP (VBG investigating) (PP (IN for) (NP (NP (NN improvement)) (PP (IN of) (NP (NNP Doc_24055495_1810_1828_Disease))) (VP (VBN associated) (PP (IN with) (NP (NP (JJ Doc_24055495_1845_1852_Chemical) (NN hypometabolism)) (PP (IN in) (NP (NNP Doc_24055495_1871_1873_Disease)))))))))))))) (. .)))
24067251	0	(S1 (NP (NP (NP (DT An) (NN investigation)) (PP (IN of) (NP (NP (DT the) (NN pattern)) (PP (IN of) (NP (NNP Doc_24067251_35_48_Disease))))) (PP (IN in) (NP (NP (JJ HIV-positive) (NNS persons)) (VP (VBN exposed) (PP (TO to) (NP (NNP Doc_24067251_84_113_Chemical))))))) (: :) (NP (NP (DT an) (NN examination)) (PP (IN of) (NP (NP (DT a) (JJ large) (NN population) (NN database)) (PRN (-LRB- -LRB-) (NP (NN MHRA) (NN database)) (-RRB- -RRB-))))) (. .)))
24067251	1	(S1 (S (NP (NP (DT The) (NN potential)) (PP (IN for) (NP (NNP Doc_24067251_196_205_Chemical))) (SBAR (S (VP (TO to) (VP (VB cause) (NP (NP (DT a) (NN range)) (PP (IN of) (NP (NNP Doc_24067251_226_242_Disease))))))))) (VP (AUX has) (VP (AUX been) (VP (VBN established) (PP (IN from) (NP (NP (NN mechanistic)) (CC and) (NP (JJ randomised) (JJ clinical) (NNS trials))))))) (. .)))
24067251	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ exact) (NN pattern)) (PP (IN of) (NP (NN kidney) (NN involvement)))) (VP (AUX is) (ADVP (RB still)) (ADJP (JJ uncertain))) (. .)))
24067251	3	(S1 (S (NP (PRP We)) (VP (VP (VBD undertook) (NP (NP (DT a) (JJ descriptive) (NN analysis)) (PP (IN of) (NP (NP (NNP Yellow) (NNP Card) (NNS records)) (PP (IN of) (NP (NP (CD 407) (JJ HIV-positive) (NNS persons)) (VP (VBG taking) (NP (NP (NNP Doc_24067251_476_505_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24067251_507_510_Chemical)) (-RRB- -RRB-))) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (PRP$ their) (JJ antiretroviral) (NN therapy) (NN regimen)))))))))))) (CC and) (VP (VBD submitted) (PP (TO to) (NP (NP (DT the) (NNP Medicines)) (CC and) (NP (NP (NNP Healthcare) (NNPS Products) (NNP Regulatory) (NNP Agency)) (PRN (-LRB- -LRB-) (NP (NNP MHRA)) (-RRB- -RRB-))))) (PP (IN with) (NP (JJ suspected) (NN kidney) (JJ adverse) (NNS effects))))) (. .)))
24067251	4	(S1 (S (NP (NP (NNS Reports)) (SBAR (WHNP (WDT that)) (S (VP (VB satisfy) (NP (VBN defined) (NNS criteria)))))) (VP (AUX were) (VP (VBN classified) (PP (IN as) (NP (NP (NNP Doc_24067251_736_783_Disease)) (CC and) (NP (NNP Doc_24067251_788_804_Disease)))))) (. .)))
24067251	5	(S1 (S (PP (IN Of) (NP (NP (DT the) (CD 407) (NNP Yellow) (NNP Card) (NNS records)) (VP (VBN analysed)))) (, ,) (NP (NP (CD 106) (JJ satisfied) (NNS criteria)) (PP (IN for) (NP (JJ TDF-related) (NNP Doc_24067251_886_900_Disease))) (, ,) (SBAR (WHPP (IN of) (WHNP (WDT which))) (S (NP (CD 53)) (VP (PRN (-LRB- -LRB-) (NP (CD 50) (NN %)) (-RRB- -RRB-)) (AUX had) (NP (NP (NNS features)) (PP (IN of) (NP (NN kidney) (NNP Doc_24067251_943_962_Disease))))))) (, ,) (NP (NP (CD 35)) (PRN (-LRB- -LRB-) (NP (CD 33) (NN %)) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN found) (S (VP (TO to) (VP (AUX have) (NP (NP (NP (NNS features)) (PP (IN of) (NP (NNP Doc_24067251_1004_1026_Disease)))) (CC and) (NP (NP (CD 18)) (PRN (-LRB- -LRB-) (NP (CD 17) (NN %)) (-RRB- -RRB-)))) (VP (AUX had) (NP (NNP Doc_24067251_1044_1060_Disease)))))))) (. .)))
24067251	6	(S1 (S (NP (DT The) (JJ median) (NN TDF) (NN exposure)) (VP (AUX was) (NP (NP (CD 316) (NNS days)) (PRN (-LRB- -LRB-) (NP (NN interquartile) (NN range) (CD 120-740)) (-RRB- -RRB-)))) (. .)))
24067251	7	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NN hospitalisation))) (PP (IN for) (NP (NNP TDF) (NN kidney) (JJ adverse) (NNS effects)))) (VP (AUX was) (ADJP (JJ high)) (, ,) (PP (ADVP (RB particularly)) (IN amongst) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNS features)) (PP (IN of) (NP (NNP Doc_24067251_1251_1267_Disease)))))))) (. .)))
24067251	8	(S1 (S (NP (NP (DT The) (NN pattern)) (PP (IN of) (NP (NNP Doc_24067251_1284_1300_Disease))) (PP (IN in) (NP (DT this) (NN population) (NN series)))) (VP (VBZ mirrors) (SBAR (IN that) (S (VP (VBN reported) (PP (IN in) (NP (JJ randomised) (JJ clinical) (NNS trials))))))) (. .)))
24067251	9	(S1 (S (NP (NP (NN Cessation)) (PP (IN of) (NP (NNP TDF)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ complete) (NN Doc_24067251_1426_1456_Disease)) (PP (IN in) (NP (NP (RB up) (NN half)) (PP (IN of) (NP (NP (DT the) (NNS patients)) (PP (IN in) (NP (DT this) (NN report))))))))))) (. .)))
24068571	0	(S1 (S (NP (NP (NN Incidence)) (PP (IN of) (NP (NNP Doc_24068571_13_35_Disease)))) (VP (AUX is) (ADJP (JJ high)) (ADVP (RB even)) (PP (IN in) (NP (NP (DT a) (NN population)) (PP (IN without) (NP (JJ known) (NN risk) (NNS factors)))))) (. .)))
24068571	1	(S1 (S (NP (NN Doc_24068571_102_124_Disease)) (VP (AUX is) (NP (NP (DT a) (VBN recognized) (NN complication)) (PP (IN in) (NP (NP (NNS populations)) (PP (IN at) (NP (NN risk))))))) (. .)))
24068571	2	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX is) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (JJ early) (NNP Doc_24068571_237_259_Disease))) (PP (IN in) (NP (DT a) (NN population)))) (PP (IN without) (NP (NP (VBN known) (NN risk) (NNS factors)) (VP (VBN admitted) (PP (TO to) (NP (DT the) (NNP ICU))) (PP (IN for) (NP (JJ postoperative) (NN monitoring))) (PP (IN after) (NP (JJ elective) (JJ major) (NN surgery)))))))))) (. .)))
24068571	3	(S1 (S (NP (NP (DT The) (JJ secondary) (NN outcome)) (VP (VBN investigated))) (VP (AUX is) (S (VP (TO to) (VP (VB identify) (NP (JJ eventual) (JJ independent) (NN risk) (NNS factors)) (PP (IN among) (NP (NP (NP (JJ demographic) (NNS data)) (CC and) (NP (JJ anesthetic) (NNS drugs))) (VP (VBN used)))))))) (. .)))
24068571	4	(S1 (S (NP (DT An) (JJ observational) (, ,) (JJ prospective) (NN study)) (VP (AUX was) (VP (VBN conducted) (PP (IN on) (NP (NP (DT a) (JJ consecutive) (NN cohort)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBN admitted) (PP (TO to) (NP (PRP$ our) (NNS ICU))) (PP (IN within) (CC and) (PP (IN for) (NP (QP (IN at) (JJS least) (CD 24)) (NNP h)))) (PP (IN after) (NP (JJ major) (JJ surgical) (NNS procedures)))))))))) (. .)))
24068571	5	(S1 (S (NP (NN Exclusion) (NNS criteria)) (VP (AUX were) (NP (NP (DT any) (JJ preexisting) (NN predisposing) (NN factor)) (PP (IN for) (NP (ADJP (JJ Doc_24068571_757_765_Disease) (CC or) (JJ other)) (ADJP (RB potentially) (JJ confounding)) (NN Doc_24068571_799_824_Disease))))) (. .)))
24068571	6	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN assessed) (ADVP (RB daily)) (S (VP (VBG using) (NP (NP (DT the) (NN confusion) (NN assessment) (NN method)) (PP (IN for) (NP (DT the) (NNP ICU) (NN scale))) (PP (IN for) (NP (CD 3) (NN days)))) (PP (IN after) (NP (DT the) (JJ surgical) (NN procedure))))))) (. .)))
24068571	7	(S1 (S (NP (JJ Early) (JJ Doc_24068571_958_980_Disease) (NN incidence) (NN risk) (NNS factors)) (VP (AUX were) (ADVP (RB then)) (VP (VBN assessed) (PP (IN through) (NP (CD three) (JJ different) (JJ multiple) (NN regression) (NNS models))))) (. .)))
24068571	8	(S1 (S (PP (VBG According) (PP (TO to) (NP (NP (DT the) (NN confusion) (NN assessment) (NN method)) (PP (IN for) (NP (DT the) (NNP ICU) (NN scale)))))) (, ,) (NP (NP (CD 28) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (AUX were) (VP (VBN diagnosed) (PP (IN with) (NP (JJ early) (NNP Doc_24068571_1191_1213_Disease))))) (. .)))
24068571	9	(S1 (S (S (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NNP Doc_24068571_1226_1237_Chemical)))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN associated) (PP (IN with) (NP (NP (DT an) (JJ eight-fold-higher) (NN risk)) (PP (IN for) (NP (NNP Doc_24068571_1302_1310_Disease))))) (PP (VBN compared) (PP (TO to) (NP (NNP Doc_24068571_1323_1331_Chemical))))))) (PRN (-LRB- -LRB-) (NP (NP (CD 57.1) (NN %)) (CC vs.) (NP (CD 7.1) (NN %))) (, ,) (NP (NNP RR)) (VP (SYM =) (NP (CD 8.0))) (, ,)) (NP (NNP X2)) (VP (SYM =) (NP (CD 4.256)))) (: ;) (S (NP (NN df)) (VP (SYM =) (NP (NP (CD 1)) (PRN (: ;) (ADVP (NP (CD 0.05) (NN <)) (RB p)) (NP (QP (CD <) (CD 0.02))) (-RRB- -RRB-))))) (. .)))
24068571	10	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (NP (RB early) (NNP Doc_24068571_1429_1451_Disease)) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (NP (DT a) (ADJP (RB very) (JJ common)) (NN complication)) (PP (IN after) (NP (JJ major) (NN surgery)))))) (, ,) (PP (ADVP (RB even)) (IN in) (NP (NP (DT a) (NN population)) (PP (IN without) (NP (JJ known) (NN risk) (NNS factors))))))) (. .)))
24068571	11	(S1 (S (NP (NN Doc_24068571_1565_1576_Chemical)) (VP (AUX was) (ADVP (RB independently)) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (PRP$ its) (JJ relative) (NN risk))))))) (. .)))
24072398	0	(S1 (S (NP (NP (DT A) (JJ single) (JJ neurotoxic) (NN dose)) (PP (IN of) (NP (NNP Doc_24072398_28_43_Chemical)))) (VP (VBZ induces) (NP (NP (DT a) (JJ long-lasting) (JJ Doc_24072398_67_77_Disease-like) (NN behaviour)) (PP (IN in) (NP (NNS mice))))) (. .)))
24072398	1	(S1 (S (S (NP (NP (NNP Doc_24072398_102_117_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24072398_119_123_Chemical)) (-RRB- -RRB-))) (VP (VBZ triggers) (NP (NP (DT a) (NN disruption)) (PP (IN of) (NP (DT the) (JJ monoaminergic) (NN system)))))) (CC and) (S (NP (JJ Doc_24072398_179_183_Chemical) (NN abuse)) (VP (VBZ leads) (PP (TO to) (NP (NP (JJ negative) (JJ emotional) (NNS states)) (VP (VBG including) (NP (NNP Doc_24072398_235_254_Disease)) (PP (IN during) (NP (NN drug) (NN withdrawal)))))))) (. .)))
24072398	2	(S1 (S (ADVP (RB However)) (, ,) (NP (PRP it)) (VP (AUX is) (ADVP (RB currently)) (ADJP (JJ unknown)) (SBAR (IN if) (S (NP (NP (DT the) (JJ acute) (JJ toxic) (NN dosage)) (PP (IN of) (NP (NNP Doc_24072398_341_345_Chemical)))) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (DT a) (JJ long-lasting) (NN Doc_24072398_373_393_Disease)) (CC and) (NP (JJ persistent) (JJ monoaminergic) (NNS deficits))))))) (. .)))
24072398	3	(S1 (S (ADVP (RB Thus)) (, ,) (NP (PRP we)) (ADVP (RB now)) (VP (VBD assessed) (NP (NP (DT the) (JJ Doc_24072398_459_469_Disease-like) (NN behaviour)) (PP (IN in) (NP (NNS mice)))) (PP (IN at) (NP (JJ early) (CC and) (JJ long-term) (NNS periods))) (PP (VBG following) (NP (NP (DT a) (JJ single) (JJ high) (JJ Doc_24072398_548_552_Chemical) (NN dose)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN mg/kg)) (, ,) (NP (NN i.p.)) (-RRB- -RRB-))))) (. .)))
24072398	4	(S1 (S (NP (NNP Doc_24072398_576_580_Chemical)) (VP (AUX did) (RB not) (VP (VP (VB alter) (NP (NP (NP (DT the) (NN motor) (NN function)) (CC and) (NP (JJ procedural) (NN memory))) (PP (IN of) (NP (NNS mice)))) (SBAR (IN as) (S (VP (VBN assessed) (PP (IN by) (S (VP (VBG swimming) (NP (NN speed))))))))) (CC and) (VP (VB escape) (NP (NN latency)) (S (VP (TO to) (VP (VB find) (NP (DT the) (NN platform)) (PP (IN in) (NP (NP (DT a) (JJ cued) (NN version)) (PP (IN of) (NP (DT the) (NN water) (NN maze) (NN task))))))))))) (. .)))
24072398	5	(S1 (S (ADVP (RB However)) (, ,) (NP (NNP Doc_24072398_765_769_Chemical)) (ADVP (RB significantly)) (VP (VBD increased) (NP (DT the) (JJ immobility) (NN time)) (PP (IN in) (NP (DT the) (NN tail) (NN suspension) (NN test))) (PP (IN at) (NP (CD 3) (CC and) (CD 49) (NNS days) (NN post-administration)))) (. .)))
24072398	6	(S1 (S (NP (NP (DT This) (JJ Doc_24072398_885_895_Disease-like) (NN profile)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_24072398_920_924_Chemical))))) (VP (AUX was) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT a) (JJ marked) (NN depletion)) (PP (IN of) (NP (NP (JJ frontostriatal) (NN dopaminergic)) (CC and) (NP (JJ serotonergic) (NN neurotransmission)))) (, ,) (VP (VBN indicated) (PP (IN by) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_24072398_1072_1080_Chemical) (, ,) (NNP Doc_24072398_1082_1087_Chemical) (CC and) (NNP Doc_24072398_1092_1095_Chemical)) (, ,) (NP (JJ Doc_24072398_1097_1105_Chemical) (NN hydroxylase)) (CC and) (NP (NP (NNP Doc_24072398_1122_1131_Chemical)) (, ,) (VP (VBN observed) (PP (IN at) (NP (DT both) (CD 3) (CC and) (CD 49) (NNS days) (NN post-administration)))))))))))))))) (. .)))
24072398	7	(S1 (S (PP (IN In) (NP (NN parallel))) (, ,) (NP (NP (NP (DT another) (JJ neurochemical) (NN feature)) (PP (IN of) (NP (JJ depression--astroglial) (NNS dysfunction--was))) (UCP (ADJP (JJ unaffected) (PP (IN in) (NP (DT the) (NN cortex)))) (CC and) (NP (NP (DT the) (JJ striatal) (NNS levels)) (PP (IN of) (NP (DT the) (JJ astrocytic) (NN protein) (NN marker)))))) (, ,) (NP (JJ glial) (JJ fibrillary) (NN acidic) (NN protein)) (, ,)) (VP (AUX were) (ADVP (RB only) (RB transiently)) (VP (VBN increased) (PP (IN at) (NP (CD 3) (NNS days))))) (. .)))
24072398	8	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP demonstrate) (PP (IN for) (NP (NP (DT the) (JJ first) (NN time)) (SBAR (WHNP (IN that)) (S (NP (NP (DT a) (JJ single) (JJ high) (NN dose)) (PP (IN of) (NP (NNP Doc_24072398_1503_1507_Chemical)))) (VP (VBZ induces) (NP (NP (JJ long-lasting) (JJ Doc_24072398_1529_1539_Disease-like) (NN behaviour)) (PP (IN in) (NP (NP (NNS mice)) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJ persistent) (NN disruption)) (PP (IN of) (NP (NP (JJ frontostriatal) (NN dopaminergic)) (CC and) (NP (JJ serotonergic) (NN homoeostasis)))))))))))))))) (. .)))
24088636	0	(S1 (NP (JJ Doc_24088636_0_9_Chemical-induced) (NN Doc_24088636_18_34_Disease) (. .)))
24088636	1	(S1 (S (NP (JJ Many) (JJ systemic) (NNS antimicrobials)) (VP (AUX have) (VP (AUX been) (VP (VBN implicated) (S (VP (TO to) (VP (VB cause) (NP (JJ ocular) (JJ adverse) (NNS effects)))))))) (. .)))
24088636	2	(S1 (S (NP (DT This)) (VP (AUX is) (ADJP (RB especially) (JJ relevant) (PP (IN in) (NP (JJ multidrug) (NN therapy)))) (SBAR (WHADVP (WRB where)) (S (NP (QP (JJR more) (IN than) (CD one)) (NN drug)) (VP (MD can) (VP (VB cause) (NP (DT a) (JJ similar) (JJ ocular) (JJ adverse) (NN effect))))))) (. .)))
24088636	3	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ progressive) (NN Doc_24088636_270_284_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_24088636_301_310_Chemical) (NN therapy)))))))) (. .)))
24088636	4	(S1 (S (NP (NP (DT A) (JJ 45-year-old) (NN male) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (PP (IN on) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (JJ multiple) (JJ second-line) (JJ anti-Doc_24088636_399_410_Disease) (NNS drugs)) (PP (VBG including) (NP (NNP Doc_24088636_427_436_Chemical) (CC and) (NNP Doc_24088636_441_451_Chemical))))) (PP (IN for) (NP (NP (RB extensively) (NNP Doc_24088636_468_495_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24088636_497_503_Disease)) (-RRB- -RRB-)))))))))) (VP (VBD presented) (PP (TO to) (NP (PRP us))) (PP (IN with) (NP (NP (JJ painless) (JJ progressive) (NN Doc_24088636_547_561_Disease)) (PP (IN in) (NP (DT both) (NNS eyes)))))) (. .)))
24088636	5	(S1 (S (S (NP (JJ Color) (NN vision)) (VP (AUX was) (ADJP (JJ defective)))) (CC and) (S (NP (JJ fundus) (NN examination)) (VP (VBD revealed) (NP (NN Doc_24088636_635_651_Disease)) (PP (IN in) (NP (DT both) (NNS eyes))))) (. .)))
24088636	6	(S1 (S (S (NP (JJ Doc_24088636_666_676_Chemical-induced) (NN Doc_24088636_685_707_Disease)) (VP (AUX was) (VP (VBN suspected)))) (CC and) (S (NP (JJ tablet) (NN Doc_24088636_733_743_Chemical)) (VP (AUX was) (VP (VBN withdrawn)))) (. .)))
24088636	7	(S1 (S (NP (NN Doc_24088636_759_782_Disease)) (VP (VBD occurred) (PP (IN despite) (NP (NP (NN withdrawal)) (PP (IN of) (NP (NNP Doc_24088636_814_824_Chemical)))))) (. .)))
24088636	8	(S1 (S (NP (NP (NN Discontinuation)) (PP (IN of) (NP (NNP Doc_24088636_845_854_Chemical)))) (VP (VBD resulted) (PP (IN in) (NP (JJ marked) (NNP Doc_24088636_874_895_Disease)))) (. .)))
24088636	9	(S1 (S (NP (PRP$ Our) (NN report)) (VP (VBZ emphasizes) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (NN monitoring)) (PP (IN of) (NP (JJ visual) (NN function))))) (PP (IN in) (NP (NNS patients))) (PP (IN on) (NP (JJ long-term) (JJ Doc_24088636_987_996_Chemical) (NN treatment))))) (. .)))
24091473	0	(S1 (NP (NP (NP (NN Resuscitation)) (PP (IN with) (NP (NN lipid)))) (, ,) (NP (NNP Doc_24091473_26_37_Chemical)) (, ,) (CC or) (NP (NP (DT both)) (PP (IN in) (NP (NP (NNP Doc_24091473_50_65_Chemical-induced) (NNP Doc_24091473_74_90_Disease)) (PP (IN in) (NP (JJ newborn) (NNS piglets)))))) (. .)))
24091473	1	(S1 (S (NP (NP (DT The) (JJ optimal) (NN dosing) (NNS regimens)) (PP (IN of) (NP (NP (NN lipid) (NN emulsion)) (, ,) (NP (NNP Doc_24091473_170_181_Chemical)) (, ,) (CC or) (NP (DT both))))) (VP (AUX are) (ADJP (ADVP (RB not) (RB yet)) (VBN determined) (PP (IN in) (NP (NP (NNS neonates)) (PP (IN in) (NP (NP (NNS cases)) (PP (IN of) (NP (NP (JJ local) (JJ anaesthetic) (JJ systemic) (NN Doc_24091473_265_273_Disease)) (PRN (-LRB- -LRB-) (JJ LAST) (-RRB- -RRB-)))))))))) (. .)))
24091473	2	(S1 (S (NP (NP (JJ Newborn) (NNS piglets)) (VP (VBN received) (NP (NNP Doc_24091473_316_331_Chemical)) (PP (IN until) (NP (NNP Doc_24091473_338_361_Disease))))) (VP (VBD occurred)) (. .)))
24091473	3	(S1 (S (S (NP (JJ Standard) (NN cardiopulmonary) (NN resuscitation)) (VP (AUX was) (VP (VBN started)))) (CC and) (S (NP (NP (NN electrocardiogram)) (PRN (-LRB- -LRB-) (NP (NNP ECG)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN monitored) (PP (IN for) (NP (NP (NNP Doc_24091473_469_492_Disease)) (, ,) (NP (NNP Doc_24091473_494_506_Disease)) (, ,) (CC or) (NP (NNS QRS) (NN prolongation))))))) (. .)))
24091473	4	(S1 (S (NP (NNS Piglets)) (VP (AUX were) (ADVP (RB then)) (VP (ADVP (RB randomly)) (VBN allocated) (PP (TO to) (NP (NP (NP (CD four) (NNS groups) (PRN (: :) (NP (NP (NP (NN control)) (PRN (-LRB- -LRB-) (NP (NN saline)) (-RRB- -RRB-))) (, ,) (NP (NNP Intralipid))) (-LRB- -LRB-) (-RRB- -RRB-))) (ADJP (RB alone))) (, ,) (NP (NP (NNP Doc_24091473_621_632_Chemical)) (UCP (ADVP (RB alone)) (, ,) (CC or) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NNP Intralipd) (CC plus) (NNP Doc_24091473_675_686_Chemical)))))))))) (. .)))
24091473	5	(S1 (S (NP (NN Resuscitation)) (VP (VBD continued) (UCP (PP (IN for) (NP (CD 30) (NN min))) (CC or) (SBAR (IN until) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (NN return)) (PP (IN of) (NP (NP (JJ spontaneous) (NN circulation)) (PRN (-LRB- -LRB-) (NP (NNP ROSC)) (-RRB- -RRB-)) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT a) (JJ mean) (JJ arterial) (NN pressure)) (PP (ADVP (IN at) (CC or) (JJ superior) (PP (TO to) (NP (NP (DT the) (NN baseline) (NN pressure)) (CC and) (NP (JJ normal) (JJ sinus) (NN rhythm))))) (IN for) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (CD 30) (NN min)))))))))))))))) (. .)))
24091473	6	(S1 (S (NP (NN ROSC)) (VP (AUX was) (VP (VBN achieved) (PP (IN in) (NP (NP (RB only) (CD one)) (PP (IN of) (NP (DT the) (NN control) (NNS piglets))))) (PP (VBN compared) (PP (IN with) (NP (NP (JJS most)) (PP (IN of) (NP (DT the) (VBN treated) (NNS piglets)))))))) (. .)))
24091473	7	(S1 (S (NP (NN Mortality)) (VP (VP (AUX was) (RB not) (ADJP (RB significantly) (JJ different) (PP (IN between) (NP (DT the) (CD three) (NN treatment) (NNS groups))))) (, ,) (CC but) (VP (AUX was) (ADJP (RB significantly) (JJR lower)) (PP (IN in) (NP (NP (PDT all) (DT the) (NN treatment) (NNS groups)) (VP (VBN compared) (PP (IN with) (NP (NN control)))))))) (. .)))
24091473	8	(S1 (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (JJ ECG) (NNS abnormalities)))) (VP (AUX was) (NP (NP (NP (CD zero)) (PP (IN in) (NP (DT the) (JJ Intralipid) (JJ only) (NN group)))) (, ,) (CC but) (NP (NP (CD 14) (CC and) (CD 17)) (, ,) (ADVP (RB respectively))) (, ,)) (PP (IN in) (NP (NP (DT the) (NNP Doc_24091473_1282_1293_Chemical)) (CC and) (NP (NP (NP (NNP Doc_24091473_1298_1309_Chemical)) (CC plus) (NP (NN lipid) (NNS groups))) (PRN (-LRB- -LRB-) (NP (NNP P<0.05)) (-RRB- -RRB-)))))) (. .)))
24091473	9	(S1 (S (NP (NP (NN Lipid) (NN emulsion)) (PP (IN with) (CC or) (IN without) (NP (NP (NNP Doc_24091473_1382_1393_Chemical)) (, ,) (CC or) (NP (NNP Doc_24091473_1398_1409_Chemical)) (ADVP (RB alone))))) (VP (AUX were) (ADJP (RB equally) (JJ effective) (PP (IN in) (S (VP (VBG achieving) (NP (NP (DT a) (NN return)) (PP (TO to) (NP (JJ spontaneous) (NN circulation)))) (PP (IN in) (NP (NP (DT this) (NN model)) (PP (IN of) (NP (JJ LAST)))))))))) (. .)))
24091473	10	(S1 (S (NP (NP (NN Doc_24091473_1511_1522_Chemical)) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN lipid))))))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN number)) (PP (IN of) (NP (JJ ECG) (NNS abnormalities))))) (PP (VBN compared) (PP (IN with) (NP (NP (NN lipid) (NN emulsion)) (ADVP (RB alone))))))) (. .)))
24100055	0	(S1 (NP (NP (NP (NP (NP (NN Incidence)) (PP (IN of) (NP (JJ Doc_24100055_13_20_Chemical-induced) (NNP Doc_24100055_29_53_Disease)))) (CC and) (NP (NP (JJ postoperative) (NN recovery)) (PP (IN of) (NP (NN platelet) (NN count))))) (PP (IN in) (NP (NN liver) (NN graft) (NNS recipients)))) (: :) (NP (DT a) (NN retrospective) (NN cohort) (NN analysis)) (. .)))
24100055	1	(S1 (S (NP (NP (NN Doc_24100055_171_187_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ end-stage) (NNP Doc_24100055_215_228_Disease)))))) (VP (AUX is) (NP (NP (DT a) (JJ common) (NN disorder)) (VP (VBN caused) (PP (ADVP (RB mainly)) (IN by) (NP (NP (NP (NNP portal) (NNP Doc_24100055_274_286_Disease)) (, ,) (NP (NP (JJ low) (NNS levels)) (PP (IN of) (NP (NN thrombopoetin)))) (, ,)) (CC and) (NP (NNP Doc_24100055_321_332_Disease))))))) (. .)))
24100055	2	(S1 (S (NP (NP (DT The) (NN impact)) (PP (IN of) (NP (NP (JJ immune-mediated) (JJ Doc_24100055_364_371_Chemical-induced) (NNP Doc_24100055_380_404_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24100055_406_417_Disease)) (-RRB- -RRB-)))) (PP (IN as) (NP (NP (DT a) (NN cause)) (PP (IN of) (NP (NNP Doc_24100055_433_449_Disease))))) (PP (IN after) (NP (NN liver) (NN transplantation)))) (VP (AUX is) (RB not) (VP (ADVP (RB yet)) (VBN understood) (, ,) (PP (IN with) (S (NP (JJ few) (NN literature) (NNS citations)) (VP (VBG reporting) (NP (JJ contradictory) (NNS results))))))) (. .)))
24100055	3	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (PRP$ our) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VP (VB demonstrate) (NP (NP (DT the) (JJ perioperative) (NN course)) (PP (IN of) (NP (NNP Doc_24100055_632_648_Disease))) (PP (IN after) (NP (NN liver) (NN transplantation))))) (CC and) (VP (VB determine) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (JJ clinical) (NN Doc_24100055_718_729_Disease))))))))) (. .)))
24100055	4	(S1 (S (NP (PRP We)) (ADVP (RB retrospectively)) (VP (VBN evaluated) (NP (NP (DT the) (JJ medical) (NNS records)) (PP (IN of) (NP (NP (CD 205) (JJ consecutive) (NN adult) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NP (JJ full-size) (NN liver) (NN transplantation)) (PP (IN between) (NP (NP (NNP January) (CD 2006)) (CC and) (NP (NNP December) (CD 2010))))) (PP (JJ due) (TO to) (NP (NP (NN end-stage)) (CC or) (NP (JJ malignant) (NNP Doc_24100055_937_950_Disease))))))))))) (. .)))
24100055	5	(S1 (S (NP (NP (JJ Preoperative) (NN platelet) (NN count)) (, ,) (NP (NP (NN postoperative) (NN course)) (PP (IN of) (NP (NNS platelets)))) (, ,) (CC and) (NP (NP (JJ clinical) (NNS signs)) (PP (IN of) (NP (NNP Doc_24100055_1038_1049_Disease))))) (VP (AUX were) (VP (VBN analyzed))) (. .)))
24100055	6	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 155))) (PRN (-LRB- -LRB-) (NP (CD 75.6) (NN %)) (-RRB- -RRB-)) (PP (IN of) (NP (CD 205) (NNS patients)))) (VP (AUX had) (NP (NN Doc_24100055_1117_1133_Disease)) (PP (IN before) (NP (NP (NN transplantation)) (, ,) (VP (ADVP (RB significantly)) (VBN influenced) (PP (IN by) (NP (NP (NNP Model)) (PP (IN of) (NP (NP (NNP End-Stage) (NNP Doc_24100055_1205_1218_Disease) (NN score)) (CC and) (NP (NN liver) (NN Doc_24100055_1235_1244_Disease)))))))))) (. .)))
24100055	7	(S1 (S (S (NP (DT The) (NN platelet) (NN count)) (VP (VBD exceeded) (NP (NN 100,000/uL)) (PP (IN in) (NP (NP (JJS most)) (PP (IN of) (NP (DT the) (NNS patients))))))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 193)) (-RRB- -RRB-)) (S (PP (IN at) (NP (NP (DT a) (NN medium)) (PP (IN of) (NP (NP (CD 7) (NNP d.)) (VP (VBG Regarding) (NP (NNP Doc_24100055_1349_1355_Disease))))))) (, ,) (NP (EX there)) (VP (AUX were) (NP (CD four) (PRN (-LRB- -LRB-) (NP (CD 1.95) (NN %)) (-RRB- -RRB-)) (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN background)) (PP (IN of) (NP (NNP Doc_24100055_1411_1422_Disease))))))) (. .)))
24100055	8	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NN HIT))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ end-stage) (NNP Doc_24100055_1485_1500_Disease)))))) (VP (AUX is) (, ,) (PP (IN with) (NP (QP (RB about) (CD 1.95)) (NN %))) (, ,) (ADJP (JJ rare))) (. .)))
24100055	9	(S1 (S (PP (IN For) (NP (NP (JJ further) (NN reduction)) (PP (IN of) (NP (NNP Doc_24100055_1554_1565_Disease))))) (, ,) (S (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_24100055_1590_1597_Chemical)))) (VP (MD should) (VP (AUX be) (VP (VBN avoided))))) (CC and) (S (NP (DT the) (JJ prophylactic) (NN anticoagulation)) (VP (MD should) (VP (AUX be) (VP (VBN performed) (PP (IN with) (NP (JJ low-molecular-weight) (NN Doc_24100055_1699_1706_Chemical))) (PP (IN after) (NP (NP (NN normalization)) (PP (IN of) (NP (NN platelet) (NN count))))))))) (. .)))
24100257	0	(S1 (NP (NP (NP (NN Doc_24100257_0_18_Disease)) (PRN (-LRB- -LRB-) (CC or) (NNP Doc_24100257_23_49_Disease) (-RRB- -RRB-))) (ADJP (JJ secondary) (TO to) (JJ Doc_24100257_64_76_Chemical)) (. .)))
24100257	1	(S1 (S (NP (NP (NP (NNP Doc_24100257_78_96_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24100257_98_100_Disease)) (-RRB- -RRB-))) (, ,) (VP (ADVP (RB also)) (VBN known) (PP (IN as) (NP (NNP Doc_24100257_117_138_Disease)))) (, ,)) (VP (AUX is) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ left) (JJ ventricle) (JJ apical) (NN ballooning)) (PP (IN with) (NP (NP (JJ elevated) (JJ cardiac) (NNS biomarkers)) (CC and) (NP (NP (JJ electrocardiographic) (NNS changes)) (PP (JJ suggestive) (IN of) (NP (NP (DT an) (NNP Doc_24100257_276_299_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN ie)) (, ,) (NP (JJ ST-segment) (NN elevation)) (, ,) (NP (JJ T) (NN wave) (NNS inversions)) (, ,) (CC and) (NP (JJ pathologic) (NNP Q) (NNS waves))) (-RRB- -RRB-))))))))))) (. .)))
24100257	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ 54-year-old) (NN woman)) (PP (IN with) (NP (NP (JJ medical) (NN history)) (PP (IN of) (NP (NP (NNP Doc_24100257_433_454_Disease) (CC and) (NNP Doc_24100257_459_468_Disease)) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBN admitted) (PP (TO to) (NP (NP (DT the) (NN hospital)) (PP (IN for) (NP (NP (JJ substernal) (NN Doc_24100257_518_528_Disease) (CC and) (NN electrocardiogram)) (VP (VBN demonstrated) (PP (IN 1/2) (S (VP (VBG mm) (NP (NP (JJ ST-segment) (NN elevation)) (PP (IN in) (NP (NP (NP (NNS leads)) (NP (NP (NNP II)) (, ,) (NP (NNP III)) (, ,) (NP (CD aVF)) (, ,) (NP (NNP V5)) (, ,) (CC and) (NP (NNP V6)))) (CC and) (NP (JJ positive) (JJ troponin) (NNP I.) (NNP Emergent) (JJ coronary) (NN angiogram) (VBD revealed) (JJ normal) (JJ coronary) (NNS arteries))))) (PP (IN with) (NP (NP (ADJP (RB moderately) (JJ reduced)) (JJ left) (JJ ventricular) (NN ejection) (NN fraction)) (PP (IN with) (NP (NNP Doc_24100257_777_802_Disease))) (ADJP (JJ consistent) (PP (IN with) (NP (NNP Doc_24100257_819_821_Disease)))))))))))))))))))))))))) (. .)))
24100257	3	(S1 (S (NP (JJ Detailed) (NN history)) (VP (VBD obtained) (SBAR (S (ADVP (RB retrospectively)) (VP (VBD revealed) (SBAR (IN that) (S (NP (DT the) (NN patient)) (VP (VBD took) (NP (NNP Doc_24100257_896_908_Chemical)) (ADVP (RB sparingly)) (SBAR (WHADVP (RB only) (WRB when)) (S (NP (PRP she)) (VP (AUX had) (NP (NN Doc_24100257_937_946_Disease)))))))))))) (. .)))
24100257	4	(S1 (S (CC But) (PP (IN before) (NP (DT this) (NN event))) (, ,) (NP (PRP she)) (VP (AUX was) (VP (VBG taking) (NP (NNP Doc_24100257_986_998_Chemical) (CD 2-3) (NNS times)) (ADVP (RB daily)) (PP (IN for) (NP (JJ several) (NNS days))) (PP (IN because) (IN of) (NP (DT a) (JJ persistent) (NN Doc_24100257_1056_1064_Disease) (NN Doc_24100257_1065_1073_Disease))))) (. .)))
24100257	5	(S1 (S (NP (PRP She)) (ADVP (RB otherwise)) (VP (VBD reported) (SBAR (IN that) (S (NP (PRP she)) (VP (VP (AUX is) (ADVP (RB quite)) (ADJP (JJ active))) (, ,) (VP (NNS rides) (NP (NNS horses))) (, ,) (CC and) (VP (AUX does) (VP (VB show) (S (VP (VBG jumping) (PP (IN without) (NP (NP (DT any) (NNS limitations)) (PP (IN in) (NP (PRP$ her) (JJ physical) (NN activity))))))))))))) (. .)))
24100257	6	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (DT any) (JJ recent) (NN stress) (CC or) (NN Doc_24100257_1256_1274_Disease))))) (. .)))
24100257	7	(S1 (S (S (NP (JJ Extensive) (NN literature) (NN search)) (VP (VBD revealed) (NP (NP (JJ multiple) (NNS cases)) (PP (IN of) (NP (JJ Doc_24100257_1331_1346_Disease) (NN vasospasm) (JJ secondary))) (PP (TO to) (NP (NNP Doc_24100257_1370_1382_Chemical)))))) (, ,) (CC but) (S (NP (NP (NN none)) (PP (IN of) (NP (DT the) (NNS cases)))) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_24100257_1427_1429_Disease)))))) (. .)))
24114426	0	(S1 (NP (NP (NN Doc_24114426_0_10_Disease)) (, ,) (NP (NNP Doc_24114426_12_25_Disease)) (, ,) (NP (NN sleep)) (, ,) (CC and) (NP (NP (NN memory)) (PP (IN in) (NP (JJ past) (CC and) (JJ present) (NN polydrug) (NNS users))) (PP (IN of) (NP (NP (NNP Doc_24114426_83_116_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24114426_118_122_Chemical)) (, ,) (NP (NNP Doc_24114426_124_131_Chemical)) (-RRB- -RRB-))))) (. .)))
24114426	1	(S1 (S (NP (NP (NNP Doc_24114426_145_152_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24114426_154_187_Chemical)) (, ,) (NP (NNP Doc_24114426_189_193_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (NNP worldwide) (JJ recreational) (NN drug)) (PP (IN of) (NP (NN abuse))))) (. .)))
24114426	2	(S1 (S (ADVP (RB Unfortunately)) (, ,) (NP (NP (DT the) (NNS results)) (PP (IN from) (NP (NP (JJ human) (NN research)) (VP (VBG investigating) (NP (PRP$ its) (JJ psychological) (NNS effects)))))) (VP (AUX have) (VP (AUX been) (ADJP (JJ inconsistent)))) (. .)))
24114426	3	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBD aimed) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (JJS largest)) (PP (TO to) (NP (NN date)))) (PP (IN in) (NP (NP (NN sample) (NN size)) (CC and) (NP (JJ 5HT-related) (NNS behaviors)))) (: ;) (NP (NP (NP (DT the) (JJ first)) (SBAR (S (VP (TO to) (VP (VB compare) (NP (JJ present) (JJ Doc_24114426_482_489_Chemical) (NNS users)) (PP (IN with) (NP (JJ past) (NNS users))) (PP (IN after) (NP (NP (DT an) (NN abstinence)) (PP (IN of) (NP (QP (CD 4) (CC or) (JJR more)) (NNS years)))))))))) (, ,) (CC and) (NP (NP (DT the) (JJ first)) (SBAR (S (VP (TO to) (VP (VB include) (NP (NP (JJ robust) (NNS controls)) (PP (IN for) (NP (JJ other) (JJ recreational) (NNS substances)))))))))))))) (. .)))
24114426	4	(S1 (S (NP (NP (DT A) (NN sample)) (PP (IN of) (NP (CD 997) (NNS participants))) (PRN (-LRB- -LRB-) (NP (CD 52) (NN %) (NN male)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN recruited) (PP (TO to) (NP (NP (NP (NP (CD four) (NN control) (NNS groups)) (PRN (-LRB- -LRB-) (JJ non-drug) (-LRB- -LRB-) (NP (NNP ND)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_24114426_731_738_Chemical/Doc_24114426_739_747_Chemical)) (PRN (-LRB- -LRB-) (DT AN) (-RRB- -RRB-)) (, ,) (ADJP (JJ cannabis/Doc_24114426_763_770_Chemical/Doc_24114426_771_779_Chemical) (S (VP (-LRB- -LRB-) (MD CAN) (-RRB- -RRB-)))) (, ,) (NP (JJ non-Doc_24114426_791_798_Chemical) (NN polydrug) (PRN (-LRB- -LRB-) (NNP PD) (-RRB- -RRB-) (-RRB- -RRB-))) (, ,) (CC and) (NP (CD two) (NNP Doc_24114426_823_830_Chemical) (NN polydrug) (NNS groups))) (PRN (-LRB- -LRB-) (JJ present) (-LRB- -LRB-) (NP (NNP Doc_24114426_857_861_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ past) (NNS users)) (PRN (-LRB- -LRB-) (JJ EX-Doc_24114426_882_886_Chemical) (-RRB- -RRB-))))))) (. .)))
24114426	5	(S1 (S (NP (NNS Participants)) (VP (VBD completed) (NP (NP (DT a) (NN drug) (NN history) (NN questionnaire)) (, ,) (NP (NP (NNP Beck) (NNP Doc_24114426_947_957_Disease) (NN Inventory)) (, ,) (NP (NP (NP (NNP Barratt) (NNP Impulsiveness) (NNP Scale)) (, ,) (NP (NNP Pittsburgh) (NNP Sleep) (NNP Quality) (NNP Index)) (, ,)) (CC and) (NP (NP (NNP Wechsler) (NN Memory) (NNP Scale-Revised)) (SBAR (WHNP (WDT which)) (S (, ,) (PP (IN in) (NP (NN total))) (, ,) (VP (VBD provided) (NP (CD 13) (JJ psychometric) (NNS measures)))))))))) (. .)))
24114426	6	(S1 (S (SBAR (IN While) (S (NP (DT the) (NN CAN) (CC and) (NN PD) (NNS groups)) (VP (VBD tended) (S (VP (TO to) (VP (VB record) (NP (JJR greater) (NNS deficits)) (PP (IN than) (NP (DT the) (JJ non-drug) (NNS controls))))))))) (, ,) (NP (DT the) (NNP Doc_24114426_1219_1223_Chemical) (CC and) (NNP Doc_24114426_1228_1235_Chemical) (NNS groups)) (VP (VBD recorded) (NP (JJR greater) (NNS deficits)) (PP (IN than) (NP (NP (PDT all) (DT the) (NN control) (NNS groups)) (PP (IN on) (NP (NP (CD ten)) (PP (IN of) (NP (DT the) (CD 13) (JJ psychometric) (NNS measures)))))))) (. .)))
24114426	7	(S1 (S (ADVP (RB Strikingly)) (, ,) (PP (IN despite) (NP (NP (JJ prolonged) (NN abstinence)) (PRN (-LRB- -LRB-) (NP (NP (NN mean)) (, ,) (NP (CD 4.98)) (: ;) (NP (NP (NN range)) (, ,) (NP (CD 4-9) (NNS years)))) (-RRB- -RRB-)))) (, ,) (NP (JJ past) (JJ Doc_24114426_1415_1422_Chemical) (NNS users)) (VP (VBD showed) (NP (NP (JJ few) (NNS signs)) (PP (IN of) (NP (NN recovery))))) (. .)))
24114426	8	(S1 (S (PP (VBN Compared) (PP (IN with) (NP (JJ present) (JJ Doc_24114426_1481_1488_Chemical) (NNS users)))) (, ,) (NP (DT the) (JJ past) (NNS users)) (VP (VBD showed) (NP (NP (NP (DT no) (NN change)) (PP (IN for) (NP (CD ten) (NNS measures)))) (, ,) (NP (NP (NN Doc_24114426_1546_1566_Disease)) (PP (IN for) (NP (CD two) (NNS measures)))) (, ,) (CC and) (NP (NP (NN improvement)) (PP (IN on) (NP (QP (RB just) (CD one)) (NN measure)))))) (. .)))
24114426	9	(S1 (S (PP (VBN Given) (NP (NP (NP (DT this) (NN record)) (PP (IN of) (NP (NNP Doc_24114426_1656_1671_Disease)))) (CC and) (NP (NP (ADJP (RB clinically) (JJ significant)) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_24114426_1709_1719_Disease)) (, ,) (NP (NNP Doc_24114426_1721_1734_Disease)) (, ,) (CC and) (NP (NNP Doc_24114426_1740_1757_Disease))))))) (, ,) (NP (NP (DT the) (NN prognosis)) (PP (IN for) (NP (NP (DT the) (JJ current) (NN generation)) (PP (IN of) (NP (JJ Doc_24114426_1803_1810_Chemical) (NNS users)))))) (VP (AUX is) (NP (NP (DT a) (JJ major) (NN cause)) (PP (IN for) (NP (NN concern))))) (. .)))
24126708	0	(S1 (NP (NP (NN Association)) (PP (IN of) (NP (NP (JJ common) (JJ genetic) (NNS variants)) (PP (IN of) (NP (CD HOMER1) (NN gene))))) (PP (IN with) (NP (NP (JJ Doc_24126708_59_67_Chemical) (JJ adverse) (NNS effects)) (PP (IN in) (NP (NNP Doc_24126708_87_106_Disease) (NNS patients))))) (. .)))
24126708	1	(S1 (S (S (NP (NN Doc_24126708_117_125_Chemical)) (VP (AUX is) (NP (NP (DT the) (ADJP (RBS most) (JJ effective)) (JJ symptomatic) (NN therapy)) (PP (IN for) (NP (NNP Doc_24126708_172_191_Disease)))))) (, ,) (CC but) (S (NP (PRP$ its) (JJ chronic) (NN use)) (VP (MD could) (VP (VB lead) (PP (TO to) (NP (NP (JJ chronic) (JJ adverse) (NNS outcomes)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN motor) (NNS fluctuations)) (, ,) (NP (NP (NNP Doc_24126708_281_291_Disease)) (CC and) (NP (NNP Doc_24126708_296_317_Disease)))))))))) (. .)))
24126708	2	(S1 (S (NP (NNP HOMER1)) (VP (AUX is) (NP (NP (DT a) (NN protein)) (PP (IN with) (NP (NP (JJ pivotal) (NN function)) (PP (IN in) (NP (NP (NNP Doc_24126708_364_373_Chemical) (NNP transmission)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX has) (VP (AUX been) (ADJP (JJ related) (PP (TO to) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (DT these) (NNS complications)))))))))))))))) (. .)))
24126708	3	(S1 (S (NP (DT This) (NN study)) (VP (VBZ investigates) (SBAR (IN whether) (S (NP (NP (NNS polymorphisms)) (PP (IN in) (NP (DT the) (JJ HOMER1) (NN gene) (NN promoter) (NN region)))) (VP (AUX are) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NP (DT the) (JJ chronic) (NNS complications)) (PP (IN of) (NP (JJ Doc_24126708_603_611_Chemical) (NN therapy)))))))))))) (. .)))
24126708	4	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 205) (NNS patients))) (PP (IN with) (NP (NNP Doc_24126708_650_680_Disease)))) (VP (AUX were) (VP (VBN investigated))) (. .)))
24126708	5	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN genotyped) (PP (IN for) (NP (NP (CD rs4704559)) (, ,) (NP (CD rs10942891)) (CC and) (NP (CD rs4704560)))) (PP (IN by) (NP (NP (JJ allelic) (NN discrimination)) (PP (IN with) (NP (JJ Taqman) (NNS assays))))))) (. .)))
24126708	6	(S1 (S (NP (DT The) (CD rs4704559) (NNP G) (NN allele)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJR lower) (NN prevalence)) (PP (IN of) (NP (NP (NP (NNP Doc_24126708_875_885_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ prevalence) (NN ratio)) (PRN (-LRB- -LRB-) (NP (NNP PR)) (-RRB- -RRB-)) (NP (CD =0.615))) (, ,) (NP (NP (ADJP (CD 95) (NN %)) (NN confidence) (NN interval)) (PRN (-LRB- -LRB-) (NP (NNP CI)) (-RRB- -RRB-)) (NP (CD 0.426-0.887)))) (, ,) (NP (NNP P=0.009)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_24126708_971_992_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NNP PR=0.515)) (, ,) (NP (CD 95) (NN %) (QP (CD CI) (CD 0.295-0.899)))) (, ,) (NP (NNP P=0.020)) (-RRB- -RRB-))))))))) (. .)))
24126708	7	(S1 (S (NP (PRP$ Our) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN HOMER1) (CD rs4704559) (NNP G) (NN allele)) (VP (AUX has) (NP (NP (DT a) (JJ protective) (NN role)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ Doc_24126708_1127_1135_Chemical) (JJ adverse) (NNS effects)))))))))) (. .)))
24132704	0	(S1 (S (NP (NN Doc_24132704_0_6_Chemical)) (VP (VBZ improves) (NP (NP (NN lipid) (NN dysregulation)) (PP (IN in) (NP (JJ subacute) (JJ Doc_24132704_48_56_Chemical) (NN exposure)))) (PP (IN through) (NP (NP (JJ ERK1/2) (NN pathway)) (PP (IN in) (NP (NN rat) (NN liver)))))) (. .)))
24132704	1	(S1 (NP (NP (NNP Doc_24132704_117_125_Chemical) (NNP Yis)) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (ADJP (RBS most) (RB broadly) (VBN used)) (JJ Doc_24132704_159_175_Chemical) (NNS insecticides)) (PP (IN in) (NP (NN agriculture)))))) (. .)))
24132704	2	(S1 (S (NP (PRP It)) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (NN exposure)) (PP (TO to) (NP (NNP Doc_24132704_240_248_Chemical)))) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NN lipid) (NN metabolism)))))))))) (. .)))
24132704	3	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (JJ hypolipidemic) (NN effect)) (PP (IN of) (NP (NNP Doc_24132704_324_330_Chemical)))) (VP (AUX has) (VP (AUX been) (VP (VBN established)))) (. .)))
24132704	4	(S1 (S (NP (JJR Earlier) (NNS studies)) (VP (VBD revealed) (NP (NP (DT the) (JJ major) (NN role)) (PP (IN of) (NP (JJ Extracellular) (JJ signal-regulated) (NN kinase) (PRN (-LRB- -LRB-) (NP (NNP ERK)) (-RRB- -RRB-)) (NNS pathways))) (PP (IN in) (NP (NN low-density) (NN lipoprotein) (NN receptor) (-LRB- -LRB-) (NNP LDLr) (-RRB- -RRB-) (NN expression))))) (. .)))
24132704	5	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB evaluate) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (NN lipid) (NN metabolism)) (, ,) (NP (NN ERK)) (CC and) (NP (NN LDLr) (NN expression)))))) (PP (IN in) (NP (NP (DT the) (NN liver)) (PP (IN of) (NP (NP (NNS rats)) (VP (VBN exposed) (S (VP (TO to) (VP (VB subacute) (NP (NNP Doc_24132704_654_662_Chemical))))))))))))))) (. .)))
24132704	6	(S1 (S (NP (NP (ADJP (RB Furthermore) (JJ ameliorating)) (NN effect)) (PP (IN of) (NP (NNP Doc_24132704_699_705_Chemical))) (PP (IN on) (NP (NNP Doc_24132704_709_717_Chemical) (VBN induced) (VBN disturbed) (JJ Doc_24132704_736_747_Chemical) (NNS homeostasis)))) (VP (AUX was) (VP (VBN studied))) (. .)))
24132704	7	(S1 (S (NP (CD 24) (NNS Rats)) (VP (AUX were) (VP (VP (VBN divided) (PP (IN into) (NP (CD 4) (NNS groups)))) (CC and) (VP (VBN received) (NP (NP (JJ following) (NNS treatments)) (PP (IN for) (NP (NP (CD 4) (NNS weeks)) (: ;) (NP (NP (NP (NN Corn) (NN oil) (PRN (-LRB- -LRB-) (NP (NN control)) (-RRB- -RRB-)) (, ,) (NNP Doc_24132704_884_892_Chemical)) (PRN (-LRB- -LRB-) (VP (VBN 15mg/kg) (PP (IN per) (NP (NN day))) (, ,) (ADVP (RB orally))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_24132704_923_929_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 12.5) (CC and) (CD 25mg/kg)) (PP (IN per) (NP (NN day)))) (, ,) (ADVP (RB intraperitoneally)) (-RRB- -RRB-))))))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NNP Doc_24132704_996_1004_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 15) (NN mg/kg)) (-RRB- -RRB-))))))))) (. .)))
24132704	8	(S1 (S (NP (NP (DT The) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_24132704_1031_1042_Chemical)) (, ,) (NP (NNP Doc_24132704_1044_1056_Chemical)) (CC and) (NP (NNP LDL)))) (PP (IN in) (NP (NP (NN blood)) (PP (IN of) (NP (NNS rats)))))) (VP (AUX were) (VP (VBN analyzed))) (. .)))
24132704	9	(S1 (S (ADVP (RB Moreover)) (NP (NP (NN mRNA) (NNS levels)) (PP (IN of) (NP (NP (NNP LDLr) (CC and) (NNP ERK1/2)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NN protein) (NNS levels)) (PP (IN of) (NP (NP (NN total)) (CC and) (NP (NP (VBN activated) (NNS forms)) (PP (IN of) (NP (NNP ERK1/2)))))) (PP (IN in) (NP (NN rat) (NN liver))))))) (VP (AUX were) (VP (VBN evaluated) (PP (IN by) (NP (NP (JJ Western) (VBG blotting)) (CC and) (NP (NP (JJ quantitative) (JJ real) (NN time) (NN polymerase) (NN chain) (NN reaction)) (NP (NN analysis))))))) (. .)))
24132704	10	(S1 (S (NP (PRP$ Our) (NNS data)) (VP (VBD showed) (SBAR (IN that) (S (VP (VB subacute) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (JJ Doc_24132704_1364_1372_Chemical) (ADJP (RB significantly) (JJ increased)) (NNS concentrations)) (PP (IN of) (NP (NP (NNP Doc_24132704_1415_1426_Chemical)) (, ,) (NP (NNP Doc_24132704_1428_1440_Chemical)) (CC and) (NP (NNP LDL))))))))))) (. .)))
24132704	11	(S1 (S (ADVP (RB Moreover)) (NP (NNP Doc_24132704_1459_1467_Chemical)) (VP (VBD decreased) (NP (CD ERK1/2) (NN protein)) (NP (NP (NN phosphorylation)) (CC and) (NP (NN LDLr) (NN transcript)))) (. .)))
24132704	12	(S1 (S (NP (NNP Doc_24132704_1530_1536_Chemical)) (VP (VP (VBD reduced) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (JJ ERK) (NN activation)) (CC and) (NP (JJ Doc_24132704_1578_1586_Chemical-induced) (NN Doc_24132704_1595_1607_Disease)))))) (CC and) (VP (VBD increased) (NP (NP (NNS levels)) (PP (IN of) (NP (NNP LDLr) (NN transcript)))))) (. .)))
24132704	13	(S1 (S (NP (NNP Doc_24132704_1662_1668_Chemical)) (VP (MD may) (VP (AUX be) (VP (VBN considered) (PP (IN as) (NP (NP (DT a) (JJ novel) (JJ protective) (NN agent)) (PP (IN in) (NP (JJ Doc_24132704_1718_1726_Chemical-induced) (NNP Doc_24132704_1735_1747_Disease))))) (PP (IN through) (NP (NP (NP (NN modulating)) (PP (IN of) (NP (NN ERK) (NN pathway)))) (CC and) (NP (NP (NN increase)) (PP (IN of) (NP (NNP LDLr) (NN expression))))))))) (. .)))
24158386	0	(S1 (S (NP (JJ Doc_24158386_0_5_Chemical) (NN chemotherapy)) (VP (AUX is) (ADJP (JJ active)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ relapsed) (NNP Doc_24158386_58_74_Disease)))))) (. .)))
24158386	1	(S1 (S (NP (NP (NN Doc_24158386_76_92_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24158386_94_96_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (DT a) (ADJP (RB relatively) (JJ chemosensitive)) (NN Doc_24158386_129_139_Disease))) (. .)))
24158386	2	(S1 (S (ADVP (RB However)) (, ,) (PP (IN for) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBP relapse)))))) (, ,) (NP (NP (JJ high-dose) (NN chemotherapy)) (PP (IN with) (NP (JJ autologous) (NN stem) (NN cell) (NN transplant)))) (VP (AUX is) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN choice))) (SBAR (WHNP (WDT which)) (S (VP (VBZ relies) (PP (IN on) (NP (NP (JJ adequate) (NN disease) (NN control)) (PP (IN with) (NP (NN salvage) (NN chemotherapy)))))))))) (. .)))
24158386	3	(S1 (S (NP (NP (NNS Regimens)) (ADJP (RB commonly) (VBN used))) (VP (VP (ADVP (RB often)) (VBP require) (NP (NN inpatient) (NN administration))) (CC and) (VP (MD can) (VP (AUX be) (ADJP (JJ difficult) (SBAR (S (VP (TO to) (VP (VB deliver) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_24158386_429_437_Disease)))))))))))) (. .)))
24158386	4	(S1 (S (NP (NP (NNP Doc_24158386_439_450_Chemical)) (CC and) (NP (NNP Doc_24158386_455_464_Chemical))) (VP (VP (AUX have) (NP (NP (NN activity)) (PP (IN in) (NP (NP (NNP Doc_24158386_482_484_Disease)) (, ,) (NP (NP (JJ non-overlapping) (NN Doc_24158386_502_510_Disease)) (PP (IN with) (NP (JJ first-line) (NNS chemotherapeutics)))) (, ,))))) (CC and) (VP (MD may) (VP (AUX be) (VP (VBN delivered) (PP (IN in) (NP (DT an) (NN outpatient) (NN setting))))))) (. .)))
24158386	5	(S1 (S (PP (IN In) (NP (DT this) (JJ retrospective) (NN single-centre) (NN analysis))) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NP (ADJP (JJ relapsed) (CC or) (JJ refractory)) (NNP Doc_24158386_676_678_Disease)) (VP (VBN treated) (PP (IN with) (NP (JJ Doc_24158386_692_703_Chemical) (ADJP (CD 1,000) (NN mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NN day))))) (PRN (-LRB- -LRB-) (NP (NNP D)) (-RRB- -RRB-)) (NP (CD 1) (, ,) (NNP D8) (CC and) (NNP D15)) (: ;) (NP (NP (NNP Doc_24158386_740_758_Chemical) (CD 1,000)) (NP (JJ mg) (NNP D1-5))) (: ;) (CC and) (NP (NP (NNP Doc_24158386_778_787_Chemical)) (NP (NP (QP (CD 100) (CD mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NNP D15)) (, ,) (NP (NP (DT every) (CD 28) (NNS days)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24158386_820_825_Chemical)) (-RRB- -RRB-)))))))) (VP (AUX were) (VP (VBN included))) (. .)))
24158386	6	(S1 (S (ADVP (JJ Demographic)) (, ,) (NP (NP (NN survival)) (, ,) (NP (NN response)) (CC and) (NP (JJ Doc_24158386_878_886_Disease) (NNS data))) (VP (AUX were) (VP (VBN recorded))) (. .)))
24158386	7	(S1 (S (S (NP (JJ Forty-one) (NN eligible) (NNS patients)) (VP (AUX were) (VP (VBN identified)))) (: :) (S (ADJP (JJ median) (NP (NN age) (CD 27)))) (. .)))
24158386	8	(S1 (S (NP (NP (QP (CD One) (CD hundred) (CC and) (CD twenty-two)) (NNS cycles)) (PP (IN of) (NP (NNP Doc_24158386_1004_1009_Chemical)))) (VP (AUX were) (VP (VBN administered) (PP (IN in) (NP (NN total))) (PRN (-LRB- -LRB-) (S (NP (JJ median) (CD 3) (NNS cycles)) (: ;) (VP (VBP range) (ADVP (RB 1-6)))) (-RRB- -RRB-)))) (. .)))
24158386	9	(S1 (S (NP (NP (CD Twenty)) (PP (IN of) (NP (CD 41) (PRN (-LRB- -LRB-) (NP (CD 48) (NN %)) (-RRB- -RRB-)) (NNS patients)))) (VP (VBD received) (NP (NNP Doc_24158386_1105_1110_Chemical)) (PP (IN as) (NP (NP (JJ second-line) (NN treatment)) (CC and) (NP (NP (CD 11/41)) (PRN (-LRB- -LRB-) (NP (CD 27) (NN %)) (-RRB- -RRB-))))) (PP (IN as) (NP (JJ third-line) (NN therapy)))) (. .)))
24158386	10	(S1 (S (NP (NP (JJ Overall) (NN response) (NN rate)) (PRN (-LRB- -LRB-) (NP (NNP ORR)) (-RRB- -RRB-)) (PP (TO to) (NP (NP (NNP Doc_24158386_1207_1212_Chemical)) (PP (IN in) (NP (DT the) (JJ entire) (NN cohort)))))) (VP (AUX was) (NP (NP (CD 80) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ complete) (NN response)) (PRN (-LRB- -LRB-) (NP (NNP CR)) (-RRB- -RRB-)) (NP (CD 37) (NN %))) (, ,) (NP (NP (JJ partial) (NN response)) (NP (CD 44) (NN %)))) (-RRB- -RRB-))) (PP (IN with) (NP (NP (CD 14/15) (NNS CR)) (VP (VBN confirmed) (PP (IN as) (NP (NP (DT a) (JJ metabolic) (NN CR)) (PP (IN on) (NP (NP (NNP PET) (CC and) (NNP ORR)) (PP (IN of) (NP (CD 85) (NN %))) (PP (IN in) (NP (DT the) (CD 20) (JJ second-line) (NNS patients))))))))))) (. .)))
24158386	11	(S1 (NP (NP (NP (DT The) (RBS most) (JJ common) (NN grade) (NNS 3/4)) (SBAR (S (NP (NNP Doc_24158386_1419_1429_Disease)) (VP (AUX were) (ADJP (JJ haematological)))))) (: :) (NP (NP (NNP Doc_24158386_1451_1462_Disease) (CD 54) (NN %)) (CC and) (NP (NNP Doc_24158386_1472_1488_Disease) (CD 51) (NN %))) (. .)))
24158386	12	(S1 (S (NP (NP (JJ Median) (NN follow-up)) (PP (IN from) (NP (NP (DT the) (NN start)) (PP (IN of) (NP (NNP Doc_24158386_1530_1535_Chemical)))))) (VP (AUX was) (NP (CD 4.5) (NNS years))) (. .)))
24158386	13	(S1 (S (PP (VBG Following) (NP (NNP Doc_24158386_1561_1566_Chemical))) (, ,) (S (NP (JJ 5-year) (JJ progression-free) (NN survival)) (VP (AUX was) (NP (NP (CD 46) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD 95) (NN %)) (NN confidence) (NN interval)) (PRN (-LRB- -LRB-) (NP (NNP CI)) (-RRB- -RRB-))) (, ,) (NP (CD 30-62) (NN %))) (-RRB- -RRB-))))) (CC and) (S (NP (JJ 5-year) (JJ overall) (NN survival)) (VP (AUX was) (NP (NP (CD 59) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 95) (NN %)) (NN CI)) (, ,) (NP (CD 43-74) (NN %))) (-RRB- -RRB-))))) (. .)))
24158386	14	(S1 (S (NP (NP (CD Fourteen)) (PP (IN of) (NP (CD 41) (NNS patients)))) (VP (VBD proceeded) (ADVP (RB directly)) (PP (TO to) (NP (JJ autologous) (NN transplant)))) (. .)))
24158386	15	(S1 (S (NP (NNP Doc_24158386_1777_1782_Chemical)) (VP (AUX is) (NP (NP (DT a) (NN salvage)) (ADJP (JJ chemotherapy) (PP (IN with) (NP (ADJP (RB relatively) (JJ high)) (NN response) (NNS rates))))) (, ,) (PP (VBG leading) (PP (TO to) (NP (NP (JJ successful) (NN transplantation)) (PP (IN in) (NP (JJ appropriate) (NNS patients)))))) (, ,) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (ADJP (JJ relapsed) (CC or) (JJ refractory)) (NNP Doc_24158386_1952_1954_Disease)))))) (. .)))
24190587	0	(S1 (S (NP (NP (NP (JJ Basal) (NN functioning)) (PP (IN of) (NP (DT the) (JJ hypothalamic-pituitary-adrenal) (PRN (-LRB- -LRB-) (NP (NNP HPA)) (-RRB- -RRB-)) (NN axis)))) (CC and) (NP (NP (NNP Doc_24190587_71_93_Disease)) (PP (IN in) (NP (JJ recreational) (NNP Doc_24190587_110_117_Chemical))))) (VP (VBD polydrug) (NP (NNS users))) (. .)))
24190587	1	(S1 (S (NP (NP (NNP Doc_24190587_145_152_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24190587_154_158_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (JJ psychostimulant) (NN drug)) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADVP (RB increasingly)) (VP (VBN associated) (PP (IN with) (NP (NN Doc_24190587_224_252_Disease))))))))) (. .)))
24190587	2	(S1 (S (SBAR (IN While) (S (NP (DT some) (JJ recent) (NNS studies)) (VP (VBP suggest) (NP (NP (JJ acute) (NNS changes)) (PP (IN in) (NP (JJ neuroendocrine) (NN function))))))) (, ,) (NP (JJR less)) (VP (AUX is) (VP (VBN known) (PP (IN about) (NP (NP (JJ long-term) (NNS changes)) (PP (IN in) (NP (NP (NN HPA) (NN functionality)) (PP (IN in) (NP (JJ recreational) (NNS users))))))))) (. .)))
24190587	3	(S1 (S (NP (DT The) (JJ current) (NN study)) (VP (AUX is) (NP (NP (DT the) (JJ first)) (SBAR (S (VP (TO to) (VP (VP (VB explore) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ Doc_24190587_481_488_Chemical-polydrug) (NN use))) (PP (IN on) (NP (NNP Doc_24190587_505_527_Disease))))) (CC and) (VP (VB basal) (NP (NP (NN functioning)) (PP (IN of) (NP (DT the) (NNP HPA) (NN axis)))) (PP (IN through) (S (VP (VBG assessing) (NP (NP (DT the) (NN secretion)) (PP (IN of) (NP (NNP Doc_24190587_601_609_Chemical)))) (PP (IN across) (NP (DT the) (JJ diurnal) (NN period))))))))))))) (. .)))
24190587	4	(S1 (S (NP (NP (JJ Seventy-six) (NNS participants)) (PRN (-LRB- -LRB-) (NP (NP (CD 21) (NNS nonusers)) (, ,) (NP (CD 29) (JJ light) (JJ Doc_24190587_693_700_Chemical-polydrug) (NNS users)) (, ,) (NP (CD 26) (JJ heavy) (JJ Doc_24190587_726_733_Chemical-polydrug) (NNS users))) (-RRB- -RRB-))) (VP (VBD completed) (NP (NP (NP (NP (DT a) (NN substance) (NN use) (NN inventory)) (CC and) (NP (NP (NNS measures)) (PP (IN of) (NP (NNP Doc_24190587_802_824_Disease))))) (PP (IN at) (NP (NN baseline)))) (, ,) (RB then) (NP (NP (CD two) (JJ consecutive) (NNS days)) (PP (IN of) (NP (NNP Doc_24190587_867_875_Chemical) (NN sampling))) (PRN (-LRB- -LRB-) (PP (IN on) (NP (NP (NN awakening)) (, ,) (NP (CD 30) (NN min) (NN post) (NN awakening)) (, ,) (NP (QP (IN between) (CD 1400) (CC and) (CD 1600)) (NNS hours)) (CC and) (NP (JJ pre) (NN bedtime)))) (-RRB- -RRB-))))) (. .)))
24190587	5	(S1 (S (PP (IN On) (NP (NN day) (CD 2))) (, ,) (NP (NNS participants)) (ADVP (RB also)) (VP (VBD attended) (NP (DT the) (NN laboratory) (S (VP (TO to) (VP (VB complete) (NP (DT a) (JJ 20-min) (NN multitasking) (NN stressor))))))) (. .)))
24190587	6	(S1 (S (NP (DT Both) (NN user) (NNS groups)) (VP (VBD exhibited) (NP (NP (ADJP (RB significantly) (JJR greater)) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_24190587_1133_1140_Disease)) (CC and) (NP (NNP Doc_24190587_1145_1155_Disease)))) (PP (IN than) (NP (NNS nonusers))))) (. .)))
24190587	7	(S1 (S (PP (IN On) (NP (NN day) (CD 1))) (, ,) (NP (DT all) (NNS participants)) (VP (VBD exhibited) (NP (DT a) (JJ typical) (JJ Doc_24190587_1218_1226_Chemical) (NN profile)) (, ,) (SBAR (IN though) (S (NP (NN light) (NNS users)) (VP (AUX had) (ADVP (RB significantly)) (ADJP (NP (JJ elevated) (NNS levels)) (JJ pre-bed)))))) (. .)))
24190587	8	(S1 (S (PP (IN On) (NP (NN day) (CD 2))) (, ,) (NP (NP (NP (JJ heavy) (NNS users)) (VP (VBN demonstrated) (NP (JJ elevated) (NNS levels)) (PP (IN upon) (NP (NN awakening))))) (CC and) (NP (NP (DT all) (JJ Doc_24190587_1372_1379_Chemical-polydrug) (NNS users)) (VP (VBN demonstrated)))) (VP (VBD elevated) (NP (JJ pre-bed) (NNS levels)) (PP (VBN compared) (PP (TO to) (NP (NNS non-users))))) (. .)))
24190587	9	(S1 (S (NP (NP (JJ Significant)) (PP (IN between) (NP (NN group) (NNS differences)))) (VP (AUX were) (ADVP (RB also)) (VP (VBN observed) (PP (PP (IN in) (NP (NN afternoon) (NN Doc_24190587_1525_1533_Chemical) (NNS levels))) (CC and) (PP (IN in) (NP (NP (JJ overall) (JJ Doc_24190587_1556_1564_Chemical) (NN secretion)) (PP (IN across) (NP (DT the) (NN day)))))))) (. .)))
24190587	10	(S1 (S (NP (NP (DT The) (NNS increases)) (PP (IN in) (NP (NP (NNP Doc_24190587_1621_1628_Disease)) (CC and) (NP (NNP Doc_24190587_1633_1643_Disease))))) (VP (AUX are) (PP (IN in) (NP (NP (NN line)) (PP (IN with) (NP (NP (JJ previous) (NNS observations)) (PP (IN in) (NP (JJ recreational) (JJ Doc_24190587_1699_1706_Chemical-polydrug) (NNS users)))))))) (. .)))
24190587	11	(S1 (S (S (NP (JJ Dysregulated) (JJ diurnal) (NN Doc_24190587_1744_1752_Chemical)) (VP (MD may) (VP (AUX be) (ADJP (JJ indicative) (PP (IN of) (NP (NP (JJ inappropriate) (NN anticipation)) (PP (IN of) (NP (JJ forthcoming) (NNS demands))))))))) (CC and) (S (NP (NNP Doc_24190587_1828_1842_Disease)) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (DT the) (VBN increased) (ADJP (JJ psychological) (CC and) (JJ physical)) (NN morbidity)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ heavy) (JJ recreational) (NN use)) (PP (IN of) (NP (NNP Doc_24190587_1948_1955_Chemical))))))))))) (. .)))
24209900	0	(S1 (NP (NP (JJ Doc_24209900_0_10_Chemical) (JJ related) (NN Doc_24209900_19_33_Disease)) (: :) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (DT a) (JJ timely) (NN EEG) (NN evaluation)))) (. .)))
24209900	1	(S1 (S (NP (NN Doc_24209900_85_95_Chemical)) (VP (AUX is) (NP (NP (DT an) (VBG alkylating) (NN agent)) (ADJP (JJ useful) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (DT a) (JJ wide) (NN range)) (PP (IN of) (NP (NNP Doc_24209900_162_169_Disease))) (PP (VBG including) (NP (NP (NNP Doc_24209900_180_188_Disease)) (, ,) (NP (NNP Doc_24209900_190_198_Disease)) (, ,) (NP (NN gynecologic)) (CC and) (NP (NNP Doc_24209900_216_234_Disease))))))))))) (. .)))
24209900	2	(S1 (S (NP (NN Doc_24209900_236_250_Disease)) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (NP (CD 10-40) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ high-dose) (NNP IV) (NNP Doc_24209900_314_324_Chemical)))))))))) (. .)))
24209900	3	(S1 (S (VP (TO To) (VP (VB highlight) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (NN electroencephalogram)) (PRN (-LRB- -LRB-) (NP (NNP EEG)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (DT the) (JJ early) (NN detection) (CC and) (NN management)) (PP (IN of) (NP (JJ Doc_24209900_430_440_Chemical) (JJ related) (NN Doc_24209900_449_463_Disease)))))))) (. .)))
24209900	4	(S1 (S (NP (NP (NN Retrospective) (NN chart) (NN review)) (PP (VBG including) (NP (NP (JJ clinical) (NNS data)) (CC and) (NP (NNP EEG) (NNS recordings))))) (VP (AUX was) (VP (AUX done) (PP (IN on) (NP (NP (CD five) (NNS patients)) (, ,) (VP (VBN admitted) (PP (TO to) (NP (NP (NNP MD) (NNP Anderson) (NNP Doc_24209900_595_601_Disease) (NNP Center)) (PP (IN between) (NP (NNS years) (CD 2009) (CC and) (CD 2012)))))) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (JJ Doc_24209900_652_662_Chemical) (JJ related) (JJ acute) (NN Doc_24209900_677_691_Disease))))))))) (. .)))
24209900	5	(S1 (S (NP (DT All) (CD five) (NNS patients)) (VP (VBD experienced) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NNP Doc_24209900_744_758_Disease)))) (PP (ADVP (RB soon)) (IN after) (PRN (-LRB- -LRB-) (PP (IN within) (NP (CD 12) (JJ h-2) (NNS days))) (-RRB- -RRB-)) (S (VP (VBG receiving) (NP (NNP Doc_24209900_801_811_Chemical)))))) (. .)))
24209900	6	(S1 (S (NP (CD Two) (NNS patients)) (VP (VBD developed) (NP (JJ generalized) (NN Doc_24209900_848_859_Disease)) (SBAR (IN while) (S (NP (CD one) (NN patient)) (VP (VBD developed) (NP (NP (JJ continuous) (NN non-Doc_24209900_903_932_Disease)) (PRN (-LRB- -LRB-) (NP (NN NCSE)) (-RRB- -RRB-)) (SBAR (WHNP (WDT that)) (S (VP (VBD required) (NP (NP (CD ICU) (NN admission)) (CC and) (NP (NN intubation))))))))))) (. .)))
24209900	7	(S1 (S (S (NP (JJ Initial) (NNS EEG)) (VP (VBD showed) (NP (NNP Doc_24209900_1003_1026_Disease)) (PP (IN in) (NP (CD three) (NNS patients))))) (: ;) (S (NP (NP (NN run)) (PP (IN of) (NP (JJ triphasic) (NNS waves))) (PP (IN in) (NP (NP (CD one) (NN patient)) (CC and) (NP (JJ moderate) (NN degree) (NN diffuse))))) (VP (VBD generalized) (VP (VBG slowing)))) (. .)))
24209900	8	(S1 (S (NP (NP (VBN Mixed) (NN pattern)) (PP (IN with) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT both) (NNP sharps) (CC and) (JJ triphasic) (NNS waves)))))) (VP (AUX were) (ADVP (RB also)) (VP (VBN noted))) (. .)))
24209900	9	(S1 (S (NP (NP (NN Repeat) (NNS EEGs)) (PP (IN within) (NP (NP (NNS 24_h)) (PP (IN of) (NP (NN symptom) (NN onset)))))) (VP (VBD showed) (NP (NP (JJ marked) (NN improvement)) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (VP (VBN correlated) (PP (IN with) (NP (JJ clinical) (NN improvement))))))))) (. .)))
24209900	10	(S1 (S (NP (NP (NN Severity)) (PP (IN of) (NP (JJ Doc_24209900_1356_1366_Chemical) (JJ related) (NN Doc_24209900_1375_1389_Disease) (NNS correlates))) (PP (IN with) (NP (NNP EEG)))) (VP (VBZ changes)) (. .)))
24209900	11	(S1 (S (NP (PRP We)) (VP (VBP suggest) (NP (NP (DT a) (JJ timely) (NN EEG) (NN evaluation)) (PP (IN for) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_24209900_1477_1487_Chemical))) (SBAR (WHNP (WP who)) (S (VP (VBP develop) (NP (NP (NNS features)) (PP (IN of) (NP (NNP Doc_24209900_1512_1526_Disease))))))))))) (. .)))
24220752	0	(S1 (NP (NP (NN Incidence)) (PP (IN of) (NP (JJ contrast-induced) (NN Doc_24220752_30_41_Disease))) (PP (IN in) (NP (NP (JJ hospitalised) (NNS patients)) (PP (IN with) (NP (NNP Doc_24220752_72_78_Disease))))) (. .)))
24220752	1	(S1 (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (NN frequency)) (PP (IN of)))))) (CC and) (S (NP (JJ possible) (NNS factors)) (VP (VBD related) (PP (TO to) (NP (NP (JJ contrast-induced) (NNP Doc_24220752_171_182_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24220752_184_187_Disease)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (JJ hospitalised) (NNS patients)) (PP (IN with) (NP (NNP Doc_24220752_219_225_Disease))))))) (. .)))
24220752	2	(S1 (S (NP (CD Ninety) (JJ adult) (NNS patients)) (VP (AUX were) (VP (VBD enrolled))) (. .)))
24220752	3	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NN risk) (NNS factors))) (PP (IN for) (NP (NNP Doc_24220752_304_323_Disease)))) (VP (AUX were) (VP (VBN excluded))) (. .)))
24220752	4	(S1 (S (NP (NN Blood) (NNS samples)) (VP (AUX were) (VP (VP (VBN examined) (NP (DT the) (NN day)) (PP (IN before) (NP (NP (JJ contrast-enhanced) (JJ computed) (NN tomography)) (PRN (-LRB- -LRB-) (NP (NNP CT)) (-RRB- -RRB-))))) (CC and) (ADVP (RB serially)) (VP (PP (IN for) (NP (CD 3) (NNS days))) (ADVP (RB thereafter))))) (. .)))
24220752	5	(S1 (S (NP (NNP Doc_24220752_461_464_Disease)) (VP (AUX was) (VP (VBN defined) (PP (IN as) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NP (NP (JJ serum) (NNP Doc_24220752_501_511_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Cr)) (-RRB- -RRB-))) (PP (IN of) (NP (QP (CD 0.5) (NN mg/dl) (CC or) (JJR more))))) (, ,) (CC or) (NP (NP (NN elevation)) (PP (IN of) (NP (NNP Doc_24220752_555_557_Chemical)))))) (PP (TO to) (NP (CD 25) (NN %))) (PP (IN over) (NP (NN baseline))))))) (. .)))
24220752	6	(S1 (S (NP (NP (NNS Relationships)) (PP (IN between) (NP (NP (NNP Doc_24220752_603_606_Disease)) (CC and) (NP (JJ possible) (NN risk) (NNS factors))))) (VP (AUX were) (VP (VBN investigated))) (. .)))
24220752	7	(S1 (S (NP (NN Doc_24220752_661_664_Disease)) (VP (AUX was) (VP (VBN detected) (PP (IN in) (NP (CD 18/90) (PRN (-LRB- -LRB-) (NP (CD 20) (NN %)) (-RRB- -RRB-)) (NNS patients))))) (. .)))
24220752	8	(S1 (S (NP (NNP Doc_24220752_704_707_Disease)) (VP (VBD developed) (PP (PP (IN in) (NP (NP (ADJP (CD 25.5) (NN %)) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NN chemotherapy))))))) (CC and) (PP (IN in) (NP (NP (ADJP (CD 11) (NN %)) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX did) (RB not)))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.1)) (-RRB- -RRB-)))))) (. .)))
24220752	9	(S1 (S (S (NP (NNP Doc_24220752_808_811_Disease)) (VP (ADVP (RBR more) (RB frequently)) (VBD developed) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN undergone) (NP (NN CT)) (PP (IN within) (NP (CD 45) (NNS days))))))))) (PP (IN after) (NP (DT the) (JJ last) (NN chemotherapy))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.005)) (-RRB- -RRB-)))) (: ;) (S (NP (PRP it)) (VP (AUX was) (ADVP (RB also)) (NP (NP (DT an) (JJ independent) (NN risk) (NN factor)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.017)) (-RRB- -RRB-))))) (. .)))
24220752	10	(S1 (S (NP (NN Doc_24220752_979_982_Disease)) (VP (AUX was) (ADVP (RB significantly) (RBR more)) (PP (IN after) (NP (NN treatment))) (PP (PP (IN with) (NP (NN bevacizumab/Doc_24220752_1039_1049_Chemical))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.021)) (-RRB- -RRB-)) (CC and) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_24220752_1083_1095_Disease))))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.044)) (-RRB- -RRB-)))) (. .)))
24220752	11	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_24220752_1139_1142_Disease))) (PP (IN after) (NP (NN CT))) (PP (IN in) (NP (JJ hospitalised) (JJ oncological) (NNS patients)))) (VP (AUX was) (NP (CD 20) (NN %))) (. .)))
24220752	12	(S1 (S (NP (NN Doc_24220752_1199_1202_Disease)) (VP (VBD developed) (NP (NN 4.5-times)) (ADVP (RBR more) (RB frequently)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_24220752_1256_1262_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (VBN undergone) (NP (JJ recent) (NN chemotherapy))))))))) (. .)))
24220752	13	(S1 (S (NP (NP (NN Doc_24220752_1302_1314_Disease)) (CC and) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NN bevacizumab/Doc_24220752_1350_1360_Chemical))))) (VP (MD may) (VP (AUX be) (NP (JJ additional) (NN risk) (NNS factors)) (PP (IN for) (NP (JJ Doc_24220752_1396_1399_Disease) (NN development))))) (. .)))
24220752	14	(S1 (NP (NN KEY) (NNS POINTS) (: :) (. .)))
24220752	15	(S1 (S (NP (NP (NN Doc_24220752_1427_1455_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24220752_1457_1460_Disease)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (NN concern)) (PP (IN for) (NP (NP (JJ oncological) (NNS patients)) (VP (VBG undergoing) (NP (NN CT.))))))) (. .)))
24220752	16	(S1 (S (NP (NN Doc_24220752_1517_1520_Disease)) (VP (VBZ occurs) (ADVP (RBR more) (RB often)) (SBAR (WHADVP (WRB when)) (S (NP (NN CT)) (VP (AUX is) (VP (VBN performed) (PP (NP (CD <45) (NNS days)) (IN after) (NP (NN chemotherapy.)))))))) (. .)))
24220752	17	(S1 (S (NP (NP (NP (NN Doc_24220752_1591_1603_Disease)) (CC and) (NP (NN treatment))) (PP (IN with) (NP (NN bevacizumab)))) (VP (VBP appear) (S (VP (TO to) (VP (AUX be) (NP (JJ additional) (NN risk) (NNS factors)))))) (. .)))
24234943	0	(S1 (NP (NP (NN Syndrome)) (PP (IN of) (NP (NNP Doc_24234943_12_56_Disease))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_24234943_73_87_Chemical)))) (. .)))
24234943	1	(S1 (S (S (VP (TO To) (VP (VB report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_24234943_120_167_Disease))))))) (PRN (-LRB- -LRB-) (NP (NNP Doc_24234943_169_174_Disease)) (-RRB- -RRB-)) (NP (NN secretion)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_24234943_202_216_Chemical)))) (. .)))
24234943	2	(S1 (NP (NP (NN CASE) (NN SUMMARY)) (: :) (NP (NP (DT A) (JJ 57-year) (JJ old) (NN female)) (PP (IN with) (NP (NN hyponatraemia)))) (. .)))
24234943	3	(S1 (S (S (NP (PRP$ Her) (NNS medications)) (VP (VBN included) (NP (NNP Doc_24234943_298_312_Chemical)))) (, ,) (CC and) (S (NP (NNS symptoms)) (VP (VBD included) (NP (NP (NNP Doc_24234943_336_342_Disease)) (, ,) (NP (NNP Doc_24234943_344_351_Disease)) (CC and) (NP (NNP Doc_24234943_356_365_Disease))))) (. .)))
24234943	4	(S1 (S (S (NP (NP (DT The) (NN serum) (NN Doc_24234943_377_383_Chemical)) (PP (IN at) (NP (DT this) (NN time)))) (VP (AUX was) (NP (QP (CD 120) (CD mmol/L))))) (, ,) (S (NP (NN serum) (NN osmolality)) (VP (AUX was) (NP (NP (CD 263) (NN mosmol/kg)) (, ,) (NP (NP (NN urine)) (NP (QP (CD osmolality) (CD 410)) (NNS mosmol/kg))) (CC and) (NP (NN urine) (JJ Doc_24234943_490_496_Chemical) (QP (CD 63) (CD mmol/L)))) (, ,) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT a) (NN diagnosis)) (PP (IN of) (NP (NNP Doc_24234943_539_544_Disease)))))))) (. .)))
24234943	5	(S1 (S (S (NP (NN Doc_24234943_546_560_Chemical)) (VP (AUX was) (VP (VBN ceased)))) (CC and) (S (NP (JJ fluid) (NN restriction)) (VP (VBN implemented))) (. .)))
24234943	6	(S1 (S (PP (IN After) (NP (CD 4) (NNS days))) (NP (DT the) (NNP Doc_24234943_624_630_Chemical) (ADJP (ADJP (JJ increased) (PP (TO to) (NP (CD 128) (NN mmol/L)))) (CC and) (ADJP (JJ fluid))) (NN restriction)) (VP (AUX was) (VP (VBN relaxed))) (. .)))
24234943	7	(S1 (S (PP (IN During) (NP (PRP$ her) (JJ further) (ADJP (CD 3) (NNS weeks) (JJ inpatient)) (NN admission))) (NP (DT the) (JJ serum) (NNP Doc_24234943_747_753_Chemical)) (VP (VBD ranged) (PP (IN from) (NP (QP (CD 134) (TO to) (CD 137)) (NNS mmol/L))) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_24234943_806_817_Chemical)))))) (. .)))
24234943	8	(S1 (S (NP (NN Doc_24234943_831_836_Disease)) (VP (AUX has) (VP (AUX been) (ADVP (RB widely)) (VP (VBN reported) (PP (IN with) (NP (NP (DT a) (NN range)) (PP (IN of) (NP (NNS antidepressants)))))))) (. .)))
24234943	9	(S1 (S (NP (DT This) (NN case) (NN report)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP Doc_24234943_926_940_Chemical)) (VP (MD might) (VP (VB cause) (NP (ADJP (RB clinically) (JJ significant)) (NN Doc_24234943_976_988_Disease))))))) (. .)))
24234943	10	(S1 (S (NP (NNS Clinicians)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NNS antidepressants)))))) (S (VP (TO to) (VP (VP (VB cause) (NP (NN Doc_24234943_1076_1088_Disease))) (, ,) (CC and) (VP (VB take) (NP (JJ appropriate) (JJ corrective) (NN action)))))) (SBAR (WHADVP (WRB where)) (FRAG (ADJP (JJ necessary)))))) (. .)))
24275640	0	(S1 (NP (NP (JJ Oxidative) (NN stress)) (PP (IN on) (NP (NNP Doc_24275640_20_34_Disease))) (PP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (JJ single) (CC and) (JJ multiple) (NNS doses)) (PP (IN of) (NP (NNP Doc_24275640_85_96_Chemical))))))) (. .)))
24275640	1	(S1 (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (NP (NNP Doc_24275640_115_126_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24275640_128_131_Chemical)) (-RRB- -RRB-))))) (VP (VBD -induced) (SBAR (S (NP (NNP Doc_24275640_141_155_Disease)) (VP (VBZ remains) (ADJP (JJ controversial)))))) (. .)))
24275640	2	(S1 (S (S (NP (NP (JJ Wistar) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 66)) (-RRB- -RRB-))) (VP (VP (VBD received) (NP (NNP Doc_24275640_209_212_Chemical) (NNS injections)) (ADVP (RB intraperitoneally))) (CC and) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (CD 2) (JJ experimental) (NNS protocols))))))) (: :) (S (NP (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-)) (NNS rats)) (VP (AUX were) (VP (VBN killed) (ADVP (RB before)) (PRN (-LRB- -LRB-) (NP (CD -24) (NNP h)) (, ,) (NP (NNP n) (SYM =) (CD 8)) (-RRB- -RRB-))))) (CC and) (S (NP (NP (CD 24) (NNP h)) (PP (IN after) (PRN (-LRB- -LRB-) (NP (CD +24) (NNP h)) (, ,) (NP (NNP n) (SYM =) (CD 8)) (-RRB- -RRB-)) (NP (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (S (NP (NP (NNP Doc_24275640_388_391_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 4) (CD mg/kg)) (NN body) (NN weight)) (-RRB- -RRB-))) (VP (TO to) (VP (VB determine) (NP (DT the) (JJ Doc_24275640_431_434_Chemical) (JJ acute) (NN effect))))))) (CC and) (NP (NP (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 58)) (-RRB- -RRB-)))))) (VP (VP (VBD received) (NP (NP (CD 4) (NNS injections)) (PP (IN of) (NP (NP (NNP Doc_24275640_495_498_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 4) (CD mg/kg)) (NN body) (NN weight/week)) (-RRB- -RRB-)))))) (CC and) (VP (AUX were) (VP (VBN killed) (PP (IN before) (NP (NP (NP (DT the) (JJ first) (NN injection)) (PRN (-LRB- -LRB-) (NP (NNP M0)) (-RRB- -RRB-))) (CC and) (NP (CD 1) (NN week)))) (PP (IN after) (NP (DT each) (NN injection))) (PRN (-LRB- -LRB-) (NP (NNP M1) (, ,) (NNP M2) (, ,) (NNP M3)) (, ,) (CC and) (NNP M4) (-RRB- -RRB-)) (S (VP (TO to) (VP (VB determine) (NP (DT the) (JJ chronological) (NNS effects))))))))) (. .)))
24275640	3	(S1 (S (NP (NP (NNS Animals)) (VP (VBN used) (PP (IN at) (NP (NNP M0))))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 8)) (-RRB- -RRB-)) (VP (AUX were) (ADVP (RB also)) (VP (VBN used) (PP (IN at) (NP (NP (NP (NN moment) (CD -24)) (NP (NNP h))) (PP (IN of) (NP (JJ acute) (NN study))))))) (. .)))
24275640	4	(S1 (S (NP (NP (NP (JJ Cardiac) (JJ total) (NN antioxidant) (NN performance)) (PRN (-LRB- -LRB-) (INTJ (VB TAP)) (-RRB- -RRB-))) (, ,) (NP (NN DNA) (NN damage)) (, ,) (CC and) (NP (NN morphology) (NNS analyses))) (VP (AUX were) (VP (VBN carried) (PRT (RP out)) (PP (IN at) (NP (DT each) (NN time) (NN point))))) (. .)))
24275640	5	(S1 (S (NP (NP (JJ Single) (NN dose)) (PP (IN of) (NP (NNP Doc_24275640_874_877_Chemical)))) (VP (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ increased) (NNP Doc_24275640_908_930_Disease)) (, ,) (NP (NNP Doc_24275640_932_940_Disease)) (, ,) (CC and) (NP (NP (NN DNA) (NN damage)) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ strand) (NNS breaks)) (PRN (-LRB- -LRB-) (NP (NNP SBs)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_24275640_982_1002_Chemical))) (-RRB- -RRB-))))))) (CC and) (VP (VBD decreased) (S (VP (VB TAP))))) (. .)))
24275640	6	(S1 (S (S (NP (DT The) (JJ chronological) (NN study)) (VP (VBD showed) (NP (NP (NP (DT an) (NN effect)) (PP (IN of) (NP (DT a) (JJ cumulative) (NN dose))) (PP (IN on) (NP (NN body) (NN weight)))) (PRN (-LRB- -LRB-) (NP (SYM R) (X (SYM =)) (CD -0.99)) (, ,) (NP (NNP p) (SYM =) (CD 0.011)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_24275640_1124_1132_Disease)) (PRN (-LRB- -LRB-) (NP (NP (QP (SYM R) (SYM =) (CD 1.00))) (, ,) (NP (NNP p) (SYM =) (CD 0.004))) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_24275640_1156_1159_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (SYM R) (SYM =) (CD 0.95))) (, ,) (NP (NNP p) (SYM =) (CD 0.049))) (-RRB- -RRB-))))) (, ,) (CC and) (S (NP (NNP DNA)) (VP (VBZ SBs) (PRN (-LRB- -LRB-) (FRAG (NP (SYM R)) (X (SYM =)) (X (NN -0.95) (, ,) (FW p) (SYM =)) (NP (CD 0.049))) (-RRB- -RRB-)))) (. .)))
24275640	7	(S1 (S (NP (NN DNA) (NNS SBs) (NN damage)) (VP (AUX was) (ADVP (RB negatively)) (VP (VBN associated) (PP (IN with) (NP (NP (NP (VB TAP)) (PRN (-LRB- -LRB-) (S (NP (SYM R) (X (SYM =)) (CD -0.98) (, ,) (CD p)) (VP (SYM =) (NP (CD 0.018)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_24275640_1297_1305_Disease)) (PRN (-LRB- -LRB-) (S (NP (SYM R) (X (SYM =)) (CD -0.97) (, ,) (CD p)) (VP (SYM =) (NP (CD 0.027)))) (-RRB- -RRB-))))))) (. .)))
24275640	8	(S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ oxidative) (NN damage)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ acute) (NN Doc_24275640_1397_1411_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NNP Doc_24275640_1440_1443_Chemical) (RB only))))))))))))) (. .)))
24275640	9	(S1 (S (NP (NP (VBN Increased) (NN resistance)) (PP (TO to) (NP (DT the) (JJ oxidative) (NN stress)))) (VP (AUX is) (ADJP (JJ plausible) (PP (IN for) (NP (NP (DT the) (JJ multiple) (NN dose)) (PP (IN of) (NP (NNP Doc_24275640_1533_1536_Chemical))))))) (. .)))
24275640	10	(S1 (S (ADVP (RB Thus)) (, ,) (NP (JJ different) (NNS mechanisms)) (VP (MD may) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (JJ acute) (NN Doc_24275640_1590_1598_Disease)) (CC versus) (NP (JJ chronic) (NN Doc_24275640_1614_1622_Disease))))))) (. .)))
24283660	0	(S1 (NP (NP (JJ Doc_24283660_0_10_Chemical-related) (NN Doc_24283660_19_26_Disease)) (PP (IN after) (NP (JJ pediatric) (NN liver) (NN transplantation--a) (NN single-center) (NN experience))) (. .)))
24283660	1	(S1 (FRAG (S (S (VP (TO To) (VP (VB identify) (NP (DT the) (NN risk) (NNS factors)) (PP (IN for) (NP (JJ new-onset) (NNP Doc_24283660_137_145_Disease))) (PP (IN after) (NP (JJ pediatric) (NNS LT)))))) (CC and) (S (VP (TO to) (VP (VB assess) (NP (NP (PRP$ their) (JJ clinical) (NNS implications)) (CC and) (NP (JJ long-term) (NN prognosis))))))) (. .)))
24283660	2	(S1 (S (NP (NP (DT The) (JJ clinical) (CC and) (NN laboratory) (NNS data)) (PP (IN of) (NP (CD 27) (JJ consecutive) (NNS children))) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NN LT)) (PP (PP (IN from) (NP (NNP January) (CD 2007))) (PP (TO to) (NP (NNP December) (CD 2010)))) (PP (IN in) (NP (PRP$ our) (NN center))))))) (VP (AUX were) (VP (VBN analyzed) (ADVP (RB retrospectively)))) (. .)))
24283660	3	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN divided) (PP (IN into) (NP (NP (JJ Doc_24283660_416_424_Disease) (NN group)) (CC and) (NP (DT a) (JJ non-Doc_24283660_441_449_Disease) (NN group)))))) (. .)))
24283660	4	(S1 (S (NP (ADJP (ADJP (JJ Pre-operative)) (, ,) (ADJP (JJ intra-operative)) (, ,) (CC and) (ADJP (JJ post-operative))) (NNS data)) (VP (AUX were) (VP (VBN collected))) (. .)))
24283660	5	(S1 (S (NP (NN Doc_24283660_529_537_Disease)) (VP (VBD occurred) (PP (IN in) (NP (NP (CD four) (NNS children)) (, ,) (NP (NP (DT an) (NN incidence)) (PP (IN of) (NP (CD 14.8) (NN %))))))) (. .)))
24283660	6	(S1 (S (NP (DT All)) (VP (VBD exhibited) (NP (JJ generalized) (NNP Doc_24283660_614_635_Disease)) (PP (IN within) (NP (DT the) (JJ first) (CD two) (NNS wk))) (SBAR (IN after) (S (NP (NNP LT.) (NNP Univariate) (NN analysis)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (DT the) (NN risk) (NNS factors)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_24283660_735_743_Disease))) (PP (IN after) (NP (JJ pediatric) (NNS LT))))) (VP (VBD included) (NP (NP (NN gender)) (, ,) (NP (NP (JJ pediatric) (JJ end-stage) (NN Doc_24283660_800_813_Disease) (NN score)) (PP (IN before) (NP (NN surgery)))) (, ,) (NP (NP (JJ Child-Pugh) (NN score)) (PP (IN before) (NP (NN surgery)))) (, ,) (NP (NP (JJ serum) (JJ total) (NN Doc_24283660_881_890_Chemical)) (PP (IN after) (NP (NN surgery)))) (, ,) (CC and) (NP (NN trough) (JJ Doc_24283660_917_920_Chemical) (NN level)))))))))) (. .)))
24283660	7	(S1 (S (NP (JJ Multivariate) (NN analysis)) (VP (VBD showed) (SBAR (S (NP (DT that) (NN trough) (JJ Doc_24283660_969_972_Chemical) (NN level)) (VP (AUX was) (NP (NP (DT the) (JJ only) (JJ independent) (NN risk) (NN factor)) (VP (VBN associated) (PP (IN with) (NP (DT the) (NNP Doc_24283660_1036_1044_Disease))))))))) (. .)))
24283660	8	(S1 (S (NP (NP (DT All) (NNS children)) (SBAR (WHNP (WP who)) (S (VP (VBD experienced) (NP (NNP Doc_24283660_1075_1083_Disease)))))) (VP (VP (VBD survived) (PP (IN with) (NP (JJ good) (NN graft) (NN function)))) (CC and) (VP (VBD remained) (ADJP (JJ Doc_24283660_1131_1138_Disease-free)) (PP (IN without) (NP (JJ anti-Doc_24283660_1157_1166_Disease) (NNS drugs))) (PP (IN over) (NP (NP (DT a) (JJ mean) (JJ follow-up) (NN period)) (PP (IN of) (NP (NP (CD 33.7) (NNS +)) (NP (CD 14.6) (NNS months)))))))) (. .)))
24283660	9	(S1 (S (NP (JJ High) (NN trough) (NNP Doc_24283660_1237_1240_Chemical) (NN level)) (VP (AUX was) (NP (NP (DT the) (JJ predominant) (NN factor)) (SBAR (WHNP (WDT that)) (S (VP (VBD contributed) (PP (TO to) (NP (NP (NNP Doc_24283660_1294_1302_Disease)) (PP (IN in) (NP (DT the) (JJ early) (JJ post-operative) (NN period))))) (SBAR (IN after) (S (NP (NP (JJ pediatric) (NNP LT.) (NNP High) (NNP PELD)) (CC and) (NP (NP (JJ Child-Pugh) (NNS scores)) (PP (IN before) (NP (NP (NNP LT)) (CC and) (NP (JJ high) (JJ post-operative) (NN serum) (NNP Tbil)))))) (VP (MD may) (VP (AUX be) (NP (JJ contributory) (NN risk) (NNS factors)) (PP (IN for) (NP (JJ Doc_24283660_1472_1475_Chemical-related) (NNP Doc_24283660_1484_1492_Disease)))))))))))) (. .)))
24284476	0	(S1 (S (NP (DT The) (JJ flavonoid) (NNP Doc_24284476_14_22_Chemical)) (VP (VBZ delays) (PP (VBG forgetting) (PP (IN of) (NP (NP (JJ passive) (NN avoidance) (NN conditioning)) (PP (IN in) (NP (NNS rats))))))) (. .)))
24284476	1	(S1 (S (NP (DT The) (JJ present) (NNS experiments)) (VP (AUX were) (VP (VBN performed) (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (DT the) (JJ flavonoid) (NNP Doc_24284476_160_168_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 20) (CD mg/kg)) (NN intraperitoneally)) (PRN (-LRB- -LRB-) (NP (CD i.p.)) (-RRB- -RRB-))) (, ,) (NP (NP (CD 1) (NNP h)) (PP (IN before) (NP (NN acquisition)))) (-RRB- -RRB-)))))))) (, ,) (PP (IN on) (NP (NP (CD 24) (NNP h) (NN retention) (NN performance)) (CC and) (NP (NP (VBG forgetting)) (PP (IN of) (NP (DT a) (JJ step-through) (JJ passive) (NN avoidance) (NN task)))))) (, ,) (PP (IN in) (NP (JJ young) (JJ male) (NNP Wistar) (NNS rats))))) (. .)))
24284476	2	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (NNS differences)) (PP (IN between) (NP (NP (JJ saline-) (CC and) (JJ Doc_24284476_390_398_Chemical-treated) (NNS groups)) (PP (IN in) (NP (DT the) (CD 24) (NNP h) (NN retention) (NN trial))))))) (. .)))
24284476	3	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NNP Doc_24284476_456_464_Chemical)) (VP (AUX did) (RB not) (VP (VB prevent) (NP (NP (DT the) (NNP Doc_24284476_485_492_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_24284476_504_515_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NN 1mg/kg)) (, ,) (NP (NN i.p.)) (, ,) (NP (NP (CD 30) (NN min)) (PP (IN before) (NP (DT the) (NN acquisition))))) (-RRB- -RRB-)))))))) (. .)))
24284476	4	(S1 (S (NP (NP (DT The) (JJ saline-) (CC and) (JJ Doc_24284476_579_587_Chemical-treated) (NNS rats)) (SBAR (WHNP (WDT that)) (S (VP (AUX did) (RB not) (VP (VB step) (ADVP (RB through)) (PP (IN into) (NP (DT the) (JJ dark) (NN compartment))) (PP (IN during) (NP (DT the) (JJ cut-off) (NN time)))))))) (PRN (-LRB- -LRB-) (NP (CD 540)) (PRP s) (-RRB- -RRB-)) (VP (AUX were) (VP (VBN retested) (ADVP (RB weekly)) (PP (IN for) (NP (QP (IN up) (TO to) (CD eight)) (NNS weeks))))) (. .)))
24284476	5	(S1 (S (PP (IN In) (NP (DT the) (JJ saline) (VBN treated) (NN group))) (, ,) (S (NP (NP (DT the) (JJ first) (JJ significant) (NN decline)) (PP (IN in) (NP (JJ passive) (NN avoidance) (NN response)))) (VP (AUX was) (VP (VBN observed) (PP (IN at) (NP (CD four) (NNS weeks)))))) (, ,) (CC and) (S (NP (JJ complete) (NN Doc_24284476_859_870_Disease)) (VP (AUX was) (VP (VBN found) (NP (CD five) (NNS weeks)) (PP (IN after) (NP (NP (DT the) (NN acquisition)) (PP (IN of) (NP (DT the) (JJ passive) (NN avoidance) (NN task)))))))) (. .)))
24284476	6	(S1 (S (PP (IN At) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT the) (JJ experimental) (NN period))))) (, ,) (NP (NP (CD 60) (NN %)) (PP (IN of) (NP (NP (DT the) (NNS animals)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_24284476_1016_1024_Chemical))))))) (ADVP (RB still)) (VP (AUX did) (RB not) (VP (VB step) (ADVP (RB through)))) (. .)))
24284476	7	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (LST (LS 1) (-RRB- -RRB-)) (NP (NNP Doc_24284476_1080_1088_Chemical)) (VP (VBZ delays) (NP (DT the) (JJ long-term) (VBG forgetting)) (PRN (CC but) (S (VP (AUX did) (RB not) (VP (VBP modulate) (NP (NP (DT the) (CD 24) (NNP h) (NN retention)) (PP (IN of) (NP (NP (NN fear) (NN memory)) (CC and) (NP (CD 2)))))))) (-RRB- -RRB-)) (SBAR (S (NP (NP (DT the) (VBN obtained) (JJ beneficial) (NN effect)) (PP (IN of) (NP (NNP Doc_24284476_1217_1225_Chemical))) (PP (IN on) (NP (DT the) (JJ passive) (NN avoidance) (NN conditioning)))) (VP (AUX is) (VP (VBN mediated) (PP (IN by) (NP (NP (NNS mechanisms)) (SBAR (WHNP (WDT that)) (S (VP (AUX do) (RB not) (VP (VB implicate) (NP (NP (PRP$ its) (NN action)) (PP (IN on) (NP (DT the) (JJ muscarinic) (JJ cholinergic) (NN system)))))))))))))))))) (. .)))
2429800	0	(S1 (NP (NP (NP (JJ Doc_2429800_0_9_Chemical) (NNS antagonists)) (CC and) (NP (JJ Doc_2429800_26_40_Chemical-induced) (NN Doc_2429800_49_60_Disease))) (PP (IN in) (NP (JJ cardiac) (JJ surgical) (NNS patients))) (. .)))
2429800	1	(S1 (S (NP (NP (NP (JJ Hemodynamic) (NNS effects)) (CC and) (NP (JJ Doc_2429800_115_124_Chemical) (NN release))) (PP (IN by) (NP (NP (JJ bolus) (NN injection)) (PP (IN of) (NP (NP (CD 0.35) (NN mg/kg)) (PP (IN of) (NP (NNP Doc_2429800_169_183_Chemical)))))))) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (CD 24) (NNS patients))))) (. .)))
2429800	2	(S1 (S (NP (NP (ADJP (JJ H1-) (CC and) (JJ H2-Doc_2429800_224_233_Chemical)) (NNS antagonists)) (CC or) (NP (NN placebo))) (VP (AUX were) (VP (VBN given) (PP (IN before) (S (VP (VBG dosing) (PP (IN with) (NP (NNP Doc_2429800_287_301_Chemical))) (PP (IN in) (NP (DT a) (JJ randomized) (JJ double-blind) (NN fashion))) (PP (TO to) (NP (NP (CD four) (NNS groups)) (: :) (NP (NP (NN group) (NN 1--placebo)) (: ;) (NP (NP (NN group) (NN 2--Doc_2429800_382_392_Chemical)) (, ,) (NP (CD 4) (NN mg/kg)) (, ,) (CC plus) (NP (NN placebo))) (: ;) (NP (NP (NN group) (NN 3--Doc_2429800_426_442_Chemical)) (, ,) (NP (CD 0.1) (NN mg/kg)) (, ,) (CC plus) (NP (NN placebo))) (: ;) (CC and) (NP (NN group) (NN 4--Doc_2429800_482_492_Chemical)) (CC plus) (NP (NNP Doc_2429800_498_514_Chemical)))))))))) (. .)))
2429800	3	(S1 (S (NP (JJ Doc_2429800_516_525_Chemical) (NN release)) (VP (VBD occurred) (PP (IN in) (NP (JJS most) (NNS patients))) (, ,) (NP (NP (DT the) (JJS highest) (NN level)) (PP (NP (CD 2) (NNS minutes)) (IN after) (NP (JJ Doc_2429800_595_609_Chemical) (NN dosing))))) (. .)))
2429800	4	(S1 (S (NP (NNP Group) (CD 1)) (VP (AUX had) (NP (NP (DT a) (JJ moderate) (JJ negative) (NN correlation)) (PP (IN between) (NP (NP (NN plasma) (JJ Doc_2429800_677_686_Chemical) (NN change)) (CC and) (NP (JJ systemic) (JJ vascular) (NN resistance)))) (PRN (-LRB- -LRB-) (NP (NP (QP (SYM r) (SYM =) (CD 0.58))) (: ;) (NP (QP (RB P) (JJR less) (IN than) (CD 0.05)))) (-RRB- -RRB-)) (ADJP (RB not) (JJ present) (PP (IN in) (NP (NN group) (CD 4)))))) (. .)))
2429800	5	(S1 (S (NP (NP (JJ Prior) (NN dosing)) (PP (IN with) (NP (NNS antagonists)))) (ADVP (RB partially)) (VP (VBD prevented) (NP (DT the) (NN fall)) (PP (IN in) (NP (JJ systemic) (NN vascular) (NN resistance)))) (. .)))
2429800	6	(S1 (S (NP (DT These) (NNS data)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (DT the) (JJ hemodynamic) (NNS changes)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_2429800_940_954_Chemical) (NN dosing))))) (VP (AUX are) (ADVP (RB only) (RB partially)) (VP (VBN explained) (PP (IN by) (NP (JJ Doc_2429800_994_1003_Chemical) (NN release)))))))) (. .)))
2429800	7	(S1 (S (NP (NP (RB Thus) (JJ prior) (NN dosing)) (PP (IN with) (NP (NP (NNP H1-)) (CC and) (NP (NNP H2-antagonists))))) (VP (VBZ provides) (NP (ADJP (RB only) (JJ partial)) (NN protection))) (. .)))
24309294	0	(S1 (S (NP (NN Doc_24309294_0_15_Chemical-Doc_24309294_16_27_Chemical)) (VP (VBD restored) (NP (NP (JJ Doc_24309294_37_45_Chemical-induced) (JJ hippocampal) (JJ long-term) (NN potentiation) (NN impairment)) (PP (IN in) (NP (NNS rats))))) (. .)))
24309294	1	(S1 (S (NP (NP (NP (NNP Doc_24309294_109_124_Chemical-Doc_24309294_125_136_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP CCK-8)) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (NP (DT a) (JJ typical) (JJ brain-gut) (NN peptide))))) (, ,)) (VP (VBZ exerts) (NP (NP (DT a) (JJ wide) (NN range)) (PP (IN of) (NP (JJ biological) (NNS activities)))) (PP (IN on) (NP (DT the) (JJ central) (JJ nervous) (NN system)))) (. .)))
24309294	2	(S1 (S (NP (PRP We)) (VP (AUX have) (ADVP (RB previously)) (VP (VBN reported) (SBAR (IN that) (S (NP (NNS CCK-8)) (VP (VP (ADVP (RB significantly)) (VBD alleviated) (NP (JJ Doc_24309294_324_332_Chemical-induced) (NNP Doc_24309294_341_348_Disease))) (CC and) (VP (VBD reversed) (NP (NN spine) (NN density) (NNS decreases)) (PP (IN in) (NP (NP (DT the) (JJ CA1) (NN region)) (PP (IN of) (NP (DT the) (NN hippocampus))) (PP (IN in) (NP (JJ Doc_24309294_426_434_Chemical-treated) (NNS animals))))))))))) (. .)))
24309294	3	(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NP (JJ CCK-8)) (PP (IN on) (NP (NP (JJ long-term) (NN potentiation)) (PRN (-LRB- -LRB-) (NP (NNP LTP)) (-RRB- -RRB-)))) (PP (IN in) (NP (DT the) (JJ lateral) (NN perforant) (NN path)))) (PRN (-LRB- -LRB-) (NP (NNP LPP)) (-RRB- -RRB-)) (NP (NP (JJ -granule) (NN cell) (NN synapse)) (PP (IN of) (NP (NP (NN rat) (NN dentate) (NNS gyrus)) (PRN (-LRB- -LRB-) (NP (NNP DG)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (JJ acute) (NN saline)) (CC or) (NP (JJ Doc_24309294_629_637_Chemical-treated) (NNS rats))))))))) (. .)))
24309294	4	(S1 (S (NP (NP (NP (NN Population) (NNS spikes)) (PRN (-LRB- -LRB-) (NP (NNP PS)) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VBN evoked) (PP (IN by) (NP (NP (NN stimulation)) (PP (IN of) (NP (DT the) (NNP LPP))))))))) (, ,)) (VP (AUX were) (VP (VBN recorded) (PP (IN in) (NP (DT the) (CD DG) (NN region))))) (. .)))
24309294	5	(S1 (S (S (NP (JJ Acute) (NNP Doc_24309294_759_767_Chemical) (PRN (-LRB- -LRB-) (NP (NP (NN 30mg/kg)) (, ,) (NP (NNP s.c.))) (-RRB- -RRB-)) (NN treatment)) (VP (ADVP (RB significantly)) (VBD attenuated) (NP (JJ hippocampal) (NN LTP)))) (CC and) (S (NP (NP (NN CCK-8)) (PRN (-LRB- -LRB-) (NP (NN 1ug)) (, ,) (NP (NN i.c.v.)) (-RRB- -RRB-))) (VP (VBD restored) (NP (NP (DT the) (NN amplitude)) (PP (IN of) (NP (NNP PS))) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (VP (VBN attenuated) (PP (IN by) (NP (JJ Doc_24309294_911_919_Chemical) (NN injection)))))))))) (. .)))
24309294	6	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN microinjection)) (PP (IN of) (NP (NN CCK-8))) (PRN (-LRB- -LRB-) (NP (CD 0.1) (CC and) (CD 1ug) (, ,) (CD i.c.v.)) (-RRB- -RRB-))) (ADVP (RB also)) (VP (ADVP (RB significantly)) (VBD augmented) (NP (NP (JJ hippocampal) (NNS LTP)) (PP (IN in) (NP (JJ saline-treated) (PRN (-LRB- -LRB-) (NP (NP (NN 1ml/kg)) (, ,) (NP (NNP s.c.))) (-RRB- -RRB-)) (NNS rats))))) (. .)))
24309294	7	(S1 (S (S (NP (NP (NN Pre-treatment)) (PP (IN of) (NP (NP (DT the) (JJ CCK2) (NN receptor) (NN antagonist) (NNP Doc_24309294_1120_1125_Chemical,260)) (PRN (-LRB- -LRB-) (NP (NN 10ug)) (, ,) (NP (NN i.c.v)) (-RRB- -RRB-))))) (VP (VBD reversed) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN CCK-8)))))) (, ,) (CC but) (S (NP (NP (DT the) (ADJP (CD CCK1) (NN receptor)) (NN antagonist) (NN L-364,718)) (PRN (-LRB- -LRB-) (NP (NN 10ug)) (, ,) (NP (NN i.c.v)) (-RRB- -RRB-))) (VP (AUX did) (RB not))) (. .)))
24309294	8	(S1 (S (NP (DT The) (JJ present) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NN CCK-8)) (VP (VP (VBZ attenuates) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_24309294_1309_1317_Chemical))) (PP (IN on) (NP (JJ hippocampal) (NNS LTP)))) (PP (IN through) (NP (JJ CCK2) (NNS receptors)))) (CC and) (VP (VBP suggest) (NP (NP (DT an) (JJ ameliorative) (NN function)) (PP (IN of) (NP (NN CCK-8)))) (PP (IN on) (NP (JJ Doc_24309294_1409_1417_Chemical-induced) (NNP Doc_24309294_1426_1443_Disease)))))))) (. .)))
24333387	0	(S1 (NP (NP (NP (JJ Glial) (NN activation)) (CC and) (NP (NN post-Doc_24333387_26_48_Disease))) (: :) (NP (NP (DT the) (JJ key) (NNS events)) (PP (IN in) (NP (NP (NNP Doc_24333387_68_82_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP ICV)) (-RRB- -RRB-)))) (VP (VBN induced) (NP (NNP Doc_24333387_97_114_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
24333387	1	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (JJ glial) (NN activation)) (CC and) (NP (NN post) (JJ synaptic) (NN Doc_24333387_192_200_Disease)))) (PP (IN in) (NP (NNP ICV) (NNP Doc_24333387_208_222_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_24333387_224_227_Chemical)) (-RRB- -RRB-)) (VBN induced) (NNP Doc_24333387_237_252_Disease) (NNS rats)))) (VP (AUX was) (VP (VBN explored))) (. .)))
24333387	2	(S1 (S (S (PP (IN In) (NP (NN experiment))) (VP (VBD set) (PRT (RP up)) (NP (CD 1)))) (: :) (S (NP (NNP Doc_24333387_296_310_Disease)) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NNP Morris) (NN water) (NN maze) (NN test))) (PP (IN on) (NP (CD 14-16) (NNS days))) (PP (IN after) (NP (NNP Doc_24333387_367_370_Chemical) (PRN (-LRB- -LRB-) (NP (NP (NNP ICV)) (: ;) (NP (CD 3mg/Kg))) (-RRB- -RRB-)) (NN administration)))))) (. .)))
24333387	3	(S1 (S (NP (JJ Doc_24333387_401_404_Chemical) (NNS causes)) (VP (VBD increased) (NP (NP (NN expression)) (PP (IN of) (NP (NP (NNP GFAP)) (, ,) (NP (NNP CD11b)) (CC and) (NP (NNP TNF-a))))) (S (VP (VBG indicating) (NP (JJ glial) (NN activation) (CC and) (NN neuroinflammation))))) (. .)))
24333387	4	(S1 (S (NP (NN Doc_24333387_509_512_Chemical)) (ADVP (RB also)) (VP (VP (ADVP (RB significantly)) (VBD increased) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NNP ROS) (, ,) (NNP Doc_24333387_560_567_Chemical) (, ,) (NNP Doc_24333387_569_575_Chemical))))) (CC and) (VP (VBD reduced) (NP (NP (DT the) (JJ mitochondrial) (NN activity)) (PP (IN in) (NP (NP (JJ synaptosomal) (NN preparation)) (VP (VBG illustrating) (NP (NP (JJ free) (JJ radical) (NN generation)) (CC and) (NP (NN excitotoxicity))))))))) (. .)))
24333387	5	(S1 (S (NP (NP (JJ Increased) (NN expression) (CC and) (NN activity)) (PP (IN of) (NP (NNP Caspase-3)))) (VP (AUX was) (ADVP (RB also)) (VP (VBN observed) (PP (IN in) (NP (NP (JJ Doc_24333387_768_771_Chemical) (VBN treated) (NN rat)) (SBAR (WHNP (WDT which)) (S (VP (VB specify) (NP (JJ apoptotic) (NN cell) (NN death)) (PP (IN in) (NP (NP (NN hippocampus)) (CC and) (NP (NN cortex))))))))))) (. .)))
24333387	6	(S1 (S (NP (JJ Doc_24333387_846_849_Chemical) (NN treatment)) (VP (VBD showed) (NP (NP (NN decrease) (NN expression)) (PP (IN of) (NP (JJ post) (JJ synaptic) (NNS markers) (NNP CaMKIIa) (CC and) (NNP PSD-95)))) (, ,) (SBAR (IN while) (, ,) (S (NP (NP (NN expression)) (PP (IN of) (NP (JJ pre) (JJ synaptic) (NNS markers))) (PRN (-LRB- -LRB-) (NP (NP (NN synaptophysin)) (CC and) (NP (CD SNAP-25))) (-RRB- -RRB-))) (VP (VBZ remains) (ADJP (JJ unaltered)) (S (VP (VBG indicating) (NP (JJ selective) (NN post) (NN Doc_24333387_1046_1068_Disease)))))))) (. .)))
24333387	7	(S1 (S (NP (NP (JJ Oral) (NN treatment)) (PP (IN with) (NP (NP (NP (NNP Doc_24333387_1090_1099_Chemical)) (PRN (-LRB- -LRB-) (NP (NN 10mg/kg)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_24333387_1114_1123_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg/kg)) (-RRB- -RRB-))))) (ADVP (RB daily)) (PP (IN for) (NP (CD 13) (NNS days)))) (VP (VBD attenuated) (NP (NP (JJ Doc_24333387_1164_1167_Chemical) (VBN induced) (JJ glial) (NN activation)) (, ,) (NP (NP (JJ apoptotic) (NN cell) (NN death) (CC and) (NN post)) (ADJP (JJ Doc_24333387_1224_1246_Disease) (PP (IN in) (NP (NN rat) (NN brain))))))) (. .)))
24333387	8	(S1 (S (ADVP (RBR Further)) (, ,) (PP (IN in) (NP (NN experiment))) (VP (VBD set) (ADVP (RB up) (NP (CD 2))) (: :) (SBAR (WHADVP (WRB where)) (S (NP (NN memory) (NN function)) (VP (AUX was) (RB not) (VP (VBN affected) (ADVP (FW i.e.) (NP (CD 7-9) (NNS days))) (PP (IN after) (NP (JJ Doc_24333387_1353_1356_Chemical) (NN treatment)))))))) (. .)))
24333387	9	(S1 (S (NP (NP (DT The) (NN level)) (PP (IN of) (NP (NNP GFAP) (, ,) (NNP CD11b) (, ,) (NNP TNF-a) (, ,) (NNP ROS) (CC and) (NNP Doc_24333387_1409_1416_Chemical) (NNS levels)))) (VP (AUX were) (VP (VBN increased))) (. .)))
24333387	10	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NP (JJ apoptotic) (NN marker)) (, ,) (NP (JJ synaptic) (NN markers)) (, ,) (NP (JJ mitochondrial) (NN activity)) (CC and) (NP (JJ Doc_24333387_1522_1528_Chemical) (NNS levels))) (VP (VBD remained) (ADJP (JJ unaffected))) (. .)))
24333387	11	(S1 (S (NP (JJ Collective) (NN data)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NP (JJ neuroinflammatory) (NN process)) (CC and) (NP (JJ oxidative) (NN stress))) (VP (VP (VBZ occurs) (ADVP (RB earlier)) (PP (TO to) (NP (NN apoptosis)))) (CC and) (VP (AUX does) (RB not) (VP (VB affect) (NP (NN memory) (NN function)))))))) (. .)))
24333387	12	(S1 (S (NP (JJ Present) (NN study)) (ADVP (RB clearly)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (JJ glial) (NN activation) (CC and) (NN post) (NN Doc_24333387_1762_1784_Disease)) (VP (AUX are) (NP (NP (DT the) (JJ key) (NNS factors)) (PP (IN in) (NP (NP (JJ Doc_24333387_1808_1811_Chemical) (VBN induced) (NN Doc_24333387_1820_1837_Disease)) (CC and) (NP (JJ neuronal) (NN cell) (NN death))))))))) (. .)))
24341598	0	(S1 (NP (NP (NN Comparison)) (PP (IN of) (NP (NP (NNS effects)) (PP (IN of) (NP (NNP Doc_24341598_25_49_Chemical))))) (PP (IN with) (NP (NNP Doc_24341598_55_64_Chemical))) (PP (IN in) (NP (NP (NN prevention)) (PP (IN of) (NP (JJ contrast-induced) (NNP Doc_24341598_99_110_Disease))))) (. .)))
24341598	1	(S1 (NP (NP (NP (NN INTRODUCTION)) (CC AND) (NP (NN OBJECTIVE))) (: :) (S (NP (NP (NNP Doc_24341598_140_168_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24341598_170_173_Disease)) (-RRB- -RRB-))) (VP (ADVP (RB significantly)) (VBZ increases) (NP (NP (DT the) (NN morbidity) (CC and) (NN mortality)) (PP (IN of) (NP (NNS patients)))))) (. .)))
24341598	2	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX is) (S (VP (TO to) (VP (VB investigate) (CC and) (VB compare) (NP (NP (DT the) (JJ protective) (NNS effects)) (PP (IN of) (NP (NNP Doc_24341598_318_342_Chemical))) (PP (IN with) (NP (NP (JJ Doc_24341598_348_366_Chemical) (NN infusion)) (CC and) (NP (JJ Doc_24341598_380_404_Chemical) (NN infusion))))) (PP (IN with) (NP (NP (NP (NNP Doc_24341598_419_428_Chemical)) (, ,) (NP (DT a) (NNP Doc_24341598_432_439_Chemical) (NN channel) (NN blocker)) (, ,)) (PP (IN in) (S (VP (VBG preventing) (NP (NNP Doc_24341598_471_474_Disease))))))))))) (. .)))
24341598	3	(S1 (FRAG (NP (NNS MATERIALS) (CC AND) (NNS METHODS)) (: :) (S (NP (PRP$ Our) (NN study)) (VP (VBD included) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN administered) (NP (NP (NP (CD 30-60) (NNS mL)) (PP (IN of) (NP (JJ iodinated) (NN contrast) (NN agent))) (PP (IN for) (NP (JJ percutaneous) (JJ coronary) (NN angiography))) (PRN (-LRB- -LRB-) (NP (NNP PCAG)) (-RRB- -RRB-))) (, ,) (NP (NP (DT all)) (PP (IN with) (NP (NP (JJ Doc_24341598_641_651_Chemical) (NNS values)) (PP (IN between) (NP (QP (CD 1.1) (CC and) (CD 3.1) (CD mg/dL))))))))))))))) (. .)))
24341598	4	(S1 (S (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN divided) (PP (IN into) (NP (CD three) (NNS groups)))))) (CC and) (S (NP (DT each) (NN group)) (VP (AUX had) (NP (CD 20) (NNS patients)))) (. .)))
24341598	5	(S1 (S (S (NP (NP (DT The) (JJ first) (NN group)) (PP (IN of) (NP (NNS patients)))) (VP (AUX was) (VP (VBN administered) (NP (NNP Doc_24341598_803_827_Chemical))))) (: ;) (S (NP (DT the) (JJ second) (NN group)) (VP (AUX was) (VP (VBN administered) (NP (NP (DT a) (NN solution)) (SBAR (WHNP (WDT that)) (S (NP (QP (IN of) (CD 5)) (NN %)) (ADJP (JJ Doc_24341598_885_893_Chemical) (CC and) (JJ Doc_24341598_898_916_Chemical))))) (, ,) (SBAR (IN while) (S (NP (DT the) (JJ third) (NN group)) (VP (AUX was) (VP (VBN administered) (NP (NNP Doc_24341598_957_981_Chemical)) (PP (IN before) (CC and) (IN after) (NP (DT the) (NN contrast) (NN injection)))))))))) (. .)))
24341598	6	(S1 (S (NP (DT The) (JJ third) (NN group)) (VP (VBD received) (NP (NP (DT an) (JJ additional) (NN injection)) (PP (IN of) (NP (NNP Doc_24341598_1075_1084_Chemical)))) (NP (DT the) (NN day)) (PP (IN before) (NP (QP (CC and) (RB first) (CD 2)) (NNS days))) (PP (IN after) (NP (DT the) (NN contrast) (NN injection)))) (. .)))
24341598	7	(S1 (S (NP (NP (DT All)) (PP (IN of) (NP (NP (NP (NP (DT the) (NNS patients) (POS ')) (NN plasma) (NN blood) (NNP Doc_24341598_1181_1194_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP BUN)) (-RRB- -RRB-))) (CC and) (NP (JJ Doc_24341598_1205_1215_Chemical) (NNS levels))))) (VP (AUX were) (VP (VBN measured) (PP (IN on) (NP (NP (DT the) (JJ second) (CC and) (JJ seventh) (NN day)) (PP (IN after) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (JJ intravenous) (NN contrast) (NN material))))))))) (. .)))
24341598	8	(S1 (S (NP (DT The) (JJ basal) (JJ Doc_24341598_1345_1355_Chemical) (NNS levels)) (VP (AUX were) (ADJP (JJ similar) (PP (IN for) (NP (NP (DT all) (CD three) (NNS groups)) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD >) (CD 0.05))) (-RRB- -RRB-)))))) (. .)))
24341598	9	(S1 (S (PP (IN Among) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (NP (CD 60) (NNS patients)) (VP (VBN included) (PP (IN in) (NP (DT the) (NN study)))))))) (, ,) (NP (CD 16) (NNS patients)) (VP (VBD developed) (NP (NP (NNP Doc_24341598_1483_1502_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24341598_1504_1507_Disease)) (-RRB- -RRB-))) (PP (IN on) (NP (DT the) (JJ second) (NN day))) (SBAR (IN after) (S (NP (NN contrast) (NN material)) (VP (AUX was) (VP (VBN injected) (PRN (-LRB- -LRB-) (NP (CD 26.6) (NN %)) (-RRB- -RRB-))))))) (. .)))
24341598	10	(S1 (S (S (NP (NP (DT The) (NN number)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_24341598_1610_1613_Disease)) (PP (IN on) (NP (DT the) (JJ second) (NN day))) (PP (IN after) (NP (NP (DT the) (NN injection)) (PP (IN in) (NP (DT the) (JJ first) (NN group) (S (VP (AUX was) (NP (NP (CD five)) (PRN (-LRB- -LRB-) (NP (CD 25) (NN %)) (-RRB- -RRB-))))))))) (, ,) (PP (IN in) (NP (DT the) (JJ second) (NN group))))))))) (VP (AUX was) (NP (NP (CD six)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN %)) (-RRB- -RRB-))))) (CC and) (S (NP (DT the) (JJ third) (NN group)) (VP (AUX was) (NP (NP (NP (CD five)) (PRN (-LRB- -LRB-) (NP (CD 25) (NN %)) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NNP p) (NNP >) (CD 0.05)) (-RRB- -RRB-)))) (. .)))
24341598	11	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN between) (NP (NP (NNP Doc_24341598_1824_1848_Chemical)) (, ,) (NP (NNP Doc_24341598_1850_1868_Chemical)) (CC and) (NP (NNP Doc_24341598_1873_1897_Chemical)))) (PP (IN with) (NP (NP (JJ Doc_24341598_1903_1912_Chemical) (NN application)) (PP (IN in) (NP (NP (NN prevention)) (PP (IN of) (NP (NNP Doc_24341598_1942_1945_Disease))))))))) (. .)))
24345882	0	(S1 (NP (NP (NP (ADJP (JJ Neurocognitive) (CC and) (JJ neuroradiologic)) (JJ central) (JJ nervous) (NN system) (JJ late) (NNS effects)) (PP (IN in) (NP (NP (NNS children)) (VP (VBN treated) (PP (IN on) (NP (NP (NP (NNP Pediatric) (NNP Oncology) (NNP Group) (PRN (-LRB- -LRB-) (NP (NNP POG)) (-RRB- -RRB-)) (NNP Doc_24345882_125_130_Chemical)) (PRN (-LRB- -LRB-) (NP (JJ standard) (NN risk)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_24345882_151_156_Chemical) (PRN (-LRB- -LRB-) (NP (JJR lesser) (NN risk)) (-RRB- -RRB-)) (NNP Doc_24345882_171_199_Disease) (NNS protocols)) (PRN (-LRB- -LRB-) (NP (CD ACCL0131)) (-RRB- -RRB-))))))))) (: :) (NP (DT a) (JJ methotrexate) (NN consequence)) (. ?)))
24345882	1	(S1 (NP (NP (DT A) (NN report)) (PP (IN from) (NP (NP (DT the) (NNS Children) (POS 's)) (NNP Oncology) (NNP Group))) (. .)))
24345882	2	(S1 (S (NP (NP (NNS Concerns)) (PP (IN about) (NP (NP (JJ long-term) (NNP Doc_24345882_320_332_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_24345882_334_337_Chemical)) (-RRB- -RRB-)) (NNP Doc_24345882_339_352_Disease)) (PP (IN in) (NP (DT the) (NNS 1990s)))))) (VP (VBD led) (PP (TO to) (NP (NP (NNS modifications)) (PP (IN in) (NP (NP (JJ intrathecal) (PRN (-LRB- -LRB-) (NP (PRP IT)) (-RRB- -RRB-)) (NN therapy)) (, ,) (NP (NN leucovorin) (NN rescue)) (, ,) (CC and) (NP (NP (NN frequency)) (PP (IN of) (NP (JJ systemic) (NNP Doc_24345882_461_464_Chemical) (NN administration))) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (NNP Doc_24345882_497_525_Disease))))))))))) (. .)))
24345882	3	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (NP (JJ neurocognitive) (NNS outcomes)) (CC and) (NP (NP (JJ neuroradiologic) (NN evidence)) (PP (IN of) (NP (NNP Doc_24345882_598_617_Disease))))) (VP (AUX were) (VP (VBN compared) (PP (IN in) (NP (NP (NNS children)) (VP (VBN treated) (PP (IN with) (S (NP (NP (JJ intense) (JJ central) (JJ nervous) (NN system)) (PRN (-LRB- -LRB-) (NP (NNP CNS)) (-RRB- -RRB-)) (NP (NP (JJ -directed) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NNP P9605)) (-RRB- -RRB-))) (CC versus) (NP (DT those))) (VP (VBG receiving) (NP (JJR fewer) (JJ CNS-directed) (NN treatment) (NNS days)) (PP (IN during) (NP (NP (JJ intensive) (NN consolidation)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24345882_808_813_Chemical)) (-RRB- -RRB-)))))))))))) (. .)))
24345882	4	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (CD 66) (NNS children)) (PP (IN from) (NP (CD 16) (JJ Pediatric) (NNP Oncology) (NNP Group) (NNS institutions))) (PP (IN with) (NP (NP (`` ``) (JJ standard-risk) ('' '') (NNP Doc_24345882_906_934_Disease)) (, ,) (NP (NP (QP (CD 1.00) (TO to) (CD 9.99)) (NNS years)) (PP (IN at) (NP (NN diagnosis))) (, ,) (PP (IN without) (NP (NP (NN evidence)) (PP (IN of) (NP (NNP Doc_24345882_989_1001_Disease))) (PP (IN at) (NP (NN diagnosis))))))))))) (VP (AUX were) (VP (VBD enrolled) (PP (IN on) (NP (NP (CD ACCL0131)) (: :) (NP (NP (NP (CD 28)) (PP (IN from) (NP (NNP Doc_24345882_1050_1055_Chemical)))) (CC and) (NP (NP (CD 38)) (PP (IN from) (NP (CD P9605))))))))) (. .)))
24345882	5	(S1 (S (NP (NP (JJ Magnetic) (NN resonance) (NN imaging) (NNS scans)) (CC and) (NP (JJ standard) (NN neuropsychological) (NNS tests))) (VP (AUX were) (VP (VBN performed) (NP (CD >2.6) (NNS years)) (PP (IN after) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (NN treatment))))))) (. .)))
24345882	6	(S1 (S (NP (ADJP (RB Significantly) (JJR more)) (NNP P9605) (NNS patients)) (VP (VBD developed) (NP (NNP Doc_24345882_1244_1263_Disease)) (PP (VBN compared) (PP (IN with) (NP (NP (NP (JJ Doc_24345882_1278_1283_Chemical) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD 68) (NN %)) (, ,) (NP (NP (NP (NP (ADJP (CD 95) (NN %)) (NN confidence)) (JJ interval) (CD 49) (NN %)) (NP (CD -83) (NN %))) (PP (IN vs.) (NP (CD 22) (NN %)))) (, ,) (NP (NP (ADJP (CD 95) (NN %)) (NN confidence)) (JJ interval) (CD 5) (NN %))) (NP (CD -44) (NN %))) (: ;) (NP (NNP P=0.001))) (-RRB- -RRB-))) (VP (VBN identified) (PP (NP (QP (RB as) (JJ late) (IN as) (CD 7.7)) (NNS years)) (IN after) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (NN treatment)))))))))) (. .)))
24345882	7	(S1 (S (ADVP (RB Overall)) (, ,) (NP (NP (CD 40) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (VBD scored) (NP (CD <85)) (PP (IN on) (NP (NP (DT either) (JJ Verbal)) (CC or) (NP (NNP Performance) (NNP IQ))))) (. .)))
24345882	8	(S1 (S (S (NP (NP (NNS Children)) (PP (IN on) (NP (DT both) (NNS studies)))) (VP (AUX had) (NP (JJ significant) (NN attention) (NNS problems)))) (, ,) (CC but) (S (NP (NNP P9605) (NNS children)) (VP (VBD scored) (PP (IN below) (NP (NN average))) (PP (IN on) (NP (NP (ADJP (RBR more) (JJ neurocognitive)) (NNS measures)) (PP (IN than) (NP (NP (DT those)) (VP (VBN treated) (PP (IN on) (NP (NP (NNP Doc_24345882_1668_1673_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 82) (NN %)) (, ,) (NP (CD 14/17) (NNS measures))) (CC vs.) (NP (NP (CD 24) (NN %)) (, ,) (NP (CD 4/17) (NNS measures)))) (-RRB- -RRB-))))))))))) (. .)))
24345882	9	(S1 (S (NP (DT This)) (VP (VBZ supports) (NP (NP (JJ ongoing) (NNS concerns)) (PP (IN about) (NP (JJ intensive) (JJ Doc_24345882_1767_1770_Chemical) (NN exposure)))) (PP (IN as) (NP (NP (DT a) (JJ major) (NN contributor)) (PP (TO to) (NP (JJ CNS) (JJ late) (NNS effects)))))) (. .)))
24434397	0	(S1 (S (NP (JJ Doc_24434397_0_15_Chemical) (NN overdosage-induced)) (VP (VBD generalized) (NP (NNP Doc_24434397_47_54_Disease)) (PP (IN in) (NP (NNP Doc_24434397_58_71_Disease)))) (. .)))
24434397	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (JJ 45-year-old) (NN lady)) (PP (IN with) (NP (NP (JJ chronic) (NNP Doc_24434397_115_129_Disease) (NN stage) (CD 4)) (PP (JJ due) (TO to) (NP (JJ chronic) (NNP Doc_24434397_153_177_Disease))))))) (. .)))
24434397	2	(S1 (S (NP (PRP She)) (VP (AUX was) (VP (VBN admitted) (PP (TO to) (NP (PRP$ our) (NN center))) (PP (IN for) (NP (NP (NP (JJ severe) (NN Doc_24434397_221_227_Disease)) (PP (JJ due) (TO to) (NP (NNP Doc_24434397_235_246_Disease)))) (CC and) (NP (NP (NN deterioration)) (PP (IN of) (NP (JJ renal) (NN function)))))))) (. .)))
24434397	3	(S1 (S (NP (PRP She)) (VP (AUX was) (VP (VBN infused) (NP (NP (CD three) (NNS units)) (PP (IN of) (NP (VBN packed) (NNS cells)))) (PP (IN during) (NP (NP (DT a) (NN session)) (PP (IN of) (NP (NN hemodialysis))))))) (. .)))
24434397	4	(S1 (S (NP (JJ Doc_24434397_362_377_Chemical) (PRN (-LRB- -LRB-) (NP (NNP TNA)) (-RRB- -RRB-)) (CD 1) (NNP g) (NN 8-hourly)) (VP (AUX was) (VP (VBN administered) (PP (TO to) (NP (PRP her))) (S (VP (TO to) (VP (VB control) (NP (NNP Doc_24434397_432_440_Disease)) (PP (IN per) (NP (NN vaginum)))))))) (. .)))
24434397	5	(S1 (S (PP (NP (CD Two) (NNS hours)) (IN after) (NP (NP (DT the) (JJ sixth) (NN dose)) (PP (IN of) (NP (NNP TNA))))) (, ,) (NP (PRP she)) (VP (AUX had) (NP (NP (DT an) (NN episode)) (PP (IN of) (NP (JJ generalized) (NNP Doc_24434397_527_551_Disease))))) (. .)))
24434397	6	(S1 (S (NP (NNP TNA)) (VP (AUX was) (VP (VBN discontinued))) (. .)))
24434397	7	(S1 (S (NP (NP (NNS Investigations)) (PP (IN of) (NP (DT the) (NN patient)))) (VP (VBD revealed) (NP (NP (DT no) (ADJP (JJ biochemical) (CC or) (JJ structural)) (JJ central) (NN Doc_24434397_651_679_Disease)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (AUX have) (VP (VBN provoked) (NP (DT the) (NNP Doc_24434397_709_720_Disease))))))))) (. .)))
24434397	8	(S1 (S (NP (PRP She)) (VP (AUX did) (RB not) (VP (VB require) (NP (DT any) (JJ further) (JJ dialytic) (NN support)))) (. .)))
24434397	9	(S1 (S (NP (PRP She)) (VP (AUX had) (NP (NP (DT no) (JJ further) (NNS episodes)) (PP (IN of) (NP (NNP Doc_24434397_803_813_Disease)))) (PP (PP (IN till) (NP (NN dis-charge))) (CC and) (PP (IN during) (NP (NP (DT the) (CD two) (NNS months)) (PP (IN of) (NP (NN follow-up))))))) (. .)))
24434397	10	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (DT the) (VBG precipitating) (NN cause)) (PP (IN of) (NP (NNP Doc_24434397_903_914_Disease)))) (VP (AUX was) (VP (VBN believed) (S (VP (TO to) (VP (AUX be) (NP (NP (DT an) (NN Doc_24434397_937_945_Disease)) (PP (IN of) (NP (NNS TNA))))))))) (. .)))
24438483	0	(S1 (NP (NP (NN Pre-treatment)) (PP (IN of) (NP (NNP Doc_24438483_17_28_Chemical-induced) (NNP Doc_24438483_37_62_Disease))) (VP (VBG using) (NP (NP (JJ different) (NN lipid) (NNS formulations)) (PP (IN of) (NP (NNP Doc_24438483_101_109_Chemical))))) (. .)))
24438483	1	(S1 (S (S (NP (NP (NN Pre-treatment)) (PP (IN with) (NP (NN lipid) (NNS emulsions)))) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VB increase) (NP (NP (JJ lethal) (NNS doses)) (PP (IN of) (NP (NN Doc_24438483_201_212_Chemical))))))))))) (, ,) (CC and) (S (NP (NP (DT the) (NN lipid) (NN content)) (PP (IN of) (NP (NNP Doc_24438483_239_247_Chemical)))) (VP (MD may) (VP (VB alleviate) (NP (JJ Doc_24438483_262_273_Chemical-induced) (NN Doc_24438483_282_296_Disease))))) (. .)))
24438483	2	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX is) (S (VP (TO to) (VP (VP (VB investigate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_24438483_353_361_Chemical)))) (PP (IN in) (NP (NN intralipid)))) (CC or) (VP (VB medialipid) (NP (NNS emulsions)) (PP (IN on) (NP (JJ Doc_24438483_403_414_Chemical-induced) (NNP Doc_24438483_423_437_Disease)))))))) (. .)))
24438483	3	(S1 (S (NP (NNS Rats)) (VP (VP (AUX were) (VP (VBN anaesthetised) (PP (IN with) (NP (NNP Doc_24438483_477_485_Chemical))))) (CC and) (VP (AUX were) (VP (VBN given) (NP (CD 0.5) (NN mg/kg/min)) (NP (NP (NP (NP (NNP Doc_24438483_515_523_Chemical)) (PP (IN in) (NP (NN intralipid)))) (PRN (-LRB- -LRB-) (NP (NNP Group) (NNP P)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NNP Doc_24438483_549_557_Chemical)) (PP (IN in) (NP (NN medialipid)))) (PRN (-LRB- -LRB-) (NP (NNP Group) (NNP L)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NN saline)) (PRN (-LRB- -LRB-) (NP (NNP Group) (NNP C)) (-RRB- -RRB-)))) (PP (IN over) (NP (CD 20) (NN min)))))) (. .)))
24438483	4	(S1 (S (ADVP (RB Thereafter)) (, ,) (NP (CD 2) (JJ mg/kg/min) (NNP Doc_24438483_640_651_Chemical) (CD 0.5) (NN %)) (VP (AUX was) (VP (VBN infused))) (. .)))
24438483	5	(S1 (S (NP (PRP We)) (VP (VBD recorded) (NP (NN time)) (PP (TO to) (NP (NP (JJ first) (JJ Doc_24438483_696_707_Disease) (NN occurrence)) (, ,) (NP (NP (JJ respective) (NNS times)) (PP (TO to) (NP (NP (NP (QP (CD 25) (NN %) (CC and) (CD 50) (NN %)) (NN reduction)) (PP (IN of) (NP (NP (DT the) (NN heart) (NN rate)) (PRN (-LRB- -LRB-) (NP (NN HR)) (-RRB- -RRB-))))) (CC and) (NP (JJ mean) (JJ arterial) (NN pressure))))) (, ,) (CC and) (NP (NP (NN time)) (PP (TO to) (NP (NNP Doc_24438483_825_833_Disease)))) (CC and) (NP (NP (JJ total) (NN amount)) (PP (IN of) (NP (JJ Doc_24438483_854_865_Chemical) (NN consumption))))))) (. .)))
24438483	6	(S1 (S (NP (NN Blood) (CC and) (NN tissue) (NNS samples)) (VP (AUX were) (VP (VBN collected) (PP (VBG following) (NP (NN Doc_24438483_929_937_Disease))))) (. .)))
24438483	7	(S1 (S (NP (NP (NP (DT The) (NN time)) (PP (TO to) (NP (NP (JJ first) (JJ Doc_24438483_966_977_Disease) (NN occurrence)) (, ,) (NP (NP (NN time)) (PP (TO to) (NP (CD 25) (NN %)))) (CC and) (NP (NP (ADJP (CD 50) (NN %)) (NNS reductions)) (PP (IN in) (NP (NNP HR))))))) (, ,) (CC and) (NP (NN time)) (PP (TO to) (NP (NNP Doc_24438483_1040_1048_Disease)))) (VP (AUX were) (ADJP (ADJP (JJR longer) (PP (IN in) (NP (NNP Group) (NNP P)))) (PP (IN than) (NP (DT the) (JJ other) (NNS groups))))) (. .)))
24438483	8	(S1 (S (S (NP (NP (DT The) (JJ cumulative) (JJ Doc_24438483_1110_1121_Chemical) (NN dose)) (VP (VBN given) (PP (IN at) (NP (DT those) (NN time) (NNS points))))) (VP (AUX was) (ADJP (ADJP (JJR higher)) (SBAR (IN in) (S (NP (NNP Group) (NNP P.) (NN Plasma) (NN Doc_24438483_1184_1195_Chemical) (NNS levels)) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR lower) (PP (IN in) (NP (NNP Group) (NNP P)))) (SBAR (IN than) (S (PP (IN in) (NP (NP (NNP Group) (NNP C.) (NNP Doc_24438483_1256_1267_Chemical) (NNS levels)) (PP (IN in) (NP (DT the) (NN brain) (CC and) (NN heart))))) (VP (AUX were) (ADJP (ADJP (RB significantly) (JJR lower) (PP (IN in) (NP (NP (NNP Group) (NNP P)) (CC and) (NP (NNP Group) (NNP L))))) (PP (IN than) (PP (IN in) (NP (NNP Group) (NNP C.) (NN CONCLUSION))))))))))))))) (: :) (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (NN pre-treatment)) (PP (IN with) (NP (NP (NNP Doc_24438483_1411_1419_Chemical)) (PP (IN in) (NP (NN intralipid))))) (, ,) (VP (VBN compared) (PP (IN with) (NP (NP (NNP Doc_24438483_1449_1457_Chemical)) (PP (IN in) (NP (NN medialipid) (CC or) (NN saline)))))) (, ,)) (VP (VBD delayed) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NP (JJ Doc_24438483_1504_1515_Chemical-induced) (NNP Doc_24438483_1524_1535_Disease) (NNS effects)) (CONJP (RB as) (RB well) (IN as)) (NP (JJ reduced) (NN plasma) (NN Doc_24438483_1570_1581_Chemical) (NNS levels)))))))))) (. .)))
24438483	9	(S1 (S (NP (JJ Further) (NNS studies)) (VP (AUX are) (VP (VBN needed) (S (VP (TO to) (VP (VP (VB explore) (NP (NP (NN tissue) (NN Doc_24438483_1635_1646_Chemical) (NNS levels)) (PP (IN of) (NP (NNP Doc_24438483_1657_1665_Chemical)))) (PP (IN in) (NP (NN medialipid)))) (CC and) (VP (VB adapt) (NP (DT these) (NNS results)) (PP (TO to) (NP (JJ clinical) (NN practice))))))))) (. .)))
24451297	0	(S1 (NP (NP (JJ Drug-Induced) (JJ Acute) (NN Doc_24451297_19_31_Disease)) (PP (IN Within) (NP (NP (CD 12) (NNS Hours)) (PP (IN After) (NP (JJ Doc_24451297_54_65_Chemical) (NN Therapy))))) (. .)))
24451297	1	(S1 (S (SBAR (IN Although) (S (NP (NNP Doc_24451297_84_91_Chemical)) (VP (AUX are) (ADVP (RB generally)) (VP (VBN well-tolerated) (NP (NNS drugs)))))) (, ,) (NP (NP (JJ recent) (NNS cases)) (PP (IN of) (NP (NNP Doc_24451297_144_169_Disease))) (VP (VBN associated) (PP (IN with) (NP (PRP$ their) (NN use))))) (VP (AUX have) (VP (AUX been) (VP (VBN reported)))) (. .)))
24451297	2	(S1 (S (NP (DT A) (JJ 52-year-old) (JJ Chinese) (NN man)) (VP (VBD reported) (PP (IN with) (NP (NP (NNP Doc_24451297_256_268_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD appeared) (NP (CD 12) (NNS hours)) (PP (IN after) (S (VP (VBG beginning) (NP (NN treatment)) (PP (IN with) (NP (NNP Doc_24451297_325_336_Chemical)))))))))))) (. .)))
24451297	3	(S1 (S (NP (NN Patient)) (VP (VBD presented) (PP (IN with) (NP (NP (NNS complaints)) (PP (IN of) (S (VP (VBG increasing) (NP (NP (NNP Doc_24451297_386_392_Disease)) (, ,) (NP (NNP Doc_24451297_394_402_Disease)) (, ,) (CC and) (NP (JJ upper) (NN Doc_24451297_414_428_Disease))))))))) (. .)))
24451297	4	(S1 (S (NP (PRP$ His) (NN laboratory) (NNS values)) (VP (VBD showed) (NP (NP (JJ elevated) (JJ Doc_24451297_468_476_Chemical) (NN kinase)) (CC and) (NP (NNS transaminases)))) (. .)))
24451297	5	(S1 (S (NP (NP (NN Testing)) (PP (IN for) (NP (NNS autoantibodies)))) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ negative))) (. .)))
24451297	6	(S1 (S (NP (DT The) (NN liver) (NNS biochemistries)) (ADVP (RB eventually)) (VP (VBN normalized) (PP (IN within) (NP (NP (CD 3) (NNS weeks)) (PP (IN of) (S (VP (VBG stopping) (NP (DT the) (NNP Doc_24451297_627_638_Chemical)))))))) (. .)))
24451297	7	(S1 (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBG prescribing) (NP (NNS statins))))) (, ,) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NNP Doc_24451297_696_710_Disease)))) (VP (MD should) (VP (AUX be) (VP (VBN taken) (PP (IN into) (NP (NN account)))))) (. .)))
24459006	0	(S1 (S (NP (NN Doc_24459006_0_11_Chemical)) (VP (VBN associated) (NP (NP (NNP Doc_24459006_23_38_Disease)) (CC and) (NP (NNP Doc_24459006_43_59_Disease)))) (. .)))
24459006	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (JJ second) (NN case)) (PP (IN of) (NP (NNP Doc_24459006_96_107_Chemical))) (VP (VBN associated) (NP (NNP Doc_24459006_119_134_Disease)) (PP (IN with) (NP (NP (NN Doc_24459006_140_156_Disease)) (CC and) (NP (NN recovery)))))) (PP (IN upon) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NN therapy)))))) (. .)))
24459006	2	(S1 (S (NP (DT The) (NN patient)) (VP (VP (VBD began) (S (VP (TO to) (VP (AUX have) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (JJ white) (NN blood) (NNS cells)) (CC and) (NP (NNS platelets)))) (PP (IN within) (NP (NP (CD 48) (NNP h)) (PP (IN of) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_24459006_305_316_Chemical)))))))))))) (CC and) (VP (VBD began) (S (VP (TO to) (VP (VB recover) (PP (IN with) (NP (NP (CD 48) (NNP h)) (PP (IN of) (NP (NN discontinuation)))))))))) (. .)))
24459006	3	(S1 (S (NP (DT This) (NN case)) (VP (VBZ highlights) (SBAR (IN that) (S (NP (JJ drug-induced) (NN Doc_24459006_407_423_Disease)) (VP (MD can) (VP (VB occur) (ADVP (RB unexpectedly)) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NN treatment))) (PP (IN with) (NP (NP (DT a) (ADJP (RB commonly) (VBN used)) (NN drug)) (VP (VBN thought) (S (VP (TO to) (VP (AUX be) (ADJP (`` ``) (JJ safe) ('' ''))))))))))))))) (. .)))
24459006	4	(S1 (S (PP (VBG According) (PP (TO to) (NP (NP (NNP Naranjo) (POS 's)) (NN algorithm)))) (NP (DT the) (NN likelihood) (SBAR (IN that) (S (NP (NP (PRP$ our) (NN patient) (POS 's)) (NNP Doc_24459006_599_614_Disease) (CC and) (NNP Doc_24459006_619_635_Disease)) (VP (VBD occurred) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NN therapy))) (PP (IN with) (NP (NNP Doc_24459006_673_684_Chemical))))))))) (VP (AUX is) (ADJP (JJ probable)) (, ,) (PP (IN with) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD six) (NNS points)))))) (. .)))
24459006	5	(S1 (S (NP (PRP We)) (VP (VBP feel) (SBAR (IN that) (S (NP (NP (DT the) (NN weight)) (PP (IN of) (NP (NP (DT the) (JJ overall) (NN evidence)) (PP (IN of) (NP (DT this) (NN evidence)))))) (VP (AUX is) (ADJP (JJ strong)))))) (. .)))
24459006	6	(S1 (FRAG (PP (IN In) (NP (NP (NP (JJ particular) (DT the) (JJ temporal) (NN relationship)) (PP (IN of) (NP (NNP Doc_24459006_845_868_Disease))) (PP (TO to) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NNP Doc_24459006_890_901_Chemical)))))) (CC and) (NP (NP (DT the) (NN abatement)) (PP (IN of) (NP (NP (NNS symptoms)) (SBAR (WHNP (WDT that)) (S (VP (ADVP (RB rapidly)) (VBD reversed) (ADVP (RB immediately)) (PP (VBG following) (NP (NN discontinuation))))))))))) (. .)))
24464946	0	(S1 (S (NP (JJ Two-dimensional) (JJ speckle) (NN tracking) (NN echocardiography)) (VP (VBN combined) (PP (IN with) (NP (NP (JJ high-sensitive) (JJ cardiac) (NN troponin) (NNS T)) (PP (IN in) (NP (NP (JJ early) (NN detection)) (CC and) (NP (NP (NN prediction)) (PP (IN of) (NP (NNP Doc_24464946_135_149_Disease))) (PP (IN during) (NP (JJ Doc_24464946_157_168_Chemical-based) (NN chemotherapy))))))))) (. .)))
24464946	1	(S1 (S (VP (TO To) (VP (VB investigate) (SBAR (IN whether) (S (NP (NP (NP (NNS alterations)) (PP (IN of) (NP (NNP Doc_24464946_233_250_Disease)))) (CC and) (NP (NP (JJ high-sensitive) (JJ cardiac) (NN troponin) (NNS T)) (PRN (-LRB- -LRB-) (NP (NN cTnT)) (-RRB- -RRB-)))) (VP (MD could) (VP (VB predict) (NP (JJ future) (NN Doc_24464946_317_336_Disease)) (PP (IN in) (NP (NNS patients))) (PP (IN after) (NP (NNP Doc_24464946_355_365_Chemical) (NN exposure))))))))) (. .)))
24464946	2	(S1 (S (NP (NP (JJ Seventy-five) (NNS patients)) (PP (IN with) (NP (NNP Doc_24464946_412_432_Disease))) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_24464946_446_456_Chemical))))) (VP (AUX were) (VP (VBN studied))) (. .)))
24464946	3	(S1 (S (NP (NP (NN Blood) (NN collection)) (CC and) (NP (NN echocardiography))) (VP (AUX were) (VP (VBN performed) (PP (IN at) (NP (NP (NN baseline)) (, ,) (NP (NP (CD 1) (NN day)) (PP (IN after) (NP (DT the) (JJ third) (NN cycle)))) (, ,) (CC and) (NP (NP (CD 1) (NN day)) (PP (IN after) (NP (NP (NN completion)) (PP (IN of) (NP (NN chemotherapy)))))))))) (. .)))
24464946	4	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN studied) (S (VP (VBG using) (NP (NN echocardiography)) (PP (IN during) (NP (NN follow-up))))))) (. .)))
24464946	5	(S1 (S (NP (NP (NP (JJ Global) (JJ longitudinal) (PRN (-LRB- -LRB-) (NNS GLS) (-RRB- -RRB-) (, ,)) (JJ circumferential)) (PRN (-LRB- -LRB-) (NP (NNP GCS)) (-RRB- -RRB-))) (, ,) (CC and) (NP (JJ radial) (NN strain)) (PRN (-LRB- -LRB-) (NP (NNP GRS)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN calculated) (S (VP (VBG using) (NP (JJ speckle) (NN tracking) (NN echocardiography)))))) (. .)))
24464946	6	(S1 (S (NP (JJ Left) (NN ventricular) (NN ejection) (NN fraction)) (VP (AUX was) (VP (VBN analysed) (PP (IN by) (NP (JJ real-time) (NN 3D) (NN echocardiography))))) (. .)))
24464946	7	(S1 (S (NP (NN Doc_24464946_886_900_Disease)) (VP (AUX was) (VP (VBN defined) (PP (IN as) (NP (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (NP (DT the) (NN LVEF)) (PP (IN of) (NP (QP (CD >5) (NN %) (TO to) (CD <55)) (NN %))) (PP (IN with) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NNP Doc_24464946_972_985_Disease)))))))) (CC or) (NP (NP (DT an) (JJ asymptomatic) (NN reduction)) (PP (IN of) (NP (NP (DT the) (NN LVEF)) (PP (IN of) (NP (QP (CD >10) (NN %) (TO to) (CD <55) (NN %))))))))))) (. .)))
24464946	8	(S1 (S (NP (NP (CD Fourteen) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 18.67) (NN %)) (-RRB- -RRB-))) (VP (VBD developed) (NP (NNP Doc_24464946_1090_1104_Disease)) (PP (IN after) (NP (NN treatment)))) (. .)))
24464946	9	(S1 (S (S (NP (NP (NP (NNS GLS)) (PRN (-LRB- -LRB-) (NP (NP (CD -18.48) (NNS +)) (NP (NP (QP (CD 1.72) (NN %) (CC vs.) (CD -15.96) (CD +))) (NP (CD 1.6) (NN %)))) (-RRB- -RRB-))) (, ,) (NP (NP (NNS GCS)) (PRN (-LRB- -LRB-) (NP (NP (CD -20.93) (NNS +)) (NP (NP (QP (CD 2.86) (NN %) (CC vs.) (CD -19.20) (CD +))) (NP (CD 3.21) (NN %)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNS GRS)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 39.23)) (ADJP (QP (CD +) (CD 6.44)) (NN %))) (CC vs.) (NP (NP (CD 34.98) (NN +)) (NP (CD 6.2) (NN %)))) (-RRB- -RRB-)))) (VP (AUX were) (RB markedly) (VP (VBN reduced)))) (CC and) (S (NP (NN cTnT)) (VP (AUX was) (ADJP (JJ elevated) (PP (IN from) (NP (NP (QP (CD 0.0010) (CD +)) (QP (CD 0.0020) (TO to) (CD 0.0073) (NNS +) (CD 0.0038) (CD ng/mL))) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (DT all) (CD <) (CD 0.01))) (-RRB- -RRB-))))) (PP (IN at) (NP (NP (DT the) (NN completion)) (PP (IN of) (NP (NN chemotherapy))))) (PP (VBN compared) (PP (IN with) (NP (NN baseline) (NNS values)))))) (. .)))
24464946	10	(S1 (S (NP (NP (DT A) (ADJP (CD >15.9) (NN %)) (NN decrease)) (PP (IN in) (NP (NP (NNS GLS) (NN -LSB-sensitivity)) (, ,) (NP (NP (NP (CD 86) (NN %)) (: ;) (NP (NP (NN specificity)) (, ,) (NP (CD 75) (NN %))) (: ;) (NP (NP (NN area)) (SBAR (S (PP (IN under) (NP (DT the) (NN curve))) (-LRB- -LRB-) (NP (NNP AUC)) (-RRB- -RRB-) (VP (SYM =) (NP (CD 0.815)))))) (: ;) (NP (NNP P) (SYM =))) (NP (CD 0.001) (NN -RSB-))) (CC and) (NP (NP (DT a) (ADJP (CD >0.004) (NN ng/mL)) (NN elevation)) (PP (IN in) (NP (NP (NN cTnT)) (PRN (-LRB- -LRB-) (NP (NP (NN sensitivity)) (, ,) (NP (NP (CD 79) (NN %)) (: ;) (NP (NP (NN specificity)) (, ,) (NP (CD 64) (NN %))) (: ;) (NP (NNP AUC) (SYM =) (CD 0.757)) (: ;) (NP (NNP P) (SYM =) (CD 0.005)))) (-RRB- -RRB-)))) (PP (IN from) (NP (NN baseline))) (PP (TO to) (NP (NP (DT the) (JJ third) (NN cycle)) (PP (IN of) (NP (NN chemotherapy))))))))) (VP (VBD predicted) (ADVP (RB later)) (NP (NNP Doc_24464946_1686_1700_Disease))) (. .)))
24464946	11	(S1 (S (NP (NP (DT The) (NN decrease)) (PP (IN in) (NP (NNS GLS)))) (VP (VBD remained) (NP (NP (DT the) (JJ only) (JJ independent) (NN predictor)) (PP (IN of) (NP (NP (NNP Doc_24464946_1765_1779_Disease)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.000)) (-RRB- -RRB-)))))) (. .)))
24464946	12	(S1 (S (NP (NP (NNS GLS)) (VP (VBN combined) (PP (IN with) (NP (NN cTnT))))) (VP (MD may) (VP (VB provide) (NP (NP (DT a) (ADJP (JJ reliable) (CC and) (JJ non-invasive)) (NN method)) (SBAR (S (VP (TO to) (VP (VB predict) (NP (NN Doc_24464946_1887_1906_Disease)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ Doc_24464946_1929_1942_Chemical-based) (NN chemotherapy)))))))))))) (. .)))
24535067	0	(S1 (NP (NP (NP (NN Prevention)) (PP (IN of) (NP (JJ Doc_24535067_14_23_Chemical-induced) (NNP Doc_24535067_32_41_Disease))) (: :) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADJP (JJ superior)))))) (: :) (NP (NP (NNP Doc_24535067_62_70_Chemical)) (, ,) (NP (NNP Doc_24535067_72_81_Chemical)) (, ,) (CC or) (NP (DT a) (NN combination))) (. ?)))
24535067	1	(S1 (NP (DT A) (JJ Retrospective) (JJ comparative) (NN study) (. .)))
24535067	2	(S1 (S (PP (IN In) (NP (DT this) (JJ retrospective) (JJ comparative) (NN study))) (, ,) (NP (PRP we)) (VP (VBD aimed) (S (VP (TO to) (VP (VB compare) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NP (NNP Doc_24535067_230_238_Chemical)) (, ,) (NP (NNP Doc_24535067_240_249_Chemical)) (, ,) (CC and) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_24535067_272_280_Chemical)) (CC and) (NP (NNP Doc_24535067_285_294_Chemical)))) (S (VP (TO to) (VP (VB prevent) (NP (JJ Doc_24535067_306_315_Chemical-induced) (NNP Doc_24535067_324_333_Disease))))))))))))) (. .)))
24535067	3	(S1 (NP (NP (NP (NN MATERIAL)) (CC AND) (NP (NNS METHODS))) (: :) (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN performed) (PP (VBN based) (PP (IN on) (NP (NN anesthesia) (NNS records))))))) (. .)))
24535067	4	(S1 (S (VP (VBG Depending) (PP (IN on) (NP (NP (DT the) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD would) (VP (AUX be) (VP (VBN given) (PP (IN before) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NP (NP (NN anesthesia)) (PP (IN with) (NP (NNP Doc_24535067_494_503_Chemical))) (PRN (, ,) (S (NP (DT the) (NNS patients)) (VP (AUX were) (VP (VBN separated) (PP (IN into) (NP (NP (CD 4) (NNS groups)) (: :) (NP (NP (NP (NP (NP (DT no) (NN pretreatment)) (PRN (-LRB- -LRB-) (NP (NNP Group) (NNP NP)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_24535067_576_584_Chemical) (CD 1))) (JJ ug.kg-1) (PRN (-LRB- -LRB-) (NP (NNP Group) (NNP F)) (-RRB- -RRB-)) (, ,) (NNP Doc_24535067_606_615_Chemical) (CD 0.03)) (JJ mg.kg-1)) (PRN (-LRB- -LRB-) (NP (NNP Group) (NNP M)) (-RRB- -RRB-)))))))) (, ,))) (CC and) (NP (NNP Doc_24535067_644_653_Chemical) (CD 0.015) (JJ mg.kg-1) (NX (NX (NNP +) (NNP Doc_24535067_670_678_Chemical) (CD 0.5) (JJ ug.kg-1)) (PRN (-LRB- -LRB-) (NP (NNP Group) (NNP FM)) (-RRB- -RRB-)))))))))))))))) (. .)))
24535067	5	(S1 (S (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (DT the) (JJ same) (JJ anesthetic) (NN procedure)))))) (VP (AUX were) (VP (VBN selected)))) (: :) (S (PP (NP (CD 2) (NNS minutes)) (IN after) (NP (NP (JJ intravenous) (NNS injections)) (PP (IN of) (NP (DT the) (JJ pretreatment) (NNS drugs))))) (, ,) (NP (NN anesthesia)) (VP (AUX is) (VP (VBN induced) (PP (IN with) (NP (NP (CD 0.3) (JJ mg.kg-1) (NN Doc_24535067_875_884_Chemical)) (VP (VBD injected) (ADVP (RB intravenously)) (PP (IN over) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (CD 20-30) (NNS seconds))))))))))) (. .)))
24535067	6	(S1 (S (NP (NN Doc_24535067_940_959_Disease)) (VP (AUX are) (VP (VBN evaluated) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (VP (VP (VBN observed)) (CC and) (VP (VBN graded) (PP (VBG according) (PP (TO to) (NP (JJ clinical) (NN severity)))) (PP (IN during) (NP (NP (DT the) (CD 2) (NNS minutes)) (PP (IN after) (NP (JJ Doc_24535067_1064_1073_Chemical) (NN injection)))))))))))) (. .)))
24535067	7	(S1 (S (NP (NP (DT The) (NN severity)) (PP (IN of) (NP (NNP Doc_24535067_1101_1105_Disease))) (PP (JJ due) (TO to) (NP (NP (JJ Doc_24535067_1113_1122_Chemical) (NN injection)) (, ,) (NP (JJ mean) (JJ arterial) (NN pressure)) (, ,) (NP (NN heart) (NN rate)) (, ,) (CC and) (NP (JJ adverse) (NNS effects))))) (VP (AUX were) (ADVP (RB also)) (VP (VBN evaluated))) (. .)))
24535067	8	(S1 (S (NP (NN Study) (NNS results)) (VP (VP (VBD showed) (SBAR (IN that) (S (NP (JJ Doc_24535067_1246_1255_Disease) (NN incidence)) (VP (AUX was) (NP (NP (CD 85) (NN %)) (, ,) (NP (CD 40) (NN %)) (, ,) (NP (CD 70) (NN %)) (, ,) (CC and) (NP (NP (CD 25) (NN %)) (PP (IN in) (NP (NP (NNP Group) (NNP NP)) (, ,) (NP (NNP Group) (NNP F)) (, ,) (NP (NNP Group) (NNP M)) (, ,) (CC and) (NP (NNP Group) (NNP FM)) (, ,) (ADVP (RB respectively)))))))))) (, ,) (CC and) (VP (AUX were) (ADJP (RB significantly) (JJR lower)) (PP (IN in) (NP (NP (NNP Group) (NNP F)) (CC and) (NP (NNP Group) (NNP FM)))))) (. .)))
24535067	9	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (NP (NN pretreatment)) (PP (IN with) (NP (NNP Doc_24535067_1454_1462_Chemical)))) (CC or) (NP (NP (NN combination)) (PP (IN of) (NP (NP (NNP Doc_24535067_1481_1489_Chemical)) (CC and) (NP (NNP Doc_24535067_1494_1503_Chemical)))))) (VP (AUX was) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG preventing) (NP (JJ Doc_24535067_1532_1541_Chemical-induced) (NNP Doc_24535067_1550_1559_Disease)))))))))) (. .)))
2453942	0	(S1 (FRAG (NP (NP (NP (JJ Convulsant) (NN effect)) (PP (IN of) (NP (NNP Doc_2453942_21_28_Chemical)))) (CC and) (NP (NP (JJ regional) (NN brain) (NN concentration)) (PP (IN of) (NP (NP (NNP Doc_2453942_65_69_Chemical)) (CC and) (NP (NNP Doc_2453942_74_82_Chemical)))))) (. .)))
2453942	1	(S1 (S (NP (NP (NNP Doc_2453942_84_91_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2453942_93_120_Chemical)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT an) (JJ Doc_2453942_128_142_Chemical) (NN insecticide)) (PP (IN with) (NP (JJ known) (NN Doc_2453942_166_176_Disease) (NNS effects))))) (. .)))
2453942	2	(S1 (S (NP (NP (PRP$ Its) (NN mechanism)) (PP (IN of) (NP (NN action)))) (VP (AUX is) (RB not) (ADVP (RB well)) (VP (VBN understood) (SBAR (IN although) (S (NP (PRP it)) (VP (AUX has) (VP (AUX been) (VP (VBN proposed) (SBAR (IN that) (S (NP (NNP Doc_2453942_268_275_Chemical)) (VP (VBZ acts) (PP (IN as) (NP (NP (DT a) (JJ non-competitive) (NN antagonist)) (PP (IN at) (NP (DT the) (JJ Doc_2453942_320_343_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_2453942_345_349_Chemical)) (-RRB- -RRB-)) (JJ -A) (NN receptor))))))))))))))) (. .)))
2453942	3	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_2453942_388_395_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 150) (NN mg/kg)) (-RRB- -RRB-)))) (PP (IN on) (NP (DT the) (JJ GABAergic) (CC and) (JJ dopaminergic) (NNS systems)))) (PP (IN by) (S (VP (VBG measuring) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NP (NNP Doc_2453942_484_488_Chemical)) (, ,) (NP (NNP Doc_2453942_490_498_Chemical)) (CC and) (NP (PRP$ its) (NNS metabolites))))) (PP (IN in) (NP (CD 7) (NN brain) (NNS areas))) (PP (IN at) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNP Doc_2453942_552_560_Disease))))))))) (. .)))
2453942	4	(S1 (S (NP (DT All) (NNS animals)) (VP (VBD suffered) (NP (NN tonic) (NN Doc_2453942_589_600_Disease)) (PP (IN at) (NP (CD 18.3) (NN +/-))) (NP (CD 1.4) (NN min)) (PP (IN after) (NP (NNP Doc_2453942_627_634_Chemical) (NN administration)))) (. .)))
2453942	5	(S1 (S (NP (NP (DT The) (NN concentration)) (PP (IN of) (NP (NNP Doc_2453942_672_676_Chemical)))) (VP (VP (AUX was) (ADVP (RB only) (RB slightly))) (CC but) (VP (ADVP (RB significantly)) (VBN decreased) (PP (IN in) (NP (DT the) (NNS colliculi))) (PP (IN without) (NP (NP (NNS modifications)) (PP (IN in) (NP (DT the) (JJ other) (NNS areas))))))) (. .)))
2453942	6	(S1 (S (S (NP (NP (DT The) (NN concentration)) (PP (IN of) (NP (NNP Doc_2453942_803_811_Chemical)))) (VP (AUX was) (VP (VBN increased) (PP (IN in) (NP (DT the) (NN mesencephalon)))))) (CC and) (S (NP (NP (DT that)) (PP (IN of) (NP (PRP$ its) (JJ metabolite) (NN Doc_2453942_874_879_Chemical)))) (VP (AUX was) (ADVP (RB also)) (VP (VBN increased) (PP (IN in) (NP (NP (DT the) (NN mesencephalon)) (CC and) (NP (DT the) (NN striatum))))))) (. .)))
24554916	0	(S1 (NP (NP (JJ Cholestatic) (NN presentation)) (PP (IN of) (NP (JJ yellow) (JJ Doc_24554916_35_45_Chemical) (NN poisoning))) (. .)))
24554916	1	(S1 (S (NP (NP (NNP Yellow) (NNP Doc_24554916_64_74_Chemical)) (, ,) (NP (NP (DT a) (NN component)) (PP (IN of) (NP (NP (JJ certain) (NN pesticide) (NNS pastes)) (CC and) (NP (NNS fireworks))))) (, ,)) (VP (AUX is) (VP (ADVP (RB well)) (VBN known) (S (VP (TO to) (VP (VB cause) (NP (NN hepatotoxicity))))))) (. .)))
24554916	2	(S1 (S (NP (NP (NN Poisoning)) (PP (IN with) (NP (JJ yellow) (NN Doc_24554916_192_202_Chemical)))) (ADVP (RB classically)) (VP (VBZ manifests) (PP (IN with) (NP (NP (JJ acute) (NN Doc_24554916_236_245_Disease)) (VP (VBG leading) (PP (TO to) (NP (NP (NNP Doc_24554916_257_276_Disease)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (AUX need) (NP (NN liver) (NN transplantation)))))))))))) (. .)))
24554916	3	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (JJ yellow) (JJ Doc_24554916_343_353_Chemical) (NN poisoning))) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT a) (NN patient)) (VP (VBD presented) (PP (IN with) (NP (NP (JJ florid) (JJ clinical) (NNS features)) (PP (IN of) (NP (NNP Doc_24554916_426_437_Disease))) (VP (VBG highlighting) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP (NNP Doc_24554916_465_476_Disease)) (VP (MD can) (ADVP (RB rarely)) (VP (AUX be) (NP (NP (DT a) (VBG presenting) (NN feature)) (PP (IN of) (NP (JJ yellow) (JJ Doc_24554916_522_532_Chemical) (NN hepatotoxicity))))))))))))))))) (. .)))
24571687	0	(S1 (S (NP (NP (NN Doc_24571687_0_17_Disease)) (CC and) (NP (JJ severe) (JJ Doc_24571687_29_40_Disease) (NN following))) (VP (VB intranasal) (NP (NNP Doc_24571687_62_77_Chemical)) (PP (IN for) (NP (JJ pediatric) (JJ procedural) (NN sedation)))) (. .)))
24571687	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (NN syncope)) (CC and) (NP (NNP Doc_24571687_135_146_Disease))) (PP (IN in) (NP (NP (DT an) (JJ 11-year-old) (NN girl)) (PP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (JJ intranasal) (NNP Doc_24571687_209_224_Chemical))) (PP (IN for) (NP (NN sedation))) (PP (IN for) (NP (DT a) (JJ voiding) (NN cystourethrogram)))))))) (. .)))
24571687	2	(S1 (S (PP (VBG Following) (NP (NP (NP (JJ successful) (NN completion)) (PP (IN of) (NP (NN VCUG)))) (CC and) (NP (DT a) (JJ 60-min) (NN recovery) (NN period)))) (, ,) (NP (NP (NP (DT the) (NN patient) (POS 's)) (NN level)) (PP (IN of) (NP (NP (NN consciousness)) (CC and) (NP (JJ vital) (NNS signs))))) (VP (VBD returned) (PP (TO to) (NP (JJ presedation) (NNS levels)))) (. .)))
24571687	3	(S1 (S (PP (IN Upon) (S (VP (VBG leaving) (NP (DT the) (NN sedation) (NN area))))) (, ,) (NP (DT the) (NN patient)) (VP (VBD collapsed) (, ,) (PP (IN with) (NP (DT no) (JJ apparent) (VBG inciting) (NN event)))) (. .)))
24571687	4	(S1 (S (NP (DT The) (NN patient)) (ADVP (RB quickly)) (VP (VBD regained) (SBAR (S (NP (NP (NN consciousness)) (CC and) (NP (DT no) (NN injury))) (VP (VBD occurred))))) (. .)))
24571687	5	(S1 (S (S (NP (DT The) (JJ primary) (NN abnormality)) (VP (VBD found) (SBAR (S (VP (AUX was) (NP (JJ persistent) (NN Doc_24571687_625_636_Disease))))))) (, ,) (CC and) (S (NP (PRP she)) (VP (AUX was) (VP (VBN admitted) (PP (TO to) (NP (DT the) (NN hospital))) (PP (IN for) (NP (JJ telemetric) (NN observation)))))) (. .)))
24571687	6	(S1 (S (S (NP (DT The) (NNP Doc_24571687_707_718_Disease)) (VP (VBD lasted) (S (VP (VBG ~2) (NP (NNP h)))))) (, ,) (CC and) (S (NP (JJ further) (JJ cardiac) (NN workup)) (VP (VBD revealed) (NP (DT no) (JJ underlying) (NN abnormality)))) (. .)))
24571687	7	(S1 (S (NP (ADJP (ADJP (JJ Unanticipated)) (CC and) (ADJP (RB previously) (JJ unreported))) (NNS outcomes)) (VP (MD may) (VP (AUX be) (VP (VBN witnessed) (SBAR (IN as) (S (NP (PRP we)) (VP (VBP expand) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ certain) (NNS sedatives)))) (PP (TO to) (NP (NP (JJ alternative) (NNS routes)) (PP (IN of) (NP (NN administration))))))))))) (. .)))
24582773	0	(S1 (S (NP (JJ Paradoxical) (JJ severe) (NN Doc_24582773_19_28_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ add-on) (NNS high-doses)) (ADJP (JJ Doc_24582773_58_68_Chemical) (PP (IN in) (NP (NNP Doc_24582773_72_97_Disease))))))) (. .)))
24582773	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 35-year-old) (NN patient)) (VP (VBG suffering) (PP (IN from) (NP (NNP Doc_24582773_158_183_Disease))) (PP (IN since) (NP (NP (DT the) (NN age)) (PP (IN of) (NP (NP (CD 19) (NNS years)) (, ,) (VP (VBN treated) (PP (IN by) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (JJ first-generation) (NNS antipsychotics)) (, ,) (NP (NP (NP (NNP Doc_24582773_272_286_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 100) (NN mg/day)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_24582773_304_311_Chemical) (PRN (-LRB- -LRB-) (NP (CD 1200) (NN mg/day)) (-RRB- -RRB-)) (-LRB- -LRB-) (NP (NP (NN serum)) (NP (CD Doc_24582773_333_340_Chemical=0.85) (NNS mEq/l))) (-RRB- -RRB-))))))))))))))))) (. .)))
24582773	2	(S1 (S (NP (DT This) (NN patient)) (VP (AUX had) (ADVP (RB no)) (VP (VBN associated) (NP (NP (NP (NNP Doc_24582773_385_405_Disease)) (PRN (-LRB- -LRB-) (ADVP (RB particularly)) (NP (DT no) (NNP Doc_24582773_423_442_Disease)) (-RRB- -RRB-))) (CC and) (NP (DT no) (NNP Doc_24582773_451_475_Disease))))) (. .)))
24582773	3	(S1 (S (PP (IN Within) (NP (DT the) (CD 48))) (NP (NNP h)) (PP (VBG following) (NP (NP (DT the) (JJ gradual) (NN introduction)) (PP (IN of) (NP (NP (NNP Doc_24582773_531_541_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (IN up) (TO to) (CD 600)) (NN mg/day)) (-RRB- -RRB-)))))) (, ,) (NP (DT the) (NN patient)) (VP (VBD presented) (NP (JJ severe) (NN Doc_24582773_591_600_Disease)) (PP (IN without) (NP (NP (DT an) (JJ environmental) (NN explanation)) (, ,) (VP (VBG contrasting) (PP (IN with) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (NNP Doc_24582773_684_698_Disease)) (CC or) (NP (NNP Doc_24582773_702_722_Disease)))))))))))) (. .)))
24582773	4	(S1 (S (NP (NP (DT The) (NNS diagnoses)) (PP (IN of) (NP (NP (JJ Doc_24582773_741_746_Disease) (NN shift)) (CC and) (NP (NN Doc_24582773_757_766_Disease))))) (VP (AUX were) (VP (VBN dismissed))) (. .)))
24582773	5	(S1 (S (NP (NP (NP (DT The) (NN withdrawal)) (CC and) (NP (NP (DT the) (JJ gradual) (NN reintroduction)) (PP (IN of) (NP (NNP Doc_24582773_832_842_Chemical))) (ADVP (NP (CD 2) (NNS weeks)) (RBR later)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD led) (PP (TO to) (NP (DT another) (JJ severe) (NN Doc_24582773_886_895_Disease)))))) (, ,)) (VP (VBD enabled) (S (NP (PRP us)) (VP (TO to) (VP (VB attribute) (NP (DT the) (NN Doc_24582773_925_934_Disease)) (ADVP (RB specifically)) (PP (TO to) (NP (NNP Doc_24582773_951_961_Chemical))))))) (. .)))
24587916	0	(S1 (NP (NP (JJ Antioxidant) (NNS effects)) (PP (IN of) (NP (JJ bovine) (NNP Doc_24587916_30_41_Chemical))) (PP (IN on) (NP (NP (NNP Doc_24587916_45_58_Chemical-induced) (NNP Doc_24587916_67_79_Disease)) (PP (IN in) (NP (NN rat))))) (. .)))
24587916	1	(S1 (S (NP (NP (NN Doc_24587916_88_101_Chemical-)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24587916_104_108_Chemical)) (-RRB- -RRB-)) (VP (VBN induced) (NP (NNP Doc_24587916_118_130_Disease)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (JJ enhanced) (JJ oxidative) (NN stress))))) (. .)))
24587916	2	(S1 (S (NP (NP (NN Doc_24587916_177_188_Chemical)) (PRN (-LRB- -LRB-) (NP (NN LF)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT an) (JJ Doc_24587916_200_204_Chemical-binding) (NN glycoprotein)) (PP (IN with) (NP (JJ antihypertensive) (NNS properties))))) (. .)))
24587916	3	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN chronic) (NN administration)) (PP (IN of) (NP (NNP LF))))) (PP (IN on) (NP (NP (JJ oxidative) (NN stress)) (CC and) (NP (NP (NNP Doc_24587916_358_370_Disease)) (PP (IN upon) (NP (NNP Doc_24587916_376_379_Chemical) (NN administration)))))))) (. .)))
24587916	4	(S1 (S (NP (JJ Male) (JJ Wistar) (NNS rats)) (VP (AUX were) (VP (VP (VBN treated) (PP (IN by) (NP (NP (NNP Doc_24587916_429_432_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 30) (NNP u) (NN g/kg/day) (NN subcutaneously)) (-RRB- -RRB-))))) (CC or) (VP (VBN saline) (PP (IN for) (NP (CD 14) (NNS days)))))) (. .)))
24587916	5	(S1 (S (NP (NP (JJ Oral) (JJ bovine) (NNS LF)) (PRN (-LRB- -LRB-) (NP (CD 30) (, ,) (CD 100) (, ,) (CD 300) (NNS mg/kg)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN given) (PP (IN from) (NP (NN day) (CD 8))) (PP (TO to) (NP (CD 14))) (PP (IN in) (NP (DT a) (NN reversal) (NN study))))) (. .)))
24587916	6	(S1 (S (PP (IN In) (NP (DT a) (NN prevention) (NN study))) (, ,) (NP (NNS rats)) (VP (VP (VBD received) (NP (NP (CD 4) (NNS days)) (PP (IN of) (NP (NP (JJ LF) (NN treatment)) (VP (VBN followed) (PP (IN by) (NP (NNP Doc_24587916_644_647_Chemical)))))))) (CC and) (VP (VBD continued) (PP (IN during) (NP (DT the) (NN test) (NN period))))) (. .)))
24587916	7	(S1 (S (NP (NP (JJ Systolic) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN SBP)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN measured) (S (VP (VBG using) (NP (NN tail-cuff) (NN method)))))) (. .)))
24587916	8	(S1 (S (NP (JJ Thymus) (NN weight)) (VP (AUX was) (VP (VBN used) (PP (IN as) (NP (NP (DT a) (NN marker)) (PP (IN of) (NP (JJ glucocorticoid) (NN activity))))))) (. .)))
24587916	9	(S1 (S (NP (NP (NN Plasma) (NNP Doc_24587916_823_840_Chemical) (PRN (-LRB- -LRB-) (NNP Doc_24587916_842_846_Chemical) (-RRB- -RRB-)) (NN concentration)) (CC and) (NP (JJ ferric) (VBG reducing) (NN antioxidant) (NN power) (PRN (-LRB- -LRB-) (NN FRAP) (-RRB- -RRB-)) (NN value))) (VP (AUX were) (VP (VBN determined))) (. .)))
24587916	10	(S1 (S (NP (NN Doc_24587916_930_943_Chemical)) (VP (VP (ADVP (RB significantly)) (VBD increased) (NP (NN SBP))) (CC and) (VP (NN plasma) (NP (NP (JJ Doc_24587916_983_987_Chemical) (NN level)) (CC and) (NP (NN Doc_24587916_998_1031_Disease))))) (. .)))
24587916	11	(S1 (S (S (NP (NNP LF)) (VP (VBD lowered))) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.01))) (-RRB- -RRB-)) (CC and) (S (NP (NN dose)) (ADVP (RB dependently)) (VP (VBD prevented) (NP (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.001))) (-RRB- -RRB-)) (JJ Doc_24587916_1098_1101_Chemical-induced) (NN Doc_24587916_1110_1122_Disease)))) (. .)))
24587916	12	(S1 (S (NP (NNS LF)) (VP (VP (VBD prevented) (NP (NN body)) (NP (NNP Doc_24587916_1142_1153_Disease))) (CC and) (VP (ADVP (RB significantly)) (VBD reduced) (NP (NP (DT the) (JJ elevated) (NN plasma) (NN Doc_24587916_1200_1204_Chemical)) (CC and) (NP (VBN increased) (NN FRAP) (NNS values))))) (. .)))
24587916	13	(S1 (S (NP (NP (NN Chronic) (NN administration)) (PP (IN of) (NP (NNS LF)))) (ADVP (RB strongly)) (VP (VBD reduced) (NP (NP (DT the) (NN blood) (NN pressure)) (CC and) (NP (NP (NN production)) (PP (IN of) (NP (NP (NNS ROS)) (CC and) (NP (JJ improved) (NN antioxidant) (NN capacity)))))) (PP (IN in) (NP (JJ Doc_24587916_1356_1359_Chemical-induced) (NNP Doc_24587916_1368_1380_Disease))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ oxidative) (NN stress)))))) (PP (IN as) (NP (NP (DT another) (NN mechanism)) (PP (IN of) (NP (NP (JJ antihypertensive) (NN action)) (PP (IN of) (NP (NNP LF)))))))))) (. .)))
24588023	0	(S1 (NP (NP (NP (DT The) (NN association)) (PP (IN between) (NP (NNP Doc_24588023_24_39_Chemical) (CC and) (NNP Doc_24588023_44_54_Disease) (NNP Doc_24588023_55_63_Disease))) (PP (IN after) (NP (JJ cardiac) (NN surgery)))) (: :) (NP (NP (DT a) (JJ multivariate) (NN analysis)) (PP (IN in) (NP (QP (CD 11) (CD 529)) (NNS patients)))) (. .)))
24588023	1	(S1 (S (PP (IN Because) (IN of) (NP (NP (DT a) (NN lack)) (PP (IN of) (NP (NP (JJ contemporary) (NNS data)) (VP (VBG regarding) (NP (NNP Doc_24588023_180_188_Disease)) (PP (IN after) (NP (JJ cardiac) (NN surgery)))))))) (, ,) (NP (PRP we)) (VP (VBD undertook) (NP (NP (DT a) (JJ retrospective) (NN analysis)) (PP (IN of) (NP (NP (ADJP (RB prospectively) (VBN collected)) (NNS data)) (PP (IN from) (NP (NP (QP (CD 11) (CD 529)) (NNS patients)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (JJ cardiopulmonary) (NN bypass)) (VP (AUX was) (VP (VBN used) (PP (PP (IN from) (NP (NNP January) (CD 2004))) (PP (TO to) (NP (NNP December) (CD 2010)))))))))))))) (. .)))
24588023	2	(S1 (S (NP (DT A) (NNP Doc_24588023_381_391_Disease) (NNP Doc_24588023_392_399_Disease)) (VP (AUX was) (VP (VBN defined) (PP (IN as) (NP (NP (DT a) (JJ transient) (NN episode)) (PP (IN of) (NP (NP (JJ disturbed) (NN brain) (NN function)) (VP (VBN characterised) (PP (IN by) (NP (JJ abnormal) (JJ involuntary) (NN motor) (NNS movements)))))))))) (. .)))
24588023	3	(S1 (S (NP (JJ Multivariate) (NN regression) (NN analysis)) (VP (AUX was) (VP (VBN performed) (S (VP (TO to) (VP (VB identify) (NP (NP (JJ independent) (NNS predictors)) (PP (IN of) (NP (JJ postoperative) (NN Doc_24588023_617_625_Disease))))))))) (. .)))
24588023	4	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 100) (PRN (-LRB- -LRB-) (NP (CD 0.9) (NN %)) (-RRB- -RRB-)) (NNS patients)))) (VP (VBD developed) (NP (JJ postoperative) (NNP Doc_24588023_682_692_Disease) (NNP Doc_24588023_693_701_Disease))) (. .)))
24588023	5	(S1 (S (NP (ADJP (JJ Generalised) (CC and) (JJ focal)) (NNP Doc_24588023_725_733_Disease)) (VP (AUX were) (VP (VBN identified) (PP (IN in) (NP (QP (CD 68) (CC and) (CD 32)) (NNS patients))) (, ,) (ADVP (RB respectively)))) (. .)))
24588023	6	(S1 (S (NP (NP (DT The) (JJ median) (PRN (-LRB- -LRB-) (NP (JJ IQR) (JJ -LSB-range) (NNS -RSB-)) (-RRB- -RRB-)) (NN time)) (PP (IN after) (NP (NN surgery))) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NNP Doc_24588023_840_847_Disease)) (VP (VBD occurred))))) (VP (AUX was) (NP (NP (NP (NP (CD 7)) (PRN (-LRB- -LRB-) (NP (QP (CD 6-12) (CD -LSB-1-216)) (NNS -RSB-)) (-RRB- -RRB-))) (NP (NNP h))) (CC and) (NP (NP (NP (CD 8)) (PRN (-LRB- -LRB-) (NP (QP (CD 6-11) (CD -LSB-4-18)) (NNS -RSB-)) (-RRB- -RRB-))) (NP (NNP h)))) (, ,) (ADVP (RB respectively))) (. .)))
24588023	7	(S1 (S (NP (NP (JJ Epileptiform) (NNS findings)) (PP (IN on) (NP (NN electroencephalography)))) (VP (AUX were) (VP (VBN seen) (PP (IN in) (NP (CD 19) (NNS patients))))) (. .)))
24588023	8	(S1 (S (NP (NP (JJ Independent) (NNS predictors)) (PP (IN of) (NP (JJ postoperative) (NNP Doc_24588023_1031_1039_Disease)))) (VP (VBD included) (NP (NP (NN age)) (, ,) (NP (NN female) (NN sex)) (, ,) (NP (VB redo) (JJ cardiac) (NN surgery)) (, ,) (NP (NP (NN calcification)) (PP (IN of) (S (VP (VBG ascending) (NP (NP (NN aorta)) (, ,) (NP (NNP Doc_24588023_1122_1146_Disease)) (, ,) (NP (JJ deep) (JJ hypothermic) (NN Doc_24588023_1165_1183_Disease)) (, ,) (NP (NP (NN duration)) (PP (IN of) (NP (JJ aortic) (NN cross-clamp)))) (CC and) (NP (NNP Doc_24588023_1220_1235_Chemical))))))))) (. .)))
24588023	9	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN tested) (PP (IN in) (NP (DT a) (JJ multivariate) (NN regression) (NN analysis)))))) (, ,) (NP (NNP Doc_24588023_1288_1303_Chemical)) (VP (AUX was) (NP (NP (DT a) (JJ strong) (JJ independent) (NN predictor)) (PP (IN of) (NP (NP (NNP Doc_24588023_1342_1350_Disease)) (PRN (-LRB- -LRB-) (NP (NP (QP (CC OR) (CD 14.3))) (, ,) (NP (NP (CD 95) (NN %) (QP (CD CI) (CD 5.5-36.7))) (: ;) (NP (QP (CD p) (CD <)) (NNS 0.001)))) (-RRB- -RRB-)))))) (. .)))
24588023	10	(S1 (S (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NNP Doc_24588023_1404_1414_Disease) (NNP Doc_24588023_1415_1423_Disease)))) (VP (AUX had) (NP (CD 2.5) (NNS times)))) (NP (NP (JJR higher) (JJ in-hospital) (NN mortality) (NNS rates)) (CC and) (NP (NP (RB twice) (DT the) (NN length)) (PP (IN of) (NP (NN hospital))))) (VP (VBP stay) (PP (VBN compared) (PP (IN with) (NP (NNS patients)))) (PP (IN without) (NP (NNP Doc_24588023_1542_1552_Disease) (NNP Doc_24588023_1553_1561_Disease)))) (. .)))
24588023	11	(S1 (S (NP (NP (JJ Mean) (PRN (-LRB- -LRB-) (NP (CD IQR) (JJ -LSB-range) (NNS -RSB-)) (-RRB- -RRB-)) (NN length)) (PP (IN of) (NP (NN stay))) (PP (IN in) (NP (DT the) (JJ intensive) (NN care) (NN unit)))) (VP (AUX was) (NP (NP (NP (NP (CD 115)) (PRN (-LRB- -LRB-) (NP (QP (CD 49-228) (CD -LSB-32-481)) (NN -RSB-)) (-RRB- -RRB-))) (NP (NNP h))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_24588023_1669_1679_Disease) (NNP Doc_24588023_1680_1688_Disease)))))) (PP (VBN compared) (PP (IN with) (NP (NP (NP (CD 26)) (PRN (-LRB- -LRB-) (NP (QP (CD 22-69) (CD -LSB-14-1080)) (NN -RSB-)) (-RRB- -RRB-))) (NP (NNP h)) (PP (IN in) (NP (NNS patients))) (PP (IN without) (NP (NP (NNP Doc_24588023_1746_1754_Disease)) (PRN (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.001)) (-RRB- -RRB-)))))))) (. .)))
24588023	12	(S1 (S (NP (NNP Doc_24588023_1768_1778_Disease) (NNP Doc_24588023_1779_1787_Disease)) (VP (AUX are) (NP (NP (DT a) (JJ serious) (NN Doc_24588023_1802_1828_Disease)) (PP (IN after) (NP (JJ cardiac) (NN surgery))))) (. .)))
24588023	13	(S1 (S (SBAR (IN As) (S (NP (NNP Doc_24588023_1855_1870_Chemical)) (VP (AUX is) (NP (DT the) (JJ only) (JJ modifiable) (NN factor))))) (, ,) (NP (PRP$ its) (NN administration)) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (NP (NNS doses)) (VP (VBG exceeding) (NP (NP (CD 80) (NNS mg.kg)) (PRN (-LRB- -LRB-) (NP (NN -1)) (-RRB- -RRB-)))))) (, ,) (VP (MD should) (VP (AUX be) (VP (VBN weighed) (PP (IN against) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ postoperative) (NNP Doc_24588023_2020_2028_Disease)))))))) (. .)))
24595967	0	(S1 (NP (NP (JJ Dysfunctional) (JJ overnight) (NN memory) (NN consolidation)) (PP (IN in) (NP (JJ Doc_24595967_48_55_Chemical) (NNS users))) (. .)))
24595967	1	(S1 (S (NP (NN Sleep)) (VP (VBZ plays) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NN consolidation) (CC and) (NN integration)) (PP (IN of) (NP (NN memory))) (PP (IN in) (NP (NP (DT a) (NN process)) (VP (VBN called) (S (NP (JJ overnight) (NN memory) (NN consolidation))))))))) (. .)))
24595967	2	(S1 (S (NP (JJ Previous) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ Doc_24595967_223_230_Chemical) (NNS users)) (VP (AUX have) (VP (VP (VBN marked)) (CC and) (VP (NP (NP (JJ persistent) (NN neurocognitive)) (CC and) (NP (NNP Doc_24595967_283_308_Disease))))))))) (. .)))
24595967	3	(S1 (S (NP (PRP We)) (VP (VBP extend) (PP (IN past) (NP (NN research))) (PP (IN by) (S (VP (VBG examining) (NP (NP (JJ overnight) (NN memory) (NN consolidation)) (PP (IN among) (NP (NP (NP (JJ regular) (JJ Doc_24595967_392_399_Chemical) (NNS users)) (PRN (-LRB- -LRB-) (NP (CD n=12)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug) (JJ naive) (JJ healthy) (NNS controls)) (PRN (-LRB- -LRB-) (NP (CD n=26)) (-RRB- -RRB-)))))))))) (. .)))
24595967	4	(S1 (S (NP (NN Doc_24595967_453_480_Disease)) (VP (AUX was) (VP (VBN evaluated) (PP (IN before) (CC and) (IN after) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (NN sleep))))) (, ,) (PP (PP (IN with)) (CC and) (PP (IN without) (NP (NP (NN interference)) (PP (ADVP (RB prior)) (TO to) (NP (NN testing)))))))) (. .)))
24595967	5	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP we)) (VP (VBD assessed) (NP (JJ neurocognitive) (NNS performances)) (PP (IN across) (NP (NP (NNS tasks)) (PP (IN of) (NP (NP (NN learning)) (, ,) (NP (NN memory)) (CC and) (NP (NN executive) (NN functioning))))))) (. .)))
24595967	6	(S1 (S (NP (NN Doc_24595967_692_699_Chemical) (NNS users)) (VP (VBD demonstrated) (NP (VBN impaired) (JJ overnight) (NN memory) (NN consolidation)) (, ,) (NP (NP (DT a) (NN finding)) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (ADJP (RBR more) (JJ pronounced)) (PP (VBG following) (NP (JJ associative) (NN interference)))))))) (. .)))
24595967	7	(S1 (S (ADVP (RB Additionally)) (, ,) (NP (NNP Doc_24595967_845_852_Chemical) (NNS users)) (VP (VBD demonstrated) (NP (NNS impairments)) (PP (IN on) (NP (NP (NNS tasks) (NN recruiting) (NN frontostriatal)) (CC and) (NP (JJ hippocampal) (JJ neural) (NN circuitry)))) (, ,) (PP (IN in) (NP (NP (DT the) (NNS domains)) (PP (IN of) (NP (NP (JJ proactive) (NN interference) (NN memory)) (, ,) (NP (JJ long-term) (NN memory)) (, ,) (NP (NN encoding)) (, ,) (NP (JJ working) (NN memory)) (CC and) (NP (JJ complex) (NN planning))))))) (. .)))
24595967	8	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ Doc_24595967_1083_1090_Chemical-associated) (NN dysfunction)) (PP (IN in) (NP (JJ fronto-temporal) (NN circuitry)))) (VP (MD may) (VP (VB underlie) (NP (NP (JJ overnight) (NN consolidation) (NN Doc_24595967_1180_1198_Disease)) (PP (IN in) (NP (JJ regular) (JJ Doc_24595967_1210_1217_Chemical) (NNS users))))))))) (. .)))
24614773	0	(S1 (NP (NP (NNP Normoammonemic) (NNP Doc_24614773_15_29_Disease)) (: :) (NP (RB solely) (JJ Doc_24614773_38_47_Chemical) (ADJP (VBN induced) (CC or) (JJ multiple)) (NNS mechanisms)) (. ?)))
24614773	1	(S1 (S (NP (DT A) (JJ 77-year-old) (NN woman)) (VP (VBD presented) (PP (IN with) (NP (NN subacute) (NN onset) (JJ progressive) (NNP Doc_24614773_142_151_Disease) (, ,) (NNP Doc_24614773_153_163_Disease) (, ,) (NNP Doc_24614773_165_188_Disease) (CC and) (NNP Doc_24614773_193_202_Disease)))) (. .)))
24614773	2	(S1 (S (PP (IN In) (NP (DT the) (JJ preceding) (NNS months))) (, ,) (NP (DT the) (NN patient)) (VP (VP (AUX had) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NNS admissions)))) (PP (IN with) (NP (JJ transient) (NNP Doc_24614773_283_305_Disease))) (PP (IN with) (NP (JJ facial) (NN droop)))) (, ,) (CC and) (VP (AUX had) (VP (AUX been) (VP (VBN started) (PP (IN on) (NP (NNP Doc_24614773_349_358_Chemical))) (PP (IN for) (NP (JJ presumed) (NN Doc_24614773_372_391_Disease))))))) (. .)))
24614773	3	(S1 (S (S (NP (NN Doc_24614773_393_402_Chemical)) (VP (AUX was) (VP (VBN withdrawn) (PP (ADVP (RB soon)) (IN after) (NP (NN admission)))))) (CC and) (S (NP (PRP$ her) (JJ cognitive) (NNS abilities)) (VP (AUX have) (ADVP (RB gradually)) (VP (VBN improved) (PP (IN over) (NP (NP (CD 3) (NNS months)) (PP (IN of) (NP (NN follow-up)))))))) (. .)))
24614773	4	(S1 (S (S (NP (NP (JJ Doc_24614773_518_527_Chemical) (NNS levels)) (VP (VBN taken) (ADVP (RB prior)) (PP (TO to) (NP (NN withdrawal))))) (VP (AUX were) (ADJP (JJ subtherapeutic)))) (CC and) (S (NP (DT the) (NN patient)) (VP (AUX was) (ADJP (JJ normoammonaemic)))) (. .)))
24614773	5	(S1 (S (S (NP (NP (NNP EEG)) (VP (VBN undertaken) (PP (IN during) (NP (NN inpatient) (NN stay))))) (VP (VBD showed) (NP (NP (NNS changes)) (ADJP (JJ consistent) (PP (IN with) (NP (NNP Doc_24614773_686_700_Disease))))))) (, ,) (CC and) (S (NP (JJ low) (NN titre) (NNP Doc_24614773_716_736_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_24614773_738_742_Chemical)) (-RRB- -RRB-)) (NN receptor) (NNS antibodies)) (VP (AUX were) (ADJP (JJ present)) (PP (IN in) (NP (DT this) (NN patient))))) (. .)))
24614773	6	(S1 (S (NP (NP (DT The) (JJ possible) (NNS aetiologies)) (PP (IN of) (NP (NP (JJ Doc_24614773_822_831_Chemical-induced) (NN Doc_24614773_840_854_Disease)) (CC and) (NP (JJ Doc_24614773_859_863_Chemical) (JJ receptor-associated) (NN Doc_24614773_884_896_Disease))))) (VP (VBP present) (NP (DT a) (JJ diagnostic) (NN dilemma))) (. .)))
24614773	7	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (JJ putative) (NN combinatorial) (NN hypothesis)) (SBAR (S (VP (TO to) (VP (VB explain) (NP (NP (DT this) (NN patient) (POS 's)) (NNS symptoms)))))))) (. .)))
24618873	0	(S1 (S (NP (NN Doc_24618873_0_37_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ rapid) (NN infusion)) (PP (IN of) (NP (NNP Doc_24618873_67_76_Chemical)))))) (. .)))
24618873	1	(S1 (S (NP (NN Doc_24618873_78_87_Chemical)) (VP (AUX is) (NP (NP (DT an) (NN opioid)) (SBAR (WHNP (WDT that)) (S (VP (VBZ gains) (NP (NP (PRP$ its) (NN popularity)) (PP (IN for) (NP (DT the) (JJ effective) (NN Doc_24618873_145_149_Disease) (NN control)))) (PP (IN through) (S (VP (VBG acting) (PP (IN on) (NP (DT the) (NNS opioid-receptors))))))))))) (. .)))
24618873	2	(S1 (S (ADVP (RB However)) (, ,) (NP (JJ Doc_24618873_207_217_Disease) (NN relief)) (ADVP (RB sometimes)) (VP (VBZ brings) (PP (IN about) (NP (NP (JJ unfavourable) (NN side) (NNS effects)) (SBAR (WHNP (WDT that)) (S (ADVP (RB largely)) (VP (VBP limit) (NP (PRP$ its) (JJ clinical) (NN utility)))))))) (. .)))
24618873	3	(S1 (S (NP (JJ Common) (NN side) (NNS effects)) (VP (VBP include) (NP (NP (NNP Doc_24618873_343_349_Disease)) (, ,) (NP (NNP Doc_24618873_351_359_Disease)) (CC and) (NP (NNP Doc_24618873_364_375_Disease)))) (. .)))
24618873	4	(S1 (S (PP (IN In) (NP (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_24618873_394_427_Disease)))) (, ,) (CC and) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (AUX need) (NP (JJ long-term) (JJ Doc_24618873_458_462_Disease) (NN control)))))))) (, ,) (NP (NNP Doc_24618873_472_481_Chemical)) (VP (MD may) (VP (VB cause) (NP (JJ excitatory) (ADJP (JJ central) (JJ nervous)) (NN system) (PRN (-LRB- -LRB-) (NP (NNP CNS)) (-RRB- -RRB-)) (NNS effects)) (PP (IN through) (NP (NP (PRP$ its) (JJ neurotoxic) (NN metabolite)) (, ,) (NP (NNP Doc_24618873_575_587_Chemical)) (, ,) (VP (VBG resulting) (PP (IN in) (NP (NNP Doc_24618873_602_614_Disease) (CC and) (NNP Doc_24618873_619_626_Disease) (NN attack)))))))) (. .)))
24618873	5	(S1 (S (PP (IN On) (NP (DT the) (NN contrary))) (, ,) (SBAR (IN though) (FRAG (RB not) (ADJP (RB clinically) (JJ apparent)))) (, ,) (NP (NNP Doc_24618873_684_693_Chemical)) (ADVP (RB potentially)) (VP (VP (VBZ causes) (NP (NN inhibitory) (NNS impacts)) (PP (IN on) (NP (DT the) (NNS CNS)))) (CC and) (VP (VBZ impairs) (NP (JJ normal) (NN cerebellar) (CC and) (NN oculomotor) (NN function)) (PP (IN in) (NP (DT the) (JJ short) (NN term))))) (. .)))
24618873	6	(S1 (S (PP (IN In) (NP (DT this) (NN case) (NN report))) (, ,) (NP (PRP we)) (VP (VB highlight) (NP (NP (NN opioid) (POS 's)) (JJ inhibitory) (NN side) (NNS effects)) (PP (IN on) (NP (NP (DT the) (JJ cerebellar) (NN structure)) (SBAR (WHNP (WDT that)) (S (VP (VBZ causes) (SBAR (S (NP (NP (NNP Doc_24618873_923_932_Disease)) (, ,) (NP (NNP Doc_24618873_934_944_Disease)) (, ,)) (VP (VP (VBD reduced) (NP (JJ smooth) (NN pursuit) (NN gain))) (CC and) (VP (VBD decreased) (NP (JJ saccadic) (NN velocity)))))))))))) (. .)))
24641119	0	(S1 (S (NP (NN Doc_24641119_0_15_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_24641119_27_39_Chemical)))) (. .)))
24641119	1	(S1 (S (NP (DT A) (JJ 27-year-old) (NN male) (NN patient)) (VP (VBD presented) (PP (IN with) (NP (DT a) (JJ maculopapular) (NN Doc_24641119_99_107_Disease))) (PP (IN on) (NP (NP (DT the) (JJ flexural) (NNS areas)) (CC and) (NP (NNS buttocks)))) (PP (IN after) (S (VP (VBG using) (NP (JJ oral) (NNP Doc_24641119_160_172_Chemical)))))) (. .)))
24641119	2	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (VP (VBN diagnosed) (PP (IN with) (NP (NP (JJ drug-induced) (NNP Doc_24641119_218_233_Disease)) (VP (VBN based) (PP (IN on) (NP (NP (PRP$ his) (NN history)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD included) (NP (JJ prior) (NN sensitivity)) (PP (TO to) (NP (NP (JJ topical) (NN Doc_24641119_300_312_Chemical)) (, ,) (NP (DT a) (JJ physical) (NN examination)) (, ,) (CC and) (NP (JJ histopathological) (NNS findings)))))))))))))) (. .)))
24641119	3	(S1 (S (NP (NN Doc_24641119_370_385_Disease)) (VP (AUX is) (NP (NP (DT a) (NN drug-) (CC or) (NN contact) (JJ allergen-related) (NN maculopapular) (NN Doc_24641119_439_447_Disease)) (SBAR (WHNP (WDT that)) (S (ADVP (RB typically)) (VP (VBZ involves) (NP (DT the) (JJ flexural) (CC and) (JJ gluteal) (NNS areas))))))) (. .)))
24641119	4	(S1 (S (PP (TO To) (NP (NP (DT the) (JJS best)) (PP (IN of) (NP (PRP$ our) (NN knowledge))))) (, ,) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (JJ reported) (NN case)) (PP (IN of) (NP (NNP Doc_24641119_569_581_Chemical-induced) (NNP Doc_24641119_590_605_Disease))) (PP (IN in) (NP (DT the) (JJ English) (NN literature))))) (. .)))
24653743	0	(S1 (NP (NP (DT A) (NN Case)) (PP (IN of) (NP (JJ Sudden) (NNP Doc_24653743_17_30_Disease))) (PP (JJ due) (TO to) (NP (NNP Doc_24653743_38_50_Chemical-Induced) (NNP Doc_24653743_59_78_Disease))) (. .)))
24653743	1	(S1 (S (S (NP (DT An) (JJ 84-year-old) (NN male)) (VP (VBD received) (NP (NP (JJ oral) (NNP Doc_24653743_114_126_Chemical)) (, ,) (NP (NP (DT a) (JJ pure) (JJ Doc_24653743_135_141_Chemical) (NN channel) (NN blocker)) (PP (IN with) (NP (JJ slow) (NN recovery) (NNS kinetics)))) (, ,)) (S (VP (TO to) (VP (VB convert) (NP (PRP$ his) (JJ paroxysmal) (NN Doc_24653743_213_232_Disease)) (PP (TO to) (NP (DT a) (JJ sinus) (NN rhythm)))))))) (: ;) (S (NP (DT the) (NN patient)) (VP (VBD developed) (NP (NNP Doc_24653743_274_294_Disease)) (ADVP (NP (CD two) (NNS days)) (RB later)))) (. .)))
24653743	2	(S1 (S (NP (NP (DT The) (NNP Holter) (NN electrocardiogram)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN worn) (PP (IN by) (NP (NN chance))))))) (, ,)) (VP (VBD revealed) (NP (NNP Doc_24653743_376_394_Disease)) (PP (IN with) (NP (ADJP (RB gradually) (VBN prolonged)) (NN QT) (NNS intervals)))) (. .)))
24653743	3	(S1 (S (S (NP (DT This) (NN drug)) (VP (AUX is) (ADVP (RB rapidly)) (VP (VBN absorbed) (PP (IN from) (NP (DT the) (JJ gastrointestinal) (NN tract)))))) (, ,) (CC and) (S (NP (NP (JJS most)) (PP (IN of) (NP (PRP it)))) (VP (AUX is) (VP (VBN excreted) (PP (IN from) (NP (DT the) (NN kidney)))))) (. .)))
24653743	4	(S1 (S (SBAR (IN Although) (S (S (NP (NP (DT the) (NN patient) (POS 's)) (JJ renal) (NN function)) (VP (AUX was) (RB not) (ADJP (RB highly) (JJ impaired)))) (CC and) (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NNP Doc_24653743_619_631_Chemical)))) (VP (AUX was) (ADJP (JJ low)))))) (, ,) (NP (NP (DT the) (NN plasma) (NN concentration)) (PP (IN of) (NP (NNP Doc_24653743_669_681_Chemical)))) (VP (MD may) (VP (AUX have) (VP (AUX been) (NP (NP (NN high)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (VB produce) (NP (NN Doc_24653743_720_739_Disease)) (PP (IN in) (NP (DT the) (NN octogenarian))))))))))) (. .)))
24653743	5	(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NN class) (NN IC) (NNS drugs)) (, ,) (PP (VBG including) (NP (NNP Doc_24653743_823_835_Chemical))) (, ,)))) (VP (AUX is) (ADJP (JJ effective)) (S (VP (TO to) (VP (VB terminate) (NP (NN Doc_24653743_863_882_Disease)))))))) (, ,) (NP (JJ careful) (NN consideration)) (VP (MD must) (VP (AUX be) (VP (VBN taken) (PP (IN before) (S (VP (VBG giving) (NP (DT these) (NNS drugs)) (PP (TO to) (NP (NNS octogenarians))))))))) (. .)))
24658375	0	(S1 (NP (NP (JJ Doc_24658375_0_23_Chemical-induced) (JJ inflammatory) (NN Doc_24658375_45_53_Disease)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_24658375_72_100_Disease))))) (. .)))
24658375	1	(S1 (S (NP (NP (NP (NNP Doc_24658375_102_125_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24658375_127_131_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NN component)) (PP (IN of) (NP (JJ standard) (NN therapy))) (PP (IN for) (NP (NP (NNP Doc_24658375_170_198_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24658375_200_203_Disease)) (-RRB- -RRB-))))) (, ,)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (ADJP (RB potentially) (JJ serious) (CC but) (JJ treatable)) (JJ adverse) (NNS effects)) (VP (VBG involving) (NP (NP (JJ numerous) (NN organ) (NNS systems)) (, ,) (PP (VBG including) (NP (JJ rare) (JJ skeletal) (NN muscle) (NN involvement))))))))) (. .)))
24658375	2	(S1 (S (NP (NP (RB Only) (DT a) (NN handful)) (PP (IN of) (NP (NP (NNS cases)) (PP (IN of) (NP (NP (NNP Doc_24658375_380_384_Chemical-induced) (NNP Doc_24658375_393_401_Disease)) (PP (IN in) (NP (NNS children)))))))) (VP (VP (AUX have) (VP (AUX been) (VP (VBN reported)))) (, ,) (CC and) (VP (NP (NN none)) (PP (IN in) (NP (DT the) (JJ radiology) (NN literature))))) (. .)))
24658375	3	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (PDT such) (DT a) (NN case)) (PP (IN in) (NP (NP (DT a) (JJ 15-year-old) (NN boy)) (PP (IN with) (NP (NP (NNP Doc_24658375_521_524_Disease)) (, ,) (SBAR (WHADVP (WRB where)) (S (NP (NP (NN recognition)) (PP (IN of) (NP (NN imaging) (NNS findings)))) (VP (VBD played) (NP (DT a) (JJ crucial) (NN role)) (PP (IN in) (S (VP (VBG making) (NP (DT the) (NN diagnosis) (CC and) (JJ facilitated) (JJ prompt) (, ,) (JJ effective) (NN treatment))))))))))))) (. .)))
24659727	0	(S1 (NP (NP (NN Tolerability)) (PP (IN of) (NP (NNP Doc_24659727_16_25_Chemical))) (PP (IN in) (NP (NN combination))) (PP (IN with) (NP (NNP Doc_24659727_46_62_Chemical))) (PP (IN in) (NP (NP (NNS dogs)) (PP (IN with) (NP (NNP Doc_24659727_76_84_Disease))))) (. .)))
24659727	1	(S1 (S (NP (DT This) (NN retrospective) (NN study)) (VP (VBZ describes) (NP (NP (NNP Doc_24659727_121_129_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (NN protocol)) (PP (IN of) (NP (NP (NP (NNP Doc_24659727_160_169_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24659727_171_175_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_24659727_181_197_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24659727_199_202_Chemical)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (NNS dogs)) (PP (IN with) (NP (NNP Doc_24659727_217_225_Disease)))))))))) (. .)))
24659727	2	(S1 (S (S (NP (NNP Doc_24659727_227_231_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (IN per) (NP (NP (NN os)) (PRN (-LRB- -LRB-) (NP (NNP PO)) (-RRB- -RRB-)))) (PP (IN at) (NP (NP (DT a) (JJ targeted) (NN dosage)) (PP (IN of) (NP (NP (CD 60) (NNS mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NP (NN body) (NN surface) (NN area)))))) (PP (IN on) (NP (NN day) (CD 0)))))) (, ,) (S (NP (NNP Doc_24659727_324_327_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (VBG PO) (PP (IN at) (NP (NP (DT a) (JJ targeted) (NN dosage)) (PP (IN of) (NP (NP (NP (CD 250) (NNS mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (VP (VBN divided) (PP (IN over) (NP (NNS days) (CD 0) (IN through) (CD 4)))))))))))) (, ,) (CC and) (S (NP (DT all) (NNS dogs)) (VP (VBD received) (NP (JJ prophylactic) (NNS antibiotics)))) (. .)))
24659727	3	(S1 (S (NP (CD Ninety) (NNS treatments)) (VP (AUX were) (VP (VBN given) (PP (TO to) (NP (NP (DT the) (CD 57) (NNS dogs)) (VP (VBN included) (PP (IN in) (NP (DT the) (NN study)))))))) (. .)))
24659727	4	(S1 (S (S (NP (NN Doc_24659727_530_541_Disease)) (VP (AUX was) (NP (DT the) (JJ principal) (JJ toxic) (NN effect)))) (, ,) (CC and) (S (NP (NP (DT the) (JJ overall) (NN frequency)) (PP (IN of) (NP (NN grade) (CD 4) (NN Doc_24659727_611_622_Disease))) (PP (IN after) (NP (NP (DT the) (JJ first) (NN treatment)) (PP (IN of) (NP (NNP Doc_24659727_652_656_Chemical/Doc_24659727_657_660_Chemical)))))) (VP (AUX was) (NP (NP (CD 30) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 95) (NN %)) (NN confidence) (NN interval)) (, ,) (NP (CD 19-43) (NN %))) (-RRB- -RRB-))))) (. .)))
24659727	5	(S1 (S (NP (NP (DT The) (JJ mean) (NN body) (NN weight)) (PP (IN of) (NP (NP (NNS dogs)) (PP (IN with) (NP (NP (NN grade) (CD 4) (NNP Doc_24659727_746_757_Disease)) (PRN (-LRB- -LRB-) (NP (QP (CD 19.7) (CD kg)) (NNP +) (CD 13.4) (NN kg)) (-RRB- -RRB-))))))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR less)) (PP (IN than) (NP (NP (DT the) (JJ mean) (NN body) (NN weight)) (PP (IN of) (NP (NP (NNS dogs)) (SBAR (WHNP (WDT that)) (S (VP (AUX did) (RB not) (VP (VB develop) (NP (NP (NN grade) (CD 4) (NNP Doc_24659727_864_875_Disease)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 31.7) (CD kg)) (NNP +) (CD 12.4) (NN kg)) (: ;) (NP (NNP P)) (X (SYM =)) (CD .005)) (-RRB- -RRB-))))))))))))) (. .)))
24659727	6	(S1 (S (NP (NP (CD One) (NN dog)) (PRN (-LRB- -LRB-) (NP (CD 3) (NN %)) (-RRB- -RRB-))) (VP (VBD developed) (NP (NP (JJ hematologic) (NNS changes) (NN suggestive)) (PP (IN of) (NP (NN hepatotoxicity))))) (. .)))
24659727	7	(S1 (S (NP (DT No) (NNS dogs)) (VP (AUX had) (NP (NP (NN evidence)) (PP (IN of) (NP (CC either) (NP (NNP Doc_24659727_1011_1025_Disease)) (CC or) (NP (NNP Doc_24659727_1029_1049_Disease)))))) (. .)))
24659727	8	(S1 (S (NP (JJ Adverse) (JJ gastrointestinal) (NNS effects)) (VP (AUX were) (ADJP (JJ uncommon))) (. .)))
24659727	9	(S1 (S (PP (IN On) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (DT the) (NNS findings)) (SBAR (S (VP (VBD reported) (NP (NN herein)) (, ,) (S (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 60) (NNS mg/m))) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_24659727_1169_1173_Chemical)))) (VP (VBN combined) (PP (IN with) (NP (QP (CD 250) (CD mg/m))))))))) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_24659727_1203_1206_Chemical) (PRN (-LRB- -LRB-) (VP (VBN divided) (PP (IN over) (NP (CD 5) (NNS days)))) (-RRB- -RRB-)) (NNP q))))))) (NP (CD 4) (NN wk)) (VP (AUX is) (ADJP (JJ tolerable)) (PP (IN in) (NP (JJ Doc_24659727_1252_1257_Disease-bearing) (NNS dogs)))) (. .)))
24664478	0	(S1 (NP (NP (NP (JJ Doc_24664478_0_10_Chemical) (NN Doc_24664478_11_24_Disease)) (PP (IN with) (NP (JJ concurrent) (JJ intrathecal) (NNS chemotherapy)))) (: :) (NP (NP (NNP Case) (NN report) (CC and) (NN review)) (PP (IN of) (NP (NN literature)))) (. .)))
24664478	1	(S1 (S (NP (NP (JJ Severe) (NNP Doc_24664478_112_122_Chemical) (NNP Doc_24664478_123_136_Disease)) (PP (IN in) (NP (DT a) (NN patient))) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (JJ concurrent) (NN intrathecal)) (S (-LRB- -LRB-) (NP (PRP IT)) (-RRB- -RRB-) (VP (VB chemotherapy))))))) (VP (AUX is) (VP (VBN reported))) (. .)))
24664478	2	(S1 (S (NP (NP (DT A) (JJ 37-year-old) (JJ Caucasian) (NN woman)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_24664478_265_294_Disease)))))) (VP (AUX was) (VP (VBN admitted) (PP (IN for) (NP (NN Doc_24664478_312_328_Disease))))) (. .)))
24664478	3	(S1 (S (NP (PRP She)) (VP (AUX was) (ADVP (RB originally)) (VP (VBN treated) (PP (IN with) (NP (NP (JJ induction) (NNS chemotherapy)) (VP (VBN followed) (PP (IN by) (NP (DT an) (JJ autologous) (NN transplant)))))))) (. .)))
24664478	4	(S1 (S (NP (PRP She)) (VP (VBD developed) (NP (NNP Doc_24664478_437_453_Disease)) (ADVP (NP (CD 10) (NNS months)) (RB later)) (PP (IN with) (NP (NNP Doc_24664478_475_495_Disease)))) (. .)))
24664478	5	(S1 (S (NP (PRP She)) (VP (AUX was) (ADJP (JJ re-induced) (PP (IN with) (NP (NP (NNP Doc_24664478_521_531_Chemical) (CD 1500) (NNS mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))))) (PP (IN on) (NP (NNS days))) (NP (CD 1) (, ,) (CD 3) (, ,) (CC and) (CD 5)) (PP (IN with) (NP (NP (NP (CD 1) (NN dose)) (PP (IN of) (NP (PRP IT)))) (JJ Doc_24664478_583_593_Chemical) (NP (NP (CD 100) (NNS mg)) (PP (IN on) (NP (NN day) (CD 2))) (PP (IN as) (NP (JJ central) (JJ nervous) (NN system))) (PRN (-LRB- -LRB-) (NP (NNP CNS)) (-RRB- -RRB-))) (NNS prophylaxis)))) (. .)))
24664478	6	(S1 (S (PP (IN At) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NN treatment))))) (, ,) (NP (PRP she)) (VP (AUX was) (PP (IN on) (NP (NP (JJ continuous) (JJ renal) (NN replacement) (NN therapy)) (ADJP (JJ due) (PP (TO to) (NP (NP (NNS sequelae)) (PP (IN of) (NP (NP (NNP Doc_24664478_748_768_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24664478_770_773_Disease)) (-RRB- -RRB-)))))))))) (. .)))
24664478	7	(S1 (S (NP (PRP She)) (VP (VP (VBD tolerated) (NP (NN therapy)) (ADVP (RB well))) (, ,) (VP (VBD entered) (NP (DT a) (JJ complete) (NN remission))) (, ,) (CC and) (VP (VBD recovered) (NP (PRP$ her) (JJ renal) (NN function)))) (. .)))
24664478	8	(S1 (S (NP (PRP She)) (VP (VBD received) (NP (NP (DT a) (JJ second) (NN cycle)) (PP (IN of) (NP (NNP Doc_24664478_899_909_Chemical)))) (PP (IN without) (NP (JJ additional))) (SBAR (S (NP (PRP IT)) (VP (VBZ prophylaxis) (ADVP (NP (CD one) (NN month)) (RB later)))))) (. .)))
24664478	9	(S1 (S (NP (NP (DT A) (NN week)) (PP (IN after) (NP (DT this) (JJ second) (NN cycle)))) (, ,) (NP (PRP she)) (VP (VBD noted) (NP (NN numbness)) (PP (IN in) (NP (PRP$ her) (JJR lower) (NNS extremities)))) (. .)))
24664478	10	(S1 (S (ADVP (RB Predominantly) (JJ sensory)) (, ,) (SBAR (IN though) (S (ADVP (RB also)) (ADJP (NN motor) (CC and) (JJ autonomic)))) (, ,) (NP (NNP Doc_24664478_1094_1115_Disease)) (VP (VP (VBD started) (PP (IN in) (NP (PRP$ her) (NNS feet)))) (, ,) (VP (VBD ascended) (ADVP (RB proximally)) (PP (TO to) (NP (DT the) (JJ mid-thoracic) (NN region)))) (, ,) (CC and) (VP (ADVP (RB eventually)) (VBD included) (NP (PRP$ her) (JJ distal) (JJ upper) (NNS extremities)))) (. .)))
24664478	11	(S1 (S (NP (NP (DT A) (JJ magnetic) (NN resonance) (NN imaging)) (PRN (-LRB- -LRB-) (NP (NNP MRI)) (-RRB- -RRB-)) (PP (IN of) (NP (PRP$ her) (NN spine)))) (VP (VBD demonstrated) (NP (NP (NNS changes)) (PP (IN from) (NP (NNP C2)))) (S (VP (TO to) (VP (VB C6) (ADJP (JJ consistent) (PP (IN with) (NP (JJ subacute) (NN Doc_24664478_1347_1368_Disease)))))))) (. .)))
24664478	12	(S1 (S (NP (NN Doc_24664478_1370_1380_Chemical)) (VP (AUX was) (VP (VBN felt) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (PRP$ her) (NNS symptoms))))))))) (. .)))
24664478	13	(S1 (S (S (NP (PRP$ Her) (NNP Doc_24664478_1427_1437_Disease)) (VP (VP (VP (VBN stabilized)) (CC and) (VP (VBD showed) (NP (JJ slight) (NN improvement)))) (CC and) (VP (ADVP (RB ultimately)) (VBN received) (NP (NP (DT an) (JJ unrelated) (, ,) (JJ reduced-intensity) (JJ allogeneic) (NN transplant) (NN while)) (PP (IN in) (NP (JJ complete) (NN remission))))))) (, ,) (CC but) (S (NP (NNP Doc_24664478_1590_1606_Disease)) (ADVP (NP (CD 10) (NNS weeks)) (RB later))) (. .)))
24664478	14	(S1 (S (NP (PRP She)) (VP (AUX is) (ADVP (RB currently)) (VP (AUXG being) (VP (VBN treated) (PP (IN with) (NP (ADJP (RB best) (JJ supportive)) (NN care)))))) (. .)))
24664478	15	(S1 (S (PP (TO To) (NP (PRP$ our) (NN knowledge))) (, ,) (NP (DT this)) (VP (AUX is) (NP (NP (DT the) (JJ first) (JJ published) (NN case) (NN report)) (PP (IN of) (NP (NP (JJ severe) (NN Doc_24664478_1749_1762_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_24664478_1773_1783_Chemical))) (PP (IN in) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (ADJP (JJ concurrent) (NP (PRP IT))) (NN chemotherapy)))))))))))) (. .)))
24665854	0	(S1 (NP (NP (JJ Doc_24665854_0_9_Chemical-induced) (JJ hyperammonemic) (NN Doc_24665854_33_47_Disease)) (PP (IN in) (NP (DT a) (JJ renal) (JJ transplanted) (NN patient))) (. .)))
24665854	1	(S1 (S (NP (NP (NN Doc_24665854_81_107_Disease)) (PP (IN after) (NP (JJ renal) (NN transplantation)))) (VP (VBP constitute) (NP (NP (DT an) (JJ important) (NN cause)) (PP (IN of) (NP (NP (NN morbidity)) (CC and) (NP (NN mortality)))))) (. .)))
24665854	2	(S1 (S (NP (PRP$ Their) (NN differential) (NN diagnosis)) (VP (AUX is) (ADJP (ADJP (JJ difficult)) (CC and) (ADJP (JJ essential))) (PP (IN for) (NP (NP (JJ subsequent) (NN patient) (POS 's)) (NN management)))) (. .)))
24665854	3	(S1 (S (NP (JJ Doc_24665854_287_296_Chemical-induced) (JJ hyperammonemic) (NN Doc_24665854_320_334_Disease)) (VP (AUX is) (NP (NP (DT an) (ADJP (ADJP (JJ uncommon)) (CC but) (ADJP (JJ serious))) (NN effect)) (PP (IN of) (NP (JJ Doc_24665854_372_381_Chemical) (NN treatment))))) (. .)))
24665854	4	(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP describe) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 15-year-old) (NN girl)) (SBAR (WHNP (WP who)) (S (VP (VP (AUX was) (PP (IN on) (NP (NP (DT a) (JJ long-term) (NN therapy)) (PP (IN with) (NP (NNP Doc_24665854_478_487_Chemical))))) (ADVP (RB due) (PP (TO to) (NP (NNP Doc_24665854_495_503_Disease))))) (CC and) (VP (VBD revealed) (NP (NNP Doc_24665854_517_539_Disease)) (PP (IN with) (NP (NNP Doc_24665854_545_559_Disease))) (PP (NP (CD 12) (NNS days)) (IN after) (NP (JJ renal) (NN transplantation))))))))))) (. .)))
24665854	5	(S1 (S (PP (IN After) (NP (NP (VB withdraw)) (PP (IN of) (NP (NNP Doc_24665854_615_624_Chemical))))) (, ,) (NP (NP (NP (NNS patients) (POS ')) (NNS symptoms)) (VP (VBN resolved) (PP (IN within) (NP (CD 24) (NNP h.) (NNPS Clinicians))))) (VP (MD should) (VP (VB increase) (NP (NP (PRP$ their) (NN awareness)) (PP (IN for) (NP (NP (JJ potential) (NN complication)) (PP (IN of) (NP (NNP Doc_24665854_740_749_Chemical)))))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (JJ transplanted) (NNS patients))))) (. .)))
24671324	0	(S1 (S (VP (VB Doc_24671324_0_21_Disease) (PP (IN after) (NP (NP (NN Doc_24671324_28_38_Chemical)) (CC and) (NP (JJ Doc_24671324_43_56_Chemical-containing) (NN regimen)))) (PP (IN in) (NP (NP (DT an) (JJ elderly) (NN patient)) (PP (IN of) (NP (NNP Doc_24671324_101_131_Disease)))))) (. .)))
24671324	1	(S1 (S (NP (ADJP (JJ Doc_24671324_133_143_Chemical) (CC and) (JJ high-dose)) (JJ Doc_24671324_158_171_Chemical-containing) (NNS regimens)) (VP (AUX are) (VP (VBN considered) (S (VP (TO to) (VP (AUX be) (ADJP (RB generally) (JJ tolerable) (PP (IN with) (NP (NP (JJ few) (JJ severe) (NN Doc_24671324_249_269_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ B-cell) (NNS malignancies))))))))))))) (. .)))
24671324	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NN information)) (VP (AUX is) (VP (VBN limited) (PP (VBG concerning) (NP (NP (DT the) (NN safety)) (PP (IN of) (NP (DT the) (NN regimen))) (PP (IN in) (NP (JJ elderly) (NNS patients))))))) (. .)))
24671324	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (DT a) (JJ 76-year-old) (NN man)) (PP (IN with) (NP (NNP Doc_24671324_441_471_Disease))) (SBAR (WHNP (WP who)) (S (VP (VBD suffered) (S (VP (VBG necrotising) (NP (NNP Doc_24671324_497_506_Disease)) (PP (IN without) (NP (NNP Doc_24671324_515_526_Disease))) (PP (IN after) (NP (NP (DT the) (NN combination) (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_24671324_564_574_Chemical)) (, ,) (NP (NP (JJ high-dose) (NN Doc_24671324_586_599_Chemical)) (CC and) (NP (NN rituximab)))))))))))))))) (. .)))
24671324	4	(S1 (S (PP (IN Despite) (NP (JJ immediate) (JJ intravenous) (NN antimicrobial) (NN therapy))) (, ,) (NP (PRP he)) (VP (VBD succumbed) (NP (CD 23) (NNP h)) (PP (IN after) (NP (DT the) (NN onset)))) (. .)))
24671324	5	(S1 (S (S (NP (NNS Physicians)) (VP (MD should) (VP (VB recognise) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NP (JJ fatal) (NNP Doc_24671324_756_776_Disease)) (VP (VBN related) (PP (TO to) (NP (NP (NP (NNP Doc_24671324_788_798_Chemical)) (CC plus) (NP (JJ high-dose) (NNP Doc_24671324_814_827_Chemical))) (PP (IN in) (NP (JJ elderly) (NNS patients)))))))))))) (, ,) (CC and) (S (NP (PRP we)) (VP (VBP believe) (SBAR (S (NP (DT this) (NN case)) (VP (VBZ warrants) (NP (JJ further) (NN investigation))))))) (. .)))
24675088	0	(S1 (NP (NP (DT An) (VBN integrated) (NN characterization)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ serological)) (, ,) (ADJP (JJ pathological)) (, ,) (CC and) (ADJP (JJ functional))) (NNS events)) (PP (IN in) (NP (NNP Doc_24675088_86_97_Chemical-induced) (NNP Doc_24675088_106_120_Disease))))) (. .)))
24675088	1	(S1 (S (S (NP (JJ Many) (JJ efficacious) (NNP Doc_24675088_139_145_Disease) (NNS treatments)) (VP (VBP cause) (NP (JJ significant) (NNP Doc_24675088_175_192_Disease)))) (, ,) (CC yet) (S (NP (NP (NP (NNS biomarkers)) (CC or) (NP (NP (JJ functional) (NNS indices)) (PP (IN of) (NP (JJ early) (NN damage))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD would) (VP (VB allow) (NP (NP (NN monitoring)) (CC and) (NP (NN intervention))))))) (, ,)) (VP (AUX are) (VP (VBG lacking)))) (. .)))
24675088	2	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (AUX have) (VP (VBN utilized) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (JJ progressive) (NNP Doc_24675088_367_378_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_24675088_380_383_Chemical)) (-RRB- -RRB-)) (JJ -induced) (NNP Doc_24675088_393_407_Disease)))) (, ,) (S (VP (VBG applying) (NP (NP (JJ multiple) (NNS approaches)) (, ,) (PP (VBG including) (NP (NP (JJ cardiac) (JJ magnetic) (NN resonance) (NN imaging)) (PRN (-LRB- -LRB-) (NP (NNP MRI)) (-RRB- -RRB-)))) (, ,)) (S (VP (TO to) (VP (VB provide) (NP (NP (DT the) (ADJP (RBS most) (JJ comprehensive)) (NN characterization)) (PP (TO to) (NP (NN date))) (PP (IN of) (NP (NP (DT the) (NN timecourse)) (PP (IN of) (NP (NP (ADJP (JJ serological) (, ,) (JJ pathological) (, ,) (CC and) (JJ functional)) (NNS events)) (VP (VBG underlying) (NP (DT this) (NNP Doc_24675088_636_644_Disease))))))))))))))) (. .)))
24675088	3	(S1 (S (NP (NNP Hannover) (NNP Wistar) (NNS rats)) (VP (AUX were) (VP (VBN dosed) (PP (IN with) (NP (NP (CD 1.25) (JJ mg/kg) (JJ Doc_24675088_694_697_Chemical) (NN weekly)) (PP (IN for) (NP (NP (CD 8) (NNS weeks)) (VP (VBN followed) (PP (IN by) (NP (DT a) (ADJP (CD 4) (NN week) (JJ off-dosing)) (`` ``) (NN recovery) ('' '') (NN period)))))))))) (. .)))
24675088	4	(S1 (S (NP (NP (NNP Electron) (NN microscopy)) (PP (IN of) (NP (DT the) (NN myocardium)))) (VP (VP (VBD revealed) (NP (JJ subcellular) (NN degeneration))) (CC and) (VP (VBD marked) (NP (JJ mitochondrial) (NNS changes)) (PP (IN after) (NP (DT a) (JJ single) (NN dose))))) (. .)))
24675088	5	(S1 (S (NP (JJ Histopathological) (NN analysis)) (VP (VBD revealed) (NP (NP (JJ progressive) (NN Doc_24675088_942_968_Disease)) (, ,) (NP (NNP Doc_24675088_970_981_Disease/cytomegaly)) (, ,) (CC and) (NP (JJ extensive) (NN vacuolation))) (PP (IN after) (NP (CD two) (NNS doses)))) (. .)))
24675088	6	(S1 (S (NP (NP (JJ Extensive) (NN replacement) (NN Doc_24675088_1059_1067_Disease)) (PRN (-LRB- -LRB-) (VP (VBN quantified) (PP (IN by) (NP (JJ Sirius) (JJ red) (NN staining)))) (-RRB- -RRB-))) (VP (VBD developed) (PP (IN during) (NP (DT the) (JJ off-dosing) (NN period)))) (. .)))
24675088	7	(S1 (S (NP (NP (JJ Functional) (NNS indices)) (VP (VBN assessed) (PP (IN by) (NP (NP (JJ cardiac) (NNP MRI)) (PRN (-LRB- -LRB-) (PP (VBG including) (NP (NP (NP (JJ left) (JJ ventricular) (NN ejection) (NN fraction)) (PRN (-LRB- -LRB-) (NP (NN LVEF)) (-RRB- -RRB-))) (, ,) (NP (JJ cardiac) (NN output)) (, ,) (CC and) (NP (NNP E/A) (NN ratio)))) (-RRB- -RRB-)))))) (VP (VBD declined) (ADVP (RB progressively)) (, ,) (S (VP (VP (VBG reaching) (NP (JJ statistical) (NN significance)) (PP (IN after) (NP (CD two) (NNS doses)))) (CC and) (VP (VBG culminating) (PP (IN in) (NP (`` ``) (JJ clinical) ('' '') (NNP Doc_24675088_1376_1390_Disease))) (PP (IN by) (NP (CD 12) (NNS weeks))))))) (. .)))
24675088	8	(S1 (S (NP (NP (JJ Significant) (NNS increases)) (PP (IN in) (NP (NP (JJ peak) (JJ myocardial) (NN contrast) (NN enhancement)) (CC and) (NP (JJ serological) (JJ cardiac) (NN troponin) (NN I)))) (PRN (-LRB- -LRB-) (NP (NN cTnI)) (-RRB- -RRB-))) (VP (VBD emerged) (PP (IN after) (NP (CD eight) (NNS doses))) (, ,) (S (ADVP (RB importantly)) (VP (VBG preceding) (NP (DT the) (NN LVEF) (NN decline)) (PP (TO to) (NP (CD <50) (NN %)))))) (. .)))
24675088	9	(S1 (S (NP (JJ Doc_24675088_1583_1591_Chemical) (NN I) (NNS levels)) (ADVP (RB positively)) (VP (VBN correlated) (PP (IN with) (NP (NP (JJ delayed) (CC and) (JJ peak) (JJ Doc_24675088_1645_1655_Chemical) (NN contrast) (NN enhancement)) (, ,) (NP (JJ histopathological) (NN grading)) (, ,) (CC and) (NP (NNP Doc_24675088_1709_1730_Disease))))) (. .)))
24675088	10	(S1 (S (PP (IN In) (NP (NN summary))) (, ,) (NP (JJ subcellular) (NN Doc_24675088_1756_1782_Disease)) (VP (AUX was) (NP (DT the) (JJS earliest) (NN marker)) (, ,) (S (VP (VBN followed) (PP (IN by) (NP (NP (JJ progressive) (JJ functional) (NN decline)) (CC and) (NP (JJ histopathological) (NNS manifestations))))))) (. .)))
24675088	11	(S1 (S (NP (NP (JJ Myocardial) (NN contrast) (NN enhancement)) (CC and) (NP (NP (NNS elevations)) (PP (IN in) (NP (NNS cTnI))))) (VP (VBD occurred) (ADVP (RB later))) (. .)))
24675088	12	(S1 (S (ADVP (RB However)) (, ,) (NP (DT all) (NNS indices)) (VP (VP (VBD predated) (NP (`` ``) (JJ clinical) ('' '') (NN Doc_24675088_2001_2015_Disease))) (CC and) (ADVP (RB thus)) (VP (VBP warrant) (NP (JJ further) (NN evaluation)) (PP (IN as) (NP (JJ predictive) (NNS biomarkers))))) (. .)))
24684312	0	(S1 (NP (NP (NNP Intradermal) (NNP Doc_24684312_12_21_Chemical) (CC and) (NNP Doc_24684312_26_35_Chemical) (NNS injections)) (: :) (NP (NP (NP (NN intra-)) (CC and) (NP (JJ interindividual) (NN variability))) (PP (IN of) (NP (NP (VBN provoked) (NNP Doc_24684312_99_111_Disease)) (CC and) (NP (NNP Doc_24684312_116_125_Disease))))) (. .)))
24684312	1	(S1 (S (NP (NP (JJ Intradermal) (NNS injections)) (PP (IN of) (NP (NNP Doc_24684312_153_162_Chemical) (CC and) (NNP Doc_24684312_167_176_Chemical)))) (VP (AUX are) (ADJP (JJ attractive) (S (VP (TO to) (VP (VB use) (PP (IN in) (NP (JJ human) (NNP Doc_24684312_208_225_Disease) (NNS models))) (SBAR (IN because) (S (NP (NP (NNP Doc_24684312_241_253_Disease)) (CC and) (NP (NNP Doc_24684312_258_267_Disease))) (VP (VBP mimic) (NP (NP (JJ isolated) (NNS aspects)) (PP (IN of) (NP (JJ clinical) (NNP Doc_24684312_303_317_Disease)))))))))))) (. .)))
24684312	2	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN reproducibility)) (PP (IN of) (NP (DT these) (NNS models)))))))) (. .)))
24684312	3	(S1 (S (NP (NP (CD Twenty) (JJ healthy) (NN male) (NNS volunteers)) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ mean) (NN age)) (NP (CD 24) (NNS years))) (: ;) (NP (NP (NN range)) (NP (CD 18-38) (NNS years)))) (-RRB- -RRB-))) (VP (VBD received) (NP (NP (JJ intradermal) (NNS injections)) (PP (IN of) (NP (NP (NNP Doc_24684312_509_518_Chemical)) (CC and) (NP (NNP Doc_24684312_523_532_Chemical))))) (PP (IN in) (NP (DT the) (JJ volar) (NN forearm)))) (. .)))
24684312	4	(S1 (S (NP (NP (NNS Magnitudes)) (PP (IN of) (NP (NP (JJ secondary) (JJ pinprick) (NN Doc_24684312_588_600_Disease)) (CC and) (NP (JJ brush-evoked) (NN Doc_24684312_618_627_Disease))))) (VP (AUX were) (VP (VBN investigated) (S (VP (VBG using) (NP (NP (NP (NNP von) (NNP Frey) (NNS filaments)) (PRN (-LRB- -LRB-) (NP (NP (NNS gauges) (CD 10) (, ,) (CD 15) (, ,) (CD 60) (CC and) (CD 100)) (NP (NNP g))) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_24684312_705_718_Disease))))))) (. .)))
24684312	5	(S1 (S (NP (NP (NNS Areas)) (PP (IN of) (NP (NP (JJ secondary) (NNP Doc_24684312_739_751_Disease)) (CC and) (NP (NNP Doc_24684312_756_765_Disease))))) (VP (AUX were) (VP (VBN quantified) (ADVP (RB immediately)) (PP (PP (IN after) (NP (NN injection))) (CC and) (PP (IN after) (NP (CD 15) (, ,) (CD 30) (CC and) (CD 60) (NN min)))))) (. .)))
24684312	6	(S1 (S (NP (NP (CD Two) (JJ identical) (NNS experiments)) (VP (VBN separated) (PP (IN by) (NP (QP (IN at) (JJS least) (CD 7)) (NNS days))))) (VP (AUX were) (VP (VBN performed))) (. .)))
24684312	7	(S1 (S (NP (NP (NN Reproducibility)) (PP (IN across) (CC and) (PP (IN within) (NP (NNS volunteers))) (PRN (-LRB- -LRB-) (FRAG (NP (NP (NN inter-)) (CC and) (NP (JJ intra-individual) (NN variation))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-)))) (VP (AUX was) (VP (VBN assessed) (S (VP (VBG using) (NP (NP (JJ intraclass) (NN correlation) (NN coefficient)) (PRN (-LRB- -LRB-) (NP (NNP ICC)) (-RRB- -RRB-)) (CC and) (NP (NP (NN coefficient)) (PP (IN of) (NP (NN variation))) (PRN (-LRB- -LRB-) (NP (NNP CV)) (-RRB- -RRB-)))))))) (. .)))
24684312	8	(S1 (S (NP (JJ Secondary) (NN pinprick) (NNP Doc_24684312_1123_1135_Disease)) (VP (AUX was) (VP (VBN observed) (SBAR (IN as) (S (NP (NP (DT a) (JJ marked) (NN increase)) (PP (IN in) (NP (NP (DT the) (JJ visual) (NN analogue) (NN scale) (PRN (-LRB- -LRB-) (NNP VAS) (-RRB- -RRB-)) (NN response)) (PP (TO to) (NP (NNP von) (NNP Frey)))))) (VP (VBZ gauges) (NP (NP (QP (CD 60) (CC and) (CD 100)) (NNP g)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.001))) (-RRB- -RRB-))) (PP (IN after) (NP (JJ Doc_24684312_1264_1273_Chemical) (NN injection)))))))) (. .)))
24684312	9	(S1 (S (PP (IN For) (NP (NNP Doc_24684312_1289_1298_Chemical))) (, ,) (NP (JJ secondary) (NN pinprick) (NN Doc_24684312_1319_1331_Disease)) (VP (AUX was) (VP (VBN detected) (PP (IN with) (NP (NP (DT all) (NNP von) (NNP Frey) (NNS gauges)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.001))) (-RRB- -RRB-)))))) (. .)))
24684312	10	(S1 (S (NP (NNP Doc_24684312_1383_1392_Chemical)) (VP (VBD evoked) (NP (NP (JJ reproducible) (NN VAS) (NN response)) (PP (TO to) (NP (NP (NP (DT all) (NNP von) (NNP Frey) (NNS gauges)) (PRN (-LRB- -LRB-) (NP (QP ($ ICC) (CD >) (CD 0.60))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_24684312_1466_1479_Disease)) (PRN (-LRB- -LRB-) (NP (NNP ICC) (QP (CD >) (CD 0.83))) (-RRB- -RRB-))))))) (. .)))
24684312	11	(S1 (S (NP (JJ Doc_24684312_1494_1503_Chemical) (NN injection)) (VP (AUX was) (NP (NP (NN reproducible)) (PP (IN for) (NP (NP (NP (JJ secondary) (NNP Doc_24684312_1545_1557_Disease)) (PRN (-LRB- -LRB-) (NP (NNP ICC) (QP (CD >) (CD 0.70))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_24684312_1575_1584_Disease)) (PRN (-LRB- -LRB-) (NP (NNP ICC) (QP (CD >) (CD 0.71))) (-RRB- -RRB-))))))) (. .)))
24684312	12	(S1 (S (NP (JJ Intra-individual) (NN variability)) (VP (AUX was) (ADJP (RB generally) (JJR lower)) (PP (IN for) (NP (NP (DT the) (JJ VAS) (NN response)) (PP (TO to) (NP (NP (NNP von) (NNP Frey)) (CC and) (NP (NN brush)))))) (PP (VBN compared) (PP (IN with) (NP (NP (NNS areas)) (PP (IN of) (NP (JJ secondary) (NNP Doc_24684312_1724_1736_Disease) (CC and) (NNP Doc_24684312_1741_1750_Disease))))))) (. .)))
24684312	13	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (S (NP (NNP Doc_24684312_1767_1776_Chemical) (CC and) (NNP Doc_24684312_1781_1790_Chemical)) (VP (VBP yield) (NP (JJ reproducible) (UCP (NNP Doc_24684312_1810_1822_Disease) (CC and) (JJ allodynic)) (NNS responses)))) (, ,) (CC and) (S (NP (DT the) (JJ present) (NN model)) (VP (AUX is) (VP (ADVP (RB well)) (VBN suited) (PP (IN for) (NP (JJ basic) (NN research))) (, ,) (PP (CONJP (RB as) (RB well) (IN as)) (PP (IN for) (S (VP (VBG assessing) (NP (NP (DT the) (NN modulation)) (PP (IN of) (NP (JJ central) (NNS phenomena))))))))))) (. .)))
24691439	0	(S1 (S (NP (JJ Ocular-specific) (NN ER) (NN stress) (NN reduction)) (VP (VBZ rescues) (NP (NNP Doc_24691439_44_52_Disease)) (PP (IN in) (NP (JJ murine) (JJ glucocorticoid-induced) (NN Doc_24691439_86_94_Disease)))) (. .)))
24691439	1	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NNS glucocorticoids)))) (VP (VBZ induces) (NP (NN Doc_24691439_138_157_Disease)) (PP (IN in) (NP (DT some) (NNS patients)))) (. .)))
24691439	2	(S1 (S (SBAR (IN If) (FRAG (ADJP (JJ untreated)))) (, ,) (NP (DT these) (NNS patients)) (VP (MD can) (VP (VB develop) (NP (NP (DT a) (NN Doc_24691439_219_237_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBZ resembles) (NP (NP (NNP Doc_24691439_253_280_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24691439_282_286_Disease)) (-RRB- -RRB-))))))))) (. .)))
24691439	3	(S1 (S (NP (NP (DT The) (JJ underlying) (NN pathology)) (PP (IN of) (NP (JJ glucocorticoid-induced) (NNP Doc_24691439_340_348_Disease)))) (VP (AUX is) (RB not) (VP (ADVP (RB fully)) (VBN understood) (, ,) (S (ADJP (JJ due) (PP (IN in) (NP (NN part))) (PP (TO to) (NP (NP (NN lack)) (PP (IN of) (NP (DT an) (JJ appropriate) (NN animal) (NN model))))))))) (. .)))
24691439	4	(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBD developed) (NP (NP (DT a) (JJ murine) (NN model)) (PP (IN of) (NP (JJ glucocorticoid-induced) (NNP Doc_24691439_486_494_Disease))) (SBAR (WHNP (WDT that)) (S (NP (NNS exhibits)) (VP (VBP Doc_24691439_509_517_Disease) (NP (NP (NNS features)) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (VP (VBN observed) (PP (IN in) (NP (NNS patients))))))))))))) (. .)))
24691439	5	(S1 (S (NP (NP (NP (NN Treatment)) (PP (IN of) (NP (NP (JJ WT) (NNS mice)) (PP (IN with) (NP (JJ topical) (NN ocular)))))) (NP (CD 0.1) (NN %)) (NNP Doc_24691439_604_617_Chemical)) (VP (VBD led) (PP (TO to) (NP (NP (NP (NN elevation)) (PP (IN of) (NP (NP (JJ intraocular) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN IOP)) (-RRB- -RRB-))))) (, ,) (NP (JJ functional) (CC and) (JJ Doc_24691439_681_716_Disease) (NNS cells)) (, ,) (CC and) (NP (NNP Doc_24691439_728_747_Disease)))) (, ,) (S (VP (VBG resembling) (NP (JJ glucocorticoid-induced) (NNP Doc_24691439_783_791_Disease)) (PP (IN in) (NP (JJ human) (NNS patients)))))) (. .)))
24691439	6	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NNP Doc_24691439_824_837_Chemical-induced) (NNP Doc_24691439_846_865_Disease)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ chronic) (JJ ER) (NN stress)) (PP (IN of) (NP (NP (DT the) (JJ trabecular) (NN meshwork)) (PRN (-LRB- -LRB-) (NP (NNP TM)) (-RRB- -RRB-)))))))) (. .)))
24691439	7	(S1 (S (S (ADJP (JJ Similar) (PP (TO to) (NP (NNS patients))))) (, ,) (NP (NP (NN withdrawal)) (PP (IN of) (NP (JJ Doc_24691439_972_985_Chemical) (NN treatment)))) (VP (VBD reduced) (NP (NP (JJ elevated) (NN IOP)) (CC and) (NP (JJ ER) (NN stress))) (PP (IN in) (NP (DT this) (NN animal) (NN model)))) (. .)))
24691439	8	(S1 (S (S (NP (NN Doc_24691439_1053_1066_Chemical)) (VP (VBN induced) (S (NP (DT the) (JJ transcriptional) (NN factor)) (VP (VB CHOP) (, ,) (NP (NP (DT a) (NN marker)) (PP (IN for) (NP (JJ chronic) (NN ER) (NN stress)))) (, ,) (PP (IN in) (NP (DT the) (NNP anterior) (NN segment) (NNS tissues))))))) (, ,) (CC and) (S (NP (NNP Doc_24691439_1177_1190_Disease)) (VP (VP (VBD reduced) (NP (CD ER) (NN stress)) (PP (IN in) (NP (DT these) (NNS tissues)))) (CC and) (VP (VBD prevented) (NP (JJ Doc_24691439_1240_1253_Chemical-induced) (NNP Doc_24691439_1262_1281_Disease))))) (. .)))
24691439	9	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN reduction)) (PP (IN of) (NP (NN ER) (NN stress))) (PP (IN in) (NP (NP (DT the) (NNS TM)) (PP (IN with) (NP (NNP Doc_24691439_1334_1357_Chemical)))))) (VP (VBD prevented) (NP (JJ Doc_24691439_1368_1381_Chemical-induced) (NNP Doc_24691439_1390_1409_Disease)) (PP (IN in) (NP (JJ WT) (NNS mice)))) (. .)))
24691439	10	(S1 (S (NP (PRP$ Our) (NNS data)) (VP (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ ER) (NN stress)) (VP (VBZ contributes) (PP (TO to) (NP (JJ glucocorticoid-induced) (NN Doc_24691439_1493_1512_Disease))))))) (CC and) (VP (VBP suggest) (SBAR (IN that) (S (S (VP (VBG reducing) (NP (CD ER) (NN stress)))) (VP (AUX has) (ADJP (JJ potential) (PP (IN as) (NP (NP (DT a) (JJ therapeutic) (NN strategy)) (PP (IN for) (S (VP (VBG treating) (NP (JJ glucocorticoid-induced) (NNP Doc_24691439_1625_1633_Disease))))))))))))) (. .)))
24709919	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NNP Doc_24709919_11_23_Chemical))) (PP (IN on) (NP (NP (JJ opioid-induced) (NN Doc_24709919_42_54_Disease)) (PP (IN in) (NP (NNS mice))))) (. .)))
24709919	1	(S1 (S (NP (NP (JJ Opioid-induced) (NNP Doc_24709919_79_91_Disease)) (PRN (-LRB- -LRB-) (NP (NNP OIH)) (-RRB- -RRB-))) (VP (AUX is) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ nociceptive) (NN sensitization)) (VP (VBN caused) (PP (IN by) (NP (NP (DT the) (NN cessation)) (PP (IN of) (NP (JJ chronic) (JJ opioid) (NN use)))))))))) (. .)))
24709919	2	(S1 (S (NP (NN OIH)) (VP (MD can) (VP (VP (VB limit) (NP (NP (DT the) (JJ clinical) (NN use)) (PP (IN of) (NP (JJ opioid) (NNS analgesics))))) (CC and) (VP (VB complicate) (NP (NP (NN withdrawal)) (PP (IN from) (NP (NNP Doc_24709919_274_290_Disease))))))) (. .)))
24709919	3	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NNP Re)) (, ,) (NP (NNP Doc_24709919_342_345_Chemical)) (, ,) (CC and) (NP (NP (NNP Rb1) (NNP Doc_24709919_355_367_Chemical)) (, ,) (NP (NP (DT the) (JJ bioactive) (NNS components)) (PP (IN of) (NP (NN ginseng)))) (, ,)))) (PP (IN on) (NP (NN OIH))))) (. .)))
24709919	4	(S1 (S (NP (NN OIH)) (VP (AUX was) (VP (VBN achieved) (PP (IN in) (NP (NNS mice))) (PP (IN after) (NP (NP (NP (NP (JJ subcutaneous) (NN administration)) (PP (IN of) (NP (NNP Doc_24709919_476_484_Chemical))) (PP (IN for) (NP (CD 7) (JJ consecutive) (NNS days)))) (NP (CD three) (NNS times))) (PP (IN per) (NP (NN day))))))) (. .)))
24709919	5	(S1 (S (PP (IN During) (NP (NP (NN withdrawal)) (PRN (-LRB- -LRB-) (NP (NNS days) (CD 8) (CC and) (CD 9)) (-RRB- -RRB-)))) (, ,) (NP (DT these) (NNS mice)) (VP (AUX were) (VP (VBN administered) (NP (NP (NNP Re)) (, ,) (NP (NNP Doc_24709919_596_599_Chemical)) (, ,) (CC or) (NP (NNP Rb1))) (ADVP (RB intragastrically) (NP (CD two) (NNS times)) (PP (IN per) (NP (NN day)))))) (. .)))
24709919	6	(S1 (S (PP (IN On) (NP (NP (DT the) (NN test) (NN day)) (PRN (-LRB- -LRB-) (NP (NN day) (CD 10)) (-RRB- -RRB-)))) (, ,) (NP (NNS mice)) (VP (AUX were) (VP (VBN subjected) (PP (TO to) (NP (NP (DT the) (JJ thermal) (NN sensitivity) (NN test)) (CC and) (NP (DT the) (JJ Doc_24709919_730_741_Chemical-induced) (VBG writhing) (NN test)))))) (. .)))
24709919	7	(S1 (S (NP (NP (NNP Re)) (PRN (-LRB- -LRB-) (NP (CD 300) (NN mg/kg)) (-RRB- -RRB-))) (VP (VBD inhibited) (NP (NN OIH)) (PP (IN in) (NP (NP (PDT both) (DT the) (JJ thermal) (NN sensitivity) (NN test)) (CC and) (NP (DT the) (JJ Doc_24709919_839_850_Chemical-induced) (VBG writhing) (NN test))))) (. .)))
24709919	8	(S1 (S (ADVP (RB However)) (, ,) (NP (DT the) (NNP Doc_24709919_887_890_Chemical) (CC and) (NNP Rb1) (NNP Doc_24709919_899_911_Chemical)) (VP (VBD failed) (S (VP (TO to) (VP (VB prevent) (NP (NN OIH)) (PP (IN in) (NP (DT either) (NN test))))))) (. .)))
24709919	9	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NNP Doc_24709919_963_966_Chemical)) (VP (VBD showed) (NP (NP (DT a) (NN tendency)) (SBAR (S (VP (TO to) (VP (VB aggravate) (NP (NN OIH)) (PP (IN in) (NP (DT the) (JJ Doc_24709919_1009_1020_Chemical-induced) (VBG writhing) (NN test))))))))) (. .)))
24709919	10	(S1 (S (NP (PRP$ Our) (NNS data)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NP (DT the) (NNP Doc_24709919_1072_1086_Chemical)) (, ,) (CONJP (CC but) (RB not)) (NP (NP (NNP Doc_24709919_1096_1099_Chemical)) (CC or) (NP (NNP Rb1))) (, ,)) (VP (MD may) (VP (VB contribute) (PP (IN toward) (NP (NP (NN reversal)) (PP (IN of) (NP (NN OIH)))))))))) (. .)))
24717468	0	(S1 (NP (NP (DT A) (NN comparison)) (PP (IN of) (NP (JJ severe) (JJ hemodynamic) (NNS disturbances))) (PP (IN between) (NP (NP (NNP Doc_24717468_56_71_Chemical) (CC and) (NNP Doc_24717468_76_84_Chemical)) (PP (IN for) (NP (NN sedation))) (PP (IN in) (NP (JJ neurocritical) (NN care) (NNS patients))))) (. .)))
24717468	1	(S1 (S (NP (NP (NNP Doc_24717468_141_156_Chemical)) (CC and) (NP (NNP Doc_24717468_161_169_Chemical))) (VP (AUX are) (NP (NP (ADJP (RB commonly) (VBN used)) (NNS sedatives)) (PP (IN in) (NP (JJ neurocritical) (NN care)))) (SBAR (IN as) (S (NP (PRP they)) (VP (VBP allow) (PP (IN for) (NP (JJ frequent) (JJ neurologic) (NNS examinations))))))) (. .)))
24717468	2	(S1 (S (ADVP (RB However)) (, ,) (NP (DT both) (NNS agents)) (VP (AUX are) (VP (VBN associated) (PP (IN with) (NP (JJ significant) (JJ hemodynamic) (NN side) (NNS effects))))) (. .)))
24717468	3	(S1 (S (NP (NP (DT The) (JJ primary) (NN objective)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX is) (S (VP (TO to) (VP (VB compare) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (NP (JJ severe) (JJ hemodynamic) (NNS effects)) (PP (IN in) (NP (NP (JJ neurocritical) (NN care) (NNS patients)) (VP (VBG receiving) (NP (NP (NNP Doc_24717468_487_502_Chemical)) (CC and) (NP (NNP Doc_24717468_507_515_Chemical))))))))))))) (. .)))
24717468	4	(S1 (NP (NP (NN Multicenter)) (, ,) (NP (NN retrospective)) (, ,) (NP (JJ propensity-matched) (NN cohort) (NN study)) (. .)))
24717468	5	(S1 (NP (NP (JJ Neurocritical) (NN care) (NNS units)) (PP (IN at) (NP (NP (CD two) (JJ academic) (JJ medical) (NNS centers)) (PP (IN with) (NP (NP (VBN dedicated) (JJ neurocritical) (NN care) (NNS teams)) (CC and) (NP (JJ board-certified) (NNS neurointensivists)))))) (. .)))
24717468	6	(S1 (S (NP (NP (JJ Neurocritical) (NN care) (NNS patients)) (VP (VBN admitted) (PP (IN between) (NP (NNP July) (CD 2009) (CC and) (NP (NNP September) (CD 2012)))))) (VP (AUX were) (VP (VP (VBN evaluated)) (CC and) (VP (ADVP (RB then)) (VBN matched) (ADVP (RB 1:1)) (PP (VBN based) (PP (IN on) (NP (NP (NN propensity) (NN scoring)) (PP (IN of) (NP (NN baseline) (NNS characteristics))))))))) (. .)))
24717468	7	(S1 (NP (NP (JJ Continuous) (NN sedation)) (PP (IN with) (NP (NP (NNP Doc_24717468_948_963_Chemical)) (CC or) (NP (NNP Doc_24717468_967_975_Chemical)))) (. .)))
24717468	8	(S1 (S (NP (NP (NNS MEASUREMENTS)) (CC AND) (NP (NP (JJ MAIN) (NNS RESULTS)) (: :) (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (CD 342) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD 105) (NN Doc_24717468_1037_1052_Chemical)) (CC and) (NP (CD 237) (NN Doc_24717468_1061_1069_Chemical))) (-RRB- -RRB-))))))) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (DT the) (NN analysis))) (, ,) (SBAR (IN with) (S (NP (CD 190)) (VP (VBN matched) (PRN (-LRB- -LRB-) (NP (NP (CD 95)) (PP (IN in) (NP (DT each) (NN group)))) (-RRB- -RRB-)) (PP (IN by) (NP (NN propensity) (NN score)))))))) (. .)))
24717468	9	(S1 (S (NP (NP (DT The) (JJ primary) (NN outcome)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (NP (NP (DT a) (JJ composite)) (PP (IN of) (NP (NP (NP (JJ severe) (NNP Doc_24717468_1219_1230_Disease)) (PRN (-LRB- -LRB-) (NP (NP (JJ mean) (JJ arterial) (NN pressure)) (VP (VBN <) (NP (QP (CD 60) (CD mm)) (NNP Hg)))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_24717468_1271_1282_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN heart) (NN rate)) (NP (QP (RB <) (CD 50)) (NN beats/min))) (-RRB- -RRB-)))))) (PP (IN during) (NP (JJ sedative) (NN infusion)))) (. .)))
24717468	10	(S1 (S (NP (NP (DT No) (NN difference)) (PP (IN in) (NP (DT the) (JJ primary) (JJ composite) (NN outcome))) (PP (IN in) (NP (NP (NP (PDT both) (DT the) (JJ unmatched)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 30) (NN %)) (NNP vs) (CD 30) (NN %)) (, ,) (NP (NNP p) (SYM =) (CD 0.94))) (-RRB- -RRB-))) (CC or) (NP (NP (VBN matched) (NNS cohorts)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 28) (NN %)) (NNP vs) (CD 34) (NN %)) (, ,) (NP (NNP p) (SYM =) (CD 0.35))) (-RRB- -RRB-)))))) (VP (MD could) (VP (AUX be) (VP (VBN found)))) (. .)))
24717468	11	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN analyzed) (ADVP (RB separately))))) (, ,) (NP (DT no) (NNS differences)) (VP (MD could) (VP (AUX be) (VP (VBN found) (PP (IN in) (NP (NP (DT the) (NN prevalence)) (PP (IN of) (NP (JJ severe) (NNP Doc_24717468_1571_1582_Disease) (CC or) (NNP Doc_24717468_1586_1597_Disease))) (PP (IN in) (NP (CC either) (NP (DT the) (JJ unmatched)) (CC or) (NP (VBN matched) (NNS cohorts))))))))) (. .)))
24717468	12	(S1 (S (NP (NP (JJ Severe) (NNP Doc_24717468_1662_1673_Disease)) (CC and) (NP (NNP Doc_24717468_1678_1689_Disease))) (VP (VBP occur) (PP (IN at) (NP (NP (JJ similar) (NN prevalence)) (PP (IN in) (NP (NP (JJ neurocritical) (NN care) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP receive) (NP (NP (NNP Doc_24717468_1761_1776_Chemical)) (CC or) (NP (NNP Doc_24717468_1780_1788_Chemical))))))))))) (. .)))
24717468	13	(S1 (S (NP (NNS Providers)) (VP (MD should) (ADVP (RB similarly)) (VP (VB consider) (NP (NP (DT the) (NN likelihood)) (PP (IN of) (NP (NP (NNP Doc_24717468_1844_1855_Disease)) (CC or) (NP (NNP Doc_24717468_1859_1870_Disease))))) (PP (IN before) (S (VP (VBG starting) (NP (DT either) (NN sedative))))))) (. .)))
24727461	0	(S1 (S (NP (JJ Doc_24727461_0_14_Chemical) (NNS ameliorates)) (VP (VBP oxidative) (NP (NP (NN stress)) (CC and) (NP (NNP Doc_24727461_48_73_Disease))) (PP (IN in) (NP (NP (NNP Doc_24727461_77_88_Chemical-induced) (NNP Doc_24727461_97_111_Disease)) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NNP Doc_24727461_125_138_Disease)))))))) (. .)))
24727461	1	(S1 (S (NP (JJ Oxidative) (NN stress)) (VP (VP (AUX is) (VP (VBN involved) (PP (IN in) (NP (NP (JJ several) (NNS processes)) (PP (VBG including) (NP (NP (NNP Doc_24727461_200_206_Disease)) (, ,) (NP (NN aging)) (CC and) (NP (NNP Doc_24727461_218_240_Disease)))))))) (, ,) (CC and) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (VP (VB potentiate) (NP (NP (DT the) (JJ therapeutic) (NN effect)) (PP (IN of) (NP (NP (NNS drugs)) (PP (JJ such) (IN as) (NP (NNP Doc_24727461_315_326_Chemical))))))))))))) (. .)))
24727461	2	(S1 (S (NP (NN Doc_24727461_328_339_Chemical)) (VP (VBZ causes) (NP (NP (JJ significant) (NN Doc_24727461_359_373_Disease)) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ marked) (NNS increases)) (PP (IN in) (NP (NP (JJ oxidative) (NN stress)) (CC and) (NP (NNP Doc_24727461_432_457_Disease))))))))) (. .)))
24727461	3	(S1 (S (ADVP (RB Herein)) (, ,) (NP (PRP we)) (VP (VB investigate) (SBAR (IN whether) (S (NP (JJ Doc_24727461_490_501_Chemical-associated) (NN chronic) (NN Doc_24727461_521_537_Disease)) (VP (MD can) (VP (AUX be) (VP (VBN ameliorated) (PP (IN with) (NP (NP (DT the) (JJ antioxidant) (NN Doc_24727461_578_592_Chemical)) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NNP Doc_24727461_606_619_Disease))))))))))))) (. .)))
24727461	4	(S1 (S (NP (NP (JJ Thirty-six) (NNS rats)) (VP (VBG bearing) (S (NP (NNP Doc_24727461_645_658_Disease)) (VP (VBN induced) (ADVP (RB chemically)))))) (VP (AUX were) (VP (VBN divided) (PP (IN into) (NP (NP (NP (CD 4) (NNS groups)) (: :) (NP (NN control))) (, ,) (NP (NP (NP (NNP Doc_24727461_715_729_Chemical)) (PRN (-LRB- -LRB-) (NP (NN 0.5mg/kg)) (, ,) (NP (NN 5days/week)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_24727461_754_765_Chemical)) (PRN (-LRB- -LRB-) (NP (NN 1mg/kg/week)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNP Doc_24727461_785_796_Chemical) (CC plus) (NNP Doc_24727461_802_816_Chemical))))))) (. .)))
24727461	5	(S1 (S (NP (NP (JJ Cardiac) (NNS disturbances)) (PP (IN at) (NP (NP (DT the) (JJ cellular) (CC and) (JJ mitochondrial) (NN level)) (, ,) (NP (JJ mitochondrial) (NNP electron) (NN transport) (NN chain) (NNS complexes) (NX (NX (NNP I-IV)) (CC and) (NX (JJ apoptosis-inducing) (NN factor)))) (, ,) (CC and) (NP (JJ oxidative) (NN stress) (NNS markers))))) (VP (AUX have) (VP (AUX been) (VP (VBN analyzed)))) (. .)))
24727461	6	(S1 (S (NP (NN Doc_24727461_1014_1028_Chemical)) (VP (VBD improved) (NP (NP (DT the) (NNP Doc_24727461_1042_1062_Disease)) (VP (VBN enhanced) (PP (IN by) (NP (NNP Doc_24727461_1075_1086_Chemical))) (PP (IN by) (S (VP (ADVP (RB significantly)) (VBG reducing) (NP (NP (DT the) (NN percentage)) (PP (IN of) (NP (NP (JJ altered) (NN mitochondria)) (CC and) (NP (JJ oxidative) (NN damage))))))))))) (. .)))
24727461	7	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_24727461_1201_1215_Chemical)) (VP (VBP improve) (NP (DT the) (JJ mitochondrial) (NNP electron) (NN transport) (NN chain)))))) (. .)))
24727461	8	(S1 (S (NP (DT This) (NN study)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (NNP Doc_24727461_1297_1311_Chemical)) (VP (VB protect) (NP (NP (NN rat) (NN heart) (NN damage)) (VP (VBN provoked) (PP (IN by) (S (NP (NNP Doc_24727461_1349_1360_Chemical)) (VP (VBG decreasing) (NP (NP (JJ oxidative) (NN damage)) (CC and) (NP (JJ mitochondrial) (NNS alterations)))))))))))) (. .)))
24729111	0	(S1 (NP (JJ Doc_24729111_0_10_Chemical-induced) (NN Doc_24729111_19_33_Disease) (. .)))
24729111	1	(S1 (S (NP (DT A) (JJ 62-year-old) (NN man)) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX have) (NP (NP (NNP Doc_24729111_71_82_Disease)) (, ,) (NP (NNP Doc_24729111_84_95_Disease)) (CC and) (NP (NNP Doc_24729111_100_119_Disease))) (PP (NP (CD 3) (NNS weeks)) (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (JJ Doc_24729111_148_158_Chemical) (NN therapy)) (PP (IN for) (NP (NNP Doc_24729111_171_190_Disease)))))))))))) (. .)))
24729111	2	(S1 (S (S (NP (JJ Thyroid-stimulating) (NN hormone)) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX be) (NP (NP (CD 168) (NNS uIU/mL)) (PRN (-LRB- -LRB-) (NP (QP (CD nl.) (CD 0.3-5)) (NNS uIU/mL)) (-RRB- -RRB-))))))))) (CC and) (S (NP (NP (JJ free) (NNP Doc_24729111_275_284_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP FT4)) (-RRB- -RRB-))) (VP (AUX was) (NP (NP (CD <0.2) (NN ng/dL)) (PRN (-LRB- -LRB-) (NP (QP (CD nl.) (CD 0.8-1.8)) (NNS ng/dL)) (-RRB- -RRB-))))) (. .)))
24729111	3	(S1 (S (S (NP (PRP He)) (VP (VBD received) (NP (NP (JJ intravenous) (NNS fluids)) (, ,) (NP (NN vasopressor) (NN therapy)) (CC and) (NP (NN stress) (NN dose))) (NP (NNP Doc_24729111_395_403_Chemical)))) (: ;) (S (NP (PRP he)) (VP (VP (AUX was) (VP (VBN intubated))) (CC and) (VP (VBD admitted) (PP (TO to) (NP (DT the) (JJ intensive) (NN care) (NN unit)))))) (. .)))
24729111	4	(S1 (S (NP (PRP He)) (VP (VBD received) (NP (NP (NP (CD 500) (NN ug)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_24729111_497_510_Chemical))) (PP (IN in) (NP (NP (DT the) (JJ first) (CD 18) (NNP h)) (PP (IN of) (NP (NN therapy)))))) (, ,) (CC and) (NP (NP (CD 150) (NNS ug)) (NP (JJ intravenous) (NN daily)))) (ADVP (RB thereafter))) (. .)))
24729111	5	(S1 (S (NP (JJ Haemodynamic) (NN improvement)) (, ,) (PP (IN along) (PP (IN with) (NP (NP (JJ complete) (NN recovery)) (PP (IN of) (NP (JJ mental) (NN status)))))) (, ,) (VP (VBD occurred) (PP (IN after) (NP (NP (CD 48) (NNP h.) (NNP Twelve) (NNS hours)) (PP (IN after) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NN therapy))))) (, ,) (SBAR (WHNP (WDT FT4)) (S (VP (AUX was) (NP (CD 0.96) (NN ng/dL)))))))) (. .)))
24729111	6	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (VP (VBN maintained) (PP (IN on) (NP (NNP Doc_24729111_772_785_Chemical) (CD 175))) (PRN (-LRB- -LRB-) (NP (NNP g)) (ADVP (RB POorally)) (ADVP (RB daily))))) (. .)))
24729111	7	(S1 (S (NP (DT A) (JJ thyroid) (NN ultrasound)) (VP (VBD showed) (NP (JJ diffuse) (NN heterogeneity))) (. .)))
24729111	8	(S1 (S (NP (NP (DT The) (ADJP (CD 24) (NN hour)) (NN excretion)) (PP (IN of) (NP (NNP Doc_24729111_885_891_Chemical)))) (VP (AUX was) (NP (NP (CD 3657)) (PRN (-LRB- -LRB-) (JJ mcg) (-LRB- -LRB-) (JJ 25-756) (-LRB- -LRB-) (NP (NN mcg)) (-RRB- -RRB-)))) (. .)))
24729111	9	(S1 (S (NP (NP (DT The) (JJ only) (CD two) (NNS cases)) (PP (IN of) (NP (NP (NNP Doc_24729111_944_954_Chemical-induced) (NNP Doc_24729111_963_977_Disease)) (PP (IN in) (NP (DT the) (NN literature)))))) (VP (VBP report) (NP (NN patient) (NN Doc_24729111_1011_1016_Disease)) (PP (IN despite) (NP (NP (JJ supportive) (NN therapy)) (CC and) (NP (JJ thyroid) (NN hormone) (NN replacement))))) (. .)))
24729111	10	(S1 (S (NP (DT This) (NN case)) (VP (VBZ represents) (NP (NP (DT the) (ADJP (RBS most) (RB thoroughly) (VBN investigated)) (NN case)) (PP (IN of) (NP (NNP Doc_24729111_1139_1149_Chemical-induced) (NNP Doc_24729111_1158_1172_Disease))) (PP (IN with) (NP (NP (DT a) (NN history)) (ADJP (JJ significant) (PP (IN for) (NP (NNP Doc_24729111_1204_1231_Disease)))))))) (. .)))
24733133	0	(S1 (NP (NP (NP (NP (NN Use)) (PP (IN of) (NP (NNP Doc_24733133_7_17_Chemical)))) (CC and) (NP (NP (JJ catheter-directed) (NN thrombolysis)) (PP (IN with) (NP (NN alteplase))))) (PP (IN in) (NP (NP (DT an) (JJ oncology) (NN patient)) (PP (IN with) (NP (NP (JJ Doc_24733133_96_103_Chemical-induced) (NNS thrombocytopenia)) (PP (IN with) (NP (NN thrombosis))))))) (. .)))
24733133	1	(S1 (S (NP (NP (DT The) (NN case)) (PP (IN of) (NP (NP (DT an) (JJ oncology) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VP (VBD developed) (NP (NP (JJ Doc_24733133_201_208_Chemical-induced) (NN thrombocytopenia)) (PP (IN with) (NP (NP (NNS thrombosis)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24733133_251_255_Disease)) (-RRB- -RRB-)))))) (CC and) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NNP Doc_24733133_278_288_Chemical)) (CC plus) (NP (JJ catheter-directed) (NNS thrombolysis))) (PRN (-LRB- -LRB-) (NP (NNP CDT)) (-RRB- -RRB-)))) (PP (IN with) (NP (NN alteplase))))))))))) (VP (AUX is) (VP (VBN presented))) (. .)))
24733133	2	(S1 (S (NP (NP (DT A) (JJ 63-year-old) (JJ Caucasian) (NN man)) (PP (IN with) (NP (NNP Doc_24733133_402_419_Disease))) (VP (VBG undergoing) (NP (JJ peripheral) (NN blood)))) (VP (VBP stem) (NP (NN cell) (NN collection)) (PP (IN for) (NP (NP (DT an) (JJ autologous) (NN stem) (NN cell) (NN transplant)) (VP (VBN developed) (S (NP (NP (NP (JJ extensive) (JJ bilateral) (NN upper-extremity) (NNP Doc_24733133_554_576_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24733133_578_581_Disease)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_24733133_587_605_Disease))) (ADJP (JJ secondary) (PP (TO to) (NP (JJ Doc_24733133_619_626_Chemical-induced) (NNP Doc_24733133_635_651_Disease))))))))) (. .)))
24733133	3	(S1 (S (S (NP (NP (DT A) (JJ continuous) (NN i.v.) (NN infusion)) (PP (IN of) (NP (NNP Doc_24733133_683_693_Chemical)))) (VP (AUX was) (VP (VBN initiated)))) (, ,) (CC and) (S (NP (DT the) (NN patient)) (VP (AUX was) (VP (VBN managed) (PP (IN on) (NP (DT the) (JJ general) (JJ medical) (NN floor)))))) (. .)))
24733133	4	(S1 (S (PP (IN After) (NP (NP (CD one) (NN week)) (PP (IN of) (NP (NN therapy))))) (, ,) (NP (PRP he)) (VP (AUX was) (VP (VBN transferred) (PP (TO to) (NP (DT the) (JJ intensive) (NN care) (NN unit))) (PP (IN with) (NP (NP (JJ cardiopulmonary) (NN compromise)) (VP (VBN related) (PP (TO to) (NP (JJ superior) (JJ vena) (FW cava) (PRN (-LRB- -LRB-) (NP (NNP SVC)) (-RRB- -RRB-)) (NN syndrome)))))))) (. .)))
24733133	5	(S1 (S (S (NP (NP (DT A) (JJ percutaneous) (JJ mechanical) (NN thrombectomy)) (CC and) (NP (NP (NNP CDT)) (PP (IN with) (NP (NN alteplase))))) (VP (AUX were) (ADJP (JJ attempted)))) (, ,) (CC but) (S (NP (DT the) (NN procedure)) (VP (AUX was) (VP (VBN aborted) (PP (JJ due) (TO to) (NP (NNP Doc_24733133_1033_1042_Disease)))))) (. .)))
24733133	6	(S1 (S (S (NP (DT The) (NNP Doc_24733133_1048_1057_Disease)) (VP (VBD resolved) (NP (DT the) (JJ next) (NN day)))) (, ,) (CC and) (S (NP (DT the) (NN patient)) (VP (AUX was) (VP (VBN restarted) (PP (IN on) (NP (NNP Doc_24733133_1114_1124_Chemical)))))) (. .)))
24733133	7	(S1 (S (NP (DT A) (JJ second) (JJ percutaneous) (JJ mechanical) (NN thrombectomy)) (VP (VP (AUX was) (VP (VBN performed) (ADVP (NP (CD six) (NNS days)) (RB later)))) (CC and) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ partial) (NN revascularization)) (PP (IN of) (NP (DT the) (JJ SVC) (CC and) (JJ central) (NNS veins))))))) (. .)))
24733133	8	(S1 (S (NP (NP (JJ Postthrombectomy) (JJ continuous) (NN CDT)) (PP (IN with) (NP (NN alteplase)))) (VP (AUX was) (VP (VBD commenced) (SBAR (IN while) (S (S (NP (NNP Doc_24733133_1340_1350_Chemical)) (VP (AUX was) (VP (VBN withheld)))) (, ,) (CC and) (S (NP (NP (JJ complete) (NN patency)) (PP (IN of) (NP (DT the) (JJ SVC) (CC and) (JJ central) (NNS veins)))) (VP (AUX was) (VP (VBN achieved) (PP (IN after) (NP (NP (CD three) (NNS days)) (PP (IN of) (NP (NN therapy)))))))))))) (. .)))
24733133	9	(S1 (S (S (S (NP (NN Alteplase)) (VP (AUX was) (VP (VBN discontinued)))) (, ,) (CC and) (S (NP (DT the) (NN patient)) (VP (AUX was) (VP (VBN reinitiated) (PP (IN on) (NP (NNP Doc_24733133_1520_1530_Chemical))))))) (: ;) (S (ADVP (RB ultimately)) (, ,) (NP (PRP he)) (VP (AUX was) (VP (VBN transitioned) (S (VP (TO to) (VP (VB Doc_24733133_1567_1575_Chemical) (PP (IN for) (NP (JJ long-term) (NN anticoagulation))))))))) (. .)))
24733133	10	(S1 (S (SBAR (IN Although) (S (NP (DT the) (NN patient)) (VP (VBD recovered)))) (, ,) (NP (PRP he)) (VP (VBD experienced) (NP (NP (JJ permanent) (NN Doc_24733133_1664_1670_Disease)) (CC and) (NP (NP (NNP Doc_24733133_1675_1687_Disease)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NNP Doc_24733133_1700_1723_Disease))))) (. .)))
24733133	11	(S1 (S (NP (NP (DT A) (JJ 63-year-old) (NN man)) (PP (IN with) (NP (NNP Doc_24733133_1760_1777_Disease) (CC and) (NNP Doc_24733133_1782_1794_Disease) (JJ secondary))) (PP (TO to) (NP (NNP Doc_24733133_1808_1812_Disease)))) (VP (AUX was) (ADVP (RB successfully)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_24733133_1843_1853_Chemical)) (CC and) (NP (NNP CDT)))) (PP (IN with) (NP (NN alteplase))))) (. .)))
24739405	0	(S1 (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NNP Doc_24739405_11_33_Chemical))) (PP (IN in) (NP (NNP Doc_24739405_37_48_Chemical-induced)))) (VP (VBP Doc_24739405_57_70_Disease) (NP (NP (NNS models)) (PP (IN in) (NP (NNS mice))))) (. .)))
24739405	1	(S1 (FRAG (S (VP (TO To) (VP (VB examine) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_24739405_124_146_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24739405_148_152_Chemical)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (JJ animal) (NNS models)) (PP (IN of) (NP (NNP Doc_24739405_174_187_Disease))))))))) (. .)))
24739405	2	(S1 (S (NP (NP (CD Seventy) (JJ Swiss) (NN albino) (NN female) (NNS mice)) (PRN (-LRB- -LRB-) (NP (CD 25-35) (NNP g)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN divided) (PP (IN into) (NP (NP (CD 4) (NNS groups)) (: :) (NP (NP (NP (NNP Doc_24739405_269_280_Chemical-free)) (PRN (-LRB- -LRB-) (NP (NN control)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_24739405_297_308_Chemical)) (, ,) (NP (CD 50)) (, ,) (CC and) (NP (CD 100) (JJ mg/kg) (NNP Doc_24739405_328_332_Chemical))))))) (. .)))
24739405	3	(S1 (S (NP (DT The) (NNP Doc_24739405_338_342_Chemical)) (VP (AUX was) (VP (VBN administered) (ADVP (RB intraperitoneally)) (PRN (-LRB- -LRB-) (NP (NN ip)) (-RRB- -RRB-)) (PP (IN for) (NP (CD 5) (NN days))))) (. .)))
24739405	4	(S1 (S (S (NP (NP (NN Doc_24739405_395_406_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 3) (CD mg/kg)) (NN ip)) (-RRB- -RRB-))) (VP (VBN induced) (NP (JJ Doc_24739405_428_433_Disease) (NN locomotion)))) (, ,) (S (NP (NP (NNP Doc_24739405_446_457_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1.5) (CD mg/kg)) (JJ subcutaneously) (NN -LSB-sc) (NN -RSB-)) (-RRB- -RRB-))) (VP (VBN induced) (S (VP (VBG climbing))))) (, ,) (CC and) (S (NP (NP (NNP Doc_24739405_512_523_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1.5) (CD mg/kg)) (NN sc)) (-RRB- -RRB-))) (VP (VBN induced) (SBAR (S (NP (NNP Doc_24739405_547_556_Disease) (NNS tests)) (VP (AUX were) (VP (VBN used) (PP (IN as) (NP (NP (NN animal) (NNS models)) (PP (IN of) (NP (NNP Doc_24739405_593_606_Disease))))))))))) (. .)))
24739405	5	(S1 (S (NP (DT The) (NN study)) (VP (AUX was) (VP (VBN conducted) (PP (IN at) (NP (NP (DT the) (NN Animal) (NN Experiment)) (NP (NP (NNP Laboratories)) (, ,) (NP (NP (NP (NNP Department)) (PP (IN of) (NP (NP (NNP Pharmacology)) (, ,) (NP (NNP Medical) (NNP School))))) (, ,) (NP (NP (NNP Eskisehir) (NNP Osmangazi) (NNP University)) (, ,) (NP (NNP Eskisehir)) (, ,) (NP (NP (NNP Turkey)) (PP (IN between) (NP (NP (NNP March)) (CC and) (NP (NNP May) (CD 2012)))))))))))) (. .)))
24739405	6	(S1 (S (NP (JJ Statistical) (NN analysis)) (VP (AUX was) (VP (VBN carried) (PRT (RP out)) (S (VP (VBG using) (NP (NNP Kruskal-Wallis) (NN test)) (PP (IN for) (NP (NP (NP (NP (JJ Doc_24739405_860_865_Disease) (NN locomotion)) (, ,) (CC and) (NP (JJ one-way) (NN ANOVA))) (PP (IN for) (S (VP (VBG climbing))))) (CC and) (NP (JJ Doc_24739405_913_922_Disease) (NNS tests)))))))) (. .)))
24739405	7	(S1 (S (PP (IN In) (NP (DT the) (JJ Doc_24739405_946_957_Chemical-induced) (NN locomotion) (NN test))) (, ,) (NP (EX there)) (VP (AUX were) (NP (NP (JJ significant) (NNS increases)) (PP (IN in) (NP (DT all) (NNS movements)))) (PP (VBN compared) (PP (IN with) (NP (DT the) (JJ Doc_24739405_1051_1062_Chemical-free) (NN group))))) (. .)))
24739405	8	(S1 (S (NP (NP (NP (DT Both) (JJ Doc_24739405_1080_1084_Chemical) (CD 50) (NNS mg/kg)) (PRN (-LRB- -LRB-) (NP (CD p<0.05)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (CD 100) (NNS mg/kg)) (PRN (-LRB- -LRB-) (NP (CD p<0.01)) (-RRB- -RRB-)))) (ADVP (RB significantly)) (VP (VBD decreased) (NP (DT all) (NNS movements)) (PP (VBN compared) (PP (IN with) (NP (DT the) (JJ Doc_24739405_1183_1194_Chemical-induced) (NN locomotion) (NN group))))) (. .)))
24739405	9	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (NN difference)) (PP (IN between) (NP (NP (NNS groups)) (PP (IN in) (NP (NP (DT the) (JJ Doc_24739405_1278_1289_Chemical-induced) (NN Doc_24739405_1298_1307_Disease) (NN test)) (PRN (-LRB- -LRB-) (NP (NNS p<0.05)) (-RRB- -RRB-)))))))) (. .)))
24739405	10	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN between) (NP (NP (NNS groups)) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (JJ total) (VBG climbing) (NN time)) (PP (IN in) (NP (NP (DT the) (JJ Doc_24739405_1413_1424_Chemical-induced) (VBG climbing) (NN test)) (PRN (-LRB- -LRB-) (NP (CD p>0.05)) (-RRB- -RRB-)))))))))))) (. .)))
24739405	11	(S1 (S (NP (PRP We)) (VP (VBD observed) (SBAR (IN that) (S (NP (NNP Doc_24739405_1486_1490_Chemical)) (VP (VP (VBD reduced) (NP (NN locomotor) (NN activity))) (CC and) (VP (VBD increased) (NP (NNP Doc_24739405_1532_1541_Disease)) (PP (IN at) (NP (DT both) (NNS doses))) (, ,) (SBAR (IN while) (S (NP (PRP it)) (VP (AUX had) (NP (DT no) (NN effect)) (PP (IN on) (S (VP (VBG climbing) (NP (NN behavior))))))))))))) (. .)))
24739405	12	(S1 (S (NP (PRP We)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_24739405_1618_1622_Chemical)) (VP (VP (VBZ displays) (NP (JJ typical) (JJ Doc_24739405_1640_1651_Disease-like) (NNS effects))) (, ,) (CC and) (VP (MD may) (VP (AUX be) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN Doc_24739405_1702_1715_Disease)))))))))))) (. .)))
24742750	0	(S1 (S (NP (NP (NN Availability)) (PP (IN of) (NP (JJ human) (VBN induced) (NN pluripotent)))) (VP (VBP stem) (NP (NP (JJ cell-derived) (NNS cardiomyocytes)) (PP (IN in) (NP (NP (NN assessment)) (PP (IN of) (NP (NN drug) (NN potential))) (PP (IN for) (NP (NNP Doc_24742750_111_126_Disease))))))) (. .)))
24742750	1	(S1 (S (NP (NP (NN Field) (JJ potential) (NN duration)) (PRN (-LRB- -LRB-) (NP (NNP FPD)) (-RRB- -RRB-)) (PP (IN in) (NP (NP (JJ human-induced) (NN pluripotent) (NN stem) (JJ cell-derived) (NNS cardiomyocytes)) (PRN (-LRB- -LRB-) (NP (NNS hiPS-CMs)) (-RRB- -RRB-)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD can) (VP (VB express) (NP (CD QT) (NN interval)) (PP (IN in) (NP (DT an) (NN electrocardiogram))))))) (, ,)) (VP (AUX is) (VP (VBN reported) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJ useful) (NN tool)) (SBAR (S (VP (TO to) (VP (VB predict) (NP (NP (JJ Doc_24742750_331_335_Chemical) (NN channel) (CC and) (JJ Doc_24742750_348_354_Chemical) (NN channel) (NN blocker) (NNS effects)) (PP (IN on) (NP (CD QT) (NN interval)))))))))))))) (. .)))
24742750	2	(S1 (S (ADVP (RB However)) (, ,) (NP (EX there)) (VP (AUX is) (NP (NP (DT no) (NN report)) (VP (VBG showing) (SBAR (IN that) (S (NP (DT this) (NN technique)) (VP (MD can) (VP (AUX be) (VP (VBN used) (S (VP (TO to) (VP (VB predict) (NP (JJ multichannel) (NN blocker) (NN potential)) (PP (IN for) (NP (NN Doc_24742750_509_524_Disease)))))))))))))) (. .)))
24742750	3	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX is) (S (VP (TO to) (VP (VB show) (SBAR (IN that) (S (S (NP (NP (NNS FPD)) (PP (IN from) (NP (NNP MEA))) (PRN (-LRB- -LRB-) (NP (NNP Multielectrode) (NN array)) (-RRB- -RRB-)) (SBAR (IN of) (S (NP (NNS hiPS-CMs)) (VP (MD can) (VP (VB detect) (S (NP (NNP Doc_24742750_623_638_Disease)) (VP (VBN induced) (PP (IN by) (NP (JJ multichannel) (JJ blockers.) (NNS hiPS-CMs)))))))))) (VP (AUX were) (VP (VBN seeded) (PP (IN onto) (NP (NNP MEA)))))) (CC and) (S (NP (NNP FPD)) (VP (AUX was) (VP (VBN measured) (PP (IN for) (S (VP (VBG 2min) (NP (NP (DT every) (NN 10min)) (PP (IN for) (NP (NN 30min)))) (PP (IN after) (NP (NN drug) (NN exposure))) (PP (IN for) (NP (NP (DT the) (NN vehicle)) (CC and) (NP (DT each) (NN drug) (NN concentration)))))))))))))))) (. .)))
24742750	4	(S1 (S (NP (NNP IKr) (CC and) (NNP IKs)) (VP (VBZ blockers) (NP (NP (JJ concentration-dependently) (JJ prolonged) (VBN corrected) (NNS FPD)) (PRN (-LRB- -LRB-) (NP (NNP FPDc)) (-RRB- -RRB-))) (, ,) (SBAR (IN whereas) (S (NP (JJ Doc_24742750_907_913_Chemical) (NN channel) (NNS blockers)) (ADVP (RB concentration-dependently)) (VP (VBN shortened) (NP (NNP FPDc)))))) (. .)))
24742750	5	(S1 (S (ADVP (RB Also)) (, ,) (NP (DT the) (NN multichannel)) (VP (VBZ blockers) (NP (NNP Doc_24742750_1005_1015_Chemical) (, ,) (NNP Doc_24742750_1017_1027_Chemical) (, ,) (NNP Doc_24742750_1029_1040_Chemical) (CC and) (NNP Doc_24742750_1045_1055_Chemical) (JJ prolonged) (NNS FPDc)) (PP (IN in) (NP (DT a) (NN concentration) (JJ dependent) (NN manner)))) (. .)))
24742750	6	(S1 (S (ADVP (RB Finally)) (, ,) (NP (NP (DT the) (NN IKr) (NNS blockers) (, ,) (NNP Doc_24742750_1135_1146_Chemical) (CC and) (NNP Doc_24742750_1151_1161_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX are) (VP (VBN reported) (S (VP (TO to) (VP (VB cause) (NP (NP (NNP Doc_24742750_1191_1209_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24742750_1211_1214_Disease)) (-RRB- -RRB-))) (PP (IN in) (NP (JJ clinical) (NN practice)))))))))) (, ,)) (VP (VBD produced) (NP (NP (JJ early) (NN afterdepolarization)) (PRN (-LRB- -LRB-) (INTJ (UH EAD)) (-RRB- -RRB-)) (. .)) (NP (NP (NNS hiPS-CMs)) (SBAR (S (S (VP (VBG using) (NP (NP (NNP MEA) (NN system)) (CC and) (NP (NNP FPDc))))) (VP (MD can) (VP (VB predict) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug) (NNS candidates))) (PP (IN on) (NP (CD QT) (NN interval)))))))))) (. .)))
24742750	7	(S1 (S (NP (DT This) (NN study)) (ADVP (RB also)) (VP (VBZ shows) (SBAR (IN that) (S (NP (DT this) (NN assay)) (VP (MD can) (VP (VB help) (VP (VB detect) (NP (NN EAD)) (PP (IN for) (NP (NP (NNS drugs)) (PP (IN with) (NP (JJ Doc_24742750_1447_1450_Disease) (NN potential))))))))))) (. .)))
24753331	0	(S1 (S (VP (VB Dermal) (NP (NP (JJ developmental) (NN Doc_24753331_21_29_Disease)) (PP (IN of) (NP (NP (JJ Doc_24753331_33_46_Chemical) (NNS herbicides)) (PP (IN in) (NP (NNS rats))))))) (. .)))
24753331	1	(S1 (S (NP (NNP Doc_24753331_79_86_Chemical) (CC and) (NNP Doc_24753331_91_98_Chemical)) (VP (VP (AUX are) (NP (JJ Doc_24753331_103_116_Chemical) (NNS herbicides))) (CC and) (VP (VBD produced) (NP (NP (NN embryolethality)) (, ,) (NP (NP (NN teratogenicity)) (PRN (-LRB- -LRB-) (ADVP (RB mainly)) (NP (NP (NN Doc_24753331_181_207_Disease)) (CC and) (NP (JJ wavy) (NNS ribs))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NNP Doc_24753331_228_246_Disease))) (PP (IN in) (NP (NNS rats))) (PP (IN in) (NP (JJ conventional) (JJ oral) (JJ developmental) (NNP Doc_24753331_290_298_Disease) (NNS studies))))) (. .)))
24753331	2	(S1 (S (NP (NP (PRP$ Our) (NN objective)) (PP (IN in) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (SBAR (IN whether) (S (NP (DT the) (NNS compounds)) (VP (VB induce) (NP (JJ developmental) (NN Doc_24753331_398_406_Disease)) (PP (IN via) (NP (NP (DT the) (JJ dermal) (NN route)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADJP (ADJP (RBR more) (JJ relevant) (PP (TO to) (NP (JJ occupational) (NN exposure)))) (, ,) (ADJP (RB hence) (JJR better) (S (VP (VBG addressing) (NP (JJ human) (NN health) (NNS risks)))))))))))))))))) (. .)))
24753331	3	(S1 (S (S (NP (NNP Doc_24753331_531_538_Chemical)) (VP (AUX was) (VP (VBN administered) (ADVP (RB dermally) (PP (TO to) (NP (NNS rats)))) (PP (IN at) (NP (NP (CD 30)) (, ,) (NP (CD 100)) (, ,) (CC and) (NP (QP (CD 300) (CD mg/kg))))) (PP (IN during) (NP (NN organogenesis)))))) (, ,) (CC and) (S (NP (NNP Doc_24753331_625_632_Chemical)) (VP (AUX was) (VP (VBN administered) (PP (IN at) (NP (NP (CD 200)) (, ,) (NP (CD 400)) (, ,) (CC and) (NP (NP (QP (CD 800) (CD mg/kg))) (PRN (-LRB- -LRB-) (NP (DT the) (NN maximum) (JJ applicable) (NN dose) (NN level)) (-RRB- -RRB-)))))))) (. .)))
24753331	4	(S1 (S (NP (NNS Fetuses)) (VP (AUX were) (VP (VP (VBN obtained) (PP (IN by) (NP (DT a) (JJ Cesarean) (NN section)))) (CC and) (VP (VBN examined) (PP (IN for) (NP (NNP external) (, ,) (NNP Doc_24753331_785_819_Disease)))))) (. .)))
24753331	5	(S1 (S (NP (NP (JJ Dermal) (NN exposure)) (PP (IN of) (NP (NNS rats))) (PP (TO to) (NP (NNP Doc_24753331_857_864_Chemical))) (PP (IN at) (NP (CD 300) (NNS mg/kg)))) (VP (VBD produced) (NP (NP (NNS patterns)) (PP (IN of) (NP (JJ developmental) (NNP Doc_24753331_913_921_Disease))) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBG resulting) (PP (IN from) (NP (JJ oral) (NN exposure))))))))) (. .)))
24753331	6	(S1 (S (NP (NN Doc_24753331_969_977_Disease)) (VP (VBD included) (NP (NP (NN embryolethality)) (, ,) (NP (NN teratogenicity)) (, ,) (CC and) (NP (NN Doc_24753331_1024_1042_Disease)))) (. .)))
24753331	7	(S1 (S (S (NP (NP (JJ Dermal) (NN administration)) (PP (IN of) (NP (NNP Doc_24753331_1069_1076_Chemical))) (PP (IN at) (NP (CD 800) (NNS mg/kg)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (VBN increased) (NN incidence)) (PP (IN of) (NP (NNP Doc_24753331_1128_1143_Disease) (CC and) (NNP Doc_24753331_1148_1173_Disease))))))) (, ,) (CC but) (S (NP (JJ retarded) (JJ fetal) (NN growth)) (VP (AUX was) (RB not) (ADJP (JJ observed)) (SBAR (IN as) (S (NP (PRP it)) (VP (AUX was) (VP (VBG following) (NP (NP (JJ oral) (NN exposure)) (PP (TO to) (NP (NNP Doc_24753331_1255_1262_Chemical)))))))))) (. .)))
24753331	8	(S1 (S (PP (VBN Based) (PP (IN on) (NP (DT the) (NNS results)))) (, ,) (NP (NP (NNP Doc_24753331_1299_1306_Chemical)) (CC and) (NP (NNP Doc_24753331_1311_1318_Chemical))) (VP (AUX were) (ADJP (JJ teratogenic)) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (ADVP (RB dermally)) (PP (TO to) (NP (JJ pregnant) (NNS rats))) (SBAR (IN as) (SINV (AUX were) (NP (NP (DT the) (NNS compounds)) (VP (VBN administered) (ADVP (RB orally)))))))))) (. .)))
24753331	9	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (NP (NN investigation)) (PP (IN of) (NP (DT the) (NN mechanism)))) (CC and) (NP (PRP$ its) (JJ human) (NN relevancy))) (VP (VBP become) (ADJP (RBR more) (JJ important))) (. .)))
24778426	0	(S1 (NP (NP (NNS Rates)) (PP (IN of) (NP (NNP Doc_24778426_9_23_Disease))) (PP (PP (IN in) (NP (NNP Doc_24778426_27_33_Disease) (NNPS Patients) (NN Receiving) (NNP Doc_24778426_53_62_Chemical) (NNP With))) (CC and) (PP (IN Without) (NP (NNP Doc_24778426_80_88_Chemical)))) (. .)))
24778426	1	(S1 (S (NP (NN Doc_24778426_102_111_Chemical)) (VP (AUX is) (NP (DT a) (ADJP (RB widely) (VBN used)) (NN antineoplastic))) (. .)))
24778426	2	(S1 (S (NP (NP (CD One)) (PP (IN of) (NP (NP (DT the) (JJ major) (NNS complications)) (PP (IN of) (NP (JJ Doc_24778426_179_188_Chemical) (NN use)))))) (VP (AUX is) (VP (VBG dose-limiting) (NP (NN nephrotoxicity)))) (. .)))
24778426	3	(S1 (S (NP (EX There)) (VP (AUX are) (NP (NP (JJ many) (NNS strategies)) (SBAR (S (VP (TO to) (VP (VB prevent) (NP (DT this) (NN Doc_24778426_268_276_Disease))))))) (, ,) (PP (VBG including) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_24778426_299_307_Chemical))) (PP (IN as) (NP (NP (DT a) (NN nephroprotectant)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN hydration)))))))))) (. .)))
24778426	4	(S1 (S (NP (PRP We)) (VP (VBD aimed) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NNS rates)) (PP (IN of) (NP (JJ Doc_24778426_406_415_Chemical-induced) (NN nephrotoxicity))) (PP (IN in) (NP (NP (JJ Doc_24778426_442_448_Disease) (NNS patients)) (VP (VBG receiving) (NP (JJ single-agent) (NNP Doc_24778426_481_490_Chemical)) (PP (IN with) (CC and) (PP (IN without) (NP (NNP Doc_24778426_508_516_Chemical)))))))))))) (. .)))
24778426	5	(S1 (S (NP (DT This) (NN single-center) (NN retrospective) (NN analysis)) (VP (AUX was) (NP (NP (DT a) (JJ quasi) (NN experiment)) (VP (VBN created) (PP (IN by) (NP (DT the) (JJ national) (JJ Doc_24778426_616_624_Chemical) (NN shortage)))))) (. .)))
24778426	6	(S1 (S (NP (NNS Data)) (VP (AUX were) (VP (VBN collected) (PP (IN on) (NP (NP (NN adult) (NN Doc_24778426_664_670_Disease) (NNS patients)) (VP (VBG receiving) (NP (JJ single-agent) (NNP Doc_24778426_703_712_Chemical)) (PP (IN as) (NP (NP (DT an) (NN outpatient)) (PP (PP (IN from) (NP (NNP January) (CD 2011))) (PP (TO to) (NP (NNP September) (CD 2012))))))))))) (. .)))
24778426	7	(S1 (S (NP (DT The) (JJ primary) (NN outcome)) (VP (AUX was) (NP (NP (NNP Doc_24778426_791_810_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24778426_812_815_Disease)) (-RRB- -RRB-)))) (. .)))
24778426	8	(S1 (S (S (NP (PRP We)) (VP (VBN evaluated) (NP (NP (CD 143) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (JJ single-agent) (NN Doc_24778426_879_888_Chemical)))))))) (: ;) (S (NP (NP (CD 97.2) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (AUX had) (NP (NN Doc_24778426_912_932_Disease)) (PP (IN as) (NP (PRP$ their) (JJ primary) (NN malignancy))))) (. .)))
24778426	9	(S1 (S (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (AUX did) (RB not) (VP (VB receive) (NP (NNP Doc_24778426_991_999_Chemical))))))) (VP (AUX were) (ADJP (RBR more) (JJ likely) (S (VP (TO to) (VP (VB develop) (NP (NN nephrotoxicity)))))))) (: :) (S (NP (NNS odds) (NN ratio) (JJ -LSB-OR) (NN -RSB-)) (VP (SYM =) (NP (CD 2.646)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 95) (NN %)) (NP (NNP CI) (SYM =) (CD 1.008) (, ,) (CD 6.944))) (: ;) (NP (NNP P) (SYM =) (CD 0.048))) (-RRB- -RRB-)))) (. .)))
24778426	10	(S1 (S (NP (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (DT the) (ADJP (ADJP (CD 100) (NN mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (NN dosing)))))) (CC and) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_24778426_1183_1195_Disease))))))))) (ADVP (RB also)) (VP (AUX had) (NP (NP (NP (DT a) (JJR higher) (NN likelihood)) (PP (IN of) (S (VP (VBG developing) (NP (NN nephrotoxicity)))))) (: :) (CC OR) (NP (NP (NP (NP (SYM =) (CD 11.494)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 95) (NN %)) (NP (NNP CI) (SYM =) (CD 4.149) (, ,) (CD 32.258))) (: ;) (NP (NP (CD P) (NNS <)) (NP (CD 0.0001)))) (-RRB- -RRB-))) (CC and) (NP (QP (CC OR) (SYM =) (CD 3.219)))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 95) (NN %)) (NP (NNP CI) (SYM =) (CD 1.228) (, ,) (CD 8.439))) (: ;) (NP (NNP P)) (X (SYM =)) (CD 0.017)) (-RRB- -RRB-)))) (, ,) (ADVP (RB respectively))) (. .)))
24778426	11	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NP (JJ limited) (NNS quantities)) (PP (IN of) (NP (NNP Doc_24778426_1409_1417_Chemical)))) (VP (AUX are) (ADJP (JJ available))))) (, ,) (NP (PRP it)) (VP (MD should) (ADVP (RB preferentially)) (VP (AUX be) (VP (VBN given) (PP (TO to) (NP (NNS patients))) (PP (IN at) (NP (NP (ADJP (RB particularly) (JJ high)) (NN risk)) (PP (IN of) (NP (NN nephrotoxicity)))))))) (. .)))
24778426	12	(S1 (S (NP (PRP$ Our) (NN analysis)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (NP (DT those) (NNS patients)) (VP (VBG receiving) (NP (NP (DT the) (JJ dosing) (NN schedule)) (PP (IN of) (NP (QP (CD 100) (CD mg/m)) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-)) (NNP Doc_24778426_1611_1620_Chemical)))) (NP (DT every) (CD 3) (NNS weeks)))) (CC and) (NP (NP (DT those)) (PP (IN with) (NP (NNP Doc_24778426_1650_1662_Disease))))) (VP (VP (AUX are) (PP (IN at) (NP (NP (DT the) (JJS greatest) (NN risk)) (PP (IN of) (NP (NN nephrotoxicity)))))) (CC and) (VP (MD would) (VP (VB benefit) (PP (IN from) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NNP Doc_24778426_1745_1753_Chemical))))))))))) (. .)))
24802403	0	(S1 (S (NP (NN Doc_24802403_0_9_Chemical)) (VP (VBZ protects) (PP (IN against) (NP (NP (NNP Doc_24802403_27_35_Disease) (, ,) (NNP learning) (CC and) (NNP Doc_24802403_50_68_Disease)) (CC and) (NP (NP (JJ oxidative) (NN damage)) (VP (VBN induced) (PP (IN by) (NP (NP (JJ Doc_24802403_101_119_Chemical-induced) (NN kindling)) (PP (IN in) (NP (NNS mice)))))))))) (. .)))
24802403	1	(S1 (S (NP (NP (NNP Doc_24802403_146_166_Disease)) (, ,) (NP (NP (DT the) (ADJP (RBS most) (JJ common) (CC and) (JJ severe)) (NN comorbidity)) (PP (IN of) (NP (NNP Doc_24802403_210_218_Disease)))) (, ,)) (ADVP (RB greatly)) (VP (VBZ diminishes) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (NN life))))) (. .)))
24802403	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (JJ current) (JJ therapeutic) (NNS interventions)) (PP (IN for) (NP (NNP Doc_24802403_307_315_Disease)))) (VP (MD can) (ADVP (RB also)) (VP (VB cause) (NP (JJ untoward) (JJ cognitive) (NNS effects)))) (. .)))
24802403	3	(S1 (S (ADVP (RB Thus)) (, ,) (NP (EX there)) (VP (AUX is) (NP (NP (DT an) (JJ urgent) (NN need)) (PP (IN for) (NP (NP (JJ new) (NNS kinds)) (PP (IN of) (NP (NP (NNS agents)) (VP (VBG targeting) (NP (DT both) (NNP Doc_24802403_428_436_Disease) (CC and) (NNP Doc_24802403_441_459_Disease))))))))) (. .)))
24802403	4	(S1 (S (S (NP (JJ Oxidative) (NN stress)) (VP (AUX is) (VP (VBN considered) (S (VP (TO to) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (NN epileptogenesis)) (CC and) (NP (NN Doc_24802403_541_559_Disease)))))))))) (, ,) (CC and) (S (NP (NNS antioxidants)) (VP (AUX have) (NP (DT a) (JJ putative) (JJ antiepileptic) (NN potential)))) (. .)))
24802403	5	(S1 (S (NP (NP (NNP Doc_24802403_619_628_Chemical)) (, ,) (NP (DT the) (ADJP (RBS most) (RB commonly) (VBN prescribed)) (JJ antidiabetic) (JJ oral) (NN drug)) (, ,)) (VP (AUX has) (NP (NN antioxidant) (NNS properties))) (. .)))
24802403	6	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ ameliorative) (NNS effects)) (PP (IN of) (NP (NNP Doc_24802403_775_784_Chemical))) (PP (IN on) (NP (NP (NNP Doc_24802403_788_796_Disease)) (, ,) (NP (NNP Doc_24802403_798_818_Disease)) (CC and) (NP (NP (NN brain) (NN oxidative) (NN stress) (NNS markers)) (VP (VBN observed) (PP (IN in) (NP (JJ Doc_24802403_866_884_Chemical-induced) (VBG kindling) (NNS animals))))))))))))) (. .)))
24802403	7	(S1 (S (NP (JJ Male) (NNP C57BL/6) (NNS mice)) (VP (AUX were) (VP (VBN administered) (PP (IN with) (NP (NP (JJ subconvulsive) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_24802403_974_992_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 37) (NN mg/kg)) (, ,) (NP (NNP i.p.)) (-RRB- -RRB-)))))) (NP (DT every) (JJ other) (NN day)) (PP (IN for) (NP (CD 14) (NNS injections))))) (. .)))
24802403	8	(S1 (S (NP (NNP Doc_24802403_1045_1054_Chemical)) (VP (AUX was) (VP (VBN injected) (ADVP (RB intraperitoneally)) (PP (IN in) (NP (NP (NN dose)) (PP (IN of) (NP (CD 200mg/kg))))) (PP (IN along) (PP (IN with) (NP (JJ alternate-day) (NNP Doc_24802403_1131_1134_Chemical)))))) (. .)))
24802403	9	(S1 (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (NNP Doc_24802403_1150_1159_Chemical)) (VP (VP (VBD suppressed) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NN kindling))))) (, ,) (VP (VBD ameliorated) (NP (DT the) (NNP Doc_24802403_1216_1236_Disease))) (CC and) (VP (VBD decreased) (NP (NN brain) (JJ oxidative) (NN stress))))))) (. .)))
24802403	10	(S1 (S (ADVP (RB Thus)) (NP (DT the) (JJ present) (NN study)) (VP (VBD concluded) (SBAR (IN that) (S (NP (NNP Doc_24802403_1313_1322_Chemical)) (VP (MD may) (VP (AUX be) (NP (NP (NP (DT a) (JJ potential) (NN agent)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_24802403_1369_1377_Disease)))))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT a) (JJ protective) (NN medicine)) (PP (IN against) (NP (NP (NNP Doc_24802403_1419_1439_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_24802403_1451_1459_Disease))))))))))))) (. .)))
24812279	0	(S1 (S (NP (NN P53) (NN inhibition)) (VP (VBZ exacerbates) (NP (JJ late-stage) (NNP Doc_24812279_38_51_Chemical) (NNP Doc_24812279_52_66_Disease))) (. .)))
24812279	1	(S1 (S (NP (NP (NNP Doc_24812279_74_85_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24812279_87_90_Chemical)) (-RRB- -RRB-))) (VP (VP (AUX is) (NP (DT an) (JJ effective) (JJ anti-Doc_24812279_113_119_Disease) (JJ therapeutic))) (, ,) (CC but) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (DT both) (ADJP (JJ acute) (CC and) (JJ late-stage)) (NNP Doc_24812279_182_196_Disease)))))) (. .)))
24812279	2	(S1 (S (NP (NNS Children)) (VP (AUX are) (ADJP (RB particularly) (JJ sensitive) (PP (TO to) (NP (NNP Doc_24812279_237_240_Chemical-induced) (NNP Doc_24812279_249_262_Disease))))) (. .)))
24812279	3	(S1 (S (ADVP (RB Here)) (, ,) (NP (NP (DT the) (NN impact)) (PP (IN of) (NP (NN p53) (NN inhibition))) (PP (IN on) (NP (ADJP (ADJP (JJ acute)) (CC vs.) (ADJP (JJ late-stage))) (NNP Doc_24812279_323_326_Chemical) (NNP Doc_24812279_327_341_Disease)))) (VP (AUX was) (VP (VBN examined) (PP (IN in) (NP (DT a) (JJ juvenile) (NN model))))) (. .)))
24812279	4	(S1 (FRAG (NP (NNS METHODS) (CC AND) (NNS RESULTS)) (: :) (S (NP (NP (NP (JJ Two-week-old) (JJ MHC-CB7) (NNS mice)) (PRN (-LRB- -LRB-) (SBAR (WHNP (WDT which)) (S (VP (VBP express) (NP (NP (JJ dominant-interfering) (NN p53)) (PP (IN in) (NP (NNS cardiomyocytes))))))) (-RRB- -RRB-))) (CC and) (NP (PRP$ their) (JJ non-transgenic) (PRN (-LRB- -LRB-) (NP (NNP Doc_24812279_508_515_Chemical)) (-RRB- -RRB-)) (NNS littermates))) (VP (VBD received) (NP (JJ weekly) (JJ Doc_24812279_545_548_Chemical) (NNS injections)) (PP (IN for) (NP (NP (CD 5) (NNS weeks)) (PRN (-LRB- -LRB-) (NP (CD 25) (JJ mg/kg) (JJ cumulative) (NN dose)) (-RRB- -RRB-)))))) (. .)))
24812279	5	(S1 (S (NP (NP (CD One) (NN week)) (PP (IN after) (NP (NP (DT the) (JJ last) (JJ Doc_24812279_624_627_Chemical) (NN treatment)) (PRN (-LRB- -LRB-) (NP (JJ acute) (NN stage)) (-RRB- -RRB-))))) (, ,) (NP (JJ MHC-CB7) (NNS mice)) (VP (VBD exhibited) (NP (NP (NP (JJ improved) (JJ cardiac) (NN function)) (CC and) (NP (JJR lower) (NNS levels))) (PP (IN of) (NP (JJ cardiomyocyte) (NNS apoptosis)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (DT the) (JJ NON-TXG) (NNS mice))))))) (. .)))
24812279	6	(S1 (S (ADVP (RB Surprisingly)) (, ,) (PP (IN by) (NP (NP (CD 13) (NNS weeks)) (VP (VBG following) (NP (NP (DT the) (JJ last) (JJ Doc_24812279_828_831_Chemical) (NN treatment)) (PRN (-LRB- -LRB-) (NP (JJ late) (NN stage)) (-RRB- -RRB-)))))) (, ,) (NP (NNP MHC-CB7)) (VP (VBD exhibited) (NP (NP (DT a) (JJ progressive) (NN decrease)) (PP (IN in) (NP (NP (JJ cardiac) (NN function)) (CC and) (NP (JJR higher) (NNS rates)))) (PP (IN of) (NP (JJ cardiomyocyte) (NNS apoptosis)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NP (NNP NON-TXG) (FW mice.) (NN p53) (NN inhibition)) (VP (VBN blocked) (NP (JJ transient) (JJ Doc_24812279_1027_1030_Chemical-induced) (NN STAT3) (NN activation)) (PP (IN in) (NP (NP (JJ MHC-CB7) (NNS mice)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ enhanced) (NN induction)) (PP (IN of) (NP (DT the) (NN DNA) (NN repair) (NNS proteins) (NNP Ku70) (CC and) (NNP Ku80)))))))))))))))))) (. .)))
24812279	7	(S1 (S (NP (NP (NNS Mice)) (PP (IN with) (NP (NP (JJ cardiomyocyte-restricted) (NN deletion)) (PP (IN of) (NP (NNP STAT3)))))) (VP (VBD exhibited) (NP (NP (JJR worse) (JJ cardiac) (NN function)) (, ,) (NP (NP (JJR higher) (NNS levels)) (PP (IN of) (NP (JJ cardiomyocyte) (NNS apoptosis)))) (, ,) (CC and) (NP (NP (DT a) (JJR greater) (NN induction)) (PP (IN of) (NP (NP (NNP Ku70)) (CC and) (NP (NNP Ku80)))))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (JJ Doc_24812279_1345_1348_Chemical) (NN treatment)) (PP (IN during) (NP (DT the) (JJ acute) (NN stage))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NN control) (NNS animals))))))) (. .)))
24812279	8	(S1 (S (NP (DT These) (NNS data)) (VP (VBP support) (NP (NP (DT a) (NN model) (NN wherein)) (SBAR (S (NP (NP (DT a) (JJ p53-dependent) (NN cardioprotective) (NN pathway)) (, ,) (VP (VBN mediated) (PP (IN via) (NP (CD STAT3) (NN activation)))) (, ,)) (VP (VBZ mitigates) (NP (JJ Doc_24812279_1548_1551_Chemical-induced) (JJ myocardial) (NN stress)) (PP (IN during) (NP (NN drug) (NN delivery)))))))) (. .)))
24812279	9	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (DT these) (NNS data)) (VP (VBP suggest) (NP (DT an) (NN explanation)) (PP (IN as) (PP (TO to) (SBAR (WHADVP (WRB how)) (S (NP (NN p53) (NN inhibition)) (VP (VP (MD can) (VP (VB result) (PP (IN in) (NP (NN cardioprotection))) (PP (IN during) (NP (NN drug) (NN treatment))))) (CC and) (, ,) (ADVP (RB paradoxically)) (, ,) (VP (VBD enhanced) (NP (NNP Doc_24812279_1754_1768_Disease)) (PP (ADVP (RB long)) (IN after) (NP (NP (DT the) (NN cessation)) (PP (IN of) (NP (NN drug) (NN treatment)))))))))))) (. .)))
24816962	0	(S1 (NP (NP (JJ Doc_24816962_0_13_Chemical-induced) (NN Doc_24816962_22_36_Disease)) (: :) (NP (DT an) (JJ uncommon) (NN scenario)) (. .)))
24816962	1	(S1 (S (NP (NN Doc_24816962_60_73_Chemical)) (VP (MD can) (VP (VB produce) (NP (NN neurological) (NNS complications)) (SBAR (IN although) (S (NP (PRP it)) (VP (AUX is) (RB not) (NP (DT a) (JJ common) (NN scenario))))))) (. .)))
24816962	2	(S1 (S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (NN case)) (SBAR (WHADVP (WRB where)) (S (NP (DT a) (NN patient)) (VP (VBD developed) (NP (NP (NNS features)) (PP (IN of) (NP (NNP Doc_24816962_207_221_Disease)))) (PP (VBG following) (NP (JJ prolonged) (JJ Doc_24816962_242_255_Chemical) (NN intake)))))))) (. .)))
24816962	3	(S1 (S (NP (JJ Magnetic) (NN resonance) (NN imaging) (PRN (-LRB- -LRB-) (NNP MRI) (-RRB- -RRB-)) (NN brain)) (VP (VBD showed) (NP (NP (JJ abnormal) (NN signal) (NN intensity)) (VP (VBG involving) (NP (NP (NP (DT both) (JJ dentate) (NNS nuclei)) (PP (IN of) (NP (NN cerebellum)))) (CC and) (NP (NP (NN splenium)) (PP (IN of) (NP (JJ corpus) (NN callosum)))))))) (. .)))
24816962	4	(S1 (S (NP (NP (DT The) (NN diagnosis)) (PP (IN of) (NP (JJ Doc_24816962_430_443_Chemical) (NN toxicity)))) (VP (VP (AUX was) (VP (VBN made) (PP (IN by) (NP (DT the) (NNP MRI) (NNS findings))))) (CC and) (VP (VBD supported) (ADVP (RB clinically)))) (. .)))
24840785	0	(S1 (S (NP (JJ Doc_24840785_0_9_Chemical-induced) (JJ Doc_24840785_18_22_Chemical) (NN overload)) (VP (VP (VBZ causes) (NP (NN Doc_24840785_39_49_Disease))) (CC and) (VP (VBZ triggers) (NP (NN apoptosis)) (PP (IN through) (NP (NP (CD p38) (NNS MAPK)) (VP (VBG signaling) (NP (NP (NN pathway)) (PP (IN in) (NP (NNS rats))))))))) (. .)))
24840785	1	(S1 (S (NP (NN Doc_24840785_117_126_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ major) (NN bioactive)) (ADJP (JJ Doc_24840785_148_168_Chemical) (PP (IN with) (NP (NP (JJ high) (NN content)) (VP (VBN derived) (PP (IN from) (NP (JJ herbal) (NN aconitum) (NNS plants))))))))) (. .)))
24840785	2	(S1 (S (NP (VBG Emerging) (NN evidence)) (VP (VBZ indicates) (SBAR (IN that) (S (NP (JJ voltage-dependent) (JJ Doc_24840785_275_280_Chemical) (NNS channels)) (VP (AUX have) (NP (JJ pivotal) (NNS roles)) (PP (IN in) (NP (NP (DT the) (NNP Doc_24840785_316_330_Disease)) (PP (IN of) (NP (NNP Doc_24840785_334_343_Chemical))))))))) (. .)))
24840785	3	(S1 (S (ADVP (RB However)) (, ,) (NP (DT no) (NNS reports)) (VP (AUX are) (ADJP (JJ available)) (PP (IN on) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNP Doc_24840785_394_400_Chemical))) (PP (IN in) (NP (NNP Doc_24840785_404_413_Chemical) (NNP Doc_24840785_414_423_Disease)))))) (. .)))
24840785	4	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD explored) (NP (NP (DT the) (NN importance)) (PP (IN of) (NP (JJ pathological) (NNP Doc_24840785_483_489_Chemical))) (PP (VBG signaling) (PP (IN in) (NP (NNP Doc_24840785_503_512_Chemical) (NNP Doc_24840785_513_522_Disease))) (PP (IN in) (NP (NN vitro))) (CC and) (PP (IN in) (NP (NN vivo)))))) (. .)))
24840785	5	(S1 (S (NP (PRP We)) (VP (VP (VBD found) (NP (DT that) (JJ Doc_24840785_559_565_Chemical) (NN overload) (NN lead)) (PP (TO to) (NP (NP (JJ accelerated) (VBG beating) (NN rhythm)) (PP (IN in) (NP (NN adult) (NN rat) (NN ventricular) (NNS myocytes)))))) (CC and) (VP (VBD caused) (NP (NNP Doc_24840785_655_665_Disease)) (PP (IN in) (NP (JJ conscious) (ADJP (RB freely) (JJ moving)) (NNS rats))))) (. .)))
24840785	6	(S1 (S (S (VP (TO To) (VP (VB investigate) (NP (NP (NNS effects)) (PP (IN of) (NP (NNP Doc_24840785_725_734_Chemical)))) (PP (IN on) (NP (NNP Doc_24840785_738_755_Disease)))))) (, ,) (NP (PRP we)) (VP (VBD performed) (NP (NNP Doc_24840785_770_782_Disease) (NN assay)) (PP (IN in) (NP (NP (JJ neonatal) (NN rat) (NN ventricular) (NNS myocytes)) (PRN (-LRB- -LRB-) (NP (NNP NRVMs)) (-RRB- -RRB-)))) (, ,) (ADVP (RB as) (RB well) (SBAR (IN as) (S (VP (VBN measured) (NP (JJ Doc_24840785_855_862_Chemical) (NN dehydrogenase) (NN level)) (PP (IN in) (NP (NP (DT the) (NN culture) (NN medium)) (PP (IN of) (NP (NP (NNS NRVMs) (CC and) (NNS activities)) (PP (IN of) (NP (NP (JJ serum) (JJ cardiac) (NNS enzymes)) (PP (IN in) (NP (NNS rats)))))))))))))) (. .)))
24840785	7	(S1 (S (NP (DT The) (NNS results)) (VP (VBD showed) (SBAR (IN that) (S (NP (NNP Doc_24840785_987_996_Chemical)) (VP (VBD resulted) (PP (IN in) (NP (NP (NNP Doc_24840785_1009_1026_Disease)) (CC and) (NP (VBN reduced) (JJ NRVMs) (NN viability) (NN dose-dependently)))))))) (. .)))
24840785	8	(S1 (S (S (VP (TO To) (VP (VB confirm) (NP (DT the) (JJ pro-apoptotic) (NNS effects))))) (, ,) (NP (PRP we)) (VP (VBD performed) (NP (NP (NN flow) (JJ cytometric) (NN detection)) (, ,) (NP (JJ cardiac) (NN histology)) (, ,) (NP (NN transmission) (NNP electron) (NN microscopy)) (CC and) (NP (NN terminal) (NN deoxynucleotidyl) (JJ transferase-mediated) (NNP Doc_24840785_1254_1258_Chemical-Doc_24840785_1259_1265_Chemical) (NNP nick) (NN end) (VBG labeling) (NN assay)))) (. .)))
24840785	9	(S1 (S (NP (DT The) (NNS results)) (VP (VBD showed) (NP (DT that) (JJ Doc_24840785_1315_1324_Chemical) (VBN stimulated) (NN apoptosis) (NN time-dependently))) (. .)))
24840785	10	(S1 (S (NP (NP (DT The) (NN expression) (NN analysis)) (PP (IN of) (NP (JJ Doc_24840785_1391_1397_Chemical) (NN handling) (NNS proteins)))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NNP Doc_24840785_1434_1443_Chemical)) (VP (VBD promoted) (NP (JJ Doc_24840785_1453_1459_Chemical) (NN overload)) (PP (IN through) (NP (NP (DT the) (NN expression) (NN regulation)) (PP (IN of) (NP (JJ Doc_24840785_1506_1512_Chemical) (NN handling) (NNS proteins))))))))) (. .)))
24840785	11	(S1 (S (NP (NP (DT The) (NN expression) (NN analysis)) (PP (IN of) (NP (JJ apoptosis-related) (NNS proteins)))) (VP (VBD revealed) (SBAR (IN that) (S (S (NP (JJ pro-apoptotic) (NN protein) (NN expression)) (VP (AUX was) (VP (VBN upregulated)))) (, ,) (CC and) (S (NP (JJ anti-apoptotic) (NN protein) (NN BCL-2) (NN expression)) (VP (AUX was) (VP (VBN downregulated))))))) (. .)))
24840785	12	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (VBN increased) (NN phosphorylation)) (PP (IN of) (NP (NP (JJ MAPK) (NN family) (NNS members)) (, ,) (ADVP (RB especially)) (NP (DT the) (JJ P-P38/P38) (NN ratio))))) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (JJ cardiac) (NNS tissues))))) (. .)))
24840785	13	(S1 (S (ADVP (RB Hence)) (, ,) (NP (PRP$ our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_24840785_1869_1878_Chemical)) (VP (VP (ADVP (RB significantly)) (VP (VBZ aggravates) (NP (JJ Doc_24840785_1904_1910_Chemical) (NN overload))) (CC and) (VP (VBZ causes) (NP (NNP Doc_24840785_1931_1941_Disease)))) (CC and) (VP (ADVP (RB finally)) (VBZ promotes) (NP (JJ apoptotic) (NN development)) (PP (IN via) (NP (NP (NN phosphorylation)) (PP (IN of) (NP (CD P38) (JJ mitogen-activated) (NN protein) (NN kinase)))))))))) (. .)))
24842192	0	(S1 (S (NP (NP (JJ Chronic) (NN treatment)) (PP (IN with) (NP (NNP Doc_24842192_23_32_Chemical)))) (VP (VP (VBZ suppresses) (NP (NN toll-like) (NN receptor) (CD 4)) (S (VP (VBG signaling)))) (CC and) (VP (VBZ attenuates) (NP (NNP Doc_24842192_90_118_Disease)) (S (VP (VBG following) (NP (NNP Doc_24842192_129_150_Disease)))))) (. .)))
24842192	1	(S1 (S (NP (NP (JJ Acute) (NN treatment)) (PP (IN with) (NP (NNP Doc_24842192_173_182_Chemical)))) (VP (AUX has) (NP (DT a) (JJ protective) (NN effect)) (PP (IN in) (NP (NNP Doc_24842192_210_231_Disease))) (PP (IN by) (NP (NP (NN suppression)) (PP (IN of) (NP (NP (JJ Doc_24842192_250_262_Disease) (NNS responses)) (ADJP (JJ due) (PP (TO to) (NP (NP (NN activation)) (PP (IN of) (NP (NP (JJ Doc_24842192_294_297_Chemical-activated) (NN protein) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NNP AMPK)) (-RRB- -RRB-)))))))))))) (. .)))
24842192	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ chronic) (ADJP (JJ pre-treatment) (PP (IN with) (NP (NP (NP (NP (NNP Doc_24842192_394_403_Chemical)) (PP (IN on) (NP (NNP Doc_24842192_407_426_Disease)))) (CC and) (NP (JJ toll-like) (NN receptor) (CD 4))) (PRN (-LRB- -LRB-) (NP (NNP TLR4)) (-RRB- -RRB-))))) (NNS activities)) (VP (VBG following) (NP (NNP Doc_24842192_480_501_Disease)))))) (CC and) (NP (NP (PRP$ their) (NN relation)) (PP (IN with) (NP (NNP AMPK))))) (VP (AUX were) (VP (VBN assessed))) (. .)))
24842192	3	(S1 (S (S (NP (JJ Male) (JJ Wistar) (NNS rats)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN assigned) (PP (TO to) (NP (NP (CD one)) (PP (IN of) (NP (NP (CD 5) (NNS groups)) (PRN (-LRB- -LRB-) (NP (CD n=6)) (-RRB- -RRB-))))))))) (: :) (S (NP (JJ normal) (NN control) (CC and) (NNS groups)) (VP (AUX were) (VP (VBN injected) (NP (NNP Doc_24842192_652_665_Chemical)) (PP (IN after) (NP (NN chronic) (NN pre-treatment))) (PP (IN with) (NP (NP (CD 0)) (, ,) (NP (CD 25)) (, ,) (NP (CD 50)) (, ,) (CC or) (NP (NP (CD 100mg/kg)) (PP (IN of) (NP (NNP Doc_24842192_725_734_Chemical)))))) (ADVP (ADVP (RB twice) (RB daily)) (PP (IN for) (NP (CD 14) (NNS days))))))) (. .)))
24842192	4	(S1 (S (NP (NP (NN Doc_24842192_760_773_Chemical)) (PRN (-LRB- -LRB-) (NP (NN 100mg/kg)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN injected) (ADVP (RB subcutaneously)) (PP (IN on) (NP (NP (DT the) (ADJP (JJ 13th) (CC and) (JJ 14th)) (NNS days)) (SBAR (S (VP (TO to) (VP (VB induce) (NP (NNP Doc_24842192_849_876_Disease)))))))))) (. .)))
24842192	5	(S1 (S (NP (NNP Doc_24842192_878_891_Chemical)) (ADVP (RB alone)) (VP (VBD decreased) (NP (NP (JJ left) (JJ ventricular) (JJ systolic) (NN pressure)) (CC and) (NP (NP (JJ myocardial) (NN contractility)) (VP (VBN indexed) (PP (IN as) (NP (NP (NNP LVdp/dtmax)) (CC and) (NP (NNP LVdp/dtmin)))))))) (. .)))
24842192	6	(S1 (S (NP (DT The) (NNP Doc_24842192_1014_1042_Disease)) (VP (AUX was) (ADJP (RB significantly) (JJR lower)) (PP (IN in) (NP (NP (DT the) (NNS groups)) (VP (VBN treated) (PP (IN with) (NP (NP (QP (CD 25) (CC and) (CD 50mg/kg))) (PP (IN of) (NP (NNP Doc_24842192_1112_1121_Chemical))))))))) (. .)))
24842192	7	(S1 (S (NP (NNP Doc_24842192_1123_1132_Chemical)) (ADVP (RB markedly)) (VP (VBD lowered) (NP (JJ Doc_24842192_1150_1163_Chemical-induced) (NN elevation)) (PP (IN in) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (JJ TLR4) (NN mRNA)) (, ,) (NP (NP (JJ myeloid) (NN differentiation) (NN protein)) (NP (NP (CD 88)) (PRN (-LRB- -LRB-) (NP (NNP MyD88)) (-RRB- -RRB-)))) (, ,) (NP (NP (NNP Doc_24842192_1254_1259_Disease) (NNP Doc_24842192_1260_1268_Disease) (NN factor-alpha)) (PRN (-LRB- -LRB-) (NP (NNP TNF-a)) (-RRB- -RRB-))) (, ,) (CC and) (RB interleukin) (NP (CD 6) (-LRB- -LRB-) (NN IL-6) (-RRB- -RRB-)))) (PP (IN in) (NP (DT the) (NN heart) (NNS tissues)))))) (. .)))
24842192	8	(S1 (S (NP (JJ Similar) (NNS changes)) (VP (AUX were) (ADVP (RB also)) (VP (VBN seen) (PP (IN in) (NP (NP (DT the) (JJ serum) (NNS levels)) (PP (IN of) (NP (NP (NN TNF-a)) (CC and) (NP (NN IL-6)))))))) (. .)))
24842192	9	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJR lower) (NNS doses)) (PP (IN of) (NP (NP (CD 25)) (CC and) (NP (CD 50mg/kg))))) (VP (AUX were) (ADJP (ADJP (RBR more) (JJ effective)) (PP (IN than) (NP (NN 100mg/kg))))) (. .)))
24842192	10	(S1 (S (NP (NP (NNP Phosphorylated) (NNP AMPKa)) (PRN (-LRB- -LRB-) (NP (NN p-AMPK)) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (NN myocardium)))) (VP (AUX was) (ADJP (RB significantly) (JJ elevated) (PP (IN by) (NP (NP (NNS 25mg/kg)) (PP (IN of) (NP (NNP Doc_24842192_1575_1584_Chemical)))))) (, ,) (PP (RB slightly) (PP (IN by) (NP (CD 50mg/kg))) (, ,) (CC but) (RB not) (PP (IN by) (NP (NN 100mg/kg))))) (. .)))
24842192	11	(S1 (S (NP (NP (JJ Chronic) (NN pre-treatment)) (PP (IN with) (NP (NNP Doc_24842192_1655_1664_Chemical)))) (VP (VP (VBZ reduces) (NP (NN post-Doc_24842192_1678_1719_Disease))) (CC and) (VP (VBZ suppresses) (NP (JJ Doc_24842192_1735_1747_Disease) (NNS responses))) (, ,) (PP (ADVP (RB possibly)) (IN through) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ TLR4) (NNS activities)))))) (. .)))
24842192	12	(S1 (S (NP (DT This) (NN mechanism)) (VP (MD can) (VP (AUX be) (VP (VBN considered) (PP (IN as) (NP (NP (DT a) (NN target)) (SBAR (S (VP (TO to) (VP (VB protect) (NP (JJ infarcted) (NN myocardium))))))))))) (. .)))
2484903	0	(S1 (NP (NP (NP (JJ Unusual) (NNS complications)) (PP (IN of) (NP (JJ antithyroid) (NN drug) (NN therapy)))) (: :) (NP (NP (CD four) (NN case) (NNS reports)) (CC and) (NP (NP (NN review)) (PP (IN of) (NP (NN literature))))) (. .)))
2484903	1	(S1 (S (NP (NP (NP (CD Two) (NNS cases)) (PP (IN of) (NP (ADJP (JJ Doc_2484903_108_124_Chemical-associated) (JJ acute)) (NNP Doc_2484903_142_151_Disease)))) (, ,) (NP (NP (CD one) (NN case)) (PP (IN of) (NP (JJ fatal) (JJ Doc_2484903_171_182_Chemical-associated) (NN hepatocellular) (NN Doc_2484903_209_217_Disease)))) (CC and) (NP (NP (CD one) (NN case)) (PP (IN of) (NP (JJ Doc_2484903_234_250_Chemical-associated) (NNP Doc_2484903_262_281_Disease))))) (VP (AUX are) (VP (VBN described))) (. .)))
2484903	2	(S1 (S (S (NP (DT The) (NN literature)) (VP (VBN related) (S (VP (TO to) (VP (VB antithyroid) (NP (NN drug) (NN side) (NNS effects))))))) (CC and) (S (NP (NP (DT the) (NNS mechanisms)) (PP (IN for) (NP (PRP$ their) (NN occurrence)))) (VP (VP (AUX are) (VP (VBN reviewed))) (CC and) (VP (NP (NP (DT the) (NN efficacy)) (CC and) (NP (NP (NNS complications)) (PP (IN of) (NP (NNP thyroidectomy) (CC and) (NNP Doc_2484903_462_473_Chemical))))) (PP (VBN compared) (PP (TO to) (NP (NP (DT those)) (PP (IN of) (NP (JJ antithyroid) (NNS drugs))))))))) (. .)))
2484903	3	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (PP (IN in) (NP (JJS most) (NNS circumstances))) (NP (PRP 131I)) (VP (AUX is) (NP (NP (DT the) (NN therapy)) (PP (IN of) (NP (NN choice))) (PP (IN for) (NP (NN Doc_2484903_591_606_Disease))))))))) (. .)))
24881749	0	(S1 (S (NP (NN Doc_24881749_0_30_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NN combination) (NN therapy)) (PP (IN with) (NP (NP (NNP Doc_24881749_67_80_Chemical)) (CC and) (NP (NNP Doc_24881749_85_93_Chemical)))))) (PP (IN in) (NP (NP (DT a) (JJ Japanese) (NN patient)) (PP (IN with) (NP (NNP Doc_24881749_121_141_Disease))))) (PP (IN at) (NP (NP (DT the) (JJ terminal) (NN stage)) (PP (IN of) (NP (JJ recurrent) (NNP Doc_24881749_177_190_Disease)))))) (. .)))
24881749	1	(S1 (S (NP (PRP We)) (ADVP (RB herein)) (VP (VBP describe) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT an) (JJ 81-year-old) (JJ Japanese) (NN woman)) (PP (IN with) (NP (NNP Doc_24881749_258_288_Disease))) (SBAR (WHNP (WDT that)) (S (VP (VBD occurred) (NP (CD 36) (NNS days)) (PP (IN after) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NP (NN combination) (NN therapy)) (PP (IN with) (NP (NP (NP (NNP Doc_24881749_360_368_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 75) (NN mg/day)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_24881749_385_398_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 12.5) (NN mg/day)) (-RRB- -RRB-))))) (PP (IN for) (NP (NNP Doc_24881749_417_437_Disease)))))))))))))) (. .)))
24881749	2	(S1 (S (NP (DT The) (NN patient)) (VP (AUX had) (VP (AUX been) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_24881749_473_481_Chemical)) (CC or) (NP (NNP Doc_24881749_485_498_Chemical)))) (PP (ADVP (RB alone)) (IN without) (NP (NP (DT any) (JJ adverse) (NNS effects)) (PP (IN before) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (DT the) (NN combination) (NN therapy)))))))))) (. .)))
24881749	3	(S1 (S (NP (PRP She)) (ADVP (RB also)) (VP (AUX had) (NP (JJ advanced) (NN Doc_24881749_609_622_Disease)) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN combination) (NN therapy)) (VP (AUX was) (VP (VBN initiated)))))) (. .)))
24881749	4	(S1 (S (PP (TO To) (NP (NP (DT the) (JJS best)) (PP (IN of) (NP (PRP$ our) (NN knowledge))))) (, ,) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP Doc_24881749_715_745_Disease))) (PP (JJ due) (TO to) (NP (NP (NN combination) (NN therapy)) (PP (IN with) (NP (NP (NNP Doc_24881749_778_791_Chemical)) (CC and) (NP (NNP Doc_24881749_796_804_Chemical))))))) (VP (AUX has) (RB not) (VP (AUX been) (VP (ADVP (RB previously)) (VBN reported)))) (. .)))
24881749	5	(S1 (S (NP (NN Doc_24881749_839_852_Chemical)) (VP (MD should) (VP (AUX be) (VP (VBN administered) (ADVP (RB very) (RB carefully)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (JJ neuroleptic) (NNS drugs))))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (DT a) (VBG worsening) (JJ general) (NN condition)))))))) (. .)))
24894748	0	(S1 (S (NP (DT A) (JJ Doc_24894748_2_12_Chemical-Doc_24894748_13_24_Chemical) (NN combination)) (VP (VBN induced) (NP (NNP Doc_24894748_45_56_Disease))) (. .)))
24894748	1	(S1 (S (S (VP (TO To) (VP (VB report) (NP (DT a) (JJ sinus) (NN Doc_24894748_76_87_Disease))))) (VP (VBN induced) (PP (IN by) (NP (NP (JJ Doc_24894748_99_109_Chemical) (CC and) (JJ Doc_24894748_114_125_Chemical) (NN drug-drug) (NN interaction)) (CC and) (NP (PRP$ its) (NN management))))) (. .)))
24894748	2	(S1 (S (NP (NP (DT A) (CD 63) (JJ year-old) (NNP Caucasian) (NN man)) (PP (IN on) (NP (NNP Doc_24894748_199_209_Chemical) (CD 200) (NN mg/day))) (PP (IN for) (NP (JJ stable) (NNP Doc_24894748_232_255_Disease)))) (VP (AUX was) (VP (VBN prescribed) (NP (NP (DT a) (JJ 90-day) (NN course)) (PP (IN of) (NP (NP (JJ oral) (NNP Doc_24894748_295_306_Chemical) (CD 250) (NN mg/day)) (PP (IN for) (NP (NNP Doc_24894748_322_335_Disease)))))))) (. .)))
24894748	3	(S1 (S (PP (IN On) (NP (NP (DT the) (JJ 49th) (NN day)) (PP (IN of) (NP (JJ Doc_24894748_356_367_Chemical) (NN therapy))))) (, ,) (NP (PRP he)) (VP (VP (AUX was) (VP (VBN brought) (PP (TO to) (NP (DT the) (NN emergency) (NN room))) (PP (IN for) (NP (NP (DT a) (NN decrease)) (PP (IN of) (NP (PRP$ his) (JJ global) (NN health) (NN status))))) (, ,) (NP (NNP Doc_24894748_458_467_Disease)))) (CC and) (VP (VBZ falls))) (. .)))
24894748	4	(S1 (S (NP (DT The) (NN electrocardiogram)) (VP (VBD revealed) (NP (DT a) (CD 37) (NN beats/min) (JJ sinus) (NN Doc_24894748_531_542_Disease))) (. .)))
24894748	5	(S1 (S (NP (NP (DT A) (NN score)) (PP (IN of) (NP (CD 7))) (PP (IN on) (NP (DT the) (NNP Naranjo) (NNP Doc_24894748_572_593_Disease) (NN probability) (NN scale)))) (VP (VBZ indicates) (NP (NP (DT a) (JJ probable) (NN relationship)) (PP (IN between) (NP (NP (NP (DT the) (NN patient) (POS 's)) (JJ sinus) (NN Doc_24894748_674_685_Disease)) (CC and) (NP (DT the) (NN drug) (NN interaction)))) (PP (IN between) (NP (NNP Doc_24894748_719_729_Chemical) (CC and) (NNP Doc_24894748_734_745_Chemical))))) (. .)))
24894748	6	(S1 (S (NP (DT The) (NN heart) (NN rate)) (VP (VBD ameliorated) (ADVP (RB first)) (PP (IN with) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NNP Doc_24894748_811_821_Chemical)))))))) (. .)))
24894748	7	(S1 (S (S (NP (PRP It)) (VP (AUX was) (ADVP (RB subsequently)) (VP (VBN changed) (PP (TO to) (NP (NNP Doc_24894748_854_864_Chemical)))))) (CC and) (S (NP (DT the) (NN heart) (NN rate)) (VP (VBD remained) (ADJP (JJ normal)))) (. .)))
24894748	8	(S1 (S (PP (IN By) (S (VP (VBG inhibiting) (NP (DT the) (JJ cytochrome) (CD P450) (NN 2D6))))) (, ,) (NP (NNP Doc_24894748_940_951_Chemical)) (VP (AUX had) (VP (VBN decreased) (NP (NP (NNP Doc_24894748_966_976_Chemical) (POS 's)) (NN clearance)) (, ,) (S (VP (VBG leading) (PP (IN in) (NP (NP (JJ Doc_24894748_1001_1011_Chemical) (NN accumulation)) (SBAR (WHNP (WDT which)) (S (VP (AUX has) (VP (VBN resulted) (PP (IN in) (NP (ADJP (RB clinically) (JJ significant)) (NN sinus) (NN Doc_24894748_1076_1087_Disease))))))))))))) (. .)))
24897009	0	(S1 (S (NP (NP (NNP Optochiasmatic)) (CC and) (NP (NNP Doc_24897009_19_40_Disease))) (PP (JJ due) (TO to) (NP (NNP Doc_24897009_48_58_Chemical))) (VP (VBP overtreatment)) (. .)))
24897009	1	(S1 (S (NP (NN Doc_24897009_74_84_Chemical)) (VP (AUX is) (VP (VBN known) (S (VP (TO to) (VP (VB cause) (NP (ADJP (JJ Doc_24897009_103_119_Disease) (CC and) (, ,) (ADVP (RBR more) (RB rarely)) (, ,) (JJ axonal)) (NN Doc_24897009_145_159_Disease))))))) (. .)))
24897009	2	(S1 (S (NP (PRP We)) (VP (VBP characterize) (NP (DT the) (JJ clinical) (, ,) (ADJP (ADJP (JJ neurophysiological)) (, ,) (CC and) (ADJP (JJ neuroimaging))) (NNS findings)) (PP (IN in) (NP (NP (DT a) (JJ 72-year-old) (NN man)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_24897009_272_283_Disease) (CC and) (NNS paresthesias)) (PP (IN after) (NP (NP (CD 11) (NNS weeks)) (PP (IN of) (NP (NP (NN exposure)) (PP (TO to) (NP (NP (DT a) (JJ supratherapeutic) (NN dose)) (PP (IN of) (NP (NNP Doc_24897009_358_368_Chemical))))))))))))))) (. .)))
24897009	3	(S1 (S (NP (DT This) (NN case)) (VP (VBZ demonstrates) (NP (NP (DT the) (JJ selective) (NN vulnerability)) (PP (IN of) (NP (NP (DT the) (NNP anterior) (JJ visual) (NNS pathways)) (CC and) (NP (JJ peripheral) (NNS nerves)))) (PP (TO to) (NP (NNP Doc_24897009_478_488_Chemical) (NNP Doc_24897009_489_497_Disease))))) (. .)))
24902786	0	(S1 (S (NP (NN Doc_24902786_0_12_Chemical)) (VP (VBZ ameliorates) (NP (NP (JJ Doc_24902786_25_39_Chemical-induced) (NN Doc_24902786_48_65_Disease)) (PP (IN in) (NP (JJ male) (NNS rats))))) (. .)))
24902786	1	(S1 (S (S (VP (TO To) (VP (VB study) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_24902786_109_121_Chemical))) (PP (IN on) (NP (NNP Doc_24902786_125_139_Chemical))))))) (PRN (-LRB- -LRB-) (NP (NNP Doc_24902786_141_144_Chemical)) (-RRB- -RRB-)) (VP (VBD -induced) (NP (NNP Doc_24902786_154_171_Disease)) (PP (IN in) (NP (JJ male) (NNS rats)))) (. .)))
24902786	2	(S1 (S (S (NP (JJ Adult) (JJ male) (NNP Wistar) (NNS rats)) (VP (AUX were) (ADVP (RB intracerebroventricularly)) (PRN (-LRB- -LRB-) (NP (CD icv)) (-RRB- -RRB-)) (VP (VBN infused) (PP (IN with) (NP (NNP Doc_24902786_268_271_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 750) (NN ug)) (-RRB- -RRB-)) (PP (IN on) (NP (NP (NNP d) (CD 1)) (CC and) (NP (NNP d) (CD 3))))))) (, ,) (CC and) (S (NP (DT a) (JJ passive) (NN avoidance) (NN task)) (VP (AUX was) (VP (VBN assessed) (NP (CD 2) (NNS weeks)) (PP (IN after) (NP (NP (DT the) (JJ first) (NN injection)) (PP (IN of) (NP (NNP Doc_24902786_376_379_Chemical)))))))) (. .)))
24902786	3	(S1 (S (S (NP (JJ Castration) (NN surgery)) (VP (AUX was) (VP (VBN performed) (PP (IN in) (NP (NP (DT another) (NN group)) (PP (IN of) (NP (NNS rats)))))))) (, ,) (CC and) (S (NP (DT the) (JJ passive) (NN avoidance) (NN task)) (VP (AUX was) (VP (VBN assessed) (NP (CD 4) (NNS weeks)) (PP (IN after) (NP (DT the) (NN operation)))))) (. .)))
24902786	4	(S1 (S (NP (NP (NP (NNP Doc_24902786_513_525_Chemical) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 1) (CD mg.kg)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (NN .d)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (, ,) (CD sc)) (-RRB- -RRB-)) (, ,) (NP (NP (DT the) (NNP Doc_24902786_555_563_Chemical) (NN receptor) (NN antagonist) (NNP Doc_24902786_584_593_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 10) (CD mg.kg)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (NN .d)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (, ,) (CD ip)) (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (NNP Doc_24902786_624_632_Chemical) (NN receptor) (NN antagonist) (NNP Doc_24902786_653_662_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 1) (CD mg.kg)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (NN .d)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (, ,) (CD ip)) (-RRB- -RRB-))) (CC or) (NP (DT the) (JJ aromatase) (NN inhibitor))) (NNP Doc_24902786_714_723_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD 4) (CD mg.kg)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-)) (NN .d)) (PRN (-LRB- -LRB-) (JJ -1) (-RRB- -RRB-))) (, ,) (NP (CD ip))) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN administered) (PP (IN for) (NP (NP (CD 6) (NNP d)) (PP (IN after) (NP (NP (DT the) (JJ first) (NN injection)) (PP (IN of) (NP (NNP Doc_24902786_803_806_Chemical))))))))) (. .)))
24902786	5	(S1 (S (NP (NP (JJ Doc_24902786_817_820_Chemical) (NN administration)) (CC and) (NP (NN castration))) (ADVP (RB markedly)) (VP (VBD decreased) (NP (NP (NP (DT both) (NNS STL1)) (PRN (-LRB- -LRB-) (NP (DT the) (JJ short) (NN memory)) (-RRB- -RRB-))) (CC and) (NP (NP (NNS STL2)) (PRN (-LRB- -LRB-) (NP (DT the) (JJ long) (NN memory)) (-RRB- -RRB-)))) (PP (IN in) (NP (JJ passive) (NN avoidance) (NNS tests)))) (. .)))
24902786	6	(S1 (S (NP (JJ Doc_24902786_954_966_Chemical) (NN replacement)) (ADVP (RB almost)) (VP (VP (VBD restored) (NP (NP (DT the) (NNS STL1) (CC and) (NNS STL2)) (PP (IN in) (NP (VBN castrated) (NNS rats))))) (, ,) (CC and) (VP (ADVP (RB significantly)) (VBN prolonged) (NP (DT the) (NNS STL1) (CC and) (NNS STL2)) (PP (IN in) (NP (JJ Doc_24902786_1081_1084_Chemical-treated) (NNS rats))))) (. .)))
24902786	7	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NNP Doc_24902786_1117_1126_Chemical) (, ,) (NNP Doc_24902786_1128_1137_Chemical) (CC or) (NNP Doc_24902786_1141_1150_Chemical)))) (VP (VP (ADVP (RB significantly)) (VBN impaired) (NP (DT the) (NN memory)) (PP (IN in) (NP (JJ intact) (NNS rats)))) (, ,) (CC and) (VP (ADVP (RB significantly)) (VBN attenuated) (NP (DT the) (JJ Doc_24902786_1234_1246_Chemical) (NN replacement)) (PP (IN in) (S (VP (VBG improving) (NP (JJ Doc_24902786_1272_1275_Chemical-) (CC and) (JJ castration-induced) (NN Doc_24902786_1300_1317_Disease))))))) (. .)))
24902786	8	(S1 (S (NP (JJ Doc_24902786_1331_1343_Chemical) (NN administration)) (VP (VBZ ameliorates) (NP (NP (NNP Doc_24902786_1371_1374_Chemical-)) (CC and) (NP (JJ castration-induced) (NNP Doc_24902786_1399_1416_Disease))) (PP (IN in) (NP (JJ male) (JJ Wistar) (NNS rats)))) (. .)))
24911645	0	(S1 (S (NP (NP (JJ Behavioral) (CC and) (JJ neurochemical) (NNS studies)) (PP (IN in) (NP (NP (NNS mice)) (VP (VBN pretreated) (PP (IN with) (NP (NN garcinielliptone))))))) (VP (VBP FC) (PP (IN in) (NP (JJ Doc_24911645_84_95_Chemical-induced) (NNP Doc_24911645_104_112_Disease)))) (. .)))
24911645	1	(S1 (S (NP (NP (NNP Doc_24911645_114_133_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24911645_135_138_Chemical)) (-RRB- -RRB-))) (VP (VBD isolated) (PP (IN from) (NP (JJ hexanic) (NN fraction) (NN seed))) (S (VP (VB extract) (PP (IN of) (NP (NNS species))))) (NP (NNP Platonia) (FW insignis) (NNP Mart))) (. .)))
24911645	2	(S1 (S (NP (PRP It)) (VP (AUX is) (ADVP (RB widely)) (VP (VBN used) (PP (IN in) (NP (NN folk) (NN medicine))) (S (VP (TO to) (VP (VB treat) (NP (NP (NN Doc_24911645_263_276_Disease)) (PP (IN in) (NP (DT both) (NP (NNS humans)) (CC and) (NP (NNS animals))))) (ADVP (ADVP (RB as) (RB well)) (SBAR (IN as) (S (NP (DT the) (NN seed) (NN decoction)) (VP (AUX has) (VP (AUX been) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NP (NNS diarrheas)) (CC and) (NP (NNP Doc_24911645_371_392_Disease))))))))))))))))) (. .)))
24911645	3	(S1 (S (ADVP (RB However)) (, ,) (NP (EX there)) (VP (AUX is) (NP (NP (DT no) (NN research)) (PP (IN on) (NP (NP (JJ Doc_24911645_427_430_Chemical) (NNS effects)) (PP (IN in) (NP (NP (DT the) (JJ central) (JJ nervous) (NN system)) (PP (IN of) (NP (NNS rodents))))))))) (. .)))
24911645	4	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBD aimed) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (JJ Doc_24911645_521_524_Chemical) (NNS effects)) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (CD 25) (, ,) (CD 50) (CC or) (CD 75) (NNS mg/kg))))) (PP (IN on) (NP (NNP Doc_24911645_567_574_Disease) (NNS parameters) (S (VP (TO to) (VP (VB determine) (NP (NP (NP (PRP$ their) (JJ anticonvulsant) (NN activity)) (CC and) (NP (NP (PRP$ its) (NNS effects)) (PP (IN on) (NP (NP (NNP Doc_24911645_648_658_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24911645_660_679_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_24911645_681_685_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_24911645_688_697_Chemical) (, ,) (NNP Doc_24911645_699_708_Chemical) (CC and) (NNP Doc_24911645_713_724_Chemical)) (-RRB- -RRB-))))) (NNS levels)) (PP (IN as) (ADVP (RB well))) (PP (IN as) (PP (IN on) (NP (NP (JJ acetylcholinesterase) (PRN (-LRB- -LRB-) (NP (NNP AChE)) (-RRB- -RRB-)) (NN activity)) (PP (IN in) (NP (NP (NNS mice)) (PP (JJ hippocampus) (IN after) (NP (NNP Doc_24911645_810_818_Disease))))))))))))))))))) (. .)))
24911645	5	(S1 (S (NP (NNP Doc_24911645_820_823_Chemical)) (VP (VBD produced) (NP (NP (DT an) (VBN increased) (NN latency)) (PP (TO to) (NP (JJ first) (NNP Doc_24911645_863_870_Disease))) (, ,) (PP (IN at) (NP (NP (NP (NNS doses) (NNS 25mg/kg)) (PRN (-LRB- -LRB-) (NP (NP (CD 20.12) (NNS +)) (NP (CD 2.20) (NN min))) (-RRB- -RRB-))) (, ,) (NP (NP (NNS 50mg/kg)) (PRN (-LRB- -LRB-) (NP (NP (CD 20.95) (NNS +)) (NP (CD 2.21) (NN min))) (-RRB- -RRB-))) (CC or) (NP (NP (CD 75) (NNS mg/kg)) (PRN (-LRB- -LRB-) (NP (NP (CD 23.43) (NNS +)) (NP (CD 1.99) (NN min))) (-RRB- -RRB-)))))) (ADVP (WRB when)) (PP (VBN compared) (PP (IN with) (NP (VBN seized) (NNS mice))))) (. .)))
24911645	6	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (JJ Doc_24911645_1012_1016_Chemical) (NN content)) (PP (IN of) (NP (NP (NNS mice)) (VP (ADVP (RB hippocampus)) (VBN treated) (PP (IN with) (NP (CD GFC75) (CC plus) (CD P400))))))) (VP (VBD showed) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (CD 46.90) (NN %)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (VBN seized) (NNS mice))))))) (. .)))
24911645	7	(S1 (S (PP (IN In) (NP (NNP Doc_24911645_1138_1147_Chemical))) (, ,) (NP (NNP Doc_24911645_1149_1158_Chemical) (CC and) (NNP Doc_24911645_1163_1172_Chemical) (NNS levels)) (VP (VBD detected) (NP (NP (DT a) (NN decrease)) (PP (IN of) (NP (NP (NP (CD 5.21) (NN %)) (, ,) (NP (CD 13.55) (NN %)) (CC and) (NP (CD 21.80) (NN %)) (, ,) (ADVP (RB respectively))) (PP (IN in) (NP (NP (NNS mice)) (ADJP (JJ hippocampus) (PP (VBN treated) (PP (IN with) (NP (CD GFC75) (CC plus) (CD P400)))))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (VBN seized) (NNS mice))))))) (. .)))
24911645	8	(S1 (S (NP (NP (JJ Hippocampus) (NNS mice)) (VP (VBN treated) (PP (IN with) (NP (CD GFC75) (CC plus) (CD P400))))) (VP (VBD showed) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN AChE) (NN activity)) (PRN (-LRB- -LRB-) (NP (CD 63.30) (NN %)) (-RRB- -RRB-))))) (ADVP (WRB when)) (PP (VBN compared) (PP (IN with) (NP (VBN seized) (NNS mice))))) (. .)))
24911645	9	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_24911645_1472_1475_Chemical)) (VP (MD can) (VP (VP (VB exert) (NP (JJ anticonvulsant) (NN activity))) (CC and) (VP (VB reduce) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NP (NN installation)) (PP (IN of) (NP (JJ Doc_24911645_1554_1565_Chemical-induced) (NNP Doc_24911645_1574_1592_Disease))))))) (, ,) (SBAR (IN as) (S (VP (VBN demonstrated) (PP (IN by) (NP (NP (NP (NN increase)) (PP (IN in) (NP (NP (NN latency)) (PP (TO to) (NP (JJ first) (NNP Doc_24911645_1642_1649_Disease)))))) (CC and) (NP (NP (NN decrease)) (PP (IN in) (NP (NP (NN mortality) (NN rate)) (PP (IN of) (NP (NNS animals)))))))))))))))) (. .)))
24911645	10	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (PRP$ our) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_24911645_1730_1733_Chemical)) (VP (MD may) (VP (VP (VB influence) (PP (IN in) (NP (NN epileptogenesis)))) (CC and) (VP (VB promote) (NP (NN anticonvulsant) (NNS actions)) (PP (IN in) (NP (NNP Doc_24911645_1805_1816_Chemical) (NN model))) (PP (PP (IN by) (S (VP (VBG modulating) (NP (DT the) (NNP Doc_24911645_1841_1845_Chemical) (CC and) (NNP Doc_24911645_1850_1859_Chemical) (NNS contents))))) (CC and) (PP (IN of) (NP (NP (NN AChE) (NN activity)) (PP (IN in) (NP (VBN seized) (NNS mice) (JJ hippocampus)))))))))))) (. .)))
24911645	11	(S1 (S (S (NP (DT This) (NN compound)) (VP (MD may) (VP (AUX be) (ADJP (JJ useful) (S (VP (TO to) (VP (VB produce) (NP (JJ neuronal) (NN protection))))))))) (CC and) (S (NP (PRP it)) (VP (MD can) (VP (AUX be) (VP (VBN considered) (PP (IN as) (NP (DT an) (JJ anticonvulsant) (NN agent))))))) (. .)))
24923469	0	(S1 (NP (NP (NP (NP (JJ Standard) (NN operating) (NNS procedures)) (PP (IN for) (NP (JJ antibiotic) (NN therapy)))) (CC and) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP Doc_24923469_75_94_Disease))))) (: :) (NP (DT a) (JJ prospective) (, ,) (JJ clinical) (, ,) (JJ non-interventional) (, ,) (JJ observational) (NN study)) (. .)))
24923469	1	(S1 (S (NP (NP (NNP Doc_24923469_176_195_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24923469_197_200_Disease)) (-RRB- -RRB-))) (VP (VBZ occurs) (PP (IN in) (NP (NP (NP (CD 7) (NN %)) (PP (IN of) (NP (VBN hospitalized)))) (CC and) (NP (NP (CD 66) (NN %)) (PP (IN of) (NP (JJ Intensive) (NN Care) (NN Unit) (PRN (-LRB- -LRB-) (NP (NNP ICU)) (-RRB- -RRB-)) (NNS patients))))))) (. .)))
24923469	2	(S1 (S (NP (PRP It)) (VP (VBZ increases) (NP (NP (NN mortality)) (, ,) (NP (NP (NN hospital) (NN length)) (PP (IN of) (NP (NN stay)))) (, ,) (CC and) (NP (NNS costs)))) (. .)))
24923469	3	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (, ,) (SBAR (IN whether) (S (NP (EX there)) (VP (AUX is) (NP (NP (DT an) (NN association)) (PP (IN between) (NP (NP (NP (NN adherence)) (PP (TO to) (NP (NP (NNS guidelines)) (PRN (-LRB- -LRB-) (NP (NP (JJ standard) (NN operating) (NNS procedures)) (PRN (-LRB- -LRB-) (NP (NNP SOP)) (-RRB- -RRB-))) (-RRB- -RRB-)))) (PP (IN for) (NP (ADJP (RB potentially) (JJ nephrotoxic)) (NNS antibiotics)))) (CC and) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP Doc_24923469_544_547_Disease)))))))))))))) (. .)))
24923469	4	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (VBD carried) (PRT (RP out)) (PP (IN as) (NP (DT a) (JJ prospective) (, ,) (JJ clinical) (, ,) (JJ non-interventional) (, ,) (JJ observational) (NN study))))) (. .)))
24923469	5	(S1 (S (NP (NNS Data) (NN collection)) (VP (AUX was) (VP (VBN performed) (PP (IN over) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD 170) (NNS days))) (PP (IN in) (NP (NP (NP (CD three) (NNS ICUs)) (PP (IN at) (NP (NNP Doc_24923469_726_733_Chemical)))) (: -) (NP (NNP Universitaetsmedizin) (NNP Berlin)))))))) (. .)))
24923469	6	(S1 (S (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 675) (NNS patients)))) (VP (AUX were) (VP (VBN included)))) (: ;) (S (NP (NP (CD 163)) (PP (IN of) (NP (DT these)))) (VP (AUX had) (NP (NN therapy)) (PP (IN with) (NP (NP (NNP Doc_24923469_834_844_Chemical)) (, ,) (NP (NNP Doc_24923469_846_856_Chemical)) (, ,) (CC or) (NP (NNP Doc_24923469_861_871_Chemical)))))) (: ;) (S (VP (AUX were) (NP (CD >18) (NNS years)) (: ;) (CC and) (VP (VBN treated) (PP (IN in) (NP (DT the) (NNP ICU))) (PP (IN for) (NP (CD >24) (NNS hours)))))) (. .)))
24923469	7	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (DT an) (NN adherence) (S (VP (TO to) (VP (VB SOP) (NP (CD >70) (NN %)))))))) (VP (AUX were) (VP (VBN classified) (PP (IN into) (NP (NP (NP (DT the) (JJ high) (NN adherence) (NN group)) (PRN (-LRB- -LRB-) (NP (NNP HAG)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT an) (NN adherence)) (PP (IN of) (NP (CD <70) (NN %))))) (PP (IN into) (NP (DT the) (JJ low) (NN adherence) (NN group)))) (PRN (-LRB- -LRB-) (NP (NN LAG)) (-RRB- -RRB-))))))) (. .)))
24923469	8	(S1 (S (NP (NN Doc_24923469_1093_1096_Disease)) (VP (AUX was) (VP (VBN defined) (PP (VBG according) (PP (TO to) (NP (NNP RIFLE) (NNS criteria)))))) (. .)))
24923469	9	(S1 (S (NP (NP (NN Adherence)) (PP (TO to) (NP (NNS SOPs)))) (VP (AUX was) (VP (VBN evaluated) (PP (IN by) (NP (NN retrospective) (NN expert) (NN audit))))) (. .)))
24923469	10	(S1 (S (NP (NP (NN Development)) (PP (IN of) (NP (NNP Doc_24923469_1216_1219_Disease)))) (VP (AUX was) (PP (VBN compared) (PP (IN between) (NP (NP (NNS groups)) (PP (IN with) (NP (NP (JJ exact) (NN Chi2-test)) (CC and) (NP (NP (JJ multivariate) (JJ logistic) (NN regression) (NN analysis)) (PRN (-LRB- -LRB-) (NP (JJ two-sided) (JJ P) (NNS <0.05)) (-RRB- -RRB-))))))))) (. .)))
24923469	11	(S1 (S (NP (NN LAG)) (VP (VBD consisted) (PP (IN of) (NP (NP (NP (CD 75) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 46) (NN %)) (-RRB- -RRB-))) (CC versus) (NP (NP (CD 88) (NN HAG) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 54) (NN %)) (-RRB- -RRB-)))))) (. .)))
24923469	12	(S1 (S (NP (NN Doc_24923469_1410_1413_Disease)) (VP (VBD occurred) (ADVP (RB significantly)) (ADVP (RBR more) (RB often)) (PP (IN in) (NP (NN LAG))) (PP (IN with) (NP (NP (CD 36) (NN %)) (CC versus) (NP (NP (CD 21) (NN %)) (PP (IN in) (NP (NNP HAG))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.035)) (-RRB- -RRB-)))))) (. .)))
24923469	13	(S1 (S (NP (JJ Basic) (NNS characteristics)) (VP (AUX were) (ADJP (JJ comparable)) (, ,) (PP (IN except) (NP (NP (DT an) (VBN increased) (NN rate)) (PP (IN of) (NP (NP (JJ soft) (NNP Doc_24923469_1567_1584_Disease)) (PP (IN in) (NP (NN LAG)))))))) (. .)))
24923469	14	(S1 (S (NP (JJ Multivariate) (NN analysis)) (VP (VBD revealed) (NP (NP (DT an) (NNS odds) (NN ratio)) (PP (IN of) (NP (NN 2.5-fold))) (PP (IN for) (NP (NNP Doc_24923469_1654_1657_Chemical)))) (S (VP (TO to) (VP (VB develop) (NP (NNP Doc_24923469_1669_1672_Disease)) (PP (VBN compared) (PP (IN with) (NP (NP (NNP HAG)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 95) (NN %)) (NN confidence)) (JJ interval) (QP (CD 1.195) (TO to) (CD 5.124))) (, ,) (NP (NNP P) (SYM =) (CD 0.039)) (-RRB- -RRB-))))))))) (. .)))
24923469	15	(S1 (S (NP (NP (JJ Low) (NN adherence)) (PP (TO to) (NP (NNS SOPs))) (PP (IN for) (NP (ADJP (RB potentially) (JJ nephrotoxic)) (NNS antibiotics)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJR higher) (NN occurrence)) (PP (IN of) (NP (NN Doc_24923469_1861_1864_Disease))))))) (. .)))
24923469	16	(S1 (NP (NP (NN TRIAL) (NN REGISTRATION)) (: :) (NP (NP (JJ Current) (JJ Controlled) (NNS Trials)) (NP (CD ISRCTN54598675))) (. .)))
24923469	17	(S1 (FRAG (NP (NNP Registered) (CD 17)) (NP (NNP August) (CD 2007)) (. .)))
24927617	0	(S1 (S (NP (NP (NN Doc_24927617_0_14_Disease)) (PP (IN in) (NP (NNP Doc_24927617_18_46_Disease) (NN patient)))) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_24927617_68_78_Chemical)) (CC and) (NP (NNP Doc_24927617_83_94_Chemical))))) (. .)))
24927617	1	(S1 (S (NP (NP (DT A) (JJ 46-year) (JJ old) (NN man)) (PP (IN with) (NP (DT a) (NN Doc_24927617_121_156_Disease)))) (VP (VBD received) (NP (NP (JJ triple) (NN therapy)) (PP (IN with) (NP (NP (NNP Doc_24927617_186_195_Chemical)) (, ,) (NP (NNP Doc_24927617_197_217_Chemical)) (CC and) (NP (NNP Doc_24927617_222_232_Chemical)))))) (. .)))
24927617	2	(S1 (S (NP (DT The) (NN patient)) (ADVP (RB also)) (VP (VBD received) (NP (NN Doc_24927617_260_271_Chemical))) (. .)))
24927617	3	(S1 (S (PP (NP (CD One) (NN month)) (IN after) (S (VP (VBG starting) (NP (DT the) (JJ antiviral) (NN therapy))))) (, ,) (NP (DT the) (NN patient)) (VP (AUX was) (VP (VBN admitted) (PP (TO to) (NP (DT the) (NN hospital))) (SBAR (IN because) (S (NP (PRP he)) (VP (VBD developed) (NP (NN Doc_24927617_383_397_Disease))))))) (. .)))
24927617	4	(S1 (S (PP (IN At) (NP (NN admission))) (NP (NP (NNP Doc_24927617_412_423_Chemical)) (CC and) (NP (DT all) (JJ antiviral) (NNS drugs))) (VP (AUX were) (VP (VBN discontinued) (SBAR (IN because) (S (NP (NNP Doc_24927617_474_482_Disease)) (PP (JJ due) (TO to) (NP (DT a) (JJ drug-drug) (NN interaction))) (VP (AUX was) (VP (VBN suspected))))))) (. .)))
24927617	5	(S1 (S (S (NP (DT The) (JJ Doc_24927617_533_541_Chemical) (NN kinase)) (VP (VBD peaked) (PP (IN at) (NP (CD 62,246) (NN IU/L))))) (CC and) (S (NP (DT the) (NN patient)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (JJ intravenous) (JJ normal) (NN saline)))))) (. .)))
24927617	6	(S1 (S (NP (NP (DT The) (NN patient) (POS 's)) (JJ renal) (NN function)) (VP (VBD remained) (ADJP (JJ unaffected))) (. .)))
24927617	7	(S1 (S (PP (NP (CD Fourteen) (NNS days)) (IN after) (NP (NN hospitalization))) (, ,) (S (NP (JJ Doc_24927617_718_726_Chemical) (NN kinase) (NN level)) (VP (AUX had) (VP (VBN returned) (PP (TO to) (NP (QP (CD 230) (CD IU/L))))))) (CC and) (S (NP (DT the) (NN patient)) (VP (AUX was) (VP (VBN discharged)))) (. .)))
24927617	8	(S1 (S (NP (NNP Doc_24927617_797_807_Chemical)) (VP (AUX was) (VP (VBN considered) (NP (NP (DT the) (JJ probable) (NN causative) (NN agent)) (PP (IN of) (NP (DT an) (NN interaction))) (PP (IN with) (NP (NNP Doc_24927617_875_886_Chemical)))) (PP (VBG according) (PP (TO to) (NP (DT the) (NNP Drug) (NNP Interaction) (NN Probability) (NN Scale)))))) (. .)))
24927617	9	(S1 (S (NP (DT The) (NN interaction)) (VP (AUX is) (ADJP (JJ due) (PP (TO to) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ CYP3A4-mediated) (JJ Doc_24927617_996_1007_Chemical) (NN clearance))))))) (. .)))
24927617	10	(S1 (S (NP (JJ Doc_24927617_1019_1030_Chemical) (NN plasma) (NN concentration)) (VP (VP (VBD increased) (NP (CD 30) (NNS times)) (PP (IN in) (NP (DT this) (NN patient)))) (CC and) (VP (ADVP (RB statin)) (VBN induced) (SBAR (S (NP (NNP Doc_24927617_1106_1121_Disease)) (VP (AUX is) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (DT the) (NN statin))) (PP (IN in) (NP (NN blood))))))))))) (. .)))
24927617	11	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (PP (IN with) (NP (DT this) (NN case))) (NP (PRP we)) (VP (VBP illustrate) (SBAR (IN that) (S (NP (NNP Doc_24927617_1227_1237_Chemical) (CONJP (RB as) (RB well) (IN as)) (NNS statins)) (VP (AUX are) (ADJP (JJ susceptible) (PP (TO to) (NP (JJ clinical) (JJ relevant) (NN drug-drug) (NNS interactions)))))))) (. .)))
24928523	0	(S1 (S (NP (NP (NN Combination)) (PP (IN of) (NP (NP (NNP Doc_24928523_15_25_Chemical)) (, ,) (NP (NNP Doc_24928523_27_38_Chemical)) (, ,) (CC and) (NP (NP (NNP Doc_24928523_44_57_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP VTD)) (-RRB- -RRB-))))) (PP (IN as) (NP (DT a) (NN consolidation)))) (VP (NN therapy) (PP (IN after) (NP (JJ autologous) (NN stem) (NN cell) (NN transplantation))) (PP (IN for) (NP (NP (JJ symptomatic) (NN Doc_24928523_150_166_Disease)) (PP (IN in) (NP (JJ Japanese) (NNS patients)))))) (. .)))
24928523	1	(S1 (S (NP (NP (NN Consolidation) (NN therapy)) (PP (IN for) (NP (NNS patients))) (PP (IN with) (NP (NP (NNP Doc_24928523_229_245_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24928523_247_249_Disease)) (-RRB- -RRB-))))) (VP (AUX has) (VP (AUX been) (ADVP (RB widely)) (VP (VBN adopted) (S (VP (TO to) (VP (VB improve) (NP (NN treatment) (NN response)) (PP (VBG following) (NP (JJ autologous) (NN stem) (NN cell) (NN transplantation))))))))) (. .)))
24928523	2	(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (ADVP (RB retrospectively)) (VP (VBD analyzed) (NP (NP (DT the) (NN safety) (CC and) (NN efficacy)) (PP (IN of) (NP (NP (NN combination) (NN regimen)) (PP (IN of) (NP (NP (NNP Doc_24928523_446_456_Chemical)) (, ,) (NP (NNP Doc_24928523_458_469_Chemical)) (, ,) (CC and) (NP (NP (NNP Doc_24928523_475_488_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP VTD)) (-RRB- -RRB-)))))))) (PP (IN as) (NP (NN consolidation) (NN therapy))) (PP (IN in) (NP (NP (CD 24) (JJ Japanese) (NNS patients)) (PP (IN with) (NP (ADJP (RB newly) (VBN diagnosed)) (NNP Doc_24928523_565_567_Disease)))))) (. .)))
24928523	3	(S1 (S (NP (NNP VTD)) (VP (VBD consisted) (PP (IN of) (NP (NP (NP (NNP Doc_24928523_586_596_Chemical)) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 1.3) (NN mg/m))))) (PRN (-LRB- -LRB-) (NP (CD 2)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_24928523_626_639_Chemical)))) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 40) (NN mg/day))) (PP (IN on) (NP (NP (NNS days) (CD 1) (, ,) (CD 8) (, ,) (CD 15) (, ,) (CC and) (CD 22)) (PP (IN of) (NP (DT a) (JJ 35-day) (NN cycle))) (, ,) (PP (IN with) (NP (NP (JJ daily) (JJ oral) (NNP Doc_24928523_723_734_Chemical)) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 100) (NN mg/day)))))))))))) (. .)))
24928523	4	(S1 (S (S (NP (NN Grade) (NN 3-4) (NNP Doc_24928523_770_781_Disease) (CC and) (NNP Doc_24928523_786_802_Disease)) (VP (AUX were) (VP (VBN documented) (PP (IN in) (NP (NP (CD four) (CC and) (CD three) (NNS patients)) (PRN (-LRB- -LRB-) (NP (QP (CD 17) (CC and) (CD 13)) (NN %)) (-RRB- -RRB-)))) (, ,) (ADVP (RB respectively))))) (, ,) (CC but) (S (NP (NP (NN drug) (NN dose) (NN reduction)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_24928523_906_915_Disease))))) (VP (AUX was) (RB not) (VP (VBN required) (PP (IN in) (NP (DT any) (NN case)))))) (. .)))
24928523	5	(S1 (S (S (NP (NN Doc_24928523_946_967_Disease)) (VP (AUX was) (ADJP (JJ common)) (PRN (-LRB- -LRB-) (NP (CD 63) (NN %)) (-RRB- -RRB-)))) (, ,) (CC but) (S (NP (JJ severe) (NN grade) (NN 3-4) (NN Doc_24928523_1008_1029_Disease)) (VP (AUX was) (RB not) (ADJP (JJ observed)))) (. .)))
24928523	6	(S1 (S (NP (NP (ADJP (RB Very) (JJ good)) (JJ partial) (NN response)) (CC or) (NP (NP (JJR better) (NN response)) (PRN (-LRB- -LRB-) (NP (NN >VGPR)) (-RRB- -RRB-)))) (VP (VBZ rates) (SBAR (IN before) (S (CC and) (PP (IN after) (NP (NN consolidation))) (NP (NN therapy)) (VP (AUX were) (NP (NP (CD 54)) (CC and) (NP (CD 79) (NN %))) (, ,) (ADVP (RB respectively)))))) (. .)))
24928523	7	(S1 (S (NP (NNS Patients)) (VP (AUX had) (NP (NP (DT a) (JJ significant) (NN probability)) (PP (IN of) (S (VP (VBG improving) (PP (IN from) (S (VP (VBG <VGPR) (PP (IN before) (NP (NN consolidation))) (NP (NN therapy)) (S (VP (TO to) (VP (VB >VGPR) (PP (IN after) (NP (NP (NN consolidation) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.041)) (-RRB- -RRB-))))))))))))))) (. .)))
24928523	8	(S1 (S (NP (DT The) (JJ VTD) (NN regimen)) (VP (MD may) (VP (AUX be) (ADJP (JJ safe) (CC and) (JJ effective)) (PP (IN as) (NP (NP (DT a) (NN consolidation) (NN therapy)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_24928523_1410_1412_Disease)) (PP (IN in) (NP (JJ Japanese) (NN population))))))))))) (. .)))
24971338	0	(S1 (S (S (NP (NP (NN Conversion)) (PP (TO to) (NP (NNP Doc_24971338_14_23_Chemical)))) (VP (VBZ ameliorates) (NP (JJ Doc_24971338_36_48_Chemical-induced) (NN Doc_24971338_57_68_Disease)) (PP (IN in) (NP (DT the) (NN rat))))) (: :) (S (NP (NP (NN focus)) (PP (IN on) (NP (NP (NN serum)) (, ,) (NP (NN urine)) (, ,) (NP (NN gene)) (, ,) (CC and) (NP (NN protein) (JJ renal) (NN expression))))) (VP (VBZ biomarkers))) (. .)))
24971338	1	(S1 (S (S (NP (NP (NNS Protocols)) (PP (IN of) (NP (NP (NN conversion)) (PP (IN from) (NP (NP (NNP Doc_24971338_180_193_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24971338_195_198_Chemical)) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (NNP Doc_24971338_203_212_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_24971338_214_217_Chemical)) (-RRB- -RRB-))))))) (VP (AUX have) (VP (AUX been) (VP (ADVP (RB widely)) (VBN used) (PP (IN in) (NP (NN immunotherapy))) (PP (IN after) (NP (NP (NN transplantation)) (SBAR (S (VP (TO to) (VP (VB prevent) (NP (JJ Doc_24971338_291_294_Chemical-induced) (NN Doc_24971338_303_314_Disease)))))))))))) (, ,) (CC but) (S (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (VP (VBG underlying) (NP (DT these) (NNS protocols)))) (VP (VBP remain) (ADJP (JJ nuclear)))) (. .)))
24971338	2	(S1 (S (NP (DT This) (NN study)) (VP (VBD aimed) (S (VP (TO to) (VP (VP (VB identify) (NP (DT the) (JJ molecular) (NNS pathways))) (CC and) (VP (VB putative) (NP (NP (NNS biomarkers)) (PP (IN of) (NP (JJ Doc_24971338_467_470_Chemical-to-Doc_24971338_474_477_Chemical) (NN conversion)))) (PP (IN in) (NP (DT a) (NN rat) (NN model)))))))) (. .)))
24971338	3	(S1 (S (NP (NP (CD Four) (NN animal) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 6)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN tested) (PP (IN during) (NP (NP (CD 9) (NNS weeks)) (: :) (NP (NP (NP (NN control)) (, ,) (NP (NNP Doc_24971338_569_572_Chemical) (, ,) (NNP Doc_24971338_574_577_Chemical)) (, ,)) (CC and) (NP (NP (NN conversion)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_24971338_595_598_Chemical)) (PP (IN for) (NP (CD 3) (NNS weeks))) (VP (VBN followed) (PP (IN by) (NP (NNP Doc_24971338_623_626_Chemical))) (PP (IN for) (NP (CD 6) (NNS weeks))))) (-RRB- -RRB-)))))))) (. .)))
24971338	4	(S1 (S (NP (NP (JJ Classical) (CC and) (NN emergent) (NN serum)) (, ,) (NP (NN urinary)) (, ,) (CC and) (NP (NN kidney) (NN tissue) (PRN (-LRB- -LRB-) (NP (NP (NN gene)) (CC and) (NP (NN protein) (NN expression))) (-RRB- -RRB-)) (NNS markers))) (VP (AUX were) (VP (VBN assessed))) (. .)))
24971338	5	(S1 (S (NP (NN Doc_24971338_751_764_Disease)) (VP (AUX were) (VP (VBN analyzed) (PP (IN in) (NP (NP (NP (NNP Doc_24971338_782_793_Chemical) (CC and) (NNP Doc_24971338_798_803_Chemical)) (, ,) (NP (JJ periodic) (NN acid-Schiff)) (, ,)) (CC and) (NP (NP (NNP Masson) (POS 's)) (JJ trichrome) (NNS stains)))))) (. .)))
24971338	6	(S1 (S (NP (JJ Doc_24971338_858_861_Chemical-treated) (NNS rats)) (VP (VBD presented) (NP (NP (NP (NNP Doc_24971338_885_896_Disease)) (CC and) (NP (NNP NGAL))) (PRN (-LRB- -LRB-) (NP (NP (NN serum)) (CC and) (NP (NN urinary))) (-RRB- -RRB-))) (PP (IN as) (NP (NP (DT the) (JJS best) (NNS markers)) (PP (IN of) (NP (NNP Doc_24971338_949_965_Disease)))))) (. .)))
24971338	7	(S1 (S (NP (JJ Short) (JJ Doc_24971338_973_976_Chemical) (NN treatment)) (VP (VBD presented) (NP (JJ slight) (CC or) (ADJP (ADJP (RB even) (JJ Doc_24971338_1012_1033_Disease)) (CC and) (ADJP (JJ TGF-b))) (, ,) (JJ NF-) (NN kb) (, ,) (NN mTOR) (, ,) (NN PCNA) (, ,) (CD TP53) (, ,) (CD KIM-1) (, ,) (CC and) (CD CTGF)) (PP (IN as) (NP (NP (JJ relevant) (NN gene)) (CC and) (NP (NN protein) (NNS changes))))) (. .)))
24971338	8	(S1 (S (NP (VBN Prolonged) (NNP Doc_24971338_1135_1138_Chemical) (NN exposure)) (VP (VBN aggravated) (NP (NNP Doc_24971338_1159_1171_Disease)) (, ,) (PP (PP (IN without) (NP (NP (JJ clear) (NNS changes)) (PP (IN on) (NP (DT the) (JJ traditional) (NNS markers))))) (, ,) (CC but) (PP (IN with) (NP (NP (NP (NNS changes)) (PP (IN in) (NP (JJ serums) (NNS TGF-))) (UCP (NNP b) (CC and) (JJ IL-7))) (, ,) (NP (NNS TBARs) (NN clearance)) (, ,) (CC and) (NP (NP (NN kidney) (NN TGF-b)) (CC and) (NP (NN mTOR))))))) (. .)))
24971338	9	(S1 (S (NP (NP (NN Conversion)) (PP (TO to) (NP (NNP Doc_24971338_1325_1328_Chemical)))) (VP (VBD prevented) (NP (NP (NNP Doc_24971338_1339_1342_Chemical-induced) (NNP Doc_24971338_1351_1373_Disease)) (PRN (-LRB- -LRB-) (NP (NN absent/mild) (NN grade) (NNS lesions)) (-RRB- -RRB-))) (, ,) (SBAR (IN while) (S (NP (NP (NNP NGAL)) (PRN (-LRB- -LRB-) (NP (NP (NN serum)) (CC versus) (NP (NN urine))) (-RRB- -RRB-))) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJ feasible) (NN biomarker)) (PP (IN of) (NP (NP (JJ Doc_24971338_1471_1474_Chemical) (NN replacement)) (PP (TO to) (NP (NNP Doc_24971338_1490_1493_Chemical))))))))))))) (. .)))
24975837	0	(S1 (S (NP (NP (JJ Kinin) (JJ B2) (NN receptor) (NN deletion)) (CC and) (NP (NN blockage))) (VP (VBZ ameliorates) (NP (JJ Doc_24975837_52_61_Chemical-induced) (NN Doc_24975837_70_88_Disease))) (. .)))
24975837	1	(S1 (S (S (NP (JJ Doc_24975837_90_99_Chemical) (NN treatment)) (VP (AUX has) (VP (AUX been) (VP (VBN adopted) (PP (IN in) (NP (DT some) (NNS chemotherapies))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (DT this) (NN drug)) (VP (MD can) (VP (VB induce) (NP (NNP Doc_24975837_181_200_Disease) (RRC (ADJP (JJ due)) (NP (NP (PRP$ its) (NN ability) (S (VP (TO to) (VP (VP (ADVP (RB negatively)) (VB affect) (NP (JJ renal) (NN function))) (, ,) (VP (VB augment) (NP (NP (NN serum) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_24975837_278_288_Chemical)) (CC and) (NP (NNP Doc_24975837_293_297_Chemical)))))) (, ,) (VP (VB increase) (NP (DT the) (NNP Doc_24975837_312_334_Disease) (NN score))))))) (CC and) (NP (NP (JJ up-regulate) (NNS cytokines)) (PRN (-LRB- -LRB-) (ADJP (JJ e.g.) (, ,) (JJ IL-1b) (CC and) (JJ TNF-a)) (-RRB- -RRB-))))))))) (. .)))
24975837	2	(S1 (S (S (NP (DT The) (NN kinin) (NN B2) (NN receptor)) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN inflammation) (NN process)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ cytokine) (NN expression)))))))))) (, ,) (CC and) (S (NP (PRP$ its) (NN deletion)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (NN improvement)) (PP (IN in) (NP (DT the) (JJ Doc_24975837_566_586_Disease) (NN status))))))) (. .)))
24975837	3	(S1 (S (S (VP (TO To) (VP (VB examine) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (DT the) (JJ kinin) (JJ B2) (NN receptor))) (PP (IN in) (NP (JJ Doc_24975837_643_652_Chemical-induced) (NN Doc_24975837_661_680_Disease))))))) (, ,) (NP (JJ kinin) (JJ B2) (NN receptor) (NN knockout) (NNS mice)) (VP (AUX were) (VP (VBN challenged) (PP (IN with) (NP (NNP Doc_24975837_735_744_Chemical))))) (. .)))
24975837	4	(S1 (S (ADVP (RB Additionally)) (, ,) (NP (NN WT) (NNS mice)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (DT a) (JJ B2) (NN receptor) (NN antagonist))) (PP (IN after) (NP (NNP Doc_24975837_817_826_Chemical) (NN administration))))) (. .)))
24975837	5	(S1 (S (NP (JJ B2) (NN receptor-deficient) (NNS mice)) (VP (AUX were) (ADJP (ADJP (RBR less) (JJ sensitive) (PP (TO to) (NP (DT this) (NN drug)))) (PP (IN than) (NP (DT the) (JJ WT) (NNS mice)))) (, ,) (SBAR (IN as) (S (VP (VBN shown) (PP (IN by) (NP (NP (JJ reduced) (NN Doc_24975837_941_952_Disease)) (, ,) (NP (NP (JJR better) (NN preservation)) (PP (IN of) (NP (NN kidney) (NN function)))) (, ,) (NP (NP (JJ down) (NN regulation)) (PP (IN of) (NP (JJ inflammatory) (NNS cytokines)))) (CC and) (NP (JJR less) (NN Doc_24975837_1045_1067_Disease)))))))) (. .)))
24975837	6	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (NN treatment)) (PP (IN with) (NP (DT the) (JJ kinin) (JJ B2) (NN receptor) (NN antagonist)))) (ADVP (RB effectively)) (VP (VBD reduced) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NN serum) (NN Doc_24975837_1167_1177_Chemical) (CC and) (NN blood)))) (NP (NNP Doc_24975837_1188_1192_Chemical)) (PP (IN after) (NP (NNP Doc_24975837_1199_1208_Chemical) (NN administration)))) (. .)))
24975837	7	(S1 (S (ADVP (RB Thus)) (, ,) (NP (PRP$ our) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT the) (JJ kinin) (NN B2) (NN receptor)) (VP (AUX is) (VP (VBN involved) (PP (IN in) (NP (JJ Doc_24975837_1290_1299_Chemical-induced) (NN Doc_24975837_1308_1327_Disease))) (PP (IN by) (S (VP (VBG mediating) (NP (NP (DT the) (JJ necrotic) (NN process)) (CC and) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (JJ inflammatory) (NNS cytokines)))))))) (, ,) (S (ADVP (RB thus)) (VP (VBG resulting) (PP (IN in) (NP (VBN declined) (JJ renal) (NN function)))))))))) (. .)))
24975837	8	(S1 (S (NP (DT These) (NNS results)) (VP (VB highlight) (NP (NP (DT the) (ADJP (RB kinin) (JJ B2)) (NN receptor) (NN antagonist) (NN treatment)) (PP (IN in) (NP (NP (NN amelioration)) (PP (IN of) (NP (NP (NN nephrotoxicity)) (VP (VBN induced) (PP (IN by) (NP (JJ Doc_24975837_1563_1572_Chemical) (NN therapy)))))))))) (. .)))
24999722	0	(S1 (NP (NP (NP (NN Safety)) (CC and) (NP (NN efficacy))) (PP (IN of) (NP (NP (JJ Doc_24999722_23_45_Chemical) (JJ intravitreal) (NN implant)) (PRN (-LRB- -LRB-) (NP (CD 0.59) (NN mg)) (-RRB- -RRB-)))) (PP (IN in) (NP (NNP Doc_24999722_80_108_Disease))) (. .)))
24999722	1	(S1 (S (VP (TO To) (VP (VB report) (NP (NP (DT the) (NN treatment) (NNS outcomes)) (PP (IN of) (NP (NP (DT the) (JJ Doc_24999722_159_181_Chemical) (JJ intravitreal) (NN implant)) (PRN (-LRB- -LRB-) (NP (CD 0.59) (NN mg)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_24999722_230_258_Disease)) (SBAR (WHNP (WP$ whose) (NN disease)) (S (VP (AUX is) (ADJP (JJ refractory) (CC or) (JJ intolerant) (PP (TO to) (NP (JJ conventional) (NN immunomodulatory) (NN therapy)))))))))))))) (. .)))
24999722	2	(S1 (S (NP (DT A) (NN retrospective) (NN case) (NN series)) (VP (VBG involving) (NP (NP (CD 11) (JJ Doc_24999722_393_421_Disease) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 11) (NNS eyes)) (-RRB- -RRB-)))) (. .)))
24999722	3	(S1 (S (NP (NP (CD Eleven) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 11) (NNS eyes)) (-RRB- -RRB-))) (VP (VBD underwent) (NP (NN surgery)) (PP (IN for) (NP (NP (JJ Doc_24999722_490_512_Chemical) (NN implant)) (PRN (-LRB- -LRB-) (NP (CD 0.59) (NN mg)) (-RRB- -RRB-))))) (. .)))
24999722	4	(S1 (S (NP (NP (NN Treatment) (NNS outcomes)) (PP (IN of) (NP (NN interest)))) (VP (AUX were) (VP (VBN noted) (PP (IN at) (NP (NN baseline))) (, ,) (PP (IN before) (NP (JJ Doc_24999722_594_616_Chemical) (NN implant))) (, ,) (PP (CONJP (CC and) (RB then)) (PP (IN at) (NP (NP (NP (CD 6) (NNS months)) (, ,) (NP (CD 1) (NN year))) (, ,) (NP (CD 2) (NNS years)) (, ,) (NP (CD 3) (NNS years)))) (, ,) (CC and) (PP (IN beyond) (NP (CD 3) (NNS years)))))) (. .)))
24999722	5	(S1 (S (NP (NP (NN Disease) (NN activity) (NNS markers)) (, ,) (PP (VBG including) (NP (NP (NP (NNS signs)) (PP (IN of) (NP (NNP Doc_24999722_739_758_Disease)))) (, ,) (NP (NP (NN evidence)) (PP (IN of) (NP (NNP Doc_24999722_772_790_Disease)))) (, ,) (NP (JJ Swedish) (JJ interactive) (NN threshold) (NN algorithm-short) (NN wavelength) (VBN automated) (NN perimetry) (NNP Humphrey) (JJ visual) (NN field) (NN analysis)) (, ,) (NP (JJ electroretinographic) (NNS parameters)) (, ,) (CC and) (NP (JJ optical) (NN coherence) (NN tomography))))) (VP (AUX were) (VP (VBN recorded))) (. .)))
24999722	6	(S1 (S (NP (NP (NNS Data)) (PP (IN on) (NP (NP (NP (NN occurrence)) (PP (IN of) (NP (NNP Doc_24999722_1004_1012_Disease)))) (CC and) (NP (VBN raised) (NN intraocular) (NN pressure))))) (VP (AUX were) (VP (VBN collected) (PP (IN in) (NP (DT all) (NNS eyes))))) (. .)))
24999722	7	(S1 (S (NP (NNP Intraocular) (NNP Doc_24999722_1094_1106_Disease)) (VP (AUX was) (ADJP (JJ present) (PP (IN in) (NP (NP (CD 54.5)) (, ,) (NP (CD 9.9)) (, ,) (NP (CD 11.1)) (, ,) (CC and) (NP (NP (CD 0) (NN %)) (PP (IN of) (NP (NNS patients))) (PP (PP (IN at) (NP (NP (NN baseline)) (, ,) (NP (NP (NP (CD 6) (NNS months)) (, ,) (NP (CD 1) (NN year))) (, ,) (NP (CD 2) (NNS years)) (, ,) (NP (CD 3) (NNS years))))) (, ,) (CC and) (PP (IN beyond) (NP (NP (CD 3) (NNS years)) (PP (IN after) (S (VP (VBG receiving) (NP (DT the) (NN implant))))))))) (, ,) (ADVP (RB respectively)))))) (. .)))
24999722	8	(S1 (S (NP (JJ Active) (NN Doc_24999722_1276_1286_Disease)) (VP (AUX was) (VP (VP (VBN noted) (PP (IN in) (NP (ADJP (CD 36.3) (NN %)) (NNS patients))) (PP (IN at) (NP (NN baseline)))) (CC and) (VP (NP (CD 0) (NN %)) (PP (IN at) (NP (NP (CD 3) (NNS years)) (PP (IN of) (NP (NN follow-up)))))))) (. .)))
24999722	9	(S1 (S (NP (NP (NP (NP (QP (JJR More) (IN than) (CD 20)) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 47.61-67.2) (NN %)) (-RRB- -RRB-))) (NN reduction)) (PP (IN in) (NP (JJ central) (JJ retinal) (NN thickness)))) (VP (AUX was) (VP (VBN noted) (PP (IN in) (NP (NP (DT all) (NNS patients)) (PP (IN with) (NP (NNP Doc_24999722_1457_1478_Disease))))) (PP (IN at) (NP (NP (CD 6) (NNS months)) (, ,) (NP (CD 1) (NN year)) (, ,) (NP (CD 2) (NNS years)) (, ,) (CC and) (NP (CD 3) (NNS years) (JJ postimplant)))))) (. .)))
24999722	10	(S1 (S (PP (IN At) (NP (NN baseline))) (, ,) (NP (ADJP (CD 54.5) (NN %)) (NNS patients)) (VP (AUX were) (PP (IN on) (NP (JJ immunomodulatory) (NNS agents)))) (. .)))
24999722	11	(S1 (S (NP (DT This) (NN percentage)) (VP (VBD decreased) (PP (TO to) (NP (NP (CD 45.45)) (, ,) (NP (CD 44.4)) (, ,) (CC and) (NP (CD 14.28) (NN %)))) (PP (IN at) (NP (CD 1) (NN year))) (, ,) (ADVP (NP (NP (CD 2) (NNS years)) (, ,) (CC and) (NP (CD 3) (NNS years) (JJ postimplant)) (, ,)) (RB respectively))) (. .)))
24999722	12	(S1 (S (NP (JJ Adverse) (NNS events)) (VP (VBD included) (NP (NP (NP (NNP Doc_24999722_1731_1761_Disease)) (PRN (-LRB- -LRB-) (NP (CD 54.5) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ Doc_24999722_1774_1782_Disease) (NN formation)) (PRN (-LRB- -LRB-) (NP (CD 100) (NN %)) (-RRB- -RRB-))))) (. .)))
24999722	13	(S1 (S (NP (DT The) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ Doc_24999722_1835_1857_Chemical) (NN implant)) (PRN (-LRB- -LRB-) (NP (CD 0.59) (NN mg)) (-RRB- -RRB-))) (VP (VBZ helps) (S (VP (TO to) (VP (VB control) (NP (NNP Doc_24999722_1893_1905_Disease)) (PP (IN in) (NP (NP (ADJP (RB otherwise) (JJ treatment-refractory)) (NNS cases)) (PP (IN of) (NP (NN Doc_24999722_1949_1977_Disease)))))))))))) (. .)))
24999722	14	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ significant) (JJ side) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_24999722_2029_2037_Disease)) (CC and) (NP (NNP Doc_24999722_2042_2061_Disease)))) (VP (VBG requiring) (NP (NN treatment))))))) (. .)))
25006369	0	(S1 (S (NP (NP (JJ Optimal) (JJ precurarizing) (NN dose)) (PP (IN of) (NP (NNP Doc_25006369_30_40_Chemical)))) (VP (TO to) (VP (VB decrease) (NP (NP (NNP Doc_25006369_53_66_Disease)) (CC and) (NP (NNP Doc_25006369_71_78_Disease))) (PP (VBG following) (NP (NNP Doc_25006369_89_104_Chemical) (NN administration))))) (. .)))
25006369	1	(S1 (S (NP (NN Doc_25006369_133_148_Chemical)) (ADVP (RB commonly)) (VP (VBZ produces) (NP (NP (JJ frequent) (JJ adverse) (NNS effects)) (, ,) (PP (VBG including) (NP (NP (NNP Doc_25006369_203_223_Disease)) (CC and) (NP (NNP Doc_25006369_228_235_Disease)))))) (. .)))
25006369	2	(S1 (S (NP (DT The) (JJ current) (NN study)) (VP (VP (VBD identified) (NP (NP (DT the) (JJ optimal) (NN dose)) (PP (IN of) (NP (NNP Doc_25006369_286_296_Chemical)))) (S (VP (TO to) (VP (VB prevent) (NP (NNP Doc_25006369_308_323_Chemical-induced) (NNP Doc_25006369_332_345_Disease) (CC and) (NNP Doc_25006369_350_357_Disease)))))) (CC and) (VP (VBN evaluated) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NNP Doc_25006369_389_399_Chemical)))) (PP (IN on) (NP (NP (DT the) (NN speed)) (PP (IN of) (NP (NP (NN onset)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_25006369_434_449_Chemical)))))))))) (. .)))
25006369	3	(S1 (S (NP (DT This) (JJ randomized) (, ,) (JJ double-blinded) (NN study)) (VP (AUX was) (VP (VBN conducted) (PP (IN in) (NP (NP (CD 100) (NNS patients)) (VP (ADVP (RB randomly)) (VBN allocated) (PP (IN into) (NP (NP (CD five) (NNS groups)) (PP (IN of) (NP (NP (CD 20) (NNS patients)) (NP (DT each))))))))))) (. .)))
25006369	4	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN randomized) (S (VP (TO to) (VP (VB receive) (NP (CD 0.02) (, ,) (CD 0.03) (, ,) (CD 0.04) (, ,) (CD 0.05) (CC and) (CD 0.06) (NN mg/kg) (NNP Doc_25006369_659_669_Chemical)) (PP (IN as) (NP (DT a) (JJ precurarizing) (NN dose)))))))) (. .)))
25006369	5	(S1 (S (NP (NP (JJ Neuromuscular) (NN monitoring)) (PP (IN after) (NP (DT each) (JJ precurarizing) (NN dose)))) (VP (AUX was) (VP (VBN recorded) (PP (IN from) (S (NP (DT the) (NN adductor) (NN pollicis) (NN muscle)) (VP (VBG using) (NP (NN acceleromyography)) (PP (IN with) (NP (NP (JJ train-of-four) (NN stimulation)) (PP (IN of) (NP (DT the) (JJ ulnar) (NN nerve)))))))))) (. .)))
25006369	6	(S1 (S (NP (DT All) (NNS patients)) (VP (VP (VBD received) (NP (NNP Doc_25006369_894_909_Chemical) (CD 1.5) (NNS mg/kg)) (PP (IN at) (NP (CD 2) (NNS minutes))) (PP (IN after) (NP (DT the) (NN precurarization)))) (, ,) (CC and) (VP (AUX were) (VP (VBN assessed) (NP (NP (DT the) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (NNP Doc_25006369_1008_1022_Disease)))) (, ,) (SBAR (IN while) (S (NP (NNP Doc_25006369_1030_1037_Disease)) (VP (AUX was) (VP (VBN assessed) (PP (IN at) (NP (NP (CD 24) (NNS hours)) (PP (IN after) (NP (NN surgery)))))))))))) (. .)))
25006369	7	(S1 (S (NP (NP (DT The) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (JJ visible) (NNP Doc_25006369_1125_1145_Disease)))) (VP (AUX was) (ADJP (RB significantly) (JJR less)) (PP (IN with) (S (VP (VBG increasing) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NP (JJ precurarizing) (NN dose)) (PP (IN of) (NP (NNP Doc_25006369_1221_1231_Chemical))))) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.001))) (-RRB- -RRB-))))))) (. .)))
25006369	8	(S1 (S (S (NP (NP (DT Those)) (PP (IN of) (NP (NNP Doc_25006369_1254_1261_Disease)))) (VP (VBP tend) (S (VP (TO to) (VP (VB decrease) (PP (VBG according) (PP (TO to) (S (VP (VBG increasing) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NP (JJ precurarizing) (NN dose)) (PP (IN of) (NP (NNP Doc_25006369_1339_1349_Chemical))))))))))))))) (, ,) (CC but) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (NN significance)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD 0.072)) (-RRB- -RRB-))))) (. .)))
25006369	9	(S1 (S (NP (NP (DT The) (NN onset) (NN time)) (PP (IN of) (NP (NNP Doc_25006369_1412_1427_Chemical)))) (VP (AUX was) (ADVP (RB significantly) (RBR longer)) (PP (IN with) (S (VP (VBG increasing) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NP (JJ precurarizing) (NN dose)) (PP (IN of) (NP (NNP Doc_25006369_1505_1515_Chemical))))) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.001))) (-RRB- -RRB-))))))) (. .)))
25006369	10	(S1 (S (NP (NP (NN Precurarization)) (PP (IN with) (NP (CD 0.04) (NN mg/kg) (NNP Doc_25006369_1574_1584_Chemical)))) (VP (AUX was) (NP (NP (DT the) (JJ optimal) (NN dose)) (VP (VBG considering) (NP (NP (DT the) (NN reduction)) (PP (IN in) (NP (NP (NP (DT the) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (NNP Doc_25006369_1665_1678_Disease) (CC and) (NNP Doc_25006369_1683_1690_Disease))) (PP (IN with) (NP (JJ acceptable) (NN onset) (NN time)))) (, ,) (CC and) (NP (DT the) (ADJP (JJ safe) (CC and) (JJ effective)) (NN precurarization)))))))) (. .)))
25006961	0	(S1 (S (NP (NP (NN Absence)) (PP (IN of) (NP (NN PKC-alpha)))) (VP (VBZ attenuates) (NP (JJ Doc_25006961_32_39_Chemical-induced) (NN Doc_25006961_48_78_Disease))) (. .)))
25006961	1	(S1 (S (NP (NP (NNP Doc_25006961_80_87_Chemical)) (, ,) (NP (DT an) (JJ effective) (NN antipsychotic)) (, ,)) (VP (VBZ induces) (NP (NP (NNP Doc_25006961_125_155_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_25006961_157_160_Disease)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (CD 40) (NN %)) (PP (IN of) (NP (NNS patients)))))) (. .)))
25006961	2	(S1 (S (NP (DT The) (VBN decreased) (NN capacity) (S (VP (TO to) (VP (VB concentrate) (NP (NN urine)))))) (VP (AUX is) (ADVP (RB likely)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_25006961_244_251_Chemical)))) (S (VP (VP (ADVP (RB acutely)) (VBG disrupting) (NP (DT the) (JJ Doc_25006961_275_279_Chemical) (NN pathway))) (CC and) (VP (ADVP (RB chronically)) (VBG reducing) (NP (NP (NP (JJ Doc_25006961_313_317_Chemical) (NN transporter)) (PRN (-LRB- -LRB-) (JJ UT-A1) (-RRB- -RRB-))) (CC and) (NP (NP (NN water) (NN channel) (PRN (-LRB- -LRB-) (NNP AQP2) (-RRB- -RRB-)) (NN expression)) (PP (IN in) (NP (DT the) (JJ inner) (NN medulla))))))))) (. .)))
25006961	3	(S1 (S (S (VP (VBG Targeting) (NP (NP (DT an) (JJ alternative) (VBG signaling) (NN pathway)) (, ,) (PP (JJ such) (IN as) (NP (JJ PKC-mediated) (VBG signaling))) (, ,)))) (VP (MD may) (VP (AUX be) (NP (NP (DT an) (JJ effective) (NN method)) (PP (IN of) (S (VP (VBG treating) (NP (JJ Doc_25006961_511_518_Chemical-induced) (NNP Doc_25006961_527_535_Disease)))))))) (. .)))
25006961	4	(S1 (S (NP (NP (NP (NN PKC-alpha) (NN null) (NNS mice)) (PRN (-LRB- -LRB-) (NP (NNP PKCa) (NNP KO)) (-RRB- -RRB-))) (CC and) (NP (JJ strain-matched) (JJ wild) (NN type) (PRN (-LRB- -LRB-) (NP (NNP WT)) (-RRB- -RRB-)) (NNS controls))) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_25006961_628_635_Chemical))) (PP (IN for) (NP (NP (CD 0)) (, ,) (NP (QP (CD 3) (CC or) (CD 5)) (NNS days)))))) (. .)))
25006961	5	(S1 (S (NP (NN WT) (NNS mice)) (VP (VP (AUX had) (VP (VBN increased) (NP (NN urine) (NN output)))) (CC and) (VP (VBD lowered) (NP (NN urine) (NN osmolality)) (PP (IN after) (NP (NP (QP (CD 3) (CC and) (CD 5)) (NNS days)) (PP (IN of) (NP (NN treatment))))) (SBAR (IN whereas) (S (NP (NNP PKCa) (NNP KO) (NNS mice)) (VP (AUX had) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NP (NN urine) (NN output)) (CC or) (NP (NN concentration)))))))))) (. .)))
25006961	6	(S1 (S (S (NP (NNP Western) (NNP blot) (NN analysis)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (JJ AQP2) (NN expression)) (PP (IN in) (NP (JJ medullary) (NNS tissues)))) (VP (AUX was) (VP (VBN lowered) (PP (IN after) (NP (NP (QP (CD 3) (CC and) (CD 5)) (NNS days)) (PP (IN in) (NP (JJ WT) (NNS mice))))))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NN AQP2)) (VP (AUX was) (ADJP (JJ unchanged)) (PP (IN in) (NP (NNP PKCa) (NNP KO))))) (. .)))
25006961	7	(S1 (S (NP (JJ Similar) (NNS results)) (VP (AUX were) (VP (VBN observed) (PP (IN with) (NP (JJ UT-A1) (NN expression))))) (. .)))
25006961	8	(S1 (S (NP (NNS Animals)) (VP (AUX were) (ADVP (RB also)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_25006961_1061_1068_Chemical))) (PP (IN for) (NP (CD 6) (NNS weeks))))) (. .)))
25006961	9	(S1 (S (NP (JJ Doc_25006961_1082_1089_Chemical-treated) (NN WT) (NNS mice)) (VP (AUX had) (NP (JJ 19-fold) (VBN increased) (NN urine) (NN output)) (SBAR (IN whereas) (S (NP (VBN treated) (NNP PKCa) (NNP KO) (NNS animals)) (VP (AUX had) (NP (NP (DT a) (JJ 4-fold) (NN increase)) (PP (IN in) (NP (NN output)))))))) (. .)))
25006961	10	(S1 (S (NP (NP (NN AQP2)) (CC and) (NP (JJ UT-A1) (NN expression))) (VP (AUX was) (VP (VBN lowered) (PP (IN in) (NP (CD 6) (NN week))) (NP (JJ Doc_25006961_1254_1261_Chemical-treated) (NN WT) (NNS animals)) (SBAR (IN whereas) (S (PP (IN in) (NP (VBN treated) (NNP PKCa) (NNP KO) (NNS mice))) (, ,) (S (NP (NNP AQP2)) (VP (AUX was) (ADVP (RB only)) (VP (VBN reduced) (PP (IN by) (NP (NN 2-fold)))))) (CC and) (S (NP (JJ UT-A1) (NN expression)) (VP (AUX was) (ADJP (JJ unaffected)))))))) (. .)))
25006961	11	(S1 (S (NP (NP (NNP Urinary) (NNP Doc_25006961_1391_1397_Chemical)) (, ,) (NP (NNP Doc_25006961_1399_1408_Chemical)) (CC and) (NP (NNP Doc_25006961_1413_1420_Chemical))) (VP (AUX were) (UCP (ADJP (JJ elevated) (PP (IN in) (NP (JJ Doc_25006961_1438_1445_Chemical-fed) (NNS WT)))) (CC but) (PP (RB not) (IN in) (NP (JJ Doc_25006961_1464_1471_Chemical-fed) (NNP PKCa) (NNP KO) (NNS mice))))) (. .)))
25006961	12	(S1 (S (NP (PRP$ Our) (NNS data)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NN ablation)) (PP (IN of) (NP (NNP PKCa)))) (VP (VP (VBZ preserves) (NP (NP (NN AQP2)) (CC and) (NP (NP (NP (JJ UT-A1) (NN protein) (NN expression)) (CC and) (NP (NN localization))) (PP (IN in) (NP (NNP Doc_25006961_1590_1597_Chemical-induced) (NNP Doc_25006961_1606_1609_Disease)))))) (, ,) (CC and) (VP (VBZ prevents) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (DT the) (JJ severe) (NN Doc_25006961_1654_1662_Disease)) (VP (VBN associated) (PP (IN with) (NP (JJ Doc_25006961_1679_1686_Chemical) (NN therapy)))))))))))) (. .)))
25031906	0	(S1 (SQ (AUX Is) (NP (NNP Dysguesia)) (VP (VBG Going) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJ Rare)) (CC or) (NP (NP (DT a) (JJ Common) (NN Side-effect)) (PP (IN of) (NP (NN Doc_25031906_59_69_Chemical))))))))) (. ?)))
25031906	1	(S1 (S (NP (NP (DT A) (ADJP (RB very) (JJ rare)) (NN side-effect)) (PP (IN of) (NP (NNP Doc_25031906_98_108_Chemical)))) (VP (AUX is) (NP (NN dysguesia))) (. .)))
25031906	2	(S1 (S (NP (NP (DT A) (NN review)) (PP (IN of) (NP (DT the) (NN literature)))) (VP (VBD produced) (NP (QP (RB only) (CD one)) (NN case))) (. .)))
25031906	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (DT a) (NN case)) (PP (IN about) (NP (NP (DT a) (NN female)) (PP (IN with) (NP (JJ essential) (NNP Doc_25031906_221_233_Disease))) (PP (IN on) (NP (NP (NN drug) (NN treatment)) (PP (IN with) (NP (JJ Doc_25031906_257_267_Chemical) (JJ developed) (NNP Doc_25031906_278_301_Disease)))))))) (. .)))
25031906	4	(S1 (S (NP (NN Condition)) (ADVP (RB moderately)) (VP (VBD improved) (PP (IN on) (NP (NP (NN stoppage)) (PP (IN of) (NP (DT the) (NN drug))) (PP (IN for) (NP (CD 25) (NNS days)))))) (. .)))
25031906	5	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NNP Doc_25031906_387_397_Chemical)) (VP (MD can) (VP (VB cause) (NP (NN dysguesia))))))) (. .)))
25031906	6	(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VP (VB describe) (NP (DT the) (JJ clinical) (NN presentation))) (CC and) (VP (VB review) (NP (NP (DT the) (JJ relevant) (NN literature)) (PP (IN on) (NP (NP (NN Doc_25031906_501_511_Chemical)) (CC and) (NP (NN dysguesia))))))) (. .)))
25041770	0	(S1 (NP (NP (NP (NP (NN Doc_25041770_0_14_Disease)) (PP (IN in) (NP (NN association))) (PP (IN with) (NP (NNP Doc_25041770_35_46_Chemical)))) (CC and) (NP (NN dosage) (NN increment))) (PP (IN in) (NP (NNP Doc_25041770_71_85_Chemical))) (. .)))
25041770	1	(S1 (S (NP (NN Doc_25041770_87_101_Chemical)) (VP (AUX is) (NP (NP (DT the) (ADJP (RBS most) (VBN documented)) (JJ cytochrome) (JJ P450) (NN 3A4) (PRN (-LRB- -LRB-) (NP (NNP CYP3A4)) (-RRB- -RRB-)) (NN inhibitor)) (SBAR (S (VP (TO to) (VP (VB cause) (NP (NP (DT an) (JJ adverse) (NN interaction)) (PP (IN with) (NP (NNP Doc_25041770_201_212_Chemical)))))))))) (. .)))
25041770	2	(S1 (S (NP (DT This) (JJ particular) (NN case)) (VP (AUX is) (PP (IN of) (NP (NN interest))) (SBAR (IN as) (S (NP (NNP Doc_25041770_253_267_Disease)) (ADVP (RB only)) (VP (VBD occurred) (PP (IN after) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NNP Doc_25041770_315_329_Chemical))))))))))) (. .)))
25041770	3	(S1 (S (NP (DT The) (NN patient)) (VP (VBD developed) (NP (VBN raised) (JJ cardiac) (NNS biomarkers)) (PP (IN without) (NP (DT any) (JJ obvious) (JJ cardiac) (NNS issues))) (, ,) (NP (NP (DT a) (NN phenomenon)) (SBAR (WHNP (WDT that)) (S (VP (AUX has) (VP (AUX been) (VP (VBN linked) (PP (TO to) (NP (NNP Doc_25041770_452_466_Disease))) (ADVP (RB previously))))))))) (. .)))
25041770	4	(S1 (S (PP (TO To) (NP (NN date))) (, ,) (NP (EX there)) (VP (AUX has) (VP (AUX been) (NP (NP (DT no) (JJ reported) (NN effect)) (PP (IN of) (NP (NNP Doc_25041770_525_539_Disease))) (PP (IN on) (NP (NP (DT the) (NN structure) (CC and) (NN function)) (PP (IN of) (NP (JJ cardiac) (NN muscle)))))))) (. .)))
25041770	5	(S1 (S (NP (NNS Clinicians)) (VP (AUX need) (S (VP (TO to) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (S (VP (VBG prescribing) (NP (NP (JJ concomitant) (NNS medications)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_25041770_682_690_Disease))))) (CC or) (VP (VBP inhibit) (NP (DT the) (JJ CYP3A4) (NN enzyme))))))))))))))) (. .)))
25041770	6	(S1 (S (NP (PRP$ Our) (NN case)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (JJ troponin) (NN elevation)) (VP (MD could) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (ADJP (RB statin) (VBN induced)) (NNP Doc_25041770_803_817_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB warrant) (NP (JJ further) (NNS studies)))))))))))))) (. .)))
25054547	0	(S1 (S (NP (NP (NN Characterization)) (PP (IN of) (NP (NP (DT a) (JJ novel) (NN BCHE) (`` ``) (JJ silent) ('' '') (NN allele)) (: :) (NP (NP (NN point) (NN mutation)) (PRN (-LRB- -LRB-) (JJ p.Val204Asp) (-RRB- -RRB-)))))) (VP (VBZ causes) (NP (NP (NNP Doc_25054547_86_102_Disease)) (CC and) (NP (JJ prolonged) (NNP Doc_25054547_117_122_Disease))) (PP (IN with) (NP (NNP Doc_25054547_128_141_Chemical)))) (. .)))
25054547	1	(S1 (S (NP (NN Doc_25054547_143_175_Disease)) (VP (AUX is) (VP (VBN characterized) (PP (IN by) (NP (JJ prolonged) (NNP Doc_25054547_206_211_Disease))) (PP (IN after) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NN muscle) (NNS relaxants)) (PRN (-LRB- -LRB-) (NP (NNP Doc_25054547_247_260_Chemical) (CC or) (NNP Doc_25054547_264_274_Chemical)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX have) (VP (NNS mutations) (PP (IN in) (NP (DT the) (NN BCHE) (NN gene))))))))))))) (. .)))
25054547	2	(S1 (S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_25054547_351_380_Disease)))) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_25054547_405_418_Chemical))) (VP (VBG leading) (PP (TO to) (NP (NP (DT the) (NN discovery)) (PP (IN of) (NP (NP (DT a) (JJ novel) (NN BCHE) (NN variant)) (PRN (-LRB- -LRB-) (INTJ (INTJ (UH c.695T>A)) (, ,) (INTJ (VB p.Val204Asp))) (-RRB- -RRB-)))))))))) (. .)))
25054547	3	(S1 (S (NP (NP (NN Inhibition) (NNS studies)) (, ,) (NP (JJ kinetic) (NN analysis)) (CC and) (NP (JJ molecular) (NNS dynamics))) (VP (AUX were) (VP (VBN undertaken) (S (VP (TO to) (VP (VB understand) (SBAR (WHADVP (WRB how)) (S (NP (DT this) (NN mutation)) (VP (VP (VBZ disrupts) (NP (DT the) (JJ catalytic) (NNP triad))) (CC and) (VP (VBZ determines) (NP (DT a) (`` ``) (JJ silent) ('' '') (NN phenotype))))))))))) (. .)))
25054547	4	(S1 (S (S (NP (NP (JJ Low) (NN activity)) (PP (IN of) (NP (JJ patient) (NN plasma)))) (VP (VBP butyrylcholinesterase) (PP (IN with) (NP (NP (NP (NNP Doc_25054547_725_743_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_25054547_745_748_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_25054547_754_768_Chemical)))))) (, ,) (CC and) (S (NP (NP (NNS values)) (PP (IN of) (NP (NNP Doc_25054547_784_793_Chemical) (CC and) (NNP Doc_25054547_798_806_Chemical) (NNS numbers)))) (VP (VBP fit) (PP (IN with) (NP (JJ heterozygous) (JJ atypical) (JJ silent) (NN genotype))))) (. .)))
25054547	5	(S1 (S (NP (NP (NP (JJ Electrophoretic) (NN analysis)) (PP (IN of) (NP (NP (NN plasma) (NN BChE)) (PP (IN of) (NP (DT the) (NN proband)))))) (CC and) (NP (PRP$ his) (NN mother))) (VP (VBD showed) (SBAR (SBAR (IN that) (S (NP (NN patient)) (VP (AUX has) (NP (NP (DT a) (VBN reduced) (NN amount)) (PP (IN of) (NP (JJ tetrameric) (NN enzyme)))) (PP (IN in) (NP (NN plasma)))))) (CC and) (SBAR (IN that) (S (NP (NP (JJ minor) (JJ fast-moving) (NN BChE) (NNS components)) (: :) (NP (NP (NN monomer)) (, ,) (NP (NN dimer)) (, ,) (CC and) (NP (NN monomer-albumin) (NN conjugate)))) (VP (AUX are) (VP (VBG missing))))))) (. .)))
25054547	6	(S1 (S (NP (JJ Kinetic) (NN analysis)) (VP (VBD showed) (SBAR (IN that) (S (NP (DT the) (JJ p.Val204Asp/p.Asp70Gly-p))))) (. .)))
25054547	7	(S1 (S (NP (NNP Ala539Thr) (NNP BChE)) (VP (VBZ displays) (NP (NP (DT a) (JJ pure) (JJ Michaelian) (NN behavior)) (PP (IN with) (NP (NP (NNS BTC)) (PP (IN as) (NP (DT the) (NN substrate))))))) (. .)))
25054547	8	(S1 (S (S (NP (DT Both) (JJ catalytic) (NNS parameters) (NNS Km)) (VP (SYM =) (NP (NP (CD 265) (NN uM)) (PP (IN for) (NP (NNP BTC))) (, ,) (ADJP (ADJP (NP (CD two) (NNS times)) (JJR higher)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (JJ atypical) (NN enzyme))))))))) (, ,) (CC and) (S (NP (DT a) (JJ low) (NN Vmax)) (VP (AUX are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (NN activity)) (PP (IN against) (NP (NNP Doc_25054547_1409_1422_Chemical)))))))))) (. .)))
25054547	9	(S1 (S (NP (JJ Doc_25054547_1424_1441_Disease) (PRN (-LRB- -LRB-) (NP (NNP Doc_25054547_1443_1445_Disease)) (-RRB- -RRB-)) (NNS simulations)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (DT the) (JJ overall) (NN effect)) (PP (IN of) (NP (DT the) (NN mutation) (NN p.Val204Asp)))) (VP (AUX is) (NP (NP (NN disruption)) (PP (IN of) (NP (NP (JJ Doc_25054547_1535_1543_Chemical) (NN bonding)) (PP (IN between) (NP (NNP Doc_25054547_1560_1563_Chemical223) (CC and) (NNP Doc_25054547_1571_1574_Chemical441)))))) (, ,) (S (VP (VBG leading) (S (NP (NNP Ser198) (CC and) (NNP His438)) (VP (TO to) (VP (VB move) (ADVP (RB away)) (PP (IN from) (NP (DT each) (JJ other))) (PP (IN with) (NP (NP (JJ subsequent) (NN disruption)) (PP (IN of) (NP (DT the) (JJ catalytic) (NNP triad) (NN functionality))))) (ADVP (RB regardless) (PP (IN of) (NP (NP (DT the) (NN type)) (PP (IN of) (NP (NN substrate))))))))))))))) (. .)))
25054547	10	(S1 (S (NP (NN Doc_25054547_1735_1737_Disease)) (ADVP (RB also)) (VP (VBD showed) (SBAR (IN that) (S (NP (DT the) (JJ enzyme) (NN volume)) (VP (AUX is) (VP (VBN increased) (, ,) (S (VP (VBG suggesting) (NP (DT a) (JJ pre-denaturation) (NN state))))))))) (. .)))
25054547	11	(S1 (S (NP (DT This)) (VP (VBZ fits) (PP (IN with) (NP (NP (DT the) (VBN reduced) (NN concentration)) (PP (IN of) (NP (NN p.Ala204Asp/p.Asp70Gly-p)))))) (. .)))
25054547	12	(S1 (S (NP (NNS Ala539Thr)) (VP (VBP tetrameric) (NP (NP (NP (NN enzyme)) (PP (IN in) (NP (DT the) (NN plasma)))) (CC and) (NP (NP (JJ non-detectable) (JJ fast) (NNS moving-bands)) (PP (IN on) (NP (NN electrophoresis) (NNS gels)))))) (. .)))
25071004	0	(S1 (NP (NP (NP (JJ Delayed) (NN Doc_25071004_8_14_Disease)) (PP (IN after) (NP (NN treatment))) (PP (IN with) (NP (NP (JJ injectable) (NNP Doc_25071004_47_57_Chemical)) (PP (IN in) (NP (NP (DT the) (NNP Democratic) (NNP Republic)) (PP (IN of) (NP (DT the) (NNP Congo)))))))) (: :) (NP (DT a) (JJ manageable) (NN issue)) (. .)))
25071004	1	(S1 (S (NP (NP (NNS Cases)) (PP (IN of) (NP (JJ delayed) (NNP Doc_25071004_136_152_Disease)))) (VP (AUX have) (VP (AUX been) (VP (VBN described) (PP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NNP injectable) (NNP Doc_25071004_205_215_Chemical)) (, ,) (NP (NP (NP (NP (DT the) (JJ current) (NNP World) (NNP Health) (NNP Organization)) (PRN (-LRB- -LRB-) (NP (WP WHO)) (-RRB- -RRB-))) (JJ -recommended) (JJ first-line) (NN drug)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ severe) (NNP Doc_25071004_317_324_Disease))))))))))))) (. .)))
25071004	2	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (CD 350) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD 215) (CD -LSB-61.4)) (NN %)) (ADJP (JJ -RSB-) (NP (NP (QP (CD <) (CD 5)) (NNS years)) (PP (IN of) (NP (NN age)))))) (CC and) (NP (NP (NP (QP (CD 135) (CD -LSB-38.6)) (NN %)) (NP (QP (JJ -RSB-) (CD >) (CD 5)) (NNS years))) (PP (IN of) (NP (NN age))))) (-RRB- -RRB-))))) (VP (AUX were) (ADJP (JJ followed-up)) (PP (IN after) (NP (NN treatment))) (PP (IN with) (NP (JJ injectable) (NNP Doc_25071004_463_473_Chemical))) (PP (IN for) (NP (NP (JJ severe) (NN Doc_25071004_485_492_Disease)) (PP (IN in) (NP (NP (NNS hospitals)) (CC and) (NP (NP (NN health) (NNS centers)) (PP (IN of) (NP (NP (DT the) (NNP Democratic) (NNP Republic)) (PP (IN of) (NP (DT the) (NNP Congo))))))))))) (. .)))
25071004	3	(S1 (S (NP (NP (NP (JJ Complete) (NN series)) (PP (IN of) (NP (NN hemoglobin)))) (PRN (-LRB- -LRB-) (NP (NNP Hb)) (-RRB- -RRB-)) (NNS measurements)) (VP (AUX were) (ADJP (JJ available) (PP (IN for) (NP (CD 201) (NNS patients))))) (. .)))
25071004	4	(S1 (S (NP (NP (DT A) (NN decrease)) (PP (IN in) (NP (JJ Hb) (NNS levels))) (PP (IN between) (NP (QP (CD 2) (CC and) (CD 5)) (NN g/dL)))) (VP (AUX was) (VP (VBN detected) (PP (IN in) (NP (CD 23) (PRN (-LRB- -LRB-) (NP (CD 11.4) (NN %)) (-RRB- -RRB-)) (NNS patients))) (PP (IN during) (NP (DT the) (JJ follow-up) (NN period))))) (. .)))
25071004	5	(S1 (S (PP (IN For) (NP (CD five) (NNS patients))) (, ,) (NP (NNP Hb) (NNS levels)) (VP (VBD decreased) (PP (IN below) (NP (CD 5) (NN g/dL))) (PP (IN during) (NP (QP (IN at) (JJS least) (CD one)) (NN follow-up) (NN visit)))) (. .)))
25071004	6	(S1 (S (NP (NP (DT All) (NNS cases)) (PP (IN of) (NP (JJ delayed) (NNP Doc_25071004_867_873_Disease)))) (VP (VP (AUX were) (ADJP (RB clinically) (JJ manageable))) (CC and) (VP (VBN resolved) (PP (IN within) (NP (CD one) (NN month))))) (. .)))
25080425	0	(S1 (S (NP (NP (NP (NN Regulation)) (PP (IN of) (NP (NP (NN signal) (NN transducer) (CC and) (NN activator)) (PP (IN of) (NP (NN transcription) (CD 3)))))) (CC and) (NP (NP (JJ apoptotic) (NNS pathways)) (PP (IN by) (NP (NNP Doc_25080425_91_98_Chemical))))) (VP (VBZ attenuates) (NP (NP (JJ Doc_25080425_110_123_Chemical-induced) (JJ acute) (NN Doc_25080425_138_155_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
25080425	1	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (JJ cardioprotective) (NNS effects)) (PP (IN of) (NP (NNP Doc_25080425_243_250_Chemical))) (PP (IN on) (NP (NP (NP (NP (NNP Doc_25080425_254_279_Disease)) (VP (VBN induced) (ADVP (RB experimentally)) (PP (IN in) (NP (NP (NNS rats)) (VP (VBG focusing) (PP (IN on) (NP (NP (NN regulation)) (PP (IN of) (NP (NP (NN signal) (NN transducer) (CC and) (NN activator)) (PP (IN of) (NP (NN transcription) (CD 3)))))))))))) (PRN (-LRB- -LRB-) (NP (NNP STAT3)) (-RRB- -RRB-))) (CC and) (NP (JJ apoptotic) (NNS pathways))))) (PP (IN as) (NP (NP (DT the) (JJ potential) (NN mechanism)) (VP (VBG underlying) (NP (DT the) (NN drug) (NN effect)))))))))) (. .)))
25080425	2	(S1 (S (NP (JJ Male) (NNP Sprague) (NNP Dawley) (NNS rats)) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_25080425_517_524_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 100)) (, ,) (NP (CD 200)) (, ,) (CC and) (NP (CD 400) (NN mg/kg))) (-RRB- -RRB-)))) (PP (ADVP (RB orally)) (IN for) (NP (CD 40) (NNS days))))) (. .)))
25080425	3	(S1 (S (NP (JJ Acute) (NN Doc_25080425_577_603_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN in) (NP (NNS rats))) (PP (IN by) (NP (NP (JJ subcutaneous) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_25080425_653_666_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 85) (NN mg/kg)) (-RRB- -RRB-)))))) (, ,) (PP (IN for) (NP (CD two) (JJ consecutive) (NNS days))))) (. .)))
25080425	4	(S1 (S (NP (NP (NP (JJ Serum) (JJ cardiac) (NN marker) (NN enzyme)) (, ,) (NP (JJ histopathological) (NNS variables)) (CC and) (NP (NN expression))) (PP (IN of) (NP (NN protein) (NNS levels)))) (VP (AUX were) (VP (VBN analyzed))) (. .)))
25080425	5	(S1 (S (NP (NP (JJ Oral) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_25080425_833_840_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 200) (CC and) (CD 400)) (NN mg/kg)) (-RRB- -RRB-))))) (VP (VP (ADVP (RB significantly)) (VBN reduced) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (JJ cardiac) (NN marker) (NN enzyme)))) (PP (IN in) (NP (DT the) (NN serum)))) (CC and) (VP (VBN prevented) (NP (JJ left) (JJ ventricular) (NN remodeling)))) (. .)))
25080425	6	(S1 (S (NP (NNP Western) (NNP blot) (NN analysis)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (JJ Doc_25080425_1008_1021_Chemical-induced) (NN phosphorylation)) (PP (IN of) (NP (NNS STAT3)))) (VP (AUX was) (VP (VP (VBN maintained)) (CC or) (VP (ADVP (RB further)) (VBN enhanced) (PP (IN by) (NP (JJ Doc_25080425_1093_1100_Chemical) (NN treatment))) (PP (IN in) (NP (NN myocardium))))))))) (. .)))
25080425	7	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NNP Doc_25080425_1139_1146_Chemical) (PRN (-LRB- -LRB-) (NP (QP (CD 200) (CC and) (CD 400)) (NN mg/kg)) (-RRB- -RRB-)) (NN treatment)) (VP (VP (VBN increased) (NP (NP (DT the) (JJ ventricular) (NN expression)) (PP (IN of) (NP (NN Bcl-2))))) (CC and) (VP (VBN reduced) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NNP Bax))))) (, ,) (S (ADVP (RB therefore)) (VP (VBG causing) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN ratio)) (PP (IN of) (NP (NNP Bcl-2/Bax))))))))) (. .)))
25080425	8	(S1 (S (NP (NP (DT The) (JJ protective) (NN role)) (PP (IN of) (NP (NNP Doc_25080425_1344_1351_Chemical))) (PP (IN on) (NP (NNP Doc_25080425_1355_1372_Disease)))) (VP (AUX was) (ADVP (RB further)) (VP (VBN confirmed) (PP (IN by) (NP (JJ histopathological) (NN examination))))) (. .)))
25080425	9	(S1 (S (PP (IN In) (NP (NN summary))) (, ,) (NP (PRP$ our) (NNS results)) (VP (VBD showed) (SBAR (IN that) (S (NP (JJ Doc_25080425_1465_1472_Chemical) (NN pretreatment)) (VP (VBD attenuated) (NP (JJ Doc_25080425_1497_1510_Chemical-induced) (NNP Doc_25080425_1519_1544_Disease)) (PP (IN via) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (NNS STAT3)) (CC and) (NP (JJ apoptotic) (NNS pathways)))))))))) (. .)))
25084821	0	(S1 (NP (NP (JJ Doc_25084821_0_10_Chemical-induced) (NN Doc_25084821_19_30_Disease)) (PP (IN in) (NP (NP (DT a) (JJ Doc_25084821_36_43_Disease) (NN patient)) (PP (IN with) (NP (NNP Doc_25084821_57_81_Disease))))) (. .)))
25084821	1	(S1 (S (NP (NNP Doc_25084821_94_104_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ Doc_25084821_110_127_Chemical) (NN derivative)) (, ,) (ADJP (JJ similar) (PP (TO to) (NP (NNP Doc_25084821_151_160_Chemical)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX has) (NP (NP (DT the) (JJS highest) (NN risk)) (PP (IN of) (S (VP (VBG causing) (NP (NNP Doc_25084821_200_216_Disease) (, ,) (RB especially) (NN Doc_25084821_229_240_Disease))))))))))) (. .)))
25084821	2	(S1 (S (S (NP (EX There)) (VP (AUX are) (NP (NP (DT some) (NN case) (NNS reports)) (PP (IN about) (NP (NP (DT this) (NN side) (NN effect)) (PP (IN of) (NP (NNP Doc_25084821_296_306_Chemical)))))))) (, ,) (CC but) (S (NP (JJ possible) (NN risk) (NNS factors)) (VP (AUX are) (ADVP (RB seldom)) (VP (VP (VBN discussed)) (CC and) (VP (VBN identified))))) (. .)))
25084821	3	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_25084821_396_420_Disease))))) (SBAR (WHNP (WDT that)) (S (VP (VBD developed) (NP (NN Doc_25084821_436_447_Disease)) (PP (IN after) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_25084821_469_479_Chemical))))))) (VP (AUX is) (VP (VBN described) (ADVP (RB here)))) (. .)))
25084821	4	(S1 (NP (NN CASE) (NN REPORT) (: :) (S (NP (NP (DT A) (JJ 62-year-old) (JJ Taiwanese) (NN widow)) (PP (IN with) (NP (NNP Doc_25084821_547_563_Disease)))) (VP (AUX was) (VP (VBN diagnosed) (PP (IN with) (NP (NNP Doc_25084821_583_607_Disease))) (PP (IN at) (NP (NN age) (CD 60)))))) (. .)))
25084821	5	(S1 (S (NP (PRP She)) (VP (VBD developed) (NP (NN Doc_25084821_633_643_Disease)) (PP (IN after) (S (VP (AUXG being) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_25084821_669_679_Chemical)))))))) (. .)))
25084821	6	(S1 (S (SBAR (IN After) (S (NP (NNP Doc_25084821_687_697_Chemical)) (VP (AUX was) (VP (VBN discontinued))))) (, ,) (NP (PRP$ her) (JJ white) (NN blood) (NN cell) (NN count)) (VP (VBD returned) (PP (TO to) (NP (JJ normal)))) (. .)))
25084821	7	(S1 (S (SBAR (IN Although) (S (NP (NNP Doc_25084821_785_796_Disease)) (VP (AUX is) (RB not) (NP (NP (DT a) (JJ common) (NN side) (NN effect)) (PP (IN of) (NP (NNP Doc_25084821_828_838_Chemical))))))) (, ,) (NP (NNS physicians)) (VP (MD should) (VP (AUX be) (ADJP (JJ cautious) (PP (IN about) (NP (NP (PRP$ its) (NN presentation)) (CC and) (NP (JJ associated) (NN risk) (NNS factors))))))) (. .)))
25084821	8	(S1 (S (S (NP (NN Doc_25084821_922_941_Disease)) (VP (MD may) (VP (AUX be) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (JJ possible) (NN risk) (NNS factors))))))) (, ,) (CC and) (S (NP (NN concomitant) (NN fever)) (VP (MD may) (VP (AUX be) (NP (NP (DT a) (JJ diagnostic) (NN marker)) (PP (IN for) (NP (NP (JJ adverse) (NN reaction)) (PP (TO to) (NP (NNP Doc_25084821_1056_1066_Chemical))))))))) (. .)))
25096313	0	(S1 (S (NP (JJ Lateral) (NN antebrachial) (NNS cutaneous)) (VP (VBP Doc_25096313_31_41_Disease) (PP (IN after) (NP (JJ Doc_25096313_48_55_Chemical) (NN injection))) (PP (IN at) (NP (JJ lateral) (NN epicondyle)))) (. .)))
25096313	1	(S1 (NP (NP (NP (NN BACKGROUND)) (CC AND) (NP (NNS OBJECTIVES))) (: :) (S (NP (DT This) (NN report)) (VP (VBD aimed) (S (VP (TO to) (VP (VB present) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (JJ lateral) (JJ antebrachial) (JJ cutaneous) (NNP Doc_25096313_186_196_Disease)) (PRN (-LRB- -LRB-) (NP (NNP LACNP)) (-RRB- -RRB-)))) (SBAR (WHNP (WDT that)) (S (VP (VBD occurred) (PP (IN after) (NP (NP (DT a) (JJ Doc_25096313_227_234_Chemical) (NN injection)) (PP (IN in) (NP (DT the) (JJ lateral) (NN epicondyle) (S (VP (TO to) (VP (VB treat) (NP (NNP Doc_25096313_280_301_Disease)) (PP (IN in) (NP (DT a) (JJ 40-year-old) (NN woman))))))))))))))))))) (. .)))
25096313	2	(S1 (NP (NP (NN MATERIAL) (CC AND) (NN METHOD)) (: :) (NP (NP (DT A) (JJ 40-year-old) (NN woman)) (VP (VBN presented) (PP (IN with) (NP (NP (NNP Doc_25096313_382_401_Disease)) (CC and) (NP (NP (NNS paresthesia)) (PP (IN over) (NP (PRP$ her) (JJ right) (JJ lateral) (NN forearm)))))))) (: ;) (S (NP (DT the) (NN paresthesia)) (VP (AUX had) (VP (VBN occurred) (PP (IN after) (NP (NP (DT a) (JJ Doc_25096313_487_494_Chemical) (NN injection)) (PP (IN in) (NP (NP (NP (DT the) (JJ right) (JJ lateral) (NN epicondyle)) (NP (CD 3) (NNS months))) (ADVP (IN before))))))))) (. .)))
25096313	3	(S1 (S (NP (NP (NP (PRP$ Her) (NN sensation)) (PP (IN of) (NP (JJ light) (NN touch)))) (CC and) (NP (NNP Doc_25096313_587_591_Disease))) (VP (AUX was) (VP (VBN diminished) (PP (IN over) (NP (NP (DT the) (JJ lateral) (NN side)) (PP (IN of) (NP (DT the) (JJ right) (NN forearm) (CC and) (NN wrist) (NN area))))))) (. .)))
25096313	4	(S1 (S (NP (NP (DT The) (JJ sensory) (NN action) (JJ potential) (NN amplitude)) (PP (IN of) (NP (NP (DT the) (JJ right) (JJ lateral) (JJ antebrachial) (NN cutaneous) (NN nerve)) (-LRB- -LRB-) (NP (NNP LACN)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD 6.2) (NN uV)) (-RRB- -RRB-))) (VP (AUX was) (ADJP (ADJP (JJR lower)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (NP (DT the) (JJ left)) (PRN (-LRB- -LRB-) (NP (CD 13.1) (NN uV)) (-RRB- -RRB-)))))))) (. .)))
25096313	5	(S1 (S (NP (NP (DT The) (NN difference)) (PP (IN of) (NP (NN amplitude))) (PP (IN between) (NP (DT both) (NNS sides)))) (VP (AUX was) (ADJP (JJ significant)) (SBAR (IN because) (S (NP (EX there)) (VP (AUX was) (ADVP (RBR more) (IN than)) (NP (DT a) (ADJP (CD 50) (NN %)) (NN reduction)))))) (. .)))
25096313	6	(S1 (S (NP (PRP She)) (VP (AUX was) (VP (VBN diagnosed) (PP (IN with) (NP (NP (JJ right) (NNS LACNP)) (PRN (-LRB- -LRB-) (NP (RB mainly) (JJ axonal) (NN involvement)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NP (DT the) (JJ clinical) (NN manifestation)) (CC and) (NP (DT the) (JJ electrodiagnostic) (NNS findings)))))))) (. .)))
25096313	7	(S1 (S (NP (PRP$ Her) (NNS symptoms)) (VP (VP (VBD improved) (PP (IN through) (NP (JJ physical) (NN therapy)))) (CC but) (VP (VBD persisted) (PP (TO to) (NP (DT some) (NN degree))))) (. .)))
25096313	8	(S1 (S (NP (DT This) (NN report)) (VP (VBZ describes) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NP (DT a) (NN woman)) (PP (IN with) (NP (NP (NNS LACNP)) (SBAR (WHNP (WDT that)) (S (VP (VBD developed) (PP (IN after) (NP (NP (DT a) (JJ Doc_25096313_1238_1245_Chemical) (NN injection)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_25096313_1277_1298_Disease)))))))))))))))) (. .)))
25096313	9	(S1 (S (NP (NP (DT An) (JJ electrodiagnostic) (NN study)) (, ,) (PP (VBG including) (NP (NP (DT a) (NN nerve) (NN conduction) (NN study)) (PP (IN of) (NP (DT the) (NN LACN))))) (, ,)) (VP (AUX was) (ADJP (JJ helpful) (S (VP (VP (TO to) (VP (VB diagnose) (NP (JJ right) (NNS LACNP)))) (CC and) (VP (TO to) (VP (VB find) (NP (NP (DT the) (NN passage)) (PP (IN of) (NP (NP (DT the) (NNS LACN)) (PP (IN on) (NP (DT the) (JJ lateral) (NN epicondyle)))))))))))) (. .)))
25119790	0	(S1 (S (NP (NN Doc_25119790_0_8_Chemical)) (VP (VBZ prevents) (NP (NP (JJ maleate-induced) (NN nephrotoxicity)) (: :) (NP (NP (NP (NN relation)) (PP (TO to) (NP (JJ hemodynamic) (NNS alterations)))) (, ,) (NP (JJ oxidative) (NN stress)) (, ,) (NP (JJ mitochondrial) (JJ Doc_25119790_119_125_Chemical) (NN consumption)) (CC and) (NP (NP (NN activity)) (PP (IN of) (NP (JJ respiratory) (JJ complex) (NN I))))))) (. .)))
25119790	1	(S1 (S (NP (NP (DT The) (JJ potential) (JJ protective) (NN effect)) (PP (IN of) (NP (NP (DT the) (JJ dietary) (NN antioxidant) (NN Doc_25119790_236_244_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 120) (NN mg/Kg/day)) (PP (IN for) (NP (CD 6) (NNS days)))) (-RRB- -RRB-)))) (PP (IN against) (NP (NP (DT the) (NNP Doc_25119790_284_296_Disease)) (VP (VBN induced) (PP (IN by) (NP (NN maleate))))))) (VP (AUX was) (VP (VBN evaluated))) (. .)))
25119790	2	(S1 (S (NP (NP (JJ Tubular) (NN Doc_25119790_339_350_Disease)) (CC and) (NP (JJ oxidative) (NN stress))) (VP (AUX were) (VP (VBN induced) (PP (IN by) (NP (NP (DT a) (JJ single) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_25119790_410_417_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 400) (NN mg/kg)) (-RRB- -RRB-)))))) (PP (IN in) (NP (NNS rats))))) (. .)))
25119790	3	(S1 (S (NP (JJ Doc_25119790_439_446_Chemical-induced) (NNP Doc_25119790_455_467_Disease)) (VP (VBD included) (NP (NP (NP (NN increase)) (PP (PP (IN in) (NP (JJ renal) (JJ vascular) (NN resistance))) (CC and) (PP (IN in) (NP (NP (NP (DT the) (JJ urinary) (NN excretion)) (PP (IN of) (NP (JJ total) (NN protein)))) (, ,) (NP (NNP Doc_25119790_562_569_Chemical)) (, ,) (NP (NNP Doc_25119790_571_577_Chemical)) (, ,) (NP (NP (JJ neutrophil) (JJ gelatinase-associated) (NN lipocalin)) (PRN (-LRB- -LRB-) (NP (NNP NGAL)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ Doc_25119790_633_641_Chemical) (NN b-D-glucosaminidase)) (PRN (-LRB- -LRB-) (NP (NNP NAG)) (-RRB- -RRB-))))))) (, ,) (NP (NP (NN upregulation)) (PP (IN of) (NP (NNP Doc_25119790_685_698_Disease) (NN molecule) (PRN (-LRB- -LRB-) (NNP KIM) (-RRB- -RRB-)) (NN -1)))) (, ,) (NP (NP (NN decrease)) (PP (IN in) (NP (JJ renal) (NN blood) (NN flow)))) (CC and) (NP (NP (JJ claudin-2) (NN expression)) (PP (IN besides) (IN of) (NP (NP (NNP Doc_25119790_782_790_Disease)) (CC and) (S (NP (NP (NN apoptosis)) (PP (IN of) (NP (JJ tubular) (NNS cells))) (PP (IN on) (NP (CD 24) (NNP h.) (NNP Oxidative) (NN stress)))) (VP (AUX was) (VP (VBN determined) (PP (IN by) (S (VP (VBG measuring) (NP (NP (NP (DT the) (NN oxidation)) (PP (IN of) (NP (NNS lipids) (CC and) (NNS proteins)))) (CC and) (NP (NN diminution))) (PP (IN in) (NP (JJ renal) (NNP Nrf2) (NNS levels)))))))))))))) (. .)))
25119790	4	(S1 (S (NP (NNS Studies)) (VP (AUX were) (ADVP (RB also)) (VP (VBN conducted) (PP (PP (IN in) (NP (JJ renal) (JJ epithelial) (NN LLC-PK1) (NNS cells))) (CC and) (PP (IN in) (NP (NP (NNS mitochondria)) (VP (VBN isolated) (PP (IN from) (NP (NP (NNS kidneys)) (PP (IN of) (NP (PDT all) (DT the) (JJ experimental) (NNS groups))))))))))) (. .)))
25119790	5	(S1 (S (NP (NP (JJ Maleate) (VBN induced) (NN cell) (NN damage)) (CC and) (NP (NP (JJ reactive) (JJ Doc_25119790_1127_1133_Chemical) (NNS species)) (PRN (-LRB- -LRB-) (NP (NNP ROS)) (-RRB- -RRB-)))) (VP (NN production) (PP (IN in) (NP (NP (JJ LLC-PK1) (NNS cells)) (PP (IN in) (NP (NN culture)))))) (. .)))
25119790	6	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (JJ maleate) (NN treatment)) (VP (VBD reduced) (NP (JJ Doc_25119790_1227_1233_Chemical) (NN consumption)) (PP (IN in) (NP (NP (JJ Doc_25119790_1249_1252_Chemical-stimulated) (NN mitochondria)) (CC and) (NP (JJ diminished) (JJ respiratory) (NN control) (NN index)))) (SBAR (WHADVP (WRB when)) (S (VP (VBG using) (NP (NNP Doc_25119790_1329_1335_Chemical/Doc_25119790_1336_1345_Chemical)) (PP (IN as) (NP (NN substrate))))))) (. .)))
25119790	7	(S1 (S (NP (NP (DT The) (NNS activities)) (PP (IN of) (NP (DT both) (NN complex)))) (NP (NP (PRP I)) (CC and) (NP (NN aconitase))) (VP (AUX were) (ADVP (RB also)) (VP (VBN diminished))) (. .)))
25119790	8	(S1 (S (NP (PDT All) (DT the) (JJ above-described) (NNS alterations)) (VP (AUX were) (VP (VBN prevented) (PP (IN by) (NP (NNP Doc_25119790_1483_1491_Chemical))))) (. .)))
25119790	9	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NNP Doc_25119790_1514_1522_Chemical)) (VP (AUX is) (ADJP (JJ able) (S (VP (TO to) (VP (VB attenuate) (PP (PP (IN in) (NP (JJ vivo) (JJ maleate-induced) (NN Doc_25119790_1568_1579_Disease))) (CC and) (PP (IN in) (NP (NN vitro) (NN cell) (NN damage))))))))))))) (. .)))
25119790	10	(S1 (S (S (NP (NP (DT The)) (PP (IN in) (NP (NN vivo) (NN protection)))) (VP (AUX was) (VP (VBN associated) (PP (TO to) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NP (JJ oxidative) (NN stress)) (CC and) (NP (NP (NN preservation)) (PP (IN of) (NP (NP (JJ mitochondrial) (JJ Doc_25119790_1716_1722_Chemical) (NN consumption) (CC and) (NN activity)) (PP (IN of) (NP (NP (NN respiratory) (NN complex)) (NP (PRP I)))))))))))))) (, ,) (CC and) (S (NP (NP (DT the)) (PP (IN in) (NP (NN vitro) (NN protection)))) (VP (AUX was) (VP (VBN associated) (PP (TO to) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NNP ROS) (NN production)))))))) (. .)))
2553470	0	(S1 (NP (NP (JJ Anticonvulsant) (NNS actions)) (PP (IN of) (NP (NNP Doc_2553470_26_32_Chemical))) (PP (IN on) (NP (NP (DT the) (JJ Doc_2553470_40_47_Chemical-Doc_2553470_48_59_Chemical) (NN model)) (PP (IN of) (NP (NNP Doc_2553470_69_87_Disease))) (PP (IN in) (NP (NNS rats))))) (. .)))
2553470	1	(S1 (S (NP (NP (NNP Doc_2553470_97_103_Chemical)) (, ,) (NP (DT a) (JJ noncompetitive) (NNP Doc_2553470_122_142_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_2553470_144_148_Chemical)) (-RRB- -RRB-)) (NN receptor) (NN antagonist)) (, ,)) (VP (AUX was) (VP (VBN tested) (PP (IN for) (NP (NP (JJ anticonvulsant) (NNS effects)) (PP (IN in) (NP (NP (NNS rats)) (VP (VBG using) (NP (NP (CD two) (JJ Doc_2553470_227_234_Disease) (NNS models)) (, ,) (NP (NP (NN coadministration)) (PP (IN of) (NP (NNP Doc_2553470_263_270_Chemical) (CC and) (NNP Doc_2553470_275_286_Chemical)))) (CC and) (NP (NP (NN administration)) (PP (IN of) (NP (NP (DT a) (JJ high) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_2553470_324_335_Chemical)) (ADVP (RB alone))))))))))))))) (. .)))
2553470	2	(S1 (S (NP (CD Three) (JJ major) (NNS results)) (VP (AUX are) (VP (VBN reported))) (. .)))
2553470	3	(S1 (S (ADVP (JJ First)) (, ,) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NNP Doc_2553470_402_408_Chemical)))) (VP (VBD produced) (NP (DT an) (ADJP (JJ effective) (CC and) (JJ dose-dependent)) (NN anticonvulsant) (NN action)) (PP (PP (IN with) (NP (DT the) (JJ Doc_2553470_481_488_Chemical-Doc_2553470_489_500_Chemical) (NN model))) (CONJP (CC but) (RB not)) (PP (IN with) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_2553470_538_549_Chemical)) (ADVP (RB alone)))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (JJ different) (JJ biochemical) (NNS mechanisms)) (VP (VBP control) (NP (NNP Doc_2553470_614_622_Disease)) (PP (IN in) (NP (DT these) (CD two) (NNS models))))))))) (. .)))
2553470	4	(S1 (S (ADVP (JJ Second)) (, ,) (NP (NP (DT the) (JJ anticonvulsant) (NN effect)) (PP (IN of) (NP (NNP Doc_2553470_681_687_Chemical))) (PP (IN in) (NP (DT the) (JJ Doc_2553470_695_702_Chemical-Doc_2553470_703_714_Chemical) (NN model)))) (ADVP (RB only)) (VP (VBD occurred) (PP (IN after) (NP (NP (JJ initial) (NNS periods)) (PP (IN of) (NP (JJ Doc_2553470_760_767_Disease) (NN activity)))))) (. .)))
2553470	5	(S1 (S (NP (DT This) (NN observation)) (VP (AUX is) (VP (VBN suggested) (S (VP (TO to) (VP (AUX be) (DT an) (PP (IN in) (NP (NP (NN vivo) (NN demonstration)) (PP (IN of) (NP (NP (DT the) (NN conclusion)) (VP (VBN derived) (PP (IN from) (PP (IN in) (NP (NP (NN vitro) (NNS experiments)) (SBAR (WHNP (WDT that)) (S (NP (NNP Doc_2553470_896_902_Chemical) (VBG binding)) (VP (VBZ requires) (NP (NP (JJ agonist-induced) (NN opening)) (PP (IN of) (NP (NP (DT the) (NN channel) (NNS sites)) (PP (IN of) (NP (DT the) (JJ Doc_2553470_972_976_Chemical) (NN receptor)))))))))))))))))))))) (. .)))
2553470	6	(S1 (S (ADVP (LS Third)) (, ,) (SBAR (IN although) (S (NP (PRP it)) (VP (AUX is) (ADJP (RB relatively) (JJ easy) (SBAR (S (VP (TO to) (VP (VB block) (NP (NP (NNP Doc_2553470_1034_1042_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_2553470_1054_1061_Chemical)) (CC and) (NP (NNP Doc_2553470_1066_1077_Chemical)))) (PP (IN by) (NP (NP (NN administration)) (PP (IN of) (NP (NNS anticonvulsants))))))) (ADVP (RB prior) (PP (TO to) (NP (NNP Doc_2553470_1124_1135_Chemical)))))))))))) (, ,) (NP (PRP it)) (VP (AUX is) (ADJP (RBR more) (JJ difficult) (S (VP (TO to) (VP (VP (VB terminate) (NP (JJ ongoing) (NN Doc_2553470_1179_1197_Disease))) (CC and) (VP (VB block) (NP (NP (DT the) (NN lethality)) (PP (IN of) (NP (DT the) (NNP Doc_2553470_1229_1237_Disease)))))))))) (. .)))
2553470	7	(S1 (S (NP (NP (NP (NN Administration)) (PP (IN of) (NP (NNP Doc_2553470_1257_1263_Chemical) (CD 30)))) (CC or) (NP (NP (CD 60) (NN min)) (PP (IN after) (NP (NP (NNP Doc_2553470_1283_1294_Chemical)) (, ,) (NP (FW i.e.)))))) (, ,) (PP (IN during) (NP (NN Doc_2553470_1309_1327_Disease))) (, ,) (VP (VP (ADVP (RB gradually)) (VBD reduced) (NP (ADJP (JJ electrical) (CC and) (JJ behavioral)) (JJ Doc_2553470_1373_1380_Disease) (NN activity))) (CC and) (VP (ADVP (RB greatly)) (VBD enhanced) (NP (DT the) (NN survival) (NN rate)))) (. .)))
2553470	8	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN activation)) (PP (IN of) (NP (JJ Doc_2553470_1471_1475_Chemical) (NNS receptors)))) (VP (VBZ plays) (NP (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (NNP Doc_2553470_1513_1531_Disease)) (CC and) (NP (NNP Doc_2553470_1536_1548_Disease))))) (PP (IN in) (NP (DT the) (JJ Doc_2553470_1556_1563_Chemical-Doc_2553470_1564_1575_Chemical) (NN model))))))) (. .)))
2553470	9	(S1 (S (NP (DT This)) (VP (AUX was) (ADVP (RB further)) (VP (VBN supported) (PP (IN by) (NP (NP (NNS results)) (VP (VBG showing) (SBAR (IN that) (S (NP (NP (JJ nonconvulsive) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_2553470_1657_1661_Chemical)) (CC and) (NP (NNP Doc_2553470_1666_1677_Chemical))))) (VP (AUX were) (ADJP (JJ synergistic)) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (NNP Doc_2553470_1709_1727_Disease)) (CC and) (NP (JJ subsequent) (NN mortality)))))))))))))) (. .)))
256433	0	(S1 (S (NP (JJ Continuous) (NN infusion) (NN Doc_256433_20_30_Chemical)) (VP (VBN combined) (PP (IN with) (NP (NNP Doc_256433_45_58_Chemical))) (PP (IN for) (NP (NP (NNP Doc_256433_63_73_Disease)) (PP (IN in) (NP (NNP Doc_256433_77_83_Disease) (NNS patients)))))) (. .)))
256433	1	(S1 (S (NP (NP (DT The) (NN cure) (NN rate)) (PP (IN of) (NP (NNP Doc_256433_111_121_Disease))) (PP (IN in) (NP (NNP Doc_256433_125_131_Disease) (NNS patients)))) (VP (AUX is) (ADVP (RB adversely)) (VP (VBN affected) (PP (IN by) (NP (NNP Doc_256433_166_177_Disease))) (PRN (-LRB- -LRB-) (NP (NP (JJR less)) (PP (IN than) (NP (NNS 1,000/mm3)))) (-RRB- -RRB-)))) (. .)))
256433	2	(S1 (S (PP (IN In) (NP (NN particular))) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ severe) (NNP Doc_256433_237_248_Disease)) (PRN (-LRB- -LRB-) (NP (QP (JJR less) (IN than) (CD 100/mm3))) (-RRB- -RRB-))))) (VP (AUX have) (VP (VBN shown) (NP (NP (DT a) (JJ poor) (NN response)) (PP (TO to) (NP (NNS antibiotics)))))) (. .)))
256433	3	(S1 (S (S (VP (TO To) (VP (VB overcome) (NP (NP (DT the) (JJ adverse) (NNS effects)) (PP (IN of) (NP (NN Doc_256433_347_358_Disease))))))) (, ,) (NP (NNP Doc_256433_360_370_Chemical)) (VP (AUX was) (VP (VP (VBN given) (PP (IN by) (NP (JJ continuous) (NN infusion)))) (CC and) (VP (VBN combined) (PP (IN with) (NP (JJ intermittent) (NN Doc_256433_435_448_Chemical)))))) (. .)))
256433	4	(S1 (S (S (NP (NN Doc_256433_450_460_Chemical)) (VP (AUX was) (VP (VBN given) (PP (TO to) (NP (NP (DT a) (JJ total) (JJ daily) (NN dose)) (PP (IN of) (NP (QP (CD 300) (CD mg/m2))))))))) (CC and) (S (NP (NNP Doc_256433_510_523_Chemical)) (VP (AUX was) (VP (VBN given) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 5))))) (S (NP (NNP gm)) (NP (DT every) (CD four) (NNS hours)))))) (. .)))
256433	5	(S1 (S (NP (EX There)) (VP (AUX were) (NP (CD 125) (NNP Doc_256433_585_595_Disease) (NNS episodes)) (PP (IN in) (NP (NP (CD 116) (JJ Doc_256433_612_618_Disease) (NNS patients)) (VP (VBG receiving) (NP (JJ myelosuppressive) (NN chemotherapy)))))) (. .)))
256433	6	(S1 (S (NP (DT The) (JJ overall) (NN cure) (NN rate)) (VP (AUX was) (NP (CD 70) (NN %))) (. .)))
256433	7	(S1 (S (S (NP (NN Doc_256433_700_709_Disease)) (VP (AUX was) (NP (DT the) (ADJP (RBS most) (JJ common)) (NN Doc_256433_730_739_Disease)))) (CC and) (S (NP (NP (CD 61) (NN %)) (PP (IN of) (NP (CD 59) (NNS episodes)))) (VP (AUX were) (VP (VBN cured)))) (. .)))
256433	8	(S1 (S (S (NP (JJ Gram-negative) (NNS bacilli)) (VP (AUX were) (NP (DT the) (ADJP (RBS most) (JJ common)) (JJ causative) (NNS organisms)))) (CC and) (S (NP (NP (CD 69) (NN %)) (PP (IN of) (NP (DT these) (NNP Doc_256433_855_865_Disease)))) (VP (AUX were) (VP (VBN cured)))) (. .)))
256433	9	(S1 (S (S (NP (DT The) (ADJP (RBS most) (JJ common)) (NN pathogen)) (VP (AUX was) (ADJP (JJ Doc_256433_907_928_Disease)))) (CC and) (S (NP (DT this)) (, ,) (PP (ADVP (RB together)) (IN with) (NP (NNP Doc_256433_953_964_Disease) (NNS coli) (CC and) (NNP Doc_256433_974_996_Disease))) (, ,) (VP (VBD accounted) (PP (IN for) (NP (NP (CD 74) (NN %)) (PP (IN of) (NP (DT all) (JJ gram-negative) (NN Doc_256433_1037_1057_Disease))))))) (. .)))
256433	10	(S1 (S (NP (NN Response)) (VP (AUX was) (RB not) (VP (VBN influenced) (PP (IN by) (NP (DT the) (JJ initial) (NN neutrophil) (NN count))) (, ,) (PP (IN with) (NP (NP (DT a) (ADJP (CD 62) (NN %)) (NN cure) (NN rate)) (PP (IN for) (NP (NP (CD 39) (NNS episodes)) (VP (VBN associated) (PP (IN with) (NP (JJ severe) (NN Doc_256433_1180_1191_Disease)))))))))) (. .)))
256433	11	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN failure)) (PP (IN of) (NP (DT the) (JJ neutrophil) (NN count))) (S (VP (TO to) (VP (VB increase) (PP (IN during) (NP (NN therapy))))))) (ADVP (RB adversely)) (VP (VBD affected) (NP (NN response))) (. .)))
256433	12	(S1 (S (S (NP (NN Doc_256433_1290_1298_Disease)) (VP (AUX was) (NP (NP (DT the) (JJ major) (NN side) (NN effect)) (VP (VBN recognized))))) (, ,) (CC and) (S (NP (PRP it)) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 11) (NN %)) (PP (IN of) (NP (NNS episodes))))))) (. .)))
256433	13	(S1 (S (NP (NP (NNP Major) (NNP Doc_256433_1379_1387_Disease)) (PRN (-LRB- -LRB-) (NP (NP (JJ serum) (NNP Doc_256433_1395_1405_Chemical)) (ADJP (QP (JJR greater) (IN than) (CD 2.5) (CD mg/dl) (CC or) (CD BUN)) (JJR greater) (PP (IN than) (NP (CD 50) (NN mg/dl))))) (-RRB- -RRB-))) (VP (VBD occurred) (PP (IN in) (NP (QP (RB only) (CD 2)) (NN %)))) (. .)))
256433	14	(S1 (S (NP (NN Doc_256433_1480_1488_Disease)) (VP (AUX was) (RB not) (VP (VBN related) (PP (TO to) (NP (NP (NN duration)) (PP (IN of) (NP (NN therapy) (CC or) (NN serum) (NN Doc_256433_1537_1547_Chemical) (NN concentration))))))) (. .)))
256433	15	(S1 (S (NP (DT This) (JJ antibiotic) (NN regimen)) (VP (VBD showed) (NP (DT both) (JJ therapeutic) (ADJP (JJ efficacy) (CC and) (JJ acceptable)) (NN Doc_256433_1635_1649_Disease)) (PP (IN for) (NP (DT these) (NNS patients)))) (. .)))
25907210	0	(S1 (NP (NP (NP (NN Incidence)) (PP (IN of) (NP (JJ solid) (NNP Doc_25907210_19_26_Disease))) (PP (IN among) (NP (NP (NN pesticide) (NNS applicators)) (VP (VBN exposed) (PP (TO to) (NP (NP (DT the) (JJ Doc_25907210_70_85_Chemical) (NN insecticide) (NN Doc_25907210_98_106_Chemical)) (PP (IN in) (NP (DT the) (NNP Agricultural) (NNP Health) (NNP Study))))))))) (: :) (NP (DT an) (VBN updated) (NN analysis)) (. .)))
25907210	1	(S1 (S (S (NP (NP (NNP Doc_25907210_173_181_Chemical)) (, ,) (NP (NP (DT a) (JJ common) (JJ Doc_25907210_192_207_Chemical) (NN insecticide)) (PP (IN with) (NP (JJ genotoxic) (NNS properties)))) (, ,)) (VP (AUX was) (ADVP (RB previously)) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_25907210_278_289_Disease)) (PP (IN in) (NP (DT the) (NNP Agricultural) (NNP Health) (NNP Study) (PRN (-LRB- -LRB-) (INTJ (UH AHS)) (-RRB- -RRB-)) (NN cohort)))))))) (, ,) (CC but) (S (NP (JJ few) (JJ other) (NN epidemiological) (NNS studies)) (VP (AUX have) (VP (VBN examined) (NP (JJ Doc_25907210_389_397_Chemical-associated) (JJ Doc_25907210_409_415_Disease) (NN risk))))) (. .)))
25907210	2	(S1 (S (NP (PRP We)) (VP (VBD used) (NP (NP (VBN updated) (JJ Doc_25907210_438_446_Chemical) (NN exposure)) (CC and) (NP (JJ Doc_25907210_460_466_Disease) (NN incidence) (NN information))) (S (VP (TO to) (VP (VB evaluate) (NP (JJ solid) (NN tumour) (NN risk)) (PP (IN in) (NP (DT the) (UH AHS))))))) (. .)))
25907210	3	(S1 (S (S (NP (NP (JJ Male) (NN pesticide) (NNS applicators)) (PP (IN in) (NP (NP (NNP Iowa)) (CC and) (NP (NNP North) (NNP Carolina))))) (VP (VBD reported) (NP (NN lifetime) (JJ Doc_25907210_612_620_Chemical) (NN use)) (PP (IN at) (NP (NP (NP (NN enrolment)) (PRN (-LRB- -LRB-) (NP (CD 1993-1997)) (-RRB- -RRB-))) (CC and) (NP (NP (NN follow-up)) (PRN (-LRB- -LRB-) (NP (CD 1998-2005)) (-RRB- -RRB-))))))) (: ;) (S (NP (NNP Doc_25907210_677_683_Disease) (NN incidence)) (VP (AUX was) (VP (VBN assessed) (PP (IN through) (NP (NP (CD 2010)) (PRN (-LRB- -LRB-) (NP (NNP North) (NNP Carolina)) (-RRB- -RRB-)) (NP (NP (CD /2011)) (PRN (-LRB- -LRB-) (NP (NNP Iowa)) (-RRB- -RRB-)))))))) (. .)))
25907210	4	(S1 (S (PP (IN Among) (NP (NNS applicators))) (PP (IN with) (NP (NP (NN usage) (NN information)) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB evaluate) (NP (JJ exposure-response) (NNS patterns)))))))) (, ,) (NP (PRP we)) (VP (VBD used) (NP (NNP Poisson) (NN regression)) (S (VP (TO to) (VP (VB estimate) (NP (NP (NP (VBN adjusted) (NN rate) (NNS ratios)) (PRN (-LRB- -LRB-) (NNS RRs) (-RRB- -RRB-))) (CC and) (NP (NP (CD 95) (NN %) (NNS CI)) (PP (IN for) (NP (NP (JJ Doc_25907210_921_927_Disease) (NNS sites)) (PP (IN with) (NP (NP (CD >10) (VBN exposed) (NNS cases)) (PP (IN for) (NP (NP (DT both) (NN lifetime) (PRN (-LRB- -LRB-) (NP (NNP LT)) (-RRB- -RRB-)) (NN exposure) (NNS days)) (CC and) (NP (NP (JJ intensity-weighted) (PRN (-LRB- -LRB-) (NP (NNP IW)) (-RRB- -RRB-)) (NN lifetime) (NN exposure) (NNS days)) (PRN (-LRB- -LRB-) (NP (NP (NN accounting)) (PP (IN for) (NP (NP (NNS factors)) (VP (VBG impacting) (NP (NN exposure)))))) (-RRB- -RRB-))))))))))))))) (. .)))
25907210	5	(S1 (S (NP (PRP We)) (VP (VBD observed) (NP (NP (JJ elevated) (JJ Doc_25907210_1120_1131_Disease) (NNS risks)) (PRN (-LRB- -LRB-) (NP (NNP N=283)) (-RRB- -RRB-))) (PP (IN among) (NP (NP (NNS applicators)) (PP (IN with) (NP (NP (DT the) (JJS greatest) (NN number)) (PP (IN of) (NP (NP (NP (NNS LT)) (PRN (-LRB- -LRB-) (NP (NP (CD RR=1.60)) (: ;) (NP (CD 95) (NN %) (QP (RB CI) (CD 1.11) (TO to) (CD 2.31))) (: ;) (NP (CD Ptrend=0.02))) (-RRB- -RRB-))) (CC and) (NP (NP (CD IW) (NNS days)) (PP (IN of) (NP (JJ Doc_25907210_1254_1262_Chemical) (NN use))) (PRN (-LRB- -LRB-) (NP (NP (CD RR=1.41)) (: ;) (NP (CD 95) (NN %) (QP (RB CI) (CD 0.98) (TO to) (CD 2.04))) (: ;) (NP (CD Ptrend=0.08))) (-RRB- -RRB-)))))))))) (. .)))
25907210	6	(S1 (S (NP (JJ Doc_25907210_1312_1325_Disease) (PRN (-LRB- -LRB-) (NP (NNP N=94)) (-RRB- -RRB-)) (NNS risks)) (VP (AUX were) (ADJP (ADJP (RB non-significantly) (JJ elevated)) (PRN (-LRB- -LRB-) (NP (NP (NN RRLT) (CD days=1.77)) (: ;) (NP (NP (CD 95) (NN %) (QP (CD CI) (CD 0.90) (TO to) (CD 3.51))) (: ;) (NP (CD Ptrend=0.09)) (: ;) (NP (NP (CD RRIW) (NNS days)) (NP (CD 1.37))) (: ;) (NP (NP (CD 95) (NN %) (QP (CD CI) (CD 0.64))) (PP (TO to) (NP (CD 2.92)))) (: ;) (NP (CD Ptrend=0.50)))) (-RRB- -RRB-))) (, ,) (SBAR (IN as) (S (VP (AUX were) (NP (NP (NNS risks)) (PP (IN for) (NP (NP (JJ aggressive) (NNP Doc_25907210_1502_1517_Disease)) (PRN (-LRB- -LRB-) (NP (NNP N=656)) (-RRB- -RRB-))))))))) (. .)))
25907210	7	(S1 (S (NP (NP (PRP$ Our) (VBN updated) (NN evaluation)) (PP (IN of) (NP (NNP Doc_25907210_1566_1574_Chemical)))) (VP (VBZ provides) (NP (NP (JJ additional) (NN evidence)) (PP (IN of) (NP (NP (DT an) (NN association)) (PP (IN with) (NP (JJ Doc_25907210_1627_1638_Disease) (NN risk))))))) (. .)))
25907210	8	(S1 (S (NP (NP (NP (ADJP (RB Newly) (VBN identified)) (NNS links)) (PP (TO to) (NP (NN Doc_25907210_1671_1684_Disease)))) (CC and) (NP (NP (NNS associations)) (PP (IN with) (NP (JJ aggressive) (NNP Doc_25907210_1718_1733_Disease))))) (VP (VBP require) (NP (JJ further) (NN evaluation))) (. .)))
25951420	0	(S1 (NP (NP (NP (NP (NNS Associations)) (PP (IN of) (NP (NNP Doc_25951420_16_21_Chemical)))) (CC and) (NP (NP (CD PM2.5) (NNS Concentrations)) (PP (IN With) (NP (NNP Doc_25951420_52_71_Disease))))) (PP (IN Among) (NP (NP (NNS Participants)) (PP (IN in) (NP (DT the) (NNP Agricultural) (NNP Health) (NNP Study))))) (. .)))
25951420	1	(S1 (S (NP (DT This) (NN study)) (VP (VBZ describes) (NP (NP (NP (NNS associations)) (PP (IN of) (NP (NNP Doc_25951420_173_178_Chemical)))) (CC and) (NP (JJ fine) (JJ particulate) (NN matter))) (PP (IN with) (NP (NP (NNP Doc_25951420_212_231_Disease)) (VP (VBD observed) (PP (IN among) (NP (NP (NNS farmers)) (PP (IN in) (NP (NP (NNP North) (NNP Carolina)) (CC and) (NP (NNP Iowa)))))))))) (. .)))
25951420	2	(S1 (S (NP (PRP We)) (VP (VBD used) (NP (JJ logistic) (NN regression)) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NNS associations)) (PP (IN of) (NP (DT these) (NNS pollutants))) (PP (IN with) (NP (JJ self-reported) (, ,) (JJ doctor-diagnosed) (NN Doc_25951420_407_426_Disease)))))))) (. .)))
25951420	3	(S1 (S (NP (NNP Daily)) (VP (VBD predicted) (SBAR (S (NP (NN pollutant) (NNS concentrations)) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VP (VB derive) (NP (NP (NNS surrogates)) (PP (IN of) (NP (JJ long-term) (NN exposure))))) (CC and) (VP (VB link) (NP (PRP them))) (S (VP (TO to) (VP (VB study) (NP (NP (NNS participants) (POS ')) (JJ geocoded) (NNS addresses))))))))))))) (. .)))
25951420	4	(S1 (S (NP (PRP We)) (VP (VBD observed) (NP (NP (JJ positive) (NNS associations)) (PP (IN of) (NP (NNP Doc_25951420_625_644_Disease)))) (PP (IN with) (NP (NP (NP (NNP Doc_25951420_650_655_Chemical)) (PRN (-LRB- -LRB-) (S (NP (NNS odds) (NN ratio)) (VP (SYM =) (NP (NP (CD 1.39)) (: ;) (NP (NP (CD 95) (NN %)) (NP (NNS CI))) (: :) (NP (QP (CD 0.98) (TO to) (CD 1.98)))))) (-RRB- -RRB-))) (CC and) (NP (NP (JJ fine) (JJ particulate) (NN matter)) (PRN (-LRB- -LRB-) (S (NP (NNS odds) (NN ratio)) (VP (SYM =) (NP (NP (CD 1.34)) (: ;) (NP (NP (CD 95) (NN %)) (NP (NNS CI))) (: :) (NP (QP (CD 0.93) (TO to) (CD 1.93)))))) (-RRB- -RRB-))))) (PP (PP (IN in) (NP (NNP North) (NNP Carolina))) (CC but) (PP (RB not) (IN in) (NP (NNP Iowa))))) (. .)))
25951420	5	(S1 (S (NP (NP (DT The) (NN plausibility)) (PP (IN of) (NP (NP (DT an) (NN effect)) (PP (IN of) (NP (NP (JJ ambient) (NNS concentrations)) (PP (IN of) (NP (DT these) (NNS pollutants))) (PP (IN on) (NP (JJ Doc_25951420_895_914_Disease) (NN risk)))))))) (VP (AUX is) (VP (VBN supported) (PP (IN by) (NP (NP (JJ experimental) (NNS data)) (VP (VBG demonstrating) (NP (NNP Doc_25951420_968_998_Disease)) (PP (IN at) (NP (JJ relevant) (NNS concentrations)))))))) (. .)))
25951420	6	(S1 (S (NP (JJ Additional) (NNS studies)) (VP (AUX are) (VP (VBN needed) (S (VP (VP (TO to) (VP (VB address) (NP (NP (NNS uncertainties)) (VP (VBN related) (PP (TO to) (NP (NN confounding))))))) (CC and) (VP (TO to) (VP (VB examine) (NP (NP (JJ temporal) (NNS aspects)) (PP (IN of) (NP (NP (DT the) (NNS associations)) (SBAR (S (NP (PRP we)) (VP (VBD observed))))))))))))) (. .)))
25986755	0	(S1 (S (NP (NP (JJ Low) (JJ functional) (NN programming)) (PP (IN of) (NP (JJ renal) (NNS AT2R)))) (VP (VBZ mediates) (NP (NP (DT the) (JJ developmental) (NN origin)) (PP (IN of) (NP (NNP Doc_25986755_78_96_Disease))) (PP (IN in) (NP (NP (NN adult) (NN offspring)) (VP (VBN induced) (PP (IN by) (NP (JJ prenatal) (JJ Doc_25986755_136_144_Chemical) (NN exposure)))))))) (. .)))
25986755	1	(S1 (S (NP (PRP$ Our) (JJ previous) (NN study)) (VP (AUX has) (VP (VBN indicated) (SBAR (IN that) (S (NP (NP (JJ prenatal) (JJ Doc_25986755_214_222_Chemical) (NN exposure)) (PRN (-LRB- -LRB-) (NP (NN PCE)) (-RRB- -RRB-))) (VP (MD could) (VP (VB induce) (NP (NP (NP (NNP Doc_25986755_251_282_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_25986755_284_288_Disease)) (-RRB- -RRB-))) (PP (IN of) (NP (NN offspring)))))))))) (. .)))
25986755	2	(S1 (S (NP (JJ Recent) (NN research)) (VP (VBD suggested) (SBAR (IN that) (S (NP (NNP Doc_25986755_335_339_Disease)) (VP (AUX is) (NP (NP (DT a) (NN risk) (NN factor)) (PP (IN for) (NP (NN Doc_25986755_361_379_Disease)))))))) (. .)))
25986755	3	(S1 (S (ADVP (RB However)) (, ,) (NP (IN whether) (NN PCE)) (VP (MD could) (VP (VB induce) (S (NP (NP (NNP Doc_25986755_415_433_Disease)) (CC and) (NP (PRP$ its) (VBG underlying) (NNS mechanisms))) (VP (VB remain) (ADJP (JJ unknown)))))) (. .)))
25986755	4	(S1 (S (NP (DT This) (NN study)) (VP (VBD aimed) (S (VP (TO to) (VP (VB demonstrate) (NP (NP (DT the) (NN induction)) (PP (TO to) (NP (NNP Doc_25986755_529_547_Disease))) (PP (IN in) (NP (NN adult) (NN offspring))) (PP (IN by) (NP (NP (NN PCE)) (CC and) (NP (PRP$ its) (JJ intrauterine) (NN programming) (NNS mechanisms))))))))) (. .)))
25986755	5	(S1 (S (NP (NP (DT A) (NN rat) (NN model)) (PP (IN of) (NP (NNP Doc_25986755_634_638_Disease)))) (VP (AUX was) (VP (VBN established) (PP (IN by) (NP (NP (NN PCE)) (, ,) (NP (JJ male) (NNS fetuses)) (CC and) (NP (NN adult) (NN offspring)))) (PP (IN at) (NP (NP (DT the) (NN age)) (PP (IN of) (NP (NP (JJ postnatal) (NN week)) (SBAR (WHNP (CD 24)) (S (VP (AUX were) (VP (VBN euthanized))))))))))) (. .)))
25986755	6	(S1 (S (NP (DT The) (NNS results)) (VP (VBD revealed) (SBAR (IN that) (S (NP (DT the) (NN adult) (NN offspring)) (VP (VBZ kidneys) (PP (IN in) (NP (NP (DT the) (NN PCE) (NN group)) (VP (VBD exhibited) (NP (NP (NNP Doc_25986755_826_844_Disease)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ interstitial) (NNP Doc_25986755_869_877_Disease)) (, ,) (VP (VBN accompanied) (PP (IN by) (NP (NP (JJ elevated) (NNS levels)) (PP (IN of) (NP (NP (NN serum) (NN Doc_25986755_919_929_Chemical)) (CC and) (NP (NN urine) (NN protein)))))))))))))))) (. .)))
25986755	7	(S1 (S (NP (JJ Renal) (NN angiotensin) (NNP II) (NN receptor) (NN type)) (NP (NP (CD 2) (-LRB- -LRB-) (NN AT2R) (-RRB- -RRB-) (NN gene) (NN expression)) (PP (IN in) (NP (NN adult) (NN offspring)))) (VP (AUX was) (VP (VBN reduced) (PP (IN by) (NP (NN PCE))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (JJ renal) (JJ angiotensin) (NNP II) (NN receptor) (NN type) (NNS 1a)) (PRN (-LRB- -LRB-) (NP (NNP AT1aR)) (-RRB- -RRB-))) (VP (VBP /AT2R) (SBAR (S (NP (NN expression) (NN ratio)) (VP (AUX was) (VP (VBN increased)))))))))) (. .)))
25986755	8	(S1 (S (NP (NP (DT The) (JJ fetal) (NNS kidneys)) (PP (IN in) (NP (DT the) (NN PCE) (NN group)))) (VP (VBD displayed) (NP (NP (DT an) (JJ enlarged) (NP (NNP Bowman) (POS 's)) (NN space)) (CC and) (NP (NP (DT a) (JJ shrunken) (NN glomerular) (NN tuft)) (, ,) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT a) (JJ reduced) (NN cortex) (NN width)) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (DT the) (JJ nephrogenic) (JJ zone/cortical) (NN zone) (NN ratio)))))))))) (. .)))
25986755	9	(S1 (S (S (NP (NP (NN Observation)) (PP (IN by) (NP (JJ electronic) (NN microscope)))) (VP (VBD revealed) (NP (NP (JJ structural) (NN damage)) (PP (IN of) (NP (NNS podocytes)))))) (: ;) (S (NP (NP (DT the) (JJ reduced) (NN expression) (NN level)) (PP (IN of) (NP (NP (JJ podocyte) (NN marker) (NNS genes)) (, ,) (ADJP (JJ nephrin) (CC and) (JJ Doc_25986755_1491_1498_Chemical)) (, ,)))) (VP (AUX was) (ADVP (RB also)) (VP (VBN detected) (PP (IN by) (NP (NN q-PCR)))))) (. .)))
25986755	10	(S1 (S (ADVP (RB Moreover)) (, ,) (NP (NP (NN AT2R) (NN gene) (CC and) (NN protein) (NNS expressions)) (PP (IN in) (NP (JJ fetal) (NNS kidneys)))) (VP (AUX were) (VP (VBD inhibited) (PP (IN by) (NP (NP (NN PCE)) (, ,) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN repression)) (PP (IN of) (NP (NP (DT the) (NN gene) (NN expression)) (PP (IN of) (NP (NP (JJ glial-cell-line-derived) (JJ neurotrophic) (NN factor) (PRN (-LRB- -LRB-) (NNP GDNF) (-RRB- -RRB-)) (JJ /Doc_25986755_1720_1728_Chemical) (NN kinase) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN c-Ret)) (-RRB- -RRB-)) (VP (VBG signaling) (NP (NN pathway)))))))))))))) (. .)))
25986755	11	(S1 (S (NP (DT These) (NNS results)) (VP (VBD demonstrated) (SBAR (IN that) (S (S (NP (NN PCE)) (VP (MD could) (VP (VB induce) (NP (NP (NP (NNP Doc_25986755_1821_1830_Disease)) (PP (IN of) (NP (JJ fetal) (NNS kidneys)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NNP Doc_25986755_1859_1877_Disease)) (PP (IN of) (NP (NN adult) (NN offspring)))))))) (, ,) (CC and) (S (NP (NP (DT the) (JJ low) (JJ functional) (NN programming)) (PP (IN of) (NP (JJ renal) (NNS AT2R)))) (VP (MD might) (VP (VB mediate) (NP (NP (DT the) (JJ developmental) (NN origin)) (PP (IN of) (NP (JJ adult) (NNP Doc_25986755_1995_2013_Disease)))))))))) (. .)))
26002693	0	(S1 (NP (NP (NP (NN Doc_26002693_0_13_Chemical)) (, ,) (NP (NN Doc_26002693_15_18_Disease)) (CC and) (NP (DT the) (NNP t) (PRN (-LRB- -LRB-) (NP (CD 9:22)) (-RRB- -RRB-)) (NN translocation))) (: :) (NP (DT A) (NN reality) (NN check)) (. .)))
26002693	1	(S1 (S (NP (NP (JJ Epidemiological) (NNS studies)) (PP (IN of) (NP (NNP Doc_26002693_106_119_Chemical)))) (VP (AUX have) (VP (VB suggest) (SBAR (IN that) (S (NP (NP (NNS exposures)) (PP (TO to) (NP (NNS humans)))) (VP (AUX are) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_26002693_178_202_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_26002693_204_207_Disease)) (-RRB- -RRB-)))))))))) (. .)))
26002693	2	(S1 (S (S (NP (NN Doc_26002693_210_213_Disease)) (VP (AUX has) (NP (NP (DT a) (JJ well-documented) (NN association)) (PP (IN with) (NP (JJ ionizing) (NN radiation)))))) (, ,) (CC but) (S (NP (NP (NNS reports)) (PP (IN of) (NP (NNS associations))) (PP (IN with) (NP (NN chemical) (NNS exposures)))) (VP (AUX have) (VP (AUX been) (VP (VBN questioned))))) (. .)))
26002693	3	(S1 (S (S (NP (JJ Ionizing) (NN radiation)) (VP (AUX is) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG inducing) (NP (NP (DT the) (JJ requisite) (JJ Doc_26002693_403_406_Disease-associated) (NN t) (PRN (-LRB- -LRB-) (NP (CD 9:22)) (-RRB- -RRB-)) (NN translocation)) (PRN (-LRB- -LRB-) (NP (NNP Doc_26002693_441_464_Disease)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (JJ appropriate) (NNS cells)) (PP (IN in) (NP (NN vitro))))))))))) (CC but) (, ,) (S (ADVP (RB thus) (RB far)) (, ,) (NP (NNS chemicals)) (VP (AUX have) (RB not) (VP (VBN shown) (NP (DT this) (NN capacity))))) (. .)))
26002693	4	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN proposed) (SBAR (IN that) (S (NP (JJ Doc_26002693_573_586_Chemical) (NNS metabolites)) (VP (AUX be) (ADVP (RB so)) (VP (VBN tested) (PP (IN as) (NP (NP (DT a) (NN reality) (NN check)) (PP (IN on) (NP (DT the) (JJ epidemiological) (NNS reports))))))))))) (. .)))
26002693	5	(S1 (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB conduct) (NP (JJ reliable) (NN testing)) (PP (IN in) (NP (DT this) (NN regard))))))) (, ,) (NP (PRP it)) (VP (AUX is) (ADJP (JJ essential)) (SBAR (IN that) (S (NP (NP (DT a) (JJ positive) (NN control)) (PP (IN for) (NP (NN induction)))) (VP (AUX be) (ADJP (JJ available)))))) (. .)))
26002693	6	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBN used) (NP (NN ionizing) (NN radiation)) (S (VP (TO to) (VP (VB develop) (NP (PDT such) (DT a) (NN control))))))) (. .)))
26002693	7	(S1 (S (NP (NNS Results)) (VP (VP (VBD described) (SBAR (S (ADVP (RB here)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (DT this) (NN agent)) (VP (AUX does) (PP (IN in) (NP (NN fact))) (VP (VB induce) (NP (JJ pathogenic) (JJ t) (PRN (-LRB- -LRB-) (CD 9:22) (-RRB- -RRB-)) (NNS translocations)) (PP (IN in) (NP (NP (DT a) (JJ human) (NN myeloid) (NN cell) (NN line)) (PP (IN in) (NP (NN vitro))))))))))))) (, ,) (CC but) (VP (AUX does) (ADVP (RB so)) (PP (IN at) (NP (JJ low) (NNS frequencies))))) (. .)))
26002693	8	(S1 (S (NP (NP (NNS Conditions)) (SBAR (WHNP (WDT that)) (S (VP (MD will) (VP (AUX be) (VP (VBN required) (PP (IN for) (NP (NP (NNS studies)) (PP (IN of) (NP (NNP Doc_26002693_1067_1080_Chemical))))))))))) (VP (AUX are) (VP (VBN discussed))) (. .)))
26033014	0	(S1 (NP (NP (NP (NP (JJ Doc_26033014_0_6_Disease) (NN incidence)) (CC and) (NP (JJ Doc_26033014_21_32_Chemical) (NN use))) (PP (IN in) (NP (DT the) (NNP Agricultural) (NNP Health) (NNP Study)))) (: :) (NP (DT An) (NN update)) (. .)))
26033014	1	(S1 (S (NP (NP (NNP Doc_26033014_94_105_Chemical)) (, ,) (NP (DT a) (ADJP (RB widely) (VBN used)) (NN herbicide)) (, ,)) (VP (AUX is) (VP (VBN classified) (PP (IN as) (NP (NP (DT a) (NNP Group) (NNP C) (NN carcinogen)) (PP (IN by) (NP (NP (DT the) (NNP U.S.) (NNP Environmental) (NNP Protection) (NNP Agency)) (VP (VBN based) (PP (IN on) (NP (NP (VBN increased) (NN Doc_26033014_233_248_Disease)) (PP (IN in) (NP (JJ female) (NNS rats)))))))))))) (. .)))
26033014	2	(S1 (S (NP (NP (JJ Epidemiologic) (NNS studies)) (PP (IN of) (NP (NP (DT the) (NN health) (NNS effects)) (PP (IN of) (NP (NNP Doc_26033014_312_323_Chemical)))))) (VP (AUX have) (VP (AUX been) (VP (VBN limited)))) (. .)))
26033014	3	(S1 (S (NP (NP (DT The) (NNP Agricultural) (NNP Health) (NNP Study)) (PRN (-LRB- -LRB-) (INTJ (UH AHS)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (JJ prospective) (JJ cohort) (NN study)) (PP (VBG including) (NP (NP (JJ licensed) (UCP (JJ private) (CC and) (JJ commercial)) (NN pesticide) (NNS applicators)) (PP (IN in) (NP (NP (NNP Iowa)) (CC and) (NP (NP (NNP North) (NNP Carolina)) (VP (VBD enrolled) (NP (CD 1993-1997)))))))))) (. .)))
26033014	4	(S1 (S (S (NP (PRP We)) (VP (VBN evaluated) (NP (JJ Doc_26033014_533_539_Disease) (NN incidence)) (PP (IN through) (NP (NP (CD 2010/2011)) (PRN (-LRB- -LRB-) (NP (NNP NC/IA)) (-RRB- -RRB-)))) (PP (IN for) (NP (CD 49,616) (NNS applicators))))) (, ,) (NP (NP (CD 53) (NN %)) (WHPP (IN of) (WHNP (WP whom)))) (VP (VBD reported) (S (ADVP (RB ever)) (VP (VBG using) (NP (NNP Doc_26033014_632_643_Chemical))))) (. .)))
26033014	5	(S1 (S (NP (PRP We)) (VP (VBD used) (NP (NNP Poisson) (NN regression)) (S (VP (TO to) (VP (VB evaluate) (NP (NP (NNS relations)) (PP (IN between) (NP (NP (NP (NP (CD two) (NNS metrics)) (PP (IN of) (NP (JJ Doc_26033014_717_728_Chemical) (NN use)))) (PRN (-LRB- -LRB-) (NP (NN lifetime) (NNS days)) (, ,) (NP (JJ intensity-weighted) (NN lifetime) (NNS days)) (-RRB- -RRB-))) (CC and) (NP (JJ Doc_26033014_787_793_Disease) (NN incidence))))))))) (. .)))
26033014	6	(S1 (S (NP (PRP We)) (VP (VBD saw) (NP (NP (DT no) (NN association)) (PP (IN between) (NP (NP (NP (NP (NNP Doc_26033014_835_846_Chemical) (NX (NX (NN use)) (CC and) (NX (NN incidence)))) (PP (IN of) (NP (NP (DT all) (NN Doc_26033014_872_879_Disease)) (VP (VBN combined))))) (PRN (-LRB- -LRB-) (NP (NP (NNP n) (SYM =) (CD 5,701)) (PP (IN with) (NP (DT a) (JJ 5-year) (NN lag)))) (-RRB- -RRB-))) (CC or) (NP (ADJP (RBS most) (JJ site-specific)) (NNP Doc_26033014_941_948_Disease)))))) (. .)))
26033014	7	(S1 (S (PP (IN For) (NP (NNP Doc_26033014_954_966_Disease))) (, ,) (PP (IN in) (NP (NP (NNS analyses)) (VP (VBN restricted) (PP (TO to) (NP (JJ exposed) (NNS workers)))))) (, ,) (NP (NP (NNS elevations)) (VP (VBN observed) (PP (IN at) (NP (NP (JJR higher) (NNS categories)) (PP (IN of) (NP (NN use))))))) (VP (AUX were) (RB not) (ADJP (RB statistically) (JJ significant))) (. .)))
26033014	8	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NNS trends)) (PP (IN for) (NP (NP (UCP (DT both) (NN lifetime) (CC and) (JJ intensity-weighted)) (NN lifetime) (NNS days)) (PP (IN of) (NP (JJ Doc_26033014_1169_1179_Chemical) (NN use)))))) (VP (AUX were) (ADJP (ADJP (JJ positive)) (CC and) (ADJP (RB statistically) (JJ significant) (PP (IN with) (NP (DT an) (JJ unexposed) (NN reference) (NN group)))))) (. .)))
26033014	9	(S1 (S (S (NP (DT A) (JJ similar) (NN pattern)) (VP (AUX was) (VP (VBN observed) (PP (IN for) (NP (NNP Doc_26033014_1298_1322_Disease)))))) (, ,) (CC but) (S (NP (DT no) (JJ other) (NN Doc_26033014_1337_1345_Disease)) (VP (VBZ subtypes))) (. .)))
26033014	10	(S1 (S (NP (NP (DT An) (JJR earlier) (NN suggestion)) (PP (IN of) (NP (JJ Doc_26033014_1381_1402_Disease) (NN risk))) (PP (IN at) (NP (NP (JJ high) (NNS levels)) (PP (IN of) (NP (JJ Doc_26033014_1426_1437_Chemical) (NN use))))) (PP (IN in) (NP (DT this) (NN cohort)))) (VP (AUX was) (RB not) (VP (VBN confirmed) (PP (IN in) (NP (DT this) (NN update))))) (. .)))
26033014	11	(S1 (S (NP (NP (DT This) (NN suggestion)) (PP (IN of) (NP (NP (DT an) (NN association)) (PP (IN between) (NP (NNP Doc_26033014_1533_1544_Chemical) (CC and) (NNP Doc_26033014_1549_1561_Disease))))) (PP (IN among) (NP (NN pesticide) (NNS applicators)))) (VP (AUX is) (NP (NP (NP (DT a) (JJ novel) (NN finding)) (CC and) (NP (NNS echoes) (NN observation))) (PP (IN of) (NP (NP (VBN increased) (NN Doc_26033014_1645_1660_Disease)) (PP (IN in) (NP (DT some) (NN animal) (NNS studies))))))) (. .)))
26033014	12	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (PRP$ our) (NNS findings)) (PP (IN for) (NP (DT both) (NNP Doc_26033014_1716_1728_Disease) (CC and) (NNP Doc_26033014_1733_1757_Disease)))) (VP (VBP warrant) (NP (NP (NN follow-up)) (SBAR (S (VP (TO to) (ADVP (RB better)) (VP (VB differentiate) (NP (NP (NNS effects)) (PP (IN of) (NP (JJ Doc_26033014_1811_1822_Chemical) (NN use))) (PP (IN from) (NP (JJ other) (NNS factors)))))))))) (. .)))
26115410	0	(S1 (NP (NP (NP (NNS Mechanisms) (VBG Underlying) (NN Latent) (NNP Disease) (NNP Risk) (NNP Associated)) (PP (IN with) (NP (JJ Early-Life) (JJ Doc_26115410_69_76_Chemical) (NN Exposure)))) (: :) (NP (NP (JJ Current) (NN Research) (NNS Trends)) (CC and) (NP (NNP Scientific) (NNP Gaps))) (. .)))
26115410	1	(S1 (S (NP (NP (NP (NNS Millions)) (PP (IN of) (NP (NNS individuals))) (NP (NNP worldwide))) (, ,) (NP (NP (RB particularly) (DT those)) (VP (VBG living) (PP (IN in) (NP (JJ rural) (CC and) (VBG developing) (NNS areas))))) (, ,)) (VP (AUX are) (VP (VBN exposed) (PP (TO to) (NP (NP (JJ harmful) (NNS levels)) (PP (IN of) (NP (NP (JJ inorganic) (NNP Doc_26115410_279_286_Chemical)) (PRN (-LRB- -LRB-) (INTJ (UH iAs)) (-RRB- -RRB-)))) (PP (IN in) (NP (PRP$ their) (NN drinking) (NN water))))))) (. .)))
26115410	2	(S1 (S (NP (NP (NN Inorganic)) (PP (IN As) (NP (NN exposure))) (PP (IN during) (NP (JJ key) (JJ developmental) (NNS periods)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (JJ adverse) (NN health) (NNS effects))) (PP (VBG including) (NP (NP (DT those)) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (ADJP (JJ evident)) (PP (IN in) (NP (NN adulthood)))))))))))) (. .)))
26115410	3	(S1 (S (NP (EX There)) (VP (AUX is) (NP (NP (JJ considerable) (NN interest)) (PP (IN in) (S (VP (VBG identifying) (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (SBAR (WHNP (WDT that)) (S (VP (VBP relate) (NP (NP (JJ early-life) (NN iAs) (NN exposure)) (PP (TO to) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT these) (NN latent) (NNS diseases)))))))))))))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (NP (NN relationship)) (PP (TO to) (NP (NNP Doc_26115410_659_665_Disease)))))) (. .)))
26115410	4	(S1 (S (NP (DT This) (NN work)) (VP (VBZ summarizes) (NP (NP (NN research)) (PP (IN on) (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (SBAR (WHNP (WDT that)) (S (VP (VB underlie) (NP (NP (DT the) (VBN increased) (NN risk)) (PP (IN of) (NP (JJ Doc_26115410_773_779_Disease) (NN development)))) (PP (IN in) (NP (NP (NN adulthood)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (JJ early-life) (JJ iAs) (NN exposure)))))))))))))))) (. .)))
26115410	5	(S1 (S (NP (NP (JJ Epigenetic) (NN reprogramming)) (SBAR (WHNP (WDT that)) (S (VP (VBZ imparts) (NP (NP (JJ functional) (NNS changes)) (PP (IN in) (NP (NP (NN gene) (NN expression)) (, ,) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ Doc_26115410_962_968_Disease) (NN stem) (NNS cells)))) (, ,) (CC and) (NP (NN immunomodulation))))))))) (VP (AUX are) (NP (NP (JJ plausible) (VBG underlying) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (JJ early-life) (NN iAs) (NN exposure)) (VP (VBZ elicits) (NP (NN latent) (JJ carcinogenic) (NNS effects))))))) (. .)))
26115410	6	(S1 (S (NP (NN Evidence)) (VP (AUX is) (VP (VBG mounting) (SBAR (WHNP (WDT that)) (S (VP (VBZ relates) (NP (NP (JJ early-life) (NN iAs) (NN exposure)) (CC and) (NP (JJ Doc_26115410_1183_1189_Disease) (NN development))) (ADVP (RB later) (PP (IN in) (NP (NN life))))))))) (. .)))
26115410	7	(S1 (S (NP (JJ Future) (NN research)) (VP (MD should) (VP (VB include) (NP (NP (NN animal) (NNS studies)) (SBAR (WHNP (WDT that)) (S (VP (VBP address) (NP (NP (JJ mechanistic) (NNS hypotheses) (CC and) (NNS studies)) (PP (IN of) (NP (JJ human) (NNS populations))) (SBAR (WHNP (WDT that)) (S (VP (VB integrate) (NP (NP (JJ early-life) (NN exposure)) (, ,) (NP (JJ molecular) (NNS alterations)) (, ,) (CC and) (NP (NN latent) (NN disease) (NNS outcomes))))))))))))) (. .)))
2614930	0	(S1 (S (NP (NN Doc_2614930_0_10_Chemical)) (VP (VBN induced) (NP (NNP Doc_2614930_19_30_Disease)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_2614930_49_69_Disease)))))) (. .)))
2614930	1	(S1 (S (NP (NP (DT An) (ADJP (CD 80) (NN year)) (JJ old) (NN Doc_2614930_86_99_Disease)) (PP (IN with) (NP (NP (NN evidence)) (PP (IN of) (NP (NNP Doc_2614930_117_152_Disease)))))) (VP (AUX was) (VP (VBN admitted) (PP (IN with) (NP (NNP Doc_2614930_171_181_Disease))))) (. .)))
2614930	2	(S1 (S (NP (PRP He)) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX have) (NP (NN Doc_2614930_204_218_Disease)) (PP (IN at) (NP (NP (DT a) (JJ ventricular) (NN rate)) (PP (IN of) (NP (NN 70/min))) (SBAR (WHNP (WDT which)) (S (VP (VBD slowed) (ADVP (RB down)) (S (VP (TO to) (VP (VB 30-40/min) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_2614930_287_297_Chemical)) (VP (PRN (-LRB- -LRB-) (NP (CD 60) (NN mg)) (-RRB- -RRB-)) (PP (IN in) (NP (NP (CD 3) (VBN divided) (NNS doses)) (, ,) (SBAR (WHPP (IN during) (WHNP (WDT which))) (S (NP (PRP he)) (VP (AUX was) (VP (VBN paced) (PP (IN at) (NP (NP (DT a) (NN rate)) (PP (IN of) (NP (NN 70/min))))))))))))))))))))))))))) (. .)))
2614930	3	(S1 (S (NP (DT This)) (VP (AUX is) (ADJP (JJ inconsistent) (PP (IN with) (NP (NP (DT the) (JJ well-established) (NN finding)) (SBAR (WHNP (WDT that)) (S (NP (NNP Doc_2614930_433_443_Chemical)) (VP (VBZ induces) (NP (NNP Doc_2614930_452_463_Disease)) (PP (IN in) (NP (ADJP (RB normally) (VBN innervated)) (NNS hearts)))))))))) (. .)))
2614930	4	(S1 (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (NP (NNS hearts)) (VP (VBN deprived) (PP (IN of) (NP (JJ compensatory) (JJ sympathetic) (NN drive)))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NNP Doc_2614930_573_584_Disease))))) (. .)))
2625524	0	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_2625524_14_25_Chemical)) (PP (IN in) (NP (NP (NNP Doc_2625524_29_36_Chemical)) (CC and) (NP (NNP Doc_2625524_41_52_Chemical))))))) (VP (VBP intoxication)) (. .)))
2625524	1	(S1 (S (NP (NP (DT The) (NN effectiveness)) (PP (IN of) (NP (JJ Doc_2625524_88_99_Chemical) (NN pretreatment))) (PP (IN in) (S (VP (VBG preventing) (NP (NP (DT the) (JJ toxic) (NNS effects)) (PP (IN of) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_2625524_162_173_Chemical)) (CC and) (NP (NNP Doc_2625524_178_185_Chemical))))))))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NNS rats))))) (. .)))
2625524	2	(S1 (S (PP (IN In) (NP (DT this) (NN model))) (, ,) (NP (JJ toxic) (NNS effects)) (VP (AUX were) (VP (VBN induced) (PP (IN by) (NP (NP (JJ intraperitoneal) (-LRB- -LRB-) (NN i.p.) (-RRB- -RRB-) (NN injection)) (PP (IN of) (NP (NP (NP (NNP Doc_2625524_288_299_Chemical) (CD 75) (NNS mg/kg)) (PRN (-LRB- -LRB-) (NP (NP (CD 100) (NN %)) (NP (JJ Doc_2625524_315_320_Disease) (NN rate))) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_2625524_330_337_Chemical) (CD 70) (NNS mg/kg)) (PRN (-LRB- -LRB-) (NP (NP (CD 82) (NN %)) (NP (JJ Doc_2625524_352_357_Disease) (NN rate))) (-RRB- -RRB-))))))))) (. .)))
2625524	3	(S1 (S (S (NP (NN Doc_2625524_365_376_Chemical)) (VP (VBD failed) (S (VP (TO to) (VP (VB prevent) (NP (JJ Doc_2625524_395_406_Chemical-induced) (NNP Doc_2625524_415_423_Disease))))))) (, ,) (CC but) (S (VP (AUX did) (VP (VB lower) (NP (DT the) (NN mortality) (NN rate)) (PP (IN at) (NP (NP (JJS most) (NNS doses)) (VP (VBN tested))))))) (. .)))
2625524	4	(S1 (S (S (NP (NN Doc_2625524_480_491_Chemical)) (VP (VBD decreased) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_2625524_519_526_Chemical-induced) (NNP Doc_2625524_535_543_Disease))) (PP (IN at) (NP (DT the) (CD two) (JJS highest) (NNS doses)))))) (, ,) (CC but) (S (NP (NP (DT the) (VBG lowering)) (PP (IN of) (NP (DT the) (NN mortality) (NN rate)))) (VP (AUX did) (RB not) (VP (VB reach) (NP (JJ statistical) (NN significance)) (PP (IN at) (NP (DT any) (NN dose)))))) (. .)))
2625524	5	(S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (NP (NP (DT a) (JJ protective) (NN role)) (PP (IN for) (NP (NP (DT the) (JJ central) (JJ Doc_2625524_714_722_Chemical) (NN blocker) (NN Doc_2625524_731_742_Chemical)) (PP (IN against) (NP (NNP Doc_2625524_751_756_Disease))) (PP (IN from) (NP (JJ high-dose) (JJ Doc_2625524_772_783_Chemical) (NN exposure)))))) (PP (IN without) (S (VP (VBG reducing) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_2625524_827_835_Disease)))))))) (. .)))
2625524	6	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NNP Doc_2625524_850_861_Chemical)) (VP (VBD demonstrated) (NP (DT an) (NN ability) (S (VP (TO to) (VP (VB reduce) (NP (JJ Doc_2625524_896_903_Chemical-induced) (NN Doc_2625524_912_920_Disease)) (PP (IN without) (S (VP (ADVP (RB significantly)) (VBG reducing) (NP (NN mortality)))))))))) (. .)))
2650911	0	(S1 (S (NP (NP (JJ Autoradiographic) (NN evidence)) (PP (IN of) (NP (NP (JJ Doc_2650911_29_37_Chemical) (JJ binding) (NNS sites)) (PP (IN in) (NP (NP (NNS nuclei)) (PP (IN of) (NP (NNP Doc_2650911_65_84_Chemical)))))))) (VP (VBN induced) (NP (JJ hamster) (NNP Doc_2650911_101_117_Disease))) (. .)))
2650911	1	(S1 (S (S (NP (JJ Doc_2650911_119_127_Chemical) (JJ binding) (NNS sites)) (VP (AUX were) (VP (VBN demonstrated) (PP (IN by) (NP (NN autoradiography))) (PP (IN in) (NP (CD one) (NN transplantable)))))) (CC and) (S (NP (CD five) (JJ primary) (NN Doc_2650911_218_237_Chemical)) (VP (VBN induced) (NP (NNP Doc_2650911_246_262_Disease)) (PP (IN in) (NP (CD three) (NNS hamsters))))) (. .)))
2650911	2	(S1 (S (S (NP (NP (NN Radiolabelling)) (, ,) (VP (VBG following) (NP (NP (DT the) (RB in) (JJ vivo) (NN injection)) (PP (IN of) (NP (NNP Doc_2650911_333_353_Chemical))))) (, ,)) (VP (AUX was) (VP (VBN increased) (ADVP (RB only)) (PP (IN over) (NP (NP (DT the) (NN nuclei)) (PP (IN of) (NP (JJ Doc_2650911_393_398_Disease) (NNS cells)))))))) (: ;) (S (NP (JJ stereologic) (NN analysis)) (VP (VBD revealed) (NP (NP (DT a) (NN 4.5-)) (PP (TO to) (NP (NP (ADJP (JJ 6.7-times) (JJR higher)) (NN concentration)) (PP (IN of) (NP (VBN reduced) (NNP Doc_2650911_488_494_Chemical) (NNS grains))) (PP (IN over) (NP (FW nuclei))))) (PP (IN than) (NP (NP (NN cytoplasm)) (PP (IN of) (NP (DT these) (NNS cells)))))))) (. .)))
2650911	3	(S1 (S (PP (IN Despite) (NP (NP (JJ rapid) (JJ tubular) (NN excretion)) (PP (IN of) (NP (NNP Doc_2650911_580_589_Chemical))) (SBAR (WHNP (WDT which)) (S (VP (VBD peaked) (PP (IN in) (NP (QP (JJR less) (IN than) (CD 1)) (NNP h)))))))) (, ,) (NP (DT the) (JJ normal) (NNS cells)) (VP (AUX did) (RB not) (VP (VB appear) (PP (TO to) (NP (NN bind))) (NP (DT the) (NN ligand)))) (. .)))
2650911	4	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (JJ published) (NN report)) (VP (VBG documenting) (NP (DT the) (JJ preferential)) (PP (IN in) (NP (NP (NN vivo) (VBG binding)) (PP (IN of) (NP (NNP Doc_2650911_756_764_Chemical))) (PP (TO to) (NP (NP (NN nuclei)) (PP (IN of) (NP (NP (NNS cells)) (PP (IN in) (NP (NNP Doc_2650911_787_795_Chemical))))) (VP (VBN induced) (NP (JJ hamster) (NNP Doc_2650911_812_828_Disease)))))))))) (. .)))
2710809	0	(S1 (S (VP (VB Doc_2710809_0_11_Disease) (ADJP (JJ due) (S (VP (TO to) (VP (VB biperiden)))))) (. .)))
2710809	1	(S1 (S (PP (IN In) (NP (NP (DT a) (JJ 38-year-old) (NN male) (NN patient)) (VP (VBG suffering) (PP (IN from) (NP (DT a) (JJ severe) (NN Doc_2710809_84_117_Disease)))))) (, ,) (NP (NP (JJ intravenous) (NN application)) (PP (IN of) (NP (CD 10) (NN mg) (NNP Doc_2710809_152_169_Chemical)))) (VP (VBD led) (PP (TO to) (NP (NP (DT a) (JJ long-lasting) (JJ paradoxical) (NN reaction)) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ considerable) (NNP Doc_2710809_243_254_Disease)) (, ,) (NP (NNP Doc_2710809_256_266_Disease)) (, ,) (CC and) (NP (NNP Doc_2710809_272_281_Disease)))))))) (. .)))
2710809	2	(S1 (S (NP (DT The) (NN heart) (NN rate)) (VP (AUX was) (ADVP (RB back) (PP (TO to) (NP (JJ normal)))) (PP (IN within) (NP (CD 12) (NNS hours))) (PP (IN upon) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_2710809_356_369_Chemical))))) (PP (IN under) (NP (NP (JJ cardiac) (NN monitoring)) (PP (IN in) (NP (DT an) (JJ intensive) (NN care) (NN unit)))))) (. .)))
2710809	3	(S1 (S (NP (NP (NN Doc_2710809_422_433_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2710809_445_454_Chemical))))) (VP (AUX is) (VP (VBN attributed) (PP (PP (TO to) (NP (NP (DT the) (NN speed)) (PP (IN of) (NP (NN injection))))) (CC and) (PP (TO to) (NP (NP (DT a) (JJ dose-related) (JJ dual) (NN effect)) (PP (IN of) (NP (JJ Doc_2710809_532_540_Chemical-like) (NNS drugs))) (PP (IN on) (NP (JJ muscarine) (NNS receptors)))))))) (. .)))
2718706	0	(S1 (S (NP (JJ Deliberate) (NNP Doc_2718706_11_22_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_2718706_34_43_Chemical))) (PP (IN with) (NP (NP (NNP Doc_2718706_49_58_Chemical)) (, ,) (NP (NNP Doc_2718706_60_69_Chemical)) (CC or) (NP (NNP Doc_2718706_73_83_Chemical)))) (PP (IN for) (NP (JJ middle-ear) (NN surgery)))) (. .)))
2718706	1	(S1 (S (NP (NP (DT The) (NN feasibility)) (PP (IN of) (S (VP (VBG using) (NP (NP (NNP Doc_2718706_133_142_Chemical)) (, ,) (NP (DT an) (ADJP (JJ alpha-) (CC and) (JJ beta-adrenergic)) (VBG blocking) (NN agent)) (, ,)) (PP (IN as) (NP (NP (DT a) (JJ Doc_2718706_195_206_Disease) (NN agent)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (JJ inhalation) (NNS anaesthetics)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2718706_258_267_Chemical) (, ,) (NNP Doc_2718706_269_278_Chemical) (CC or) (NNP Doc_2718706_282_292_Chemical)) (-RRB- -RRB-)))))))))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NP (CD 23) (NN adult) (NNS patients)) (VP (VBG undergoing) (NP (JJ middle-ear) (NN surgery))))))) (. .)))
2718706	2	(S1 (S (NP (DT The) (JJ mean) (JJ arterial) (NN pressure)) (VP (AUX was) (VP (VBN decreased) (PP (IN from) (NP (NP (CD 86) (NNS +/-)) (SBAR (S (NP (NP (CD 5)) (PRN (-LRB- -LRB-) (FW s.e.) (VP (VB mean)) (-RRB- -RRB-))) (VP (VBD mmHg) (PP (TO to) (NP (NP (CD 52) (NN +/-) (QP (CD 1) (CD mmHg))) (PRN (-LRB- -LRB-) (NP (NP (CD 11.5) (NN +/-) (QP (CD 0.7) (TO to) (CD 6.9) (NN +/-))) (NP (CD 0.1) (NN kPa))) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (NP (CD 98) (NNS +/-)) (NP (CD 10) (NN min))) (PP (IN in) (NP (DT the) (NNP Doc_2718706_506_515_Chemical) (PRN (-LRB- -LRB-) (NP (NNP H)) (-RRB- -RRB-)) (NN group))) (, ,) (PP (IN from) (NP (NP (CD 79) (NNS +/-)) (NP (QP (CD 5) (TO to) (CD 53) (NN +/-)) (QP (CD 1) (CD mmHg))))))) (PRN (-LRB- -LRB-) (NP (CD 10.5) (NN +/-) (QP (CD 0.7) (TO to) (CD 7.1) (NN +/-))) (NP (CD 0.1) (NN kPa)) (-RRB- -RRB-)) (PP (IN for) (NP (NP (NP (CD 129) (NNS +/-)) (NP (CD 11) (NN min))) (PP (PP (IN in) (NP (DT the) (NNP Doc_2718706_618_627_Chemical) (PRN (-LRB- -LRB-) (NP (NNP E)) (-RRB- -RRB-)) (NN group))) (, ,) (CC and) (PP (IN from) (NP (NP (CD 80) (NN +/-)) (NP (QP (CD 4) (TO to) (CD 49)) (JJ +/-) (CD 1) (NNS mmHg))))))) (PRN (-LRB- -LRB-) (NP (QP (CD 10.7) (JJ +/-) (CD 0.5) (TO to) (CD 6.5) (NN +/-))) (NP (CD 0.1) (NN kPa)) (-RRB- -RRB-)) (PP (IN for) (NP (NP (NP (CD 135) (NNS +/-)) (NP (CD 15) (NN min))) (PP (IN in) (NP (DT the) (NNP Doc_2718706_734_744_Chemical) (PRN (-LRB- -LRB-) (NNP I) (-RRB- -RRB-)) (NN group)))))))))))) (. .)))
2718706	3	(S1 (S (NP (NP (DT The) (JJ mean) (NNP H) (NN concentration)) (PP (IN during) (NP (NNP Doc_2718706_788_799_Disease))) (PP (IN in) (NP (DT the) (JJ inspiratory) (NN gas)))) (VP (AUX was) (NP (NP (CD 0.7) (NN +/-) (CD 0.1) (NN vol) (NN %)) (, ,) (NP (NP (NP (NP (NP (DT the) (JJ mean) (NN E) (NN concentration)) (CD 1.6) (NN +/-) (CD 0.2) (NN vol) (NN %)) (, ,) (CC and) (NP (DT the) (JJ mean) (CD I) (NN concentration))) (NP (CD 1.0) (NNS +/-))) (CD 0.1) (NN vol) (NN %)))) (. .)))
2718706	4	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (DT the) (NNS patients)) (VP (VBD received) (NP (NP (NNP Doc_2718706_970_978_Chemical)) (CC and) (NP (NNP Doc_2718706_983_997_Chemical)))) (. .)))
2718706	5	(S1 (S (NP (NP (DT The) (JJ initial) (NN dose)) (PP (IN of) (NP (NNP Doc_2718706_1019_1028_Chemical))) (PP (IN for) (S (VP (VBG lowering) (NP (NN blood) (NN pressure)))))) (VP (AUX was) (ADJP (JJ similar) (, ,) (QP (CD 0.52-0.59) (CD mg/kg))) (, ,) (PP (IN in) (NP (PDT all) (DT the) (NNS groups)))) (. .)))
2718706	6	(S1 (S (PP (IN During) (NP (NN Doc_2718706_1113_1124_Disease))) (, ,) (NP (DT the) (NN heart) (NN rate)) (VP (AUX was) (ADJP (JJ stable)) (PP (IN without) (NP (NP (NN tachy-)) (CC or) (NP (NN Doc_2718706_1170_1181_Disease))))) (. .)))
2718706	7	(S1 (S (NP (NP (DT The) (VBG operating) (NNS conditions)) (VP (VBG regarding) (NP (NN bleeding)))) (VP (VP (AUX were) (VP (VBN estimated) (PP (IN in) (NP (DT a) (JJ double-blind) (NN manner))))) (, ,) (CC and) (VP (AUX did) (RB not) (VP (VB differ) (ADVP (RB significantly)) (PP (IN between) (NP (DT the) (NNS groups)))))) (. .)))
2718706	8	(S1 (S (PP (IN During) (NP (NNP Doc_2718706_1328_1339_Disease))) (, ,) (NP (DT the) (JJ serum) (JJ Doc_2718706_1351_1361_Chemical) (NN concentration)) (VP (VP (VBD rose) (ADVP (RB significantly)) (PP (IN in) (NP (NP (DT all) (NNS groups)) (PP (IN from) (NP (NP (DT the) (NNS values)) (PP (IN before) (NP (NNP Doc_2718706_1432_1443_Disease)))))))) (CC and) (VP (VBD returned) (ADVP (RB postoperatively)) (PP (TO to) (NP (NP (DT the) (JJ initial) (NN level)) (PP (IN in) (NP (NP (DT the) (JJ other) (NNS groups)) (, ,) (PP (IN except) (NP (DT the) (NNP Doc_2718706_1526_1536_Chemical) (NN group))))))))) (. .)))
2718706	9	(S1 (S (PP (IN After) (NP (NNP Doc_2718706_1550_1561_Disease))) (NP (EX there)) (VP (AUX was) (NP (DT no) (NN rebound) (NN phenomenon)) (PP (IN in) (NP (DT either) (NP (NN blood) (NN pressure)) (CC or) (NP (NN heart) (NN rate))))) (. .)))
2718706	10	(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NNP Doc_2718706_1662_1671_Chemical)) (VP (VBZ induces) (NP (ADJP (RB easily) (JJ adjustable)) (NN Doc_2718706_1698_1709_Disease)) (PP (IN without) (NP (NP (NN Doc_2718706_1718_1742_Disease)) (CC and) (NP (NP (NN rebound)) (NP (NNP Doc_2718706_1755_1767_Disease))))))))) (. .)))
2765447	0	(S1 (S (VP (VB Doc_2765447_0_10_Disease) (S (VP (VBG following) (NP (JJ intravenous) (JJ Doc_2765447_33_44_Chemical) (NN angiography))))) (. .)))
2765447	1	(S1 (S (NP (NN Doc_2765447_58_79_Disease)) (VP (VBD followed) (NP (NP (JJ intravenous) (JJ Doc_2765447_101_112_Chemical) (NN injection)) (PP (IN for) (NP (JJ fundus) (NN angiography)))) (PP (IN in) (NP (DT a) (JJ 47-year-old) (NN male)))) (. .)))
2765447	2	(S1 (S (PP (IN Despite) (NP (NNS precautions))) (NP (DT this) (JJ adverse) (NN reaction)) (VP (VBD recurred) (PP (IN on) (NP (NN re-exposure))) (PP (TO to) (NP (JJ intravenous) (NNP Doc_2765447_250_261_Chemical)))) (. .)))
2767010	0	(S1 (NP (NP (NP (NN Pharmacology)) (PP (IN of) (NP (NNP Doc_2767010_16_24_Chemical)))) (PRN (-LRB- -LRB-) (NP (JJ Doc_2767010_26_35_Chemical) (NN prodrug)) (-RRB- -RRB-)) (. .)))
2767010	1	(S1 (S (NP (NP (NN Doc_2767010_46_54_Chemical)) (, ,) (NP (NP (DT the) (NNP Doc_2767010_60_84_Chemical)) (PP (IN of) (NP (NNP Doc_2767010_88_125_Chemical)))) (, ,)) (VP (AUX is) (NP (NP (DT a) (NN prodrug)) (PP (IN of) (NP (NNP Doc_2767010_143_152_Chemical))) (PP (IN with) (NP (JJ advantageous) (JJ physicochemical) (NNS properties))))) (. .)))
2767010	2	(S1 (S (NP (NN Doc_2767010_199_207_Chemical)) (VP (AUX is) (ADVP (RB rapidly)) (VP (VBN converted) (ADVP (RB enzymatically)) (PP (TO to) (NP (NNP Doc_2767010_246_255_Chemical))) (PP (IN in) (NP (NN vivo))))) (. .)))
2767010	3	(S1 (S (NP (NNP Doc_2767010_265_273_Chemical) (CC and) (NNP Doc_2767010_278_294_Chemical)) (VP (AUX have) (S (NP (NP (JJ equivalent) (NN anticonvulsant) (NN activity)) (PP (IN against) (NP (NNP Doc_2767010_343_351_Disease)))) (VP (VBN induced) (PP (IN by) (NP (NP (JJ maximal) (NN electroshock)) (PRN (-LRB- -LRB-) (NP (NNP MES)) (-RRB- -RRB-)))) (PP (IN in) (NP (NNS mice))) (PP (VBG following) (NP (NP (NN i.p.)) (, ,) (NP (JJ oral)) (, ,) (CC or) (NP (NN i.v.) (NN administration))))))) (. .)))
2767010	4	(S1 (S (NP (DT The) (CD ED50) (NNS doses)) (VP (AUX were) (NP (NP (NP (CD 16) (NN mg/kg)) (PP (IN for) (NP (NNP i.v.) (NNP Doc_2767010_482_490_Chemical)))) (CC and) (NP (NP (CD 8) (NN mg/kg)) (PP (IN for) (NP (NNP i.v.) (NNP Doc_2767010_512_528_Chemical)))))) (. .)))
2767010	5	(S1 (S (NP (NP (NNP Doc_2767010_530_538_Chemical)) (CC and) (NP (NNP Doc_2767010_543_559_Chemical))) (VP (AUX have) (NP (JJ similar) (JJ antiarrhythmic) (NN activity)) (PP (IN against) (NP (NP (NNP Doc_2767010_605_612_Chemical-induced) (NNP Doc_2767010_621_644_Disease)) (PP (IN in) (NP (JJ anesthetized) (NNS dogs)))))) (. .)))
2767010	6	(S1 (S (NP (NP (NP (DT The) (JJ total) (NNS doses)) (PP (IN of) (NP (NNP Doc_2767010_686_694_Chemical) (CC or) (NNP Doc_2767010_698_714_Chemical)))) (ADJP (JJ necessary) (S (VP (TO to) (VP (VB convert) (NP (DT the) (NNP Doc_2767010_740_750_Disease)) (PP (TO to) (NP (DT a) (JJ normal) (JJ sinus) (NN rhythm)))))))) (VP (AUX were) (NP (CD 24) (ADJP (JJ +/-) (NP (CD 6) (CC and) (CD 14))) (JJ +/-) (CD 3) (NN mg/kg)) (, ,) (ADVP (RB respectively))) (. .)))
2767010	7	(S1 (S (NP (RB Only) (NNP Doc_2767010_829_845_Chemical)) (VP (VBD displayed) (PP (IN in) (NP (NP (NN vitro) (NN antiarrhythmic) (NN activity)) (PP (IN against) (NP (JJ Doc_2767010_897_911_Chemical-induced) (NNP Doc_2767010_920_931_Disease))))) (PP (IN in) (NP (NN guinea) (NN pig) (JJ right) (NNS atria)))) (. .)))
2767010	8	(S1 (S (PP (IN In) (NP (JJ anesthetized) (NNS dogs))) (, ,) (S (NP (NP (DT a) (JJ high) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_2767010_996_1004_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 31) (NN mg/kg)) (-RRB- -RRB-))))) (VP (AUX was) (VP (VBN infused) (PP (IN over) (NP (NP (CD 15)) (, ,) (NP (CD 20)) (, ,) (CC and) (NP (CD 30) (NN min))))))) (CC and) (S (NP (DT the) (NNS responses)) (VP (AUX were) (PP (VBN compared) (PP (TO to) (NP (NP (DT an) (JJ equimolar) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_2767010_1108_1124_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 21) (NN mg/kg)) (-RRB- -RRB-))))))))) (. .)))
2767010	9	(S1 (S (NP (DT The) (NNP Doc_2767010_1141_1149_Chemical) (CC and) (NNP Doc_2767010_1154_1170_Chemical) (NNS treatments)) (VP (VBD produced) (NP (NP (JJ similar) (JJ marked) (NN Doc_2767010_1206_1244_Disease)) (CC and) (NP (NP (JJ contractile) (NN force)) (PRN (-LRB- -LRB-) (NP (NNP LVdP/dt)) (-RRB- -RRB-))))) (. .)))
2767010	10	(S1 (S (NP (NP (DT The) (JJ maximum) (NNS effects)) (PP (IN of) (NP (DT each) (NN treatment)))) (VP (VBD occurred) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (JJ maximum) (JJ Doc_2767010_1348_1364_Chemical) (NNS levels)))))) (. .)))
2767010	11	(S1 (S (NP (NP (JJ Acute) (JJ Doc_2767010_1379_1387_Disease) (NNS studies)) (PP (IN of) (NP (NNP Doc_2767010_1399_1407_Chemical) (CC and) (NNP Doc_2767010_1412_1428_Chemical)))) (VP (AUX were) (VP (VBN carried) (PRT (RP out)) (PP (IN in) (NP (NP (NNS mice)) (, ,) (NP (NNS rats)) (, ,) (NP (NNS rabbits)) (, ,) (CC and) (NP (NNS dogs)))) (PP (IN by) (NP (NP (NN i.v.)) (, ,) (NP (NNP i.m.)) (, ,) (CC and) (NP (NP (JJ i.p.) (NNS routes)) (PP (IN of) (NP (NN administration)))))))) (. .)))
2767010	12	(S1 (S (NP (NP (DT The) (JJ systemic) (JJ toxic) (NNS signs)) (PP (IN of) (NP (DT both) (NNS agents)))) (VP (VP (AUX were) (ADJP (JJ similar))) (CC and) (VP (VBD occurred) (PP (IN at) (NP (ADJP (RB approximately) (JJ equivalent)) (NNS doses))))) (. .)))
2767010	13	(S1 (S (ADVP (RB Importantly)) (, ,) (NP (NP (DT the) (JJ local) (NN irritation)) (PP (IN of) (NP (NNP Doc_2767010_1667_1675_Chemical)))) (VP (AUX was) (ADJP (ADJP (RB markedly) (JJR less)) (PP (IN than) (NP (NP (JJ Doc_2767010_1699_1715_Chemical) (JJ following) (NNP i.m.) (NNS administration.)) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-))))))))
2782734	0	(S1 (S (NP (NP (NNS Tachyphylaxis)) (PP (PP (TO to) (NP (JJ systemic))) (CC but) (RB not) (PP (TO to) (NP (JJ airway) (NNS responses)))) (PP (IN during) (NP (NP (JJ prolonged) (NN therapy)) (PP (IN with) (NP (JJ high) (NN dose)))))) (VP (VBD inhaled) (NP (NNP Doc_2782734_102_112_Chemical)) (PP (IN in) (NP (NNS asthmatics)))) (. .)))
2782734	1	(S1 (S (NP (NP (JJ High) (NNS doses)) (PP (IN of) (NP (JJ inhaled) (NNP Doc_2782734_150_160_Chemical)))) (VP (VP (VBP produce) (NP (NP (JJ substantial) (NNS improvements)) (PP (IN in) (NP (NP (JJ airway) (NN response)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_2782734_230_236_Disease))))))))) (, ,) (CC and) (VP (AUX are) (VP (VBN associated) (PP (IN with) (NP (JJ dose-dependent) (JJ systemic) (NN beta-adrenoceptor) (NNS responses)))))) (. .)))
2782734	2	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB investigate) (SBAR (IN whether) (S (NP (NN tachyphylaxis)) (VP (VBZ occurs) (PP (IN during) (NP (NP (JJ prolonged) (NN treatment)) (PP (IN with) (NP (NP (JJ high) (NN dose)) (VP (VBD inhaled) (NP (NNP Doc_2782734_446_456_Chemical)))))))))))))) (. .)))
2782734	3	(S1 (S (NP (NP (NP (CD Twelve) (NNP Doc_2782734_465_474_Disease) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NNP FEV1)) (, ,) (NP (NP (CD 81) (NN +/-)) (SBAR (S (NP (CD 4) (NN %)) (VP (VBD predicted))))) (-RRB- -RRB-))) (, ,) (VP (VBG requiring) (NP (JJ only) (JJ occasional) (JJ inhaled) (NNS beta-agonists)) (PP (IN as) (NP (PRP$ their) (JJ sole) (NN therapy)))) (, ,)) (VP (AUX were) (VP (VBN given) (NP (NP (DT a) (JJ 14-day) (NN treatment)) (PP (IN with) (NP (NP (JJ high) (NN dose)) (VP (VBN inhaled) (S (NP (NP (NNP Doc_2782734_637_647_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2782734_649_652_Disease)) (-RRB- -RRB-)) (, ,) (ADJP (NP (CD 4,000) (NNS micrograms)) (JJ daily)) (, ,) (NP (NP (JJ low) (NN dose)) (VP (VBN inhaled) (NP (NP (NP (NNP Doc_2782734_696_706_Chemical)) (PRN (-LRB- -LRB-) (INTJ (UH LDS)) (-RRB- -RRB-)) (, ,) (ADJP (NP (CD 800) (NNS micrograms)) (JJ daily)) (, ,)) (CC or) (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (NN PI)) (-RRB- -RRB-)))) (PP (IN by) (NP (NP (JJ metered-dose) (NN inhaler)) (PP (IN in) (NP (DT a) (JJ double-blind) (, ,) (JJ randomized) (NN crossover) (NN design))))))))))))))) (. .)))
2782734	4	(S1 (S (PP (PP (IN During) (NP (DT the) (JJ 14-day) (NN run-in))) (CC and) (PP (IN during) (NP (NN washout) (NNS periods)))) (, ,) (S (NP (JJ inhaled) (NNS beta-agonists)) (VP (AUX were) (VP (VBN withheld)))) (CC and) (S (NP (NNP Doc_2782734_917_936_Chemical)) (VP (AUX was) (VP (VBN substituted) (PP (IN for) (NP (NN rescue) (NNS purposes)))))) (. .)))
2782734	5	(S1 (S (PP (IN At) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT each) (JJ 14-day) (NN treatment))))) (, ,) (S (NP (NP (DT a) (JJ dose-response) (NN curve)) (PRN (-LRB- -LRB-) (NP (NNP DRC)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN performed)))) (, ,) (CC and) (S (NP (NP (NP (NP (JJ airway) (PRN (-LRB- -LRB-) (NP (NNP FEV1)) (, ,) (NP (CD FEF25-75)) (-RRB- -RRB-)) (JJ chronotropic)) (PRN (-LRB- -LRB-) (NP (NNP HR)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_2782734_1101_1107_Disease)) (, ,)) (CC and) (NP (JJ metabolic) (PRN (-LRB- -LRB-) (NP (NNP Doc_2782734_1124_1125_Chemical)) (, ,) (NP (NNP Doc_2782734_1127_1130_Chemical)) (-RRB- -RRB-)) (NNS responses))) (VP (AUX were) (VP (VBN measured) (PP (IN at) (NP (NP (DT each) (NN step)) (PRN (-LRB- -LRB-) (PP (IN from) (NP (QP (CD 100) (TO to) (CD 4,000)) (NNS micrograms))) (-RRB- -RRB-))))))) (. .)))
2782734	6	(S1 (S (NP (NN Treatment)) (VP (AUX had) (NP (NP (DT no) (JJ significant) (NN effect)) (PP (IN on) (NP (NN baseline) (NNS values))))) (. .)))
2782734	7	(S1 (S (S (NP (EX There)) (VP (AUX were) (NP (NP (JJ dose-dependent) (NNS increases)) (PP (IN in) (NP (NP (NNP FEV1)) (CC and) (NP (NP (CD FEF25-75)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-)))))))) (, ,) (CC and) (S (NP (NP (NN pretreatment)) (PP (IN with) (NP (NNP Doc_2782734_1357_1360_Disease)))) (VP (AUX did) (RB not) (VP (VB displace) (NP (DT the) (NNP DRC)) (PP (TO to) (NP (DT the) (NN right)))))) (. .)))
2782734	8	(S1 (S (NP (NP (NNP DRC)) (PP (IN for) (NP (NP (NP (NNP HR)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP K)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_2782734_1459_1462_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.005))) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN attenuated) (PP (IN after) (NP (NN treatment))) (PP (IN with) (NP (NNP Doc_2782734_1520_1523_Chemical))) (PP (VBN compared) (PP (IN with) (NP (NN PI)))))) (. .)))
2782734	9	(S1 (S (NP (EX There)) (VP (AUX were) (ADVP (RB also)) (NP (NP (NNS differences)) (PP (IN between) (NP (NP (NP (NP (NNP Doc_2782734_1578_1581_Disease)) (CC and) (NP (NP (NNS LDS)) (PP (IN for) (NP (NN HR))))) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_2782734_1621_1624_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)))))) (NP (NNS responses))) (. .)))
2782734	10	(S1 (NP (NP (NP (NP (NN Frequency)) (CC and) (NP (NN severity))) (PP (IN of) (NP (NP (JJ subjective) (JJ adverse) (NNS effects)) (SBAR (S (VP (AUX were) (ADVP (RB also)) (VP (VBN reduced) (PP (IN after) (NP (NNP Doc_2782734_1732_1735_Disease)))))))))) (: :) (NP (NP (NNP Doc_2782734_1737_1743_Disease)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-)) (, ,) (NP (NP (NNS palpitations)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-)))) (. .) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-))))
2818777	0	(S1 (S (NP (NN Doc_2818777_0_9_Chemical)) (VP (VBN induced) (NP (JJ fatal) (NNP Doc_2818777_24_38_Disease))) (. .)))
2818777	1	(S1 (S (NP (DT A) (CD 61) (NN year) (JJ old) (NN female)) (VP (VBD developed) (NP (JJ fatal) (NN Doc_2818777_77_92_Disease)) (PP (IN after) (NP (NNP Doc_2818777_99_108_Chemical) (NN administration)))) (. .)))
2818777	2	(S1 (S (NP (DT A) (JJ typical) (NN multisystem) (JJ clinical) (NN pattern)) (VP (VBZ precedes) (NP (NP (DT the) (NNS manifestations)) (PP (IN of) (NP (NNP Doc_2818777_195_209_Disease))))) (. .)))
2818777	3	(S1 (S (NP (DT The) (JJ hematologic) (, ,) (JJ biochemical) (CC and) (JJ pathologic) (NNS features)) (VP (VBP indicate) (NP (NP (DT a) (JJ mixed) (NN Doc_2818777_281_302_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NN drug) (NN Doc_2818777_315_331_Disease)))))) (. .)))
2818777	4	(S1 (S (PP (IN In) (NP (NP (DT a) (JJ patient) (NN receiving) (NN Doc_2818777_356_365_Chemical)) (SBAR (WHNP (WP who)) (S (VP (VBZ presents) (NP (DT a) (JJ viral-like) (NN illness))))))) (, ,) (NP (NP (NP (JJ early) (NN recognition)) (CC and) (NP (NN discontinuation))) (PP (IN of) (NP (DT the) (NN drug)))) (VP (AUX are) (ADJP (JJ mandatory))) (. .)))
2884595	0	(S1 (NP (NP (NN Treatment)) (PP (IN of) (NP (JJ lethal) (NN pertussis) (NN vaccine) (NN reaction))) (PP (IN with) (NP (NNP Doc_2884595_52_61_Chemical) (NNP H1) (NNS antagonists))) (. .)))
2884595	1	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NN mortality)) (PP (IN after) (NP (NP (NN pertussis) (NN immunization)) (PP (IN in) (NP (DT the) (NN mouse)))))) (. .)))
2884595	2	(S1 (S (PP (IN Without) (NP (NN treatment))) (, ,) (NP (NP (CD 73)) (PP (IN of) (NP (CD 92) (NNS animals))) (PRN (-LRB- -LRB-) (NP (CD 80) (NN %)) (-RRB- -RRB-))) (VP (VBD died) (PP (IN after) (NP (NP (NN injection)) (PP (IN of) (NP (NP (JJ bovine) (NN serum) (NN albumin)) (PRN (-LRB- -LRB-) (NP (NNP BSA)) (-RRB- -RRB-)))))) (PP (IN on) (NP (NP (NN day) (NN +7)) (PP (IN of) (NP (NN pertussis) (NN immunization)))))) (. .)))
2884595	3	(S1 (S (PP (IN After) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NP (CD 3) (NN mg)) (PP (IN of) (NP (NNP Doc_2884595_304_318_Chemical))))))) (, ,) (NP (NP (NP (QP (CD 2) (CD mg))) (NP (NNP Doc_2884595_325_334_Chemical))) (, ,) (CC or) (NP (NP (QP (CD 2) (CD mg))) (NP (NNP Doc_2884595_344_360_Chemical))) (, ,) (NP (NP (RB only) (CD 5)) (PP (IN of) (NP (CD 105) (NNS animals))) (PRN (-LRB- -LRB-) (NP (CD 5) (NN %)) (-RRB- -RRB-)))) (VP (VBD died) (PP (IN after) (S (VP (VBG receiving) (NP (NNP BSA)) (PP (IN on) (NP (NP (NN day) (NNS +7)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-)))))))) (. .)))
2884595	4	(S1 (S (NP (NP (NN Blockade)) (PP (IN of) (NP (NNP Doc_2884595_457_466_Chemical) (NNP H1) (NNS receptors)))) (VP (MD may) (VP (VB reduce) (NP (NN mortality)) (PP (IN in) (NP (NP (NN pertussis) (JJ immunization-induced) (NN Doc_2884595_535_549_Disease)) (PP (IN in) (NP (NNS mice))))))) (. .)))
2904523	0	(S1 (NP (NP (NP (NN Support)) (PP (IN for) (NP (JJ Doc_2904523_12_22_Chemical-Doc_2904523_23_35_Disease) (NNS hypothesis)))) (: :) (NP (NP (ADJP (CD 18) (NN hour)) (NN pressor) (NN effect)) (PP (IN after) (NP (NP (CD 6) (NNS hours)) (NP (JJ Doc_2904523_85_95_Chemical) (NN infusion))))) (. .)))
2904523	1	(S1 (S (PP (IN In) (NP (DT a) (JJ double) (JJ blind) (, ,) (JJ crossover) (NN study))) (NP (NP (CD 6) (NNP h) (NNS infusions)) (PP (IN of) (NP (NP (NP (NNP Doc_2904523_158_168_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 15) (NN ng/kg/min)) (: ;) (S (NP (CD 1) (NN ng)) (VP (SYM =) (NP (CD 5.458) (NN pmol)))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_2904523_204_217_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN ng/kg/min)) (: ;) (S (NP (CD 1) (NN ng)) (VP (SYM =) (NP (CD 5.911) (NN pmol)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (DT a) (ADJP (CD 5) (NN %)) (NNP Doc_2904523_262_270_Chemical) (NN solution)) (PRN (-LRB- -LRB-) (NP (CD 5.4) (NN ml/h)) (-RRB- -RRB-))) (, ,)))) (VP (AUX were) (VP (VBN given) (PP (TO to) (NP (NP (CD ten) (JJ healthy) (NNS volunteers)) (PP (IN in) (NP (NP (JJ random) (NN order)) (ADVP (NP (CD 2) (NNS weeks)) (RB apart)))))))) (. .)))
2904523	2	(S1 (S (PP (IN By) (NP (NP (NNS means)) (PP (IN of) (NP (JJ intra-arterial) (JJ ambulatory) (NN monitoring))))) (NP (DT the) (JJ haemodynamic) (NNS effects)) (VP (AUX were) (VP (VBN followed) (PP (IN for) (NP (CD 18) (NNP h))) (SBAR (IN after) (S (NP (DT the) (NNS infusions)) (VP (AUX were) (VP (VBN stopped))))))) (. .)))
2904523	3	(S1 (S (NP (NP (NN Doc_2904523_491_501_Chemical)) (, ,) (CC but) (RB not) (NP (NNP Doc_2904523_511_524_Chemical)) (, ,)) (VP (VBD caused) (NP (DT a) (ADJP (JJ delayed) (CC and) (JJ protracted)) (NN pressor) (NN effect))) (. .)))
2904523	4	(S1 (S (PP (IN Over) (NP (NP (DT the) (JJ total) (NN postinfusion) (NN period)) (ADJP (JJ systolic) (CC and) (JJ diastolic)))) (NP (JJ arterial) (NN pressure)) (VP (AUX were) (NP (NP (CD 6)) (PRN (-LRB- -LRB-) (NP (NNP SEM) (CD 2)) (-RRB- -RRB-)) (NP (NN %)) (CC and) (NP (CD 7) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (NN %))) (, ,) (ADVP (RB respectively)) (, ,) (ADJP (ADJP (JJR higher)) (PP (IN than) (PP (IN after) (NP (NP (JJ Doc_2904523_710_718_Chemical) (NN infusion)) (PRN (-LRB- -LRB-) (NP (NNP ANOVA)) (, ,) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-))))))) (. .)))
2904523	5	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (`` ``) (NN stress) ('' '') (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_2904523_781_791_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 230) (NN pg/ml)) (-RRB- -RRB-)))) (PP (IN for) (NP (CD 6) (NNP h)))) (VP (VBP cause) (NP (DT a) (ADJP (JJ delayed) (CC and) (JJ protracted)) (NN pressor) (NN effect))) (. .)))
2904523	6	(S1 (S (NP (DT These) (NNS findings)) (VP (AUX are) (NP (NP (JJ strong) (NN support)) (PP (IN for) (NP (NP (DT the) (JJ Doc_2904523_901_911_Chemical-Doc_2904523_912_924_Disease) (NN hypothesis)) (PP (IN in) (NP (NN man))))))) (. .)))
2907577	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_2907577_10_24_Chemical))) (PP (IN on) (NP (NP (NNP Doc_2907577_28_38_Chemical-induced) (NNP Doc_2907577_47_66_Disease)) (PP (IN in) (NP (DT the) (NN rat))))) (. .)))
2907577	1	(S1 (S (NP (JJ Doc_2907577_79_88_Chemical) (NNS antagonists)) (VP (AUX have) (VP (AUX been) (ADVP (RB previously)) (VP (VBN shown) (S (VP (TO to) (VP (AUX be) (PP (IN of) (NP (NN benefit))) (PP (IN in) (NP (NP (DT some) (JJ ischaemic) (CC and) (JJ nephrotoxic) (NNS models)) (PP (IN of) (NP (NP (NNP Doc_2907577_189_208_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2907577_210_213_Disease)) (-RRB- -RRB-)))))))))))) (. .)))
2907577	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (CD three) (NN Doc_2907577_259_273_Chemical)) (PP (IN with) (NP (NP (JJ different) (NNS potencies)) (PP (IN as) (NP (NNP Doc_2907577_302_311_Chemical) (NNS antagonists) (NNP Doc_2907577_324_344_Chemical) (, ,) (NNP Doc_2907577_346_358_Chemical) (CC and) (NNP Doc_2907577_363_375_Chemical) (, ,)))))))) (VP (AUX were) (VP (VBN examined) (PP (IN in) (NP (NP (NNS rats)) (VP (VBG developing) (NP (NNP Doc_2907577_410_429_Disease)) (PP (IN after) (NP (NP (CD 4) (JJ daily) (NNS injections)) (PP (IN of) (NP (NP (NNP Doc_2907577_458_468_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 200) (CD mg)) (NN kg-1)) (-RRB- -RRB-))))))))))) (. .)))
2907577	3	(S1 (S (NP (JJ Renal) (NN function)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (NP (JJ biochemical) (PRN (-LRB- -LRB-) (NP (NN plasma) (NNP Doc_2907577_535_539_Chemical) (CC and) (NNP Doc_2907577_544_554_Chemical)) (-RRB- -RRB-)) (, ,) (ADJP (ADJP (JJ functional)) (PRN (-LRB- -LRB-) (NP (NP (NN urine) (NN analysis)) (CC and) (NP (JJ Doc_2907577_588_628_Chemical) (NNS clearances))) (-RRB- -RRB-)) (CC and) (ADJP (JJ morphological)) (PRN (-LRB- -LRB-) (NP (NP (NN degree)) (PP (IN of) (NP (NNP Doc_2907577_670_678_Disease)))) (-RRB- -RRB-))) (NNS indices))))) (. .)))
2907577	4	(S1 (S (NP (DT The) (JJ various) (NN drug) (NNS treatments)) (VP (VBD produced) (NP (NP (NNS improvements)) (PP (IN in) (NP (NP (NP (DT some)) (, ,) (CC but) (RB not) (NP (DT all)) (, ,) (NP (NNS measurements))) (PP (IN of) (NP (JJ renal) (NN function))))))) (. .)))
2907577	5	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT any) (NN improvement)) (VP (VBN produced) (PP (IN by) (NP (NN drug) (NN treatment))))) (VP (AUX was) (ADVP (RB largely)) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (DT a) (JJ beneficial) (NN effect)) (VP (VBN exerted) (PP (IN by) (NP (NP (PRP$ its) (NN vehicle)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_2907577_913_932_Chemical)) (CC and) (NP (NNP Doc_2907577_937_941_Chemical))) (-RRB- -RRB-))))))))) (. .)))
2907577	6	(S1 (S (NP (NP (DT The) (NN lack)) (PP (IN of) (NP (NP (DT any) (JJ consistent) (JJ protective) (NN effect)) (VP (VBN noted) (PP (IN with) (NP (NP (DT the) (NNP Doc_2907577_1004_1018_Chemical)) (VP (VBN tested) (PP (IN in) (NP (DT the) (JJ present) (NN study)))))))))) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NNP Doc_2907577_1062_1071_Chemical)) (VP (VBZ plays) (NP (JJ little) (PRN (, ,) (PP (IN if) (NP (DT any))) (, ,)) (JJ pathophysiological) (NN role)) (PP (IN in) (NP (JJ Doc_2907577_1121_1131_Chemical-induced) (NN Doc_2907577_1140_1143_Disease))))))) (. .)))
2931989	0	(S1 (S (NP (JJ Adverse) (NN ocular) (NNS reactions)) (ADVP (RB possibly)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_2931989_50_62_Chemical)))) (. .)))
2931989	1	(S1 (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 261) (JJ adverse) (NN ocular) (NNS reactions)))) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 237) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (NNP Doc_2931989_142_154_Chemical)) (, ,) (NP (NP (DT a) (ADJP (RB commonly) (VBN used)) (NN drug)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ severe) (JJ cystic) (NN acne))))))))))))) (. .)))
2931989	2	(S1 (S (S (NP (NP (NNP Blepharoconjunctivitis)) (, ,) (NP (NP (JJ subjective) (NNS complaints)) (PP (IN of) (NP (NNP Doc_2931989_266_274_Disease)))) (, ,)) (VP (VBD blurred) (NP (NP (NN vision)) (, ,) (NP (NN contact) (NN lens) (NN intolerance))))) (, ,) (CC and) (S (NP (NNP Doc_2931989_322_337_Disease)) (VP (AUX are) (NP (JJ reversible) (NN side) (NNS effects)))) (. .)))
2931989	3	(S1 (S (S (NP (ADJP (RBR More) (JJ serious)) (JJ ocular) (JJ adverse) (NNS reactions)) (VP (VBP include) (NP (NP (NP (NNP Doc_2931989_413_424_Disease)) (, ,) (NP (NNP Doc_2931989_426_437_Disease) (NNP cerebri)) (, ,)) (CC and) (NP (ADJP (JJ white) (CC or) (JJ gray)) (JJ subepithelial) (JJ corneal) (NNS opacities))))) (: ;) (S (NP (NP (DT all)) (PP (IN of) (NP (DT these)))) (VP (AUX are) (ADJP (JJ reversible)) (SBAR (IN if) (S (NP (DT the) (NN drug)) (VP (AUX is) (VP (VBN discontinued))))))) (. .)))
2931989	4	(S1 (S (NP (NP (JJ Reported) (NNS cases)) (PP (IN of) (NP (VBN decreased) (JJ dark) (NN adaptation)))) (VP (AUX are) (PP (IN under) (NP (NN investigation)))) (. .)))
2931989	5	(S1 (S (NP (NNP Doc_2931989_624_636_Chemical)) (VP (AUX is) (VP (VBN contraindicated) (PP (IN in) (NP (NN pregnancy))) (PP (IN because) (IN of) (NP (NP (DT the) (ADJP (RB many) (VBN reported)) (NN Doc_2931989_698_722_Disease)) (PP (IN after) (NP (NP (JJ maternal) (NN use)) (PRN (-LRB- -LRB-) (PP (VBG including) (NP (NP (NNP Doc_2931989_753_790_Disease)) (, ,) (CC and) (NP (NNP Doc_2931989_796_818_Disease)))) (-RRB- -RRB-)))))))) (. .)))
2933998	0	(S1 (NP (NP (NP (NNP Doc_2933998_0_10_Chemical)) (CC and) (NP (NNP Doc_2933998_15_26_Chemical))) (PP (IN in) (NP (NNP Doc_2933998_30_46_Disease))) (. .)))
2933998	1	(S1 (NP (NP (DT A) (JJ double-blind) (, ,) (JJ placebo-controlled) (, ,) (JJ cross-over) (NN study)) (. .)))
2933998	2	(S1 (S (NP (NP (NNP Doc_2933998_102_112_Chemical)) (, ,) (NP (DT a) (JJ new) (JJ beta-2) (NN adrenoceptor) (NN stimulant)) (, ,)) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NP (DT a) (JJ double-blind) (, ,) (JJ placebo-controlled) (, ,) (JJ cross-over) (NN trial)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_2933998_236_252_Disease))))))))) (. .)))
2933998	3	(S1 (S (NP (NP (JJ Oral) (NNP Doc_2933998_259_269_Chemical) (CD 50) (NNS micrograms) (NNS b.d.)) (, ,) (NP (NP (NNP Doc_2933998_290_300_Chemical) (CD 100) (NN micrograms) (NN b.d.)) (, ,) (CC and) (NP (NNP Doc_2933998_326_337_Chemical) (CD 5) (NN mg) (NN t.i.d.))) (, ,)) (VP (AUX were) (VP (VBN compared) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (ADVP (RB randomly)) (PP (IN in) (NP (JJ 1-week) (NN treatment) (NNS periods)))))))) (. .)))
2933998	4	(S1 (S (NP (DT The) (JJS best) (JJ clinical) (NN effect)) (VP (AUX was) (VP (VBN found) (PP (IN with) (NP (NNP Doc_2933998_454_465_Chemical))))) (. .)))
2933998	5	(S1 (S (NP (NP (DT Both) (JJ anti-Doc_2933998_477_486_Disease) (CC and) (JJ tremorgenic) (NNS effects)) (PP (IN of) (NP (NNP Doc_2933998_514_524_Chemical)))) (VP (AUX were) (ADJP (JJ dose-related))) (. .)))
2933998	6	(S1 (S (S (NP (NN Doc_2933998_544_554_Chemical)) (VP (VBD appeared) (ADJP (JJ effective)) (PP (IN in) (NP (NP (DT the) (NNS doses)) (VP (VBN tested)))))) (, ,) (CC and) (S (NP (DT a) (ADJP (RB twice) (JJ daily)) (NN regimen)) (VP (MD would) (VP (VB appear) (S (VP (TO to) (VP (AUX be) (ADJP (JJ suitable) (PP (IN with) (NP (DT this) (NN drug)))))))))) (. .)))
2974281	0	(S1 (S (NP (NP (JJ Subacute) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_2974281_20_31_Chemical)) (CC and) (NP (NNP B) (CD 24/76)))) (PP (IN on) (NP (JJ Doc_2974281_47_60_Chemical-induced) (NN rat)))) (VP (VBP Doc_2974281_73_90_Disease) (PP (IN in) (NP (NN correlation))) (PP (IN with) (NP (NN blood) (NN pressure)))) (. .)))
2974281	1	(S1 (S (NP (PRP We)) (VP (VBD compared) (NP (NP (DT the) (JJ potential) (NN beta-receptor) (NN blocker)) (, ,) (NP (NNP B) (CD 24/76))) (PP (FW i.e.) (NP (NP (JJ 1-) (PRN (-LRB- -LRB-) (JJ 2,4-dichlorophenoxy) (-RRB- -RRB-)) (NN -3-LSB-2-3,4-dimethoxyphenyl) (-RRB- -RRB-) (NN ethanolamino) (NN -RSB-) (NN -prop) (NN an-2-ol)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ beta) (NN 1-adrenoceptor) (VBG blocking)) (CC and) (NP (NP (JJ beta) (JJ 2-adrenoceptor) (JJ stimulating) (NNS properties)) (PP (IN with) (NP (NNP Doc_2974281_372_383_Chemical))))))))))))) (. .)))
2974281	2	(S1 (S (NP (DT The) (NNS studies)) (VP (AUX were) (VP (VBN performed) (S (VP (VBG using) (NP (NP (DT an) (JJ experimental) (NN model)) (PP (IN of) (NP (NP (NNP Doc_2974281_443_456_Chemical-induced) (NNP Doc_2974281_465_482_Disease)) (PP (IN in) (NP (NNS rats)))))))))) (. .)))
2974281	3	(S1 (S (NP (NP (DT A) (NN correlation)) (PP (IN of) (NP (DT the) (NN blood) (NN pressure)))) (VP (AUX was) (ADVP (RB neither)) (VP (VBN found) (PP (PP (IN in) (NP (DT the) (NN development))) (CC nor) (PP (IN in) (NP (DT the) (NN attempt) (S (VP (TO to) (VP (VB suppress) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_2974281_615_632_Disease)))) (PP (IN with) (NP (DT the) (CD two) (JJ beta-receptor) (NNS blockers))))))))))) (. .)))
2974281	4	(S1 (S (NP (DT Both) (NNS beta-blockers)) (VP (VBD influenced) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_2974281_719_730_Disease)))) (PP (TO to) (NP (DT a) (ADJP (ADJP (JJ different)) (, ,) (CC but) (ADJP (RB not) (JJ reproducible))) (NN extent)))) (. .)))
2974281	5	(S1 (S (S (NP (PRP It)) (VP (AUX was) (ADJP (JJ possible) (S (VP (TO to) (VP (VB suppress) (NP (DT the) (VBN increased) (JJ Doc_2974281_818_827_Chemical) (NN decarboxylase) (NN activity)) (PP (IN with) (NP (NP (DT both) (NNS beta-blockers)) (PP (IN in) (NP (JJ Doc_2974281_878_891_Disease) (NNS hearts))))))))))) (, ,) (CC but) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (DT the) (NN heart) (NN mass)))))) (. .)))
2974281	6	(S1 (S (CC Neither) (NP (NP (NNP Doc_2974281_951_962_Chemical)) (CC nor) (NP (NNP B) (CD 24/76))) (VP (MD could) (VP (VB stop) (NP (NP (DT the) (NNS changes)) (PP (IN in) (NP (NP (DT the) (JJ characteristic) (NN myosin) (NN isoenzyme) (NN pattern)) (PP (IN of) (NP (DT the) (NNP Doc_2974281_1052_1065_Disease) (NN rat) (NN heart)))))))) (. .)))
2974281	7	(S1 (S (ADVP (RB Thus)) (, ,) (NP (DT the) (NNS investigations)) (VP (AUX did) (RB not) (VP (VB provide) (NP (DT any) (NN evidence) (SBAR (IN that) (S (NP (DT the) (NN beta-receptor)) (VP (VBZ blockers) (SBAR (S (NP (NP (NNP Doc_2974281_1163_1174_Chemical)) (CC and) (NP (NNP B) (CD 24/76))) (VP (AUX have) (NP (DT the) (NN potency) (S (VP (TO to) (VP (VB prevent) (NP (NNP Doc_2974281_1215_1228_Chemical)) (PP (IN from) (S (VP (VBG producing) (NP (NN Doc_2974281_1244_1261_Disease)))))))))))))))))) (. .)))
2983630	0	(S1 (FRAG (NP (NP (VBN Increased) (JJ anxiogenic) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_2983630_32_40_Chemical)) (PP (IN in) (NP (NNP Doc_2983630_44_59_Disease)))))) (. .)))
2983630	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_2983630_99_107_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg)) (-RRB- -RRB-)))))) (PP (IN on) (NP (NP (JJ behavioral) (NNS ratings)) (, ,) (NP (JJ somatic) (NNS symptoms)) (, ,) (NP (NN blood) (NN pressure)) (CC and) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NP (NNP Doc_2983630_196_233_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_2983630_235_239_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_2983630_245_253_Chemical)))))))) (VP (AUX were) (VP (VBN determined) (PP (IN in) (NP (NP (CD 17) (JJ healthy) (NNS subjects)) (CC and) (NP (NP (CD 21) (NNS patients)) (VP (VBG meeting) (NP (NP (JJ DSM-III) (NNS criteria)) (PP (IN for) (NP (NNP Doc_2983630_338_349_Disease)))) (PP (IN with) (NP (NP (NNP Doc_2983630_355_360_Disease) (NNS attacks)) (CC or) (NP (NNP Doc_2983630_372_386_Disease)))))))))) (. .)))
2983630	2	(S1 (S (NP (NNP Doc_2983630_388_396_Chemical)) (VP (VBD produced) (NP (NP (ADJP (RB significantly) (JJR greater)) (NNS increases)) (PP (IN in) (NP (NP (JJ subject-rated) (NN Doc_2983630_455_462_Disease)) (, ,) (NP (NN nervousness)) (, ,) (NP (NN fear)) (, ,) (NP (NNP Doc_2983630_483_489_Disease)) (, ,) (NP (NNS palpitations)) (, ,) (NP (NN restlessness)) (, ,) (CC and) (NP (NNP Doc_2983630_523_530_Disease))))) (PP (IN in) (NP (DT the) (NNS patients))) (PP (VBN compared) (PP (IN with) (NP (JJ healthy) (NNS subjects))))) (. .)))
2983630	3	(S1 (S (PP (IN In) (NP (NP (DT the) (NNS patients)) (, ,) (CONJP (CC but) (RB not)) (NP (DT the) (JJ healthy) (NNS subjects)))) (, ,) (NP (DT these) (NNS symptoms)) (VP (AUX were) (ADVP (RB significantly)) (VP (VBN correlated) (PP (IN with) (NP (NN plasma) (JJ Doc_2983630_683_691_Chemical) (NNS levels))))) (. .)))
2983630	4	(S1 (S (NP (NP (JJ Seventy-one) (NN percent)) (PP (IN of) (NP (DT the) (NNS patients)))) (VP (VBD reported) (SBAR (IN that) (S (NP (NP (DT the) (JJ behavioral) (NNS effects)) (PP (IN of) (NP (NNP Doc_2983630_776_784_Chemical)))) (VP (AUX were) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN experienced) (PP (IN during) (NP (JJ Doc_2983630_826_831_Disease) (NNS attacks))))))))))) (. .)))
2983630	5	(S1 (S (NP (NNP Doc_2983630_841_849_Chemical)) (VP (AUX did) (RB not) (VP (VB alter) (NP (NP (NN plasma) (NN Doc_2983630_871_875_Chemical) (NNS levels)) (PP (IN in) (NP (CC either) (NP (DT the) (JJ healthy) (NNS subjects)) (CC or) (NP (NNS patients))))))) (. .)))
2983630	6	(S1 (S (NP (NN Doc_2983630_927_935_Chemical)) (VP (VBD increased) (NP (NN plasma) (JJ Doc_2983630_953_961_Chemical) (NNS levels)) (ADVP (RB equally)) (PP (IN in) (NP (DT the) (ADJP (JJ patient) (CC and) (JJ healthy)) (NNS groups)))) (. .)))
2983630	7	(S1 (S (SBAR (IN Because) (S (NP (NNP Doc_2983630_1020_1028_Chemical)) (VP (AUX is) (NP (DT an) (JJ Doc_2983630_1035_1044_Chemical) (NN receptor) (NN antagonist))))) (, ,) (NP (DT these) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT some) (NNP Doc_2983630_1098_1112_Disease) (NNS patients)) (VP (MD may) (VP (AUX have) (NP (NNS abnormalities)) (PP (IN in) (NP (NP (JJ neuronal) (NNS systems)) (VP (VBG involving) (NP (NNP Doc_2983630_1175_1184_Chemical)))))))))) (. .)))
2983630	8	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NNP Doc_2983630_1200_1217_Disease)))) (VP (MD may) (VP (VB benefit) (PP (IN by) (S (VP (VBG avoiding) (NP (JJ Doc_2983630_1242_1250_Chemical-containing) (NNS foods) (CC and) (NNS beverages))))))) (. .)))
3074291	0	(S1 (NP (NP (NN Comparison)) (PP (PP (IN of) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_3074291_28_46_Chemical))))) (CC and) (PP (IN of) (NP (NP (JJ slow-release) (NN Doc_3074291_67_79_Chemical)) (PP (IN on) (NP (JJ nocturnal) (NN asthma)))))) (. .)))
3074291	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (PP (IN of) (NP (NP (DT a) (JJ new) (JJ inhaled) (JJ antimuscarinic) (NN drug)) (, ,) (NP (NNP Doc_3074291_151_169_Chemical)))) (, ,) (CC and) (PP (IN of) (NP (NP (DT a) (JJ slow-release) (JJ Doc_3074291_193_205_Chemical) (NN preparation)) (PP (IN upon) (NP (JJ nocturnal) (NN asthma))))))) (VP (AUX were) (VP (VBN compared) (PP (IN in) (NP (DT a) (JJ placebo-controlled) (NN double-blind) (NN study))))) (. .)))
3074291	2	(S1 (S (S (NP (CD Two) (NNS samples)) (VP (AUX were) (VP (VBN studied)))) (: :) (S (NP (NP (CD 12) (NNS patients)) (VP (VBD received) (NP (NNP Doc_3074291_345_355_Chemical)) (PP (PP (IN at) (NP (NP (CD 600) (NNS micrograms)) (PRN (-LRB- -LRB-) (NP (CD 6) (NNS subjects)) (-RRB- -RRB-)))) (CC or) (PP (IN at) (NP (NP (CD 400) (NNS micrograms)) (VP (VBN t.i.d.) (PRN (-LRB- -LRB-) (NP (CD 6) (NNS subjects)) (-RRB- -RRB-)) (PP (IN whereas) (NP (CD 11))))))))) (VP (VBD received) (SBAR (S (NP (NP (NP (NNP Doc_3074291_448_460_Chemical)) (PP (IN at) (NP (QP (CD 300) (CD mg)) (VBN b.i.d.) (NN Morning) (VBG dipping)))) (, ,) (VP (VBN assessed) (PP (IN by) (NP (NP (DT the) (NN fall)) (PP (IN in) (NP (NN peak) (NN flow))))) (ADVP (RB overnight))) (, ,)) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN reduced) (PP (IN in) (NP (NP (DT the) (NNS periods)) (SBAR (WHADVP (WRB when)) (S (NP (DT either) (JJ active) (NN drug)) (VP (AUX was) (VP (VBN taken))))))) (, ,) (SBAR (IN whereas) (S (NP (DT no) (NN difference)) (VP (AUX was) (VP (VBN noticed) (PP (IN during) (NP (DT the) (NN placebo) (NN administration))))))))))))) (. .)))
3074291	3	(S1 (S (NP (DT No) (JJ significant) (NN difference)) (VP (AUX was) (VP (VBN noticed) (PP (IN between) (NP (NP (NNS results)) (VP (VBN obtained) (PP (PP (IN with) (NP (DT either) (JJ active) (NN drug))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN with) (NP (NP (DT either) (NN dosage)) (PP (IN of) (NP (NNP Doc_3074291_806_816_Chemical))))))))))) (. .)))
3074291	4	(S1 (S (NP (DT No) (NN subject)) (VP (VBD reported) (NP (NP (JJ side) (NNS effects)) (PP (IN of) (NP (NNP Doc_3074291_854_864_Chemical)))) (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NP (CD three) (NNS subjects)) (VP (VBG reporting) (NP (NP (NNP Doc_3074291_906_912_Disease)) (, ,) (NP (NNP Doc_3074291_914_922_Disease)) (CC and) (NP (NNP Doc_3074291_927_934_Disease))) (PP (IN after) (NP (NNP Doc_3074291_941_953_Chemical)))))))))) (. .)))
3074291	5	(S1 (S (NP (NN Doc_3074291_955_965_Chemical)) (VP (VBZ proves) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJ valuable) (NN alternative)) (PP (TO to) (NP (NNP Doc_3074291_1005_1017_Chemical)))) (PP (IN in) (NP (JJ nocturnal) (NN asthma)))))) (, ,) (SBAR (IN since) (S (NP (PRP it)) (VP (VP (AUX is) (ADJP (RB equally) (JJ potent) (, ,) (JJR safer))) (CC and) (VP (AUX does) (RB not) (VP (VB require) (NP (NP (DT the) (NN titration)) (PP (IN of) (NP (NN dosage)))))))))) (. .)))
3083835	0	(S1 (NP (NNP Doc_3083835_0_10_Chemical) (NNP Doc_3083835_11_22_Disease) (. .)))
3083835	1	(S1 (S (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (JJ oral) (NNP Doc_3083835_39_49_Chemical) (NNP Doc_3083835_50_61_Disease)))) (VP (AUX is) (VP (VBN described)))) (, ,) (CC and) (S (NP (NP (NP (DT the) (NN terminology)) (, ,) (NP (NN occurrence)) (, ,) (NP (JJ clinical) (NNS manifestations)) (, ,) (NP (NN pathogenesis)) (, ,) (NP (NN prevention)) (, ,) (CC and) (NP (NN treatment))) (PP (IN of) (NP (NNP Doc_3083835_177_188_Disease)))) (VP (AUX are) (VP (VBN reviewed)))) (. .)))
3083835	2	(S1 (S (NP (NN Emergency) (NNS physicians)) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (JJ oral) (NNP Doc_3083835_248_258_Chemical) (NNP Doc_3083835_259_270_Disease)))) (PP (IN in) (NP (NN order))) (S (VP (VP (TO to) (VP (VB prevent) (NP (PRP$ its) (NN occurrence)) (PP (IN by) (S (VP (VBG prescribing) (NP (DT the) (JJ antibiotic)) (ADVP (ADVP (RB judiciously)) (CC and) (ADVP (RB knowledgeably)))))))) (CC and) (VP (TO to) (VP (VB offer) (NP (JJ optimal) (JJ medical) (NN therapy)))))) (SBAR (IN once) (S (NP (DT this) (JJ life-threatening) (NN reaction)) (VP (AUX has) (VP (VBN begun))))))) (. .)))
3084231	0	(S1 (NP (NP (JJ Reversible) (JJ Doc_3084231_11_24_Chemical-induced) (NN Doc_3084231_33_41_Disease)) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
3084231	1	(S1 (S (NP (JJ Reversible) (JJ Doc_3084231_69_82_Chemical-induced) (NN Doc_3084231_91_99_Disease)) (VP (AUX was) (VP (VBN documented) (PP (IN in) (NP (NP (DT a) (JJ 21-year-old) (NN man)) (PP (IN with) (NP (NNP Doc_3084231_141_149_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (DT a) (JJ 3-year) (NN history)) (PP (IN of) (NP (NP (JJ insidious) (JJ progressive) (NN Doc_3084231_200_237_Disease)) (VP (VBN documented) (PP (IN by) (NP (JJ serial) (JJ neuropsychological) (NNS studies)))))))))))))) (. .)))
3084231	2	(S1 (S (NP (NP (NP (NN Repeat) (JJ neuropsychological) (NN testing)) (NP (CD 7) (NNS weeks))) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (DT the) (NN drug)))))) (VP (VBD revealed) (NP (NP (JJ dramatic) (NN improvement)) (PP (IN in) (NP (NP (NNP IQ) (, ,) (NN memory) (, ,) (NN naming) (, ,) (CC and) (JJ other) (NNS tasks)) (ADJP (JJ commensurate) (PP (IN with) (NP (NP (JJ clinical) (NN recovery)) (PP (IN in) (NP (PRP$ his) (JJ intellectual) (NN capacity)))))))))) (. .)))
3084231	3	(S1 (S (NP (NP (JJ Possible) (JJ pathophysiological) (NNS mechanisms)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (AUX have) (VP (AUX been) (ADJP (JJ operative)) (PP (IN in) (NP (NP (NP (DT this) (NN case)) (SBAR (S (VP (VBP include) (: :) (NP (NP (DT a) (JJ direct) (JJ central) (JJ nervous) (NN system) (PRN (-LRB- -LRB-) (NNP CNS) (-RRB- -RRB-)) (JJ toxic) (NN effect)) (PP (IN of) (NP (NNP Doc_3084231_643_656_Chemical)))))))) (: ;) (NP (NP (DT a) (JJ paradoxical) (JJ epileptogenic) (NN effect)) (ADJP (JJ secondary) (PP (TO to) (NP (DT the) (NN drug))))) (: ;) (CC and) (NP (DT an) (JJ indirect) (NNS CNS)))) (NP (JJ toxic) (NN effect)))))))) (VP (VBD mediated) (PP (IN through) (NP (JJ Doc_3084231_766_779_Chemical-induced) (NNP Doc_3084231_788_802_Disease)))) (. .)))
3088653	0	(S1 (NP (NP (NN Reversal)) (PP (IN of) (NP (NP (JJ Doc_3088653_12_23_Chemical-induced) (NN Doc_3088653_32_39_Disease)) (PP (IN of) (NP (NN passive) (NN avoidance))))) (PP (IN by) (NP (ADJP (JJ pre-) (CC and) (JJ post-training)) (NNP Doc_3088653_87_95_Chemical))) (. .)))
3088653	1	(S1 (S (PP (IN In) (NP (NP (DT a) (NN series)) (PP (IN of) (NP (CD five) (NNS experiments))))) (, ,) (NP (NP (DT the) (JJ modulating) (NN role)) (PP (IN of) (NP (NNP Doc_3088653_153_161_Chemical))) (PP (IN on) (NP (DT a) (JJ Doc_3088653_167_178_Chemical-induced) (NN Doc_3088653_187_204_Disease))) (PP (IN in) (NP (DT a) (JJ passive) (NN avoidance) (NN paradigm)))) (VP (AUX was) (VP (VBN investigated) (PP (IN in) (NP (NNS mice))))) (. .)))
3088653	2	(S1 (S (NP (NP (NN Doc_3088653_263_274_Chemical)) (, ,) (CONJP (CC but) (RB not)) (NP (NP (NNP Doc_3088653_284_302_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CC and) (CD 3)) (NN mg/kg)) (-RRB- -RRB-))) (, ,)) (VP (VBN induced) (NP (DT an) (NN Doc_3088653_331_338_Disease)) (SBAR (IN as) (S (VP (VBN measured) (PP (IN by) (NP (NN latency) (CC and) (NN duration) (NNS parameters))))))) (. .)))
3088653	3	(S1 (S (NP (NP (NNP Doc_3088653_387_395_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.3) (, ,) (CD 1) (, ,) (CD 3) (, ,) (CC and) (CD 10) (CD mg/kg)) (-RRB- -RRB-))) (VP (VBD injected) (ADVP (RB prior) (PP (TO to) (NP (NP (NN training)) (VP (VBN attenuated) (NP (DT the) (NNP Doc_3088653_464_481_Disease)) (PP (IN with) (NP (NP (DT a) (NN peak)) (PP (IN of) (NP (NP (NN activity)) (PP (IN at) (NP (QP (CD 3) (CD mg/kg))))))))))))) (. .)))
3088653	4	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_3088653_532_540_Chemical)))) (VP (MD could) (VP (AUX be) (VP (VBN antagonized) (PP (IN with) (NP (NP (NNP Doc_3088653_567_575_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (CD 1)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 10) (NN mg/kg))) (-RRB- -RRB-)))) (, ,) (S (VP (VBG demonstrating) (NP (NP (DT the) (JJ opioid) (NN specificity)) (PP (IN of) (NP (DT the) (JJ Doc_3088653_642_650_Chemical) (NN effect))))))))) (. .)))
3088653	5	(S1 (S (NP (NP (JJ Post-training) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_3088653_691_699_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 3) (NN mg/kg)) (-RRB- -RRB-))) (PP (IN as) (NP (DT a) (JJ single))) (CC or) (PP (IN as) (NP (DT a) (JJ split) (NN dose))))) (ADVP (RB also)) (VP (VBD attenuated) (NP (DT the) (JJ Doc_3088653_761_772_Chemical-induced) (NNP Doc_3088653_781_788_Disease))) (. .)))
3088653	6	(S1 (S (NP (NN Control) (NNS experiments)) (VP (VBD indicated) (SBAR (IN that) (S (NP (DT neither) (NP (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NNP Doc_3088653_848_852_Disease) (NN sensitivity)))) (-LRB- -LRB-) (NP (JJ pre-training) (NNP Doc_3088653_879_887_Chemical)) (-RRB- -RRB-)) (CC nor) (NP (NP (DT an) (VBN induced) (NN aversive) (NN state)) (-LRB- -LRB-) (NP (JJ post-training) (NNP Doc_3088653_934_942_Chemical)) (-RRB- -RRB-))) (VP (VBP appear) (S (VP (TO to) (VP (AUX be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NNP Doc_3088653_990_998_Chemical))) (PP (IN on) (NP (DT the) (JJ Doc_3088653_1006_1017_Chemical-induced) (NN Doc_3088653_1026_1043_Disease))))))))))))) (. .)))
3088653	7	(S1 (S (NP (DT These) (NNS results)) (VP (VBP extend) (NP (NP (JJ previous) (NNS findings)) (VP (VBG implicating) (NP (NP (DT a) (JJ cholinergic-opioid) (NN interaction)) (PP (IN in) (NP (NN memory) (NNS processes))))))) (. .)))
3088653	8	(S1 (S (NP (NP (DT A) (JJ possible) (NN mechanism)) (PP (IN for) (NP (NP (DT this) (NN interaction)) (VP (VBG involving) (NP (DT the) (JJ septo-hippocampal) (JJ cholinergic) (NN pathway)))))) (VP (AUX is) (VP (VBN discussed))) (. .)))
3109094	0	(S1 (NP (NP (NNP Electron)) (NP (NP (NP (JJ microscopic) (NNS investigations)) (PP (IN of) (NP (NP (DT the) (JJ Doc_3109094_43_59_Chemical-induced) (NNS lesions)) (PP (IN of) (NP (NP (DT the) (JJ urinary) (NN bladder)) (PP (IN of) (NP (DT the) (NN rat)))))))) (CC and) (NP (NP (PRP$ their) (NN prevention)) (PP (IN by) (NP (NNP Doc_3109094_134_139_Chemical))))) (. .)))
3109094	1	(S1 (S (NP (ADJP (RB Fully) (VBN developed)) (NNP Doc_3109094_157_173_Chemical-induced) (NNP Doc_3109094_182_190_Disease)) (VP (AUX is) (VP (VBN characterized) (PP (IN by) (NP (NP (ADJP (RB nearly) (JJ complete)) (NN detachment)) (PP (IN of) (NP (NP (DT the) (JJ urothelium) (, ,) (JJ severe) (NNP Doc_3109094_264_280_Disease) (NN owing)) (PP (TO to) (NP (NP (NN damage)) (PP (TO to) (NP (NP (DT the) (JJ microvascular) (NN bed)) (CC and) (NP (JJ focal) (NN Doc_3109094_332_347_Disease)))))))))))) (. .)))
3109094	2	(S1 (S (NP (NP (DT The) (JJ initial) (NN response)) (PP (TO to) (NP (NP (DT the) (JJ primary) (NN attack)) (PP (IN by) (NP (DT the) (JJ Doc_3109094_399_415_Chemical) (NNS metabolites)))))) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (NP (NP (NN fragmentation)) (PP (IN of) (NP (DT the) (JJ luminal) (NN membrane)))))))) (. .)))
3109094	3	(S1 (S (NP (DT This)) (VP (VBZ damages) (NP (NP (DT the) (JJ cellular) (NN barrier)) (PP (IN against) (NP (DT the) (JJ hypertonic) (NN urine))))) (. .)))
3109094	4	(S1 (S (NP (NP (JJ Subsequent) (NNS breaks)) (PP (IN in) (NP (NP (NP (DT the) (JJ lateral) (NN cell) (NNS membranes)) (PP (PP (IN of) (NP (DT the) (JJ superficial) (NNS cells))) (CC and) (PP (IN in) (NP (NP (PDT all) (DT the) (NN plasma) (NNS membranes)) (PP (IN of) (NP (DT the) (JJ intermediate) (CC and) (JJ basal) (NNS cells))))))) (, ,) (NP (NN intercellular) (CC and) (NN intracellular) (NN Doc_3109094_717_722_Disease)) (CC and) (NP (NP (NN disintegration)) (PP (IN of) (NP (DT the) (NNS desmosomes) (CC and) (NNS hemidesmosomes))))))) (VP (VBP lead) (PP (TO to) (NP (NP (JJ progressive) (NN degeneration)) (CC and) (NP (NP (NN detachment)) (PP (IN of) (NP (DT the) (JJ epithelial) (NNS cells))) (PP (IN with) (NP (NP (NN exposure)) (CC and) (NP (NP (NN splitting)) (PP (IN of) (NP (DT the) (JJ basal) (NN membrane)))))))))) (. .)))
3109094	5	(S1 (S (NP (NP (NP (DT The) (JJ morphological) (NNS changes)) (PP (IN of) (NP (DT the) (JJ endothelial) (NNS cells))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP become) (ADJP (RBR more) (JJ pronounced)) (PP (IN in) (NP (NP (DT the) (JJ later) (NNS stages)) (PP (IN of) (NP (DT the) (NN experiment))))))))) (, ,) (NP (NP (DT the) (NN involvement)) (PP (IN of) (NP (NP (NN blood) (NNS vessels)) (ADVP (RB regardless) (PP (IN of) (NP (PRP$ their) (NN diameter))))))) (CC and) (NP (NP (DT the) (JJ location-dependent) (NN extent)) (PP (IN of) (NP (DT the) (NN damage))))) (VP (VBP indicate) (NP (NP (DT a) (JJ direct) (NN type)) (PP (IN of) (NP (NN damage))) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN preceded) (PP (IN by) (NP (NP (DT a) (JJ mediator-induced) (NN increase)) (PP (IN in) (NP (NP (NN permeability)) (, ,) (NP (NP (DT the) (JJ morphological) (NN correlate)) (PP (IN of) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NNS gaps))) (PP (IN in) (NP (NP (DT the) (JJ interendothelial) (NN cell) (NNS connections)) (PP (IN on) (NP (DT the) (NNS venules))))))))))))))))))))) (. .)))
3109094	6	(S1 (S (NP (DT These) (NNS changes)) (VP (MD can) (VP (AUX be) (VP (ADVP (RB effectively)) (VBN prevented) (PP (IN by) (NP (NNP Doc_3109094_1396_1401_Chemical)))))) (. .)))
3109094	7	(S1 (S (NP (NP (DT The) (JJ only) (NN sign)) (PP (IN of) (NP (DT a) (JJ possible) (NN involvement)))) (VP (AUX is) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (JJ specific) (NNS granules))) (PP (IN with) (NP (NP (DT a) (VBN presumed) (JJ lysosomal) (NN function)) (PP (IN in) (NP (DT the) (JJ superficial) (NNS cells))))))))) (. .)))
3125850	0	(S1 (NP (NP (NP (NN Increase)) (PP (IN in) (NP (JJ intragastric) (NN pressure))) (PP (IN during) (NP (NNP Doc_3125850_41_54_Chemical-induced) (NNP Doc_3125850_63_84_Disease))) (PP (IN in) (NP (NNS children)))) (: :) (NP (NP (NN inhibition)) (PP (IN by) (NP (NNP Doc_3125850_112_122_Chemical)))) (. .)))
3125850	1	(S1 (S (NP (NP (NNS Changes)) (PP (IN in) (NP (NP (JJ intragastric) (NN pressure)) (PP (IN after) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (QP (JJ Doc_3125850_185_198_Chemical) (CD 1.5) (CD mg)) (JJ kg-1) (NNS i.v.)))))))) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (CD 32) (NNS children))) (PRN (-LRB- -LRB-) (NP (JJ mean) (NN age)) (NP (CD 6.9) (NN yr)) (-RRB- -RRB-)) (PP (VBN pretreated) (PP (IN with) (NP (NP (DT either) (JJ physiological) (NN saline)) (CC or) (NP (NNP Doc_3125850_309_319_Chemical) (CD 50) (NNS micrograms) (NN kg-1))))))) (. .)))
3125850	2	(S1 (S (NP (NN Anaesthesia)) (VP (AUX was) (VP (VBN induced) (PP (IN with) (NP (NNP Doc_3125850_369_380_Chemical) (CD 5) (NN mg) (NN kg-1))))) (. .)))
3125850	3	(S1 (S (NP (NP (DT The) (NN incidence) (CC and) (NN intensity)) (PP (IN of) (NP (NNP Doc_3125850_423_444_Disease))) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_3125850_455_468_Chemical))))) (VP (AUX were) (ADJP (RB significantly) (JJR greater)) (PP (IN in) (NP (DT the) (NN control))) (PP (IN than) (PP (IN in) (NP (DT the) (NNP Doc_3125850_523_533_Chemical) (NN group))))) (. .)))
3125850	4	(S1 (S (NP (NP (DT The) (JJ intragastric) (NN pressure)) (PP (IN during) (NP (NNP Doc_3125850_574_595_Disease)))) (VP (AUX was) (ADJP (ADJP (ADJP (RB significantly) (JJR higher) (PP (IN in) (NP (DT the) (NN control) (NN group)))) (PRN (-LRB- -LRB-) (S (NP (NP (QP (CD 16) (CD +/-)) (CD 0.7)) (PRN (-LRB- -LRB-) (NP (NNP SEM)) (-RRB- -RRB-))) (VP (VBG cm) (NP (NNP Doc_3125850_663_666_Chemical)))) (-RRB- -RRB-))) (PP (IN than) (PP (IN in) (NP (NP (DT the) (JJ Doc_3125850_680_690_Chemical) (NN group)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 7.7) (NN +/-)) (NP (NP (CD 1.5)) (PRN (-LRB- -LRB-) (NP (NNP SEM)) (-RRB- -RRB-)))) (VP (VBN cm) (NP (NNP Doc_3125850_719_722_Chemical)))) (-RRB- -RRB-))))))) (. .)))
3125850	5	(S1 (S (NP (NP (DT The) (NN increase)) (PP (IN in) (NP (JJ intragastric) (NN pressure)))) (VP (AUX was) (VP (ADVP (RB directly)) (VBN related) (PP (TO to) (NP (NP (DT the) (NN intensity)) (PP (IN of) (NP (NP (NNP Doc_3125850_804_825_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN regression) (NN line)) (: :) (NP (NP (QP (CD y) (SYM =) (CD 0.5) (CD +)) (NN 4.78x)) (PP (IN with) (NP (NP (NN r)) (PP (IN of) (NP (CD 0.78))))))) (-RRB- -RRB-)))))))) (. .)))
3125850	6	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (JJ intragastric) (NN pressure)) (VP (VBZ increases) (ADVP (RB significantly)) (PP (IN during) (NP (NP (NN Doc_3125850_951_972_Disease)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_3125850_983_996_Chemical))) (PP (IN in) (NP (JJ healthy) (NNS children))))))))))) (. .)))
3125850	7	(S1 (S (S (NP (NN Doc_3125850_1018_1028_Chemical)) (ADVP (NP (CD 50) (NNS micrograms) (JJ kg-1)) (RB effectively)) (VP (VBZ inhibits) (NP (NP (DT the) (NN incidence) (CC and) (NN intensity)) (PP (IN of) (NP (JJ Doc_3125850_1100_1113_Chemical-induced) (NNP Doc_3125850_1122_1143_Disease)))))) (: ;) (S (ADVP (RB moreover)) (, ,) (NP (JJ intragastric) (NN pressure)) (VP (VBZ remains) (PP (IN at) (NP (PRP$ its) (NN control) (NN value))))) (. .)))
3155884	0	(S1 (S (NP (JJ Acute) (NN insulin) (NN treatment)) (VP (VBZ normalizes) (NP (NP (DT the) (NN resistance)) (PP (TO to) (NP (NP (DT the) (JJ Doc_3155884_57_68_Disease) (NN effect)) (PP (IN of) (NP (NNP Doc_3155884_79_92_Chemical))) (PP (IN in) (NP (NNP Doc_3155884_96_110_Chemical) (NNP Doc_3155884_111_119_Disease) (NNS rats))))))) (. .)))
3155884	1	(S1 (NP (NP (DT A) (JJ morphometric) (NN study)) (PP (IN of) (NP (NNP Doc_3155884_150_163_Chemical) (VBN induced) (NN Doc_3155884_172_191_Disease))) (. .)))
3155884	2	(S1 (S (NP (NP (DT The) (JJ acute) (NN effect)) (PP (IN of) (NP (NN insulin) (NN treatment))) (PP (IN on) (NP (NP (DT the) (RBR earlier) (JJ reported) (JJ protective) (NN effect)) (PP (IN of) (NP (NNP Doc_3155884_276_290_Chemical) (NNP Doc_3155884_291_307_Disease)))))) (NP (NP (DT the) (JJ Doc_3155884_312_323_Disease) (NN effect)) (PP (IN of) (NP (NP (JJ high) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_3155884_348_361_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3155884_363_366_Chemical)) (-RRB- -RRB-))))))) (VP (AUX was) (VP (VBN investigated) (PP (IN in) (NP (NNS rats))))) (. .)))
3155884	3	(S1 (S (PP (NP (QP (CD Thirty) (TO to) (CD 135) (NN min))) (IN after) (NP (NP (DT the) (NN injection)) (PP (IN of) (NP (JJ crystalline) (NN insulin))))) (, ,) (S (NP (NNP Doc_3155884_456_459_Chemical)) (VP (AUX was) (VP (VBN given) (ADVP (RB subcutaneously))))) (CC and) (S (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_3155884_494_497_Chemical)) (VP (VBN induced) (S (NP (NNP Doc_3155884_506_514_Disease)) (PP (IN in) (NP (DT the) (NN myocardium))))))) (VP (AUX was) (ADVP (RB morphometrically)) (VP (VBN analyzed) (ADVP (NP (CD 7) (NNS days)) (RB later)) (, ,) (NP (NP (DT a) (ADJP (RB highly) (JJ significant)) (NN correlation)) (PRN (-LRB- -LRB-) (NP (NN r) (SYM =) (CD 0.83)) (, ,) (NP (NP (CD 2) (NN p)) (NP (SYM =) (CD 0.006))) (-RRB- -RRB-)) (PP (TO to) (NP (NP (DT the) (NN slope)) (PP (IN of) (NP (NP (DT the) (NN fall)) (PP (IN in) (NP (NN blood))) (NP (NNP Doc_3155884_668_675_Chemical)) (SBAR (IN after) (S (NP (NN insulin) (NN treatment)) (VP (VBD appeared)))))))))))) (. .)))
3155884	4	(S1 (S (NP (NP (DT The) (JJ myocardial) (NN content)) (PP (IN of) (NP (NNP Doc_3155884_736_750_Chemical)))) (VP (AUX was) (VP (VBN estimated) (PP (IN in) (NP (DT these) (CD 8) (NN day) (NN Doc_3155884_780_788_Disease) (NNS rats))))) (. .)))
3155884	5	(S1 (S (NP (DT The) (JJ Doc_3155884_799_813_Chemical) (NN content)) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN increased) (SBAR (IN while) (S (NP (NNP Doc_3155884_856_867_Chemical)) (VP (VBD remained) (ADJP (JJ unchanged))))))) (. .)))
3155884	6	(S1 (S (NP (NP (DT An) (JJ enhanced) (JJ sympathetic) (JJ nervous) (NN system) (NN activity)) (PP (IN with) (NP (NP (DT a) (JJ consequent) (JJ down) (NN regulation)) (PP (IN of) (NP (DT the) (JJ myocardial) (JJ beta-adrenergic) (NNS receptors)))))) (VP (MD could) (, ,) (ADVP (RB therefore)) (, ,) (VP (VB explain) (NP (DT this) (JJ Doc_3155884_1045_1058_Chemical) (NN resistance)))) (. .)))
3155884	7	(S1 (S (NP (NP (DT The) (JJ rapid) (NN reversion)) (PP (IN after) (NP (NN insulin) (NN treatment)))) (VP (VP (VBZ excludes) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP (NP (NNP Doc_3155884_1145_1159_Chemical)) (PP (IN in) (NP (PRP itself)))) (VP (VBZ causes) (NP (DT the) (JJ Doc_3155884_1181_1184_Chemical) (NN resistance))))))) (CC and) (VP (VBZ points) (PP (IN towards) (NP (NP (DT a) (JJ direct) (NN insulin) (NN effect)) (PP (IN on) (NP (NP (JJ myocardial) (JJ Doc_3155884_1253_1266_Chemical) (NN sensitivity)) (PP (IN in) (NP (JJ Doc_3155884_1282_1290_Disease) (NNS rats))))))))) (. .)))
3155884	8	(S1 (S (NP (NP (DT The) (NN phenomenon)) (VP (VBN described))) (VP (VP (MD might) (VP (VB elucidate) (NP (JJ pathogenetic) (NNS mechanisms)) (PP (IN behind) (NP (JJ toxic) (JJ myocardial) (NN cell) (NN degeneration))))) (CC and) (VP (MD may) (ADVP (RB possibly)) (VP (AUX have) (NP (NN relevance)) (PP (IN for) (NP (NP (JJ acute) (NNP Doc_3155884_1446_1474_Disease)) (PP (IN in) (NP (NNP Doc_3155884_1478_1486_Disease) (NNS patients)))))))) (. .)))
3191389	0	(S1 (S (NP (NP (NN Differential) (NNS effects)) (PP (IN of) (NP (JJ non-steroidal) (JJ anti-inflammatory) (NNS drugs))) (PP (IN on) (NP (NNP Doc_3191389_65_73_Disease)))) (VP (VBN produced) (PP (IN by) (NP (NP (NNP Doc_3191389_86_97_Chemical)) (PP (IN in) (NP (NNS rats)))))) (. .)))
3191389	1	(S1 (S (NP (DT The) (JJ muscarinic) (JJ cholinergic) (NN agonist) (NN Doc_3191389_142_153_Chemical)) (VP (VBZ induces) (PP (IN in) (NP (NNS rats) (NNP Doc_3191389_170_178_Disease) (CC and) (NNP Doc_3191389_183_201_Disease))) (S (VP (VBN followed) (PP (IN by) (NP (NP (JJ widespread) (NN damage)) (PP (TO to) (NP (DT the) (NN forebrain)))))))) (. .)))
3191389	2	(S1 (S (NP (DT The) (JJ present) (NN study)) (VP (AUX was) (VP (VBN designed) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (CD 5) (JJ non-steroidal) (JJ anti-inflammatory) (NNS drugs)) (, ,) (NP (NNP Doc_3191389_351_368_Chemical) (, ,) (NNP Doc_3191389_370_384_Chemical) (, ,) (NNP Doc_3191389_386_398_Chemical) (, ,) (NNP Doc_3191389_400_409_Chemical) (CC and) (NNP Doc_3191389_414_428_Chemical)) (, ,))) (PP (IN on) (NP (NP (NNP Doc_3191389_433_441_Disease)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_3191389_454_465_Chemical)))))))))))) (. .)))
3191389	3	(S1 (S (NP (NP (NN Pretreatment)) (PP (IN of) (NP (NNS rats))) (PP (IN with) (NP (NP (NNP Doc_3191389_493_510_Chemical)) (, ,) (NP (NP (QP (CD ED50) (CD 103)) (NNS mg/kg)) (PRN (-LRB- -LRB-) (NP (CD 60-174)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_3191389_541_555_Chemical)) (, ,) (NP (CD 59) (NN mg/kg)) (PRN (-LRB- -LRB-) (NP (CD 50-70)) (-RRB- -RRB-)))))) (VP (VBD converted) (NP (NP (DT the) (JJ non-convulsant) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_3191389_611_622_Chemical)) (, ,) (NP (CD 200) (NN mg/kg)) (, ,)))) (PP (TO to) (NP (DT a) (JJ convulsant) (CD one)))) (. .)))
3191389	4	(S1 (S (NP (NP (NP (NNP Doc_3191389_656_668_Chemical)) (, ,) (NP (CD 1-10) (NN mg/kg)) (, ,)) (CC and) (NP (NP (NNP Doc_3191389_686_695_Chemical)) (, ,) (NP (CD 10-100) (NN mg/kg)) (, ,))) (VP (VBD failed) (S (VP (TO to) (VP (VBP modulate) (NP (NP (NNP Doc_3191389_730_738_Disease)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_3191389_751_762_Chemical))))))))) (. .)))
3191389	5	(S1 (S (NP (NP (NNP Doc_3191389_764_778_Chemical)) (, ,) (NP (CD 26) (-LRB- -LRB-) (NN 22-30) (-RRB- -RRB-) (NN mg/kg)) (, ,)) (VP (VBD prevented) (NP (NP (NNP Doc_3191389_808_816_Disease)) (CC and) (NP (VBN protected) (NNS rats))) (PP (IN from) (NP (NP (NNP Doc_3191389_841_848_Disease-related) (NNP Doc_3191389_857_869_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_3191389_881_892_Chemical)) (, ,) (NP (CD 380) (NN mg/kg)))))))) (. .)))
3191389	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ non-steroidal) (JJ anti-inflammatory) (NNS drugs)) (ADVP (RB differentially)) (VP (VBP modulate) (NP (NP (DT the) (NN threshold)) (PP (IN for) (NP (JJ Doc_3191389_1013_1024_Chemical-induced) (NN Doc_3191389_1033_1041_Disease)))))))) (. .)))
3289726	0	(S1 (NP (NP (NN Doc_3289726_0_28_Disease)) (PP (IN after) (NP (NP (JJ high-dose) (JJ Doc_3289726_45_54_Chemical) (NN therapy)) (PP (IN for) (NP (NNP Doc_3289726_67_83_Disease))))) (. .)))
3289726	1	(S1 (S (NP (NP (NNP Doc_3289726_85_94_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3289726_96_105_Chemical)) (-RRB- -RRB-))) (VP (AUX has) (VP (AUX been) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (JJ many) (JJ solid) (NNP Doc_3289726_152_158_Disease)) (CC and) (NP (NNP Doc_3289726_163_187_Disease))))))))) (. .)))
3289726	2	(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN used) (PP (PP (IN in) (NP (JJ high) (NNS doses))) (CC and) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (JJ autologous) (NN bone) (NN marrow) (NN transplantation))))))))) (, ,) (NP (DT this) (NN agent)) (VP (AUX has) (NP (NN activity)) (PP (IN against) (NP (NP (JJ several) (JJ treatment-resistant) (NN Doc_3289726_337_344_Disease)) (PP (VBG including) (NP (NNP Doc_3289726_355_371_Disease)))))) (. .)))
3289726	3	(S1 (S (PP (IN In) (NP (NP (CD six)) (PP (IN of) (NP (NP (NP (CD eight) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 75) (NN %)) (-RRB- -RRB-))) (SBAR (WHNP (WP who)) (S (NP (PRP we)) (VP (VBD treated) (PP (IN for) (NP (NN recurrent) (CC or) (NN resistant) (NN Doc_3289726_446_452_Disease)))))))))) (, ,) (NP (NNP Doc_3289726_454_492_Disease)) (VP (VBD occurred)) (. .)))
3289726	4	(S1 (S (NP (DT This)) (VP (VBD developed) (NP (NP (DT a) (NN median)) (PP (IN of) (NP (CD 9) (NNS days)))) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ high-dose) (JJ Doc_3289726_567_576_Chemical) (NN therapy)))))) (. .)))
3289726	5	(S1 (S (NP (JJ Significant) (JJ clinical) (NNS manifestations)) (VP (AUX have) (VP (VBN included) (NP (NP (NNP Doc_3289726_636_645_Disease)) (, ,) (NP (NNP Doc_3289726_647_658_Disease)) (, ,) (NP (NP (NNP Doc_3289726_660_670_Disease)) (, ,) (NP (NP (NN exacerbation)) (PP (IN of) (NP (NN motor) (NNS deficits)))) (, ,)) (CC and) (NP (NP (JJ sharp) (NN increase)) (PP (IN in) (NP (JJ Doc_3289726_726_733_Disease) (NN activity))))))) (. .)))
3289726	6	(S1 (S (NP (DT These) (NNS abnormalities)) (VP (VBD resolved) (ADVP (RB rapidly)) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (JJ high-dose) (JJ intravenous) (NN Doc_3289726_823_836_Chemical) (NN therapy)))))) (. .)))
3289726	7	(S1 (S (PP (IN In) (NP (DT all) (NNS patients))) (, ,) (NP (JJ computerized) (JJ tomographic) (PRN (-LRB- -LRB-) (NP (NNP CT)) (-RRB- -RRB-)) (NN brain) (NNS scans)) (VP (VBD demonstrated) (NP (NP (NN stability)) (PP (IN in) (NP (NP (JJ Doc_3289726_931_936_Disease) (NN size)) (CC and) (NP (NN peritumor) (NN Doc_3289726_956_961_Disease))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NN pretransplant) (NNS scans))))))) (. .)))
3289726	8	(S1 (S (NP (DT This) (NN complication)) (VP (VBZ appears) (S (VP (TO to) (VP (VB represent) (NP (NP (DT a) (JJ significant) (JJ new) (NN Doc_3289726_1059_1067_Disease)) (PP (IN of) (NP (JJ high-dose) (JJ Doc_3289726_1081_1090_Chemical) (NN therapy))) (PP (IN for) (NP (NN Doc_3289726_1103_1119_Disease)))))))) (. .)))
3297909	0	(S1 (NP (NP (NNP Progressive) (NNP Doc_3297909_12_28_Disease)) (PP (IN after) (NP (NNP Doc_3297909_35_48_Chemical) (NN administration))) (. .)))
3297909	1	(S1 (S (NP (DT A) (JJ 27-yr-old) (NN man)) (VP (VBD developed) (NP (NNP Doc_3297909_91_99_Disease) (CD 2)) (ADVP (RB wk)) (PP (IN after) (NP (NP (NN exposure)) (PP (TO to) (NP (NNP Doc_3297909_123_136_Chemical)))))) (. .)))
3297909	2	(S1 (S (NP (NN Doc_3297909_138_149_Disease)) (VP (VBD persisted) (PP (IN for) (NP (NP (CD 3) (NN yr)) (, ,) (SBAR (WHPP (IN at) (WHNP (WDT which) (NN time))) (S (NP (DT a) (NN liver) (NN transplant)) (VP (AUX was) (VP (VBN performed)))))))) (. .)))
3297909	3	(S1 (S (NP (NP (CD Two) (NN liver) (NN biopsy) (NNS specimens)) (CC and) (NP (DT the) (JJ hepatectomy) (NNS specimen))) (VP (AUX were) (ADJP (JJ remarkable) (PP (IN for) (NP (NP (ADJP (RB almost) (JJ complete)) (NN disappearance)) (PP (IN of) (NP (JJ interlobular) (JJ bile) (NNS ducts))))))) (. .)))
3297909	4	(S1 (S (S (NP (NP (JJ Prominent) (NN Doc_3297909_362_370_Disease)) (CC and) (NP (JJ hepatocellular) (NN regeneration))) (VP (AUX were) (ADVP (RB also)) (ADJP (JJ present)))) (: ;) (S (ADVP (RB however)) (, ,) (NP (DT the) (JJ lobular) (NN architecture)) (VP (AUX was) (VP (VBN preserved)))) (. .)))
3297909	5	(S1 (S (NP (DT This) (NN case)) (VP (VBZ represents) (NP (NP (DT an) (NN example)) (PP (IN of) (NP (NP (`` ``) (JJ idiosyncratic) ('' '') (JJ drug-induced) (NNP Doc_3297909_535_547_Disease)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (DT the) (JJ primary) (NN target)) (PP (IN of) (NP (NN injury)))) (VP (AUX is) (NP (DT the) (JJ bile) (NN duct))))))))) (. .)))
3297909	6	(S1 (S (NP (NP (DT An) (JJ autoimmune) (NN pathogenesis)) (PP (IN of) (NP (DT the) (JJ bile) (NN duct) (NN destruction)))) (VP (AUX is) (VP (VBN suggested))) (. .)))
3323259	0	(S1 (NP (NP (NP (NN Differential) (NNS effects)) (PP (IN of) (NP (JJ Doc_3323259_24_51_Chemical) (NN channel) (NNS blockers)))) (: :) (NP (JJ therapeutic) (NNS implications)) (. .)))
3323259	1	(S1 (S (NP (NP (JJ Increasing) (NN recognition)) (PP (IN of) (NP (NP (DT the) (NN importance)) (PP (IN of) (NP (NNP Doc_3323259_140_147_Chemical))) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NNP Doc_3323259_171_193_Disease)))))))) (VP (AUX has) (VP (VBN stimulated) (NP (NN research)) (PP (IN into) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (JJ Doc_3323259_234_241_Chemical) (NN channel)) (VP (VBG blocking) (NP (NNS agents)) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNP Doc_3323259_296_319_Disease)))))))))))))) (. .)))
3323259	2	(S1 (S (NP (NP (DT The) (JJ favorable) (NN efficacy) (CC and) (NN tolerability) (NNS profiles)) (PP (IN of) (NP (DT these) (NNS agents)))) (VP (VBP make) (NP (DT them) (JJ attractive) (JJ therapeutic) (NNS modalities))) (. .)))
3323259	3	(S1 (S (NP (NP (JJ Clinical) (NNS applications)) (PP (IN of) (NP (JJ Doc_3323259_456_463_Chemical) (NN channel) (NNS blockers)))) (VP (VB parallel) (NP (PRP$ their) (NN tissue) (NN selectivity))) (. .)))
3323259	4	(S1 (S (PP (IN In) (NP (NP (NN contrast)) (PP (TO to) (NP (NP (NNP Doc_3323259_531_540_Chemical) (CC and) (NNP Doc_3323259_545_554_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX are) (ADJP (RB roughly) (JJ equipotent) (PP (IN in) (NP (PRP$ their) (NNS actions)))) (PP (IN on) (NP (NP (DT the) (NN heart)) (CC and) (NP (JJ vascular) (JJ smooth) (NN muscle))))))))))) (, ,) (NP (DT the) (NNP Doc_3323259_647_670_Chemical) (NN channel) (NNS blockers)) (VP (AUX are) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (JJ potent) (JJ peripheral) (NN vasodilator) (NNS agents))) (SBAR (WHNP (WDT that)) (S (VP (VBP exert) (NP (NP (JJ minimal) (JJ electrophysiologic) (NNS effects)) (PP (IN on) (NP (NP (JJ cardiac) (NN nodal)) (CC or) (NP (JJ conduction) (NN tissue)))))))))) (. .)))
3323259	5	(S1 (S (PP (IN As) (NP (NP (DT the) (JJ first) (NN Doc_3323259_838_853_Chemical)) (ADJP (JJ available) (PP (IN for) (NP (NP (NN use)) (PP (IN in) (NP (DT the) (NNP United) (NNPS States)))))))) (, ,) (NP (NNP Doc_3323259_894_904_Chemical)) (VP (VBZ controls) (NP (NP (NNP Doc_3323259_914_920_Disease)) (CC and) (NP (NNP Doc_3323259_925_937_Disease))) (PP (IN with) (NP (NP (JJ minimal) (NN Doc_3323259_951_961_Disease)) (PP (IN of) (NP (JJ cardiac) (NN function)))))) (. .)))
3323259	6	(S1 (S (NP (NP (JJ Additional) (NNS members)) (PP (IN of) (NP (NP (DT this) (NN group)) (PP (IN of) (NP (JJ Doc_3323259_1019_1026_Chemical) (NN channel) (NNS blockers)))))) (VP (AUX have) (VP (AUX been) (VP (VBN studied) (PP (IN for) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS indications) (SBAR (WHPP (IN for) (WHNP (WDT which))) (S (NP (PRP they)) (VP (MD may) (VP (VB offer) (NP (NNS advantages)) (PP (IN over) (NP (JJ current) (NN therapy)))))))))))))) (. .)))
3323259	7	(S1 (SINV (ADVP (RB Once) (CC or) (RB twice) (NP (JJ daily) (NN dosage))) (ADJP (JJ possible) (PP (IN with) (NP (NP (NNP Doc_3323259_1190_1202_Chemical)) (CC and) (NP (NNP Doc_3323259_1207_1218_Chemical))))) (VP (VBZ offers)) (NP (NP (DT a) (JJ convenient) (NN administration) (NN schedule)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ encourages) (NP (JJ patient) (NN compliance)) (PP (IN in) (NP (NP (JJ long-term) (NN therapy)) (PP (IN of) (NP (NNP Doc_3323259_1324_1336_Disease))))))))) (. .)))
3323259	8	(S1 (S (NP (NP (DT The) (JJ coronary) (JJ vasodilating) (NNS properties)) (PP (IN of) (NP (NNP Doc_3323259_1378_1389_Chemical)))) (VP (AUX have) (VP (VBN led) (PP (TO to) (NP (NP (DT the) (NN investigation)) (PP (IN of) (NP (NP (DT this) (NN agent)) (PP (IN for) (NP (NP (NN use)) (PP (IN in) (NP (NNP Doc_3323259_1445_1451_Disease))))))))))) (. .)))
3323259	9	(S1 (S (NP (NP (NN Selectivity)) (PP (IN for) (NP (DT the) (JJ cerebrovascular) (NN bed)))) (VP (VBZ makes) (S (NP (NNP Doc_3323259_1499_1509_Chemical)) (ADJP (RB potentially) (JJ useful) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_3323259_1549_1572_Disease)) (, ,) (NP (NNP Doc_3323259_1574_1591_Disease)) (, ,) (NP (NNP Doc_3323259_1593_1601_Disease)) (, ,) (CC and) (NP (NNP Doc_3323259_1607_1613_Disease))))))))) (. .)))
3323259	10	(S1 (S (PP (IN In) (ADJP (JJ general))) (, ,) (NP (DT the) (NNP Doc_3323259_1631_1654_Chemical) (NN channel) (NNS blockers)) (VP (AUX are) (ADVP (RB usually)) (VP (ADVP (RB well)) (VBN tolerated) (, ,) (PP (IN with) (S (NP (NP (NP (NNP Doc_3323259_1705_1713_Disease)) (, ,) (NP (JJ facial) (NN flushing) (, ,) (NNS palpitations) (, ,) (NNP Doc_3323259_1746_1751_Disease) (, ,) (NNP Doc_3323259_1753_1759_Disease) (, ,) (NNP Doc_3323259_1761_1769_Disease)) (, ,)) (CC and) (NP (NNP Doc_3323259_1775_1784_Disease))) (VP (AUXG being) (NP (DT the) (RBR more) (JJ common) (JJ adverse) (NNS effects))))))) (. .)))
3323599	0	(S1 (NP (NP (DT The) (NN enhancement)) (PP (IN of) (NP (NNP Doc_3323599_19_34_Chemical) (NNP Doc_3323599_35_44_Disease))) (PP (IN by) (NP (NP (DT the) (NN co-administration)) (PP (IN of) (NP (NNP Doc_3323599_73_82_Chemical))))) (. .)))
3323599	1	(S1 (S (NP (NP (DT An) (JJ experimental) (NN model)) (PP (IN of) (NP (NP (NNP Doc_3323599_109_145_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3323599_147_151_Disease)) (-RRB- -RRB-))))) (VP (AUX was) (VP (VBN developed) (PP (IN in) (NP (NNS rats))) (PP (IN by) (NP (NP (DT the) (VBN combined) (NN administration)) (PP (IN of) (NP (NP (NP (NNP Doc_3323599_209_234_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3323599_236_240_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_3323599_246_263_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP PS)) (-RRB- -RRB-))))))))) (. .)))
3323599	2	(S1 (S (NP (NP (JJ Male) (JJ Sprague-Dawley) (NNS rats)) (, ,) (VP (VBN uninephrectomized) (ADVP (NP (CD three) (NNS weeks)) (RB before))) (, ,)) (VP (VBD received) (NP (NP (JJ daily) (NNS injections)) (PP (IN of) (NP (NP (NP (JJ subcutaneous) (NNS AMNS)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CD mg/100)) (NNP g) (NN body) (NNS wt)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ intravenous) (NNP PS)) (PRN (-LRB- -LRB-) (NP (NP (CD 2) (JJ separated) (NNS doses)) (PP (IN of) (NP (QP (CD 2.5) (CD mg/100)) (NNP g) (NN body) (NNS wt)))) (-RRB- -RRB-)))))) (PP (IN for) (NP (CD four) (NNS days)))) (. .)))
3323599	3	(S1 (S (NP (NP (DT The) (NN series)) (PP (IN of) (NP (NNS injections)))) (VP (AUX were) (VP (VBN repeated) (NP (DT another) (CD three) (NNS times)) (PP (IN at) (NP (CD 10) (NN day) (NNS intervals))))) (. .)))
3323599	4	(S1 (S (NP (DT The) (NNS animals)) (VP (AUX were) (VP (VBN sacrificed) (PP (IN on) (NP (NNS days))) (NP (NP (CD 24)) (, ,) (NP (CD 52)) (, ,) (CC and) (NP (CD 80))))) (. .)))
3323599	5	(S1 (S (NP (PRP They)) (VP (VBD developed) (NP (NP (NNP Doc_3323599_627_645_Disease)) (CC and) (NP (NNP Doc_3323599_650_671_Disease)))) (. .)))
3323599	6	(S1 (S (NP (NP (DT The) (JJ time-course) (NN curve)) (PP (IN of) (NP (JJ Doc_3323599_698_708_Chemical) (NN clearance)))) (VP (VP (VBD dropped)) (CC and) (VP (VBD showed) (NP (NP (JJ significant) (NN difference)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-))) (PP (IN from) (NP (NP (DT that)) (PP (IN of) (NP (DT each) (NN control) (NN group))))) (, ,) (ADJP (JJ such) (SBAR (IN as) (, ,) (S (NP (NP (NP (NNS AMNS)) (ADVP (RB alone))) (, ,) (NP (NP (NNP PS)) (ADVP (RB alone))) (CC or) (NP (NN saline))) (VP (VBN injected))))))) (. .)))
3323599	7	(S1 (S (NP (PRP$ Their) (NNS glomeruli)) (VP (VBD showed) (NP (NP (NNS changes)) (PP (IN of) (NP (JJ progressive) (NNP Doc_3323599_909_913_Disease))))) (. .)))
3323599	8	(S1 (S (NP (NP (DT The) (JJ ultrastructural) (NNS studies)) (PP (IN in) (NP (DT the) (JJ initial) (NN stage)))) (VP (VP (VBD revealed) (NP (NP (JJ significant) (NN lack)) (PP (IN of) (NP (NP (NNS particles)) (PP (IN of) (NP (NP (JJ perfused) (JJ Doc_3323599_1015_1024_Chemical) (NN red)) (PP (IN on) (NP (DT the) (FW lamina) (FW rara) (FW externa))))))))) (CC and) (VP (VBD marked) (NP (NP (NNS changes)) (PP (IN in) (NP (JJ epithelial) (NN cell) (NN cytoplasm)))))) (. .)))
3323599	9	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (PRP it)) (VP (AUX is) (VP (VBN suggested) (SBAR (IN that) (S (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP PS)))) (VP (VP (VBZ enhances) (NP (NP (DT the) (NN Doc_3323599_1175_1183_Disease)) (PP (IN of) (NP (NNS AMNS)))) (PP (IN on) (NP (DT the) (NN glomerulus)))) (CC and) (VP (ADVP (RB readily)) (VBZ produces) (NP (JJ progressive) (NN Doc_3323599_1243_1247_Disease)) (PP (IN in) (NP (NP (NNS rats)) (VP (VBG resulting) (PP (IN in) (NP (DT the) (NNP Doc_3323599_1273_1296_Disease)))))))))))) (. .)))
3339945	0	(S1 (NP (NP (NNP Doc_3339945_0_12_Chemical) (NNP Doc_3339945_13_26_Disease)) (PP (IN in) (NP (JJ pregnant) (NNS rats))) (. .)))
3339945	1	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN investigation)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (DT the) (NNP Doc_3339945_108_121_Disease)) (PP (IN of) (NP (NNP Doc_3339945_125_137_Chemical)))) (VP (AUX is) (VP (VBN altered) (PP (IN in) (NP (JJ advanced) (NN pregnancy))))))))))) (. .)))
3339945	2	(S1 (S (NP (NP (NP (JJ Sprague-Dawley) (NNS rats)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (ADJP (NP (CD 20) (NNS days)) (JJ pregnant)))))) (CC and) (NP (NP (JJ nonpregnant) (NNS rats)) (PP (IN of) (NP (DT the) (JJ same) (NN age) (CC and) (NN strain))))) (VP (VBD received) (NP (NP (NNS infusions)) (PP (IN of) (NP (NNP Doc_3339945_289_302_Chemical)))) (PP (IN until) (NP (NP (NN onset)) (PP (IN of) (NP (JJ maximal) (NNP Doc_3339945_326_334_Disease))) (SBAR (WHNP (WDT which)) (S (VP (VBD occurred) (PP (IN after) (NP (QP (CD 28) (CC and) (CD 30)) (NNS minutes))) (ADVP (RB respectively)))))))) (. .)))
3339945	3	(S1 (S (S (NP (NP (JJ Doc_3339945_388_400_Chemical) (NNS concentrations)) (PP (IN at) (NP (DT this) (NN endpoint))) (PP (IN in) (NP (NP (NP (NN serum)) (PRN (-LRB- -LRB-) (NP (NN total)) (-RRB- -RRB-))) (CC and) (NP (NNP CSF))))) (VP (AUX were) (ADJP (JJ similar) (CC but) (JJ serum)))) (PRN (-LRB- -LRB-) (VB free) (-RRB- -RRB-)) (CC and) (S (NP (NN brain) (NNS concentrations)) (VP (AUX were) (ADJP (RB slightly) (JJ different)) (PP (IN in) (NP (JJ pregnant) (NNS rats))))) (. .)))
3339945	4	(S1 (S (NP (NP (JJ Doc_3339945_555_567_Chemical) (NN serum) (NN protein) (VBG binding)) (VP (VBN determined) (PP (IN by) (NP (NN equilibrium) (NN dialysis))))) (VP (AUX was) (ADJP (JJR lower)) (PP (IN in) (NP (JJ pregnant) (NNS rats)))) (. .)))
3339945	5	(S1 (S (NP (NP (JJ Fetal) (NN serum) (NNS concentrations)) (PP (IN at) (NP (NP (NN onset)) (PP (IN of) (NP (NNP Doc_3339945_692_700_Disease))))) (PP (IN in) (NP (DT the) (NN mother)))) (VP (VP (AUX were) (ADJP (JJ similar) (PP (TO to) (NP (JJ maternal) (NN brain) (CC and) (NNP CSF) (NNS concentrations))))) (CC and) (VP (VBD correlated) (ADVP (RB significantly)) (PP (IN with) (NP (DT the) (JJ former))))) (. .)))
3339945	6	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (JJ advanced) (NN pregnancy)) (VP (AUX has) (NP (NP (DT a) (JJ negligible) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ Doc_3339945_886_896_Disease) (NN response)) (PP (TO to) (NP (NP (NNP Doc_3339945_909_921_Chemical)) (PP (IN in) (NP (NNS rats))))))))))))) (. .)))
3375885	0	(S1 (S (NP (NN Doc_3375885_0_12_Disease)) (VP (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_3375885_24_36_Chemical)) (CC and) (NP (NNP Doc_3375885_41_49_Chemical))))) (CC and) (VP (VBN reversed) (PP (IN by) (NP (NNP Doc_3375885_66_81_Chemical))))) (. .)))
3375885	1	(S1 (S (NP (PRP We)) (VP (AUX have) (VP (VBD described) (NP (NP (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (JJ severe) (NNP Doc_3375885_123_143_Disease)))) (CC and) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_3375885_161_175_Chemical) (NNP Doc_3375885_176_187_Disease))))) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NP (NNP Doc_3375885_196_208_Disease)) (CC and) (NP (JJ inappropriate) (NNP Doc_3375885_227_244_Disease))) (VP (AUX were) (VP (VBN caused) (PP (IN by) (NP (DT both) (NNP Doc_3375885_265_277_Chemical) (CC and) (NNP Doc_3375885_282_290_Chemical))) (, ,) (PP (IN without) (NP (JJ major) (NN Doc_3375885_306_331_Disease)))))))))) (. .)))
3375885	2	(S1 (S (NP (PRP It)) (VP (AUX is) (ADJP (JJ likely)) (SBAR (IN that) (S (NP (JJ preexisting) (NNP Doc_3375885_363_376_Disease)) (VP (VBD predisposed) (NP (DT this) (NN patient)) (PP (TO to) (NP (NP (NN type) (NN Doc_3375885_410_435_Disease)) (PP (IN with) (NP (JJ Doc_3375885_441_454_Chemical) (NN synthetase) (NNS inhibitors))))))))) (. .)))
3375885	3	(S1 (S (SBAR (IN Because) (S (NP (PRP he)) (VP (AUX was) (ADJP (JJ unable) (S (VP (TO to) (VP (VB discontinue) (NP (JJ nonsteroidal) (JJ anti-inflammatory) (NN drug) (NN therapy))))))))) (, ,) (NP (NNP Doc_3375885_560_575_Chemical) (AUX was)) (VP (VBD added) (, ,) (S (VP (VP (VBG correcting) (NP (DT the) (NNP Doc_3375885_602_614_Disease))) (CC and) (VP (VBG allowing) (NP (NP (JJ Doc_3375885_628_640_Chemical) (NN therapy)) (SBAR (S (VP (TO to) (VP (AUX be) (VP (VBN continued) (ADVP (RB safely)))))))))))) (. .)))
3383127	0	(S1 (S (VP (VBP Doc_3383127_0_11_Disease) (PP (IN as) (NP (NP (DT a) (NN manifestation)) (PP (IN of) (NP (NNP Doc_3383127_34_48_Disease))))) (PP (IN in) (NP (NP (CD three) (NNS patients)) (VP (VBG receiving) (NP (NP (NNP Doc_3383127_77_86_Chemical)) (CC and) (NP (NNP Doc_3383127_91_105_Chemical))))))) (. .)))
3383127	1	(S1 (S (NP (NP (NN Doc_3383127_107_123_Disease)) (, ,) (PP (VBG including) (NP (NNP Doc_3383127_135_146_Disease))) (, ,)) (VP (VBD developed) (PP (IN in) (NP (CD three) (NNS patients))) (PP (IN with) (NP (JJ advanced) (NN Doc_3383127_190_210_Disease))) (SBAR (IN while) (S (VP (AUXG being) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NNP Doc_3383127_236_245_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3383127_247_251_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_3383127_257_271_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3383127_273_277_Chemical)) (-RRB- -RRB-)))))))))) (. .)))
3383127	2	(S1 (S (PP (IN In) (NP (CD two) (NNS patients))) (, ,) (NP (NNP Doc_3383127_297_308_Disease)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (JJ severe) (NN Doc_3383127_336_364_Disease))))) (. .)))
3383127	3	(S1 (S (NP (DT All) (CD three) (NNS patients)) (VP (VBD required) (NP (NN therapy) (NN discontinuation))) (. .)))
3383127	4	(S1 (S (NP (JJ Cardiac) (NNS enzymes)) (VP (VBD remained) (ADJP (JJ normal)) (PP (IN despite) (NP (JJ transient) (JJ electrocardiographic) (PRN (-LRB- -LRB-) (JJ EKG) (-RRB- -RRB-)) (NNS changes)))) (. .)))
3383127	5	(S1 (S (NP (NP (NP (DT The) (NN presentation)) (CC and) (NP (JJ cardiac) (NN evaluation))) (PRN (-LRB- -LRB-) (ADJP (JJ hemodynamic) (, ,) (JJ echocardiographic) (, ,) (CC and) (JJ scintigraphic)) (-RRB- -RRB-)) (PP (IN of) (NP (DT these) (NNS patients)))) (VP (VBP suggest) (NP (NP (JJ new) (NNS manifestations)) (PP (IN of) (NP (NNP Doc_3383127_645_649_Chemical) (NNP Doc_3383127_650_664_Disease))) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (AUX be) (VP (VBN influenced) (PP (IN by) (NP (NNP Doc_3383127_691_695_Chemical)))))))))) (. .)))
3383127	6	(S1 (S (NP (DT The) (JJ possible) (JJ pathophysiologic) (NNS mechanisms)) (VP (AUX are) (VP (VBN discussed))) (. .)))
3409843	0	(S1 (NP (NP (JJ Fatal) (NNP Doc_3409843_6_21_Disease)) (PP (IN in) (NP (DT a) (NN patient))) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_3409843_48_61_Chemical)))) (. .)))
3409843	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (JJ fatal) (NNP Doc_3409843_79_94_Disease))) (PP (JJ due) (TO to) (NP (NP (JJ Doc_3409843_102_115_Chemical) (NN treatment)) (PP (IN in) (NP (DT an) (JJ Doc_3409843_132_141_Disease) (NN woman)))))) (VP (AUX is) (VP (VBN reported))) (. .)))
3409843	2	(S1 (S (PP (IN Despite) (NP (NP (NNS concerns)) (PP (IN of) (NP (JJ fatal) (NN bone) (NN Doc_3409843_192_207_Disease))) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_3409843_215_228_Chemical)))))) (, ,) (NP (DT this)) (VP (AUX is) (ADVP (RB only)) (NP (DT the) (ADJP (RB fourth) (VBN documented) (CC and) (VBN published)) (NN report))) (. .)))
3409843	3	(S1 (S (S (NP (NNP Doc_3409843_287_300_Chemical)) (VP (AUX is) (NP (DT a) (JJ safe) (NN drug)))) (, ,) (CC but) (S (NP (NP (NNS physicians)) (CC and) (NP (NNS patients))) (VP (MD should) (VP (AUX be) (ADJP (JJ aware) (PP (IN of) (NP (NP (DT the) (ADJP (ADJP (RB exceedingly) (JJ rare)) (CC but) (ADJP (RB potentially) (JJ fatal))) (JJ side) (NNS effects)) (, ,) (VP (ADVP (RB better)) (VBN prevented) (PP (IN by) (S (VP (JJ clinical) (PP (IN than) (PP (IN by) (NP (NN laboratory) (NN monitoring)))))))))))))) (. .)))
3423103	0	(S1 (NP (NP (NN Participation)) (PP (IN of) (NP (DT a) (JJ bulbospinal) (JJ serotonergic) (NN pathway))) (PP (IN in) (NP (NP (DT the) (NN rat) (NN brain)) (PP (IN in) (NP (NNP Doc_3423103_72_81_Chemical-induced) (NNP Doc_3423103_90_101_Disease) (CC and) (NNP Doc_3423103_106_117_Disease))))) (. .)))
3423103	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NN microinjection)) (PP (IN of) (NP (NP (NNP Doc_3423103_152_161_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (JJ 1-10) (NNS micrograms)) (PP (IN in) (NP (CD 1) (NN microliter)))) (-RRB- -RRB-)))))) (PP (IN into) (NP (NP (DT a) (NN region)) (ADJP (JJ adjacent) (PP (TO to) (NP (NP (DT the) (JJ ventrolateral) (NN surface)) (PP (IN of) (NP (DT the) (NN medulla) (NN oblongata)))))))) (PP (IN on) (NP (JJ cardiovascular) (NN function)))) (VP (AUX were) (VP (VBN assessed) (PP (IN in) (NP (JJ Doc_3423103_317_325_Chemical-anesthetized) (NNS rats))))) (. .)))
3423103	2	(S1 (S (NP (NP (NN Intramedullary) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_3423103_378_387_Chemical)) (, ,) (CONJP (CC but) (RB not)) (NP (NN saline) (NN vehicle)) (, ,)))) (VP (VBD caused) (NP (NP (DT a) (JJ dose-dependent) (NN decrease)) (PP (IN in) (NP (NP (PDT both) (DT the) (JJ mean) (JJ arterial) (NN pressure)) (CC and) (NP (DT the) (NN heart) (NN rate)))))) (. .)))
3423103	3	(S1 (S (NP (DT The) (JJ Doc_3423103_505_514_Chemical-induced) (NN Doc_3423103_523_534_Disease)) (VP (AUX was) (VP (VBN antagonized) (PP (IN by) (NP (NP (JJ prior) (JJ spinal) (NN transection)) (, ,) (CONJP (CC but) (RB not)) (NP (JJ bilateral) (NN vagotomy)))))) (. .)))
3423103	4	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (DT the) (JJ Doc_3423103_631_640_Chemical-induced) (NN Doc_3423103_649_660_Disease)) (VP (AUX was) (VP (VBN antagonized) (PP (IN by) (NP (NP (JJ prior) (JJ bilateral) (NN vagotomy)) (, ,) (CONJP (CC but) (RB not)) (NP (JJ spinal) (NN transection)))))) (. .)))
3423103	5	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (JJ selective) (NN destruction)) (PP (IN of) (NP (NP (DT the) (JJ spinal) (JJ Doc_3423103_783_787_Chemical) (NNS nerves)) (, ,) (VP (VBN produced) (PP (IN by) (NP (NP (JJ bilateral) (NN spinal) (NN injection)) (PP (IN of) (NP (NNP Doc_3423103_838_861_Chemical)))))) (, ,)))) (VP (VBD reduced) (NP (NP (NP (DT the) (NN magnitude)) (PP (IN of) (NP (DT the) (NN vasodepressor)))) (CC or) (NP (NP (DT the) (JJ bradycardiac) (NNS responses)) (PP (TO to) (NP (NNP Doc_3423103_939_948_Chemical))) (VP (VBN microinjected) (PP (IN into) (NP (NP (DT the) (NN area)) (PP (IN near) (NP (NP (DT the) (JJ ventrolateral) (NN surface)) (PP (IN of) (NP (NP (DT the) (JJ medulla) (NN oblongata)) (PP (IN in) (NP (NNS rats))))))))))))) (. .)))
3423103	6	(S1 (S (NP (DT The) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (DT a) (JJ bulbospinal) (NN serotonergic) (NN pathway)) (VP (AUX is) (VP (VBN involved) (PP (IN in) (NP (NP (NN development)) (PP (IN of) (NP (NNP Doc_3423103_1130_1139_Chemical-induced) (NNP Doc_3423103_1148_1159_Disease) (CC and) (NNP Doc_3423103_1164_1175_Disease)))))))))) (. .)))
3423103	7	(S1 (S (NP (DT The) (VBN induced) (NN Doc_3423103_1189_1200_Disease)) (VP (AUX is) (VP (VBN brought) (PRT (RP about)) (PP (IN by) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (JJ sympathetic) (NN efferent) (NN activity))))) (, ,) (SBAR (IN whereas) (S (NP (DT the) (VBN induced) (NN Doc_3423103_1286_1297_Disease)) (VP (AUX was) (ADJP (JJ due) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ vagal) (NN efferent) (NN activity))))))))))) (. .)))
3439580	0	(S1 (S (NP (NP (NN Doc_3439580_0_12_Disease)) (PP (IN in) (NP (NNP Doc_3439580_16_29_Disease)))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_3439580_41_51_Chemical)))) (. .)))
3439580	1	(S1 (S (NP (NN Doc_3439580_53_65_Disease)) (VP (AUX is) (NP (NP (DT a) (JJ well-known) (NN finding)) (PP (IN in) (NP (NP (DT some) (NNS patients)) (PP (IN with) (NP (NNP Doc_3439580_112_125_Disease))))))) (. .)))
3439580	2	(S1 (S (ADVP (RB However)) (, ,) (NP (PRP it)) (VP (AUX has) (RB not) (ADVP (RB previously)) (VP (AUX been) (VP (VBN described) (PP (IN in) (NP (NN association))) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_3439580_204_214_Chemical)))))))) (. .)))
3439580	3	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NP (JJ severe) (NNP Doc_3439580_251_263_Disease)) (PRN (-LRB- -LRB-) (NP (NN blood) (NN pressure) (CD 190/160)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (DT a) (JJ 4-year-old) (NN girl)) (PP (IN with) (NP (NNP Doc_3439580_315_328_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBN given) (NP (NNP Doc_3439580_343_353_Chemical)) (S (VP (TO to) (VP (VB control) (NP (DT a) (NNP Doc_3439580_367_384_Disease))))))))))))) (. .)))
3439580	4	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN determined) (ADVP (RB later)) (SBAR (IN that) (S (NP (NP (DT this) (NN patient) (POS 's)) (NNP Doc_3439580_430_435_Disease)) (VP (AUX was) (VP (VBG recurring) (PP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (PRP$ her) (JJ Doc_3439580_469_481_Disease) (NN episode))))))))))) (. .)))
3439580	5	(S1 (S (SBAR (IN Since) (S (NP (PRP she)) (VP (AUX had) (NP (DT no) (NN blood) (NN pressure) (NN elevation)) (PP (IN at) (NP (NP (JJ initial) (NN diagnosis)) (CC and) (NP (NN none)))) (PP (VBG following) (NP (NP (NN discontinuation)) (PP (IN of) (NP (NP (DT the) (NNP Doc_3439580_596_606_Chemical)) (PRN (-LRB- -LRB-) (SBAR (WHADVP (WRB when)) (S (NP (PRP she)) (VP (AUX was) (PP (IN in) (NP (JJ florid) (NN relapse)))))) (-RRB- -RRB-))))))))) (, ,) (NP (PRP we)) (VP (VBP believe) (SBAR (IN that) (S (NP (NP (DT this) (NN drug)) (PP (RB rather) (IN than) (NP (PRP$ her) (JJ underlying) (NN disease)))) (ADVP (RB alone)) (VP (VBD caused) (NP (PRP$ her) (NN Doc_3439580_719_731_Disease)))))) (. .)))
3439580	6	(S1 (S (NP (NP (DT The) (NN mechanism)) (PP (IN for) (NP (DT this) (NN reaction)))) (VP (AUX is) (VP (VBN believed) (S (VP (TO to) (VP (AUX be) (NP (NP (VBN increased) (NNS levels)) (PP (IN of) (NP (JJ vasoactive) (NNP Doc_3439580_814_828_Chemical)))) (ADVP (RB due) (PP (TO to) (NP (NP (NN interference)) (PP (IN of) (NP (PRP$ their) (JJ physiologic) (NN inactivation))) (PP (IN by) (NP (NNP Doc_3439580_886_896_Chemical))))))))))) (. .)))
3439580	7	(S1 (S (PP (IN From) (NP (DT this) (NN experience))) (, ,) (NP (PRP we)) (VP (VBP urge) (NP (JJ extreme) (NN caution)) (PP (IN in) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (JJ tricyclic) (NNS antidepressants))) (PP (IN in) (NP (NP (NNS children)) (PP (IN with) (NP (JJ active) (NN Doc_3439580_1008_1021_Disease)))))))) (. .)))
3475563	0	(S1 (NP (NP (NN Rechallenge)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NN Doc_3475563_38_68_Disease)) (PP (IN with) (NP (NNP Doc_3475563_74_101_Chemical)))))))) (. .)))
3475563	1	(S1 (S (PP (IN Of) (NP (NP (CD 158) (JJ Doc_3475563_110_119_Disease) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN placed) (PP (IN on) (NP (JJ inhaled) (NN Doc_3475563_156_170_Chemical))))))))) (, ,) (NP (NP (CD 15)) (PRN (-LRB- -LRB-) (NP (CD 9.5) (NN %)) (-RRB- -RRB-))) (VP (VBD developed) (NP (NP (NP (DT either) (NN Doc_3475563_199_226_Disease)) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (DT both)) (PRN (-LRB- -LRB-) (NP (CD 1)) (-RRB- -RRB-))))) (. .)))
3475563	2	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (PRP$ their) (JJ adverse) (NNS reactions)) (VP (VBN subsided)))) (, ,) (NP (NP (CD seven)) (PP (IN of) (NP (DT these) (CD 15) (NNS patients)))) (VP (AUX were) (VP (VBN rechallenged) (PP (IN with) (NP (JJ inhaled) (NNP Doc_3475563_342_356_Chemical))))) (. .)))
3475563	3	(S1 (S (NP (DT These)) (VP (VBD included) (NP (NP (NP (CD five) (NNS cases)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NN hoarseness)))))) (CC and) (NP (NP (CD three)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NN Doc_3475563_433_444_Disease)))))))) (. .)))
3475563	4	(S1 (S (NP (CD One) (NN patient)) (VP (AUX had) (NP (DT both))) (. .)))
3475563	5	(S1 (S (S (NP (NN Doc_3475563_468_479_Disease)) (VP (AUX did) (RB not) (VP (VB recur)))) (, ,) (CC but) (S (NP (NP (NP (CD 60) (NN %)) (PRN (-LRB- -LRB-) (NP (NN 3/5)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NN hoarseness)))))) (VP (AUX had) (NP (NN recurrence)))) (. .)))
3475563	6	(S1 (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NNS patients)) (VP (MD may) (VP (AUX be) (VP (VBN restarted) (PP (IN on) (NP (JJ inhaled) (NN Doc_3475563_607_621_Chemical))) (SBAR (WHADVP (WRB when)) (S (ADVP (RB clinically)) (VP (VBN indicated))))))))))) (: ;) (S (ADVP (RB however)) (, ,) (PP (IN because) (IN of) (NP (DT the) (JJ high) (NN recurrence) (NN rate))) (, ,) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP develop) (NP (NN hoarseness)))))) (VP (MD should) (RB not) (VP (AUX be) (ADJP (JJ re-challenged))))) (. .)))
3475563	7	(S1 (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NP (JJ oral) (NNP Doc_3475563_780_790_Chemical)) (CC and) (NP (JJ topical) (NNP Doc_3475563_803_817_Chemical))))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (S (VP (VBG developing) (NP (NP (NN hoarseness)) (CC or) (NP (NN Doc_3475563_868_879_Disease))))))))) (. .)))
3533179	0	(S1 (NP (NP (NNP Doc_3533179_0_16_Chemical) (NNP Doc_3533179_17_31_Disease)) (: :) (NP (NP (DT an) (NN analysis)) (PP (IN of) (NP (NN dosing))) (PP (IN as) (NP (DT a) (NN risk) (NN factor)))) (. .)))
3533179	1	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBP undergo) (NP (NN bone) (NN marrow) (NN transplantation)))))) (VP (AUX are) (ADVP (RB generally)) (VP (VBN immunosuppressed) (PP (IN with) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_3533179_168_184_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3533179_186_189_Chemical)) (-RRB- -RRB-)))) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADVP (RB usually)) (VP (VBN calculated) (PP (VBN based) (PP (IN on) (NP (NP (DT the) (NN patient) (POS 's)) (NN weight)))))))))))) (. .)))
3533179	2	(S1 (S (PP (IN At) (NP (NP (DT these) (JJ high) (NNS doses)) (PP (IN of) (NP (NNP Doc_3533179_273_276_Chemical))))) (, ,) (S (NP (JJ serious) (NN Doc_3533179_286_300_Disease)) (VP (MD may) (VP (VB occur)))) (, ,) (CC but) (S (NP (NP (JJ definitive) (NN risk) (NNS factors)) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ such) (NN Doc_3533179_368_382_Disease)))))) (VP (AUX have) (RB not) (VP (AUX been) (VP (VBN described))))) (. .)))
3533179	3	(S1 (S (SBAR (IN Since) (S (NP (JJ chemotherapeutic) (NN agent) (NNP Doc_3533179_437_445_Disease)) (ADVP (RB generally)) (VP (VBZ correlates) (PP (IN with) (NP (NN dose))) (PP (IN per) (NP (NN body) (NN surface) (NN area)))))) (, ,) (NP (PRP we)) (ADVP (RB retrospectively)) (VP (VBD calculated) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NNP Doc_3533179_542_545_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN transplanted) (PP (IN at) (NP (PRP$ our) (NN institution) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_3533179_628_631_Chemical) (NNP Doc_3533179_632_646_Disease)))) (VP (VBD correlated) (PP (IN with) (NP (NP (DT the) (NN dose)) (PP (IN per) (NP (NN body) (NN surface) (NN area)))))))))))))))))) (. .)))
3533179	4	(S1 (S (NP (NP (NN Eighty) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (S (VP (TO to) (VP (VB receive) (NP (NNP Doc_3533179_731_734_Chemical) (CD 50) (NNS mg/kg/d)) (PP (IN for) (NP (CD four) (NNS days))) (PP (IN as) (NP (NP (NN preparation)) (PP (IN for) (NP (JJ marrow) (NN grafting)))))))))))) (VP (VBD underwent) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD 84) (NNS transplants)))) (PP (IN for) (NP (NP (NNP Doc_3533179_835_850_Disease)) (, ,) (NP (NNP Doc_3533179_852_876_Disease)) (, ,) (CC or) (NP (JJ severe) (NNP Doc_3533179_888_922_Disease))))) (. .)))
3533179	5	(S1 (S (NP (NP (CD Fourteen)) (PP (IN of) (NP (CD 84) (PRN (-LRB- -LRB-) (NP (CD 17) (NN %)) (-RRB- -RRB-)) (NNS patients)))) (VP (AUX had) (NP (NP (NP (NNS symptoms)) (CC and) (NP (NNS signs))) (ADJP (JJ consistent) (PP (IN with) (NP (NNP Doc_3533179_993_996_Chemical) (NNP Doc_3533179_997_1011_Disease))))) (PP (IN within) (NP (NP (CD ten) (NNS days)) (PP (IN of) (S (VP (VBG receiving) (NP (NP (QP (CD 1) (TO to) (CD 4)) (NNS doses)) (PP (IN of) (NP (NNP Doc_3533179_1057_1060_Chemical)))))))))) (. .)))
3533179	6	(S1 (S (NP (NP (CD Six)) (PP (IN of) (NP (DT the) (CD 14) (NNS patients)))) (VP (VBD died) (PP (IN with) (NP (NNP Doc_3533179_1095_1119_Disease)))) (. .)))
3533179	7	(S1 (S (S (NP (NP (DT The) (NN dose)) (PP (IN of) (NP (NNP Doc_3533179_1133_1136_Chemical))) (PP (IN per) (NP (NN body) (NN surface) (NN area)))) (VP (AUX was) (VP (VBN calculated) (PP (IN for) (NP (DT all) (NNS patients)))))) (CC and) (S (NP (DT the) (NNS patients)) (VP (AUX were) (VP (VBN divided) (PP (IN into) (NP (NP (NP (CD two) (NNS groups)) (VP (VBN based) (PP (IN on) (NP (JJ daily) (JJ Doc_3533179_1252_1255_Chemical) (NN dose))))) (: :) (NP (NP (NNP Group) (CD 1)) (, ,) (NP (NP (NNP Doc_3533179_1271_1274_Chemical)) (UCP (ADVP (RBR less) (IN than)) (CC or) (ADJP (JJ equal) (PP (TO to) (NP (QP (CD 1.55) (CD g/m2/d))))))) (: ;) (NP (NP (NNP Group) (CD 2)) (, ,) (NP (NP (NNP Doc_3533179_1319_1322_Chemical)) (QP (JJR greater) (IN than) (CD 1.55) (CD g/m2/d)))))))))) (. .)))
3533179	8	(S1 (NP (NP (NN Doc_3533179_1349_1363_Disease)) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (VP (VBN thought) (S (VP (TO to) (VP (AUX be) (VP (VBN related) (PP (TO to) (NP (NP (S (NP (NNP Doc_3533179_1398_1401_Chemical)) (VP (VBD occurred) (PP (PP (IN in) (NP (NP (CD 1/32)) (PRN (-LRB- -LRB-) (NP (CD 3) (NN %)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (NNP Group) (CD 1))))))) (CC and) (PP (IN in) (NP (CD 13/52)))))) (PRN (-LRB- -LRB-) (NP (CD 25) (NN %)) (-RRB- -RRB-)) (NNS patients)) (PP (IN in) (NP (NP (NNP Group) (CD 2)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.025))) (-RRB- -RRB-)))))))))))))) (. .)))
3533179	9	(S1 (S (NP (NP (NN Doc_3533179_1507_1531_Disease)) (VP (VP (VBN caused)) (CC or) (VP (VBD contributed) (PP (TO to) (NP (NN death))) (PP (IN in) (NP (NP (CD 0/32) (NNS patients)) (PP (IN in) (NP (NNP Group) (CD 1)))))))) (VP (VBD v) (NP (NP (CD 6/52)) (PRN (-LRB- -LRB-) (NP (CD 12) (NN %)) (-RRB- -RRB-)) (PP (IN of) (NP (NNS patients)))) (PP (IN in) (NP (NP (NNP Group) (CD 2)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.25))) (-RRB- -RRB-))))) (. .)))
3533179	10	(S1 (S (NP (EX There)) (VP (AUX was) (NP (DT no) (NN difference)) (PP (IN in) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NP (NN engraftment)) (PP (IN of) (NP (NP (JJ evaluable) (NNS patients)) (PP (IN in) (NP (NP (DT the) (CD two) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR greater) (IN than) (CD 0.5))) (-RRB- -RRB-))))))))))) (. .)))
3533179	11	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (DT the) (NNP Doc_3533179_1781_1784_Chemical) (NNP Doc_3533179_1785_1799_Disease)) (VP (VBZ correlates) (PP (IN with) (NP (JJ Doc_3533179_1816_1819_Chemical) (NN dosage))) (SBAR (SBAR (IN as) (S (VP (VBN calculated) (PP (IN by) (NP (NN body) (NN surface) (NN area)))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_3533179_1886_1901_Disease)) (CC and) (NP (NNP Doc_3533179_1906_1924_Disease))))) (VP (MD can) (VP (AUX be) (VP (ADVP (RB effectively)) (VBN prepared) (PP (IN for) (NP (NP (NN bone) (NN marrow)) (VP (VBG grafting) (PP (IN at) (NP (NP (DT a) (JJ Doc_3533179_1983_1986_Chemical) (NN dose)) (PP (IN of) (NP (NP (CD 1.55) (NNS g/m2/d)) (PP (IN for) (NP (NP (CD four) (NNS days)) (PP (IN with) (NP (NP (DT a) (JJR lower) (NN incidence)) (PP (IN of) (NP (NNP Doc_3533179_2047_2061_Disease))) (PP (IN than) (NP (NP (NNS patients)) (SBAR (WHNP (WP$ whose) (JJ Doc_3533179_2082_2085_Chemical) (NN dosage)) (S (VP (AUX is) (VP (VBN calculated) (PP (VBN based) (PP (IN on) (NP (NN weight))))))))))))))))))))))))))))))) (. .)))
3533179	12	(S1 (S (NP (DT This) (NN study)) (VP (VBZ reaffirms) (NP (DT the) (NN principle) (SBAR (IN that) (S (NP (NN drug) (NNP Doc_3533179_2169_2177_Disease)) (VP (VBZ correlates) (PP (IN with) (NP (NN dose))) (PP (IN per) (NP (NN body) (NN surface) (NN area)))))))) (. .)))
3538855	0	(S1 (NP (NP (NNS Studies)) (PP (IN of) (NP (NN risk) (NNS factors))) (PP (IN for) (NP (JJ Doc_3538855_28_42_Chemical) (NN nephrotoxicity))) (. .)))
3538855	1	(S1 (S (NP (NP (DT The) (NN epidemiology)) (PP (IN of) (NP (JJ Doc_3538855_79_93_Chemical-induced) (NN nephrotoxicity)))) (VP (AUX is) (RB not) (ADVP (RB fully)) (VP (VBN understood))) (. .)))
3538855	2	(S1 (S (S (NP (NP (JJ Experimental) (NNS studies)) (PP (IN in) (NP (JJ healthy) (JJ human) (NNS volunteers)))) (VP (VBP indicate) (S (NP (NNP Doc_3538855_200_215_Chemical)) (VP (VB cause) (NP (NP (JJ proximal) (JJ tubular) (NN damage)) (PP (IN in) (NP (JJS most) (NNS patients)))))))) (, ,) (CC but) (S (ADVP (RB rarely)) (, ,) (SBAR (IN if) (FRAG (ADVP (RB ever)))) (, ,) (VP (VBP cause) (NP (NN Doc_3538855_291_324_Disease)))) (. .)))
3538855	3	(S1 (S (NP (NP (JJ Clinical) (NNS trials)) (PP (IN of) (NP (NNP Doc_3538855_345_360_Chemical))) (PP (IN in) (NP (ADJP (RB seriously) (JJ ill)) (NNS patients)))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NP (DT the) (JJ relative) (NN risk)) (PP (IN for) (S (VP (VBG developing) (NP (NN Doc_3538855_434_453_Disease)) (PP (IN during) (NP (NP (NN therapy) (NNS ranges)) (PP (IN from) (NP (QP (CD 8) (TO to) (CD 10)))))))))) (CC and) (NP (IN that) (DT the) (JJ attributable) (NN risk))) (VP (AUX is) (NP (QP (CD 70) (NN %) (TO to) (CD 80) (NN %))))))) (. .)))
3538855	4	(S1 (S (NP (NP (JJ Further) (NN analysis)) (PP (IN of) (NP (DT these) (NNS data)))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NP (NN therapy)) (, ,) (NP (NN plasma) (NNP Doc_3538855_612_626_Chemical) (NNS levels)) (, ,) (NP (NNP Doc_3538855_635_648_Disease)) (, ,) (NP (JJ advanced) (NN age)) (, ,) (NP (JJ high) (JJ initial) (VBN estimated) (JJ Doc_3538855_687_697_Chemical) (NN clearance)) (CC and) (, ,) (ADVP (RB possibly)) (, ,) (NP (JJ female) (NN gender))))) (DT all) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN for) (NP (NN nephrotoxicity)))))))) (. .)))
3538855	5	(S1 (S (NP (NP (JJ Other) (NNS causes)) (PP (IN of) (NP (NNP Doc_3538855_795_814_Disease))) (, ,) (PP (JJ such) (IN as) (NP (NNP Doc_3538855_824_829_Disease))) (, ,)) (VP (VBP appear) (S (VP (TO to) (VP (AUX have) (NP (DT an) (JJ additive) (NN effect)))))) (. .)))
3538855	6	(S1 (S (NP (JJ Predictive) (NNS models)) (VP (AUX have) (VP (AUX been) (VP (VBN developed) (PP (IN from) (NP (NP (DT these) (NNS analyses)) (SBAR (WHNP (WDT that)) (S (VP (MD should) (VP (AUX be) (ADJP (JJ useful) (PP (IN for) (S (VP (VBG identifying) (NP (NNS patients)) (PP (IN at) (NP (JJ high) (NN risk)))))))))))))))) (. .)))
3538855	7	(S1 (S (NP (DT These) (NNS models)) (VP (MD may) (ADVP (RB also)) (VP (AUX be) (ADJP (JJ useful) (PP (IN in) (S (VP (VBG developing) (NP (NNS insights)) (PP (IN into) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (JJ Doc_3538855_1068_1082_Chemical-induced) (NN nephrotoxicity))))))))))) (. .)))
35781	0	(S1 (NP (NP (JJ Central) (NN action)) (PP (IN of) (NP (JJ narcotic) (NNS analgesics))) (. .)))
35781	1	(S1 (NP (NNP Part) (NNP IV) (. .)))
35781	2	(S1 (NP (NP (JJ Noradrenergic) (NNS influences)) (PP (IN on) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NP (NNS analgesics)) (PP (IN in) (NP (NNS rats))))))) (. .)))
35781	3	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NNP Doc_35781_126_135_Chemical) (, ,) (NNP Doc_35781_137_148_Chemical) (CC and) (NNP Doc_35781_153_167_Chemical))) (PP (PP (IN on) (NP (NP (NNP Doc_35781_171_180_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_35781_192_200_Chemical) (, ,) (NNP Doc_35781_202_209_Chemical) (, ,) (NNP Doc_35781_211_219_Chemical) (CC and) (NNP Doc_35781_224_235_Chemical)))))) (, ,) (CC and) (PP (IN on) (NP (NP (JJ cataleptic) (NN effect)) (PP (IN of) (NP (NNP Doc_35781_265_273_Chemical) (, ,) (NNP Doc_35781_275_281_Chemical) (CC and) (NNP Doc_35781_286_294_Chemical))))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NNS rats))))) (. .)))
35781	4	(S1 (S (NP (NP (DT The) (JJ biochemical) (NNS assays)) (PP (IN on) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (CD four) (NNS analgesics))) (PP (IN on) (NP (NP (DT the) (NN brain) (NN concentration) (CC and) (NN turnover)) (PP (IN of) (NP (NNP Doc_35781_418_431_Chemical)))))))) (PRN (-LRB- -LRB-) (PP (TO NA)) (-RRB- -RRB-)) (VP (AUX were) (ADVP (RB also)) (VP (VBN performed))) (. .)))
35781	5	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN found) (SBAR (IN that) (S (NP (NP (CD three) (NNS drugs)) (VP (VBG stimulating) (ADVP (JJ central) (PP (TO NA) (NP (NNS receptors)))))) (VP (VBD failed) (S (S (VP (TO to) (VP (VB affect) (NP (NP (DT the) (JJ analgesic) (CD ED50)) (PP (IN of) (NP (DT all) (JJ antinociceptive) (NNS agents))))))) (CC and) (S (NP (PRP they)) (VP (VBD enhanced) (S (NP (NNP Doc_35781_605_614_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_35781_626_634_Chemical)) (CC and) (NP (NNP Doc_35781_639_647_Chemical)))))))))))))) (. .)))
35781	6	(S1 (S (NP (NNP Doc_35781_649_656_Chemical) (NNP Doc_35781_657_666_Disease)) (VP (AUX was) (VP (VP (VBN increased) (PP (IN by) (NP (NNP Doc_35781_684_693_Chemical)))) (CC and) (VP (VBN decreased) (PP (IN by) (NP (NP (NNP Doc_35781_711_722_Chemical)) (CC and) (NP (NNP Doc_35781_727_741_Chemical))))))) (. .)))
35781	7	(S1 (FRAG (NP (DT The) (NN brain) (NN concentration)) (SBAR (IN of) (S (S (TO NA) (VP (AUX was) (RB not) (VP (VBN changed) (PP (IN by) (NP (NP (NNP Doc_35781_792_800_Chemical)) (CC and) (NP (NNP Doc_35781_805_813_Chemical))))))) (, ,) (CC but) (S (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_35781_839_846_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 45) (NN mg/kg)) (-RRB- -RRB-))))))) (VP (ADVP (RB slightly)) (VBD enhanced) (NP (PRP it)))))) (. .)))
35781	8	(S1 (S (NP (NN Doc_35781_880_891_Chemical)) (ADVP (RB dose-dependently)) (VP (VBD decreased) (NP (NP (DT the) (NN brain) (NN level)) (PP (IN of) (NP (TO NA))))) (. .)))
35781	9	(S1 (S (NP (NP (DT The) (NN rate)) (PP (IN of) (PP (TO NA) (NP (NN turnover))))) (VP (AUX was) (RB not) (VP (VBN altered) (PP (IN by) (NP (NP (NNS analgesics)) (PP (IN except) (PP (IN for) (NP (NP (DT the) (JJR higher) (NN dose)) (PP (IN of) (NP (NNP Doc_35781_1026_1034_Chemical) (PRN (-LRB- -LRB-) (NP (CD 0.2) (NN mg/kg)) (-RRB- -RRB-)) (NN following)))))) (SBAR (WHNP (WDT which)) (S (NP (NP (DT the) (NN disappearance)) (PP (IN of) (NP (TO NA))) (PP (IN from) (NP (DT the) (NN brain)))) (VP (AUX was) (VP (VBN diminished))))))))) (. .)))
35781	10	(S1 (S (NP (DT The) (NNS results)) (VP (AUX are) (VP (VBN discussed) (PP (IN in) (NP (NP (DT the) (NN light)) (PP (IN of) (NP (NP (JJ various) (CC and) (JJ non-uniform) (NNS data)) (PP (IN from) (NP (DT the) (NN literature))))))))) (. .)))
35781	11	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN suggested) (SBAR (IN that) (S (PP (IN in) (NP (NNS rats))) (NP (DT the) (NN brain)) (TO NA) (VP (VBZ plays) (NP (NP (DT a) (ADJP (RBR less) (JJ important)) (NN function)) (PP (IN than) (NP (NP (DT the) (JJ other) (NN Doc_35781_1299_1309_Chemical)) (PP (IN in) (NP (NP (DT the) (JJ behavioural) (NN activity)) (PP (IN of) (NP (JJ potent) (NNS analgesics))))))))))))) (. .)))
3685052	0	(S1 (NP (NP (NP (JJ Doc_3685052_0_9_Chemical) (JJ Doc_3685052_10_17_Disease) (NNS thresholds)) (PP (IN in) (NP (NP (NNS mice)) (VP (VBN treated) (ADVP (RB neonatally)) (PP (IN with) (NP (NP (DT a) (JJ single) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_3685052_83_103_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3685052_105_108_Chemical)) (-RRB- -RRB-)))))))))) (: :) (NP (NP (NN evaluation)) (PP (IN of) (NP (NP (JJ experimental) (NNS parameters)) (PP (IN in) (NP (NNP Doc_3685052_152_161_Chemical) (NNP Doc_3685052_162_169_Disease) (NN testing)))))) (. .)))
3685052	1	(S1 (S (NP (NP (NNP Monosodium) (NNP Doc_3685052_190_199_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_3685052_201_204_Chemical)) (-RRB- -RRB-)) (NN administration)) (PP (TO to) (NP (JJ neonatal) (NNS rodents)))) (VP (VBZ produces) (NP (NNP Doc_3685052_250_261_Disease) (CC and) (NNS results)) (PP (IN in) (NP (NP (JJ numerous) (NN biochemical)) (CC and) (NP (NN Doc_3685052_302_321_Disease))))) (. .)))
3685052	2	(S1 (S (NP (DT These) (NNS studies)) (VP (AUX were) (VP (VBN undertaken) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (NP (NN neonatal) (NN administration)) (PP (IN of) (NP (NNP Doc_3685052_396_399_Chemical)))) (VP (VBD produced) (NP (JJ permanent) (NNS alterations)) (PP (IN in) (NP (JJ Doc_3685052_434_441_Disease) (NN susceptibility))))))))) (, ,) (SBAR (IN since) (S (NP (JJ previous) (NNS investigations)) (VP (AUX were) (ADJP (JJ inconclusive))))))) (. .)))
3685052	3	(S1 (S (NP (JJ Doc_3685052_507_524_Chemical) (JJ Doc_3685052_525_532_Disease) (NN screening) (NN technique)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB evaluate) (NP (NP (JJ Doc_3685052_574_581_Disease) (NN susceptibility)) (PP (IN in) (NP (NP (NN adult) (NNS mice)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NP (JJ neonatal) (NNS injections)) (PP (IN of) (NP (NP (NNP Doc_3685052_648_651_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 4) (NN mg/g) (CC and) (CD 1) (NN mg/g))) (-RRB- -RRB-)))))))))))))))) (. .)))
3685052	4	(S1 (S (NP (JJ Doc_3685052_673_676_Chemical) (NN treatment)) (VP (VP (VBD resulted) (PP (IN in) (NP (NP (JJ significant) (NNS reductions)) (PP (IN in) (NP (JJ whole) (NN brain) (NN weight)))))) (CC but) (VP (AUX did) (RB not) (VP (VB alter) (NP (JJ Doc_3685052_762_769_Disease) (NN threshold))))) (. .)))
3685052	5	(S1 (S (NP (DT A) (NNP Doc_3685052_783_791_Chemical) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg/kg)) (-RRB- -RRB-)) (NN challenge)) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ ineffective)) (PP (IN in) (S (VP (VBG altering) (NP (NP (DT the) (JJ Doc_3685052_849_856_Disease) (NNS thresholds)) (PP (IN of) (NP (NP (DT either) (NN control)) (PP (IN of) (NP (JJ Doc_3685052_889_892_Chemical-treated) (NNS mice)))))))))) (. .)))
3685052	6	(S1 (S (S (NP (NN Doc_3685052_907_922_Chemical)) (VP (VBD produced) (NP (NP (NN Doc_3685052_932_943_Disease)) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN correlated) (PP (IN with) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NNP Doc_3685052_986_995_Chemical) (NN exposure)))))))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NP (DT the) (NN relationship)) (PP (IN of) (NP (NNP Doc_3685052_1035_1046_Disease))) (PP (TO to) (NP (NNP Doc_3685052_1050_1057_Disease) (NN induction)))) (VP (AUX was) (ADJP (JJ unclear)))) (. .)))
3685052	7	(S1 (S (NP (JJ Doc_3685052_1081_1090_Chemical) (JJ Doc_3685052_1091_1098_Disease) (NN testing)) (VP (VBD proved) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (ADJP (JJ rapid) (CC and) (JJ reliable)) (NN technique)) (SBAR (WHPP (IN with) (WHNP (WDT which))) (S (VP (TO to) (VP (VB evaluate) (NP (JJ Doc_3685052_1174_1181_Disease) (NN susceptibility))))))))))) (. .)))
3708328	0	(S1 (S (NP (NP (NN Susceptibility)) (PP (TO to) (NP (NNP Doc_3708328_18_26_Disease)))) (VP (VBD produced) (PP (IN by) (NP (NNP Doc_3708328_39_50_Chemical))) (PP (IN in) (NP (NNS rats))) (PP (IN after) (NP (NP (NN microinjection)) (PP (IN of) (NP (NP (NNP Doc_3708328_83_92_Chemical)) (CC or) (NP (NNP Doc_3708328_96_112_Chemical)))) (PP (IN into) (NP (DT the) (NN substantia) (NN nigra)))))) (. .)))
3708328	1	(S1 (S (NP (NP (NN Doc_3708328_140_151_Chemical)) (, ,) (VP (VBN given) (ADVP (RB intraperitoneally)) (PP (TO to) (NP (NNS rats)))) (, ,)) (VP (VP (VBZ reproduces) (NP (NP (DT the) (JJ neuropathological) (NNS sequelae)) (PP (IN of) (NP (NNP Doc_3708328_231_253_Disease))))) (CC and) (VP (VBZ provides) (NP (NP (DT a) (JJ relevant) (NN animal) (NN model)) (PP (IN for) (S (VP (VBG studying) (NP (NP (NP (NNS mechanisms)) (PP (IN of) (NP (NP (NN buildup)) (PP (IN of) (NP (JJ Doc_3708328_329_339_Disease) (NN activity)))))) (CC and) (NP (NP (NNS pathways)) (PP (JJ operative) (IN in) (NP (NP (DT the) (NN generalization) (CC and) (NN propagation)) (PP (IN of) (NP (NNP Doc_3708328_413_421_Disease))) (PP (IN within) (NP (DT the) (NN forebrain))))))))))))) (. .)))
3708328	2	(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (, ,) (NP (NP (DT the) (NNS effects)) (PP (IN of) (S (VP (VBG manipulating) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT the) (JJ Doc_3708328_514_537_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_3708328_539_543_Chemical)) (-RRB- -RRB-)) (JJ -mediated) (JJ synaptic) (NN inhibition)))) (PP (IN within) (NP (NP (DT the) (NN substantia) (NN nigra)) (PP (IN on) (NP (NNP Doc_3708328_605_613_Disease))) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_3708328_626_637_Chemical))) (PP (IN in) (NP (NNS rats)))) (, ,))))))) (VP (AUX were) (VP (VBN investigated))) (. .)))
3708328	3	(S1 (S (PP (IN In) (NP (NP (NNS animals)) (VP (VBN pretreated) (PP (IN with) (NP (NP (NP (NNS microinjections)) (PP (IN of) (NP (NNP Doc_3708328_712_721_Chemical)))) (, ,) (NP (CD 150) (NNS micrograms)) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NP (NN activity)) (PP (IN of) (NP (DT the) (JJ Doc_3708328_771_775_Chemical-synthesizing) (NN enzyme)))))) (, ,) (NP (NNP Doc_3708328_797_812_Chemical) (NN decarboxylase)) (, ,))) (PP (IN into) (NP (NP (DT the) (NN substantia) (NN nigra) (NNS pars) (NN reticulata)) (PRN (-LRB- -LRB-) (NP (NNP SNR)) (-RRB- -RRB-))))))) (, ,) (ADVP (RB bilaterally)) (, ,) (NP (NP (JJ non-convulsant) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_3708328_914_925_Chemical)) (, ,) (NP (QP (CD 100) (CC and) (CD 200)) (NN mg/kg)) (, ,)))) (VP (VBD resulted) (PP (IN in) (NP (JJ severe) (NN motor) (NN limbic) (NNP Doc_3708328_978_986_Disease) (CC and) (NNP Doc_3708328_991_1009_Disease)))) (. .)))
3708328	4	(S1 (S (NP (NP (NN Electroencephalographic)) (CC and) (NP (JJ behavioral) (NN monitoring))) (VP (VBD revealed) (NP (NP (DT a) (JJ profound) (NN reduction)) (PP (IN of) (NP (DT the) (NN threshold))) (PP (IN for) (NP (NNP Doc_3708328_1112_1123_Chemical-induced) (NNP Doc_3708328_1132_1143_Disease))))) (. .)))
3708328	5	(S1 (S (NP (NP (JJ Morphological) (NN analysis)) (PP (IN of) (NP (NP (JJ frontal) (NN forebrain) (NNS sections)) (PP (IN with) (NP (JJ light) (NN microscopy)))))) (VP (VBD revealed) (NP (NP (JJ Doc_3708328_1229_1236_Disease-related) (NN damage)) (PP (TO to) (NP (NP (DT the) (JJ hippocampal) (NN formation)) (, ,) (NP (NP (NN thalamus)) (, ,) (NP (NN amygdala)) (, ,) (NP (NN olfactory) (NN cortex)) (, ,) (NP (NN substantia) (NN nigra)) (CC and) (NP (NN neocortex))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (ADVP (RB typically)) (VP (VBN observed) (PP (IN with) (NP (NNP Doc_3708328_1385_1396_Chemical))) (PP (IN in) (NP (NP (NNS doses)) (VP (VBG exceeding) (NP (CD 350) (NNS mg/kg))))))))))))) (. .)))
3708328	6	(S1 (S (NP (NP (JJ Bilateral) (JJ intrastriatal) (NNS injections)) (PP (IN of) (NP (NNP Doc_3708328_1465_1474_Chemical)))) (VP (AUX did) (RB not) (VP (VB augment) (NP (NP (NN Doc_3708328_1491_1499_Disease)) (VP (VBN produced) (PP (IN by) (NP (NP (NNP Doc_3708328_1512_1523_Chemical)) (, ,) (NP (QP (CD 200) (CD mg/kg))))))))) (. .)))
3708328	7	(S1 (S (NP (NP (NN Application)) (PP (IN of) (NP (NP (DT an) (JJ irreversible) (NN inhibitor)) (PP (IN of) (NP (NP (JJ Doc_3708328_1580_1584_Chemical) (NN transaminase)) (, ,) (NP (NP (NNP Doc_3708328_1599_1615_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3708328_1617_1645_Chemical)) (-RRB- -RRB-))) (, ,) (NP (CD 5) (NNS micrograms)) (, ,))) (PP (IN into) (NP (DT the) (NNP SNR)))))) (, ,) (ADVP (RB bilaterally)) (, ,) (VP (VBD suppressed) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (NP (JJ electrographic) (CC and) (JJ behavioral) (NN Doc_3708328_1748_1756_Disease)) (VP (VBN produced) (PP (IN by) (NP (NP (NNP Doc_3708328_1769_1780_Chemical)) (, ,) (NP (CD 380) (NN mg/kg))))))))) (. .)))
3708328	8	(S1 (S (NP (DT This) (NN treatment)) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB protect) (NP (NNS animals)) (PP (IN from) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP Doc_3708328_1870_1882_Disease)))))))))) (. .)))
3708328	9	(S1 (S (NP (NP (NNS Microinjections)) (PP (IN of) (NP (NP (NNP Doc_3708328_1903_1919_Chemical)) (, ,) (NP (CD 5) (NN micrograms)) (, ,))) (PP (IN into) (NP (DT the) (JJ dorsal) (NN striatum)))) (, ,) (ADVP (RB bilaterally)) (, ,) (VP (VBD failed) (S (VP (TO to) (VP (VB prevent) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NNP Doc_3708328_2011_2022_Disease)) (VP (VBN produced) (PP (IN by) (NP (NP (NNP Doc_3708328_2035_2046_Chemical)) (, ,) (NP (CD 380) (NN mg/kg)))))))))))) (. .)))
3708328	10	(S1 (S (NP (DT The) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (DT the) (NN threshold)) (PP (IN for) (NP (NP (NNP Doc_3708328_2106_2117_Chemical-induced) (NNP Doc_3708328_2126_2134_Disease)) (PP (IN in) (NP (NNS rats)))))) (VP (AUX is) (VP (VBN subjected) (PP (TO to) (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (NP (DT the) (JJ Doc_3708328_2181_2185_Chemical-mediated) (JJ synaptic) (NN inhibition)) (PP (IN within) (NP (DT the) (NN substantia) (NN nigra)))))))))))) (. .)))
3711722	0	(S1 (NP (NP (ADJP (JJ Human) (CC and) (JJ canine)) (JJ ventricular) (JJ vasoactive) (NN intestinal) (NN polypeptide)) (: :) (NP (NP (NN decrease)) (PP (IN with) (NP (NNP Doc_3711722_78_91_Disease)))) (. .)))
3711722	1	(S1 (S (NP (NP (JJ Vasoactive) (JJ intestinal) (NN polypeptide)) (PRN (-LRB- -LRB-) (NP (NN VIP)) (-RRB- -RRB-))) (VP (AUX is) (NP (NP (DT a) (ADJP (JJ systemic) (CC and) (JJ coronary)) (NN vasodilator)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (AUX have) (NP (JJ positive) (JJ inotropic) (NNS properties)))))))) (. .)))
3711722	2	(S1 (S (NP (NP (JJ Myocardial) (NNS levels)) (PP (IN of) (NP (NN VIP)))) (VP (AUX were) (VP (VBN assayed) (PP (IN before) (CC and) (IN after) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_3711722_291_304_Disease))) (PP (IN in) (NP (CD two) (JJ canine) (NNS models))))))) (. .)))
3711722	3	(S1 (S (S (PP (IN In) (NP (DT the) (JJ first))) (, ,) (NP (NNP Doc_3711722_341_347_Chemical) (NNP Doc_3711722_348_362_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN in) (NP (CD eight) (NNS dogs)))))) (: ;) (S (NP (NP (NN VIP)) (PRN (-LRB- -LRB-) (PP (IN by) (NP (NN radioimmunoassay))) (-RRB- -RRB-))) (VP (VBD decreased) (PP (IN from) (NP (CD 35) (NN +/-))) (NP (NP (CD 11) (CD pg/mg) (NN protein)) (PRN (-LRB- -LRB-) (NP (JJ mean) (JJ +/-) (NN SD)) (-RRB- -RRB-)) (TO to) (NP (CD 5) (NN +/-) (CD 4) (NN pg/mg) (NN protein)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))))) (. .)))
3711722	4	(S1 (S (PP (IN In) (NP (NP (CD six) (NNS dogs)) (PP (IN with) (NP (NNP Doc_3711722_531_542_Chemical-induced) (NNP Doc_3711722_551_564_Disease))))) (, ,) (NP (NN VIP)) (VP (VBD decreased) (PP (IN from) (NP (CD 31) (NN +/-))) (NP (NP (NP (QP (CD 7) (TO to) (CD 11) (NN +/-))) (NP (QP (CD 4) (CD pg/mg)) (NN protein))) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)))) (. .)))
3711722	5	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN VIP) (NN content)) (PP (IN of) (NP (NP (JJ left) (JJ ventricular) (NN muscle)) (PP (IN of) (NP (JJ resected) (VBG failing) (NNS hearts))) (PP (IN in) (NP (NP (CD 10) (NNS patients)) (VP (VBG receiving) (NP (DT a) (NN heart) (NN transplant)))))))) (VP (AUX was) (VP (VBN compared) (PP (IN with) (S (NP (NP (DT the) (JJ papillary) (NNS muscles)) (PP (IN in) (NP (NP (CD 14) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD five)) (PP (IN with) (NP (NNP Doc_3711722_829_846_Disease)))) (, ,) (NP (NP (CD nine)) (PP (IN with) (NP (NNP Doc_3711722_858_881_Disease)))) (-RRB- -RRB-))))) (VP (VBG receiving) (NP (JJ mitral) (NN valve) (NNS prostheses))))))) (. .)))
3711722	6	(S1 (S (NP (DT The) (JJS lowest) (JJ myocardial) (NNP Doc_3711722_940_943_Chemical) (NN concentration)) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NP (DT the) (NNS hearts)) (PP (IN of) (NP (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_3711722_999_1015_Disease))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD one) (NN patient)) (VP (VBG receiving) (NP (DT a) (NN transplant)))) (CC and) (NP (CD three) (NN receiving) (NN mitral) (NNS prostheses))) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NP (CD 6.3) (NN +/-)) (NP (QP (CD 1.9) (CD pg/mg)) (NN protein))) (-RRB- -RRB-)))))))) (. .)))
3711722	7	(S1 (S (NP (NP (DT The) (JJ other) (NNS patients)) (VP (VBG undergoing) (NP (NN transplantation)))) (VP (AUX had) (NP (NP (DT an) (JJ average) (NN ejection) (NN fraction)) (PP (IN of) (NP (NP (NP (CD 17) (NN %)) (JJ +/-) (CD 6) (NN %)) (CC and) (NP (NP (DT a) (JJ VIP) (NN level)) (PP (IN of) (NP (CD 8.8) (NN +/-) (CD 3.9) (NN pg/mg) (NN protein)))))))) (. .)))
3711722	8	(S1 (S (S (NP (NP (DT The) (NNS hearts)) (PP (IN without) (NP (NNP Doc_3711722_1278_1301_Disease))) (PRN (-LRB- -LRB-) (NP (NP (JJ average) (NN ejection) (NN fraction)) (PP (IN of) (NP (NP (DT this) (NN group) (ADJP (CD 62) (NN %)) (NN +/-)) (ADJP (CD 10) (NN %))))) (-RRB- -RRB-))) (VP (AUX had) (NP (NP (DT a) (JJ VIP) (NN concentration)) (PP (IN of) (NP (NP (CD 14.1) (NN +/-)) (NP (CD 7.9) (CD pg/mg) (NN protein))))))) (, ,) (CC and) (S (NP (DT this)) (VP (AUX was) (ADJP (ADJP (JJR greater)) (PP (IN than) (PP (IN in) (NP (NP (NNS hearts)) (PP (IN of) (NP (NP (NP (DT the) (NNS patients)) (PP (IN with) (NP (NNP Doc_3711722_1468_1484_Disease)))) (CC and) (NP (NP (DT the) (NNS hearts)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (DT a) (NN transplant)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))))))))))))))) (. .)))
3711722	9	(S1 (S (S (NP (NNP Myocardial) (NNP Doc_3711722_1566_1580_Chemical)) (VP (AUX were) (ADVP (RB also)) (VP (VBN determined) (PP (IN in) (NP (CD 14) (NNS subjects)))))) (: ;) (S (NP (NP (DT a) (JJ weak) (NN correlation)) (PRN (-LRB- -LRB-) (NP (QP (SYM r) (SYM =) (CD 0.57))) (, ,) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)) (PP (IN between) (NP (NP (DT the) (NN tissue) (NNS concentrations)) (PP (IN of) (NP (NNP VIP) (CC and) (NNP Doc_3711722_1711_1725_Chemical)))))) (VP (AUX was) (VP (VBN noted.) (PRN (-LRB- -LRB-) (NP (NP (JJ ABSTRACT)) (VP (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS))))) (-RRB- -RRB-)))))))
3746148	0	(S1 (S (NP (NP (JJ Non-invasive) (NN detection)) (PP (IN of) (NP (NNP Doc_3746148_26_49_Disease))) (PP (IN by) (NP (NN body)))) (VP (VBP surface) (NP (JJ electrocardiographic) (NN mapping)) (PP (IN after) (NP (JJ Doc_3746148_101_113_Chemical) (NN infusion)))) (. .)))
3746148	1	(S1 (S (NP (NP (JJ Electrocardiographic) (NNS changes)) (PP (IN after) (NP (JJ Doc_3746148_159_171_Chemical) (NN infusion))) (PRN (-LRB- -LRB-) (NP (QP (CD 0.568) (CD mg/kg/4)) (NN min)) (-RRB- -RRB-))) (VP (AUX were) (VP (VP (VBN studied) (PP (IN in) (NP (NP (CD 41) (NNS patients)) (PP (IN with) (NP (NNP Doc_3746148_234_257_Disease)))))) (CC and) (VP (VBN compared) (PP (IN with) (NP (NP (DT those)) (PP (IN after) (NP (NP (JJ submaximal) (NN treadmill) (NN exercise)) (PP (IN by) (NP (NP (NN use)) (PP (IN of) (NP (DT the) (NN body) (NN surface) (NN mapping) (NN technique)))))))))))) (. .)))
3746148	2	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN divided) (PP (IN into) (NP (NP (CD three) (NNS groups)) (: ;) (NP (NP (CD 19) (NNS patients)) (PP (IN without) (NP (NP (NP (NNP Doc_3746148_425_446_Disease)) (PRN (-LRB- -LRB-) (NP (JJ non-MI) (NN group)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (CD 14)) (PP (IN with) (NP (NP (NNP anterior) (NNP Doc_3746148_480_490_Disease)) (PRN (-LRB- -LRB-) (NP (NNP ANT-MI)) (-RRB- -RRB-))))) (CC and) (NP (NP (CD eight)) (PP (IN with) (NP (NP (JJ inferior) (NNP Doc_3746148_524_534_Disease)) (PRN (-LRB- -LRB-) (NP (NNP INF-MI)) (-RRB- -RRB-))))))))))))) (. .)))
3746148	3	(S1 (S (NP (NP (NP (JJ Eighty-seven) (NN unipolar) (NNS electrocardiograms)) (PRN (-LRB- -LRB-) (NP (NNP ECGs)) (-RRB- -RRB-))) (VP (VBN distributed) (PP (IN over) (NP (DT the) (JJ entire) (JJ thoracic) (NN surface))))) (VP (AUX were) (ADVP (RB simultaneously)) (VP (VBN recorded))) (. .)))
3746148	4	(S1 (S (PP (IN After) (NP (NNP Doc_3746148_674_686_Chemical))) (, ,) (NP (NP (JJ ischemic) (JJ ST-segment) (NN Doc_3746148_708_718_Disease)) (PRN (-LRB- -LRB-) (NP (QP (CD 0.05) (CD mV) (CC or) (JJR more))) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (NP (CD 84) (NN %)) (PP (IN of) (NP (DT the) (NN non-MI) (NN group)))) (, ,) (NP (NP (CD 29) (NN %)) (PP (IN of) (NP (DT the) (NNP ANT-MI) (NN group)))) (, ,) (NP (NP (CD 63) (NN %)) (PP (IN of) (NP (DT the) (NNP INF-MI) (NN group)))) (CC and) (NP (NP (CD 61) (NN %)) (PP (IN of) (NP (DT the) (JJ total) (NN population)))))))) (. .)))
3746148	5	(S1 (S (NP (JJ Exercise-induced) (NNP ST) (NNP Doc_3746148_880_890_Disease)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (NP (CD 84) (NN %)) (PP (IN of) (NP (DT the) (NN non-MI) (NN group)))) (, ,) (NP (NP (CD 43) (NN %)) (PP (IN of) (NP (DT the) (NNP ANT-MI) (NN group)))) (, ,) (NP (NP (CD 38) (NN %)) (PP (IN of) (NP (DT the) (NNP INF-MI) (NN group)))) (CC and) (NP (NP (CD 61) (NN %)) (PP (IN of) (NP (DT the) (NN total)))))))) (. .)))
3746148	6	(S1 (S (PP (IN For) (NP (JJ individual) (NNS patients))) (, ,) (NP (EX there)) (VP (AUX were) (NP (NP (DT no) (JJ obvious) (NNS differences)) (PP (IN between) (NP (NP (DT the) (NN body) (NN surface) (NN distribution)) (PP (IN of) (NP (NNP ST) (NNP Doc_3746148_1106_1116_Disease))) (PP (IN in) (NP (DT both) (NNS tests))))))) (. .)))
3746148	7	(S1 (S (NP (NP (DT The) (NN increase)) (PP (IN in) (NP (NN pressure) (NN rate) (NN product))) (PP (IN after) (NP (NNP Doc_3746148_1176_1188_Chemical)))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR less)) (PP (IN than) (NP (NP (DT that)) (PP (IN during) (NP (DT the) (NN treadmill) (NN exercise))))))) (. .)))
3746148	8	(S1 (S (NP (DT The) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT the) (JJ Doc_3746148_1279_1291_Chemical-induced) (NN Doc_3746148_1300_1319_Disease)) (VP (AUX is) (VP (VBN caused) (PP (IN by) (NP (NP (DT the) (JJ inhomogenous) (NN distribution)) (PP (IN of) (NP (JJ myocardial) (NN blood) (NN flow)))))))))) (. .)))
3746148	9	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (DT the) (JJ Doc_3746148_1410_1422_Chemical) (NN ECG) (NN test)) (VP (AUX is) (ADJP (RB as) (JJ useful) (PP (IN as) (NP (NP (DT the) (NN exercise) (NN ECG) (NN test)) (PP (IN for) (NP (NP (DT the) (NN assessment)) (PP (IN of) (NP (NNP Doc_3746148_1492_1515_Disease)))))))))))) (. .)))
3798047	0	(S1 (NP (NP (NN Doc_3798047_0_11_Disease)) (PP (IN after) (NP (JJ high-dose) (JJ intravenous) (NN Doc_3798047_40_58_Chemical) (NN therapy))) (. .)))
3798047	1	(S1 (S (S (PP (IN In) (NP (NP (CD 5) (JJ consecutive) (NNS patients)) (PP (IN with) (NP (NNP Doc_3798047_99_119_Disease))) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (JJ intravenous) (JJ high-dose) (NNP Doc_3798047_155_173_Chemical) (PRN (-LRB- -LRB-) (NP (NNP MP)) (-RRB- -RRB-)) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NP (CD 1) (NNP g) (NN daily)) (PP (IN for) (NP (QP (CD 2) (CC or) (CD 3)) (JJ consecutive) (NNS days)))) (-RRB- -RRB-)))))))) (, ,) (NP (NP (DT a) (NN decline)) (PP (IN in) (NP (NN pulse) (NN rate)))) (VP (AUX was) (VP (VBN observed)))) (, ,) (NP (RBS most)) (VP (VBN pronounced) (PP (IN on) (NP (NN day) (CD 4)))) (. .)))
3798047	2	(S1 (S (PP (IN In) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (CD 5) (NNS patients))))) (NP (DT the) (NNP Doc_3798047_321_332_Disease)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NNS complaints)) (PP (IN of) (NP (JJ substernal) (NN pressure))))))) (. .)))
3798047	3	(S1 (S (NP (NP (NN Reversal)) (PP (TO to) (NP (JJ normal) (NN heart) (NN rate)))) (VP (AUX was) (VP (VBN found) (PP (IN on) (NP (NN day) (CD 7))))) (. .)))
3798047	4	(S1 (S (NP (JJ Electrocardiographic) (NNS registrations)) (VP (VBD showed) (NP (JJ sinus) (NN Doc_3798047_486_497_Disease)) (PP (IN in) (NP (DT all) (NNS cases)))) (. .)))
3798047	5	(S1 (S (NP (NP (DT No) (JJ significant) (NNS changes)) (PP (IN in) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NNS electrolytes)))))) (VP (AUX were) (VP (VBN found))) (. .)))
3798047	6	(S1 (S (NP (NP (JJ Careful) (NN observation)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ high-dose) (NNP MP)))))) (VP (AUX is) (VP (VBN recommended))) (. .)))
3798047	7	(S1 (S (NP (NNP High-dose) (NNP MP)) (VP (MD may) (VP (AUX be) (VP (VBN contraindicated) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ known) (NN Doc_3798047_718_731_Disease)))))))) (. .)))
3812624	0	(S1 (S (NP (NP (NP (CD Two) (NNS cases)) (PP (IN of) (NP (NN downbeat) (NN Doc_3812624_22_31_Disease)))) (CC and) (NP (NNS oscillopsia))) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_3812624_64_77_Chemical)))) (. .)))
3812624	1	(S1 (S (NP (NN Doc_3812624_79_97_Disease)) (VP (VP (AUX is) (ADVP (RB often)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ structural) (NNS lesions)) (PP (IN at) (NP (DT the) (JJ craniocervical) (NN junction))))))) (, ,) (CC but) (VP (AUX has) (ADVP (RB occasionally)) (VP (AUX been) (VP (VBN reported) (PP (IN as) (NP (NP (DT a) (NN manifestation)) (PP (IN of) (NP (NP (NN metabolic) (NN imbalance)) (CC or) (NP (NN drug) (NN intoxication)))))))))) (. .)))
3812624	2	(S1 (S (NP (PRP We)) (VP (VBD recorded) (NP (NP (DT the) (NN eye) (NNS movements)) (PP (IN of) (NP (CD two) (NNS patients))) (PP (IN with) (NP (NP (JJ reversible) (NN downbeat) (NN Doc_3812624_344_353_Disease)) (VP (VBN related) (PP (TO to) (NP (JJ Doc_3812624_365_378_Chemical) (NN therapy)))))))) (. .)))
3812624	3	(S1 (S (NP (NP (DT The) (NNP Doc_3812624_392_401_Disease)) (PP (IN of) (NP (DT both) (NNS patients)))) (VP (VBD resolved) (PP (IN after) (NP (NP (NN reduction)) (PP (IN of) (NP (DT the) (JJ serum) (JJ Doc_3812624_457_470_Chemical) (NNS levels)))))) (. .)))
3812624	4	(S1 (S (NP (NP (JJ Neuroradiologic) (NNS investigations)) (PP (VBG including) (NP (NP (JJ magnetic) (NN resonance) (NN imaging) (NNS scans)) (PP (IN in) (NP (DT both) (NNS patients)))))) (VP (VBD showed) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NNP Doc_3812624_592_616_Disease))))) (. .)))
3812624	5	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NN downbeat) (NN Doc_3812624_644_653_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX are) (VP (VBG taking) (NP (NN anticonvulsant) (NNS medications)))))))) (, ,) (NP (NN consideration)) (VP (MD should) (VP (AUX be) (VP (VBN given) (PP (TO to) (NP (NN reduction))) (PP (IN in) (NP (NN dose))) (SBAR (IN before) (S (NP (JJ further) (NN investigation)) (VP (AUX is) (VP (VBN undertaken)))))))) (. .)))
3831029	0	(S1 (NP (NP (NN Improvement)) (PP (IN by) (NP (NP (NP (NNP Doc_3831029_15_25_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_3831029_27_33_Chemical)) (-RRB- -RRB-))) (PP (IN of) (NP (NNP Doc_3831029_38_51_Chemical-induced) (NNP Doc_3831029_60_75_Disease))))) (PP (IN in) (NP (DT the) (NN dog) (NN heart-lung) (NN preparation))) (. .)))
3831029	1	(S1 (S (NP (NP (DT The) (NN efficacy)) (PP (IN of) (NP (NP (NNP Doc_3831029_127_137_Chemical)) (, ,) (NP (DT an) (ADJP (RB orally) (JJ active)) (NN beta) (NN 1-adrenoceptor) (NN agonist)) (, ,))) (PP (IN in) (NP (VBG improving) (NNP Doc_3831029_198_213_Disease)))) (VP (AUX was) (VP (VBN assessed) (PP (IN in) (NP (NN dog) (NN heart-lung) (NNS preparations))))) (. .)))
3831029	2	(S1 (S (NP (JJ Cardiac) (NNS functions)) (VP (VBP Doc_3831029_277_286_Disease) (PP (IN by) (NP (NP (JJ Doc_3831029_290_303_Chemical) (PRN (-LRB- -LRB-) (NP (CD 118) (JJ +/-) (CD 28) (NNS mg)) (: ;) (S (VP (VB mean) (NP (NN value) (JJ +/-) (NNS SD)))) (-RRB- -RRB-)) (JJ such)) (SBAR (IN that) (S (S (NP (NP (JJ cardiac) (NN output) (CC and) (NN maximum) (NN rate)) (PP (IN of) (NP (NP (NN rise)) (PP (IN of) (NP (NP (JJ left) (JJ ventricular) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NNP LV) (NNP dP/dt) (NNP max)) (-RRB- -RRB-))))))) (VP (AUX had) (VP (AUX been) (VP (VBN reduced) (PP (IN by) (NP (QP (RB about) (CD 35)) (NN %))))))) (CC and) (S (NP (NP (CD 26) (NN %)) (PP (IN of) (NP (DT the) (JJ respective) (NNS controls)))) (VP (AUX were) (VP (VBN improved) (PP (IN by) (NP (NP (NNP Doc_3831029_515_525_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10-300) (NNS micrograms)) (-RRB- -RRB-)))) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))))))))))) (. .)))
3831029	3	(S1 (S (PP (IN With) (NP (CD 100) (NNS micrograms))) (NP (NNP Doc_3831029_594_604_Chemical)) (, ,) (NP (NP (ADJP (RB almost) (JJ complete)) (NN restoration)) (PP (IN of) (NP (JJ cardiac) (NN performance)))) (VP (AUX was) (VP (VBN attained) (, ,) (PP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJ slight) (NN increase)) (PP (IN in) (NP (NN heart) (NN rate)))))))) (. .)))
3831029	4	(S1 (S (NP (DT No) (NN Doc_3831029_723_734_Disease)) (VP (AUX were) (VP (VBN induced) (PP (IN by) (NP (NP (DT these) (NNS doses)) (PP (IN of) (NP (NNP Doc_3831029_766_776_Chemical))))))) (. .)))
3831029	5	(S1 (S (NP (DT The) (NNS results)) (VP (VBP warrant) (NP (NP (JJ clinical) (NNS trials)) (PP (IN of) (NP (NNP Doc_3831029_817_827_Chemical)))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_3831029_848_863_Disease)))))) (. .)))
3832950	0	(S1 (S (NP (NN Doc_3832950_0_10_Chemical)) (VP (VBD monotherapy) (PP (IN for) (NP (NNP Doc_3832950_27_35_Disease))) (PP (IN in) (NP (NN childhood)))) (. .)))
3832950	1	(S1 (S (NP (NP (NP (CD Sixty) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN age-range)) (NP (CD one) (NN month))) (PP (TO to) (NP (CD 14) (NNS years)))) (-RRB- -RRB-))) (PP (IN with) (NP (NP (JJ other) (NNS types)) (PP (IN of) (NP (NNP Doc_3832950_119_127_Disease))))) (PP (IN than) (NP (NNP Doc_3832950_133_149_Disease)))) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_3832950_168_178_Chemical))))) (. .)))
3832950	2	(S1 (S (NP (NP (NP (NN Disappearance)) (PP (IN of) (NP (NNP Doc_3832950_197_205_Disease)))) (CC and) (NP (NP (NN normalization)) (PP (IN of) (NP (NP (JJ abnormal) (NNS EEG)) (PP (IN with) (NP (NP (NN disappearance)) (PP (IN of) (NP (NNP Doc_3832950_262_270_Disease))))))))) (VP (AUX were) (VP (VBN recognized) (PP (IN in) (NP (NP (CD 77) (NN %)) (CC and) (NP (CD 50) (NN %)) (, ,) (ADVP (RB respectively)))))) (. .)))
3832950	3	(S1 (S (NP (NN Doc_3832950_317_325_Disease)) (VP (VBD disappeared) (PP (IN in) (NP (NP (NP (CD 71) (NN %)) (PP (IN of) (NP (NP (DT the) (NNS patients)) (PP (IN with) (NP (JJ generalized) (NN Doc_3832950_378_386_Disease)))))) (CC and) (NP (NP (CD 89) (NN %)) (PP (IN of) (NP (JJ partial) (NNP Doc_3832950_406_414_Disease))))))) (. .)))
3832950	4	(S1 (S (NP (NP (NN Improvement)) (PP (IN of) (NP (JJ abnormal) (NNS EEG)))) (VP (AUX was) (VP (VBN noticed) (PP (PP (IN in) (NP (NP (CD 76) (NN %)) (PP (IN of) (NP (JJ diffuse) (NNS paroxysms))))) (CC and) (PP (IN in) (NP (NP (CD 67) (NN %)) (PP (IN of) (NP (JJ focal) (NNS paroxysms)))))))) (. .)))
3832950	5	(S1 (S (S (PP (IN In) (NP (JJ excellent) (NNS cases))) (, ,) (NP (JJ mean) (JJ effective) (NNS dosages)) (VP (AUX were) (NP (NP (CD 0.086) (JJ +/-) (JJ 0.021) (NN mg/kg/day)) (PP (IN in) (NP (NP (NNS infants)) (CC and) (NP (NP (CD 0.057) (NNS +/-)) (NP (CD 0.022) (NN mg/kg/day)))))) (PP (IN in) (NP (NNS schoolchildren))))) (, ,) (NP (DT this) (NN difference)) (VP (AUX was) (ADJP (RB statistically) (JJ significant)) (PRN (-LRB- -LRB-) (NP (QP (RB p) (JJR less) (IN than) (CD 0.005))) (-RRB- -RRB-))) (. .)))
3832950	6	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NP (JJ side) (NNS effects)) (PP (JJ such) (IN as) (NP (NP (NN drowsiness)) (CC and) (NP (NN Doc_3832950_769_775_Disease))))))) (VP (AUX was) (NP (QP (RB only) (CD 5)) (NN %))) (. .)))
3833372	0	(S1 (S (NP (NP (JJ Postmarketing) (NN study)) (PP (IN of) (NP (NNP Doc_3833372_23_50_Chemical)))) (VP (VBP antihypertensive) (NP (NN therapy))) (. .)))
3833372	1	(S1 (S (NP (DT A) (JJ postmarketing) (NN surveillance) (NN study)) (VP (AUX was) (VP (VBN conducted) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN safety) (CC and) (NN efficacy)) (PP (IN of) (NP (NP (DT a) (NN fixed-ratio) (NN combination)) (VP (VBG containing) (NP (NP (NP (CD 10) (NN mg)) (PP (IN of) (NP (NNP Doc_3833372_212_227_Chemical)))) (CC and) (NP (NP (CD 25) (NN mg)) (PP (IN of) (NP (NNP Doc_3833372_241_260_Chemical)))))))) (, ,) (VP (VBN administered) (ADVP (RB twice) (RB daily)) (PP (IN for) (NP (NP (CD one) (NN month)) (PP (TO to) (NP (NNP Doc_3833372_304_316_Disease) (NNS patients)))))))))))) (. .)))
3833372	2	(S1 (S (NP (NP (NNS Data)) (PP (IN on) (NP (CD 9,037) (NNS patients)))) (VP (AUX were) (VP (VBN collected) (PP (IN by) (NP (CD 1,455) (VBG participating) (NNS physicians))))) (. .)))
3833372	3	(S1 (S (NP (JJ Mean) (JJ systolic) (NN blood) (NN pressure)) (VP (VBD decreased) (SBAR (S (NP (NP (CD 25) (NN mmHg)) (CC and) (NP (JJ mean) (JJ diastolic) (NN blood) (NN pressure))) (VP (VBD declined) (NP (CD 15) (NN mmHg)) (PP (IN after) (NP (NP (CD one) (NN month)) (PP (IN of) (NP (NP (JJ Doc_3833372_517_544_Chemical) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.01))) (, ,) (NP (DT both) (NNS comparisons)) (-RRB- -RRB-)))))))))) (. .)))
3833372	4	(S1 (S (NP (NP (NN Age)) (, ,) (NP (NN race)) (, ,) (CC and) (NP (NN sex))) (VP (VBD appeared) (S (VP (TO to) (VP (AUX have) (NP (DT no) (NN influence)) (PP (IN on) (NP (NP (DT the) (NN decrease)) (PP (IN in) (NP (NN blood) (NN pressure))))))))) (. .)))
3833372	5	(S1 (S (NP (NP (DT The) (JJ antihypertensive) (NN effect)) (PP (IN of) (NP (DT the) (NN drug)))) (VP (AUX was) (ADJP (JJR greater)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (ADJP (RBR more) (JJ severe)) (NN Doc_3833372_756_768_Disease)))))) (. .)))
3833372	6	(S1 (S (ADVP (RB Overall)) (, ,) (NP (CD 1,453) (NNS patients)) (VP (VBD experienced) (NP (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD 2,658) (JJ adverse) (NNS events)))) (, ,) (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (NN being) (NN fatigue)) (, ,) (NP (NP (NNP Doc_3833372_870_879_Disease)) (, ,) (CC and) (NP (NNP Doc_3833372_885_893_Disease)))))) (. .)))
3833372	7	(S1 (S (NP (NP (NN Treatment)) (PP (IN in) (NP (CD 590) (NNS patients)))) (VP (AUX was) (VP (VBN discontinued) (PP (IN because) (IN of) (NP (JJ adverse) (NNS events))))) (. .)))
3864191	0	(S1 (NP (NP (NP (JJ Doc_3864191_0_10_Chemical) (NN Doc_3864191_11_22_Disease)) (PP (IN in) (NP (DT the) (NNP Gunn) (NN rat)))) (: :) (NP (NP (JJ potential) (NN role)) (PP (IN of) (NP (NNP Doc_3864191_58_72_Chemical)))) (. .)))
3864191	1	(S1 (S (NP (PRP We)) (VP (VBD examined) (NP (NP (DT the) (JJ potential) (NN role)) (PP (IN of) (NP (NNP Doc_3864191_108_122_Chemical))) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ analgesic) (NN Doc_3864191_155_166_Disease))) (PP (IN in) (NP (NP (DT the) (NNP Gunn) (NN strain)) (PP (IN of) (NP (NN rat))))))))) (. .)))
3864191	2	(S1 (S (NP (DT The) (JJ homozygous) (NNP Gunn) (NNS rats)) (VP (AUX have) (NP (ADJP (NNP Doc_3864191_224_255_Disease) (JJ due) (PP (TO to) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NNP Doc_3864191_278_288_Chemical)))))) (NN transferase)) (, ,) (PP (VBG leading) (PP (TO to) (NP (NP (JJ marked) (JJ Doc_3864191_320_329_Chemical) (NN deposition)) (PP (IN in) (NP (NP (JJ renal) (NN medulla)) (CC and) (NP (NN papilla)))))))) (. .)))
3864191	3	(S1 (S (NP (DT These) (NNS rats)) (VP (AUX are) (ADVP (RB also)) (ADJP (RB highly) (JJ susceptible) (S (VP (TO to) (VP (VB develop) (NP (NN Doc_3864191_421_439_Disease)) (PP (IN with) (NP (JJ analgesic) (NN administration)))))))) (. .)))
3864191	4	(S1 (S (NP (PRP We)) (VP (VBD used) (NP (NP (NP (NNS homozygous)) (PRN (-LRB- -LRB-) (NP (CD jj)) (-RRB- -RRB-))) (CC and) (NP (JJ phenotypically) (JJ normal) (JJ heterozygous) (PRN (-LRB- -LRB-) (JJ jJ) (-RRB- -RRB-)) (NNS animals)))) (. .)))
3864191	5	(S1 (S (S (NP (NP (NP (CD Four) (NNS groups)) (PP (IN of) (NP (NNS rats)))) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 7)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN studied)))) (: :) (S (NP (NN jj) (CC and) (NN jJ) (NNS rats)) (VP (VBD treated) (ADVP (RB either)) (PP (IN with) (NP (NNP Doc_3864191_625_632_Chemical) (CD 300))) (PP (IN mg/kg) (NP (DT every) (JJ other) (NN day) (CC or) (JJ sham-treated))))) (. .)))
3864191	6	(S1 (S (PP (IN After) (NP (CD one) (NN week))) (, ,) (S (NP (NP (NNS slices)) (PP (IN of) (NP (NP (NN cortex) (, ,) (JJ outer) (CC and) (JJ inner) (NN medulla)) (PP (IN from) (NP (CD one) (NN kidney)))))) (VP (AUX were) (VP (VBN incubated) (PP (IN in) (NP (NN buffer)))))) (CC and) (S (NP (JJ Doc_3864191_779_792_Chemical) (NN synthesis)) (VP (AUX was) (VP (VBN determined) (PP (IN by) (NP (NN radioimmunoassay)))))) (. .)))
3864191	7	(S1 (S (NP (DT The) (JJ other) (NN kidney)) (VP (AUX was) (VP (VBN examined) (ADVP (RB histologically)))) (. .)))
3864191	8	(S1 (S (NP (NP (DT A) (JJ marked) (NN corticomedullary) (NN gradient)) (PP (IN of) (NP (JJ Doc_3864191_923_936_Chemical) (NN synthesis)))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (DT all) (NNS groups))))) (. .)))
3864191	9	(S1 (S (NP (JJ Doc_3864191_975_979_Chemical) (NN synthesis)) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR higher) (PP (IN in) (NP (NP (NP (JJ outer) (NN medulla)) (, ,) (CONJP (CC but) (RB not)) (NP (NP (NN cortex)) (CC or) (NP (JJ inner) (NN medulla))) (, ,)) (PP (IN of) (NP (NP (NNS jj)) (PRN (-LRB- -LRB-) (NP (NP (CD 38) (NNS +/-)) (NP (CD 6) (CD ng/mg) (NN prot))) (-RRB- -RRB-))))))) (PP (IN than) (NP (NP (NP (CD jJ) (NNS rats)) (-LRB- -LRB-) (NP (CD 15) (NN +/-) (CD 3)) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-)))))) (. .)))
3864191	10	(S1 (S (S (NP (JJ Doc_3864191_1138_1145_Chemical) (NN treatment)) (VP (VBD reduced) (NP (JJ Doc_3864191_1164_1168_Chemical) (NN synthesis)) (PP (IN in) (NP (DT all) (NNS regions))))) (, ,) (CC but) (S (NP (JJ outer) (NN medullary) (NNP Doc_3864191_1215_1219_Chemical)) (VP (VBD remained) (ADJP (ADJP (JJR higher) (PP (IN in) (NP (NP (NNS jj)) (PRN (-LRB- -LRB-) (NP (QP (CD 18) (CD +/-)) (CD 3)) (-RRB- -RRB-))))) (PP (IN than) (NP (NP (NP (CD jJ) (NNS rats)) (-LRB- -LRB-) (NP (QP (CD 9) (CD +/-)) (CD 2)) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-))))))) (. .)))
3864191	11	(S1 (S (NP (NNP Doc_3864191_1296_1306_Chemical)) (VP (AUX was) (ADVP (RB also)) (ADJP (RB significantly) (JJR higher)) (PP (IN in) (NP (NP (DT the) (JJ outer) (NN medulla)) (PP (IN of) (NP (NP (JJ jj) (NNS rats)) (PP (IN with) (CC and) (PP (IN without) (NP (NNP Doc_3864191_1386_1393_Chemical) (NN administration))) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)))))))) (. .)))
3864191	12	(S1 (S (NP (NP (DT The) (NNS changes)) (PP (IN in) (NP (JJ renal) (JJ Doc_3864191_1450_1463_Chemical) (NN synthesis)))) (VP (AUX were) (VP (VBN accompanied) (PP (IN by) (NP (NP (NP (NN evidence)) (PP (IN of) (NP (NNP Doc_3864191_1506_1518_Disease))) (PP (IN in) (NP (NP (JJ Doc_3864191_1522_1529_Chemical-treated) (NNS jj)) (CC but) (NP (NP (QP (RB not) (CD jJ)) (NNS rats)) (SBAR (IN as) (S (VP (VBN evidenced) (PP (IN by))))))))) (: :) (NP (NP (VBN increased) (NN incidence) (CC and) (NN severity)) (PP (IN of) (NP (NNP Doc_3864191_1610_1619_Disease))) (PRN (-LRB- -LRB-) (ADVP (RB p)) (NP (QP (JJR less) (IN than) (CD 0.01))) (-RRB- -RRB-))) (: ;) (NP (NP (VBN increased) (NN serum)) (NP (NP (NNP Doc_3864191_1656_1666_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)))) (: ;) (CC and) (NP (NP (NN increase)) (PP (IN in) (NP (NP (JJ outer) (JJ medullary) (JJ histopathologic) (NNS lesions)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (RB p) (JJR less) (IN than) (CD 0.005))) (PP (VBN compared) (PP (TO to) (NP (DT either) (JJ sham-treated) (NN jj))))) (CC or) (NP (JJ Doc_3864191_1800_1807_Chemical-treated) (NN jJ))) (-RRB- -RRB-))))))))) (. .)))
3864191	13	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (JJ enhanced) (JJ Doc_3864191_1857_1870_Chemical) (NN synthesis)) (VP (VBZ contributes) (PP (TO to) (NP (NP (NN maintenance)) (PP (IN of) (NP (NP (JJ renal) (NN function)) (CC and) (NP (JJ morphological) (NN integrity))))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ Doc_3864191_1978_1991_Chemical) (NN synthesis)))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (JJ pathological) (JJ renal) (NN medullary) (NNS lesions)) (CC and) (NP (NP (NN deterioration)) (PP (IN of) (NP (JJ renal) (NN function)))))))))))) (. .)))
3895875	0	(S1 (NP (NP (NNP Prophylactic) (NNP Doc_3895875_13_22_Chemical)) (PP (IN in) (NP (NP (DT the) (JJ early) (NN phase)) (PP (IN of) (NP (JJ suspected) (NNP Doc_3895875_55_76_Disease))))) (. .)))
3895875	1	(S1 (S (NP (NP (QP (CD Four) (CD hundred) (CD two)) (NNS patients)) (PP (IN with) (NP (NP (VBN suspected) (NN Doc_3895875_119_140_Disease)) (VP (VBN seen) (PP (IN within) (NP (NP (CD 6) (NNS hours)) (PP (IN of) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNS symptoms))))))))))) (VP (VBD entered) (NP (NP (DT a) (JJ double-blind) (JJ randomized) (NN trial)) (PP (IN of) (NP (NNP Doc_3895875_229_238_Chemical) (NNP vs) (NN placebo))))) (. .)))
3895875	2	(S1 (S (PP (IN During) (NP (NP (DT the) (CD 1) (NN hour)) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (DT the) (NN drug))))))) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_3895875_319_343_Disease)) (CC or) (NP (JJ sustained) (NNP Doc_3895875_357_380_Disease)))) (PP (IN among) (NP (DT the) (CD 204) (NNS patients))) (PP (IN with) (NP (NNP Doc_3895875_409_436_Disease)))) (VP (AUX was) (ADJP (JJ low)) (, ,) (NP (CD 1.5) (NN %))) (. .)))
3895875	3	(S1 (S (NP (NP (NN Doc_3895875_452_461_Chemical)) (, ,) (VP (VBN given) (PP (IN in) (NP (NP (DT a) (ADJP (CD 300) (NN mg)) (NN dose)) (VP (ADVP (RB intramuscularly)) (VBN followed) (PP (IN by) (NP (QP (CD 100) (CD mg)) (NN intravenously))))))) (, ,)) (VP (AUX did) (RB not) (VP (VB prevent) (NP (JJ sustained) (NNP Doc_3895875_562_585_Disease)) (, ,) (SBAR (IN although) (S (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_3895875_661_680_Disease))) (PP (IN between) (NP (NP (CD 15) (CC and) (CD 45) (NNS minutes)) (PP (IN after) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_3895875_735_744_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)))))))))))))))))) (. .)))
3895875	4	(S1 (S (NP (NP (DT The) (JJ average) (NN plasma) (JJ Doc_3895875_784_793_Chemical) (NN level)) (PP (NP (CD 10) (NNS minutes)) (IN after) (NP (NN administration))) (PP (IN for) (NP (NP (NNS patients)) (PP (IN without) (NP (DT a) (NN Doc_3895875_855_876_Disease)))))) (VP (AUX was) (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN than) (NP (NP (DT that)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (DT an) (JJ acute) (NN Doc_3895875_939_949_Disease))))))))) (. .)))
3895875	5	(S1 (S (NP (NP (DT The) (JJ mean) (NN plasma) (JJ Doc_3895875_967_976_Chemical) (NN level)) (PP (IN of) (NP (NNS patients))) (PP (IN on) (NP (JJ beta-blocking) (NNS agents)))) (VP (AUX was) (ADJP (RB no) (JJ different) (PP (IN from) (NP (NP (DT that)) (PP (IN in) (NP (NNS patients)))))) (PP (RB not) (IN on) (NP (JJ beta) (VBG blocking) (NNS agents)))) (. .)))
3895875	6	(S1 (S (S (PP (IN During) (NP (DT the) (JJ 1-hour) (NN study) (NN period))) (, ,) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ central) (JJ nervous) (NN system) (NN side) (NNS effects)))) (VP (AUX was) (ADJP (RB significantly) (JJR greater)) (PP (IN in) (NP (DT the) (NNP Doc_3895875_1205_1214_Chemical) (NN group))))) (, ,) (NP (NNP Doc_3895875_1222_1233_Disease)) (VP (VBD occurred) (PP (IN in) (NP (NP (NP (NP (CD 11) (NNS patients)) (, ,) (SBAR (WHNP (CD nine) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (AUX had) (VP (VBN received) (NP (NNP Doc_3895875_1285_1294_Chemical)))))) (, ,)) (CC and) (NP (NP (CD four) (NNS patients)) (VP (VBN died) (PP (IN from) (NP (NNP Doc_3895875_1324_1332_Disease)))))) (, ,) (SBAR (WHNP (CD three) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (AUX had) (VP (AUX had) (NP (NNP Doc_3895875_1356_1365_Chemical))))))))) (. .)))
3895875	7	(S1 (S (NP (PRP We)) (ADVP (RB cannot)) (VP (VBP advocate) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_3895875_1408_1417_Chemical)))) (ADVP (RB prophylactically)) (PP (IN in) (NP (NP (DT the) (JJ early) (NNS hours)) (PP (IN of) (NP (VBN suspected) (NNP Doc_3895875_1467_1488_Disease)))))) (. .)))
3925479	0	(S1 (NP (NP (NN Evidence)) (PP (IN for) (NP (NP (DT a) (JJ cholinergic) (NN role)) (PP (IN in) (NP (NNP Doc_3925479_35_46_Chemical-induced) (NNP Doc_3925479_55_64_Disease))))) (. .)))
3925479	1	(S1 (S (NP (NP (NNS Experiments)) (PP (IN in) (NP (NNS mice)))) (VP (VBD tested) (NP (JJ previous) (NN evidence) (SBAR (SBAR (IN that) (S (NP (NP (NN activation)) (PP (IN of) (NP (JJ cholinergic) (NNS systems)))) (VP (VBZ promotes) (NP (NNP Doc_3925479_159_168_Disease))))) (CC and) (SBAR (IN that) (S (NP (JJ cholinergic) (NNS mechanisms)) (VP (AUX need) (S (VP (TO to) (VP (AUX be) (ADJP (JJ intact)) (PP (IN for) (NP (NP (JJ full) (NN expression)) (PP (IN of) (NP (JJ neuroleptic-induced) (NN Doc_3925479_262_271_Disease)))))))))))))) (. .)))
3925479	2	(S1 (S (NP (NP (NP (JJ Large) (NNS doses)) (PP (IN of) (NP (DT the) (NN cholinomimetic)))) (, ,) (NP (NNP Doc_3925479_308_319_Chemical)) (, ,)) (VP (MD could) (VP (VB induce) (NP (NN Doc_3925479_334_343_Disease)) (SBAR (WHADVP (WRB when)) (S (NP (JJ peripheral) (JJ cholinergic) (NNS receptors)) (VP (AUX were) (VP (VBN blocked))))))) (. .)))
3925479	3	(S1 (S (NP (NP (JJ Low) (NNS doses)) (PP (IN of) (NP (NNP Doc_3925479_409_420_Chemical)))) (VP (VBD caused) (NP (NP (NP (DT a) (JJ pronounced) (NN enhancement)) (PP (IN of) (NP (DT the) (NNP Doc_3925479_460_469_Disease))) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (DT the) (JJ dopaminergic) (NN blocker)))))))) (, ,) (NP (NNP Doc_3925479_516_527_Chemical)))) (. .)))
3925479	4	(S1 (S (NP (NP (DT A) (JJ muscarinic) (NN receptor) (NN blocker)) (, ,) (NP (NNP Doc_3925479_560_568_Chemical)) (, ,)) (VP (VBD disrupted) (NP (JJ Doc_3925479_580_591_Chemical-induced) (NNP Doc_3925479_600_609_Disease))) (. .)))
3925479	5	(S1 (S (NP (NP (JJ Intracranial) (NN injection)) (PP (IN of) (NP (NP (DT an) (NNP Doc_3925479_640_653_Chemical-synthesis) (NN inhibitor)) (, ,) (NP (NNP Doc_3925479_675_688_Chemical)) (, ,)))) (VP (VBD prevented) (NP (NP (DT the) (NN Doc_3925479_704_713_Disease)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (ADVP (RB usually)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_3925479_741_752_Chemical))))))))) (. .)))
3925479	6	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (NP (DT the) (NN hypothesis)) (SBAR (IN that) (S (NP (NP (DT the) (NN Doc_3925479_801_810_Disease)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (VP (VBN produced) (PP (IN by) (NP (NP (NNS neuroleptics)) (PP (JJ such) (IN as) (NP (NNP Doc_3925479_852_863_Chemical)))))))))) (VP (AUX is) (ADVP (RB actually)) (VP (VBN mediated) (PP (IN by) (NP (JJ intrinsic) (JJ central) (NN cholinergic) (NNS systems)))))))) (. .)))
3925479	7	(S1 (S (ADVP (RB Alternatively)) (, ,) (NP (NP (NN activation)) (PP (IN of) (NP (JJ central) (NN cholinergic) (NNS systems)))) (VP (MD could) (VP (VB promote) (NP (NNP Doc_3925479_998_1007_Disease)) (PP (IN by) (NP (NP (NN suppression)) (PP (IN of) (NP (JJ dopaminergic) (NNS systems))))))) (. .)))
3975902	0	(S1 (S (NP (NP (NP (NN Doc_3975902_0_26_Disease)) (CC and) (NP (NN Doc_3975902_31_47_Disease))) (PP (TO to) (NP (NNP Doc_3975902_51_71_Chemical)))) (VP (VBN induced) (PP (IN by) (NP (JJ chronic) (JJ Doc_3975902_91_106_Chemical) (NN ingestion)))) (. .)))
3975902	1	(S1 (S (NP (JJ Doc_3975902_118_124_Chemical-supplemented) (JJ Long-Evans) (JJ hooded) (NNS rats)) (VP (AUX were) (VP (VBN characterized) (PP (IN by) (NP (NP (DT a) (JJ persistent) (NN Doc_3975902_196_208_Disease)) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (ADJP (JJ evident)) (PP (IN after) (NP (NP (CD 1) (NN month)) (PP (IN of) (NP (NNP Doc_3975902_243_249_Chemical) (PRN (-LRB- -LRB-) (NP (QP (CD 100) (CD micrograms/ml)) (NN mineral) (JJ fortified) (NN water)) (-RRB- -RRB-)) (NN treatment)))))))))))) (. .)))
3975902	2	(S1 (S (NP (NP (NP (NN Analysis)) (PP (IN of) (PP (IN in) (NP (NP (NNP vivo) (NNP Doc_3975902_325_348_Disease)) (, ,) (NP (NN contractility)) (, ,))))) (CC and) (NP (NP (JJ metabolic) (NNS characteristics)) (PP (IN at) (NP (CD 16) (NNS months))))) (VP (VBD revealed) (NP (NP (JJ other) (JJ significant) (JJ Doc_3975902_435_441_Chemical-induced) (NNS disturbances)) (PP (IN within) (NP (DT the) (JJ cardiovascular) (NN system))))) (. .)))
3975902	3	(S1 (S (NP (NP (DT The) (ADJP (RBS most) (JJ distinctive)) (NN aspect)) (PP (IN of) (NP (DT the) (JJ Doc_3975902_532_538_Chemical) (NN effect)))) (VP (AUX was) (NP (NP (DT a) (VBN demonstrated) (NN Doc_3975902_565_581_Disease)) (PP (IN of) (NP (DT the) (JJ cardiovascular) (NN system))) (PP (TO to) (NP (NNP Doc_3975902_614_634_Chemical))))) (. .)))
3975902	4	(S1 (S (PP (IN Under) (NP (JJ Doc_3975902_642_653_Chemical) (NN anesthesia))) (, ,) (NP (NP (RB virtually) (DT all)) (PP (IN of) (NP (DT the) (JJ myocardial) (JJ contractile) (NNS indices)))) (VP (AUX were) (VP (VBN depressed) (ADVP (RB significantly)) (PP (IN in) (NP (NP (JJ Doc_3975902_750_756_Chemical-exposed) (NNS rats)) (ADJP (JJ relative) (PP (TO to) (NP (DT the) (JJ corresponding) (JJ control-fed) (NNS rats)))))))) (. .)))
3975902	5	(S1 (S (NP (NP (DT The) (NN lack)) (PP (IN of) (NP (NP (DT a) (JJ similar) (NN response)) (PP (TO to) (NP (NNP Doc_3975902_852_860_Chemical) (CC and) (NNP Doc_3975902_865_873_Chemical) (NNS anesthesia)))))) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (DT the) (JJ cardiovascular) (NNS actions)) (PP (IN of) (NP (NNP Doc_3975902_929_949_Chemical))) (PP (IN in) (NP (JJ Doc_3975902_953_959_Chemical-treated) (NNS rats)))) (VP (VP (AUX were) (VP (VBN linked) (ADVP (RB specifically)) (PP (TO to) (NP (DT this) (NN anesthetic))))) (, ,) (CC and) (VP (AUX were) (RB not) (NP (NP (NN representative)) (PP (IN of) (NP (DT a) (JJ generalized) (JJ anesthetic) (NN response))))))))) (. .)))
3975902	6	(S1 (S (NP (NP (JJ Other) (JJ myocardial) (ADJP (JJ pathophysiologic) (CC and) (JJ metabolic)) (NNS changes)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_3975902_1151_1157_Chemical))))) (VP (AUX were) (ADJP (JJ manifest)) (, ,) (ADVP (RB irrespective) (PP (IN of) (NP (NP (DT the) (JJ anesthetic)) (VP (VBN employed)))))) (. .)))
3975902	7	(S1 (S (NP (NP (DT The) (JJ contractile) (NN element) (NN shortening) (NN velocity)) (PP (IN of) (NP (DT the) (JJ cardiac) (NN muscle) (NNS fibers)))) (VP (AUX was) (ADJP (RB significantly) (JJR slower)) (PP (IN in) (NP (NP (DT both) (NNS groups)) (PP (IN of) (NP (JJ Doc_3975902_1330_1336_Chemical-treated) (NNS rats))) (ADJP (JJ relative) (PP (TO to) (NP (NP (DT the) (NN control) (NNS groups)) (, ,) (NP (NP (RB irrespective)) (PP (IN of) (NP (DT the) (JJ anesthetic) (NN regimen)))))))))) (. .)))
3975902	8	(S1 (S (ADVP (RB Similarly)) (, ,) (NP (NP (JJ significant) (NNS disturbances)) (PP (IN in) (NP (JJ myocardial) (NN energy) (NN metabolism)))) (VP (AUX were) (VP (VBN detected) (PP (IN in) (NP (NP (DT the) (JJ Doc_3975902_1511_1517_Chemical-exposed) (NNS rats)) (SBAR (WHNP (WDT which)) (S (VP (AUX were) (ADJP (JJ consistent) (PP (IN with) (NP (DT the) (VBN reduced) (NN contractile) (NN element) (NN shortening) (NN velocity))))))))))) (. .)))
3975902	9	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (DT the) (NN excitability)) (PP (IN of) (NP (DT the) (JJ cardiac) (NN conduction) (NN system)))) (VP (AUX was) (VP (VBN depressed) (ADVP (RB preferentially)) (PP (IN in) (NP (NP (DT the) (JJ atrioventricular) (JJ nodal) (NN region)) (PP (IN of) (NP (NNS hearts))) (PP (IN from) (NP (JJ Doc_3975902_1755_1761_Chemical-exposed) (NNS rats))))))) (. .)))
3975902	10	(S1 (S (ADVP (JJ Overall)) (, ,) (NP (NP (DT the) (JJ altered) (JJ cardiac) (NN contractility) (CC and) (NN excitability) (NNS characteristics)) (, ,) (NP (DT the) (JJ myocardial) (JJ metabolic) (NNS disturbances)) (, ,) (CC and) (NP (NP (DT the) (NN Doc_3975902_1900_1916_Disease)) (PP (IN of) (NP (DT the) (JJ cardiovascular) (NN system))) (PP (TO to) (NP (NNP Doc_3975902_1949_1969_Chemical))))) (VP (VBP suggest) (NP (NP (DT the) (NN existence)) (PP (IN of) (NP (NP (DT a) (ADJP (RB heretofore) (VBN undescribed)) (NN Doc_3975902_2020_2044_Disease)) (VP (VBN induced) (PP (IN by) (NP (JJ chronic) (JJ Doc_3975902_2064_2070_Chemical) (NN exposure)))))))) (. .)))
3975902	11	(S1 (S (NP (DT These) (JJ experimental) (NNS findings)) (VP (VBP represent) (NP (DT the) (JJ first) (NN indication) (SBAR (IN that) (S (NP (JJ life-long) (JJ Doc_3975902_2155_2161_Chemical) (NN ingestion)) (VP (MD may) (VP (AUX have) (NP (JJ significant) (JJ adverse) (NNS effects)) (PP (IN on) (NP (DT the) (JJ mammalian) (JJ cardiovascular) (NN system))))))))) (. .)))
3987172	0	(S1 (NP (NP (JJ Doc_3987172_0_11_Chemical) (NN antagonism)) (PP (IN of) (NP (NNP Doc_3987172_26_45_Chemical-induced) (NNP Doc_3987172_54_66_Disease))) (. .)))
3987172	1	(S1 (S (NP (NNP Doc_3987172_68_87_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_3987172_89_92_Chemical)) (-RRB- -RRB-)) (NNP Doc_3987172_94_102_Disease)) (VP (MD can) (VP (VB cause) (NP (NP (JJ severe) (NNP Doc_3987172_120_132_Disease)) (, ,) (NP (NNP Doc_3987172_134_158_Disease)) (, ,) (CC and) (NP (NNP Doc_3987172_164_169_Disease))))) (. .)))
3987172	2	(S1 (S (NP (PRP We)) (VP (VBD studied) (NP (NP (DT the) (NN efficacy) (CC and) (NN safety)) (PP (IN of) (NP (NNP Doc_3987172_209_220_Chemical))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_3987172_241_244_Chemical-induced) (NNP Doc_3987172_253_265_Disease))))))) (. .)))
3987172	3	(S1 (S (NP (NNS Subjects)) (VP (VBD received) (NP (NNP Doc_3987172_285_296_Chemical)) (PP (CC either) (PP (IN by) (NP (NP (NN mouth)) (PP (IN for) (NP (NP (CD 48) (NNS hours)) (PP (IN before) (NP (NNP Doc_3987172_333_336_Chemical))))))) (CC or) (PP (IN as) (NP (NP (DT a) (JJ rapid) (JJ intravenous) (NN infusion)) (PP (IN after) (NP (NNP Doc_3987172_378_381_Chemical))))))) (. .)))
3987172	4	(S1 (S (S (NP (NP (NNP Doc_3987172_383_386_Chemical)) (, ,) (NP (NP (CD 75) (NN mg)) (ADVP (RB alone))) (, ,)) (VP (VBD increased) (NP (NP (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 31) (NN +/-)) (NP (CD 14) (NNS mm))) (ADJP (NNP Hg) (JJ systolic))) (, ,) (NP (NP (CD 20) (NN +/-)) (NP (CD 5) (JJ mm) (NNP Hg) (NN diastolic))) (-RRB- -RRB-))))) (, ,) (CC and) (S (NP (JJ Doc_3987172_484_495_Chemical) (NN pretreatment)) (VP (VBD antagonized) (NP (NP (DT this) (NN increase)) (PRN (-LRB- -LRB-) (NP (NP (CD 12) (NNS +/-)) (NP (CD 10) (JJ mm) (NNP Hg) (NN systolic))) (, ,) (NP (NP (CD 10) (NNS +/-)) (NP (CD 7) (JJ mm) (NNP Hg) (NN diastolic))) (-RRB- -RRB-))))) (. .)))
3987172	5	(S1 (S (NP (NP (JJ Intravenous) (NN Doc_3987172_601_612_Chemical)) (PP (IN after) (NP (NNP Doc_3987172_619_622_Chemical)))) (ADVP (RB also)) (VP (VBD decreased) (NP (NN blood) (NN pressure))) (. .)))
3987172	6	(S1 (S (NP (NP (JJ Left) (JJ ventricular) (NN function)) (PRN (-LRB- -LRB-) (VP (VBN assessed) (PP (IN by) (NP (NN echocardiography)))) (-RRB- -RRB-))) (VP (VBD showed) (SBAR (IN that) (S (NP (NNP Doc_3987172_723_726_Chemical)) (VP (VBD increased) (NP (NP (NP (DT the) (NNP Doc_3987172_741_747_Disease) (NN volume) (CD 30) (NN %)) (-LRB- -LRB-) (PP (IN from) (NP (NP (CD 62.5) (NNS +/-)) (NP (QP (CD 20.9) (TO to) (CD 80.8)) (JJ +/-) (CD 22.4) (NNS ml)))) (-RRB- -RRB-)) (, ,) (NP (NP (DT the) (NN ejection) (NN fraction)) (ADJP (CD 9) (NN %))) (PRN (-LRB- -LRB-) (NP (NP (QP (IN from) (CD 64)) (NN %)) (JJ +/-) (ADJP (QP (CD 10) (NN %) (TO to) (CD 70) (NN %))) (JJ +/-) (CD 7) (NN %)) (-RRB- -RRB-)) (, ,) (CC and) (NP (NP (NP (JJ cardiac) (NN output)) (NP (CD 14) (NN %))) (PRN (-LRB- -LRB-) (PP (IN from) (NP (CD 3.6) (NN +/-) (QP (CD 0.6) (TO to) (CD 4.1) (NNS +/-)))) (NP (CD 1.0) (NN L/min)) (-RRB- -RRB-)))))))) (. .)))
3987172	7	(S1 (S (NP (JJ Intravenous) (NNP Doc_3987172_936_947_Chemical)) (VP (VBD reversed) (NP (DT these) (NNS effects))) (. .)))
3987172	8	(S1 (S (NP (JJ Systemic) (NN vascular) (NN resistance)) (VP (VP (AUX was) (VP (VBN increased) (PP (IN by) (NP (NNP Doc_3987172_1018_1021_Chemical))) (NP (CD 28) (NN %)) (PRN (-LRB- -LRB-) (PP (IN from) (NP (QP (CD 1710) (JJ +/-) (CD 200) (TO to) (CD 2190)) (JJ +/-) (CD 700) (JJ dyne) (NNP X) (NNS sec/cm5))) (-RRB- -RRB-)))) (CC and) (VP (AUX was) (VP (RBR further) (VBN increased) (PP (IN by) (NP (NNP Doc_3987172_1106_1117_Chemical))) (NP (CD 22) (NN %)) (PRN (-LRB- -LRB-) (NP (QP (TO to) (CD 2660)) (JJ +/-) (CD 1200) (JJ dyne) (NNP X) (NN sec/cm5)) (-RRB- -RRB-))))) (. .)))
3987172	9	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (SBAR (IN that) (S (NP (NNP Doc_3987172_1174_1177_Chemical)) (VP (VBZ increases) (NP (NN blood) (NN pressure)) (PP (IN by) (S (VP (VBG increasing) (NP (NP (JJ systemic) (JJ vascular) (NN resistance)) (CC and) (NP (JJ cardiac) (NN output))))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NNP Doc_3987172_1275_1286_Chemical)) (VP (VBZ antagonizes) (NP (DT this) (NN increase)) (PP (IN by) (S (VP (VBG reversing) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNP Doc_3987172_1340_1343_Chemical))) (PP (IN on) (NP (JJ cardiac) (NN output)))))))))))) (. .)))
3987172	10	(S1 (S (NP (DT That) (NN Doc_3987172_1368_1379_Chemical)) (VP (VBZ antagonizes) (SBAR (S (NP (NP (DT the) (JJ pressor) (NN effect)) (PP (IN of) (NP (NNP Doc_3987172_1414_1417_Chemical)))) (VP (AUX is) (PP (IN in) (NP (NP (NN contrast)) (PP (TO to) (NP (NP (DT the) (NN interaction)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NNP Doc_3987172_1461_1472_Chemical)) (VP (VBZ enhances) (NP (NP (DT the) (JJ pressor) (NN effect)) (PP (IN of) (NP (NNP Doc_3987172_1504_1518_Chemical))))))))))))))) (. .)))
3987172	11	(S1 (S (NP (DT This)) (VP (AUX is) (ADVP (RB probably)) (SBAR (IN because) (S (NP (NNP Doc_3987172_1545_1548_Chemical)) (VP (AUX has) (ADJP (ADJP (RBR less) (JJ beta)) (NP (CD 2) (NN activity)) (SBAR (IN than) (S (VP (AUX does) (ADJP (JJ Doc_3987172_1584_1598_Chemical)))))))))) (. .)))
3990093	0	(S1 (NP (NP (NP (JJ Mesangial) (NN function)) (CC and) (NP (NN Doc_3990093_23_43_Disease))) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NNP Doc_3990093_57_72_Chemical) (NNP Doc_3990093_73_82_Disease))))) (. .)))
3990093	1	(S1 (S (NP (NP (DT The) (JJ possible) (NN relationship)) (PP (IN between) (NP (NP (NN Doc_3990093_118_139_Disease) (CC and) (NN development)) (PP (IN of) (NP (NNP Doc_3990093_159_179_Disease)))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (DT the) (NNP Doc_3990093_199_224_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_3990093_226_229_Chemical)) (-RRB- -RRB-)) (NN model))))) (. .)))
3990093	2	(S1 (S (S (NP (CD Five) (JJ male) (NNP Wistar) (NNS rats)) (VP (VBD received) (NP (VBN repeated) (JJ subcutaneous) (NNP Doc_3990093_291_294_Chemical) (NNS injections)))) (: ;) (S (NP (CD five) (NNS controls)) (VP (VBD received) (NP (NN saline)) (ADVP (RB only)))) (. .)))
3990093	3	(S1 (S (S (PP (IN After) (NP (CD 4) (NNS weeks))) (NP (DT the) (JJ Doc_3990093_361_364_Chemical) (NNS rats)) (VP (AUX were) (ADJP (ADJP (RB severely) (JJ proteinuric)) (PRN (-LRB- -LRB-) (NP (CD 190) (JJ +/-) (QP (CD 80) (CD mg/24)) (NNS hr)) (-RRB- -RRB-))))) (, ,) (CC and) (S (NP (DT all) (NNS rats)) (VP (AUX were) (VP (VBN given) (NP (NP (JJ colloidal) (NNP Doc_3990093_453_459_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP CC)) (-RRB- -RRB-))) (ADVP (RB intravenously))))) (. .)))
3990093	4	(S1 (S (S (PP (IN At) (NP (CD 5) (NNS months))) (NP (NNP Doc_3990093_492_512_Disease)) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NP (NP (CD 7.6) (NN +/-)) (NP (CD 3.4) (NN %))) (PP (IN of) (NP (NP (DT the) (NNS glomeruli)) (PP (IN of) (NP (JJ Doc_3990093_559_562_Chemical) (NNS rats)))))))))) (: ;) (S (NP (NP (NNS glomeruli)) (PP (IN of) (NP (DT the) (NNS controls)))) (VP (AUX were) (ADJP (JJ normal)))) (. .)))
3990093	5	(S1 (S (NP (NP (NNS Glomeruli)) (PP (IN of) (NP (JJ Doc_3990093_621_624_Chemical) (NNS rats)))) (VP (VBD contained) (NP (NP (ADJP (RB significantly) (JJR more)) (NN CC)) (PP (IN than) (NP (NP (NNS glomeruli)) (PP (IN of) (NP (NNS controls))))))) (. .)))
3990093	6	(S1 (S (NP (NP (NNS Glomeruli)) (PP (IN with) (NP (NNP Doc_3990093_705_714_Disease)))) (VP (VBD contained) (NP (NP (ADJP (RB significantly) (JJR more)) (NN CC)) (PP (IN than) (NP (NP (JJ non-sclerotic) (NNS glomeruli)) (PP (IN in) (NP (DT the) (JJ same) (NNS kidneys))))))) (. .)))
3990093	7	(S1 (S (NP (NN CC)) (VP (AUX was) (ADVP (RB preferentially)) (VP (VBN localized) (PP (IN within) (NP (NP (DT the) (JJ sclerotic) (NNS areas)) (PP (IN of) (NP (DT the) (JJ affected) (NNS glomeruli))))))) (. .)))
3990093	8	(S1 (S (SBAR (IN Since) (S (NP (NP (JJ mesangial) (JJ CC) (NN clearance)) (PP (IN from) (NP (DT the) (NN mesangium)))) (VP (AUX did) (RB not) (VP (VB change) (PP (IN during) (NP (JJ chronic) (JJ Doc_3990093_961_964_Chemical) (NN treatment))))))) (, ,) (NP (PRP we)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (DT this) (JJ preferential) (NN CC) (NN localization)) (PP (IN within) (NP (DT the) (NNS lesions)))) (VP (AUX is) (VP (VBN caused) (PP (IN by) (NP (NP (DT an) (VBN increased) (NN CC)) (VP (VBD uptake) (PP (ADVP (RB shortly)) (IN after) (NP (NN injection))) (PP (IN in) (NP (NP (JJ apparent) (JJ vulnerable) (NNS areas)) (SBAR (WHADVP (WRB where)) (S (NP (NNP Doc_3990093_1141_1150_Disease)) (VP (MD will) (VP (VB develop) (ADVP (RB subsequently)))))))))))))))) (. .)))
3990093	9	(S1 (S (NP (NN Cluster) (NN analysis)) (VP (VBD showed) (NP (NP (DT a) (JJ random) (NN distribution)) (PP (IN of) (NP (NNS lesions)))) (PP (IN in) (NP (NP (DT the) (JJ Doc_3990093_1242_1245_Chemical) (NNS glomeruli)) (PP (IN in) (NP (NN concordance))))) (PP (IN with) (NP (NP (DT the) (JJ random) (NN localization)) (PP (IN of) (NP (NP (JJ mesangial) (NNS areas)) (PP (IN with) (NP (NN dysfunction))))))) (PP (IN in) (NP (DT this) (NN model)))) (. .)))
3990093	10	(S1 (S (NP (NP (ADJP (JJ Similar) (PP (TO to) (NP (NP (DT the) (JJ remnant) (NN kidney) (NN model)) (PP (IN in) (NP (NNP Doc_3990093_1390_1393_Chemical) (NNP Doc_3990093_1394_1403_Disease)))))) (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_3990093_1423_1443_Disease)))) (VP (MD may) (VP (AUX be) (VP (VBN related) (PP (TO to) (`` ``) (NP (JJ mesangial) (NN overloading)))))) (. .) ('' '')))
4010471	0	(S1 (NP (NP (NN Relationship)) (PP (IN between) (NP (NP (NNP Doc_4010471_21_29_Chemical-induced) (NNP Doc_4010471_38_46_Disease)) (CC and) (NP (JJ hippocampal) (JJ nicotinic) (NNS receptors)))) (. .)))
4010471	1	(S1 (S (NP (DT A) (NN controversy)) (VP (AUX has) (VP (VBN existed) (PP (IN for) (NP (NP (JJ several) (NNS years)) (VP (VBG concerning) (NP (NP (DT the) (JJ physiological) (NN relevance)) (PP (IN of) (NP (NP (DT the) (JJ nicotinic) (NN receptor)) (VP (VBN measured) (PP (IN by) (NP (NNP Doc_4010471_205_223_Chemical) (VBG binding)))))))))))) (. .)))
4010471	2	(S1 (S (S (VP (VBG Using) (NP (NP (NNS mice)) (VP (VBN derived) (PP (IN from) (NP (NP (DT a) (JJ classical) (NN F2)) (CC and) (NP (JJ backcross) (JJ genetic) (NN design)))))))) (, ,) (NP (NP (DT a) (NN relationship)) (PP (IN between) (NP (NP (JJ Doc_4010471_325_333_Chemical-induced) (NN Doc_4010471_342_350_Disease)) (CC and) (NP (JJ alpha-bungarotoxin) (JJ nicotinic) (NN receptor) (NN concentration))))) (VP (AUX was) (VP (VBN found))) (. .)))
4010471	3	(S1 (S (NP (NP (NNS Mice)) (ADJP (JJ sensitive) (PP (TO to) (NP (NP (DT the) (JJ convulsant) (NNS effects)) (PP (IN of) (NP (NNP Doc_4010471_462_470_Chemical))))))) (VP (AUX had) (NP (JJR greater) (NN alpha-bungarotoxin) (VBG binding)) (PP (IN in) (NP (NP (DT the) (NN hippocampus)) (PP (IN than) (NP (NNP Doc_4010471_534_541_Disease) (JJ insensitive) (NNS mice)))))) (. .)))
4010471	4	(S1 (S (NP (NP (DT The) (JJ binding) (NNS sites)) (PP (IN from) (NP (JJ Doc_4010471_583_590_Disease) (ADJP (JJ sensitive) (CC and) (JJ resistant)) (NNS mice)))) (VP (AUX were) (ADVP (RB equally)) (VP (VBN affected) (PP (IN by) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NNP Doc_4010471_660_674_Chemical)) (, ,) (NP (NP (NN trypsin)) (CC or) (NP (NN heat))))))))) (. .)))
4010471	5	(S1 (S (ADVP (RB Thus)) (NP (PRP it)) (VP (VBZ appears) (SBAR (IN that) (S (NP (NP (DT the) (NN difference)) (PP (IN between) (NP (NNP Doc_4010471_737_744_Disease) (ADJP (JJ sensitive) (CC and) (JJ insensitive)) (NNS animals)))) (VP (MD may) (VP (AUX be) (ADVP (RB due) (PP (TO to) (NP (NP (DT a) (NN difference)) (PP (IN in) (NP (JJ hippocampal) (JJ nicotinic) (NN receptor) (NN concentration)))))) (SBAR (IN as) (S (VP (VBN measured) (PP (IN with) (NP (JJ alpha-bungarotoxin) (VBG binding))))))))))) (. .)))
4082192	0	(S1 (NP (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NNP Doc_4082192_12_25_Chemical))) (PP (IN in) (NP (JJ Doc_4082192_29_42_Chemical-induced) (NN nephrotoxicity)))) (: :) (NP (NP (NP (NN effect)) (PP (IN of) (NP (NNP Doc_4082192_77_105_Chemical))) (PP (IN on) (NP (NNP Doc_4082192_109_122_Chemical)))) (CC and) (NP (NP (NP (JJ Doc_4082192_127_140_Chemical) (NN nephrotoxicity)) (CC and) (NP (NN metabolism))) (PP (IN in) (NP (NNP Fischer) (CD 344) (NNS rats))))) (. .)))
4082192	1	(S1 (S (NP (NP (NNP Doc_4082192_192_205_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_4082192_207_211_Chemical)) (-RRB- -RRB-))) (VP (VBZ produces) (NP (NP (JJ proximal) (NN Doc_4082192_231_247_Disease)) (PP (IN in) (NP (NP (NP (NNP Fischer) (CD 344)) (PRN (-LRB- -LRB-) (NP (NNP F344)) (-RRB- -RRB-))) (NNS rats))))) (. .)))
4082192	2	(S1 (S (ADVP (RB Recently)) (, ,) (NP (NP (NP (NNP Doc_4082192_286_299_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_4082192_301_304_Chemical)) (-RRB- -RRB-))) (, ,) (NP (DT a) (JJ known) (JJ potent) (NN nephrotoxicant)) (, ,)) (VP (AUX was) (VP (VBN identified) (PP (IN as) (NP (NP (DT a) (NN metabolite)) (PP (IN of) (NP (NNP Doc_4082192_372_376_Chemical))) (PP (IN in) (NP (JJ F344) (NNS rats))))))) (. .)))
4082192	3	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (JJ Doc_4082192_437_440_Chemical) (NN formation)) (VP (AUX is) (NP (NP (DT a) (JJ requisite) (NN step)) (PP (IN in) (NP (JJ Doc_4082192_474_478_Chemical-induced) (NN nephrotoxicity))))))))))) (. .)))
4082192	4	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NP (NNP Doc_4082192_528_556_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_4082192_558_562_Chemical)) (-RRB- -RRB-))) (, ,) (NP (DT an) (JJ acylamidase) (NN inhibitor)) (, ,))) (PP (IN on) (NP (NP (NNP Doc_4082192_594_598_Chemical) (CC and) (NNP Doc_4082192_603_606_Chemical) (NN nephrotoxicity)) (CC and) (NP (NN metabolism))))) (VP (AUX was) (VP (VBN determined))) (. .)))
4082192	5	(S1 (S (NP (NP (NNP BNPP)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (TO to) (CD 8)) (NN mM)) (-RRB- -RRB-))) (VP (VBD reduced) (NP (NP (JJ Doc_4082192_678_682_Chemical) (NN deacetylation)) (CC and) (NP (JJ covalent) (VBG binding))) (PP (IN in) (NP (CD F344) (JJ renal) (JJ cortical) (NNS homogenates))) (PP (IN in) (NP (DT a) (JJ concentration-dependent) (NN manner)))) (. .)))
4082192	6	(S1 (S (NP (NP (NN Pretreatment)) (PP (IN of) (NP (NNS animals))) (PP (IN with) (NP (NNP BNPP)))) (ADVP (RB prior) (PP (TO to) (NP (NNP Doc_4082192_833_837_Chemical) (CC or) (NNP Doc_4082192_841_844_Chemical) (NN administration)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (JJ marked) (NN reduction)) (PP (IN of) (NP (NNP Doc_4082192_892_896_Chemical) (PRN (-LRB- -LRB-) (NP (CD 900) (NN mg/kg)) (-RRB- -RRB-)) (NN nephrotoxicity)))) (CONJP (CC but) (RB not)) (NP (JJ Doc_4082192_932_935_Chemical) (NN nephrotoxicity))))) (. .)))
4082192	7	(S1 (S (NP (DT This) (NN result)) (VP (AUX was) (RB not) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ altered) (NN disposition)) (PP (IN of) (NP (NP (DT either) (JJ Doc_4082192_1009_1013_Chemical) (CC or) (JJ acetylated) (NNS metabolites)) (PP (IN in) (NP (NP (NN plasma) (CC or) (JJ renal) (NN cortical)) (CC and) (NP (JJ hepatic) (NN tissue)))))))))) (. .)))
4082192	8	(S1 (S (ADVP (RB Rather)) (, ,) (NP (NNP BNPP) (NN pretreatment)) (VP (VBD reduced) (NP (NP (DT the) (NN fraction)) (PP (IN of) (NP (NP (NNP Doc_4082192_1138_1142_Chemical)) (VP (VBN excreted) (PP (IN as) (NP (NNP Doc_4082192_1155_1158_Chemical))))))) (PP (IN by) (NP (QP (CD 64) (CC and) (CD 75)) (NN %))) (PP (IN after) (NP (NP (JJ Doc_4082192_1179_1183_Chemical) (NNS doses)) (PP (IN of) (NP (QP (CD 750) (CC and) (CD 900)) (NNS mg/kg)))))) (. .)))
4082192	9	(S1 (S (NP (NNP BNPP)) (VP (VP (AUX did) (RB not) (VP (VB alter) (NP (NP (NP (DT the) (NN excretion)) (PP (IN of) (NP (NNP Doc_4082192_1248_1252_Chemical)))) (CC or) (NP (NP (DT any)) (PP (IN of) (NP (PRP$ its) (JJ non-deacetylated) (NNS metabolites))))))) (CC nor) (VP (AUX did) (RB BNPP) (VP (VB alter) (NP (NP (NN excretion)) (PP (IN of) (NP (NP (NNP Doc_4082192_1328_1331_Chemical)) (CC or) (NP (PRP$ its) (NNS metabolites)))) (PP (IN after) (NP (NP (JJ Doc_4082192_1357_1360_Chemical) (NNS doses)) (PP (IN of) (NP (QP (CD 150) (CC and) (CD 300)) (NNS mg/kg))))))))) (. .)))
4082192	10	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT the) (JJ BNPP-induced) (NN reduction)) (PP (IN in) (NP (JJ Doc_4082192_1430_1434_Chemical-induced) (NN nephrotoxicity)))) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (ADVP (RB due) (PP (TO to) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ Doc_4082192_1493_1497_Chemical) (NN deacetylation)))))))))) (. .)))
4082192	11	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (JJ Doc_4082192_1534_1537_Chemical) (NN formation)) (, ,) (PP (IN in) (NP (NN vivo))) (, ,) (VP (VBZ accounts) (, ,) (PP (ADVP (IN at) (JJS least)) (IN in) (NP (NN part))) (, ,) (PP (IN for) (NP (NNP Doc_4082192_1590_1594_Chemical-induced) (NNP Doc_4082192_1603_1625_Disease)))))))) (. .)))
4082466	0	(S1 (NP (NP (JJ Doc_4082466_0_8_Chemical-induced) (NN Doc_4082466_17_25_Disease)) (PP (IN in) (NP (ADJP (JJ newborn)) (NNS infants))) (. .)))
4082466	1	(S1 (S (NP (CD Two) (NNS neonates)) (VP (VBD suffered) (PP (IN from) (NP (JJ generalized) (NN Doc_4082466_85_93_Disease))) (PP (IN during) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_4082466_127_143_Chemical))) (PP (IN for) (NP (JJ post-operative) (NN Doc_4082466_163_172_Disease)))))) (. .)))
4082466	2	(S1 (S (NP (PRP They)) (VP (VBD received) (NP (NNP Doc_4082466_188_196_Chemical)) (PP (IN in) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (NP (CD 32) (NNS micrograms/kg/hr)) (CC and) (NP (CD 40) (NNS micrograms/kg/hr))) (ADJP (ADJP (JJR larger)) (PP (IN than) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NP (CD 10) (NNS neonates)) (SBAR (WHNP (WP who)) (S (VP (VP (VBD received) (NP (CD 6-24) (NN micrograms/kg/hr))) (CC and) (VP (AUX had) (NP (DT no) (NN Doc_4082466_334_342_Disease)))))))))))))))) (. .)))
4082466	3	(S1 (S (NP (NP (NN Plasma) (NNS concentrations)) (PP (IN of) (NP (NNP Doc_4082466_369_377_Chemical))) (PP (IN in) (NP (DT these) (NNS neonates)))) (VP (AUX was) (ADJP (JJ excessive)) (PRN (-LRB- -LRB-) (NP (QP (CD 60) (CC and) (CD 90) (CD mg/ml))) (-RRB- -RRB-))) (. .)))
4082466	4	(S1 (S (S (NP (NP (JJ Other) (JJ known) (NNS reasons)) (PP (IN for) (NP (NNP Doc_4082466_453_461_Disease)))) (VP (AUX were) (VP (VBN ruled) (PRT (RP out))))) (CC and) (S (NP (DT the) (NNP Doc_4082466_485_496_Disease)) (VP (VP (VBD stopped) (NP (DT a) (JJ few) (NNS hours)) (PP (IN after) (NP (NP (NN cessation)) (PP (IN of) (NP (NNP Doc_4082466_536_544_Chemical)))))) (CC and) (VP (AUX did) (RB not) (VP (VB reoccur) (PP (IN in) (NP (DT the) (JJ subsequent) (CD 8) (NNS months))))))) (. .)))
4082466	5	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN suggested) (SBAR (IN that) (S (NP (JJ post-operative) (JJ intravenous) (NN Doc_4082466_641_649_Chemical)) (VP (MD should) (RB not) (VP (VB exceed) (NP (CD 20) (NN micrograms/kg/ml)) (PP (IN in) (NP (NNS neonates))))))))) (. .)))
439781	0	(S1 (S (S (NP (NN Doc_439781_0_12_Chemical)) (VP (VBN induced) (NP (NNP Doc_439781_21_32_Disease)) (PP (IN in) (NP (NNP Doc_439781_36_42_Chemical))))) (CC and) (S (NP (NN volume)) (VP (VBD depleted) (NP (NNS rats)))) (. .)))
439781	1	(S1 (S (PP (IN After) (NP (NP (DT a) (JJ single) (JJ oral) (NN dose)) (PP (IN of) (NP (CD 4) (NN mg/kg))))) (NP (NP (NNP Doc_439781_105_117_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP IDM)) (-RRB- -RRB-)) (TO to) (NP (NNP Doc_439781_127_133_Chemical)) (CC and) (NP (NN volume))) (VP (VBD depleted) (SBAR (S (NP (NP (NP (NNS rats) (NN plasma) (NN renin) (NN activity)) (PRN (-LRB- -LRB-) (NP (NNP PRA)) (-RRB- -RRB-))) (CC and) (NP (JJ systolic) (NN blood) (NN pressure))) (VP (VBD fell) (ADVP (RB significantly)) (PP (IN within) (NP (CD four) (NNS hours))))))) (. .)))
439781	2	(S1 (S (PP (IN In) (NP (JJ Doc_439781_256_262_Chemical) (JJ repleted) (NNS animals))) (NP (NNP Doc_439781_280_292_Chemical)) (VP (AUX did) (RB not) (VP (VB change) (NP (NP (JJ systolic) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NNP BP)) (-RRB- -RRB-))) (SBAR (IN although) (S (NP (NN plasma) (NN renin) (NN activity)) (VP (AUX was) (VP (VBN decreased))))))) (. .)))
439781	3	(S1 (S (ADVP (RB Thus)) (, ,) (NP (NP (NN Doc_439781_389_401_Chemical)) (PP (IN by) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ Doc_439781_419_432_Chemical) (NN synthesis)))))) (VP (MD may) (VP (VB diminish) (NP (DT the) (NN blood) (NN pressure)) (S (VP (VBG maintaining) (NP (NP (NN effect)) (PP (IN of) (NP (NP (DT the) (VBN stimulated) (JJ renin-Doc_439781_518_529_Chemical) (NN system)) (PP (IN in) (NP (NP (NNP Doc_439781_540_546_Chemical)) (CC and) (NP (NN volume) (NN depletion))))))))))) (. .)))
44072	0	(S1 (FRAG (PP (IN On) (NP (NP (DT the) (JJ antiarrhythmic) (NN activity)) (PP (IN of) (NP (NP (CD one) (JJ Doc_44072_38_62_Chemical) (NN derivative)) (PP (IN of) (NP (NNP Doc_44072_77_134_Chemical))))))) (. .)))
44072	1	(S1 (S (NP (NP (DT The) (JJ antiarrhythmic) (NN activity)) (PP (IN of) (NP (NP (DT the) (JJ compound) (NNP Doc_44072_180_288_Chemical)) (, ,) (VP (VBN referred) (PP (TO to) (NP (QP (RB as) (CD P11))))) (, ,)))) (VP (AUX is) (VP (VBN studied) (PP (PP (IN on) (NP (NP (JJ anaesthesized) (NNS cats)) (CC and) (NP (JJ Wistar) (NN albino) (NNS rats)))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN on) (NP (JJ non-anaesthesized) (NNS rabbits)))))) (. .)))
44072	2	(S1 (S (NP (NP (CD Four) (NNS types)) (PP (IN of) (NP (JJ experimental) (NNP Doc_44072_435_445_Disease)))) (VP (AUX are) (NP (JJ used--with) (NNP Doc_44072_461_466_Chemical)) (, ,) (PP (PP (IN with) (NP (NNP Doc_44072_473_483_Chemical-Doc_44072_484_494_Chemical))) (, ,) (PP (IN with) (NP (NNP Doc_44072_501_515_Chemical))) (CC and) (PP (IN with) (NP (NNP Doc_44072_525_534_Chemical))))) (. .)))
44072	3	(S1 (S (NP (DT The) (NN compound) (NN P11)) (VP (AUX is) (VP (VBN introduced) (PP (IN in) (NP (NP (NNS doses)) (PP (IN of) (NP (CD 0.25) (CC and) (CD 0.50) (NN mg/kg))))) (ADVP (ADVP (RB intravenously)) (CC and) (ADVP (NP (CD 10) (NN mg/kg)) (RB orally))))) (. .)))
44072	4	(S1 (S (NP (NP (DT The) (JJ compound) (NNS manifests) (NN antiarrhythmic) (NN activity)) (PP (IN in) (NP (NP (DT all) (NNS models)) (PP (IN of) (NP (JJ experimental) (NNP Doc_44072_711_721_Disease)))))) (VP (VBD used) (, ,) (S (VP (VBG causing) (NP (NP (JJS greatest) (NN inhibition)) (PP (IN on) (NP (NP (DT the) (NNP Doc_44072_763_773_Disease)) (VP (VBN induced) (PP (PP (IN by) (NP (NNP Doc_44072_785_795_Chemical-Doc_44072_796_806_Chemical))) (PRN (-LRB- -LRB-) (PP (IN in) (NP (NP (CD 90)) (PP (IN per) (NP (NN cent))))) (-RRB- -RRB-)) (CC and) (PP (IN with) (NP (NNP Doc_44072_833_838_Chemical))) (PRN (-LRB- -LRB-) (PP (IN in) (NP (NP (CD 84)) (PP (IN per) (NP (NN cent))))) (-RRB- -RRB-)))))))))) (. .)))
44072	5	(S1 (S (NP (NP (DT The) (NNS results)) (VP (VBN obtained))) (VP (AUX are) (VP (VBN associated) (PP (PP (IN with) (NP (DT the) (NN beta-adrenoblocking))) (CC and) (PP (IN with) (NP (NP (DT the) (JJ membrane-stabilizing) (NN action)) (PP (IN of) (NP (DT the) (NN compound)))))))) (. .)))
448423	0	(S1 (S (NP (NNP Recurrent) (NNP Doc_448423_10_33_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ Doc_448423_50_67_Chemical) (NN therapy)) (CC and) (NP (NN Doc_448423_80_109_Disease))))) (. .)))
448423	1	(S1 (S (NP (NN Case)) (VP (VBP report)) (. .)))
448423	2	(S1 (S (NP (NP (NNP Doc_448423_124_149_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_448423_151_155_Chemical)) (-RRB- -RRB-))) (VP (AUX has) (VP (AUX been) (VP (VBN used) (S (VP (TO to) (VP (VB prevent) (NP (NN rebleeding)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_448423_210_233_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_448423_235_238_Disease)) (-RRB- -RRB-)))))))))))) (. .)))
448423	3	(S1 (S (SBAR (IN Although) (S (NP (DT this) (NN agent)) (VP (AUX does) (VP (VB decrease) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NN rebleeding)))))))) (, ,) (NP (JJ several) (NNS reports)) (VP (AUX have) (VP (VBN described) (NP (NP (JJ Doc_448423_335_345_Disease) (NNS complications)) (PP (IN of) (NP (JJ Doc_448423_363_367_Chemical) (NN therapy)))))) (. .)))
448423	4	(S1 (S (NP (DT These) (NNS complications)) (VP (AUX have) (VP (VBN included) (NP (NP (JJ clinical) (NN deterioration)) (CC and) (NP (NNP Doc_448423_438_470_Disease))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_448423_488_491_Disease)) (, ,) (NP (NP (ADJP (JJ arteriolar) (CC and) (JJ capillary)) (NN fibrin) (NNS thrombi)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ fibrinolytic) (NNS syndromes)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_448423_586_590_Chemical))))))))) (, ,) (CC or) (NP (JJ other) (NNP Doc_448423_601_615_Disease) (NNS phenomena)))))))) (. .)))
448423	5	(S1 (S (SBAR (IN Since) (S (NP (JJ intravascular) (NN fibrin) (NNS thrombi)) (VP (AUX are) (ADVP (RB often)) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_448423_698_720_Disease))))))))) (, ,) (NP (NNP Doc_448423_722_726_Chemical)) (VP (MD should) (RB not) (VP (AUX be) (VP (VBN implicated) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NP (JJ fibrin) (NNS thrombi)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (VBN disseminated) (NN Doc_448423_820_845_Disease)) (CC or) (NP (JJ other) (`` ``) (NX (NNP Doc_448423_856_882_Disease)))))))))))))) (. .) ('' '')))
448423	6	(S1 (S (NP (DT This) (NN report)) (VP (VBZ describes) (NP (JJ subtotal) (NN Doc_448423_916_940_Disease)) (PP (JJ due) (TO to) (NP (NP (NNP Doc_448423_948_958_Disease)) (PP (IN of) (NP (DT a) (JJ normal) (JJ renal) (NN artery)))))) (. .)))
448423	7	(S1 (S (NP (DT This) (NN occlusion)) (VP (VBD occurred) (PP (IN after) (NP (JJ Doc_448423_1015_1019_Chemical) (NN therapy))) (PP (IN in) (NP (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_448423_1046_1049_Disease)))) (CC and) (NP (NP (JJ histopathological) (NN documentation)) (PP (IN of) (NP (JJ recurrent) (NNP Doc_448423_1099_1102_Disease))))))) (. .)))
448423	8	(S1 (S (NP (DT The) (JJ corresponding) (JJ clinical) (NN event)) (VP (AUX was) (VP (VBN characterized) (PP (IN by) (NP (NP (JJ marked) (NNP Doc_448423_1165_1177_Disease)) (CC and) (NP (NNP Doc_448423_1182_1215_Disease)))))) (. .)))
4631913	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_4631913_10_29_Chemical))) (PP (IN on) (NP (NP (NNP Doc_4631913_33_55_Disease)) (PP (IN in) (NP (NNS monkeys))))) (. .)))
4631913	1	(S1 (S (S (PP (IN In) (NP (JJ rhesus) (NNS monkeys))) (, ,) (NP (NP (JJ intravenous) (NN challenge)) (PP (IN with) (NP (NP (CD 0.6) (NNP x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 10)) (-RRB- -RRB-)))) (PP (TO to) (NP (QP (CD 2.2) (SYM x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 10)) (-RRB- -RRB-)) (NNP Doc_4631913_142_174_Disease)))) (VP (VBD caused) (NP (NP (JJ acute) (NN illness)) (PP (IN of) (NP (NP (QP (CD 4) (TO to) (CD 5)) (NNS days) (POS ')) (NN duration))) (PP (IN with) (NP (NP (JJ spontaneous) (NN recovery)) (PP (IN in) (NP (NP (CD 13)) (PP (IN of) (NP (CD 15) (NNS monkeys)))))))))) (: ;) (S (NP (NN blood) (NNS cultures)) (VP (VBD became) (ADJP (JJ negative)) (PP (NP (QP (CD 3) (TO to) (CD 17)) (NNS days)) (IN after) (NP (NN challenge))))) (. .)))
4631913	2	(S1 (S (NP (NN Doc_4631913_329_341_Disease)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (DT all) (NNS monkeys))))) (. .)))
4631913	3	(S1 (S (NP (NP (ADJP (JJ Intravenous) (CC or) (JJ intratracheal)) (NN inoculation)) (PP (IN of) (NP (NP (QP (CD 2.0) (TO to) (CD 2.5)) (NNS mg)) (PP (IN of) (NP (NNP Doc_4631913_432_451_Chemical)))))) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (NNP Doc_4631913_468_478_Disease))) (PP (IN in) (NP (QP (CD 4) (TO to) (CD 5)) (NNS days))))) (. .)))
4631913	4	(S1 (S (NP (NP (JJ Intravenous) (NN inoculation)) (PP (IN of) (NP (NP (NP (NP (NP (NP (CD 4.2) (SYM x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 10)) (-RRB- -RRB-))) (PP (TO to) (NP (NP (CD 7.8) (NNP x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD 10)) (-RRB- -RRB-))))) (NNP Doc_4631913_551_557_Chemical) (NN type)) (NP (CD 6) (NNP Pseudomonas) (NNS organisms))) (PP (IN in) (NP (NNS monkeys))) (VP (VBN given) (NP (NNP Doc_4631913_604_623_Chemical) (CD 4) (NNS days)))))) (ADVP (RB previously)) (VP (VBD resulted) (PP (IN in) (NP (JJ fatal) (NNP Doc_4631913_660_669_Disease))) (PP (IN in) (NP (NP (CD 11)) (PP (IN of) (NP (CD 14) (NNS monkeys))))) (, ,) (SBAR (IN whereas) (S (NP (NP (NN none)) (PP (IN of) (NP (NP (CD four) (NN receiving) (NNS Pseudomonas)) (ADVP (RB alone))))) (VP (VBD died))))) (. .)))
4631913	5	(S1 (S (NP (DT These) (NNS studies)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (DT an) (JJ Doc_4631913_776_790_Chemical-induced) (NN Doc_4631913_799_809_Disease)) (VP (VBZ predisposes) (PP (TO to) (NP (JJ severe) (NN Doc_4631913_832_850_Disease)))))) (CC and) (SBAR (IN that) (S (NP (JJ such) (NNS monkeys)) (VP (MD may) (VP (VB serve) (PP (IN as) (NP (NP (DT a) (JJ biological) (NN model)) (PP (IN for) (NP (NP (NN study)) (PP (IN of) (NP (NP (JJ comparative) (NN efficacy)) (PP (IN of) (NP (JJ antimicrobial) (NNS agents))))))))))))))) (. .)))
48835	0	(S1 (NP (NP (NN Modification)) (PP (IN by) (NP (NP (NNP Doc_48835_16_27_Chemical)) (PP (IN of) (NP (NP (JJ cardiovascular) (NNS effects)) (PP (IN of) (NP (VBN induced) (NNS hypoglycaemia))))))) (. .)))
48835	1	(S1 (S (NP (NP (DT The) (JJ cardiovascular) (NNS effects)) (PP (IN of) (NP (NN hypoglycaemia)))) (, ,) (PP (PP (IN with)) (CC and) (PP (IN without) (NP (NN beta-blockade)))) (, ,) (VP (AUX were) (VP (VBN compared) (PP (IN in) (NP (CD fourteen) (JJ healthy) (NNS men))))) (. .)))
48835	2	(S1 (S (S (NP (CD Eight)) (VP (VBD received) (NP (NP (NN insulin)) (ADVP (RB alone))))) (, ,) (CC and) (S (NP (NP (CD eight)) (, ,) (PP (VBG including) (NP (NP (CD two)) (PP (IN of) (NP (DT the) (JJ original) (JJ insulin-only) (NN group))))) (, ,)) (VP (AUX were) (VP (VBN given) (NP (NP (NN Doc_48835_298_309_Chemical)) (CC and) (NP (NN insulin)))))) (. .)))
48835	3	(S1 (S (PP (IN In) (NP (DT the) (NN insulin-group))) (NP (NP (DT the) (NN period)) (PP (IN of) (NP (NN hypoglycaemia)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN heart-rate)))) (CC and) (NP (NP (DT a) (NN fall)) (PP (IN in) (NP (JJ diastolic) (NN blood-pressure)))))))) (. .)))
48835	4	(S1 (S (PP (IN In) (NP (DT the) (JJ Doc_48835_465_476_Chemical-insulin) (NN group))) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (NN fall)) (PP (IN in) (NP (NP (NP (NN heart-rate)) (PP (IN in) (NP (JJS most) (NNS subjects)))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ diastolic) (NN pressure)))))))) (. .)))
48835	5	(S1 (S (NP (JJ Typical) (JJ S-T/T) (NNS changes)) (VP (VBD occurred) (PP (PP (IN in) (NP (DT the) (NN insulin-group))) (CC but) (PP (IN in) (NP (NP (NN none)) (PP (IN of) (NP (DT the) (JJ Doc_48835_661_672_Chemical-insulin) (NN group))))))) (. .)))
48835	6	(S1 (S (NP (NP (NN Doc_48835_688_700_Disease)) (PP (IN in) (NP (NP (NNS diabetics)) (ADJP (JJ prone) (PP (TO to) (NP (NN hypoglycaemia) (NNS attacks))))))) (VP (MD should) (RB not) (VP (AUX be) (VP (VBN treated) (PP (IN with) (NP (NNS beta-blockers))) (SBAR (IN because) (S (NP (DT these) (NNS drugs)) (VP (MD may) (VP (VB cause) (NP (NP (DT a) (JJ sharp) (NN rise)) (PP (IN in) (NP (NN blood-pressure))) (PP (IN in) (NP (JJ such) (NNS patients))))))))))) (. .)))
573555	0	(S1 (NP (NP (NP (JJ Long-term) (JJ Doc_573555_10_21_Chemical) (NN therapy)) (PP (IN in) (NP (NN pregnancy)))) (: :) (NP (NP (NN maternal)) (CC and) (NP (JJ fetal) (NN outcome))) (. .)))
573555	1	(S1 (S (NP (NP (NNP Doc_573555_72_83_Chemical)) (, ,) (NP (DT a) (JJ beta-adrenergic) (VBG blocking) (NN agent)) (, ,)) (VP (AUX has) (VP (VBN found) (NP (NP (DT an) (JJ important) (NN position)) (PP (IN in) (NP (NP (DT the) (NN practice)) (PP (IN of) (NP (NN medicine)))))))) (. .)))
573555	2	(S1 (S (NP (NP (PRP$ Its) (NN use)) (PP (IN in) (NP (NN pregnancy)))) (, ,) (ADVP (RB however)) (, ,) (VP (AUX is) (NP (DT an) (JJ open) (NN question)) (SBAR (IN as) (S (NP (NP (DT a) (NN number)) (PP (IN of) (NP (JJ detrimental) (NN side) (NNS effects)))) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (DT the) (NN fetus) (CC and) (NN neonate))))))))) (. .)))
573555	3	(S1 (S (NP (NP (CD Ten) (NNS patients)) (CC and) (NP (CD 12) (NNS pregnancies))) (VP (AUX are) (VP (VBN reported) (SBAR (WHADVP (WRB where)) (S (NP (JJ chronic) (NNP Doc_573555_375_386_Chemical)) (VP (AUX has) (VP (AUX been) (VP (VBN administered)))))))) (. .)))
573555	4	(S1 (S (NP (NP (CD Five) (NNS patients)) (PP (IN with) (NP (NP (JJ serial) (NNS pregnancies)) (PP (PP (IN with)) (CC and) (PP (IN without) (NP (JJ Doc_573555_465_476_Chemical) (NN therapy))))))) (VP (AUX are) (ADVP (RB also)) (VP (VBN examined))) (. .)))
573555	5	(S1 (S (NP (ADJP (ADJP (JJ Maternal)) (, ,) (ADJP (JJ fetal)) (, ,) (CC and) (ADJP (JJ neonatal))) (NNS complications)) (VP (AUX are) (VP (VBN examined))) (. .)))
573555	6	(S1 (S (NP (DT An) (NN attempt)) (VP (AUX is) (VP (VBN made) (S (VP (TO to) (VP (VB differentiate) (NP (JJ drug-related) (NNS complications)) (PP (IN from) (NP (JJ maternal) (JJ disease--related) (NNS complications)))))))) (. .)))
573555	7	(S1 (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (ADVP (RB previously)) (VP (VBN reported) (NP (NNP Doc_573555_708_720_Disease) (, ,) (NNP Doc_573555_722_740_Disease) (, ,) (NNP Doc_573555_742_754_Disease) (, ,) (JJ neonatal) (NNP Doc_573555_765_770_Disease))))))) (, ,) (CC and) (S (NP (NNP Doc_573555_776_787_Disease)) (VP (VP (AUX are) (RB not) (ADJP (JJ invariable))) (CC and) (VP (ADVP (RB cannot)) (AUX be) (ADVP (RB statistically)) (VP (VBN correlated) (PP (IN with) (NP (JJ chronic) (JJ Doc_573555_859_870_Chemical) (NN therapy))))))) (. .)))
573555	8	(S1 (S (NP (NN Doc_573555_880_898_Disease)) (, ,) (ADVP (RB however)) (, ,) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (ADJP (JJ significant)) (PP (IN in) (NP (NP (DT both)) (PP (IN of) (NP (PRP$ our) (NNS series))))))))) (. .)))
6106951	0	(S1 (NP (NP (NP (JJ Central) (JJ excitatory) (NNS actions)) (PP (IN of) (NP (NNP Doc_6106951_30_40_Chemical)))) (. .)))
6106951	1	(S1 (S (NP (NP (JJ Toxic) (NNS actions)) (PP (IN of) (NP (NP (NNP Doc_6106951_59_69_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP FZP)) (-RRB- -RRB-))))) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NP (NNS cats)) (, ,) (NP (NNS mice)) (CC and) (NP (NNS rats)))))) (. .)))
6106951	2	(S1 (S (NP (JJ High) (NNS doses)) (VP (VBD caused) (NP (NP (DT an) (JJ apparent) (JJ central) (NN excitation)) (, ,) (VP (ADVP (RBS most) (RB clearly)) (VBN seen) (PP (IN as) (NP (JJ clonic) (NN Doc_6106951_191_202_Disease)))) (, ,) (VP (VBN superimposed) (PP (IN on) (NP (JJ general) (NN Doc_6106951_228_238_Disease)))))) (. .)))
6106951	3	(S1 (S (PP (VBG Following) (NP (DT a) (JJ lethal) (NN dose))) (, ,) (NP (NNP Doc_6106951_265_270_Disease)) (VP (AUX was) (ADVP (RB always)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_6106951_298_309_Disease))))) (. .)))
6106951	4	(S1 (S (S (VP (VBG Comparing) (NP (NP (DT the) (JJ relative) (NN sensitivity)) (PP (TO to) (NP (JJ central) (NN Doc_6106951_357_367_Disease) (CC and) (NN excitation)))))) (VP (VBD revealed) (SBAR (IN that) (S (NP (NNS rats)) (VP (AUX were) (ADJP (RBS least) (JJ likely) (S (VP (TO to) (VP (AUX have) (NP (NN Doc_6106951_428_439_Disease)) (PP (IN at) (NP (NP (NNS doses)) (SBAR (WHNP (WDT that)) (S (VP (AUX did) (RB not) (ADVP (RB first)) (VP (VB cause) (NP (NNP Doc_6106951_474_495_Disease)) (, ,) (SBAR (IN while) (S (NP (NNS cats)) (ADVP (RBS most) (RB clearly)) (VP (VBD showed) (NP (JJ marked) (JJ central) (NN excitatory) (NNS actions))))))))))))))))))) (. .)))
6106951	5	(S1 (S (NP (NP (NNS Signs)) (PP (IN of) (NP (NP (NN FZP) (NN toxocity)) (PP (IN in) (NP (NNS cats)))))) (VP (VBD included) (NP (NP (ADJP (NNP Doc_6106951_602_622_Disease) (, ,) (JJ extreme)) (NNP Doc_6106951_632_653_Disease)) (, ,) (UCP (NN retching) (, ,) (NN muscle) (NNP Doc_6106951_672_679_Disease) (CC and) (NNP Doc_6106951_684_695_Disease)))) (. .)))
6106951	6	(S1 (S (NP (NP (DT An) (NN interaction)) (PP (IN between) (NP (NP (NNP FZP)) (CC and) (NP (NP (NNP Doc_6106951_728_745_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6106951_747_750_Chemical)) (-RRB- -RRB-)))))) (VP (AUX was) (VP (VBN shown) (PP (IN by) (S (VP (VBG pretreating) (NP (NP (NNS mice)) (PP (IN with) (NP (NN FZP)))) (PP (IN before) (NP (NNP Doc_6106951_798_801_Chemical) (NN challenge)))))))) (. .)))
6106951	7	(S1 (S (PP (IN As) (NP (NP (DT a) (NN function)) (PP (IN of) (NP (NN dose))))) (, ,) (NP (NN FZP)) (ADVP (RB first)) (VP (VBN protected) (PP (IN against) (NP (NP (NNP Doc_6106951_864_875_Disease)) (CC and) (NP (NNP Doc_6106951_880_885_Disease))))) (. .)))
6106951	8	(S1 (S (PP (IN At) (NP (JJR higher) (NNS doses))) (, ,) (ADVP (RB however)) (, ,) (NP (NNP Doc_6106951_913_924_Disease)) (ADVP (RB again)) (VP (VBD emerged)) (. .)))
6106951	9	(S1 (S (NP (NP (DT These) (NNS doses)) (PP (IN of) (NP (NNS FZP)))) (VP (AUX were) (ADJP (ADJP (JJR lower)) (PP (IN than) (NP (NP (DT those)) (SBAR (WHNP (WDT that)) (S (VP (MD would) (ADVP (RB alone)) (VP (VB cause) (NP (NN Doc_6106951_1004_1015_Disease)))))))))) (. .)))
6106951	10	(S1 (S (NP (DT These) (NNS results)) (VP (MD may) (VP (AUX be) (ADJP (JJ relevant) (PP (TO to) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN FZP))) (PP (IN in) (NP (NP (JJ clinical) (NNS situations)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (EX there)) (VP (AUX is) (NP (VBN increased) (JJ neural) (NN excitability))))) (, ,) (PP (JJ such) (IN as) (NP (NP (NNP Doc_6106951_1145_1153_Disease)) (CC or) (NP (JJ sedative-hypnotic) (NN drug) (NN withdrawal))))))))))) (. .)))
611664	0	(S1 (NP (NP (NN Use)) (PP (IN of) (NP (NNP Doc_611664_7_18_Chemical))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_611664_39_73_Disease))))) (. .)))
611664	1	(S1 (S (NP (NP (CD Five) (NNS patients)) (PP (IN with) (NP (NNP Doc_611664_94_128_Disease))) (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (ADJP (JJ physiologic) (CC and) (JJ biochemical)) (NN evidence)) (PP (IN of) (NP (JJ severe) (NN Doc_611664_184_205_Disease)))))))) (VP (AUX were) (VP (VBN included) (PP (IN in) (NP (DT the) (NN study))))) (. .)))
611664	2	(S1 (S (NP (PRP They)) (DT all) (VP (VP (VBD exhibited) (NP (RB markedly) (JJ reduced) (NN plasma) (NN Doc_611664_277_291_Chemical) (CC and) (NN plasma) (NN renin) (NN activity)) (PP (IN in) (NP (DT both) (NN recumbent) (CC and) (NN upright) (NNS positions)))) (CC and) (VP (AUX had) (VP (VBN marked) (NP (NNP Doc_611664_373_389_Disease)) (PP (TO to) (NP (NP (DT the) (JJ pressor) (NNS effects)) (PP (IN of) (NP (VBN infused) (NNP Doc_611664_424_438_Chemical)))))))) (. .)))
611664	3	(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NNP Doc_611664_455_465_Chemical))) (VP (VBN administered) (ADVP (RB intravenously)) (PRN (-LRB- -LRB-) (NP (CD 1-5) (NN mg)) (-RRB- -RRB-)))) (VP (VBD produced) (NP (NNP Doc_611664_511_557_Disease)) (PP (IN in) (NP (NP (CD 4)) (PP (IN of) (NP (NP (DT the) (CD 5) (NNS individuals)) (PP (IN with) (NP (NP (NNS rises)) (VP (VBG ranging) (PP (IN from) (NP (CD 11/6))) (PP (TO to) (NP (QP (CD 22/11) (CD mmHg)))))))))))) (. .)))
611664	4	(S1 (S (NP (NP (JJ Chronic) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_611664_659_670_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 40-160) (NN mg/day)) (-RRB- -RRB-))))) (ADVP (RB also)) (VP (VBD elevated) (NP (NP (DT the) (NN blood) (NNS pressures)) (PP (IN of) (NP (DT these) (NNS individuals)))) (PP (IN with) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (DT the) (NN order)) (PP (IN of) (NP (NP (CD 20-35/15-25) (NNP mmg)) (VP (AUXG being) (VP (VBD observed)))))))))) (. .)))
611664	5	(S1 (S (PP (IN In) (NP (CD 1) (NN patient))) (, ,) (S (NP (JJ marked) (NN Doc_611664_826_838_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_611664_854_865_Chemical)))))) (CC and) (S (NP (DT the) (NN drug)) (VP (AUX had) (S (VP (TO to) (VP (AUX be) (VP (VBN withdrawn))))))) (. .)))
611664	6	(S1 (S (S (NP (PRP It)) (ADVP (RB otherwise)) (VP (AUX was) (ADVP (RB well)) (VP (VBN tolerated)))) (CC and) (S (NP (DT no) (JJ important) (NN side) (NNS effects)) (VP (AUX were) (VP (VBN observed)))) (. .)))
611664	7	(S1 (S (NP (NN Treatment)) (VP (AUX has) (VP (AUX been) (VP (VBN continued) (PP (IN in) (NP (CD 3) (NNS individuals))) (PP (IN for) (NP (CD 6-13) (NNS months))) (PP (IN with) (NP (NP (NN persistence)) (PP (IN of) (NP (DT the) (NN pressor) (NN effect))))) (, ,) (SBAR (IN although) (S (NP (EX there)) (VP (VBZ appears) (S (VP (TO to) (VP (AUX have) (VP (AUX been) (NP (DT some) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NP (NN response)) (PP (IN with) (NP (NN time))))))))))))))))) (. .)))
611664	8	(S1 (S (NP (NP (JJ Hemodynamic) (NNS measurements)) (PP (IN in) (NP (NP (CD 1)) (PP (IN of) (NP (DT the) (NNS patients)))))) (VP (VBD demonstrated) (NP (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ total) (JJ peripheral) (NN resistance)))) (CC and) (NP (NP (RB essentially) (DT no) (NN change)) (PP (IN in) (NP (NP (JJ cardiac) (NN output)) (VP (VBG following) (NP (JJ Doc_611664_1322_1333_Chemical) (NN therapy)))))))) (. .)))
611664	9	(S1 (S (NP (DT The) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_611664_1368_1379_Chemical)) (VP (AUX is) (NP (DT a) (JJ useful) (NN drug)) (PP (IN in) (NP (NP (JJ selected) (NNS patients)) (PP (IN with) (NP (JJ severe) (NN Doc_611664_1430_1464_Disease))))))))) (. .)))
612112	0	(S1 (NP (NP (JJ Total) (JJ intravenous) (NNS anesthesia)) (PP (IN with) (NP (NNP Doc_612112_34_43_Chemical))) (. .)))
612112	1	(S1 (NP (NNP III) (. .)))
612112	2	(S1 (NP (NP (NP (DT Some) (NNS observations)) (PP (IN in) (NP (NNS adults)))) (. .)))
612112	3	(S1 (S (NP (DT An) (NN investigation)) (VP (AUX was) (VP (VBN undertaken) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (NNP Doc_612112_138_147_Chemical))) (VP (VBN required) (S (VP (TO to) (VP (VB maintain) (NP (NN sleep)) (PP (IN in) (NP (NP (NNS adults)) (VP (VBG undergoing) (NP (NN surgery)) (PP (IN under) (NP (JJ regional) (JJ local) (NN anesthesia)))))))))))))))) (. .)))
612112	4	(S1 (S (S (NP (NP (NN Premedication)) (PP (IN of) (NP (NP (NNP Doc_612112_254_262_Chemical) (CD 10) (NNS mg)) (CC and) (NP (NNP Doc_612112_273_281_Chemical) (CD 0.5) (NNS mg))))) (VP (AUX was) (VP (VBN given)))) (, ,) (CC and) (S (NP (NN sleep)) (VP (AUX was) (VP (VBN induced) (CC and) (VBN maintained) (PP (IN by) (NP (NP (JJ intermittent) (JJ intravenous) (NNS injections)) (PP (IN of) (NP (JJ Doc_612112_379_388_Chemical) (NNS 0.1/mg/kg))))) (, ,) (PP (VBN given) (SBAR (WHADVP (WRB whenever)) (S (NP (DT the) (NN patient)) (VP (MD would) (VP (VB open) (NP (PRP$ his) (NNS eyes)) (PP (IN on) (NP (NN request))))))))))) (. .)))
612112	5	(S1 (S (S (NP (NP (DT A) (JJ mean) (JJ overall) (NN dose)) (PP (IN of) (NP (NNP Doc_612112_482_491_Chemical) (CD 17.4) (NNS microgram/kg/min.)))) (VP (AUX was) (VP (VBN required) (S (VP (TO to) (VP (VB maintain) (NP (NN sleep)))))))) (, ,) (CC but) (S (NP (JJ great) (JJ individual) (NN variation)) (VP (VBD occurred) (, ,) (PP (IN with) (NP (NP (JJR older) (NNS patients)) (VP (VBG requiring) (NP (JJR less) (NN drug))))))) (. .)))
612112	6	(S1 (S (NP (DT The) (NN investigation)) (VP (AUX was) (VP (VBN discontinued) (PP (IN after) (NP (CD 18) (NNS patients))) (PP (IN because) (IN of) (NP (NP (DT the) (NN frequency) (CC and) (NN intensity)) (PP (IN of) (NP (NP (NNS side-effects)) (, ,) (ADVP (RB particularly)) (NP (NP (NNP Doc_612112_751_755_Disease)) (CC and) (NP (NNP myoclonia))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD caused) (S (NP (DT the) (NN technique)) (VP (TO to) (VP (AUX be) (VP (VBN abandoned) (PP (IN in) (NP (CD two) (NNS cases)))))))))))))))) (. .)))
612112	7	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN considered) (S (ADJP (JJ unlikely)) (SBAR (IN that) (S (NP (NNP Doc_612112_859_868_Chemical)) (VP (MD will) (VP (VB prove) (S (VP (TO to) (VP (AUX be) (NP (NP (DT the) (JJ hypnotic)) (PP (IN of) (NP (NN choice)))) (PP (IN for) (NP (NP (DT a) (ADJP (RB totally) (JJ intravenous)) (NN anesthetic) (NN technique)) (PP (IN in) (NP (NNS adults))))) (PP (IN because) (IN of) (NP (NP (DT the) (JJ high) (NN incidence)) (PP (IN of) (NP (NN myoclonia))))) (PP (IN after) (NP (VBN prolonged) (NN administration))))))))))))) (. .)))
612112	8	(S1 (S (PP (IN In) (NP (JJ several) (NNS patients))) (NP (NN uncontrollable) (NN muscle) (NNS movements)) (VP (VBD persisted) (PP (IN for) (NP (JJ many) (NNS minutes))) (PP (IN after) (NP (NP (JJ complete) (NN recovery)) (PP (IN of) (NP (NN consciousness)))))) (. .)))
6299641	0	(S1 (NP (NP (NN Evidence)) (PP (IN for) (NP (NP (JJ cardiac) (JJ beta) (NNS 2-adrenoceptors)) (PP (IN in) (NP (NN man))))) (. .)))
6299641	1	(S1 (S (NP (PRP We)) (VP (VBD compared) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ single) (NNS doses)) (PP (IN of) (NP (NP (NP (CD 50) (NNS mg)) (NP (NP (NNP Doc_6299641_99_107_Chemical)) (PRN (-LRB- -LRB-) (NP (NN cardioselective)) (-RRB- -RRB-)))) (, ,) (NP (NP (CD 40) (NNS mg)) (NP (NP (NNP Doc_6299641_133_144_Chemical)) (PRN (-LRB- -LRB-) (NP (NN nonselective)) (-RRB- -RRB-)))) (, ,) (CC and) (NP (NN placebo)))))) (PP (IN on) (NP (DT both) (ADJP (JJ exercise-) (CC and) (JJ Doc_6299641_195_208_Chemical-induced)) (NNP Doc_6299641_217_228_Disease)))) (PP (IN in) (NP (NP (CD two) (NNS experiments)) (VP (VBG involving) (NP (CD nine) (JJ normal) (NNS subjects)))))) (. .)))
6299641	2	(S1 (S (S (NP (JJ Maximal) (NN exercise) (NN heart) (NN rate)) (VP (AUX was) (VP (VBN reduced) (PP (IN from) (NP (NP (QP (CD 187) (JJ +/-) (CD 4))) (PRN (-LRB- -LRB-) (NP (NNP SEM)) (-RRB- -RRB-)))) (PP (IN after) (NP (NN placebo))) (PP (TO to) (NP (NP (NP (NP (CD 146) (NN +/-)) (NP (CD 7) (NN bpm))) (PP (IN after) (NP (NNP Doc_6299641_377_385_Chemical)))) (CC and) (NP (NP (NP (CD 138) (NN +/-)) (NP (CD 6) (NN bpm))) (PP (IN after) (NP (NNP Doc_6299641_410_421_Chemical))))))))) (, ,) (CC but) (S (NP (EX there)) (VP (AUX were) (NP (NP (DT no) (NNS differences)) (PP (IN between) (NP (DT the) (NNS drugs)))))) (. .)))
6299641	3	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN on) (NP (NNP Doc_6299641_487_500_Chemical) (NNP Doc_6299641_501_512_Disease)))) (VP (AUX were) (VP (VBN determined) (PP (IN before) (CC and) (IN after) (NP (NP (NNP Doc_6299641_546_554_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.04) (RB mg/kg) (NNP IV)) (-RRB- -RRB-)))))) (. .)))
6299641	4	(S1 (S (S (NP (JJ Doc_6299641_572_585_Chemical) (NN sensitivity)) (VP (AUX was) (VP (VBN determined) (PP (IN as) (NP (NP (DT the) (JJ intravenous) (NN dose)) (SBAR (WHNP (WDT that)) (S (VP (VBD increased) (NP (NN heart) (NN rate)) (PP (IN by) (NP (NP (CD 25) (NNS bpm)) (PRN (-LRB- -LRB-) (NP (CD CD25)) (-RRB- -RRB-)))))))))))) (CC and) (S (NP (DT this)) (VP (AUX was) (VP (VBN increased) (PP (IN from) (NP (CD 1.8) (JJ +/-) (CD 0.3) (NNS micrograms))) (PP (IN after) (NP (NP (NP (NP (QP (NN placebo) (TO to) (CD 38.9) (NN +/-))) (NP (CD 8.3) (NNS micrograms))) (PP (IN after) (NP (NNP Doc_6299641_778_789_Chemical)))) (CC and) (NP (NP (NP (CD 8.3) (NN +/-)) (NP (CD 1.7) (NNS micrograms))) (PP (IN after) (NP (NNP Doc_6299641_823_831_Chemical))))))))) (. .)))
6299641	5	(S1 (S (NP (NP (DT The) (NN difference)) (PP (IN in) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (DT the) (CD two)))))) (VP (AUX was) (ADJP (JJ significant))) (. .)))
6299641	6	(S1 (S (S (PP (IN After) (NP (NNP Doc_6299641_897_905_Chemical))) (NP (DT the) (CD CD25)) (VP (AUX was) (ADJP (JJ unchanged)) (PP (IN after) (NP (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (CD 2.3) (JJ +/-) (CD 0.3) (NNS micrograms)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_6299641_972_980_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 7.7) (JJ +/-) (CD 1.3) (NNS micrograms)) (-RRB- -RRB-))))))) (: ;) (S (NP (PRP it)) (VP (VP (AUX was) (VP (VBN reduced) (PP (IN after) (NP (NP (NNP Doc_6299641_1028_1039_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 24.8) (JJ +/-) (CD 5.0) (NNS micrograms)) (-RRB- -RRB-)))))) (, ,) (CC but) (VP (VBD remained) (ADJP (JJ different) (PP (IN from) (NP (NNP Doc_6299641_1095_1103_Chemical))))))) (. .)))
6299641	7	(S1 (S (S (NP (NP (DT This) (NN change)) (PP (IN with) (NP (JJ Doc_6299641_1122_1133_Chemical) (NN sensitivity)))) (VP (AUX was) (VP (VBN calculated) (PP (IN as) (NP (DT the) (JJ apparent) (NN Ka)))))) (, ,) (S (NP (DT this)) (VP (AUX was) (ADJP (JJ unchanged)) (PP (IN by) (NP (NP (NNP Doc_6299641_1203_1211_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 11.7) (ADJP (JJ +/-) (NP (CD 2.1) (CC and) (CD 10.1))) (JJ +/-) (CD 2.5) (NN ml/ng)) (-RRB- -RRB-)))))) (. .)))
6299641	8	(S1 (S (NP (DT These) (NNS data)) (VP (AUX are) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT the) (NN hypothesis)) (SBAR (WHNP (WDT that)) (S (VP (VBD exercise-induced) (NP (JJ Doc_6299641_1319_1330_Disease) (NNS results)) (PP (ADVP (RB largely)) (IN from) (NP (NP (JJ beta) (NN 1-receptor) (NN activation)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (VP (VBN blocked) (PP (IN by) (NP (DT both) (JJ cardioselective) (CC and) (JJ nonselective) (NNS drugs))))))))) (, ,) (SBAR (IN whereas) (S (NP (NNP Doc_6299641_1451_1464_Chemical)) (VP (VBZ activates) (NP (DT both) (NN beta) (NN 1-) (CC and) (NN beta) (NNS 2-receptors)) (SBAR (RB so) (IN that) (S (PP (IN after) (NP (JJ cardioselective) (NN blockade))) (NP (EX there)) (VP (VBZ remains) (NP (NP (DT a) (JJ beta) (NN 2-component)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (AUX be) (VP (VBN blocked) (PP (IN with) (NP (DT a) (JJ nonselective) (NN drug)))))))))))))))))))))) (. .)))
6299641	9	(S1 (S (SBAR (IN While) (S (NP (EX there)) (VP (VBP appear) (S (VP (TO to) (VP (AUX be) (NP (NN beta) (NNS 2-receptors)) (PP (IN in) (NP (DT the) (JJ human) (NN heart))))))))) (, ,) (NP (PRP$ their) (ADJP (JJ physiologic) (CC or) (JJ pathologic)) (NNS roles)) (VP (VBP remain) (S (VP (TO to) (VP (AUX be) (VP (VBN defined)))))) (. .)))
6305660	0	(S1 (NP (NP (NP (NNS Hormones)) (CC and) (NP (NN risk))) (PP (IN of) (NP (NNP Doc_6305660_21_34_Disease))) (. .)))
6305660	1	(S1 (S (NP (DT This) (NN paper)) (VP (VBZ reports) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (NP (DT a) (NN study)) (PP (IN of) (NP (NP (CD 50) (JJ menopausal) (NNS women)) (VP (VBG receiving) (NP (JJ hormonal) (NN replacement) (NN therapy))))))))) (. .)))
6305660	2	(S1 (S (S (NP (NP (DT The) (NN majority)) (PRN (-LRB- -LRB-) (NP (CD 29)) (-RRB- -RRB-))) (VP (AUX had) (NP (JJ surgical) (NN menopause)))) (: ;) (S (NP (PRP$ their) (JJ mean) (NN age)) (VP (AUX was) (NP (CD 45.7) (NNS years)))) (. .)))
6305660	3	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN hypothesized) (SBAR (IN that) (S (NP (NNP Doc_6305660_239_249_Chemical)) (VP (MD could) (VP (VB equilibrate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (DT the) (JJ estrogenic) (NN stimulation))) (PP (IN on) (NP (NP (DT the) (JJ mammary) (CC and) (JJ endometrial) (NN target) (NNS tissues)) (PP (IN of) (NP (NNS women))) (PP (IN on) (NP (JJ hormonal) (NN replacement) (NN therapy)))))))))))) (. .)))
6305660	4	(S1 (S (NP (DT The) (NN treatment) (NN schedule)) (VP (VBD consisted) (PP (IN of) (NP (NP (JJ conjugated) (NNP Doc_6305660_445_454_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6305660_456_464_Chemical)) (-RRB- -RRB-)))) (NP (NP (NP (CD 1.25) (NN mg/day)) (PP (IN for) (NP (CD 21) (NNS days)))) (CC and) (NP (NP (NNP Doc_6305660_494_521_Chemical) (CD 10) (NN mg/day)) (PP (IN for) (NP (NP (CD 10) (NNS days)) (PP (IN in) (NP (DT each) (NN month)))))))) (. .)))
6305660	5	(S1 (S (NP (DT The) (JJ mean) (NN treatment) (NN period)) (VP (AUX was) (NP (CD 18) (NNS months))) (. .)))
6305660	6	(S1 (S (PP (IN During) (NP (DT the) (JJ follow-up) (NN period))) (, ,) (NP (NN attention)) (VP (AUX was) (ADJP (JJ Doc_6305660_643_671_Disease)) (SBAR (IN as) (S (VP (VBN evidenced) (PP (IN by) (NP (NP (NN symptomatology)) (, ,) (NP (NN physical) (NN examination)) (, ,) (CC and) (NP (NN plate) (NN thermography)))))))) (. .)))
6305660	7	(S1 (S (S (NP (NN Doc_6305660_750_760_Disease)) (VP (AUX was) (VP (VBN reported) (PP (IN by) (NP (CD 21) (NNS patients)))))) (, ,) (CC and) (S (NP (JJ physical) (NN examination)) (VP (VBD revealed) (NP (NP (NP (DT a) (JJ light) (NN Doc_6305660_832_859_Disease)) (PP (IN in) (NP (CD 12) (NNS women)))) (CC and) (NP (NP (DT a) (JJ moderate) (NN increase)) (PP (IN in) (NP (NP (NN breast) (NN nodularity)) (PP (IN in) (NP (CD 2) (NNS women))))))))) (. .)))
6305660	8	(S1 (S (NP (NN Themography)) (VP (VBD confirmed) (NP (NP (DT the) (NN existence)) (PP (IN of) (NP (DT an) (JJ excessive) (NN breast) (NN stimulation)))) (PP (PP (IN in) (NP (NP (CD 1) (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD complained) (PP (IN of) (NP (JJ moderate) (NNP Doc_6305660_1038_1048_Disease)))))))) (CC and) (PP (IN in) (NP (NP (CD 5)) (PP (IN of) (NP (NP (DT the) (CD 7) (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD complained) (PP (IN of) (NP (JJ severe) (NN Doc_6305660_1098_1108_Disease)))))))))))) (. .)))
6305660	9	(S1 (S (NP (NN Normalization)) (VP (AUX was) (VP (VBN obtained) (PP (IN by) (S (VP (VBG halving) (NP (DT the) (JJ Doc_6305660_1152_1160_Chemical) (NN dose))))))) (. .)))
6305660	10	(S1 (FRAG (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ hormonal) (NN replacement) (NN therapy)) (VP (MD can) (VP (AUX be) (ADVP (RB safely)) (VP (VBN prescribed) (SBAR (IN if) (S (NP (DT the) (JJ following) (NNS criteria)) (VP (AUX are) (ADJP (JJ satisfied)))))))))))) (: :) (NP (NP (LST (LS 1) (-RRB- -RRB-)) (NP (JJ preliminary) (NN evaluation)) (PP (IN of) (NP (NNS patients))) (PP (IN from) (NP (DT a) (ADJP (JJ clinical) (, ,) (JJ metabolic) (, ,) (JJ cytologic) (, ,) (CC and) (JJ mammographic)) (NN perspective)))) (: ;) (NP (LST (LS 2) (-RRB- -RRB-)) (NP (JJ cyclic) (NN treatment) (NN schedule)) (, ,) (PP (IN with) (NP (NP (DT a) (JJ progestative) (NN phase)) (PP (IN of) (NP (CD 10) (NNS days)))))) (: ;) (CC and) (NP (CD 3))) (-RRB- -RRB-) (NP (JJ periodic) (JJ complete) (NN follow-up)) (, ,) (PP (IN with) (NP (NP (JJ accurate) (JJ thermographic) (NN evaluation)) (PP (IN of) (NP (DT the) (NN breast) (NN target) (NNS tissues))))) (. .)))
6310832	0	(S1 (NP (NP (JJ Early) (NN Doc_6310832_6_16_Disease)) (PP (IN in) (NP (NP (NN kidney)) (, ,) (NP (NN heart)) (, ,) (CC and) (NP (NN liver) (NN transplant) (NNS recipients)))) (PP (IN on) (NP (NNP Doc_6310832_70_82_Chemical))) (. .)))
6310832	1	(S1 (S (NP (NP (NP (JJ Eighty-one) (JJ renal)) (, ,) (NP (CD seventeen) (NN heart)) (, ,)) (CC and) (NP (JJ twenty-four) (NN liver) (NN transplant) (NNS patients))) (VP (AUX were) (VP (VBN followed) (PP (IN for) (NP (NNP Doc_6310832_179_188_Disease))))) (. .)))
6310832	2	(S1 (S (NP (CD Seventeen) (JJ renal) (NNS patients)) (VP (VBD received) (NP (NP (NP (NNP Doc_6310832_224_236_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6310832_238_241_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NNP Doc_6310832_247_257_Chemical))) (PP (IN as) (NP (NP (NN part)) (PP (IN of) (NP (NP (DT a) (JJ randomized) (NN trial)) (PP (IN of) (NP (NN immunosuppression))) (PP (IN with) (NP (CD 21) (JJ Doc_6310832_317_344_Chemical-treated) (JJ renal) (NN transplant) (NNS patients)))))))) (. .)))
6310832	3	(S1 (S (NP (DT All) (NNS others)) (VP (VBD received) (NP (NP (NNP Doc_6310832_400_412_Chemical)) (CC and) (NP (NNP Doc_6310832_417_427_Chemical)))) (. .)))
6310832	4	(S1 (S (NP (DT The) (JJ randomized) (NNP Doc_6310832_444_447_Chemical) (NNS patients)) (VP (AUX had) (ADJP (ADJP (ADJP (RBR more) (JJ Doc_6310832_466_484_Disease)) (PRN (-LRB- -LRB-) (NP (QP (RB P) (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)) (CC and) (ADJP (RBR more) (JJ Doc_6310832_513_532_Disease)) (PRN (-LRB- -LRB-) (PP (VBG P) (NP (QP (JJR less) (IN than) (CD 0.02)))) (-RRB- -RRB-))) (PP (IN than) (NP (DT the) (JJ randomized) (JJ Doc_6310832_572_584_Chemical) (NNS patients))))) (. .)))
6310832	5	(S1 (S (NP (NN Heart) (CC and) (NN liver) (NNS patients)) (VP (AUX had) (ADJP (ADJP (ADJP (RBR more) (JJ Doc_6310832_629_639_Disease)) (PP (IN than) (NP (JJ Doc_6310832_645_657_Chemical) (JJ renal) (NNS patients)))) (CC but) (ADJP (ADJP (RBR fewer) (JJ Doc_6310832_683_693_Disease)) (PP (IN than) (NP (DT the) (JJ Doc_6310832_703_706_Chemical) (JJ renal) (NNS patients)))))) (. .)))
6310832	6	(S1 (S (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (JJ infectious) (NNS deaths)) (PP (IN in) (NP (NP (JJ renal) (NN transplant) (NNS patients)) (PP (IN on) (NP (NNP Doc_6310832_787_799_Chemical) (CC or) (NNP Doc_6310832_803_806_Chemical)))))))) (, ,) (CC but) (S (NP (NNP Doc_6310832_812_821_Disease)) (VP (VBD played) (NP (DT a) (JJ major) (NN role)) (PP (PP (IN in) (NP (NP (CD 3) (NN out)) (PP (IN of) (NP (CD 6) (JJ cardiac) (NN transplant) (NNS deaths))))) (CC and) (PP (IN in) (NP (NP (CD 8) (NN out)) (PP (IN of) (NP (ADJP (CD 9) (NN liver)) (NN transplant) (NNS deaths)))))))) (. .)))
6310832	7	(S1 (NP (NP (JJ Renal) (NNS patients)) (PP (IN on) (NP (NNP Doc_6310832_943_955_Chemical) (AUX had) (DT the) (NNP Doc_6310832_964_982_Disease))) (. .)))
6310832	8	(S1 (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NP (NN site)) (PP (IN of) (NP (NNP Doc_6310832_1004_1013_Disease)))))) (VP (VBD showed) (NP (NP (DT a) (NN preponderance)) (PP (IN of) (NP (NP (NP (NNP Doc_6310832_1040_1060_Disease)) (PP (IN in) (NP (NN liver) (NNS patients)))) (, ,) (NP (NP (NNP Doc_6310832_1080_1104_Disease)) (PP (IN in) (NP (NN heart) (NNS patients)))) (, ,) (CC and) (NP (NP (NNP Doc_6310832_1128_1152_Disease)) (PP (IN in) (NP (JJ renal) (NNS patients)))))))) (. .)))
6310832	9	(S1 (S (NP (NN Doc_6310832_1172_1192_Disease)) (VP (AUX were) (ADJP (RBR less) (JJ common)) (PP (IN in) (NP (JJ Doc_6310832_1213_1225_Chemical-treated) (JJ renal) (NNS patients))) (PP (IN than) (PP (IN in) (NP (NP (JJ Doc_6310832_1257_1260_Chemical-treated) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)))))) (. .)))
6310832	10	(S1 (S (S (NP (JJ Doc_6310832_1298_1301_Chemical) (NNS patients)) (VP (AUX had) (NP (NP (ADJP (RB significantly) (JJR more)) (NN Doc_6310832_1334_1359_Disease)) (PP (IN than) (NP (NP (DT all) (JJ other) (NN transplant) (NNS groups)) (PRN (-LRB- -LRB-) (NP (NNP P) (QP (JJR less) (IN than) (CD 0.005))) (-RRB- -RRB-))))))) (, ,) (CC and) (S (NP (JJ systemic) (NN Doc_6310832_1427_1444_Disease)) (VP (VBD occurred) (ADVP (RB only)) (PP (IN in) (NP (DT the) (NN liver) (NN transplant) (NN group))))) (. .)))
6310832	11	(S1 (S (NP (NP (JJ Cytomegalovirus) (PRN (-LRB- -LRB-) (NP (NNP CMV)) (-RRB- -RRB-)) (NN shedding)) (CC or) (NP (NP (JJ serological) (NNS rises)) (PP (IN in) (NP (NP (NN antibody) (NN titer)) (, ,) (CC or) (NP (DT both)))))) (VP (VBD occurred) (PP (IN in) (NP (NP (NP (CD 78) (NN %)) (PP (IN of) (NP (JJ Doc_6310832_1588_1600_Chemical) (NNS patients)))) (CC and) (NP (NP (CD 76) (NN %)) (PP (IN of) (NP (JJ Doc_6310832_1621_1624_Chemical) (NNS patients))))))) (. .)))
6310832	12	(S1 (S (PP (IN Of) (NP (DT the) (JJ Doc_6310832_1642_1654_Chemical) (NNS patients))) (, ,) (NP (CD 15) (NN %)) (VP (AUX had) (NP (NP (NNS symptoms)) (VP (VBN related) (PP (TO to) (NP (NN Doc_6310832_1693_1706_Disease)))))) (. .)))
6310832	13	(S1 (S (NP (NP (JJ Serological) (NN evidence)) (PP (IN for) (NP (NNP Doc_6310832_1733_1761_Disease)))) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NP (CD 20) (NN %)) (PP (IN of) (NP (NP (CD 65) (JJ Doc_6310832_1785_1797_Chemical) (NNS patients)) (VP (VBN studied)))))))) (. .)))
6310832	14	(S1 (S (S (NP (CD Three)) (VP (AUX had) (VP (VBN associated) (NP (NNS symptoms))))) (, ,) (CC and) (S (NP (CD one)) (VP (VBD developed) (NP (DT a) (NN Doc_6310832_1867_1875_Disease)))) (. .)))
6316193	0	(S1 (NP (NP (NP (NN Structure-activity)) (CC and) (NP (JJ dose-effect) (NNS relationships))) (PP (IN of) (NP (NP (DT the) (NN antagonism)) (PP (IN of) (NP (JJ Doc_6316193_70_80_Chemical-induced) (NN Doc_6316193_89_97_Disease))))) (PP (IN by) (NP (NP (NNP Doc_6316193_101_116_Chemical) (, ,) (NNS fragments) (CC and) (NNS analogues)) (PP (IN of) (NP (NP (NNP Doc_6316193_145_160_Chemical)) (PP (IN in) (NP (NNS mice))))))) (. .)))
6316193	1	(S1 (S (NP (NP (NP (JJ Intraperitoneal) (NN administration)) (PP (IN of) (NP (NP (NNP Doc_6316193_204_246_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP CCK-8-SE)) (-RRB- -RRB-))))) (CC and) (NP (NP (JJ nonsulphated) (JJ Doc_6316193_275_290_Chemical) (NN octapeptide)) (PRN (-LRB- -LRB-) (NP (NNP CCK-8-NS)) (-RRB- -RRB-)))) (VP (VBD enhanced) (NP (NP (DT the) (NN latency)) (PP (IN of) (NP (NNP Doc_6316193_338_346_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_6316193_358_368_Chemical))) (PP (IN in) (NP (NNS mice)))))) (. .)))
6316193	2	(S1 (S (NP (NP (NNS Experiments)) (PP (IN with) (NP (NP (NNP Doc_6316193_395_396_Chemical-)) (CC and) (NP (JJ Doc_6316193_402_403_Chemical-terminal) (NNS fragments))))) (VP (VBD revealed) (SBAR (IN that) (S (NP (DT the) (JJ Doc_6316193_441_442_Chemical-terminal) (NN tetrapeptide) (PRN (-LRB- -LRB-) (JJ CCK-5-8) (-RRB- -RRB-))) (VP (AUX was) (NP (NP (DT the) (JJ active) (NNP centre)) (PP (IN of) (NP (DT the) (NNP CCK) (NNP Doc_6316193_508_519_Chemical) (NN molecule)))))))) (. .)))
6316193	3	(S1 (S (NP (NP (NP (DT The) (NNS analogues)) (ADJP (JJ CCK-8-SE) (CC and) (JJ CCK-8-NS)) (PRN (-LRB- -LRB-) (NP (NP (NN dose) (NN range)) (NP (CD 0.2-6.4) (NN mumol/kg))) (-RRB- -RRB-))) (CC and) (NP (JJ Doc_6316193_600_609_Chemical) (NN dose))) (VP (VBP range) (SBAR (S (NP (CD 0.1-0.8) (NN mumol/kg)) (-RRB- -RRB-) (VP (VBD showed) (NP (JJ bell-shaped) (JJ dose-effect) (NNS curves)) (, ,) (PP (IN with) (NP (NP (DT the) (JJS greatest) (NN maximum) (NN inhibition)) (PP (IN for) (NP (NNS CCK-8-NS))))))))) (. .)))
6316193	4	(S1 (S (NP (DT The) (NN peptide) (NN CCK-5-8)) (VP (AUX had) (NP (JJ weak) (JJ anticonvulsant) (NN activity)) (PP (IN in) (NP (NP (NN comparison)) (PP (TO to) (NP (NP (DT the) (NNS octapeptides)) (, ,) (NP (CD 3.2) (NNS mumol/kg)) (CC and) (NP (NP (JJR larger) (NNS doses)) (PP (IN of) (NP (NP (DT the) (NN reference) (NN drug)) (, ,) (NP (NP (NNP Doc_6316193_870_878_Chemical)) (, ,) (NP (NP (ADJP (RB totally) (VBN prevented)) (JJ Doc_6316193_898_908_Chemical-induced) (NN Doc_6316193_917_925_Disease)) (CC and) (NP (NN mortality)))))))))))) (. .)))
6316193	5	(S1 (S (NP (NP (DT The) (JJ maximum) (NN effect)) (PP (IN of) (NP (NP (DT the) (NNS peptides)) (VP (VBN tested))))) (VP (AUX was) (ADJP (ADJP (JJR less)) (PP (IN than) (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_6316193_1005_1013_Chemical))))))) (. .)))
6316193	6	(S1 (S (NP (NP (NP (NNS Experiments)) (PP (IN with) (NP (NNS analogues)))) (CC and) (NP (NP (NNS derivatives)) (PP (IN of) (NP (NN CCK-5-8))))) (VP (VBD demonstrated) (SBAR (SBAR (IN that) (S (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NP (DT the) (JJ Doc_6316193_1112_1123_Chemical) (NNS derivatives)) (PP (IN of) (NP (NN CCK-5-8)))))) (VP (AUX were) (VP (VBN enhanced))))) (CC and) (SBAR (IN that) (S (NP (PRP they)) (VP (AUX were) (ADJP (JJ equipotent) (PP (IN with) (NP (NN CCK-8-SE))))))))) (. .)))
6316193	7	(S1 (S (PP (IN Of) (NP (DT the) (JJ CCK-2-8) (NNS analogues))) (, ,) (NP (NP (NP (NNP Ser)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6316193_1236_1240_Chemical)) (-RRB- -RRB-)) (NP (NP (NN 7-Ac-CCK-2-8-SE)) (CC and) (NP (NNP Thr) (PRN (-LRB- -LRB-) (NP (NNP Doc_6316193_1265_1269_Chemical)) (-RRB- -RRB-)) (NN 7-Ac-CCK-2-8-SE)))) (CC and) (NP (NNP Hyp) (PRN (-LRB- -LRB-) (NNP Doc_6316193_1294_1298_Chemical) (-RRB- -RRB-)) (NN -Ac-CCK-2-8-SE))) (VP (AUX were) (ADJP (ADJP (RB slightly) (RBR more) (JJ active)) (PP (IN than) (NP (NN CCK-8-SE))))) (. .)))
6321816	0	(S1 (NP (NP (NN Doc_6321816_0_11_Chemical)) (PP (IN as) (NP (NP (DT a) (JJ possible) (NN contributor)) (PP (TO to) (NP (NNP Doc_6321816_41_53_Disease))))) (. .)))
6321816	1	(S1 (S (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NNP Doc_6321816_67_78_Chemical))) (PP (IN as) (NP (DT a) (JJ pressor) (NN agent))) (PP (TO to) (NP (DT the) (NNP Doc_6321816_105_117_Disease) (NN process)))) (VP (AUX was) (VP (VBN examined))) (. .)))
6321816	2	(S1 (S (NP (NN Doc_6321816_140_151_Chemical)) (VP (VBZ plays) (NP (DT a) (JJ major) (NN role)) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NNP Doc_6321816_194_198_Chemical-salt) (NNP Doc_6321816_204_216_Disease))))) (, ,) (SBAR (IN since) (S (NP (NP (DT the) (NN elevation)) (PP (IN of) (NP (NN blood) (NN pressure)))) (VP (AUX was) (RB not) (ADJP (JJ substantial)) (PP (IN in) (NP (NP (DT the) (NNS rats)) (PP (IN with) (NP (JJ Doc_6321816_293_300_Chemical-treated) (NNP Doc_6321816_309_327_Disease))))) (PP (IN after) (NP (JJ Doc_6321816_334_338_Chemical-salt) (NN treatment))))))) (. .)))
6321816	3	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NNP Doc_6321816_373_378_Chemical))) (SBAR (WHNP (WDT which)) (S (VP (AUX has) (NP (NP (JJ antidiuretic) (NN action)) (CC but) (NP (JJ minimal) (NN vasopressor) (NN effect))))))) (VP (VBD failed) (S (VP (TO to) (VP (VB increase) (NP (NN blood) (NN pressure)) (PP (TO to) (NP (NP (DT the) (NNS levels)) (VP (VBN observed) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_6321816_521_524_Chemical)))))))))))) (. .)))
6321816	4	(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (DT the) (NN pressor) (NN action)) (PP (IN of) (NP (NNP Doc_6321816_561_572_Chemical)))) (VP (VBZ appears) (S (VP (TO to) (VP (AUX be) (ADJP (JJ important)) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (DT this) (NN model)) (PP (IN of) (NP (NNP Doc_6321816_633_645_Disease)))))))))) (, ,) (SBAR (IN since) (S (NP (NP (DT the) (JJ enhanced) (NN pressor) (NN responsiveness)) (PP (TO to) (NP (DT the) (NN hormone)))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (JJ initial) (NN stage)) (PP (IN of) (NP (NNP Doc_6321816_741_753_Disease)))))))))) (. .)))
6321816	5	(S1 (S (NP (NP (JJ Increased) (NN secretion)) (PP (IN of) (NP (NNP Doc_6321816_778_789_Chemical))) (PP (IN from) (NP (NN neurohypophysis)))) (ADVP (RB also)) (VP (VBZ promotes) (NP (NP (DT the) (NN function)) (PP (IN of) (NP (DT the) (NN hormone)))) (PP (IN as) (NP (NP (DT a) (JJ pathogenetic) (NN factor)) (PP (IN in) (NP (NNP Doc_6321816_881_893_Disease)))))) (. .)))
6321816	6	(S1 (S (NP (NP (DT An) (JJ unproportional) (NN release)) (PP (IN of) (NP (NNP Doc_6321816_924_935_Chemical))) (PP (VBN compared) (PP (TO to) (NP (NN plasma) (NN osmolality))))) (VP (MD may) (VP (AUX be) (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (DT an) (VBG adjusting) (NN control)) (PP (IN of) (S (VP (VBG angiotensin) (NP (NP (NNP II) (VBG forming) (CC and) (NN receptor) (VBG binding) (NN capacity)) (PP (IN for) (NP (NP (JJ Doc_6321816_1080_1086_Chemical) (NN balance)) (PP (IN in) (NP (DT the) (NN brain)))))))))))))))) (. .)))
6321816	7	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNP Doc_6321816_1130_1141_Chemical)))) (VP (VBZ remains) (S (VP (TO to) (VP (AUX be) (VP (VBN determined) (PP (IN in) (NP (JJ human) (JJ essential) (NN Doc_6321816_1186_1198_Disease)))))))) (. .)))
6453500	0	(S1 (S (NP (NN Doc_6453500_0_15_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_6453500_27_37_Chemical))) (PP (IN in) (NP (DT a) (JJ non-alcoholic)))) (. .)))
6453500	1	(S1 (S (NP (DT A) (JJ reversible) (NN Doc_6453500_71_89_Disease)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (DT a) (JJ non-alcoholic) (NN woman)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_6453500_141_151_Chemical)))))))) (. .)))
6453500	2	(S1 (S (NP (DT The) (JJ causative) (NN relationship)) (VP (AUX was) (VP (VBN proven) (PP (IN by) (NP (NN challenge))))) (. .)))
6517710	0	(S1 (S (NP (NP (NN Doc_6517710_0_17_Disease)) (VP (VBG involving) (NP (NP (DT the) (NN heart)) (PP (IN of) (NP (JJ F-344) (NNS rats)))))) (VP (VBD ingesting) (NP (NNP Doc_6517710_62_86_Chemical))) (. .)))
6517710	1	(S1 (S (NP (NN Doc_6517710_88_112_Chemical)) (VP (AUX is) (ADJP (JJ toxic) (PP (IN for) (NP (NP (DT the) (NN heart)) (PP (IN of) (NP (JJ F-344) (NNS rats))))))) (. .)))
6517710	2	(S1 (S (NP (NP (NNS Rats)) (VP (VBN treated) (PP (IN with) (NP (CD 500) (NN ppm) (NNP Doc_6517710_177_201_Chemical))) (PP (IN in) (NP (DT the) (NN diet))))) (DT all) (VP (VBD developed) (NP (NP (DT a) (JJ high) (NN incidence)) (PP (IN of) (NP (JJ left) (NNP Doc_6517710_253_270_Disease))))) (. .)))
6517710	3	(S1 (S (NP (DT The) (NN lesion)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NNP Doc_6517710_303_322_Disease)) (CC and) (NP (NNP Doc_6517710_327_337_Disease))) (CC and) (NP (JJ focal) (NNP Doc_6517710_348_371_Disease)))))) (. .)))
6517710	4	(S1 (S (NP (NNS Rats)) (VP (VBD died) (PP (IN from) (NP (NNP Doc_6517710_388_407_Disease))) (PP (IN with) (NP (NP (JJ severe) (JJ acute) (CC and) (JJ chronic) (NN congestion)) (PP (IN of) (NP (NP (DT the) (NNS lungs)) (, ,) (NP (NN liver)) (, ,) (CC and) (NP (JJ other) (NNS organs))))))) (. .)))
6517710	5	(S1 (S (NP (NP (CD Seventy) (NN percent)) (PP (IN of) (NP (NNS rats))) (VP (VBN given) (NP (QP (CD 250) (CD ppm) (NN Doc_6517710_526_550_Chemical) (CC and) (CD 1,000) (CD ppm)) (NNP Doc_6517710_565_579_Chemical)) (ADVP (RB simultaneously)) (PP (IN in) (NP (DT the) (NN diet))))) (VP (AUX had) (NP (NP (NN Doc_6517710_611_621_Disease)) (PP (IN of) (NP (NP (DT the) (NN atria)) (PP (IN of) (NP (DT the) (NN heart)))))) (, ,) (SBAR (IN while) (S (NP (NP (JJ untreated) (NN control) (NNS rats)) (PP (IN in) (NP (DT this) (NN laboratory)))) (VP (AUX did) (RB not) (VP (AUX have) (NP (NN Doc_6517710_710_727_Disease))))))) (. .)))
6517710	6	(S1 (S (NP (NP (NN Doc_6517710_729_743_Chemical)) (PP (IN in) (NP (NN combination))) (PP (IN with) (NP (NNP Doc_6517710_764_788_Chemical)))) (VP (VBD appeared) (S (VP (TO to) (VP (AUX have) (NP (DT no) (JJ additional) (NN effect)))))) (. .)))
6529939	0	(S1 (S (S (VP (VBG Alternating) (NP (NP (JJ sinus) (NN rhythm)) (CC and) (NP (JJ intermittent) (NN Doc_6529939_42_58_Disease))))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_6529939_70_81_Chemical)))) (. .)))
6529939	1	(S1 (S (S (VP (VBG Alternating) (NP (NP (JJ sinus) (NN rhythm)) (CC and) (NP (JJ intermittent) (NN sinoatrial) (PRN (-LRB- -LRB-) (NP (NNP S-A)) (-RRB- -RRB-)) (NN block))))) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (DT a) (JJ 57-year-old) (NN woman))) (, ,) (PP (IN under) (NP (NP (NN treatment)) (PP (IN for) (NP (NP (NNP Doc_6529939_205_211_Disease)) (PP (IN with) (NP (CD 80) (JJ mg) (NNP Doc_6529939_223_234_Chemical) (NN daily))))))))) (. .)))
6529939	2	(S1 (S (NP (DT The) (NN electrocardiogram)) (VP (VBD showed) (NP (NP (NN alternation)) (PP (IN of) (NP (ADJP (ADJP (JJ long)) (CC and) (ADJP (JJ short))) (NX (NX (JJ P-P) (NNS intervals)) (CC and) (NX (JJ occasional) (VBZ pauses))))))) (. .)))
6529939	3	(S1 (S (NP (DT These) (VBZ pauses)) (VP (VP (AUX were) (ADVP (RB always)) (VP (VBN preceded) (PP (IN by) (NP (DT the) (JJ short) (JJ P-P) (NNS intervals))))) (CC and) (VP (AUX were) (ADVP (RB usually)) (VP (VBN followed) (PP (IN by) (NP (NP (QP (CD one) (CC or) (CD two)) (JJ P-P) (NNS intervals)) (PP (IN of) (NP (NP (CD 0.92-0.95) (NNP s)) (VP (VBG representing) (NP (DT the) (JJ basic) (NN sinus) (NN cycle)))))))))) (. .)))
6529939	4	(S1 (S (PP (VBG Following) (NP (DT these) (JJ basic) (JJ sinus) (NNS cycles))) (, ,) (NP (VBG alternating) (NN rhythm)) (VP (VBD started) (PP (IN with) (NP (DT the) (ADJP (RBR longer) (JJ P-P)) (NN interval)))) (. .)))
6529939	5	(S1 (S (NP (DT The) (JJ long) (JJ P-P) (NNS intervals)) (VP (VBD ranged) (PP (IN between) (NP (NP (CD 1.04-1.12) (NNP s) (CC and) (DT the) (JJ short) (JJ P-P) (NNS intervals)) (PP (IN between) (NP (JJ 0.80-0.84) (NNP s))))) (, ,) (ADVP (RB respectively))) (. .)))
6529939	6	(S1 (S (NP (NP (DT The) (NN duration)) (PP (IN of) (NP (DT the) (VBZ pauses)))) (VP (AUX were) (ADJP (ADJP (JJ equal)) (CC or) (ADJP (RB almost) (JJ equal) (PP (PP (TO to) (NP (CD one) (JJ short) (CC plus) (CD one) (JJ long) (JJ P-P) (NN interval))) (CC or) (PP (TO to) (NP (RB twice) (DT the) (JJ basic) (JJ sinus) (NN cycle))))))) (. .)))
6529939	7	(S1 (S (PP (IN In) (NP (CD one) (NN recording))) (NP (NP (DT a) (JJ short) (NN period)) (PP (IN of) (NP (JJ regular) (JJ sinus) (NN rhythm))) (PP (IN with) (NP (JJ intermittent) (JJ 2/1) (JJ S-A) (NN block)))) (VP (AUX was) (VP (VBN observed))) (. .)))
6529939	8	(S1 (S (NP (NP (DT This) (JJ short) (NN period)) (PP (IN of) (NP (JJ sinus) (NN rhythm)))) (VP (AUX was) (VP (VBN interrupted) (PP (IN by) (NP (NP (JJ sudden) (NN prolongation)) (PP (IN of) (NP (NP (DT the) (JJ P-P) (NN interval)) (VP (VBG starting) (NP (DT the) (NN alternative) (NN rhythm))))))))) (. .)))
6529939	9	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (JJ small) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN shape)) (PP (IN of) (NP (DT the) (NP (JJ P) (NNS waves)) (CC and) (NP (JJ P-R) (NNS intervals)))))))) (. .)))
6529939	10	(S1 (S (NP (NP (JJ S-A) (NN conduction)) (PP (IN through) (NP (NP (CD two) (NNS pathways)) (, ,) (NP (NP (DT the) (JJ first)) (PP (PP (IN with) (NP (NP (CD 2/1) (NN block)) (SBAR (S (NP (DT the) (NN second) (AUXG having) (CD 0.12-0.14)) (VP (VBZ s) (NP (ADJP (JJR longer) (NN conduction)) (NN time))))))) (CC and) (PP (IN with) (NP (JJ occasional) (NN 2/1) (NN block)))))))) (VP (AUX was) (VP (VBN proposed) (PP (IN for) (NP (NP (DT the) (NN explanation)) (PP (IN of) (NP (DT the) (VBG alternating) (JJ P-P) (NN interval) (CC and) (JJ other) (JJ electrocardiographic) (NNS features))) (VP (VBN seen)))))) (. .)))
6529939	11	(S1 (S (NP (NP (NNP Doc_6529939_1395_1403_Chemical) (CD 1)) (ADJP (RB mg) (VBN given))) (ADVP (RB intravenously)) (VP (VBD resulted) (PP (IN in) (NP (NP (NN shortening)) (PP (IN of) (NP (DT all) (JJ P-P) (NNS intervals))))) (PP (IN without) (S (VP (VBG changing) (NP (DT the) (NN rhythm)))))) (. .)))
6529939	12	(S1 (S (NP (DT The) (JJ abnormal) (NN rhythm)) (VP (VBD disappeared) (PP (IN with) (NP (NP (DT the) (NN withdrawal)) (PP (IN of) (NP (NNP Doc_6529939_1557_1568_Chemical))))) (S (CC and) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN drug)) (VP (AUX was) (VP (VBN restarted))))) (NP (DT a) (JJ 2/1) (JJ S-A) (NN block)) (VP (AUX was) (VP (VBN seen))))) (. .)))
6529939	13	(S1 (S (NP (DT This)) (VP (AUX was) (VP (VBN accepted) (PP (IN as) (NP (NN evidence))) (PP (IN for) (S (NP (NNP Doc_6529939_1661_1672_Chemical)) (VP (AUXG being) (NP (NP (DT the) (NN cause)) (PP (IN of) (NP (DT this) (NN Doc_6529939_1697_1716_Disease))))))))) (. .)))
6585590	0	(S1 (NP (NP (NN Antitumor) (NN effect)) (, ,) (NP (NN Doc_6585590_18_32_Disease)) (, ,) (CC and) (NP (NP (NN nephrotoxicity)) (PP (IN of) (NP (NNP Doc_6585590_56_67_Chemical))) (PP (IN in) (NP (DT the) (NNP IgM) (JJ solid) (JJ immunocytoma-bearing) (JJ LOU/M/WSL) (NN rat)))) (. .)))
6585590	1	(S1 (S (NP (NP (NP (NN Antitumor) (NN activity)) (, ,) (NP (NNP Doc_6585590_141_155_Disease)) (, ,)) (CC and) (NP (NP (NN nephrotoxicity)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_6585590_187_198_Chemical)))))) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NP (JJ LOU/M/WSL) (JJ inbred) (NNS rats)) (VP (DT each) (VBG bearing) (NP (DT a) (JJ transplantable) (JJ solid) (JJ IgM) (NN immunocytoma))))))) (. .)))
6585590	2	(S1 (S (NP (NP (NNS Animals)) (PP (IN with) (NP (NP (DT a) (NNP Doc_6585590_306_311_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN diameter)) (, ,) (NP (NP (CD 15.8) (NN +/-)) (NP (CD 3.3) (NNS mm)))) (-RRB- -RRB-))))) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (NNP iv) (NNS injections)) (PP (IN of) (NP (NNP Doc_6585590_375_386_Chemical))))) (PP (IN on) (NP (NP (CD 5) (JJ consecutive) (NNS days)) (, ,) (VP (VBN followed) (PP (IN by) (NP (NP (CD 1) (JJ weekly) (NN injection)) (PP (IN for) (NP (NP (CD 7) (NNS weeks)) (PRN (-LRB- -LRB-) (NP (NN dose) (NN range)) (, ,) (NP (CD 0.015-4.0) (NN mg/kg) (NN body) (NNS wt)) (-RRB- -RRB-))))))))))) (. .)))
6585590	3	(S1 (S (NP (JJ Doc_6585590_492_497_Disease) (NN regression)) (VP (AUX was) (VP (VBN observed) (PP (IN with) (NP (CD 0.5) (JJ mg) (NNS Doc_6585590_534_545_Chemical/kg))))) (. .)))
6585590	4	(S1 (S (NP (NP (JJ Complete) (NN disappearance)) (PP (IN of) (NP (DT the) (NNP Doc_6585590_580_585_Disease)))) (VP (AUX was) (VP (VBN induced) (PP (IN with) (NP (QP (CD 1.0) (CD mg)) (NN Doc_6585590_610_621_Chemical/kg))))) (. .)))
6585590	5	(S1 (S (NP (NP (JJ Histologic) (NN evidence)) (PP (IN of) (NP (NNP Doc_6585590_649_663_Disease)))) (VP (VBD scored) (SBAR (IN as) (S (NP (NNP grade) (NNP III)) (VP (AUX was) (ADVP (RB only)) (VP (VBN observed) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 1.0) (NN mg) (NNP Doc_6585590_722_733_Chemical/kg)))))))))) (. .)))
6585590	6	(S1 (S (NP (NP (JJ Light) (JJ microscopic) (NN evidence)) (PP (IN of) (NP (NNP Doc_6585590_768_780_Disease)))) (VP (AUX was) (VP (VBN seen) (PP (IN above) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 0.5) (NN mg) (NNP Doc_6585590_813_824_Chemical/kg))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD resulted) (PP (IN in) (NP (NP (NNP Doc_6585590_847_858_Disease)) (CC and) (NP (ADJP (RB very) (JJ low)) (JJ serum) (JJ albumin) (NNS levels))))))))))) (. .)))
6585590	7	(S1 (S (PP (IN In) (NP (NP (DT the) (NN group)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (QP (CD 1.0) (CD mg)) (NNS Doc_6585590_928_939_Chemical/kg))))))) (, ,) (NP (DT the) (NN serum) (NN albumin) (NN level)) (VP (VBD decreased) (PP (IN from) (NP (QP (CD 33.6) (JJ +/-) (CD 4.1) (TO to) (CD 1.5)) (NNS +/-))) (NP (CD 0.5) (NN g/liter))) (. .)))
6585590	8	(S1 (S (NP (NP (NNS Ascites)) (CC and) (NP (NNS hydrothorax))) (VP (AUX were) (VP (VBN observed) (ADVP (RB simultaneously)))) (. .)))
6585590	9	(S1 (S (NP (DT The) (JJ same) (NNS experiments)) (VP (AUX were) (VP (VBN performed) (PP (IN with) (NP (NP (JJ non-Doc_6585590_1119_1124_Disease-bearing) (NNS rats)) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT no) (JJ major) (NNS differences)) (VP (AUX were) (VP (VBN observed))))))))) (. .)))
6585590	10	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NN antitumor) (NN activity)) (, ,) (NP (NN Doc_6585590_1219_1233_Disease)) (, ,) (CC and) (NP (NN nephrotoxicity))) (VP (AUX were) (VP (VBN studied) (ADVP (RB simultaneously)) (PP (IN in) (NP (DT the) (JJ same) (NNP LOU/M/WSL) (NN rat))))) (. .)))
6585590	11	(S1 (S (S (NP (NP (NN Doc_6585590_1309_1320_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_6585590_1328_1340_Disease))))) (VP (VBD led) (PP (TO to) (NP (ADJP (RB extremely) (JJ low)) (JJ serum) (NN albumin) (NNS levels))))) (, ,) (CC so) (S (NP (NP (NNS ascites)) (CC and) (NP (NN hydrothorax))) (VP (AUX were) (RB not) (ADVP (RB necessarily)) (NP (NP (DT a) (NN consequence)) (PP (IN of) (NP (DT the) (VBN observed) (NNP Doc_6585590_1462_1476_Disease)))))) (. .)))
6615679	0	(S1 (S (NP (NP (NNP Intraoperative) (NNP Doc_6615679_15_26_Disease) (CC and) (NNP Doc_6615679_31_42_Disease)) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_6615679_59_66_Chemical) (CC and) (NNP Doc_6615679_71_82_Chemical) (NN eye))))) (VP (VBZ drops)) (. .)))
6615679	1	(S1 (S (NP (NP (DT A) (JJ 69-yr-old) (NN man)) (, ,) (SBAR (WHNP (WP who)) (S (VP (AUX was) (ADVP (RB concurrently)) (VP (AUXG being) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_6615679_151_170_Chemical) (CC and) (NNP Doc_6615679_175_190_Chemical) (NN eye) (NNS drops)))))))) (, ,)) (VP (VP (VBD developed) (NP (DT a) (NN Doc_6615679_214_225_Disease))) (CC and) (VP (VBD became) (NP (NNP Doc_6615679_237_248_Disease)) (PP (IN during) (NP (JJ Doc_6615679_256_265_Chemical) (NNS anaesthesia))))) (. .)))
6615679	2	(S1 (S (NP (PDT Both) (NP (NNP Doc_6615679_284_291_Chemical)) (CC and) (NP (NNP Doc_6615679_296_307_Chemical))) (VP (AUX were) (ADVP (RB subsequently)) (VP (VBN identified) (PP (IN in) (NP (NP (DT a) (JJ 24-h) (NN collection)) (PP (IN of) (NP (NN urine))))))) (. .)))
6615679	3	(S1 (S (S (NP (NP (NN Doc_6615679_368_375_Chemical)) (PRN (-LRB- -LRB-) (CC but) (ADJP (RB not) (JJ Doc_6615679_385_396_Chemical)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN detected) (PP (IN in) (NP (NP (DT a) (NN sample)) (PP (IN of) (NP (NP (NN plasma)) (VP (VBN removed) (PP (IN during) (NP (NN surgery))))))))))) (: ;) (S (NP (NP (DT the) (NN plasma) (NN concentration)) (PP (IN of) (NP (NP (NNP Doc_6615679_485_492_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 2.6) (CD ng)) (NN ml-1)) (-RRB- -RRB-))))) (VP (AUX was) (ADJP (JJ consistent) (PP (IN with) (NP (JJ partial) (NN beta-adrenoceptor) (NN blockade)))))) (. .)))
6615679	4	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN postulated) (SBAR (IN that) (S (NP (DT this) (NN action)) (VP (MD may) (VP (AUX have) (VP (AUX been) (VP (VBN enhanced) (PP (IN during) (NP (NP (JJ Doc_6615679_627_636_Chemical) (NNS anaesthesia)) (PP (IN with) (NP (JJ resultant) (NNP Doc_6615679_664_675_Disease) (CC and) (NNP Doc_6615679_680_691_Disease))))))))))))) (. .)))
6615679	5	(S1 (S (NP (NN Doc_6615679_693_704_Chemical)) (VP (MD may) (VP (AUX have) (VP (AUX had) (NP (DT a) (JJ contributory) (NN effect))))) (. .)))
6627074	0	(S1 (NP (NP (JJ Doc_6627074_0_15_Chemical) (NN apnoea)) (: :) (NP (NP (VBN attempted) (NN reversal)) (PP (IN with) (NP (NNS anticholinesterases)))) (. .)))
6627074	1	(S1 (S (NP (NNS Anticholinesterases)) (VP (AUX were) (VP (VBN administered) (PP (IN in) (NP (DT an) (NN attempt) (S (VP (TO to) (VP (VB antagonize) (NP (JJ prolonged) (NNP Doc_6627074_145_167_Disease)) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_6627074_200_215_Chemical))) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (ADVP (RB later)) (VBN found) (S (VP (TO to) (VP (AUX be) (ADJP (JJ homozygous)) (PP (IN for) (NP (JJ atypical) (NN plasma) (NN cholinesterase)))))))))))))))))) (. .)))
6627074	2	(S1 (S (NP (JJ Doc_6627074_294_305_Chemical) (CD 10) (NN mg)) (, ,) (S (VP (VBN given) (NP (CD 74) (NN min)) (PP (IN after) (NP (NNP Doc_6627074_332_347_Chemical))) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (JJ train-of-four) (NN stimulation)) (VP (AUX was) (ADJP (JJ characteristic) (PP (IN of) (NP (NN phase) (NNP II) (NN block))))))))) (, ,) (VP (VBD produced) (NP (NP (JJ partial) (NN antagonism)) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (RB not) (VP (VBN sustained))))))) (. .)))
6627074	3	(S1 (S (NP (NP (JJ Repeated) (NNS doses)) (PP (IN of) (NP (NP (NP (NNP Doc_6627074_489_500_Chemical)) (PP (TO to) (NP (CD 70) (NN mg)))) (CC and) (NP (NNP Doc_6627074_514_525_Chemical)))) (PP (TO to) (NP (CD 2.5) (NN mg)))) (VP (AUX did) (RB not) (VP (VB antagonize) (CC or) (VB augment) (NP (DT the) (NN block)))) (. .)))
6627074	4	(S1 (S (NP (JJ Spontaneous) (NN respiration)) (VP (VBD recommenced) (NP (CD 200) (NN min)) (PP (IN after) (NP (NNP Doc_6627074_627_642_Chemical) (NN administration)))) (. .)))
6627074	5	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NNS anticholinesterases)) (VP (AUX are) (ADJP (ADVP (RB only) (RB partially)) (JJ effective) (PP (IN in) (S (VP (VBG restoring) (NP (NN neuromuscular) (NN function)) (PP (IN in) (NP (JJ Doc_6627074_768_783_Chemical) (NN apnoea))) (SBAR (IN despite) (S (NP (NN muscle)) (VP (VB twitch) (S (NP (NN activity)) (ADJP (JJ typical) (PP (IN of) (NP (NN phase) (NNP II) (NN block))))))))))))))))) (. .)))
6631522	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_6631522_10_21_Chemical))) (PP (IN on) (NP (NP (NNP Doc_6631522_25_56_Chemical) (NNP Doc_6631522_57_80_Disease)) (CC and) (NP (NP (NN echocardiography)) (PP (IN in) (NP (NNS dogs)))))) (. .)))
6631522	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (JJ serial) (NN treatment)) (PP (IN with) (NP (NNP Doc_6631522_148_159_Chemical))))) (PP (PP (IN on) (NP (NP (JJ dynamic) (NN Doc_6631522_171_194_Disease)) (PP (IN with) (NP (NP (NNP Doc_6631522_200_231_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6631522_233_238_Chemical) (NNP HA)) (-RRB- -RRB-)))))) (, ,) (CC and) (PP (IN on) (NP (JJ global) (JJ left-ventricular) (NN function))))) (VP (VBD determined) (SBAR (S (ADVP (RB echocardiographically)) (, ,) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (CD nine) (JJ mongrel) (NNS dogs)))))))))) (. .)))
6631522	2	(S1 (S (NP (JJ Total) (JJ extractable) (NN myocardial) (NN lipid)) (VP (AUX was) (NP (NP (VBN compared) (NN postmortem)) (PP (IN between) (NP (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NN control) (NNS dogs)))) (CC and) (NP (JJ Doc_6631522_459_470_Chemical-treated) (NNS dogs)))))) (. .)))
6631522	3	(S1 (S (NP (DT A) (ADJP (ADJP (JJ significant)) (CC and) (ADJP (RB then) (JJ progressive))) (NN Doc_6631522_520_546_Disease)) (VP (AUX was) (VP (VBN observed) (PP (IN at) (NP (NP (DT a) (JJ cumulative) (JJ Doc_6631522_576_587_Chemical) (NN dose)) (PP (IN of) (NP (CD 4) (NN mg/kg))))))) (. .)))
6631522	4	(S1 (S (NP (NP (DT A) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (DT the) (JJ myocardial) (NN t1/2)) (PP (IN of) (NP (DT the) (JJ I-131) (NNS HA)))))) (VP (AUX was) (VP (VBN observed) (ADVP (RB only)) (PP (IN at) (NP (NP (DT a) (JJR higher) (JJ cumulative) (NN dose)) (, ,) (NP (CD 10) (NN mg/kg)))))) (. .)))
6631522	5	(S1 (S (NP (NP (DT No) (JJ significant) (NN alteration)) (PP (IN in) (NP (JJ total) (JJ extractable) (NN myocardial) (NNS lipids)))) (VP (AUX was) (VP (VBN observed) (PP (IN between) (NP (NP (NN control) (NNS dogs)) (CC and) (NP (NP (DT those)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_6631522_846_857_Chemical))))))))) (. .)))
6631522	6	(S1 (S (NP (PRP$ Our) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (NNS changes)) (VP (VBG leading) (PP (TO to) (NP (NP (DT an) (NN alteration)) (PP (IN of) (NP (JJ myocardial) (JJ dynamic) (NN imaging))) (PP (IN with) (NP (JJ I-131) (NNS HA))))))) (VP (AUX are) (RB not) (NP (NP (DT the) (JJ initiating) (NN factor)) (PP (IN in) (NP (NNP Doc_6631522_999_1010_Chemical) (NNP Doc_6631522_1011_1025_Disease)))))))) (. .)))
6673474	0	(S1 (NP (NP (NP (NNS Hemodynamics)) (CC and) (NP (JJ myocardial) (NN metabolism))) (PP (IN under) (NP (JJ deliberate) (NNP Doc_6673474_56_67_Disease))) (. .)))
6673474	1	(S1 (NP (NP (DT An) (JJ experimental) (NN study)) (PP (IN in) (NP (NNS dogs))) (. .)))
6673474	2	(S1 (S (NP (NP (JJ Coronary) (NN blood) (NN flow)) (, ,) (NP (JJ cardiac) (NN work)) (CC and) (NP (NN metabolism))) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NP (NNS dogs)) (PP (IN under) (NP (NP (NP (NNP Doc_6673474_176_196_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6673474_198_201_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_6673474_207_218_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6673474_220_223_Chemical)) (-RRB- -RRB-))))))) (NP (JJ deliberate) (NNP Doc_6673474_236_247_Disease)) (PRN (-LRB- -LRB-) (S (NP (NP (CD 20) (NN %)) (CC and) (NP (CD 40) (NN %))) (VP (VBP mean) (NP (NN pressure) (NN decrease)) (PP (IN from) (NP (NN baseline))))) (-RRB- -RRB-)))) (. .)))
6673474	3	(S1 (S (PP (VBG Regarding) (NP (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ drug-induced) (NNP Doc_6673474_338_349_Disease))) (PP (IN on) (NP (JJ coronary) (NN blood) (NN flow)))) (, ,) (NP (NN aortic)) (CC and) (NP (JJ coronary) (JJ sinus) (JJ metabolic) (NNS data)))) (PRN (-LRB- -LRB-) (NP (CD pH)) (, ,) (NP (NNP Doc_6673474_420_423_Chemical)) (, ,) (NP (NNP Doc_6673474_425_429_Chemical)) (-RRB- -RRB-)) (NP (PRP we)) (VP (MD could) (VP (VB confirm) (SBAR (IN that) (S (NP (NNP Doc_6673474_453_466_Chemical) (NNP Doc_6673474_467_478_Disease)) (VP (MD could) (VP (AUX be) (VP (ADVP (RB safely)) (VBN used) (PP (TO to) (NP (CD 30) (NN %))) (S (VP (VB mean) (NP (NN blood) (NN pressure)) (VP (VB decrease) (PP (PP (IN from) (NP (NP (NN control)) (, ,) (NP (JJ trimetaphan) (NNP Doc_6673474_562_573_Disease)))) (PP (TO to) (NP (ADJP (CD 20) (NN %)) (JJ mean) (NN blood) (NN pressure) (NN decrease)))))))))))))) (. .)))
6673474	4	(S1 (S (NP (JJ Cardiac) (NN work)) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN reduced) (PP (IN during) (NP (NNP SNP) (NNP Doc_6673474_661_672_Disease))))) (. .)))
6673474	5	(S1 (S (NP (NP (JJ Myocardial) (JJ Doc_6673474_685_687_Chemical) (NN consumption)) (CC and) (NP (JJ Doc_6673474_704_706_Chemical) (NN availability))) (VP (AUX were) (ADJP (RB directly) (JJ dependent) (PP (IN on) (NP (DT the) (JJ coronary) (NN perfusion))))) (. .)))
6673474	6	(S1 (S (NP (NP (JJ Careful) (JJ invasive) (NN monitoring)) (PP (IN of) (NP (NP (DT the) (NN blood) (NN pressure)) (, ,) (NP (NN blood) (NNS gases)) (CC and) (PP (IN of) (NP (DT the) (JJ ECG) (NN ST-T) (NN segment)))))) (VP (AUX is) (ADJP (JJ mandatory))) (. .)))
6687006	0	(S1 (NP (NP (NN Evidence)) (PP (IN for) (NP (NP (DT a) (JJ selective) (NN brain) (NN noradrenergic) (NN involvement)) (PP (IN in) (NP (NP (DT the) (JJ locomotor) (NN stimulant) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_6687006_95_106_Chemical)) (PP (IN in) (NP (DT the) (NN rat))))))))) (. .)))
6687006	1	(S1 (S (NP (JJ Male) (NNS rats)) (VP (VBD received) (NP (NP (DT the) (JJ Doc_6687006_142_155_Chemical) (NN neurotoxin) (NN Doc_6687006_167_171_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg/kg)) (-RRB- -RRB-)) (NP (CD 7) (NNS days))) (ADVP (RB prior) (PP (TO to) (NP (NP (NN injection)) (PP (IN of) (NP (NP (NNP Doc_6687006_212_225_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (CC or) (CD 40)) (NN mumol/kg) (NN i.p.)) (-RRB- -RRB-)))))))) (. .)))
6687006	2	(S1 (S (NP (NP (NP (DT The) (NNP Doc_6687006_256_269_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_6687006_281_294_Chemical))))) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mumol/kg)) (-RRB- -RRB-))) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN reduced) (PP (IN by) (NP (JJ Doc_6687006_338_342_Chemical) (NN pretreatment))))) (. .)))
6687006	3	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ increased) (NNS rearings)) (CC and) (NP (DT the) (JJ Doc_6687006_397_408_Chemical-induced) (NNS stereotypies))) (VP (AUX were) (RB not) (VP (VBN blocked) (PP (IN by) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NNP Doc_6687006_468_472_Chemical))))))) (. .)))
6687006	4	(S1 (S (NP (NP (DT The) (NN reduction)) (PP (IN of) (NP (NNP Doc_6687006_491_502_Chemical) (NNP Doc_6687006_503_516_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_6687006_528_532_Chemical))))) (VP (AUX was) (VP (VBN blocked) (PP (IN by) (NP (NN pretreatment))) (PP (IN with) (NP (NP (DT the) (JJ Doc_6687006_570_583_Chemical-uptake) (VBG blocking) (NN agent)) (, ,) (NP (NNP Doc_6687006_607_618_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ prevents) (NP (NP (DT the) (JJ Doc_6687006_639_649_Disease) (NN action)) (PP (IN of) (NP (NNP Doc_6687006_660_664_Chemical))))))))))) (. .)))
6687006	5	(S1 (S (NP (DT The) (JJ present) (NNS results)) (VP (VBP suggest) (NP (NP (DT a) (JJ selective) (NN involvement)) (PP (IN of) (NP (JJ central) (JJ noradrenergic) (NNS neurones))) (PP (IN in) (NP (NP (DT the) (JJ locomotor) (NN stimulant) (NN effect)) (PP (IN of) (NP (NP (NNP Doc_6687006_789_800_Chemical)) (PP (IN in) (NP (DT the) (NN rat))))))))) (. .)))
6695685	0	(S1 (S (VP (VBN Accelerated) (NP (NNP Doc_6695685_12_30_Disease)) (PP (IN during) (NP (JJ oral) (JJ Doc_6695685_43_52_Chemical) (NN therapy)))) (. .)))
6695685	1	(S1 (S (NP (DT This) (NN study)) (VP (VP (VBD examined) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NNP Doc_6695685_99_133_Disease))))) (CC and) (VP (VBD accelerated) (NP (NN Doc_6695685_150_168_Disease)) (PP (IN in) (NP (NP (CD 59) (NNS patients)) (VP (VBG receiving) (NP (JJ oral) (NNP Doc_6695685_199_208_Chemical))))))) (. .)))
6695685	2	(S1 (S (NP (NP (JJ Accelerated) (NNP Doc_6695685_222_240_Disease)) (CC and) (NP (NNP Doc_6695685_245_260_Disease))) (VP (AUX were) (ADJP (JJ frequent)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_6695685_292_325_Disease)) (, ,) (NP (RB particularly) (NN AV) (NN nodal) (NN reentry))))))) (. .)))
6695685	3	(S1 (S (NP (NP (JJ Doc_6695685_358_367_Chemical) (NN administration)) (PP (TO to) (NP (DT these) (NNS patients)))) (VP (VBD led) (PP (TO to) (NP (NP (DT an) (JJ asymptomatic) (NN increase)) (PP (IN in) (NP (NP (NN activity)) (PP (IN of) (NP (DT these) (JJ junctional) (NNS pacemakers)))))))) (. .)))
6695685	4	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ various) (NN chest) (NNP Doc_6695685_508_522_Disease))))) (, ,) (NP (NNP Doc_6695685_524_533_Chemical)) (VP (CC neither) (VP (VBD increased) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NNP Doc_6695685_569_587_Disease))))) (CC nor) (VP (VBD suppressed) (NP (NP (PRP$ their) (NN role)) (PP (IN as) (NP (NP (NN escape) (NNS rhythms)) (PP (IN under) (NP (ADJP (RB physiologically) (JJ appropriate)) (NNS circumstances)))))))) (. .)))
6728873	0	(S1 (S (VP (VB Interstrain) (NP (NN variation)) (PP (IN in) (NP (NP (JJ acute) (JJ Doc_6728873_31_36_Disease) (NN response)) (PP (TO to) (NP (NP (NNP Doc_6728873_49_57_Chemical)) (PP (IN among) (NP (JJ inbred) (NNS mice)))))))) (. .)))
6728873	1	(S1 (S (NP (NP (JJ Acute) (JJ Doc_6728873_83_88_Disease) (JJ dosage-dependent) (JJ behavioral) (NNS effects)) (PP (IN of) (NP (NNP Doc_6728873_128_136_Chemical)))) (VP (AUX were) (VP (VBN compared) (PP (IN in) (NP (NP (NN adult) (NNS males)) (PP (IN from) (NP (NP (CD seven) (JJ inbred) (NN mouse) (NNS strains)) (PRN (-LRB- -LRB-) (NP (NP (NNP A/J)) (, ,) (NP (NNP BALB/cJ) (, ,) (NNP CBA/J) (, ,) (NNP C3H/HeJ) (, ,) (NNP C57BL/6J) (, ,) (NNP DBA/2J) (, ,) (NNP SWR/J))) (-RRB- -RRB-)))))))) (. .)))
6728873	2	(S1 (S (NP (NP (NN C57BL/6J)) (, ,) (VP (VBN chosen) (PP (IN as) (NP (DT a) (`` ``) (JJ prototypic) ('' '') (NN mouse) (NN strain)))) (, ,)) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB determine) (NP (NP (JJ behavioral) (NNS responses)) (PP (TO to) (NP (NP (NP (DT a) (JJ broad) (NN range)) (PRN (-LRB- -LRB-) (NP (CD 5-500) (NN mg/kg)) (-RRB- -RRB-))) (PP (IN of) (NP (JJ Doc_6728873_381_389_Chemical) (NNS doses))))))))))) (. .)))
6728873	3	(S1 (S (NP (CD Five) (JJ phenotypic) (NN characteristics--locomotor) (NN activity)) (, ,) (S (VP (VBG righting) (NP (NP (NN ability)) (, ,) (NP (JJ clonic) (NN Doc_6728873_475_482_Disease) (NN induction)) (, ,) (NP (JJ stress-induced) (NN lethality))))) (, ,) (NP (NNP Doc_6728873_520_525_Disease)) (PP (IN without) (NP (JJ external) (NN stress--were))) (VP (VBD scored) (PP (IN at) (NP (JJ various) (JJ Doc_6728873_574_582_Chemical) (NNS doses))) (PP (IN in) (NP (JJ drug-naive) (NNS animals))) (PP (IN under) (NP (ADJP (RB empirically) (VBN optimized)) (, ,) (ADJP (RB rigidly) (JJ constant)) (JJ experimental) (NNS conditions)))) (. .)))
6728873	4	(S1 (S (NP (NP (NNS Mice)) (PRN (-LRB- -LRB-) (NP (NP (NNP n) (SYM =) (CD 12)) (PP (IN for) (NP (DT each) (NN point)))) (-RRB- -RRB-))) (VP (VBD received) (NP (NP (JJ single) (JJ IP) (NNS injections)) (PP (IN of) (NP (NP (DT a) (JJ fixed) (JJ volume/g) (NN body) (NN weight)) (PP (IN of) (NP (JJ physiological) (NN saline) (NN carrier)))))) (PP (IN with) (CC or) (IN without) (NP (NNP Doc_6728873_821_829_Chemical))) (PP (IN in) (NP (NP (NNS doses)) (VP (VBG ranging) (PP (IN from) (NP (CD 125-500) (CD mg/kg))))))) (. .)))
6728873	5	(S1 (S (NP (NP (NN Loss)) (PP (IN of) (NP (VBG righting) (NN ability)))) (VP (AUX was) (VP (VP (VBN scored) (PP (IN at) (NP (CD 1) (, ,) (CD 3) (, ,) (CD 5) (NN min) (NN post) (NN dosing)))) (CC and) (VP (PP (IN at) (NP (CD 5) (JJ min) (NNS intervals))) (ADVP (RB thereafter)) (PP (IN for) (NP (CD 20) (NN min)))))) (. .)))
6728873	6	(S1 (S (PP (IN In) (NP (DT the) (JJ same) (NNS animals))) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP Doc_6728873_1014_1029_Disease)))) (VP (AUX was) (VP (VBN scored) (PP (IN as) (PP (TO to) (NP (NP (NN time)) (PP (IN of) (NP (NP (NN onset)) (CC and) (NP (NN severity)))) (PP (IN for) (NP (CD 20) (NN min))) (PP (IN after) (NP (NN drug) (NN administration)))))))) (. .)))
6728873	7	(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (DT these)) (VP (VBD proceeded) (PP (TO to) (NP (NN tonic) (NN Doc_6728873_1142_1150_Disease)))))) (, ,) (NP (NNP Doc_6728873_1152_1157_Disease)) (VP (VBD occurred) (PP (IN in) (NP (QP (JJR less) (IN than) (CD 20)) (NN min)))) (. .)))
6728873	8	(S1 (S (S (NP (NP (NNS Animals)) (VP (VBG surviving) (PP (IN for) (NP (CD 20) (NN min))))) (VP (AUX were) (ADVP (RB immediately)) (VP (VBN stressed) (PP (IN by) (NP (NP (DT a) (VBP swim) (NN test)) (PP (IN in) (NP (CD 25) (NNS degrees) (NN C) (NN water)))))))) (, ,) (CC and) (S (NP (JJ Doc_6728873_1285_1290_Disease-producing) (NN tonic) (NNP Doc_6728873_1307_1315_Disease)) (VP (AUX were) (VP (VBN scored) (PP (IN for) (NP (CD 2) (NN min)))))) (. .)))
6728873	9	(S1 (S (PP (IN In) (NP (JJ other) (NNS animals))) (NP (NN locomotor) (NN activity)) (VP (AUX was) (VP (VBN measured) (NP (QP (CD 15) (CC or) (CD 60)) (NN min)) (PP (IN after) (NP (NNP Doc_6728873_1407_1415_Chemical) (NN administration))))) (. .)))
6728873	10	(S1 (S (PP (IN By) (NP (NP (DT any) (JJ single) (JJ behavioral) (NNP criterion)) (CC or) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (DT these) (NNS criteria)))))) (, ,) (NP (NP (VBN marked) (NNS differences)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NNP Doc_6728873_1537_1542_Disease) (NNP Doc_6728873_1543_1551_Chemical) (NNS doses)))))) (VP (AUX were) (VP (VBN observed) (PP (IN between) (NP (NNS strains))))) (. .)))
6728873	11	(S1 (S (NP (DT These) (NNS results)) (VP (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ behavioral) (JJ Doc_6728873_1628_1636_Disease) (NN testing)) (PP (IN of) (NP (NNP Doc_6728873_1648_1662_Chemical))) (PP (IN in) (NP (DT a) (JJ single) (NN mouse) (NN strain)))) (VP (MD may) (VP (AUX be) (ADJP (JJ misleading))))))) (CC and) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ Doc_6728873_1723_1728_Disease) (NNS responses)) (PP (IN of) (NP (DT the) (JJ central) (JJ nervous) (NN system))) (PP (TO to) (NP (NP (DT this) (NN class)) (PP (IN of) (NP (NNS compounds)))))) (VP (AUX are) (RB genetically) (VP (VBN influenced) (PP (IN in) (NP (NNS mammals))))))))) (. .)))
6806735	0	(S1 (NP (NP (NN Treatment)) (PP (IN of) (NP (NNP Doc_6806735_13_27_Disease))) (PP (IN with) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NNP Doc_6806735_50_62_Chemical) (, ,) (NNP Doc_6806735_64_74_Chemical) (, ,) (NNP Doc_6806735_76_92_Chemical) (CC and) (NNP Doc_6806735_97_115_Chemical))))) (. .)))
6806735	1	(S1 (S (PP (IN During) (NP (DT the) (JJ last) (QP (CD 2) (CD 1/2)) (NNS years))) (, ,) (NP (NP (CD 38) (NNS patients)) (PP (IN with) (NP (NNP Doc_6806735_163_177_Disease)))) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NP (NNP Doc_6806735_213_224_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP CPDD)) (-RRB- -RRB-))) (, ,) (NP (CD 50) (NN mg/m2)) (, ,) (NP (NNP Doc_6806735_243_253_Chemical)) (, ,) (NP (NP (CD 30) (NNS mg/m2)) (, ,) (NP (NP (NP (NNP Doc_6806735_265_281_Chemical)) (, ,) (NP (CD 300) (NN mg/m2)) (, ,) (PP (IN on) (NP (NN day) (CD 1)))) (: ;) (CC and) (NP (NP (NNP Doc_6806735_308_326_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_6806735_328_331_Chemical)) (-RRB- -RRB-))))))))) (, ,) (ADVP (NP (CD 6) (NN mg/kg)) (RB daily)) (, ,) (PP (IN for) (NP (CD 14) (NNS days))))) (. .)))
6806735	2	(S1 (S (NP (DT Each) (NN course)) (VP (AUX was) (VP (VBN repeated) (SBAR (S (NP (QP (CD monthly.) (CD 2)) (NNS patients)) (VP (AUX had) (VP (VB stage) (NP (NP (NNP II)) (, ,) (NP (CD 14) (NN stage) (NNP III)) (CC and) (NP (CD 22) (NN stage))) (SBAR (S (NP (NP (NP (NNP IV) (FW disease.)) (SBAR (S (NP (NP (CD 14)) (PP (IN of) (NP (DT the) (CD 38) (NNS patients)))) (VP (AUX were) (ADVP (RB previously)) (VP (VBN treated) (PP (IN with) (NP (NN chemotherapy)))))))) (, ,) (NP (NP (CD 1)) (PP (IN with) (NP (NN radiation)))) (, ,) (NP (NP (CD 6)) (PP (IN with) (NP (DT both) (NN chemotherapy) (CC and) (NN radiation)))) (, ,) (CC and) (NP (CD 17))) (VP (AUX did) (RB not) (VP (AUX have) (NP (DT any) (NN treatment)) (SBAR (IN before) (S (NP (NNP CPDD)) (VP (VBD combination.) (SBAR (S (NP (NP (CD 31)) (PP (IN of) (NP (NP (DT the) (CD 38) (NNS cases)) (PRN (-LRB- -LRB-) (NP (CD 81.5) (NN %)) (-RRB- -RRB-))))) (VP (VBD demonstrated) (NP (NP (JJ objective) (NNS responses)) (VP (VBG lasting) (PP (IN for) (NP (CD 2) (NNS months) (QP (CC or) (JJR more)))))))))))))))))))))) (. .)))
6806735	3	(S1 (S (NP (DT These) (NNS responses)) (VP (AUX were) (ADJP (ADJP (JJ partial) (PP (IN in) (NP (CD 19)))) (CC and) (ADJP (JJ complete) (PP (IN in) (NP (CD 12) (NNS cases)))))) (. .)))
6806735	4	(S1 (S (NP (NN Doc_6806735_792_812_Disease)) (VP (AUX was) (UCP (ADJP (JJ moderate)) (CC and) (PP (IN with) (NP (NP (JJ reversible) (NN Doc_6806735_846_852_Disease) (VBG developing)) (PP (IN in) (NP (NP (CD 71) (NN %)) (PP (IN of) (NP (NNS patients))))))))) (. .)))
6806735	5	(S1 (S (NP (NP (JJ Gastrointestinal) (JJ side) (NNS effects)) (PP (IN from) (NP (NNP CPDD)))) (VP (AUX were) (ADJP (JJ universal))) (. .)))
6806735	6	(S1 (S (NP (NNP HMM) (NNP Doc_6806735_944_969_Disease)) (VP (VBD necessitated) (NP (NP (NN discontinuation)) (PP (IN of) (NP (DT the) (NN drug))) (PP (IN in) (NP (CD 5) (NNS patients))))) (. .)))
6806735	7	(S1 (S (NP (JJ Severe) (NN nephrotoxicity)) (VP (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (CD 2) (NNS patients))))) (CC but) (VP (AUX was) (ADJP (JJ reversible)))) (. .)))
6806735	8	(S1 (S (NP (EX There)) (VP (AUX were) (NP (DT no) (JJ drug-related) (NN Doc_6806735_1122_1128_Disease))) (. .)))
6884395	0	(S1 (S (NP (NNP Nontraumatic)) (VP (VBG dissecting) (NP (NNP Doc_6884395_24_54_Disease))) (. .)))
6884395	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NP (JJ nontraumatic) (VBG dissecting) (NN Doc_6884395_90_120_Disease)) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (NP (NNP Doc_6884395_141_153_Disease)) (, ,) (NP (NN smoke)) (, ,) (CC and) (NP (JJ oral) (NNS contraceptives))))))))) (VP (AUX is) (VP (VBN reported) (PP (IN in) (NP (NP (DT a) (JJ young) (NN female) (NN patient)) (PP (IN with) (NP (DT a) (NNP Doc_6884395_231_249_Disease))))))) (. .)))
689020	0	(S1 (NP (NP (NP (DT A) (NN method)) (PP (IN for) (NP (NP (DT the) (NN measurement)) (PP (IN of) (NP (NNP Doc_689020_32_38_Disease)))))) (, ,) (CC and) (NP (NP (DT a) (NN comparison)) (PP (IN of) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ tocolytic) (NNS beta-mimetics)))))) (. .)))
689020	1	(S1 (S (NP (NP (DT A) (NN method)) (VP (VBG permitting) (NP (NP (NN measurement)) (PP (IN of) (NP (NN finger) (NN Doc_689020_142_148_Disease)))) (PP (IN as) (NP (DT a) (JJ displacement-time) (NN curve))))) (VP (AUX is) (VP (VBN described) (, ,) (S (VP (VBG using) (NP (NP (DT a) (NN test) (NN system)) (PP (IN with) (NP (JJ simple) (NN amplitude) (NN calibration)))))))) (. .)))
689020	2	(S1 (S (NP (NP (DT The) (VBZ coordinates)) (PP (IN of) (NP (NP (DT the) (JJ inversion) (NNS points)) (PP (IN of) (NP (DT the) (JJ displacement-time) (NNS curves)))))) (VP (AUX were) (VP (VBN transferred) (PP (IN through) (NP (NP (JJ graphical) (NN input) (NN equipment)) (PP (TO to) (NP (JJ punched) (NN tape))))))) (. .)))
689020	3	(S1 (S (PP (IN By) (NP (NP (NNS means)) (PP (IN of) (NP (DT a) (NN computer) (NN program))))) (, ,) (NP (NP (NNS periods) (CC and) (NNS amplitudes)) (PP (IN of) (NP (JJ Doc_689020_445_451_Disease) (NNS oscillations)))) (VP (AUX were) (VP (VP (VBN calculated)) (CC and) (VP (VBN classified)))) (. .)))
689020	4	(S1 (S (NP (NP (DT The) (NN event) (NN frequency)) (PP (IN for) (NP (NP (DT each) (NN class)) (PP (IN of) (NP (NP (NNS periods)) (CC and) (NP (NNS amplitudes))))))) (VP (AUX was) (VP (VBN determined))) (. .)))
689020	5	(S1 (S (NP (NP (DT The) (NNS actions)) (PP (IN of) (NP (NP (NNP Doc_689020_589_598_Chemical-Doc_689020_599_611_Chemical)) (, ,) (NP (NNP Doc_689020_613_621_Chemical-Doc_689020_622_625_Chemical)) (CC and) (NP (NN placebo)))) (VP (VBN given) (PP (TO to) (NP (CD 10) (JJ healthy) (NNS subjects))) (PP (IN by) (NP (JJ intravenous) (NN infusion))) (PP (IN in) (NP (DT a) (JJ double-blind) (NN crossover) (NN study))))) (VP (AUX were) (VP (VBN tested) (PP (IN by) (NP (DT this) (NN method))))) (. .)))
689020	6	(S1 (S (PP (IN At) (NP (JJ therapeutic) (NNS doses))) (NP (DT both) (NNS substances)) (VP (VBD raised) (NP (DT the) (JJ mean) (NN Doc_689020_806_812_Disease) (NN amplitude)) (PP (TO to) (NP (QP (RB about) (CD three) (NNS times)) (DT the) (NN control) (NN level)))) (. .)))
689020	7	(S1 (S (PP (IN At) (NP (DT the) (JJ same) (NN time))) (, ,) (NP (NP (DT the) (JJ mean) (NN period)) (PP (IN within) (NP (NP (DT each) (NN class)) (PP (IN of) (NP (NP (NNS amplitudes)) (VP (VBN shortened) (PP (IN by) (NP (CD 10--20) (NN ms)))))) (, ,) (SBAR (IN whereas) (S (NP (DT the) (JJ mean) (NNS periods)) (VP (VBN calculated) (PP (IN from) (NP (DT all) (NNS oscillations))))))))) (ADVP (RB together)) (VP (AUX did) (RB not) (VP (VB change) (ADVP (RB significantly)))) (. .)))
689020	8	(S1 (S (PP (IN After) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (JJ Doc_689020_1067_1076_Chemical-Doc_689020_1077_1089_Chemical) (NN infusion))))) (, ,) (NP (NNP Doc_689020_1100_1106_Disease) (NNS amplitudes)) (VP (VBD decreased) (ADVP (RB significantly)) (ADVP (RBR faster) (PP (IN than) (NP (NP (DT those)) (VP (VBG following) (NP (JJ Doc_689020_1170_1182_Chemical) (NN infusion))))))) (. .)))
6893265	0	(S1 (NP (JJ Doc_6893265_0_16_Chemical-induced) (NN Doc_6893265_25_39_Disease) (. .)))
6893265	1	(S1 (S (NP (NP (CD Two) (NNS cases)) (PP (IN of) (NP (NNP Doc_6893265_54_70_Chemical-induced) (NNP Doc_6893265_79_91_Disease)))) (VP (AUX have) (VP (AUX been) (VP (VBN observed)))) (. .)))
6893265	2	(S1 (S (S (NP (DT The) (JJ first) (NN case)) (VP (AUX is) (PP (IN of) (NP (NP (DT an) (JJ acute) (NN type)) (PP (IN of) (NP (NN damage))) (, ,) (VP (VBN proven) (PP (IN by) (NP (NN rechallenge)))))))) (: ;) (S (NP (DT the) (NN second)) (VP (VBZ presents) (NP (NP (DT a) (ADJP (JJ clinical) (CC and) (JJ histologic)) (NN picture)) (VP (VBG resembling) (NP (NNP Doc_6893265_246_270_Disease)))) (, ,) (PP (IN with) (NP (JJ spontaneous) (NN remission))))) (. .)))
6985297	0	(S1 (NP (NP (NNS Studies)) (PP (IN on) (NP (DT the) (NNP Doc_6985297_15_26_Disease))) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_6985297_38_46_Chemical)))) (. .)))
6985297	1	(S1 (S (NP (NP (NNP Doc_6985297_48_56_Chemical)) (, ,) (NP (NP (DT a) (JJ novel) (JJ active) (NN compound)) (PP (IN for) (NP (NP (JJ prophylactic) (NN treatment)) (PP (IN of) (NP (NNP Doc_6985297_112_127_Disease)))))) (, ,)) (VP (VBN induced) (S (NP (NP (JJ persistent) (NN Doc_6985297_148_159_Disease)) (CC and) (NP (NP (DT a) (JJ non-specific) (JJ anti-tachycardial) (NN effect)) (, ,) (NP (NP (DT the) (NNS mechanisms)) (SBAR (WHPP (IN of) (WHNP (WDT which))) (S (VP (AUX were) (VP (VBN investigated) (PP (PP (IN in) (NP (NN vitro))) (CC and) (PP (IN in) (NP (NN vivo))))))))))))) (. .)))
6985297	2	(S1 (S (PP (IN In) (NP (NP (NN vitro) (NN perfusion)) (PP (IN of) (NP (NNP Doc_6985297_291_299_Chemical))))) (PP (IN in) (NP (NP (DT the) (JJ life-support) (NN medium)) (PP (IN for) (NP (NP (VBN isolated) (JJ sino-atrial) (NN tissue)) (PP (IN from) (NP (NN rabbit) (NN heart))))))) (, ,) (VP (VBD caused) (NP (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NN action) (NN potential)))) (PRN (-LRB- -LRB-) (NP (NNP AP)) (-RRB- -RRB-)) (NP (NP (JJ spike) (NN frequency)) (PRN (-LRB- -LRB-) (VP (VBN recorded) (PP (IN by) (NP (NNP Doc_6985297_451_454_Chemical) (NNS microelectrodes)))) (-RRB- -RRB-)))) (PP (VBG starting) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (CD 5) (NNP X) (CD 10) (-LRB- -LRB-) (NN -6) (-RRB- -RRB-) (NNP M))))))) (. .)))
6985297	3	(S1 (S (NP (DT This) (NN effect)) (VP (AUX was) (ADJP (JJ dose-dependent)) (PP (IN up) (PP (TO to) (NP (NP (NNS concentrations)) (PP (IN of) (NP (NP (NP (CD 5) (NNP X) (CD 10)) (PRN (-LRB- -LRB-) (NP (NN -5)) (-RRB- -RRB-))) (NP (NP (NNP M)) (, ,) (NP (NP (NN whereupon) (NN blockade)) (PP (IN of) (NP (NP (JJ sinus) (NN activity)) (VP (VBN set) (PP (IN in))))))))))))) (. .)))
6985297	4	(S1 (S (VP (VB Doc_6985297_621_629_Chemical) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 5) (NNP X) (CD 10) (-LRB- -LRB-) (NN -6) (-RRB- -RRB-) (NNP M))) (, ,) (VP (VBN induced) (NP (NP (DT a) (JJ concomitant) (NN reduction)) (PP (IN in) (NP (NNP AP) (NN amplitude))) (PRN (-LRB- -LRB-) (VP (VBG falling) (PP (IN from) (NP (CD 71) (NNS +/-) (QP (CD 8) (CD mV)))) (PP (TO to) (NP (QP (CD 47) (CD +/-)) (QP (CD 6) (CD mV))))) (-RRB- -RRB-)) (, ,) (NP (JJ maximum) (JJ systolic) (NN depolarization) (NN velocity)) (PRN (-LRB- -LRB-) (NP (NN phase) (CD 0)) (-RRB- -RRB-)) (SBAR (WHNP (WDT which)) (S (VP (VBD fell) (PP (IN from) (NP (NP (CD 1.85) (NNS +/-)) (NP (CD 0.35) (NNP V/s)))) (PP (TO to) (NP (NP (CD 0.84) (NNS +/-)) (NP (CD 0.28) (NNP V/s)))) (, ,) (ADVP (RB together) (PP (IN with) (NP (NP (JJ maximum) (JJ diastolic) (NN depolarization) (NN velocity)) (PRN (-LRB- -LRB-) (NP (NN phase) (CD 4)) (-RRB- -RRB-)) (SBAR (WHNP (WDT which)) (S (VP (VBD fell) (PP (IN from) (NP (CD 38) (NNS +/-))) (NP (CD 3) (NN mV/s)) (PP (TO to) (NP (QP (CD 24) (CD +/-)) (QP (CD 5) (CD mV/s)))))))))))))))))) (. .)))
6985297	5	(S1 (S (PP (IN In) (NP (NP (NN vivo) (NN injection)) (PP (IN of) (NP (NNP Doc_6985297_990_998_Chemical))) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (NP (CD 5) (NN mg/kg)) (PRN (-LRB- -LRB-) (NP (NN i.v.)) (-RRB- -RRB-)))))) (PP (IN into) (NP (CD 6) (JJ anaesthetized) (NNS dogs))) (SBAR (WHNP (WDT which)) (S (VP (AUX had) (VP (VBN undergone) (NP (NP (NN ablation)) (PP (IN of) (NP (PDT all) (DT the) (JJ extrinsic) (JJ cardiac) (NN afferent) (NN nerve) (NN supply)))))))))) (, ,) (ADVP (RB together) (PP (IN with) (NP (DT a) (JJ bilateral) (NN medullo-adrenalectomy)))) (, ,) (VP (VBD caused) (NP (NP (DT a) (JJ marked) (NN reduction)) (PP (IN in) (NP (NP (NN heart) (NN rate)) (SBAR (WHNP (WDT which)) (S (VP (VBD fell) (PP (IN from) (NP (CD 98.7) (NNS +/-))) (NP (CD 4.2) (NN beats/min)) (PP (TO to) (NP (NP (CD 76) (NNS +/-)) (NP (NP (CD 5.3) (NN beats/min)) (VP (VBN sustained) (PP (IN for) (NP (QP (JJR more) (IN than) (CD 45)) (NN min)))))))))))))) (. .)))
6985297	6	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN concluded) (SBAR (IN that) (S (NP (NNP Doc_6985297_1339_1347_Chemical)) (VP (VBZ reduces) (NP (NN heart) (NN rate)) (PP (IN by) (S (VP (VBG acting) (ADVP (RB directly)) (PP (IN on) (NP (DT the) (JJ sinus) (NN node))))))))))) (. .)))
6985297	7	(S1 (NP (NP (DT This) (NN effect)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ results) (SBAR (S (PP (IN in) (NP (NP (DT a) (NN flattening)) (PP (IN of) (NP (DT the) (NN phase))))) (NP (NP (CD 0)) (CC and) (NP (NN phase) (CD 4) (NN slope))) (, ,) (ADVP (RB together) (PP (IN with) (NP (DT a) (JJR longer) (NNP AP) (NN duration)))) (, ,) (VP (MD may) (VP (AUX be) (ADJP (JJ due) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN time) (NNS constants)) (PP (PP (IN of) (NP (NP (JJ slow) (JJ inward) (JJ ionic) (NNS currents)) (PRN (-LRB- -LRB-) (VP (ADVP (RB already)) (VBN demonstrated) (ADVP (RB elsewhere))) (-RRB- -RRB-)))) (, ,) (CC but) (RB also) (PP (TO to) (NP (NP (DT an) (VBN increased) (NN time)) (PP (JJ constant) (IN for) (NP (NP (NN deactivation)) (PP (IN of) (NP (NP (DT the) (JJ outward) (JJ Doc_6985297_1701_1710_Chemical) (NN current)) (PRN (-LRB- -LRB-) (NP (NNP Ip)) (-RRB- -RRB-)))))))))))))))) (. .))))))))
6985498	0	(S1 (NP (NP (NP (NN Doc_6985498_0_9_Disease)) (CC and) (NP (NNP Doc_6985498_14_36_Disease))) (PP (IN after) (NP (NP (NNS anesthesia)) (PP (IN with) (NP (NNP Doc_6985498_59_73_Chemical))))) (. .)))
6985498	1	(S1 (S (NP (NP (DT A) (JJ 69-year-old) (NN man)) (VP (VBN operated) (PP (IN for) (NP (JJ acute) (NN Doc_6985498_112_125_Disease))) (PP (IN under) (NP (JJ Doc_6985498_132_146_Chemical) (NNS anesthesia))))) (VP (VBD developed) (ADVP (RB postoperatively)) (NP (DT a) (NNP Doc_6985498_186_216_Disease) (CC and) (NNP Doc_6985498_221_243_Disease))) (. .)))
6985498	2	(S1 (S (NP (JJ Massive) (NN Doc_6985498_253_261_Disease)) (VP (VBD appeared) (PP (IN during) (NP (NP (NN surgery)) (SBAR (WHNP (WDT which)) (S (VP (VBD lasted) (PP (IN for) (NP (CD six) (NNS hours))))))))) (. .)))
6985498	3	(S1 (S (S (NP (JJ Postoperative) (NN evolution)) (PP (IN under) (NP (JJ supportive) (NN therapy)))) (VP (AUX was) (ADJP (JJ favourable))) (. .)))
6985498	4	(S1 (S (NP (JJ Complete) (NN recovery)) (VP (AUX was) (VP (VBN confirmed) (PP (IN by) (NP (NP (VBN repeated) (NNS controls)) (VP (VBN performed) (PP (IN over) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (CD one) (NN year))) (PP (IN after) (NP (NN surgery)))))))))) (. .)))
7018927	0	(S1 (S (NP (JJ Pituitary) (NN response)) (VP (TO to) (VP (VB luteinizing) (S (VP (VBG hormone-releasing) (NP (NN hormone)) (PP (IN during) (NP (JJ Doc_7018927_67_78_Chemical-induced) (NN Doc_7018927_87_105_Disease))))))) (. .)))
7018927	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (DT a) (JJ 6-hour) (NN infusion)) (PP (IN with) (NP (NNP Doc_7018927_145_156_Chemical))))) (PP (IN on) (NP (NP (NN serum) (NN prolactin)) (CC and) (NP (JJ luteinizing) (NN hormone) (PRN (-LRB- -LRB-) (NP (NNP LH)) (-RRB- -RRB-)) (NNS levels))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (JJ male) (NNS subjects))))))) (. .)))
7018927	2	(S1 (S (PP (NP (CD Five) (NNS hours)) (IN after) (S (VP (VBG starting) (NP (DT the) (NNS infusions))))) (, ,) (NP (NP (DT a) (NN study)) (PP (IN of) (NP (NP (DT the) (JJ pituitary) (NNS responses)) (PP (TO to) (NP (JJ LH-releasing) (NN hormone))))) (PRN (-LRB- -LRB-) (NP (NNP LH-RH)) (-RRB- -RRB-))) (VP (AUX was) (VP (VBN carried) (PRT (RP out)))) (. .)))
7018927	3	(S1 (S (NP (NN Control) (NNS patients)) (VP (VBD received) (NP (NP (NNS infusions)) (PP (IN of) (NP (ADJP (CD 0.9) (NN %)) (JJ Doc_7018927_422_426_Chemical) (NN solution))))) (. .)))
7018927	4	(S1 (S (PP (IN During) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (JJ Doc_7018927_458_469_Chemical) (NNS infusions))))) (, ,) (NP (JJ significant) (NN Doc_7018927_493_511_Disease)) (VP (AUX was) (VP (VBN found) (, ,) (ADVP (RB together) (PP (IN with) (NP (NP (DT an) (VBN abolished) (JJ pituitary) (NN response)) (PP (TO to) (NP (NN LH-RH)))))) (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (NP (NNS responses)) (PP (IN of) (NP (NN control) (NNS subjects)))))))))) (. .)))
7121659	0	(S1 (S (NP (NP (NP (JJ Doc_7121659_0_14_Chemical) (NNS antibodies)) (PP (IN in) (NP (JJ acute) (JJ Doc_7121659_35_45_Chemical-associated) (NNP Doc_7121659_57_70_Disease.) (CD 5) (NNS patients))) (PP (IN with) (NP (NNP Doc_7121659_88_107_Disease))) (PRN (-LRB- -LRB-) (NP (NP (CD 3)) (PP (IN with) (NP (NP (NNP Doc_7121659_116_128_Disease)) (CC and) (NP (NNP Doc_7121659_133_142_Disease))))) (-RRB- -RRB-))) (VP (VBN induced) (PP (IN by) (NP (NP (DT the) (NN reintroduction)) (PP (IN of) (NP (NNP Doc_7121659_177_187_Chemical))))))) (VP (AUX are) (VP (VBN described))) (. .)))
7121659	1	(S1 (S (NP (DT No) (NN correlation)) (VP (AUX was) (VP (VBN found) (PP (IN between) (NP (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (JJ clinical) (NNS manifestations)))) (CC and) (NP (NP (DT the) (JJ total) (NN dose)) (VP (VBN taken) (PP (IN by) (NP (DT the) (NNS patients))))))))) (. .)))
7121659	2	(S1 (S (PP (IN In) (NP (NP (DT all)) (PP (IN but) (NP (CD 1) (NN patient))))) (, ,) (NP (NNP Doc_7121659_340_354_Chemical) (NNS antibodies)) (VP (AUX were) (VP (VBN detected))) (. .)))
7121659	3	(S1 (S (NP (NP (NNS Antibodies)) (VP (VBN suggested) (S (VP (TO to) (VP (AUX be) (PP (IN of) (NP (DT the) (JJ IgM) (NN class)))))))) (VP (AUX were) (VP (VBN detected) (PP (IN in) (NP (NP (DT all) (CD 3) (NNS patients)) (PP (IN with) (NP (NNP Doc_7121659_462_485_Disease))))))) (. .)))
7121659	4	(S1 (S (NP (NP (DT The) (NN pattern)) (PP (IN of) (NP (NP (JJ non-specific) (NNP Doc_7121659_515_537_Disease)) (VP (VBN found) (PP (IN in) (NP (NP (DT the) (CD 2) (JJ biopsied) (NNS patients)) (, ,) (ADJP (JJ indistinguishable) (PP (IN from) (NP (NP (DT that)) (PP (IN of) (NP (JJ Doc_7121659_603_611_Disease) (NN origin)))))) (, ,))))))) (VP (VBD raised) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (DT a) (JJ vascular-mediated) (NN damage))))) (. .)))
7121659	5	(S1 (S (PP (IN In) (NP (CD 3) (NNS patients))) (, ,) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (DT a) (VBG triggering) (NN immunoallergic) (NN mechanism)))) (VP (AUX is) (VP (VBN discussed))) (. .)))
7147232	0	(S1 (S (NP (NP (JJ Cardiovascular) (NNS effects)) (PP (IN of) (NP (NNP Doc_7147232_26_37_Disease)))) (VP (VBN induced) (PP (IN by) (NP (NP (NNP Doc_7147232_49_71_Chemical)) (CC and) (NP (NNP Doc_7147232_76_96_Chemical)))) (PP (IN on) (NP (NP (NNS dogs)) (PP (IN with) (NP (JJ denervated) (NNS hearts)))))) (. .)))
7147232	1	(S1 (S (NP (NP (NP (NNP Doc_7147232_129_151_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7147232_153_156_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_7147232_162_182_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7147232_184_187_Chemical)) (-RRB- -RRB-)))) (VP (AUX are) (VP (VBN administered) (PP (TO to) (NP (NNS patients))) (S (VP (TO to) (VP (VB induce) (CC and) (VB control) (NP (NNP Doc_7147232_240_251_Disease)) (PP (IN during) (NP (NN anesthesia)))))))) (. .)))
7147232	2	(S1 (S (S (NP (NN Doc_7147232_271_274_Chemical)) (VP (AUX is) (VP (VBN authorized) (PP (IN for) (NP (JJ clinical) (NN use))) (PP (IN in) (NP (NP (NNP USA)) (CC and) (NP (NNP UK))))))) (, ,) (CC and) (S (NP (NNP Doc_7147232_325_328_Chemical)) (VP (AUX is) (ADVP (RB clinically)) (VP (VBN used) (PP (IN in) (NP (NP (JJ other) (NNS countries)) (PP (JJ such) (IN as) (NP (NNP Japan)))))))) (. .)))
7147232	3	(S1 (S (NP (PRP We)) (VP (VBD investigated) (SBAR (WHADVP (WRB how)) (S (NP (DT these) (CD two) (NNS drugs)) (VP (VBP act) (PP (IN on) (NP (NP (DT the) (JJ cardiovascular) (NNS systems)) (PP (IN of) (NP (CD 20) (NNS dogs))) (SBAR (WHNP (WP$ whose) (NNS hearts)) (S (VP (AUX had) (VP (AUX been) (VP (VBN denervated) (PP (IN by) (NP (NP (DT a) (NN procedure)) (SBAR (S (NP (PRP we)) (VP (AUX had) (VP (VBN devised)))))))))))))))))) (. .)))
7147232	4	(S1 (S (NP (NP (NP (JJ Doc_7147232_527_530_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10) (NNS dogs)) (-RRB- -RRB-))) (CC or) (NP (NP (JJ Doc_7147232_544_547_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10) (NNS dogs)) (-RRB- -RRB-)))) (VP (AUX was) (VP (VBN administered) (S (VP (TO to) (VP (VB reduce) (NP (JJ mean) (JJ arterial) (NN pressure)) (PP (IN by) (NP (CD 30) (NN %))) (PP (TO to) (NP (NP (CD 70) (NN %)) (PP (IN of) (NP (NN control)))))))))) (. .)))
7147232	5	(S1 (FRAG (PP (IN Before)) (, ,) (SBAR (IN during) (S (CC and) (SBAR (IN after) (S (VP (VBN induced) (NP (NN Doc_7147232_667_678_Disease))))) (, ,) (NP (PRP we)) (VP (VBD measured) (NP (JJ major) (NN Doc_7147232_698_723_Disease))))) (. .)))
7147232	6	(S1 (S (S (NP (NP (NN Doc_7147232_725_736_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_7147232_748_751_Chemical))))) (VP (AUX was) (VP (VBN accompanied) (PP (IN by) (NP (NP (JJ significant) (NNS decreases)) (PP (IN in) (VP (VP (VB mean) (NP (NP (JJ pulmonary) (JJ arterial) (NN pressure)) (PRN (-LRB- -LRB-) (ADVP (RB p) (JJR less)) (PP (IN than) (NP (CD 0.001))) (-RRB- -RRB-)) (, ,) (NP (JJ central) (JJ venous) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-)) (, ,) (NP (JJ left) (JJ ventricular) (JJ end-diastolic) (NN pressure)) (PRN (-LRB- -LRB-) (ADVP (RB p) (JJR less)) (PP (IN than) (NP (CD 0.001))) (-RRB- -RRB-)) (, ,) (NP (JJ total) (JJ peripheral) (NN resistance)) (PRN (-LRB- -LRB-) (ADVP (RB p)) (NP (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-)) (, ,) (NP (NN rate) (NN pressure) (NN product)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-)) (, ,) (NP (JJ total) (NN body) (JJ Doc_7147232_1059_1065_Chemical) (NN consumption)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)) (, ,) (CC and) (NP (NN heart) (NN rate)))) (PRN (-LRB- -LRB-) (ADVP (RB p) (JJR less)) (PP (IN than) (NP (CD 0.001))) (-RRB- -RRB-))))))))) (: ;) (S (NP (PDT all) (DT these) (NNS variables)) (VP (VBD returned) (ADVP (RB normal)) (PP (IN within) (NP (CD 30) (NN min))) (SBAR (IN after) (S (NP (NNP Doc_7147232_1190_1193_Chemical)) (VP (AUX was) (VP (VBN stopped))))))) (. .)))
7147232	7	(S1 (S (NP (JJ Cardiac) (NN output)) (VP (AUX did) (RB not) (VP (VB change))) (. .)))
7147232	8	(S1 (S (PP (IN During) (NP (NNP Doc_7147232_1245_1256_Disease))) (S (VP (VBN produced) (PP (IN by) (NP (JJ Doc_7147232_1269_1272_Chemical) (JJ similar) (NNS decreases))))) (VP (AUX were) (VP (VBN observed) (PP (IN in) (S (VP (VBP mean) (NP (NP (JJ pulmonary) (JJ arterial) (NN pressure)) (PRN (-LRB- -LRB-) (ADVP (RB p) (JJR less)) (PP (IN than) (NP (CD 0.01))) (-RRB- -RRB-)) (, ,) (NP (JJ central) (JJ venous) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-)) (, ,) (NP (JJ left) (JJ ventricular) (JJ end-diastolic) (NN pressure)) (PRN (-LRB- -LRB-) (ADVP (RB p) (JJR less)) (PP (IN than) (NP (CD 0.01))) (-RRB- -RRB-)) (, ,) (NP (JJ total) (JJ peripheral) (NN resistance)) (PRN (-LRB- -LRB-) (ADVP (RB p) (JJR less)) (PP (IN than) (NP (CD 0.001))) (-RRB- -RRB-)) (, ,) (NP (NN rate) (NN pressure) (NN product)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-)) (, ,) (CC and) (NP (NP (JJ Doc_7147232_1562_1568_Chemical) (NN content) (NN difference)) (PP (IN between) (NP (NP (ADJP (JJ arterial) (CC and) (JJ mixed)) (JJ venous) (NN blood)) (PRN (-LRB- -LRB-) (ADVP (RB p)) (NP (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)) (, ,) (SBAR (IN while) (S (NP (NP (NP (NN heart) (NN rate)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.001))) (-RRB- -RRB-))) (CC and) (NP (NP (JJ cardiac) (NN output)) (PRN (-LRB- -LRB-) (NP (NNP p) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN increased)))))))))))))) (. .)))
7147232	9	(S1 (S (NP (NP (NNS Recoveries)) (PP (IN of) (NP (NP (NN heart) (NN rate)) (CC and) (NP (JJ left) (JJ ventricular) (JJ end-diastolic) (NN pressure))))) (VP (AUX were) (RB not) (VP (VBN shown) (PP (IN within) (NP (CD 60) (NN min))) (SBAR (IN after) (S (NP (NNP Doc_7147232_1843_1846_Chemical)) (VP (AUX had) (VP (AUX been) (VP (VBN stopped)))))))) (. .)))
7147232	10	(S1 (S (NP (CC Both) (NP (NNP Doc_7147232_1870_1873_Chemical)) (CC and) (NP (NNP Doc_7147232_1878_1881_Chemical))) (VP (MD should) (VP (VB act) (PP (IN on) (NP (NP (DT the) (NN pacemaker) (NN tissue)) (PP (IN of) (NP (DT the) (NN heart))))))) (. .)))
7173007	0	(S1 (NP (NP (JJ Comparative) (NN study)) (: :) (NP (NP (NP (NP (NNP Doc_7173007_19_30_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7173007_32_43_Chemical)) (-RRB- -RRB-)) (, ,) (NP (NNP Vasurix) (NNP Doc_7173007_54_64_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7173007_66_77_Chemical)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Dimer-X)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7173007_89_98_Chemical)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_7173007_104_112_Chemical)) (PRN (-LRB- -LRB-) (NP (NN ioxaglate)) (-RRB- -RRB-)))) (PP (IN in) (NP (NN hysterosalpingography)))) (. .)))
7173007	1	(S1 (S (NP (NP (JJ Side) (NNS effects)) (PP (IN of) (NP (NN hysterosalpingography))) (PP (IN with) (NP (NP (NNP Dimer-X) (, ,) (NNP Hexabrix) (, ,) (NNP Vasurix) (NNP Doc_7173007_221_231_Chemical) (CC and) (NNP Doc_7173007_236_247_Chemical)) (PP (IN in) (NP (NP (CD 142) (JJ consecutive) (NNS patients)) (, ,) (VP (VBG receiving) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (CD four) (VBN tested) (NNS media)))))))))) (VP (AUX were) (VP (VBN evaluated) (PP (IN from) (NP (NP (NNS replies)) (PP (TO to) (NP (JJ postal) (NNS questionnaires))))))) (. .)))
7173007	2	(S1 (S (NP (DT The) (JJ Dimer-X) (NN group)) (VP (AUX had) (NP (NP (DT a) (JJR higher) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_7173007_414_420_Disease)) (CC and) (NP (NNP Doc_7173007_425_434_Disease)))))) (. .)))
7173007	3	(S1 (S (NP (DT The) (NNP Doc_7173007_440_451_Chemical) (NN group)) (VP (AUX had) (NP (NP (DT a) (JJR higher) (NN incidence)) (PP (IN of) (NP (NNP Doc_7173007_484_498_Disease))))) (. .)))
7173007	4	(S1 (S (NP (DT These) (NNS differences)) (VP (VBP occur) (ADVP (RB especially)) (PP (IN in) (NP (DT the) (NN age) (NNS groups))) (PP (IN under) (NP (CD 30) (NNS years)))) (. .)))
7173007	5	(S1 (S (NP (NNP Hexabrix) (CC and) (NNP Vasurix) (NNP Doc_7173007_590_600_Chemical)) (VP (AUX are) (VP (VBN considered) (UCP (NP (NP (DT the) (JJS best) (NN contrast) (NNS media)) (PP (IN for) (NP (NN hysterosalpingography)))) (CC and) (PP (ADVP (RB perhaps)) (IN because) (IN of) (NP (NP (PRP$ its) (NN low)) (SBAR (S (NP (NNP Doc_7173007_697_705_Disease) (NNP Hexabrix)) (VP (MD should) (VP (AUX be) (VP (VBN preferred))))))))))) (. .)))
7176945	0	(S1 (NP (NP (NP (JJ Post-Doc_7176945_5_18_Chemical) (NNS pains)) (PP (IN in) (NP (NNP Nigerian) (JJ surgical) (NNS patients)))) (. .)))
7176945	1	(S1 (S (ADVP (JJ Contrary) (PP (TO to) (NP (NP (DT an) (JJR earlier) (NN report)) (PP (IN by) (NP (NNP Doc_7176945_89_94_Chemical)))))) (, ,) (NP (NNP Doc_7176945_96_103_Chemical) (NNP Doc_7176945_104_108_Disease)) (VP (VBZ occurs) (PP (IN in) (NP (JJ African) (NNS negroes)))) (. .)))
7176945	2	(S1 (S (NP (PRP$ Its) (NN incidence)) (VP (AUX was) (VP (VBN determined) (PP (IN in) (NP (NP (DT a) (JJ prospective) (NN study)) (VP (VBG involving) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (NP (CD 100) (JJ Nigerian) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (CD 50) (NNS out-patients)) (CC and) (NP (CD 50) (NNS in-patients))) (-RRB- -RRB-)))))))))) (. .)))
7176945	3	(S1 (S (NP (NP (QP (RB About) (CD 62)) (NN %)) (PP (IN of) (NP (DT the) (NNS out-patients)))) (VP (VBD developed) (NP (NNP Doc_7176945_309_316_Chemical) (NNP Doc_7176945_317_321_Disease)) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (QP (RB about) (CD 26)) (NN %))) (PP (IN among) (NP (DT the) (NNS in-patients))))))) (. .)))
7176945	4	(S1 (S (NP (NP (DT The) (NN abolition)) (PP (IN of) (NP (NNP Doc_7176945_389_410_Disease)))) (PRN (-LRB- -LRB-) (PP (IN by) (NP (NP (JJ 0.075mg/kg) (NN dose)) (PP (IN of) (NP (NNP Doc_7176945_434_444_Chemical))))) (-RRB- -RRB-)) (VP (AUX did) (RB not) (VP (VB influence) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NNP Doc_7176945_482_489_Chemical) (NNP Doc_7176945_490_494_Disease)))))) (. .)))
7176945	5	(S1 (S (NP (CC Neither) (NP (NP (DT the) (NN type)) (PP (IN of) (NP (NP (NN induction) (NN agent)) (PRN (-LRB- -LRB-) (NP (NNP Althesin) (CC or) (NNP Doc_7176945_545_556_Chemical)) (-RRB- -RRB-))))) (CC nor) (NP (NP (DT the) (NN salt) (NN preparation)) (PP (IN of) (NP (NP (NP (NNP Doc_7176945_586_599_Chemical)) (VP (VBN used))) (PRN (-LRB- -LRB-) (NP (NNP Doc_7176945_606_614_Chemical) (CC or) (NNP Doc_7176945_618_625_Chemical)) (-RRB- -RRB-)) (, ,))))) (VP (VBD affected) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_7176945_654_661_Chemical) (NNP Doc_7176945_662_666_Disease))))) (. .)))
7248895	0	(S1 (S (NP (NNP Invasive) (NNP Doc_7248895_9_38_Disease)) (VP (VBG following) (NP (NP (JJ Doc_7248895_49_65_Chemical) (NN therapy)) (PP (IN for) (NP (NN nonmalignant) (NN disease))))) (. .)))
7248895	1	(S1 (S (NP (NP (DT A) (JJ 47-year-old) (NN woman)) (PP (IN with) (NP (NP (JJ right) (NNS hydroureteronephrosis)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_7248895_160_195_Disease))))))) (VP (AUX had) (NP (JJ gross) (NN Doc_7248895_206_215_Disease)) (PP (IN after) (S (VP (AUXG being) (VP (VBN treated) (PP (IN for) (NP (CD five) (NNS years))) (PP (IN wtih) (NP (NP (NNP Doc_7248895_256_272_Chemical)) (PP (IN for) (NP (NNP Doc_7248895_277_296_Disease)))))))))) (. .)))
7248895	2	(S1 (S (NP (DT A) (JJ right) (NN nephroureterectomy)) (VP (AUX was) (VP (VBN required) (PP (IN for) (NP (NP (NN control)) (PP (IN of) (NP (NNP Doc_7248895_353_361_Disease))))))) (. .)))
7248895	3	(S1 (S (NP (DT The) (JJ pathology) (NNS specimen)) (VP (VBD contained) (NP (ADJP (RB clinically) (JJ occult)) (NN invasive) (NN Doc_7248895_423_452_Disease))) (. .)))
7248895	4	(S1 (S (SBAR (IN Although) (S (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NNP Doc_7248895_478_494_Chemical))) (S (VP (TO to) (VP (VB cause) (NP (NP (NN Doc_7248895_504_524_Disease) (CC and) (NN urine) (NN cytologic) (NNS abnormalities)) (ADJP (JJ indistinguishable) (PP (IN from) (NP (JJ high) (NN grade) (NN Doc_7248895_593_602_Disease))))))))) (VP (AUX is) (ADJP (RB well) (VBN known))))) (, ,) (NP (PRP it)) (VP (AUX is) (VP (ADVP (RBR less) (RB widely)) (VBN appreciated) (SBAR (IN that) (S (NP (PRP it)) (VP (AUX is) (ADVP (RB also)) (VP (VBN associated) (PP (IN with) (NP (NP (NNP Doc_7248895_680_689_Disease)) (PP (IN of) (NP (DT the) (JJ urinary) (NN tract))))))))))) (. .)))
7248895	5	(S1 (S (NP (NP (NP (NN Doc_7248895_712_729_Disease)) (PP (IN of) (NP (DT the) (JJ urinary) (NN bladder)))) (CC and) (NP (CD one) (NN Doc_7248895_761_786_Disease))) (VP (AUX have) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (PRP$ its) (NN use)))))))) (. .)))
7248895	6	(S1 (S (NP (DT The) (JJ present) (NN case)) (VP (AUX is) (NP (NP (DT the) (JJ first) (NN Doc_7248895_865_894_Disease)) (VP (VBN reported) (PP (IN in) (NP (NN association))) (PP (IN with) (NP (JJ Doc_7248895_924_940_Chemical) (NN treatment)))))) (. .)))
7248895	7	(S1 (S (NP (PRP It)) (VP (AUX is) (NP (NP (DT the) (JJ third) (NN Doc_7248895_968_988_Disease)) (VP (VBN reported) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (NP (JJ Doc_7248895_1018_1034_Chemical) (NN treatment)) (PP (IN for) (NP (NN nonmalignant) (NN disease)))))))))) (. .)))
7248895	8	(S1 (S (NP (NP (DT The) (NN association)) (PP (IN of) (NP (DT the) (NNP Doc_7248895_1094_1099_Disease))) (PP (IN with) (NP (JJ preexisting) (NNS hydroureteronephrosis)))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NNP Doc_7248895_1153_1159_Disease)) (VP (VBN prolonged) (CC and) (VBD intensified) (NP (NP (NN exposure)) (PP (IN of) (NP (JJ upper) (JJ urinary) (NN tract) (NN epithelium))) (PP (TO to) (NP (NNP Doc_7248895_1232_1248_Chemical)))))))) (. .)))
7248895	9	(S1 (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (AUX are) (NP (NP (NNS candidates)) (PP (IN for) (NP (JJ long-term) (JJ Doc_7248895_1292_1308_Chemical) (NN treatment)))))))) (VP (MD should) (VP (AUX be) (ADVP (RB routinely)) (VP (VBN evaluated) (NP (NNP Doc_7248895_1349_1373_Disease))))) (. .)))
7315949	0	(S1 (NP (NP (JJ Medial) (NNS changes)) (PP (IN in) (NP (NP (JJ arterial) (NN Doc_7315949_27_32_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_7315949_44_60_Chemical)))))) (. .)))
7315949	1	(S1 (S (PP (IN In) (NP (JJ normal) (NNS rats))) (, ,) (S (NP (NP (DT the) (NN media)) (PP (IN of) (NP (NP (JJ small) (NNS arteries)) (PRN (-LRB- -LRB-) (NP (NP (CD 0.4--0.2) (NNS mm)) (PP (IN in) (NP (NN diameter)))) (-RRB- -RRB-))))) (ADVP (RB previously)) (VP (AUX was) (VP (VBN shown) (S (VP (TO to) (VP (VB contain) (NP (JJ intracellular) (NNS vacuoles)))))))) (, ,) (VP (VBD identified) (ADVP (RB ultrastructurally)) (PP (IN as) (NP (NP (NNS herniations)) (PP (IN of) (NP (CD one) (JJ smooth) (NN muscle) (NN cell))))) (PP (IN into) (NP (DT another)))) (. .)))
7315949	2	(S1 (S (NP (NP (DT The) (NN hypothesis)) (SBAR (WHNP (WDT that)) (S (NP (JJ intense) (NN vasoconstriction)) (VP (MD would) (VP (VB increase) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (JJ such) (NNS vacuoles))))))))) (VP (AUX has) (VP (AUX been) (VP (VBN tested)))) (. .)))
7315949	3	(S1 (S (PP (IN In) (NP (NP (DT the) (NNS media)) (PP (IN of) (NP (NP (DT the) (JJ saphenous) (NN artery)) (CC and) (NP (PRP$ its) (JJ distal) (NN branch)))))) (, ,) (NP (NP (NN vasoconstriction)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_7315949_465_481_Chemical))))) (VP (VBD produced) (NP (JJ many) (NN cell-to-cell) (NNS hernias)) (PP (IN within) (NP (CD 15) (NNS minutes)))) (. .)))
7315949	4	(S1 (S (PP (IN At) (NP (CD 1) (NN day))) (NP (PRP$ their) (NN number)) (VP (AUX was) (VP (VBN reduced) (PP (TO to) (NP (NP (QP (RB about) (CD 1/10))) (PP (IN of) (NP (DT the) (JJ original) (NN number))))))) (. .)))
7315949	5	(S1 (S (PP (IN By) (NP (CD 7) (NN days))) (NP (DT the) (NN vessel)) (VP (AUX was) (ADVP (RB almost)) (VP (VBN restored) (PP (TO to) (ADJP (JJ normal))))) (. .)))
7315949	6	(S1 (S (NP (NP (JJ Triple) (NN stimulation)) (PP (IN over) (NP (CD 1) (NN day)))) (VP (VBN induced) (NP (JJR more) (JJ severe) (NNS changes)) (PP (IN in) (NP (DT the) (NNS media)))) (. .)))
7315949	7	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ smooth) (NN muscle) (NNS cells)) (VP (AUX are) (ADJP (JJ susceptible) (PP (TO to) (NP (NN damage)))) (PP (IN in) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (PRP$ their) (JJ specific) (NN function))))))))) (. .)))
7315949	8	(S1 (S (NP (DT The) (JJ experimental) (NNS data)) (VP (AUX are) (VP (VBN discussed) (PP (IN in) (NP (NP (NN relation)) (PP (TO to) (NP (NP (JJ medial) (NNS changes)) (VP (VBN observed) (PP (IN in) (NP (NP (JJ other) (NNS instances)) (PP (IN of) (NP (JJ arterial) (NNP Doc_7315949_954_959_Disease)))))))))))) (. .)))
7315949	9	(S1 (S (NP (NP (JJ Endothelial) (NNS changes)) (SBAR (WHNP (WDT that)) (S (VP (VBD developed) (PP (IN in) (NP (DT the) (JJ same) (JJ experimental) (NN model))))))) (VP (AUX were) (VP (VBN described) (PP (IN in) (NP (DT a) (JJ previous) (NN paper))))) (. .)))
733189	0	(S1 (NP (NP (NP (NP (NN Doc_733189_0_24_Disease)) (CC and) (NP (NN choriocapillaris) (NN occlusion))) (VP (VBG following) (NP (NP (DT the) (NN injection)) (PP (IN of) (NP (NP (JJ long-acting) (JJ corticosteroid) (NNS suspensions)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (NNS drugs)))))))))) (: :) (NP (NNP I.) (JJ Clinical) (NNS studies)) (. .)))
733189	1	(S1 (S (NP (NP (CD Two) (JJ well-documented) (NNS cases)) (PP (IN of) (NP (NP (JJ bilateral) (JJ retinal) (NN artery) (CC and) (NN choriocapillaris) (NNS occlusions)) (PP (IN with) (NP (NNP Doc_733189_267_276_Disease))))) (VP (VBG following) (NP (NN head) (CC and) (NN neck) (NN soft-tissue) (NN injection)) (PP (IN with) (NP (NNP Doc_733189_328_354_Chemical))) (PP (IN in) (NP (NN combination))) (PP (IN with) (NP (NP (NNP Doc_733189_375_384_Chemical)) (, ,) (NP (NNP Doc_733189_386_397_Chemical)) (, ,) (CC or) (NP (NNP Doc_733189_402_412_Chemical)))))) (VP (AUX are) (VP (VBN reported))) (. .)))
733189	2	(S1 (S (NP (CD One) (NN case)) (VP (AUX had) (ADVP (RB only)) (NP (DT a) (JJ unilateral) (NN injection))) (. .)))
733189	3	(S1 (S (NP (DT The) (JJ acute) (NNS observations)) (VP (VBD included) (NP (JJ hazy) (NN sensorium)) (, ,) (S (NP (JJ superior)) (VP (VBP gaze) (NP (NP (NNP palsy)) (, ,) (NP (NNP Doc_733189_538_561_Disease)) (, ,) (CC and) (NP (NNP Doc_733189_567_591_Disease))) (PP (IN with) (NP (NNP Doc_733189_597_602_Disease)))))) (. .)))
733189	4	(S1 (S (NP (JJ Follow-up) (NNS changes)) (VP (VBD showed) (NP (NP (JJ marked) (NN Doc_733189_636_647_Disease)) (, ,) (NP (JJ constricted) (JJ visual) (NNS fields)) (, ,) (NP (JJ optic) (NN nerve) (NN pallor)) (, ,) (NP (NN vascular) (NN attenuation)) (, ,) (CC and) (NP (NN Doc_733189_722_743_Disease)))) (. .)))
733189	5	(S1 (S (S (NP (DT The) (NN literature)) (VP (AUX is) (VP (VBN reviewed)))) (, ,) (CC and) (S (NP (JJ possible) (NNS causes)) (VP (AUX are) (VP (VBN discussed)))) (. .)))
7369302	0	(S1 (NP (NP (NP (NP (NNS Abnormalities)) (PP (IN of) (NP (DT the) (NN pupil)))) (CC and) (NP (JJ visual-evoked) (NN potential))) (PP (IN in) (NP (JJ quinine) (NNP Doc_7369302_66_75_Disease))) (. .)))
7369302	1	(S1 (S (NP (NP (NN Doc_7369302_77_92_Disease)) (PP (IN with) (NP (NP (DT a) (JJ transient) (NN tonic) (NN pupillary) (NN response)) (, ,) (NP (NN denervation) (NN supersensitivity)) (, ,) (CC and) (NP (JJ abnormal) (JJ visual-evoked) (NNS potentials))))) (VP (VBD developed) (PP (IN in) (NP (DT a) (JJ 54-year-old) (NN man))) (PP (IN after) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_7369302_252_267_Chemical))) (PP (IN for) (NP (NN leg) (NNS cramps)))))) (. .)))
7369302	2	(S1 (S (NP (PRP He)) (ADVP (RB later)) (VP (VBD recovered) (NP (JJ normal) (JJ visual) (NN acuity))) (. .)))
7369302	3	(S1 (S (NP (NP (DT A) (JJ transient) (NN tonic) (NN pupillary) (NN response)) (, ,) (NP (NN denervation) (NN supersensitivity)) (, ,) (CC and) (NP (NP (JJ abnormal) (JJ visual-evoked) (NNS potentials)) (PP (IN in) (NP (NNP Doc_7369302_434_441_Chemical) (NNP Doc_7369302_442_450_Disease)))) (, ,) (PP (TO to) (NP (PRP$ our) (NN knowledge))) (, ,)) (VP (AUX have) (RB not) (VP (AUX been) (ADVP (RB previously)) (VP (VBN reported)))) (. .)))
7378868	0	(S1 (NP (NP (NP (NP (JJ Doc_7378868_0_13_Chemical-induced) (NN Doc_7378868_22_35_Disease)) (CC and) (NP (NNP Doc_7378868_40_47_Disease))) (VP (VBN associated) (PP (IN with) (NP (JJ atypical) (NN cholinesterase))))) (: :) (NP (NN case) (NN report)) (. .)))
7378868	1	(S1 (S (NP (DT An) (JJ 11-year-old) (NN boy)) (VP (AUX was) (VP (VBN given) (NP (NP (NNP Doc_7378868_131_140_Chemical) (, ,) (NNP Doc_7378868_142_155_Chemical) (CC and) (NNP Doc_7378868_160_166_Chemical)) (, ,) (NP (NNP Doc_7378868_168_179_Chemical) (CD 0.4) (NN mg)) (CC and) (NP (NNP Doc_7378868_191_204_Chemical) (CD 100) (NN mg))) (PP (IN for) (NP (NP (NN induction)) (PP (IN of) (NP (NN anaesthesia))))))) (. .)))
7378868	2	(S1 (S (PP (IN In) (NP (NP (NN response)) (PP (TO to) (NP (DT this))))) (NP (DT a) (JJ marked) (NN Doc_7378868_271_284_Disease)) (VP (VBD occurred) (SBAR (SBAR (WHNP (WDT which)) (S (VP (VBD lasted) (PP (IN for) (NP (CD two) (NNS minutes)))))) (CC and) (SBAR (S (NP (DT the) (NNS anaesthesia)) (VP (AUX were) (VP (VBN terminated))))))) (. .)))
7378868	3	(S1 (S (S (NP (NP (CD Four) (NNS hours)) (PP (IN of) (NP (NN apnoea)))) (VP (VBD ensued))) (CC and) (S (NP (PRP he)) (VP (VBD suffered) (NP (NP (JJ generalized) (JJ severe) (NN Doc_7378868_423_430_Disease)) (VP (VBG lasting) (PP (IN for) (NP (CD one) (NN week))))))) (. .)))
7378868	4	(S1 (S (NP (PRP He)) (VP (AUX was) (VP (VBN found) (S (VP (TO to) (VP (AUX have) (NP (JJ atypical) (NN plasma) (NN cholinesterase)) (PP (IN with) (NP (NP (DT a) (JJ Doc_7378868_512_521_Chemical) (NN number)) (PP (IN of) (NP (CD 12)))))))) (, ,) (S (VP (VBG indicating) (NP (NN homozygocity)))))) (. .)))
7378868	5	(S1 (S (NP (DT This)) (VP (AUX was) (VP (VBN verified) (PP (IN by) (NP (NP (NN study)) (PP (IN of) (NP (DT the) (NN family))))))) (. .)))
7378868	6	(S1 (S (NP (DT The) (NN case)) (VP (VBZ shows) (SBAR (IN that) (S (NP (JJ prolonged) (NNP Doc_7378868_633_645_Disease) (CC and) (NNP Doc_7378868_650_657_Disease)) (VP (MD may) (VP (VB occur) (PP (IN after) (NP (NNP Doc_7378868_674_687_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ atypical) (NN cholinesterase))))) (PP (IN despite) (NP (NP (NN pretreatment)) (PP (IN with) (NP (NNP Doc_7378868_755_766_Chemical)))))))))) (. .)))
7411769	0	(S1 (NP (NP (JJ Doc_7411769_0_12_Chemical-induced) (NN Doc_7411769_21_33_Disease)) (PP (IN in) (NP (NP (CD three) (NNS patients)) (PP (IN with) (NP (JJ gouty) (NNP Doc_7411769_63_72_Disease))))) (. .)))
7411769	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (CD three) (NNS patients)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NP (JJ severe) (, ,) (JJ life-threatening) (NNP Doc_7411769_134_146_Disease)) (CC and) (NP (NNP Doc_7411769_151_170_Disease))) (VP (VBD developed) (PP (IN after) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_7411769_200_221_Disease)) (PP (IN with) (NP (NNP Doc_7411769_227_239_Chemical)))))))))))) (. .)))
7411769	2	(S1 (S (NP (DT This) (NN complication)) (VP (MD may) (VP (VB result) (PP (IN from) (NP (NP (DT an) (NN inhibition)) (PP (IN of) (NP (NP (JJ Doc_7411769_292_305_Chemical) (NN synthesis)) (CC and) (NP (JJ consequent) (NN Doc_7411769_331_362_Disease)))))))) (. .)))
7411769	3	(S1 (S (NP (NP (JJ Careful) (NN attention)) (PP (TO to) (NP (NP (JJ renal) (NN function)) (CC and) (NP (JJ Doc_7411769_404_413_Chemical) (NN balance)))) (PP (IN in) (NP (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_7411769_444_456_Chemical)))) (CC or) (NP (JJ other) (JJ nonsteroidal) (JJ anti-inflammatory) (NNS agents))))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (NP (DT those) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_7411769_541_558_Disease)) (CC or) (NP (JJ preexisting) (NNP Doc_7411769_574_587_Disease)))))) (, ,) (VP (MD will) (VP (VB help) (S (VP (VB prevent) (NP (DT this) (ADJP (RB potentially) (JJ serious)) (NN complication)))))) (. .)))
7457821	0	(S1 (NP (NP (NN Doc_7457821_0_9_Chemical)) (: :) (NP (DT a) (JJ foreshortened) (JJ clinical) (NN trial)) (. .)))
7457821	1	(S1 (S (NP (NP (DT A) (JJ clinical) (NN evaluation)) (PP (IN of) (NP (NNP Doc_7457821_68_77_Chemical))) (PP (IN for) (NP (NN outpatient) (NNS cystoscopy)))) (VP (AUX was) (VP (VBN embarked) (PP (IN upon)))) (. .)))
7457821	2	(S1 (S (NP (JJ Unpremedicated) (NNS patients)) (VP (AUX were) (VP (VBN given) (NP (NNP Doc_7457821_158_166_Chemical) (CD 1)) (SBAR (IN microgram/kg) (S (VP (VBN followed) (PP (IN by) (NP (NNP Doc_7457821_194_203_Chemical))) (NP (CD 0.3) (NN mg/kg))))))) (. .)))
7457821	3	(S1 (S (NP (NN Anaesthesia)) (VP (AUX was) (VP (VBN maintained) (PP (IN with) (NP (NP (JJ intermittent) (NN Doc_7457821_260_269_Chemical)) (PP (IN in) (NP (JJ 2-4) (NN mg) (NNS doses))))))) (. .)))
7457821	4	(S1 (S (NP (NNS Patients)) (VP (VP (AUX were) (VP (VBN interviewed) (ADVP (RB personally)) (PP (RB later) (NP (DT the) (JJ same) (NN day))))) (, ,) (CC and) (VP (PP (IN by) (NP (NN questionnaire))) (ADVP (NP (QP (CD three) (TO to) (CD four)) (NNS weeks)) (RBR later)))) (. .)))
7457821	5	(S1 (S (NP (DT The) (NN trial)) (VP (AUX was) (VP (VBN discontinued) (PP (IN after) (NP (CD 20) (NNS cases))) (PP (IN because) (IN of) (NP (NP (DT an) (JJ unacceptable) (NN incidence)) (PP (IN of) (NP (NN side) (NNS effects))))))) (. .)))
7457821	6	(S1 (S (NP (NN Doc_7457821_488_499_Disease)) (VP (VBD occurred) (PP (IN in) (NP (NP (NP (NP (NP (CD 68) (NN %)) (PP (IN of) (NP (NNS patients)))) (CC and) (NP (CD 50) (NN %))) (AUX had) (NN redness)) (, ,) (NP (NNP Doc_7457821_549_553_Disease)) (CC or) (NP (NP (VBG swelling)) (VP (VBN related) (PP (TO to) (NP (DT the) (NN injection) (NN site))))))) (, ,) (PP (IN in) (NP (NP (DT some) (NNS cases)) (VP (VBG lasting) (NP (QP (IN up) (TO to) (CD three)) (NNS weeks)) (PP (IN after) (NP (NN anaesthesia))))))) (. .)))
7457821	7	(S1 (S (NP (NN Doc_7457821_656_674_Disease)) (VP (VBD occurred) (PP (IN in) (NP (NP (NP (NP (NP (CD 50) (NN %)) (PP (IN of) (NP (NNS patients)))) (: ;) (NP (CD 30) (NN %))) (JJ experienced) (NN respiratory) (NN upset)) (, ,) (NP (NP (NN one)) (ADJP (RB sufficiently) (JJ severe) (S (VP (TO to) (VP (VB necessitate) (S (VP (VBG abandoning) (NP (DT the) (NN technique)))))))))))) (. .)))
7457821	8	(S1 (S (NP (NP (NNP Doc_7457821_804_810_Disease)) (CC and) (NP (NNP Doc_7457821_815_823_Disease))) (VP (VBD occurred) (PP (IN in) (S (NP (NP (CD 40) (NN %)) (CC and) (NP (CD 25) (NN %))) (AUX had) (VP (VBG disturbing) (NP (NN emergence) (NN Doc_7457821_873_882_Disease)))))) (. .)))
7477981	0	(S1 (S (NP (JJ Doc_7477981_0_8_Chemical-induced) (NNP Doc_7477981_17_28_Disease)) (VP (AUX are) (VP (VBN improved) (PP (IN by) (NP (NNP Doc_7477981_45_55_Chemical))))) (. .)))
7477981	1	(S1 (S (NP (PRP We)) (VP (VBN evaluated) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NNP Doc_7477981_86_102_Disease) (CC and) (NNP Doc_7477981_107_118_Disease))) (PP (IN in) (NP (NP (CD seven) (JJ Doc_7477981_128_136_Chemical-responsive) (NNS patients)) (PP (IN with) (NP (NNP Doc_7477981_162_181_Disease)))))) (PP (IN after) (NP (NP (NP (DT an) (JJ acute) (NN challenge)) (PP (IN with) (NP (DT the) (JJ mixed) (NNP Doc_7477981_222_230_Chemical) (NN agonist)))) (, ,) (NP (NNP Doc_7477981_240_251_Chemical)) (, ,))) (PP (IN before) (CC and) (IN after) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NNP Doc_7477981_292_302_Chemical))))) (PRN (-LRB- -LRB-) (NP (NP (CD 20) (NNS mg)) (PP (RB twice) (IN per) (NP (NN day)))) (-RRB- -RRB-)) (PP (IN for) (NP (CD 11) (JJ +/-) (CD 1) (NNS days)))) (. .)))
7477981	2	(S1 (S (PP (IN After) (NP (JJ Doc_7477981_350_360_Chemical) (NN treatment))) (, ,) (NP (EX there)) (VP (AUX was) (NP (NP (DT a) (JJ significant) (ADJP (CD 47) (NN %)) (NN improvement)) (PRN (-LRB- -LRB-) (NP (QP ($ p) (CD <) (CD 0.05))) (-RRB- -RRB-)) (PP (IN of) (NP (NNP Doc_7477981_426_437_Chemical-induced) (NNP Doc_7477981_446_457_Disease)))) (PP (IN without) (NP (NP (NN modification)) (PP (IN of) (NP (NNP Doc_7477981_482_494_Disease) (NNP Doc_7477981_495_511_Disease)))))) (. .)))
7477981	3	(S1 (S (NP (DT The) (NNP Doc_7477981_517_528_Disease)) (VP (AUX were) (VP (VBN reduced) (ADVP (RB predominantly)) (PP (IN in) (NP (DT the) (JJR lower) (NNS limbs))) (PP (PP (IN during) (NP (NP (DT the) (NN onset) (CC and) (NN disappearance)) (PP (IN of) (NP (NP (NNP Doc_7477981_613_633_Disease)) (PRN (-LRB- -LRB-) (NP (ADJP (JJ onset-) (CC and) (JJ end-of-dose)) (NNP Doc_7477981_658_669_Disease)) (-RRB- -RRB-)))))) (CC and) (PP (IN in) (NP (DT the) (JJ upper) (NNS limbs)))) (PP (IN during) (NP (JJ choreic) (JJ mid-dose) (NN Doc_7477981_718_729_Disease))))) (. .)))
7477981	4	(S1 (S (NP (DT The) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (VBN increased) (NN brain) (NN serotoninergic) (NN transmission)) (PP (IN with) (NP (NNP Doc_7477981_805_815_Chemical)))) (VP (MD may) (VP (VB reduce) (NP (NP (NN Doc_7477981_827_835_Chemical-)) (CC or) (NP (JJ Doc_7477981_840_848_Chemical) (JJ agonist-induced) (NN Doc_7477981_865_876_Disease))) (PP (IN without) (S (VP (VBG aggravating) (NP (NNP Doc_7477981_897_909_Disease) (NNP Doc_7477981_910_926_Disease)))))))))) (. .)))
7479194	0	(S1 (FRAG (NP (NP (DT A) (JJ large) (JJ population-based) (NN follow-up) (NN study)) (PP (IN of) (NP (NP (NNP Doc_7479194_44_73_Chemical)) (, ,) (NP (NNP Doc_7479194_75_87_Chemical)) (, ,) (CC and) (NP (NNP Doc_7479194_93_103_Chemical)))) (PP (IN for) (NP (JJ uncommon) (JJ serious) (NN Doc_7479194_125_138_Disease)))) (. .)))
7479194	1	(S1 (S (NP (PRP We)) (VP (VBD conducted) (NP (NP (DT a) (JJ population-based) (JJ 45-day) (JJ follow-up) (NN study)) (PP (IN of) (NP (NP (CD 232,390) (NNS people)) (SBAR (WHNP (WP who)) (S (VP (AUX were) (VP (VBN prescribed) (NP (NP (NP (NNP Doc_7479194_233_262_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7479194_264_267_Chemical-SMZ)) (-RRB- -RRB-))) (, ,) (NP (NP (CD 266,951) (JJ prescribed) (NNP Doc_7479194_293_305_Chemical)) (ADVP (RB alone))) (, ,) (CC and) (NP (CD 196,397) (JJ prescribed) (NNP Doc_7479194_336_346_Chemical)) (, ,)) (S (VP (TO to) (VP (VB estimate) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ serious) (NN liver) (, ,) (NN blood) (, ,) (NN skin) (, ,) (CC and) (NNP Doc_7479194_404_419_Disease))) (VP (VBG resulting) (PP (IN in) (NP (NP (NN referral) (CC or) (NN hospitalization)) (VP (VBN associated) (PP (IN with) (NP (DT these) (NNS drugs))))))))))))))))))) (. .)))
7479194	2	(S1 (S (NP (DT The) (NNS results)) (VP (AUX were) (VP (VBN based) (PP (IN on) (NP (NP (NN information)) (VP (VBN recorded) (PP (IN on) (NP (NN office) (NNS computers))) (PP (IN by) (NP (VBN selected) (JJ general) (NNS practitioners))) (PP (IN in) (NP (DT the) (NNP United) (NNP Kingdom))) (, ,) (ADVP (RB together)) (PP (IN with) (NP (NP (DT a) (NN review)) (PP (IN of) (NP (JJ clinical) (NNS records)))))))))) (. .)))
7479194	3	(S1 (S (NP (NP (DT The) (NN risk)) (PP (IN of) (NP (ADJP (RB clinically) (JJ important)) (NN Doc_7479194_691_715_Disease)))) (VP (AUX was) (ADJP (JJ similar) (PP (IN for) (NP (NP (NNS persons)) (VP (VBN prescribed) (NP (NP (NP (NNP Doc_7479194_751_754_Chemical-SMZ)) (PRN (-LRB- -LRB-) (NP (CD 5.2/100,000)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (DT those) (JJ prescribed) (NNP Doc_7479194_794_806_Chemical)) (ADVP (RB alone))) (PRN (-LRB- -LRB-) (NP (CD 3.8/100,000)) (-RRB- -RRB-))))))))) (. .)))
7479194	4	(S1 (S (NP (NP (DT The) (NN risk)) (PP (IN for) (NP (NP (DT those)) (VP (VBN prescribed) (NP (NNP Doc_7479194_858_868_Chemical)))))) (VP (AUX was) (ADJP (ADJP (RB somewhat) (JJR lower)) (PRN (-LRB- -LRB-) (NP (CD 2.0/100,000)) (-RRB- -RRB-)))) (. .)))
7479194	5	(S1 (S (S (NP (QP (RB Only) (CD five)) (NNS patients)) (VP (VBD experienced) (NP (NP (NNP Doc_7479194_934_949_Disease)) (, ,) (SBAR (WHNP (CD one) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (AUX was) (VP (VBN exposed) (PP (TO to) (NP (NNP Doc_7479194_978_981_Chemical-SMZ)))))))))) (: ;) (S (PP (IN of) (NP (NP (CD seven)) (PP (IN with) (NP (NP (NNP Doc_7479194_1001_1020_Disease)) (CC and) (NP (NNP Doc_7479194_1025_1049_Disease)))))) (, ,) (NP (CD four)) (VP (AUX were) (VP (VBN exposed) (PP (TO to) (NP (NNP Doc_7479194_1072_1075_Chemical-SMZ)))))) (. .)))
7479194	6	(S1 (S (NP (NP (DT The) (CD one) (NN case)) (PP (IN of) (NP (NNP Doc_7479194_1097_1123_Disease)))) (VP (VBD occurred) (PP (IN in) (NP (NP (DT a) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD took) (NP (NN Doc_7479194_1155_1165_Chemical)))))))) (. .)))
7479194	7	(S1 (S (ADVP (RB Finally)) (, ,) (NP (NP (QP (RB only) (CD five)) (NNS cases)) (PP (IN of) (NP (JJ acute) (JJ parenchymal) (NN Doc_7479194_1213_1226_Disease)))) (VP (VBD occurred) (, ,) (S (NP (NN none)) (ADJP (JJ likely) (S (VP (TO to) (VP (AUX be) (VP (VBN caused) (PP (IN by) (NP (DT a) (NN study) (NN drug)))))))))) (. .)))
7479194	8	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (DT the) (JJ serious) (NNS diseases)) (VP (VBN studied))))) (VP (VP (AUX is) (ADJP (JJ small) (PP (IN for) (NP (DT the) (CD three) (NNS agents))))) (, ,) (CC and) (VP (VBZ compares) (ADVP (RB reasonably)) (PP (IN with) (NP (NP (DT the) (NN risk)) (PP (IN for) (NP (JJ many) (JJ other) (NNS antibiotics)))))))))) (. .)))
7492040	0	(S1 (NP (NP (JJ Clinical) (NN safety)) (PP (IN of) (NP (NNP Doc_7492040_19_28_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_7492040_46_53_Chemical-associated) (NNP Doc_7492040_65_86_Disease))))) (. .)))
7492040	1	(S1 (NP (NN STUDY) (NN OBJECTIVE) (: :) (S (VP (TO To) (VP (VB evaluate) (NP (NP (DT the) (NN safety)) (PP (IN of) (NP (NNP Doc_7492040_131_140_Chemical)))) (PP (IN in) (NP (NP (DT the) (NN setting)) (PP (IN of) (NP (NP (JJ Doc_7492040_159_166_Chemical-induced) (NNP Doc_7492040_175_196_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7492040_198_200_Disease)) (-RRB- -RRB-))))))))) (. .)))
7492040	2	(S1 (NP (NP (DT A) (NN retrospective)) (, ,) (NP (NN multicenter) (NN study)) (. .)))
7492040	3	(S1 (NP (NP (JJ Twenty-nine) (NN university)) (, ,) (NP (NN university-affiliated)) (, ,) (CC or) (NP (NP (NN community) (NNS hospitals)) (PP (IN during) (NP (NP (DT a) (JJ 6-year) (NN period)) (PRN (-LRB- -LRB-) (NP (NP (JJ total)) (PP (IN of) (NP (CD 117) (JJ cumulative) (NNS hospital-years)))) (-RRB- -RRB-))))) (. .)))
7492040	4	(S1 (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (NNP Doc_7492040_419_426_Chemical-associated) (NNP Doc_7492040_438_440_Disease)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NNP Doc_7492040_454_463_Chemical)) (PP (IN in) (NP (DT the) (NN emergency) (NN department)))))))) (. .)))
7492040	5	(S1 (S (PP (IN Of) (NP (NP (CD 29) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NNP Doc_7492040_530_539_Chemical)) (PP (IN in) (NP (NP (DT the) (NN setting)) (PP (IN of) (NP (NNP Doc_7492040_558_565_Chemical-associated) (NNP Doc_7492040_577_579_Disease)))))))))) (, ,) (NP (DT no) (NN patient)) (VP (VP (VBD died)) (: ;) (VP (VBD exhibited) (NP (NP (NNS bradydysrhythmias)) (, ,) (NP (NP (NNP Doc_7492040_627_650_Disease)) (, ,) (CC or) (NP (NNP Doc_7492040_655_679_Disease))))) (: ;) (CC or) (VP (VBD experienced) (NP (NNP Doc_7492040_696_704_Disease)) (PP (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_7492040_729_738_Chemical))))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 95) (NN %)) (NN confidence) (NN interval)) (, ,) (NP (QP (CD 0) (NN %) (TO to) (CD 11) (NN %)))) (-RRB- -RRB-)))) (. .)))
7492040	6	(S1 (S (PP (IN Despite) (NP (NP (JJ theoretical) (NNS concerns)) (SBAR (WHNP (IN that)) (S (NP (NNP Doc_7492040_823_832_Chemical)) (VP (MD may) (VP (VB enhance) (NP (JJ Doc_7492040_845_852_Chemical) (NN toxicity)))))))) (, ,) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_7492040_874_883_Chemical))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_7492040_901_908_Chemical-associated) (NNP Doc_7492040_920_922_Disease)))))) (VP (AUX was) (RB not) (VP (VBN associated) (PP (IN with) (NP (JJ significant) (NN Doc_7492040_959_1008_Disease))))) (. .)))
753803	0	(S1 (NP (NP (NP (JJ Experimental) (JJ progressive) (NN Doc_753803_25_43_Disease)) (CC and) (NP (PRP$ its) (NN treatment))) (PP (IN with) (NP (NP (JJ high) (NNS doses)) (VP (VBG anabolizing) (NP (NNS agents))))) (. .)))
753803	1	(S1 (S (NP (PRP We)) (VP (AUX are) (ADVP (RB still)) (NP (NP (DT a) (JJ long) (NN way)) (PP (IN from) (S (VP (VBG discovering) (NP (NP (DT an) (JJ unequivocal) (NN pathogenetic) (NN interpretation)) (PP (IN of) (NP (NP (JJ progressive) (NNP Doc_753803_197_215_Disease)) (PP (IN in) (NP (NN man))))))))))) (. .)))
753803	2	(S1 (S (S (NP (JJ Noteworthy) (NNS efforts)) (VP (AUX have) (VP (AUX been) (VP (VBN made) (PP (IN in) (NP (DT the) (JJ experimental) (NN field))))))) (: ;) (S (NP (NP (DT a) (JJ recessive) (NN autosomic) (NN form)) (VP (VBN found) (PP (IN in) (NP (DT the) (NN mouse))))) (VP (VBZ seems) (S (VP (TO to) (VP (VB bear) (NP (NP (DT the) (JJS closest) (NN resemblance)) (PP (TO to) (NP (DT the) (JJ human) (NN form)))) (PP (IN from) (NP (NP (DT the) (JJ genetic) (NN point)) (PP (IN of) (NP (NN view)))))))))) (. .)))
753803	3	(S1 (S (NP (NP (NN Doc_753803_419_427_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NP (NN lack)) (PP (IN of) (NP (NNP Doc_753803_443_452_Chemical) (CC and) (NNP Doc_753803_457_465_Disease))) (VP (VBN induced) (PP (IN by) (NP (JJ certain) (NNS viruses)))))))) (VP (AUX have) (RB much) (PP (IN in) (NP (NN common))) (ADVP (RB anatomically) (CC and) (RB pathologically)) (PP (IN with) (NP (DT the) (JJ human) (NN form)))) (. .)))
753803	4	(S1 (S (NP (DT The) (NNS authors)) (VP (VBN induced) (NP (NNP Doc_753803_586_598_Disease)) (PP (IN in) (NP (DT the) (NN rat))) (PP (IN by) (S (VP (VBG giving) (NP (PRP it)) (NP (NP (DT a) (NN diet)) (VP (VBG lacking) (PP (IN in) (NP (NNP Doc_753803_641_650_Chemical))))))))) (. .)))
753803	5	(S1 (S (NP (NP (NP (DT The) (JJ pharmacological) (NNS characteristics)) (PP (IN of) (NP (NNP Doc_753803_691_700_Chemical)))) (CC and) (NP (NP (DT the) (JJ degenerative) (NNS changes)) (VP (VBN brought) (PRT (RP about)) (PP (IN by) (NP (PRP$ its) (NN deficiency)))))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (DT the) (NNS muscles))) (, ,) (VP (AUX are) (VP (VBN illustrated))) (. .)))
753803	6	(S1 (S (NP (PRP It)) (VP (AUX is) (ADVP (RB thus)) (VP (VBN confirmed) (SBAR (IN that) (S (NP (NP (DT the) (JJ histological) (NNS characteristics)) (PP (IN of) (NP (NNP Doc_753803_869_878_Disease) (NN rat) (NN muscle))) (VP (VBN induced) (ADVP (RB experimentally)))) (VP (AUX are) (ADJP (RB extraordinarily) (JJ similar) (PP (TO to) (NP (NP (DT those)) (PP (IN of) (NP (JJ human) (NNP Doc_753803_959_967_Disease)))))) (SBAR (IN as) (S (VP (VBN confirmed) (PP (IN during) (NP (NP (NNS biopsies)) (VP (VBN performed) (PP (IN at) (NP (NP (DT the) (NNP Orthopaedic) (NNP Traumatological) (NNP Centre)) (, ,) (NP (NNP Florence))))))))))))))) (. .)))
753803	7	(S1 (S (NP (NP (DT The) (JJ encouraging) (NNS results)) (VP (VBN obtained) (PP (IN in) (NP (NP (JJ various) (JJ authoratative) (NNS departments)) (PP (IN in) (NP (NNP Doc_753803_1133_1142_Disease) (NNS patients))))) (PP (IN by) (S (VP (VBG using) (NP (JJ anabolizing) (NNP Doc_753803_1173_1181_Chemical))))))) (VP (AUX have) (VP (VBN encouraged) (S (NP (DT the) (NNS authors)) (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (JJ beneficial) (NNS effects)) (PP (IN of) (NP (NP (CD one) (JJ anabolizing) (NN agent)) (PRN (-LRB- -LRB-) (NP (NNP Doc_753803_1274_1282_Chemical)) (, ,) (NP (NNP Doc_753803_1284_1288_Chemical)) (-RRB- -RRB-)))) (PP (IN at) (NP (NP (JJ high) (NNS doses)) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN rendered) (NP (NNP Doc_753803_1321_1330_Disease)) (PP (IN by) (NP (NP (DT a) (NN diet) (NN deficient)) (PP (IN in) (NP (NNP Doc_753803_1354_1363_Chemical)))))))))))))))) (. .)))
753803	8	(S1 (S (S (PP (IN In) (NP (DT this) (NN way))) (NP (PRP they)) (VP (VBD obtained) (NP (JJ appreciable) (NNS changes)) (PP (IN in) (NP (NP (NN body) (NN weight)) (PRN (-LRB- -LRB-) (VP (VBN increased) (PP (IN from) (NP (QP (CD 50) (TO to) (CD 70)) (NNP g))) (PP (IN after) (NP (NP (CD forty) (NNS days)) (PP (IN at) (NP (NP (DT a) (NN dose)) (PP (IN of) (NP (CD 5) (NN mg))))) (PP (IN per) (NP (NP (NN day)) (PP (IN of) (NP (JJ anabolizing) (NN agent)))))))) (-RRB- -RRB-)))))) (, ,) (CC but) (S (NP (NP (JJS most)) (PP (IN of) (NP (NP (DT all)) (SBAR (S (NP (PRP they)) (VP (VBD found) (NP (NP (JJ histological) (NNS changes)) (ADJP (JJ due) (PP (TO to) (NP (NP (`` ``) (JJ regenerative) ('' '') (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN muscle) (NN tissue)) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB however)) (VP (VBD maintained) (NP (PRP$ its) (NNP Doc_753803_1648_1657_Disease) (NNS characteristics)) (PP (IN in) (NP (NP (DT the) (NN control) (NNS animals)) (SBAR (WHNP (WDT that)) (S (VP (AUX were) (RB not) (VP (VBN treated) (PP (IN with) (NP (DT the) (JJ anabolizing) (NN agent))))))))))))))))))))))))) (. .)))
753803	9	(S1 (S (S (NP (DT The) (NNS authors)) (VP (VBP conclude) (PP (IN by) (S (VP (VBG affirming) (NP (NP (DT the) (JJ undoubted) (NN efficacy)) (PP (IN of) (NP (DT the) (VBG anabolizing) (NNP Doc_753803_1823_1831_Chemical)))) (PP (IN in) (NP (JJ experimental) (NNP Doc_753803_1848_1865_Disease)))))))) (, ,) (CC but) (S (NP (PRP they)) (VP (AUX have) (NP (NNS reservations)) (SBAR (PP (IN as) (PP (TO to) (NP (NP (DT the) (NN transfer)) (PP (IN of) (NP (NP (DT the) (NNS results)) (PP (IN into) (NP (DT the) (JJ human) (NN field))))) (, ,) (SBAR (SBAR (WHADVP (WRB where)) (S (NP (JJ high) (NN dosage) (NN cannot)) (VP (AUX be) (VP (VBN carried) (PRT (RP out)) (ADVP (RB continuously)) (PP (IN because) (IN of) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (DT the) (NN drug))) (PP (IN on) (NP (NN virility))))) (: ;) (SBAR (IN because) (S (NP (DT the) (NNP Doc_753803_2063_2076_Disease)) (ADVP (RB too) (RB often)) (VP (VBZ occurs) (PP (IN at) (NP (DT an) (JJ irreversible) (NN stage) (NN vis-a-vis))) (NP (NP (DT the) (`` ``) (NN regeneration) ('' '')) (PP (IN of) (NP (DT the) (NN muscle) (NN tissue))))))))))) (: ;) (CC and) (RB finally))))) (IN because) (S (NP (DT the) (NNP Doc_753803_2194_2214_Disease) (NN agent)) (VP (AUX is) (ADVP (RB certainly)) (RB not) (NP (NP (DT the) (NN lack)) (PP (IN of) (NP (NP (NNP Doc_753803_2250_2259_Chemical)) (CC but) (NP (NP (NN something)) (PP (IN as) (ADJP (RB yet) (JJ unknown)))))))))))) (. .)))
7644931	0	(S1 (S (NP (NP (JJ Doc_7644931_0_10_Chemical) (JJ 3-hour) (NN infusion)) (VP (VP (VBN given) (ADVP (RB alone))) (CC and) (VP (VBN combined) (PP (IN with) (NP (NNP Doc_7644931_57_68_Chemical)))))) (: :) (NP (NP (JJ preliminary) (NNS results)) (PP (IN of) (NP (JJ dose-escalation) (NNS trials)))) (. .)))
7644931	1	(S1 (S (NP (NP (NN Doc_7644931_117_127_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_7644931_129_134_Chemical)) (: ;) (NP (NP (NNP Bristol-Myers) (NNP Squibb) (NNP Company)) (, ,) (NP (NNP Princeton)))) (, ,) (NP (NNP NJ)) (-RRB- -RRB-)) (PP (IN by) (NP (JJ 3-hour) (NN infusion)))) (VP (AUX was) (VP (VBN combined) (PP (IN with) (NP (NNP Doc_7644931_218_229_Chemical))) (PP (IN in) (NP (NP (DT a) (NN phase) (NNP I/II) (NN study)) (VP (VBN directed) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_7644931_278_304_Disease)))))))))) (. .)))
7644931	2	(S1 (S (NP (NN Doc_7644931_306_317_Chemical)) (VP (AUX was) (VP (VBN given) (PP (IN at) (NP (DT a) (VBN fixed) (NN target) (NN area))) (PP (IN under) (NP (NP (DT the) (JJ concentration-time) (NN curve)) (PP (IN of) (NP (CD 6.0))))) (PP (IN by) (NP (DT the) (NNP Calvert) (NN formula))) (, ,) (SBAR (IN whereas) (S (NP (NNP Doc_7644931_425_435_Chemical)) (VP (AUX was) (VP (VBN escalated) (PP (IN in) (NP (NP (JJ patient) (NNS cohorts)) (PP (PP (IN from) (NP (NP (CD 150) (NNS mg/m2)) (PRN (-LRB- -LRB-) (NN dose) (NN level) (NN I) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (CD 175)) (, ,) (NP (CD 200)) (, ,) (NP (CD 225)) (, ,) (CC and) (NP (QP (CD 250) (CD mg/m2)))))))))))))) (. .)))
7644931	3	(S1 (S (NP (DT The) (ADJP (CD 225) (NN mg/m2)) (NN level)) (VP (AUX was) (VP (VBN expanded) (PP (IN for) (NP (NP (DT the) (NN phase) (NNP II) (NN study)) (PP (IN since) (NP (NP (DT the) (JJS highest) (NN level)) (VP (VP (VBN achieved)) (PRN (-LRB- -LRB-) (NP (CD 250) (NNS mg/m2)) (-RRB- -RRB-))))) (VP (VBN required) (NP (NN modification)) (PP (IN because) (IN of) (NP (NP (JJ nonhematologic) (NNP Doc_7644931_681_691_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_7644931_693_703_Disease) (CC and) (NNP Doc_7644931_708_726_Disease)) (-RRB- -RRB-))))))))) (. .)))
7644931	4	(S1 (S (NP (JJ Therapeutic) (NNS effects)) (VP (AUX were) (VP (VBN noted) (PP (IN at) (NP (DT all) (NN dose) (NNS levels))) (, ,) (PP (IN with) (NP (NP (JJ objective) (NNS responses)) (PP (IN in) (NP (NP (NP (CD 17)) (PRN (-LRB- -LRB-) (NP (CD two) (JJ complete) (CC and) (CD 15) (JJ partial) (NNS regressions)) (-RRB- -RRB-))) (PP (IN of) (NP (CD 41) (ADJP (RB previously) (JJ untreated)) (NNS patients))))))))) (. .)))
7644931	5	(S1 (S (NP (NNP Doc_7644931_890_900_Disease)) (VP (AUX were) (PP (VBN compared) (PP (IN with) (NP (NP (DT a) (NN cohort)) (PP (IN of) (NP (NNS patients))) (PP (IN in) (NP (NP (DT a) (NN phase) (NN I) (NN trial)) (PP (IN of) (NP (NP (NNP Doc_7644931_963_973_Chemical)) (ADVP (RB alone)))) (PP (IN at) (NP (JJ identical) (NN dose) (NNS levels))))))))) (. .)))
7644931	6	(S1 (S (S (NP (NN Doc_7644931_1006_1017_Chemical)) (VP (AUX did) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB add) (PP (TO to) (NP (NP (DT the)) (SBAR (S (NP (NNP Doc_7644931_1047_1069_Disease)) (VP (VBD observed)))))))))))) (, ,) (CC and) (S (NP (DT the) (NNP Doc_7644931_1088_1098_Chemical/Doc_7644931_1099_1110_Chemical) (NN combination)) (VP (MD could) (VP (AUX be) (VP (VBN dosed) (NP (DT every) (CD 3) (NNS weeks)))))) (. .)))
7661171	0	(S1 (NP (NP (DT The) (JJ dose-dependent) (NN effect)) (PP (IN of) (NP (NNP Doc_7661171_29_40_Chemical))) (PP (IN on) (NP (NP (NNP Doc_7661171_44_56_Chemical-induced) (NNP Doc_7661171_65_82_Disease)) (PP (IN in) (NP (ADJP (RB well) (VBN compensated)) (NNP Doc_7661171_103_112_Disease))))) (. .)))
7661171	1	(S1 (S (NP (NP (NN Doc_7661171_114_125_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 200) (NNS micrograms)) (-RRB- -RRB-))) (VP (AUX has) (VP (AUX been) (VP (VBN shown) (S (VP (TO to) (ADVP (RB acutely)) (VP (VB counteract) (NP (NP (DT the) (JJ Doc_7661171_184_196_Chemical-induced) (NN Doc_7661171_205_222_Disease)) (PP (IN in) (NP (ADJP (RB well) (VBN compensated)) (JJ cirrhotic) (NNS patients)))))))))) (. .)))
7661171	2	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (NP (DT the) (JJ prophylactic) (NN value)) (PP (IN of) (NP (NNP Doc_7661171_331_342_Chemical)))) (VP (AUX was) (NP (NN dose-dependent))))))))) (. .)))
7661171	3	(S1 (S (NP (NP (NNS Parameters)) (PP (IN of) (NP (NP (JJ renal) (NNS hemodynamics)) (CC and) (NP (JJ tubular) (JJ Doc_7661171_408_414_Chemical) (CC and) (NN water) (NN handling))))) (VP (AUX were) (VP (VBN assessed) (PP (IN by) (NP (NN clearance) (NNS techniques))) (PP (IN in) (NP (CD 26) (ADJP (RB well) (VBN compensated)) (JJ cirrhotic) (NNS patients))) (PP (IN before) (CC and) (IN after) (NP (NP (DT an) (JJ oral) (NN combination)) (PP (IN of) (NP (NP (NP (CD 50) (NN mg)) (PP (IN of) (NP (NNP Doc_7661171_563_575_Chemical)))) (CC and) (NP (NP (JJ various) (NNS doses)) (PP (IN of) (NP (NNP Doc_7661171_597_608_Chemical)))))))))) (. .)))
7661171	4	(S1 (S (NP (DT The) (JJ 200-micrograms) (NN dose)) (VP (AUX was) (ADJP (JJ able) (S (VP (TO to) (ADVP (RB totally)) (VP (VB abolish) (NP (NP (DT the) (JJ deleterious) (JJ renal) (NNS effects)) (PP (IN of) (NP (NNP Doc_7661171_695_707_Chemical)))))))) (, ,) (SBAR (IN whereas) (S (NP (DT the) (JJ 800-micrograms) (NN dose)) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ significant) (VBG worsening)) (PP (IN of) (NP (NP (JJ renal) (NN hemodynamics)) (CC and) (NP (JJ Doc_7661171_801_807_Chemical) (NN retention)))))))))) (. .)))
7661171	5	(S1 (S (NP (DT These) (NNS changes)) (VP (VP (AUX were) (ADJP (JJ maximal) (PP (IN in) (NP (DT the) (NN hour)))) (PP (ADVP (RB immediately)) (IN after) (NP (NNS medications)))) (CC and) (VP (ADVP (RB slowly)) (VBN returned) (PP (IN toward) (NP (JJ base-line) (NNS levels))) (ADVP (RB thereafter)))) (. .)))
7661171	6	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (JJ renal) (JJ protective) (NNS effects)) (PP (IN of) (NP (NNP Doc_7661171_1003_1014_Chemical)))) (VP (AUX is) (ADJP (JJ dose-dependent)))))) (. .)))
7661171	7	(S1 (S (ADVP (RB However)) (, ,) (SBAR (IN until) (S (NP (NP (DT this) (JJ apparent) (NN ability)) (PP (IN of) (NP (NP (CD 200) (NNS micrograms)) (PP (IN of) (NP (NNP Doc_7661171_1092_1103_Chemical))))) (S (VP (TO to) (VP (VB prevent) (NP (NP (DT the) (JJ adverse) (NNS effects)) (PP (IN of) (NP (NNP Doc_7661171_1138_1150_Chemical))) (PP (IN on) (NP (JJ renal) (NN function)))))))) (VP (AUX is) (VP (VBN confirmed) (PP (IN with) (NP (JJ chronic) (JJ frequent) (NN dosing))))))) (, ,) (NP (PRP it)) (VP (MD would) (VP (AUX be) (ADJP (JJ prudent) (S (VP (TO to) (VP (VB avoid) (NP (JJ nonsteroidal) (NN anti-inflammatory) (NN therapy)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_7661171_1297_1306_Disease))))))))))) (. .)))
7671401	0	(S1 (S (NP (NP (VBN Increased) (NN frequency) (CC and) (NN severity)) (PP (IN of) (NP (NNP Doc_7671401_36_48_Disease)))) (VP (VBD related) (PP (TO to) (NP (NP (JJ long-term) (NN therapy)) (PP (IN with) (NP (NP (JJ Doc_7671401_83_94_Chemical-converting) (JJ enzyme) (NN inhibitor)) (PP (IN in) (NP (CD two) (NNS patients)))))))) (. .)))
7671401	1	(S1 (S (NP (NP (JJ Adverse) (NNS reactions)) (PP (TO to) (NP (NNS drugs)))) (VP (AUX are) (ADVP (RB well)) (VP (VBN recognized) (PP (IN as) (NP (NP (DT a) (NN cause)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ acute)) (CC or) (ADJP (JJ chronic))) (NNP Doc_7671401_218_227_Disease)) (, ,) (CC and) (NP (NNP Doc_7671401_233_245_Disease)))))))) (. .)))
7671401	2	(S1 (S (S (NP (NP (JJ Angiotensin-converting) (NN enzyme) (PRN (-LRB- -LRB-) (NP (NNP ACE)) (-RRB- -RRB-)) (NNS inhibitors)) (, ,) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NP (NNP Doc_7671401_309_321_Disease)) (CC and) (NP (NNP Doc_7671401_326_350_Disease))))))) (, ,)) (VP (AUX were) (VP (VBN introduced) (PP (IN in) (NP (NP (NNP Europe)) (PP (IN in) (NP (NP (DT the) (NN middle)) (PP (IN of) (NP (DT the) (NNS eighties)))))))))) (, ,) (CC and) (S (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (AUX has) (VP (VBN increased) (ADVP (RB progressively))))) (. .)))
7671401	3	(S1 (S (PP (ADVP (RB Soon)) (IN after) (NP (NP (DT the) (NN introduction)) (PP (IN of) (NP (NN ACE) (NNS inhibitors))))) (, ,) (NP (NP (JJ acute) (NNS bouts)) (PP (IN of) (NP (NNP Doc_7671401_527_539_Disease)))) (VP (AUX were) (VP (VBN reported) (PP (IN in) (NP (NN association))) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT these) (NNS drugs))))))) (. .)))
7671401	4	(S1 (S (NP (PRP We)) (VP (VBP wish) (S (VP (TO to) (VP (VB draw) (NP (NN attention)) (PP (TO to) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NP (JJ adverse) (NNS reactions)) (PP (TO to) (NP (NP (NN ACE) (NNS inhibitors)) (PP (PP (IN after) (NP (JJ long-term) (NN use))) (CC and) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ pre-existing) (NN Doc_7671401_736_748_Disease)))))))))))))))) (. .)))
7727612	0	(S1 (S (NP (NN Doc_7727612_0_9_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ Doc_7727612_26_35_Chemical) (NN therapy)) (PP (IN in) (NP (NN very-Doc_7727612_52_76_Disease)))))) (. .)))
7727612	1	(S1 (S (NP (NN Doc_7727612_78_87_Chemical)) (VP (AUX is) (VP (AUXG being) (VP (VBN used) (PP (IN with) (NP (JJ increasing) (NN frequency))) (PP (IN as) (NP (NP (DT a) (NN sedative)) (PP (IN in) (NP (NP (DT the) (JJ newborn)) (CC and) (NP (DT the) (JJ young) (NN infant))))))))) (. .)))
7727612	2	(S1 (S (NP (NN Concern)) (VP (AUX has) (VP (AUX been) (VP (VBN raised) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (NP (DT the) (NN safety)) (PP (IN of) (NP (NNP Doc_7727612_232_241_Chemical))))))) (PP (IN in) (NP (DT this) (NN age) (NN group))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (JJ very-low-birth-weight) (PRN (-LRB- -LRB-) (NP (NP (NN VLBW)) (: ;) (NP (NNP <) (CD 1,500) (NNP g))) (-RRB- -RRB-)) (NNS infants)))))) (. .)))
7727612	3	(S1 (S (NP (NP (CD Three) (JJ young) (NNS infants)) (, ,) (NP (NP (DT all)) (PP (IN of) (NP (NN birth) (NN weight) (NNS <) (NX (CD 1,500) (NNP g))))) (, ,)) (VP (VBD experienced) (NP (NNP Doc_7727612_388_397_Disease)) (PP (VBG following) (NP (NP (DT the) (JJ intravenous) (NN administration)) (PP (IN of) (NP (NNP Doc_7727612_442_451_Chemical)))))) (. .)))
7727612	4	(S1 (S (NP (NP (DT The) (JJ potential) (JJ Doc_7727612_467_477_Disease) (NNS effects)) (PP (IN of) (NP (NP (DT the) (NN drug)) (-LRB- -LRB-) (CC and) (NP (PRP$ its) (NN vehicle)) (-RRB- -RRB-))) (PP (IN in) (NP (DT this) (NN population)))) (VP (AUX are) (VP (VBN discussed))) (. .)))
7727612	5	(S1 (S (NP (NNP Injectable) (NNP Doc_7727612_561_570_Chemical)) (VP (MD should) (VP (AUX be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (JJ VLBW) (NNS infants)))))) (. .)))
7739955	0	(S1 (NP (NP (JJ Transvenous) (JJ right) (JJ ventricular) (NN pacing)) (PP (IN during) (NP (NP (JJ cardiopulmonary) (NN resuscitation)) (PP (IN of) (NP (NP (JJ pediatric) (NNS patients)) (PP (IN with) (NP (JJ acute) (NNP Doc_7739955_107_121_Disease))))))) (. .)))
7739955	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT the) (JJ cardiopulmonary) (NN resuscitation) (NNS efforts)) (PP (IN on) (NP (NP (CD five) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD presented) (PP (IN in) (NP (NNP Doc_7739955_211_236_Disease))) (PP (IN from) (NP (NN Doc_7739955_242_264_Disease)))))))))) (. .)))
7739955	2	(S1 (S (S (NP (CD Three) (NNS patients)) (VP (AUX had) (NP (JJ acute) (NN Doc_7739955_291_308_Disease)))) (, ,) (S (NP (PRP one)) (VP (AUX had) (NP (DT a) (JJ Doc_7739955_320_333_Chemical-induced) (JJ acute) (NN Doc_7739955_348_372_Disease)))) (, ,) (CC and) (S (NP (PRP one)) (VP (AUX had) (NP (NP (JJ cardiac) (NN Doc_7739955_394_407_Disease)) (VP (VBG resulting) (PP (IN in) (NP (JJ acute) (NNP Doc_7739955_427_444_Disease))))))) (. .)))
7739955	3	(S1 (S (NP (DT All) (NNS patients)) (VP (AUX were) (ADVP (RB continuously)) (VP (VBN monitored) (PP (IN with) (NP (NP (JJ central) (NNS venous)) (CC and) (NP (JJ arterial) (NNS catheters)))) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (JJ routine) (NN noninvasive) (NN monitoring))))))) (. .)))
7739955	4	(S1 (S (NP (NP (DT An) (NN introducer) (NN sheath)) (, ,) (NP (DT a) (NN pacemaker)) (, ,) (CC and) (NP (JJ sterile) (NN pacing) (NNS wires))) (VP (AUX were) (VP (VBN made) (S (ADJP (RB readily) (JJ available) (PP (IN for) (NP (DT the) (NNS patients))))) (, ,) (SQ (MD should) (NP (DT the) (NN need)) (VP (VB arise) (S (VP (TO to) (VP (VB terminate) (NP (JJ resistant) (NN Doc_7739955_728_748_Disease))))))))) (. .)))
7739955	5	(S1 (S (NP (DT All) (NNS patients)) (VP (VBD developed) (NP (NP (NN Doc_7739955_773_797_Disease)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ extreme) (NNP Doc_7739955_822_833_Disease)) (CC and) (NP (NP (NP (NNP Doc_7739955_838_850_Disease)) (PP (IN within) (NP (NP (DT the) (JJ first) (CD 48) (NNS hours)) (PP (IN of) (NP (NP (PRP$ their) (NN admission)) (PP (TO to) (NP (DT the) (JJ pediatric) (JJ intensive) (NN care) (NN unit)))))))) (PRN (-LRB- -LRB-) (NP (NNP PICU)) (-RRB- -RRB-)))))))) (. .)))
7739955	6	(S1 (S (NP (JJ Right) (NN ventricular) (NN pacemaker) (NNS wires)) (VP (AUX were) (VP (VBN inserted) (PP (IN in) (NP (NP (DT all)) (PP (IN of) (NP (PRP them))))) (PP (IN during) (NP (NP (JJ cardiopulmonary) (NN resuscitation)) (PRN (-LRB- -LRB-) (NP (NN CPR)) (-RRB- -RRB-)))))) (. .)))
7739955	7	(S1 (S (PP (IN In) (NP (CD four) (NNS patients))) (, ,) (NP (JJ cardiac) (NN pacing)) (VP (AUX was) (VP (VBN used) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (JJ temporary) (VBN captured) (NN rhythm)) (CC and) (NP (NP (NN restoration)) (PP (IN of) (NP (PRP$ their) (JJ cardiac) (NN output)))))))))) (. .)))
7739955	8	(S1 (S (NP (DT These) (NNS patients)) (VP (AUX had) (NP (NP (DT a) (JJ second) (NN event)) (PP (IN of) (NP (NNP Doc_7739955_1210_1224_Disease))) (, ,) (VP (VBG resulting) (PP (IN in) (NP (NNP Doc_7739955_1239_1244_Disease)))) (, ,)) (PP (IN within) (NP (QP (CD 10) (TO to) (CD 60)) (NNS minutes)))) (. .)))
7739955	9	(S1 (S (PP (IN In) (NP (CD one) (NN patient))) (, ,) (NP (JJ cardiac) (NN pacing)) (VP (AUX was) (RB not) (VP (VBN used) (, ,) (SBAR (IN because) (S (NP (PRP he)) (VP (VBD converted) (PP (TO to) (NP (JJ normal) (JJ sinus) (NN rhythm))) (PP (IN by) (NP (JJ electrical) (NN defibrillation))) (PP (IN within) (NP (NP (CD three) (NNS minutes)) (PP (IN of) (NP (VBG initiating) (NNS CPR)))))))))) (. .)))
7739955	10	(S1 (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (JJ cardiac) (NN pacing)) (PP (IN during) (NP (NP (JJ resuscitative) (NNS efforts)) (PP (IN in) (NP (NP (JJ pediatric) (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (NNP Doc_7739955_1527_1555_Disease))))))))) (VP (MD may) (RB not) (VP (AUX have) (NP (JJ long-term) (NN value)) (PP (IN in) (CC and) (IN of) (NP (PRP itself))))))))) (: ;) (S (ADVP (RB however)) (, ,) (SBAR (IN if) (S (NP (JJ temporary) (JJ hemodynamic) (NN stability)) (VP (AUX is) (VP (VBN achieved) (PP (IN by) (NP (DT this) (NN procedure))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB provide) (NP (NP (JJ additional) (NN time)) (VP (VBD needed) (S (VP (TO to) (VP (VB institute) (NP (JJ other) (JJ therapeutic) (NNS modalities)))))))))) (. .)))
7931490	0	(S1 (NP (NP (NP (NN Efficacy)) (CC and) (NP (NN safety))) (PP (IN of) (NP (NP (NNP Doc_7931490_23_34_Chemical)) (, ,) (NP (DT a) (JJ selective) (JJ Doc_7931490_48_67_Chemical-3) (NN receptor) (NN antagonist)) (, ,))) (PP (IN in) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NP (NNP Doc_7931490_112_118_Disease)) (CC and) (NP (NNP Doc_7931490_123_131_Disease)))) (VP (VBN induced) (PP (IN by) (NP (JJ high-dose) (NNP Doc_7931490_153_162_Chemical)))))) (. .)))
7931490	1	(S1 (S (S (VP (TO To) (VP (VB assess) (NP (NP (DT the) (JJ antiemetic) (NNS effects)) (CC and) (NP (NP (NN safety) (NN profile)) (PP (IN of) (NP (NP (CD four) (JJ different) (NNS doses)) (PP (IN of) (NP (NP (NNP Doc_7931490_252_263_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Kytril)) (: ;) (NP (NNP SmithKline) (NNP Beecham) (NNP Pharmaceuticals))) (, ,) (NP (NP (NNP Philadelphia)) (, ,) (NP (NNP PA))) (-RRB- -RRB-)))))))) (ADVP (WRB when))))) (VP (VBN administered) (PP (IN as) (NP (NP (DT a) (JJ single) (JJ intravenous) (PRN (-LRB- -LRB-) (NP (NNP IV)) (-RRB- -RRB-)) (NN dose)) (PP (IN for) (NP (NP (NN prophylaxis)) (PP (IN of) (NP (NNP Doc_7931490_398_407_Chemical-induced) (NNP Doc_7931490_416_422_Disease) (CC and) (NNP Doc_7931490_427_435_Disease)))))))) (. .)))
7931490	2	(S1 (S (NP (NNS PATIENTS) (CC AND) (NNS METHODS)) (: :) (NP (NP (QP (CD One) (CD hundred)) (JJ eighty-four) (JJ chemotherapy-naive) (NNS patients)) (VP (VBG receiving) (NP (NP (JJ high-dose) (NN Doc_7931490_531_540_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 81) (TO to) (CD 120)) (NNS mg/m2)) (-RRB- -RRB-))))) (VP (AUX were) (VP (VBN randomized) (S (VP (TO to) (VP (VB receive) (NP (NP (NP (QP (CD one) (IN of) (CD four)) (JJ Doc_7931490_598_609_Chemical) (NNS doses)) (PRN (-LRB- -LRB-) (NP (NP (CD 5)) (, ,) (NP (CD 10)) (, ,) (NP (CD 20)) (, ,) (CC or) (NP (CD 40) (NN micrograms/kg))) (-RRB- -RRB-))) (VP (VBN administered) (PP (IN before) (NP (NN chemotherapy)))))))))) (. .)))
7931490	3	(S1 (S (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN observed) (PP (IN on) (NP (NP (DT an) (JJ inpatient) (NN basis)) (PP (IN for) (NP (QP (CD 18) (TO to) (CD 24)) (NNS hours)))))))) (, ,) (CC and) (S (NP (NP (JJ vital) (NNS signs)) (, ,) (NP (NP (NNP Doc_7931490_765_771_Disease)) (, ,) (NP (NNP Doc_7931490_773_781_Disease))) (, ,) (NP (NN retching)) (, ,) (CC and) (NP (NN appetite))) (VP (AUX were) (VP (VBN assessed)))) (. .)))
7931490	4	(S1 (S (NP (NN Safety) (NNS analyses)) (VP (VBD included) (NP (NP (NN incidence)) (PP (IN of) (NP (NP (JJ adverse) (NNS experiences)) (CC and) (NP (NN laboratory) (NN parameter) (NNS changes)))))) (. .)))
7931490	5	(S1 (S (PP (IN After) (NP (NP (JJ Doc_7931490_928_939_Chemical) (NNS doses)) (PP (IN of) (NP (NP (CD 5)) (, ,) (NP (CD 10)) (, ,) (NP (CD 20)) (, ,) (CC and) (NP (CD 40) (NN micrograms/kg)))))) (, ,) (NP (DT a) (JJ major) (NN response) (-LRB- -LRB-) (NNP <) (CC or) (SYM =)) (NP (NP (CD two) (JJ Doc_7931490_1011_1019_Disease) (CC or) (JJ retching) (NNS episodes)) (, ,) (CC and) (NP (DT no) (JJ antiemetic) (NN rescue)) (-RRB- -RRB-)) (VP (AUX was) (VP (VBN recorded) (PP (IN in) (NP (NP (NP (CD 23) (NN %)) (, ,) (NP (CD 57) (NN %)) (, ,) (NP (CD 58) (NN %)) (, ,) (CC and) (NP (NP (CD 60) (NN %)) (PP (IN of) (NP (NNS patients)))) (, ,) (ADVP (RB respectively)) (, ,) (CC and) (NP (DT a) (JJ complete) (NN response))) (PRN (-LRB- -LRB-) (NP (NP (DT no) (NNP Doc_7931490_1162_1170_Disease)) (CC or) (NP (NP (NN retching)) (, ,) (CC and) (NP (DT no) (JJ antiemetic) (NN rescue)))) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (CD 18) (NN %)) (, ,) (NP (CD 41) (NN %)) (, ,) (NP (CD 40) (NN %)) (, ,) (CC and) (NP (NP (CD 47) (NN %)) (PP (IN of) (NP (NNS patients)))) (, ,) (ADVP (RB respectively)))))) (. .)))
7931490	6	(S1 (S (S (NP (EX There)) (VP (AUX was) (NP (NP (DT a) (ADJP (RB statistically) (JJR longer)) (NN time)) (PP (TO to) (NP (NP (JJ first) (NN episode)) (PP (IN of) (NP (NP (NNP Doc_7931490_1321_1352_Disease)) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD .0001)) (-RRB- -RRB-))))))))) (, ,) (CC and) (S (NP (JJR fewer) (NNS patients)) (VP (AUX were) (VP (VBN administered) (NP (JJ additional) (JJ antiemetic) (NN medication)) (PP (IN in) (NP (DT the) (JJ 10-micrograms/kg) (JJ dosing) (NNS groups))) (PP (IN than) (PP (IN in) (NP (DT the) (JJ 5-micrograms/kg) (NN dosing) (NN group))))))) (. .)))
7931490	7	(S1 (S (PP (IN As) (NP (NNP Doc_7931490_1519_1530_Chemical) (NN dose) (VBN increased))) (, ,) (NP (NN appetite) (NN return)) (VP (VBD increased) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (SYM =) (NP (CD .040)))) (-RRB- -RRB-))) (. .)))
7931490	8	(S1 (S (NP (NN Doc_7931490_1585_1593_Disease)) (VP (AUX was) (NP (NP (DT the) (ADJP (ADVP (RBS most) (RB frequently)) (VBN reported)) (JJ adverse) (NN event)) (PRN (-LRB- -LRB-) (NP (CD 20) (NN %)) (-RRB- -RRB-)))) (. .)))
7931490	9	(S1 (S (NP (NP (DT A) (JJ single) (ADJP (JJ 10-) (, ,) (JJ 20-) (, ,) (CC or) (JJ 40-micrograms/kg)) (NN dose)) (PP (IN of) (NP (NNP Doc_7931490_1707_1718_Chemical)))) (VP (AUX was) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG controlling) (NP (NNP Doc_7931490_1748_1756_Disease)) (PP (IN in) (NP (NP (QP (CD 57) (NN %) (TO to) (CD 60)) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VP (VBD received) (NP (NNP Doc_7931490_1796_1805_Chemical)) (PP (IN at) (NP (NP (NNS doses)) (ADJP (ADJP (JJR greater)) (PP (IN than) (NP (CD 81) (NN mg/m2))))))) (CC and) (VP (ADVP (RB totally)) (VBD prevented) (NP (NNP Doc_7931490_1859_1867_Disease)) (PP (IN in) (NP (NP (QP (CD 40) (NN %) (TO to) (CD 47) (NN %))) (PP (IN of) (NP (NNS patients)))))))))))))))))) (. .)))
7931490	10	(S1 (S (NP (EX There)) (VP (AUX were) (NP (NP (DT no) (ADJP (RB statistically) (JJ significant)) (NNS differences)) (PP (IN in) (NP (NN efficacy))) (PP (IN between) (NP (NP (DT the) (JJ 10-micrograms/kg) (NN dose)) (CC and) (NP (DT the) (JJ 20-) (CC and) (JJ 40-micrograms/kg) (NNS doses)))))) (. .)))
7931490	11	(S1 (S (NP (NN Doc_7931490_2033_2044_Chemical)) (VP (AUX was) (ADVP (RB well)) (VP (VBN tolerated) (PP (IN at) (NP (DT all) (NNS doses))))) (. .)))
7949506	0	(S1 (NP (NP (JJ Adverse) (NN interaction)) (PP (IN between) (NP (NP (NNP Doc_7949506_28_37_Chemical)) (CC and) (NP (NNP Doc_7949506_42_51_Chemical)))) (. .)))
7949506	1	(S1 (FRAG (S (VP (TO To) (VP (VB report) (NP (NP (CD two) (NNS cases)) (PP (IN of) (NP (NP (DT a) (JJ possible) (JJ adverse) (NN interaction)) (PP (IN between) (NP (NNP Doc_7949506_126_135_Chemical) (CC and) (NNP Doc_7949506_140_149_Chemical))) (VP (VBG resulting) (PP (IN in) (NP (NP (NP (NNP Doc_7949506_163_190_Disease)) (PP (IN in) (NP (DT both) (NNS patients)))) (CC and) (NP (NP (JJ severe) (NNP Doc_7949506_219_230_Disease)) (PP (IN in) (NP (CD one) (NN patient))))))))))))) (. .)))
7949506	2	(S1 (NP (NP (NN CASE) (NNS SUMMARIES)) (: :) (S (NP (NP (DT A) (JJ 54-year-old) (NN woman)) (PP (IN with) (NP (NNP Doc_7949506_288_306_Disease)))) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_7949506_324_333_Chemical) (CD 480) (NN mg/d)) (CC and) (NP (NNP Doc_7949506_347_361_Chemical) (CD 100) (NN mg/d))))))) (. .)))
7949506	3	(S1 (S (PP (IN After) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NP (DT a) (JJ minimal) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_7949506_412_421_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 0.15) (CD mg)) (NN bid)) (-RRB- -RRB-)))))))) (, ,) (NP (PRP she)) (VP (VBD developed) (NP (NP (JJ complete) (NN Doc_7949506_460_468_Disease)) (CC and) (NP (NP (JJ severe) (NNP Doc_7949506_480_491_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD resolved) (PP (IN upon) (NP (NP (NN cessation)) (PP (IN of) (NP (DT all) (NNS medications))))))))))) (. .)))
7949506	4	(S1 (S (NP (DT A) (JJ 65-year-old) (NN woman)) (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (JJ extended-release) (NNP Doc_7949506_597_606_Chemical) (CD 240) (NNS mg/d))))) (. .)))
7949506	5	(S1 (S (PP (IN After) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NNP Doc_7949506_639_648_Chemical) (CD 0.15) (NN mg) (NN bid))))) (NP (PRP she)) (VP (VBD developed) (NP (NP (JJ complete) (NNP Doc_7949506_684_692_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD resolved) (SBAR (IN after) (S (NP (DT all) (NN therapy)) (VP (AUX was) (VP (VBN stopped)))))))))) (. .)))
7949506	6	(S1 (S (NP (NP (DT An) (JJ adverse) (NN interaction)) (PP (IN between) (NP (NP (NNP Doc_7949506_783_792_Chemical)) (CC and) (NP (NNP Doc_7949506_797_806_Chemical))))) (VP (AUX has) (RB not) (VP (AUX been) (VP (VBN reported) (ADVP (RB previously))))) (. .)))
7949506	7	(S1 (S (NP (PRP We)) (VP (VP (VB describe) (NP (CD two) (JJ such) (NNS cases))) (CC and) (VP (VB discuss) (NP (NP (DT the) (JJ various) (NNS mechanisms)) (SBAR (WHNP (WDT that)) (S (VP (MD might) (VP (VB cause) (NP (PDT such) (DT an) (NN interaction))))))))) (. .)))
7949506	8	(S1 (S (NP (NNS Clinicians)) (VP (MD should) (VP (AUX be) (VP (VBN acquainted) (PP (IN with) (NP (NP (DT this) (ADJP (RB possibly) (JJ fatal)) (NN interaction)) (PP (IN between) (NP (CD two) (ADJP (RB commonly) (VBN used)) (JJ antihypertensive) (NNS drugs)))))))) (. .)))
7949506	9	(S1 (S (NP (NN Caution)) (VP (AUX is) (ADJP (VBN recommended) (PP (IN in) (S (VP (VBG combining) (NP (NNP Doc_7949506_1109_1118_Chemical) (CC and) (NNP Doc_7949506_1123_1132_Chemical) (NN therapy)))))) (, ,) (PP (ADVP (RB even)) (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (AUX do) (RB not) (VP (AUX have) (ADJP (ADJP (JJ sinus)) (CC or) (ADJP (JJ Doc_7949506_1184_1203_Disease)))))))))) (. .)))
7949506	10	(S1 (S (NP (DT The) (CD two) (NNS drugs)) (VP (MD may) (VP (VB act) (ADVP (RB synergistically)) (PP (IN on) (NP (CC both) (NP (DT the) (JJ AV) (NN node)) (CC and) (NP (DT the) (JJ peripheral) (NN circulation)))))) (. .)))
7967231	0	(S1 (NP (NP (NP (JJ Pharmacological) (NNS studies)) (PP (IN on) (NP (DT a) (JJ new) (JJ Doc_7967231_33_62_Chemical) (JJ antagonist) (, ,) (JJ S-312-d.) (JJ 5th) (NN communication)))) (: :) (NP (NP (JJ anticonvulsant) (NNS effects)) (PP (IN in) (NP (NNS mice)))) (. .)))
7967231	1	(S1 (S (NP (NNP Doc_7967231_135_140_Chemical)) (, ,) (S (S (NP (NP (NNP S-312-d)) (, ,) (CC but) (RB not) (NP (NNP Doc_7967231_159_166_Chemical)) (, ,) (NP (NNP L-type) (NNP Doc_7967231_175_182_Chemical) (NN channel) (NNS antagonists)) (, ,)) (VP (VBD showed) (NP (NP (JJ anticonvulsant) (NNS effects)) (PP (IN on) (NP (NP (DT the) (JJ audiogenic) (NN tonic) (NNP Doc_7967231_258_269_Disease)) (PP (IN in) (NP (NNP DBA/2) (NNS mice)))))))) (: ;) (CC and) (S (NP (PRP$ their) (CD ED50) (NNS values)) (VP (AUX were) (NP (NP (NP (NP (CD 18.4)) (PRN (-LRB- -LRB-) (NP (CD 12.8-27.1)) (-RRB- -RRB-))) (NN mg/kg)) (, ,) (NP (NP (NP (CD p.o.) (CC and) (CD 15.0)) (PRN (-LRB- -LRB-) (NP (CD 10.2-23.7)) (-RRB- -RRB-)) (NNS mg/kg)) (, ,) (NP (CD p.o.)))) (, ,) (ADVP (RB respectively))))) (, ,) (SBAR (IN while) (S (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_7967231_403_414_Chemical)))) (VP (AUX was) (NP (CD 34.0) (-LRB- -LRB-) (CD 26.0-44.8) (-RRB- -RRB-) (NNS mg/kg)) (, ,) (S (VP (VBG p.o.) (SBAR (IN Although) (S (NP (NP (JJ moderate) (JJ anticonvulsant) (NNS effects)) (PP (IN of) (NP (NNP S-312-d))) (PP (IN in) (NP (JJR higher) (NNS doses)))) (VP (AUX were) (VP (VBN observed) (PP (IN against) (NP (NP (DT the) (JJ clonic) (NNP Doc_7967231_549_560_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NP (NNP Doc_7967231_572_590_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 85) (NNS mg/kg)) (, ,) (NP (NNP s.c.)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_7967231_611_620_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 40) (NNS mg/kg)) (, ,) (NP (NNP s.c.)) (-RRB- -RRB-))))))))))))))))) (, ,) (NP (DT no) (NNS effects)) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (NNP Doc_7967231_667_678_Disease))) (S (VP (VP (VBN induced) (PP (IN by) (NP (NNP Doc_7967231_690_710_Chemical) (, ,) (NNP Doc_7967231_712_722_Chemical)))) (, ,) (CC or) (VP (VB electroshock) (PP (IN in) (NP (NP (NNP Slc)) (: :) (NP (JJ ddY) (NNS mice))))))))) (. .)))
7967231	2	(S1 (S (NP (NN S-312-d)) (VP (MD may) (VP (AUX be) (ADJP (JJ useful)) (PP (IN in) (NP (NP (DT the) (NN therapy)) (PP (IN of) (NP (NP (JJ certain) (NNS types)) (PP (IN of) (NP (JJ human) (NN Doc_7967231_820_828_Disease))))))))) (. .)))
8096565	0	(S1 (S (VP (VB Doc_8096565_0_32_Disease) (PP (IN with) (NP (NNP Doc_8096565_38_49_Chemical)))) (. .)))
8096565	1	(S1 (S (PP (IN For) (NP (NNP Doc_8096565_55_66_Chemical))) (, ,) (NP (NP (NN tightness)) (PP (IN in) (NP (NP (DT the) (NN chest)) (VP (VBN caused) (PP (IN by) (NP (DT an) (JJ unknown) (NN mechanism))))))) (VP (AUX has) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (NP (CD 3-5) (NN %)) (PP (IN of) (NP (NNS users)))))))) (. .)))
8096565	2	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT a) (JJ 47-year-old) (NN woman)) (PP (IN with) (NP (DT an) (NN Doc_8096565_198_225_Disease)))) (SBAR (IN after) (S (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_8096565_250_261_Chemical) (CD 6)))) (VP (VBD mg) (ADVP (RB subcutaneously)) (PP (IN for) (NP (NNP Doc_8096565_286_302_Disease))))))) (. .)))
8096565	3	(S1 (S (NP (DT The) (NN patient)) (VP (AUX had) (NP (NP (DT no) (NN history)) (PP (IN of) (NP (JJ underlying) (NNP Doc_8096565_345_368_Disease) (CC or) (NNP Doc_8096565_372_391_Disease))))) (. .)))
8096565	4	(S1 (S (NP (PRP She)) (VP (VBD recovered) (PP (IN without) (NP (NNS complications)))) (. .)))
8135424	0	(S1 (S (NP (NN Doc_8135424_0_10_Chemical)) (VP (VBZ induces) (NP (NP (NNP Doc_8135424_19_27_Disease)) (CC and) (NP (NNP Doc_8135424_32_37_Disease))) (PP (IN in) (NP (JJ mixed) (JJ Doc_8135424_47_54_Chemical-Doc_8135424_55_63_Chemical) (NNS intoxications)))) (. .)))
8135424	1	(S1 (NP (NP (NN STUDY) (NNS HYPOTHESIS)) (: :) (NP (NP (NNP Administration)) (PP (IN of) (NP (NP (DT the) (JJ Doc_8135424_119_133_Chemical) (NN antagonist)) (SBAR (S (NP (NNP Doc_8135424_145_155_Chemical)) (VP (MD may) (VP (VB unmask) (NP (NNP Doc_8135424_167_175_Disease)) (PP (IN in) (NP (JJ mixed) (JJ Doc_8135424_185_192_Chemical-Doc_8135424_193_207_Chemical) (NN intoxication)))))))))) (. .)))
8135424	2	(S1 (S (NP (JJ Male) (NNP Sprague-Dawley) (NNS rats)) (VP (VBD received) (NP (NP (NP (QP (CD 100) (CD mg/kg)) (JJ Doc_8135424_274_281_Chemical) (NNS IP)) (ADVP (RB alone))) (, ,) (NP (NP (NP (CD 5) (NN mg/kg)) (NP (NNP Doc_8135424_300_308_Chemical))) (ADVP (RB alone))) (, ,) (CC or) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_8135424_336_344_Chemical)) (CC and) (NP (NNP Doc_8135424_349_356_Chemical))))))) (. .)))
8135424	3	(S1 (S (ADVP (NP (CD Three) (NNS minutes)) (RB later)) (, ,) (NP (NNS groups)) (VP (AUX were) (VP (VBN challenged) (PP (IN with) (NP (NP (NN vehicle)) (CC or) (NP (QP (JJ Doc_8135424_418_428_Chemical) (CD 5) (CC or) (CD 10)) (JJ mg/kg) (NNS IP)))))) (. .)))
8135424	4	(S1 (S (NP (NP (NN Animal) (NN behavior)) (, ,) (NP (NP (NP (NNP Doc_8135424_464_472_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN time)) (PP (TO to) (CC and) (NP (NN incidence)))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_8135424_498_503_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NN time)) (PP (TO to) (CC and) (NP (NN incidence)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (JJ cortical) (NNP EEG) (NNS tracings)))) (VP (AUX were) (VP (VBN recorded))) (. .)))
8135424	5	(S1 (NP (NP (NN Administration)) (PP (IN of) (NP (NNP Doc_8135424_603_613_Chemical))) (PP (TO to) (NP (NNS animals) (SBAR (IN after) (S (NP (PRP they)) (VP (AUX had) (VP (VBN received) (NP (NP (DT a) (NN combination) (NN dose)) (PP (IN of) (NP (NP (NNP Doc_8135424_671_678_Chemical)) (CC and) (NP (NNP Doc_8135424_683_691_Chemical))))))))))) (. .)))
8135424	6	(S1 (S (PP (IN In) (NP (NN group) (CD 1))) (, ,) (NP (NNS animals)) (VP (VBD received) (NP (NP (NN Doc_8135424_731_738_Chemical)) (VP (VBN followed) (PP (IN by) (NP (NN vehicle)))))) (. .)))
8135424	7	(S1 (S (NP (DT This)) (VP (VBD resulted) (PP (IN in) (S (NP (CD 100) (NN %)) (VP (VBG developing) (NP (NP (NNP Doc_8135424_793_801_Disease)) (CC and) (NP (NNP Doc_8135424_806_811_Disease))))))) (. .)))
8135424	8	(S1 (S (NP (NN Group) (CD 2)) (VP (VBD received) (NP (NP (NN Doc_8135424_830_838_Chemical)) (VP (ADVP (RB alone)) (VBN followed) (PP (IN by) (NP (NN vehicle)))))) (. .)))
8135424	9	(S1 (S (S (NP (NNS Animals)) (VP (VBD became) (NP (NN somnolent)))) (CC and) (S (NP (NN none)) (VP (VBD died))) (. .)))
8135424	10	(S1 (S (NP (NNP Group) (CD 3)) (VP (VBD received) (NP (NP (NN Doc_8135424_923_931_Chemical)) (VP (VBN followed) (PP (IN by) (NP (CD 5) (NN mg/kg) (NNP Doc_8135424_952_962_Chemical)))))) (. .)))
8135424	11	(S1 (S (NP (NNS Animals)) (VP (VP (VBD became) (NP (NN somnolent)) (PP (IN after) (NP (NNP Doc_8135424_995_1003_Chemical)))) (CC and) (RB then) (ADJP (JJ active)) (PP (IN after) (NP (NNP Doc_8135424_1026_1036_Chemical) (NN administration)))) (. .)))
8135424	12	(S1 (S (PP (IN In) (NP (NN group) (CD 4))) (, ,) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_8135424_1082_1089_Chemical)) (CC and) (NP (NNP Doc_8135424_1094_1102_Chemical))))) (VP (AUX was) (VP (VBN administered) (ADVP (RB simultaneously)))) (. .)))
8135424	13	(S1 (S (NP (DT This)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT no) (NN overt) (CC or) (NN EEG-detectable) (NN Doc_8135424_1180_1188_Disease)) (CC and) (NP (NP (DT a) (ADJP (CD 50) (NN %)) (NN incidence)) (PP (IN of) (NP (NNP Doc_8135424_1212_1217_Disease))))))) (. .)))
8135424	14	(S1 (S (NP (NNP Group) (CD 5)) (VP (VBD received) (NP (NP (DT a) (JJ similar) (NN combination)) (PP (IN of) (NP (NP (NNP Doc_8135424_1261_1268_Chemical)) (CC and) (NP (NNP Doc_8135424_1273_1281_Chemical))))) (, ,) (S (VP (VBN followed) (ADVP (RB later)) (PP (IN by) (NP (CD 5) (NN mg/kg) (NNP Doc_8135424_1309_1319_Chemical)))))) (. .)))
8135424	15	(S1 (S (NP (DT This)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (VBN increased) (NN incidence)) (PP (IN of) (NP (NP (NP (NNP Doc_8135424_1364_1372_Disease)) (, ,) (NP (CD 90) (NN %)) (PRN (-LRB- -LRB-) (NP (NNP P) (NNP <) (CD .01)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_8135424_1393_1398_Disease)) (, ,) (NP (CD 100) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NNP P) (NNP <)) (CC or) (NP (SYM =) (CD .01))) (-RRB- -RRB-))) (, ,))))) (PP (VBN compared) (PP (IN with) (NP (NN group) (CD 4))))) (. .)))
8135424	16	(S1 (S (NP (NNP Group) (CD 6)) (VP (VBD received) (NP (NP (NNP Doc_8135424_1461_1468_Chemical) (CC and) (NNP Doc_8135424_1473_1481_Chemical)) (VP (VBN followed) (PP (IN by) (NP (CD 10) (NN mg/kg) (NNP Doc_8135424_1503_1513_Chemical)))))) (. .)))
8135424	17	(S1 (S (NP (DT This)) (ADVP (RB also)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT an) (VBN increased) (NN incidence)) (PP (IN of) (NP (NP (NP (NNP Doc_8135424_1563_1571_Disease)) (, ,) (NP (CD 90) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NNP P) (NNP <)) (CC or) (NP (SYM =) (CD .01))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_8135424_1597_1602_Disease)) (, ,) (NP (CD 90) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (NNP P) (NNP <)) (CC or) (NP (SYM =) (CD .05))) (-RRB- -RRB-))) (, ,))))) (PP (VBN compared) (PP (IN with) (NP (NN group) (CD 4))))) (. .)))
8135424	18	(S1 (S (NP (NN Doc_8135424_1659_1669_Chemical)) (VP (MD can) (VP (VP (VB unmask) (NP (NNP Doc_8135424_1681_1689_Disease))) (CC and) (VP (VB increase) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_8135424_1720_1725_Disease))) (PP (IN in) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (JJ combined) (JJ Doc_8135424_1749_1756_Chemical-Doc_8135424_1757_1765_Chemical) (NNS intoxications))))))))) (. .)))
8160791	0	(S1 (NP (NP (NNS Mechanisms)) (PP (IN for) (NP (NP (JJ protective) (NNS effects)) (PP (IN of) (NP (NP (JJ free) (JJ radical) (NNS scavengers)) (PP (IN on) (NP (NP (NNP Doc_8160791_64_74_Chemical-mediated) (NNP Doc_8160791_84_95_Disease)) (PP (IN in) (NP (NNS rats))))))))) (. .)))
8160791	1	(S1 (S (NP (NNS Studies)) (VP (AUX were) (VP (VBN performed) (S (VP (TO to) (VP (VB examine) (NP (NP (DT the) (NNS mechanisms)) (PP (IN for) (NP (NP (DT the) (JJ protective) (NNS effects)) (PP (IN of) (NP (NP (JJ free) (JJ radical) (NNS scavengers)) (PP (IN on) (NP (NNP Doc_8160791_211_221_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_8160791_223_225_Chemical)) (-RRB- -RRB-)) (JJ -mediated) (NN Doc_8160791_236_247_Disease))))))))))))) (. .)))
8160791	2	(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NNP Doc_8160791_267_269_Chemical))) (PP (IN at) (NP (NP (CD 40) (JJ mg/kg) (NNS sc)) (PP (IN for) (NP (CD 13) (NNS days))) (PP (TO to) (NP (NNS rats)))))) (VP (VP (VBN induced) (NP (NP (NP (DT a) (JJ significant) (NN Doc_8160791_327_356_Disease)) (PRN (-LRB- -LRB-) (NP (NNP RBF)) (-RRB- -RRB-))) (CC and) (NP (NP (NN inulin) (NN clearance)) (PRN (-LRB- -LRB-) (NP (NNP CIn)) (-RRB- -RRB-))))) (CONJP (RB as) (RB well) (IN as)) (VP (VBD marked) (NP (NNP Doc_8160791_408_422_Disease)))) (. .)))
8160791	3	(S1 (S (NP (NP (NP (DT A) (JJ significant) (NN reduction)) (PP (IN in) (NP (JJ urinary) (NNP Doc_8160791_459_495_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_8160791_497_501_Chemical)) (-RRB- -RRB-)) (NN excretion)))) (CC and) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NP (JJ renal) (JJ cortical) (NN renin)) (CC and) (NP (JJ endothelin-1) (NNS contents)))))) (VP (AUX were) (ADVP (RB also)) (VP (VBN observed) (PP (IN in) (NP (NNP Doc_8160791_612_614_Chemical-mediated) (NNP Doc_8160791_624_635_Disease))))) (. .)))
8160791	4	(S1 (S (NP (NP (NP (JJ Doc_8160791_637_647_Chemical) (NN dismutase)) (PRN (-LRB- -LRB-) (NP (NNP SOD)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_8160791_667_683_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8160791_685_689_Chemical)) (-RRB- -RRB-)))) (ADVP (RB significantly)) (VP (VBD lessened) (NP (NP (DT the) (JJ Doc_8160791_718_720_Chemical-induced) (NN decrement)) (PP (IN in) (NP (NNP CIn))))) (. .)))
8160791	5	(S1 (S (NP (NP (DT The) (JJ SOD-induced) (NN increase)) (PP (IN in) (NP (JJ glomerular) (NN filtration) (NN rate)))) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJ marked) (NN improvement)) (PP (IN in) (NP (NP (CD RBF)) (, ,) (NP (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ urinary) (JJ Doc_8160791_874_878_Chemical) (NN excretion)))) (, ,) (CC and) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (JJ renal) (NN renin)) (CC and) (NP (JJ endothelin-1) (NN content)))))))))))) (. .)))
8160791	6	(S1 (S (NP (NN SOD)) (VP (AUX did) (RB not) (VP (VB attenuate) (NP (DT the) (NNP Doc_8160791_972_986_Disease)))) (. .)))
8160791	7	(S1 (S (PP (IN In) (NP (NN contrast))) (, ,) (S (NP (NNP Doc_8160791_1001_1005_Chemical)) (VP (ADVP (RB significantly)) (VBD reduced) (NP (DT the) (NN Doc_8160791_1032_1046_Disease) (CC and) (NN lipid) (NN peroxidation)))) (, ,) (CC but) (S (NP (PRP it)) (VP (AUX did) (RB not) (VP (VB affect) (NP (NP (JJ renal) (NNS hemodynamics)) (CC and) (NP (JJ vasoactive) (NNS substances)))))) (. .)))
8160791	8	(S1 (S (NP (CC Neither) (NP (NNP SOD)) (CC nor) (NP (NNP Doc_8160791_1155_1159_Chemical))) (VP (VBD affected) (NP (NP (DT the) (JJ renal) (JJ cortical) (JJ Doc_8160791_1188_1190_Chemical) (NN content)) (PP (IN in) (NP (JJ Doc_8160791_1202_1204_Chemical-treated) (NNS rats))))) (. .)))
8160791	9	(S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (S (LST (LS 1) (-RRB- -RRB-)) (NP (DT both) (NNP SOD) (CC and) (NNP Doc_8160791_1262_1266_Chemical)) (VP (AUX have) (NP (NP (JJ protective) (NNS effects)) (PP (IN on) (NP (NP (NNP Doc_8160791_1294_1296_Chemical-mediated) (NNP Doc_8160791_1306_1317_Disease)) (, ,) (NP (CD 2)) (-RRB- -RRB-)))) (NP (DT the) (NNS mechanisms)) (SBAR (IN for) (S (NP (DT the) (JJ protective) (NNS effects)) (VP (VBP differ) (PP (IN for) (NP (NNP SOD) (CC and) (NNP Doc_8160791_1383_1387_Chemical)))))))) (, ,) (CC and) (S (LST (LS 3) (-RRB- -RRB-)) (NP (JJ Doc_8160791_1396_1406_Chemical) (NNS anions)) (VP (VBP play) (NP (NP (DT a) (JJ critical) (NN role)) (PP (IN in) (NP (JJ Doc_8160791_1438_1440_Chemical-induced) (JJ renal) (NN vasoconstriction))))))))) (. .)))
816141	0	(S1 (FRAG (NP (JJ Doc_816141_0_11_Chemical-induced) (JJ immune) (NN Doc_816141_27_43_Disease)) (. .)))
816141	1	(S1 (S (NP (NP (DT A) (NN patient)) (PP (IN with) (NP (NNP Doc_816141_60_73_Disease)))) (VP (VBD developed) (NP (JJ Coombs-positive) (NN Doc_816141_100_116_Disease)) (SBAR (IN while) (S (VP (VBG receiving) (NP (JJ Doc_816141_133_144_Chemical) (NN therapy)))))) (. .)))
816141	2	(S1 (S (NP (DT An) (JJ anti-Doc_816141_162_173_Chemical) (NNP IgG) (NN antibody)) (VP (AUX was) (VP (VBN detected) (PP (PP (IN in) (NP (NP (DT the) (NN patient) (POS 's)) (NN serum))) (CC and) (PP (IN in) (NP (NP (DT the) (NNS eluates)) (PP (IN from) (NP (PRP$ her) (NNS erythrocytes)))))))) (. .)))
816141	3	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NP (JJ nonimmunologic) (VBG binding)) (PP (IN of) (NP (JJ normal)))) (CC and) (NP (NP (NP (NN patient) (POS 's)) (JJ serum) (NNS proteins)) (PP (TO to) (NP (PRP$ her) (ADJP (JJ own) (CC and) (JJ Doc_816141_355_366_Chemical-coated)) (JJ normal) (JJ red) (NNS cells))))) (VP (AUX was) (VP (VBN demonstrated))) (. .)))
816141	4	(S1 (S (NP (NP (NN Skin) (NNS tests)) (CC and) (NP (ADJP (IN in) (NN vitro)) (NN lymphocyte) (NN stimulation))) (VP (VBD revealed) (SBAR (IN that) (S (NP (DT the) (NN patient)) (VP (AUX was) (VP (VBN sensitized) (PP (PP (TO to) (NP (NNP Doc_816141_500_511_Chemical))) (CC and) (PP (ADVP (RB also)) (TO to) (NP (NNP Doc_816141_524_534_Chemical))))))))) (. .)))
816141	5	(S1 (S (NP (NP (JJ Careful) (NN investigation)) (PP (IN of) (NP (JJ drug-induced) (NNP Doc_816141_574_591_Disease)))) (VP (VBZ reveals) (NP (NP (DT the) (NN complexity)) (PP (IN of) (NP (NP (DT the) (JJ immune) (NNS mechanisms)) (VP (VBN involved)))))) (. .)))
8184922	0	(S1 (NP (NP (NN Assessment)) (PP (IN of) (NP (JJ cardiomyocyte) (NN DNA) (NN synthesis))) (PP (IN during) (NP (NP (NNP Doc_8184922_49_60_Disease)) (PP (IN in) (NP (NN adult) (NNS mice))))) (. .)))
8184922	1	(S1 (S (NP (NP (DT The) (NN ability)) (PP (IN of) (NP (NNS cardiomyocytes))) (S (VP (TO to) (VP (VB synthesize) (NP (NN DNA)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (ADJP (RB experimentally) (VBN induced)) (NNP Doc_8184922_162_181_Disease))))))))) (VP (AUX was) (VP (VBN assessed) (PP (IN in) (NP (NN adult) (NNS mice))))) (. .)))
8184922	2	(S1 (S (NP (NP (NN Doc_8184922_210_223_Chemical)) (VP (VBN delivered) (PP (IN by) (NP (JJ osmotic) (NN minipump) (NN implantation))) (PP (IN in) (NP (JJ adult) (NNP C3Heb/FeJ) (NNS mice))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (ADJP (CD 46) (NN %)) (NN increase)) (PP (IN in) (NP (NN heart) (NN weight)))) (CC and) (NP (NP (DT a) (ADJP (CD 19.3) (NN %)) (NN increase)) (PP (IN in) (NP (NN cardiomyocyte) (NN area))))))) (. .)))
8184922	3	(S1 (S (NP (NP (DT No) (NN DNA) (NN synthesis)) (, ,) (SBAR (IN as) (S (VP (VBN assessed) (PP (IN by) (NP (NP (JJ autoradiographic) (NN analysis)) (PP (IN of) (NP (JJ isolated) (NNS cardiomyocytes)))))))) (, ,)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (NN control)) (CC or) (NP (JJ Doc_8184922_492_504_Disease) (NNS hearts)))))) (. .)))
8184922	4	(S1 (S (NP (NP (DT A) (NN survey)) (PP (IN of) (NP (NP (CD 15) (JJ independent) (JJ inbred) (NNS strains)) (PP (IN of) (NP (NNS mice)))))) (VP (VBD revealed) (SBAR (IN that) (S (NP (JJ ventricular) (JJ cardiomyocyte) (JJ nuclear) (NN number)) (VP (VBD ranged) (PP (IN from) (NP (QP (CD 3) (TO to) (CD 13)) (NN %)) (NP (NNP Doc_8184922_639_651_Chemical))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (JJ cardiomyocyte) (NN terminal) (NN differentiation)) (VP (AUX is) (VP (VBN influenced) (ADVP (RB directly) (CC or) (RB indirectly)) (PP (IN by) (NP (JJ genetic) (NN background))))))))))))) (. .)))
8184922	5	(S1 (S (S (VP (TO To) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (DT the) (NN capacity)) (PP (IN for) (NP (JJ reactive) (NN DNA) (NN synthesis)))) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ subject) (PP (TO to) (NP (JJ genetic) (NN regulation)))))))))) (, ,) (NP (NNP Doc_8184922_869_888_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN in) (NP (NP (DT the) (NNS strains)) (PP (IN of) (NP (NP (NNS mice)) (VP (VBG comprising) (NP (NP (DT the) (NNS extremes)) (PP (IN of) (NP (DT the) (JJ nuclear) (NN number) (NN survey))))))))))) (. .)))
8184922	6	(S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (JJ adult) (NN mouse) (NN atrial) (CC and) (NN ventricular) (NNS cardiomyocytes)) (VP (AUX do) (RB not) (VP (VB synthesize) (NP (NN DNA)) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (JJ Doc_8184922_1090_1103_Chemical-induced) (NN Doc_8184922_1112_1131_Disease)))))))))) (. .)))
8188982	0	(S1 (S (NP (NP (JJ Central) (JJ cardiovascular) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_8188982_34_37_Chemical)) (CC and) (NP (NNP ANP)))) (UCP (PP (IN in) (NP (NN normotensive))) (CC and) (ADVP (RB spontaneously)))) (VP (VBP Doc_8188982_80_92_Disease) (NP (NNS rats))) (. .)))
8188982	1	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB compare) (PP (NN influence) (PP (PP (IN of) (NP (NP (JJ central) (NNP Doc_8188982_168_188_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8188982_190_193_Chemical)) (-RRB- -RRB-)))) (CC and) (PP (IN of) (NP (NP (JJ atrial) (JJ natriuretic) (NN peptide) (PRN (-LRB- -LRB-) (NNP ANP) (-RRB- -RRB-))) (PP (IN on) (NP (NP (NN control)) (PP (IN of) (NP (NP (NP (JJ arterial) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN MAP)) (-RRB- -RRB-))) (CC and) (NP (NP (NN heart) (NN rate)) (PRN (-LRB- -LRB-) (NP (NNP HR)) (-RRB- -RRB-))))))) (PP (IN in) (NP (ADJP (JJ normotensive) (PRN (-LRB- -LRB-) (NP (NNP WKY)) (-RRB- -RRB-)) (CC and) (ADJP (RB spontaneously) (JJ Doc_8188982_339_351_Disease))) (PRN (-LRB- -LRB-) (NP (NNP SHR)) (-RRB- -RRB-)) (NNS rats))))))))))) (. .)))
8188982	2	(S1 (S (NP (NP (CD Three) (NNS series)) (PP (IN of) (NP (NNS experiments)))) (VP (AUX were) (VP (VBN performed) (PP (IN on) (NP (NP (NP (NP (CD 30) (NNP WKY)) (CC and) (NP (NP (CD 30) (NNP SHR)) (, ,) (VP (ADVP (RB chronically)) (VBN instrumented) (PP (IN with) (NP (NN guide) (NNS tubes))) (PP (IN in) (NP (DT the) (JJ lateral) (NN ventricle)))))) (PRN (-LRB- -LRB-) (NP (NNP LV)) (-RRB- -RRB-))) (CC and) (NP (ADJP (JJ arterial) (CC and) (JJ venous)) (NNS catheters)))))) (. .)))
8188982	3	(S1 (S (NP (NP (NN MAP)) (CC and) (NP (NN HR))) (VP (AUX were) (VP (VBN monitored) (PP (IN before) (CC and) (IN after) (S (VP (VBG i.v.) (NP (NP (NNS injections)) (PP (IN of) (NP (NP (DT either) (NN vehicle)) (CC or) (NP (NP (CD 1) (, ,) (CD 10) (CC and) (CD 50) (NN ng)) (PP (IN of) (NP (NNP Doc_8188982_635_638_Chemical) (CC and) (CD 25) (, ,) (CD 125) (CC and) (CD 500) (NNS ng))) (PP (IN of) (NP (NN ANP)))))))))))) (. .)))
8188982	4	(S1 (S (NP (NP (NN Sensitivity)) (PP (IN of) (NP (NP (JJ cardiac) (NN component)) (PP (IN of) (NP (NN baroreflex))))) (PRN (-LRB- -LRB-) (NP (NNP CCB)) (-RRB- -RRB-)) (, ,)) (VP (VBD expressed) (SBAR (IN as) (S (NP (NP (DT a) (NN slope)) (PP (IN of) (NP (DT the) (NN regression) (NN line)))) (VP (AUX was) (VP (VBN determined) (PP (IN from) (NP (NP (NNS relationships)) (PP (IN between) (NP (NP (NP (JJ systolic) (JJ arterial) (NN pressure)) (PRN (-LRB- -LRB-) (INTJ (VB SAP)) (-RRB- -RRB-)) (CC and) (NP (NP (JJ HR) (NN period)) (PRN (-LRB- -LRB-) (NP (NNP HRp)) (-RRB- -RRB-)))) (PP (IN during) (NP (NP (NNP Doc_8188982_870_883_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8188982_885_888_Chemical)) (-RRB- -RRB-)))) (NP (NP (JJ -induced) (NNP Doc_8188982_898_910_Disease) (CC and) (NNP Doc_8188982_915_935_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP SN)) (-RRB- -RRB-))) (JJ -induced))) (NP (NNP Doc_8188982_949_960_Disease))))))))) (. .)))
8188982	5	(S1 (S (NP (NNP CCB)) (VP (AUX was) (VP (VBN measured) (PP (IN before) (CC and) (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NP (DT either) (NN vehicle)) (, ,) (NP (NP (NNP Doc_8188982_1030_1033_Chemical)) (, ,) (NP (NNP ANP))) (, ,)))) (CC or) (NP (NP (DT both) (NNS peptides)) (ADVP (RB together)))))) (. .)))
8188982	6	(S1 (S (NP (NN Doc_8188982_1067_1083_Disease)) (VP (VBD occurred) (PP (IN after) (NP (NP (NN LV) (NN administration)) (PP (IN of) (NP (NP (NP (CD 1) (, ,) (CD 10) (CC and) (CD 50) (NNS ng)) (PP (IN of) (NP (NP (NNP Doc_8188982_1139_1142_Chemical)) (PP (IN in) (NP (NNP WKY)))))) (CC and) (NP (NP (QP (IN of) (CD 10) (CC and) (CD 50) (NNS ng))) (PP (IN in) (NP (NNP SHR))))))))) (. .)))
8188982	7	(S1 (S (S (NP (NNP ANP)) (VP (AUX did) (RB not) (VP (VB cause) (NP (NP (JJ significant) (NNS changes)) (PP (IN in) (NP (NN MAP))) (PP (IN in) (NP (DT both) (NNS strains)))) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NN vehicle))))))))) (, ,) (CC but) (S (NP (PRP it)) (VP (VBD abolished) (NP (NP (JJ Doc_8188982_1280_1283_Chemical-induced) (NN MAP) (NN increase)) (PP (IN in) (NP (NP (NNP WKY)) (CC and) (NP (NNP SHR))))))) (. .)))
8188982	8	(S1 (S (NP (NNP CCB)) (VP (AUX was) (VP (VBN reduced) (PP (IN in) (NP (NP (NNP WKY)) (CC and) (NP (NNP SHR)))) (PP (IN after) (S (VP (VBG LV) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_8188982_1379_1382_Chemical)))) (PP (IN during) (NP (JJ SN-induced) (NN Doc_8188982_1401_1412_Disease)))))))) (. .)))
8188982	9	(S1 (S (PP (PP (IN In) (NP (NNP SHR))) (CC but) (PP (RB not) (IN in) (NP (NP (JJ WKY) (NN administration)) (PP (IN of) (NP (NN ANP)))))) (, ,) (NP (NNP Doc_8188982_1459_1462_Chemical) (CC and) (NNP Doc_8188982_1467_1470_Chemical) (NNP +) (NNP Doc_8188982_1473_1476_Chemical)) (VP (VBD decreased) (NP (NNP Doc_8188982_1487_1490_Chemical)) (PP (IN during) (NP (JJ Doc_8188982_1498_1501_Chemical-induced) (NN MAP) (NN elevation)))) (. .)))
8188982	10	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (ADJP (RB centrally) (VBN applied)) (NNP Doc_8188982_1569_1572_Chemical) (CC and) (NNP ANP)) (VP (VP (VBP exert) (NP (NP (NN differential) (NNS effects)) (PP (IN on) (NP (NP (NN blood) (NN pressure)) (CC and) (NP (NN baroreflex) (NN control)))) (PP (IN of) (NP (NN heart) (NN rate)))) (PP (IN in) (NP (NNP WKY) (CC and) (NNP SHR)))) (CC and) (VP (VBP suggest) (NP (NP (NN interaction)) (PP (IN of) (NP (DT these) (CD two) (NNS peptides)))) (PP (IN in) (NP (NP (NN blood) (NN pressure) (NN regulation)) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (ADJP (JJ central) (JJ nervous)) (NN system)))))))))))) (. .)))
8308951	0	(S1 (NP (NP (NP (JJ Cutaneous) (NN exposure)) (PP (TO to) (NP (NP (JJ Doc_8308951_22_30_Chemical-like) (NN anticoagulant)) (VP (VBG causing) (NP (DT an) (NN Doc_8308951_61_85_Disease)))))) (: :) (NP (DT a) (NN case) (NN report)) (. .)))
8308951	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (JJ intercerebral) (NNP Doc_8308951_126_134_Disease))) (PP (JJ due) (TO to) (NP (NNP Doc_8308951_142_150_Chemical-induced) (NNP Doc_8308951_159_171_Disease)))) (VP (AUX is) (VP (VBN presented))) (. .)))
8308951	2	(S1 (S (NP (DT The) (JJ 39-year-old) (NN woman)) (VP (AUX had) (VP (VBN spread) (NP (DT a) (JJ Doc_8308951_221_229_Chemical-type) (NN rat) (NN poison)) (PP (IN around) (NP (NP (PRP$ her) (NN house)) (VP (ADVP (RB weekly)) (VBG using) (NP (PRP$ her) (JJ bare) (NNS hands))))) (, ,) (PP (IN with) (NP (DT no) (VBG washing) (NN post) (NN application))))) (. .)))
8308951	3	(S1 (S (NP (NP (JJ Percutaneous) (NN absorption)) (PP (IN of) (NP (NP (NNP Doc_8308951_353_361_Chemical)) (VP (VBG causing) (NP (NNP Doc_8308951_370_382_Disease))))) (, ,) (VP (VBN reported) (NP (CD three) (NNS times)) (PP (IN in) (NP (DT the) (NN past)))) (, ,)) (VP (AUX is) (NP (DT a) (JJ significant) (NN risk) (SBAR (IN if) (S (NP (NP (JJ protective) (NNS measures)) (, ,) (PP (JJ such) (IN as) (NP (NNS gloves))) (, ,)) (VP (AUX are) (RB not) (VP (VBN used))))))) (. .)))
8308951	4	(S1 (S (NP (NP (DT An) (JJ adverse) (NN drug) (NN interaction)) (PP (IN with) (NP (NP (NNP Doc_8308951_527_536_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (NP (PRP she)) (VP (VBD took) (ADVP (RB occasionally))))) (, ,)))) (VP (MD may) (VP (AUX have) (VP (VBN exacerbated) (NP (DT the) (NNP Doc_8308951_592_604_Disease))))) (. .)))
8312343	0	(S1 (NP (NP (JJ Pediatric) (NN heart) (NN transplantation)) (PP (IN without) (NP (JJ chronic) (NN maintenance) (NN Doc_8312343_60_68_Chemical))) (. .)))
8312343	1	(S1 (S (PP (PP (IN From) (NP (CD 1986))) (PP (TO to) (NP (NNP February) (CD 1993)))) (, ,) (NP (NP (CD 40) (NNS children)) (VP (VBN aged) (NP (NP (QP (CD 2) (NNS months) (TO to) (CD 18)) (NNS years)) (PRN (-LRB- -LRB-) (NP (NP (JJ average) (NN age)) (NP (CD 10.4) (JJ +/-) (CD 5.8) (NNS years))) (-RRB- -RRB-))))) (VP (VBD underwent) (NP (NN heart) (NN transplantation))) (. .)))
8312343	2	(S1 (S (NP (NP (NNS Indications)) (PP (IN for) (NP (NN transplantation)))) (VP (AUX were) (NP (NP (NP (JJ idiopathic) (NNP Doc_8312343_250_264_Disease) (PRN (-LRB- -LRB-) (NP (CD 52) (NN %)) (-RRB- -RRB-)) (, ,) (NNP Doc_8312343_272_296_Disease) (PRN (-LRB- -LRB-) (NP (CD 35) (NN %)) (-RRB- -RRB-) (PP (IN with) (CC and) (PP (IN without) (NP (NP (JJ prior) (NN repair)) (PRN (-LRB- -LRB-) (NP (NP (CD 71) (NN %)) (CC and) (NP (CD 29) (NN %))) (, ,) (ADVP (RB respectively)) (-RRB- -RRB-))))) (, ,)) (NNP Doc_8312343_362_389_Disease)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_8312343_396_418_Disease) (PRN (-LRB- -LRB-) (NP (CD 3) (NN %)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NNP Doc_8312343_429_440_Chemical) (NNP Doc_8312343_441_455_Disease)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN %)) (-RRB- -RRB-))))) (. .)))
8312343	3	(S1 (S (NP (NNS Patients)) (VP (AUX were) (VP (VBN managed) (PP (IN with) (NP (NP (NNP Doc_8312343_489_501_Chemical)) (CC and) (NP (NNP Doc_8312343_506_518_Chemical)))))) (. .)))
8312343	4	(S1 (S (NP (NP (DT No) (NN prophylaxis)) (PP (IN with) (NP (JJ antilymphocyte) (NN globulin)))) (VP (AUX was) (VP (VBN used))) (. .)))
8312343	5	(S1 (S (S (NP (NNP Doc_8312343_574_582_Chemical)) (VP (AUX were) (VP (VBN given) (PP (TO to) (NP (NP (CD 39) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN for) (NP (JJ refractory) (NN rejection)))))))))) (, ,) (CC but) (S (NP (NN weaning)) (VP (AUX was) (ADJP (ADJP (RB always) (JJ attempted)) (CC and) (ADJP (RB generally) (JJ successful))) (PRN (-LRB- -LRB-) (NP (CD 64) (NN %)) (-RRB- -RRB-)))) (. .)))
8312343	6	(S1 (S (NP (NP (CD Five) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 14) (NN %)) (-RRB- -RRB-))) (VP (VBD received) (NP (NN maintenance) (NN Doc_8312343_745_753_Chemical))) (. .)))
8312343	7	(S1 (S (S (NP (CD Four) (NNS patients)) (VP (VBD died) (PP (IN in) (NP (DT the) (JJ perioperative) (NN period))))) (CC and) (S (NP (CD one)) (VP (VBD died) (ADVP (NP (CD 4) (NNS months)) (RB later)))) (. .)))
8312343	8	(S1 (S (NP (EX There)) (VP (AUX have) (VP (AUX been) (NP (NP (DT no) (NNS deaths)) (VP (VBN related) (PP (TO to) (NP (NP (NN rejection)) (CC or) (NP (NN Doc_8312343_881_890_Disease)))))))) (. .)))
8312343	9	(S1 (S (NP (JJ Average) (NN follow-up)) (VP (AUX was) (NP (NP (CD 36) (JJ +/-) (CD 19) (NNS months)) (PRN (-LRB- -LRB-) (VP (VBP range) (NP (QP (CD 1) (TO to) (CD 65)) (NNS months))) (-RRB- -RRB-)))) (. .)))
8312343	10	(S1 (S (NP (JJ Cumulative) (NN survival)) (VP (AUX is) (NP (CD 88) (NN %)) (PP (IN at) (NP (CD 5) (NNS years)))) (. .)))
8312343	11	(S1 (S (PP (IN In) (NP (NP (NNS patients)) (ADJP (ADJP (JJR less)) (PP (IN than) (NP (NP (CD 7) (NNS years)) (PP (IN of) (NP (NN age)))))))) (, ,) (NP (NN rejection)) (VP (AUX was) (VP (VBN monitored) (ADVP (RB noninvasively)))) (. .)))
8312343	12	(S1 (S (PP (IN In) (NP (DT the) (JJ first) (JJ postoperative) (NN month))) (, ,) (NP (NP (CD 89) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (AUX were) (VP (VBN treated) (PP (IN for) (NP (NN rejection))))) (. .)))
8312343	13	(S1 (S (NP (NP (NN Freedom)) (PP (IN from) (NP (JJ serious) (NNP Doc_8312343_1170_1180_Disease)))) (VP (AUX was) (NP (NP (NP (CD 83) (NN %)) (PP (IN at) (NP (CD 1) (NN month)))) (CC and) (NP (NP (CD 65) (NN %)) (PP (IN at) (NP (CD 1) (NN year)))))) (. .)))
8312343	14	(S1 (S (NP (NN Doc_8312343_1219_1245_Disease)) (VP (AUX were) (VP (VBN treated) (ADVP (RB successfully)) (PP (IN with) (NP (NNP Doc_8312343_1277_1288_Chemical))) (PP (IN in) (NP (CD 11) (NNS patients))))) (. .)))
8312343	15	(S1 (S (NP (DT No) (NN Doc_8312343_1308_1328_Disease)) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (NP (NNS children)) (SBAR (WHNP (WP who)) (S (VP (VBD underwent) (NP (NN transplantation)) (PP (VBN compared) (PP (IN with) (NP (DT a) (JJ control) (NN population))))))))))) (. .)))
8312343	16	(S1 (S (S (NP (NP (CD Twenty-one) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 60) (NN %)) (-RRB- -RRB-))) (VP (AUX have) (VP (VBN undergone) (NP (JJ annual) (NNS catheterizations))))) (CC and) (S (NP (NP (DT no) (NN sign)) (PP (IN of) (NP (NN graft) (NN Doc_8312343_1506_1521_Disease)))) (VP (AUX has) (VP (AUX been) (VP (VBN observed))))) (. .)))
8312343	17	(S1 (S (S (NP (NN Doc_8312343_1541_1549_Disease)) (VP (VBD occurred) (PP (IN in) (NP (NP (CD five) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 14) (NN %)) (-RRB- -RRB-)))))) (CC and) (S (NP (NNP Doc_8312343_1586_1598_Disease)) (VP (AUX was) (VP (VBN treated) (PP (IN in) (NP (NP (CD 10) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 28) (NN %)) (-RRB- -RRB-))))))) (. .)))
8312343	18	(S1 (S (S (NP (DT No) (NN patient)) (VP (AUX was) (VP (VBN disabled)))) (CC and) (S (NP (DT no) (JJ lymphoproliferative) (NN disorder)) (VP (AUX was) (VP (VBN observed.)))) (PRN (-LRB- -LRB-) (VP (ADVP (JJ ABSTRACT)) (VBN TRUNCATED) (PP (IN AT) (NP (CD 250) (NNS WORDS)))) (-RRB- -RRB-))))
8312983	0	(S1 (NP (NP (NN Delirium)) (PP (IN during) (NP (JJ Doc_8312983_16_26_Chemical) (NN treatment))) (. .)))
8312983	1	(S1 (S (NP (DT A) (NN case)) (VP (VBP report)) (. .)))
8312983	2	(S1 (S (NP (NP (DT The) (NN correlation)) (PP (IN between) (NP (NP (JJ high) (JJ serum) (NN tricyclic) (NN antidepressant) (NNS concentrations)) (CC and) (NP (JJ central) (JJ nervous) (NN system) (NN side) (NNS effects))))) (VP (AUX has) (VP (AUX been) (ADJP (RB well) (VBN established)))) (. .)))
8312983	3	(S1 (S (NP (QP (RB Only) (DT a) (JJ few)) (NNS reports)) (VP (VBP exist) (, ,) (ADVP (RB however)) (, ,) (PP (IN on) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NP (DT the) (JJ serum) (NNS concentrations)) (PP (IN of) (NP (NP (JJ selective) (JJ Doc_8312983_296_305_Chemical) (NN reuptake) (NNS inhibitors)) (PRN (-LRB- -LRB-) (NP (NNP SSRIs)) (-RRB- -RRB-))))) (CC and) (NP (PRP$ their) (JJ toxic) (NNS effects))))))) (. .)))
8312983	4	(S1 (S (PP (IN In) (NP (DT some) (NNS cases))) (, ,) (NP (NP (DT a) (JJ high) (NN serum) (NN concentration)) (PP (IN of) (NP (NP (NNP Doc_8312983_404_414_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP >) (QP (CD 600) (CD nmol/L))) (-RRB- -RRB-)))) (PP (IN in) (NP (JJ elderly) (NNS patients)))) (VP (AUX has) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NP (VBN increased) (NN somnolence)) (CC and) (NP (NN movement) (NNS difficulties))))))) (. .)))
8312983	5	(S1 (S (NP (NP (JJ Widespread) (NNP Doc_8312983_534_553_Disease)) (, ,) (PP (JJ such) (IN as) (NP (NNP Doc_8312983_563_571_Disease))) (, ,)) (VP (AUX have) (RB not) (VP (AUX been) (ADVP (RB previously)) (VP (VBN linked) (PP (IN with) (NP (NP (JJ high) (NN blood) (NNS levels)) (PP (IN of) (NP (NN SSRIs)))))))) (. .)))
8312983	6	(S1 (S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP (PRP we)) (VP (VBP describe) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_8312983_681_708_Disease)) (VP (VBN connected) (PP (IN with) (NP (DT a) (JJ high) (NN serum) (NN total) (NNP Doc_8312983_743_753_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_8312983_755_765_Chemical) (CC plus) (NNP Doc_8312983_771_790_Chemical)) (-RRB- -RRB-)) (NN concentration)))))))) (. .)))
8318674	0	(S1 (NP (NP (NP (NP (NN Doc_8318674_0_15_Disease)) (CC and) (NP (NN Doc_8318674_20_25_Disease))) (PP (IN after) (NP (NP (JJ high-dose) (NN Doc_8318674_42_51_Chemical-C)) (PP (IN for) (NP (NNP Doc_8318674_58_66_Disease)))))) (: ;) (NP (NP (JJ possible) (NN role)) (PP (IN of) (NP (NNP TNF-alpha) (CC and) (NNP PAF)))) (. .)))
8318674	1	(S1 (S (NP (NP (CD Four)) (PP (IN out) (PP (IN of) (NP (NP (CD 23) (JJ consecutive) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (JJ high-dose) (NN Doc_8318674_163_168_Chemical))) (PP (IN for) (NP (NNP Doc_8318674_173_182_Disease))) (PP (IN in) (NP (PRP$ our) (NN institution)))))))) (VP (VBD developed) (NP (DT a) (ADJP (RB strikingly) (JJ similar)) (NN syndrome)) (PP (IN during) (NP (DT the) (NN perfusion)))) (. .)))
8318674	2	(S1 (S (NP (PRP It)) (VP (AUX was) (VP (VBN characterized) (PP (IN by) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NNP Doc_8318674_301_306_Disease) (, ,) (NNP Doc_8318674_308_316_Disease) (, ,) (NNP Doc_8318674_318_323_Disease) (, ,) (NNP Doc_8318674_325_340_Disease) (, ,) (NNP Doc_8318674_342_361_Disease) (, ,) (NNP Doc_8318674_363_381_Disease) (, ,) (NNP Doc_8318674_383_394_Disease) (CC and) (NNP Doc_8318674_399_411_Disease))))))) (. .)))
8318674	3	(S1 (S (NP (JJ Thorough) (JJ bacteriological) (NN screening)) (VP (VBD failed) (S (VP (TO to) (VP (VB provide) (NP (NP (NN evidence)) (PP (IN of) (NP (NN Doc_8318674_478_487_Disease)))))))) (. .)))
8318674	4	(S1 (S (NP (NP (JJ Sequential) (JJ biological) (NNS assays)) (PP (IN of) (NP (NN IL-1) (, ,) (NN IL-2) (, ,) (NN TNF) (CC and) (NN PAF)))) (VP (AUX were) (VP (VBN performed) (PP (IN during) (NP (JJ Doc_8318674_567_572_Chemical) (NN infusion))) (PP (TO to) (NP (NP (CD ten) (NNS patients)) (, ,) (PP (VBG including) (NP (NP (DT the) (CD four)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (DT the) (NN syndrome))))))))))) (. .)))
8318674	5	(S1 (S (NP (NN TNF) (CC and) (NN PAF) (NN activity)) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NP (DT the) (NN serum)) (PP (IN of) (NP (NP (RB respectively) (CD two)) (CC and) (NP (NP (CD four)) (PP (IN of) (NP (DT the) (NNS cases)))))))) (, ,) (FRAG (CC but) (RB not) (PP (IN in) (NP (DT the) (CD six) (NNS controls)))))) (. .)))
8318674	6	(S1 (S (SBAR (IN As) (S (NP (NP (NNP TNF)) (CC and) (NP (NNP PAF))) (VP (AUX are) (VP (VBN thought) (S (VP (TO to) (VP (AUX be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (NNP Doc_8318674_826_838_Disease)) (CC and) (NP (JJ adult) (NNP Doc_8318674_849_878_Disease)))))))))))))) (, ,) (NP (PRP we)) (VP (VBP hypothesize) (SBAR (IN that) (S (NP (JJ high-dose) (NNP Doc_8318674_910_915_Chemical)) (VP (MD may) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (JJ cytokine) (NN release))))))))) (. .)))
8392553	0	(S1 (NP (NP (JJ Protective) (NN effect)) (PP (IN of) (NP (NNP Doc_8392553_21_31_Chemical))) (PP (IN against) (NP (NP (NNP Doc_8392553_40_51_Chemical-induced) (NNP Doc_8392553_60_74_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
8392553	1	(S1 (S (NP (PRP We)) (VP (VBD investigated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_8392553_115_125_Chemical)) (, ,) (NP (DT a) (JJ Doc_8392553_129_156_Chemical) (NN antagonist)) (, ,))) (PP (IN on) (NP (NP (NNP Doc_8392553_172_183_Chemical-induced) (NNP Doc_8392553_192_206_Disease)) (PP (IN in) (NP (NNS rats))))))) (. .)))
8392553	2	(S1 (S (PP (IN With) (NP (JJ 2-week) (JJ chronic) (JJ Doc_8392553_236_247_Chemical) (NN infusion))) (, ,) (S (NP (NP (CD 16)) (PP (IN of) (NP (CD 30) (NNS rats)))) (VP (VBD died) (PP (IN within) (NP (CD 4) (NNS days))))) (, ,) (CC and) (S (NP (NP (JJ severe) (NNP Doc_8392553_303_319_Disease) (CC and) (NNP Doc_8392553_324_332_Disease)) (PP (IN of) (NP (DT the) (JJ left) (NNS ventricles)))) (VP (AUX were) (VP (VBN observed)))) (. .)))
8392553	3	(S1 (S (PP (IN In) (NP (JJ Doc_8392553_374_385_Chemical-treated) (NNS rats))) (, ,) (VP (VP (VBD left) (NP (NN atrial))) (CC and) (VP (VBD left) (SBAR (S (S (NP (NP (JJ ventricular) (NN papillary) (NN muscle) (NN contractile) (NNS responses)) (PP (TO to) (NP (NNP Doc_8392553_475_488_Chemical)))) (VP (AUX were) (VP (VBN reduced)))) (, ,) (CC but) (S (NP (NP (NNS responses)) (PP (TO to) (NP (NNP Doc_8392553_520_527_Chemical)))) (VP (AUX were) (ADJP (JJ normal) (CC or) (JJ enhanced)) (PP (VBN compared) (PP (TO to) (NP (NNS controls)))))))))) (. .)))
8392553	4	(S1 (S (NP (JJ Left) (NN ventricular) (NN alpha) (CC and) (NN beta) (NN adrenoceptor) (NNS densities)) (VP (AUX were) (ADVP (RB also)) (VP (VBN reduced) (PP (VBN compared) (PP (TO to) (NP (NNS controls)))))) (. .)))
8392553	5	(S1 (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NNP Doc_8392553_684_694_Chemical)))) (VP (VP (VBD prevented) (NP (NP (JJ Doc_8392553_705_716_Chemical-induced) (NN Doc_8392553_725_730_Disease)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD .05))) (-RRB- -RRB-)))) (, ,) (CC and) (VP (VBD attenuated) (NP (DT the) (NNP Doc_8392553_761_789_Disease) (CC and) (NNP Doc_8392553_794_802_Disease))) (, ,) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner)))) (. .)))
8392553	6	(S1 (S (S (NP (NP (VBN Left) (ADJP (JJ atrial) (CC and) (JJ left)) (JJ ventricular) (JJ papillary) (NN muscle) (NN contractile) (NNS responses)) (PP (TO to) (NP (NNP Doc_8392553_907_920_Chemical)))) (VP (AUX were) (VP (VBN reduced) (PP (VBN compared) (PP (TO to) (NP (NNS controls)))) (PP (IN in) (NP (NP (NNS groups)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_8392553_978_988_Chemical)) (ADVP (RB alone)))))))))) (, ,) (CC but) (S (S (VP (VBN combined) (PP (IN with) (NP (NNP Doc_8392553_1014_1025_Chemical))))) (, ,) (NP (NNP Doc_8392553_1027_1037_Chemical)) (VP (VP (VBD restored) (NP (JJ left) (JJ atrial) (NNS responses))) (CC and) (VP (VBD enhanced) (NP (NP (JJ left) (JJ ventricular) (NN papillary) (NNS responses)) (PP (TO to) (NP (NNP Doc_8392553_1122_1135_Chemical))))))) (. .)))
8392553	7	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (NP (NNP Doc_8392553_1155_1165_Chemical)) (VP (AUX did) (RB not) (VP (VB prevent) (NP (NP (JJ Doc_8392553_1182_1193_Chemical-induced) (NN down-regulation)) (PP (IN of) (NP (NN alpha) (CC and) (NN beta) (NNS adrenoceptors)))))) (. .)))
8392553	8	(S1 (S (ADVP (RB Interestingly)) (, ,) (NP (NP (NNP Doc_8392553_1266_1276_Chemical)) (, ,) (VP (VBN infused) (ADVP (RB alone))) (, ,)) (VP (VBD resulted) (PP (IN in) (NP (NP (VBN decreased) (JJ adrenergic) (NN receptor) (NNS densities)) (PP (IN in) (NP (DT the) (JJ left) (NN ventricle)))))) (. .)))
8392553	9	(S1 (S (NP (NN Doc_8392553_1368_1378_Chemical)) (ADVP (RB also)) (VP (AUX did) (RB not) (VP (VB prevent) (NP (NP (DT the) (VBN enhanced) (NNS responses)) (PP (TO to) (NP (NP (NNP Doc_8392553_1426_1433_Chemical)) (VP (VBN seen) (PP (IN in) (NP (DT the) (JJ Doc_8392553_1446_1457_Chemical-treated) (NNS animals))))))) (, ,) (SBAR (IN although) (S (NP (NP (DT the) (JJ high) (NN dose)) (PP (IN of) (NP (NNP Doc_8392553_1501_1511_Chemical)))) (ADVP (RB partially)) (VP (VBD attenuated) (NP (NP (DT the) (JJ maximal) (NN response)) (PP (TO to) (NP (NNP Doc_8392553_1557_1564_Chemical))) (PP (VBN compared) (PP (TO to) (NP (JJ Doc_8392553_1577_1588_Chemical-treated) (NNS animals)))))))))) (. .)))
8392553	10	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NNP Doc_8392553_1621_1631_Chemical)) (VP (VBD attenuated) (NP (JJ Doc_8392553_1643_1654_Chemical-induced) (NNP Doc_8392553_1663_1677_Disease)) (, ,) (PP (ADVP (RB possibly)) (IN through) (NP (NP (PRP$ its) (NN effect)) (PP (IN on) (NP (DT the) (JJ adrenergic) (NN pathway)))))) (. .)))
851038	0	(S1 (NP (NP (JJ Kaliuretic) (NN effect)) (PP (IN of) (NP (NP (JJ Doc_851038_21_27_Chemical) (NN treatment)) (PP (IN in) (NP (JJ Doc_851038_41_53_Disease) (NNS patients))))) (. .)))
851038	1	(S1 (S (NP (NN Doc_851038_64_75_Disease)) (, ,) (S (ADVP (RB sometimes)) (ADJP (JJ severe))) (, ,) (VP (AUX was) (VP (VBN observed) (PP (IN in) (NP (DT some) (JJ Doc_851038_116_122_Chemical-treated) (JJ Doc_851038_131_143_Disease) (NNS patients))))) (. .)))
851038	2	(S1 (S (NP (NP (DT The) (NN influence)) (PP (IN of) (NP (NNP Doc_851038_171_177_Chemical))) (PP (IN on) (NP (NP (DT the) (JJ renal) (NN excretion)) (PP (IN of) (NP (NNP Doc_851038_204_213_Chemical)))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (CD 3) (NNS patients))) (PP (PP (IN with) (NP (NNP Doc_851038_245_256_Disease))) (CC and) (PP (IN in) (NP (CD 5) (JJ normokalemic) (NNS patients)))) (PP (IN by) (NP (NP (NN determination)) (PP (IN of) (NP (NP (JJ renal) (NN plasma) (NN flow)) (, ,) (NP (NN glomerular) (NN filtration) (NN rate)) (, ,) (NP (NP (NN plasma) (NN concentration)) (PP (IN of) (NP (NNP Doc_851038_379_388_Chemical) (CC and) (NNP Doc_851038_393_399_Chemical)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ urinary) (NN excretion)) (PP (IN of) (NP (NNP Doc_851038_432_441_Chemical) (, ,) (NNP Doc_851038_443_449_Chemical) (CC and) (NNP Doc_851038_454_465_Chemical)))))))))) (. .)))
851038	3	(S1 (S (NP (JJ Doc_851038_467_473_Chemical) (NN intake)) (VP (AUX was) (VP (VBN found) (S (VP (VP (TO to) (VP (VB cause) (NP (NP (DT an) (VBN increased) (NN excretion)) (PP (IN of) (NP (NNP Doc_851038_526_535_Chemical)))))) (, ,) (CC and) (ADVP (RB sometimes)) (ADVP (RB also)) (PP (IN of) (NP (NNP Doc_851038_559_565_Chemical))) (, ,) (PP (PP (IN in) (NP (DT the) (NNP Doc_851038_574_585_Disease))) (CONJP (CC but) (RB not)) (PP (IN in) (NP (DT the) (JJ normokalemic) (NNS patients)))))))) (. .)))
851038	4	(S1 (S (NP (NP (DT This) (NN effect)) (PP (IN on) (NP (DT the) (JJ renal) (NN function)))) (VP (MD could) (VP (AUX be) (VP (VBN prohibited) (PP (IN by) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (DT a) (JJ peripheral) (NN dopa) (NN decarbodylase) (NN inhibitor)))))))) (. .)))
851038	5	(S1 (S (S (NP (PRP It)) (VP (AUX is) (RB not) (VP (VBN known) (SBAR (WHADVP (WRB why)) (S (NP (DT this) (NN effect)) (VP (VBD occurred) (PP (PP (IN in) (NP (DT some) (NNS individuals))) (CC but) (PP (RB not) (IN in) (NP (NNS others)))))))))) (, ,) (CC but) (S (NP (PRP$ our) (NNS results)) (VP (VBP indicate) (NP (NP (DT a) (NN correlation)) (PP (IN between) (NP (NP (JJ Doc_851038_873_884_Chemical) (NN production)) (CC and) (NP (NP (DT this) (JJ renal) (NN effect)) (PP (IN of) (NP (NNP Doc_851038_921_927_Chemical))))))))) (. .)))
8511251	0	(S1 (S (NP (NN Doc_8511251_0_7_Chemical)) (VP (VBN induced) (NP (NNP Doc_8511251_16_35_Disease))) (. .)))
8511251	1	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (NNP Doc_8511251_57_76_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_8511251_88_95_Chemical)))))))) (. .)))
8511251	2	(S1 (S (NP (NP (DT The) (NN Doc_8511251_101_109_Disease)) (VP (ADVP (RB probably)) (VBN induced) (PP (IN by) (NP (NNP Doc_8511251_130_151_Disease))))) (VP (AUX was) (VP (VBN reversed) (PP (IN by) (NP (NP (NNP Doc_8511251_168_181_Chemical)) (CC and) (NP (JJ Doc_8511251_186_193_Chemical) (VBG blocking) (NNS agents)))))) (. .)))
8603459	0	(S1 (S (NP (JJ Doc_8603459_0_11_Chemical-induced) (NNP Doc_8603459_20_34_Disease)) (VP (VBN monitored) (PP (IN by) (NP (NN ECG))) (PP (IN in) (NP (ADJP (RB freely) (JJ moving)) (NNS mice)))) (. .)))
8603459	1	(S1 (S (NP (DT A) (JJ new) (NN model)) (VP (TO to) (VP (VB test) (NP (JJ potential) (NNS protectors)))) (. .)))
8603459	2	(S1 (S (PP (IN In) (NP (NN laboratory) (NNS animals))) (, ,) (NP (NN histology)) (VP (AUX is) (ADVP (RBS most) (RB commonly)) (VP (VBN used) (S (VP (TO to) (VP (VB study) (NP (JJ Doc_8603459_181_192_Chemical-induced) (NN Doc_8603459_201_215_Disease))))))) (. .)))
8603459	3	(S1 (S (ADVP (RB However)) (, ,) (PP (IN for) (S (VP (VBG monitoring) (PP (IN during) (NP (NN treatment)))))) (, ,) (NP (NP (JJ large) (NNS numbers)) (PP (IN of) (NP (NNS animals)))) (VP (AUX are) (VP (VBN needed))) (. .)))
8603459	4	(S1 (S (ADVP (RB Recently)) (NP (PRP we)) (VP (VBD developed) (NP (NP (DT a) (JJ new) (NN method)) (SBAR (S (VP (TO to) (VP (VB measure) (NP (NN ECG) (NNS values)) (PP (IN in) (NP (ADJP (RB freely) (JJ moving)) (NNS mice))) (PP (IN by) (NP (NN telemetry))))))))) (. .)))
8603459	5	(S1 (S (PP (IN With) (NP (DT this) (NN model))) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (JJ chronic) (NNP Doc_8603459_443_454_Chemical) (NN administration))) (PP (IN on) (NP (NP (NP (DT the) (NN ECG)) (PP (IN of) (NP (ADJP (RB freely) (JJ moving)) (NN BALB/c) (NNS mice)))) (CC and) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NNP Doc_8603459_530_538_Chemical))))))) (PP (IN as) (NP (DT a) (JJ protective) (NN agent)))) (. .)))
8603459	6	(S1 (S (NP (DT The) (NNP ST) (NN interval)) (VP (ADVP (RB significantly)) (VBN widened) (PP (IN from) (NP (NP (NP (CD 15.0) (NN +/-)) (NP (QP (CD 1.5) (TO to) (CD 56.8)) (JJ +/-) (CD 11.8) (NNS ms))) (PP (IN in) (NP (NP (NN week) (CD 10)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 7) (JJ weekly) (NNS doses)) (PP (IN of) (NP (CD 4) (JJ mg/kg) (JJ Doc_8603459_676_687_Chemical) (VBN given) (NN i.v.)))) (CC plus) (NP (NP (CD 3) (NNS weeks)) (PP (IN of) (NP (NN observation))))) (-RRB- -RRB-))))))) (. .)))
8603459	7	(S1 (S (NP (NP (DT The) (NNS ECG)) (PP (IN of) (NP (DT the) (NN control) (NNS animals)))) (VP (AUX did) (RB not) (VP (VB change) (PP (IN during) (NP (DT the) (JJ entire) (NN study))))) (. .)))
8603459	8	(S1 (S (S (PP (IN After) (NP (NN sacrifice))) (NP (NP (DT the) (NNS hearts)) (PP (IN of) (NP (JJ Doc_8603459_830_841_Chemical-treated) (NNS animals)))) (VP (AUX were) (ADJP (JJ enlarged)))) (CC and) (S (NP (DT the) (NNS atria)) (VP (AUX were) (ADJP (JJ Doc_8603459_891_903_Disease)))) (. .)))
8603459	9	(S1 (S (SBAR (IN As) (S (NP (DT this) (NN schedule)) (VP (VBN exerted) (ADJP (ADJP (RBR more) (JJ Doc_8603459_935_943_Disease)) (SBAR (IN than) (S (VP (VBN needed) (S (VP (TO to) (VP (VB investigate) (NP (JJ protective) (NNS agents)))))))))))) (, ,) (NP (NP (DT the) (NN protection)) (PP (IN of) (NP (NNP Doc_8603459_1008_1016_Chemical)))) (VP (AUX was) (VP (VBN determined) (S (VP (VBG using) (NP (NP (DT a) (NN dose) (NN schedule)) (PP (IN with) (NP (NP (JJR lower) (JJ general) (NNP Doc_8603459_1073_1081_Disease)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 6) (JJ weekly) (NNS doses)) (PP (IN of) (NP (CD 4) (JJ mg/kg) (JJ Doc_8603459_1109_1120_Chemical) (VBN given) (NN i.v.)))) (CC plus) (NP (NP (CD 2) (NNS weeks)) (PP (IN of) (NP (NN observation))))) (-RRB- -RRB-))))))))) (. .)))
8603459	10	(S1 (S (PP (IN On) (NP (DT this) (NN schedule))) (, ,) (NP (NP (DT the) (NNS animals) (POS ')) (NNS hearts)) (VP (VBD appeared) (ADJP (JJ normal)) (SBAR (IN after) (S (NP (NP (NN sacrifice)) (CC and) (NP (NP (NNP Doc_8603459_1236_1244_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 50) (CD mg/kg)) (VBN given) (CD i.p.) (CD 1) (NNP h)) (PP (IN before) (NP (NNP Doc_8603459_1277_1288_Chemical)))) (-RRB- -RRB-)))) (VP (VBD provided) (NP (ADJP (RB almost) (JJ full)) (NN protection)))))) (. .)))
8603459	11	(S1 (S (NP (DT These) (NNS data)) (VP (AUX were) (VP (VBN confirmed) (PP (IN by) (NP (NN histology))))) (. .)))
8603459	12	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (DT this) (JJ new) (NN model)) (VP (VP (AUX is) (ADJP (RB very) (JJ sensitive))) (CC and) (VP (VBZ enables) (NP (NP (NN monitoring)) (PP (IN of) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_8603459_1467_1481_Disease))))) (PP (IN with) (NP (NN time))))))))) (. .)))
8603459	13	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP result) (PP (IN in) (NP (NP (DT a) (NN model)) (SBAR (WHNP (WDT that)) (S (VP (VBZ allows) (NP (NP (DT the) (NN testing)) (PP (IN of) (NP (NNS protectors)))) (PP (IN against) (NP (NNP Doc_8603459_1572_1583_Chemical-induced) (NNP Doc_8603459_1592_1606_Disease))) (SBAR (IN as) (S (VP (VBN demonstrated) (PP (IN by) (NP (NP (DT the) (NN protection)) (VP (VBN provided) (PP (IN by) (NP (NNP Doc_8603459_1653_1661_Chemical))))))))))))))) (. .)))
8659767	0	(S1 (S (NP (JJ Doc_8659767_0_11_Chemical) (NN dysrhythmogenicity)) (VP (AUX is) (RB not) (VP (VBN enhanced) (PP (IN by) (NP (NP (JJ subtoxic) (NN Doc_8659767_59_70_Chemical)) (PP (IN in) (NP (NNS dogs))))))) (. .)))
8659767	1	(S1 (S (SBAR (IN Since) (S (NP (NP (NNP Doc_8659767_86_97_Chemical)) (CC and) (NP (NNP Doc_8659767_102_113_Chemical))) (VP (MD may) (DT both) (VP (VB precipitate) (NP (NNP Doc_8659767_135_147_Disease)))))) (, ,) (S (VP (VBG circulating) (NP (NNP Doc_8659767_161_172_Chemical)) (PP (IN during) (NP (JJ regional) (NNS anesthesia))))) (VP (MD could) (VP (VB potentiate) (NP (NP (JJ dysrhythmogenic) (NNS effects)) (PP (IN of) (NP (NNP Doc_8659767_244_255_Chemical)))))) (. .)))
8659767	2	(S1 (S (NP (PRP We)) (ADVP (RB therefore)) (VP (VBD examined) (SBAR (IN whether) (S (NP (NNP Doc_8659767_287_298_Chemical)) (VP (VBZ alters) (NP (NP (DT the) (NN dysrhythmogenicity)) (PP (IN of) (NP (NP (JJ subsequent) (NN administration)) (PP (IN of) (NP (NNP Doc_8659767_361_372_Chemical))))) (PP (PP (IN in) (NP (JJ conscious) (, ,) (JJ healthy) (NNS dogs))) (CC and) (PP (IN in) (NP (NP (JJ anesthetized) (NNS dogs)) (PP (IN with) (NP (NNP Doc_8659767_430_451_Disease))))))))))) (. .)))
8659767	3	(S1 (S (NP (JJ Forty-one) (JJ conscious) (NNS dogs)) (VP (VBD received) (NP (CD 10) (JJ micrograms.kg-1.min-1) (NNP Doc_8659767_512_523_Chemical))) (. .)))
8659767	4	(S1 (S (NP (NNP Seventeen) (NNS animals)) (VP (VBD responded) (PP (IN with) (NP (NP (NNP Doc_8659767_558_581_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8659767_583_585_Disease)) (-RRB- -RRB-)))) (PP (IN within) (NP (CD 3) (NN min)))) (. .)))
8659767	5	(S1 (S (PP (IN After) (NP (NNP 3) (NNP h))) (, ,) (NP (DT these) (NNS responders)) (ADVP (RB randomly)) (VP (VBD received) (NP (NP (QP (CD 1) (CC or) (CD 2)) (NN mg/kg)) (ADJP (JJ Doc_8659767_660_671_Chemical) (CC or) (JJ saline))) (PP (IN over) (NP (CD 5) (NN min))) (, ,) (S (VP (VBN followed) (PP (IN by) (NP (CD 10) (JJ micrograms.kg-1.min-1) (NNP Doc_8659767_731_742_Chemical)))))) (. .)))
8659767	6	(S1 (S (PP (IN In) (NP (DT the) (JJ Doc_8659767_751_762_Chemical) (NNS groups))) (, ,) (NP (NNP Doc_8659767_771_782_Chemical)) (VP (VBD caused) (NP (JJR fewer) (JJ prodysrhythmic) (NNS effects)) (PP (IN than) (PP (IN without) (NP (NNP Doc_8659767_832_843_Chemical))))) (. .)))
8659767	7	(S1 (S (S (S (NP (NN Doc_8659767_845_847_Disease)) (VP (VBD appeared) (PP (PP (IN in) (NP (JJR fewer) (NNS dogs))) (CC and) (PP (IN at) (NP (DT a) (JJ later) (NN time)))))) (, ,) (CC and) (S (NP (EX there)) (VP (AUX were) (ADJP (RBR more) (JJ sinoatrial))))) (VP (VBZ beats) (NP (QP (CC and) (JJR less)) (NNS ectopies))) (. .)))
8659767	8	(S1 (S (NP (NN Doc_8659767_948_959_Chemical)) (VP (VBN shortened) (NP (NN QT)) (ADVP (ADVP (RBR less)) (PP (IN after) (NP (NNP Doc_8659767_984_995_Chemical))) (PP (IN than) (PP (IN in) (NP (NN control) (NNS animals)))))) (. .)))
8659767	9	(S1 (S (PP (NP (CD One) (NN day)) (IN after) (NP (JJ experimental) (NN Doc_8659767_1048_1069_Disease))) (, ,) (NP (NP (CD six) (JJ additional) (JJ Doc_8659767_1086_1095_Chemical-anesthetized) (NNS dogs)) (VP (VBN received) (NP (CD 4) (JJ micrograms.kg-1.min-1) (NNP Doc_8659767_1147_1158_Chemical)) (PP (IN until) (NP (NNP Doc_8659767_1165_1167_Disease))))) (VP (VBD appeared)) (. .)))
8659767	10	(S1 (S (PP (IN After) (NP (CD 45) (NN min))) (, ,) (NP (QP (CD 1) (CD mg/kg)) (NNP Doc_8659767_1200_1211_Chemical)) (VP (AUX was) (VP (VBN injected) (PP (IN over) (NP (NP (CD 5) (NN min)) (, ,) (VP (ADVP (RB again)) (VBN followed) (PP (IN by) (NP (CD 4) (JJ micrograms.kg-1.min-1) (NNP Doc_8659767_1279_1290_Chemical)))))))) (. .)))
8659767	11	(S1 (S (PP (IN In) (NP (DT these) (NNS dogs))) (, ,) (NP (NP (DT the) (JJ prodysrhythmic) (NN response)) (PP (TO to) (NP (NNP Doc_8659767_1338_1349_Chemical)))) (VP (AUX was) (ADVP (RB also)) (VP (VBN mitigated) (PP (IN by) (S (VP (VBG preceding) (NP (NNP Doc_8659767_1382_1393_Chemical))))))) (. .)))
8659767	12	(S1 (S (NP (NN Doc_8659767_1395_1406_Chemical)) (VP (VBZ antagonizes) (NP (NP (JJ Doc_8659767_1419_1430_Chemical) (NN dysrhythmogenicity)) (PP (PP (IN in) (NP (NP (JJ conscious) (NNS dogs)) (ADJP (JJ susceptible) (PP (TO to) (NP (NNP Doc_8659767_1483_1485_Disease)))))) (CC and) (PP (IN in) (NP (NP (JJ anesthetized) (NNS dogs)) (PP (IN with) (NP (JJ spontaneous) (NNP Doc_8659767_1528_1552_Disease)))))))) (. .)))
8659767	13	(S1 (S (NP (EX There)) (VP (AUX is) (NP (DT no) (NN evidence) (SBAR (IN that) (S (NP (JJ systemic) (JJ subtoxic) (JJ Doc_8659767_1598_1609_Chemical) (NN administration)) (VP (VBZ enhances) (NP (NP (DT the) (NN dysrhythmogenicity)) (PP (IN of) (NP (JJ subsequent) (NN Doc_8659767_1671_1682_Chemical))))))))) (. .)))
8667442	0	(S1 (S (NP (NN Doc_8667442_0_20_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_8667442_32_42_Chemical))) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NNP Doc_8667442_61_79_Disease)))))) (. .)))
8667442	1	(S1 (S (NP (NN Doc_8667442_81_101_Disease)) (VP (AUX was) (ADVP (RB first)) (VP (VBN described) (ADVP (NP (CD 70) (NNS years)) (RB ago)) (PP (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_8667442_170_190_Disease))))))) (PP (IN with) (NP (NP (JJ large) (NNS amounts)) (PP (IN of) (NP (NP (NNP Doc_8667442_213_220_Chemical)) (CC and) (NP (NNP alkali)))))))) (. .)))
8667442	2	(S1 (S (SBAR (IN Although) (S (PP (IN with) (NP (NP (JJ current) (JJ Doc_8667442_255_260_Disease) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NP (JJ H-2) (NNS blockers)) (, ,) (NP (NP (NNP Doc_8667442_284_294_Chemical)) (, ,) (CC and) (NP (NNP Doc_8667442_300_310_Chemical)))) (-RRB- -RRB-)))) (, ,) (NP (NP (DT the) (NN frequency)) (PP (IN of) (NP (NNP Doc_8667442_330_350_Disease)))) (VP (AUX has) (VP (VBN decreased) (ADVP (RB significantly)))))) (, ,) (NP (NP (DT the) (JJ classic) (NNP triad)) (PP (IN of) (NP (NP (NNP Doc_8667442_401_414_Disease)) (, ,) (NP (NNP Doc_8667442_416_425_Disease)) (, ,) (CC and) (NP (NNP Doc_8667442_431_447_Disease))))) (VP (VBZ remains) (NP (DT the) (NNP Doc_8667442_460_484_Disease))) (. .)))
8667442	3	(S1 (S (NP (NN Doc_8667442_486_506_Disease)) (VP (MD can) (VP (VB present) (NP (ADJP (ADJP (JJ serious)) (CC and) (ADJP (RB occasionally) (JJ life-threatening))) (NN illness)) (SBAR (IN unless) (S (VP (VP (VBN diagnosed)) (CC and) (VP (VBN treated) (ADVP (RB appropriately)))))))) (. .)))
8667442	4	(S1 (S (NP (DT This) (NN article)) (VP (VBZ presents) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_8667442_650_668_Disease)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_8667442_690_707_Chemical) (CC and) (NNP Doc_8667442_712_722_Chemical)) (VP (VBG resulting) (PP (IN in) (NP (NP (CD two) (NNS admissions)) (PP (TO to) (NP (DT the) (NN hospital))) (PP (IN for) (NP (NNP Doc_8667442_771_791_Disease)))))))))))))))) (. .)))
8667442	5	(S1 (S (NP (DT The) (NN patient)) (VP (AUX was) (ADVP (RB successfully)) (VP (VBN treated) (PP (IN with) (NP (JJ intravenous) (NNP Doc_8667442_847_858_Chemical))) (PP (PP (IN on) (NP (PRP$ his) (JJ first) (NN admission))) (CC and) (PP (IN with) (NP (NP (NNP Doc_8667442_891_905_Chemical)) (PP (IN on) (NP (DT the) (NN second)))))))) (. .)))
8667442	6	(S1 (S (NP (DT This)) (VP (VBZ illustrates) (NP (JJ intravenous) (NN Doc_8667442_950_961_Chemical)) (PP (IN as) (NP (NP (DT a) (JJ valuable) (JJ therapeutic) (NN tool)) (SBAR (WHADVP (WRB when)) (S (NP (NNP Doc_8667442_998_1018_Disease)) (VP (VBZ presents) (PP (IN as) (NP (JJ hypercalcemic) (NN emergency))))))))) (. .)))
8701013	0	(S1 (NP (JJ Doc_8701013_0_10_Chemical-associated) (NN Doc_8701013_22_30_Disease) (. .)))
8701013	1	(S1 (NP (NP (NP (DT A) (NN series)) (PP (IN of) (NP (CD six) (NNS cases)))) (. .)))
8701013	2	(S1 (S (NP (NNP Doc_8701013_55_65_Chemical)) (VP (VP (AUX is) (NP (NP (DT a) (NNP Doc_8701013_71_80_Chemical) (NNP H2-receptor) (NN antagonist)) (VP (VBN used) (PP (IN in) (NP (NN inpatient) (NNS settings))) (PP (IN for) (NP (NP (NN prevention)) (PP (IN of) (NP (NN stress) (NN Doc_8701013_156_162_Disease)))))))) (CC and) (VP (AUX is) (VP (VBG showing) (S (VP (VBG increasing) (NP (NN popularity)) (PP (IN because) (IN of) (NP (PRP$ its) (JJ low) (NN cost)))))))) (. .)))
8701013	3	(S1 (S (SBAR (IN Although) (S (NP (NP (DT all)) (PP (IN of) (NP (DT the) (ADJP (RB currently) (JJ available)) (JJ H2-receptor) (NNS antagonists)))) (VP (AUX have) (VP (VBN shown) (NP (DT the) (NN propensity) (S (VP (TO to) (VP (VB cause) (NP (NN Doc_8701013_324_332_Disease)))))))))) (, ,) (NP (QP (RB only) (CD two)) (ADJP (RB previously) (VBN reported)) (NNS cases)) (VP (AUX have) (VP (AUX been) (VP (VBN associated) (PP (IN with) (NP (NNP Doc_8701013_395_405_Chemical)))))) (. .)))
8701013	4	(S1 (S (NP (DT The) (NNS authors)) (VP (VBP report) (PP (IN on) (NP (NP (CD six) (NNS cases)) (PP (IN of) (NP (NNP Doc_8701013_442_452_Chemical-associated) (NNP Doc_8701013_464_472_Disease))))) (PP (IN in) (NP (NP (VBN hospitalized) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD cleared) (ADVP (RB completely)) (PP (IN upon) (NP (NP (NN removal)) (PP (IN of) (NP (NNP Doc_8701013_537_547_Chemical))))))))))) (. .)))
8701013	5	(S1 (S (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (NNP Doc_8701013_573_583_Chemical)))) (VP (AUX are) (VP (VBN reviewed) (, ,) (PP (IN with) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NP (PRP$ its) (NN metabolism)) (PP (IN in) (NP (NP (DT the) (JJ elderly) (NN population)) (VP (VBN seen)))))))))) (. .)))
8701013	6	(S1 (S (NP (NP (DT The) (NNS implications)) (PP (IN of) (S (VP (VBG using) (NP (NNP Doc_8701013_689_699_Chemical)) (PP (IN in) (NP (JJ elderly) (NNS persons))))))) (VP (AUX are) (VP (VBN discussed))) (. .)))
8748050	0	(S1 (S (S (VP (VB Doc_8748050_0_14_Disease) (PP (IN during) (NP (JJ Doc_8748050_22_35_Chemical) (NN therapy))))) (: :) (SINV (AUX are) (NP (NNP Doc_8748050_49_79_Disease) (CC and) (NNP Doc_8748050_84_93_Chemical) (NN syndrome) (NN spectrum) (NNS disorders))) (. ?)))
8748050	1	(S1 (S (NP (DT This) (NN report)) (VP (VBZ describes) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NP (NNP Doc_8748050_155_169_Disease)) (VP (VBN developed) (PP (IN in) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (JJ Doc_8748050_197_210_Chemical) (NN therapy))))))))) (, ,) (PP (IN during) (NP (NP (DT a) (NN remission)) (PP (IN of) (NP (NNP Doc_8748050_242_261_Disease)))))) (. .)))
8748050	2	(S1 (S (NP (DT This) (NN patient)) (VP (MD could) (VP (AUX have) (VP (AUX been) (VP (VBN diagnosed) (PP (IN as) (S (VP (AUXG having) (NP (NP (NP (DT either) (NNP Doc_8748050_319_349_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8748050_351_354_Disease)) (-RRB- -RRB-))) (CC or) (NP (NP (JJ Doc_8748050_359_368_Chemical) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8748050_379_381_Disease)) (-RRB- -RRB-))))))))))) (. .)))
8748050	3	(S1 (S (NP (NP (DT The) (JJ major) (NN determinant)) (PP (IN of) (NP (DT the) (NNS symptoms)))) (VP (MD may) (VP (AUX have) (VP (AUX been) (NP (JJ Doc_8748050_436_444_Chemical/Doc_8748050_445_454_Chemical) (NN imbalance)) (PP (IN in) (NP (DT the) (JJ central) (JJ nervous) (NN system)))))) (. .)))
8748050	4	(S1 (S (NP (NP (DT The) (JJ Doc_8748050_500_503_Disease-like) (NN Doc_8748050_509_523_Disease)) (SBAR (WHNP (WDT that)) (S (VP (VBZ develops) (PP (IN in) (NP (NN association))) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNS antidepressants))))))))) (VP (VBZ indicates) (SBAR (IN that) (S (NP (NP (NNP Doc_8748050_600_603_Disease)) (CC and) (NP (NNP Doc_8748050_608_610_Disease))) (VP (AUX are) (NP (NP (NN spectrum) (NNS disorders)) (VP (VBN induced) (PP (IN by) (NP (NNS drugs))) (PP (IN with) (NP (DT both) (JJ antidopaminergic) (CC and) (JJ serotonergic) (NNS effects))))))))) (. .)))
8755612	0	(S1 (NP (NP (NN Doc_8755612_0_18_Disease)) (PP (IN of) (NP (NP (JJ Doc_8755612_22_27_Disease) (NN growth)) (CC and) (NP (JJ Doc_8755612_39_50_Disease) (NNS phenotypes)))) (PP (IN in) (NP (DT an) (JJ Doc_8755612_68_76_Chemical-induced) (NN Doc_8755612_85_90_Disease))) (. .)))
8755612	1	(S1 (S (NP (NP (NN Chronic) (NN administration)) (PP (IN of) (NP (NNP Doc_8755612_118_126_Chemical))) (PP (TO to) (NP (DT the) (NNP Fischer) (CD 344) (-LRB- -LRB-) (NNP F344) (-RRB- -RRB-) (NN rat)))) (VP (VBZ induces) (NP (NP (NN growth)) (PP (IN of) (NP (JJ large) (, ,) (JJ Doc_8755612_182_193_Disease) (NNP Doc_8755612_194_210_Disease))))) (. .)))
8755612	2	(S1 (S (NP (NP (CD Ten) (NNS weeks)) (PP (IN of) (NP (NNP Doc_8755612_225_243_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_8755612_245_248_Chemical)) (-RRB- -RRB-)) (NN treatment)))) (VP (VBD caused) (S (NP (JJ female) (NNP F344) (NN rat) (NNS pituitaries)) (VP (VP (TO to) (VP (VB grow) (PP (TO to) (NP (NP (DT an) (NN average)) (PP (IN of) (NP (NP (CD 109.2) (JJ +/-) (CD 6.3) (NNS mg)) (PRN (-LRB- -LRB-) (S (VP (VB mean) (NP (JJ +/-) (FW SE)))) (-RRB- -RRB-)))))) (PP (IN versus) (NP (NP (CD 11.3) (NN +/-) (QP (CD 1.4) (CD mg))) (PP (IN for) (NP (JJ untreated) (NNS rats))))))) (, ,) (CC and) (VP (TO to) (VP (VB become) (ADJP (RB highly) (JJ Doc_8755612_415_426_Disease))))))) (. .)))
8755612	3	(S1 (S (NP (DT The) (JJ same) (JJ Doc_8755612_437_440_Chemical) (NN treatment)) (VP (VBD produced) (NP (NP (NP (DT no) (JJ significant) (NN growth)) (PRN (-LRB- -LRB-) (NP (NP (NP (NP (CD 8.9) (NN +/-)) (NP (CD 0.5) (NN mg))) (PP (IN for) (NP (VBN treated) (NNS females)))) (CC versus) (NP (NP (NP (CD 8.7) (NN +/-)) (NP (CD 1.1))) (PP (IN for) (NP (JJ untreated) (NNS females))))) (-RRB- -RRB-))) (CC or) (NP (NP (JJ morphological) (NNS changes)) (PP (IN in) (NP (NNP Brown) (NNP Norway) (PRN (-LRB- -LRB-) (NP (NNP BN)) (-RRB- -RRB-)) (NN rat) (NNS pituitaries)))))) (. .)))
8755612	4	(S1 (S (NP (NP (DT An) (JJ F1) (NN hybrid)) (PP (IN of) (NP (NNP F344) (CC and) (NNP BN)))) (VP (VBD exhibited) (NP (JJ significant) (JJ pituitary) (NN growth)) (PP (IN after) (NP (NP (CD 10) (NNS weeks)) (PP (IN of) (NP (JJ Doc_8755612_708_711_Chemical) (NN treatment))))) (PP (IN with) (NP (NP (DT an) (JJ average) (NN mass)) (PP (IN of) (NP (NP (CD 26.3) (JJ +/-) (CD 0.7) (NNS mg)) (PP (VBN compared) (PP (IN with) (NP (NP (CD 8.6) (JJ +/-) (CD 0.9) (NNS mg)) (PP (IN for) (NP (JJ untreated) (NNS rats))))))))))) (. .)))
8755612	5	(S1 (S (ADVP (RB Surprisingly)) (, ,) (NP (DT the) (NNP F1) (NN hybrid) (NN Doc_8755612_839_845_Disease)) (VP (VP (AUX were) (RB not) (ADJP (JJ Doc_8755612_855_866_Disease))) (CC and) (VP (AUX had) (NP (NP (NN hemoglobin) (NN content)) (CC and) (NP (NN outward) (NN appearance)))) (ADJP (JJ identical) (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NNS BN))))))) (. .)))
8755612	6	(S1 (S (NP (NP (NN Expression)) (PP (IN of) (NP (DT both) (NN growth) (CC and) (NN morphological) (NNS changes)))) (VP (AUX is) (ADJP (JJ due) (PP (TO to) (NP (JJ multiple) (NNS genes))))) (. .)))
8755612	7	(S1 (S (ADVP (RB However)) (, ,) (SBAR (IN while) (S (NP (JJ Doc_8755612_1035_1038_Chemical-induced) (NN pituitary) (NN growth)) (VP (VBD exhibited) (NP (JJ quantitative) (, ,) (JJ additive) (NN inheritance))))) (, ,) (NP (DT the) (NNP Doc_8755612_1114_1125_Disease) (NN phenotype)) (VP (VBD exhibited) (NP (NN recessive)) (, ,) (NP (JJ epistatic) (NN inheritance))) (. .)))
8755612	8	(S1 (S (S (NP (QP (RB Only) (CD 5) (IN of) (DT the) (CD 160)) (NNP F2) (NNS pituitaries)) (VP (VBD exhibited) (NP (DT the) (NNP Doc_8755612_1227_1238_Disease) (NN phenotype)))) (: ;) (S (NP (NP (CD 36)) (PP (IN of) (NP (DT the) (CD 160) (NNP F2) (NNS pituitaries)))) (VP (AUX were) (PP (IN in) (NP (NP (DT the) (JJ F344) (NN range)) (PP (IN of) (NP (NN mass))))))) (, ,) (CC but) (S (NP (NP (CD 31)) (PP (IN of) (NP (DT these)))) (VP (AUX were) (RB not) (ADJP (JJ Doc_8755612_1336_1347_Disease)) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (DT the) (NNP Doc_8755612_1369_1380_Disease) (NN phenotype)) (VP (AUX is) (RB not) (ADVP (RB merely)) (NP (NP (DT a) (NN consequence)) (PP (IN of) (NP (JJ extensive) (NN growth))))))))))) (. .)))
8755612	9	(S1 (S (NP (DT The) (NNP Doc_8755612_1444_1455_Disease) (NNP F2) (NNS pituitaries)) (VP (AUX were) (ADVP (RB all)) (PP (IN among) (NP (DT the) (RBS most) (JJ massive))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NP (DT some)) (PP (IN of) (NP (DT the) (NNS genes)))) (VP (VB regulate) (NP (DT both) (NNS phenotypes)))))))) (. .)))
8808730	0	(S1 (NP (NP (VBN Increased) (NN expression)) (PP (IN of) (NP (JJ neuronal) (JJ Doc_8808730_33_45_Chemical) (NN synthase))) (PP (IN in) (NP (NP (NN bladder) (NN afferent) (NNS pathways)) (VP (VBG following) (NP (JJ chronic) (NNP Doc_8808730_102_120_Disease))))) (. .)))
8808730	1	(S1 (S (NP (JJ Immunocytochemical) (NNS techniques)) (VP (AUX were) (VP (VBN used) (S (VP (TO to) (VP (VB examine) (NP (NNS alterations)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ neuronal) (JJ Doc_8808730_215_227_Chemical) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NNP NOS)) (-RRB- -RRB-)))) (PP (IN in) (NP (NN bladder) (NNS pathways))))) (PP (VBG following) (NP (NP (ADJP (JJ acute) (CC and) (JJ chronic)) (NN irritation)) (PP (IN of) (NP (NP (DT the) (JJ urinary) (NN tract)) (PP (IN of) (NP (DT the) (NN rat)))))))))))) (. .)))
8808730	2	(S1 (S (NP (NN Doc_8808730_335_352_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NP (NP (NNP Doc_8808730_368_384_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP CYP)) (-RRB- -RRB-)) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN metabolized) (PP (TO to) (NP (NNP Doc_8808730_415_423_Chemical)))))))) (, ,) (NP (NP (DT an) (NN irritant)) (VP (VBN eliminated) (PP (IN in) (NP (DT the) (NN urine))))))))) (. .)))
8808730	3	(S1 (S (NP (NP (NN Injection)) (PP (IN of) (NP (NP (NNS CYP)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 10)) (, ,) (NP (NP (CD 75) (NNS mg/kg)) (, ,) (NP (CD i.p.))) (-RRB- -RRB-)))) (ADVP (NP (CD 2) (NNS hours)) (RB prior) (PP (TO to) (NP (NP (NN perfusion)) (PRN (-LRB- -LRB-) (NP (JJ acute) (NN treatment)) (-RRB- -RRB-)) (PP (IN of) (NP (DT the) (NNS animals))))))) (VP (VBD increased) (ADJP (JJ Fos-immunoreactivity) (PRN (-LRB- -LRB-) (JJ IR) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NNS neurons)) (PP (IN in) (NP (NP (DT the) (JJ dorsal) (NN commissure)) (, ,) (NP (JJ dorsal) (NN horn)) (, ,) (CC and) (NP (JJ autonomic) (NNS regions)))) (PP (IN of) (NP (NP (JJ spinal) (NNS segments)) (PRN (-LRB- -LRB-) (NP (NNP L1-L2) (CC and) (NNP L6-S1)) (-RRB- -RRB-)) (SBAR (WHNP (WDT which)) (S (VP (VBP receive) (NP (NP (JJ afferent) (NNS inputs)) (PP (IN from) (NP (NP (DT the) (NN bladder)) (, ,) (NP (NN urethra)) (, ,) (CC and) (NP (NN ureter))))))))))))) (. .)))
8808730	4	(S1 (S (NP (NP (NN Fos-IR)) (PP (IN in) (NP (DT the) (JJ spinal) (NN cord)))) (VP (AUX was) (RB not) (VP (VBN changed) (PP (IN in) (NP (NP (NNS rats)) (VP (VBG receiving) (NP (NP (JJ chronic) (NN CYP) (NN treatment)) (PRN (-LRB- -LRB-) (NP (NP (NNP n) (SYM =) (CD 15)) (, ,) (NP (CD 75) (NN mg/kg))) (, ,) (NP (NP (CD i.p.)) (, ,) (NP (NP (DT every) (JJ 3rd) (NN day)) (PP (IN for) (NP (CD 2) (NNS weeks))))) (-RRB- -RRB-)))))))) (. .)))
8808730	5	(S1 (S (PP (PP (IN In) (NP (NN control) (NNS animals))) (CC and) (PP (IN in) (NP (NP (NNS animals)) (VP (VBN treated) (ADVP (RB acutely)) (PP (IN with) (NP (NN CYP))))))) (, ,) (NP (NP (RB only) (JJ small) (NNS numbers)) (PP (IN of) (NP (NP (JJ NOS-IR) (NNS cells)) (PRN (-LRB- -LRB-) (NP (CD 0.5-0.7) (NN cell) (NNS profiles/sections)) (-RRB- -RRB-))))) (VP (AUX were) (VP (VBN detected) (PP (IN in) (NP (NP (DT the) (JJ L6-S1) (JJ dorsal) (NN root) (NN ganglia)) (PRN (-LRB- -LRB-) (NP (NNP DRG)) (-RRB- -RRB-)))))) (. .)))
8808730	6	(S1 (S (NP (JJ Chronic) (JJ Doc_8808730_1103_1106_Chemical) (NN administration)) (VP (VP (ADVP (RB significantly) (PRN (-LRB- -LRB-) (NP (NNP P) (NNP <) (CC or) (SYM =) (CD .002)) (-RRB- -RRB-))) (VBD increased) (NP (NN bladder) (NN weight)) (PP (IN by) (NP (CD 60) (NN %)))) (CC and) (VP (VBD increased) (PRN (-LRB- -LRB-) (ADJP (JJ 7-) (TO to) (JJ 11-fold)) (-RRB- -RRB-)) (NP (NP (DT the) (NNS numbers)) (PP (IN of) (NP (JJ NOS-immunoreactive) (PRN (-LRB- -LRB-) (NP (NNP IR)) (-RRB- -RRB-)) (NN afferent) (NNS neurons))) (PP (IN in) (NP (DT the) (NNP L6-S1) (NNP DRG)))))) (. .)))
8808730	7	(S1 (S (S (NP (NP (DT A) (JJ small) (NN increase)) (PRN (-LRB- -LRB-) (JJ 1.5-fold) (-RRB- -RRB-))) (ADVP (RB also)) (VP (VBD occurred) (PP (IN in) (NP (DT the) (NNP L1) (NNP DRG))))) (, ,) (CC but) (S (NP (DT no) (NN change)) (VP (AUX was) (VP (VBN detected) (PP (IN in) (NP (DT the) (NNP L2) (CC and) (NNP L5) (NNP DRG)))))) (. .)))
8808730	8	(S1 (S (S (NP (NP (NN Bladder) (NN afferent) (NNS cells)) (PP (IN in) (NP (NP (DT the) (NNP L6-S1) (NNP DRG)) (VP (VBN labeled) (PP (IN by) (NP (NP (NNP Fluorogold)) (PRN (-LRB- -LRB-) (NP (CD 40) (NNS microliters)) (-RRB- -RRB-))))))) (VP (VBN injected) (PP (IN into) (NP (DT the) (NN bladder) (NN wall))))) (VP (AUX did) (RB not) (VP (VB exhibit) (NP (NN NOS-IR)) (PP (IN in) (NP (NN control) (NNS animals)))))) (: ;) (S (ADVP (RB however)) (, ,) (PP (VBG following) (NP (JJ chronic) (NN CYP) (NN administration))) (, ,) (NP (NP (DT a) (JJ significant) (NN percentage)) (PP (IN of) (NP (NN bladder) (NN afferent) (NNS neurons)))) (VP (AUX were) (ADJP (JJ NOS-IR)) (: :) (NP (NP (NP (NNP L6)) (PRN (-LRB- -LRB-) (NP (CD 19.8) (NN +/-) (CD 4.6) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP S1)) (PRN (-LRB- -LRB-) (NP (CD 25.3) (NN +/-) (CD 2.9) (NN %)) (-RRB- -RRB-)))))) (. .)))
8808730	9	(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (JJ neuronal) (NN gene) (NN expression)) (PP (IN in) (NP (JJ visceral) (JJ sensory) (NNS pathways)))) (VP (MD can) (VP (AUX be) (VP (VBN upregulated) (PP (IN by) (NP (NP (NN chemical) (NN irritation)) (PP (IN of) (NP (JJ afferent) (NNS receptors))))) (PP (IN in) (NP (NP (DT the) (JJ urinary) (NN tract) (NN and/or)) (SBAR (WHNP (IN that)) (S (NP (NP (JJ pathological) (NNS changes)) (PP (IN in) (NP (DT the) (JJ urinary) (NN tract)))) (VP (MD can) (VP (VB initiate) (NP (NP (NN chemical) (NNS signals)) (SBAR (WHNP (WDT that)) (S (VP (VBP alter) (NP (NP (DT the) (JJ chemical) (NNS properties)) (PP (IN of) (NP (JJ visceral) (NN afferent) (NNS neurons)))))))))))))))))))) (. .)))
8819482	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NP (DT a) (JJ new) (JJ Doc_8819482_17_24_Chemical) (NN antagonist)) (, ,) (NP (NNP Doc_8819482_37_43_Chemical)) (, ,))) (PP (IN on) (NP (NP (NNP Doc_8819482_48_61_Chemical-induced) (NNP Doc_8819482_70_89_Disease)) (PP (IN in) (NP (NP (NNS dogs)) (PP (IN with) (NP (JJ partial) (NNP Doc_8819482_111_128_Disease))))))) (. .)))
8819482	1	(S1 (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NNP Doc_8819482_141_147_Chemical))) (PP (IN on) (NP (NP (NNP Doc_8819482_151_164_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8819482_166_169_Chemical)) (-RRB- -RRB-))))) (VP (VBD -induced) (SBAR (S (S (NP (NNP Doc_8819482_179_198_Disease)) (VP (AUX were) (VP (VBN studied) (PP (IN in) (NP (NP (NNS dogs)) (PP (IN with) (NP (NP (JJ partial) (NNP Doc_8819482_233_250_Disease)) (PP (IN of) (NP (DT the) (JJ left) (NN circumflex) (JJ coronary) (NN artery)))))))))) (CC and) (S (NP (NNS findings)) (VP (AUX were) (VP (VBN compared) (PP (IN with) (NP (NP (DT those)) (PP (IN for) (NP (NNP Doc_8819482_332_342_Chemical) (CC or) (NNP Doc_8819482_346_355_Chemical))))))))))) (. .)))
8819482	2	(S1 (S (PP (IN In) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_8819482_376_400_Disease))))) (, ,) (NP (NP (JJ 3-min) (NNS periods)) (PP (IN of) (NP (NP (JJ intracoronary) (JJ Doc_8819482_433_436_Chemical) (NN infusion)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN ng/kg/min)) (-RRB- -RRB-))))) (VP (VBD increased) (NP (NP (NN heart) (NN rate) (CC and) (NN maximal) (NN rate)) (PP (IN of) (NP (NP (JJ left) (JJ ventricular) (NN pressure) (NN rise)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (NN percentage) (JJ segmental) (NN shortening)) (CC and) (NP (NP (JJ ST-segment) (NN elevation)) (PP (IN of) (NP (DT the) (JJ epicardial) (NN electrocardiogram))))))))))))))) (. .)))
8819482	3	(S1 (S (SBAR (IN After) (S (NP (NP (DT the) (NN control) (JJ Doc_8819482_678_681_Chemical) (NN infusion)) (PP (IN with) (NP (NNP Doc_8819482_696_704_Disease)))) (VP (AUX was) (VP (VBN performed))))) (, ,) (NP (NP (JJ equihypotensive) (NNS doses)) (PP (IN of) (NP (NP (NP (NNP Doc_8819482_745_751_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 3) (CC and) (CD 10)) (NN micrograms/kg/min)) (, ,) (NP (NNP n) (SYM =) (CD 7))) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_8819482_789_799_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 1) (CC and) (CD 3) (NN micrograms/kg/min))) (, ,) (NP (NNP n) (SYM =) (CD 9))) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_8819482_838_847_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 10) (CC and) (CD 30) (NN micrograms/kg/min))) (, ,) (NP (NNP n) (SYM =) (CD 7))) (-RRB- -RRB-)))))) (VP (AUX were) (VP (VBN infused) (NP (CD 5) (NN min)) (PP (IN before) (CC and) (IN during) (NP (DT the) (ADJP (JJ second) (CC and) (JJ third)) (JJ Doc_8819482_943_946_Chemical) (NN infusion))))) (. .)))
8819482	4	(S1 (S (NP (NP (DT Both) (NNP Doc_8819482_962_968_Chemical) (CC and) (NNP Doc_8819482_973_982_Chemical)) (, ,) (CONJP (CC but) (RB not)) (NP (NNP Doc_8819482_992_1002_Chemical)) (, ,)) (ADVP (RB significantly)) (VP (VBD reduced) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NP (NN heart) (NN rate)) (VP (VBN induced) (PP (IN by) (NP (JJ Doc_8819482_1064_1067_Chemical) (NN infusion)))))))) (. .)))
8819482	5	(S1 (S (PP (IN In) (NP (NP (NN contrast)) (PP (TO to) (NP (NNP Doc_8819482_1093_1103_Chemical))))) (, ,) (NP (NP (NNP Doc_8819482_1105_1111_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN micrograms/kg/min)) (-RRB- -RRB-))) (VP (VBD prevented) (NP (NP (DT the) (NN decrease)) (PP (IN in) (NP (NN percentage) (NN segmental)))) (PP (VBG shortening) (PP (IN from) (NP (QP (CD 32) (JJ +/-) (CD 12) (NN %) (TO to) (CD 115) (NN +/-)) (NP (NP (CD 26) (NN %)) (PP (IN of) (NP (NP (DT the) (NN control) (NN value)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD .01))) (-RRB- -RRB-))))) (CC and) (NP (NP (JJ ST-segment) (NN elevation)) (PP (IN from) (NP (NP (QP (CD 5.6) (JJ +/-) (CD 1.0) (NN mV) (TO to) (CD 1.6) (NN +/-)) (QP (CD 1.3) (CD mV))) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD .01))) (-RRB- -RRB-)))) (PP (IN at) (NP (NP (CD 3) (NN min)) (PP (IN after) (NP (NP (JJ Doc_8819482_1343_1346_Chemical) (NN infusion)) (PP (IN with) (NP (NNP Doc_8819482_1361_1369_Disease)))))))))))) (. .)))
8819482	6	(S1 (S (NP (NP (NNP Doc_8819482_1371_1380_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN micrograms/kg/min)) (-RRB- -RRB-))) (ADVP (RB also)) (VP (VBD prevented) (NP (NP (DT the) (NN decrease)) (PP (IN in) (NP (NN percentage) (JJ segmental) (NN shortening)))) (PP (IN from) (NP (QP (CD 34) (CD +/-) (CD 14) (NN %) (TO to) (CD 63) (CD +/-)) (NP (NP (CD 18) (NN %)) (PP (IN of) (NP (NP (DT the) (NN control) (NN value)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD .05))) (-RRB- -RRB-))))) (CC and) (NP (JJ ST-segment) (NN elevation)))) (PP (IN from) (NP (NP (NP (CD 4.7) (NN +/-)) (NP (CD 0.7) (NNS mV))) (PP (TO to) (NP (NP (CD 2.1) (JJ +/-) (CD 0.7) (NNS mV)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD .01))) (-RRB- -RRB-)))))) (PP (IN at) (NP (NP (CD 3) (NN min)) (PP (IN after) (NP (NP (JJ Doc_8819482_1616_1619_Chemical) (NN infusion)) (PP (IN with) (NP (NNP Doc_8819482_1634_1642_Disease)))))))) (. .)))
8819482	7	(S1 (S (NP (DT These) (NNS data)) (VP (VP (VBP show) (SBAR (IN that) (S (NP (NNP Doc_8819482_1665_1671_Chemical)) (VP (VBZ improves) (NP (NNP Doc_8819482_1681_1700_Disease)) (PP (IN during) (NP (NP (JJ Doc_8819482_1708_1711_Chemical) (NN infusion)) (PP (IN with) (NP (NNP Doc_8819482_1726_1734_Disease))))))))) (CC and) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (DT the) (JJ negative) (JJ chronotropic) (NN property)) (PP (IN of) (NP (NNP Doc_8819482_1790_1796_Chemical)))) (VP (VBZ plays) (NP (DT a) (JJ major) (NN role)) (PP (IN in) (NP (NP (DT the) (JJ beneficial) (NNS effects)) (PP (IN of) (NP (NNP Doc_8819482_1845_1851_Chemical)))))))))) (. .)))
8825380	0	(S1 (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (JJ recombinant) (JJ human) (JJ insulin-like) (NN growth) (NNS factor-I))) (PP (IN on) (NP (NP (JJ chronic) (NNP Doc_8825380_72_97_Chemical) (NNP Doc_8825380_98_109_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
8825380	1	(S1 (S (NP (PRP We)) (ADVP (RB recently)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (JJ recombinant) (NN hGH)) (VP (VBZ exacerbates) (NP (JJ renal) (JJ functional) (CC and) (JJ Doc_8825380_198_215_Disease)) (PP (IN in) (NP (NP (JJ chronic) (NNP Doc_8825380_227_252_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_8825380_254_257_Chemical)) (-RRB- -RRB-)) (NNP Doc_8825380_259_270_Disease)) (, ,) (NP (NP (DT an) (JJ experimental) (NN model)) (PP (IN of) (NP (NNP Doc_8825380_297_315_Disease)))))))))) (. .)))
8825380	2	(S1 (S (ADVP (RB Therefore)) (, ,) (NP (PRP we)) (VP (VBD examined) (SBAR (IN whether) (S (NP (JJ recombinant) (JJ human) (-LRB- -LRB-) (NN rh) (-RRB- -RRB-) (NN IGF-I)) (VP (AUX is) (NP (NP (DT a) (JJR safer) (NN alternative)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNP Doc_8825380_421_435_Disease))) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (JJ chronic) (NNP Doc_8825380_457_460_Chemical) (NNP Doc_8825380_461_472_Disease)))))))))))) (. .)))
8825380	3	(S1 (S (NP (DT The) (NNP Doc_8825380_478_492_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NP (CD seven) (JJ serial) (NNS injections)) (PP (IN of) (NP (NNP Doc_8825380_535_538_Chemical))))) (PP (IN over) (NP (CD 12) (NN wk))))) (. .)))
8825380	4	(S1 (S (NP (NP (JJ Experimental) (NNS animals)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 6)) (-RRB- -RRB-))) (VP (VBD received) (NP (NP (NN rhIGF-I)) (, ,) (NP (CD 400) (NNS micrograms/d)) (, ,)) (SBAR (IN whereas) (S (NP (NP (NN control) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 6)) (-RRB- -RRB-))) (VP (VBD received) (NP (NP (DT the) (ADJP (FW vehicle.) (FW rhIGF-I)) (VBN improved) (NN Doc_8825380_684_695_Disease)) (PP (IN by) (NP (CD 14) (NN %))) (PRN (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.05)) (-RRB- -RRB-))) (, ,) (PP (IN without) (S (VP (VBG altering) (NP (NN hematocrit) (CC or) (NN blood) (NN pressure)) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NNP Doc_8825380_774_787_Disease)))))))))))) (. .)))
8825380	5	(S1 (S (NP (JJ Urinary) (NN protein) (NN excretion)) (VP (AUX was) (ADJP (JJ unaltered) (PP (IN by) (NP (NP (JJ rhIGF-I) (NN treatment)) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (JJ chronic) (NNP Doc_8825380_871_874_Chemical) (NNP Doc_8825380_875_886_Disease))))))))) (. .)))
8825380	6	(S1 (S (PP (IN After) (NP (CD 12) (NNS wk))) (, ,) (NP (DT the) (NN inulin) (NN clearance)) (VP (AUX was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (JJ rhIGF-I-treated) (NNS rats)) (, ,) (NP (NP (CD 0.48) (NNS +/-)) (NP (CD 0.08))) (CC versus) (NP (NP (NP (CD 0.24) (NN +/-) (QP (CD 0.06) (CD mL/min/100))) (NP (NNP g))) (PP (IN of) (NP (NN body) (NN weight))) (PP (IN in) (NP (JJ untreated) (NNP Doc_8825380_1034_1037_Chemical) (NNP Doc_8825380_1038_1049_Disease) (NNS animals)))))) (, ,) (S (VP (VBG p) (NP (NNP <) (CD 0.05))))) (. .)))
8825380	7	(S1 (S (NP (NP (DT The) (NN improvement)) (PP (IN in) (NP (NNP GFR)))) (VP (VP (AUX was) (RB not) (VP (VBN associated) (PP (IN with) (NP (JJ enhanced) (NNP Doc_8825380_1125_1147_Disease))))) (CC or) (VP (VBD increased) (NP (NP (NNP Doc_8825380_1161_1189_Disease)) (, ,) (NP (NNP Doc_8825380_1191_1216_Disease)) (, ,) (CC or) (NP (JJ renal) (JJ cortical) (NNP Doc_8825380_1236_1251_Chemical) (NN content))))) (. .)))
8825380	8	(S1 (S (PP (IN In) (NP (NP (NNS rats)) (PP (IN with) (NP (NNP Doc_8825380_1274_1277_Chemical) (NNP Doc_8825380_1278_1289_Disease))))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NN rhIGF-I)))) (VP (VBD increased) (NP (NP (NN IGF-I)) (CC and) (NP (NN GH) (NN receptor) (NN gene) (NN expression))) (, ,) (PP (IN without) (S (VP (VBG altering) (NP (NP (DT the) (JJ steady) (NN state) (NN level)) (PP (IN of) (NP (JJ IGF-I) (NN receptor) (NNS mRNA)))))))) (. .)))
8825380	9	(S1 (S (PP (IN In) (NP (NP (JJ normal) (NNS rats)) (PP (IN with) (NP (JJ intact) (NNS kidneys))))) (, ,) (NP (NP (JJ rhIGF-I) (NN administration)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 4)) (-RRB- -RRB-))) (VP (VP (AUX did) (RB not) (VP (VB alter) (NP (NP (NP (NP (NNP Doc_8825380_1511_1522_Disease)) (, ,) (NP (NN blood) (NN pressure)) (, ,) (NP (NNP Doc_8825380_1540_1551_Disease)) (, ,) (X (SYM GFR)) (, ,) (NP (NP (JJ glomerular) (NNP planar) (NN area)) (, ,) (NP (JJ renal) (JJ cortical) (JJ Doc_8825380_1597_1612_Chemical) (NN content)) (, ,) (CC or) (NP (JJ glomerular) (CC or) (JJ tubulointerstitial) (NN damage)) (, ,) (PP (VBN compared) (PP (IN with) (NP (NP (JJ untreated) (NNS animals)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 4)) (-RRB- -RRB-)))))) (. .)) (NN rhIGF-I) (NN treatment)) (VP (VBN reduced) (NP (DT the) (JJ steady) (NN state) (JJ renal) (JJ IGF-I) (NN mRNA) (NN level)))))) (CC but) (VP (AUX did) (RB not) (VP (VB modify) (NP (NP (NN gene) (NN expression)) (PP (IN of) (NP (DT the) (JJ IGF-I) (CC or) (JJ GH) (NNS receptors))))))) (. .)))
8825380	10	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (S (: :) (LST (LS 1) (-RRB- -RRB-)) (NP (NP (NN administration)) (PP (IN of) (NP (NN rhIGF-I)))) (VP (VBZ improves) (NP (NP (NN growth) (CC and) (NN GFR)) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (JJ chronic) (NNP Doc_8825380_1930_1933_Chemical) (NNP Doc_8825380_1934_1945_Disease)))))))) (CC and) (S (LST (LS 2) (-RRB- -RRB-)) (PP (IN unlike) (NP (NN rhGH))) (, ,) (NP (NP (JJ long-term) (NN use)) (PP (IN of) (NP (NN rhIGF-I)))) (VP (AUX does) (RB not) (VP (VB worsen) (ADJP (ADJP (JJ renal) (JJ functional)) (CC and) (ADJP (JJ Doc_8825380_2028_2045_Disease) (PP (IN in) (NP (DT this) (NN disease) (NN model))))))))))) (. .)))
8829135	0	(S1 (S (S (NP (NP (NNP Doc_8829135_0_11_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8829135_13_20_Chemical)) (-RRB- -RRB-))) (VP (VBZ reverses) (NP (NP (JJ Doc_8829135_31_42_Chemical-induced) (NN Doc_8829135_51_58_Disease)) (PP (IN of) (NP (DT a) (JJ passive) (NN avoidance) (NN response)))))) (: :) (S (NP (NP (JJ delayed) (NN emergence)) (PP (IN of) (NP (DT the) (NN memory) (NN retention)))) (VP (VBZ effects))) (. .)))
8829135	1	(S1 (S (NP (NN Doc_8829135_143_154_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ novel) (JJ Doc_8829135_166_177_Chemical) (NN derivative)) (SBAR (WHNP (WDT which)) (S (VP (VBZ attenuates) (NP (NP (JJ Doc_8829135_206_217_Chemical-induced) (NN learning)) (CC and) (NP (JJ post-training) (NN consolidation) (NNS deficits)))))))) (. .)))
8829135	2	(S1 (S (PP (VBN Given) (SBAR (IN that) (S (NP (NNP Doc_8829135_288_299_Chemical)) (VP (VBZ inhibits) (NP (JJ passive) (NN avoidance) (NN retention)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (PP (IN during) (NP (NN training))) (CC or) (PP (IN in) (NP (DT a) (VBN defined) (JJ 10-12h) (JJ post-training) (NN period))))))))))) (, ,) (NP (PRP we)) (VP (VBN evaluated) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (NNP Doc_8829135_437_448_Chemical))) (S (VP (TO to) (VP (VB attenuate) (S (NP (NNP Doc_8829135_462_469_Disease)) (VP (VBN induced) (PP (IN by) (NP (JJ dopaminergic) (NN agonism)))))))))) (. .)))
8829135	3	(S1 (S (S (NP (DT A) (JJ step-down) (NN passive) (NN avoidance) (NN paradigm)) (VP (AUX was) (VP (VBN employed)))) (CC and) (S (NP (NP (NP (NNP Doc_8829135_559_570_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 3) (NN mg/kg)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_8829135_585_596_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NN mg/kg)) (-RRB- -RRB-)))) (VP (AUX were) (VP (VBN given) (UCP (ADVP (RB alone)) (CC or) (PP (PP (IN in) (NP (NP (NN combination)) (PP (IN during) (NP (NN training))))) (CC and) (PP (IN at) (NP (NP (DT the) (JJ 10-12h) (JJ post-training) (NN period)) (PP (IN of) (NP (NN consolidation)))))))))) (. .)))
8829135	4	(S1 (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (NNP Doc_8829135_738_749_Chemical)) (CC and) (NP (NNP Doc_8829135_754_765_Chemical)))) (PP (IN during) (NP (NN training) (CC or) (NN 10h)))) (ADVP (RB thereafter)) (VP (VBD produced) (NP (DT no) (JJ significant) (NN anti-Doc_8829135_829_836_Disease) (NN effect))) (. .)))
8829135	5	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_8829135_872_883_Chemical))) (PP (IN during) (NP (NN training)))) (ADVP (RB completely)) (VP (VBD reversed) (S (S (NP (DT the) (NNP Doc_8829135_924_931_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_8829135_943_954_Chemical))) (PP (IN at) (NP (DT the) (JJ 10h) (JJ post-training) (NN time))))) (CC and) (S (NP (DT the) (NN converse)) (VP (AUX was) (ADVP (RB also)) (ADJP (JJ true)))))) (. .)))
8829135	6	(S1 (S (NP (DT These) (NNS effects)) (VP (AUX were) (RB not) (VP (VBN mediated) (PP (IN by) (NP (DT a) (JJ dopaminergic) (NN mechanism))) (SBAR (IN as) (S (NP (NNP Doc_8829135_1080_1091_Chemical)) (, ,) (PP (IN at) (NP (JJ millimolar) (NNS concentrations))) (, ,) (VP (VBD failed) (S (VP (TO to) (VP (VB displace) (NP (DT either) (NNP Doc_8829135_1149_1162_Chemical) (CC or) (NNP Doc_8829135_1166_1179_Chemical)) (PP (VBG binding) (PP (IN from) (NP (NNP D1) (CC or) (NNP D2) (NNP Doc_8829135_1202_1210_Chemical) (NN receptor) (NNS subtypes)))) (, ,) (ADVP (RB respectively)))))))))) (. .)))
8829135	7	(S1 (S (NP (PRP It)) (VP (AUX is) (VP (VBN suggested) (SBAR (IN that) (S (NP (NNP Doc_8829135_1265_1276_Chemical)) (VP (VBZ augments) (NP (JJ molecular) (NNS processes)) (PP (IN in) (NP (NP (DT the) (JJ early) (NNS stages)) (PP (IN of) (NP (NP (NNS events)) (SBAR (WHNP (WDT which)) (S (ADVP (RB ultimately)) (VP (VBP lead) (PP (TO to) (NP (NP (NN consolidation)) (PP (IN of) (NP (NN memory))))))))))))))))) (. .)))
891494	0	(S1 (NP (NP (NP (JJ Doc_891494_0_9_Chemical) (NN Doc_891494_10_24_Disease)) (PP (IN as) (NP (JJ probable) (JJ idiosyncratic) (NN reaction)))) (: :) (NP (NN case) (NN report)) (. .)))
891494	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NNP Doc_891494_84_93_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_891494_95_98_Chemical)) (-RRB- -RRB-)) (NNP Doc_891494_100_114_Disease))) (PP (IN with) (NP (VBG increasing) (UCP (NNP Doc_891494_131_139_Disease) (CC and) (NNP EEG) (CC and) (JJ mental)) (NNS changes)))) (VP (AUX is) (VP (VBN described))) (. .)))
891494	2	(S1 (S (PP (IN Despite) (NP (NP (JJ adequate) (JJ oral) (NN dosage)) (PP (IN of) (NP (NP (NNP Doc_891494_213_216_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg/kg/daily)) (-RRB- -RRB-)))))) (NP (DT the) (NN plasma) (NN level)) (VP (AUX was) (ADJP (RB very) (JJ low)) (PRN (-LRB- -LRB-) (NP (CD 2.8) (NN microgramg/ml)) (-RRB- -RRB-))) (. .)))
891494	3	(S1 (S (NP (DT The) (NNP Doc_891494_288_302_Disease)) (VP (AUX was) (ADVP (RB probably)) (NP (DT an) (ADJP (JJ idiosyncratic) (CC and) (RB not) (ADJP (JJ toxic)) (CC or) (ADJP (JJ Doc_891494_350_367_Disease))))) (. .)))
891494	4	(S1 (S (PP (IN In) (NP (NN fact))) (S (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (JJ free) (NNP Doc_891494_403_406_Chemical)))) (VP (AUX was) (ADJP (JJ normal)))) (, ,) (S (NP (DT the) (NN patient)) (VP (VBD presented) (NP (DT a) (NN Doc_891494_443_469_Disease)) (PP (IN during) (NP (JJ Doc_891494_477_480_Chemical) (NN treatment))))) (, ,) (S (NP (DT the) (NN protidogram)) (VP (AUX was) (ADJP (JJ normal)))) (, ,) (CC and) (S (NP (DT an) (JJ intradermic) (JJ Doc_891494_539_542_Chemical) (NN injection)) (VP (AUX had) (NP (DT no) (JJ local) (NN effect)))) (. .)))
891494	5	(S1 (S (NP (DT The) (NNS authors)) (VP (VBP conclude) (SBAR (IN that) (S (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBG starting) (NP (JJ Doc_891494_622_625_Chemical) (NN treatment)) (NP (NP (DT an) (JJ unexpected) (NN increase)) (PP (IN in) (NP (NNP Doc_891494_662_670_Disease))))))) (, ,) (PP (IN with) (S (NP (NP (NNP EEG)) (CC and) (NP (JJ mental) (NNS changes))) (VP (VBG occurring) (ADVP (RB simultaneously))))) (, ,) (VP (MD should) (VP (VB alert) (NP (DT the) (NN physician)) (PP (TO to) (NP (NP (DT the) (JJ possible) (NN need)) (PP (IN for) (S (VP (VBG eliminating) (NP (NNP Doc_891494_790_793_Chemical)) (PP (IN from) (NP (DT the) (JJ therapeutic) (NN regimen)))))))) (, ,) (SBAR (RB even) (IN if) (S (NP (NN plasma) (NNS concentrations)) (VP (AUX are) (ADJP (JJ low)))))))))) (. .)))
89511	0	(S1 (NP (NP (NP (NN Prevention)) (CC and) (NP (NN treatment))) (PP (IN of) (NP (NNP Doc_89511_28_47_Disease))) (PP (IN in) (NP (NP (JJ climacteric) (NNS women)) (VP (VBG receiving) (NP (JJ Doc_89511_79_88_Chemical) (NN therapy))))) (. .)))
89511	1	(S1 (S (NP (DT The) (NN treatment) (NNS regimens)) (VP (AUX are) (VP (VBN described) (PP (IN in) (NP (NP (CD 74) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_89511_155_174_Disease)) (PP (IN among) (NP (NP (CD 850) (JJ climacteric) (NNS women)) (VP (VBG receiving) (NP (JJ Doc_89511_213_222_Chemical) (NN therapy))))))))))) (. .)))
89511	2	(S1 (S (NP (NN Doc_89511_232_250_Disease)) (VP (AUX was) (VP (VBN associated) (PP (IN with) (NP (NP (JJ unopposed) (JJ Doc_89511_281_290_Chemical) (NN therapy)) (PP (IN without) (NP (NN progestagen))))))) (. .)))
89511	3	(S1 (S (S (NP (NP (CD Two) (NNS courses)) (PP (IN of) (NP (NP (CD 21) (NNS days)) (PP (IN of) (NP (CD 5) (JJ mg) (NNP Doc_89511_351_365_Chemical) (NN daily)))))) (VP (VBD caused) (NP (NN reversion)) (PP (TO to) (NP (JJ normal))) (PP (IN in) (NP (NP (DT all) (CD 57) (NNS cases)) (PP (IN of) (NP (NNP Doc_89511_418_436_Disease))))))) (CC and) (S (NP (NP (CD 6)) (PP (IN of) (NP (NP (DT the) (CD 8) (NNS cases)) (PP (IN of) (NP (NP (NNP Doc_89511_461_481_Disease.) (CD 4) (NNS cases)) (PP (IN of) (NP (NNP Doc_89511_494_515_Disease)))))))) (VP (VBD referred) (PP (IN from) (NP (NP (RB elsewhere)) (VP (VBN demonstrated) (NP (NP (NP (DT the) (NNS problems)) (PP (IN of) (NP (ADJP (JJ inappropriate) (CC and) (JJ unsupervised)) (JJ unopposed) (JJ Doc_89511_610_619_Chemical) (NN therapy)))) (CC and) (NP (NP (DT the) (NN difficulty)) (PP (IN in) (S (VP (VBG distinguishing) (NP (JJ severe) (NN Doc_89511_672_683_Disease)) (PP (IN from) (NP (NNP Doc_89511_689_699_Disease))))))))))))) (. .)))
89511	4	(S1 (S (NP (NP (JJ Cyclical) (JJ low-dose) (JJ Doc_89511_719_728_Chemical) (NN therapy)) (PP (IN with) (NP (NP (CD 7--13) (NNS days)) (PP (IN of) (NP (NNP Doc_89511_756_767_Chemical)))))) (VP (AUX does) (RB not) (VP (VB seem) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN Doc_89511_806_842_Disease))))))))) (. .)))
895432	0	(S1 (NP (NP (NNS Effects)) (PP (IN of) (NP (NN exercise))) (PP (IN on) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NNP Doc_895432_39_52_Chemical-induced) (NNP Doc_895432_61_82_Disease))))) (. .)))
895432	1	(S1 (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN exercise))) (PP (IN on) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (NNP Doc_895432_126_139_Chemical-induced) (NNP Doc_895432_148_169_Disease)))))) (VP (AUX was) (VP (VBN studied) (PP (IN in) (NP (JJ male) (NNS rats))))) (. .)))
895432	2	(S1 (S (NP (JJ Ninety-three) (NNS rats)) (VP (AUX were) (ADVP (RB randomly)) (VP (VBN divided) (PP (IN into) (NP (CD three) (NNS groups))))) (. .)))
895432	3	(S1 (S (NP (DT The) (JJ exercise-Doc_895432_268_281_Chemical) (PRN (-LRB- -LRB-) (JJ E-1) (-RRB- -RRB-)) (CC and) (NN exercise) (NN control) (-LRB- -LRB-) (NNP EC) (-RRB- -RRB-) (NNS groups)) (VP (VBN exercised) (ADVP (RB daily)) (PP (IN for) (NP (CD thirty) (NNS days))) (PP (IN on) (NP (DT a) (NN treadmill))) (PP (IN at) (NP (NP (CD 1) (NN mph)) (, ,) (NP (ADJP (CD 2) (NN %)) (NN grade)))) (SBAR (IN while) (S (NP (NP (NNS animals)) (PP (IN of) (NP (DT the) (JJ sedentary-Doc_895432_418_431_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_895432_433_436_Chemical)) (-RRB- -RRB-)) (NN group)))) (VP (VBD remained) (ADJP (JJ sedentary)))))) (. .)))
895432	4	(S1 (S (NP (CD Eight) (NNS animals)) (VP (AUX were) (VP (VBN assigned) (PP (TO to) (NP (NP (DT the) (NN sedentary) (NN control) (-LRB- -LRB-) (NN SC) (-RRB- -RRB-) (NN group)) (SBAR (WHNP (WDT which)) (S (VP (VBD remained) (ADJP (JJ sedentary)) (PP (IN throughout) (NP (DT the) (JJ experimental) (NN period)))))))))) (. .)))
895432	5	(S1 (S (PP (NP (JJ Forty-eight) (NNS hours)) (IN after) (NP (DT the) (JJ final) (NN exercise) (NN period))) (, ,) (NP (NP (NNP Doc_895432_640_643_Chemical)) (CC and) (NP (JJ E-I) (NNS animals))) (VP (VBD received) (NP (NP (DT a) (JJ single) (JJ subcutaneous) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_895432_704_717_Chemical)) (PRN (-LRB- -LRB-) (NP (QP (CD 250) (CD mg/kg)) (NN body) (NN weight)) (-RRB- -RRB-)))))) (. .)))
895432	6	(S1 (S (NP (NP (NNS Animals)) (PP (IN of) (NP (DT the) (NNP Doc_895432_758_761_Chemical) (NN group)))) (VP (VBD exhibited) (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NNP Pp) (QP (JJR less) (IN than) (CD 0.05))) (-RRB- -RRB-)) (NP (NP (JJR greater) (NN mortality)) (PP (IN from) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNP Doc_895432_850_863_Chemical))))) (PP (IN than) (NP (NP (NNS animals)) (PP (IN of) (NP (DT the) (JJ E-I) (NN group))))))) (. .)))
895432	7	(S1 (S (NP (NP (NN Serum) (NN CPK) (NN activity)) (PP (IN for) (NP (JJ E-I) (NNS animals)))) (VP (AUX was) (ADJP (RB significantly) (ADVP (NP (-LRB- -LRB-) (QP (RB p) (JJR less) (IN than) (CD 0.05)) (-RRB- -RRB-)) (JJR greater)) (PP (IN than) (PP (IN for) (NP (NP (NNS animals)) (PP (IN in) (NP (NP (DT the) (NNP Doc_895432_999_1002_Chemical) (CC and) (NNP EC) (NNS groups)) (VP (NP (CD twenty) (NNS hours)) (VBG following) (NP (NNP Doc_895432_1040_1053_Chemical) (NN injection)))))))))) (. .)))
895432	8	(S1 (S (NP (DT No) (ADJP (RB statistically) (JJ significant)) (NNS differences)) (VP (AUX were) (VP (VBN observed) (PP (IN between) (NP (NP (DT the) (CD two) (JJ Doc_895432_1136_1149_Chemical) (VBN treated) (NNS groups)) (PP (IN for) (NP (NP (NP (NN severity)) (PP (IN of) (NP (DT the) (VBN induced) (NNS lesions)))) (, ,) (NP (NP (NNS changes)) (PP (IN in) (NP (NN heart) (NN weight)))) (, ,) (CC or) (NP (NP (NN heart) (NN weight)) (PP (TO to) (NP (NN body) (NN weight) (NNS ratios)))))))))) (. .)))
895432	9	(S1 (S (NP (DT The) (NNS results)) (VP (VBD indicated) (SBAR (IN that) (S (NP (NN exercise)) (VP (VP (VBD reduced) (NP (NP (DT the) (NN mortality)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ large) (NNS dosages)) (PP (IN of) (NP (NNP Doc_895432_1372_1385_Chemical)))))))))) (CC but) (VP (AUX had) (ADVP (RB little)) (PP (IN on) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (DT the) (NNP Doc_895432_1424_1434_Disease)))))))))) (. .)))
8957205	0	(S1 (S (NP (NP (JJ Human) (JJ corticotropin-releasing) (NN hormone)) (CC and) (NP (JJ thyrotropin-releasing) (NN hormone))) (VP (VBP modulate) (NP (NP (DT the) (JJ hypercapnic) (NN ventilatory) (NN response)) (PP (IN in) (NP (NNS humans))))) (. .)))
8957205	1	(S1 (S (NP (JJ Human) (NX (NX (NX (JJ corticotropin-releasing) (NN hormone)) (PRN (-LRB- -LRB-) (NP (NNP hCRH)) (-RRB- -RRB-))) (CC and) (NX (NX (JJ thyrotropin-releasing) (NN hormone)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8957205_209_212_Chemical)) (-RRB- -RRB-))))) (VP (AUX are) (VP (VBN known) (S (VP (TO to) (VP (VB stimulate) (NP (NN ventilation)) (PP (IN after) (S (VP (VBG i.v.) (NP (NN administration)) (PP (IN in) (NP (NNS humans))))))))))) (. .)))
8957205	2	(S1 (S (PP (IN In) (NP (DT a) (JJ placebo-controlled) (, ,) (JJ single-blind) (NN study))) (NP (PRP we)) (VP (VBD aimed) (S (VP (TO to) (VP (VB clarify) (SBAR (IN if) (S (NP (DT both) (NNS peptides)) (VP (VBP act) (PP (IN by) (S (VP (VBG altering) (NP (JJ central) (NN chemosensitivity)))))))))))) (. .)))
8957205	3	(S1 (S (NP (CD Two) (JJ subsequent) (JJ Doc_8957205_424_427_Chemical-rebreathing) (NNS tests)) (VP (AUX were) (VP (VBN performed) (PP (IN in) (NP (JJ healthy) (JJ young) (NNS volunteers))))) (. .)))
8957205	4	(S1 (S (S (PP (IN During) (NP (NP (DT the) (JJ first) (NN test)) (NP (CD 0.9) (NN %)))) (NP (NNP Doc_8957205_517_521_Chemical)) (VP (AUX was) (VP (VBN given) (NP (NN i.v.))))) (: ;) (S (PP (IN during) (NP (NP (NP (DT the) (JJ second) (NN test)) (NP (CD 200) (NNS micrograms))) (PP (IN of) (NP (NP (NP (NNS hCRH)) (PRN (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 12)) (-RRB- -RRB-))) (CC or) (NP (NP (CD 400) (NNS micrograms)) (PP (IN of) (NP (NNP Doc_8957205_614_617_Chemical)))))))) (-LRB- -LRB-) (NP (NNP n) (SYM =) (CD 6)) (-RRB- -RRB-) (VP (AUX was) (VP (VBN administered) (SBAR (S (NP (QP (CD i.v.) (CD Nine)) (NNS subjects)) (VP (VBD received) (NP (CD 0.9) (NN %)) (NP (NNP Doc_8957205_676_680_Chemical) (CD i.v.)) (PP (IN during) (NP (DT both) (VBG rebreathing) (NNS manoeuvres))))))))) (. .)))
8957205	5	(S1 (S (NP (NP (DT The) (JJ Doc_8957205_726_729_Chemical-response) (NNS curves)) (PP (IN for) (NP (DT the) (CD two) (NNS tests)))) (VP (AUX were) (VP (VBN compared) (PP (IN within) (NP (DT the) (JJ same) (NN subject))))) (. .)))
8957205	6	(S1 (S (PP (IN In) (NP (DT the) (JJ hCRH) (NN group))) (NP (NP (DT a) (VBN marked) (JJ parallel) (NN shift)) (PP (IN of) (NP (DT the) (JJ Doc_8957205_852_855_Chemical-response) (NN curve))) (PP (TO to) (NP (DT the) (NN left)))) (VP (AUX was) (VP (VBN observed) (PP (IN after) (NP (NP (NNS hCRH)) (PRN (-LRB- -LRB-) (NP (QP ($ P) (CD <) (CD 0.01))) (-RRB- -RRB-)))))) (. .)))
8957205	7	(S1 (S (NP (DT The) (JJ same) (NN effect)) (VP (VP (VBD occurred) (PP (VBG following) (NP (NNP Doc_8957205_954_957_Chemical)))) (CC but) (VP (AUX was) (ADJP (ADJP (RBR less) (JJ striking)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (SYM =) (NP (CD 0.05)))) (-RRB- -RRB-))))) (. .)))
8957205	8	(S1 (S (NP (NP (NNP hCRH)) (CC and) (NP (NNP Doc_8957205_1001_1004_Chemical))) (VP (VBD caused) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (DT the) (JJ Doc_8957205_1031_1034_Chemical) (NN threshold))))) (. .)))
8957205	9	(S1 (S (NP (NP (DT The) (JJ Doc_8957205_1050_1053_Chemical-response) (NNS curves)) (PP (IN in) (NP (DT the) (NN control) (NN group)))) (VP (AUX were) (ADJP (RB nearly) (JJ identical))) (. .)))
8957205	10	(S1 (S (NP (DT The) (NNS results)) (VP (VBP indicate) (NP (NP (DT an) (JJ additive) (NN effect)) (PP (IN of) (NP (DT both) (VBG releasing) (NNS hormones))) (PP (IN on) (NP (NP (DT the) (JJ hypercapnic) (NN ventilatory) (NN response)) (PP (IN in) (NP (NNS humans))))) (, ,) (ADJP (RB presumably) (JJ independent) (PP (IN of) (NP (JJ central) (NN chemosensitivity)))))) (. .)))
8985298	0	(S1 (S (NP (NN Doc_8985298_0_10_Chemical)) (VP (AUX is) (ADJP (JJ effective) (PP (IN in) (S (VP (VBG suppressing) (NP (JJ Doc_8985298_39_50_Disease) (NN virus) (NN DNA)) (PP (IN in) (NP (JJ Chinese) (NNP Doc_8985298_72_83_Disease) (NN surface) (NN antigen) (NNS carriers))))))) (: :) (NP (DT a) (JJ placebo-controlled) (NN trial))) (. .)))
8985298	1	(S1 (S (NP (NNP Doc_8985298_138_148_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ novel) (JJ Doc_8985298_160_182_Chemical) (NN analogue)) (SBAR (WHNP (WDT that)) (S (VP (AUX has) (NP (NP (JJ potent) (JJ inhibitory) (NNS effects)) (PP (IN on) (NP (NP (JJ Doc_8985298_230_241_Disease) (NN virus) (NN replication)) (PP (PP (IN in) (NP (NN vitro))) (CC and) (PP (IN in) (NP (NN vivo)))))))))))) (. .)))
8985298	2	(S1 (S (NP (PRP We)) (VP (VBD performed) (NP (NP (DT a) (JJ single-blind) (, ,) (JJ placebo-controlled) (NN study)) (SBAR (S (VP (TO to) (VP (VB assess) (NP (NP (NP (PRP$ its) (NN effectiveness)) (CC and) (NP (NN safety))) (PP (IN in) (NP (JJ Chinese) (NNP Doc_8985298_386_397_Disease) (NN surface) (NN antigen) (-LRB- -LRB-) (NN HBsAg) (-RRB- -RRB-) (NNS carriers)))))))))) (. .)))
8985298	3	(S1 (S (NP (JJ Forty-two) (JJ Chinese) (NN HBsAg) (NNS carriers)) (VP (AUX were) (VP (VBN randomized) (S (VP (TO to) (VP (VB receive) (NP (NP (NP (NN placebo)) (PRN (-LRB- -LRB-) (NP (CD 6) (NNS patients)) (-RRB- -RRB-))) (CC or) (NP (JJ Doc_8985298_516_526_Chemical) (NN orally))) (PP (IN in) (NP (NP (NNS dosages)) (PP (IN of) (NP (NP (CD 25) (NNS mg)) (, ,) (NP (CD 100) (NNS mg)) (, ,) (CC or) (NP (NP (QP (CD 300) (CD mg)) (NN daily)) (PRN (-LRB- -LRB-) (NP (NP (CD 12) (NNS patients)) (PP (IN for) (NP (DT each) (NN dosage)))) (-RRB- -RRB-)))))))))))) (. .)))
8985298	4	(S1 (S (NP (DT The) (NN drug)) (VP (AUX was) (VP (VBN given) (PP (IN for) (NP (CD 4) (NNS weeks))))) (. .)))
8985298	5	(S1 (S (NP (DT The) (NNS patients)) (VP (AUX were) (ADVP (RB closely)) (VP (VBN monitored) (UCP (ADVP (RB clinically)) (, ,) (ADVP (RB biochemically)) (, ,) (CC and) (ADVP (RB serologically) (NP (QP (IN up) (TO to) (CD 4)) (NNS weeks))) (PP (IN after) (NP (NN drug) (NN treatment)))))) (. .)))
8985298	6	(S1 (S (NP (NP (DT All) (CD 36) (NNS patients)) (VP (VBG receiving) (NP (NNP Doc_8985298_785_795_Chemical)))) (VP (AUX had) (NP (NP (DT a) (JJ Doc_8985298_802_825_Disease) (NN virus)) (PRN (-LRB- -LRB-) (NP (NNP HBV)) (-RRB- -RRB-))) (NP (NP (NN DNA) (NNS values)) (PP (IN of) (NP (NP (CD >90) (NN %)) (PRN (-LRB- -LRB-) (NP (NP (QP ($ P) (CD <) (CD .001))) (VP (VBN compared) (PP (IN with) (NP (NN placebo))))) (-RRB- -RRB-)))))) (. .)))
8985298	7	(S1 (S (SBAR (IN Although) (S (NP (NP (CD 25) (NN mg)) (PP (IN of) (NP (NNP Doc_8985298_909_919_Chemical)))) (VP (AUX was) (ADJP (ADVP (RB slightly) (RBR less)) (JJ effective) (PP (IN than) (NP (NP (NP (QP (CD 100) (CD mg))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD .011)) (-RRB- -RRB-))) (CC and) (NP (NP (QP (CD 300) (CD mg))) (PRN (-LRB- -LRB-) (NP (NNP P) (SYM =) (CD .005)) (-RRB- -RRB-))))))))) (, ,) (NP (PRP it)) (ADVP (RB still)) (VP (VBN induced) (NP (NP (ADJP (CD 94) (NN %)) (NN suppression)) (PP (IN of) (NP (NNP HBV) (NNP DNA)))) (PP (IN after) (NP (NP (DT the) (JJ fourth) (NN week)) (PP (IN of) (NP (NN therapy)))))) (. .)))
8985298	8	(S1 (S (NP (NN HBV) (NN DNA) (NNS values)) (VP (VBD returned) (PP (TO to) (NP (JJ pretreatment) (NNS levels))) (PP (IN within) (NP (NP (CD 4) (NNS weeks)) (PP (IN of) (NP (NP (NN cessation)) (PP (IN of) (NP (NN therapy)))))))) (. .)))
8985298	9	(S1 (S (NP (EX There)) (VP (AUX was) (NP (NP (DT no) (NN change)) (PP (PP (IN in) (NP (DT the) (NNP Doc_8985298_1186_1197_Disease) (NN e) (NN antigen) (NN status))) (CC or) (PP (IN in) (NP (JJ aminotransferase) (NNS levels)))))) (. .)))
8985298	10	(S1 (S (NP (DT No) (JJ serious) (JJ adverse) (NNS events)) (VP (AUX were) (VP (VBN observed))) (. .)))
8985298	11	(S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (DT a) (JJ 4-week) (NN course)) (PP (IN of) (NP (NNP Doc_8985298_1321_1331_Chemical)))) (VP (AUX was) (ADJP (ADJP (JJ safe)) (CC and) (ADJP (JJ effective))) (PP (IN in) (NP (NP (NN suppression)) (PP (IN of) (NP (NP (NNP HBV) (NNP DNA)) (PP (IN in) (NP (JJ Chinese) (NN HBsAg) (NNS carriers)))))))) (. .)))
8985298	12	(S1 (S (NP (DT The) (NN suppression)) (VP (AUX was) (ADJP (CD >90) (NN %) (CC but) (JJ reversible))) (. .)))
8985298	13	(S1 (S (NP (NP (NNS Studies)) (PP (IN with) (NP (JJ long-term) (JJ Doc_8985298_1472_1482_Chemical) (NN administration)))) (VP (MD should) (VP (AUX be) (VP (VBN performed) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (NP (VBN prolonged) (NN suppression)) (PP (IN of) (NP (NNP HBV) (NNP DNA)))) (VP (MD can) (VP (AUX be) (VP (VBN achieved)))))))))))) (. .)))
8996419	0	(S1 (S (NP (NP (JJ Population-based) (NN study)) (PP (IN of) (NP (NP (NN risk)) (PP (IN of) (NP (NNP Doc_8996419_34_56_Disease)))))) (VP (VBN associated) (PP (IN with) (NP (JJ various) (NNP Doc_8996419_81_100_Chemical)))) (. .)))
8996419	1	(S1 (S (NP (NP (CD Four) (NNS studies)) (VP (VBN published) (PP (IN since) (NP (NP (NNP December)) (, ,) (NP (CD 1995)) (, ,))))) (VP (VBD reported) (SBAR (IN that) (S (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (NNP Doc_8996419_190_212_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_8996419_214_217_Disease)) (-RRB- -RRB-))))) (VP (AUX was) (ADJP (ADJP (JJR higher) (PP (IN in) (NP (NP (NNS women)) (SBAR (WHNP (WP who)) (S (VP (VBD used) (NP (NP (NNP Doc_8996419_248_267_Chemical) (PRN (-LRB- -LRB-) (NP (NNP OCs)) (-RRB- -RRB-)) (VP (VBG containing) (NP (DT the) (JJ third-generation) (JJ Doc_8996419_306_318_Chemical) (NN gestodene)))) (CC or) (NP (NNP Doc_8996419_332_343_Chemical))))))))) (PP (IN than) (PP (IN in) (NP (NP (NNS users)) (PP (IN of) (NP (NP (NNS OCs)) (VP (VBG containing) (NP (NN second-generation) (NNS progestagens))))))))))))) (. .)))
8996419	2	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (NP (NN confounding)) (CC and) (NP (NN bias))) (PP (IN in) (NP (NP (DT the) (NN design)) (PP (IN of) (NP (DT these) (NNS studies)))))) (VP (MD may) (VP (AUX have) (VP (VBN affected) (NP (DT the) (NNS findings))))) (. .)))
8996419	3	(S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (PRP$ our) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VB re-examine) (NP (NP (DT the) (NN association)) (PP (IN between) (NP (NP (NP (NN risk)) (PP (IN of) (NP (NNP Doc_8996419_572_575_Disease)))) (CC and) (NP (NP (VBN OC) (NN use)) (PP (IN with) (NP (NP (DT a) (JJ different) (NN study) (NN design)) (CC and) (NP (NN analysis)))) (S (VP (TO to) (VP (VB avoid) (NP (NP (DT some)) (PP (IN of) (NP (NP (DT the) (NN bias) (CC and) (NN confounding)) (PP (IN of) (NP (DT the) (JJR earlier) (NNS studies))))))))))))))))) (. .)))
8996419	4	(S1 (S (NP (PRP We)) (VP (VBD used) (NP (NP (NN computer) (NNS records)) (PP (IN of) (NP (NNS patients)))) (PP (IN from) (NP (CD 143) (JJ general) (NNS practices))) (PP (IN in) (NP (DT the) (NNP UK)))) (. .)))
8996419	5	(S1 (S (NP (DT The) (NN study)) (VP (AUX was) (VP (VBN based) (PP (IN on) (NP (NP (DT the) (JJ medical) (NNS records)) (PP (IN of) (NP (NP (QP (RB about) (CD 540,000)) (NNS women)) (VP (VBN born) (PP (IN between) (NP (NP (CD 1941)) (CC and) (NP (CD 1981))))))))))) (. .)))
8996419	6	(S1 (S (NP (NP (DT All) (NNS women)) (SBAR (SBAR (WHNP (WP who)) (S (VP (AUX had) (NP (NP (DT a) (JJ recorded) (NN diagnosis)) (PP (IN of) (NP (NP (NNP Doc_8996419_916_936_Disease)) (, ,) (NP (NP (NNP Doc_8996419_938_955_Disease)) (VP (RB not) (ADVP (RB otherwise)) (VBN specified))) (, ,) (CC or) (NP (NNP Doc_8996419_984_1001_Disease))))) (PP (IN during) (NP (DT the) (NN study) (NN period)))))) (, ,) (CC and) (SBAR (WHNP (WP who)) (S (VP (AUX had) (VP (AUX been) (VP (VBN treated) (PP (IN with) (NP (DT an) (NN anticoagulant)))))))))) (VP (AUX were) (VP (VBN identified) (PP (IN as) (NP (NP (JJ potential) (NNS cases)) (PP (IN of) (NP (NNP Doc_8996419_1112_1115_Disease))))))) (. .)))
8996419	7	(S1 (S (NP (PRP We)) (VP (AUX did) (NP (NP (DT a) (JJ cohort) (NN analysis)) (SBAR (S (S (VP (TO to) (VP (VB estimate) (CC and) (VB compare) (NP (NP (NN incidence)) (PP (IN of) (NP (NNP Doc_8996419_1179_1182_Disease))) (PP (IN in) (NP (NP (NNS users)) (PP (IN of) (NP (DT the) (JJ main) (CD OC) (NNS preparations))))))))) (, ,) (CC and) (S (NP (DT a) (JJ nested) (JJ case-control) (NN study)) (VP (TO to) (VP (VB calculate) (NP (NP (DT the) (NNS odds) (NNS ratios)) (PP (IN of) (NP (NNP Doc_8996419_1285_1288_Disease))) (VP (VBN associated) (PP (IN with) (NP (NP (NN use)) (PP (IN of) (NP (NP (JJ different) (NNS types)) (PP (IN of) (NP (NNS OC)))))))))))) (, ,) (PP (IN after) (NP (NP (NN adjustment)) (PP (IN for) (NP (JJ potential) (VBG confounding) (NNS factors))))))))) (. .)))
8996419	8	(S1 (S (PP (IN In) (NP (DT the) (JJ case-control) (NN study))) (, ,) (NP (PRP we)) (VP (VBD matched) (NP (NNS cases)) (PP (TO to) (NP (NNS controls))) (PP (IN by) (NP (NP (JJ exact) (NN year)) (PP (IN of) (NP (NP (NN birth)) (, ,) (NP (NN practice)) (, ,) (CC and) (NP (NP (JJ current) (NN use)) (PP (IN of) (NP (NNS OCs))))))))) (. .)))
8996419	9	(S1 (S (NP (PRP We)) (VP (VBD used) (NP (NP (NP (DT a) (JJ multiple) (JJ logistic) (NN regression) (NN model)) (SBAR (WHNP (WDT that)) (S (VP (VBD included) (NP (NP (JJ body-mass) (NN index) (, ,) (NN number)) (PP (IN of) (NP (NNS cycles)))))))) (, ,) (NP (NP (NN change)) (PP (IN in) (NP (NP (NN type)) (PP (IN of) (NP (NP (NNS OC)) (VP (VBN prescribed) (PP (IN within) (NP (NP (CD 3) (NNS months)) (PP (IN of) (NP (NP (DT the) (NN event)) (, ,) (NP (JJ previous) (NN pregnancy)) (, ,) (CC and) (NP (JJ concurrent) (NN disease)))))))))))))) (. .)))
8996419	10	(S1 (S (NP (CD 85) (NNS women)) (VP (VBD met) (NP (NP (DT the) (NN inclusion) (NNS criteria)) (PP (IN for) (NP (NNP Doc_8996419_1751_1754_Disease))) (, ,) (SBAR (WHNP (WHNP (CD two)) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (AUX were) (NP (NP (NNS users)) (PP (IN of) (NP (JJ progestagen-only) (NNS OCs))))))))) (. .)))
8996419	11	(S1 (S (PP (IN Of) (NP (NP (DT the) (CD 83) (NNS cases)) (PP (IN of) (NP (NNP Doc_8996419_1823_1826_Disease))) (VP (VBN associated) (PP (IN with) (NP (NP (NN use)) (PP (IN of) (NP (JJ combined) (NNS OCs)))))))) (, ,) (S (NP (CD 43)) (VP (AUX were) (VP (VBN recorded) (PP (IN as) (NP (NP (NNP Doc_8996419_1884_1904_Disease)) (, ,) (NP (CD 35)))) (PP (IN as) (NP (NNP Doc_8996419_1912_1932_Disease)))))) (, ,) (CC and) (S (NP (NP (CD five)) (PP (IN as) (NP (NNP Doc_8996419_1946_1963_Disease)))) (VP (RB not) (ADVP (RB otherwise)) (VBN specified))) (. .)))
8996419	12	(S1 (S (NP (NP (DT The) (NN crude) (NN rate)) (PP (IN of) (NP (NNP Doc_8996419_2007_2010_Disease))) (PP (IN per) (NP (CD 10,000) (NNS woman-years)))) (VP (AUX was) (NP (NP (NP (CD 4.10)) (PP (IN in) (NP (NP (JJ current) (NNS users)) (PP (IN of) (NP (DT any) (NN OC)))))) (, ,) (NP (NP (CD 3.10)) (PP (IN in) (NP (NP (NNS users)) (PP (IN of) (NP (NN second-generation) (NNS OCs)))))) (, ,) (CC and) (NP (NP (CD 4.96)) (PP (IN in) (NP (NP (NNS users)) (PP (IN of) (NP (NN third-generation) (NNS preparations)))))))) (. .)))
8996419	13	(S1 (S (PP (IN After) (NP (NP (NN adjustment)) (PP (IN for) (NP (NN age))))) (, ,) (NP (NP (DT the) (NN rate) (NN ratio)) (PP (IN of) (NP (NNP Doc_8996419_2207_2210_Disease))) (PP (IN in) (NP (NP (NNS users)) (PP (IN of) (NP (JJ third-generation) (NN relative))))) (PP (TO to) (NP (JJ second-generation) (NNS OCs)))) (VP (AUX was) (NP (NP (CD 1.68)) (PRN (-LRB- -LRB-) (NP (CD 95) (NN %) (QP (CD CI) (CD 1.04-2.75))) (-RRB- -RRB-)))) (. .)))
8996419	14	(S1 (S (NP (JJ Logistic) (NN regression)) (VP (VBD showed) (NP (NP (DT no) (JJ significant) (NN difference)) (PP (IN in) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_8996419_2371_2374_Disease))))) (PP (IN between) (NP (NP (NNS users)) (PP (IN of) (NP (NP (NN third-generation)) (CC and) (NP (NN second-generation) (NNS OCs)))))))) (. .)))
8996419	15	(S1 (S (PP (IN Among) (NP (NP (NNS users)) (PP (IN of) (NP (JJ third-generation) (NNS progestagens))))) (, ,) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NNP Doc_8996419_2494_2497_Disease)))) (VP (AUX was) (ADJP (ADJP (JJR higher) (PP (IN in) (NP (NP (NNS users)) (PP (IN of) (NP (NNP Doc_8996419_2521_2532_Chemical))) (PP (IN with) (NP (CD 20) (NNP g) (NNP Doc_8996419_2543_2560_Chemical)))))) (PP (IN than) (PP (IN in) (NP (NP (NNS users)) (PP (IN of) (NP (NNP Doc_8996419_2578_2587_Chemical) (CC or) (NNP Doc_8996419_2591_2602_Chemical))) (PP (IN with) (NP (CD 30) (NNP g) (NNP Doc_8996419_2613_2630_Chemical)))))))) (. .)))
8996419	16	(S1 (S (PP (IN With) (NP (NP (DT all) (JJ second-generation) (NNS OCs)) (PP (IN as) (NP (DT the) (NN reference))))) (, ,) (NP (NP (DT the) (NNS odds) (NNS ratios)) (PP (IN for) (NP (NNP Doc_8996419_2701_2704_Disease)))) (VP (AUX were) (NP (NP (CD 3.49) (-LRB- -LRB-) (NN 1.21-10.12) (-RRB- -RRB-)) (PP (IN for) (NP (NP (NP (NNP Doc_8996419_2732_2743_Chemical)) (CC plus) (NP (CD 20) (NNP g) (NNP Doc_8996419_2754_2771_Chemical))) (CC and) (NP (NP (CD 1.18)) (PRN (-LRB- -LRB-) (NP (CD 0.66-2.17)) (-RRB- -RRB-))))) (PP (IN for) (NP (DT the) (JJ other) (JJ third-generation) (NNS progestagens))))) (. .)))
8996419	17	(S1 (S (NP (NP (DT The) (ADJP (RB previously) (VBN reported)) (NN increase)) (PP (IN in) (NP (NP (NNS odds) (NN ratio)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ third-generation) (NNS OCs)) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NN second-generation) (NNS products)))))))))))) (VP (AUX is) (ADJP (JJ likely) (S (VP (TO to) (VP (AUX have) (VP (AUX been) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NP (JJ residual) (NN confounding)) (PP (IN by) (NP (NN age)))))))))))) (. .)))
8996419	18	(S1 (S (NP (NP (DT The) (VBN increased) (NNS odds) (NN ratio)) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NNS products)) (VP (VBG containing) (NP (NP (CD 20) (NNS micrograms)) (NP (NP (NNP Doc_8996419_3125_3142_Chemical)) (CC and) (NP (NNP Doc_8996419_3147_3158_Chemical)))))) (VP (VBN compared) (PP (IN with) (NP (DT the) (CD 30) (NNS micrograms) (NN product)))))))) (VP (VP (AUX is) (ADJP (RB biologically) (JJ implausible))) (, ,) (CC and) (VP (AUX is) (ADJP (JJ likely) (S (VP (TO to) (VP (VP (AUX be) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (JJ preferential) (NN prescribing))))) (CC and) (, ,) (ADVP (RB thus)) (, ,) (S (VP (VBG confounding))))))))) (. .)))
9061777	0	(S1 (S (NP (NN Doc_9061777_0_6_Chemical)) (VP (VP (VBZ augments) (NP (JJ Doc_9061777_16_27_Chemical-induced) (JJ electrographic) (NN Doc_9061777_51_58_Disease))) (CC but) (VP (VBZ protects) (PP (IN against) (NP (NP (NNP Doc_9061777_80_92_Disease)) (PP (IN in) (NP (NNP rats.) (CD 1))))))) (. .)))
9061777	1	(S1 (S (NP (DT The) (NNS authors)) (VP (VBD examined) (NP (NP (DT the) (JJ anticonvulsant) (NNS effects)) (PP (IN of) (NP (NNP Doc_9061777_156_162_Chemical))) (PP (IN on) (NP (DT the) (JJ Doc_9061777_170_181_Chemical-induced) (NN Doc_9061777_190_197_Disease) (NN model))))) (. .)))
9061777	2	(S1 (S (NP (NP (JJ Intraperitoneal) (NN injection)) (PP (IN of) (NP (NNP Doc_9061777_234_245_Chemical))) (PRN (-LRB- -LRB-) (NP (CD 400) (NN mg/kg)) (-RRB- -RRB-))) (VP (VBN induced) (NP (NNP Doc_9061777_266_290_Disease))) (. .)))
9061777	3	(S1 (S (S (NP (NP (NP (NNP Doc_9061777_292_303_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN mg/kg)) (-RRB- -RRB-))) (CC and) (NP (NP (NNP Doc_9061777_319_332_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg/kg)) (-RRB- -RRB-)))) (VP (VBD prevented) (NP (NP (NN development)) (PP (IN of) (NP (JJ Doc_9061777_368_379_Chemical-induced) (JJ behavioral) (NN Doc_9061777_399_406_Disease)))))) (CC but) (S (NP (NP (NNP Doc_9061777_411_417_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NN mg/kg)) (-RRB- -RRB-))) (VP (AUX did) (NP (NN not.) (CD 2)))) (. .)))
9061777	4	(S1 (S (NP (NP (DT An) (JJ electrical) (NN Doc_9061777_456_463_Disease)) (VP (VBN measured) (PP (IN with) (NP (JJ hippocampal) (NNS EEG))))) (VP (VBD appeared) (PP (IN in) (NP (DT the) (JJ Doc_9061777_510_521_Chemical-treated) (NN group)))) (. .)))
9061777	5	(S1 (S (NP (NP (NNP Doc_9061777_537_548_Chemical)) (CC and) (NP (NNP Doc_9061777_553_566_Chemical))) (VP (VBD blocked) (SBAR (S (NP (DT the) (JJ Doc_9061777_579_590_Chemical-induced) (JJ electrographic) (NAC (NNP Doc_9061777_614_621_Disease) (, ,) (NNP Doc_9061777_623_629_Chemical)) (NN treatment)) (VP (VBD augmented) (NP (NP (DT the) (JJ electrographic) (NN Doc_9061777_669_676_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_9061777_688_699_Chemical.) (CD 3))))))))) (. .)))
9061777	6	(S1 (S (NP (NN Brain) (NN damage)) (VP (AUX was) (VP (VBN assessed) (PP (IN by) (S (VP (VBG examining) (NP (DT the) (JJ hippocampus) (NN microscopically))))))) (. .)))
9061777	7	(S1 (S (NP (NN Doc_9061777_776_787_Chemical)) (VP (VBD produced) (NP (NN Doc_9061777_797_811_Disease)) (PP (IN in) (NP (NP (DT the) (NN hippocampus)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD showed) (NP (JJ pyknotic) (NNS changes)))))))) (. .)))
9061777	8	(S1 (S (NP (NNP Doc_9061777_863_876_Chemical) (, ,) (NNP Doc_9061777_878_889_Chemical) (CC and) (NNP Doc_9061777_894_900_Chemical)) (VP (VBD protected) (NP (DT the) (NNP Doc_9061777_915_927_Disease)) (PP (IN by) (NP (NNP Doc_9061777_931_942_Chemical))) (, ,) (SBAR (IN though) (S (PP (IN in) (NP (DT the) (JJ Doc_9061777_958_964_Chemical-treated) (NN group))) (, ,) (NP (NP (DT the) (JJ pyramidal) (NNS cells)) (PP (IN of) (NP (NNS hippocampus)))) (VP (VBD appeared) (ADJP (ADJP (JJR darker)) (PP (IN than) (ADJP (JJ normal)))))))) (. .)))
9061777	9	(S1 (S (PP (IN In) (NP (DT all) (NNS treatments))) (, ,) (NP (NP (JJ granule) (NNS cells)) (PP (IN of) (NP (DT the) (JJ dentate) (NNS gyrus)))) (VP (AUX were) (RB not) (VP (VBN affected.) (NP (CD 4)))) (. .)))
9061777	10	(S1 (S (NP (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN Doc_9061777_1148_1166_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_9061777_1178_1189_Chemical))))) (VP (AUX is) (VP (VP (VBN initiated) (PP (IN by) (NP (JJ cholinergic) (NN overstimulation)))) (CC and) (VP (VBN propagated) (PP (IN by) (NP (JJ glutamatergic) (NN transmission)))))))) (, ,) (SBAR (S (NP (NP (DT the) (NN elevation)) (PP (IN of) (NP (WDT which)))) (VP (MD may) (VP (VB cause) (NP (NNP Doc_9061777_1313_1325_Disease)) (PP (IN through) (NP (DT an) (JJ excitatory) (NNP Doc_9061777_1348_1352_Chemical) (JJ receptor-mediated) (NN mechanism)))))))) (. .)))
9071336	0	(S1 (NP (NP (NP (NP (NNP Doc_9071336_0_10_Chemical)) (, ,) (NP (NNP Doc_9071336_12_26_Chemical)) (, ,) (CC and) (NP (NNP Doc_9071336_32_44_Chemical))) (PP (IN in) (NP (JJ metastatic) (NNP Doc_9071336_59_72_Disease)))) (: :) (S (NP (NP (CD BRE-26)) (, ,) (NP (NP (DT a) (NN phase)) (NP (NNP II) (NNP trial.) (NNP Doc_9071336_100_114_Chemical))) (CC plus) (NP (NP (NNP Doc_9071336_120_132_Chemical) (CC and) (NNP Doc_9071336_137_147_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_9071336_149_154_Chemical)) (: ;) (NP (NP (NNP Bristol-Myers) (NNP Squibb) (NNP Company)) (, ,) (NP (NNP Princeton)))) (, ,) (NP (NNP NJ)) (-RRB- -RRB-)))) (VP (AUX are) (NP (NP (JJ effective) (NN salvage) (NNS therapies)) (PP (IN for) (NP (JJ metastatic) (NNP Doc_9071336_248_261_Disease) (NNS patients)))))) (. .)))
9071336	1	(S1 (S (NP (NP (NNP Doc_9071336_272_282_Chemical)) (CC and) (NP (NNP Doc_9071336_287_301_Chemical))) (VP (AUX have) (NP (JJ additive) (NN Doc_9071336_316_328_Disease)) (PP (IN in) (NP (JJ MCF-7) (NN cell) (NNS lines)))) (. .)))
9071336	2	(S1 (S (NP (PRP We)) (VP (VBD performed) (NP (NP (DT a) (NN phase) (NNP II) (NN trial)) (PP (IN of) (NP (NNP Doc_9071336_383_393_Chemical) (CD 175) (NNS mg/m2)))) (PP (IN over) (NP (CD 3) (NNS hours))) (PP (IN on) (NP (NP (NN day)) (SBAR (S (NP (PRP I)) (VP (VBD followed) (PP (IN by) (NP (NNP Doc_9071336_438_450_Chemical) (CD 300) (NNS mg))) (PP (IN over) (NP (CD 1) (NN hour))) (PP (IN before) (NP (NP (NP (NP (NP (NNP Doc_9071336_477_491_Chemical) (CD 350) (NN mg/m2)) (PP (IN on) (NP (NNS days)))) (NP (QP (CD 1) (TO to) (CD 3) (DT every) (CD 28)) (NNS days))) (PRN (-LRB- -LRB-) (NP (NNP TFL)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NNS women)) (PP (IN with) (NP (JJ metastatic) (NNP Doc_9071336_562_575_Disease))))))))))))) (. .)))
9071336	3	(S1 (S (S (NP (NN Analysis)) (VP (AUX is) (VP (VBN reported) (PP (IN on) (NP (NP (CD 37) (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN minimum)) (PP (IN of) (NP (CD 6) (NNS months) (NN follow-up))))) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (NP (CD 192) (NNS cycles)) (PP (IN of) (NP (NNP Doc_9071336_688_691_Chemical)))))))))))))) (: :) (S (NP (NP (CD nine) (NNS cycles)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN %)) (-RRB- -RRB-))) (VP (AUX were) (VP (VBN associated) (PP (IN with) (NP (NP (NN grade) (CD 3/4) (NNP Doc_9071336_741_752_Disease)) (VP (VBG requiring) (NP (NP (NN hospitalization)) (: ;) (NP (NP (NP (CD seven)) (PRN (-LRB- -LRB-) (NP (CD 4) (NN %)) (-RRB- -RRB-)) (NNS cycles)) (PP (IN in) (NP (NP (CD two) (NNS patients)) (VP (VBN required) (S (NP (JJ granulocyte) (JJ colony-stimulating) (NN factor)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_9071336_868_879_Disease))))))))) (: ;) (NP (DT no) (JJ patient) (VBN required) (NN platelet) (NNS transfusions))))))))) (. .)))
9071336	4	(S1 (S (NP (NN Grade) (CD 3/4) (JJ nonhematologic) (NN Doc_9071336_949_959_Disease)) (VP (AUX were) (ADJP (JJ uncommon))) (. .)))
9071336	5	(S1 (S (PP (IN Among) (NP (NP (DT the) (CD 34) (NNS patients)) (ADJP (JJ evaluable) (PP (IN for) (NP (NN response)))))) (, ,) (NP (EX there)) (VP (AUX were) (NP (NP (NP (CD three) (JJ complete) (NNS responses)) (PRN (-LRB- -LRB-) (NP (CD 9) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 18) (JJ partial) (NNS responses)) (PRN (-LRB- -LRB-) (NP (CD 53) (NN %)) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (DT an) (JJ overall) (NN response) (NN rate)) (PP (IN of) (NP (CD 62) (NN %)))))) (. .)))
9071336	6	(S1 (S (PP (IN Of) (NP (NP (DT the) (CD 19) (JJ evaluable) (NNS patients)) (PP (IN with) (NP (JJ prior) (JJ Doc_9071336_1170_1181_Chemical) (NN exposure))))) (, ,) (NP (NP (CD 11)) (PRN (-LRB- -LRB-) (NP (CD 58) (NN %)) (-RRB- -RRB-))) (VP (VBD responded) (PP (VBN compared) (PP (IN with) (NP (NP (CD nine)) (PP (IN of) (NP (CD 15))) (PRN (-LRB- -LRB-) (NP (CD 60) (NN %)) (-RRB- -RRB-))))) (PP (IN without) (NP (JJ prior) (NNP Doc_9071336_1256_1267_Chemical)))) (. .)))
9071336	7	(S1 (S (NP (NN Plasma) (NN Doc_9071336_1276_1286_Chemical) (NNS concentrations)) (VP (AUX were) (VP (VBN measured) (PP (PP (IN at) (NP (NP (DT the) (NN completion)) (PP (IN of) (NP (JJ Doc_9071336_1337_1347_Chemical) (NN infusion))))) (CC and) (PP (IN at) (NP (NP (CD 24) (NNS hours)) (PP (IN in) (NP (CD 19) (NNS patients)))))))) (. .)))
9071336	8	(S1 (S (NP (NN TFL)) (VP (AUX is) (NP (NP (DT an) (JJ active) (, ,) (JJ well-tolerated) (NN regimen)) (PP (IN in) (NP (JJ metastatic) (NNP Doc_9071336_1444_1457_Disease))))) (. .)))
9125676	0	(S1 (NP (NP (NP (NN Efficacy)) (CC and) (NP (NN proarrhythmia))) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NNP Doc_9125676_43_54_Chemical))))) (PP (IN for) (NP (VBN sustained) (NN Doc_9125676_69_97_Disease))) (. .)))
9125676	1	(S1 (S (NP (DT This) (NN study)) (ADVP (RB prospectively)) (VP (VBN evaluated) (NP (NP (DT the) (JJ clinical) (NN efficacy)) (, ,) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NNP Doc_9125676_174_193_Disease)))) (, ,) (CC and) (NP (NP (DT the) (JJ presumable) (NN risk) (NNS factors)) (PP (IN for) (NP (NP (NNP Doc_9125676_231_250_Disease)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_9125676_276_287_Chemical))) (PP (IN for) (NP (JJ sustained) (NN Doc_9125676_302_330_Disease))))))))))) (. .)))
9125676	2	(S1 (S (NP (NP (NP (JJ Eighty-one) (JJ consecutive) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 54)) (PP (IN with) (NP (NNP Doc_9125676_373_396_Disease)))) (, ,) (CC and) (NP (NP (CD 20)) (PP (IN with) (NP (NNP Doc_9125676_410_432_Disease))))) (-RRB- -RRB-))) (PP (IN with) (NP (NN inducible)))) (VP (VBD sustained) (SBAR (S (NP (NP (NNP Doc_9125676_459_482_Disease)) (CC or) (NP (NNP Doc_9125676_486_510_Disease))) (VP (VBD received) (NP (JJ oral) (NNP Doc_9125676_525_536_Chemical)) (S (VP (TO to) (VP (VB prevent) (NP (NP (NN induction)) (PP (IN of) (NP (DT the) (NNP Doc_9125676_565_592_Disease))))))))))) (. .)))
9125676	3	(S1 (S (PP (IN During) (NP (NP (JJ oral) (NN loading)) (PP (IN with) (NP (NNP Doc_9125676_619_630_Chemical))))) (, ,) (NP (JJ continuous) (JJ electrocardiographic) (-LRB- -LRB-) (NN ECG) (-RRB- -RRB-) (NN monitoring)) (VP (AUX was) (VP (VBN performed))) (. .)))
9125676	4	(S1 (S (NP (NP (DT Those) (NNS patients)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NNP Doc_9125676_719_730_Chemical)) (VP (VBD prevented) (NP (NP (NN induction)) (PP (IN of) (NP (NNP Doc_9125676_754_777_Disease) (CC or) (NNP Doc_9125676_781_805_Disease)))))))) (VP (VP (AUX were) (VP (VBN discharged) (PP (IN with) (NP (DT the) (NN drug))))) (CC and) (VP (VBD followed) (PRT (RP up)) (PP (IN on) (NP (NP (DT an) (NN outpatient) (NN basis)) (PP (IN for) (NP (CD 21) (JJ +/-) (CD 18) (NNS months))))))) (. .)))
9125676	5	(S1 (S (S (NP (NP (NN Induction)) (PP (IN of) (NP (DT the) (NNP Doc_9125676_914_941_Disease)))) (VP (AUX was) (VP (VBN prevented) (PP (IN by) (NP (NP (JJ oral) (NNP Doc_9125676_964_975_Chemical)) (PP (IN in) (NP (NP (CD 35)) (PRN (-LRB- -LRB-) (NP (CD 43) (NN %)) (-RRB- -RRB-)) (NNS patients)))))))) (: ;) (S (NP (DT the) (NNP Doc_9125676_1002_1029_Disease)) (VP (VBD remained) (ADJP (JJ inducible) (PP (IN in) (NP (NP (CD 40)) (PRN (-LRB- -LRB-) (NP (CD 49) (NN %)) (-RRB- -RRB-)) (NNS patients)))))) (: ;) (S (CC and) (NP (NP (CD two)) (PRN (-LRB- -LRB-) (NP (CD 2.5) (NN %)) (-RRB- -RRB-)) (NNS patients)) (VP (AUX did) (RB not) (VP (VB tolerate) (NP (NP (QP (RB even) (CD 40)) (NN mg)) (PP (IN of) (NP (NNP Doc_9125676_1126_1137_Chemical)))) (ADVP (RB once) (RB daily))))) (. .)))
9125676	6	(S1 (S (NP (CD Four) (PRN (-LRB- -LRB-) (NP (CD 5) (NN %)) (-RRB- -RRB-)) (NNS patients)) (VP (AUX had) (VP (PP (IN from) (NP (NNP Doc_9125676_1178_1197_Disease))) (PP (IN during) (NP (NP (DT the) (JJ initial) (JJ oral) (NN treatment)) (PP (IN with) (NP (NNP Doc_9125676_1237_1248_Chemical))))))) (. .)))
9125676	7	(S1 (S (NP (CC Neither) (NP (NP (JJ ECG) (JJ -LSB-sinus-cycle) (NN length)) (PRN (-LRB- -LRB-) (NP (NNP SCL)) (-RRB- -RRB-)) (, ,) (NP (NN QT) (CC or) (NN QTc) (NN interval)) (, ,) (CC or) (NP (NNP U) (NN wave) (NN -RSB-))) (CC nor) (NP (JJ clinical) (NNS parameters))) (VP (VBD identified) (NP (NNS patients)) (PP (IN at) (NP (NP (NN risk)) (PP (IN for) (NP (NNP Doc_9125676_1376_1395_Disease)))))) (. .)))
9125676	8	(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ oral) (NN dose)) (PP (IN of) (NP (NNP Doc_9125676_1423_1434_Chemical)))) (VP (AUX was) (ADJP (RB significantly) (JJR lower)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_9125676_1476_1495_Disease)) (PRN (-LRB- -LRB-) (NP (NP (CD 200) (ADJP (JJ +/-) (NP (CD 46) (CC vs.) (CD 328))) (JJ +/-) (CD 53) (NN mg/day)) (: ;) (NP (NNP p)) (X (SYM =)) (CD 0.0017)) (-RRB- -RRB-))))))) (. .)))
9125676	9	(S1 (S (NP (NP (NN Risk) (NNS factors)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NNP Doc_9125676_1592_1611_Disease))))))) (VP (AUX were) (NP (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (DT an) (NNP U) (NN wave)))) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.049)) (-RRB- -RRB-)) (, ,) (NP (NN female) (NN gender)) (PRN (-LRB- -LRB-) (NP (NNP p) (SYM =) (CD 0.015)) (-RRB- -RRB-)) (, ,) (CC and) (NP (NP (JJ significant) (JJ dose-corrected) (NNS changes)) (PP (IN of) (NP (NP (NP (NNP SCL)) (, ,) (NP (CD QT) (NN interval)) (, ,)) (CC and) (NP (NP (NNP QTc) (NNP interval)) (PRN (-LRB- -LRB-) (NP (NNP p) (NNP <) (CD 0.05)) (-RRB- -RRB-)))))))) (. .)))
9125676	10	(S1 (S (PP (IN During) (NP (NN follow-up))) (, ,) (NP (CD seven) (PRN (-LRB- -LRB-) (NP (CD 20) (NN %)) (-RRB- -RRB-)) (NNS patients)) (VP (AUX had) (NP (NP (DT a) (JJ nonfatal) (NN Doc_9125676_1828_1851_Disease) (NN recurrence)) (, ,) (CC and) (NP (CD two) (PRN (-LRB- -LRB-) (NP (CD 6) (NN %)) (-RRB- -RRB-)) (NNS patients))) (VP (VBN died) (ADVP (RB suddenly)))) (. .)))
9125676	11	(S1 (S (NP (NP (CD One) (JJ female) (NN patient)) (PP (IN with) (NP (JJ stable) (NN Doc_9125676_1932_1947_Disease)))) (VP (AUX had) (NP (JJ recurrent) (NN Doc_9125676_1962_1981_Disease)) (PP (IN after) (NP (NP (CD 2) (NNS years)) (PP (IN of) (NP (NP (JJ successful) (NN treatment)) (PP (IN with) (NP (NNP Doc_9125676_2025_2036_Chemical)))))))) (. .)))
9125676	12	(S1 (S (NP (NN Doc_9125676_2038_2057_Disease)) (VP (VBD occurred) (ADVP (RB early)) (PP (IN during) (NP (NN treatment))) (PP (ADVP (RB even)) (IN with) (NP (NP (JJ low) (NNS doses)) (PP (IN of) (NP (JJ oral) (NNP Doc_9125676_2118_2129_Chemical)))))) (. .)))
9125676	13	(S1 (S (NP (NP (JJ Pronounced) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN surface) (NN ECG)) (PRN (-LRB- -LRB-) (NP (NP (NN cycle) (NN length)) (, ,) (NP (NN QT)) (, ,) (CC and) (NP (NN QTc))) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NN relation)) (PP (TO to) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (JJ oral) (NNP Doc_9125676_2229_2240_Chemical)))))))) (VP (MD might) (VP (VB identify) (NP (NP (DT a) (NN subgroup)) (PP (IN of) (NP (NNS patients)))) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN for) (NP (NNP Doc_9125676_2306_2325_Disease))))))) (. .)))
9125676	14	(S1 (S (NP (NP (JJ Other) (JJ ECG) (NNS parameters)) (PP (IN before) (NP (NP (DT the) (NN application)) (PP (IN of) (NP (NNP Doc_9125676_2374_2385_Chemical)))))) (VP (AUX did) (RB not) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJ increased) (NN risk)) (PP (IN for) (NP (NNP Doc_9125676_2434_2453_Disease))))))) (. .)))
9125676	15	(S1 (S (NP (NP (NN Recurrence) (NNS rates)) (PP (IN of) (NP (NNP Doc_9125676_2475_2503_Disease)))) (VP (AUX are) (ADJP (JJ high)) (PP (IN despite) (NP (NP (JJ complete) (NN suppression)) (PP (IN of) (NP (DT the) (NNP Doc_9125676_2549_2559_Disease))))) (PP (IN during) (NP (JJ programmed) (NN stimulation)))) (. .)))
9125676	16	(S1 (S (ADVP (RB Therefore)) (NP (NP (JJ programmed) (JJ electrical) (NN stimulation)) (PP (IN in) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (NNP Doc_9125676_2650_2661_Chemical)))))) (VP (VBZ seems) (S (VP (TO to) (VP (AUX be) (PP (IN of) (NP (JJ limited) (JJ prognostic) (NN value))))))) (. .)))
9128918	0	(S1 (NP (NP (NN Chronic) (NN Doc_9128918_8_26_Disease) (CC and) (NNS changes)) (PP (IN in) (NP (JJ Doc_9128918_42_50_Chemical) (NNS neurons))) (. .)))
9128918	1	(S1 (S (NP (DT The) (JJ tuberoinfundibular) (JJ dopaminergic) (PRN (-LRB- -LRB-) (NP (NNP TIDA)) (-RRB- -RRB-)) (NN system)) (VP (AUX is) (VP (VBN known) (S (VP (TO to) (VP (VB inhibit) (NP (FW prolactin) (PRN (-LRB- -LRB-) (NP (NNP PRL)) (-RRB- -RRB-)) (NN secretion))))))) (. .)))
9128918	2	(S1 (S (PP (IN In) (NP (JJ young) (NNS animals))) (NP (DT this) (NN system)) (VP (VBZ responds) (PP (TO to) (NP (NP (JJ acute) (NNS elevations)) (PP (IN in) (NP (NN serum) (NN PRL))))) (PP (IN by) (S (VP (VBG increasing) (NP (PRP$ its) (NN activity)))))) (. .)))
9128918	3	(S1 (S (ADVP (RB However)) (, ,) (NP (DT this) (NN responsiveness)) (VP (AUX is) (VP (VBN lost) (PP (IN in) (NP (VBG aging) (NNS rats))) (PP (IN with) (NP (RB chronically) (JJ high) (NN serum) (NN PRL) (NNS levels))))) (. .)))
9128918	4	(S1 (S (NP (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT this) (NN study)))) (VP (AUX was) (S (VP (TO to) (VP (VP (VB induce) (NP (NP (NN Doc_9128918_387_405_Disease)) (PP (IN in) (NP (NNS rats)))) (PP (IN for) (NP (NP (VBN extended) (NNS periods)) (PP (IN of) (NP (NN time)))))) (CC and) (VP (VB examine) (NP (NP (PRP$ its) (NNS effects)) (PP (IN on) (NP (JJ dopaminergic) (NNS systems)))) (PP (IN in) (NP (DT the) (NN brain)))))))) (. .)))
9128918	5	(S1 (S (S (NP (NN Doc_9128918_505_523_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN by) (NP (NN treatment))) (PP (IN with) (NP (NP (NNP Doc_9128918_554_565_Chemical)) (, ,) (NP (DT a) (NNP Doc_9128918_569_577_Chemical) (NN receptor) (NN antagonist))))))) (, ,) (CC and) (S (NP (NP (NP (NNP Palkovits) (POS ')) (NN microdissection) (NN technique)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ high-performance) (NN liquid) (NN chromatography)))))) (VP (AUX was) (VP (VBN used) (S (VP (TO to) (VP (VB measure) (NP (NP (JJ neurotransmitter) (NNS concentrations)) (PP (IN in) (NP (NP (JJ several) (NNS areas)) (PP (IN of) (NP (DT the) (NN brain)))))))))))) (. .)))
9128918	6	(S1 (S (PP (IN After) (NP (NP (CD 6) (NNS months)) (PP (IN of) (NP (NNP Doc_9128918_800_818_Disease))))) (, ,) (NP (NP (NNP Doc_9128918_820_828_Chemical) (PRN (-LRB- -LRB-) (NP (NNP DA)) (-RRB- -RRB-)) (NNS concentrations)) (PP (IN in) (NP (NP (DT the) (JJ median) (NN eminence)) (PRN (-LRB- -LRB-) (NP (PRP ME)) (-RRB- -RRB-))))) (VP (VBN increased) (PP (IN by) (NP (CD 84) (NN %))) (PP (IN over) (NP (DT the) (NN control) (NN group)))) (. .)))
9128918	7	(S1 (S (NP (NP (CD Nine) (NNS months)) (PP (IN of) (NP (NNP Doc_9128918_933_951_Disease)))) (VP (VBD produced) (NP (NP (DT a) (ADJP (CD 50) (NN %)) (NN increase)) (PP (IN in) (NP (NP (NN DA) (NNS concentrations)) (PP (IN in) (NP (DT the) (FW ME))))) (PP (IN over) (NP (DT the) (NN control) (NN group))))) (. .)))
9128918	8	(S1 (S (ADVP (RB However)) (, ,) (NP (NN DA) (NN response)) (VP (AUX was) (VP (VBN lost) (SBAR (IN if) (S (NP (DT a) (JJ 9-month) (JJ long) (JJ Doc_9128918_1079_1090_Chemical-induced) (NN Doc_9128918_1099_1117_Disease)) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (NP (DT a) (ADJP (QP (CD 1) (CD 1/2)) (NN month-long)) (ADJP (RB extremely) (JJ high)) (NN increase)) (PP (IN in) (NP (NP (NN serum) (NN PRL) (NNS levels)) (VP (VBN produced) (PP (IN by) (NP (NP (NN implantation)) (PP (IN of) (NP (NP (JJ MMQ) (NNS cells)) (PP (IN under) (NP (DT the) (NN kidney) (NN capsule)))))))))))))))))) (. .)))
9128918	9	(S1 (S (NP (EX There)) (VP (AUX was) (NP (DT no) (NN change)) (PP (IN in) (NP (NP (DT the) (NNS levels)) (PP (IN of) (NP (NP (NAC (NNP DA) (, ,) (NP (NP (NP (NNP Doc_9128918_1302_1316_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP NE)) (-RRB- -RRB-))) (, ,) (NP (NNP Doc_9128918_1323_1332_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_9128918_1334_1338_Chemical)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (PRP$ their) (NNS metabolites)) (PP (IN in) (NP (NP (DT the) (NNP Doc_9128918_1369_1384_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9128918_1386_1388_Disease)) (-RRB- -RRB-)) (, ,) (NP (JJ medial) (JJ preoptic) (NN area)) (PRN (-LRB- -LRB-) (NP (NNP MPA)) (-RRB- -RRB-)) (, ,) (NP (JJ caudate) (NNS putamen)) (PRN (-LRB- -LRB-) (NP (NNP CP)) (-RRB- -RRB-)) (, ,) (NP (NN substantia) (NN nigra)) (PRN (-LRB- -LRB-) (NP (NNP SN)) (-RRB- -RRB-)))))) (, ,) (CC and)) (NN zona) (NN incerta)) (PRN (-LRB- -LRB-) (NP (NNP ZI)) (-RRB- -RRB-)))))) (, ,) (PP (IN except) (PP (IN for) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (NNP Doc_9128918_1512_1538_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9128918_1540_1546_Chemical)) (-RRB- -RRB-)))) (PP (IN in) (NP (DT the) (NNP Doc_9128918_1555_1557_Disease))) (PP (IN after) (NP (NP (NP (NNS 6-months)) (PP (IN of) (NP (NNP Doc_9128918_1576_1594_Disease)))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN DA) (NNS concentrations)) (PP (IN in) (NP (DT the) (NNP Doc_9128918_1639_1641_Disease))) (PP (IN after) (NP (NP (NNS 9-months)) (PP (IN of) (NP (NNP Doc_9128918_1660_1678_Disease)))))))))))))) (. .)))
9128918	10	(S1 (S (NP (DT These) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (S (NP (NNP Doc_9128918_1711_1729_Disease)) (ADVP (RB specifically)) (VP (VBZ affects) (NP (NN TIDA) (NNS neurons)))) (CC and) (S (NP (DT these) (NNS effects)) (VP (VBP vary))))) (, ,) (PP (VBG depending) (PP (IN on) (NP (NP (DT the) (NN duration) (CC and) (NN intensity)) (PP (IN of) (NP (NNP Doc_9128918_1831_1849_Disease))))))) (. .)))
9128918	11	(S1 (S (NP (NP (DT The) (JJ age-related) (NN decrease)) (PP (IN in) (NP (JJ hypothalamic) (JJ Doc_9128918_1892_1900_Chemical) (NN function)))) (VP (MD may) (VP (AUX be) (VP (VBN associated) (PP (IN with) (NP (NP (NNS increases)) (PP (IN in) (NP (NN PRL) (NN secretion)))))))) (. .)))
9132810	0	(S1 (NP (NP (JJ Treatment-related) (NN Doc_9132810_18_62_Disease)) (PP (IN with) (NP (NP (JJ characteristic) (NN contrast) (NN enhancement)) (PP (IN of) (NP (DT the) (JJ white) (NN matter))))) (. .)))
9132810	1	(S1 (S (NP (DT This) (NN report)) (VP (VBZ describes) (NP (NP (JJ unique) (NN contrast) (NN enhancement)) (PP (IN of) (NP (DT the) (JJ white) (NN matter))) (PP (IN on) (NP (NP (JJ T1-weighted) (JJ magnetic) (NN resonance) (NNS images)) (PP (IN of) (NP (NP (CD two) (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_9132810_257_301_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD developed) (PP (IN from) (NP (NNP Doc_9132810_324_352_Disease))) (PP (VBN treated) (PP (IN with) (NP (JJ high-dose) (NNP Doc_9132810_376_388_Chemical))))))))))))))) (. .)))
9132810	2	(S1 (S (PP (IN In) (NP (DT both) (NNS patients))) (, ,) (NP (DT the) (NN enhancement)) (VP (AUX was) (ADJP (RBR more) (JJ pronounced)) (PP (IN near) (NP (NP (DT the) (NN base)) (PP (IN of) (NP (DT the) (NN brain))))) (PP (IN than) (PP (IN at) (NP (DT the) (NN vertex))))) (. .)))
9132810	3	(S1 (S (NP (NP (NN Necropsy)) (PP (IN of) (NP (DT the) (JJ first) (NN case)))) (VP (VBD revealed) (NP (NN Doc_9132810_527_579_Disease))) (. .)))
9132810	4	(S1 (S (NP (NP (JJ Possible) (NNS mechanisms)) (VP (VBG causing) (NP (PDT such) (DT a) (NN Doc_9132810_616_635_Disease)))) (VP (AUX are) (VP (VBN discussed))) (. .)))
9158667	0	(S1 (NP (NP (NN Doc_9158667_0_10_Disease) (NNS complications)) (PP (IN in) (NP (NP (NNP Doc_9158667_28_56_Disease)) (PP (IN during) (NP (JJ Doc_9158667_64_87_Chemical) (NN therapy))))) (. .)))
9158667	1	(S1 (S (NP (NP (DT A) (NN case)) (PP (IN of) (NP (NNP Doc_9158667_107_126_Disease))) (, ,) (UCP (ADJP (JJ due) (PP (TO to) (NP (NP (NN occlusion)) (PP (IN of) (NP (NP (JJ renal) (NNS vessels)) (PP (IN in) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (NNP Doc_9158667_180_208_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9158667_210_213_Disease)) (-RRB- -RRB-)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_9158667_228_251_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9158667_253_257_Chemical)) (-RRB- -RRB-)))))))))))))) (CC and) (NP (NNP Doc_9158667_263_278_Chemical)))) (VP (AUX has) (VP (AUX been) (VP (VBN described) (ADVP (RB recently))))) (. .)))
9158667	2	(S1 (S (NP (PRP We)) (VP (VBP report) (NP (NP (DT a) (NN case)) (PP (IN of) (NP (NNP Doc_9158667_328_347_Disease)))) (PP (IN in) (NP (NP (DT an) (JJ Doc_9158667_354_357_Disease) (NN patient)) (VP (VBN treated) (PP (IN with) (NP (NP (NNP Doc_9158667_379_383_Chemical)) (ADVP (RB alone)))))))) (. .)))
9158667	3	(S1 (S (NP (DT This) (NN case)) (ADVP (RB further)) (VP (VBZ supports) (NP (NP (DT the) (NN concern)) (PP (IN about) (NP (NP (JJ Doc_9158667_436_450_Disease) (NNS complications)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ Doc_9158667_481_485_Chemical) (NN therapy)) (PP (IN in) (NP (JJ Doc_9158667_497_500_Disease) (NNS patients)))))))))) (. .)))
9158667	4	(S1 (S (NP (NP (DT The) (NNS patients)) (, ,) (NP (DT a) (JJ 43-year-old) (NN man)) (, ,)) (VP (VP (VBD presented) (NP (NP (PDT all) (DT the) (NNS signs) (CC and) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_9158667_584_587_Disease))))) (CC and) (VP (AUX was) (VP (VBN included) (PP (IN in) (NP (NP (DT a) (NN treatment) (NN protocol)) (PP (IN with) (NP (NNP Doc_9158667_634_638_Chemical)))))))) (. .)))
9158667	5	(S1 (S (PP (IN After) (NP (NP (CD 10) (NNS days)) (PP (IN of) (NP (NN treatment))))) (, ,) (NP (PRP he)) (VP (VBD developed) (NP (NP (NN Doc_9158667_681_700_Disease)) (SBAR (WHNP (WDT that)) (S (VP (AUX was) (ADJP (RB completely) (JJ reversible)) (SBAR (IN after) (S (S (NP (NP (JJ complete) (NN remission)) (PP (IN of) (NP (NNP Doc_9158667_760_763_Disease)))) (VP (AUX was) (VP (VBN achieved)))) (CC and) (S (NP (NN therapy)) (VP (VBN discontinued)))))))))) (. .)))
9158667	6	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NNP Doc_9158667_820_824_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ valid) (JJ therapeutic) (NN choice)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_9158667_873_876_Disease)))))) (, ,) (SBAR (IN although) (S (NP (DT the) (JJ procoagulant) (NN tendency)) (VP (AUX is) (RB not) (ADVP (RB completely)) (VP (VBN corrected))))))))) (. .)))
9158667	7	(S1 (S (NP (NN Doc_9158667_942_952_Disease) (NNS events)) (, ,) (ADVP (RB however)) (, ,) (VP (MD could) (VP (AUX be) (VP (VBN avoided) (PP (IN by) (S (VP (VBG using) (NP (JJ low-dose) (NN heparin)))))))) (. .)))
9197951	0	(S1 (NP (NP (NP (JJ Pupillary) (NNS changes)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ stimulant-induced) (NN Doc_9197951_71_76_Disease))))))) (: :) (NP (NP (DT a) (NN case)) (SBAR (S (VP (VBP report))))) (. .)))
9197951	1	(S1 (S (NP (NP (DT A) (JJ 30-year-old) (JJ Doc_9197951_107_114_Chemical-dependent) (NN man)) (SBAR (WHNP (WP who)) (S (VP (AUX was) (NP (NP (DT a) (NN subject)) (PP (IN in) (NP (NP (DT a) (NN study)) (VP (VBG evaluating) (NP (NP (DT the) (JJ anticraving) (NN efficacy)) (PP (IN of) (NP (NP (DT the) (NN stimulant) (NN medication) (NNP Doc_9197951_222_236_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP DEP)) (-RRB- -RRB-))))))))))))) (VP (VBD became) (NP (NNP Doc_9197951_250_255_Disease)) (PP (IN during) (NP (PRP$ his) (JJ second) (NN week))) (PP (IN on) (NP (DT the) (NN study) (NN drug)))) (. .)))
9197951	2	(S1 (S (NP (NNP Pupillometric)) (VP (VBZ changes) (SBAR (IN while) (S (PP (IN on) (NP (NNP DEP))) (, ,) (NP (NP (RB especially) (NNS changes)) (PP (IN in) (NP (NP (DT the) (JJ total) (NN power)) (PP (IN of) (NP (NNP Doc_9197951_375_396_Disease)))))) (, ,) (VP (AUX were) (ADJP (RB dramatically) (JJ different) (PP (IN than) (NP (NP (DT those)) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (CD eight) (JJ other) (NN study) (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (AUX did) (RB not) (VP (VBN become) (NP (NN Doc_9197951_499_504_Disease)))))))))))))))) (. .)))
9197951	3	(S1 (S (NP (NP (DT The) (JJ large) (NNS changes)) (PP (IN in) (NP (NP (JJ total) (NN power)) (PP (IN of) (NP (NNP Doc_9197951_542_563_Disease)))))) (VP (VBD occurred) (SBAR (NP (DT a) (JJ few) (NNS days)) (IN before) (S (NP (DT the) (NN patient)) (VP (VBD became) (ADJP (RB fully) (JJ Doc_9197951_616_621_Disease)))))) (. .)))
9197951	4	(S1 (S (NP (NP (JJ Such) (JJ medication-associated) (NNS changes)) (PP (IN in) (NP (NP (DT the) (JJ total) (NN power)) (PP (IN of) (NP (NNP Doc_9197951_680_701_Disease)))))) (VP (MD might) (VP (AUX be) (PP (IN of) (NP (NN utility))) (PP (IN in) (S (VP (VBG identifying) (NP (NNS persons)) (PP (IN at) (NP (NP (NN risk)) (PP (IN for) (NP (NP (JJ Doc_9197951_757_762_Disease-like) (JJ adverse) (NNS effects)) (PP (IN during) (NP (NP (DT the) (JJ medical) (NN use)) (PP (IN of) (NP (NP (JJ psychomotor) (NNS stimulants)) (CC or) (NP (JJ sympathomimetic) (NNS agents))))))))))))))) (. .)))
920167	0	(S1 (S (NP (JJ Fetal) (NNS risks)) (VP (JJ due) (PP (TO to) (NP (JJ Doc_920167_19_27_Chemical) (NN therapy))) (PP (IN during) (NP (NN pregnancy)))) (. .)))
920167	1	(S1 (S (NP (NP (CD Two) (NNS mothers)) (PP (IN with) (NP (NN heart) (NN valve) (NNS prosthesis)))) (VP (AUX were) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_920167_112_120_Chemical))) (PP (IN during) (NP (NN pregnancy))))) (. .)))
920167	2	(S1 (S (PP (IN In) (NP (DT the) (JJ first) (NN case))) (NP (DT a) (JJ caesarean) (NN section)) (VP (AUX was) (ADVP (RB done)) (NP (CD one) (NN week)) (PP (IN after) (NP (NP (NN replacement)) (PP (IN of) (NP (NNP Doc_920167_216_224_Chemical))) (PP (IN with) (NP (NN heparin)))))) (. .)))
920167	3	(S1 (S (NP (DT The) (NN baby)) (VP (VBD died) (PP (IN of) (NP (NNP Doc_920167_256_289_Disease)))) (. .)))
920167	4	(S1 (S (NP (DT The) (JJ second) (NN mother)) (VP (AUX had) (NP (NP (DT a) (JJ male) (NN infant)) (PP (IN by) (NP (JJ caesarean) (NN section))))) (. .)))
920167	5	(S1 (S (NP (DT The) (NN baby)) (VP (VBD showed) (NP (NP (JJ Doc_920167_365_373_Chemical-induced) (NN Doc_920167_382_393_Disease)) (PP (IN with) (NP (NP (JJ nasal) (NNP Doc_920167_405_415_Disease)) (CC and) (NP (NP (NNP Doc_920167_420_438_Disease)) (PRN (-LRB- -LRB-) (NP (NNP Doc_920167_440_465_Disease)) (-RRB- -RRB-))))))) (. .)))
920167	6	(S1 (S (S (NP (NP (JJ Nasal) (NN Doc_920167_474_484_Disease)) (PP (IN with) (CC or) (IN without) (NP (NNP Doc_920167_501_519_Disease)))) (VP (AUX has) (ADVP (RB now)) (VP (AUX been) (VP (VBN reported) (PP (IN in) (NP (NP (CD 11) (NNS infants)) (VP (VBN born) (PP (TO to) (NP (NP (NNS mothers)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_920167_585_593_Chemical))) (PP (IN during) (NP (DT the) (JJ first) (NN trimester))))))))))))) (, ,) (CC and) (S (NP (DT a) (JJ causal) (NN association)) (VP (AUX is) (ADJP (JJ probable)))) (. .)))
920167	7	(S1 (S (PP (IN In) (NP (NP (NP (NN view)) (PP (IN of) (NP (DT the) (NNS risks))) (PP (TO to) (NP (DT both) (NN mother)))) (CC and) (NP (NP (NN fetus)) (PP (IN in) (NP (NNS women))) (PP (IN with) (NP (JJ prosthetic) (JJ cardiac) (NNS valves)))))) (NP (PRP it)) (VP (AUX is) (VP (VBN recommended) (SBAR (IN that) (S (NP (JJ therapeutic) (NN abortion)) (VP (AUX be) (VP (VBN advised) (PP (IN as) (NP (DT the) (JJ first) (NN alternative))))))))) (. .)))
9272404	0	(S1 (NP (NP (DT The) (JJ negative) (JJ mucosal) (NN potential)) (: :) (S (VP (VBG separating) (NP (NP (JJ central) (CC and) (JJ peripheral) (NNS effects)) (PP (IN of) (NP (NP (NNS NSAIDs)) (PP (IN in) (NP (NN man)))))))) (. .)))
9272404	1	(S1 (S (NP (PRP We)) (VP (VBD wanted) (S (VP (TO to) (VP (VB test) (SBAR (IN whether) (S (NP (NP (NN assessment)) (PP (IN of) (NP (NP (NP (PDT both) (DT a) (JJ central) (JJ Doc_9272404_158_162_Disease-related) (NN signal)) (PRN (-LRB- -LRB-) (NP (NP (JJ chemo-somatosensory) (JJ evoked) (NN potential)) (, ,) (NP (NNP CSSEP))) (-RRB- -RRB-))) (CC and) (NP (NP (DT a) (ADJP (RB concomitantly) (VBN recorded)) (JJ peripheral) (NN signal)) (PRN (-LRB- -LRB-) (NP (NP (JJ negative) (JJ mucosal) (NN potential)) (, ,) (NP (NNP Doc_9272404_300_303_Chemical))) (-RRB- -RRB-)))))) (VP (VBZ allows) (PP (IN for) (NP (NP (NN separation)) (PP (IN of) (NP (NP (JJ central) (CC and) (JJ peripheral) (NNS effects)) (PP (IN of) (NP (NNS NSAIDs)))))))))))))) (. .)))
9272404	2	(S1 (S (PP (IN For) (NP (DT this) (NN purpose))) (, ,) (NP (JJ experimental) (NNS conditions)) (VP (AUX were) (VP (VBN created) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NNS NSAIDs)) (VP (AUX had) (ADVP (RB previously)) (VP (AUX been) (VP (VBN observed) (S (VP (TO to) (VP (VB produce) (NP (NP (NNS effects)) (PP (IN on) (NP (NP (NN phasic)) (CC and) (NP (NNP Doc_9272404_505_515_Disease))))) (PP (IN by) (NP (DT either) (ADJP (JJ central) (CC or) (JJ peripheral)) (NNS mechanisms))))))))))))) (. .)))
9272404	3	(S1 (S (PP (VBG According) (PP (TO to) (NP (DT a) (JJ double-blind) (, ,) (VBN randomised) (, ,) (VBN controlled) (, ,) (ADJP (RB threefold) (JJ cross-over)) (NN design)))) (, ,) (NP (NP (CD 18) (JJ healthy) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NP (CD 11) (NNS males)) (, ,) (NP (NP (CD 7) (NNS females)) (: ;) (NP (NP (JJ mean) (NN age)) (NP (CD 26) (NNS years))))) (-RRB- -RRB-))) (VP (VBD received) (NP (NP (DT either) (NN placebo)) (, ,) (NP (NP (NP (QP (CD 400) (CD mg))) (NP (NNP Doc_9272404_744_753_Chemical))) (, ,) (CC or) (NP (NP (QP (CD 800) (CD mg))) (NP (NNP Doc_9272404_765_774_Chemical)))))) (. .)))
9272404	4	(S1 (S (S (NP (NNP Phasic) (NNP Doc_9272404_783_787_Disease)) (VP (AUX was) (VP (VBN applied) (PP (IN by) (NP (NP (NNS means)) (PP (IN of) (NP (NP (JJ short) (NNS pulses)) (PP (IN of) (NP (NNP Doc_9272404_828_831_Chemical))))))) (PP (TO to) (NP (NP (DT the) (JJ nasal) (NNS mucosa)) (PRN (-LRB- -LRB-) (NP (NP (NN stimulus) (NN duration)) (NP (CD 500) (NNS ms))) (, ,) (NP (ADJP (JJ interval) (QP (RB approximately) (CD 60))) (NNP s)) (-RRB- -RRB-))))))) (, ,) (CC and) (S (NP (NNP Doc_9272404_913_923_Disease)) (VP (AUX was) (VP (VBN induced) (PP (IN in) (NP (DT the) (JJ nasal) (NN cavity))) (PP (IN by) (NP (NP (NNS means)) (PP (IN of) (NP (NP (JJ dry) (NN air)) (PP (IN of) (NP (NP (VBN controlled) (NN temperature) (, ,) (NN humidity) (CC and) (NN flow) (NN rate)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 22) (NNS degrees)) (X (SYM C))) (, ,) (NP (ADJP (CD 0) (NN %)) (JJ relative) (NN humidity)) (, ,) (NP (CD 145) (NN ml.s-1))) (-RRB- -RRB-))))))))))) (. .)))
9272404	5	(S1 (S (NP (NP (DT Both) (NNS CSSEPs)) (PP (IN as) (NP (NP (NN central) (CC and) (NNS NMPs)) (PP (IN as) (NP (NP (JJ peripheral) (NNS correlates)) (PP (IN of) (NP (NNP Doc_9272404_1136_1140_Disease)))))))) (VP (AUX were) (VP (VBN obtained) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (DT the) (JJ Doc_9272404_1174_1177_Chemical) (NNS stimuli))))))) (. .)))
9272404	6	(S1 (S (ADVP (RB Additionally)) (, ,) (NP (DT the) (NNS subjects)) (VP (VBN rated) (NP (NP (DT the) (NN intensity)) (PP (IN of) (NP (DT both) (JJ phasic) (CC and) (NNP Doc_9272404_1253_1263_Disease)))) (PP (IN by) (NP (NP (NNS means)) (PP (IN of) (NP (JJ visual) (NN analogue) (NNS scales)))))) (. .)))
9272404	7	(S1 (S (SBAR (IN As) (S (VP (VBN described) (ADVP (RB earlier))))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NNP Doc_9272404_1349_1358_Chemical)))) (VP (AUX was) (VP (VBN followed) (PP (IN by) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NNP Doc_9272404_1389_1399_Disease))) (ADJP (JJ but-relative) (PP (TO to) (NP (NP (JJ placebo-an) (NN increase)) (PP (IN in) (NP (NP (NNS correlates)) (PP (IN of) (NP (JJ phasic) (NNP Doc_9272404_1460_1464_Disease)))))))) (, ,) (VP (VBG indicating) (NP (NP (DT a) (JJ specific) (NN effect)) (PP (IN of) (NP (NNP Doc_9272404_1498_1507_Chemical))) (PP (IN on) (NP (NP (DT the) (NN interaction)) (PP (IN between) (NP (NP (DT the) (JJ Doc_9272404_1539_1543_Disease) (NNS stimuli)) (PP (IN under) (NP (DT these) (JJ special) (JJ experimental) (NNS conditions))))))))))))) (. .)))
9272404	8	(S1 (S (PP (VBN Based) (PP (IN on) (NP (NP (DT the) (JJ similar) (NN behaviour)) (PP (IN of) (NP (NP (NN CSSEP)) (CC and) (NP (NN NMP))))))) (, ,) (NP (PRP it)) (VP (AUX was) (VP (VBN concluded) (SBAR (IN that) (S (NP (NP (DT the) (JJ pharmacological) (NN process)) (VP (VBG underlying) (NP (DT this) (NN phenomenon)))) (VP (AUX was) (VP (VBN localised) (PP (IN in) (NP (DT the) (NN periphery))))))))) (. .)))
9272404	9	(S1 (S (PP (IN By) (NP (NP (NNS means)) (PP (IN of) (NP (NP (DT the) (JJ simultaneous) (NN recording)) (PP (IN of) (NP (NP (JJ interrelated) (ADJP (JJ peripheral) (CC and) (JJ central)) (JJ electrophysiologic) (NNS correlates)) (PP (IN of) (NP (NN nociception))))))))) (, ,) (NP (PRP it)) (VP (AUX was) (ADJP (JJ possible) (PP (TO to) (NP (NP (JJ separate) (ADJP (JJ central) (CC and) (JJ peripheral)) (NNS effects)) (PP (IN of) (NP (DT an) (NN NSAID))))))) (. .)))
9272404	10	(S1 (S (NP (NP (DT The) (JJ major) (NN advantage)) (PP (IN of) (NP (DT this) (NNP Doc_9272404_1979_1983_Disease) (NN model)))) (VP (AUX is) (NP (NP (DT the) (NN possibility)) (PP (IN of) (S (VP (VBG obtaining) (NP (JJ peripheral) (JJ Doc_9272404_2033_2037_Disease-related) (NN activity)) (ADVP (RB directly)) (S (VP (VBG using) (NP (NP (DT a) (JJ non-invasive) (NN technique)) (PP (IN in) (NP (NNS humans))))))))))) (. .)))
931801	0	(S1 (NP (NP (NN Effect)) (PP (IN of) (NP (NNP Doc_931801_10_22_Chemical))) (PP (IN on) (NP (NP (JJ basic) (JJ antibiotic-induced) (NN Doc_931801_51_63_Disease)) (PP (IN in) (NP (NNS rats))))) (. .)))
931801	1	(S1 (S (NP (JJ Dehydrated) (NNS rats)) (ADVP (RB regularly)) (VP (VBP develop) (NP (NNP Doc_931801_107_126_Disease)) (PP (VBG following) (NP (NP (JJ single) (NN injection)) (PP (IN of) (NP (JJ Doc_931801_157_171_Chemical) (NNS antibiotics))) (PP (VBN combined) (PP (IN with) (NP (NN dextran))) (CC or) (PP (IN of) (NP (NP (NNS antibiotics)) (RB only))))))) (. .)))
931801	2	(S1 (S (NP (NP (JJ Oral) (NN administration)) (PP (IN of) (NP (NNP Doc_931801_253_296_Chemical)))) (VP (VBD protected) (NP (NP (NNS rats)) (PP (IN against) (NP (NP (NNP Doc_931801_320_333_Disease)) (VP (VBN induced) (PP (IN by) (NP (NNP Doc_931801_345_354_Chemical-dextran)))))))) (. .)))
931801	3	(S1 (S (S (NP (DT The) (JJ protective) (NN effect)) (VP (AUX was) (ADJP (JJ prevalent)) (PP (IN among) (NP (NNP Doc_931801_406_418_Chemical))))) (, ,) (CC and) (S (ADVP (RB also)) (PP (TO to) (NP (NP (JJ other) (NNP Doc_931801_438_452_Chemical)) (, ,) (NP (NNP Doc_931801_454_470_Chemical)) (CC and) (NP (NNP Doc_931801_475_492_Chemical)))) (, ,) (ADVP (IN although) (PP (PP (TO to) (NP (DT a) (JJR lesser) (NN degree))) (, ,) (CC but) (RB not) (PP (TO to) (NP (NP (NP (DT a) (NAC (NNP Doc_931801_536_546_Chemical) (, ,) (NNP Doc_931801_548_562_Chemical) (, ,)) (NNS substances) (NN inthe)) (NNP Doc_931801_581_584_Chemical) (NN cycle)) (CC and) (NP (JJ other) (JJ acidic) (NNS compounds))))))) (. .)))
931801	4	(S1 (S (NP (NN Doc_931801_619_631_Chemical)) (VP (AUX were) (ADJP (JJ effective)) (PP (IN against) (NP (NP (NNP Doc_931801_655_667_Disease)) (VP (VBN induced) (PP (IN by) (NP (NP (NN peptide) (NNS antibiotics)) (CONJP (RB as) (RB well) (IN as)) (NP (JJ various) (JJ Doc_931801_718_732_Chemical) (NNS antibitocis)))))))) (. .)))
931801	5	(S1 (S (NP (NNS Dose-responses)) (VP (AUX were) (VP (VBN observed) (PP (IN in) (NP (NP (DT the) (JJ protective) (NN effect)) (PP (IN of) (NP (NNP Doc_931801_803_815_Chemical))))))) (. .)))
931801	6	(S1 (S (PP (IN With) (NP (NP (DT a) (NN D-glucarate)) (PP (IN of) (NP (NP (DT a) (VBN fixed) (NN size)) (PP (IN of) (NP (NN dose))))))) (, ,) (NP (NP (RB approximately) (DT the) (JJ same) (NN degree)) (PP (IN of) (NP (NN protection)))) (VP (AUX was) (VP (VBN obtained) (PP (IN against) (NP (NP (NNP Doc_931801_926_939_Disease)) (VP (VBN induced) (PP (IN by) (NP (JJ different) (JJ basic) (NNS antibiotics))) (PP (IN despite) (NP (NP (JJ large) (NNS disparities)) (PP (IN in) (NP (NP (NN administration) (NNS doses)) (PP (IN of) (NP (JJ different) (NNS antibiotics)))))))))))) (. .)))
931801	7	(S1 (S (NP (NN Doc_931801_1055_1067_Chemical)) (VP (AUX had) (NP (DT the) (NN ability) (S (VP (VP (TO to) (VP (VB prevent) (NP (NNP Doc_931801_1095_1107_Disease)))) (CC but) (VP (RB not) (TO to) (VP (VB cure) (NP (PRP it)))))))) (. .)))
931801	8	(S1 (S (NP (NNS Rats)) (VP (VBD excreted) (NP (JJ acidic) (NN urine)) (SBAR (WHADVP (WRB when)) (S (NP (PRP they)) (VP (AUX were) (VP (VBN spared) (PP (IN from) (NP (JJ renal) (NNS lesions))) (PP (IN by) (NP (NN Doc_931801_1199_1214_Chemical)))))))) (. .)))
931801	9	(S1 (S (NP (NP (DT The) (NN reduction) (NN effect)) (PP (IN of) (NP (NNP Doc_931801_1240_1252_Chemical))) (PP (IN against) (NP (NP (NN nephrotoxicity)) (PP (IN of) (NP (JJ basic) (NNS antibiotics)))))) (VP (AUX was) (VP (VBN discussed))) (. .)))
9323412	0	(S1 (S (NP (JJ Acute) (JJ severe) (NN Doc_9323412_13_23_Disease)) (VP (VBG following) (NP (JJ peri-operative) (NN ondansetron))) (. .)))
9323412	1	(S1 (S (NP (NP (DT A) (JJ 41-year-old) (NN woman)) (PP (IN with) (NP (NP (DT a) (JJ strong) (NN history)) (PP (IN of) (NP (NNP Doc_9323412_107_140_Disease)))))) (VP (VBD presented) (PP (IN for) (NP (JJ abdominal) (QP (JJ hysterectomy) (CD 3)) (NNS months))) (PP (IN after) (NP (NP (DT a) (JJ previous) (NN anaesthetic)) (SBAR (WHADVP (WRB where)) (S (NP (NN ondansetron) (NNS prophylaxis)) (VP (AUX had) (VP (AUX been) (VP (VBN used))))))))) (. .)))
9323412	2	(S1 (S (NP (PRP She)) (VP (AUX had) (VP (VBN developed) (NP (DT a) (JJ severe) (JJ acute) (JJ major) (NN Doc_9323412_300_319_Disease)) (ADVP (RB almost) (RB immediately)) (ADVP (RB thereafter)) (, ,) (PP (ADVP (RB possibly)) (VBN related) (PP (TO to) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT a) (JJ Doc_9323412_384_393_Chemical) (NN antagonist)))))))) (. .)))
9323412	3	(S1 (S (ADVP (NP (CD Nine) (NNS years)) (IN before)) (NP (PRP she)) (VP (AUX had) (VP (VBN experienced) (NP (DT a) (JJ self-limited) (NN puerperal) (NN Doc_9323412_469_487_Disease)))) (. .)))
9323412	4	(S1 (S (NP (NP (NP (NN Anaesthesia)) (PP (IN with) (NP (DT a) (JJ Doc_9323412_508_516_Chemical) (NN infusion)))) (CC and) (NP (NP (NN avoidance)) (PP (IN of) (NP (JJ Doc_9323412_543_552_Chemical) (NNS antagonists))))) (VP (VBD provided) (NP (NP (DT a) (JJ Doc_9323412_576_582_Disease-free) (JJ postoperative) (NN course)) (PP (IN without) (NP (NP (NN exacerbation)) (PP (IN of) (NP (DT the) (NNP Doc_9323412_637_656_Disease))))))) (. .)))
9382023	0	(S1 (S (VP (VB Doc_9382023_0_12_Disease) (NP (NN response)) (PP (IN during) (NP (JJ Doc_9382023_29_39_Chemical) (NN stress) (NN echocardiography)))) (. .)))
9382023	1	(S1 (S (PP (IN Among) (NP (CD 3,129) (JJ Doc_9382023_77_87_Chemical) (NN stress) (NN echocardiographic) (NNS studies))) (, ,) (NP (NP (DT a) (NNP Doc_9382023_124_136_Disease) (NN response)) (, ,) (VP (VBN defined) (PP (IN as) (NP (NP (NP (JJ systolic) (NN blood) (NN pressure) (PRN (-LRB- -LRB-) (NP (NNP BP)) (-RRB- -RRB-)) (NNP >)) (CC or) (NP (QP (SYM =) (CD 220) (CD mm)) (NNP Hg) (NN and/or) (NN diastolic) (NNP BP) (NNP >))) (CC or) (NP (NP (QP (SYM =) (CD 110) (CD mm))) (NP (NNP Hg)))))) (, ,)) (VP (VBD occurred) (PP (IN in) (NP (NP (CD 30) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN %)) (-RRB- -RRB-))))) (. .)))
9382023	2	(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (DT this) (NN response)))) (VP (VP (ADVP (RBR more) (RB often)) (AUX had) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NNP Doc_9382023_328_340_Disease))))) (CC and) (VP (AUX had) (NP (NP (JJR higher) (NN resting) (NN systolic)) (CC and) (NP (JJ diastolic) (NNP BP))) (PP (IN before) (NP (JJ Doc_9382023_397_407_Chemical) (NN infusion))))) (. .)))
9428298	0	(S1 (NP (NP (NP (ADJP (RB Continuously) (VBN nebulized)) (NN Doc_9428298_23_32_Chemical)) (PP (IN in) (NP (NP (JJ severe) (NNS exacerbations)) (PP (IN of) (NP (NNP Doc_9428298_60_66_Disease))))) (PP (IN in) (NP (NNS adults)))) (: :) (NP (DT a) (JJ case-controlled) (NN study)) (. .)))
9428298	1	(S1 (S (NP (NP (DT A) (JJ retrospective) (, ,) (JJ case-controlled) (NN analysis)) (VP (VBG comparing) (NP (NP (NNS patients)) (VP (VBN admitted) (PP (TO to) (NP (DT a) (JJ medical) (JJ intensive) (NN care) (NN unit))) (PP (IN with) (NP (NP (JJ severe) (NNS exacerbations)) (PP (IN of) (NP (NNP Doc_9428298_235_241_Disease)))))) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (ADJP (RB continuously) (VBN nebulized)) (NP (NP (NP (NNP Doc_9428298_278_287_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP CNA)) (-RRB- -RRB-))) (CC versus) (NP (NP (JJ intermittent) (NNP Doc_9428298_314_323_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP INA)) (-RRB- -RRB-)))) (NNS treatments)))))))) (VP (AUX is) (VP (VBN reported))) (. .)))
9428298	2	(S1 (S (NP (NP (CD Forty) (VBN matched) (NNS pairs)) (PP (IN of) (NP (NNS patients))) (PP (IN with) (NP (NNP Doc_9428298_391_397_Disease)))) (VP (AUX are) (VP (VBN compared))) (. .)))
9428298	3	(S1 (S (NP (NNP CNA)) (VP (AUX was) (VP (VBN administered) (PP (IN for) (NP (NP (DT a) (NN mean)) (PP (IN of) (NP (CD 11) (NN +/-) (CD 10) (NN hr))))))) (. .)))
9428298	4	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_9428298_478_498_Disease)))) (VP (AUX was) (ADJP (JJ similar)) (PP (IN between) (NP (NNS groups)))) (. .)))
9428298	5	(S1 (S (NP (NNP Symptomatic) (NNP Doc_9428298_539_550_Disease)) (VP (AUX did) (RB not) (VP (VB occur))) (. .)))
9428298	6	(S1 (S (NP (NNP CNA) (NNS patients)) (VP (AUX had) (NP (JJR higher) (NN heart) (NNS rates)) (PP (IN during) (NP (NN treatment))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB reflect) (NP (NP (NN severity)) (PP (IN of) (NP (NN illness))))))))) (. .)))
9428298	7	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NN intubation)))) (VP (AUX was) (ADJP (JJ similar))) (. .)))
9428298	8	(S1 (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (NP (NNP CNA)) (CC and) (NP (NNP INA))) (VP (VBD demonstrated) (NP (JJ similar) (NNS profiles)) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (NP (NN safety)) (, ,) (NP (NN morbidity)) (, ,) (CC and) (NP (NN mortality)))))))))) (. .)))
946593	0	(S1 (FRAG (S (NP (NN Doc_946593_0_10_Disease)) (VP (VBG following) (NP (JJ intrathecal) (NNP Doc_946593_33_45_Chemical)))) (: :) (NP (NP (NP (NN report)) (PP (IN of) (NP (DT a) (NN case)))) (CC and) (NP (NP (NN review)) (PP (IN of) (NP (DT the) (NN literature))))) (. .)))
946593	1	(S1 (S (NP (NP (DT A) (NN patient)) (SBAR (WHNP (WP who)) (S (VP (VBD developed) (NP (NNP Doc_946593_118_128_Disease)) (PP (VBG following) (NP (NP (DT the) (JJ intrathecal) (NN instillation)) (PP (IN of) (NP (NNP Doc_946593_171_183_Chemical))))))))) (VP (AUX is) (VP (VBN discribed))) (. .)))
946593	2	(S1 (S (NP (NP (DT The) (CD ten) (ADJP (RB previously) (VBN reported)) (NNS cases)) (PP (IN of) (NP (DT this) (JJ unusual) (NN complication)))) (VP (AUX are) (VP (VBN reviewed))) (. .)))
946593	3	(S1 (S (NP (DT The) (JJ following) (NNS factors)) (VP (VBP appear) (S (VP (TO to) (VP (VB predispose) (PP (TO to) (NP (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT this) (NN complication)))) (: :) (NP (NP (JJ abnormal) (JJ cerebrospinal) (NNS dynamics)) (VP (VBN related) (PP (TO to) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NNP Doc_946593_418_449_Disease)) (, ,) (CC and) (NP (JJ epidural) (JJ cerebrospinal) (NN leakage)))))))) (: ;) (NP (NP (JJ elevated) (JJ cerebrospinal) (JJ fluid) (JJ Doc_946593_516_528_Chemical) (NN concentration)) (VP (VBN related) (PP (PP (TO to) (NP (JJ abnormal) (JJ cerebrospinal) (NN fluid) (NNS dynamics))) (CC and) (PP (TO to) (NP (NP (ADJP (RB inappropriately) (JJ high)) (NNP Doc_946593_620_632_Chemical) (NNS doses)) (VP (VBN based) (PP (IN on) (NP (NN body) (NN surface) (NN area) (NNS calculations))) (PP (IN in) (NP (JJR older) (NNS children) (CC and) (NNS adults))))))))) (: ;) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NNP Doc_946593_725_735_Disease) (NNS preservatives)) (PP (IN in) (NP (ADJP (RB commercially) (JJ available)) (NNP Doc_946593_776_788_Chemical) (NNS preparations) (CC and) (NNS diluents)))))) (: ;) (CC and) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (JJ Doc_946593_831_843_Chemical) (NNS diluents)) (PP (IN of) (NP (NP (JJ unphysiologic) (NN pH)) (, ,) (NP (JJ ionic) (NN content)) (CC and) (NP (NN osmolarity))))))))))))) (. .)))
946593	4	(S1 (S (NP (NP (DT The) (NN role)) (PP (IN of) (NP (NP (JJ Doc_946593_916_928_Chemical) (NNS contaminants)) (, ,) (NP (JJ local) (JJ Doc_946593_949_955_Chemical) (NN deficiency)) (, ,) (CC and) (NP (JJ cranial) (NN irradiation)))) (PP (IN in) (NP (NP (DT the) (NNS pathogenesis)) (PP (IN of) (NP (JJ intrathecal) (NNP Doc_946593_1027_1039_Chemical) (NNP Doc_946593_1040_1048_Disease)))))) (VP (AUX is) (ADJP (JJ unclear))) (. .)))
946593	5	(S1 (S (NP (NP (DT The) (NN incidence)) (PP (IN of) (NP (NNP Doc_946593_1078_1091_Disease)))) (VP (MD may) (VP (AUX be) (VP (VBN reduced) (PP (IN by) (S (VP (VBG employing) (NP (NP (JJR lower) (NNS doses)) (PP (IN of) (NP (NNP Doc_946593_1135_1147_Chemical)))) (PP (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_946593_1167_1198_Disease))))) (, ,) (PP (IN in) (NP (NP (JJR older) (NNS children)) (CC and) (NP (NNS adults)))) (, ,) (CC and) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NNP Doc_946593_1253_1269_Disease)))))))))))) (. .)))
946593	6	(S1 (S (NP (NP (JJ Only) (JJ preservative-free) (NN Doc_946593_1294_1306_Chemical)) (PP (IN in) (NP (NP (NNP Elliott) (POS 's)) (NNP B) (NN Solution))) (PP (IN at) (NP (NP (DT a) (NN concentration)) (PP (IN of) (NP (QP (RB not) (JJR more) (IN than) (CD 1)) (NN mg/ml)))))) (VP (MD should) (VP (AUX be) (VP (VBN used) (PP (IN for) (NP (JJ intrathecal) (NN administration)))))) (. .)))
946593	7	(S1 (S (NP (NP (JJ Periodic) (NN monitoring)) (PP (IN of) (NP (JJ cerebruspinal) (JJ fluid) (JJ Doc_946593_1465_1477_Chemical) (NNS levels)))) (VP (MD may) (VP (AUX be) (ADJP (JJ predictive) (PP (IN of) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ serious) (NNP Doc_946593_1533_1546_Disease)))))))) (. .)))
9538487	0	(S1 (S (NP (NN Doc_9538487_0_28_Disease)) (VP (VBD precipitated) (PP (IN by) (NP (NNP Doc_9538487_45_52_Chemical-induced) (NNP Doc_9538487_61_91_Disease)))) (. .)))
9538487	1	(S1 (S (NP (NP (DT A) (JJ 45-year-old) (NN man)) (, ,) (PP (IN with) (NP (NP (DT a) (JJ 10-year) (NN history)) (PP (IN of) (NP (NP (NNP Doc_9538487_138_154_Disease)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_9538487_168_175_Chemical)))))))) (, ,)) (VP (AUX was) (VP (VBN admitted) (PP (IN with) (NP (NP (NNP Doc_9538487_195_207_Disease)) (, ,) (NP (JJ nonketotic) (NNP Doc_9538487_220_224_Disease)))))) (. .)))
9538487	2	(S1 (S (NP (PRP He)) (VP (VBD gave) (NP (NP (DT a) (JJ five-year) (NN history)) (PP (IN of) (NP (NP (NNP Doc_9538487_257_265_Disease)) (CC and) (NP (NNP Doc_9538487_270_280_Disease)))) (, ,) (SBAR (WHPP (IN during) (WHNP (WDT which) (NN time) (NN urinalysis))) (S (VP (AUX had) (VP (AUX been) (ADJP (JJ negative)) (PP (IN for) (NP (NNP Doc_9538487_333_340_Chemical))))))))) (. .)))
9538487	3	(S1 (S (S (PP (IN After) (NP (NP (NN recovery)) (PP (IN from) (NP (NN hyperglycaemia))))) (, ,) (NP (PRP he)) (VP (VBD remained) (ADJP (JJ polyuric)) (PP (IN despite) (NP (JJ normal) (NN blood) (NN Doc_9538487_420_427_Chemical) (NNS concentrations))))) (: ;) (S (NP (NN water) (NN deprivation) (NN testing)) (VP (VBD indicated) (NP (NNP Doc_9538487_480_510_Disease)) (, ,) (ADJP (JJ likely) (S (VP (TO to) (VP (AUX be) (ADJP (JJ Doc_9538487_525_532_Chemical-induced)))))))) (. .)))
9538487	4	(S1 (S (NP (PRP We)) (VP (VBP hypothesize) (SBAR (IN that) (S (SBAR (WHADVP (WRB when)) (S (NP (DT this) (NN man)) (VP (VBD developed) (NP (NNP Doc_9538487_586_590_Disease) (CD 2) (NNP Doc_9538487_593_601_Disease))))) (, ,) (NP (NP (JJ chronic) (NN Doc_9538487_611_619_Disease)) (ADJP (JJ due) (PP (TO to) (NP (NNP Doc_9538487_627_657_Disease))))) (VP (AUX was) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB precipitate) (NP (NN Doc_9538487_688_712_Disease)))))))))) (. .)))
9570197	0	(S1 (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NP (DT the) (JJ intracoronary) (NN infusion)) (PP (IN of) (NP (NNP Doc_9570197_41_48_Chemical))) (PP (IN on) (NP (NN left)))))) (VP (VBP ventricular) (NP (NP (JJ systolic) (CC and) (JJ diastolic) (NN function)) (PP (IN in) (NP (NNS humans))))) (. .)))
9570197	1	(S1 (S (PP (IN In) (NP (NNS dogs))) (, ,) (NP (NP (DT a) (JJ large) (NN amount)) (PP (IN of) (NP (JJ intravenous) (NNP Doc_9570197_163_170_Chemical)))) (VP (VBZ causes) (NP (NP (NP (DT a) (JJ profound) (NN deterioration)) (PP (IN of) (NP (JJ left) (JJ ventricular) (PRN (-LRB- -LRB-) (NP (NNP LV)) (-RRB- -RRB-)) (JJ systolic) (NN function)))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN in) (S (VP (VBG LV) (NP (JJ end-diastolic) (NN pressure)))))))) (. .)))
9570197	2	(S1 (S (NP (DT This) (NN study)) (VP (AUX was) (VP (AUX done) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NP (DT a) (JJ high) (JJ intracoronary) (JJ Doc_9570197_360_367_Chemical) (NN concentration)) (PP (IN on) (NP (NP (JJ LV) (NN systolic)) (CC and) (NP (JJ diastolic) (NN function)))) (PP (IN in) (NP (NNS humans))))))))))) (. .)))
9570197	3	(S1 (S (S (NP (NP (NNS METHODS) (CC AND) (NNS RESULTS) (: :)) (PP (IN In) (NP (NP (CD 20) (NNS patients)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 14) (NNS men)) (CC and) (NP (CD 6) (NNS women))) (VP (VBN aged) (NP (QP (CD 39) (TO to) (CD 72)) (NNS years)))) (-RRB- -RRB-))))) (VP (VBD referred) (PP (IN for) (NP (JJ cardiac) (NN catheterization))) (PP (IN for) (NP (NP (DT the) (NN evaluation)) (PP (IN of) (NP (NNP Doc_9570197_567_577_Disease))))))) (, ,) (S (NP (PRP we)) (VP (VBD measured) (NP (NP (NP (NN heart) (NN rate)) (, ,) (NP (JJ systemic) (JJ arterial) (NN pressure)) (, ,) (NP (CD LV) (NN pressure)) (CC and) (NP (NP (PRP$ its) (JJ first) (NN derivative)) (PRN (-LRB- -LRB-) (NP (NNP dP/dt)) (-RRB- -RRB-)))) (, ,) (CC and) (NP (JJ LV) (NNS volumes) (CC and) (NN ejection) (NN fraction))) (PP (IN before) (CC and) (IN during) (NP (NP (DT the) (JJ final) (QP (CD 2) (TO to) (CD 3)) (NNS minutes)) (PP (IN of) (NP (NP (DT a) (JJ 15-minute) (NN intracoronary) (NN infusion)) (PP (IN of) (NP (JJ saline) (PRN (-LRB- -LRB-) (NP (NP (CD n=10)) (, ,) (NP (NN control) (NNS subjects))) (-RRB- -RRB-)) (CC or) (NNP Doc_9570197_833_854_Chemical))))) (NP (CD 1) (NN mg/min)) (PRN (-LRB- -LRB-) (NP (CD n=10)) (-RRB- -RRB-)))))) (. .)))
9570197	4	(S1 (S (NP (DT No) (NN variable)) (VP (VBD changed) (PP (IN with) (NP (NN saline)))) (. .)))
9570197	5	(S1 (S (PP (IN With) (NP (NNP Doc_9570197_910_917_Chemical))) (, ,) (NP (NP (DT the) (NN drug) (NN concentration)) (PP (IN in) (NP (NN blood))) (VP (VBN obtained) (PP (IN from) (NP (DT the) (JJ coronary) (NN sinus))))) (VP (AUX was) (NP (NP (CD 3.0+/-0.4) (-LRB- -LRB-) (NN mean+/-SD) (-RRB- -RRB-) (NN mg/L)) (, ,) (ADJP (JJ similar) (PP (IN in) (NP (NN magnitude))) (PP (TO to) (NP (NP (DT the) (NN blood) (JJ Doc_9570197_1050_1057_Chemical) (NN concentration)) (VP (VBN reported) (PP (IN in) (NP (NP (NNS abusers)) (VP (VBG dying) (PP (IN of) (NP (JJ Doc_9570197_1101_1108_Chemical) (NN intoxication)))))))))))) (. .)))
9570197	6	(S1 (S (S (NP (NN Doc_9570197_1123_1130_Chemical)) (VP (VBN induced) (NP (NP (DT no) (JJ significant) (NN change)) (PP (IN in) (NP (NP (NN heart) (NN rate)) (, ,) (NP (NP (JJ LV) (NNS dP/dt)) (PRN (-LRB- -LRB-) (ADJP (JJ positive) (CC or) (JJ negative)) (-RRB- -RRB-))) (, ,) (CC or) (NP (JJ LV) (JJ end-diastolic) (NN volume))))))) (, ,) (CC but) (S (NP (PRP it)) (VP (VBD caused) (NP (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ systolic) (CC and) (JJ mean) (NN arterial) (NNS pressures)))) (, ,) (NP (JJ LV) (JJ end-diastolic) (NN pressure)) (, ,) (CC and) (NP (JJ LV) (JJ end-systolic) (NN volume)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (JJ LV) (NN ejection) (NN fraction))))))) (. .)))
9570197	7	(S1 (S (PP (IN In) (NP (NNS humans))) (, ,) (NP (NP (DT the) (JJ intracoronary) (NN infusion)) (PP (IN of) (NP (NNP Doc_9570197_1460_1467_Chemical) (JJ sufficient))) (PP (IN in) (NP (NN amount) (S (VP (TO to) (VP (VB achieve) (NP (NP (DT a) (JJ high) (NN drug) (NN concentration)) (PP (IN in) (NP (JJ coronary) (JJ sinus) (NN blood)))))))))) (VP (VBZ causes) (NP (NP (DT a) (NN deterioration)) (PP (IN of) (NP (NP (JJ LV) (NN systolic)) (CC and) (NP (JJ diastolic) (NN performance)))))) (. .)))
9578276	0	(S1 (S (NP (NP (VBG Ascending) (NN dose) (NN tolerance) (NN study)) (PP (IN of) (NP (JJ intramuscular) (NNP Doc_9578276_48_58_Chemical)))) (VP (VBN administered) (PP (IN after) (NP (JJ normal) (JJ vaginal) (NN birth)))) (. .)))
9578276	1	(S1 (FRAG (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (JJ maximum) (JJ tolerated) (NN dose)) (PRN (-LRB- -LRB-) (NP (NNP MTD)) (-RRB- -RRB-)) (PP (IN of) (NP (NP (NNP Doc_9578276_160_170_Chemical)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (JJ long-acting) (NN synthetic) (NN analogue)) (PP (IN of) (NP (NNP Doc_9578276_208_216_Chemical)))) (-RRB- -RRB-)))))))) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (ADVP (RB immediately)) (IN after) (NP (JJ vaginal) (NN delivery))) (PP (IN at) (NP (NN term)))))) (. .)))
9578276	2	(S1 (FRAG (NP (NNS MATERIALS) (CC AND) (NNS METHODS)) (: :) (S (NP (NNP Doc_9578276_304_314_Chemical)) (VP (AUX was) (VP (VBN given) (PP (IN as) (NP (DT an) (JJ intramuscular) (NN injection))) (PP (ADVP (RB immediately)) (IN after) (NP (NP (DT the) (NN birth)) (PP (IN of) (NP (DT the) (NN infant))) (PP (IN in) (NP (NP (CD 45) (JJ healthy) (NNS women)) (PP (IN with) (NP (NP (JJ normal) (NNP singleton) (NNS pregnancies)) (SBAR (WHNP (WP who)) (S (VP (VBD delivered) (ADVP (RB vaginally)) (PP (IN at) (NP (NN term))))))))))))))) (. .)))
9578276	3	(S1 (S (NP (NP (NN Dosage) (NNS groups)) (PP (IN of) (NP (CD 15) (, ,) (CD 30) (, ,) (CD 50) (, ,) (CD 75) (, ,) (CD 100) (, ,) (CD 125) (, ,) (CD 150) (, ,) (CD 175) (CC or) (CD 200) (NN microg)))) (NP (NNP Doc_9578276_550_560_Chemical)) (VP (AUX were) (VP (VBN assigned) (PP (TO to) (NP (NP (NNS blocks)) (PP (IN of) (NP (CD three) (NNS women))) (PP (VBG according) (PP (TO to) (NP (NP (DT the) (JJ continual) (NN reassessment) (NN method)) (PRN (-LRB- -LRB-) (NP (NN CRM)) (-RRB- -RRB-))))))))) (. .)))
9578276	4	(S1 (S (NP (DT All) (NN dosage) (NNS groups)) (VP (VBD consisted) (PP (IN of) (NP (CD three) (NNS women))) (, ,) (PP (IN except) (NP (NP (DT those)) (PP (IN with) (NP (NP (NP (CD 100) (NN microg)) (PRN (-LRB- -LRB-) (NP (NN n=6)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 200) (NN microg)) (PRN (-LRB- -LRB-) (NP (CD n=18)) (-RRB- -RRB-)))))))) (. .)))
9578276	5	(S1 (S (NP (VBN Recorded)) (VP (VP (AUX were) (NP (NP (JJ dose-limiting) (JJ adverse) (NNS events)) (: :) (NP (NP (NN hyper-)) (CC or) (NP (NP (NP (NNP Doc_9578276_819_830_Disease)) (PRN (-LRB- -LRB-) (NP (CD three)) (-RRB- -RRB-))) (, ,) (NP (JJ severe) (NNP Doc_9578276_847_861_Disease)) (PRN (-LRB- -LRB-) (NP (CD 0)) (-RRB- -RRB-)) (, ,) (NP (NNP Doc_9578276_867_875_Disease)) (PRN (-LRB- -LRB-) (NP (CD 0)) (-RRB- -RRB-)))))) (CC and) (VP (VBD retained) (NP (NP (NN placenta)) (PRN (-LRB- -LRB-) (NP (CD four)) (-RRB- -RRB-))))) (. .)))
9578276	6	(S1 (S (NP (JJ Serious) (JJ adverse) (NNS events)) (VP (VBD occurred) (PP (IN in) (NP (NP (CD seven) (NNS women)) (: :) (NP (NP (NP (CD six) (NNS cases)) (PP (IN with) (NP (NP (NNP Doc_9578276_973_983_Disease) (NNP >)) (CC or) (NP (QP (SYM =) (CD 1000) (CD ml)))))) (, ,) (NP (NP (CD four) (NNS cases)) (PP (IN of) (NP (JJ manual) (JJ placenta) (NN removal)))) (, ,) (NP (NP (CD five) (NNS cases)) (PP (IN of) (NP (JJ additional) (NN oxytocics) (NN administration)))) (CC and) (NP (NP (CD five) (NNS cases)) (PP (IN of) (NP (NN blood) (NN transfusion)))))))) (. .)))
9578276	7	(S1 (S (NP (NNP Maximum) (NNP Doc_9578276_1134_1144_Disease)) (VP (AUX was) (ADJP (ADJP (JJS greatest) (PP (IN at) (NP (DT the) (ADJP (JJ upper) (CC and) (JJR lower)) (NN dose) (NNS levels)))) (, ,) (CC and) (ADJP (JJS lowest) (PP (IN in) (NP (DT the) (ADJP (CD 70-125) (NN microg)) (NN dose) (NN range)))))) (. .)))
9578276	8	(S1 (S (NP (NP (NP (CD Four)) (PP (IN out) (PP (IN of) (NP (CD six) (NNS cases)))) (PP (IN with) (NP (NNP Doc_9578276_1265_1275_Disease) (NNP >)))) (CC or) (NP (QP (SYM =) (CD 1000) (CD ml)))) (VP (VBD occurred) (PP (IN in) (NP (DT the) (CD 200) (NN microg) (NN group)))) (. .)))
9578276	9	(S1 (S (NP (NP (DT The) (NN majority)) (PP (IN of) (NP (NP (JJ additional) (NN administration)) (PP (IN of) (NP (NP (NP (NNS oxytocics)) (PRN (-LRB- -LRB-) (NP (CD 4/5)) (-RRB- -RRB-))) (CC and) (NP (NP (NN blood) (NN transfusion)) (PRN (-LRB- -LRB-) (NP (NN 3/5)) (-RRB- -RRB-)))))))) (VP (VBD occurred) (PP (IN in) (NP (NP (DT the) (NN dose) (NNS groups)) (PP (IN of) (NP (CD 200) (NN microg)))))) (. .)))
9578276	10	(S1 (S (NP (DT All) (VBN retained) (NNS placentae)) (VP (AUX were) (VP (VBN found) (PP (IN in) (NP (NP (DT the) (NN group)) (PP (IN of) (NP (CD 200) (NN microg))))))) (. .)))
9578276	11	(S1 (S (NP (DT The) (NN MTD)) (VP (AUX was) (VP (VBN calculated) (S (VP (TO to) (VP (AUX be) (PP (IN at) (NP (CD 200) (JJ microg) (NN Doc_9578276_1574_1584_Chemical)))))))) (. .)))
9646784	0	(S1 (NP (NP (JJ Doc_9646784_0_7_Chemical-induced) (NN Doc_9646784_16_32_Disease)) (, ,) (NP (JJ paradoxical) (NN Doc_9646784_46_61_Disease)) (, ,) (CC and) (NP (NP (JJ other) (JJ side) (NNS effects)) (PP (IN of) (NP (JJ Doc_9646784_89_96_Chemical) (NN therapy)))) (. .)))
9646784	1	(S1 (S (SBAR (IN Although) (S (NP (JJ several) (JJ new) (NN anticoagulant) (NNS drugs)) (VP (AUX are) (PP (IN in) (NP (NN development)))))) (, ,) (NP (NNP Doc_9646784_167_174_Chemical)) (VP (VBZ remains) (NP (NP (DT the) (NN drug)) (PP (IN of) (NP (NN choice))) (PP (IN for) (NP (JJS most) (NN anticoagulation) (NNS needs))))) (. .)))
9646784	2	(S1 (S (S (NP (NP (DT The) (JJ clinical) (NNS effects)) (PP (IN of) (NP (NNP Doc_9646784_258_265_Chemical)))) (VP (AUX are) (ADJP (JJ meritorious)))) (, ,) (CC but) (S (NP (NN side) (NNS effects)) (VP (AUX do) (VP (VB exist)))) (. .)))
9646784	3	(S1 (S (NP (NP (JJ Important) (JJ untoward) (NNS effects)) (PP (IN of) (NP (JJ Doc_9646784_340_347_Chemical) (NN therapy))) (PP (VBG including) (NP (NP (NNP Doc_9646784_366_373_Chemical-induced) (NNP Doc_9646784_382_398_Disease)) (, ,) (NP (NNP Doc_9646784_400_407_Chemical-associated) (NNP Doc_9646784_419_431_Disease)) (, ,) (NP (NNP Doc_9646784_433_445_Disease)) (, ,) (NP (NN skin) (NNS reactions)) (, ,) (NP (NP (NNP Doc_9646784_463_481_Disease)) (ADJP (JJ other) (PP (IN than) (NP (NNP Doc_9646784_493_509_Disease))))) (CC and) (NP (NNP Doc_9646784_514_522_Disease))))) (VP (MD will) (VP (AUX be) (VP (VBN discussed) (PP (IN in) (NP (DT this) (NN article)))))) (. .)))
9725303	0	(S1 (S (NP (NP (JJ Nonopaque) (NN crystal) (NN deposition) (VBG causing) (NN Doc_9725303_37_57_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_9725303_75_78_Disease)))))) (VP (VBG undergoing) (NP (JJ Doc_9725303_90_99_Chemical) (NN therapy))) (. .)))
9725303	1	(S1 (S (NP (PRP We)) (VP (VBP describe) (NP (NP (DT the) (JJ unique) (CD CT) (NNS features)) (PP (IN of) (NP (JJ ureteric) (NNS calculi))) (PP (IN in) (NP (NP (CD six) (JJ Doc_9725303_182_194_Disease) (NNS patients)) (VP (VBG receiving) (NP (NP (NNP Doc_9725303_214_223_Chemical)) (, ,) (NP (DT the) (ADJP (RBS most) (RB commonly) (VBN used)) (NNP Doc_9725303_248_251_Disease) (NN protease) (NN inhibitor)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN incidence)) (PP (IN of) (NP (NNP Doc_9725303_323_335_Disease))))))))))))))) (. .)))
9725303	2	(S1 (S (NP (NP (NN Doc_9725303_349_369_Disease)) (VP (VBN caused) (PP (IN by) (S (VP (VBD precipitated) (NP (JJ Doc_9725303_393_402_Chemical) (NNS crystals))))))) (VP (MD may) (VP (AUX be) (ADJP (JJ difficult) (SBAR (S (VP (TO to) (VP (VB diagnose) (PP (IN with) (NP (JJ unenhanced) (NNS CT)))))))))) (. .)))
9725303	3	(S1 (S (S (NP (DT The) (NNS calculi)) (VP (AUX are) (RB not) (ADJP (JJ opaque)))) (, ,) (CC and) (S (NP (NP (JJ secondary) (NNS signs)) (PP (IN of) (NP (NNP Doc_9725303_512_523_Disease)))) (VP (VP (MD may) (VP (AUX be) (ADJP (ADJP (JJ absent)) (CC or) (ADJP (JJ minimal))))) (CC and) (VP (MD should) (VP (AUX be) (VP (VBN sought) (ADVP (RB carefully))))))) (. .)))
9725303	4	(S1 (S (NP (NNS Images)) (VP (MD may) (VP (AUX need) (S (VP (TO to) (VP (AUX be) (VP (VBN obtained) (S (VP (VBG using) (NP (JJ i.v.) (NN contrast) (NN material)) (S (VP (TO to) (VP (VB enable) (NP (NP (NN diagnosis)) (PP (IN of) (NP (NNP Doc_9725303_664_694_Disease)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_9725303_712_725_Disease))) (SBAR (WHNP (WP who)) (S (VP (VBP receive) (NP (JJ Doc_9725303_738_747_Chemical) (NN therapy)))))))))))))))))) (. .)))
9759693	0	(S1 (S (NP (NP (NN Doc_9759693_0_16_Disease)) (CC and) (NP (NN Doc_9759693_21_32_Chemical))) (VP (VBP use)) (. .)))
9759693	1	(S1 (S (NP (NP (NNP Doc_9759693_38_59_Chemical)) (, ,) (NP (DT a) (JJ Doc_9759693_63_74_Chemical) (-LRB- -LRB-) (JJ Doc_9759693_76_95_Chemical-1) (-RRB- -RRB-) (NN receptor) (NN agonist)) (, ,)) (VP (AUX is) (NP (NP (DT an) (JJ antimigraine) (NN drug)) (SBAR (WHNP (WDT that)) (S (VP (AUX is) (VP (VBN reported) (S (VP (TO to) (VP (VB act) (PP (IN by) (S (VP (ADVP (RB selectively)) (VBG constricting) (NP (JJ intracranial) (NNS arteries)))))))))))))) (. .)))
9759693	2	(S1 (S (ADVP (RB Recently)) (, ,) (NP (NP (NN vasopressor) (NNS responses)) (SBAR (WHNP (WDT that)) (S (VP (AUX are) (ADJP (JJ distinct) (PP (IN from) (NP (DT the) (JJ cranial) (NN circulation)))))))) (VP (AUX have) (VP (AUX been) (VP (VBN demonstrated) (S (VP (TO to) (VP (VB occur) (PP (IN in) (NP (DT the) (ADJP (ADJP (JJ systemic)) (, ,) (ADJP (JJ pulmonary)) (, ,) (CC and) (ADJP (JJ coronary))) (NNS circulations))))))))) (. .)))
9759693	3	(S1 (S (NP (NNS Cases)) (VP (AUX have) (VP (AUX been) (VP (VBN published) (PP (IN of) (S (NP (NP (NNP Doc_9759693_411_429_Disease)) (, ,) (NP (NNP Doc_9759693_431_450_Disease)) (, ,) (CC and) (NP (NNP Doc_9759693_456_477_Disease))) (VP (VBG occurring) (PP (IN after) (NP (JJ Doc_9759693_494_505_Chemical) (NN use))))))))) (. .)))
9759693	4	(S1 (S (NP (PRP We)) (VP (VBP report) (PP (IN on) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (CD 8) (JJ serious) (NNS cases)) (PP (IN of) (NP (NNP Doc_9759693_562_578_Disease))))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NNP Doc_9759693_596_604_Disease)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_9759693_618_629_Chemical))))))))))) (. .)))
9782254	0	(S1 (NP (NP (NP (NN Pallidotomy)) (PP (IN with) (NP (DT the) (NN gamma) (NN knife)))) (: :) (NP (NP (NP (DT a) (JJ positive) (NN experience.)) (NP (CD 51) (NNS patients))) (PP (IN with) (NP (ADJP (RB medically) (JJ refractory)) (NN Doc_9782254_95_114_Disease) (VBD underwent) (JJ stereotactic) (JJ posteromedial) (NN pallidotomy))) (PP (IN between) (NP (NNP August) (CD 1993) (CC and) (NP (NNP February) (CD 1997)))) (PP (IN for) (NP (NP (NN treatment)) (PP (IN of) (NP (NP (NNP Doc_9782254_219_231_Disease)) (, ,) (NP (NNP Doc_9782254_233_241_Disease)) (, ,) (CC and) (NP (NNP Doc_9782254_247_253_Chemical-induced) (NNP Doc_9782254_262_273_Disease))))))) (. .)))
9782254	1	(S1 (S (S (PP (IN In) (NP (CD 29) (NNS patients))) (, ,) (NP (DT the) (NNS pallidotomies)) (VP (AUX were) (VP (VBN performed) (PP (IN with) (NP (DT the) (NNP Leksell) (NN Gamma) (NN Knife)))))) (CC and) (S (PP (IN in) (NP (CD 22))) (NP (PRP they)) (VP (AUX were) (VP (VBN performed) (PP (IN with) (NP (DT the) (JJ standard) (NN radiofrequency) (PRN (-LRB- -LRB-) (NP (NNP RF)) (-RRB- -RRB-)) (NN method)))))) (. .)))
9782254	2	(S1 (S (NP (NP (JJ Clinical) (NN assessment)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ blinded) (NNS ratings)) (PP (IN of) (NP (JJ Unified) (NNP Doc_9782254_487_506_Disease) (NNP Rating) (NNP Scale) (PRN (-LRB- -LRB-) (NP (NNP UPDRS)) (-RRB- -RRB-)) (NNS scores))))) (VP (AUX were) (VP (VBN carried) (PRT (RP out)) (UCP (ADJP (JJ pre-)) (CC and) (ADVP (RB postoperatively))))) (. .)))
9782254	3	(S1 (S (S (NP (JJ Mean) (JJ follow-up) (NN time)) (VP (AUX is) (NP (NP (CD 20.6) (NNS months)) (PRN (-LRB- -LRB-) (NP (NN range) (CD 6-48)) (-RRB- -RRB-))))) (CC and) (S (NP (NP (DT all)) (PP (IN except) (NP (CD 4) (NNS patients)))) (VP (AUX have) (VP (AUX been) (VP (VBN followed) (NP (NP (QP (JJR more) (IN than) (CD one)) (NN year.)) (SBAR (S (NP (NP (CD 85) (NN percent)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_9782254_719_730_Disease)))))) (VP (AUX were) (VP (VBN relieved) (PP (IN of) (NP (NNS symptoms)))))))) (, ,) (ADVP (RB regardless) (PP (IN of) (SBAR (IN whether) (S (NP (DT the) (NNS pallidotomies)) (VP (AUX were) (VP (VBN performed) (PP (IN with) (NP (NP (DT the) (NN Gamma) (NN Knife)) (CC or) (NP (NN radiofrequency) (NNS methods)))))))))))))) (. .)))
9782254	4	(S1 (S (NP (NP (QP (IN About) (CD 2/3))) (PP (IN of) (NP (NP (DT the) (NNS patients)) (PP (IN in) (NP (DT both) (NN Gamma) (NN Knife) (CC and) (NN radiofrequency) (NNS groups)))))) (VP (VBD showed) (NP (NP (NNS improvements)) (PP (IN in) (NP (NP (NNP Doc_9782254_956_968_Disease)) (CC and) (NP (NNP Doc_9782254_973_981_Disease))))) (, ,) (SBAR (IN although) (S (SBAR (WHADVP (WRB when)) (S (VP (VBN considered) (PP (IN as) (NP (NP (NP (DT a) (NN group)) (PP (IN neither) (NP (DT the) (NN Gamma) (NN Knife)))) (CC nor) (NP (DT the) (NN radiofrequency) (NN group))))))) (VP (VBD showed) (NP (NP (ADJP (RB statistically) (JJ significant)) (NNS improvements)) (PP (IN in) (NP (NNS UPDRS) (NNS scores)))))))) (. .)))
9782254	5	(S1 (S (S (NP (NP (CD One) (NN patient)) (PP (IN in) (NP (NP (DT the) (NN Gamma) (NNP Knife) (NN group)) (PRN (-LRB- -LRB-) (NP (CD 3.4) (NN %)) (-RRB- -RRB-))))) (VP (VBD developed) (NP (DT a) (JJ homonymous) (NNP Doc_9782254_1202_1213_Disease) (CD 9) (NNS months)) (PP (VBG following) (NP (NP (NN treatment)) (CC and) (NP (NP (CD 5) (NNS patients)) (PRN (-LRB- -LRB-) (NP (CD 27.7) (NN %)) (-RRB- -RRB-))))) (PP (IN in) (NP (DT the) (NN radiofrequency) (NN group))))) (VP (VBD became) (ADJP (RB transiently) (VBN confused)) (ADVP (RB postoperatively))) (. .)))
9782254	6	(S1 (S (NP (DT No) (JJ other) (NNS complications)) (VP (AUX were) (VP (VBN seen))) (. .)))
9782254	7	(S1 (S (NP (NN Gamma) (NNP Knife) (NN pallidotomy)) (VP (AUX is) (ADJP (RB as) (JJ effective) (PP (IN as) (NP (NP (NN radiofrequency) (NN pallidotomy)) (PP (IN in) (S (VP (VBG controlling) (NP (NP (JJ certain)) (PP (IN of) (NP (NP (DT the) (NNS symptoms)) (PP (IN of) (NP (NNP Doc_9782254_1485_1504_Disease))))))))))))) (. .)))
9782254	8	(S1 (S (NP (PRP It)) (VP (MD may) (VP (AUX be) (NP (NP (DT the) (JJ only) (JJ practical) (NN technique)) (ADJP (JJ available) (PP (IN in) (S (NP (NP (JJ certain) (NNS patients)) (, ,) (PP (JJ such) (IN as) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBP take) (NP (NNS anticoagulants))))))) (, ,)) (VP (AUX have) (NP (NP (JJ Doc_9782254_1620_1628_Disease) (NNS diatheses)) (CC or) (NP (JJ serious) (JJ systemic) (JJ medical) (NNS illnesses)))))))))) (. .)))
9782254	9	(S1 (S (NP (PRP It)) (VP (AUX is) (NP (NP (DT a) (JJ viable) (NN option)) (PP (IN for) (NP (NP (JJ other) (NNS patients)) (PP (IN as) (NP (NN well))))))) (. .)))
978847	0	(S1 (S (RB Centrally) (VP (VBD mediated) (NP (NP (JJ cardiovascular) (NNS effects)) (PP (IN of) (NP (NP (JJ intracisternal) (NN application)) (PP (IN of) (NP (NNP Doc_978847_75_84_Chemical))) (PP (IN in) (NP (JJ anesthetized) (NNS rats))))))) (. .)))
978847	1	(S1 (S (NP (NP (DT The) (JJ pressor) (NN response)) (PP (TO to) (NP (NP (DT the) (JJ intracisternal) (-LRB- -LRB-) (NN i.c.) (-RRB- -RRB-) (NN injection)) (PP (IN of) (NP (NP (NNP Doc_978847_170_179_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mug)) (-RRB- -RRB-)))))) (PP (IN in) (NP (JJ anesthetized) (NNS rats)))) (VP (AUX was) (VP (VBN analyzed))) (. .)))
978847	2	(S1 (S (S (NP (DT This) (NN response)) (VP (AUX was) (VP (ADVP (RB significantly)) (VBN reduced) (PP (IN by) (NP (NP (DT the) (JJ intravenous) (PRN (-LRB- -LRB-) (NP (CD i.v.)) (-RRB- -RRB-)) (NN injection)) (PP (IN of) (NP (NP (NP (NNP Doc_978847_302_314_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Doc_978847_323_336_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 10) (NNS mg)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_978847_348_360_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5) (NN mg)) (-RRB- -RRB-)))))))))) (, ,) (CC and) (S (ADVP (RB conversely)) (, ,) (VP (VBN potentiated) (PP (IN by) (NP (NP (JJ i.v.) (NNP Doc_978847_405_424_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.3) (NN mg)) (-RRB- -RRB-)))) (, ,) (SBAR (IN while) (S (NP (NP (NNP Doc_978847_441_452_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 0.5) (NN mg)) (-RRB- -RRB-))) (VP (VBZ i.v.) (SBAR (S (ADVP (RB selectively)) (VP (VBD inhibited) (NP (NP (NP (DT the) (NN enlargement)) (PP (IN of) (NP (NN pulse) (NN pressure)))) (CC and) (NP (NP (DT the) (NNP Doc_978847_531_542_Disease)) (VP (VBG following) (NP (NP (NNS i.c.)) (NP (NP (NNP Doc_978847_558_567_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mug)) (-RRB- -RRB-))))))))))))))) (. .)))
978847	3	(S1 (S (PP (IN On) (NP (DT the) (JJ other) (NN hand))) (, ,) (NP (NP (DT the) (NN pressor) (NN response)) (SBAR (S (VP (TO to) (VP (VB i.c.) (NP (NP (NNP Doc_978847_625_634_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mug)) (-RRB- -RRB-)))))))) (VP (AUX was) (VP (VP (ADVP (RB almost) (RB completely)) (VBN blocked) (PP (IN by) (S (VP (VBG i.c.) (NP (NP (NP (NNP Doc_978847_681_689_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 3) (NN mug)) (-RRB- -RRB-))) (CC or) (NP (NP (NNP Doc_978847_701_714_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 500) (NN mug)) (-RRB- -RRB-)))))))) (, ,) (CC and) (VP (ADVP (RB significantly)) (VBN reduced) (PP (IN by) (S (VP (VBG i.c.) (NP (NP (NNP Doc_978847_760_774_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mug)) (-RRB- -RRB-))))))) (CC but) (VP (ADVP (RB significantly)) (VBN potentiated) (PP (IN by) (S (VP (VBG i.c.) (NP (NP (NNP Doc_978847_822_841_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN mug)) (-RRB- -RRB-))))))))) (. .)))
978847	4	(S1 (S (NP (NP (DT The) (JJ pressor) (NN response)) (PP (TO to) (NP (NP (JJ i.c.) (NNP Doc_978847_881_890_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN mug)) (-RRB- -RRB-))))) (VP (VP (VBD remained) (ADJP (JJ unchanged)) (PP (IN after) (NP (NP (NN sectioning)) (PP (IN of) (NP (DT the) (JJ bilateral) (JJ cervical) (JJ vagal) (NNS nerves)))))) (CC but) (VP (VBD disappeared) (PP (IN after) (NP (NP (NN sectioning)) (PP (IN of) (NP (NP (DT the) (JJ spinal) (NN cord)) (PRN (-LRB- -LRB-) (NP (NNP C7-C8)) (-RRB- -RRB-)))))))) (. .)))
978847	5	(S1 (S (PP (IN From) (NP (DT the) (JJ above) (NN result))) (NP (PRP it)) (VP (AUX is) (VP (VBN suggested) (SBAR (SBAR (IN that) (S (NP (DT the) (NN pressor) (NN response)) (VP (TO to) (VP (VB i.c.) (NP (NP (JJ Doc_978847_1107_1116_Chemical) (NN ortral)) (CC and) (NP (JJ peripheral) (JJ adrenergic) (NNS mechanisms))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (DT the) (JJ sympathetic) (NN trunk)) (VP (AUX is) (NP (DT the) (JJ main) (NN pathway)))))))) (. .)))
9831002	0	(S1 (NP (NNP Doc_9831002_0_30_Disease) (CC and) (NNP Doc_9831002_35_50_Chemical) (. .)))
9831002	1	(S1 (S (NP (NP (DT A) (JJ 1-year-old) (NN female)) (VP (VBN presented) (PP (IN with) (NP (NN Doc_9831002_87_117_Disease))))) (ADVP (RB probably)) (VP (VBN caused) (PP (IN by) (NP (NNP Doc_9831002_137_152_Chemical)))) (. .)))
9831002	2	(S1 (S (NP (PRP She)) (VP (AUX had) (NP (NP (NNS defects)) (PP (IN in) (NP (DT the) (JJ supratentorial) (NN brain)))) (PP (VBG including) (NP (NP (DT the) (JJ basal) (NN ganglia)) (CC and) (NP (NP (DT the) (NN striatum)) (-LRB- -LRB-) (NP (JJ multicystic) (NNP Doc_9831002_256_272_Disease)) (-RRB- -RRB-) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ severe) (JJ perinatal) (NN Doc_9831002_298_329_Disease)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (AUX was) (VP (VBN considered) (S (VP (TO to) (VP (AUX be) (NP (NP (DT a) (JJ possible) (NN predisposing) (NN factor)) (VP (VBG causing) (NP (NN Doc_9831002_397_427_Disease)))))))))))))))))) (. .)))
9831002	3	(S1 (S (NP (DT A) (JJ dopaminergic) (NN blockade) (NN mechanism)) (ADVP (RB generally)) (VP (AUX is) (VP (VBN accepted) (PP (IN as) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (DT this) (NN syndrome))))))) (. .)))
9831002	4	(S1 (S (ADVP (RB However)) (, ,) (S (NP (NNP Doc_9831002_532_547_Chemical)) (VP (AUX is) (NP (NP (DT a) (JJ Doc_9831002_553_561_Chemical) (NN agonist)) (PP (IN via) (NP (NP (DT the) (NN inhibition)) (PP (IN of) (NP (NP (NN uptake)) (PP (IN of) (NP (NNP Doc_9831002_602_610_Chemical)))))))))) (, ,) (CC and) (S (NP (NP (RB therefore) (JJ dopaminergic) (NNS systems)) (PP (IN in) (NP (NP (NP (DT the) (NN brainstem)) (PRN (-LRB- -LRB-) (NP (RB mainly) (DT the) (NN midbrain)) (-RRB- -RRB-))) (CC and) (NP (DT the) (JJ spinal) (NN cord))))) (VP (AUX were) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB participate) (PP (IN in) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (DT this) (NN syndrome))))))))))) (. .)))
9831002	5	(S1 (S (NP (DT A) (JJ relative) (JJ Doc_9831002_777_800_Chemical-ergic) (NN deficiency)) (VP (MD might) (VP (VB occur) (SBAR (IN because) (S (NP (NP (NNP Doc_9831002_838_846_Chemical)) (, ,) (NP (DT a) (JJ Doc_9831002_850_873_Chemical-mimetic) (NN agent)) (, ,)) (VP (AUX was) (ADJP (RB strikingly) (JJ effective))))))) (. .)))
9831002	6	(S1 (S (NP (DT This)) (VP (AUX is) (NP (NP (DT the) (JJ first) (JJ reported) (NN patient)) (PP (IN with) (NP (NNP Doc_9831002_955_985_Disease))) (VP (ADVP (RB probably)) (VBN caused) (PP (IN by) (NP (NNP Doc_9831002_1005_1020_Chemical)))))) (. .)))
9869655	0	(S1 (NP (NP (NN Differential) (NNS effects)) (PP (IN of) (NP (NNP Doc_9869655_24_48_Chemical))) (PP (IN on) (NP (NP (DT the) (JJ neutral) (CC and) (JJ acidic) (NNS pathways)) (PP (IN of) (NP (NP (JJ Doc_9869655_87_96_Chemical) (NN synthesis)) (PP (IN in) (NP (DT the) (NN rat))))))) (. .)))
9869655	1	(S1 (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NP (NNP Doc_9869655_130_154_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9869655_156_158_Chemical)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (DT the) (ADJP (JJ neutral) (CC and) (JJ acidic)) (JJ biosynthetic) (NNS pathways)) (PP (IN of) (NP (NNP Doc_9869655_211_220_Chemical) (PRN (-LRB- -LRB-) (NP (NNP BS)) (-RRB- -RRB-)) (NN synthesis)))))) (VP (AUX were) (VP (VBN evaluated) (PP (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (DT an) (JJ intact) (JJ enterohepatic) (NN circulation))))) (CC and) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (NP (JJ long-term) (JJ bile) (NN diversion)) (SBAR (S (VP (TO to) (VP (VB induce) (NP (CD BS) (NN synthesis))))))))))))) (. .)))
9869655	2	(S1 (S (PP (IN For) (NP (DT this) (NN purpose))) (, ,) (NP (NP (NNP Doc_9869655_384_393_Chemical) (NN pool) (NN composition)) (, ,) (NP (NP (NN synthesis)) (PP (IN of) (NP (JJ individual) (NNS BS))) (PP (PP (IN in) (NP (NP (NN vivo)) (, ,) (NP (JJ hepatic) (NNS activities)) (, ,) (CC and) (NP (NP (NN expression) (NNS levels)) (PP (IN of) (NP (NP (NNP Doc_9869655_493_504_Chemical) (NN 7alpha-hydroxylase)) (PRN (-LRB- -LRB-) (NP (NNP CYP7A)) (-RRB- -RRB-))))) (, ,) (CC and) (NP (NP (JJ Doc_9869655_537_543_Chemical) (NN 27-hydroxylase)) (PRN (-LRB- -LRB-) (NP (CD CYP27)) (-RRB- -RRB-))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN of) (NP (NP (JJ other) (NNS enzymes)) (VP (VBN involved) (PP (IN in) (NP (CD BS) (NN synthesis)))))))) (, ,)) (VP (AUX were) (VP (VBN analyzed) (PP (IN in) (NP (NP (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NNP Doc_9869655_657_659_Chemical)) (PRN (-LRB- -LRB-) (NP (CD 5) (NNS mg/kg)) (, ,) (NP (CD 3) (NNS days)) (-RRB- -RRB-))) (CC or) (NP (PRP$ its) (NN vehicle))))))))) (. .)))
9869655	3	(S1 (S (S (NP (JJ BS) (NN pool) (NN size)) (VP (AUX was) (VP (VBN decreased) (PP (IN by) (NP (CD 27) (NN %)))))) (CC but) (S (NP (JJ total) (NN BS) (NN synthesis)) (VP (AUX was) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (NNP Doc_9869655_771_773_Chemical)) (PP (IN in) (NP (JJ intact) (NNS rats)))))))) (. .)))
9869655	4	(S1 (S (NP (NP (NN Synthesis)) (PP (IN of) (NP (NN cholate)))) (VP (AUX was) (VP (VBN reduced) (PP (IN by) (NP (CD 68) (NN %))) (PP (IN in) (NP (JJ Doc_9869655_833_835_Chemical-treated) (NNS rats))) (, ,) (SBAR (IN while) (S (NP (NP (DT that)) (PP (IN of) (NP (NNP Doc_9869655_864_881_Chemical)))) (VP (AUX was) (VP (VBN increased) (PP (IN by) (NP (CD 60) (NN %))))))))) (. .)))
9869655	5	(S1 (S (NP (NP (DT The) (ADJP (RB recently) (VBN identified)) (NNP Delta22-isomer)) (PP (IN of) (NP (NN beta-muricholate)))) (VP (VP (VBD contributed) (PP (IN for) (NP (NP (CD 5.4) (NN %)) (CC and) (NP (NP (CD 18.3) (NN %)) (PRN (-LRB- -LRB-) (NP (NNP P) (NNP <) (CD 0.01)) (-RRB- -RRB-))))) (PP (TO to) (NP (NP (DT the) (NN pool)) (PP (IN in) (NP (NP (NN control)) (CC and) (NP (NP (JJ Doc_9869655_1033_1035_Chemical-treated) (NNS rats)) (, ,) (ADVP (RB respectively)))))))) (, ,) (CC but) (VP (MD could) (RB not) (VP (AUX be) (VP (VBN detected) (PP (IN in) (NP (NN bile))) (PP (IN after) (NP (NP (NN exhaustion)) (PP (IN of) (NP (DT the) (NN pool))))))))) (. .)))
9869655	6	(S1 (S (S (NP (NP (DT A) (JJ clear) (NN reduction)) (PP (IN of) (NP (CD BS) (NN synthesis)))) (VP (AUX was) (VP (VBN found) (PP (IN in) (NP (NP (JJ bile-diverted) (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NNP Doc_9869655_1207_1209_Chemical))))))))) (, ,) (CC yet) (S (NP (JJ biliary) (NN BS) (NN composition)) (VP (AUX was) (ADVP (RB only) (RB minimally)) (VP (VBN affected)))) (. .)))
9869655	7	(S1 (S (NP (NP (NN Activity)) (PP (IN of) (NP (NNS CYP7A)))) (VP (AUX was) (VP (VBN decreased) (PP (IN by) (NP (NNP Doc_9869655_1302_1304_Chemical))) (PP (IN in) (NP (DT both) (ADJP (JJ intact) (CC and) (JJ bile-diverted)) (NNS rats))) (, ,) (SBAR (IN whereas) (S (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (DT the) (CD CYP27)))) (VP (AUX was) (RB not) (VP (VBN affected))))))) (. .)))
9869655	8	(S1 (S (S (NP (NP (JJ Hepatic) (NN mRNA) (NNS levels)) (PP (IN of) (NP (NNS CYP7A)))) (VP (AUX were) (VP (ADVP (RB significantly)) (VBN reduced) (PP (IN by) (NP (NNP Doc_9869655_1455_1457_Chemical))) (PP (IN in) (NP (JJ bile-diverted) (NNS rats)) (ADVP (RB only)))))) (: ;) (S (NP (CD CYP27) (NN mRNA) (NNS levels)) (VP (AUX were) (RB not) (VP (VBN affected) (PP (IN by) (NP (NNP Doc_9869655_1525_1527_Chemical)))))) (. .)))
9869655	9	(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN mRNA) (NNS levels)) (PP (IN of) (NP (NP (JJ Doc_9869655_1557_1563_Chemical) (NN 12alpha-hydroxylase)) (CC and) (NP (JJ lithocholate) (NN 6beta-hydroxylase))))) (VP (AUX were) (VP (VP (VBN increased) (PP (IN by) (NP (JJ bile) (NN diversion)))) (CC and) (VP (VBN suppressed) (PP (IN by) (NP (NNP Doc_9869655_1670_1672_Chemical)))))) (. .)))
9869655	10	(S1 (S (NP (DT This) (NN study)) (VP (VBZ shows) (SBAR (IN that) (S (NP (NP (NNP Doc_9869655_1696_1720_Chemical) (-LRB- -LRB-) (NNP Doc_9869655_1722_1724_Chemical) (-RRB- -RRB-) (JJ -induced) (NN Doc_9869655_1734_1758_Disease)) (PP (IN in) (NP (NNS rats)))) (VP (AUX is) (VP (VBN associated) (PP (IN with) (NP (NP (JJ selective) (NN inhibition)) (PP (IN of) (NP (NP (DT the) (JJ neutral) (NN pathway)) (PP (IN of) (NP (NNP Doc_9869655_1833_1842_Chemical) (PRN (-LRB- -LRB-) (NP (NNP BS)) (-RRB- -RRB-)) (NN synthesis)))))))))))) (. .)))
9869655	11	(S1 (S (NP (NP (JJ Simultaneous) (NN impairment)) (PP (IN of) (NP (NP (JJ other) (NNS enzymes)) (PP (IN in) (NP (DT the) (CD BS) (JJ biosynthetic) (NNS pathways)))))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (JJ overall) (NNS effects)) (PP (IN of) (NP (NNP Doc_9869655_1969_1971_Chemical))))) (PP (IN on) (S (VP (VBG BS) (NP (NN synthesis))))))) (. .)))
9881641	0	(S1 (S (NP (NP (JJ Doc_9881641_0_13_Chemical-sensitive) (NNP Doc_9881641_24_35_Disease)) (VP (VBN produced) (PP (IN by) (NP (NNP Doc_9881641_48_58_Chemical))))) (VP (VBD assessed) (PP (IN in) (NP (DT the) (NN rat)))) (. .)))
9881641	1	(S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NNP Doc_9881641_95_105_Chemical)) (, ,) (NP (NP (DT a) (JJ basic) (JJ 35-Doc_9881641_118_128_Chemical) (NN peptide)) (VP (VBN isolated) (PP (IN from) (NP (NP (DT the) (NN venom)) (PP (IN of) (NP (DT a) (JJ lizard) (NN salivary) (NN gland))))))) (, ,))) (PP (IN on) (NP (NP (JJ arterial) (NN blood) (NN pressure)) (CC and) (NP (NN heart) (NN rate))))) (VP (AUX were) (VP (VBN examined) (PP (IN in) (NP (DT the) (NN rat))) (, ,) (S (VP (VBG focusing) (PP (IN on) (SBAR (S (NP (NP (DT the) (NN possibility)) (PP (IN that) (NP (NP (NN activation)) (PP (IN of) (NP (JJ Doc_9881641_304_307_Chemical) (JJ sensitive) (NNP Doc_9881641_318_319_Chemical+) (PRN (-LRB- -LRB-) (NP (NP (NNP Doc_9881641_322_323_Chemical)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9881641_324_327_Chemical)) (-RRB- -RRB-))) (-RRB- -RRB-)) (NNS channels)))))) (VP (AUX is) (VP (VBN involved) (PP (IN in) (NP (DT the) (NNS responses)))))))))))) (. .)))
9881641	2	(S1 (S (NP (DT The) (NNS results)) (VP (AUX were) (ADVP (RB also)) (PP (VBN compared) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (NP (JJ vasoactive) (JJ intestinal) (NN polypeptide)) (PRN (-LRB- -LRB-) (NP (NN VIP)) (-RRB- -RRB-)))))))) (. .)))
9881641	3	(S1 (S (NP (NNP Doc_9881641_455_465_Chemical)) (VP (VBD produced) (NP (NNP Doc_9881641_475_486_Disease)) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))) (PP (IN with) (NP (NP (RB approximately) (JJ similar) (NN potency)) (CC and) (NP (NP (NN duration)) (PP (TO to) (NP (NN VIP))))))) (. .)))
9881641	4	(S1 (S (NP (NP (NN Doc_9881641_570_581_Disease)) (VP (VBN induced) (PP (IN by) (NP (DT both) (NNS peptides))))) (VP (AUX was) (ADVP (RB significantly)) (VP (VBN attenuated) (PP (IN by) (NP (NP (NNP Doc_9881641_639_652_Chemical)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD abolished) (NP (NP (DT a) (JJ levcromakalim-produced) (NN decrease)) (PP (IN in) (NP (JJ arterial) (NN blood) (NN pressure))))))))))) (. .)))
9881641	5	(S1 (S (NP (NNP Oxyhemoglobin)) (VP (AUX did) (RB not) (VP (VB affect) (NP (JJ Doc_9881641_761_771_Chemical-induced) (NN Doc_9881641_780_791_Disease)) (, ,) (SBAR (IN whereas) (S (NP (PRP it)) (VP (VBN shortened) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (JJ Doc_9881641_830_843_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_9881641_845_848_Chemical)) (-RRB- -RRB-)) (JJ -produced) (NN Doc_9881641_859_870_Disease))))))))) (. .)))
9881641	6	(S1 (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNP Doc_9881641_900_910_Chemical-produced) (NNP Doc_9881641_920_931_Disease)) (VP (AUX is) (ADVP (RB partly)) (ADJP (JJ attributable) (PP (TO to) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NP (JJ Doc_9881641_976_989_Chemical-sensitive) (JJ Doc_9881641_1000_1002_Chemical) (NNS channels)) (PRN (-LRB- -LRB-) (NP (NNP Doc_9881641_1013_1014_Chemical) (PRN (-LRB- -LRB-) (NP (NNP Doc_9881641_1015_1018_Chemical)) (-RRB- -RRB-)) (NNS channels)) (-RRB- -RRB-)))) (, ,) (SBAR (WHNP (WDT which)) (S (ADVP (RB presumably)) (VP (VBP exist) (PP (IN on) (NP (JJ arterial) (JJ smooth) (NN muscle) (NNS cells))))))))))))) (. .)))
9881641	7	(S1 (S (NP (NP (NN EDRF)) (PRN (-LRB- -LRB-) (NP (JJ endothelium-derived) (JJ relaxing) (NN factor)) (-RRB- -RRB-))) (ADVP (RB /Doc_9881641_1130_1142_Chemical)) (VP (AUX does) (RB not) (VP (VB seem) (S (VP (TO to) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (DT the) (JJ peptide-produced) (NN Doc_9881641_1207_1218_Disease)))))))) (. .)))
9889429	0	(S1 (NP (NP (NP (JJ Long-term) (NN efficacy)) (CC and) (NP (JJ adverse) (NN event))) (PP (IN of) (NP (JJ Doc_9889429_40_50_Chemical) (JJ sustained-release) (NNS tablets))) (PP (IN for) (NP (NP (NNP Doc_9889429_81_94_Chemical-induced) (NNP Doc_9889429_103_115_Disease)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NNP Doc_9889429_133_142_Disease))))))) (. .)))
9889429	1	(S1 (S (NP (NP (NNP Thirteen) (NNP Doc_9889429_153_162_Disease) (NNS patients)) (PP (IN with) (NP (NNP Doc_9889429_177_189_Disease)))) (PP (IN during) (NP (NP (DT the) (NN course)) (PP (IN of) (NP (JJ Doc_9889429_211_224_Chemical) (NN therapy))))) (VP (AUX were) (VP (VBN treated) (PP (IN for) (NP (CD 25) (NNS months))) (PP (IN with) (NP (NP (DT a) (JJ Doc_9889429_267_274_Chemical) (NN channel) (NN blocker)) (, ,) (NP (JJ sustained-release) (NNP Doc_9889429_310_320_Chemical)) (, ,) (SBAR (S (VP (TO to) (VP (VB study) (NP (NP (DT the) (JJ clinical) (JJ antihypertensive) (NNS effects)) (CC and) (NP (JJ adverse) (NNS events))) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (DT both) (NNS drugs))))))))))))) (. .)))
9889429	2	(S1 (S (NP (NP (CD Seven)) (PP (IN of) (NP (DT the) (CD 13) (NNS patients)))) (VP (AUX had) (VP (VBN exhibited) (NP (NP (DT a) (JJ subclinical) (JJ Doc_9889429_475_487_Disease) (NN state)) (PP (IN before) (NP (JJ Doc_9889429_501_514_Chemical) (NN therapy)))))) (. .)))
9889429	3	(S1 (S (S (NP (NP (DT Both) (JJ systolic) (CC and) (JJ diastolic) (NN blood) (NNS pressures)) (PP (IN of) (NP (DT these) (CD 13) (NNS patients)))) (VP (AUX were) (VP (VBN decreased) (ADVP (RB significantly)) (PP (IN after) (NP (NP (CD 4) (NNS weeks)) (PP (IN of) (NP (JJ Doc_9889429_635_645_Chemical) (NN therapy)))))))) (, ,) (CC and) (S (NP (NN blood) (NN pressure)) (VP (AUX was) (VP (VBN maintained) (PP (IN within) (NP (DT the) (JJ normal) (NN range))) (ADVP (RB thereafter)) (PP (IN for) (NP (CD 25) (NNS months)))))) (. .)))
9889429	4	(S1 (S (NP (NP (DT The) (JJ adverse) (NNS events)) (PP (IN during) (NP (NP (JJ combined) (NN therapy)) (PP (IN with) (NP (NNP Doc_9889429_787_800_Chemical) (CC and) (NNP Doc_9889429_805_815_Chemical)))))) (VP (VBD included) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN blood) (JJ Doc_9889429_846_859_Chemical) (NNS levels))) (PP (IN in) (NP (NP (NP (CD 9)) (PP (IN of) (NP (DT the) (CD 13) (NNS patients)))) (CC and) (NP (NP (NN development)) (PP (IN of) (NP (NNP Doc_9889429_910_930_Disease)))))) (PP (IN in) (NP (NP (CD 2)) (PP (IN of) (NP (DT the) (CD 13) (NNS patients))))))) (. .)))
9889429	5	(S1 (S (NP (PRP$ Our) (NNS findings)) (VP (VBP indicate) (SBAR (SBAR (IN that) (S (NP (JJ sustained-release) (NNP Doc_9889429_1001_1011_Chemical)) (VP (AUX is) (ADJP (JJ useful) (PP (IN for) (NP (NNP Doc_9889429_1026_1038_Disease) (NNP Doc_9889429_1039_1048_Disease) (NNS patients)))) (PP (IN under) (NP (NP (JJ long-term) (NN treatment)) (PP (IN with) (NP (NNP Doc_9889429_1089_1102_Chemical)))))))) (, ,) (CC but) (SBAR (IN that) (S (NP (DT these) (NNS patients)) (VP (MD should) (VP (AUX be) (VP (VBN monitored) (PP (IN for) (NP (NN Doc_9889429_1152_1172_Disease)))))))))) (. .)))
